{"text": "While blocking TPC2 activity by tetrandrine , an inhibitor for TPC237 , decreased entry of SARS-CoV-2 S pseudovirions ( Fig. 3f ) , treatment of cells with 130 , a TRPML1 inhibitor , had no effect ( Supplementary Fig. 1 ) , indicating that TPC2 , not TRPML1 , is important for SARS-CoV-2 entry .", "labels": [[224, 235, "GENE_OR_GENE_PRODUCT"], [32, 44, "ENTITY"], [15, 20, "GENE_OR_GENE_PRODUCT"], [15, 20, "GGP"], [118, 125, "CELL"], [263, 277, "ENTITY"], [32, 44, "CHEBI"], [156, 164, "PROTEIN"], [224, 235, "ENTITY"], [88, 104, "GENE_OR_GENE_PRODUCT"], [156, 164, "GENE_OR_GENE_PRODUCT"], [32, 44, "SIMPLE_CHEMICAL"], [132, 145, "CL"], [224, 235, "PROTEIN"], [132, 145, "ENTITY"], [15, 20, "PROTEIN"], [15, 20, "ENTITY"], [263, 273, "CHEMICAL"], [263, 273, "SIMPLE_CHEMICAL"], [181, 190, "ENTITY"], [72, 82, "ENTITY"], [20, 29, "ENTITY"], [190, 199, "GENE_OR_GENE_PRODUCT"], [240, 247, "PROTEIN"], [156, 164, "ENTITY"], [224, 235, "GGP"], [240, 247, "GGP"], [132, 145, "CELL"], [156, 171, "GGP"], [240, 247, "GENE_OR_GENE_PRODUCT"], [88, 104, "ENTITY"], [6, 15, "ENTITY"], [32, 44, "CHEMICAL"], [164, 171, "ENTITY"], [240, 247, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Thyroid stimulating hormone and free triiodothyronine concentrations were significantly lower in deceased patients ( 0.7 mIU/mL and 2.8 pmol/L ) than in recovered patients ( 1.4 mIU/mL and 4.3 pmol/L ) .", "labels": [[37, 54, "ENTITY"], [20, 28, "ENTITY"], [106, 115, "ORGANISM"], [153, 163, "ORGANISM"], [37, 54, "SIMPLE_CHEMICAL"], [54, 69, "ENTITY"], [153, 163, "ENTITY"], [97, 106, "ENTITY"], [37, 54, "CHEBI"], [37, 54, "CHEMICAL"], [0, 20, "ENTITY"], [0, 28, "GENE_OR_GENE_PRODUCT"], [106, 115, "ENTITY"], [20, 28, "CHEBI"], [32, 37, "ENTITY"]]}
{"text": "Based on these results , we performed virtual docking to screen for commercial medicines in the DrugBank database that could bind to the above mentioned pocket site of 2019-nCoV Mpro , and identified 10 candidate clinical medicines ( Table 1 ; Figs. 1B and S3 ) .", "labels": [[15, 23, "ENTITY"], [96, 105, "ENTITY"], [153, 160, "ENTITY"], [38, 46, "ENTITY"], [68, 79, "ENTITY"], [203, 222, "ENTITY"], [153, 160, "SO"], [168, 178, "ENTITY"]]}
{"text": "Doctors can also use a clinically approved bile therapy drug , Hymecromone ( 4-Methylumbelliferone , 4-MU ) , an inhibitor of HAS2 [ 14 ] . LPS-induced lung inflammation can be relieved by 4-MU .", "labels": [[0, 8, "ENTITY"], [43, 56, "ENTITY"], [140, 157, "DISEASE"], [113, 131, "GENE_OR_GENE_PRODUCT"], [56, 61, "ENTITY"], [108, 113, "CHEBI"], [140, 157, "ENTITY"], [23, 34, "ENTITY"], [177, 186, "CHEMICAL"], [43, 48, "MULTI-TISSUE_STRUCTURE"], [113, 126, "GGP"], [113, 126, "ENTITY"], [113, 126, "PROTEIN"], [56, 61, "CHEBI"], [177, 186, "ENTITY"], [108, 113, "ENTITY"]]}
{"text": "Since Vitamin B3 is highly lung protective , it should be used as soon as coughing begins . When breathing difficulty becomes apparent , hyaluronidase can be used intratracheally and at the same time 4-MU can be given to inhibit HAS2 .", "labels": [[6, 17, "ENTITY"], [195, 200, "SIMPLE_CHEMICAL"], [195, 200, "ENTITY"], [6, 17, "GGP"], [221, 229, "GENE_OR_GENE_PRODUCT"], [27, 32, "ENTITY"], [221, 229, "PROTEIN"], [6, 17, "SIMPLE_CHEMICAL"], [221, 229, "ENTITY"], [195, 200, "PROTEIN"], [92, 107, "ENTITY"], [6, 17, "CHEMICAL"], [27, 32, "ORGAN"], [195, 200, "CHEMICAL"], [221, 229, "GGP"]]}
{"text": "Doctors can also use a clinically approved bile therapy drug , Hymecromone ( 4-Methylumbelliferone , 4-MU ) , an inhibitor of HAS2 [ 14 ] . LPS-induced lung inflammation can be relieved by 4-MU .", "labels": [[0, 8, "ENTITY"], [43, 56, "ENTITY"], [140, 157, "DISEASE"], [56, 61, "ENTITY"], [108, 113, "CHEBI"], [140, 157, "ENTITY"], [23, 34, "ENTITY"], [177, 186, "CHEMICAL"], [43, 48, "MULTI-TISSUE_STRUCTURE"], [113, 131, "GENE_OR_GENE_PRODUCT"], [113, 126, "GGP"], [113, 126, "ENTITY"], [113, 126, "PROTEIN"], [56, 61, "CHEBI"], [177, 186, "ENTITY"], [108, 113, "ENTITY"]]}
{"text": "The administration of methylprednisolone appears to have reduced the risk of death in patients with ARDS ( HR , 0.38 ; 95 % CI , 0.20 - 0.72 ; P = .003 ) ( Figure ) .", "labels": [[100, 105, "DISEASE"], [22, 41, "SIMPLE_CHEMICAL"], [86, 95, "ORGANISM"], [69, 83, "ENTITY"], [22, 41, "CHEMICAL"], [57, 65, "ENTITY"], [22, 41, "ENTITY"], [4, 19, "ENTITY"], [100, 105, "ENTITY"], [77, 83, "DISEASE"], [22, 41, "CHEBI"], [86, 95, "ENTITY"]]}
{"text": "In Addition , all severe and moderate cases were administered corticosteroids ( methylprednisolone ) during the course of hospitalization .", "labels": [[3, 12, "ENTITY"]]}
{"text": "Antiviral ( oseltamivir , 75 mg twice a day ; ribavirin , 0.5 g twice a day ; umifenovir , 0.2 g 3 times a day ) , antibacterial ( moxifloxacin , 0.4 g every day ) , glucocorticoid ( methylprednisolone , 40 - 80 mg every day ) , and respiratory support were the main treatment approaches for the hospitalized patients ( Table 1 ) .", "labels": [[166, 183, "CHEBI"], [99, 105, "ENTITY"], [115, 131, "SIMPLE_CHEMICAL"], [0, 10, "ENTITY"], [166, 183, "ENTITY"], [166, 183, "CHEMICAL"], [166, 183, "SIMPLE_CHEMICAL"], [32, 40, "ENTITY"], [115, 131, "CHEMICAL"], [146, 152, "ENTITY"], [152, 166, "ENTITY"], [215, 233, "ENTITY"], [245, 267, "ENTITY"], [152, 166, "SIMPLE_CHEMICAL"], [277, 288, "ENTITY"], [107, 115, "ENTITY"], [115, 131, "ENTITY"]]}
{"text": "Severe patients could receive glucocorticoid at early stage , e.g. intravenous methylprednisolone 40\u201380 mg , once daily for 5 days , and the course of treatment can be prolonged according to the clinical condition and radiological manifestations .", "labels": [[48, 60, "ENTITY"], [191, 204, "ENTITY"], [0, 7, "ENTITY"], [30, 45, "ENTITY"], [7, 16, "ENTITY"], [30, 45, "SIMPLE_CHEMICAL"], [67, 98, "ORGANISM_SUBSTANCE"], [7, 16, "ORGANISM"], [79, 98, "CHEMICAL"], [218, 231, "ENTITY"]]}
{"text": "In the third case report , Chen et al. reported a 45-year-old woman with COVID-19 and stated that after treatment with Thalidomide ( 100 mg orally once a day ) and Methylprednisolone ( 40 mg intravenously bid for 3 days then reduced to once a day for 5 days ) the overall patient status was improved , oxygen index was increased , symptoms of nausea and vomiting were alleviated , and cytokine levels were decreased ( 9 ) .", "labels": [[291, 302, "SIMPLE_CHEMICAL"], [264, 280, "ENTITY"], [209, 215, "ENTITY"], [343, 354, "DISEASE"], [247, 253, "ENTITY"], [354, 368, "ENTITY"], [191, 205, "ENTITY"], [309, 319, "ENTITY"], [291, 309, "ENTITY"], [331, 343, "ENTITY"], [137, 140, "ENTITY"], [319, 331, "ENTITY"], [291, 302, "CHEMICAL"], [331, 343, "DISEASE"], [394, 406, "ENTITY"], [368, 385, "PROTEIN"], [343, 354, "ENTITY"], [7, 25, "ENTITY"], [137, 140, "ENTITY"], [291, 302, "CHEBI"], [368, 385, "ENTITY"], [147, 154, "ENTITY"]]}
{"text": "In the third case report , Chen et al. reported a 45-year-old woman with COVID-19 and stated that after treatment with Thalidomide ( 100 mg orally once a day ) and Methylprednisolone ( 40 mg intravenously bid for 3 days then reduced to once a day for 5 days ) the overall patient status was improved , oxygen index was increased , symptoms of nausea and vomiting were alleviated , and cytokine levels were decreased ( 9 ) .", "labels": [[291, 302, "SIMPLE_CHEMICAL"], [264, 280, "ENTITY"], [209, 215, "ENTITY"], [343, 354, "ENTITY"], [247, 253, "ENTITY"], [354, 368, "ENTITY"], [191, 205, "ENTITY"], [309, 319, "ENTITY"], [291, 309, "ENTITY"], [331, 343, "ENTITY"], [137, 140, "ENTITY"], [319, 331, "ENTITY"], [343, 354, "DISEASE"], [291, 302, "CHEMICAL"], [331, 343, "DISEASE"], [394, 406, "ENTITY"], [368, 385, "PROTEIN"], [7, 25, "ENTITY"], [137, 140, "ENTITY"], [291, 302, "CHEBI"], [368, 385, "ENTITY"], [147, 154, "ENTITY"]]}
{"text": "In the third case report , Chen et al. reported a 45-year-old woman with COVID-19 and stated that after treatment with Thalidomide ( 100 mg orally once a day ) and Methylprednisolone ( 40 mg intravenously bid for 3 days then reduced to once a day for 5 days ) the overall patient status was improved , oxygen index was increased , symptoms of nausea and vomiting were alleviated , and cytokine levels were decreased ( 9 ) .", "labels": [[291, 302, "SIMPLE_CHEMICAL"], [354, 368, "ENTITY"], [264, 280, "ENTITY"], [209, 215, "ENTITY"], [343, 354, "DISEASE"], [247, 253, "ENTITY"], [191, 205, "ENTITY"], [309, 319, "ENTITY"], [291, 309, "ENTITY"], [331, 343, "ENTITY"], [137, 140, "ENTITY"], [319, 331, "ENTITY"], [291, 302, "CHEMICAL"], [331, 343, "DISEASE"], [394, 406, "ENTITY"], [368, 385, "PROTEIN"], [343, 354, "ENTITY"], [7, 25, "ENTITY"], [137, 140, "ENTITY"], [291, 302, "CHEBI"], [368, 385, "ENTITY"], [147, 154, "ENTITY"]]}
{"text": "In the third case report , Chen et al. reported a 45-year-old woman with COVID-19 and stated that after treatment with Thalidomide ( 100 mg orally once a day ) and Methylprednisolone ( 40 mg intravenously bid for 3 days then reduced to once a day for 5 days ) the overall patient status was improved , oxygen index was increased , symptoms of nausea and vomiting were alleviated , and cytokine levels were decreased ( 9 ) .", "labels": [[291, 302, "SIMPLE_CHEMICAL"], [264, 280, "ENTITY"], [209, 215, "ENTITY"], [343, 354, "DISEASE"], [247, 253, "ENTITY"], [354, 368, "ENTITY"], [191, 205, "ENTITY"], [309, 319, "ENTITY"], [291, 309, "ENTITY"], [331, 343, "ENTITY"], [137, 140, "ENTITY"], [319, 331, "ENTITY"], [291, 302, "CHEMICAL"], [331, 343, "DISEASE"], [394, 406, "ENTITY"], [368, 385, "PROTEIN"], [343, 354, "ENTITY"], [7, 25, "ENTITY"], [137, 140, "ENTITY"], [291, 302, "CHEBI"], [368, 385, "ENTITY"], [147, 154, "ENTITY"]]}
{"text": "Animal experiments have found that Ang 1 - 7 infusion treatment can significantly improve vascular endothelial function and inhibit atherosclerotic lesion development in Ang 1 - 7 transgenic apolipoprotein E knockout ( ApoE KO ) mice receiving atherogenic high- fat diets28 .", "labels": [[82, 99, "GENE_OR_GENE_PRODUCT"], [176, 191, "SO"], [180, 208, "ENTITY"], [45, 54, "ENTITY"], [0, 7, "TAXON"], [35, 43, "GGP"], [124, 148, "DISEASE"], [256, 266, "ENTITY"], [208, 219, "ENTITY"], [167, 176, "GGP"], [208, 219, "GENE_OR_GENE_PRODUCT"], [208, 219, "CHEMICAL"], [124, 148, "ENTITY"], [224, 227, "ENTITY"], [35, 43, "GENE_OR_GENE_PRODUCT"], [124, 148, "PATHOLOGICAL_FORMATION"], [256, 266, "PROTEIN"], [82, 99, "CL"], [234, 244, "ENTITY"], [167, 174, "ENTITY"], [180, 191, "GENE_OR_GENE_PRODUCT"], [180, 191, "CHEMICAL"], [224, 227, "ORGANISM"], [208, 219, "GGP"], [82, 111, "ENTITY"], [0, 19, "ENTITY"], [167, 176, "GENE_OR_GENE_PRODUCT"], [35, 41, "ENTITY"], [224, 227, "TAXON"], [148, 155, "ENTITY"]]}
{"text": "Animal experiments have found that Ang 1 - 7 infusion treatment can significantly improve vascular endothelial function and inhibit atherosclerotic lesion development in Ang 1 - 7 transgenic apolipoprotein E knockout ( ApoE KO ) mice receiving atherogenic high- fat diets28 .", "labels": [[82, 99, "GENE_OR_GENE_PRODUCT"], [176, 191, "SO"], [180, 208, "ENTITY"], [45, 54, "ENTITY"], [0, 7, "TAXON"], [35, 43, "GGP"], [256, 266, "ENTITY"], [124, 148, "PATHOLOGICAL_FORMATION"], [208, 219, "ENTITY"], [167, 176, "GGP"], [208, 219, "GENE_OR_GENE_PRODUCT"], [208, 219, "CHEMICAL"], [224, 227, "ENTITY"], [35, 43, "GENE_OR_GENE_PRODUCT"], [124, 148, "DISEASE"], [256, 266, "PROTEIN"], [82, 99, "CL"], [234, 244, "ENTITY"], [167, 174, "ENTITY"], [180, 191, "GENE_OR_GENE_PRODUCT"], [180, 191, "CHEMICAL"], [124, 148, "ENTITY"], [224, 227, "ORGANISM"], [208, 219, "GGP"], [82, 111, "ENTITY"], [0, 19, "ENTITY"], [167, 176, "GENE_OR_GENE_PRODUCT"], [35, 41, "ENTITY"], [224, 227, "TAXON"], [148, 155, "ENTITY"]]}
{"text": "IFN-\u03b1 is a broad-spectrum antiviral drug , which could inhibit the synthesis of viral RNA and inhibit viral replication and spread .", "labels": [[0, 6, "GENE_OR_GENE_PRODUCT"], [30, 36, "ENTITY"], [11, 41, "ENTITY"], [30, 36, "TAXON"], [30, 36, "RNA"], [0, 6, "ENTITY"], [30, 36, "ENTITY"], [0, 6, "PROTEIN"], [36, 41, "CHEBI"]]}
{"text": "IFN-\u03b1 is a broad-spectrum antiviral drug , which could inhibit the synthesis of viral RNA and inhibit viral replication and spread .", "labels": [[0, 6, "GENE_OR_GENE_PRODUCT"], [30, 36, "RNA"], [11, 41, "ENTITY"], [30, 36, "ENTITY"], [30, 36, "TAXON"], [0, 6, "ENTITY"], [30, 36, "ENTITY"], [0, 6, "PROTEIN"], [36, 41, "CHEBI"]]}
{"text": "In the experts \u2019 consensus statements , it could be also used for treatment of COVID-19 in children [ 9 ] , IFN-\u03b1 is the only antiviral drug which is clearly recommended to be used in children with COVID-19 .", "labels": [[176, 184, "ENTITY"], [91, 108, "CHEMICAL"], [121, 136, "ENTITY"], [7, 15, "ENTITY"], [176, 184, "ORGANISM"], [126, 136, "CHEBI"]]}
{"text": "All 74 patients with COVID-19 with GI symptoms were treated in isolation with supportive and empiric medication , while 66 ( 89.19 % ) patients received antiviral treatment , including interferon-\u03b1 sprays , arbidol hydrochloride capsules ( two tablets three times daily ) , lopinavir and ritonavir two tablets ( 500 mg ) twice daily , via the oral route .", "labels": [[7, 16, "ENTITY"], [52, 60, "ENTITY"], [7, 16, "ORGANISM"], [316, 321, "ENTITY"], [63, 73, "ENTITY"], [274, 288, "SIMPLE_CHEMICAL"], [327, 339, "ENTITY"], [35, 38, "ORGAN"], [144, 163, "ENTITY"], [274, 288, "CHEMICAL"], [198, 229, "ENTITY"], [207, 229, "CHEBI"], [274, 288, "ENTITY"], [93, 112, "ENTITY"], [264, 274, "SIMPLE_CHEMICAL"], [21, 30, "ENTITY"], [35, 47, "ENTITY"], [175, 198, "ENTITY"], [207, 229, "SIMPLE_CHEMICAL"], [78, 89, "ENTITY"], [264, 274, "CHEMICAL"], [21, 30, "GENE_OR_GENE_PRODUCT"], [207, 215, "CHEMICAL"], [288, 298, "ENTITY"], [264, 274, "ENTITY"], [238, 244, "ENTITY"], [327, 335, "ORGAN"]]}
{"text": "Adverse reactions of IFN-\u03b1 mainly include low-grade fever and flu-like symptoms ( both in children with intramuscularly injection ) [ 11 ] .", "labels": [[52, 58, "ENTITY"], [21, 27, "PROTEIN"], [62, 71, "ORGAN"], [42, 52, "ENTITY"], [104, 120, "ENTITY"], [21, 27, "ENTITY"], [62, 80, "ENTITY"], [52, 58, "DISEASE"], [21, 27, "GENE_OR_GENE_PRODUCT"], [0, 18, "ENTITY"], [42, 52, "CANCER"]]}
{"text": "Adverse reactions of IFN-\u03b1 mainly include low-grade fever and flu-like symptoms ( both in children with intramuscularly injection ) [ 11 ] .", "labels": [[52, 58, "ENTITY"], [21, 27, "PROTEIN"], [62, 71, "ORGAN"], [104, 120, "ENTITY"], [21, 27, "ENTITY"], [62, 80, "ENTITY"], [42, 52, "ENTITY"], [52, 58, "DISEASE"], [21, 27, "GENE_OR_GENE_PRODUCT"], [42, 52, "CANCER"], [0, 18, "ENTITY"]]}
{"text": "ELISA assay showed less PLpro-induced TGF-?1 production by SB203580 ( 1.5-fold ) and U0126 ( 3.3-fold ) ( Fig. 7A and B ) .", "labels": [[38, 45, "CHEMICAL"], [0, 12, "ENTITY"], [59, 68, "SIMPLE_CHEMICAL"], [59, 68, "ENTITY"], [59, 68, "CHEMICAL"], [24, 45, "ENTITY"], [38, 45, "PROTEIN"], [45, 56, "ENTITY"]]}
{"text": "In our opinion , during the COVID-19 pandemic , it would be more prudent to replace these drugs , when possible , with calcium channel blockers , adrenergic receptor blockers , diuretics or vasodilators .", "labels": [[135, 166, "ENTITY"], [7, 15, "ENTITY"], [177, 190, "CHEBI"], [114, 135, "ENTITY"], [114, 127, "CHEBI"], [28, 37, "ENTITY"], [177, 190, "ENTITY"], [135, 146, "ENTITY"], [135, 166, "GENE_OR_GENE_PRODUCT"], [114, 135, "GENE_OR_GENE_PRODUCT"], [135, 157, "CHEBI"], [135, 146, "SIMPLE_CHEMICAL"], [135, 146, "CHEBI"]]}
{"text": "PKR is induced by IFN and activated by the binding of double-stranded RNA ( dsRNA ) after virus infection ( Clemens and Elia , 1997 ) . HRI is activated in red blood cells and hepatocytes by low levels of heme ( McEwenet al. , 2005 ) . GCN2 senses amino acid deficiency and is activated via binding to uncharged transfer RNAs ( Sood et al. , 2000 ) .", "labels": [[236, 248, "CHEMICAL"], [312, 321, "ORGANISM"], [291, 312, "ENTITY"], [195, 202, "GENE_OR_GENE_PRODUCT"], [166, 176, "ENTITY"], [205, 212, "PROTEIN"], [18, 22, "GGP"], [236, 248, "CHEBI"], [84, 96, "DISEASE"], [54, 74, "ENTITY"], [166, 176, "CELL_TYPE"], [7, 15, "ENTITY"], [143, 166, "CELL"], [166, 176, "CELL"], [18, 22, "CHEMICAL"], [195, 202, "PROTEIN"], [54, 74, "RNA"], [312, 321, "CHEMICAL"], [195, 202, "CHEBI"], [43, 51, "ENTITY"], [26, 36, "ENTITY"], [0, 4, "ENTITY"], [143, 166, "CELL_TYPE"], [18, 22, "ENTITY"], [143, 166, "CL"], [166, 176, "CL"], [70, 74, "SO"], [176, 195, "ENTITY"], [195, 202, "ENTITY"], [143, 166, "ENTITY"], [0, 4, "PROTEIN"], [136, 143, "ENTITY"], [0, 4, "GENE_OR_GENE_PRODUCT"], [236, 259, "ENTITY"], [259, 277, "ENTITY"], [26, 36, "ENTITY"], [205, 212, "ENTITY"], [18, 22, "GENE_OR_GENE_PRODUCT"], [236, 248, "AMINO_ACID"], [18, 22, "PROTEIN"], [84, 96, "ENTITY"]]}
{"text": "Ammonium chloride blocked VSV-G-dependent entry into both cell lines whereas entry driven by Nipah virus F and G proteins was not affected ( Figure S3A ; data not shown ) , consistent with Nipah virus but not VSV being able to fuse directly with the plasma membrane ( Bossart et al. , 2002 ) .", "labels": [[26, 42, "ENTITY"], [0, 18, "SIMPLE_CHEMICAL"], [93, 107, "TAXON"], [111, 122, "ENTITY"], [42, 48, "ENTITY"], [141, 148, "ENTITY"], [169, 184, "ENTITY"], [58, 69, "CELL"], [0, 18, "CHEBI"], [111, 122, "GENE_OR_GENE_PRODUCT"], [93, 107, "ORGANISM"], [184, 195, "TAXON"], [184, 195, "ENTITY"], [42, 48, "ENTITY"], [246, 257, "GO"], [26, 42, "GENE_OR_GENE_PRODUCT"], [93, 107, "ENTITY"], [246, 257, "CELLULAR_COMPONENT"], [58, 63, "CL"], [0, 18, "CHEMICAL"], [0, 18, "ENTITY"], [246, 257, "ENTITY"], [58, 69, "ENTITY"], [18, 26, "ENTITY"], [141, 148, "GENE_OR_GENE_PRODUCT"], [113, 122, "CHEBI"], [184, 195, "ORGANISM"], [257, 268, "SIMPLE_CHEMICAL"], [58, 69, "CELL_LINE"]]}
{"text": "Ammonium chloride treatment strongly inhibited SARS-2-S- and SARS-S- driven entry into TMPRSS2 - 293 T cells ( Figure S3 A ) , suggesting CatB/L dependence .", "labels": [[0, 18, "SIMPLE_CHEMICAL"], [61, 69, "SIMPLE_CHEMICAL"], [97, 103, "CL"], [47, 57, "GENE_OR_GENE_PRODUCT"], [87, 103, "CELL_LINE"], [0, 18, "CHEBI"], [37, 47, "ENTITY"], [18, 28, "ENTITY"], [103, 118, "ENTITY"], [127, 138, "CHEMICAL"], [87, 103, "GENE_OR_GENE_PRODUCT"], [127, 145, "ENTITY"], [103, 118, "GENE_OR_GENE_PRODUCT"], [47, 57, "ENTITY"], [87, 95, "GGP"], [0, 18, "CHEMICAL"], [95, 103, "ENTITY"], [0, 18, "ENTITY"], [61, 69, "ENTITY"], [127, 138, "CANCER"], [87, 95, "ENTITY"], [47, 57, "PROTEIN"], [127, 138, "PROTEIN"]]}
{"text": "Consistent with previous reports , 20mM NH4Cl and 100 nM bafilomycin A decreased entry of SARS-CoV S and VSV-G pseudovirions by over 99 % , compared to no treatment control .", "labels": [[105, 111, "ORGANISM"], [0, 16, "ENTITY"], [90, 99, "PROTEIN"], [35, 40, "SIMPLE_CHEMICAL"], [25, 33, "ENTITY"], [57, 69, "GGP"], [90, 99, "ENTITY"], [152, 165, "ENTITY"], [90, 99, "ORGANISM"]]}
{"text": "This in turn contributes to lung injury , as angiotensin-stimulated AT1R results in increased pulmonary vascular permeability , thereby mediating increased lung pathology ( Imai et al. , 2005 ; Kuba et al. , 2005 ) .", "labels": [[136, 146, "ENTITY"], [94, 113, "ENTITY"], [28, 40, "DISEASE"], [28, 40, "ENTITY"], [28, 33, "ORGAN"], [94, 104, "MULTI-TISSUE_STRUCTURE"], [146, 161, "ENTITY"], [84, 94, "ORGAN"]]}
{"text": "This may be accounted for by two complementary mechanisms : blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection , as well as upregulating ACE2 , thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1\u20137 .", "labels": [[134, 140, "ENTITY"], [191, 200, "GGP"], [163, 176, "GGP"], [163, 176, "GENE_OR_GENE_PRODUCT"], [83, 95, "ENTITY"], [47, 58, "ENTITY"], [263, 291, "ENTITY"], [163, 176, "PROTEIN"], [191, 200, "ENTITY"], [163, 176, "ENTITY"], [267, 291, "CHEMICAL"], [134, 140, "DISEASE"], [191, 200, "CHEMICAL"], [263, 291, "GENE_OR_GENE_PRODUCT"]]}
{"text": "This may be accounted for by two complementary mechanisms : blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection , as well as upregulating ACE2 , thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1\u20137 .", "labels": [[134, 140, "ENTITY"], [191, 200, "GGP"], [163, 176, "GGP"], [163, 176, "GENE_OR_GENE_PRODUCT"], [83, 95, "ENTITY"], [47, 58, "ENTITY"], [263, 291, "ENTITY"], [163, 176, "PROTEIN"], [191, 200, "ENTITY"], [163, 176, "ENTITY"], [267, 291, "CHEMICAL"], [134, 140, "DISEASE"], [191, 200, "CHEMICAL"], [263, 291, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the RAS cascade , ACE is responsible for the conversion of Angiotensin ( Ang ) I to Ang II , and Ang II is the vasoactive peptide principally responsible for systemic vasoconstriction and stimulation of aldosterone release ( Figure 1 ) [ 16 ]", "labels": [[7, 19, "ENTITY"], [84, 91, "ENTITY"], [62, 80, "GENE_OR_GENE_PRODUCT"], [206, 218, "ENTITY"], [110, 125, "CHEBI"], [7, 11, "GENE_OR_GENE_PRODUCT"], [84, 91, "CHEMICAL"], [110, 125, "ENTITY"], [218, 228, "ENTITY"], [84, 91, "GENE_OR_GENE_PRODUCT"], [157, 170, "ENTITY"]]}
{"text": "Ang II is an effective pulmonary vasoconstrictor .", "labels": [[23, 49, "ENTITY"], [0, 7, "GENE_OR_GENE_PRODUCT"], [33, 49, "CHEBI"], [0, 7, "ENTITY"], [0, 7, "CHEMICAL"], [0, 7, "PROTEIN"], [23, 33, "ORGAN"], [13, 23, "ENTITY"]]}
{"text": "ACE2 is a key counterregulatory enzyme that degrades angiotensin II to angiotensin-(1\u20137 ) , thereby attenuating its effects on vasoconstriction , sodium retention , and fibrosis . Although angiotensin II is the primary substrate of ACE2 , that enzyme also cleaves angiotensin I to angiotensin-(1\u20139 ) and participates in the hydrolysis of other peptides.16", "labels": [[256, 264, "ENTITY"], [53, 68, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [256, 264, "GENE_OR_GENE_PRODUCT"], [0, 5, "PROTEIN"], [207, 219, "ENTITY"], [14, 39, "ENTITY"], [53, 68, "ENTITY"], [14, 32, "GENE_OR_GENE_PRODUCT"], [219, 232, "ENTITY"], [44, 53, "ENTITY"], [53, 68, "CHEMICAL"], [0, 5, "GGP"], [219, 232, "PROTEIN"], [219, 232, "GGP"], [219, 232, "GENE_OR_GENE_PRODUCT"], [66, 71, "GENE_OR_GENE_PRODUCT"], [66, 71, "PROTEIN"], [32, 39, "SO"], [66, 71, "ENTITY"], [144, 153, "ENTITY"], [14, 39, "PROTEIN"], [53, 68, "GENE_OR_GENE_PRODUCT"], [256, 264, "PROTEIN"], [256, 264, "CHEMICAL"], [71, 88, "ENTITY"], [0, 5, "ENTITY"], [71, 88, "GENE_OR_GENE_PRODUCT"], [256, 264, "GGP"], [317, 324, "ENTITY"], [71, 88, "PROTEIN"], [53, 68, "GGP"]]}
{"text": "In the RAS cascade , ACE is responsible for the conversion of Angiotensin ( Ang ) I to Ang II , and Ang II is the vasoactive peptide principally responsible for systemic vasoconstriction and stimulation of aldosterone release ( Figure 1 ) [ 16 ]", "labels": [[7, 19, "ENTITY"], [84, 91, "ENTITY"], [62, 80, "GENE_OR_GENE_PRODUCT"], [206, 218, "ENTITY"], [110, 125, "CHEBI"], [7, 11, "GENE_OR_GENE_PRODUCT"], [84, 91, "CHEMICAL"], [110, 125, "ENTITY"], [218, 228, "ENTITY"], [84, 91, "GENE_OR_GENE_PRODUCT"], [157, 170, "ENTITY"]]}
{"text": "This could lead to toxic Ang II overaccumulation , and several pathologic sequelae such as ARDS or fulminant myocarditis may follow .", "labels": [[19, 25, "ENTITY"], [63, 74, "ENTITY"], [32, 49, "ENTITY"], [25, 32, "GENE_OR_GENE_PRODUCT"], [25, 32, "ENTITY"], [19, 25, "CHEBI"], [99, 109, "ENTITY"]]}
{"text": "Mechanistic evidence suggests two competing hypotheses : 1 ) RAS blockade decreases proinflammatory activity of Ang II , decreasing the risk of ARDS , myocarditis , or mortality in COVID-19 , or 2 ) RAS blockade increases ACE2 expression , promoting SARS-CoV-2 virulence in the lungs and heart that leads to ARDS , myocarditis , and death .", "labels": [[144, 151, "ENTITY"], [144, 151, "DISEASE"], [0, 12, "ENTITY"], [240, 261, "ENTITY"], [305, 315, "DISEASE"], [109, 116, "ENTITY"], [168, 181, "ENTITY"], [59, 65, "ENTITY"], [65, 74, "ENTITY"], [109, 116, "PROTEIN"], [151, 165, "ENTITY"], [305, 315, "ENTITY"], [109, 116, "GENE_OR_GENE_PRODUCT"], [74, 100, "ENTITY"], [278, 284, "ORGAN"], [44, 55, "ENTITY"], [240, 250, "SIMPLE_CHEMICAL"], [65, 74, "ENTITY"], [61, 65, "ENTITY"], [212, 227, "ENTITY"], [163, 168, "ENTITY"], [168, 181, "GENE_OR_GENE_PRODUCT"], [299, 305, "ENTITY"], [109, 116, "CHEMICAL"], [240, 250, "CHEMICAL"], [299, 305, "DISEASE"], [168, 195, "CELL_LINE"], [278, 284, "ENTITY"], [109, 116, "GGP"], [12, 21, "ENTITY"], [151, 165, "DISEASE"]]}
{"text": "Ang II can not only promote the growth response of vascular smooth muscle cells but also directly promote vascular remodeling and prevent pneumonia and shunts related to lung injury.13", "labels": [[32, 48, "ENTITY"], [170, 175, "ENTITY"], [0, 7, "GENE_OR_GENE_PRODUCT"], [60, 80, "CL"], [106, 126, "ENTITY"], [152, 159, "DISEASE"], [170, 175, "ORGAN"], [20, 28, "ENTITY"], [0, 7, "ENTITY"], [138, 148, "ENTITY"], [51, 80, "CELL_TYPE"], [152, 159, "ENTITY"], [51, 60, "MULTI-TISSUE_STRUCTURE"], [51, 80, "CELL"], [0, 7, "PROTEIN"], [138, 148, "DISEASE"], [51, 80, "ENTITY"]]}
{"text": "Ang II can not only promote the growth response of vascular smooth muscle cells but also directly promote vascular remodeling and prevent pneumonia and shunts related to lung injury.13", "labels": [[106, 126, "ENTITY"], [32, 48, "ENTITY"], [51, 80, "CELL"], [170, 175, "ENTITY"], [0, 7, "GENE_OR_GENE_PRODUCT"], [60, 80, "CL"], [170, 175, "ORGAN"], [152, 159, "DISEASE"], [0, 7, "ENTITY"], [138, 148, "ENTITY"], [51, 80, "ENTITY"], [152, 159, "ENTITY"], [51, 80, "CELL_TYPE"], [0, 7, "PROTEIN"], [138, 148, "DISEASE"], [51, 60, "MULTI-TISSUE_STRUCTURE"], [20, 28, "ENTITY"]]}
{"text": "Ang II can not only promote the growth response of vascular smooth muscle cells but also directly promote vascular remodeling and prevent pneumonia and shunts related to lung injury.13", "labels": [[32, 48, "ENTITY"], [51, 80, "CELL"], [170, 175, "ENTITY"], [0, 7, "GENE_OR_GENE_PRODUCT"], [60, 80, "CL"], [106, 126, "ENTITY"], [152, 159, "DISEASE"], [51, 60, "MULTI-TISSUE_STRUCTURE"], [138, 148, "DISEASE"], [170, 175, "ORGAN"], [0, 7, "ENTITY"], [51, 80, "ENTITY"], [152, 159, "ENTITY"], [51, 80, "CELL_TYPE"], [0, 7, "PROTEIN"], [138, 148, "ENTITY"], [20, 28, "ENTITY"]]}
{"text": "Ang II can not only promote the growth response of vascular smooth muscle cells but also directly promote vascular remodeling and prevent pneumonia and shunts related to lung injury.13", "labels": [[32, 48, "ENTITY"], [51, 80, "CELL"], [170, 175, "ENTITY"], [0, 7, "GENE_OR_GENE_PRODUCT"], [60, 80, "CL"], [106, 126, "ENTITY"], [152, 159, "DISEASE"], [51, 60, "MULTI-TISSUE_STRUCTURE"], [170, 175, "ORGAN"], [0, 7, "ENTITY"], [138, 148, "ENTITY"], [51, 80, "ENTITY"], [152, 159, "ENTITY"], [51, 80, "CELL_TYPE"], [0, 7, "PROTEIN"], [138, 148, "DISEASE"], [20, 28, "ENTITY"]]}
{"text": "In a small study , patients with Covid-19 appeared to have elevated levels of plasma angiotensin II , which were in turn correlated with total viral load and degree of lung injury.44", "labels": [[165, 173, "DISEASE"], [78, 97, "ENTITY"], [116, 121, "ENTITY"], [78, 97, "GENE_OR_GENE_PRODUCT"], [137, 149, "ENTITY"], [137, 143, "TAXON"], [85, 97, "CHEMICAL"], [5, 17, "ENTITY"], [78, 97, "GGP"], [78, 97, "PROTEIN"]]}
{"text": "However , Ang II can also promote the occurrence of pulmonary edema and impair lung function.14", "labels": [[52, 62, "CANCER"], [52, 62, "ENTITY"], [10, 14, "GGP"], [10, 14, "GENE_OR_GENE_PRODUCT"], [10, 14, "PROTEIN"], [10, 14, "ENTITY"], [79, 84, "ENTITY"], [79, 84, "MULTI-TISSUE_STRUCTURE"], [52, 62, "DISEASE"]]}
{"text": "However , Ang II can also promote the occurrence of pulmonary edema and impair lung function.14", "labels": [[10, 14, "GGP"], [10, 14, "GENE_OR_GENE_PRODUCT"], [52, 62, "ENTITY"], [10, 14, "PROTEIN"], [52, 62, "CANCER"], [10, 14, "ENTITY"], [52, 62, "DISEASE"], [79, 84, "ENTITY"], [79, 84, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "Recombinant human ACE2 ( rhACE2 ) protein treatment could reduce plasma Ang II levels and reduce acute lung injury in ACE2 KO mice and wild- type mice", "labels": [[90, 108, "DISEASE"], [12, 23, "GGP"], [18, 23, "ENTITY"], [123, 126, "TAXON"], [0, 12, "ENTITY"], [90, 108, "ENTITY"], [141, 146, "TAXON"], [97, 103, "ORGAN"], [65, 76, "ENTITY"], [34, 42, "ENTITY"], [58, 76, "PROTEIN"], [58, 65, "ENTITY"], [58, 76, "GGP"], [12, 18, "ENTITY"], [0, 34, "PROTEIN"], [76, 79, "ENTITY"], [141, 146, "ORGANISM"], [12, 23, "ORGANISM"], [58, 76, "ORGANISM_SUBSTANCE"], [123, 126, "ORGANISM"]]}
{"text": "Ang II promotes atherosclerosis in the cardiovascular system and promotes inflammation , oxidative stress , and migration of endothelial cells and vascular smooth muscle cells.24", "labels": [[143, 163, "ENTITY"], [74, 87, "ENTITY"], [122, 137, "CL"], [16, 32, "DISEASE"], [39, 61, "ENTITY"], [0, 7, "GENE_OR_GENE_PRODUCT"], [74, 87, "DISEASE"], [122, 137, "CELL"], [122, 137, "ENTITY"], [7, 16, "ENTITY"], [122, 137, "CELL_TYPE"], [143, 170, "CELL_TYPE"], [0, 7, "ENTITY"], [89, 99, "ENTITY"], [7, 16, "ENTITY"], [143, 170, "GENE_OR_GENE_PRODUCT"], [0, 7, "PROTEIN"], [16, 32, "ENTITY"]]}
{"text": "ACE2 has a protective effect on many diseases with reduced expression of ACE2 , such as hypertension , diabetes , and cardiovascular diseases , because it antagonizes the role of Ang II .", "labels": [[0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [0, 5, "ENTITY"], [0, 5, "ENTITY"], [51, 59, "ENTITY"], [0, 5, "PROTEIN"], [37, 46, "ENTITY"], [114, 133, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"], [114, 133, "ENTITY"], [11, 29, "ENTITY"], [0, 5, "PROTEIN"], [59, 70, "ENTITY"]]}
{"text": "Studies have shown that the protective mechanism of ACE2 against hypertension is most likely achieved by degradation of Ang II26 .", "labels": [[65, 78, "ENTITY"], [0, 8, "ENTITY"], [52, 57, "GENE_OR_GENE_PRODUCT"], [120, 129, "ENTITY"], [52, 57, "GGP"], [52, 57, "ENTITY"], [52, 57, "PROTEIN"], [120, 129, "GENE_OR_GENE_PRODUCT"], [28, 49, "ENTITY"], [120, 129, "PROTEIN"], [105, 117, "ENTITY"], [65, 78, "DISEASE"]]}
{"text": "ACE2 has a protective effect on many diseases with reduced expression of ACE2 , such as hypertension , diabetes , and cardiovascular diseases , because it antagonizes the role of Ang II .", "labels": [[0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [0, 5, "ENTITY"], [0, 5, "ENTITY"], [51, 59, "ENTITY"], [0, 5, "PROTEIN"], [37, 46, "ENTITY"], [114, 133, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"], [114, 133, "ENTITY"], [11, 29, "ENTITY"], [0, 5, "PROTEIN"], [59, 70, "ENTITY"]]}
{"text": "ACE2 has a protective effect on many diseases with reduced expression of ACE2 , such as hypertension , diabetes , and cardiovascular diseases , because it antagonizes the role of Ang II .", "labels": [[0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [0, 5, "ENTITY"], [0, 5, "ENTITY"], [51, 59, "ENTITY"], [0, 5, "PROTEIN"], [114, 133, "DISEASE"], [37, 46, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [114, 133, "ENTITY"], [11, 29, "ENTITY"], [0, 5, "PROTEIN"], [59, 70, "ENTITY"]]}
{"text": "ACE2 can also antagonize cardiac fibrosis and ventricular remodeling caused by the long-term effects of Ang II .", "labels": [[33, 42, "DISEASE"], [25, 33, "ORGAN"], [46, 58, "MULTI-TISSUE_STRUCTURE"], [0, 5, "GGP"], [104, 111, "GGP"], [0, 5, "ENTITY"], [104, 111, "GENE_OR_GENE_PRODUCT"], [104, 111, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [46, 69, "ENTITY"], [83, 93, "ENTITY"], [93, 101, "ENTITY"], [0, 5, "PROTEIN"], [14, 25, "ENTITY"], [25, 42, "ENTITY"], [104, 111, "ENTITY"]]}
{"text": "ACE2 can also antagonize cardiac fibrosis and ventricular remodeling caused by the long-term effects of Ang II .", "labels": [[33, 42, "DISEASE"], [46, 69, "ENTITY"], [25, 42, "ENTITY"], [46, 58, "MULTI-TISSUE_STRUCTURE"], [0, 5, "GGP"], [104, 111, "GGP"], [0, 5, "ENTITY"], [104, 111, "GENE_OR_GENE_PRODUCT"], [104, 111, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [83, 93, "ENTITY"], [93, 101, "ENTITY"], [25, 33, "ORGAN"], [14, 25, "ENTITY"], [0, 5, "PROTEIN"], [104, 111, "ENTITY"]]}
{"text": "ACE2 is a key counterregulatory enzyme that degrades angiotensin II to angiotensin-(1\u20137 ) , thereby attenuating its effects on vasoconstriction , sodium retention , and fibrosis . Although angiotensin II is the primary substrate of ACE2 , that enzyme also cleaves angiotensin I to angiotensin-(1\u20139 ) and participates in the hydrolysis of other peptides.16", "labels": [[256, 264, "ENTITY"], [53, 68, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [256, 264, "GENE_OR_GENE_PRODUCT"], [0, 5, "PROTEIN"], [207, 219, "ENTITY"], [14, 39, "ENTITY"], [53, 68, "ENTITY"], [14, 32, "GENE_OR_GENE_PRODUCT"], [219, 232, "ENTITY"], [44, 53, "ENTITY"], [53, 68, "CHEMICAL"], [0, 5, "GGP"], [219, 232, "PROTEIN"], [219, 232, "GGP"], [219, 232, "GENE_OR_GENE_PRODUCT"], [66, 71, "GENE_OR_GENE_PRODUCT"], [66, 71, "PROTEIN"], [32, 39, "SO"], [66, 71, "ENTITY"], [144, 153, "ENTITY"], [14, 39, "PROTEIN"], [53, 68, "GENE_OR_GENE_PRODUCT"], [256, 264, "PROTEIN"], [256, 264, "CHEMICAL"], [71, 88, "ENTITY"], [0, 5, "ENTITY"], [71, 88, "GENE_OR_GENE_PRODUCT"], [256, 264, "GGP"], [317, 324, "ENTITY"], [71, 88, "PROTEIN"], [53, 68, "GGP"]]}
{"text": "ACE2 is a key counterregulatory enzyme that degrades angiotensin II to angiotensin-(1\u20137 ) , thereby attenuating its effects on vasoconstriction , sodium retention , and fibrosis . Although angiotensin II is the primary substrate of ACE2 , that enzyme also cleaves angiotensin I to angiotensin-(1\u20139 ) and participates in the hydrolysis of other peptides.16", "labels": [[256, 264, "ENTITY"], [53, 68, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [256, 264, "GENE_OR_GENE_PRODUCT"], [0, 5, "PROTEIN"], [207, 219, "ENTITY"], [14, 39, "ENTITY"], [53, 68, "ENTITY"], [14, 32, "GENE_OR_GENE_PRODUCT"], [219, 232, "ENTITY"], [44, 53, "ENTITY"], [53, 68, "CHEMICAL"], [0, 5, "GGP"], [219, 232, "PROTEIN"], [219, 232, "GGP"], [219, 232, "GENE_OR_GENE_PRODUCT"], [66, 71, "GENE_OR_GENE_PRODUCT"], [66, 71, "PROTEIN"], [32, 39, "SO"], [66, 71, "ENTITY"], [144, 153, "ENTITY"], [14, 39, "PROTEIN"], [53, 68, "GENE_OR_GENE_PRODUCT"], [256, 264, "PROTEIN"], [256, 264, "CHEMICAL"], [71, 88, "ENTITY"], [0, 5, "ENTITY"], [71, 88, "GENE_OR_GENE_PRODUCT"], [256, 264, "GGP"], [317, 324, "ENTITY"], [71, 88, "PROTEIN"], [53, 68, "GGP"]]}
{"text": "ACE2 has a well-recognized role in myocardial recovery and injury response ; in one study , ACE2 knockout in animal models contributed to adverse left ventricular remodeling in response to acute injury driven by angiotensin II.55", "labels": [[35, 46, "ENTITY"], [106, 116, "ENTITY"], [0, 5, "ENTITY"], [0, 5, "GGP"], [0, 5, "ENTITY"], [59, 66, "ENTITY"], [186, 195, "DISEASE"], [135, 163, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [209, 224, "TISSUE"], [138, 151, "MULTI-TISSUE_STRUCTURE"], [35, 46, "MULTI-TISSUE_STRUCTURE"], [46, 55, "ENTITY"], [0, 5, "PROTEIN"], [66, 75, "ENTITY"], [186, 195, "ENTITY"]]}
{"text": "A recent hypothesis suggested that angiotensin receptor 1 ( AT1R ) inhibitors might be beneficial for patients infected by COVID-19 who experience pneumonia ( Sun , Yang , Sun , & Su , 2020 ) .", "labels": [[35, 47, "CHEMICAL"], [35, 58, "ENTITY"], [35, 58, "GGP"], [9, 20, "ENTITY"], [102, 111, "ENTITY"], [136, 147, "ENTITY"], [35, 58, "GENE_OR_GENE_PRODUCT"], [35, 58, "PROTEIN"], [136, 147, "DISEASE"]]}
{"text": "Therefore , higher ACE2 expression following chronically medicating SARS-CoV-2 infected patients with AT1R blockers , while seemingly paradoxical , may protect them against acute lung injury rather than putting them at higher risk to develop SARS .", "labels": [[234, 242, "ENTITY"], [234, 242, "DISEASE"], [124, 134, "ENTITY"], [102, 107, "GGP"], [165, 184, "DISEASE"], [102, 107, "ENTITY"], [12, 19, "ENTITY"], [45, 57, "ENTITY"], [173, 179, "ORGAN"], [102, 107, "GENE_OR_GENE_PRODUCT"], [165, 184, "ENTITY"]]}
{"text": "Patients taking ACEIs or ARBs chronically for cardiovascular diseases are assumed to have increased numbers of ACE2 receptors throughout their cardiopulmonary circulations as observed in experimental animal models .", "labels": [[111, 126, "PROTEIN"], [90, 100, "ENTITY"], [143, 172, "MULTI-TISSUE_STRUCTURE"], [30, 42, "ENTITY"], [0, 9, "ORGANISM"], [16, 22, "CHEMICAL"], [25, 30, "SIMPLE_CHEMICAL"], [16, 22, "ENTITY"], [46, 70, "DISEASE"], [46, 61, "ORGAN"], [111, 116, "GENE_OR_GENE_PRODUCT"], [200, 207, "TAXON"], [187, 200, "ENTITY"], [111, 116, "GGP"], [0, 9, "ENTITY"], [25, 30, "CHEMICAL"], [25, 30, "ENTITY"], [46, 70, "ENTITY"], [143, 172, "ENTITY"], [16, 22, "SIMPLE_CHEMICAL"], [111, 126, "ENTITY"], [100, 108, "ENTITY"], [200, 214, "ENTITY"]]}
{"text": "Since patients treated with ACEIs and ARBS will have increased numbers of ACE2 receptors in their lungs for coronavirus S proteins to bind to , they may be at increased risk of severe disease outcomes due to SARS-CoV-2 infections .", "labels": [[6, 15, "ENTITY"], [53, 63, "ENTITY"], [74, 89, "PROTEIN"], [74, 79, "GGP"], [98, 104, "ENTITY"], [6, 15, "ORGANISM"], [38, 43, "CHEMICAL"], [208, 219, "DISEASE"], [122, 131, "CHEBI"], [134, 139, "ENTITY"], [28, 34, "CHEMICAL"], [15, 28, "ENTITY"], [208, 219, "ENTITY"], [38, 43, "ENTITY"], [74, 89, "ENTITY"], [108, 131, "ENTITY"], [38, 43, "SIMPLE_CHEMICAL"], [28, 34, "SIMPLE_CHEMICAL"], [98, 104, "ORGAN"], [28, 34, "ENTITY"], [74, 79, "GENE_OR_GENE_PRODUCT"], [108, 131, "PROTEIN"], [108, 131, "ORGANISM"], [184, 192, "ENTITY"], [38, 43, "PROTEIN"]]}
{"text": "If the latter percentage would be found to be significantly smaller , this would support the notion that AT1R antagonists confer protection from severe symptoms among SARS-CoV-2 infected individuals .", "labels": [[105, 110, "ENTITY"], [14, 25, "ENTITY"]]}
{"text": "Angiotensin-converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) are highly recommended medications for patients with cardiovascular diseases , such as refractory hypertension , coronary artery disease , heart failure , and post-myocardial infarction status . 1 , 2", "labels": [[0, 41, "ENTITY"], [51, 76, "GGP"], [192, 223, "ENTITY"], [162, 170, "ORGAN"], [239, 269, "DISEASE"], [23, 41, "SO"], [173, 192, "ENTITY"], [51, 76, "ENTITY"], [239, 269, "ENTITY"], [105, 117, "ENTITY"], [223, 239, "DISEASE"], [142, 162, "ENTITY"], [192, 216, "MULTI-TISSUE_STRUCTURE"], [223, 239, "ENTITY"], [181, 192, "DISEASE"], [0, 41, "GENE_OR_GENE_PRODUCT"], [51, 76, "PROTEIN"], [192, 223, "DISEASE"], [142, 162, "DISEASE"], [239, 253, "MULTI-TISSUE_STRUCTURE"], [51, 76, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Angiotensin-converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) are highly recommended medications for patients with cardiovascular diseases , such as refractory hypertension , coronary artery disease , heart failure , and post-myocardial infarction status . 1 , 2", "labels": [[0, 41, "ENTITY"], [51, 76, "GGP"], [192, 223, "ENTITY"], [162, 170, "ORGAN"], [239, 269, "DISEASE"], [23, 41, "SO"], [192, 216, "MULTI-TISSUE_STRUCTURE"], [173, 192, "ENTITY"], [51, 76, "ENTITY"], [239, 269, "ENTITY"], [105, 117, "ENTITY"], [223, 239, "DISEASE"], [142, 162, "ENTITY"], [223, 239, "ENTITY"], [181, 192, "DISEASE"], [192, 223, "DISEASE"], [0, 41, "GENE_OR_GENE_PRODUCT"], [51, 76, "PROTEIN"], [142, 162, "DISEASE"], [239, 253, "MULTI-TISSUE_STRUCTURE"], [51, 76, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Angiotensin-converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) are highly recommended medications for patients with cardiovascular diseases , such as refractory hypertension , coronary artery disease , heart failure , and post-myocardial infarction status . 1 , 2", "labels": [[0, 41, "ENTITY"], [51, 76, "GGP"], [192, 223, "ENTITY"], [162, 170, "ORGAN"], [239, 269, "DISEASE"], [23, 41, "SO"], [192, 216, "MULTI-TISSUE_STRUCTURE"], [173, 192, "ENTITY"], [51, 76, "ENTITY"], [239, 269, "ENTITY"], [105, 117, "ENTITY"], [223, 239, "DISEASE"], [142, 162, "ENTITY"], [223, 239, "ENTITY"], [181, 192, "DISEASE"], [192, 223, "DISEASE"], [0, 41, "GENE_OR_GENE_PRODUCT"], [51, 76, "PROTEIN"], [142, 162, "DISEASE"], [239, 253, "MULTI-TISSUE_STRUCTURE"], [51, 76, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Angiotensin-converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) are highly recommended medications for patients with cardiovascular diseases , such as refractory hypertension , coronary artery disease , heart failure , and post-myocardial infarction status . 1 , 2", "labels": [[0, 41, "ENTITY"], [51, 76, "GGP"], [192, 223, "ENTITY"], [162, 170, "ORGAN"], [239, 269, "DISEASE"], [23, 41, "SO"], [192, 216, "MULTI-TISSUE_STRUCTURE"], [173, 192, "ENTITY"], [51, 76, "ENTITY"], [239, 269, "ENTITY"], [105, 117, "ENTITY"], [223, 239, "DISEASE"], [142, 162, "ENTITY"], [223, 239, "ENTITY"], [181, 192, "DISEASE"], [192, 223, "DISEASE"], [0, 41, "GENE_OR_GENE_PRODUCT"], [51, 76, "PROTEIN"], [142, 162, "DISEASE"], [239, 253, "MULTI-TISSUE_STRUCTURE"], [51, 76, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Intravenous infusions of ACEIs and ARBs in experimental animals increase the numbers of angiotensin converting enzyme 2 ( ACE2 ) receptors in the cardiopulmonary circulation . 4", "labels": [[88, 100, "CHEMICAL"], [35, 40, "ENTITY"], [88, 120, "GGP"], [25, 31, "CHEMICAL"], [25, 31, "ENTITY"], [142, 162, "ENTITY"], [25, 31, "SIMPLE_CHEMICAL"], [43, 64, "ENTITY"], [88, 120, "GENE_OR_GENE_PRODUCT"], [88, 120, "ENTITY"], [35, 40, "CHEMICAL"], [64, 73, "ENTITY"], [0, 12, "IMMATERIAL_ANATOMICAL_ENTITY"], [35, 40, "SIMPLE_CHEMICAL"], [0, 12, "ENTITY"], [56, 64, "TAXON"], [88, 129, "PROTEIN"], [12, 22, "ENTITY"]]}
{"text": "The generation of Ang II by ACE is pharmacologically inhibited by angiotensin converting enzyme inhibitors ( ACEi ) , and angiotensin receptor blockers ( ARBs ) function by blocking the downstream interaction of Ang II with the AT1 receptor [ 16 ] .", "labels": [[18, 25, "GGP"], [18, 25, "GENE_OR_GENE_PRODUCT"], [118, 143, "ENTITY"], [143, 154, "CHEMICAL"], [118, 143, "GGP"], [4, 15, "ENTITY"], [197, 212, "GGP"], [118, 143, "GENE_OR_GENE_PRODUCT"], [66, 78, "CHEMICAL"], [118, 143, "PROTEIN"], [28, 32, "GENE_OR_GENE_PRODUCT"], [186, 197, "ENTITY"], [66, 107, "GGP"], [197, 212, "ENTITY"], [28, 32, "ENTITY"], [143, 154, "ENTITY"], [28, 32, "GGP"], [18, 25, "PROTEIN"], [18, 25, "ENTITY"], [161, 173, "ENTITY"], [197, 212, "GENE_OR_GENE_PRODUCT"], [143, 154, "SIMPLE_CHEMICAL"], [224, 232, "GGP"], [35, 53, "ENTITY"], [66, 107, "PROTEIN"], [66, 107, "ENTITY"], [197, 212, "CHEMICAL"], [224, 232, "GENE_OR_GENE_PRODUCT"], [28, 32, "CHEMICAL"], [224, 232, "PROTEIN"], [224, 232, "ENTITY"], [197, 212, "PROTEIN"], [53, 63, "ENTITY"], [66, 109, "GENE_OR_GENE_PRODUCT"]]}
{"text": "It was found that the kinase domain but not the RNase activity of IRE1 was required , and treatment of a JNK inhibitor ( SP600125 ) abolished autophagosome formation after ER stress ( Ogata et al.,2006 ) .", "labels": [[132, 142, "CELLULAR_COMPONENT"], [66, 71, "ENTITY"], [132, 142, "ENTITY"], [48, 54, "GENE_OR_GENE_PRODUCT"], [66, 71, "GGP"], [22, 36, "ENTITY"], [66, 71, "PROTEIN"], [132, 142, "GO"], [142, 156, "ENTITY"], [105, 109, "ENTITY"], [48, 63, "ENTITY"], [22, 36, "PROTEIN"], [166, 175, "ENTITY"], [66, 71, "GENE_OR_GENE_PRODUCT"], [29, 36, "SO"], [48, 54, "PROTEIN"]]}
{"text": "It was found that the kinase domain but not the RNase activity of IRE1 was required , and treatment of a JNK inhibitor ( SP600125 ) abolished autophagosome formation after ER stress ( Ogata et al.,2006 ) .", "labels": [[132, 142, "CELLULAR_COMPONENT"], [66, 71, "ENTITY"], [132, 142, "ENTITY"], [48, 54, "GENE_OR_GENE_PRODUCT"], [66, 71, "GGP"], [22, 36, "ENTITY"], [66, 71, "PROTEIN"], [132, 142, "GO"], [142, 156, "ENTITY"], [105, 109, "ENTITY"], [48, 63, "ENTITY"], [22, 36, "PROTEIN"], [166, 175, "ENTITY"], [66, 71, "GENE_OR_GENE_PRODUCT"], [29, 36, "SO"], [48, 54, "PROTEIN"]]}
{"text": "Consistent with previous reports , 20mM NH4Cl and 100 nM bafilomycin A decreased entry of SARS-CoV S and VSV-G pseudovirions by over 99 % , compared to no treatment control .", "labels": [[105, 111, "ORGANISM"], [0, 16, "ENTITY"], [90, 99, "PROTEIN"], [35, 40, "SIMPLE_CHEMICAL"], [25, 33, "ENTITY"], [90, 99, "ENTITY"], [152, 165, "ENTITY"], [57, 69, "GGP"], [90, 99, "ORGANISM"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Among them , the well-known chemical probe , Bafilomycin A1 , is a potent inhibitor of the V1-ATPase , subunits of which interact with Nsp6 and M. Bafilomycin \u2019s inhibition of this cotransporter acts to prevent the acidification of the lysosome , inhibiting autophagy and endosome trafficking pathways , which may impact the viral life-cycle .", "labels": [[247, 258, "ENTITY"], [43, 57, "GENE_OR_GENE_PRODUCT"], [43, 57, "ENTITY"], [43, 57, "GGP"], [272, 293, "ENTITY"], [140, 147, "ENTITY"], [91, 103, "PROTEIN"], [45, 57, "PROTEIN"], [67, 74, "CHEBI"], [147, 162, "ENTITY"], [91, 103, "ENTITY"], [258, 272, "CELLULAR_COMPONENT"], [304, 314, "ENTITY"], [314, 331, "ENTITY"], [28, 37, "ENTITY"], [140, 147, "GENE_OR_GENE_PRODUCT"], [236, 247, "ENTITY"], [144, 147, "CHEMICAL"], [314, 321, "TAXON"], [28, 37, "CHEBI"], [258, 272, "GO"], [258, 272, "ENTITY"], [67, 74, "ENTITY"]]}
{"text": "Among them , the well-known chemical probe , Bafilomycin A1 , is a potent inhibitor of the V1-ATPase , subunits of which interact with Nsp6 and M. Bafilomycin \u2019s inhibition of this cotransporter acts to prevent the acidification of the lysosome , inhibiting autophagy and endosome trafficking pathways , which may impact the viral life-cycle .", "labels": [[247, 258, "ENTITY"], [43, 57, "GENE_OR_GENE_PRODUCT"], [43, 57, "ENTITY"], [43, 57, "GGP"], [272, 293, "ENTITY"], [140, 147, "ENTITY"], [91, 103, "PROTEIN"], [45, 57, "PROTEIN"], [67, 74, "CHEBI"], [147, 162, "ENTITY"], [91, 103, "ENTITY"], [258, 272, "CELLULAR_COMPONENT"], [304, 314, "ENTITY"], [314, 331, "ENTITY"], [28, 37, "ENTITY"], [140, 147, "GENE_OR_GENE_PRODUCT"], [144, 147, "CHEMICAL"], [236, 247, "ENTITY"], [314, 321, "TAXON"], [28, 37, "CHEBI"], [258, 272, "GO"], [258, 272, "ENTITY"], [67, 74, "ENTITY"]]}
{"text": "Among them , the well-known chemical probe , Bafilomycin A1 , is a potent inhibitor of the V1-ATPase , subunits of which interact with Nsp6 and M. Bafilomycin \u2019s inhibition of this cotransporter acts to prevent the acidification of the lysosome , inhibiting autophagy and endosome trafficking pathways , which may impact the viral life-cycle .", "labels": [[247, 258, "ENTITY"], [43, 57, "GENE_OR_GENE_PRODUCT"], [43, 57, "ENTITY"], [43, 57, "GGP"], [272, 293, "ENTITY"], [140, 147, "ENTITY"], [91, 103, "PROTEIN"], [45, 57, "PROTEIN"], [67, 74, "CHEBI"], [147, 162, "ENTITY"], [91, 103, "ENTITY"], [304, 314, "ENTITY"], [258, 272, "ENTITY"], [314, 331, "ENTITY"], [28, 37, "ENTITY"], [140, 147, "GENE_OR_GENE_PRODUCT"], [258, 272, "CELLULAR_COMPONENT"], [144, 147, "CHEMICAL"], [258, 272, "GO"], [236, 247, "ENTITY"], [314, 321, "TAXON"], [28, 37, "CHEBI"], [67, 74, "ENTITY"]]}
{"text": "Among them , the well-known chemical probe , Bafilomycin A1 , is a potent inhibitor of the V1-ATPase , subunits of which interact with Nsp6 and M. Bafilomycin \u2019s inhibition of this cotransporter acts to prevent the acidification of the lysosome , inhibiting autophagy and endosome trafficking pathways , which may impact the viral life-cycle .", "labels": [[247, 258, "ENTITY"], [43, 57, "GENE_OR_GENE_PRODUCT"], [43, 57, "ENTITY"], [43, 57, "GGP"], [272, 293, "ENTITY"], [140, 147, "ENTITY"], [91, 103, "PROTEIN"], [45, 57, "PROTEIN"], [67, 74, "CHEBI"], [147, 162, "ENTITY"], [91, 103, "ENTITY"], [258, 272, "CELLULAR_COMPONENT"], [304, 314, "ENTITY"], [314, 331, "ENTITY"], [28, 37, "ENTITY"], [140, 147, "GENE_OR_GENE_PRODUCT"], [144, 147, "CHEMICAL"], [236, 247, "ENTITY"], [314, 321, "TAXON"], [28, 37, "CHEBI"], [258, 272, "GO"], [258, 272, "ENTITY"], [67, 74, "ENTITY"]]}
{"text": "In our opinion , during the COVID-19 pandemic , it would be more prudent to replace these drugs , when possible , with calcium channel blockers , adrenergic receptor blockers , diuretics or vasodilators .", "labels": [[114, 135, "ENTITY"], [135, 166, "ENTITY"], [135, 146, "SIMPLE_CHEMICAL"], [135, 146, "ENTITY"], [7, 15, "ENTITY"], [177, 190, "CHEBI"], [114, 127, "CHEBI"], [28, 37, "ENTITY"], [177, 190, "ENTITY"], [135, 166, "GENE_OR_GENE_PRODUCT"], [135, 157, "CHEBI"], [135, 146, "CHEBI"], [114, 135, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The serine protease inhibitor camostat mesylate , approved in Japan to treat unrelated diseases , has been shown to block TMPRSS2 activity [ 28 , 29 ] and is thus an interesting candidate .", "labels": [[4, 11, "CHEBI"], [11, 30, "CHEBI"], [4, 20, "ENTITY"], [30, 48, "SIMPLE_CHEMICAL"], [116, 122, "ENTITY"], [116, 122, "GENE_OR_GENE_PRODUCT"], [116, 122, "PROTEIN"], [4, 20, "GENE_OR_GENE_PRODUCT"], [30, 48, "CHEMICAL"], [116, 122, "GGP"], [30, 48, "ENTITY"], [122, 130, "ENTITY"]]}
{"text": "Actual bicarbonate and total carbon dioxide concentration were markedly lower in deceased patients than in recovered patients .", "labels": [[81, 90, "ENTITY"], [44, 58, "ENTITY"], [0, 7, "ENTITY"], [107, 117, "ENTITY"], [7, 19, "CHEBI"], [90, 99, "ORGANISM"], [90, 99, "ORGANISM"], [90, 99, "ENTITY"], [72, 78, "ENTITY"], [29, 44, "CHEBI"], [9, 16, "ENTITY"], [7, 19, "CHEMICAL"], [7, 19, "ENTITY"], [29, 44, "CHEMICAL"], [7, 19, "SIMPLE_CHEMICAL"], [90, 99, "ENTITY"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "If bacterial infection is suspected according to the patient \u2019s clinical and imaging findings , patients of mild type can take oral antibiotics for community-acquired pneumonia , such as second- generation cephalosporins or fluoroquinolones .", "labels": [[127, 132, "CHEBI"], [26, 36, "ENTITY"], [53, 61, "ENTITY"], [105, 113, "ENTITY"], [144, 167, "ENTITY"], [3, 23, "DISEASE"], [195, 206, "CHEBI"], [144, 167, "DISEASE"], [195, 206, "CHEMICAL"], [3, 23, "ENTITY"], [53, 61, "ORGANISM"], [3, 13, "TAXON"], [187, 206, "ENTITY"]]}
{"text": "Although the nature of the clear jelly has yet to be determined , hyaluronan ( HA ) is associated with ARDS [ 12 ] ; moreover , during SARS infection , the production and regulation of hyaluronan is defective .", "labels": [[128, 140, "ENTITY"], [128, 140, "DISEASE"], [84, 98, "ENTITY"], [171, 185, "ENTITY"], [171, 185, "GENE_OR_GENE_PRODUCT"], [33, 39, "ENTITY"], [156, 171, "ENTITY"], [171, 185, "CHEMICAL"], [171, 185, "GGP"], [171, 185, "PROTEIN"], [185, 199, "ENTITY"], [140, 156, "ENTITY"]]}
{"text": "The human purine biosynthesis enzyme Inosine-5\u2032-monophosphate dehydrogenase ( IMPDH2 ) interacts with the viral protein nsp14 . Several chemically diverse compounds inhibit IMPDH2 , including the clinically approved mycophenolic acid ( 20 nM ) , the approved antiviral drug ribavirin ( 200 nM ) , and the investigational new drug Merimepodib ( 10 nM ) ( Table 1a ) .", "labels": [[207, 229, "CHEBI"], [207, 229, "ENTITY"], [4, 76, "PROTEIN"], [102, 120, "PROTEIN"], [30, 37, "SO"], [37, 62, "CHEMICAL"], [259, 274, "CHEMICAL"], [165, 173, "PROTEIN"], [295, 305, "ENTITY"], [10, 17, "CHEMICAL"], [102, 112, "TAXON"], [10, 30, "ENTITY"], [4, 17, "TAXON"], [147, 155, "ENTITY"], [165, 173, "GENE_OR_GENE_PRODUCT"], [4, 10, "ENTITY"], [250, 274, "ENTITY"], [128, 147, "ENTITY"], [30, 76, "ENTITY"], [165, 173, "GGP"], [147, 155, "CHEBI"], [37, 76, "GENE_OR_GENE_PRODUCT"], [102, 120, "ENTITY"], [155, 165, "ENTITY"], [165, 173, "ENTITY"], [4, 17, "ORGANISM"], [259, 274, "SIMPLE_CHEMICAL"], [207, 229, "SIMPLE_CHEMICAL"], [207, 229, "CHEMICAL"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "We expressed 9b-GFP in the presence of either an IFN-\u03b2 or a NF-\u03baB reporter construct and simulated an intracellular viral infection by cotransfecting Poly(I : C ) . As expected Poly(I : C ) induced both reporter constructs , but the presence of ORF-9b significantly inhibited this response ( Fig. 3A ) .", "labels": [[157, 163, "ENTITY"], [102, 116, "IMMATERIAL_ANATOMICAL_ENTITY"], [27, 36, "ENTITY"], [60, 85, "DNA"], [49, 55, "ENTITY"], [102, 122, "GO"], [27, 36, "ENTITY"], [60, 66, "CHEMICAL"], [13, 20, "GENE_OR_GENE_PRODUCT"], [252, 266, "ENTITY"], [168, 177, "GENE_OR_GENE_PRODUCT"], [49, 55, "GENE_OR_GENE_PRODUCT"], [27, 36, "SIMPLE_CHEMICAL"], [27, 36, "PROTEIN"], [116, 132, "ENTITY"], [150, 157, "GENE_OR_GENE_PRODUCT"], [266, 281, "ENTITY"], [116, 132, "DISEASE"], [168, 177, "CHEMICAL"], [60, 85, "ENTITY"], [102, 116, "ENTITY"], [60, 66, "GENE_OR_GENE_PRODUCT"], [66, 75, "SO"], [190, 212, "ENTITY"], [135, 150, "ENTITY"], [190, 212, "DNA"], [75, 85, "SO"], [3, 13, "ENTITY"], [150, 157, "CHEMICAL"]]}
{"text": "We expressed 9b-GFP in the presence of either an IFN-\u03b2 or a NF-\u03baB reporter construct and simulated an intracellular viral infection by cotransfecting Poly(I : C ) . As expected Poly(I : C ) induced both reporter constructs , but the presence of ORF-9b significantly inhibited this response ( Fig. 3A ) .", "labels": [[157, 163, "ENTITY"], [102, 116, "IMMATERIAL_ANATOMICAL_ENTITY"], [27, 36, "ENTITY"], [60, 85, "DNA"], [49, 55, "ENTITY"], [102, 122, "GO"], [27, 36, "ENTITY"], [60, 66, "CHEMICAL"], [13, 20, "GENE_OR_GENE_PRODUCT"], [252, 266, "ENTITY"], [168, 177, "GENE_OR_GENE_PRODUCT"], [49, 55, "GENE_OR_GENE_PRODUCT"], [27, 36, "SIMPLE_CHEMICAL"], [27, 36, "PROTEIN"], [116, 132, "ENTITY"], [150, 157, "GENE_OR_GENE_PRODUCT"], [266, 281, "ENTITY"], [116, 132, "DISEASE"], [168, 177, "CHEMICAL"], [60, 85, "ENTITY"], [102, 116, "ENTITY"], [60, 66, "GENE_OR_GENE_PRODUCT"], [66, 75, "SO"], [190, 212, "ENTITY"], [135, 150, "ENTITY"], [190, 212, "DNA"], [75, 85, "SO"], [3, 13, "ENTITY"], [150, 157, "CHEMICAL"]]}
{"text": "In agreement with a previous result ( Ichinohe et al. , 2010 ) , we found that IL-1\u03b2 secretion caused by influenza virus was completely blocked when the extracellular K + concentration was increased to 130 mM ( Figure 5A ) .", "labels": [[102, 115, "ENTITY"], [105, 115, "TAXON"], [79, 85, "ENTITY"], [125, 136, "ENTITY"], [167, 171, "ENTITY"], [149, 167, "GO"], [206, 211, "ENTITY"], [149, 167, "ENTITY"], [3, 13, "ENTITY"]]}
{"text": "The inhibitory effect of the K + -rich medium was also observed when cells were stimulated with lentiviruses expressing the SARS-CoV E or 3a proteins ( Figure 5B ) .", "labels": [[96, 109, "ENTITY"], [69, 75, "ENTITY"], [29, 39, "ENTITY"], [80, 91, "ENTITY"], [152, 159, "ENTITY"], [29, 33, "SIMPLE_CHEMICAL"], [69, 75, "CELL"], [124, 138, "ORGANISM"], [138, 150, "ENTITY"], [4, 15, "ENTITY"], [96, 109, "ORGANISM"], [69, 75, "CL"], [124, 150, "PROTEIN"], [39, 46, "ENTITY"], [124, 135, "ENTITY"], [109, 120, "ENTITY"], [141, 150, "CHEBI"], [29, 33, "CHEBI"], [15, 22, "ENTITY"]]}
{"text": "The inhibitory effect of the K + -rich medium was also observed when cells were stimulated with lentiviruses expressing the SARS-CoV E or 3a proteins ( Figure 5B ) .", "labels": [[96, 109, "ENTITY"], [69, 75, "ENTITY"], [29, 39, "ENTITY"], [80, 91, "ENTITY"], [152, 159, "ENTITY"], [29, 33, "SIMPLE_CHEMICAL"], [69, 75, "CELL"], [124, 138, "ORGANISM"], [138, 150, "ENTITY"], [4, 15, "ENTITY"], [96, 109, "ORGANISM"], [69, 75, "CL"], [124, 150, "PROTEIN"], [39, 46, "ENTITY"], [124, 135, "ENTITY"], [109, 120, "ENTITY"], [141, 150, "CHEBI"], [29, 33, "CHEBI"], [15, 22, "ENTITY"]]}
{"text": "Chloroquine was shown to inhibit quinone reductase 2 [ 56 ] , a structural neighbour of UDP-N-acetylglucosamine 2-epimerases [ 57 ] that are involved in the biosynthesis of sialic acids . The sialic acids are acidic monosaccharides found at the extremity of sugar chains present on cell transmembrane proteins and are critical components of ligand recognition . The possible interference of chloroquine with sialic acid biosynthesis could account for the broad antiviral spectrum of that drug since viruses such as the human coronavirus HCoV-O43 and the orthomyxoviruses use sialic acid moieties as receptors [ 58 ] .", "labels": [[0, 12, "CHEBI"], [271, 301, "GO"], [245, 264, "ENTITY"], [587, 599, "ENTITY"], [199, 216, "CHEBI"], [157, 180, "CHEMICAL"], [546, 554, "ENTITY"], [391, 408, "CHEBI"], [245, 264, "PROTEIN"], [512, 525, "ORGANISM"], [375, 391, "SIMPLE_CHEMICAL"], [391, 420, "ENTITY"], [554, 587, "PROTEIN"], [391, 408, "CHEMICAL"], [554, 575, "CHEMICAL"], [271, 301, "PROTEIN"], [245, 258, "SIMPLE_CHEMICAL"], [512, 537, "PROTEIN"], [519, 525, "ENTITY"], [519, 537, "CHEMICAL"], [157, 180, "ENTITY"], [62, 75, "ENTITY"], [375, 391, "ENTITY"], [391, 408, "SIMPLE_CHEMICAL"], [186, 199, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [238, 245, "PATHOLOGICAL_FORMATION"], [33, 53, "ENTITY"], [85, 112, "GENE_OR_GENE_PRODUCT"], [157, 180, "SIMPLE_CHEMICAL"], [209, 216, "SIMPLE_CHEMICAL"], [554, 587, "SIMPLE_CHEMICAL"], [0, 12, "CHEMICAL"], [157, 180, "CHEBI"], [186, 199, "ENTITY"], [327, 348, "ENTITY"], [33, 53, "PROTEIN"], [271, 301, "ENTITY"], [455, 471, "ENTITY"], [186, 199, "CHEBI"], [85, 112, "ENTITY"], [271, 287, "CELLULAR_COMPONENT"], [199, 216, "ENTITY"], [375, 391, "CHEBI"], [554, 587, "ENTITY"], [33, 53, "GENE_OR_GENE_PRODUCT"], [33, 41, "CHEMICAL"], [25, 33, "ENTITY"], [375, 391, "CHEMICAL"], [238, 245, "ENTITY"], [554, 575, "CHEBI"], [186, 199, "SIMPLE_CHEMICAL"], [33, 53, "GGP"], [0, 12, "ENTITY"], [525, 537, "ENTITY"], [546, 554, "TAXON"]]}
{"text": "Several potential drug candidates , including lopinavir/ritonavir ( Kaletra R ) , nucleoside analogues , neuraminidase inhibitors , remdesivir , umifenovir ( Arbidol R ) , DNA synthesis inhibitors ( such as tenofovir disoproxil and lamivudine ) , chloroquine and Chinese traditional medicines ( such as ShuFeng JieDu or Lianhua Qing- wen capsules ) , have been proposed [ 36 , 37 ] .", "labels": [[8, 18, "ENTITY"], [232, 245, "CHEMICAL"], [217, 232, "SIMPLE_CHEMICAL"], [199, 207, "ENTITY"], [217, 232, "ENTITY"], [145, 158, "CHEMICAL"], [247, 271, "ENTITY"], [93, 119, "ENTITY"], [93, 105, "GENE_OR_GENE_PRODUCT"], [119, 132, "ENTITY"], [232, 245, "SIMPLE_CHEMICAL"], [158, 166, "SO"], [283, 303, "PROTEIN"], [232, 245, "ENTITY"], [176, 186, "CHEBI"], [145, 158, "ENTITY"], [197, 217, "ENTITY"], [66, 76, "SIMPLE_CHEMICAL"], [283, 295, "CHEMICAL"], [66, 76, "ENTITY"], [303, 328, "ENTITY"], [176, 186, "ENTITY"], [158, 176, "ENTITY"], [93, 119, "CHEBI"], [197, 217, "CHEMICAL"], [158, 166, "CELLULAR_COMPONENT"], [232, 245, "CHEBI"], [283, 295, "TAXON"], [217, 232, "CHEMICAL"], [18, 34, "ENTITY"], [132, 145, "ENTITY"], [283, 303, "ORGANISM"], [197, 217, "SIMPLE_CHEMICAL"], [283, 295, "ENTITY"], [78, 93, "ENTITY"], [18, 23, "CHEBI"], [66, 76, "CHEMICAL"]]}
{"text": "Several potential drug candidates , including lopinavir/ritonavir ( Kaletra R ) , nucleoside analogues , neuraminidase inhibitors , remdesivir , umifenovir ( Arbidol R ) , DNA synthesis inhibitors ( such as tenofovir disoproxil and lamivudine ) , chloroquine and Chinese traditional medicines ( such as ShuFeng JieDu or Lianhua Qing- wen capsules ) , have been proposed [ 36 , 37 ] .", "labels": [[8, 18, "ENTITY"], [232, 245, "CHEMICAL"], [217, 232, "SIMPLE_CHEMICAL"], [199, 207, "ENTITY"], [217, 232, "ENTITY"], [145, 158, "CHEMICAL"], [247, 271, "ENTITY"], [93, 119, "ENTITY"], [93, 105, "GENE_OR_GENE_PRODUCT"], [119, 132, "ENTITY"], [232, 245, "SIMPLE_CHEMICAL"], [158, 166, "SO"], [283, 303, "PROTEIN"], [232, 245, "ENTITY"], [176, 186, "CHEBI"], [145, 158, "ENTITY"], [197, 217, "ENTITY"], [66, 76, "SIMPLE_CHEMICAL"], [283, 295, "CHEMICAL"], [66, 76, "ENTITY"], [303, 328, "ENTITY"], [176, 186, "ENTITY"], [158, 176, "ENTITY"], [93, 119, "CHEBI"], [197, 217, "CHEMICAL"], [158, 166, "CELLULAR_COMPONENT"], [232, 245, "CHEBI"], [283, 295, "TAXON"], [217, 232, "CHEMICAL"], [18, 34, "ENTITY"], [132, 145, "ENTITY"], [283, 303, "ORGANISM"], [197, 217, "SIMPLE_CHEMICAL"], [283, 295, "ENTITY"], [78, 93, "ENTITY"], [18, 23, "CHEBI"], [66, 76, "CHEMICAL"]]}
{"text": "Thyroid stimulating hormone and free triiodothyronine concentrations were significantly lower in deceased patients ( 0.7 mIU/mL and 2.8 pmol/L ) than in recovered patients ( 1.4 mIU/mL and 4.3 pmol/L ) .", "labels": [[37, 54, "ENTITY"], [20, 28, "ENTITY"], [106, 115, "ORGANISM"], [0, 28, "GENE_OR_GENE_PRODUCT"], [153, 163, "ORGANISM"], [37, 54, "SIMPLE_CHEMICAL"], [54, 69, "ENTITY"], [153, 163, "ENTITY"], [97, 106, "ENTITY"], [37, 54, "CHEBI"], [37, 54, "CHEMICAL"], [0, 20, "ENTITY"], [106, 115, "ENTITY"], [20, 28, "CHEBI"], [32, 37, "ENTITY"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "Other commonly measured blood measures that may lead to altered ACE2 expression also included red cell distribution width ( often associated with iron-deficiency , folate or B12 deficiency anemia ) , basophil percentage ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) , calcium level , urate level , HDL-cholesterol and LDL cholesterol ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) .", "labels": [[-1, 14, "ENTITY"], [277, 293, "CHEMICAL"], [64, 69, "GGP"], [247, 255, "CHEBI"], [-1, 13, "CHEMICAL"], [247, 255, "SIMPLE_CHEMICAL"], [15, 24, "ENTITY"], [247, 255, "ENTITY"], [263, 269, "CHEBI"], [247, 255, "CHEMICAL"], [94, 103, "CELL"], [209, 222, "ENTITY"], [64, 69, "PROTEIN"], [-1, 13, "SIMPLE_CHEMICAL"], [171, 189, "ENTITY"], [263, 269, "CHEMICAL"], [-1, 13, "ENTITY"], [24, 30, "ORGANISM_SUBSTANCE"], [200, 209, "ENTITY"], [277, 293, "SIMPLE_CHEMICAL"], [94, 122, "ENTITY"], [-1, 14, "ENTITY"], [24, 39, "ENTITY"], [64, 69, "GENE_OR_GENE_PRODUCT"], [94, 103, "CL"], [277, 293, "ENTITY"], [171, 189, "CHEMICAL"], [-1, 13, "CHEBI"], [263, 269, "SIMPLE_CHEMICAL"], [-1, 12, "ENTITY"], [64, 69, "ENTITY"], [69, 80, "ENTITY"], [255, 263, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "In our opinion , during the COVID-19 pandemic , it would be more prudent to replace these drugs , when possible , with calcium channel blockers , adrenergic receptor blockers , diuretics or vasodilators .", "labels": [[135, 166, "ENTITY"], [7, 15, "ENTITY"], [177, 190, "CHEBI"], [114, 135, "ENTITY"], [114, 127, "CHEBI"], [28, 37, "ENTITY"], [177, 190, "ENTITY"], [135, 146, "ENTITY"], [135, 166, "GENE_OR_GENE_PRODUCT"], [114, 135, "GENE_OR_GENE_PRODUCT"], [135, 157, "CHEBI"], [135, 146, "SIMPLE_CHEMICAL"], [135, 146, "CHEBI"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "The existence of significantly increased fibrin-degraded products and reduced platelets in severe COVID-19 patients is consistent with the presence of hyper-fibrinolysis .", "labels": [[41, 57, "CHEMICAL"], [139, 148, "ENTITY"], [31, 41, "ENTITY"], [78, 88, "CELL_TYPE"], [91, 98, "ENTITY"], [98, 107, "ENTITY"], [151, 170, "CHEMICAL"], [57, 66, "SO"], [70, 78, "ENTITY"], [4, 14, "ENTITY"], [98, 107, "DISEASE"], [107, 116, "ENTITY"], [41, 66, "ENTITY"], [78, 88, "CELL"], [78, 88, "CL"], [41, 66, "PROTEIN"], [98, 116, "ORGANISM"], [151, 170, "ENTITY"], [78, 88, "ENTITY"], [119, 135, "ENTITY"]]}
{"text": "This opinion is supported by the presence of hemorrhage in multiple organs and a positive correlation between fibrinolysis and mortality .", "labels": [[90, 102, "ENTITY"], [127, 137, "ENTITY"], [45, 56, "DISEASE"], [110, 123, "ENTITY"], [68, 75, "ORGAN"], [5, 13, "ENTITY"], [45, 56, "ENTITY"], [81, 90, "ENTITY"], [59, 75, "ENTITY"], [33, 42, "ENTITY"]]}
{"text": "Plasmin , a key player in fibrinolysis , enhances the virulence and pathogenicity of viruses containing a furin site in their envelope proteins , as is the case with the SARS-CoV-2 .", "labels": [[104, 112, "ENTITY"], [104, 112, "DNA"], [104, 112, "GGP"], [0, 8, "ENTITY"], [0, 8, "PROTEIN"], [120, 135, "GO"], [120, 135, "PROTEIN"], [0, 8, "GENE_OR_GENE_PRODUCT"], [0, 8, "GGP"], [120, 135, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Niclosamide is an FDA-approved anthelminthic drug that has been widely used in humans to treat tapeworm infections for several decades and is currently listed on the World Health Organization \u2019s list of essential medicines.1", "labels": [[0, 12, "CHEBI"], [0, 12, "SIMPLE_CHEMICAL"], [31, 50, "ENTITY"], [166, 192, "ENTITY"], [79, 86, "TAXON"], [89, 95, "ENTITY"], [18, 31, "ENTITY"], [0, 12, "ENTITY"], [0, 12, "CHEMICAL"], [79, 86, "ORGANISM"], [45, 50, "CHEBI"], [95, 115, "DISEASE"], [127, 135, "ENTITY"], [95, 115, "ENTITY"], [79, 86, "ENTITY"]]}
{"text": "Niclosamide exerts its anticestodal effect by inhibiting oxidative phosphorylation and stimulating adenosine triphosphatase activity in the mitochondria.1", "labels": [[0, 12, "CHEBI"], [87, 99, "ENTITY"], [124, 133, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [99, 109, "CHEMICAL"], [99, 124, "CHEBI"], [0, 12, "ENTITY"], [99, 124, "ENTITY"], [0, 12, "CHEMICAL"], [99, 124, "SIMPLE_CHEMICAL"], [57, 83, "ENTITY"], [46, 57, "ENTITY"], [23, 36, "ENTITY"]]}
{"text": "Niclosamide exerts its anticestodal effect by inhibiting oxidative phosphorylation and stimulating adenosine triphosphatase activity in the mitochondria.1", "labels": [[0, 12, "CHEBI"], [87, 99, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [99, 109, "CHEMICAL"], [99, 124, "CHEBI"], [57, 83, "ENTITY"], [0, 12, "ENTITY"], [99, 124, "ENTITY"], [0, 12, "CHEMICAL"], [99, 124, "SIMPLE_CHEMICAL"], [46, 57, "ENTITY"], [23, 36, "ENTITY"], [124, 133, "ENTITY"]]}
{"text": "Wu et al. found that niclosamide was able to inhibit SARS-CoV replication and totally abolished viral antigen synthesis at a concentration of 1.56 \u03bcM after screening a small marketed drug library .", "labels": [[21, 33, "SIMPLE_CHEMICAL"], [21, 33, "ENTITY"], [53, 62, "ENTITY"], [110, 120, "ENTITY"], [45, 53, "ENTITY"], [96, 110, "ENTITY"], [21, 33, "CHEMICAL"], [62, 74, "ENTITY"], [183, 196, "ENTITY"], [125, 139, "ENTITY"], [53, 62, "GGP"], [96, 102, "TAXON"], [21, 33, "CHEBI"], [156, 166, "ENTITY"], [183, 188, "CHEBI"], [53, 62, "ORGANISM"]]}
{"text": "Niclosamide suppressed the cytopathic effect ( CPE ) of SARS-CoV at a concentration of as low as 1 \u03bcM and inhibited SARS-CoV replication with an EC50 value of less than 0.1 \u03bcM in Vero E6 cells .", "labels": [[0, 12, "CHEBI"], [12, 23, "ENTITY"], [184, 187, "CL"], [106, 116, "ENTITY"], [176, 187, "CELL_LINE"], [56, 65, "ENTITY"], [106, 116, "ORGANISM"], [0, 12, "SIMPLE_CHEMICAL"], [27, 45, "ENTITY"], [0, 12, "ENTITY"], [176, 187, "ENTITY"], [0, 12, "CHEMICAL"], [176, 187, "CELL"], [106, 116, "GGP"]]}
{"text": "Niclosamide was reported to inhibit MERS-CoV replication by up to 1000-fold at 48 h p.i . at a concentration of 10 \u03bcM , while it enhanced the BENC1 level and ATG14 oligomerization , increased the number of autolysosomes by > 2-fold , and affected the autophagic flux in the MERS-CoV-infected cells.3", "labels": [[45, 57, "ENTITY"], [0, 12, "CHEBI"], [274, 292, "SIMPLE_CHEMICAL"], [158, 164, "ENTITY"], [142, 148, "ENTITY"], [28, 36, "ENTITY"], [36, 45, "GGP"], [0, 12, "SIMPLE_CHEMICAL"], [270, 292, "DNA"], [36, 45, "PROTEIN"], [0, 12, "ENTITY"], [247, 262, "ENTITY"], [0, 12, "CHEMICAL"], [36, 45, "ENTITY"], [270, 292, "ENTITY"]]}
{"text": "Niclosamide was reported to inhibit MERS-CoV replication by up to 1000-fold at 48 h p.i . at a concentration of 10 \u03bcM , while it enhanced the BENC1 level and ATG14 oligomerization , increased the number of autolysosomes by > 2-fold , and affected the autophagic flux in the MERS-CoV-infected cells.3", "labels": [[45, 57, "ENTITY"], [0, 12, "CHEBI"], [274, 292, "SIMPLE_CHEMICAL"], [158, 164, "ENTITY"], [36, 45, "GGP"], [270, 292, "ENTITY"], [28, 36, "ENTITY"], [36, 45, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [270, 292, "DNA"], [0, 12, "ENTITY"], [247, 262, "ENTITY"], [0, 12, "CHEMICAL"], [36, 45, "PROTEIN"], [142, 148, "ENTITY"]]}
{"text": "Niclosamide was reported to inhibit MERS-CoV replication by up to 1000-fold at 48 h p.i . at a concentration of 10 \u03bcM , while it enhanced the BENC1 level and ATG14 oligomerization , increased the number of autolysosomes by > 2-fold , and affected the autophagic flux in the MERS-CoV-infected cells.3", "labels": [[45, 57, "ENTITY"], [0, 12, "CHEBI"], [274, 292, "SIMPLE_CHEMICAL"], [142, 148, "ENTITY"], [36, 45, "GGP"], [28, 36, "ENTITY"], [36, 45, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [270, 292, "DNA"], [0, 12, "ENTITY"], [247, 262, "ENTITY"], [0, 12, "CHEMICAL"], [36, 45, "PROTEIN"], [270, 292, "ENTITY"], [158, 164, "ENTITY"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [706, 717, "CHEMICAL"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "SIMPLE_CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [706, 717, "ENTITY"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "Among them , tryptanthrin at 40 \u03bcM exhibited the strongest antiviral activity with a significant reduction in HCoV\u2010NL63\u2010induced CPE in LLC\u2010MK2 cells 36 and 48 h post\u2010infection ( Figure 3A ) .", "labels": [[135, 143, "ENTITY"], [135, 143, "CELL"], [110, 128, "CELL"], [59, 69, "ENTITY"], [176, 185, "ENTITY"], [135, 143, "CELL_TYPE"]]}
{"text": "In the CPE reduction assay , tryptanthrin at 0.4 , 4 , and 40 \u03bcM significantly reduced virus\u2010induced CPE in LLCMK2 cells at 37 \u00b0 C 48 h post\u2010infection , whereas the same effect was noted only for 40 \u03bcM indigodole B ( Figure 4B \u2013 C ) .", "labels": [[131, 136, "ENTITY"], [202, 217, "GENE_OR_GENE_PRODUCT"], [59, 65, "CHEMICAL"], [59, 65, "ENTITY"], [105, 115, "GGP"], [105, 115, "CELL_TYPE"], [105, 115, "ENTITY"], [7, 11, "ENTITY"], [87, 101, "ENTITY"], [202, 217, "ENTITY"], [202, 217, "CHEMICAL"], [105, 115, "CELL"]]}
{"text": "Moreover , the plaque assay revealed that tryptanthrin and indigodole B exerted a potent inhibitory effect on the in vitro progeny production of HCoV\u2010NL63 ( Figure 4D \u2013 E ) , wherein IC50 values for virus yield were 1.52 \u03bcM and 2.60 \u03bcM for tryptanthrin and indigole B , respectively ( Table 1 ) .", "labels": [[59, 70, "ENTITY"], [183, 188, "ENTITY"], [59, 70, "CHEMICAL"], [233, 240, "ENTITY"], [42, 59, "CHEMICAL"], [188, 205, "ENTITY"], [42, 59, "ENTITY"], [164, 167, "ENTITY"], [188, 199, "TAXON"], [233, 240, "CHEMICAL"], [155, 167, "GENE_OR_GENE_PRODUCT"], [233, 240, "SIMPLE_CHEMICAL"], [155, 164, "ENTITY"], [233, 240, "CHEBI"]]}
{"text": "Immunofluorescent staining indicated that tryptanthrin significantly reduced the percentage of HCoV\u2010NL63\u2010positive cells ( Figure 5A , middle and bottom ) , markedly reducing the HCoV\u2010NL63 infectivity with an IC50 value of 0.30 \u03bcM in human lung epithelial Calu\u20103 cells ( Figure 5B , Table 1 ) .", "labels": [[95, 120, "CELL_LINE"], [81, 92, "ENTITY"], [95, 120, "ENTITY"], [233, 262, "ENTITY"], [156, 165, "ENTITY"], [114, 122, "GENE_OR_GENE_PRODUCT"], [42, 55, "ENTITY"], [122, 129, "ENTITY"], [174, 188, "ENTITY"], [255, 262, "CL"], [42, 55, "CHEMICAL"], [42, 55, "CHEBI"], [230, 262, "ORGANISM"], [230, 262, "CELL_TYPE"], [114, 120, "CL"], [0, 27, "ENTITY"], [42, 55, "SIMPLE_CHEMICAL"], [69, 77, "ENTITY"], [95, 120, "CELL"], [122, 129, "GENE_OR_GENE_PRODUCT"], [114, 122, "ENTITY"]]}
{"text": "In addition , tryptanthrin exhibited a higher inhibitory activity against the production of extracellular virions in the late stage ( IC50 = 0.05 \u03bcM ) than in the early stage ( IC50 = 6.99 \u03bcM ) ( Figure 7A , B , Table 1 ) .", "labels": [[126, 134, "ENTITY"], [92, 106, "CELLULAR_COMPONENT"], [189, 196, "ENTITY"], [46, 57, "ENTITY"], [189, 196, "GENE_OR_GENE_PRODUCT"], [196, 210, "GENE_OR_GENE_PRODUCT"], [121, 126, "ENTITY"], [159, 169, "ENTITY"]]}
{"text": "ELISA assay showed less PLpro-induced TGF-?1 production by SB203580 ( 1.5-fold ) and U0126 ( 3.3-fold ) ( Fig. 7A and B ) .", "labels": [[38, 45, "CHEMICAL"], [59, 68, "SIMPLE_CHEMICAL"], [0, 12, "ENTITY"], [24, 45, "ENTITY"], [38, 45, "PROTEIN"], [59, 68, "ENTITY"], [59, 68, "CHEMICAL"], [45, 56, "ENTITY"]]}
{"text": "ELISA assay showed less PLpro-induced TGF-?1 production by SB203580 ( 1.5-fold ) and U0126 ( 3.3-fold ) ( Fig. 7A and B ) .", "labels": [[38, 45, "CHEMICAL"], [59, 68, "SIMPLE_CHEMICAL"], [0, 12, "ENTITY"], [24, 45, "ENTITY"], [38, 45, "PROTEIN"], [59, 68, "ENTITY"], [59, 68, "CHEMICAL"], [45, 56, "ENTITY"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [451, 464, "SIMPLE_CHEMICAL"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [590, 602, "CHEBI"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [451, 464, "ENTITY"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [590, 602, "CHEMICAL"], [530, 543, "CHEMICAL"], [545, 556, "ENTITY"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [590, 602, "ENTITY"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [451, 464, "CHEMICAL"], [12, 21, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "At the time , we put forward pseudoephedrine , andrographolide , chloroquine , abacavir , baricitinib , and quercetin as repurposing candidates from our list , because there were other researches also suggesting or predicting these drugs , mainly based on our Yaozh database search and literature review .", "labels": [[108, 133, "ENTITY"], [7, 12, "ENTITY"], [21, 29, "SO"], [65, 79, "SIMPLE_CHEMICAL"], [45, 51, "CHEMICAL"], [79, 90, "GENE_OR_GENE_PRODUCT"], [201, 215, "ENTITY"], [45, 51, "ENTITY"], [275, 286, "ENTITY"], [253, 266, "ENTITY"], [45, 51, "CHEBI"], [45, 51, "SIMPLE_CHEMICAL"], [79, 90, "CHEMICAL"], [65, 79, "CHEMICAL"], [65, 79, "ENTITY"], [79, 90, "ENTITY"]]}
{"text": "Full inhibition was attained when camostat mesylate and E-64d , an inhibitor of CatB/L , were added ( Figure 4A ; Figure S3B ) , indicating that SARS-2-S can use both CatB/L as well as TMPRSS2 for priming in these cell lines .", "labels": [[56, 62, "ENTITY"], [100, 109, "ENTITY"], [5, 16, "ENTITY"], [208, 219, "CELL_LINE"], [34, 52, "CHEMICAL"], [56, 62, "SIMPLE_CHEMICAL"], [109, 121, "GENE_OR_GENE_PRODUCT"], [208, 219, "ENTITY"], [177, 185, "ENTITY"], [177, 185, "GGP"], [177, 185, "GENE_OR_GENE_PRODUCT"], [109, 121, "ENTITY"], [185, 197, "ENTITY"], [177, 185, "PROTEIN"], [34, 52, "SIMPLE_CHEMICAL"], [208, 219, "CELL"], [56, 62, "GGP"], [34, 52, "ENTITY"]]}
{"text": "Full inhibition was attained when camostat mesylate and E-64d , an inhibitor of CatB/L , were added ( Figure 4A ; Figure S3B ) , indicating that SARS-2-S can use both CatB/L as well as TMPRSS2 for priming in these cell lines .", "labels": [[56, 62, "ENTITY"], [100, 109, "ENTITY"], [5, 16, "ENTITY"], [208, 219, "CELL_LINE"], [34, 52, "CHEMICAL"], [56, 62, "SIMPLE_CHEMICAL"], [109, 121, "GENE_OR_GENE_PRODUCT"], [208, 219, "ENTITY"], [177, 185, "ENTITY"], [177, 185, "GGP"], [177, 185, "GENE_OR_GENE_PRODUCT"], [109, 121, "ENTITY"], [185, 197, "ENTITY"], [177, 185, "PROTEIN"], [34, 52, "SIMPLE_CHEMICAL"], [208, 219, "CELL"], [56, 62, "GGP"], [34, 52, "ENTITY"]]}
{"text": "The antimalarial , antiinflammatory drugs , amodiaquin and the chloroquines were selectively active .", "labels": [[4, 17, "ENTITY"], [19, 36, "ENTITY"], [81, 93, "ENTITY"]]}
{"text": "At the time , we put forward pseudoephedrine , andrographolide , chloroquine , abacavir , baricitinib , and quercetin as repurposing candidates from our list , because there were other researches also suggesting or predicting these drugs , mainly based on our Yaozh database search and literature review .", "labels": [[108, 133, "ENTITY"], [7, 12, "ENTITY"], [21, 29, "SO"], [65, 79, "SIMPLE_CHEMICAL"], [45, 51, "CHEMICAL"], [79, 90, "GENE_OR_GENE_PRODUCT"], [79, 90, "ENTITY"], [45, 51, "ENTITY"], [201, 215, "ENTITY"], [275, 286, "ENTITY"], [253, 266, "ENTITY"], [79, 90, "CHEMICAL"], [45, 51, "CHEBI"], [45, 51, "SIMPLE_CHEMICAL"], [65, 79, "CHEMICAL"], [65, 79, "ENTITY"]]}
{"text": "Based on these results , we performed virtual docking to screen for commercial medicines in the DrugBank database that could bind to the above mentioned pocket site of 2019-nCoV Mpro , and identified 10 candidate clinical medicines ( Table 1 ; Figs. 1B and S3 ) .", "labels": [[15, 23, "ENTITY"], [96, 105, "ENTITY"], [153, 160, "ENTITY"], [38, 46, "ENTITY"], [68, 79, "ENTITY"], [203, 222, "ENTITY"], [153, 160, "SO"], [168, 178, "ENTITY"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [451, 464, "CHEMICAL"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "Moreover , we observed that infections by SARS-CoV-2 triggered the expected increase in the IL-6 levels in the culture supernatant , which ranged from 20- to 60-fold depending on the cell donor ( Figure 7C , open circles in nil-treated cells ) . The virus-induced enhancement of IL-6 levels were significantly prevented by treatment with ATV at 10 \u00b5M , ATV/RTV at both 1 and 10 \u00b5M and CQ at 10 \u00b5M ( Figure 7C ) .", "labels": [[244, 264, "ENTITY"], [179, 188, "ENTITY"], [203, 213, "ENTITY"], [348, 351, "ENTITY"], [224, 236, "CL"], [194, 203, "ENTITY"], [348, 351, "SIMPLE_CHEMICAL"], [345, 353, "CHEMICAL"], [264, 276, "PROTEIN"], [348, 351, "CHEMICAL"], [310, 323, "ENTITY"], [221, 236, "CELL_LINE"], [224, 236, "CELL"], [264, 276, "GENE_OR_GENE_PRODUCT"], [264, 276, "GGP"], [221, 236, "ENTITY"], [345, 353, "ENTITY"], [111, 119, "ENTITY"], [92, 97, "ENTITY"], [264, 276, "ENTITY"], [345, 353, "SIMPLE_CHEMICAL"], [391, 399, "ENTITY"], [345, 353, "PROTEIN"]]}
{"text": "One hundred and five ( 93 % ) deceased patients and 144 ( 89 % ) who recovered received empirical antibacterial therapy ( moxifloxacin , cefoperazone , or azithromycin ) .", "labels": [[112, 122, "SIMPLE_CHEMICAL"], [63, 69, "ENTITY"], [137, 155, "CHEBI"], [122, 137, "ENTITY"], [112, 122, "CHEMICAL"], [122, 137, "SIMPLE_CHEMICAL"], [88, 112, "ENTITY"], [79, 88, "ENTITY"], [122, 137, "CHEBI"], [137, 155, "ENTITY"], [30, 39, "ORGANISM"], [122, 137, "CHEMICAL"], [137, 155, "CHEMICAL"], [30, 39, "ENTITY"], [112, 122, "ENTITY"], [137, 155, "SIMPLE_CHEMICAL"]]}
{"text": "Based on these results , we performed virtual docking to screen for commercial medicines in the DrugBank database that could bind to the above mentioned pocket site of 2019-nCoV Mpro , and identified 10 candidate clinical medicines ( Table 1 ; Figs. 1B and S3 ) .", "labels": [[15, 23, "ENTITY"], [96, 105, "ENTITY"], [153, 160, "ENTITY"], [38, 46, "ENTITY"], [68, 79, "ENTITY"], [203, 222, "ENTITY"], [153, 160, "SO"], [168, 178, "ENTITY"]]}
{"text": "It is important to mention that various studies have shown that in animal models with bleomycin-induced lung injury , vitamin B3 ( niacin or nicotinamide ) is highly effective in preventing lung tissue damage [ 7 ] .", "labels": [[118, 126, "ENTITY"], [104, 109, "ORGAN"], [118, 126, "CHEBI"], [67, 81, "ENTITY"], [86, 116, "ENTITY"], [86, 116, "DISEASE"], [159, 166, "ENTITY"], [179, 202, "DISEASE"], [40, 48, "ENTITY"], [179, 202, "ENTITY"], [67, 74, "TAXON"], [118, 126, "SIMPLE_CHEMICAL"], [179, 195, "TISSUE"], [118, 126, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation , caffeine , and antibiotics .", "labels": [[137, 147, "ENTITY"], [152, 176, "ENTITY"], [66, 72, "MULTI-TISSUE_STRUCTURE"], [66, 91, "ENTITY"], [9, 39, "DISEASE"], [9, 39, "ENTITY"], [126, 131, "ENTITY"], [43, 53, "ENTITY"], [0, 9, "ENTITY"], [43, 53, "DISEASE"], [116, 120, "ENTITY"], [94, 104, "ENTITY"]]}
{"text": "Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation , caffeine , and antibiotics .", "labels": [[137, 147, "ENTITY"], [152, 176, "ENTITY"], [66, 72, "MULTI-TISSUE_STRUCTURE"], [66, 91, "ENTITY"], [9, 39, "DISEASE"], [43, 53, "DISEASE"], [126, 131, "ENTITY"], [0, 9, "ENTITY"], [116, 120, "ENTITY"], [9, 39, "ENTITY"], [43, 53, "ENTITY"], [94, 104, "ENTITY"]]}
{"text": "For clinical isolates of HCoV-HKU1 ( similar to HCoV-OC43 ) , entry was inhibited only by camostat and EST tended to increase entry ( Fig. 2 g and h ) .", "labels": [[25, 35, "ORGANISM"], [117, 126, "ENTITY"], [4, 22, "ENTITY"], [25, 35, "ENTITY"], [126, 134, "SIMPLE_CHEMICAL"]]}
{"text": "Indeed , the clinically proven serine protease inhibitor camostat mesylate , which is active against TMPRSS2 ( Kawase et al. , 2012 ) , partially blocked SARS-2-S-driven entry into Caco-2 ( Figure S3 B ) and Vero-TMPRSS2 cells ( Figure 4A ) .", "labels": [[181, 190, "ENTITY"], [57, 66, "SIMPLE_CHEMICAL"], [38, 47, "CHEBI"], [31, 38, "GENE_OR_GENE_PRODUCT"], [57, 66, "CHEMICAL"], [221, 229, "ENTITY"], [200, 208, "CELL"], [176, 208, "CELL_LINE"], [146, 170, "ENTITY"], [57, 66, "ENTITY"], [146, 154, "GENE_OR_GENE_PRODUCT"], [221, 229, "GENE_OR_GENE_PRODUCT"], [200, 208, "ENTITY"], [136, 146, "ENTITY"], [31, 38, "ENTITY"]]}
{"text": "Full inhibition was attained when camostat mesylate and E-64d , an inhibitor of CatB/L , were added ( Figure 4A ; Figure S3B ) , indicating that SARS-2-S can use both CatB/L as well as TMPRSS2 for priming in these cell lines .", "labels": [[208, 219, "CELL"], [100, 109, "ENTITY"], [5, 16, "ENTITY"], [208, 219, "CELL_LINE"], [34, 52, "CHEMICAL"], [109, 121, "GENE_OR_GENE_PRODUCT"], [177, 185, "ENTITY"], [56, 62, "SIMPLE_CHEMICAL"], [177, 185, "GGP"], [177, 185, "GENE_OR_GENE_PRODUCT"], [109, 121, "ENTITY"], [56, 62, "ENTITY"], [185, 197, "ENTITY"], [177, 185, "PROTEIN"], [34, 52, "SIMPLE_CHEMICAL"], [34, 52, "ENTITY"], [56, 62, "GGP"], [208, 219, "ENTITY"]]}
{"text": "Full inhibition was attained when camostat mesylate and E-64d , an inhibitor of CatB/L , were added ( Figure 4A ; Figure S3B ) , indicating that SARS-2-S can use both CatB/L as well as TMPRSS2 for priming in these cell lines .", "labels": [[208, 219, "CELL"], [100, 109, "ENTITY"], [5, 16, "ENTITY"], [208, 219, "CELL_LINE"], [34, 52, "CHEMICAL"], [109, 121, "GENE_OR_GENE_PRODUCT"], [177, 185, "ENTITY"], [56, 62, "SIMPLE_CHEMICAL"], [177, 185, "GGP"], [177, 185, "GENE_OR_GENE_PRODUCT"], [109, 121, "ENTITY"], [56, 62, "ENTITY"], [185, 197, "ENTITY"], [177, 185, "PROTEIN"], [34, 52, "SIMPLE_CHEMICAL"], [34, 52, "ENTITY"], [56, 62, "GGP"], [208, 219, "ENTITY"]]}
{"text": "Indeed , camostat mesylate significantly reduced MERS-S- , SARS-S- , and SARS-2-S- but not VSV-G-driven entry into the lung cell line Calu-3 ( Figure 4C ) and exerted no unwanted cytotoxic effects ( Figure S3 C ) .", "labels": [[91, 104, "ENTITY"], [115, 134, "ENTITY"], [115, 134, "CELL"], [170, 189, "ENTITY"], [189, 199, "ENTITY"], [115, 134, "CELL_LINE"], [134, 143, "ENTITY"], [9, 18, "CHEMICAL"], [170, 179, "CHEBI"], [115, 124, "CL"]]}
{"text": "Finally , camostat mesylate treatment inhibited SARS-S- and SARS-2-S- but not VSV-G-driven entry into primary human lung cells ( Figure 4E ) .", "labels": [[10, 19, "CHEMICAL"], [127, 136, "ENTITY"], [10, 19, "SIMPLE_CHEMICAL"], [110, 121, "ORGANISM"], [116, 121, "ENTITY"], [127, 136, "GENE_OR_GENE_PRODUCT"], [102, 121, "CELL_TYPE"]]}
{"text": "Similarly , camostat mesylate treatment significantly reduced Calu-3 infection with authentic SARS-CoV-2 ( Figure 4D ) .", "labels": [[105, 114, "ENTITY"], [62, 69, "ENTITY"], [12, 21, "SIMPLE_CHEMICAL"], [94, 105, "ENTITY"], [12, 21, "CHEMICAL"], [84, 94, "SO"]]}
{"text": "Collectively , SARS-CoV-2 can use TMPRSS2 for S protein priming and camostat mesylate , an inhibitor of TMPRSS2 , blocks SARS-CoV-2 infection of lung cells .", "labels": [[46, 56, "ENTITY"], [114, 121, "SIMPLE_CHEMICAL"], [68, 77, "ENTITY"], [142, 150, "ENTITY"], [68, 77, "CHEMICAL"], [114, 132, "DISEASE"], [114, 132, "ENTITY"], [142, 150, "CELL"], [68, 77, "SIMPLE_CHEMICAL"], [142, 150, "CELL_TYPE"], [142, 150, "CL"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "however , with exposure to captopril monotherapy over a period of 6 months , angiotensin-(1\u20137 ) levels increased.36", "labels": [[15, 24, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [406, 420, "CHEMICAL"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [406, 420, "ENTITY"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "Based on these results , we performed virtual docking to screen for commercial medicines in the DrugBank database that could bind to the above mentioned pocket site of 2019-nCoV Mpro , and identified 10 candidate clinical medicines ( Table 1 ; Figs. 1B and S3 ) .", "labels": [[15, 23, "ENTITY"], [96, 105, "ENTITY"], [153, 160, "ENTITY"], [38, 46, "ENTITY"], [68, 79, "ENTITY"], [203, 222, "ENTITY"], [153, 160, "SO"], [168, 178, "ENTITY"]]}
{"text": "One hundred and five ( 93 % ) deceased patients and 144 ( 89 % ) who recovered received empirical antibacterial therapy ( moxifloxacin , cefoperazone , or azithromycin ) .", "labels": [[112, 122, "SIMPLE_CHEMICAL"], [63, 69, "ENTITY"], [137, 155, "ENTITY"], [137, 155, "CHEMICAL"], [122, 137, "ENTITY"], [112, 122, "CHEMICAL"], [122, 137, "SIMPLE_CHEMICAL"], [88, 112, "ENTITY"], [79, 88, "ENTITY"], [137, 155, "CHEBI"], [122, 137, "CHEBI"], [137, 155, "SIMPLE_CHEMICAL"], [30, 39, "ORGANISM"], [122, 137, "CHEMICAL"], [30, 39, "ENTITY"], [112, 122, "ENTITY"]]}
{"text": "If bacterial infection is suspected according to the patient \u2019s clinical and imaging findings , patients of mild type can take oral antibiotics for community-acquired pneumonia , such as second- generation cephalosporins or fluoroquinolones .", "labels": [[127, 132, "CHEBI"], [26, 36, "ENTITY"], [53, 61, "ENTITY"], [105, 113, "ENTITY"], [144, 167, "ENTITY"], [3, 23, "DISEASE"], [195, 206, "CHEBI"], [144, 167, "DISEASE"], [195, 206, "CHEMICAL"], [3, 23, "ENTITY"], [53, 61, "ORGANISM"], [3, 13, "TAXON"], [187, 206, "ENTITY"]]}
{"text": "All the severe and moderate cases were given empirical antimicrobial treatment ( moxifloxacin and/or cephalosporin , etc . ) .", "labels": [[8, 15, "ENTITY"], [55, 79, "ENTITY"], [28, 34, "ENTITY"], [19, 28, "ENTITY"], [45, 55, "ENTITY"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [665, 676, "GENE_OR_GENE_PRODUCT"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "The antimalarial , antiinflammatory drugs , amodiaquin and the chloroquines were selectively active .", "labels": [[4, 17, "ENTITY"], [19, 36, "ENTITY"], [81, 93, "ENTITY"]]}
{"text": "The study demonstrated that chloroquine was highly effective in reducing viral replication , with an Effective Concentration (EC)90 of 6.90 \u03bcM that can be easily achievable with standard dosing , due to its favourable penetration in tissues , including in the lung [ 6 ] .", "labels": [[28, 40, "CHEMICAL"], [28, 40, "CHEBI"], [73, 79, "TAXON"], [51, 61, "ENTITY"], [178, 187, "ENTITY"], [207, 218, "ENTITY"], [28, 40, "ENTITY"], [64, 73, "ENTITY"], [256, 265, "CELL"], [4, 10, "ENTITY"], [73, 91, "ENTITY"], [28, 40, "SIMPLE_CHEMICAL"]]}
{"text": "Chloroquine can also impair another early stage of virus replication by interfering with the pH-dependent endosome-mediated viral entry of enveloped viruses such as Dengue virus or Chikungunya virus [ 60,61 ] .", "labels": [[181, 199, "ENTITY"], [0, 12, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [165, 178, "TAXON"], [51, 57, "TAXON"], [21, 28, "ENTITY"], [106, 124, "ENTITY"], [72, 84, "ENTITY"], [124, 136, "ENTITY"], [165, 178, "ORGANISM"], [165, 178, "ENTITY"], [139, 157, "ENTITY"], [0, 12, "CHEBI"], [93, 106, "ENTITY"], [181, 201, "ORGANISM"], [124, 130, "TAXON"], [0, 12, "ENTITY"], [51, 69, "ENTITY"], [36, 48, "ENTITY"], [149, 157, "TAXON"], [51, 57, "TAXON"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses [ 3 ] .", "labels": [[113, 124, "CANCER"], [0, 31, "ENTITY"], [0, 31, "CHEMICAL"], [193, 197, "SO"], [35, 46, "ENTITY"], [222, 231, "ENTITY"], [222, 245, "ORGANISM"], [113, 124, "ENTITY"], [0, 31, "SIMPLE_CHEMICAL"], [193, 197, "ENTITY"], [113, 124, "DISEASE"]]}
{"text": "Chloroquine was found to block SARS-CoV-2 infection at low micromolar concentration , with a half-maximal effective concentration ( EC50 ) of 1.13 \u03bcM and a half-cytotoxic concentration ( CC50 ) greater than 100 \u03bcM ( 8) .", "labels": [[31, 52, "ENTITY"], [31, 52, "CHEMICAL"], [59, 70, "SIMPLE_CHEMICAL"], [55, 59, "ENTITY"], [25, 31, "ENTITY"], [31, 42, "SIMPLE_CHEMICAL"], [154, 171, "ENTITY"], [116, 132, "ENTITY"], [0, 12, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [59, 70, "ENTITY"], [0, 12, "ENTITY"], [0, 12, "CHEBI"], [70, 84, "ENTITY"]]}
{"text": "Previous studies reported that CQ/HCQ possess a broad spectrum of antiviral effects on a variety of viruses as diverse as human immunodeficiency virus (HIV)[30 ] , Marburg virus , Zika virus [ 31 ] , dengue virus[32 ] , Ebola virus[33 ] , and SARS-CoV-1[34,35 ] , etc .", "labels": [[122, 128, "TAXON"], [122, 151, "ENTITY"], [162, 172, "ENTITY"], [122, 151, "ORGANISM"], [226, 243, "PROTEIN"], [178, 185, "ENTITY"], [226, 243, "ENTITY"], [66, 84, "ENTITY"], [100, 106, "TAXON"], [178, 185, "ORGANISM"], [180, 185, "TAXON"], [100, 108, "TAXON"], [31, 38, "CELL"], [122, 185, "DISEASE"], [200, 207, "GENE_OR_GENE_PRODUCT"], [218, 226, "GENE_OR_GENE_PRODUCT"], [207, 226, "ENTITY"], [164, 172, "TAXON"], [9, 17, "ENTITY"], [31, 38, "PROTEIN"], [31, 38, "DISEASE"], [200, 207, "CHEMICAL"], [100, 108, "ENTITY"]]}
{"text": "Chloroquine is a widely used antimalarial that was found to be a potential broad-spectrum antiviral in 2006 ( 7 ) . Chloroquine was found to block SARS-CoV-2 infection at low-micromolar concentration , with a half-maximal effective concentration ( EC50 ) of 1.13 \u03bcM and a half-cytotoxic concentration ( CC50 ) greater than 100 \u03bcM ( 8) .", "labels": [[-1, 12, "ENTITY"], [186, 196, "ORGANISM"], [-1, 15, "SIMPLE_CHEMICAL"], [-1, 37, "PROTEIN"], [0, 12, "CHEMICAL"], [-1, 37, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [203, 218, "SIMPLE_CHEMICAL"], [232, 241, "ENTITY"], [203, 218, "ENTITY"], [254, 264, "ENTITY"], [35, 48, "ENTITY"], [81, 96, "ENTITY"], [0, 12, "CHEBI"], [-1, 15, "CHEMICAL"], [-1, 15, "CHEBI"], [203, 218, "CHEBI"], [346, 354, "ENTITY"], [0, 12, "ENTITY"], [-1, 25, "ENTITY"], [-1, 12, "ENTITY"], [-1, 15, "ENTITY"]]}
{"text": "Chloroquine is a widely used antimalarial that was found to be a potential broad-spectrum antiviral in 2006 ( 7 ) . Chloroquine was found to block SARS-CoV-2 infection at low-micromolar concentration , with a half-maximal effective concentration ( EC50 ) of 1.13 \u03bcM and a half-cytotoxic concentration ( CC50 ) greater than 100 \u03bcM ( 8) .", "labels": [[-1, 12, "ENTITY"], [186, 196, "ORGANISM"], [-1, 15, "SIMPLE_CHEMICAL"], [-1, 37, "PROTEIN"], [0, 12, "CHEMICAL"], [-1, 37, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [203, 218, "SIMPLE_CHEMICAL"], [232, 241, "ENTITY"], [203, 218, "ENTITY"], [254, 264, "ENTITY"], [35, 48, "ENTITY"], [81, 96, "ENTITY"], [0, 12, "CHEBI"], [-1, 15, "CHEMICAL"], [-1, 15, "CHEBI"], [203, 218, "CHEBI"], [346, 354, "ENTITY"], [0, 12, "ENTITY"], [-1, 25, "ENTITY"], [-1, 15, "ENTITY"], [-1, 12, "ENTITY"]]}
{"text": "Chloroquine is a widely used antimalarial that was found to be a potential broad-spectrum antiviral in 2006 ( 7 ) . Chloroquine was found to block SARS-CoV-2 infection at low-micromolar concentration , with a half-maximal effective concentration ( EC50 ) of 1.13 \u03bcM and a half-cytotoxic concentration ( CC50 ) greater than 100 \u03bcM ( 8) .", "labels": [[-1, 12, "ENTITY"], [186, 196, "ORGANISM"], [-1, 15, "SIMPLE_CHEMICAL"], [-1, 37, "PROTEIN"], [0, 12, "CHEMICAL"], [-1, 37, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [203, 218, "SIMPLE_CHEMICAL"], [232, 241, "ENTITY"], [203, 218, "ENTITY"], [254, 264, "ENTITY"], [35, 48, "ENTITY"], [81, 96, "ENTITY"], [0, 12, "CHEBI"], [-1, 15, "CHEMICAL"], [-1, 15, "CHEBI"], [203, 218, "CHEBI"], [346, 354, "ENTITY"], [0, 12, "ENTITY"], [-1, 25, "ENTITY"], [-1, 12, "ENTITY"], [-1, 15, "ENTITY"]]}
{"text": "Other reported therapeutic agents that are used for the treatment of seriously ill patients have been noted in Table 1 .", "labels": [[79, 83, "ENTITY"], [83, 92, "ENTITY"], [83, 92, "ORGANISM"], [15, 34, "ENTITY"], [56, 66, "ENTITY"]]}
{"text": "Recently , chloroquine was found to inhibit SARS-CoV-2 in vitro and its hydroxylated form has been proposed as a possible therapy to treat patients infected with SARS-CoV-2 [ 4,5 ] .", "labels": [[162, 175, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Recently , the in vitro antiviral efficacy of approved drugs such as ribavirin , penciclovir , nitazoxanide , nafamostat , and chloroquine was compared with that of the two broad-spectrum antiviral drugs remdesivir and favipiravir for COVID-19 . Among the evaluated drugs , both remdesivir and chloroquine were found to be highly effective in controlling COVID-19 in vitro.63", "labels": [[169, 204, "ENTITY"], [204, 219, "ENTITY"], [204, 219, "SIMPLE_CHEMICAL"], [95, 110, "ENTITY"], [323, 330, "ENTITY"], [343, 355, "PROTEIN"], [204, 219, "CHEMICAL"], [343, 355, "ENTITY"], [204, 219, "CHEBI"], [95, 110, "GENE_OR_GENE_PRODUCT"], [95, 110, "CHEMICAL"], [272, 279, "ENTITY"], [343, 355, "SIMPLE_CHEMICAL"], [24, 34, "CHEBI"], [256, 266, "CHEBI"], [256, 266, "ENTITY"], [24, 34, "ENTITY"], [330, 343, "ENTITY"]]}
{"text": "Several articles have suggested medicines , potentially effective for the treatment of COVID-19 ( Table 1 ) .", "labels": [[32, 42, "ENTITY"], [8, 17, "ENTITY"]]}
{"text": "At the time , we put forward pseudoephedrine , andrographolide , chloroquine , abacavir , baricitinib , and quercetin as repurposing candidates from our list , because there were other researches also suggesting or predicting these drugs , mainly based on our Yaozh database search and literature review .", "labels": [[108, 133, "ENTITY"], [7, 12, "ENTITY"], [21, 29, "SO"], [79, 90, "GENE_OR_GENE_PRODUCT"], [45, 51, "CHEMICAL"], [79, 90, "ENTITY"], [45, 51, "ENTITY"], [201, 215, "ENTITY"], [275, 286, "ENTITY"], [65, 79, "CHEMICAL"], [253, 266, "ENTITY"], [79, 90, "CHEMICAL"], [45, 51, "CHEBI"], [45, 51, "SIMPLE_CHEMICAL"], [65, 79, "ENTITY"], [65, 79, "SIMPLE_CHEMICAL"]]}
{"text": "Moreover , chloroquine has immunomodulatory effects , suppressing the production/release of TNF-\u03b1 and IL-6 . It also works as a novel class of autophagy inhibitor [ 81 ] , which may interfere with viral infection and replication .", "labels": [[143, 153, "ENTITY"], [203, 217, "ENTITY"], [27, 44, "ENTITY"], [192, 203, "DISEASE"], [192, 203, "ENTITY"], [140, 153, "CHEBI"]]}
{"text": "Chloroquine-induced reduction of IL-1 and IL-6 cytokines was also found in monocytes/macrophages [ 79 ] .", "labels": [[47, 57, "ENTITY"], [33, 38, "GENE_OR_GENE_PRODUCT"], [42, 47, "GGP"], [75, 97, "CELL"], [75, 97, "CELL_TYPE"], [75, 97, "CL"], [42, 57, "PROTEIN"], [33, 38, "PROTEIN"], [75, 97, "ENTITY"], [42, 47, "GENE_OR_GENE_PRODUCT"], [42, 47, "ENTITY"], [33, 38, "ENTITY"], [0, 30, "ENTITY"], [0, 20, "CELLULAR_COMPONENT"], [33, 38, "GGP"]]}
{"text": "Moreover , we observed that infections by SARS-CoV-2 triggered the expected increase in the IL-6 levels in the culture supernatant , which ranged from 20- to 60-fold depending on the cell donor ( Figure 7C , open circles in nil-treated cells ) . The virus-induced enhancement of IL-6 levels were significantly prevented by treatment with ATV at 10 \u00b5M , ATV/RTV at both 1 and 10 \u00b5M and CQ at 10 \u00b5M ( Figure 7C ) .", "labels": [[244, 264, "ENTITY"], [179, 188, "ENTITY"], [203, 213, "ENTITY"], [348, 351, "ENTITY"], [224, 236, "CL"], [194, 203, "ENTITY"], [348, 351, "SIMPLE_CHEMICAL"], [345, 353, "CHEMICAL"], [264, 276, "PROTEIN"], [348, 351, "CHEMICAL"], [310, 323, "ENTITY"], [221, 236, "CELL_LINE"], [224, 236, "CELL"], [264, 276, "GENE_OR_GENE_PRODUCT"], [264, 276, "GGP"], [221, 236, "ENTITY"], [345, 353, "ENTITY"], [111, 119, "ENTITY"], [92, 97, "ENTITY"], [264, 276, "ENTITY"], [345, 353, "SIMPLE_CHEMICAL"], [391, 399, "ENTITY"], [345, 353, "PROTEIN"]]}
{"text": "Moreover , chloroquine has immunomodulatory effects , suppressing the production/release of TNF-\u03b1 and IL-6 . It also works as a novel class of autophagy inhibitor [ 81 ] , which may interfere with viral infection and replication .", "labels": [[143, 153, "ENTITY"], [203, 217, "ENTITY"], [27, 44, "ENTITY"], [192, 203, "DISEASE"], [192, 203, "ENTITY"], [140, 153, "CHEBI"]]}
{"text": "Chloroquine-induced inhibition of tumour necrosis factor-alpha ( TNF\u03b1 ) production by immune cells was reported to occur either through disruption of cellular iron metabolism [ 80 ] , blockade of the conversion of pro-TNF into soluble mature TNF\u03b1 molecules [ 81 ] and/or inhibition of TNF\u03b1 mRNA expression [ 72,82,83 ] .", "labels": [[222, 247, "PROTEIN"], [83, 93, "ENTITY"], [285, 295, "ENTITY"], [65, 70, "CHEBI"], [20, 34, "RNA"], [200, 214, "PROTEIN"], [34, 63, "GGP"], [0, 20, "CELLULAR_COMPONENT"], [147, 164, "ENTITY"], [227, 235, "ENTITY"], [34, 50, "DISEASE"], [0, 31, "ENTITY"], [34, 63, "PROTEIN"], [150, 159, "CHEMICAL"], [83, 93, "CELL_TYPE"], [65, 70, "ENTITY"], [83, 93, "CL"], [20, 31, "GENE_OR_GENE_PRODUCT"], [264, 271, "ENTITY"], [34, 63, "GENE_OR_GENE_PRODUCT"], [235, 242, "ENTITY"], [200, 214, "ENTITY"], [20, 31, "ENTITY"], [200, 214, "GENE_OR_GENE_PRODUCT"], [34, 63, "ENTITY"], [20, 31, "DISEASE"], [235, 242, "GENE_OR_GENE_PRODUCT"], [83, 93, "CELL"], [295, 308, "PROTEIN"], [147, 159, "CL"], [147, 159, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Moreover , chloroquine has immunomodulatory effects , suppressing the production/release of TNF-\u03b1 and IL-6 . It also works as a novel class of autophagy inhibitor [ 81 ] , which may interfere with viral infection and replication .", "labels": [[143, 153, "ENTITY"], [203, 217, "ENTITY"], [192, 203, "DISEASE"], [27, 44, "ENTITY"], [140, 153, "CHEBI"], [192, 203, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[142, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [558, 574, "ENTITY"], [269, 281, "TAXON"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [142, 150, "DISEASE"], [135, 150, "ORGANISM"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [262, 383, "SIMPLE_CHEMICAL"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [82, 92, "ENTITY"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"], [142, 150, "ENTITY"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[135, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [142, 150, "DISEASE"], [558, 574, "ENTITY"], [269, 281, "TAXON"], [142, 150, "ENTITY"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [142, 150, "ORGANISM"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [262, 383, "SIMPLE_CHEMICAL"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [82, 92, "ENTITY"], [431, 451, "ORGANISM"], [153, 168, "ORGANISM"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[142, 150, "ENTITY"], [135, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [558, 574, "ENTITY"], [269, 281, "TAXON"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [262, 383, "SIMPLE_CHEMICAL"], [142, 150, "ORGANISM"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [142, 150, "DISEASE"], [82, 92, "ENTITY"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[142, 150, "ORGANISM"], [135, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [558, 574, "ENTITY"], [269, 281, "TAXON"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [262, 383, "SIMPLE_CHEMICAL"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [142, 150, "ENTITY"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [82, 92, "ENTITY"], [142, 150, "DISEASE"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[135, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [558, 574, "ENTITY"], [269, 281, "TAXON"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [224, 242, "ORGANISM"], [142, 150, "ORGANISM"], [583, 602, "ORGANISM"], [142, 150, "ENTITY"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [262, 383, "SIMPLE_CHEMICAL"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [142, 150, "DISEASE"], [485, 491, "TAXON"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [82, 92, "ENTITY"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[142, 150, "ENTITY"], [265, 281, "ENTITY"], [135, 150, "ORGANISM"], [224, 240, "ENTITY"], [269, 281, "TAXON"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [558, 574, "ENTITY"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [262, 383, "SIMPLE_CHEMICAL"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [142, 150, "ORGANISM"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [142, 150, "DISEASE"], [82, 92, "ENTITY"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[142, 150, "ORGANISM"], [135, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [269, 281, "TAXON"], [142, 150, "DISEASE"], [558, 574, "ENTITY"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [262, 383, "SIMPLE_CHEMICAL"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [82, 92, "ENTITY"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"], [142, 150, "ENTITY"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[135, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [558, 574, "ENTITY"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [142, 150, "DISEASE"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [262, 383, "SIMPLE_CHEMICAL"], [265, 281, "ENTITY"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [142, 150, "ORGANISM"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [82, 92, "ENTITY"], [269, 281, "TAXON"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"], [142, 150, "ENTITY"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[135, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [558, 574, "ENTITY"], [269, 281, "TAXON"], [142, 150, "ORGANISM"], [363, 375, "TAXON"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "ENTITY"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [142, 150, "DISEASE"], [431, 444, "TAXON"], [142, 150, "ENTITY"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [262, 383, "SIMPLE_CHEMICAL"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [82, 92, "ENTITY"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"], [527, 545, "ENTITY"]]}
{"text": "Due to the alkalisation of endosomes , chloroquine was an effective in vitro treatment against Chikungunya virus when added to Vero cells prior to virus exposure [ 30 ] .", "labels": [[127, 132, "CELL"], [95, 107, "ORGANISM"], [127, 132, "ENTITY"], [27, 37, "GO"], [27, 37, "ENTITY"], [11, 24, "ENTITY"], [95, 107, "ENTITY"], [27, 37, "CELLULAR_COMPONENT"], [127, 132, "CELL_LINE"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[135, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [558, 574, "ENTITY"], [269, 281, "TAXON"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [142, 150, "ORGANISM"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [142, 150, "DISEASE"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [262, 383, "SIMPLE_CHEMICAL"], [142, 150, "ENTITY"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [82, 92, "ENTITY"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[135, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [558, 574, "ENTITY"], [269, 281, "TAXON"], [142, 150, "ENTITY"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [142, 150, "DISEASE"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [431, 444, "TAXON"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [142, 150, "ORGANISM"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [262, 383, "SIMPLE_CHEMICAL"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [431, 451, "ORGANISM"], [82, 92, "ENTITY"], [153, 168, "ORGANISM"], [431, 444, "ENTITY"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[224, 240, "ENTITY"], [142, 150, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [269, 281, "TAXON"], [142, 150, "ORGANISM"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [363, 375, "TAXON"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [142, 150, "DISEASE"], [431, 444, "ENTITY"], [558, 574, "ENTITY"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [262, 383, "SIMPLE_CHEMICAL"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [453, 485, "DISEASE"], [558, 574, "ORGANISM"], [135, 150, "ORGANISM"], [0, 9, "ENTITY"], [82, 92, "ENTITY"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"], [453, 491, "ENTITY"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[135, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [558, 574, "ENTITY"], [269, 281, "TAXON"], [142, 150, "ENTITY"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [142, 150, "ORGANISM"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [262, 383, "SIMPLE_CHEMICAL"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [142, 150, "DISEASE"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [82, 92, "ENTITY"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[135, 150, "ORGANISM"], [224, 240, "ENTITY"], [431, 444, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [558, 574, "ENTITY"], [269, 281, "TAXON"], [142, 150, "DISEASE"], [142, 150, "ORGANISM"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [224, 242, "ORGANISM"], [431, 451, "ORGANISM"], [431, 444, "TAXON"], [583, 602, "ORGANISM"], [485, 491, "TAXON"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [262, 383, "SIMPLE_CHEMICAL"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [82, 92, "ENTITY"], [153, 168, "ORGANISM"], [142, 150, "ENTITY"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[142, 150, "ENTITY"], [135, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [142, 150, "DISEASE"], [558, 574, "ENTITY"], [269, 281, "TAXON"], [527, 545, "SO"], [583, 602, "ENTITY"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [262, 383, "SIMPLE_CHEMICAL"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [142, 150, "ORGANISM"], [527, 539, "CELLULAR_COMPONENT"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [82, 92, "ENTITY"], [527, 545, "ENTITY"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[558, 574, "ORGANISM"], [135, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [269, 281, "TAXON"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [142, 150, "ORGANISM"], [142, 150, "DISEASE"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [142, 150, "ENTITY"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ENTITY"], [262, 383, "SIMPLE_CHEMICAL"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [82, 92, "ENTITY"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[135, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [142, 150, "DISEASE"], [558, 574, "ENTITY"], [269, 281, "TAXON"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [142, 150, "ORGANISM"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [262, 383, "SIMPLE_CHEMICAL"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [485, 491, "TAXON"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [142, 150, "ENTITY"], [82, 92, "ENTITY"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"], [527, 545, "ENTITY"]]}
{"text": "In vitro , chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [ 16 ] , poliovirus [ 17 ] , HIV [ 12,[18 ] , [ 19 ] , [ 20 ] , hepatitis A virus [ 21,22 ] , hepatitis C virus [ 23 ] , influenza A and B viruses [ 24 ] , [ 25 ] , [ 26 ] , [ 27 ] , influenza A H5N1 virus [ 28 ] , Chikungunya virus [ 29 ] , [ 30 ] , [ 31 ] , Dengue virus [ 32,33 ] , Zika virus [ 34 ] , Lassa virus [ 35 ] , Hendra and Nipah viruses [ 36,37 ] , Crimean \u2013 Congo hemorrhagic fever virus [ 38 ] and Ebola virus [ 39 ] , as well as various DNA viruses such as hepatitis B virus [ 40 ] and herpes simplex virus [ 41 ] .", "labels": [[135, 150, "ORGANISM"], [224, 240, "ENTITY"], [558, 568, "DISEASE"], [113, 119, "TAXON"], [558, 574, "ENTITY"], [269, 281, "TAXON"], [583, 602, "ENTITY"], [527, 539, "CELLULAR_COMPONENT"], [527, 545, "SO"], [46, 56, "ENTITY"], [453, 485, "DISEASE"], [363, 375, "TAXON"], [142, 150, "DISEASE"], [224, 242, "ORGANISM"], [583, 602, "ORGANISM"], [265, 281, "ENTITY"], [583, 594, "DISEASE"], [431, 444, "ENTITY"], [453, 467, "ORGANISM"], [363, 375, "ENTITY"], [242, 254, "ENTITY"], [558, 574, "ORGANISM"], [262, 383, "SIMPLE_CHEMICAL"], [431, 444, "TAXON"], [109, 113, "SO"], [109, 113, "ENTITY"], [135, 142, "ENTITY"], [135, 142, "TAXON"], [142, 150, "ORGANISM"], [142, 150, "ENTITY"], [485, 491, "TAXON"], [0, 9, "ENTITY"], [453, 491, "ENTITY"], [82, 92, "ENTITY"], [153, 168, "ORGANISM"], [431, 451, "ORGANISM"], [527, 545, "ENTITY"]]}
{"text": "Although the long use of this drug in malaria therapy demonstrates the safety of acute chloroquine administration to humans , one can not ignore the minor risk of macular retinopathy , which depends on the cumulative dose [ 52 ] , and the existence of some reports on cardiomyopathy as a severe adverse effect caused by chloroquine [ 53,54 ] .", "labels": [[202, 217, "ENTITY"], [160, 171, "DISEASE"], [38, 46, "DISEASE"], [310, 320, "ENTITY"], [283, 288, "ENTITY"], [87, 99, "ENTITY"], [117, 124, "TAXON"], [87, 99, "CHEMICAL"], [38, 54, "ENTITY"], [30, 35, "CHEBI"], [288, 303, "ENTITY"], [117, 124, "ENTITY"], [87, 99, "SIMPLE_CHEMICAL"], [30, 35, "ENTITY"], [310, 320, "CHEMICAL"], [310, 320, "SIMPLE_CHEMICAL"], [149, 155, "ENTITY"], [81, 87, "ENTITY"], [87, 99, "CHEBI"], [99, 114, "ENTITY"], [71, 78, "ENTITY"], [160, 171, "ENTITY"], [257, 268, "ENTITY"], [310, 320, "CHEBI"], [117, 124, "ORGANISM"], [257, 268, "DISEASE"]]}
{"text": "Although the long use of this drug in malaria therapy demonstrates the safety of acute chloroquine administration to humans , one can not ignore the minor risk of macular retinopathy , which depends on the cumulative dose [ 52 ] , and the existence of some reports on cardiomyopathy as a severe adverse effect caused by chloroquine [ 53,54 ] .", "labels": [[202, 217, "ENTITY"], [38, 46, "DISEASE"], [160, 171, "DISEASE"], [310, 320, "ENTITY"], [283, 288, "ENTITY"], [87, 99, "ENTITY"], [117, 124, "TAXON"], [87, 99, "CHEMICAL"], [38, 54, "ENTITY"], [30, 35, "CHEBI"], [288, 303, "ENTITY"], [117, 124, "ENTITY"], [87, 99, "SIMPLE_CHEMICAL"], [30, 35, "ENTITY"], [310, 320, "CHEMICAL"], [310, 320, "SIMPLE_CHEMICAL"], [149, 155, "ENTITY"], [81, 87, "ENTITY"], [87, 99, "CHEBI"], [99, 114, "ENTITY"], [71, 78, "ENTITY"], [160, 171, "ENTITY"], [257, 268, "ENTITY"], [310, 320, "CHEBI"], [117, 124, "ORGANISM"], [257, 268, "DISEASE"]]}
{"text": "Chloroquine can inhibit a pre-entry step of the viral cycle by interfering with viral particles binding to their cellular cell surface receptor .", "labels": [[16, 24, "ENTITY"], [80, 96, "ENTITY"], [48, 54, "TAXON"], [113, 144, "CELL"], [48, 60, "ENTITY"], [48, 54, "TAXON"], [96, 104, "ENTITY"], [113, 144, "PROTEIN"], [0, 12, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [113, 144, "ENTITY"], [0, 12, "ENTITY"], [0, 12, "CHEBI"], [113, 127, "CL"], [26, 36, "ENTITY"], [63, 75, "ENTITY"]]}
{"text": "Chloroquine was shown to inhibit quinone reductase 2 [ 56 ] , a structural neighbour of UDP-N-acetylglucosamine 2-epimerases [ 57 ] that are involved in the biosynthesis of sialic acids . The sialic acids are acidic monosaccharides found at the extremity of sugar chains present on cell transmembrane proteins and are critical components of ligand recognition . The possible interference of chloroquine with sialic acid biosynthesis could account for the broad antiviral spectrum of that drug since viruses such as the human coronavirus HCoV-O43 and the orthomyxoviruses use sialic acid moieties as receptors [ 58 ] .", "labels": [[271, 301, "GO"], [245, 264, "ENTITY"], [587, 599, "ENTITY"], [199, 216, "CHEBI"], [157, 180, "CHEMICAL"], [33, 53, "ENTITY"], [546, 554, "ENTITY"], [245, 264, "PROTEIN"], [512, 525, "ORGANISM"], [375, 391, "SIMPLE_CHEMICAL"], [391, 408, "CHEBI"], [0, 12, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [554, 575, "CHEMICAL"], [271, 301, "PROTEIN"], [245, 258, "SIMPLE_CHEMICAL"], [512, 537, "PROTEIN"], [554, 587, "SIMPLE_CHEMICAL"], [519, 525, "ENTITY"], [519, 537, "CHEMICAL"], [157, 180, "ENTITY"], [391, 408, "SIMPLE_CHEMICAL"], [62, 75, "ENTITY"], [33, 53, "GENE_OR_GENE_PRODUCT"], [375, 391, "ENTITY"], [186, 199, "CHEMICAL"], [391, 408, "CHEMICAL"], [238, 245, "PATHOLOGICAL_FORMATION"], [0, 12, "CHEBI"], [85, 112, "GENE_OR_GENE_PRODUCT"], [157, 180, "SIMPLE_CHEMICAL"], [209, 216, "SIMPLE_CHEMICAL"], [157, 180, "CHEBI"], [186, 199, "ENTITY"], [327, 348, "ENTITY"], [33, 53, "GGP"], [271, 301, "ENTITY"], [455, 471, "ENTITY"], [0, 12, "ENTITY"], [186, 199, "CHEBI"], [391, 420, "ENTITY"], [85, 112, "ENTITY"], [271, 287, "CELLULAR_COMPONENT"], [199, 216, "ENTITY"], [375, 391, "CHEBI"], [33, 41, "CHEMICAL"], [25, 33, "ENTITY"], [33, 53, "PROTEIN"], [375, 391, "CHEMICAL"], [238, 245, "ENTITY"], [554, 575, "CHEBI"], [186, 199, "SIMPLE_CHEMICAL"], [554, 587, "PROTEIN"], [554, 587, "ENTITY"], [525, 537, "ENTITY"], [546, 554, "TAXON"]]}
{"text": "The potent anti-SARS-CoV-1 effects of chloroquine in vitro were considered attributable to a deficit in the glycosylation of a virus cell surface receptor , the angiotensin-converting enzyme 2 ( ACE2 ) on Vero cells [ 59 ] .", "labels": [[93, 101, "ENTITY"], [38, 50, "CHEBI"], [27, 35, "ENTITY"], [202, 210, "ENTITY"], [38, 50, "SIMPLE_CHEMICAL"], [161, 191, "ENTITY"], [50, 59, "ENTITY"], [205, 210, "CL"], [161, 191, "PROTEIN"], [108, 122, "ENTITY"], [202, 210, "CELL_LINE"], [127, 138, "TAXON"], [11, 27, "ENTITY"], [202, 210, "CELL"], [38, 50, "CHEMICAL"], [127, 155, "ENTITY"], [161, 191, "GENE_OR_GENE_PRODUCT"], [127, 155, "PROTEIN"], [38, 50, "ENTITY"]]}
{"text": "Chloroquine can also impair another early stage of virus replication by interfering with the pH-dependent endosome-mediated viral entry of enveloped viruses such as Dengue virus or Chikungunya virus [ 60,61 ] .", "labels": [[181, 199, "ENTITY"], [0, 12, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [165, 178, "TAXON"], [51, 57, "TAXON"], [21, 28, "ENTITY"], [106, 124, "ENTITY"], [72, 84, "ENTITY"], [165, 178, "ORGANISM"], [165, 178, "ENTITY"], [139, 157, "ENTITY"], [0, 12, "CHEBI"], [124, 130, "TAXON"], [93, 106, "ENTITY"], [181, 201, "ORGANISM"], [0, 12, "ENTITY"], [51, 69, "ENTITY"], [36, 48, "ENTITY"], [149, 157, "TAXON"], [51, 57, "TAXON"], [124, 136, "ENTITY"]]}
{"text": "Due to the alkalisation of endosomes , chloroquine was an effective in vitro treatment against Chikungunya virus when added to Vero cells prior to virus exposure [ 30 ] .", "labels": [[127, 132, "CELL"], [127, 132, "ENTITY"], [95, 107, "ENTITY"], [27, 37, "GO"], [27, 37, "ENTITY"], [95, 107, "ORGANISM"], [11, 24, "ENTITY"], [27, 37, "CELLULAR_COMPONENT"], [127, 132, "CELL_LINE"]]}
{"text": "The mechanism of inhibition likely involved the prevention of endocytosis and/or rapid elevation of the endosomal pH and abrogation of virus \u2013 endosome fusion .", "labels": [[4, 14, "ENTITY"], [143, 152, "ENTITY"], [104, 114, "ENTITY"], [62, 74, "ENTITY"], [48, 59, "ENTITY"], [114, 117, "ENTITY"], [135, 152, "ORGANISM"], [17, 28, "ENTITY"], [135, 141, "TAXON"], [87, 97, "ENTITY"], [121, 132, "ENTITY"], [81, 87, "ENTITY"], [104, 114, "CELLULAR_COMPONENT"], [135, 141, "ENTITY"], [104, 114, "GO"]]}
{"text": "The mechanism of inhibition likely involved the prevention of endocytosis and/or rapid elevation of the endosomal pH and abrogation of virus \u2013 endosome fusion .", "labels": [[4, 14, "ENTITY"], [143, 152, "ENTITY"], [62, 74, "ENTITY"], [48, 59, "ENTITY"], [114, 117, "ENTITY"], [135, 152, "ORGANISM"], [17, 28, "ENTITY"], [135, 141, "TAXON"], [104, 114, "CELLULAR_COMPONENT"], [87, 97, "ENTITY"], [121, 132, "ENTITY"], [81, 87, "ENTITY"], [104, 114, "ENTITY"], [104, 114, "GO"], [135, 141, "ENTITY"]]}
{"text": "Chloroquine-mediated inhibition of hepatitis A virus was found to be associated with uncoating , thus blocking its entire replication cycle [ 22 ] .", "labels": [[35, 47, "DISEASE"], [21, 32, "ENTITY"], [122, 134, "ENTITY"], [0, 21, "ENTITY"], [69, 85, "ENTITY"], [35, 53, "ENTITY"], [85, 95, "ENTITY"], [47, 53, "TAXON"], [35, 53, "ORGANISM"]]}
{"text": "Chloroquine also inhibits the replication Dengue-2 virus by affecting the normal proteolytic processing of the flavivirus prM protein to M protein [ 32 ] .", "labels": [[111, 126, "ORGANISM"], [74, 81, "ENTITY"], [111, 122, "TAXON"], [111, 134, "PROTEIN"], [126, 134, "CHEBI"], [17, 26, "ENTITY"], [42, 51, "PROTEIN"], [42, 57, "GENE_OR_GENE_PRODUCT"], [30, 57, "ENTITY"], [111, 134, "ENTITY"], [0, 12, "CHEMICAL"], [124, 134, "ENTITY"], [81, 93, "ENTITY"], [51, 57, "TAXON"], [0, 12, "SIMPLE_CHEMICAL"], [0, 12, "ENTITY"], [0, 12, "CHEBI"]]}
{"text": "In the herpes simplex virus ( HSV ) model , chloroquine inhibited budding with accumulation of non-infectious HSV-1 particles in the trans-Golgi network [ 66 ] .", "labels": [[44, 56, "ENTITY"], [133, 145, "ENTITY"], [56, 66, "ENTITY"], [7, 22, "DISEASE"], [7, 28, "ENTITY"], [22, 28, "TAXON"], [7, 28, "ORGANISM"], [92, 116, "ENTITY"], [129, 145, "TISSUE"], [95, 116, "ORGANISM"]]}
{"text": "In the herpes simplex virus ( HSV ) model , chloroquine inhibited budding with accumulation of non-infectious HSV-1 particles in the trans-Golgi network [ 66 ] .", "labels": [[44, 56, "ENTITY"], [133, 145, "ENTITY"], [56, 66, "ENTITY"], [7, 22, "DISEASE"], [7, 28, "ENTITY"], [22, 28, "TAXON"], [7, 28, "ORGANISM"], [92, 116, "ENTITY"], [129, 145, "TISSUE"], [95, 116, "ORGANISM"]]}
{"text": "Beside affecting the virus maturation process , pH modulation by chloroquine can impair the proper maturation of viral protein [ 32 ] and the recognition of viral antigen by dendritic cells , which occurs through a Toll-like receptor-dependent pathway that requires endosomal acidification [ 69 ] .", "labels": [[21, 27, "TAXON"], [171, 184, "CL"], [113, 119, "PROTEIN"], [257, 266, "GO"], [21, 46, "ENTITY"], [266, 276, "ENTITY"], [110, 119, "PROTEIN"], [171, 184, "CELL_TYPE"], [257, 266, "CELLULAR_COMPONENT"], [113, 119, "ENTITY"], [7, 17, "ENTITY"], [110, 119, "ENTITY"], [113, 119, "TAXON"], [171, 184, "ENTITY"], [171, 184, "CELL"], [257, 266, "ENTITY"], [205, 215, "GENE_OR_GENE_PRODUCT"], [205, 244, "ENTITY"]]}
{"text": "On the contrary , other proposed effects of chloroquine on the immune system include increasing the export of soluble antigens into the cytosol of dendritic cells and the enhancement of human cytotoxic CD8 + T-cell responses against viral antigens [ 70 ] .", "labels": [[225, 239, "ENTITY"], [186, 208, "CELL_TYPE"], [33, 41, "ENTITY"], [110, 118, "PROTEIN"], [147, 157, "CELL"], [147, 157, "CELL_TYPE"], [202, 208, "ENTITY"], [147, 157, "ENTITY"], [63, 70, "ENTITY"], [147, 157, "CL"], [225, 239, "PROTEIN"], [208, 215, "ENTITY"]]}
{"text": "In the influenza virus model , it was reported that chloroquine improve the cross-presentation of non-replicating virus antigen by dendritic cells to CD8 + T-cells recruited to lymph nodes draining the site of infection , eliciting a broadly protective immune response [ 71 ] .", "labels": [[98, 120, "PROTEIN"], [174, 183, "ENTITY"], [174, 183, "MULTI-TISSUE_STRUCTURE"], [131, 141, "CL"], [150, 156, "CELL_TYPE"], [131, 141, "CELL_TYPE"], [131, 141, "ENTITY"], [17, 23, "ORGANISM"], [7, 29, "ENTITY"], [98, 120, "ENTITY"], [17, 23, "TAXON"], [131, 141, "CELL"], [234, 260, "ENTITY"], [150, 154, "GGP"], [183, 189, "ENTITY"], [150, 156, "ENTITY"]]}
{"text": "Chloroquine is known to inhibit phosphorylation ( activation ) of the p38 mitogen-activated protein kinase ( MAPK ) in THP-1 cells as well as caspase-1 [ 72 ] . Activation of cells via MAPK signalling is frequently required by viruses to achieve their replication cycle [ 73 ] . In the model of HCoV-229 coronavirus , chloroquine-induced virus inhibition occurs through inhibition of p38 MAPK [ 44 ] .", "labels": [[66, 100, "GENE_OR_GENE_PRODUCT"], [125, 131, "PROTEIN"], [116, 125, "CELL"], [66, 100, "PROTEIN"], [286, 304, "ENTITY"], [304, 318, "ENTITY"], [0, 12, "CHEMICAL"], [125, 131, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [161, 172, "CELL"], [355, 370, "ENTITY"], [277, 282, "ENTITY"], [32, 48, "ENTITY"], [66, 100, "GGP"], [0, 12, "CHEBI"], [344, 355, "PROTEIN"], [116, 125, "ENTITY"], [344, 355, "ENTITY"], [181, 190, "ENTITY"], [66, 100, "ENTITY"], [161, 172, "ENTITY"], [116, 125, "CELL_LINE"], [0, 12, "ENTITY"], [161, 172, "CL"], [116, 125, "CL"], [318, 344, "ENTITY"], [304, 318, "GENE_OR_GENE_PRODUCT"], [286, 304, "GENE_OR_GENE_PRODUCT"], [344, 355, "GENE_OR_GENE_PRODUCT"], [215, 227, "TAXON"], [24, 32, "ENTITY"], [215, 227, "ENTITY"], [125, 131, "GENE_OR_GENE_PRODUCT"], [344, 355, "GGP"]]}
{"text": "Chloroquine is known to inhibit phosphorylation ( activation ) of the p38 mitogen-activated protein kinase ( MAPK ) in THP-1 cells as well as caspase-1 [ 72 ] . Activation of cells via MAPK signalling is frequently required by viruses to achieve their replication cycle [ 73 ] . In the model of HCoV-229 coronavirus , chloroquine-induced virus inhibition occurs through inhibition of p38 MAPK [ 44 ] .", "labels": [[181, 190, "ENTITY"], [66, 100, "GENE_OR_GENE_PRODUCT"], [125, 131, "PROTEIN"], [116, 125, "CELL"], [66, 100, "PROTEIN"], [286, 304, "ENTITY"], [304, 318, "ENTITY"], [0, 12, "CHEMICAL"], [125, 131, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [161, 172, "CELL"], [355, 370, "ENTITY"], [277, 282, "ENTITY"], [32, 48, "ENTITY"], [66, 100, "GGP"], [0, 12, "CHEBI"], [344, 355, "PROTEIN"], [116, 125, "ENTITY"], [344, 355, "ENTITY"], [66, 100, "ENTITY"], [161, 172, "ENTITY"], [116, 125, "CELL_LINE"], [0, 12, "ENTITY"], [161, 172, "CL"], [116, 125, "CL"], [318, 344, "ENTITY"], [304, 318, "GENE_OR_GENE_PRODUCT"], [286, 304, "GENE_OR_GENE_PRODUCT"], [344, 355, "GENE_OR_GENE_PRODUCT"], [215, 227, "TAXON"], [24, 32, "ENTITY"], [215, 227, "ENTITY"], [125, 131, "GENE_OR_GENE_PRODUCT"], [344, 355, "GGP"]]}
{"text": "Chloroquine inhibits interleukin-1 beta ( IL-1\u03b2 ) mRNA expression in THP-1 cells and reduces IL-1\u03b2 release [ 72 ] .", "labels": [[66, 75, "CL"], [50, 55, "ENTITY"], [85, 93, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [0, 12, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [21, 40, "ENTITY"], [85, 93, "GGP"], [21, 50, "PROTEIN"], [66, 75, "ENTITY"], [0, 12, "CHEBI"], [21, 40, "GENE_OR_GENE_PRODUCT"], [85, 93, "ENTITY"], [0, 12, "ENTITY"], [21, 40, "GGP"], [66, 75, "CELL"], [66, 75, "CELL_LINE"], [12, 21, "ENTITY"], [85, 93, "PROTEIN"]]}
{"text": "Chloroquine inhibits interleukin-1 beta ( IL-1\u03b2 ) mRNA expression in THP-1 cells and reduces IL-1\u03b2 release [ 72 ] .", "labels": [[66, 75, "CL"], [50, 55, "ENTITY"], [85, 93, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [0, 12, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [21, 40, "ENTITY"], [85, 93, "GGP"], [21, 50, "PROTEIN"], [66, 75, "ENTITY"], [0, 12, "CHEBI"], [21, 40, "GENE_OR_GENE_PRODUCT"], [85, 93, "ENTITY"], [0, 12, "ENTITY"], [21, 40, "GGP"], [66, 75, "CELL"], [66, 75, "CELL_LINE"], [12, 21, "ENTITY"], [85, 93, "PROTEIN"]]}
{"text": "Chloroquine-induced reduction of IL-1 and IL-6 cytokines was also found in monocytes/macrophages [ 79 ] .", "labels": [[47, 57, "ENTITY"], [33, 38, "GENE_OR_GENE_PRODUCT"], [75, 97, "CELL"], [75, 97, "CELL_TYPE"], [75, 97, "CL"], [42, 47, "GGP"], [42, 57, "PROTEIN"], [33, 38, "PROTEIN"], [75, 97, "ENTITY"], [33, 38, "ENTITY"], [0, 30, "ENTITY"], [42, 47, "GENE_OR_GENE_PRODUCT"], [42, 47, "ENTITY"], [0, 20, "CELLULAR_COMPONENT"], [33, 38, "GGP"]]}
{"text": "Chloroquine-induced inhibition of tumour necrosis factor-alpha ( TNF\u03b1 ) production by immune cells was reported to occur either through disruption of cellular iron metabolism [ 80 ] , blockade of the conversion of pro-TNF into soluble mature TNF\u03b1 molecules [ 81 ] and/or inhibition of TNF\u03b1 mRNA expression [ 72,82,83 ] .", "labels": [[65, 70, "ENTITY"], [83, 93, "ENTITY"], [20, 34, "RNA"], [200, 214, "PROTEIN"], [34, 63, "GGP"], [0, 20, "CELLULAR_COMPONENT"], [227, 235, "ENTITY"], [147, 159, "CL"], [0, 31, "ENTITY"], [34, 50, "DISEASE"], [34, 63, "PROTEIN"], [83, 93, "CELL_TYPE"], [83, 93, "CL"], [20, 31, "GENE_OR_GENE_PRODUCT"], [264, 271, "ENTITY"], [222, 247, "PROTEIN"], [34, 63, "GENE_OR_GENE_PRODUCT"], [147, 159, "GENE_OR_GENE_PRODUCT"], [65, 70, "CHEBI"], [235, 242, "ENTITY"], [200, 214, "ENTITY"], [147, 164, "ENTITY"], [20, 31, "ENTITY"], [150, 159, "CHEMICAL"], [200, 214, "GENE_OR_GENE_PRODUCT"], [34, 63, "ENTITY"], [20, 31, "DISEASE"], [235, 242, "GENE_OR_GENE_PRODUCT"], [83, 93, "CELL"], [295, 308, "PROTEIN"], [285, 295, "ENTITY"]]}
{"text": "Chloroquine-induced inhibition of tumour necrosis factor-alpha ( TNF\u03b1 ) production by immune cells was reported to occur either through disruption of cellular iron metabolism [ 80 ] , blockade of the conversion of pro-TNF into soluble mature TNF\u03b1 molecules [ 81 ] and/or inhibition of TNF\u03b1 mRNA expression [ 72,82,83 ] .", "labels": [[222, 247, "PROTEIN"], [83, 93, "ENTITY"], [285, 295, "ENTITY"], [65, 70, "CHEBI"], [20, 34, "RNA"], [200, 214, "PROTEIN"], [34, 63, "GGP"], [0, 20, "CELLULAR_COMPONENT"], [147, 164, "ENTITY"], [227, 235, "ENTITY"], [34, 50, "DISEASE"], [0, 31, "ENTITY"], [34, 63, "PROTEIN"], [150, 159, "CHEMICAL"], [83, 93, "CELL_TYPE"], [65, 70, "ENTITY"], [83, 93, "CL"], [20, 31, "GENE_OR_GENE_PRODUCT"], [264, 271, "ENTITY"], [34, 63, "GENE_OR_GENE_PRODUCT"], [235, 242, "ENTITY"], [200, 214, "ENTITY"], [20, 31, "ENTITY"], [200, 214, "GENE_OR_GENE_PRODUCT"], [34, 63, "ENTITY"], [20, 31, "DISEASE"], [235, 242, "GENE_OR_GENE_PRODUCT"], [83, 93, "CELL"], [295, 308, "PROTEIN"], [147, 159, "CL"], [147, 159, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Inhibition of the TNF\u03b1 receptor was also reported in U937 monocytic cells treated with chloroquine [ 84 ] . In the Dengue virus model , chloroquine was found to inhibit interferon-alpha ( IFN\u03b1 ) , IFN\u03b2 , IFN\u03b3 , TNF\u03b1 , IL-6 and IL-12 gene expression in U937 cells infected with Dengue-2 virus [ 33 ] .", "labels": [[87, 99, "ENTITY"], [128, 136, "ENTITY"], [87, 99, "CHEMICAL"], [74, 87, "ENTITY"], [53, 58, "ENTITY"], [128, 136, "CHEMICAL"], [238, 252, "ENTITY"], [169, 188, "PROTEIN"], [111, 128, "ENTITY"], [188, 195, "GENE_OR_GENE_PRODUCT"], [58, 74, "CL"], [18, 32, "ENTITY"], [263, 277, "GENE_OR_GENE_PRODUCT"], [238, 252, "CELL_LINE"], [128, 136, "CHEBI"], [161, 169, "PROTEIN"], [53, 74, "CELL"], [218, 223, "GENE_OR_GENE_PRODUCT"], [53, 74, "CELL_LINE"], [18, 32, "GENE_OR_GENE_PRODUCT"], [111, 122, "ORGANISM"], [128, 136, "SIMPLE_CHEMICAL"], [0, 11, "ENTITY"], [188, 195, "PROTEIN"], [188, 195, "ENTITY"], [169, 188, "ENTITY"], [169, 188, "GENE_OR_GENE_PRODUCT"], [161, 169, "ENTITY"], [238, 252, "CELL"], [161, 169, "GENE_OR_GENE_PRODUCT"], [87, 99, "SIMPLE_CHEMICAL"], [18, 32, "PROTEIN"], [218, 223, "PROTEIN"], [223, 238, "ENTITY"], [218, 227, "GGP"], [218, 223, "ENTITY"], [87, 99, "CHEBI"], [263, 286, "CHEMICAL"], [263, 277, "ENTITY"], [111, 122, "TAXON"], [238, 252, "CL"], [53, 74, "ENTITY"]]}
{"text": "Inhibition of the TNF\u03b1 receptor was also reported in U937 monocytic cells treated with chloroquine [ 84 ] . In the Dengue virus model , chloroquine was found to inhibit interferon-alpha ( IFN\u03b1 ) , IFN\u03b2 , IFN\u03b3 , TNF\u03b1 , IL-6 and IL-12 gene expression in U937 cells infected with Dengue-2 virus [ 33 ] .", "labels": [[87, 99, "ENTITY"], [128, 136, "ENTITY"], [87, 99, "CHEMICAL"], [74, 87, "ENTITY"], [53, 58, "ENTITY"], [128, 136, "CHEMICAL"], [238, 252, "ENTITY"], [188, 195, "GENE_OR_GENE_PRODUCT"], [111, 128, "ENTITY"], [58, 74, "CL"], [263, 277, "GENE_OR_GENE_PRODUCT"], [238, 252, "CELL_LINE"], [128, 136, "CHEBI"], [161, 169, "PROTEIN"], [53, 74, "CELL"], [18, 32, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [18, 32, "GENE_OR_GENE_PRODUCT"], [53, 74, "CELL_LINE"], [111, 122, "ORGANISM"], [128, 136, "SIMPLE_CHEMICAL"], [0, 11, "ENTITY"], [188, 195, "PROTEIN"], [188, 195, "ENTITY"], [161, 169, "ENTITY"], [238, 252, "CELL"], [161, 169, "GENE_OR_GENE_PRODUCT"], [169, 188, "GENE_OR_GENE_PRODUCT"], [87, 99, "SIMPLE_CHEMICAL"], [218, 223, "PROTEIN"], [223, 238, "ENTITY"], [169, 188, "PROTEIN"], [218, 227, "GGP"], [218, 223, "ENTITY"], [87, 99, "CHEBI"], [169, 188, "ENTITY"], [263, 286, "CHEMICAL"], [263, 277, "ENTITY"], [111, 122, "TAXON"], [238, 252, "CL"], [18, 32, "ENTITY"], [53, 74, "ENTITY"]]}
{"text": "Inhibition of the TNF\u03b1 receptor was also reported in U937 monocytic cells treated with chloroquine [ 84 ] . In the Dengue virus model , chloroquine was found to inhibit interferon-alpha ( IFN\u03b1 ) , IFN\u03b2 , IFN\u03b3 , TNF\u03b1 , IL-6 and IL-12 gene expression in U937 cells infected with Dengue-2 virus [ 33 ] .", "labels": [[87, 99, "ENTITY"], [128, 136, "ENTITY"], [87, 99, "CHEMICAL"], [74, 87, "ENTITY"], [53, 58, "ENTITY"], [128, 136, "CHEMICAL"], [238, 252, "ENTITY"], [169, 188, "PROTEIN"], [111, 128, "ENTITY"], [188, 195, "GENE_OR_GENE_PRODUCT"], [58, 74, "CL"], [263, 277, "GENE_OR_GENE_PRODUCT"], [238, 252, "CELL_LINE"], [128, 136, "CHEBI"], [161, 169, "PROTEIN"], [53, 74, "CELL"], [18, 32, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [18, 32, "GENE_OR_GENE_PRODUCT"], [53, 74, "CELL_LINE"], [111, 122, "ORGANISM"], [128, 136, "SIMPLE_CHEMICAL"], [0, 11, "ENTITY"], [188, 195, "PROTEIN"], [188, 195, "ENTITY"], [169, 188, "ENTITY"], [169, 188, "GENE_OR_GENE_PRODUCT"], [161, 169, "ENTITY"], [238, 252, "CELL"], [161, 169, "GENE_OR_GENE_PRODUCT"], [87, 99, "SIMPLE_CHEMICAL"], [218, 223, "PROTEIN"], [223, 238, "ENTITY"], [218, 227, "GGP"], [218, 223, "ENTITY"], [87, 99, "CHEBI"], [263, 286, "CHEMICAL"], [263, 277, "ENTITY"], [111, 122, "TAXON"], [238, 252, "CL"], [18, 32, "ENTITY"], [53, 74, "ENTITY"]]}
{"text": "Inhibition of the TNF\u03b1 receptor was also reported in U937 monocytic cells treated with chloroquine [ 84 ] . In the Dengue virus model , chloroquine was found to inhibit interferon-alpha ( IFN\u03b1 ) , IFN\u03b2 , IFN\u03b3 , TNF\u03b1 , IL-6 and IL-12 gene expression in U937 cells infected with Dengue-2 virus [ 33 ] .", "labels": [[87, 99, "ENTITY"], [188, 195, "GENE_OR_GENE_PRODUCT"], [128, 136, "ENTITY"], [87, 99, "CHEMICAL"], [74, 87, "ENTITY"], [53, 58, "ENTITY"], [128, 136, "CHEMICAL"], [238, 252, "ENTITY"], [169, 188, "PROTEIN"], [111, 128, "ENTITY"], [58, 74, "CL"], [263, 277, "GENE_OR_GENE_PRODUCT"], [238, 252, "CELL_LINE"], [188, 195, "ENTITY"], [128, 136, "CHEBI"], [161, 169, "PROTEIN"], [53, 74, "CELL"], [18, 32, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [18, 32, "GENE_OR_GENE_PRODUCT"], [53, 74, "CELL_LINE"], [111, 122, "ORGANISM"], [128, 136, "SIMPLE_CHEMICAL"], [0, 11, "ENTITY"], [188, 195, "PROTEIN"], [169, 188, "GENE_OR_GENE_PRODUCT"], [169, 188, "ENTITY"], [161, 169, "ENTITY"], [238, 252, "CELL"], [161, 169, "GENE_OR_GENE_PRODUCT"], [87, 99, "SIMPLE_CHEMICAL"], [218, 223, "PROTEIN"], [223, 238, "ENTITY"], [218, 227, "GGP"], [218, 223, "ENTITY"], [87, 99, "CHEBI"], [263, 286, "CHEMICAL"], [263, 277, "ENTITY"], [111, 122, "TAXON"], [238, 252, "CL"], [18, 32, "ENTITY"], [53, 74, "ENTITY"]]}
{"text": "Inhibition of the TNF\u03b1 receptor was also reported in U937 monocytic cells treated with chloroquine [ 84 ] . In the Dengue virus model , chloroquine was found to inhibit interferon-alpha ( IFN\u03b1 ) , IFN\u03b2 , IFN\u03b3 , TNF\u03b1 , IL-6 and IL-12 gene expression in U937 cells infected with Dengue-2 virus [ 33 ] .", "labels": [[87, 99, "ENTITY"], [128, 136, "ENTITY"], [87, 99, "CHEMICAL"], [74, 87, "ENTITY"], [53, 58, "ENTITY"], [128, 136, "CHEMICAL"], [238, 252, "ENTITY"], [169, 188, "PROTEIN"], [111, 128, "ENTITY"], [188, 195, "GENE_OR_GENE_PRODUCT"], [58, 74, "CL"], [263, 277, "GENE_OR_GENE_PRODUCT"], [238, 252, "CELL_LINE"], [128, 136, "CHEBI"], [161, 169, "PROTEIN"], [53, 74, "CELL"], [218, 223, "GENE_OR_GENE_PRODUCT"], [53, 74, "CELL_LINE"], [111, 122, "ORGANISM"], [128, 136, "SIMPLE_CHEMICAL"], [0, 11, "ENTITY"], [188, 195, "PROTEIN"], [188, 195, "ENTITY"], [169, 188, "ENTITY"], [169, 188, "GENE_OR_GENE_PRODUCT"], [161, 169, "ENTITY"], [238, 252, "CELL"], [161, 169, "GENE_OR_GENE_PRODUCT"], [18, 32, "PROTEIN"], [87, 99, "SIMPLE_CHEMICAL"], [218, 223, "PROTEIN"], [18, 32, "ENTITY"], [223, 238, "ENTITY"], [218, 227, "GGP"], [218, 223, "ENTITY"], [87, 99, "CHEBI"], [263, 286, "CHEMICAL"], [18, 32, "GENE_OR_GENE_PRODUCT"], [263, 277, "ENTITY"], [111, 122, "TAXON"], [238, 252, "CL"], [53, 74, "ENTITY"]]}
{"text": "Inhibition of the TNF\u03b1 receptor was also reported in U937 monocytic cells treated with chloroquine [ 84 ] . In the Dengue virus model , chloroquine was found to inhibit interferon-alpha ( IFN\u03b1 ) , IFN\u03b2 , IFN\u03b3 , TNF\u03b1 , IL-6 and IL-12 gene expression in U937 cells infected with Dengue-2 virus [ 33 ] .", "labels": [[218, 223, "PROTEIN"], [87, 99, "ENTITY"], [128, 136, "ENTITY"], [87, 99, "CHEMICAL"], [74, 87, "ENTITY"], [53, 58, "ENTITY"], [128, 136, "CHEMICAL"], [238, 252, "ENTITY"], [169, 188, "PROTEIN"], [111, 128, "ENTITY"], [188, 195, "GENE_OR_GENE_PRODUCT"], [58, 74, "CL"], [263, 277, "GENE_OR_GENE_PRODUCT"], [238, 252, "CELL_LINE"], [128, 136, "CHEBI"], [161, 169, "PROTEIN"], [53, 74, "CELL"], [18, 32, "PROTEIN"], [18, 32, "GENE_OR_GENE_PRODUCT"], [53, 74, "CELL_LINE"], [111, 122, "ORGANISM"], [128, 136, "SIMPLE_CHEMICAL"], [0, 11, "ENTITY"], [188, 195, "PROTEIN"], [188, 195, "ENTITY"], [169, 188, "ENTITY"], [169, 188, "GENE_OR_GENE_PRODUCT"], [161, 169, "ENTITY"], [238, 252, "CELL"], [161, 169, "GENE_OR_GENE_PRODUCT"], [87, 99, "SIMPLE_CHEMICAL"], [223, 238, "ENTITY"], [218, 223, "ENTITY"], [218, 227, "GGP"], [87, 99, "CHEBI"], [263, 286, "CHEMICAL"], [263, 277, "ENTITY"], [218, 223, "GENE_OR_GENE_PRODUCT"], [111, 122, "TAXON"], [238, 252, "CL"], [18, 32, "ENTITY"], [53, 74, "ENTITY"]]}
{"text": "Inhibition of the TNF\u03b1 receptor was also reported in U937 monocytic cells treated with chloroquine [ 84 ] . In the Dengue virus model , chloroquine was found to inhibit interferon-alpha ( IFN\u03b1 ) , IFN\u03b2 , IFN\u03b3 , TNF\u03b1 , IL-6 and IL-12 gene expression in U937 cells infected with Dengue-2 virus [ 33 ] .", "labels": [[87, 99, "ENTITY"], [128, 136, "ENTITY"], [87, 99, "CHEMICAL"], [74, 87, "ENTITY"], [53, 58, "ENTITY"], [128, 136, "CHEMICAL"], [238, 252, "ENTITY"], [169, 188, "PROTEIN"], [111, 128, "ENTITY"], [188, 195, "GENE_OR_GENE_PRODUCT"], [58, 74, "CL"], [263, 277, "GENE_OR_GENE_PRODUCT"], [238, 252, "CELL_LINE"], [128, 136, "CHEBI"], [223, 238, "ENTITY"], [161, 169, "PROTEIN"], [53, 74, "CELL"], [18, 32, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [18, 32, "GENE_OR_GENE_PRODUCT"], [53, 74, "CELL_LINE"], [111, 122, "ORGANISM"], [128, 136, "SIMPLE_CHEMICAL"], [0, 11, "ENTITY"], [188, 195, "PROTEIN"], [188, 195, "ENTITY"], [169, 188, "ENTITY"], [169, 188, "GENE_OR_GENE_PRODUCT"], [161, 169, "ENTITY"], [238, 252, "CELL"], [161, 169, "GENE_OR_GENE_PRODUCT"], [87, 99, "SIMPLE_CHEMICAL"], [218, 223, "PROTEIN"], [218, 227, "GGP"], [218, 223, "ENTITY"], [87, 99, "CHEBI"], [263, 286, "CHEMICAL"], [263, 277, "ENTITY"], [111, 122, "TAXON"], [238, 252, "CL"], [18, 32, "ENTITY"], [53, 74, "ENTITY"]]}
{"text": "Finally , chloroquine remains a pivotal drug in the treatment of Malaria in many places in the world .", "labels": []}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses", "labels": [[113, 124, "CANCER"], [0, 31, "ENTITY"], [0, 31, "CHEMICAL"], [193, 197, "SO"], [35, 46, "ENTITY"], [113, 124, "ENTITY"], [222, 231, "ORGANISM"], [0, 31, "SIMPLE_CHEMICAL"], [193, 197, "ENTITY"], [113, 124, "DISEASE"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses [ 3 ] .", "labels": [[113, 124, "CANCER"], [0, 31, "ENTITY"], [0, 31, "CHEMICAL"], [193, 197, "SO"], [35, 46, "ENTITY"], [222, 231, "ENTITY"], [222, 245, "ORGANISM"], [113, 124, "ENTITY"], [0, 31, "SIMPLE_CHEMICAL"], [193, 197, "ENTITY"], [113, 124, "DISEASE"]]}
{"text": "For decades , CQ and HCQ are front-line medications for the treatment and prophylaxis of malaria and are also used to treat autoimmune diseases , including rheumatoid arthritis ( RA ) and systemic lupus erythematosus ( SLE ) .", "labels": [[203, 217, "DISEASE"], [203, 217, "ENTITY"], [146, 167, "DISEASE"], [4, 12, "ENTITY"], [184, 203, "ENTITY"], [29, 40, "ENTITY"], [184, 203, "DISEASE"], [124, 135, "DISEASE"], [124, 135, "ENTITY"], [146, 167, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses", "labels": [[113, 124, "DISEASE"], [0, 31, "ENTITY"], [0, 31, "CHEMICAL"], [113, 124, "CANCER"], [193, 197, "SO"], [35, 46, "ENTITY"], [0, 31, "SIMPLE_CHEMICAL"], [193, 197, "ENTITY"], [113, 124, "ENTITY"], [222, 231, "ORGANISM"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses", "labels": [[113, 124, "CANCER"], [0, 31, "ENTITY"], [0, 31, "CHEMICAL"], [193, 197, "SO"], [35, 46, "ENTITY"], [113, 124, "ENTITY"], [222, 231, "ORGANISM"], [0, 31, "SIMPLE_CHEMICAL"], [193, 197, "ENTITY"], [113, 124, "DISEASE"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses [ 3 ] .", "labels": [[0, 31, "ENTITY"], [0, 31, "CHEMICAL"], [113, 124, "ENTITY"], [113, 124, "CANCER"], [193, 197, "SO"], [35, 46, "ENTITY"], [222, 231, "ENTITY"], [222, 245, "ORGANISM"], [0, 31, "SIMPLE_CHEMICAL"], [193, 197, "ENTITY"], [113, 124, "DISEASE"]]}
{"text": "For decades , CQ and HCQ are front-line medications for the treatment and prophylaxis of malaria and are also used to treat autoimmune diseases , including rheumatoid arthritis ( RA ) and systemic lupus erythematosus ( SLE ) .", "labels": [[203, 217, "DISEASE"], [203, 217, "ENTITY"], [146, 167, "DISEASE"], [4, 12, "ENTITY"], [184, 203, "ENTITY"], [29, 40, "ENTITY"], [184, 203, "DISEASE"], [124, 135, "DISEASE"], [124, 135, "ENTITY"], [146, 167, "ENTITY"]]}
{"text": "For decades , CQ and HCQ are front-line medications for the treatment and prophylaxis of malaria and are also used to treat autoimmune diseases , including rheumatoid arthritis ( RA ) and systemic lupus erythematosus ( SLE ) .", "labels": [[146, 167, "DISEASE"], [4, 12, "ENTITY"], [29, 40, "ENTITY"], [203, 217, "DISEASE"], [203, 217, "ENTITY"], [124, 135, "DISEASE"], [124, 135, "ENTITY"], [146, 167, "ENTITY"], [184, 203, "DISEASE"], [184, 203, "ENTITY"]]}
{"text": "Previous studies reported that CQ/HCQ possess a broad spectrum of antiviral effects on a variety of viruses as diverse as human immunodeficiency virus (HIV)[30 ] , Marburg virus , Zika virus [ 31 ] , dengue virus[32 ] , Ebola virus[33 ] , and SARS-CoV-1[34,35 ] , etc .", "labels": [[122, 128, "TAXON"], [122, 151, "ENTITY"], [162, 172, "ENTITY"], [122, 151, "ORGANISM"], [226, 243, "PROTEIN"], [178, 185, "ENTITY"], [226, 243, "ENTITY"], [66, 84, "ENTITY"], [100, 106, "TAXON"], [178, 185, "ORGANISM"], [180, 185, "TAXON"], [100, 108, "TAXON"], [31, 38, "CELL"], [200, 207, "GENE_OR_GENE_PRODUCT"], [218, 226, "GENE_OR_GENE_PRODUCT"], [207, 226, "ENTITY"], [122, 185, "DISEASE"], [164, 172, "TAXON"], [9, 17, "ENTITY"], [31, 38, "PROTEIN"], [31, 38, "DISEASE"], [200, 207, "CHEMICAL"], [100, 108, "ENTITY"]]}
{"text": "Previous studies reported that CQ/HCQ possess a broad spectrum of antiviral effects on a variety of viruses as diverse as human immunodeficiency virus (HIV)[30 ] , Marburg virus , Zika virus [ 31 ] , dengue virus[32 ] , Ebola virus[33 ] , and SARS-CoV-1[34,35 ] , etc .", "labels": [[122, 128, "TAXON"], [122, 151, "ENTITY"], [164, 172, "TAXON"], [122, 151, "ORGANISM"], [226, 243, "PROTEIN"], [178, 185, "ENTITY"], [226, 243, "ENTITY"], [66, 84, "ENTITY"], [100, 106, "TAXON"], [178, 185, "ORGANISM"], [180, 185, "TAXON"], [100, 108, "TAXON"], [162, 172, "ENTITY"], [31, 38, "CELL"], [200, 207, "GENE_OR_GENE_PRODUCT"], [218, 226, "GENE_OR_GENE_PRODUCT"], [207, 226, "ENTITY"], [9, 17, "ENTITY"], [31, 38, "PROTEIN"], [31, 38, "DISEASE"], [200, 207, "CHEMICAL"], [100, 108, "ENTITY"], [122, 185, "DISEASE"]]}
{"text": "Previous studies reported that CQ/HCQ possess a broad spectrum of antiviral effects on a variety of viruses as diverse as human immunodeficiency virus (HIV)[30 ] , Marburg virus , Zika virus [ 31 ] , dengue virus[32 ] , Ebola virus[33 ] , and SARS-CoV-1[34,35 ] , etc .", "labels": [[122, 128, "TAXON"], [122, 151, "ENTITY"], [162, 172, "ENTITY"], [122, 151, "ORGANISM"], [226, 243, "PROTEIN"], [178, 185, "ENTITY"], [226, 243, "ENTITY"], [66, 84, "ENTITY"], [100, 106, "TAXON"], [178, 185, "ORGANISM"], [180, 185, "TAXON"], [100, 108, "TAXON"], [31, 38, "CELL"], [122, 185, "DISEASE"], [200, 207, "GENE_OR_GENE_PRODUCT"], [218, 226, "GENE_OR_GENE_PRODUCT"], [207, 226, "ENTITY"], [164, 172, "TAXON"], [9, 17, "ENTITY"], [31, 38, "PROTEIN"], [31, 38, "DISEASE"], [200, 207, "CHEMICAL"], [100, 108, "ENTITY"]]}
{"text": "Previous studies reported that CQ/HCQ possess a broad spectrum of antiviral effects on a variety of viruses as diverse as human immunodeficiency virus (HIV)[30 ] , Marburg virus , Zika virus [ 31 ] , dengue virus[32 ] , Ebola virus[33 ] , and SARS-CoV-1[34,35 ] , etc .", "labels": [[122, 128, "TAXON"], [122, 151, "ENTITY"], [162, 172, "ENTITY"], [122, 151, "ORGANISM"], [226, 243, "PROTEIN"], [178, 185, "ENTITY"], [226, 243, "ENTITY"], [66, 84, "ENTITY"], [100, 106, "TAXON"], [178, 185, "ORGANISM"], [180, 185, "TAXON"], [100, 108, "TAXON"], [31, 38, "CELL"], [122, 185, "DISEASE"], [200, 207, "GENE_OR_GENE_PRODUCT"], [218, 226, "GENE_OR_GENE_PRODUCT"], [207, 226, "ENTITY"], [164, 172, "TAXON"], [9, 17, "ENTITY"], [31, 38, "PROTEIN"], [31, 38, "DISEASE"], [200, 207, "CHEMICAL"], [100, 108, "ENTITY"]]}
{"text": "Previous studies reported that CQ/HCQ possess a broad spectrum of antiviral effects on a variety of viruses as diverse as human immunodeficiency virus (HIV)[30 ] , Marburg virus , Zika virus [ 31 ] , dengue virus[32 ] , Ebola virus[33 ] , and SARS-CoV-1[34,35 ] , etc .", "labels": [[122, 128, "TAXON"], [218, 226, "GENE_OR_GENE_PRODUCT"], [122, 151, "ENTITY"], [162, 172, "ENTITY"], [122, 151, "ORGANISM"], [226, 243, "PROTEIN"], [178, 185, "ENTITY"], [226, 243, "ENTITY"], [66, 84, "ENTITY"], [100, 106, "TAXON"], [178, 185, "ORGANISM"], [180, 185, "TAXON"], [100, 108, "TAXON"], [31, 38, "CELL"], [122, 185, "DISEASE"], [200, 207, "GENE_OR_GENE_PRODUCT"], [207, 226, "ENTITY"], [164, 172, "TAXON"], [9, 17, "ENTITY"], [31, 38, "PROTEIN"], [31, 38, "DISEASE"], [200, 207, "CHEMICAL"], [100, 108, "ENTITY"]]}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "ATV alone showed a nearly 10-fold increase in potency for inhibiting SARS-CoV-2 replication in A549 ( Figure 6C ) compared to Vero cells ( Figure 6B ) . ATV/RTV and CQ were similarly potent in inhibiting virus replication in both cell types ( Figure 6B and C ) .", "labels": [[0, 4, "ENTITY"], [95, 100, "CELL"], [100, 109, "CELL"], [225, 235, "ENTITY"], [123, 131, "CELL_LINE"], [146, 149, "ENTITY"], [69, 80, "CHEMICAL"], [0, 4, "PROTEIN"], [235, 243, "ENTITY"], [95, 100, "ENTITY"], [123, 131, "ENTITY"], [183, 193, "ENTITY"], [46, 54, "ENTITY"], [102, 109, "ENTITY"], [126, 131, "CL"], [69, 92, "ENTITY"], [100, 109, "ENTITY"], [58, 69, "TAXON"], [193, 210, "ENTITY"], [58, 69, "ENTITY"], [34, 43, "ENTITY"], [69, 80, "SIMPLE_CHEMICAL"], [123, 131, "CELL"], [0, 4, "SIMPLE_CHEMICAL"], [0, 4, "CHEMICAL"]]}
{"text": "ATV/RTV and CQ were similarly efficient to inhibit viral replication in the human monocytes ( Figure 7A ) .", "labels": [[0, 8, "SIMPLE_CHEMICAL"], [43, 51, "ENTITY"], [76, 82, "ENTITY"], [30, 40, "ENTITY"], [76, 92, "CELL_TYPE"], [0, 8, "CHEMICAL"], [12, 15, "SIMPLE_CHEMICAL"], [76, 92, "ORGANISM"], [12, 15, "CHEMICAL"], [12, 15, "ENTITY"], [51, 69, "ENTITY"], [82, 92, "ENTITY"], [51, 57, "TAXON"], [0, 8, "PROTEIN"], [76, 92, "TAXON"], [0, 8, "ENTITY"], [94, 101, "GENE_OR_GENE_PRODUCT"], [94, 101, "ENTITY"]]}
{"text": "Based on these results , we performed virtual docking to screen for commercial medicines in the DrugBank database that could bind to the above mentioned pocket site of 2019-nCoV Mpro , and identified 10 candidate clinical medicines ( Table 1 ; Figs. 1B and S3 ) .", "labels": [[15, 23, "ENTITY"], [96, 105, "ENTITY"], [153, 160, "ENTITY"], [38, 46, "ENTITY"], [68, 79, "ENTITY"], [203, 222, "ENTITY"], [153, 160, "SO"], [168, 178, "ENTITY"]]}
{"text": "However , corticosteroid therapy could be associated with delayed MERS-CoV RNA clearance ( adjusted hazard ratio , 0.35 ; 95 % CI , 0.17\u20130.72 ; p = 0.005 ) for critically ill patients with MERS,[40 ] and early corticosteroid treatment could be associated with higher subsequent plasma RNA load of SARS-CoV for adults with SARS.[41 ] Moreover , corticosteroid-associated psychosis and diabetes were observed in the treatment of SARS.[42,43 ] .", "labels": [[148, 160, "ENTITY"], [297, 306, "ENTITY"], [148, 160, "DISEASE"], [10, 25, "ENTITY"], [200, 210, "SIMPLE_CHEMICAL"], [370, 380, "ENTITY"], [310, 322, "PROTEIN"], [66, 75, "ENTITY"], [267, 278, "ENTITY"], [370, 380, "DISEASE"], [398, 410, "ENTITY"], [160, 175, "ORGANISM"], [414, 427, "GENE_OR_GENE_PRODUCT"], [333, 344, "ENTITY"], [200, 210, "ENTITY"], [310, 322, "ENTITY"], [414, 427, "ENTITY"], [175, 189, "GENE_OR_GENE_PRODUCT"], [160, 175, "ENTITY"], [333, 344, "DISEASE"], [267, 278, "SO"], [289, 297, "ORGANISM"], [33, 42, "ENTITY"], [10, 25, "ENTITY"], [414, 427, "PROTEIN"], [66, 75, "RNA"], [267, 278, "RNA"], [278, 285, "ENTITY"], [175, 189, "CHEMICAL"], [91, 107, "ENTITY"], [289, 297, "GGP"], [289, 297, "PROTEIN"], [289, 297, "ENTITY"], [175, 189, "ENTITY"]]}
{"text": "However , corticosteroid therapy could be associated with delayed MERS-CoV RNA clearance ( adjusted hazard ratio , 0.35 ; 95 % CI , 0.17\u20130.72 ; p = 0.005 ) for critically ill patients with MERS,[40 ] and early corticosteroid treatment could be associated with higher subsequent plasma RNA load of SARS-CoV for adults with SARS.[41 ] Moreover , corticosteroid-associated psychosis and diabetes were observed in the treatment of SARS.[42,43 ] .", "labels": [[148, 160, "ENTITY"], [297, 306, "ENTITY"], [148, 160, "DISEASE"], [10, 25, "ENTITY"], [200, 210, "SIMPLE_CHEMICAL"], [370, 380, "ENTITY"], [310, 322, "PROTEIN"], [66, 75, "ENTITY"], [267, 278, "ENTITY"], [370, 380, "DISEASE"], [398, 410, "ENTITY"], [160, 175, "ORGANISM"], [414, 427, "GENE_OR_GENE_PRODUCT"], [333, 344, "ENTITY"], [200, 210, "ENTITY"], [310, 322, "ENTITY"], [414, 427, "ENTITY"], [175, 189, "GENE_OR_GENE_PRODUCT"], [160, 175, "ENTITY"], [333, 344, "DISEASE"], [267, 278, "SO"], [289, 297, "ORGANISM"], [33, 42, "ENTITY"], [10, 25, "ENTITY"], [414, 427, "PROTEIN"], [66, 75, "RNA"], [267, 278, "RNA"], [278, 285, "ENTITY"], [175, 189, "CHEMICAL"], [91, 107, "ENTITY"], [289, 297, "GGP"], [289, 297, "PROTEIN"], [289, 297, "ENTITY"], [175, 189, "ENTITY"]]}
{"text": "However , corticosteroid therapy could be associated with delayed MERS-CoV RNA clearance ( adjusted hazard ratio , 0.35 ; 95 % CI , 0.17\u20130.72 ; p = 0.005 ) for critically ill patients with MERS,[40 ] and early corticosteroid treatment could be associated with higher subsequent plasma RNA load of SARS-CoV for adults with SARS.[41 ] Moreover , corticosteroid-associated psychosis and diabetes were observed in the treatment of SARS.[42,43 ] .", "labels": [[148, 160, "ENTITY"], [297, 306, "ENTITY"], [148, 160, "DISEASE"], [10, 25, "ENTITY"], [200, 210, "SIMPLE_CHEMICAL"], [370, 380, "ENTITY"], [310, 322, "PROTEIN"], [66, 75, "ENTITY"], [267, 278, "ENTITY"], [370, 380, "DISEASE"], [398, 410, "ENTITY"], [160, 175, "ORGANISM"], [414, 427, "GENE_OR_GENE_PRODUCT"], [333, 344, "ENTITY"], [200, 210, "ENTITY"], [310, 322, "ENTITY"], [414, 427, "ENTITY"], [175, 189, "GENE_OR_GENE_PRODUCT"], [160, 175, "ENTITY"], [333, 344, "DISEASE"], [267, 278, "SO"], [289, 297, "ORGANISM"], [33, 42, "ENTITY"], [10, 25, "ENTITY"], [414, 427, "PROTEIN"], [66, 75, "RNA"], [267, 278, "RNA"], [278, 285, "ENTITY"], [175, 189, "CHEMICAL"], [91, 107, "ENTITY"], [289, 297, "GGP"], [289, 297, "PROTEIN"], [289, 297, "ENTITY"], [175, 189, "ENTITY"]]}
{"text": "It appears that Arbidol treatment could improve the discharging rate and decrease the mortality rate ( Table 5).The efficiency of antifungal agent and corticosteroids were also analyzed in Supplementary Table 1 and Table 2 . Antifungal agent did not show influence on the outcome of COVID-19 patients . And use of corticosteroids were associated with a higher risk of death .", "labels": [[297, 306, "ENTITY"], [16, 24, "CHEMICAL"], [203, 229, "CELL"], [239, 260, "ENTITY"], [159, 175, "SIMPLE_CHEMICAL"], [297, 317, "ORGANISM"], [349, 367, "ENTITY"], [203, 229, "ENTITY"], [-1, 20, "ENTITY"], [159, 175, "ENTITY"], [159, 175, "CHEBI"], [159, 175, "ENTITY"], [-1, 11, "ENTITY"], [159, 175, "CHEBI"], [118, 129, "ENTITY"], [73, 82, "ENTITY"], [306, 317, "ENTITY"], [159, 175, "SIMPLE_CHEMICAL"], [40, 48, "ENTITY"], [159, 175, "CHEMICAL"], [286, 297, "ENTITY"], [-1, 20, "SIMPLE_CHEMICAL"], [16, 34, "ENTITY"], [86, 101, "ENTITY"], [52, 69, "ENTITY"], [297, 306, "DISEASE"], [269, 282, "ENTITY"]]}
{"text": "The authors hypothesise that approaches such as corticosteroids or Janus kinase ( JAK ) inhibitors could be considered if hyperinflammation is present .", "labels": [[29, 40, "ENTITY"], [67, 80, "PROTEIN"], [67, 80, "ENTITY"], [67, 80, "GENE_OR_GENE_PRODUCT"], [4, 12, "ENTITY"], [48, 64, "ENTITY"], [48, 64, "SIMPLE_CHEMICAL"], [48, 64, "CHEBI"]]}
{"text": "Accordingly , findings from multiple studies in humans and animals indicate that corticosteroid immunosuppression ( both inhaled and systemic ) impairs induction of anti-viral type-I interferon responses to a range of respiratory viruses,3,4 effects that are likely to also occur in the context of COVID-19 .", "labels": [[81, 96, "ENTITY"], [218, 230, "GENE_OR_GENE_PRODUCT"], [162, 194, "ENTITY"], [144, 152, "ENTITY"], [28, 37, "ENTITY"], [162, 183, "PROTEIN"]]}
{"text": "In this phase , use of corticosteroids may be justified in concert with the use of cytokine inhibitors such as tocilizumab ( IL-6 inhibitor ) or anakinra ( IL-1 receptor antagonist ) .", "labels": [[83, 92, "CHEBI"], [145, 170, "ENTITY"], [8, 14, "ENTITY"], [125, 130, "ENTITY"], [123, 130, "GGP"], [145, 170, "GGP"], [145, 170, "PROTEIN"], [145, 170, "GENE_OR_GENE_PRODUCT"], [83, 92, "ENTITY"]]}
{"text": "Also , according to Jian-ya et al. , treatment of 51 COVID-19 patients with traditional Chinese medicine , interferon , Lopinavir , Ritonavir and short-term ( 3 to 5 days ) corticosteroids was successful and resulted in recovery and discharge of 50 patients ( 3 ) .", "labels": [[166, 173, "ENTITY"], [220, 233, "ENTITY"], [53, 62, "ENTITY"], [50, 62, "ORGANISM"], [243, 249, "ENTITY"], [107, 120, "SIMPLE_CHEMICAL"], [120, 132, "SIMPLE_CHEMICAL"], [120, 132, "ENTITY"], [120, 132, "CHEMICAL"], [107, 120, "CHEMICAL"], [208, 220, "ENTITY"], [107, 120, "ENTITY"], [76, 96, "ENTITY"], [243, 249, "ORGANISM"], [166, 173, "SIMPLE_CHEMICAL"]]}
{"text": "Few patients had kidney injury indicated by elevated plasma urea ( 9 of 198 [ 4.5 % ] ) and serum creatinine ( 9 of 198 [ 4.5 % ] ) .", "labels": [[44, 53, "ENTITY"], [60, 65, "CHEBI"], [17, 31, "ENTITY"], [92, 98, "CHEBI"], [88, 98, "ENTITY"], [92, 98, "CHEMICAL"], [53, 65, "ENTITY"], [17, 24, "ORGAN"], [60, 65, "CHEMICAL"], [53, 65, "ORGANISM_SUBSTANCE"], [88, 98, "ORGANISM_SUBSTANCE"], [17, 31, "DISEASE"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "But in the severe patients , the neutrophil count , D-dimer , blood urea , and creatinine levels were higher significantly , and the lymphocyte counts continued to decrease .", "labels": [[11, 18, "ENTITY"], [79, 90, "ENTITY"], [60, 68, "GGP"], [33, 44, "ENTITY"], [60, 68, "DISEASE"], [18, 27, "ENTITY"], [60, 68, "ENTITY"], [18, 27, "ORGANISM"], [60, 68, "ORGANISM_SUBSTANCE"], [151, 164, "ENTITY"], [133, 144, "ENTITY"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 90, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [65, 90, "PROTEIN"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Those with elevated TnT levels also had higher levels of creatinine ( median [ IQR ] , 0.79 [ 0.71 - 1.17 ] vs 0.63 [ 0.55 - 0.79 ] mg/dL [ to convert to micromoles per liter , multiply by 88.4 ] ) and aspartate aminotransferase ( median [ IQR ] , 39.5 [ 27.2 - 57.8 ] vs 29.0 [21.0 - 39.0]U/L [ to convert to microkatal per liter , multiply by 0.0167 ] ) ( P < .001 , both ) , but alanine aminotransferase did not differ between the 2 groups .", "labels": [[57, 68, "CHEBI"], [186, 212, "GENE_OR_GENE_PRODUCT"], [11, 20, "ENTITY"], [24, 31, "ENTITY"], [186, 212, "GGP"], [20, 24, "ENTITY"], [57, 68, "SIMPLE_CHEMICAL"], [20, 24, "PROTEIN"], [186, 196, "CHEMICAL"], [345, 369, "PROTEIN"], [345, 369, "ENTITY"], [57, 68, "ENTITY"], [186, 212, "PROTEIN"], [57, 68, "CHEMICAL"], [212, 229, "ENTITY"], [24, 31, "ENTITY"], [186, 212, "ENTITY"], [345, 369, "GENE_OR_GENE_PRODUCT"], [20, 24, "GENE_OR_GENE_PRODUCT"], [283, 294, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "As we have previously demonstrated that several glycopeptide antibiotics , including teicoplanin and dalbavancin , exhibited specific inhibitory effects on cathepsin L , we therefore hypothesized that teicoplanin and its homologs could also inhibit the entry of 2019-nCoV.", "labels": [[153, 166, "PROTEIN"], [48, 73, "CHEBI"], [125, 134, "ENTITY"], [153, 166, "GENE_OR_GENE_PRODUCT"], [153, 166, "GGP"], [48, 73, "ENTITY"], [153, 166, "ENTITY"], [48, 61, "SIMPLE_CHEMICAL"]]}
{"text": "The data illustrated that the dalbavancin also repressed the entry of 2019-nCoV in a dose-dependent manner ( Figure 3C ) .", "labels": [[61, 67, "ENTITY"], [85, 100, "ENTITY"], [47, 57, "ENTITY"], [30, 42, "SIMPLE_CHEMICAL"], [70, 80, "ENTITY"], [30, 42, "CHEBI"], [4, 9, "ENTITY"], [109, 116, "ENTITY"], [30, 42, "CHEMICAL"], [30, 42, "ENTITY"]]}
{"text": "As we have previously demonstrated that several glycopeptide antibiotics , including teicoplanin and dalbavancin , exhibited specific inhibitory effects on cathepsin L , we therefore hypothesized that teicoplanin and its homologs could also inhibit the entry of 2019-nCoV.", "labels": [[153, 166, "PROTEIN"], [48, 73, "CHEBI"], [125, 134, "ENTITY"], [153, 166, "GENE_OR_GENE_PRODUCT"], [153, 166, "GGP"], [48, 73, "ENTITY"], [153, 166, "ENTITY"], [48, 61, "SIMPLE_CHEMICAL"]]}
{"text": "The data illustrated that the dalbavancin also repressed the entry of 2019-nCoV in a dose-dependent manner ( Figure 3C ) .", "labels": [[85, 100, "ENTITY"], [47, 57, "ENTITY"], [30, 42, "SIMPLE_CHEMICAL"], [70, 80, "ENTITY"], [61, 67, "ENTITY"], [30, 42, "CHEBI"], [4, 9, "ENTITY"], [109, 116, "ENTITY"], [30, 42, "CHEMICAL"], [30, 42, "ENTITY"]]}
{"text": "Cell experiments indicated that darunavir significantly inhibited viral replication at a concentration of 300 \u03bcM in vitro and that its inhibition efficiency was 280-fold that in the untreated group ( 9 )", "labels": [[32, 42, "ENTITY"], [0, 5, "CL"], [0, 17, "ENTITY"], [135, 146, "ENTITY"], [32, 42, "CHEMICAL"], [32, 42, "SIMPLE_CHEMICAL"], [182, 198, "ENTITY"], [66, 72, "TAXON"], [89, 103, "ENTITY"], [66, 84, "ENTITY"], [56, 66, "ENTITY"], [113, 122, "ENTITY"], [146, 157, "ENTITY"], [0, 5, "CELL"], [110, 113, "PROTEIN"]]}
{"text": "Studies have also revealed some other drugs may have potential efficacy in treating COVID-19 . One is darunavir , which is a second-generation of HIV-1 protease inhibitor . On February 4 , 2020 , researchers in China announced that darunavir inhibited SARS-CoV-2 infection in vitro ( 9 ) . Cell experiments indicated that darunavir significantly inhibited viral replication at a concentration of 300 \u03bcM in vitro and that its inhibition efficiency was 280-fold that in the untreated group ( 9 ) .", "labels": [[-1, 12, "CHEBI"], [-1, 27, "ENTITY"], [209, 219, "ORGANISM"], [450, 456, "ENTITY"], [-1, 20, "ENTITY"], [-1, 10, "CHEMICAL"], [-1, 10, "ENTITY"], [-1, 20, "CHEMICAL"], [134, 144, "ENTITY"], [134, 144, "ENTITY"], [-1, 8, "ENTITY"], [-1, 10, "ENTITY"], [481, 495, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [450, 456, "SIMPLE_CHEMICAL"], [24, 33, "ENTITY"], [-1, 19, "ENTITY"], [110, 121, "ENTITY"], [0, 8, "ENTITY"], [324, 335, "SIMPLE_CHEMICAL"], [598, 608, "ENTITY"], [-1, 14, "ENTITY"], [83, 92, "ENTITY"]]}
{"text": "Studies have also revealed some other drugs may have potential efficacy in treating COVID-19 . One is darunavir , which is a second-generation of HIV-1 protease inhibitor . On February 4 , 2020 , researchers in China announced that darunavir inhibited SARS-CoV-2 infection in vitro ( 9 ) . Cell experiments indicated that darunavir significantly inhibited viral replication at a concentration of 300 \u03bcM in vitro and that its inhibition efficiency was 280-fold that in the untreated group ( 9 ) .", "labels": [[-1, 12, "CHEBI"], [-1, 27, "ENTITY"], [209, 219, "ORGANISM"], [450, 456, "ENTITY"], [-1, 10, "CHEMICAL"], [-1, 10, "ENTITY"], [134, 144, "ENTITY"], [134, 144, "ENTITY"], [-1, 8, "ENTITY"], [-1, 10, "ENTITY"], [481, 495, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [-1, 14, "ENTITY"], [450, 456, "SIMPLE_CHEMICAL"], [24, 33, "ENTITY"], [-1, 19, "ENTITY"], [0, 8, "ENTITY"], [324, 335, "SIMPLE_CHEMICAL"], [598, 608, "ENTITY"], [-1, 20, "ENTITY"], [83, 92, "ENTITY"], [110, 121, "ENTITY"], [-1, 20, "CHEMICAL"]]}
{"text": "Studies have also revealed some other drugs may have potential efficacy in treating COVID-19 . One is darunavir , which is a second-generation of HIV-1 protease inhibitor . On February 4 , 2020 , researchers in China announced that darunavir inhibited SARS-CoV-2 infection in vitro ( 9 ) . Cell experiments indicated that darunavir significantly inhibited viral replication at a concentration of 300 \u03bcM in vitro and that its inhibition efficiency was 280-fold that in the untreated group ( 9 ) .", "labels": [[-1, 12, "CHEBI"], [-1, 27, "ENTITY"], [209, 219, "ORGANISM"], [450, 456, "ENTITY"], [-1, 20, "ENTITY"], [-1, 10, "CHEMICAL"], [-1, 10, "ENTITY"], [-1, 20, "CHEMICAL"], [134, 144, "ENTITY"], [134, 144, "ENTITY"], [-1, 8, "ENTITY"], [-1, 10, "ENTITY"], [481, 495, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [-1, 14, "ENTITY"], [450, 456, "SIMPLE_CHEMICAL"], [24, 33, "ENTITY"], [-1, 19, "ENTITY"], [110, 121, "ENTITY"], [0, 8, "ENTITY"], [324, 335, "SIMPLE_CHEMICAL"], [598, 608, "ENTITY"], [83, 92, "ENTITY"]]}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [0, 10, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [0, 10, "SIMPLE_CHEMICAL"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [0, 10, "CHEMICAL"], [198, 232, "ENTITY"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [0, 10, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [0, 10, "SIMPLE_CHEMICAL"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [0, 10, "CHEMICAL"], [198, 232, "ENTITY"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [110, 117, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [0, 10, "ENTITY"], [130, 138, "DISEASE"], [0, 10, "SIMPLE_CHEMICAL"], [337, 355, "GGP"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [0, 10, "CHEMICAL"], [110, 117, "DISEASE"], [198, 232, "ENTITY"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [297, 308, "ENTITY"], [130, 138, "DISEASE"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [0, 10, "ENTITY"], [110, 117, "DISEASE"], [0, 10, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [0, 10, "CHEMICAL"], [198, 232, "ENTITY"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [0, 10, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [0, 10, "SIMPLE_CHEMICAL"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [0, 10, "CHEMICAL"], [198, 232, "ENTITY"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [0, 10, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [0, 10, "SIMPLE_CHEMICAL"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [0, 10, "CHEMICAL"], [198, 232, "ENTITY"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [0, 10, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [0, 10, "SIMPLE_CHEMICAL"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [0, 10, "CHEMICAL"], [198, 232, "ENTITY"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [0, 10, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [0, 10, "SIMPLE_CHEMICAL"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [0, 10, "CHEMICAL"], [198, 232, "ENTITY"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [0, 10, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [0, 10, "SIMPLE_CHEMICAL"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [0, 10, "CHEMICAL"], [198, 232, "ENTITY"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Our results demonstrated that DIP ( 5 \u03bcM ) treatment significantly increased IFNB , IFIT1 , and ISG15 messenger RNA expression and promoted IFN-B secretion ( Figure 2A ) by increasing TBK1 and IRF3 phosphorylation ( Figure 2A) by increasing TBK1 and IRF3 phosphorylation ) .", "labels": [[146, 158, "ENTITY"], [53, 67, "ENTITY"], [184, 189, "GGP"], [67, 77, "GGP"], [198, 216, "ENTITY"], [67, 77, "ENTITY"], [30, 34, "SIMPLE_CHEMICAL"], [102, 112, "SO"], [184, 189, "GENE_OR_GENE_PRODUCT"], [67, 77, "PROTEIN"], [131, 140, "PROTEIN"], [112, 116, "ENTITY"], [4, 12, "ENTITY"], [30, 34, "CHEMICAL"], [92, 112, "RNA"], [131, 140, "ENTITY"], [140, 146, "ENTITY"], [184, 189, "ENTITY"], [184, 189, "PROTEIN"], [67, 77, "GENE_OR_GENE_PRODUCT"], [193, 198, "ENTITY"], [92, 112, "ENTITY"], [30, 34, "ENTITY"]]}
{"text": "Our results demonstrated that DIP ( 5 \u03bcM ) treatment significantly increased IFNB , IFIT1 , and ISG15 messenger RNA expression and promoted IFN-B secretion ( Figure 2A ) by increasing TBK1 and IRF3 phosphorylation ( Figure 2A) by increasing TBK1 and IRF3 phosphorylation ) .", "labels": [[146, 158, "ENTITY"], [53, 67, "ENTITY"], [184, 189, "GGP"], [67, 77, "GGP"], [198, 216, "ENTITY"], [67, 77, "ENTITY"], [30, 34, "SIMPLE_CHEMICAL"], [102, 112, "SO"], [184, 189, "GENE_OR_GENE_PRODUCT"], [67, 77, "PROTEIN"], [131, 140, "PROTEIN"], [112, 116, "ENTITY"], [4, 12, "ENTITY"], [140, 146, "ENTITY"], [30, 34, "CHEMICAL"], [92, 112, "RNA"], [131, 140, "ENTITY"], [184, 189, "ENTITY"], [184, 189, "PROTEIN"], [67, 77, "GENE_OR_GENE_PRODUCT"], [193, 198, "ENTITY"], [92, 112, "ENTITY"], [30, 34, "ENTITY"]]}
{"text": "Our results demonstrated that DIP ( 5 \u03bcM ) treatment significantly increased IFNB , IFIT1 , and ISG15 messenger RNA expression and promoted IFN-B secretion ( Figure 2A ) by increasing TBK1 and IRF3 phosphorylation ( Figure 2A) by increasing TBK1 and IRF3 phosphorylation ) .", "labels": [[146, 158, "ENTITY"], [53, 67, "ENTITY"], [184, 189, "GGP"], [67, 77, "GGP"], [198, 216, "ENTITY"], [67, 77, "ENTITY"], [30, 34, "SIMPLE_CHEMICAL"], [102, 112, "SO"], [184, 189, "GENE_OR_GENE_PRODUCT"], [67, 77, "PROTEIN"], [131, 140, "PROTEIN"], [112, 116, "ENTITY"], [4, 12, "ENTITY"], [140, 146, "ENTITY"], [30, 34, "CHEMICAL"], [131, 140, "ENTITY"], [184, 189, "ENTITY"], [92, 112, "ENTITY"], [184, 189, "PROTEIN"], [67, 77, "GENE_OR_GENE_PRODUCT"], [193, 198, "ENTITY"], [30, 34, "ENTITY"], [92, 112, "RNA"]]}
{"text": "Our results demonstrated that DIP ( 5 \u03bcM ) treatment significantly increased IFNB , IFIT1 , and ISG15 messenger RNA expression and promoted IFN-B secretion ( Figure 2A ) by increasing TBK1 and IRF3 phosphorylation ( Figure 2A) by increasing TBK1 and IRF3 phosphorylation ) .", "labels": [[146, 158, "ENTITY"], [53, 67, "ENTITY"], [67, 77, "GGP"], [198, 216, "ENTITY"], [67, 77, "ENTITY"], [30, 34, "SIMPLE_CHEMICAL"], [102, 112, "SO"], [184, 189, "GGP"], [67, 77, "PROTEIN"], [131, 140, "PROTEIN"], [112, 116, "ENTITY"], [4, 12, "ENTITY"], [140, 146, "ENTITY"], [30, 34, "CHEMICAL"], [92, 112, "RNA"], [131, 140, "ENTITY"], [184, 189, "PROTEIN"], [184, 189, "ENTITY"], [67, 77, "GENE_OR_GENE_PRODUCT"], [193, 198, "ENTITY"], [92, 112, "ENTITY"], [30, 34, "ENTITY"], [184, 189, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Our results demonstrated that DIP ( 5 \u03bcM ) treatment significantly increased IFNB , IFIT1 , and ISG15 messenger RNA expression and promoted IFN-B secretion ( Figure 2A ) by increasing TBK1 and IRF3 phosphorylation ( Figure 2A) by increasing TBK1 and IRF3 phosphorylation ) .", "labels": [[146, 158, "ENTITY"], [53, 67, "ENTITY"], [184, 189, "GGP"], [67, 77, "GGP"], [198, 216, "ENTITY"], [67, 77, "ENTITY"], [30, 34, "SIMPLE_CHEMICAL"], [102, 112, "SO"], [184, 189, "GENE_OR_GENE_PRODUCT"], [67, 77, "PROTEIN"], [131, 140, "PROTEIN"], [112, 116, "ENTITY"], [4, 12, "ENTITY"], [140, 146, "ENTITY"], [193, 198, "ENTITY"], [30, 34, "CHEMICAL"], [92, 112, "RNA"], [131, 140, "ENTITY"], [184, 189, "ENTITY"], [184, 189, "PROTEIN"], [67, 77, "GENE_OR_GENE_PRODUCT"], [92, 112, "ENTITY"], [30, 34, "ENTITY"]]}
{"text": "DIP administration significantly prolonged the survival rate of VSV-infected mice ( Figure 2C ) , and substantially alleviated pulmonary pathology ( Figure 2C), and substantially alleviated pulmonary pathology ) .", "labels": [[77, 82, "ORGANISM"], [116, 127, "ORGAN"], [0, 4, "ENTITY"], [137, 149, "ENTITY"], [0, 4, "CHEMICAL"], [0, 4, "SIMPLE_CHEMICAL"], [4, 19, "ENTITY"], [47, 61, "ENTITY"], [116, 137, "ENTITY"], [64, 82, "ENTITY"], [77, 82, "TAXON"], [33, 43, "ENTITY"], [84, 91, "ENTITY"]]}
{"text": "DIP administration significantly prolonged the survival rate of VSV-infected mice ( Figure 2C ) , and substantially alleviated pulmonary pathology ( Figure 2C), and substantially alleviated pulmonary pathology ) .", "labels": [[77, 82, "ORGANISM"], [47, 61, "ENTITY"], [116, 127, "ORGAN"], [0, 4, "ENTITY"], [137, 149, "ENTITY"], [0, 4, "CHEMICAL"], [0, 4, "SIMPLE_CHEMICAL"], [4, 19, "ENTITY"], [116, 137, "ENTITY"], [77, 82, "TAXON"], [64, 82, "ENTITY"], [33, 43, "ENTITY"], [84, 91, "ENTITY"]]}
{"text": "Two weeks after initiation of DIP treatment , 3 of the 6 severe cases ( 50 % ) and all 4 of the mild cases ( 100 % ) were discharged from the hospital", "labels": [[115, 122, "ENTITY"], [16, 27, "ENTITY"], [4, 10, "ENTITY"], [30, 34, "ENTITY"], [30, 34, "SIMPLE_CHEMICAL"], [34, 44, "ENTITY"], [92, 101, "ENTITY"], [133, 142, "ENTITY"], [30, 34, "CHEMICAL"]]}
{"text": "Furthermore , we observed a continuously increased trend in lymphocyte counts and significantly increased platelet numbers in patients receiving DIP treatment in comparison to the control group ( Figure 3A ) .", "labels": [[106, 115, "ENTITY"], [194, 203, "ENTITY"], [180, 188, "ENTITY"]]}
{"text": "Furthermore , we observed a continuously increased trend in lymphocyte counts and significantly increased platelet numbers in patients receiving DIP treatment in comparison to the control group ( Figure 3A ) .", "labels": [[106, 115, "ENTITY"], [194, 203, "ENTITY"], [180, 188, "ENTITY"]]}
{"text": "We measured dynamic changes in reference to the respective baseline levels for all patients , and found that the levels of D-dimer continuously rose in the control group , whereas they were decreased and stabilized in the DIP-treated group ( Figure 3A , Figure S2 ) .", "labels": [[83, 92, "ENTITY"], [222, 234, "ENTITY"], [68, 75, "ENTITY"], [83, 92, "ORGANISM"], [12, 20, "ENTITY"], [240, 249, "ENTITY"], [3, 12, "ENTITY"], [249, 254, "GENE_OR_GENE_PRODUCT"], [249, 254, "ENTITY"], [59, 68, "ENTITY"], [156, 164, "ENTITY"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [678, 691, "SIMPLE_CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [678, 691, "CHEMICAL"], [451, 464, "ENTITY"], [436, 449, "SIMPLE_CHEMICAL"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [678, 691, "ENTITY"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "In our opinion , during the COVID-19 pandemic , it would be more prudent to replace these drugs , when possible , with calcium channel blockers , adrenergic receptor blockers , diuretics or vasodilators .", "labels": [[135, 166, "ENTITY"], [7, 15, "ENTITY"], [114, 135, "ENTITY"], [114, 127, "CHEBI"], [28, 37, "ENTITY"], [135, 166, "GENE_OR_GENE_PRODUCT"], [135, 146, "ENTITY"], [135, 146, "SIMPLE_CHEMICAL"], [114, 135, "GENE_OR_GENE_PRODUCT"], [135, 157, "CHEBI"], [177, 190, "ENTITY"], [135, 146, "CHEBI"], [177, 190, "CHEBI"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [602, 616, "ENTITY"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [573, 588, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [-1, 10, "CHEMICAL"]]}
{"text": "Three days post infection , the typical cytopathic effect(CPE ) was observed under a light microscope ; the virus-induced CPE was obviously reduce in the presence of 8\u0002M emodin ( Fig. 5A ) .", "labels": [[163, 170, "SIMPLE_CHEMICAL"], [11, 26, "ENTITY"], [166, 170, "ENTITY"], [16, 26, "DISEASE"], [108, 122, "ENTITY"], [83, 91, "ENTITY"], [6, 11, "ENTITY"], [166, 170, "CHEBI"], [166, 170, "CHEMICAL"]]}
{"text": "In addition , the plaque reduction assay showed that emodin decreased the number and size of plaques in a dose-dependentmanner ; plaques were hardly detectable at 8\u0002M(Fig . 5B ) .", "labels": [[25, 35, "ENTITY"]]}
{"text": "Therefore , we suggest that emodin may contribute to reduced virus release from the SARS-CoV-infected cell through inhibition of the current medi-ated by 3a protein .", "labels": [[154, 157, "ENTITY"], [141, 157, "PROTEIN"], [84, 102, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Eplerenone ( Z = \u20131.59 ) , an aldosterone receptor antagonist , is reported to have a similar anti-inflammatory effect as melatonin .", "labels": [[0, 11, "CHEBI"], [31, 55, "GGP"], [90, 116, "ENTITY"], [0, 11, "ENTITY"], [0, 11, "SIMPLE_CHEMICAL"], [0, 11, "CHEMICAL"], [-1, 3, "CHEMICAL"], [31, 55, "ENTITY"], [31, 55, "GENE_OR_GENE_PRODUCT"], [31, 46, "PROTEIN"]]}
{"text": "Eplerenone ( Z = \u20131.59 ) , an aldosterone receptor antagonist , is reported to have a similar anti-inflammatory effect as melatonin .", "labels": [[0, 11, "CHEBI"], [31, 55, "GGP"], [90, 116, "ENTITY"], [0, 11, "ENTITY"], [0, 11, "SIMPLE_CHEMICAL"], [0, 11, "CHEMICAL"], [-1, 3, "CHEMICAL"], [31, 55, "ENTITY"], [31, 55, "GENE_OR_GENE_PRODUCT"], [31, 46, "PROTEIN"]]}
{"text": "Mesalazine ( an approved drug for inflammatory bowel disease ) , sirolimus ( an approved immunosuppressive drug ) , and equilin ( an approved agonist of the estrogen receptor for menopausal symptoms ) achieved the highest GSEA scores of 3 , followed by paroxetine and melatonin with GSEA scores of 2 .", "labels": [[0, 11, "CHEBI"], [114, 120, "SIMPLE_CHEMICAL"], [268, 278, "ENTITY"], [268, 278, "GENE_OR_GENE_PRODUCT"], [150, 166, "GENE_OR_GENE_PRODUCT"], [89, 107, "CHEBI"], [16, 25, "ENTITY"], [214, 222, "ENTITY"], [166, 190, "ENTITY"], [16, 25, "CHEBI"], [253, 268, "SIMPLE_CHEMICAL"], [150, 166, "PROTEIN"], [150, 157, "CHEMICAL"], [80, 107, "ENTITY"], [150, 166, "ENTITY"], [0, 11, "ENTITY"], [34, 53, "DISEASE"], [114, 120, "ENTITY"], [253, 268, "CHEMICAL"], [150, 166, "GGP"], [241, 253, "SIMPLE_CHEMICAL"], [114, 120, "PROTEIN"], [241, 253, "CHEBI"], [253, 268, "ENTITY"], [114, 120, "DISEASE"], [34, 53, "ENTITY"], [241, 253, "ENTITY"], [241, 253, "CHEMICAL"], [0, 11, "SIMPLE_CHEMICAL"], [0, 11, "CHEMICAL"]]}
{"text": "Favipiravir is converted into an active phosphoribosylated form ( Favipiravir is converted into an active phosphoribosylated form ) in cells and is recognized as a substrate by viral RNA polymerase , thus inhibiting RNA polymerase activity ( 11 ) .", "labels": [[0, 12, "ENTITY"], [-1, 4, "ENTITY"], [-1, 22, "PROTEIN"], [-1, 6, "TAXON"], [148, 161, "ENTITY"], [161, 167, "SO"], [161, 189, "ENTITY"], [-1, 14, "SIMPLE_CHEMICAL"], [161, 171, "PROTEIN"], [-1, 22, "ENTITY"]]}
{"text": "Favipiravir was approved for treatment of novel influenza on February 15 , 2020 in China .", "labels": [[29, 39, "ENTITY"], [0, 12, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [16, 25, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"], [29, 58, "PROTEIN"], [29, 58, "ENTITY"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [29, 58, "PROTEIN"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [29, 58, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [29, 58, "PROTEIN"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [29, 58, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [29, 58, "PROTEIN"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [29, 58, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [29, 58, "PROTEIN"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [29, 58, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [29, 58, "PROTEIN"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [29, 58, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [29, 58, "PROTEIN"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [29, 58, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [29, 58, "PROTEIN"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [29, 58, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"]]}
{"text": "Favipiravir is converted into an active phosphoribosylated form ( Favipiravir is converted into an active phosphoribosylated form ) in cells and is recognized as a substrate by viral RNA polymerase , thus inhibiting RNA polymerase activity ( 11 ) .", "labels": [[0, 12, "ENTITY"], [-1, 4, "ENTITY"], [-1, 22, "PROTEIN"], [-1, 6, "TAXON"], [148, 161, "ENTITY"], [161, 167, "SO"], [161, 189, "ENTITY"], [-1, 14, "SIMPLE_CHEMICAL"], [161, 171, "PROTEIN"], [-1, 22, "ENTITY"]]}
{"text": "The other antiviral drugs include nitazoxanide , favipiravir , nafamostat , and so on ( See Table 1 for details ) .", "labels": [[34, 47, "ENTITY"], [34, 47, "CHEMICAL"], [10, 26, "ENTITY"], [34, 47, "CHEBI"], [34, 47, "SIMPLE_CHEMICAL"]]}
{"text": "Favipiravir is the latest anti-novel coronavirus drug with specific therapeutic effects .", "labels": [[49, 54, "CHEBI"], [0, 12, "ENTITY"], [37, 54, "ENTITY"], [0, 12, "DISEASE"], [0, 12, "SIMPLE_CHEMICAL"], [68, 88, "ENTITY"], [26, 37, "ENTITY"], [37, 49, "ORGANISM"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [495, 511, "ENTITY"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "Other reported therapeutic agents that are used for the treatment of seriously ill patients have been noted in Table 1 .", "labels": [[79, 83, "ENTITY"], [83, 92, "ENTITY"], [83, 92, "ORGANISM"], [15, 34, "ENTITY"], [56, 66, "ENTITY"]]}
{"text": "7 ( 63.6 % ) severe cases and all moderate cases received antiviral therapy ( oseltamivir and/or ganciclovir ) .", "labels": [[68, 78, "ENTITY"], [90, 97, "ENTITY"], [68, 78, "CHEMICAL"], [13, 20, "ENTITY"], [34, 43, "ENTITY"], [90, 97, "SIMPLE_CHEMICAL"], [49, 68, "ENTITY"], [90, 97, "CHEMICAL"]]}
{"text": "Systemic glucocorticoids were given to 204 patients ( 18.6 % ) , with a higher percentage among those with severe disease than nonsevere disease ( 44.5 % vs. 13.7 % ) .", "labels": [[43, 52, "ENTITY"], [0, 9, "ENTITY"], [72, 79, "ENTITY"], [122, 137, "ENTITY"], [9, 25, "SIMPLE_CHEMICAL"], [9, 25, "ENTITY"], [9, 25, "CHEBI"], [9, 25, "CHEMICAL"], [43, 52, "ORGANISM"]]}
{"text": "Antibiotics , traditional Chinese medicine , intravenous glucocorticoids and immunoglobulin were also used dependent on patients \u2019 conditions .", "labels": [[45, 57, "CHEMICAL"], [0, 12, "ENTITY"], [0, 12, "CHEBI"], [43, 57, "ENTITY"], [45, 57, "CHEBI"], [26, 34, "ENTITY"], [43, 57, "ORGANISM_SUBSTANCE"]]}
{"text": "Systemic glucocorticoids were given to 204 patients ( 18.6 % ) , with a higher percentage among those with severe disease than nonsevere disease ( 44.5 % vs. 13.7 % ) .", "labels": [[43, 52, "ENTITY"], [0, 9, "ENTITY"], [72, 79, "ENTITY"], [122, 137, "ENTITY"], [9, 25, "SIMPLE_CHEMICAL"], [9, 25, "ENTITY"], [9, 25, "CHEBI"], [9, 25, "CHEMICAL"], [43, 52, "ORGANISM"]]}
{"text": "At present , systemic glucocorticoids administration was empirically used for severe complications in order to suppress CS manifestations in patients with COVID-19 , such as ARDS , acute heart injuries , acute kidney complication , and patients with higher D-dimer levels , et al[3 , 23 , 24 ]", "labels": [[250, 257, "ENTITY"], [181, 187, "ORGAN"], [193, 217, "ENTITY"], [250, 257, "PROTEIN"], [250, 257, "GENE_OR_GENE_PRODUCT"], [257, 265, "ENTITY"], [181, 193, "DISEASE"], [179, 193, "ENTITY"], [250, 257, "GGP"], [181, 187, "ORGAN"]]}
{"text": "At present , systemic glucocorticoids administration was empirically used for severe complications in order to suppress CS manifestations in patients with COVID-19 , such as ARDS , acute heart injuries , acute kidney complication , and patients with higher D-dimer levels , et al[3 , 23 , 24 ]", "labels": [[250, 257, "ENTITY"], [181, 187, "ORGAN"], [193, 217, "ENTITY"], [250, 257, "PROTEIN"], [250, 257, "GENE_OR_GENE_PRODUCT"], [257, 265, "ENTITY"], [181, 193, "DISEASE"], [179, 193, "ENTITY"], [250, 257, "GGP"], [181, 187, "ORGAN"]]}
{"text": "At present , systemic glucocorticoids administration was empirically used for severe complications in order to suppress CS manifestations in patients with COVID-19 , such as ARDS , acute heart injuries , acute kidney complication , and patients with higher D-dimer levels , et al[3 , 23 , 24 ]", "labels": [[250, 257, "ENTITY"], [181, 187, "ORGAN"], [193, 217, "ENTITY"], [250, 257, "PROTEIN"], [250, 257, "GENE_OR_GENE_PRODUCT"], [257, 265, "ENTITY"], [181, 193, "DISEASE"], [179, 193, "ENTITY"], [250, 257, "GGP"], [181, 187, "ORGAN"]]}
{"text": "At present , systemic glucocorticoids administration was empirically used for severe complications in order to suppress CS manifestations in patients with COVID-19 , such as ARDS , acute heart injuries , acute kidney complication , and patients with higher D-dimer levels , et al[3 , 23 , 24 ]", "labels": [[250, 257, "ENTITY"], [181, 187, "ORGAN"], [193, 217, "ENTITY"], [257, 265, "ENTITY"], [250, 257, "PROTEIN"], [250, 257, "GENE_OR_GENE_PRODUCT"], [181, 193, "DISEASE"], [179, 193, "ENTITY"], [250, 257, "GGP"], [181, 187, "ORGAN"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [236, 242, "ENTITY"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [300, 315, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "PKR is induced by IFN and activated by the binding of double-stranded RNA ( dsRNA ) after virus infection ( Clemens and Elia , 1997 ) . HRI is activated in red blood cells and hepatocytes by low levels of heme ( McEwenet al. , 2005 ) . GCN2 senses amino acid deficiency and is activated via binding to uncharged transfer RNAs ( Sood et al. , 2000 ) .", "labels": [[236, 248, "CHEMICAL"], [312, 321, "ORGANISM"], [291, 312, "ENTITY"], [195, 202, "GENE_OR_GENE_PRODUCT"], [166, 176, "ENTITY"], [18, 22, "GGP"], [236, 248, "CHEBI"], [84, 96, "DISEASE"], [54, 74, "ENTITY"], [205, 212, "ENTITY"], [7, 15, "ENTITY"], [166, 176, "CELL_TYPE"], [143, 166, "CELL"], [166, 176, "CELL"], [18, 22, "CHEMICAL"], [205, 212, "PROTEIN"], [195, 202, "PROTEIN"], [54, 74, "RNA"], [312, 321, "CHEMICAL"], [195, 202, "CHEBI"], [43, 51, "ENTITY"], [26, 36, "ENTITY"], [0, 4, "ENTITY"], [143, 166, "CELL_TYPE"], [18, 22, "ENTITY"], [143, 166, "CL"], [166, 176, "CL"], [70, 74, "SO"], [176, 195, "ENTITY"], [236, 259, "ENTITY"], [195, 202, "ENTITY"], [143, 166, "ENTITY"], [0, 4, "PROTEIN"], [136, 143, "ENTITY"], [0, 4, "GENE_OR_GENE_PRODUCT"], [259, 277, "ENTITY"], [26, 36, "ENTITY"], [18, 22, "GENE_OR_GENE_PRODUCT"], [236, 248, "AMINO_ACID"], [18, 22, "PROTEIN"], [84, 96, "ENTITY"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses", "labels": [[113, 124, "CANCER"], [0, 31, "CHEMICAL"], [193, 197, "SO"], [35, 46, "ENTITY"], [0, 31, "ENTITY"], [0, 31, "SIMPLE_CHEMICAL"], [113, 124, "ENTITY"], [222, 231, "ORGANISM"], [193, 197, "ENTITY"], [113, 124, "DISEASE"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses [ 3 ] .", "labels": [[113, 124, "CANCER"], [0, 31, "CHEMICAL"], [193, 197, "SO"], [35, 46, "ENTITY"], [0, 31, "ENTITY"], [222, 231, "ENTITY"], [222, 245, "ORGANISM"], [0, 31, "SIMPLE_CHEMICAL"], [113, 124, "ENTITY"], [193, 197, "ENTITY"], [113, 124, "DISEASE"]]}
{"text": "For decades , CQ and HCQ are front-line medications for the treatment and prophylaxis of malaria and are also used to treat autoimmune diseases , including rheumatoid arthritis ( RA ) and systemic lupus erythematosus ( SLE ) .", "labels": [[203, 217, "DISEASE"], [203, 217, "ENTITY"], [146, 167, "DISEASE"], [4, 12, "ENTITY"], [184, 203, "ENTITY"], [29, 40, "ENTITY"], [184, 203, "DISEASE"], [124, 135, "DISEASE"], [124, 135, "ENTITY"], [146, 167, "ENTITY"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses", "labels": [[113, 124, "DISEASE"], [113, 124, "CANCER"], [0, 31, "CHEMICAL"], [193, 197, "SO"], [35, 46, "ENTITY"], [0, 31, "ENTITY"], [0, 31, "SIMPLE_CHEMICAL"], [193, 197, "ENTITY"], [113, 124, "ENTITY"], [222, 231, "ORGANISM"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses", "labels": [[113, 124, "CANCER"], [0, 31, "CHEMICAL"], [193, 197, "SO"], [35, 46, "ENTITY"], [0, 31, "ENTITY"], [0, 31, "SIMPLE_CHEMICAL"], [113, 124, "ENTITY"], [222, 231, "ORGANISM"], [193, 197, "ENTITY"], [113, 124, "DISEASE"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses [ 3 ] .", "labels": [[113, 124, "ENTITY"], [113, 124, "CANCER"], [0, 31, "CHEMICAL"], [193, 197, "SO"], [35, 46, "ENTITY"], [0, 31, "ENTITY"], [222, 231, "ENTITY"], [222, 245, "ORGANISM"], [0, 31, "SIMPLE_CHEMICAL"], [193, 197, "ENTITY"], [113, 124, "DISEASE"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses [ 3 ] .", "labels": [[113, 124, "CANCER"], [0, 31, "CHEMICAL"], [193, 197, "SO"], [35, 46, "ENTITY"], [0, 31, "ENTITY"], [222, 231, "ENTITY"], [222, 245, "ORGANISM"], [0, 31, "SIMPLE_CHEMICAL"], [113, 124, "ENTITY"], [193, 197, "ENTITY"], [113, 124, "DISEASE"]]}
{"text": "For decades , CQ and HCQ are front-line medications for the treatment and prophylaxis of malaria and are also used to treat autoimmune diseases , including rheumatoid arthritis ( RA ) and systemic lupus erythematosus ( SLE ) .", "labels": [[203, 217, "DISEASE"], [203, 217, "ENTITY"], [146, 167, "DISEASE"], [4, 12, "ENTITY"], [184, 203, "ENTITY"], [29, 40, "ENTITY"], [184, 203, "DISEASE"], [124, 135, "DISEASE"], [124, 135, "ENTITY"], [146, 167, "ENTITY"]]}
{"text": "For decades , CQ and HCQ are front-line medications for the treatment and prophylaxis of malaria and are also used to treat autoimmune diseases , including rheumatoid arthritis ( RA ) and systemic lupus erythematosus ( SLE ) .", "labels": [[146, 167, "DISEASE"], [4, 12, "ENTITY"], [29, 40, "ENTITY"], [203, 217, "DISEASE"], [203, 217, "ENTITY"], [124, 135, "DISEASE"], [124, 135, "ENTITY"], [146, 167, "ENTITY"], [184, 203, "DISEASE"], [184, 203, "ENTITY"]]}
{"text": "Previous studies reported that CQ/HCQ possess a broad spectrum of antiviral effects on a variety of viruses as diverse as human immunodeficiency virus (HIV)[30 ] , Marburg virus , Zika virus [ 31 ] , dengue virus[32 ] , Ebola virus[33 ] , and SARS-CoV-1[34,35 ] , etc .", "labels": [[122, 128, "TAXON"], [122, 151, "ENTITY"], [162, 172, "ENTITY"], [122, 151, "ORGANISM"], [226, 243, "PROTEIN"], [178, 185, "ENTITY"], [226, 243, "ENTITY"], [66, 84, "ENTITY"], [100, 106, "TAXON"], [178, 185, "ORGANISM"], [180, 185, "TAXON"], [100, 108, "TAXON"], [31, 38, "CELL"], [200, 207, "GENE_OR_GENE_PRODUCT"], [218, 226, "GENE_OR_GENE_PRODUCT"], [207, 226, "ENTITY"], [122, 185, "DISEASE"], [164, 172, "TAXON"], [9, 17, "ENTITY"], [31, 38, "PROTEIN"], [31, 38, "DISEASE"], [200, 207, "CHEMICAL"], [100, 108, "ENTITY"]]}
{"text": "Previous studies reported that CQ/HCQ possess a broad spectrum of antiviral effects on a variety of viruses as diverse as human immunodeficiency virus (HIV)[30 ] , Marburg virus , Zika virus [ 31 ] , dengue virus[32 ] , Ebola virus[33 ] , and SARS-CoV-1[34,35 ] , etc .", "labels": [[122, 128, "TAXON"], [122, 151, "ENTITY"], [164, 172, "TAXON"], [122, 151, "ORGANISM"], [226, 243, "PROTEIN"], [178, 185, "ENTITY"], [226, 243, "ENTITY"], [66, 84, "ENTITY"], [100, 106, "TAXON"], [178, 185, "ORGANISM"], [180, 185, "TAXON"], [100, 108, "TAXON"], [162, 172, "ENTITY"], [31, 38, "CELL"], [200, 207, "GENE_OR_GENE_PRODUCT"], [218, 226, "GENE_OR_GENE_PRODUCT"], [207, 226, "ENTITY"], [9, 17, "ENTITY"], [31, 38, "PROTEIN"], [31, 38, "DISEASE"], [200, 207, "CHEMICAL"], [100, 108, "ENTITY"], [122, 185, "DISEASE"]]}
{"text": "Previous studies reported that CQ/HCQ possess a broad spectrum of antiviral effects on a variety of viruses as diverse as human immunodeficiency virus (HIV)[30 ] , Marburg virus , Zika virus [ 31 ] , dengue virus[32 ] , Ebola virus[33 ] , and SARS-CoV-1[34,35 ] , etc .", "labels": [[122, 128, "TAXON"], [122, 151, "ENTITY"], [162, 172, "ENTITY"], [122, 151, "ORGANISM"], [226, 243, "PROTEIN"], [178, 185, "ENTITY"], [226, 243, "ENTITY"], [66, 84, "ENTITY"], [100, 106, "TAXON"], [178, 185, "ORGANISM"], [180, 185, "TAXON"], [100, 108, "TAXON"], [31, 38, "CELL"], [122, 185, "DISEASE"], [200, 207, "GENE_OR_GENE_PRODUCT"], [218, 226, "GENE_OR_GENE_PRODUCT"], [207, 226, "ENTITY"], [164, 172, "TAXON"], [9, 17, "ENTITY"], [31, 38, "PROTEIN"], [31, 38, "DISEASE"], [200, 207, "CHEMICAL"], [100, 108, "ENTITY"]]}
{"text": "Previous studies reported that CQ/HCQ possess a broad spectrum of antiviral effects on a variety of viruses as diverse as human immunodeficiency virus (HIV)[30 ] , Marburg virus , Zika virus [ 31 ] , dengue virus[32 ] , Ebola virus[33 ] , and SARS-CoV-1[34,35 ] , etc .", "labels": [[122, 128, "TAXON"], [122, 151, "ENTITY"], [162, 172, "ENTITY"], [122, 151, "ORGANISM"], [226, 243, "PROTEIN"], [178, 185, "ENTITY"], [226, 243, "ENTITY"], [66, 84, "ENTITY"], [100, 106, "TAXON"], [178, 185, "ORGANISM"], [180, 185, "TAXON"], [100, 108, "TAXON"], [31, 38, "CELL"], [122, 185, "DISEASE"], [200, 207, "GENE_OR_GENE_PRODUCT"], [218, 226, "GENE_OR_GENE_PRODUCT"], [207, 226, "ENTITY"], [164, 172, "TAXON"], [9, 17, "ENTITY"], [31, 38, "PROTEIN"], [31, 38, "DISEASE"], [200, 207, "CHEMICAL"], [100, 108, "ENTITY"]]}
{"text": "Previous studies reported that CQ/HCQ possess a broad spectrum of antiviral effects on a variety of viruses as diverse as human immunodeficiency virus (HIV)[30 ] , Marburg virus , Zika virus [ 31 ] , dengue virus[32 ] , Ebola virus[33 ] , and SARS-CoV-1[34,35 ] , etc .", "labels": [[122, 128, "TAXON"], [218, 226, "GENE_OR_GENE_PRODUCT"], [122, 151, "ENTITY"], [162, 172, "ENTITY"], [122, 151, "ORGANISM"], [226, 243, "PROTEIN"], [178, 185, "ENTITY"], [226, 243, "ENTITY"], [66, 84, "ENTITY"], [100, 106, "TAXON"], [178, 185, "ORGANISM"], [180, 185, "TAXON"], [100, 108, "TAXON"], [31, 38, "CELL"], [122, 185, "DISEASE"], [200, 207, "GENE_OR_GENE_PRODUCT"], [207, 226, "ENTITY"], [164, 172, "TAXON"], [9, 17, "ENTITY"], [31, 38, "PROTEIN"], [31, 38, "DISEASE"], [200, 207, "CHEMICAL"], [100, 108, "ENTITY"]]}
{"text": "Previous studies reported that CQ/HCQ possess a broad spectrum of antiviral effects on a variety of viruses as diverse as human immunodeficiency virus (HIV)[30 ] , Marburg virus , Zika virus [ 31 ] , dengue virus[32 ] , Ebola virus[33 ] , and SARS-CoV-1[34,35 ] , etc .", "labels": [[122, 128, "TAXON"], [122, 151, "ENTITY"], [162, 172, "ENTITY"], [122, 151, "ORGANISM"], [226, 243, "PROTEIN"], [178, 185, "ENTITY"], [226, 243, "ENTITY"], [66, 84, "ENTITY"], [100, 106, "TAXON"], [178, 185, "ORGANISM"], [180, 185, "TAXON"], [100, 108, "TAXON"], [31, 38, "CELL"], [122, 185, "DISEASE"], [200, 207, "GENE_OR_GENE_PRODUCT"], [218, 226, "GENE_OR_GENE_PRODUCT"], [207, 226, "ENTITY"], [164, 172, "TAXON"], [9, 17, "ENTITY"], [31, 38, "PROTEIN"], [31, 38, "DISEASE"], [200, 207, "CHEMICAL"], [100, 108, "ENTITY"]]}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "Additional medications , including thiazolidinediones or ibuprofen , may also increase ACE2 levels , though data on this are sparse [ 21 ] .", "labels": [[11, 23, "ENTITY"], [78, 87, "ENTITY"], [87, 92, "ENTITY"], [78, 87, "GGP"], [78, 87, "GENE_OR_GENE_PRODUCT"], [78, 87, "PROTEIN"]]}
{"text": "Based on these results , we performed virtual docking to screen for commercial medicines in the DrugBank database that could bind to the above mentioned pocket site of 2019-nCoV Mpro , and identified 10 candidate clinical medicines ( Table 1 ; Figs. 1B and S3 ) .", "labels": [[15, 23, "ENTITY"], [96, 105, "ENTITY"], [153, 160, "ENTITY"], [38, 46, "ENTITY"], [68, 79, "ENTITY"], [203, 222, "ENTITY"], [153, 160, "SO"], [168, 178, "ENTITY"]]}
{"text": "Other potential drugs include type II transmembrane serine protease ( TMSPSS2 ) inhibitors and BCR-ABL kinase inhibitor imatinib .", "labels": [[30, 68, "GENE_OR_GENE_PRODUCT"], [80, 90, "ENTITY"], [30, 80, "PROTEIN"], [91, 103, "PROTEIN"], [91, 110, "ENTITY"], [91, 103, "GENE_OR_GENE_PRODUCT"], [30, 68, "GGP"], [80, 90, "SIMPLE_CHEMICAL"], [16, 22, "ENTITY"], [91, 120, "GGP"], [80, 90, "CHEMICAL"], [30, 68, "ENTITY"], [6, 16, "ENTITY"], [16, 22, "CHEBI"]]}
{"text": "Other potential drugs include type II transmembrane serine protease ( TMSPSS2 ) inhibitors and BCR-ABL kinase inhibitor imatinib .", "labels": [[8, 18, "ENTITY"], [109, 124, "PROTEIN"], [109, 124, "GENE_OR_GENE_PRODUCT"], [94, 109, "ENTITY"], [20, 26, "CHEBI"], [94, 109, "CHEBI"], [84, 94, "GGP"], [-1, 24, "ENTITY"], [-1, 24, "GGP"]]}
{"text": "Other potential drugs include type II transmembrane serine protease ( TMSPSS2 ) inhibitors and BCR-ABL kinase inhibitor imatinib .", "labels": [[30, 68, "GENE_OR_GENE_PRODUCT"], [80, 90, "ENTITY"], [80, 90, "CHEMICAL"], [91, 120, "GGP"], [30, 68, "GGP"], [30, 80, "PROTEIN"], [80, 90, "SIMPLE_CHEMICAL"], [16, 22, "ENTITY"], [91, 110, "ENTITY"], [91, 103, "PROTEIN"], [30, 68, "ENTITY"], [6, 16, "ENTITY"], [16, 22, "CHEBI"], [91, 103, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Imatinib has anticoronal activity primarily because it inhibits the fusion of virions with the endosomal membrane ( 18 ) .", "labels": [[95, 114, "ENTITY"], [0, 9, "SIMPLE_CHEMICAL"], [55, 64, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "CHEBI"], [78, 86, "CELL"], [95, 114, "CELLULAR_COMPONENT"], [78, 86, "ENTITY"], [68, 75, "ENTITY"], [13, 34, "ENTITY"], [0, 9, "CHEMICAL"], [95, 114, "GO"]]}
{"text": "Imatinib has anti-coronal activity primarily because it inhibits the fusion of virions with the endosomal membrane ( 18 ) .", "labels": [[73, 80, "ENTITY"], [17, 39, "ENTITY"], [100, 121, "GO"], [0, 9, "SIMPLE_CHEMICAL"], [0, 9, "ENTITY"], [0, 9, "CHEBI"], [100, 121, "ENTITY"], [100, 121, "CELLULAR_COMPONENT"], [83, 91, "CELL"], [60, 69, "ENTITY"], [0, 9, "CHEMICAL"], [83, 91, "ENTITY"]]}
{"text": "Other potential drugs include type II transmembrane serine protease ( TMSPSS2 ) inhibitors and BCR-ABL kinase inhibitor imatinib .", "labels": [[8, 18, "ENTITY"], [109, 124, "PROTEIN"], [109, 124, "GENE_OR_GENE_PRODUCT"], [94, 109, "ENTITY"], [20, 26, "CHEBI"], [94, 109, "CHEBI"], [-1, 24, "ENTITY"], [-1, 24, "GGP"], [84, 94, "GGP"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Irbesartan can inhibit NTCP , thus inhibiting viral entry45,46 . SLC10A1 interacts with C11orf74 , a potential transcriptional repressor that interacts with nsp-10 of SARS-CoV47 . There are several other ARBs ( such as eletriptan , frovatriptan , and zolmitriptan ) in which their targets are potentially associated with HCoV-associated host proteins in the human interactome .", "labels": [[245, 251, "ENTITY"], [211, 219, "SIMPLE_CHEMICAL"], [293, 305, "ENTITY"], [245, 251, "CHEMICAL"], [219, 232, "ENTITY"], [219, 232, "SIMPLE_CHEMICAL"], [269, 281, "ENTITY"], [211, 219, "CHEBI"], [245, 251, "CHEBI"], [46, 52, "PROTEIN"], [219, 232, "CHEMICAL"], [0, 11, "SIMPLE_CHEMICAL"], [101, 127, "ENTITY"], [46, 52, "DISEASE"], [46, 52, "ENTITY"], [101, 127, "PROTEIN"], [15, 23, "ENTITY"], [23, 28, "SIMPLE_CHEMICAL"], [0, 11, "ENTITY"], [305, 342, "PROTEIN"], [211, 219, "ENTITY"], [0, 11, "CHEMICAL"], [245, 251, "SIMPLE_CHEMICAL"], [321, 342, "CHEBI"], [354, 364, "ENTITY"], [305, 342, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"], [211, 219, "CHEMICAL"], [305, 342, "ENTITY"]]}
{"text": "We hypothesise that this is likely through inhibiting IMP\u03b1/\u03b21-mediated nuclear import of viral proteins ( Fig. 1 G ) , as shown for other RNA viruses4,5,10 ; confirmation of this mechanism in the case of SARS-CoV-2 , and identification of the specific SARS-CoV-2 and/or host component(s ) impacted ( see10 ) is an important focus future work in this laboratory .", "labels": [[270, 275, "PROTEIN"], [270, 275, "ENTITY"], [89, 104, "ENTITY"], [243, 252, "CHEMICAL"], [71, 79, "CELLULAR_COMPONENT"], [243, 252, "ENTITY"], [43, 54, "ENTITY"], [142, 158, "ENTITY"], [196, 204, "SIMPLE_CHEMICAL"], [71, 79, "GO"], [289, 298, "GGP"], [196, 204, "CHEMICAL"], [215, 221, "ENTITY"], [106, 113, "GENE_OR_GENE_PRODUCT"], [89, 104, "TAXON"], [289, 298, "GENE_OR_GENE_PRODUCT"], [289, 298, "PROTEIN"], [342, 350, "ENTITY"], [243, 252, "GENE_OR_GENE_PRODUCT"], [89, 104, "PROTEIN"], [196, 204, "ENTITY"], [270, 275, "GENE_OR_GENE_PRODUCT"], [54, 86, "ENTITY"]]}
{"text": "Several potential drug candidates , including lopinavir/ritonavir ( Kaletra R ) , nucleoside analogues , neuraminidase inhibitors , remdesivir , umifenovir ( Arbidol R ) , DNA synthesis inhibitors ( such as tenofovir disoproxil and lamivudine ) , chloroquine and Chinese traditional medicines ( such as ShuFeng JieDu or Lianhua Qing- wen capsules ) , have been proposed [ 36 , 37 ] .", "labels": [[8, 18, "ENTITY"], [199, 207, "ENTITY"], [232, 245, "ENTITY"], [145, 158, "CHEMICAL"], [247, 271, "ENTITY"], [93, 119, "ENTITY"], [93, 105, "GENE_OR_GENE_PRODUCT"], [119, 132, "ENTITY"], [158, 166, "SO"], [283, 303, "PROTEIN"], [217, 232, "SIMPLE_CHEMICAL"], [217, 232, "CHEMICAL"], [217, 232, "ENTITY"], [176, 186, "CHEBI"], [145, 158, "ENTITY"], [197, 217, "ENTITY"], [232, 245, "SIMPLE_CHEMICAL"], [66, 76, "SIMPLE_CHEMICAL"], [232, 245, "CHEMICAL"], [283, 295, "CHEMICAL"], [66, 76, "ENTITY"], [303, 328, "ENTITY"], [176, 186, "ENTITY"], [158, 176, "ENTITY"], [93, 119, "CHEBI"], [197, 217, "CHEMICAL"], [158, 166, "CELLULAR_COMPONENT"], [283, 295, "TAXON"], [18, 34, "ENTITY"], [132, 145, "ENTITY"], [232, 245, "CHEBI"], [283, 303, "ORGANISM"], [197, 217, "SIMPLE_CHEMICAL"], [283, 295, "ENTITY"], [78, 93, "ENTITY"], [18, 23, "CHEBI"], [66, 76, "CHEMICAL"]]}
{"text": "Several potential drug candidates , including lopinavir/ritonavir ( Kaletra R ) , nucleoside analogues , neuraminidase inhibitors , remdesivir , umifenovir ( Arbidol R ) , DNA synthesis inhibitors ( such as tenofovir disoproxil and lamivudine ) , chloroquine and Chinese traditional medicines ( such as ShuFeng JieDu or Lianhua Qing- wen capsules ) , have been proposed [ 36 , 37 ] .", "labels": [[8, 18, "ENTITY"], [199, 207, "ENTITY"], [232, 245, "ENTITY"], [145, 158, "CHEMICAL"], [247, 271, "ENTITY"], [93, 119, "ENTITY"], [93, 105, "GENE_OR_GENE_PRODUCT"], [119, 132, "ENTITY"], [158, 166, "SO"], [283, 303, "PROTEIN"], [217, 232, "SIMPLE_CHEMICAL"], [217, 232, "CHEMICAL"], [217, 232, "ENTITY"], [176, 186, "CHEBI"], [145, 158, "ENTITY"], [197, 217, "ENTITY"], [232, 245, "SIMPLE_CHEMICAL"], [66, 76, "SIMPLE_CHEMICAL"], [232, 245, "CHEMICAL"], [283, 295, "CHEMICAL"], [66, 76, "ENTITY"], [303, 328, "ENTITY"], [176, 186, "ENTITY"], [158, 176, "ENTITY"], [93, 119, "CHEBI"], [197, 217, "CHEMICAL"], [158, 166, "CELLULAR_COMPONENT"], [283, 295, "TAXON"], [18, 34, "ENTITY"], [132, 145, "ENTITY"], [232, 245, "CHEBI"], [283, 303, "ORGANISM"], [197, 217, "SIMPLE_CHEMICAL"], [283, 295, "ENTITY"], [78, 93, "ENTITY"], [18, 23, "CHEBI"], [66, 76, "CHEMICAL"]]}
{"text": "Furthermore , RNA synthesis inhibitors ( like 3TC , TDF ) , remdesivir , neuraminidase inhibitors , peptide ( EK1 ) , anti-inflammatory drugs , abidol , Chinese traditional medicine , such as Lianhuaqingwen and ShuFengJieDu Capsules , could be the promising COVID-19 treatments.2", "labels": [[14, 18, "ENTITY"], [87, 100, "ENTITY"], [108, 118, "ENTITY"], [87, 100, "SO"], [118, 136, "ENTITY"], [173, 192, "ENTITY"], [244, 258, "PROTEIN"], [248, 258, "CHEMICAL"], [60, 100, "SIMPLE_CHEMICAL"], [192, 211, "ORGANISM"], [60, 87, "ENTITY"], [60, 87, "CHEBI"], [192, 211, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Studies by Ferrario27 and others showed that ACE2 levels increased by 4.7 and 2.8 times when blood pressure decreased after applying ACEIs ( lisinopril ) and ARBs ( losartan ) to rats .", "labels": [[133, 139, "CHEMICAL"], [45, 50, "GGP"], [50, 57, "ENTITY"], [11, 22, "SIMPLE_CHEMICAL"], [11, 22, "ENTITY"], [0, 8, "ENTITY"], [133, 139, "SIMPLE_CHEMICAL"], [108, 118, "ENTITY"], [93, 99, "ORGANISM_SUBSTANCE"], [45, 50, "ENTITY"], [11, 22, "CHEMICAL"], [57, 67, "ENTITY"], [93, 108, "ENTITY"], [133, 139, "ENTITY"], [45, 50, "GENE_OR_GENE_PRODUCT"], [45, 50, "PROTEIN"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Several potential drug candidates , including lopinavir/ritonavir ( Kaletra R ) , nucleoside analogues , neuraminidase inhibitors , remdesivir , umifenovir ( Arbidol R ) , DNA synthesis inhibitors ( such as tenofovir disoproxil and lamivudine ) , chloroquine and Chinese traditional medicines ( such as ShuFeng JieDu or Lianhua Qing- wen capsules ) , have been proposed [ 36 , 37 ] .", "labels": [[8, 18, "ENTITY"], [232, 245, "CHEMICAL"], [199, 207, "ENTITY"], [145, 158, "CHEMICAL"], [247, 271, "ENTITY"], [93, 119, "ENTITY"], [93, 105, "GENE_OR_GENE_PRODUCT"], [119, 132, "ENTITY"], [232, 245, "SIMPLE_CHEMICAL"], [158, 166, "SO"], [283, 303, "PROTEIN"], [217, 232, "SIMPLE_CHEMICAL"], [232, 245, "ENTITY"], [217, 232, "CHEMICAL"], [217, 232, "ENTITY"], [176, 186, "CHEBI"], [145, 158, "ENTITY"], [197, 217, "ENTITY"], [66, 76, "SIMPLE_CHEMICAL"], [283, 295, "CHEMICAL"], [66, 76, "ENTITY"], [303, 328, "ENTITY"], [176, 186, "ENTITY"], [158, 176, "ENTITY"], [93, 119, "CHEBI"], [197, 217, "CHEMICAL"], [158, 166, "CELLULAR_COMPONENT"], [232, 245, "CHEBI"], [283, 295, "TAXON"], [18, 34, "ENTITY"], [132, 145, "ENTITY"], [283, 303, "ORGANISM"], [197, 217, "SIMPLE_CHEMICAL"], [283, 295, "ENTITY"], [78, 93, "ENTITY"], [18, 23, "CHEBI"], [66, 76, "CHEMICAL"]]}
{"text": "Furthermore , there is the potential for combining baricitinib with the directacting antivirals ( lopinavir or ritonavir and 121304016 ) currently being used in the COVID-19 outbreak , since it has a minimal interaction with the relevant CYP drugmetabolising enzymes . Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity , viral replication , and the aberrant host inflammatory response .", "labels": [[269, 285, "ENTITY"], [242, 259, "ENTITY"], [72, 85, "ENTITY"], [339, 346, "TAXON"], [352, 372, "ENTITY"], [386, 394, "ENTITY"], [242, 259, "SO"], [229, 238, "ENTITY"], [352, 364, "TAXON"], [161, 174, "ENTITY"], [229, 259, "GENE_OR_GENE_PRODUCT"], [302, 322, "CHEBI"], [259, 269, "ENTITY"], [394, 421, "ENTITY"], [269, 285, "CHEMICAL"], [238, 242, "ENTITY"], [339, 352, "DISEASE"], [302, 322, "ENTITY"], [194, 200, "ENTITY"], [269, 285, "GENE_OR_GENE_PRODUCT"], [339, 352, "ENTITY"], [200, 208, "ENTITY"], [229, 259, "PROTEIN"]]}
{"text": "The fifth edition of the Guidelines recommends antivirals including IFN-\u03b1 , lopinavir/ritonavir , and ribavirin for treatment of COVID-19 ( 3 ) .", "labels": [[68, 74, "ENTITY"], [126, 140, "PROTEIN"], [10, 18, "ENTITY"], [126, 140, "GENE_OR_GENE_PRODUCT"], [68, 74, "PROTEIN"], [25, 36, "ENTITY"], [47, 58, "ENTITY"], [68, 74, "GENE_OR_GENE_PRODUCT"], [47, 58, "GO"]]}
{"text": "Lopinavir/ritonavir can be used when appropriate , 2 tablets , twice daily for 14 days .", "labels": [[0, 20, "DISEASE"], [0, 20, "ENTITY"]]}
{"text": "Other reported therapeutic agents that are used for the treatment of seriously ill patients have been noted in Table 1 .", "labels": [[79, 83, "ENTITY"], [83, 92, "ENTITY"], [83, 92, "ORGANISM"], [15, 34, "ENTITY"], [56, 66, "ENTITY"]]}
{"text": "The major therapeutic drugs that might be effective in managing COVID-19 include remdesivir , lopinavir/ritonavir alone or in combination with interferon-\u03b2 , convalescent plasma , and mAbs.17", "labels": [[10, 28, "ENTITY"], [42, 52, "ENTITY"], [156, 171, "ORGANISM"], [81, 92, "ENTITY"], [158, 171, "ENTITY"], [64, 73, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"]]}
{"text": "All 74 patients with COVID-19 with GI symptoms were treated in isolation with supportive and empiric medication , while 66 ( 89.19 % ) patients received antiviral treatment , including interferon-\u03b1 sprays , arbidol hydrochloride capsules ( two tablets three times daily ) , lopinavir and ritonavir two tablets ( 500 mg ) twice daily , via the oral route .", "labels": [[175, 198, "ENTITY"], [7, 16, "ENTITY"], [52, 60, "ENTITY"], [7, 16, "ORGANISM"], [274, 288, "SIMPLE_CHEMICAL"], [316, 321, "ENTITY"], [63, 73, "ENTITY"], [327, 339, "ENTITY"], [35, 38, "ORGAN"], [144, 163, "ENTITY"], [198, 229, "ENTITY"], [207, 229, "CHEBI"], [274, 288, "CHEMICAL"], [93, 112, "ENTITY"], [264, 274, "SIMPLE_CHEMICAL"], [21, 30, "ENTITY"], [274, 288, "ENTITY"], [35, 47, "ENTITY"], [207, 229, "SIMPLE_CHEMICAL"], [78, 89, "ENTITY"], [264, 274, "CHEMICAL"], [21, 30, "GENE_OR_GENE_PRODUCT"], [207, 215, "CHEMICAL"], [288, 298, "ENTITY"], [264, 274, "ENTITY"], [238, 244, "ENTITY"], [327, 335, "ORGAN"]]}
{"text": "Fewer deceased patients ( 89 ; 79 % ) than recovered patients ( 147 ; 91 % ) received monotherapy or combination therapy with antiviral agents ( oseltamivir , arbidol , or lopinavir/ritonavir ) , whereas more deceased patients ( 99 ; 88 % ) than recovered patients ( 118 ; 73 % ) were given glucocorticoid therapy , considering the severe pneumonia and \u201c cytokine storm \u201d observed in patients who died .", "labels": [[159, 172, "SIMPLE_CHEMICAL"], [77, 86, "ENTITY"], [36, 43, "ENTITY"], [145, 157, "ENTITY"], [15, 24, "ORGANISM"], [15, 24, "ENTITY"], [355, 364, "ORGANISM"], [271, 291, "ENTITY"], [332, 339, "PROTEIN"], [86, 113, "ENTITY"], [271, 285, "SIMPLE_CHEMICAL"], [6, 15, "ENTITY"], [159, 172, "ENTITY"], [136, 145, "ENTITY"], [36, 43, "ORGANISM"], [159, 172, "CHEMICAL"], [136, 145, "CHEMICAL"], [306, 316, "ENTITY"], [355, 364, "ENTITY"], [332, 339, "ENTITY"], [43, 53, "ENTITY"], [113, 126, "ENTITY"], [43, 53, "ORGANISM"]]}
{"text": "Also , according to Jian-ya et al. , treatment of 51 COVID-19 patients with traditional Chinese medicine , interferon , Lopinavir , Ritonavir and short-term ( 3 to 5 days ) corticosteroids was successful and resulted in recovery and discharge of 50 patients ( 3 ) .", "labels": [[166, 173, "ENTITY"], [220, 233, "ENTITY"], [53, 62, "ENTITY"], [50, 62, "ORGANISM"], [243, 249, "ENTITY"], [107, 120, "SIMPLE_CHEMICAL"], [120, 132, "CHEMICAL"], [120, 132, "SIMPLE_CHEMICAL"], [107, 120, "CHEMICAL"], [208, 220, "ENTITY"], [107, 120, "ENTITY"], [76, 96, "ENTITY"], [243, 249, "ORGANISM"], [166, 173, "SIMPLE_CHEMICAL"], [120, 132, "ENTITY"]]}
{"text": "Qin et al. also reported that administration of moxifloxacin , lopinavir , and interferon to non-ICU patients and the addition of methylprednisolone to the above treatment for ICU patients resulted in 26 patients being discharged from intensive care unit ( ICU ) and 16 patients being discharged from hospital ( 4 ) .", "labels": [[48, 61, "ENTITY"], [48, 61, "SIMPLE_CHEMICAL"], [230, 250, "ENTITY"], [97, 101, "ORGANISM"], [93, 101, "ENTITY"], [48, 61, "CHEMICAL"], [97, 101, "ENTITY"], [30, 45, "ENTITY"], [93, 101, "ORGANISM"]]}
{"text": "Lopinavir/ritonavir is a medication for the human immunodeficiency virus ( HIV ) used in combination with other medications to treat adults and children over 14 days of age who are infected with HIV-1 ( 5 ) .", "labels": [[25, 36, "ENTITY"], [0, 20, "DISEASE"], [44, 50, "TAXON"], [44, 73, "ENTITY"], [44, 73, "ORGANISM"], [67, 73, "TAXON"], [127, 133, "ENTITY"], [44, 79, "DISEASE"], [0, 20, "ENTITY"]]}
{"text": "Chu et al. found that lopinavir/ ritonavir has anti-SARS-CoV activity in vitro and in clinical studies ( 6 ) .", "labels": [[86, 103, "ENTITY"], [33, 43, "ENTITY"], [47, 70, "ENTITY"], [22, 43, "CHEMICAL"], [47, 61, "DNA"], [22, 33, "ENTITY"], [70, 79, "ENTITY"], [22, 43, "GENE_OR_GENE_PRODUCT"]]}
{"text": "One antiviral-drug candidate is a combination of the HIV protease inhibitors lopinavir and ritonavir .", "labels": [[34, 46, "ENTITY"], [53, 66, "ENTITY"], [77, 87, "CHEMICAL"], [91, 101, "CHEMICAL"], [91, 101, "SIMPLE_CHEMICAL"], [77, 87, "ENTITY"], [57, 87, "SIMPLE_CHEMICAL"], [4, 19, "ENTITY"], [53, 77, "GO"], [91, 101, "ENTITY"]]}
{"text": "Lopinavir , which acts against the viral 3CL protease , has modest antiviral activity against SARS-CoV-2.1", "labels": [[60, 77, "ENTITY"], [0, 10, "SIMPLE_CHEMICAL"], [0, 10, "ENTITY"], [35, 45, "PROTEIN"], [0, 10, "CHEMICAL"], [35, 45, "ENTITY"]]}
{"text": "A tentative suggestion based on existing therapeutics , which would likely be resistant to new coronavirus mutations , is to use available angiotensin receptor 1 ( AT1R ) blockers , such as losartan , as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections .", "labels": [[95, 107, "ENTITY"], [182, 190, "ENTITY"], [129, 160, "GENE_OR_GENE_PRODUCT"], [95, 107, "DISEASE"], [182, 190, "SIMPLE_CHEMICAL"], [221, 234, "DISEASE"], [234, 253, "ENTITY"], [221, 234, "ENTITY"], [263, 285, "ENTITY"], [268, 279, "TAXON"], [263, 279, "ORGANISM"], [199, 204, "ENTITY"], [129, 160, "GGP"], [204, 221, "ENTITY"], [129, 171, "PROTEIN"], [41, 54, "ENTITY"], [12, 23, "ENTITY"], [129, 160, "ENTITY"], [182, 190, "CHEMICAL"]]}
{"text": "The AT1R antagonists losartan and olmesartan , commonly applied for reducing blood pressure in hypertensive patients , were shown to increase cardiac ACE2 expression about three-fold following chronic treatment ( 28 days ) after myocardial infarction induced by coronary artery ligation of rats ( Ishiyama et al. , 2004 ) .", "labels": [[223, 240, "ENTITY"], [77, 83, "ENTITY"], [150, 155, "ENTITY"], [4, 9, "GENE_OR_GENE_PRODUCT"], [142, 150, "GGP"], [223, 240, "DISEASE"], [183, 201, "ENTITY"], [21, 30, "CHEMICAL"], [142, 150, "PROTEIN"], [133, 142, "ENTITY"], [34, 45, "ENTITY"], [4, 21, "GGP"], [21, 30, "SIMPLE_CHEMICAL"], [4, 21, "ENTITY"], [259, 271, "MULTI-TISSUE_STRUCTURE"], [21, 30, "ENTITY"], [34, 45, "CHEMICAL"], [133, 150, "MULTI-TISSUE_STRUCTURE"], [142, 150, "ENTITY"], [240, 251, "ENTITY"], [34, 45, "SIMPLE_CHEMICAL"], [259, 278, "ENTITY"]]}
{"text": "A tentative suggestion based on existing therapeutics , which would likely be resistant to new coronavirus mutations , is to use available angiotensin receptor 1 ( AT1R ) blockers , such as losartan , as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections .", "labels": [[95, 107, "ENTITY"], [182, 190, "ENTITY"], [129, 171, "PROTEIN"], [129, 160, "GENE_OR_GENE_PRODUCT"], [95, 107, "DISEASE"], [182, 190, "SIMPLE_CHEMICAL"], [221, 234, "DISEASE"], [234, 253, "ENTITY"], [221, 234, "ENTITY"], [263, 285, "ENTITY"], [268, 279, "TAXON"], [263, 279, "ORGANISM"], [199, 204, "ENTITY"], [129, 160, "GGP"], [204, 221, "ENTITY"], [41, 54, "ENTITY"], [12, 23, "ENTITY"], [129, 160, "ENTITY"], [182, 190, "CHEMICAL"]]}
{"text": "The AT1R antagonists losartan and olmesartan , commonly applied for reducing blood pressure in hypertensive patients , were shown to increase cardiac ACE2 expression about three-fold following chronic treatment ( 28 days ) after myocardial infarction induced by coronary artery ligation of rats ( Ishiyama et al. , 2004 ) .", "labels": [[223, 240, "ENTITY"], [77, 83, "ENTITY"], [142, 150, "GGP"], [223, 240, "DISEASE"], [183, 201, "ENTITY"], [21, 30, "CHEMICAL"], [142, 150, "PROTEIN"], [133, 142, "ENTITY"], [150, 155, "ENTITY"], [34, 45, "ENTITY"], [4, 21, "GGP"], [21, 30, "SIMPLE_CHEMICAL"], [4, 21, "ENTITY"], [4, 9, "GENE_OR_GENE_PRODUCT"], [259, 271, "MULTI-TISSUE_STRUCTURE"], [21, 30, "ENTITY"], [34, 45, "CHEMICAL"], [133, 150, "MULTI-TISSUE_STRUCTURE"], [142, 150, "ENTITY"], [240, 251, "ENTITY"], [34, 45, "SIMPLE_CHEMICAL"], [259, 278, "ENTITY"]]}
{"text": "Losartan was also shown to upregulate renal ACE2 expression in chronically treated rats ( Klimas et al. , 2015 ) . In agreement with these observations , higher urinary ACE2 levels were observed in hypertensive patients treated with the AT1R antagonist olmesartan ( Furuhashi et al. , 2015 ) .", "labels": [[83, 88, "ENTITY"], [242, 253, "CHEMICAL"], [211, 228, "ENTITY"], [83, 88, "TAXON"], [83, 88, "ORGANISM"], [0, 9, "CHEMICAL"], [233, 242, "GGP"], [44, 49, "GGP"], [38, 44, "ENTITY"], [253, 266, "CHEMICAL"], [44, 49, "ENTITY"], [63, 83, "ENTITY"], [186, 198, "ENTITY"], [38, 49, "MULTI-TISSUE_STRUCTURE"], [198, 211, "ENTITY"], [0, 9, "ENTITY"], [139, 154, "ENTITY"], [0, 9, "SIMPLE_CHEMICAL"], [253, 266, "SIMPLE_CHEMICAL"], [198, 211, "ORGANISM"], [161, 169, "ENTITY"], [44, 49, "PROTEIN"], [253, 266, "ENTITY"], [44, 49, "ENTITY"], [27, 38, "ENTITY"], [161, 169, "PROTEIN"], [161, 169, "GENE_OR_GENE_PRODUCT"], [49, 60, "ENTITY"], [186, 198, "DISEASE"], [161, 169, "GGP"], [233, 253, "ENTITY"], [154, 161, "ENTITY"]]}
{"text": "Losartan , telmisartan , olmesartan ( and additional AT1R antagonists ) are widely applied in the clinic since the 1990s for control of hypertension and kidney disorders , and are known as safe drugs that are rarely implicated in adverse drugs events ( Deppe , B\u00f6ger , Weiss , & Benndorf , 2010 ; McIntyre , Caffe , Michalak , & Reid , 1997 ) .", "labels": [[244, 253, "ENTITY"], [149, 160, "ENTITY"], [149, 160, "DISEASE"], [0, 9, "CHEMICAL"], [297, 308, "DISEASE"], [42, 53, "GENE_OR_GENE_PRODUCT"], [216, 244, "ENTITY"], [269, 279, "ENTITY"], [0, 9, "ENTITY"], [261, 267, "ENTITY"], [0, 9, "SIMPLE_CHEMICAL"], [253, 259, "ENTITY"], [297, 308, "ENTITY"], [189, 194, "ENTITY"], [42, 58, "ENTITY"], [279, 295, "ENTITY"]]}
{"text": "Studies by Ferrario27 and others showed that ACE2 levels increased by 4.7 and 2.8 times when blood pressure decreased after applying ACEIs ( lisinopril ) and ARBs ( losartan ) to rats .", "labels": [[133, 139, "CHEMICAL"], [45, 50, "GGP"], [50, 57, "ENTITY"], [11, 22, "SIMPLE_CHEMICAL"], [11, 22, "ENTITY"], [0, 8, "ENTITY"], [133, 139, "SIMPLE_CHEMICAL"], [108, 118, "ENTITY"], [93, 99, "ORGANISM_SUBSTANCE"], [45, 50, "ENTITY"], [11, 22, "CHEMICAL"], [57, 67, "ENTITY"], [93, 108, "ENTITY"], [133, 139, "ENTITY"], [45, 50, "GENE_OR_GENE_PRODUCT"], [45, 50, "PROTEIN"]]}
{"text": "Losartan , telmisartan , olmesartan ( and additional AT1R antagonists ) are widely applied in the clinic since the 1990s for control of hypertension and kidney disorders , and are known as safe drugs that are rarely implicated in adverse drugs events ( Deppe , B\u00f6ger , Weiss , & Benndorf , 2010 ; McIntyre , Caffe , Michalak , & Reid , 1997 ) .", "labels": [[244, 253, "ENTITY"], [149, 160, "ENTITY"], [149, 160, "DISEASE"], [0, 9, "CHEMICAL"], [297, 308, "DISEASE"], [42, 53, "GENE_OR_GENE_PRODUCT"], [216, 244, "ENTITY"], [269, 279, "ENTITY"], [0, 9, "ENTITY"], [261, 267, "ENTITY"], [0, 9, "SIMPLE_CHEMICAL"], [253, 259, "ENTITY"], [297, 308, "ENTITY"], [189, 194, "ENTITY"], [42, 58, "ENTITY"], [279, 295, "ENTITY"]]}
{"text": "In addition , paired trials of losartan as a treatment for Covid-19 are being conducted among patients who have not previously received treatment with a RAAS inhibitor and are either hospitalized ( NCT04312009 . opens in new tab ) or not hospitalized ( NCT04311177 . opens in new tab ) .", "labels": [[14, 21, "ENTITY"], [153, 158, "GGP"], [183, 198, "CHEMICAL"]]}
{"text": "In other words , despite of the more stability of the ADPR than Losartan , Losartan can compete to ADPR for creating a complex with macrodomain protein , and in the case of TRPM2 , Losartan could be a proper inhibitor for TRPM2 .", "labels": [[201, 208, "CHEBI"], [127, 144, "PROTEIN"], [201, 208, "ENTITY"], [127, 144, "ENTITY"], [173, 181, "SIMPLE_CHEMICAL"], [127, 144, "GGP"], [173, 181, "ENTITY"], [173, 181, "CHEMICAL"], [9, 15, "ENTITY"]]}
{"text": "As shown in Fig. 5e , melatonin indirectly targets several HCoV cellular targets , including ACE2 , BCL2L1 , JUN , and IKBKB .", "labels": [[83, 93, "GENE_OR_GENE_PRODUCT"], [83, 93, "PROTEIN"], [100, 109, "GGP"], [83, 93, "ENTITY"], [100, 109, "PROTEIN"], [83, 93, "GGP"], [100, 109, "GENE_OR_GENE_PRODUCT"], [59, 64, "ORGANISM"], [100, 109, "ENTITY"], [12, 20, "GENE_OR_GENE_PRODUCT"]]}
{"text": "As shown in Fig. 5e , melatonin indirectly targets several HCoV cellular targets , including ACE2 , BCL2L1 , JUN , and IKBKB .", "labels": [[83, 93, "GENE_OR_GENE_PRODUCT"], [83, 93, "PROTEIN"], [100, 109, "GGP"], [83, 93, "ENTITY"], [100, 109, "PROTEIN"], [83, 93, "GGP"], [100, 109, "GENE_OR_GENE_PRODUCT"], [59, 64, "ORGANISM"], [100, 109, "ENTITY"], [12, 20, "GENE_OR_GENE_PRODUCT"]]}
{"text": "As shown in Fig. 5e , melatonin indirectly targets several HCoV cellular targets , including ACE2 , BCL2L1 , JUN , and IKBKB .", "labels": [[83, 93, "GENE_OR_GENE_PRODUCT"], [83, 93, "PROTEIN"], [12, 20, "GENE_OR_GENE_PRODUCT"], [83, 93, "ENTITY"], [100, 109, "PROTEIN"], [83, 93, "GGP"], [100, 109, "ENTITY"], [100, 109, "GENE_OR_GENE_PRODUCT"], [59, 64, "ORGANISM"], [100, 109, "GGP"]]}
{"text": "As shown in Fig. 5e , melatonin indirectly targets several HCoV cellular targets , including ACE2 , BCL2L1 , JUN , and IKBKB .", "labels": [[83, 93, "GENE_OR_GENE_PRODUCT"], [83, 93, "PROTEIN"], [100, 109, "GGP"], [83, 93, "ENTITY"], [100, 109, "PROTEIN"], [83, 93, "GGP"], [100, 109, "GENE_OR_GENE_PRODUCT"], [59, 64, "ORGANISM"], [100, 109, "ENTITY"], [12, 20, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Eplerenone ( Z = \u20131.59 ) , an aldosterone receptor antagonist , is reported to have a similar anti-inflammatory effect as melatonin .", "labels": [[31, 46, "PROTEIN"], [31, 55, "GGP"], [0, 11, "CHEMICAL"], [90, 116, "ENTITY"], [0, 11, "CHEBI"], [0, 11, "SIMPLE_CHEMICAL"], [-1, 3, "CHEMICAL"], [31, 55, "ENTITY"], [31, 55, "GENE_OR_GENE_PRODUCT"], [0, 11, "ENTITY"]]}
{"text": "Mercaptopurine has been reported as a selective inhibitor of both SARS-CoV and MERS-CoV by targeting papain-like protease which plays key roles in viral maturation and antagonism to interferon stimulation53,5", "labels": [[147, 164, "ENTITY"], [168, 179, "ENTITY"], [66, 75, "ENTITY"], [101, 122, "PROTEIN"], [79, 88, "ENTITY"], [48, 58, "CHEBI"], [147, 153, "TAXON"], [0, 15, "ENTITY"], [79, 88, "PROTEIN"], [48, 58, "ENTITY"], [66, 75, "PROTEIN"], [0, 15, "SIMPLE_CHEMICAL"], [91, 101, "ENTITY"], [101, 122, "ENTITY"], [79, 88, "GGP"], [66, 75, "ORGANISM"], [66, 75, "GGP"], [0, 15, "CHEMICAL"], [101, 113, "SO"]]}
{"text": "Mercaptopurine has been reported as a selective inhibitor of both SARS-CoV and MERS-CoV by targeting papain-like protease which plays key roles in viral maturation and antagonism to interferon stimulation53,5", "labels": [[147, 164, "ENTITY"], [168, 179, "ENTITY"], [101, 122, "PROTEIN"], [79, 88, "GGP"], [48, 58, "CHEBI"], [147, 153, "TAXON"], [79, 88, "PROTEIN"], [66, 75, "GGP"], [0, 15, "ENTITY"], [66, 75, "ORGANISM"], [66, 75, "PROTEIN"], [48, 58, "ENTITY"], [0, 15, "SIMPLE_CHEMICAL"], [91, 101, "ENTITY"], [101, 122, "ENTITY"], [79, 88, "ENTITY"], [66, 75, "ENTITY"], [0, 15, "CHEMICAL"], [101, 113, "SO"]]}
{"text": "Mechanistically , mercaptopurine potentially target several host proteins in HCoVs , such as JUN , PABPC1 , NPM1 , and NCL40,55 ( Fig. 5d ) .", "labels": [[115, 130, "GENE_OR_GENE_PRODUCT"], [99, 108, "PROTEIN"], [99, 108, "ENTITY"], [99, 108, "GGP"], [60, 65, "ENTITY"], [99, 108, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Mechanistically , mercaptopurine potentially target several host proteins in HCoVs , such as JUN , PABPC1 , NPM1 , and NCL40,55 ( Fig. 5d ) .", "labels": [[99, 108, "GENE_OR_GENE_PRODUCT"], [99, 108, "ENTITY"], [60, 65, "ENTITY"], [99, 108, "PROTEIN"], [99, 108, "GGP"], [115, 130, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Mechanistically , mercaptopurine potentially target several host proteins in HCoVs , such as JUN , PABPC1 , NPM1 , and NCL40,55 ( Fig. 5d ) .", "labels": [[115, 130, "GENE_OR_GENE_PRODUCT"], [99, 108, "PROTEIN"], [99, 108, "ENTITY"], [99, 108, "GGP"], [60, 65, "ENTITY"], [99, 108, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Mechanistically , mercaptopurine potentially target several host proteins in HCoVs , such as JUN , PABPC1 , NPM1 , and NCL40,55 ( Fig. 5d ) .", "labels": [[99, 108, "PROTEIN"], [99, 108, "ENTITY"], [115, 130, "GENE_OR_GENE_PRODUCT"], [99, 108, "GGP"], [60, 65, "ENTITY"], [99, 108, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [616, 630, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [616, 630, "SIMPLE_CHEMICAL"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "One hundred and five ( 93 % ) deceased patients and 144 ( 89 % ) who recovered received empirical antibacterial therapy ( moxifloxacin , cefoperazone , or azithromycin ) .", "labels": [[112, 122, "SIMPLE_CHEMICAL"], [63, 69, "ENTITY"], [122, 137, "CHEBI"], [137, 155, "CHEBI"], [122, 137, "SIMPLE_CHEMICAL"], [112, 122, "CHEMICAL"], [88, 112, "ENTITY"], [79, 88, "ENTITY"], [137, 155, "ENTITY"], [122, 137, "ENTITY"], [30, 39, "ORGANISM"], [137, 155, "CHEMICAL"], [30, 39, "ENTITY"], [112, 122, "ENTITY"], [122, 137, "CHEMICAL"], [137, 155, "SIMPLE_CHEMICAL"]]}
{"text": "All the severe and moderate cases were given empirical antimicrobial treatment ( moxifloxacin and/or cephalosporin , etc . ) .", "labels": [[8, 15, "ENTITY"], [55, 79, "ENTITY"], [28, 34, "ENTITY"], [19, 28, "ENTITY"], [45, 55, "ENTITY"]]}
{"text": "Antiviral ( oseltamivir , 75 mg twice a day ; ribavirin , 0.5 g twice a day ; umifenovir , 0.2 g 3 times a day ) , antibacterial ( moxifloxacin , 0.4 g every day ) , glucocorticoid ( methylprednisolone , 40 - 80 mg every day ) , and respiratory support were the main treatment approaches for the hospitalized patients ( Table 1 ) .", "labels": [[166, 183, "CHEBI"], [99, 105, "ENTITY"], [115, 131, "SIMPLE_CHEMICAL"], [0, 10, "ENTITY"], [166, 183, "ENTITY"], [166, 183, "CHEMICAL"], [166, 183, "SIMPLE_CHEMICAL"], [32, 40, "ENTITY"], [115, 131, "CHEMICAL"], [146, 152, "ENTITY"], [152, 166, "ENTITY"], [215, 233, "ENTITY"], [245, 267, "ENTITY"], [152, 166, "SIMPLE_CHEMICAL"], [277, 288, "ENTITY"], [107, 115, "ENTITY"], [115, 131, "ENTITY"]]}
{"text": "Qin et al. also reported that administration of moxifloxacin , lopinavir , and interferon to non-ICU patients and the addition of methylprednisolone to the above treatment for ICU patients resulted in 26 patients being discharged from intensive care unit ( ICU ) and 16 patients being discharged from hospital ( 4 ) .", "labels": [[48, 61, "ENTITY"], [230, 250, "ENTITY"], [48, 61, "CHEMICAL"], [93, 101, "ENTITY"], [48, 61, "SIMPLE_CHEMICAL"], [97, 101, "ORGANISM"], [97, 101, "ENTITY"], [30, 45, "ENTITY"], [93, 101, "ORGANISM"]]}
{"text": "The other antiviral drugs include nitazoxanide , favipiravir , nafamostat , and so on ( See Table 1 for details ) .", "labels": [[34, 47, "ENTITY"], [34, 47, "CHEMICAL"], [10, 26, "ENTITY"], [34, 47, "CHEBI"], [34, 47, "SIMPLE_CHEMICAL"]]}
{"text": "The other antiviral drugs include nitazoxanide , favipiravir , nafamostat , and so on ( See Table 1 for details ) .", "labels": [[34, 47, "ENTITY"], [34, 47, "CHEMICAL"], [10, 26, "ENTITY"], [34, 47, "CHEBI"], [34, 47, "SIMPLE_CHEMICAL"]]}
{"text": "The other antiviral drugs include nitazoxanide , favipiravir , nafamostat , and so on ( See Table 1 for details ) .", "labels": [[34, 47, "ENTITY"], [34, 47, "CHEMICAL"], [10, 26, "ENTITY"], [34, 47, "CHEBI"], [34, 47, "SIMPLE_CHEMICAL"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "It is important to mention that various studies have shown that in animal models with bleomycin-induced lung injury , vitamin B3 ( niacin or nicotinamide ) is highly effective in preventing lung tissue damage [ 7 ] .", "labels": [[118, 126, "ENTITY"], [104, 109, "ORGAN"], [118, 126, "CHEBI"], [67, 81, "ENTITY"], [86, 116, "ENTITY"], [86, 116, "DISEASE"], [159, 166, "ENTITY"], [179, 202, "DISEASE"], [40, 48, "ENTITY"], [179, 202, "ENTITY"], [67, 74, "TAXON"], [118, 126, "SIMPLE_CHEMICAL"], [179, 195, "TISSUE"], [118, 126, "CHEMICAL"]]}
{"text": "Since Vitamin B3 is highly lung protective , it should be used as soon as coughing begins . When breathing difficulty becomes apparent , hyaluronidase can be used intratracheally and at the same time 4-MU can be given to inhibit HAS2 .", "labels": [[195, 200, "SIMPLE_CHEMICAL"], [195, 200, "ENTITY"], [6, 17, "SIMPLE_CHEMICAL"], [221, 229, "GENE_OR_GENE_PRODUCT"], [27, 32, "ENTITY"], [221, 229, "PROTEIN"], [221, 229, "ENTITY"], [195, 200, "PROTEIN"], [6, 17, "CHEMICAL"], [92, 107, "ENTITY"], [6, 17, "ENTITY"], [27, 32, "ORGAN"], [6, 17, "GGP"], [195, 200, "CHEMICAL"], [221, 229, "GGP"]]}
{"text": "The AT1R antagonists losartan and olmesartan , commonly applied for reducing blood pressure in hypertensive patients , were shown to increase cardiac ACE2 expression about three-fold following chronic treatment ( 28 days ) after myocardial infarction induced by coronary artery ligation of rats ( Ishiyama et al. , 2004 ) .", "labels": [[21, 30, "SIMPLE_CHEMICAL"], [34, 45, "ENTITY"], [223, 240, "ENTITY"], [77, 83, "ENTITY"], [150, 155, "ENTITY"], [4, 9, "GENE_OR_GENE_PRODUCT"], [142, 150, "GGP"], [223, 240, "DISEASE"], [183, 201, "ENTITY"], [34, 45, "SIMPLE_CHEMICAL"], [21, 30, "ENTITY"], [142, 150, "PROTEIN"], [133, 142, "ENTITY"], [4, 21, "GGP"], [4, 21, "ENTITY"], [34, 45, "CHEMICAL"], [259, 271, "MULTI-TISSUE_STRUCTURE"], [21, 30, "CHEMICAL"], [142, 150, "ENTITY"], [133, 150, "MULTI-TISSUE_STRUCTURE"], [240, 251, "ENTITY"], [259, 278, "ENTITY"]]}
{"text": "The AT1R antagonists losartan and olmesartan , commonly applied for reducing blood pressure in hypertensive patients , were shown to increase cardiac ACE2 expression about three-fold following chronic treatment ( 28 days ) after myocardial infarction induced by coronary artery ligation of rats ( Ishiyama et al. , 2004 ) .", "labels": [[21, 30, "SIMPLE_CHEMICAL"], [34, 45, "ENTITY"], [223, 240, "ENTITY"], [77, 83, "ENTITY"], [142, 150, "GGP"], [223, 240, "DISEASE"], [183, 201, "ENTITY"], [34, 45, "SIMPLE_CHEMICAL"], [21, 30, "ENTITY"], [142, 150, "PROTEIN"], [133, 142, "ENTITY"], [150, 155, "ENTITY"], [4, 21, "GGP"], [4, 21, "ENTITY"], [34, 45, "CHEMICAL"], [4, 9, "GENE_OR_GENE_PRODUCT"], [259, 271, "MULTI-TISSUE_STRUCTURE"], [21, 30, "CHEMICAL"], [142, 150, "ENTITY"], [133, 150, "MULTI-TISSUE_STRUCTURE"], [240, 251, "ENTITY"], [259, 278, "ENTITY"]]}
{"text": "Losartan was also shown to upregulate renal ACE2 expression in chronically treated rats ( Klimas et al. , 2015 ) . In agreement with these observations , higher urinary ACE2 levels were observed in hypertensive patients treated with the AT1R antagonist olmesartan ( Furuhashi et al. , 2015 ) .", "labels": [[83, 88, "ENTITY"], [242, 253, "CHEMICAL"], [211, 228, "ENTITY"], [83, 88, "TAXON"], [83, 88, "ORGANISM"], [233, 242, "GGP"], [253, 266, "SIMPLE_CHEMICAL"], [44, 49, "GGP"], [38, 44, "ENTITY"], [253, 266, "CHEMICAL"], [44, 49, "ENTITY"], [63, 83, "ENTITY"], [186, 198, "ENTITY"], [38, 49, "MULTI-TISSUE_STRUCTURE"], [198, 211, "ENTITY"], [139, 154, "ENTITY"], [198, 211, "ORGANISM"], [161, 169, "ENTITY"], [44, 49, "PROTEIN"], [44, 49, "ENTITY"], [27, 38, "ENTITY"], [161, 169, "PROTEIN"], [161, 169, "GENE_OR_GENE_PRODUCT"], [49, 60, "ENTITY"], [253, 266, "ENTITY"], [186, 198, "DISEASE"], [0, 9, "CHEMICAL"], [161, 169, "GGP"], [233, 253, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "SIMPLE_CHEMICAL"], [154, 161, "ENTITY"]]}
{"text": "In a longitudinal cohort study involving Japanese patients with hypertension , urinary ACE2 levels were higher among patients who received long-term treatment with the ARB olmesartan than among untreated control patients , but that association was not observed with the ACE inhibitor enalapril or with other ARBs ( losartan , candesartan , valsartan , and telmisartan).41", "labels": [[350, 356, "CHEMICAL"], [168, 172, "CHEMICAL"], [326, 340, "CHEMICAL"], [87, 91, "ENTITY"], [315, 326, "SIMPLE_CHEMICAL"], [64, 77, "DISEASE"], [266, 284, "GGP"], [168, 172, "SIMPLE_CHEMICAL"], [274, 284, "ENTITY"], [50, 59, "ORGANISM"], [64, 77, "ENTITY"], [350, 356, "GENE_OR_GENE_PRODUCT"], [5, 31, "ENTITY"], [326, 340, "ENTITY"], [315, 326, "CHEMICAL"], [41, 50, "ENTITY"], [274, 284, "SIMPLE_CHEMICAL"], [50, 59, "ENTITY"], [315, 326, "ENTITY"], [274, 284, "CHEMICAL"], [326, 340, "SIMPLE_CHEMICAL"]]}
{"text": "Losartan , telmisartan , olmesartan ( and additional AT1R antagonists ) are widely applied in the clinic since the 1990s for control of hypertension and kidney disorders , and are known as safe drugs that are rarely implicated in adverse drugs events ( Deppe , B\u00f6ger , Weiss , & Benndorf , 2010 ; McIntyre , Caffe , Michalak , & Reid , 1997 ) .", "labels": [[244, 253, "ENTITY"], [149, 160, "ENTITY"], [149, 160, "DISEASE"], [297, 308, "DISEASE"], [42, 53, "GENE_OR_GENE_PRODUCT"], [0, 9, "CHEMICAL"], [216, 244, "ENTITY"], [0, 9, "ENTITY"], [269, 279, "ENTITY"], [261, 267, "ENTITY"], [253, 259, "ENTITY"], [297, 308, "ENTITY"], [0, 9, "SIMPLE_CHEMICAL"], [189, 194, "ENTITY"], [42, 58, "ENTITY"], [279, 295, "ENTITY"]]}
{"text": "Losartan , telmisartan , olmesartan ( and additional AT1R antagonists ) are widely applied in the clinic since the 1990s for control of hypertension and kidney disorders , and are known as safe drugs that are rarely implicated in adverse drugs events ( Deppe , B\u00f6ger , Weiss , & Benndorf , 2010 ; McIntyre , Caffe , Michalak , & Reid , 1997 ) .", "labels": [[244, 253, "ENTITY"], [149, 160, "ENTITY"], [149, 160, "DISEASE"], [297, 308, "DISEASE"], [42, 53, "GENE_OR_GENE_PRODUCT"], [0, 9, "CHEMICAL"], [216, 244, "ENTITY"], [0, 9, "ENTITY"], [269, 279, "ENTITY"], [261, 267, "ENTITY"], [253, 259, "ENTITY"], [297, 308, "ENTITY"], [0, 9, "SIMPLE_CHEMICAL"], [189, 194, "ENTITY"], [42, 58, "ENTITY"], [279, 295, "ENTITY"]]}
{"text": "All patients were administered with empirical antibiotic treatment , and 38 ( 93 % ) patients received antiviral therapy ( oseltamivir ) .", "labels": [[46, 57, "CHEBI"], [36, 46, "ENTITY"], [18, 31, "ENTITY"], [94, 113, "ENTITY"], [113, 123, "CHEMICAL"], [46, 67, "ENTITY"], [113, 123, "ENTITY"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Other reported therapeutic agents that are used for the treatment of seriously ill patients have been noted in Table 1 .", "labels": [[79, 83, "ENTITY"], [83, 92, "ENTITY"], [83, 92, "ORGANISM"], [15, 34, "ENTITY"], [56, 66, "ENTITY"]]}
{"text": "All patients received antiviral treatments ( virazole , oseltamivir and interferon ) .", "labels": [[22, 43, "ENTITY"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Fewer deceased patients ( 89 ; 79 % ) than recovered patients ( 147 ; 91 % ) received monotherapy or combination therapy with antiviral agents ( oseltamivir , arbidol , or lopinavir/ritonavir ) , whereas more deceased patients ( 99 ; 88 % ) than recovered patients ( 118 ; 73 % ) were given glucocorticoid therapy , considering the severe pneumonia and \u201c cytokine storm \u201d observed in patients who died .", "labels": [[159, 172, "SIMPLE_CHEMICAL"], [77, 86, "ENTITY"], [36, 43, "ENTITY"], [15, 24, "ORGANISM"], [15, 24, "ENTITY"], [355, 364, "ORGANISM"], [271, 291, "ENTITY"], [332, 339, "PROTEIN"], [86, 113, "ENTITY"], [271, 285, "SIMPLE_CHEMICAL"], [6, 15, "ENTITY"], [159, 172, "ENTITY"], [136, 145, "ENTITY"], [36, 43, "ORGANISM"], [159, 172, "CHEMICAL"], [136, 145, "CHEMICAL"], [306, 316, "ENTITY"], [355, 364, "ENTITY"], [332, 339, "ENTITY"], [43, 53, "ENTITY"], [145, 157, "ENTITY"], [43, 53, "ORGANISM"], [113, 126, "ENTITY"]]}
{"text": "7 ( 63.6 % ) severe cases and all moderate cases received antiviral therapy ( oseltamivir and/or ganciclovir ) .", "labels": [[68, 78, "ENTITY"], [90, 97, "ENTITY"], [68, 78, "CHEMICAL"], [13, 20, "ENTITY"], [34, 43, "ENTITY"], [90, 97, "SIMPLE_CHEMICAL"], [49, 68, "ENTITY"], [90, 97, "CHEMICAL"]]}
{"text": "Antiviral ( oseltamivir , 75 mg twice a day ; ribavirin , 0.5 g twice a day ; umifenovir , 0.2 g 3 times a day ) , antibacterial ( moxifloxacin , 0.4 g every day ) , glucocorticoid ( methylprednisolone , 40 - 80 mg every day ) , and respiratory support were the main treatment approaches for the hospitalized patients ( Table 1 ) .", "labels": [[166, 183, "CHEBI"], [99, 105, "ENTITY"], [115, 131, "SIMPLE_CHEMICAL"], [0, 10, "ENTITY"], [166, 183, "ENTITY"], [166, 183, "CHEMICAL"], [166, 183, "SIMPLE_CHEMICAL"], [32, 40, "ENTITY"], [115, 131, "CHEMICAL"], [146, 152, "ENTITY"], [152, 166, "ENTITY"], [215, 233, "ENTITY"], [245, 267, "ENTITY"], [152, 166, "SIMPLE_CHEMICAL"], [277, 288, "ENTITY"], [107, 115, "ENTITY"], [115, 131, "ENTITY"]]}
{"text": "A majority of the patients ( 58.0 % ) received intravenous antibiotic therapy , and 35.8 % received oseltamivir therapy ; oxygen therapy was administered in 41.3 % and mechanical ventilation in 6.1 % ; higher percentages of patients with severe disease received these therapies ( Table 3 ) .", "labels": [[112, 129, "ENTITY"], [91, 112, "ENTITY"], [129, 141, "ENTITY"], [47, 59, "CHEBI"], [209, 224, "ORGANISM"], [18, 27, "ENTITY"], [18, 27, "ORGANISM"], [224, 238, "ENTITY"], [209, 224, "ENTITY"], [162, 179, "ENTITY"], [112, 122, "CHEBI"], [38, 47, "IMMATERIAL_ANATOMICAL_ENTITY"], [112, 122, "CHEMICAL"], [112, 122, "SIMPLE_CHEMICAL"], [253, 268, "ENTITY"], [38, 70, "ENTITY"], [38, 47, "CHEMICAL"]]}
{"text": "The other antiviral drugs include nitazoxanide , favipiravir , nafamostat , and so on ( See Table 1 for details ) .", "labels": [[34, 47, "ENTITY"], [34, 47, "CHEMICAL"], [10, 26, "ENTITY"], [34, 47, "CHEBI"], [34, 47, "SIMPLE_CHEMICAL"]]}
{"text": "The other antiviral drugs include nitazoxanide , favipiravir , nafamostat , and so on ( See Table 1 for details ) .", "labels": [[34, 47, "ENTITY"], [34, 47, "CHEMICAL"], [10, 26, "ENTITY"], [34, 47, "CHEBI"], [34, 47, "SIMPLE_CHEMICAL"]]}
{"text": "The other antiviral drugs include nitazoxanide , favipiravir , nafamostat , and so on ( See Table 1 for details ) .", "labels": [[34, 47, "ENTITY"], [34, 47, "CHEMICAL"], [10, 26, "ENTITY"], [34, 47, "CHEBI"], [34, 47, "SIMPLE_CHEMICAL"]]}
{"text": "The other antiviral drugs include nitazoxanide , favipiravir , nafamostat , and so on ( See Table 1 for details ) .", "labels": [[34, 47, "ENTITY"], [34, 47, "CHEMICAL"], [10, 26, "ENTITY"], [34, 47, "CHEBI"], [34, 47, "SIMPLE_CHEMICAL"]]}
{"text": "Based on these results , we performed virtual docking to screen for commercial medicines in the DrugBank database that could bind to the above mentioned pocket site of 2019-nCoV Mpro , and identified 10 candidate clinical medicines ( Table 1 ; Figs. 1B and S3 ) .", "labels": [[15, 23, "ENTITY"], [96, 105, "ENTITY"], [153, 160, "ENTITY"], [38, 46, "ENTITY"], [68, 79, "ENTITY"], [203, 222, "ENTITY"], [153, 160, "SO"], [168, 178, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "At the time , we put forward pseudoephedrine , andrographolide , chloroquine , abacavir , baricitinib , and quercetin as repurposing candidates from our list , because there were other researches also suggesting or predicting these drugs , mainly based on our Yaozh database search and literature review .", "labels": [[108, 133, "ENTITY"], [7, 12, "ENTITY"], [21, 29, "SO"], [65, 79, "SIMPLE_CHEMICAL"], [45, 51, "CHEMICAL"], [79, 90, "GENE_OR_GENE_PRODUCT"], [79, 90, "ENTITY"], [45, 51, "ENTITY"], [201, 215, "ENTITY"], [275, 286, "ENTITY"], [253, 266, "ENTITY"], [79, 90, "CHEMICAL"], [45, 51, "CHEBI"], [45, 51, "SIMPLE_CHEMICAL"], [65, 79, "CHEMICAL"], [65, 79, "ENTITY"]]}
{"text": "At the time , we put forward pseudoephedrine , andrographolide , chloroquine , abacavir , baricitinib , and quercetin as repurposing candidates from our list , because there were other researches also suggesting or predicting these drugs , mainly based on our Yaozh database search and literature review .", "labels": [[79, 90, "GENE_OR_GENE_PRODUCT"], [7, 12, "ENTITY"], [21, 29, "SO"], [65, 79, "SIMPLE_CHEMICAL"], [45, 51, "CHEMICAL"], [108, 133, "ENTITY"], [79, 90, "ENTITY"], [45, 51, "ENTITY"], [201, 215, "ENTITY"], [275, 286, "ENTITY"], [253, 266, "ENTITY"], [79, 90, "CHEMICAL"], [45, 51, "CHEBI"], [45, 51, "SIMPLE_CHEMICAL"], [65, 79, "CHEMICAL"], [65, 79, "ENTITY"]]}
{"text": "Different directly acting antiviral drugs are approved against other viruses , by the Food and Drugs Administration ( FDA ) , such as Sofosbuvir , Ribavirin against RdRp of Hepatitis C Virus ( HCV ) .", "labels": [[165, 185, "ENTITY"], [185, 191, "ORGANISM"], [165, 185, "DISEASE"], [69, 77, "ENTITY"], [165, 185, "GGP"], [134, 147, "CHEMICAL"], [185, 191, "TAXON"], [69, 77, "TAXON"], [134, 147, "SIMPLE_CHEMICAL"], [165, 185, "ORGANISM"], [134, 147, "CHEBI"], [134, 147, "ENTITY"], [185, 191, "ENTITY"], [26, 42, "ENTITY"]]}
{"text": "The fifth edition of the Guidelines recommends antivirals including IFN-\u03b1 , lopinavir/ritonavir , and ribavirin for treatment of COVID-19 ( 3 ) .", "labels": [[68, 74, "ENTITY"], [126, 140, "PROTEIN"], [10, 18, "ENTITY"], [126, 140, "GENE_OR_GENE_PRODUCT"], [68, 74, "PROTEIN"], [25, 36, "ENTITY"], [47, 58, "ENTITY"], [68, 74, "GENE_OR_GENE_PRODUCT"], [47, 58, "GO"]]}
{"text": "Intravenous infusion of ribavirin injections at a dose of 10 mg/kg every time ( maximum 500 mg every time ) , 2\u20133 times daily was recommended for children with COVID-19 [ 17 ] .", "labels": [[50, 55, "ENTITY"], [155, 171, "GENE_OR_GENE_PRODUCT"], [34, 45, "ENTITY"], [24, 34, "CHEMICAL"], [108, 120, "ENTITY"], [0, 12, "IMMATERIAL_ANATOMICAL_ENTITY"], [24, 34, "ENTITY"], [12, 21, "ENTITY"], [0, 12, "ENTITY"], [24, 34, "SIMPLE_CHEMICAL"], [73, 78, "ENTITY"]]}
{"text": "Antiviral ( oseltamivir , 75 mg twice a day ; ribavirin , 0.5 g twice a day ; umifenovir , 0.2 g 3 times a day ) , antibacterial ( moxifloxacin , 0.4 g every day ) , glucocorticoid ( methylprednisolone , 40 - 80 mg every day ) , and respiratory support were the main treatment approaches for the hospitalized patients ( Table 1 ) .", "labels": [[166, 183, "CHEBI"], [99, 105, "ENTITY"], [115, 131, "SIMPLE_CHEMICAL"], [0, 10, "ENTITY"], [166, 183, "ENTITY"], [166, 183, "CHEMICAL"], [166, 183, "SIMPLE_CHEMICAL"], [32, 40, "ENTITY"], [115, 131, "CHEMICAL"], [146, 152, "ENTITY"], [152, 166, "ENTITY"], [215, 233, "ENTITY"], [245, 267, "ENTITY"], [152, 166, "SIMPLE_CHEMICAL"], [277, 288, "ENTITY"], [107, 115, "ENTITY"], [115, 131, "ENTITY"]]}
{"text": "Ribavirin is a nucleoside analogue with a broad-spectrum of antiviral effects . A study compared 111 patients with severe acute respiratory syndrome ( severe acute respiratory syndrome ) treated with ribavirin monotherapy and 41 patients with severe acute respiratory syndrome treated with lopinavir/ritonavir and ribavirin ; patients treated with the combined therapy had a lower risk of acute respiratory distress syndrome ( acute respiratory distress syndrome ) and death ( 6 ) .", "labels": [[180, 189, "ENTITY"], [90, 100, "ENTITY"], [21, 32, "CHEMICAL"], [0, 10, "PROTEIN"], [0, 10, "CHEMICAL"], [21, 32, "CHEBI"], [343, 356, "CHEMICAL"], [0, 10, "SIMPLE_CHEMICAL"], [-1, 23, "DISEASE"], [-1, 20, "ENTITY"], [149, 156, "ENTITY"], [0, 10, "GGP"], [21, 32, "SIMPLE_CHEMICAL"], [149, 156, "ORGANISM"], [343, 356, "SIMPLE_CHEMICAL"], [131, 140, "ENTITY"], [-1, 20, "SIMPLE_CHEMICAL"], [-1, 19, "ENTITY"], [149, 156, "ENTITY"], [180, 189, "DISEASE"], [219, 229, "ENTITY"], [0, 10, "ENTITY"], [-1, 20, "CHEMICAL"], [298, 322, "ENTITY"]]}
{"text": "Ribavirin is a nucleoside analogue with a broad-spectrum of antiviral effects . A study compared 111 patients with severe acute respiratory syndrome ( severe acute respiratory syndrome ) treated with ribavirin monotherapy and 41 patients with severe acute respiratory syndrome treated with lopinavir/ritonavir and ribavirin ; patients treated with the combined therapy had a lower risk of acute respiratory distress syndrome ( acute respiratory distress syndrome ) and death ( 6 ) .", "labels": [[180, 189, "ENTITY"], [90, 100, "ENTITY"], [21, 32, "CHEMICAL"], [0, 10, "PROTEIN"], [0, 10, "CHEMICAL"], [21, 32, "CHEBI"], [343, 356, "CHEMICAL"], [0, 10, "SIMPLE_CHEMICAL"], [-1, 23, "DISEASE"], [149, 156, "ENTITY"], [0, 10, "GGP"], [21, 32, "SIMPLE_CHEMICAL"], [149, 156, "ORGANISM"], [-1, 20, "ENTITY"], [343, 356, "SIMPLE_CHEMICAL"], [131, 140, "ENTITY"], [-1, 19, "ENTITY"], [149, 156, "ENTITY"], [-1, 20, "SIMPLE_CHEMICAL"], [-1, 20, "CHEMICAL"], [180, 189, "DISEASE"], [219, 229, "ENTITY"], [0, 10, "ENTITY"], [298, 322, "ENTITY"]]}
{"text": "Ribavirin is a nucleoside analogue with a broad-spectrum of antiviral effects . A study compared 111 patients with severe acute respiratory syndrome ( severe acute respiratory syndrome ) treated with ribavirin monotherapy and 41 patients with severe acute respiratory syndrome treated with lopinavir/ritonavir and ribavirin ; patients treated with the combined therapy had a lower risk of acute respiratory distress syndrome ( acute respiratory distress syndrome ) and death ( 6 ) .", "labels": [[180, 189, "ENTITY"], [90, 100, "ENTITY"], [21, 32, "CHEMICAL"], [0, 10, "PROTEIN"], [0, 10, "CHEMICAL"], [21, 32, "CHEBI"], [343, 356, "CHEMICAL"], [0, 10, "SIMPLE_CHEMICAL"], [-1, 23, "DISEASE"], [-1, 20, "ENTITY"], [149, 156, "ENTITY"], [0, 10, "GGP"], [21, 32, "SIMPLE_CHEMICAL"], [149, 156, "ORGANISM"], [343, 356, "SIMPLE_CHEMICAL"], [131, 140, "ENTITY"], [-1, 20, "SIMPLE_CHEMICAL"], [-1, 19, "ENTITY"], [149, 156, "ENTITY"], [180, 189, "DISEASE"], [219, 229, "ENTITY"], [0, 10, "ENTITY"], [-1, 20, "CHEMICAL"], [298, 322, "ENTITY"]]}
{"text": "Ribavirin is a broad-spectrum antiviral drug , which has inhibitory effects on RNA viruses and DNA viruses .", "labels": [[0, 10, "GGP"], [79, 83, "SO"], [79, 83, "ENTITY"], [0, 10, "CHEMICAL"], [15, 45, "ENTITY"], [0, 10, "SIMPLE_CHEMICAL"], [95, 99, "ENTITY"], [40, 45, "CHEBI"], [0, 10, "ENTITY"], [95, 99, "SO"]]}
{"text": "Ribavirin is a broad-spectrum antiviral drug , which has inhibitory effects on RNA viruses and DNA viruses .", "labels": [[0, 10, "GGP"], [79, 83, "SO"], [79, 83, "ENTITY"], [0, 10, "CHEMICAL"], [15, 45, "ENTITY"], [0, 10, "SIMPLE_CHEMICAL"], [95, 99, "ENTITY"], [40, 45, "CHEBI"], [0, 10, "ENTITY"], [95, 99, "SO"]]}
{"text": "The most common adverse reactions of ribavirin in children include fever ( 80 % ) , headache ( 62 % ) , neutropenia ( 33 % ) , fatigue ( 30 % ) , etc . [ 20 ] .", "labels": [[16, 34, "ENTITY"], [67, 73, "ENTITY"], [37, 47, "SIMPLE_CHEMICAL"], [50, 59, "ENTITY"], [67, 73, "DISEASE"], [37, 47, "ENTITY"], [37, 47, "CHEMICAL"], [50, 59, "ORGANISM"]]}
{"text": "The most common adverse reactions of ribavirin in children include fever ( 80 % ) , headache ( 62 % ) , neutropenia ( 33 % ) , fatigue ( 30 % ) , etc . [ 20 ] .", "labels": [[16, 34, "ENTITY"], [67, 73, "ENTITY"], [67, 73, "DISEASE"], [37, 47, "SIMPLE_CHEMICAL"], [50, 59, "ENTITY"], [37, 47, "ENTITY"], [37, 47, "CHEMICAL"], [50, 59, "ORGANISM"]]}
{"text": "The most common adverse reactions of ribavirin in children include fever ( 80 % ) , headache ( 62 % ) , neutropenia ( 33 % ) , fatigue ( 30 % ) , etc . [ 20 ] .", "labels": [[16, 34, "ENTITY"], [67, 73, "ENTITY"], [67, 73, "DISEASE"], [37, 47, "SIMPLE_CHEMICAL"], [50, 59, "ENTITY"], [37, 47, "ENTITY"], [37, 47, "CHEMICAL"], [50, 59, "ORGANISM"]]}
{"text": "The most common adverse reactions of ribavirin in children include fever ( 80 % ) , headache ( 62 % ) , neutropenia ( 33 % ) , fatigue ( 30 % ) , etc . [ 20 ] .", "labels": [[16, 34, "ENTITY"], [67, 73, "ENTITY"], [67, 73, "DISEASE"], [37, 47, "SIMPLE_CHEMICAL"], [50, 59, "ENTITY"], [37, 47, "ENTITY"], [37, 47, "CHEMICAL"], [50, 59, "ORGANISM"]]}
{"text": "Large doses of ribavirin could cause decreased hemoglobin and serious heart damage .", "labels": [[47, 58, "CHEBI"], [37, 47, "ENTITY"], [0, 6, "ENTITY"], [6, 12, "ENTITY"], [70, 76, "ORGAN"], [15, 25, "ENTITY"], [47, 58, "GENE_OR_GENE_PRODUCT"], [47, 58, "PROTEIN"], [15, 25, "SIMPLE_CHEMICAL"], [70, 83, "ENTITY"], [15, 25, "CHEMICAL"], [47, 58, "ENTITY"], [70, 83, "DISEASE"]]}
{"text": "Large doses of ribavirin could cause decreased hemoglobin and serious heart damage .", "labels": [[47, 58, "CHEBI"], [37, 47, "ENTITY"], [0, 6, "ENTITY"], [6, 12, "ENTITY"], [70, 76, "ORGAN"], [15, 25, "ENTITY"], [47, 58, "GENE_OR_GENE_PRODUCT"], [47, 58, "PROTEIN"], [15, 25, "SIMPLE_CHEMICAL"], [70, 83, "ENTITY"], [15, 25, "CHEMICAL"], [47, 58, "ENTITY"], [70, 83, "DISEASE"]]}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "From DrugBank", "labels": []}
{"text": "The human purine biosynthesis enzyme Inosine-5\u2032-monophosphate dehydrogenase ( IMPDH2 ) interacts with the viral protein nsp14 . Several chemically diverse compounds inhibit IMPDH2 , including the clinically approved mycophenolic acid ( 20 nM ) , the approved antiviral drug ribavirin ( 200 nM ) , and the investigational new drug Merimepodib ( 10 nM ) ( Table 1a ) .", "labels": [[4, 76, "PROTEIN"], [102, 120, "PROTEIN"], [30, 37, "SO"], [37, 62, "CHEMICAL"], [259, 274, "CHEMICAL"], [165, 173, "PROTEIN"], [295, 305, "ENTITY"], [10, 17, "CHEMICAL"], [102, 112, "TAXON"], [10, 30, "ENTITY"], [207, 229, "ENTITY"], [4, 17, "TAXON"], [207, 229, "CHEMICAL"], [147, 155, "ENTITY"], [165, 173, "GENE_OR_GENE_PRODUCT"], [4, 10, "ENTITY"], [250, 274, "ENTITY"], [128, 147, "ENTITY"], [30, 76, "ENTITY"], [165, 173, "GGP"], [147, 155, "CHEBI"], [37, 76, "GENE_OR_GENE_PRODUCT"], [207, 229, "CHEBI"], [102, 120, "ENTITY"], [207, 229, "SIMPLE_CHEMICAL"], [155, 165, "ENTITY"], [165, 173, "ENTITY"], [4, 17, "ORGANISM"], [259, 274, "SIMPLE_CHEMICAL"]]}
{"text": "Several potential drug candidates , including lopinavir/ritonavir ( Kaletra R ) , nucleoside analogues , neuraminidase inhibitors , remdesivir , umifenovir ( Arbidol R ) , DNA synthesis inhibitors ( such as tenofovir disoproxil and lamivudine ) , chloroquine and Chinese traditional medicines ( such as ShuFeng JieDu or Lianhua Qing- wen capsules ) , have been proposed [ 36 , 37 ] .", "labels": [[8, 18, "ENTITY"], [232, 245, "CHEMICAL"], [199, 207, "ENTITY"], [145, 158, "CHEMICAL"], [247, 271, "ENTITY"], [93, 119, "ENTITY"], [93, 105, "GENE_OR_GENE_PRODUCT"], [119, 132, "ENTITY"], [232, 245, "SIMPLE_CHEMICAL"], [158, 166, "SO"], [283, 303, "PROTEIN"], [217, 232, "SIMPLE_CHEMICAL"], [232, 245, "ENTITY"], [217, 232, "CHEMICAL"], [217, 232, "ENTITY"], [176, 186, "CHEBI"], [145, 158, "ENTITY"], [197, 217, "ENTITY"], [66, 76, "SIMPLE_CHEMICAL"], [283, 295, "CHEMICAL"], [66, 76, "ENTITY"], [303, 328, "ENTITY"], [176, 186, "ENTITY"], [158, 176, "ENTITY"], [93, 119, "CHEBI"], [197, 217, "CHEMICAL"], [158, 166, "CELLULAR_COMPONENT"], [232, 245, "CHEBI"], [283, 295, "TAXON"], [18, 34, "ENTITY"], [132, 145, "ENTITY"], [283, 303, "ORGANISM"], [197, 217, "SIMPLE_CHEMICAL"], [283, 295, "ENTITY"], [78, 93, "ENTITY"], [18, 23, "CHEBI"], [66, 76, "CHEMICAL"]]}
{"text": "Furthermore , there is the potential for combining baricitinib with the directacting antivirals ( lopinavir or ritonavir and 121304016 ) currently being used in the COVID-19 outbreak , since it has a minimal interaction with the relevant CYP drugmetabolising enzymes . Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity , viral replication , and the aberrant host inflammatory response .", "labels": [[269, 285, "ENTITY"], [242, 259, "ENTITY"], [72, 85, "ENTITY"], [339, 346, "TAXON"], [352, 372, "ENTITY"], [386, 394, "ENTITY"], [242, 259, "SO"], [229, 238, "ENTITY"], [352, 364, "TAXON"], [161, 174, "ENTITY"], [229, 259, "GENE_OR_GENE_PRODUCT"], [302, 322, "CHEBI"], [259, 269, "ENTITY"], [394, 421, "ENTITY"], [269, 285, "CHEMICAL"], [238, 242, "ENTITY"], [339, 352, "DISEASE"], [302, 322, "ENTITY"], [194, 200, "ENTITY"], [269, 285, "GENE_OR_GENE_PRODUCT"], [339, 352, "ENTITY"], [200, 208, "ENTITY"], [229, 259, "PROTEIN"]]}
{"text": "The fifth edition of the Guidelines recommends antivirals including IFN-\u03b1 , lopinavir/ritonavir , and ribavirin for treatment of COVID-19 ( 3 ) .", "labels": [[68, 74, "ENTITY"], [126, 140, "PROTEIN"], [10, 18, "ENTITY"], [126, 140, "GENE_OR_GENE_PRODUCT"], [68, 74, "PROTEIN"], [25, 36, "ENTITY"], [47, 58, "ENTITY"], [68, 74, "GENE_OR_GENE_PRODUCT"], [47, 58, "GO"]]}
{"text": "Lopinavir/ritonavir can be used when appropriate , 2 tablets , twice daily for 14 days .", "labels": [[0, 20, "DISEASE"], [0, 20, "ENTITY"]]}
{"text": "Other reported therapeutic agents that are used for the treatment of seriously ill patients have been noted in Table 1 .", "labels": [[79, 83, "ENTITY"], [83, 92, "ENTITY"], [83, 92, "ORGANISM"], [15, 34, "ENTITY"], [56, 66, "ENTITY"]]}
{"text": "The major therapeutic drugs that might be effective in managing COVID-19 include remdesivir , lopinavir/ritonavir alone or in combination with interferon-\u03b2 , convalescent plasma , and mAbs.17", "labels": [[10, 28, "ENTITY"], [42, 52, "ENTITY"], [156, 171, "ORGANISM"], [81, 92, "ENTITY"], [158, 171, "ENTITY"], [64, 73, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"]]}
{"text": "All 74 patients with COVID-19 with GI symptoms were treated in isolation with supportive and empiric medication , while 66 ( 89.19 % ) patients received antiviral treatment , including interferon-\u03b1 sprays , arbidol hydrochloride capsules ( two tablets three times daily ) , lopinavir and ritonavir two tablets ( 500 mg ) twice daily , via the oral route .", "labels": [[175, 198, "ENTITY"], [7, 16, "ENTITY"], [52, 60, "ENTITY"], [7, 16, "ORGANISM"], [316, 321, "ENTITY"], [63, 73, "ENTITY"], [274, 288, "SIMPLE_CHEMICAL"], [327, 339, "ENTITY"], [35, 38, "ORGAN"], [144, 163, "ENTITY"], [274, 288, "CHEMICAL"], [198, 229, "ENTITY"], [207, 229, "CHEBI"], [274, 288, "ENTITY"], [93, 112, "ENTITY"], [264, 274, "SIMPLE_CHEMICAL"], [21, 30, "ENTITY"], [35, 47, "ENTITY"], [288, 298, "ENTITY"], [207, 229, "SIMPLE_CHEMICAL"], [78, 89, "ENTITY"], [264, 274, "CHEMICAL"], [21, 30, "GENE_OR_GENE_PRODUCT"], [207, 215, "CHEMICAL"], [264, 274, "ENTITY"], [238, 244, "ENTITY"], [327, 335, "ORGAN"]]}
{"text": "Fewer deceased patients ( 89 ; 79 % ) than recovered patients ( 147 ; 91 % ) received monotherapy or combination therapy with antiviral agents ( oseltamivir , arbidol , or lopinavir/ritonavir ) , whereas more deceased patients ( 99 ; 88 % ) than recovered patients ( 118 ; 73 % ) were given glucocorticoid therapy , considering the severe pneumonia and \u201c cytokine storm \u201d observed in patients who died .", "labels": [[159, 172, "SIMPLE_CHEMICAL"], [77, 86, "ENTITY"], [36, 43, "ENTITY"], [145, 157, "ENTITY"], [15, 24, "ORGANISM"], [15, 24, "ENTITY"], [355, 364, "ORGANISM"], [271, 291, "ENTITY"], [332, 339, "PROTEIN"], [86, 113, "ENTITY"], [271, 285, "SIMPLE_CHEMICAL"], [6, 15, "ENTITY"], [159, 172, "ENTITY"], [136, 145, "ENTITY"], [36, 43, "ORGANISM"], [159, 172, "CHEMICAL"], [136, 145, "CHEMICAL"], [306, 316, "ENTITY"], [355, 364, "ENTITY"], [332, 339, "ENTITY"], [43, 53, "ENTITY"], [113, 126, "ENTITY"], [43, 53, "ORGANISM"]]}
{"text": "Also , according to Jian-ya et al. , treatment of 51 COVID-19 patients with traditional Chinese medicine , interferon , Lopinavir , Ritonavir and short-term ( 3 to 5 days ) corticosteroids was successful and resulted in recovery and discharge of 50 patients ( 3 ) .", "labels": [[166, 173, "ENTITY"], [220, 233, "ENTITY"], [53, 62, "ENTITY"], [50, 62, "ORGANISM"], [243, 249, "ENTITY"], [107, 120, "SIMPLE_CHEMICAL"], [120, 132, "SIMPLE_CHEMICAL"], [120, 132, "ENTITY"], [120, 132, "CHEMICAL"], [107, 120, "CHEMICAL"], [208, 220, "ENTITY"], [107, 120, "ENTITY"], [76, 96, "ENTITY"], [243, 249, "ORGANISM"], [166, 173, "SIMPLE_CHEMICAL"]]}
{"text": "Lopinavir/ritonavir is a medication for the human immunodeficiency virus ( HIV ) used in combination with other medications to treat adults and children over 14 days of age who are infected with HIV-1 ( 5 ) .", "labels": [[25, 36, "ENTITY"], [0, 20, "DISEASE"], [44, 50, "TAXON"], [44, 73, "ENTITY"], [44, 73, "ORGANISM"], [67, 73, "TAXON"], [127, 133, "ENTITY"], [44, 79, "DISEASE"], [0, 20, "ENTITY"]]}
{"text": "Chu et al. found that lopinavir/ ritonavir has anti-SARS-CoV activity in vitro and in clinical studies ( 6 ) .", "labels": [[86, 103, "ENTITY"], [33, 43, "ENTITY"], [47, 70, "ENTITY"], [47, 61, "DNA"], [22, 33, "ENTITY"], [22, 43, "CHEMICAL"], [70, 79, "ENTITY"], [22, 43, "GENE_OR_GENE_PRODUCT"]]}
{"text": "One antiviral-drug candidate is a combination of the HIV protease inhibitors lopinavir and ritonavir .", "labels": [[91, 101, "SIMPLE_CHEMICAL"], [91, 101, "ENTITY"], [34, 46, "ENTITY"], [53, 66, "ENTITY"], [77, 87, "CHEMICAL"], [91, 101, "CHEMICAL"], [77, 87, "ENTITY"], [57, 87, "SIMPLE_CHEMICAL"], [4, 19, "ENTITY"], [53, 77, "GO"]]}
{"text": "ATV alone showed a nearly 10-fold increase in potency for inhibiting SARS-CoV-2 replication in A549 ( Figure 6C ) compared to Vero cells ( Figure 6B ) . ATV/RTV and CQ were similarly potent in inhibiting virus replication in both cell types ( Figure 6B and C ) .", "labels": [[0, 4, "ENTITY"], [95, 100, "CELL"], [100, 109, "CELL"], [225, 235, "ENTITY"], [123, 131, "CELL_LINE"], [146, 149, "ENTITY"], [69, 80, "CHEMICAL"], [0, 4, "PROTEIN"], [235, 243, "ENTITY"], [95, 100, "ENTITY"], [123, 131, "ENTITY"], [183, 193, "ENTITY"], [46, 54, "ENTITY"], [102, 109, "ENTITY"], [126, 131, "CL"], [69, 92, "ENTITY"], [100, 109, "ENTITY"], [58, 69, "TAXON"], [193, 210, "ENTITY"], [58, 69, "ENTITY"], [34, 43, "ENTITY"], [69, 80, "SIMPLE_CHEMICAL"], [123, 131, "CELL"], [0, 4, "SIMPLE_CHEMICAL"], [0, 4, "CHEMICAL"]]}
{"text": "Baricitinib , fedratinib , and ruxolitinib are potent and selective JAK inhibitors approved for indications such as rheumatoid arthritis and myelofibrosis . All three are powerful antiinflammatories that , as JAK \u2013 STAT signalling inhibitors , are likely to be effective against the consequences of the elevated levels of cytokines ( including interferon-\u03b3 ) typically observed in people with COVID-19\u00b72", "labels": [[58, 72, "GGP"], [68, 72, "ENTITY"], [248, 261, "ENTITY"], [296, 303, "ENTITY"], [113, 127, "ENTITY"], [271, 283, "ENTITY"], [312, 322, "ENTITY"], [220, 231, "CHEBI"], [204, 213, "GENE_OR_GENE_PRODUCT"], [113, 127, "DISEASE"], [0, 12, "ENTITY"], [334, 344, "PROTEIN"], [58, 68, "GENE_OR_GENE_PRODUCT"], [369, 378, "ENTITY"], [334, 344, "ENTITY"], [381, 393, "ENTITY"], [68, 72, "PROTEIN"], [381, 393, "PROTEIN"], [0, 12, "CHEMICAL"], [68, 72, "GGP"], [0, 12, "GENE_OR_GENE_PRODUCT"], [369, 378, "ORGANISM"], [381, 393, "CHEMICAL"], [171, 180, "ENTITY"], [312, 322, "PROTEIN"], [58, 72, "ENTITY"], [334, 344, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "Mesalazine ( an approved drug for inflammatory bowel disease ) , sirolimus ( an approved immunosuppressive drug ) , and equilin ( an approved agonist of the estrogen receptor for menopausal symptoms ) achieved the highest GSEA scores of 3 , followed by paroxetine and melatonin with GSEA scores of 2 .", "labels": [[80, 107, "ENTITY"], [0, 11, "CHEBI"], [114, 120, "SIMPLE_CHEMICAL"], [268, 278, "ENTITY"], [268, 278, "GENE_OR_GENE_PRODUCT"], [150, 166, "ENTITY"], [16, 25, "ENTITY"], [214, 222, "ENTITY"], [166, 190, "ENTITY"], [16, 25, "CHEBI"], [253, 268, "SIMPLE_CHEMICAL"], [150, 166, "GENE_OR_GENE_PRODUCT"], [89, 107, "CHEBI"], [150, 157, "CHEMICAL"], [0, 11, "ENTITY"], [34, 53, "DISEASE"], [150, 166, "GGP"], [150, 166, "PROTEIN"], [114, 120, "ENTITY"], [253, 268, "CHEMICAL"], [241, 253, "SIMPLE_CHEMICAL"], [114, 120, "PROTEIN"], [241, 253, "CHEBI"], [253, 268, "ENTITY"], [114, 120, "DISEASE"], [34, 53, "ENTITY"], [241, 253, "ENTITY"], [241, 253, "CHEMICAL"], [0, 11, "SIMPLE_CHEMICAL"], [0, 11, "CHEMICAL"]]}
{"text": "Specifically , sirolimus and dactinomycin may inhibit both mTOR signaling and RNA synthesis pathway ( including DNA topoisomerase 2-alpha ( TOP2A ) and DNA topoisomerase 2-beta ( TOP2B ) ) in HCoV-infected cells ( Fig. 6b ) .", "labels": [[148, 170, "ENTITY"], [148, 170, "GENE_OR_GENE_PRODUCT"], [170, 179, "GGP"], [170, 179, "ENTITY"], [185, 192, "ENTITY"], [78, 92, "ENTITY"], [102, 112, "SO"], [102, 130, "PROTEIN"], [170, 179, "PROTEIN"], [185, 192, "CELL_LINE"], [170, 179, "GENE_OR_GENE_PRODUCT"], [102, 130, "GENE_OR_GENE_PRODUCT"], [185, 192, "CELL"], [102, 130, "ENTITY"], [148, 170, "PROTEIN"]]}
{"text": "Specifically , sirolimus and dactinomycin may inhibit both mTOR signaling and RNA synthesis pathway ( including DNA topoisomerase 2-alpha ( TOP2A ) and DNA topoisomerase 2-beta ( TOP2B ) ) in HCoV-infected cells ( Fig. 6b ) .", "labels": [[148, 170, "ENTITY"], [148, 170, "GENE_OR_GENE_PRODUCT"], [170, 179, "GGP"], [170, 179, "ENTITY"], [185, 192, "ENTITY"], [78, 92, "ENTITY"], [102, 112, "SO"], [102, 130, "PROTEIN"], [170, 179, "PROTEIN"], [185, 192, "CELL_LINE"], [102, 130, "GENE_OR_GENE_PRODUCT"], [170, 179, "GENE_OR_GENE_PRODUCT"], [185, 192, "CELL"], [102, 130, "ENTITY"], [148, 170, "PROTEIN"]]}
{"text": "Specifically , sirolimus and dactinomycin may inhibit both mTOR signaling and RNA synthesis pathway ( including DNA topoisomerase 2-alpha ( TOP2A ) and DNA topoisomerase 2-beta ( TOP2B ) ) in HCoV-infected cells ( Fig. 6b ) .", "labels": [[148, 170, "ENTITY"], [148, 170, "GENE_OR_GENE_PRODUCT"], [170, 179, "GGP"], [170, 179, "ENTITY"], [185, 192, "ENTITY"], [78, 92, "ENTITY"], [102, 112, "SO"], [102, 130, "PROTEIN"], [170, 179, "PROTEIN"], [185, 192, "CELL_LINE"], [102, 130, "GENE_OR_GENE_PRODUCT"], [170, 179, "GENE_OR_GENE_PRODUCT"], [185, 192, "CELL"], [102, 130, "ENTITY"], [148, 170, "PROTEIN"]]}
{"text": "Specifically , sirolimus and dactinomycin may inhibit both mTOR signaling and RNA synthesis pathway ( including DNA topoisomerase 2-alpha ( TOP2A ) and DNA topoisomerase 2-beta ( TOP2B ) ) in HCoV-infected cells ( Fig. 6b ) .", "labels": [[148, 170, "ENTITY"], [148, 170, "GENE_OR_GENE_PRODUCT"], [170, 179, "GGP"], [170, 179, "ENTITY"], [185, 192, "ENTITY"], [78, 92, "ENTITY"], [102, 112, "SO"], [102, 130, "PROTEIN"], [170, 179, "PROTEIN"], [185, 192, "CELL_LINE"], [102, 130, "GENE_OR_GENE_PRODUCT"], [170, 179, "GENE_OR_GENE_PRODUCT"], [185, 192, "CELL"], [102, 130, "ENTITY"], [148, 170, "PROTEIN"]]}
{"text": "SGs are induced by protein kinase R (PKR)-mediated phosphorylation of eIF2\u03b1 upon viral dsRNA recognition [ 57 ] . Promoting G3BP aggregation via the eIF4A inhibitor Zotatafin [ 58,59 ] or reducing SG disassembly by Silmitasertib inhibition of CK2 [ 60 ] warrant investigation for treatment of SARS-CoV-2 . The mTOR inhibitor rapamycin disrupts the binding of LARP1 to mTORC1 [ 61 ] and has been shown to reduce MERS infection by \u223c60 % in vitro [ 62 ] , another drug that could be tested for repurposing .", "labels": [[51, 67, "ENTITY"], [19, 36, "GENE_OR_GENE_PRODUCT"], [325, 335, "ENTITY"], [254, 262, "ENTITY"], [70, 76, "PROTEIN"], [293, 306, "ENTITY"], [114, 124, "PROTEIN"], [155, 165, "SIMPLE_CHEMICAL"], [70, 76, "ENTITY"], [19, 36, "PROTEIN"], [145, 155, "CHEBI"], [145, 165, "PROTEIN"], [229, 240, "ENTITY"], [280, 293, "CHEMICAL"], [0, 4, "ENTITY"], [200, 215, "CHEMICAL"], [335, 348, "ENTITY"], [114, 124, "ENTITY"], [395, 401, "ENTITY"], [81, 93, "TAXON"], [200, 215, "ORGANISM"], [124, 129, "ENTITY"], [293, 306, "GENE_OR_GENE_PRODUCT"], [19, 36, "ENTITY"], [348, 356, "GENE_OR_GENE_PRODUCT"], [0, 4, "GO"], [262, 280, "ENTITY"], [8, 16, "ENTITY"], [229, 243, "GENE_OR_GENE_PRODUCT"], [348, 356, "PROTEIN"], [0, 4, "GENE_OR_GENE_PRODUCT"], [145, 155, "ENTITY"], [416, 433, "ENTITY"], [188, 200, "ENTITY"], [348, 356, "ENTITY"], [19, 27, "CHEBI"], [477, 487, "ENTITY"], [155, 165, "CHEMICAL"], [280, 293, "ENTITY"], [280, 293, "SIMPLE_CHEMICAL"], [359, 368, "GENE_OR_GENE_PRODUCT"], [306, 315, "ENTITY"], [293, 325, "GGP"], [70, 76, "GENE_OR_GENE_PRODUCT"], [200, 229, "ENTITY"], [155, 165, "ENTITY"], [404, 416, "ENTITY"], [114, 124, "GENE_OR_GENE_PRODUCT"], [229, 240, "PROTEIN"], [359, 365, "PROTEIN"], [81, 105, "ENTITY"], [114, 124, "GGP"], [348, 356, "GGP"], [401, 416, "DISEASE"], [359, 365, "ENTITY"], [0, 4, "PROTEIN"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "SGs are induced by protein kinase R (PKR)-mediated phosphorylation of eIF2\u03b1 upon viral dsRNA recognition [ 57 ] . Promoting G3BP aggregation via the eIF4A inhibitor Zotatafin [ 58,59 ] or reducing SG disassembly by Silmitasertib inhibition of CK2 [ 60 ] warrant investigation for treatment of SARS-CoV-2 . The mTOR inhibitor rapamycin disrupts the binding of LARP1 to mTORC1 [ 61 ] and has been shown to reduce MERS infection by \u223c60 % in vitro [ 62 ] , another drug that could be tested for repurposing .", "labels": [[51, 67, "ENTITY"], [19, 36, "GENE_OR_GENE_PRODUCT"], [325, 335, "ENTITY"], [254, 262, "ENTITY"], [70, 76, "PROTEIN"], [293, 306, "ENTITY"], [293, 325, "GGP"], [114, 124, "PROTEIN"], [155, 165, "SIMPLE_CHEMICAL"], [70, 76, "ENTITY"], [19, 36, "PROTEIN"], [145, 155, "CHEBI"], [145, 165, "PROTEIN"], [229, 240, "ENTITY"], [280, 293, "CHEMICAL"], [359, 365, "PROTEIN"], [359, 368, "GENE_OR_GENE_PRODUCT"], [0, 4, "ENTITY"], [200, 215, "CHEMICAL"], [401, 416, "DISEASE"], [335, 348, "ENTITY"], [114, 124, "ENTITY"], [306, 315, "ENTITY"], [395, 401, "ENTITY"], [81, 93, "TAXON"], [124, 129, "ENTITY"], [200, 215, "ORGANISM"], [19, 36, "ENTITY"], [293, 306, "GENE_OR_GENE_PRODUCT"], [348, 356, "GENE_OR_GENE_PRODUCT"], [0, 4, "GO"], [262, 280, "ENTITY"], [8, 16, "ENTITY"], [359, 365, "ENTITY"], [229, 243, "GENE_OR_GENE_PRODUCT"], [348, 356, "PROTEIN"], [0, 4, "GENE_OR_GENE_PRODUCT"], [145, 155, "ENTITY"], [416, 433, "ENTITY"], [188, 200, "ENTITY"], [348, 356, "ENTITY"], [19, 27, "CHEBI"], [477, 487, "ENTITY"], [155, 165, "CHEMICAL"], [280, 293, "ENTITY"], [280, 293, "SIMPLE_CHEMICAL"], [70, 76, "GENE_OR_GENE_PRODUCT"], [200, 229, "ENTITY"], [155, 165, "ENTITY"], [404, 416, "ENTITY"], [114, 124, "GENE_OR_GENE_PRODUCT"], [229, 240, "PROTEIN"], [81, 105, "ENTITY"], [114, 124, "GGP"], [348, 356, "GGP"], [0, 4, "PROTEIN"]]}
{"text": "SGs are induced by protein kinase R (PKR)-mediated phosphorylation of eIF2\u03b1 upon viral dsRNA recognition [ 57 ] . Promoting G3BP aggregation via the eIF4A inhibitor Zotatafin [ 58,59 ] or reducing SG disassembly by Silmitasertib inhibition of CK2 [ 60 ] warrant investigation for treatment of SARS-CoV-2 . The mTOR inhibitor rapamycin disrupts the binding of LARP1 to mTORC1 [ 61 ] and has been shown to reduce MERS infection by \u223c60 % in vitro [ 62 ] , another drug that could be tested for repurposing .", "labels": [[51, 67, "ENTITY"], [19, 36, "GENE_OR_GENE_PRODUCT"], [325, 335, "ENTITY"], [254, 262, "ENTITY"], [70, 76, "PROTEIN"], [293, 306, "ENTITY"], [293, 325, "GGP"], [114, 124, "PROTEIN"], [155, 165, "SIMPLE_CHEMICAL"], [70, 76, "ENTITY"], [19, 36, "PROTEIN"], [145, 155, "CHEBI"], [145, 165, "PROTEIN"], [229, 240, "ENTITY"], [280, 293, "CHEMICAL"], [0, 4, "ENTITY"], [200, 215, "CHEMICAL"], [401, 416, "DISEASE"], [335, 348, "ENTITY"], [114, 124, "ENTITY"], [306, 315, "ENTITY"], [395, 401, "ENTITY"], [81, 93, "TAXON"], [124, 129, "ENTITY"], [200, 215, "ORGANISM"], [19, 36, "ENTITY"], [293, 306, "GENE_OR_GENE_PRODUCT"], [348, 356, "GENE_OR_GENE_PRODUCT"], [0, 4, "GO"], [262, 280, "ENTITY"], [8, 16, "ENTITY"], [229, 243, "GENE_OR_GENE_PRODUCT"], [348, 356, "PROTEIN"], [0, 4, "GENE_OR_GENE_PRODUCT"], [145, 155, "ENTITY"], [416, 433, "ENTITY"], [188, 200, "ENTITY"], [348, 356, "ENTITY"], [19, 27, "CHEBI"], [477, 487, "ENTITY"], [155, 165, "CHEMICAL"], [280, 293, "ENTITY"], [280, 293, "SIMPLE_CHEMICAL"], [359, 368, "GENE_OR_GENE_PRODUCT"], [70, 76, "GENE_OR_GENE_PRODUCT"], [200, 229, "ENTITY"], [155, 165, "ENTITY"], [404, 416, "ENTITY"], [114, 124, "GENE_OR_GENE_PRODUCT"], [229, 240, "PROTEIN"], [359, 365, "PROTEIN"], [81, 105, "ENTITY"], [114, 124, "GGP"], [348, 356, "GGP"], [359, 365, "ENTITY"], [0, 4, "PROTEIN"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Different directly acting antiviral drugs are approved against other viruses , by the Food and Drugs Administration ( FDA ) , such as Sofosbuvir , Ribavirin against RdRp of Hepatitis C Virus ( HCV ) .", "labels": [[165, 185, "ENTITY"], [185, 191, "ORGANISM"], [134, 147, "SIMPLE_CHEMICAL"], [165, 185, "DISEASE"], [69, 77, "ENTITY"], [165, 185, "GGP"], [185, 191, "TAXON"], [69, 77, "TAXON"], [134, 147, "CHEBI"], [165, 185, "ORGANISM"], [134, 147, "ENTITY"], [134, 147, "CHEMICAL"], [185, 191, "ENTITY"], [26, 42, "ENTITY"]]}
{"text": "Notably , steroids have been experimentally used widely in the treatment of SARS and are still preferred by some Chinese physicians in the treatment of COVID-19 . It is said to be capable of stopping the cytokine storm and preventing lung fibrosis .", "labels": [[223, 239, "ENTITY"], [223, 234, "ORGAN"], [234, 239, "DISEASE"], [113, 121, "ENTITY"], [204, 213, "ENTITY"]]}
{"text": "Notably , steroids have been experimentally used widely in the treatment of SARS and are still preferred by some Chinese physicians in the treatment of COVID-19 . It is said to be capable of stopping the cytokine storm and preventing lung fibrosis .", "labels": [[223, 239, "ENTITY"], [223, 234, "ORGAN"], [234, 239, "DISEASE"], [113, 121, "ENTITY"], [204, 213, "ENTITY"]]}
{"text": "Therapeutic options include steroids , intravenous immunoglobulin , selective cytokine blockade ( eg , anakinra or tocilizumab ) and JAK inhibition .", "labels": [[68, 78, "PROTEIN"], [28, 37, "ENTITY"], [28, 37, "CHEMICAL"], [39, 51, "ENTITY"], [68, 78, "ENTITY"], [39, 51, "PROTEIN"], [98, 103, "CHEMICAL"], [28, 37, "CHEBI"], [12, 20, "ENTITY"], [0, 12, "ENTITY"], [78, 87, "ENTITY"], [98, 103, "SIMPLE_CHEMICAL"], [39, 51, "ORGANISM_SUBSTANCE"], [133, 137, "ENTITY"], [28, 37, "SIMPLE_CHEMICAL"], [98, 103, "ENTITY"]]}
{"text": "This antibiotic , currently used in the treatment of Gram-positive bacterial infection , especially in Staphylococcal infections , has already showed efficacy against various viruses such as Ebola , influenza virus , flavivirus , hepatitis C virus , HIV virus and on coronavirus such as MERS-CoV and SARS-CoV [ 8,9 ] .", "labels": [[260, 267, "ORGANISM"], [217, 242, "ENTITY"], [191, 209, "ENTITY"], [287, 300, "GGP"], [100, 118, "DISEASE"], [183, 191, "GGP"], [217, 242, "GGP"], [188, 217, "DISEASE"], [100, 118, "ENTITY"], [183, 191, "PROTEIN"], [53, 77, "ENTITY"], [217, 242, "ORGANISM"], [209, 217, "TAXON"], [260, 267, "TAXON"], [53, 77, "DISEASE"], [199, 209, "TAXON"], [5, 16, "ENTITY"], [260, 267, "ENTITY"], [209, 217, "TAXON"], [217, 230, "DISEASE"], [209, 217, "ORGANISM"], [209, 217, "ENTITY"], [143, 150, "ENTITY"], [287, 300, "ENTITY"], [209, 217, "ENTITY"], [287, 300, "ORGANISM"], [5, 16, "CHEBI"], [183, 191, "ENTITY"]]}
{"text": "This antibiotic , currently used in the treatment of Gram-positive bacterial infection , especially in Staphylococcal infections , has already showed efficacy against various viruses such as Ebola , influenza virus , flavivirus , hepatitis C virus , HIV virus and on coronavirus such as MERS-CoV and SARS-CoV [ 8,9 ] .", "labels": [[260, 267, "ORGANISM"], [217, 242, "ENTITY"], [209, 217, "TAXON"], [100, 118, "DISEASE"], [209, 217, "TAXON"], [191, 209, "ENTITY"], [209, 217, "ORGANISM"], [287, 300, "GGP"], [183, 191, "GGP"], [209, 217, "ENTITY"], [209, 217, "ENTITY"], [217, 242, "GGP"], [183, 191, "PROTEIN"], [53, 77, "ENTITY"], [217, 242, "ORGANISM"], [188, 217, "DISEASE"], [260, 267, "TAXON"], [53, 77, "DISEASE"], [199, 209, "TAXON"], [5, 16, "ENTITY"], [100, 118, "ENTITY"], [260, 267, "ENTITY"], [217, 230, "DISEASE"], [143, 150, "ENTITY"], [287, 300, "ENTITY"], [287, 300, "ORGANISM"], [5, 16, "CHEBI"], [183, 191, "ENTITY"]]}
{"text": "This antibiotic , currently used in the treatment of Gram-positive bacterial infection , especially in Staphylococcal infections , has already showed efficacy against various viruses such as Ebola , influenza virus , flavivirus , hepatitis C virus , HIV virus and on coronavirus such as MERS-CoV and SARS-CoV [ 8,9 ] .", "labels": [[260, 267, "ORGANISM"], [217, 242, "ENTITY"], [100, 118, "DISEASE"], [188, 217, "DISEASE"], [287, 300, "GGP"], [183, 191, "GGP"], [191, 209, "ENTITY"], [217, 242, "GGP"], [183, 191, "PROTEIN"], [53, 77, "ENTITY"], [217, 242, "ORGANISM"], [209, 217, "TAXON"], [260, 267, "TAXON"], [53, 77, "DISEASE"], [5, 16, "ENTITY"], [100, 118, "ENTITY"], [260, 267, "ENTITY"], [209, 217, "TAXON"], [217, 230, "DISEASE"], [209, 217, "ORGANISM"], [209, 217, "ENTITY"], [143, 150, "ENTITY"], [287, 300, "ENTITY"], [199, 209, "TAXON"], [209, 217, "ENTITY"], [287, 300, "ORGANISM"], [5, 16, "CHEBI"], [183, 191, "ENTITY"]]}
{"text": "This antibiotic , currently used in the treatment of Gram-positive bacterial infection , especially in Staphylococcal infections , has already showed efficacy against various viruses such as Ebola , influenza virus , flavivirus , hepatitis C virus , HIV virus and on coronavirus such as MERS-CoV and SARS-CoV [ 8,9 ] .", "labels": [[260, 267, "ORGANISM"], [100, 118, "DISEASE"], [191, 209, "ENTITY"], [287, 300, "GGP"], [183, 191, "GGP"], [188, 217, "DISEASE"], [183, 191, "PROTEIN"], [53, 77, "ENTITY"], [260, 267, "TAXON"], [53, 77, "DISEASE"], [199, 209, "TAXON"], [5, 16, "ENTITY"], [100, 118, "ENTITY"], [217, 242, "ENTITY"], [260, 267, "ENTITY"], [217, 242, "ORGANISM"], [209, 217, "ENTITY"], [209, 217, "TAXON"], [143, 150, "ENTITY"], [287, 300, "ENTITY"], [217, 230, "DISEASE"], [209, 217, "ENTITY"], [217, 242, "GGP"], [209, 217, "ORGANISM"], [209, 217, "TAXON"], [287, 300, "ORGANISM"], [5, 16, "CHEBI"], [183, 191, "ENTITY"]]}
{"text": "This antibiotic , currently used in the treatment of Gram-positive bacterial infection , especially in Staphylococcal infections , has already showed efficacy against various viruses such as Ebola , influenza virus , flavivirus , hepatitis C virus , HIV virus and on coronavirus such as MERS-CoV and SARS-CoV [ 8,9 ] .", "labels": [[260, 267, "ORGANISM"], [217, 242, "ENTITY"], [100, 118, "DISEASE"], [209, 217, "TAXON"], [191, 209, "ENTITY"], [287, 300, "GGP"], [183, 191, "GGP"], [209, 217, "TAXON"], [217, 242, "GGP"], [188, 217, "DISEASE"], [183, 191, "PROTEIN"], [53, 77, "ENTITY"], [217, 242, "ORGANISM"], [209, 217, "ENTITY"], [209, 217, "ORGANISM"], [260, 267, "TAXON"], [53, 77, "DISEASE"], [199, 209, "TAXON"], [5, 16, "ENTITY"], [100, 118, "ENTITY"], [260, 267, "ENTITY"], [217, 230, "DISEASE"], [143, 150, "ENTITY"], [209, 217, "ENTITY"], [287, 300, "ENTITY"], [287, 300, "ORGANISM"], [5, 16, "CHEBI"], [183, 191, "ENTITY"]]}
{"text": "This antibiotic , currently used in the treatment of Gram-positive bacterial infection , especially in Staphylococcal infections , has already showed efficacy against various viruses such as Ebola , influenza virus , flavivirus , hepatitis C virus , HIV virus and on coronavirus such as MERS-CoV and SARS-CoV [ 8,9 ] .", "labels": [[260, 267, "ORGANISM"], [217, 242, "ENTITY"], [100, 118, "DISEASE"], [191, 209, "ENTITY"], [209, 217, "ORGANISM"], [287, 300, "GGP"], [183, 191, "GGP"], [209, 217, "TAXON"], [217, 242, "GGP"], [188, 217, "DISEASE"], [209, 217, "TAXON"], [183, 191, "PROTEIN"], [53, 77, "ENTITY"], [209, 217, "ENTITY"], [217, 242, "ORGANISM"], [260, 267, "TAXON"], [53, 77, "DISEASE"], [199, 209, "TAXON"], [209, 217, "ENTITY"], [5, 16, "ENTITY"], [100, 118, "ENTITY"], [260, 267, "ENTITY"], [217, 230, "DISEASE"], [143, 150, "ENTITY"], [287, 300, "ENTITY"], [287, 300, "ORGANISM"], [5, 16, "CHEBI"], [183, 191, "ENTITY"]]}
{"text": "This antibiotic , currently used in the treatment of Gram-positive bacterial infection , especially in Staphylococcal infections , has already showed efficacy against various viruses such as Ebola , influenza virus , flavivirus , hepatitis C virus , HIV virus and on coronavirus such as MERS-CoV and SARS-CoV [ 8,9 ] .", "labels": [[260, 267, "ORGANISM"], [217, 242, "ENTITY"], [100, 118, "DISEASE"], [191, 209, "ENTITY"], [287, 300, "GGP"], [183, 191, "GGP"], [209, 217, "TAXON"], [209, 217, "ENTITY"], [209, 217, "ENTITY"], [217, 242, "GGP"], [188, 217, "DISEASE"], [183, 191, "PROTEIN"], [53, 77, "ENTITY"], [217, 242, "ORGANISM"], [260, 267, "TAXON"], [53, 77, "DISEASE"], [199, 209, "TAXON"], [5, 16, "ENTITY"], [100, 118, "ENTITY"], [209, 217, "ORGANISM"], [209, 217, "TAXON"], [260, 267, "ENTITY"], [217, 230, "DISEASE"], [143, 150, "ENTITY"], [287, 300, "ENTITY"], [287, 300, "ORGANISM"], [5, 16, "CHEBI"], [183, 191, "ENTITY"]]}
{"text": "This antibiotic , currently used in the treatment of Gram-positive bacterial infection , especially in Staphylococcal infections , has already showed efficacy against various viruses such as Ebola , influenza virus , flavivirus , hepatitis C virus , HIV virus and on coronavirus such as MERS-CoV and SARS-CoV [ 8,9 ] .", "labels": [[260, 267, "ORGANISM"], [209, 217, "ENTITY"], [217, 242, "ENTITY"], [100, 118, "DISEASE"], [191, 209, "ENTITY"], [287, 300, "GGP"], [183, 191, "GGP"], [209, 217, "ORGANISM"], [217, 242, "GGP"], [188, 217, "DISEASE"], [183, 191, "PROTEIN"], [53, 77, "ENTITY"], [217, 242, "ORGANISM"], [260, 267, "TAXON"], [53, 77, "DISEASE"], [199, 209, "TAXON"], [209, 217, "TAXON"], [5, 16, "ENTITY"], [100, 118, "ENTITY"], [260, 267, "ENTITY"], [217, 230, "DISEASE"], [143, 150, "ENTITY"], [209, 217, "ENTITY"], [287, 300, "ENTITY"], [287, 300, "ORGANISM"], [209, 217, "TAXON"], [5, 16, "CHEBI"], [183, 191, "ENTITY"]]}
{"text": "According to Zhou and colleagues , in coronaviruses , teicoplanin acts on the early step of the viral life cycle by inhibiting the low pH cleavage of the viral spike protein by cathepsin L in the late endosomes thereby preventing the release of genomic viral RNA and the continuation of virus replication cycle .", "labels": [[150, 166, "ENTITY"], [92, 107, "ENTITY"], [13, 18, "ENTITY"], [160, 166, "CHEBI"], [174, 187, "GENE_OR_GENE_PRODUCT"], [22, 33, "ENTITY"], [242, 259, "ENTITY"], [192, 201, "CELLULAR_COMPONENT"], [174, 187, "ENTITY"], [174, 187, "GGP"], [174, 187, "PROTEIN"], [150, 166, "PROTEIN"], [192, 201, "GO"], [135, 138, "ENTITY"], [131, 135, "ENTITY"], [242, 259, "SO"], [284, 305, "ENTITY"], [242, 259, "RNA"], [192, 201, "ENTITY"]]}
{"text": "As we have previously demonstrated that several glycopeptide antibiotics , including teicoplanin and dalbavancin , exhibited specific inhibitory effects on cathepsin L , we therefore hypothesized that teicoplanin and its homologs could also inhibit the entry of 2019-nCoV.", "labels": [[153, 166, "PROTEIN"], [48, 73, "CHEBI"], [125, 134, "ENTITY"], [153, 166, "GENE_OR_GENE_PRODUCT"], [153, 166, "GGP"], [48, 73, "ENTITY"], [153, 166, "ENTITY"], [48, 61, "SIMPLE_CHEMICAL"]]}
{"text": "Here , we identified that teicoplanin acted specifically as a 2019-nCoV entry inhibitor in a dose-dependent manner ( Figure 2B ) .", "labels": [[115, 124, "ENTITY"]]}
{"text": "Teicoplanin , a glycopeptide antibiotic routinely used to treat bacterial infection was found to be active in vitro against SARS-CoV , has joined the list of molecules that could be used as herapeutic arsenal against COVID-19 [ 7 ]", "labels": [[64, 74, "ENTITY"], [64, 74, "DISEASE"], [0, 12, "SIMPLE_CHEMICAL"], [0, 12, "CHEMICAL"], [16, 29, "ENTITY"], [0, 12, "ENTITY"], [209, 226, "GENE_OR_GENE_PRODUCT"], [0, 12, "CHEBI"], [16, 29, "CHEBI"]]}
{"text": "Teicoplanin , a glycopeptide antibiotic routinely used to treat bacterial infection was found to be active in vitro against SARS-CoV , has joined the list of molecules that could be used as herapeutic arsenal against COVID-19 [ 7 ]", "labels": [[209, 226, "GENE_OR_GENE_PRODUCT"], [0, 12, "SIMPLE_CHEMICAL"], [0, 12, "CHEMICAL"], [64, 74, "ENTITY"], [16, 29, "ENTITY"], [0, 12, "ENTITY"], [64, 74, "DISEASE"], [0, 12, "CHEBI"], [16, 29, "CHEBI"]]}
{"text": "According to Zhou and colleagues , in coronaviruses , teicoplanin acts on the early step of the viral life cycle by inhibiting the low pH cleavage of the viral spike protein by cathepsin L in the late endosomes thereby preventing the release of genomic viral RNA and the continuation of virus replication cycle .", "labels": [[150, 166, "ENTITY"], [13, 18, "ENTITY"], [160, 166, "CHEBI"], [174, 187, "GENE_OR_GENE_PRODUCT"], [22, 33, "ENTITY"], [242, 259, "ENTITY"], [192, 201, "CELLULAR_COMPONENT"], [174, 187, "ENTITY"], [174, 187, "GGP"], [174, 187, "PROTEIN"], [150, 166, "PROTEIN"], [192, 201, "GO"], [135, 138, "ENTITY"], [131, 135, "ENTITY"], [242, 259, "SO"], [284, 305, "ENTITY"], [92, 107, "ENTITY"], [242, 259, "RNA"], [192, 201, "ENTITY"]]}
{"text": "Here , we identified that teicoplanin acted specifically as a 2019-nCoV entry inhibitor in a dose-dependent manner ( Figure 2B ) .", "labels": [[115, 124, "ENTITY"]]}
{"text": "The data showed that teicoplanin also effectively repressed virus entrance into HEK293 T cells ( Figure . 3A ) , and Huh7 cells ( Figure 3B ) .", "labels": [[66, 75, "ENTITY"], [89, 97, "ENTITY"], [113, 122, "GGP"], [21, 33, "CHEMICAL"], [113, 122, "CELL"], [113, 122, "CELL_LINE"], [60, 66, "TAXON"], [80, 89, "CELL_LINE"], [21, 33, "SIMPLE_CHEMICAL"], [4, 9, "ENTITY"], [21, 33, "ENTITY"], [80, 89, "CELL"], [21, 33, "CHEBI"], [80, 89, "ENTITY"], [50, 60, "ENTITY"], [113, 122, "ENTITY"]]}
{"text": "As we have previously demonstrated that several glycopeptide antibiotics , including teicoplanin and dalbavancin , exhibited specific inhibitory effects on cathepsin L , we therefore hypothesized that teicoplanin and its homologs could also inhibit the entry of 2019-nCoV.", "labels": [[153, 166, "PROTEIN"], [48, 73, "CHEBI"], [125, 134, "ENTITY"], [153, 166, "GENE_OR_GENE_PRODUCT"], [153, 166, "GGP"], [48, 73, "ENTITY"], [153, 166, "ENTITY"], [48, 61, "SIMPLE_CHEMICAL"]]}
{"text": "Losartan , telmisartan , olmesartan ( and additional AT1R antagonists ) are widely applied in the clinic since the 1990s for control of hypertension and kidney disorders , and are known as safe drugs that are rarely implicated in adverse drugs events ( Deppe , B\u00f6ger , Weiss , & Benndorf , 2010 ; McIntyre , Caffe , Michalak , & Reid , 1997 ) .", "labels": [[244, 253, "ENTITY"], [149, 160, "ENTITY"], [149, 160, "DISEASE"], [297, 308, "DISEASE"], [42, 53, "GENE_OR_GENE_PRODUCT"], [0, 9, "CHEMICAL"], [216, 244, "ENTITY"], [0, 9, "ENTITY"], [269, 279, "ENTITY"], [261, 267, "ENTITY"], [253, 259, "ENTITY"], [297, 308, "ENTITY"], [0, 9, "SIMPLE_CHEMICAL"], [189, 194, "ENTITY"], [42, 58, "ENTITY"], [279, 295, "ENTITY"]]}
{"text": "Losartan , telmisartan , olmesartan ( and additional AT1R antagonists ) are widely applied in the clinic since the 1990s for control of hypertension and kidney disorders , and are known as safe drugs that are rarely implicated in adverse drugs events ( Deppe , B\u00f6ger , Weiss , & Benndorf , 2010 ; McIntyre , Caffe , Michalak , & Reid , 1997 ) .", "labels": [[244, 253, "ENTITY"], [149, 160, "ENTITY"], [149, 160, "DISEASE"], [297, 308, "DISEASE"], [42, 53, "GENE_OR_GENE_PRODUCT"], [0, 9, "CHEMICAL"], [216, 244, "ENTITY"], [0, 9, "ENTITY"], [269, 279, "ENTITY"], [261, 267, "ENTITY"], [253, 259, "ENTITY"], [297, 308, "ENTITY"], [0, 9, "SIMPLE_CHEMICAL"], [189, 194, "ENTITY"], [42, 58, "ENTITY"], [279, 295, "ENTITY"]]}
{"text": "In the third case report , Chen et al. reported a 45-year-old woman with COVID-19 and stated that after treatment with Thalidomide ( 100 mg orally once a day ) and Methylprednisolone ( 40 mg intravenously bid for 3 days then reduced to once a day for 5 days ) the overall patient status was improved , oxygen index was increased , symptoms of nausea and vomiting were alleviated , and cytokine levels were decreased ( 9 ) .", "labels": [[291, 302, "SIMPLE_CHEMICAL"], [264, 280, "ENTITY"], [209, 215, "ENTITY"], [343, 354, "DISEASE"], [247, 253, "ENTITY"], [354, 368, "ENTITY"], [191, 205, "ENTITY"], [309, 319, "ENTITY"], [291, 309, "ENTITY"], [331, 343, "ENTITY"], [137, 140, "ENTITY"], [319, 331, "ENTITY"], [291, 302, "CHEMICAL"], [331, 343, "DISEASE"], [394, 406, "ENTITY"], [368, 385, "PROTEIN"], [343, 354, "ENTITY"], [7, 25, "ENTITY"], [137, 140, "ENTITY"], [291, 302, "CHEBI"], [368, 385, "ENTITY"], [147, 154, "ENTITY"]]}
{"text": "In the third case report , Chen et al. reported a 45-year-old woman with COVID-19 and stated that after treatment with Thalidomide ( 100 mg orally once a day ) and Methylprednisolone ( 40 mg intravenously bid for 3 days then reduced to once a day for 5 days ) the overall patient status was improved , oxygen index was increased , symptoms of nausea and vomiting were alleviated , and cytokine levels were decreased ( 9 ) .", "labels": [[291, 302, "SIMPLE_CHEMICAL"], [264, 280, "ENTITY"], [209, 215, "ENTITY"], [343, 354, "ENTITY"], [247, 253, "ENTITY"], [354, 368, "ENTITY"], [191, 205, "ENTITY"], [309, 319, "ENTITY"], [291, 309, "ENTITY"], [331, 343, "ENTITY"], [137, 140, "ENTITY"], [319, 331, "ENTITY"], [343, 354, "DISEASE"], [291, 302, "CHEMICAL"], [331, 343, "DISEASE"], [394, 406, "ENTITY"], [368, 385, "PROTEIN"], [7, 25, "ENTITY"], [137, 140, "ENTITY"], [291, 302, "CHEBI"], [368, 385, "ENTITY"], [147, 154, "ENTITY"]]}
{"text": "In the third case report , Chen et al. reported a 45-year-old woman with COVID-19 and stated that after treatment with Thalidomide ( 100 mg orally once a day ) and Methylprednisolone ( 40 mg intravenously bid for 3 days then reduced to once a day for 5 days ) the overall patient status was improved , oxygen index was increased , symptoms of nausea and vomiting were alleviated , and cytokine levels were decreased ( 9 ) .", "labels": [[291, 302, "SIMPLE_CHEMICAL"], [354, 368, "ENTITY"], [264, 280, "ENTITY"], [209, 215, "ENTITY"], [343, 354, "DISEASE"], [247, 253, "ENTITY"], [191, 205, "ENTITY"], [309, 319, "ENTITY"], [291, 309, "ENTITY"], [331, 343, "ENTITY"], [137, 140, "ENTITY"], [319, 331, "ENTITY"], [291, 302, "CHEMICAL"], [331, 343, "DISEASE"], [394, 406, "ENTITY"], [368, 385, "PROTEIN"], [343, 354, "ENTITY"], [7, 25, "ENTITY"], [137, 140, "ENTITY"], [291, 302, "CHEBI"], [368, 385, "ENTITY"], [147, 154, "ENTITY"]]}
{"text": "In the third case report , Chen et al. reported a 45-year-old woman with COVID-19 and stated that after treatment with Thalidomide ( 100 mg orally once a day ) and Methylprednisolone ( 40 mg intravenously bid for 3 days then reduced to once a day for 5 days ) the overall patient status was improved , oxygen index was increased , symptoms of nausea and vomiting were alleviated , and cytokine levels were decreased ( 9 ) .", "labels": [[291, 302, "SIMPLE_CHEMICAL"], [264, 280, "ENTITY"], [209, 215, "ENTITY"], [343, 354, "DISEASE"], [247, 253, "ENTITY"], [354, 368, "ENTITY"], [191, 205, "ENTITY"], [309, 319, "ENTITY"], [291, 309, "ENTITY"], [331, 343, "ENTITY"], [137, 140, "ENTITY"], [319, 331, "ENTITY"], [291, 302, "CHEMICAL"], [331, 343, "DISEASE"], [394, 406, "ENTITY"], [368, 385, "PROTEIN"], [343, 354, "ENTITY"], [7, 25, "ENTITY"], [137, 140, "ENTITY"], [291, 302, "CHEBI"], [368, 385, "ENTITY"], [147, 154, "ENTITY"]]}
{"text": "It was previously shown that thalidomide enhances TCR-mediated T cells activation by by-passing T cell need for co-stimulation by accessory molecules , such as the B7 protein together with the CD28 protein , and therefore can overcome T cell deficiency 25 .", "labels": [[226, 237, "CL"], [226, 237, "CELL"], [63, 70, "CELL"], [63, 71, "CL"], [140, 150, "CHEBI"], [63, 70, "CELL_TYPE"], [50, 71, "CELL_TYPE"], [112, 127, "ENTITY"], [130, 150, "ENTITY"], [29, 41, "ENTITY"], [193, 198, "PROTEIN"], [71, 82, "ENTITY"], [193, 198, "ENTITY"], [164, 167, "PROTEIN"], [29, 41, "CHEMICAL"], [130, 150, "PROTEIN"], [63, 71, "CELL"], [50, 71, "ENTITY"], [85, 103, "ENTITY"], [29, 41, "SIMPLE_CHEMICAL"], [63, 70, "CL"], [164, 167, "ENTITY"], [29, 41, "CHEBI"], [226, 242, "ENTITY"]]}
{"text": "Finally , it was also reported that thalidomide prevents NF-kB from binding to the promoters of its target genes , including TNF-alpha and IFN-Gamma thereby reducing excessive inflammatory response 27,28 .", "labels": [[115, 125, "PROTEIN"], [166, 198, "PROTEIN"], [157, 166, "ENTITY"], [100, 107, "DNA"], [115, 125, "GGP"], [115, 125, "CHEMICAL"], [166, 198, "ENTITY"], [115, 125, "GENE_OR_GENE_PRODUCT"], [115, 125, "ENTITY"]]}
{"text": "Finally , it was also reported that thalidomide prevents NF-kB from binding to the promoters of its target genes , including TNF-alpha and IFN-Gamma thereby reducing excessive inflammatory response 27,28 .", "labels": [[166, 198, "PROTEIN"], [115, 125, "GGP"], [100, 107, "DNA"], [166, 198, "ENTITY"], [115, 125, "GENE_OR_GENE_PRODUCT"], [115, 125, "CHEMICAL"], [157, 166, "ENTITY"], [115, 125, "ENTITY"], [115, 125, "PROTEIN"]]}
{"text": "Moreover , E protein also suppresses ER stress induced by RSV and drugs ( thapsigargin and tunicamycin ; DeDiego et al.,2011 ) .", "labels": [[37, 40, "ENTITY"]]}
{"text": "Additional medications , including thiazolidinediones or ibuprofen , may also increase ACE2 levels , though data on this are sparse [ 21 ] .", "labels": [[11, 23, "ENTITY"], [78, 87, "ENTITY"], [87, 92, "ENTITY"], [78, 87, "GGP"], [78, 87, "GENE_OR_GENE_PRODUCT"], [78, 87, "PROTEIN"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [706, 717, "ENTITY"], [480, 493, "CHEMICAL"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [480, 493, "SIMPLE_CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [480, 493, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "Known blockers of integrin binding include the antibody natalizumab ( a \u03b14\u03b21/\u03b27 integrin antagonist ) for the treatment of multiple sclerosis/Crohn 's disease , the small molecule tirofiban ( an \u03b1IIb\u03b23 inhibitor ) for the treatment of acute coronary syndrome , as well as inhibitors of \u03b1V RGD-binding integrin ( Hatley et al. , 2018 ) .", "labels": [[47, 56, "GO"], [272, 301, "ENTITY"], [272, 301, "PROTEIN"], [190, 195, "SIMPLE_CHEMICAL"], [18, 27, "ENTITY"], [190, 202, "ENTITY"], [120, 151, "ENTITY"], [18, 27, "PROTEIN"], [264, 272, "CHEBI"], [171, 180, "CHEMICAL"], [102, 110, "ENTITY"], [18, 27, "GO"], [72, 89, "GENE_OR_GENE_PRODUCT"], [47, 68, "ENTITY"], [195, 202, "CHEBI"], [161, 180, "PROTEIN"], [171, 180, "SIMPLE_CHEMICAL"], [72, 89, "ENTITY"], [72, 89, "GGP"], [283, 301, "GENE_OR_GENE_PRODUCT"], [27, 35, "ENTITY"], [264, 272, "ENTITY"], [222, 250, "ENTITY"], [6, 15, "ENTITY"], [235, 241, "ORGAN"], [165, 171, "CHEBI"], [18, 27, "GENE_OR_GENE_PRODUCT"], [161, 180, "ENTITY"], [222, 250, "DISEASE"]]}
{"text": "Known blockers of integrin binding include the antibody natalizumab ( a \u03b14\u03b21/\u03b27 integrin antagonist ) for the treatment of multiple sclerosis/Crohn 's disease , the small molecule tirofiban ( an \u03b1IIb\u03b23 inhibitor ) for the treatment of acute coronary syndrome , as well as inhibitors of \u03b1V RGD-binding integrin ( Hatley et al. , 2018 ) .", "labels": [[47, 56, "GO"], [272, 301, "ENTITY"], [272, 301, "PROTEIN"], [190, 195, "SIMPLE_CHEMICAL"], [18, 27, "ENTITY"], [190, 202, "ENTITY"], [120, 151, "ENTITY"], [18, 27, "PROTEIN"], [264, 272, "CHEBI"], [171, 180, "CHEMICAL"], [102, 110, "ENTITY"], [18, 27, "GO"], [72, 89, "GENE_OR_GENE_PRODUCT"], [47, 68, "ENTITY"], [195, 202, "CHEBI"], [161, 180, "PROTEIN"], [171, 180, "SIMPLE_CHEMICAL"], [72, 89, "ENTITY"], [72, 89, "GGP"], [283, 301, "GENE_OR_GENE_PRODUCT"], [27, 35, "ENTITY"], [264, 272, "ENTITY"], [222, 250, "ENTITY"], [6, 15, "ENTITY"], [235, 241, "ORGAN"], [165, 171, "CHEBI"], [18, 27, "GENE_OR_GENE_PRODUCT"], [161, 180, "ENTITY"], [222, 250, "DISEASE"]]}
{"text": "Tofacitinib has been shown to inhibit interferon\u03b1 production in vitro . Suppression of interferon or other mediators ( eg , interleukin 6 ) could also promote secondary bacterial infection and further complicate the disease course .", "labels": [[30, 38, "ENTITY"], [159, 179, "DISEASE"], [159, 179, "ENTITY"], [0, 12, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [38, 61, "ENTITY"], [151, 159, "ENTITY"], [212, 224, "ENTITY"], [38, 50, "CELLULAR_COMPONENT"], [159, 169, "TAXON"], [0, 12, "ENTITY"], [61, 70, "ENTITY"]]}
{"text": "As shown in Fig. 5b , toremifene potentially affects several key host proteins associated with HCoV , such as RPL19 , HNRNPA1 , NPM1 , EIF3I , EIF3F , and EIF3E40,41", "labels": [[149, 155, "PROTEIN"], [135, 143, "ENTITY"], [135, 143, "GGP"], [118, 128, "PROTEIN"], [12, 20, "CANCER"], [128, 135, "PROTEIN"], [65, 70, "ENTITY"], [17, 20, "ENTITY"], [128, 135, "GGP"], [135, 143, "GENE_OR_GENE_PRODUCT"], [118, 128, "GENE_OR_GENE_PRODUCT"], [128, 135, "ENTITY"], [118, 128, "ENTITY"], [135, 143, "PROTEIN"], [118, 128, "GGP"], [128, 135, "GENE_OR_GENE_PRODUCT"], [149, 155, "ENTITY"]]}
{"text": "As shown in Fig. 5b , toremifene potentially affects several key host proteins associated with HCoV , such as RPL19 , HNRNPA1 , NPM1 , EIF3I , EIF3F , and EIF3E40,41", "labels": [[149, 155, "PROTEIN"], [135, 143, "ENTITY"], [135, 143, "GGP"], [12, 20, "CANCER"], [118, 128, "GENE_OR_GENE_PRODUCT"], [128, 135, "PROTEIN"], [118, 128, "GGP"], [65, 70, "ENTITY"], [17, 20, "ENTITY"], [128, 135, "GGP"], [135, 143, "GENE_OR_GENE_PRODUCT"], [128, 135, "ENTITY"], [135, 143, "PROTEIN"], [118, 128, "PROTEIN"], [128, 135, "GENE_OR_GENE_PRODUCT"], [149, 155, "ENTITY"], [118, 128, "ENTITY"]]}
{"text": "As shown in Fig. 5b , toremifene potentially affects several key host proteins associated with HCoV , such as RPL19 , HNRNPA1 , NPM1 , EIF3I , EIF3F , and EIF3E40,41", "labels": [[149, 155, "PROTEIN"], [135, 143, "ENTITY"], [135, 143, "GGP"], [12, 20, "CANCER"], [128, 135, "GENE_OR_GENE_PRODUCT"], [118, 128, "ENTITY"], [65, 70, "ENTITY"], [17, 20, "ENTITY"], [135, 143, "GENE_OR_GENE_PRODUCT"], [118, 128, "GENE_OR_GENE_PRODUCT"], [128, 135, "ENTITY"], [128, 135, "PROTEIN"], [135, 143, "PROTEIN"], [118, 128, "GGP"], [128, 135, "GGP"], [149, 155, "ENTITY"], [118, 128, "PROTEIN"]]}
{"text": "As shown in Fig. 5b , toremifene potentially affects several key host proteins associated with HCoV , such as RPL19 , HNRNPA1 , NPM1 , EIF3I , EIF3F , and EIF3E40,41", "labels": [[135, 143, "PROTEIN"], [149, 155, "PROTEIN"], [12, 20, "CANCER"], [118, 128, "PROTEIN"], [128, 135, "PROTEIN"], [135, 143, "GENE_OR_GENE_PRODUCT"], [65, 70, "ENTITY"], [17, 20, "ENTITY"], [128, 135, "GGP"], [118, 128, "GENE_OR_GENE_PRODUCT"], [128, 135, "ENTITY"], [118, 128, "ENTITY"], [135, 143, "ENTITY"], [118, 128, "GGP"], [128, 135, "GENE_OR_GENE_PRODUCT"], [149, 155, "ENTITY"], [135, 143, "GGP"]]}
{"text": "As shown in Fig. 5b , toremifene potentially affects several key host proteins associated with HCoV , such as RPL19 , HNRNPA1 , NPM1 , EIF3I , EIF3F , and EIF3E40,41", "labels": [[149, 155, "PROTEIN"], [135, 143, "GGP"], [12, 20, "CANCER"], [118, 128, "PROTEIN"], [135, 143, "GENE_OR_GENE_PRODUCT"], [128, 135, "PROTEIN"], [135, 143, "PROTEIN"], [65, 70, "ENTITY"], [17, 20, "ENTITY"], [135, 143, "ENTITY"], [128, 135, "GGP"], [118, 128, "GENE_OR_GENE_PRODUCT"], [128, 135, "ENTITY"], [118, 128, "ENTITY"], [118, 128, "GGP"], [128, 135, "GENE_OR_GENE_PRODUCT"], [149, 155, "ENTITY"]]}
{"text": "As shown in Fig. 5b , toremifene potentially affects several key host proteins associated with HCoV , such as RPL19 , HNRNPA1 , NPM1 , EIF3I , EIF3F , and EIF3E40,41", "labels": [[135, 143, "ENTITY"], [149, 155, "PROTEIN"], [12, 20, "CANCER"], [118, 128, "PROTEIN"], [135, 143, "GGP"], [128, 135, "PROTEIN"], [135, 143, "PROTEIN"], [65, 70, "ENTITY"], [17, 20, "ENTITY"], [128, 135, "GGP"], [118, 128, "GENE_OR_GENE_PRODUCT"], [128, 135, "ENTITY"], [118, 128, "ENTITY"], [135, 143, "GENE_OR_GENE_PRODUCT"], [118, 128, "GGP"], [128, 135, "GENE_OR_GENE_PRODUCT"], [149, 155, "ENTITY"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [65, 90, "PROTEIN"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 81, "CHEBI"], [65, 81, "CHEMICAL"], [65, 81, "SIMPLE_CHEMICAL"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [65, 90, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Total , high-density lipoprotein , and low-density lipoprotein cholesterol levels did not differ according to TnT levels , but patients with elevated TnT levels had higher triglyceride levels ( median [ IQR ] , 92.04 [ 69.91 - 159.29 ] vs 82.30 [ 59.29- 115.04]mg/dL [ to convert to millimoles per liter , multiply by 0.0259];P=.04 ) .", "labels": [[21, 33, "CHEMICAL"], [203, 209, "SIMPLE_CHEMICAL"], [185, 194, "ENTITY"], [8, 21, "PROTEIN"], [35, 63, "GGP"], [141, 150, "GENE_OR_GENE_PRODUCT"], [269, 280, "ENTITY"], [165, 172, "SIMPLE_CHEMICAL"], [165, 172, "CHEMICAL"], [165, 185, "ENTITY"], [35, 51, "PROTEIN"], [141, 150, "PROTEIN"], [165, 172, "CHEBI"], [8, 21, "CHEBI"], [203, 209, "PROTEIN"], [141, 150, "ENTITY"], [194, 201, "ENTITY"], [35, 75, "ENTITY"], [35, 63, "SIMPLE_CHEMICAL"], [0, 6, "ENTITY"], [8, 21, "ENTITY"], [110, 114, "ENTITY"], [110, 114, "ENTITY"]]}
{"text": "Moreover , E protein also suppresses ER stress induced by RSV and drugs ( thapsigargin and tunicamycin ; DeDiego et al.,2011 ) .", "labels": [[37, 40, "ENTITY"]]}
{"text": "Several potential drug candidates , including lopinavir/ritonavir ( Kaletra R ) , nucleoside analogues , neuraminidase inhibitors , remdesivir , umifenovir ( Arbidol R ) , DNA synthesis inhibitors ( such as tenofovir disoproxil and lamivudine ) , chloroquine and Chinese traditional medicines ( such as ShuFeng JieDu or Lianhua Qing- wen capsules ) , have been proposed [ 36 , 37 ] .", "labels": [[8, 18, "ENTITY"], [232, 245, "CHEMICAL"], [199, 207, "ENTITY"], [145, 158, "ENTITY"], [247, 271, "ENTITY"], [93, 119, "ENTITY"], [93, 105, "GENE_OR_GENE_PRODUCT"], [119, 132, "ENTITY"], [232, 245, "SIMPLE_CHEMICAL"], [158, 166, "SO"], [283, 303, "PROTEIN"], [217, 232, "SIMPLE_CHEMICAL"], [232, 245, "ENTITY"], [217, 232, "CHEMICAL"], [217, 232, "ENTITY"], [176, 186, "CHEBI"], [197, 217, "ENTITY"], [66, 76, "SIMPLE_CHEMICAL"], [283, 295, "CHEMICAL"], [66, 76, "ENTITY"], [303, 328, "ENTITY"], [176, 186, "ENTITY"], [158, 176, "ENTITY"], [93, 119, "CHEBI"], [197, 217, "CHEMICAL"], [158, 166, "CELLULAR_COMPONENT"], [232, 245, "CHEBI"], [283, 295, "TAXON"], [18, 34, "ENTITY"], [132, 145, "ENTITY"], [283, 303, "ORGANISM"], [197, 217, "SIMPLE_CHEMICAL"], [145, 158, "CHEMICAL"], [283, 295, "ENTITY"], [78, 93, "ENTITY"], [18, 23, "CHEBI"], [66, 76, "CHEMICAL"]]}
{"text": "Arbidol is an antiviral that can be used to treat influenza virus . A study has revealed that arbidol can effectively inhibit SARS-CoV-2 infection at a concentration of 10 - 30 \u03bcM in vitro ( 9 ) .", "labels": [[189, 208, "ENTITY"], [144, 156, "ENTITY"], [214, 225, "ENTITY"], [0, 8, "ENTITY"], [189, 208, "DISEASE"], [96, 102, "TAXON"], [-1, 14, "ENTITY"], [0, 8, "CHEMICAL"], [189, 194, "SIMPLE_CHEMICAL"]]}
{"text": "It appears that Arbidol treatment could improve the discharging rate and decrease the mortality rate ( Table 5).The efficiency of antifungal agent and corticosteroids were also analyzed in Supplementary Table 1 and Table 2 . Antifungal agent did not show influence on the outcome of COVID-19 patients . And use of corticosteroids were associated with a higher risk of death .", "labels": [[16, 24, "CHEMICAL"], [203, 229, "CELL"], [239, 260, "ENTITY"], [349, 367, "ENTITY"], [203, 229, "ENTITY"], [-1, 20, "ENTITY"], [159, 175, "CHEMICAL"], [-1, 11, "ENTITY"], [118, 129, "ENTITY"], [73, 82, "ENTITY"], [159, 175, "CHEBI"], [159, 175, "SIMPLE_CHEMICAL"], [306, 317, "ENTITY"], [159, 175, "CHEBI"], [159, 175, "ENTITY"], [40, 48, "ENTITY"], [297, 306, "ENTITY"], [297, 306, "DISEASE"], [286, 297, "ENTITY"], [-1, 20, "SIMPLE_CHEMICAL"], [16, 34, "ENTITY"], [159, 175, "ENTITY"], [86, 101, "ENTITY"], [52, 69, "ENTITY"], [297, 317, "ORGANISM"], [269, 282, "ENTITY"], [159, 175, "SIMPLE_CHEMICAL"]]}
{"text": "The patient recovered after treatment with antiviral 50 therapy ( Arbidol ) and supportive care .", "labels": [[43, 64, "ENTITY"], [4, 12, "ENTITY"], [4, 12, "ORGANISM"], [28, 38, "ENTITY"], [12, 22, "ENTITY"], [76, 91, "ENTITY"]]}
{"text": "Symptoms improved after antiviral treatment ( Arbidol ) and supportive care", "labels": [[56, 71, "ENTITY"], [0, 9, "ENTITY"], [9, 18, "ENTITY"], [24, 44, "ENTITY"]]}
{"text": "Antiviral ( oseltamivir , 75 mg twice a day ; ribavirin , 0.5 g twice a day ; umifenovir , 0.2 g 3 times a day ) , antibacterial ( moxifloxacin , 0.4 g every day ) , glucocorticoid ( methylprednisolone , 40 - 80 mg every day ) , and respiratory support were the main treatment approaches for the hospitalized patients ( Table 1 ) .", "labels": [[166, 183, "CHEBI"], [99, 105, "ENTITY"], [115, 131, "SIMPLE_CHEMICAL"], [0, 10, "ENTITY"], [166, 183, "ENTITY"], [166, 183, "CHEMICAL"], [166, 183, "SIMPLE_CHEMICAL"], [32, 40, "ENTITY"], [115, 131, "CHEMICAL"], [146, 152, "ENTITY"], [152, 166, "ENTITY"], [215, 233, "ENTITY"], [245, 267, "ENTITY"], [152, 166, "SIMPLE_CHEMICAL"], [277, 288, "ENTITY"], [107, 115, "ENTITY"], [115, 131, "ENTITY"]]}
{"text": "Arbidol is an antiviral that can be used to treat influenza virus . A study has revealed that arbidol can effectively inhibit SARS-CoV-2 infection at a concentration of 10 - 30 \u03bcM in vitro ( 9 ) .", "labels": [[-1, 14, "ENTITY"], [189, 208, "ENTITY"], [144, 156, "ENTITY"], [214, 225, "ENTITY"], [0, 8, "ENTITY"], [189, 208, "DISEASE"], [96, 102, "TAXON"], [189, 194, "SIMPLE_CHEMICAL"], [0, 8, "CHEMICAL"]]}
{"text": "Arbidol ( umifenovir ) is a broad-spectrum antiviral compound approved in Russia and China for prophylaxis and treatment of influenza .", "labels": [[43, 53, "CHEBI"], [0, 10, "ENTITY"], [0, 8, "CHEMICAL"], [26, 53, "ENTITY"]]}
{"text": "This compound shows activities against numerous DNA and RNA viruses [ 27 ] .", "labels": [[56, 68, "SO"], [48, 52, "CELLULAR_COMPONENT"], [48, 52, "SO"], [56, 68, "ENTITY"], [48, 52, "ENTITY"], [5, 14, "CHEBI"], [20, 31, "ENTITY"], [5, 14, "ENTITY"]]}
{"text": "This compound shows activities against numerous DNA and RNA viruses [ 27 ] .", "labels": [[56, 68, "SO"], [48, 52, "CELLULAR_COMPONENT"], [48, 52, "SO"], [56, 68, "ENTITY"], [48, 52, "ENTITY"], [5, 14, "CHEBI"], [20, 31, "ENTITY"], [5, 14, "ENTITY"]]}
{"text": "Adverse reactions include nausea , diarrhea , dizziness , elevated serum aminotransferase , etc .", "labels": [[58, 73, "PROTEIN"], [58, 73, "ENTITY"], [26, 33, "DISEASE"], [58, 73, "ORGANISM_SUBSTANCE"], [0, 18, "ENTITY"], [26, 33, "ENTITY"]]}
{"text": "Adverse reactions include nausea , diarrhea , dizziness , elevated serum aminotransferase , etc .", "labels": [[26, 33, "DISEASE"], [58, 73, "PROTEIN"], [26, 33, "ENTITY"], [58, 73, "ENTITY"], [58, 73, "ORGANISM_SUBSTANCE"], [0, 18, "ENTITY"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [0, 8, "ENTITY"], [111, 121, "CHEMICAL"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "DISEASE"], [30, 39, "ENTITY"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "Adverse reactions include nausea , diarrhea , dizziness , elevated serum aminotransferase , etc .", "labels": [[26, 33, "DISEASE"], [58, 73, "PROTEIN"], [26, 33, "ENTITY"], [58, 73, "ENTITY"], [58, 73, "ORGANISM_SUBSTANCE"], [0, 18, "ENTITY"]]}
{"text": "Adverse reactions include nausea , diarrhea , dizziness , elevated serum aminotransferase , etc .", "labels": [[26, 33, "DISEASE"], [58, 73, "PROTEIN"], [26, 33, "ENTITY"], [58, 73, "ENTITY"], [58, 73, "ORGANISM_SUBSTANCE"], [0, 18, "ENTITY"]]}
{"text": "It appears that Arbidol treatment could improve the discharging rate and decrease the mortality rate ( Table 5).The efficiency of antifungal agent and corticosteroids were also analyzed in Supplementary Table 1 and Table 2 . Antifungal agent did not show influence on the outcome of COVID-19 patients . And use of corticosteroids were associated with a higher risk of death .", "labels": [[297, 306, "ENTITY"], [16, 24, "CHEMICAL"], [203, 229, "CELL"], [239, 260, "ENTITY"], [297, 317, "ORGANISM"], [349, 367, "ENTITY"], [203, 229, "ENTITY"], [-1, 20, "ENTITY"], [159, 175, "CHEMICAL"], [-1, 11, "ENTITY"], [118, 129, "ENTITY"], [73, 82, "ENTITY"], [159, 175, "CHEBI"], [159, 175, "SIMPLE_CHEMICAL"], [306, 317, "ENTITY"], [159, 175, "CHEBI"], [159, 175, "ENTITY"], [40, 48, "ENTITY"], [286, 297, "ENTITY"], [-1, 20, "SIMPLE_CHEMICAL"], [16, 34, "ENTITY"], [86, 101, "ENTITY"], [159, 175, "ENTITY"], [52, 69, "ENTITY"], [297, 306, "DISEASE"], [269, 282, "ENTITY"], [159, 175, "SIMPLE_CHEMICAL"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [111, 121, "CHEMICAL"], [30, 39, "ENTITY"], [0, 8, "DISEASE"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "ENTITY"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [0, 8, "ENTITY"], [111, 121, "CHEMICAL"], [30, 39, "ENTITY"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "DISEASE"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [0, 8, "ENTITY"], [111, 121, "CHEMICAL"], [30, 39, "ENTITY"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "DISEASE"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "Based on these results , we performed virtual docking to screen for commercial medicines in the DrugBank database that could bind to the above mentioned pocket site of 2019-nCoV Mpro , and identified 10 candidate clinical medicines ( Table 1 ; Figs. 1B and S3 ) .", "labels": [[15, 23, "ENTITY"], [96, 105, "ENTITY"], [153, 160, "ENTITY"], [38, 46, "ENTITY"], [68, 79, "ENTITY"], [203, 222, "ENTITY"], [153, 160, "SO"], [168, 178, "ENTITY"]]}
{"text": "Another PI kinase inhibitor , wortmannin , also inhibited SARS-CoV S-mediated entry into VeroE6 cells with no effect on VSV-G pseudovirus entry ( Fig. 1E ) .", "labels": [[8, 28, "GGP"], [117, 126, "ORGANISM"], [84, 96, "CELL"], [89, 96, "CL"], [84, 96, "ENTITY"], [48, 67, "ORGANISM"], [102, 110, "ENTITY"], [120, 126, "TAXON"], [8, 18, "PROTEIN"], [117, 126, "ENTITY"], [58, 67, "ENTITY"], [48, 58, "GGP"], [48, 58, "ENTITY"], [8, 28, "ENTITY"], [8, 18, "SIMPLE_CHEMICAL"], [84, 96, "CELL_LINE"]]}
{"text": "We found that entry of SARS pseudovirions into VeroE6 cells was inhibited by wortmannin with an IC50 of 80 nM ( Fig. 1F ) , which was consistent with the results reported for type III PI4Ks ( PI4KA and PI4 KB ) ( 22 , 23 ) .", "labels": [[77, 88, "ENTITY"], [184, 192, "GENE_OR_GENE_PRODUCT"], [47, 60, "CELL"], [171, 184, "ENTITY"], [96, 101, "ENTITY"], [64, 74, "ENTITY"], [171, 184, "GENE_OR_GENE_PRODUCT"], [171, 184, "PROTEIN"], [23, 28, "ENTITY"], [14, 20, "ENTITY"], [77, 88, "CHEMICAL"], [130, 145, "ENTITY"], [23, 28, "DISEASE"], [184, 192, "PROTEIN"], [47, 60, "ENTITY"], [54, 60, "CL"], [28, 42, "ENTITY"], [184, 192, "ENTITY"], [23, 42, "ORGANISM"], [47, 60, "CELL_LINE"], [77, 88, "SIMPLE_CHEMICAL"]]}
{"text": "FIGURE 7 . Model of the PI kinases and PI4P involved in SARS-CoV S-mediated entry . After SARS-CoV binds to ACE2 , PI4P , the catalytic product of PI4 KB , creates a lipid microenvironment or PI4P-enriched organelle required for the steps leading to fusion . Pharmacological inhibitors of PI4 KB , such as LY294002 or wortmannin , suppress PI4 KB activity and thereby inhibit SARSCoV S-mediated entry . Cellular factors , such as PI3Ks or Sac1 , that negatively regulate PI4P generation can also inhibit SARS-CoV S-mediated entry .", "labels": [[412, 422, "ENTITY"], [65, 76, "CL"], [24, 27, "ENTITY"], [122, 136, "ENTITY"], [56, 65, "ORGANISM"], [298, 306, "SIMPLE_CHEMICAL"], [156, 166, "SIMPLE_CHEMICAL"], [0, 7, "ENTITY"], [275, 286, "GENE_OR_GENE_PRODUCT"], [412, 422, "CHEBI"], [24, 27, "PROTEIN"], [318, 329, "ENTITY"], [259, 275, "CHEBI"], [65, 84, "PROTEIN"], [451, 462, "PROTEIN"], [298, 306, "ENTITY"], [331, 344, "ENTITY"], [172, 192, "CELL"], [275, 286, "PROTEIN"], [491, 504, "ORGANISM"], [462, 471, "ENTITY"], [306, 318, "CHEBI"], [122, 136, "PROTEIN"], [451, 462, "GENE_OR_GENE_PRODUCT"], [65, 76, "CELL"], [298, 306, "CHEMICAL"], [412, 422, "PROTEIN"], [172, 206, "ENTITY"], [65, 84, "ENTITY"], [451, 462, "ENTITY"], [476, 487, "ENTITY"], [24, 27, "GENE_OR_GENE_PRODUCT"], [368, 384, "ENTITY"], [275, 286, "ENTITY"], [56, 65, "ENTITY"], [275, 283, "ENTITY"], [156, 172, "ENTITY"], [192, 206, "GO"], [239, 250, "ENTITY"], [306, 318, "SIMPLE_CHEMICAL"], [306, 318, "ENTITY"], [156, 166, "CHEBI"], [250, 275, "ENTITY"], [306, 318, "CHEMICAL"], [412, 422, "GENE_OR_GENE_PRODUCT"]]}
{"text": "FIGURE 7 . Model of the PI kinases and PI4P involved in SARS-CoV S-mediated entry . After SARS-CoV binds to ACE2 , PI4P , the catalytic product of PI4 KB , creates a lipid microenvironment or PI4P-enriched organelle required for the steps leading to fusion . Pharmacological inhibitors of PI4 KB , such as LY294002 or wortmannin , suppress PI4 KB activity and thereby inhibit SARSCoV S-mediated entry . Cellular factors , such as PI3Ks or Sac1 , that negatively regulate PI4P generation can also inhibit SARS-CoV S-mediated entry .", "labels": [[412, 422, "ENTITY"], [65, 76, "CL"], [122, 136, "ENTITY"], [298, 306, "SIMPLE_CHEMICAL"], [156, 166, "SIMPLE_CHEMICAL"], [0, 7, "ENTITY"], [275, 286, "GENE_OR_GENE_PRODUCT"], [412, 422, "CHEBI"], [24, 27, "PROTEIN"], [318, 329, "ENTITY"], [56, 65, "ENTITY"], [24, 27, "GENE_OR_GENE_PRODUCT"], [259, 275, "CHEBI"], [65, 84, "PROTEIN"], [451, 462, "PROTEIN"], [298, 306, "ENTITY"], [331, 344, "ENTITY"], [56, 65, "ORGANISM"], [172, 192, "CELL"], [275, 286, "PROTEIN"], [491, 504, "ORGANISM"], [306, 318, "CHEBI"], [122, 136, "PROTEIN"], [451, 462, "GENE_OR_GENE_PRODUCT"], [65, 76, "CELL"], [298, 306, "CHEMICAL"], [24, 27, "ENTITY"], [412, 422, "PROTEIN"], [462, 471, "ENTITY"], [172, 206, "ENTITY"], [65, 84, "ENTITY"], [451, 462, "ENTITY"], [476, 487, "ENTITY"], [368, 384, "ENTITY"], [275, 286, "ENTITY"], [275, 283, "ENTITY"], [156, 172, "ENTITY"], [192, 206, "GO"], [239, 250, "ENTITY"], [306, 318, "SIMPLE_CHEMICAL"], [306, 318, "ENTITY"], [156, 166, "CHEBI"], [250, 275, "ENTITY"], [306, 318, "CHEMICAL"], [412, 422, "GENE_OR_GENE_PRODUCT"]]}
{"text": "TBNK lymphocyte subset analysis revealed decreased percentage of CD16 + CD56 + lymphocytes ( 4/8 ) and Th/Ts ( 1/8 ) , and increased percentage of CD3 + ( 2/8 ) , CD4 + ( 4/8 ) and CD8 + ( 1/8 ) lymphocytes . Cytokine detection assays showed increased levels of IL-6 ( 2/8 ) , IL-10 ( 5/8 ) and IFN-\u03b3 ( 2/8 ) .", "labels": [[-1, 25, "ENTITY"], [281, 287, "GENE_OR_GENE_PRODUCT"], [199, 222, "ENTITY"], [127, 137, "ENTITY"], [127, 137, "GENE_OR_GENE_PRODUCT"], [41, 51, "ENTITY"], [5, 16, "CELL"], [266, 271, "ENTITY"], [281, 293, "PROTEIN"], [127, 137, "ENTITY"], [5, 16, "ENTITY"], [0, 5, "ENTITY"], [281, 287, "ENTITY"], [159, 199, "CELL_TYPE"], [239, 246, "ENTITY"], [175, 199, "ENTITY"], [127, 137, "PROTEIN"], [51, 65, "GGP"], [65, 70, "GENE_OR_GENE_PRODUCT"], [232, 239, "ENTITY"], [281, 287, "CHEMICAL"], [127, 137, "GGP"], [5, 16, "CL"], [51, 62, "GENE_OR_GENE_PRODUCT"], [137, 157, "ENTITY"], [-1, 25, "CELL_LINE"], [137, 157, "CELL_TYPE"], [266, 271, "PROTEIN"], [185, 199, "CL"], [266, 271, "GGP"], [0, 23, "CELL_LINE"], [266, 271, "GENE_OR_GENE_PRODUCT"], [51, 62, "ENTITY"], [83, 95, "CL"]]}
{"text": "Preliminary analysis of circulating immune cells subsets as shown in Table 3 demonstrated that absolute numbers of total T lymphocytes , CD4+T cells and CD8+T cells were reduced below the lower limit of normal ( LLN ) in the vast majority of patients with either severe or moderate COVID-19 , and they were reduced more profoundly in severe cases ( 294.0 , 177.5 and 89.0 \u00d7 106/L ) than in moderate cases ( 640.5 , 381.5 and 254.0 \u00d7 106/L ) ( Figure 3A , 161 3B ) .", "labels": [[343, 349, "PROTEIN"], [36, 49, "CELL"], [24, 57, "CELL_TYPE"], [121, 135, "CELL"], [137, 143, "ENTITY"], [265, 272, "ENTITY"], [49, 57, "ENTITY"], [384, 392, "ENTITY"], [137, 143, "CELL"], [153, 159, "ENTITY"], [137, 143, "CELL_TYPE"], [275, 284, "GENE_OR_GENE_PRODUCT"], [121, 135, "CL"], [137, 143, "CL"], [104, 112, "ENTITY"], [115, 135, "CELL_TYPE"], [153, 159, "CELL"], [24, 36, "ENTITY"], [153, 159, "CELL_TYPE"], [435, 445, "ENTITY"], [115, 135, "ENTITY"], [275, 284, "ENTITY"], [0, 21, "ENTITY"], [153, 159, "CL"], [36, 49, "ENTITY"], [95, 104, "ENTITY"], [275, 284, "ENTITY"], [36, 49, "CL"]]}
{"text": "The reduced expressions of interferon-\u03b3 ( IFN-\u03b3 ) by CD4+T , CD8+T and NK cells below LLN were observed in some patients with severe ( 50 % , 16.7 % and 16.7 % ) or moderate COVID-19 ( 14.3 % , 0 % and 14.3 % ) .", "labels": [[27, 40, "ENTITY"], [165, 174, "ENTITY"], [27, 40, "GENE_OR_GENE_PRODUCT"], [4, 12, "ENTITY"], [27, 40, "PROTEIN"], [165, 174, "GENE_OR_GENE_PRODUCT"], [67, 74, "ENTITY"], [67, 74, "CELL"], [12, 24, "ENTITY"], [67, 74, "CL"], [153, 165, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "The number of MPs in patients with COVID-19 was significantly higher than that in the control group ( P<0.05 ) .", "labels": [[35, 44, "ENTITY"], [21, 30, "ENTITY"], [86, 100, "ENTITY"], [21, 30, "ORGANISM"], [14, 18, "CELL_TYPE"], [14, 18, "GGP"], [35, 44, "DISEASE"], [14, 18, "GENE_OR_GENE_PRODUCT"], [35, 44, "SIMPLE_CHEMICAL"], [14, 18, "ENTITY"]]}
{"text": "Pearson correlation analysis results showed a remarkably positive correlation of MP production and the expression of IL-6 , IL-8 and IL-10 with the severity of COVID-19 ( Table 4 ) .", "labels": [[81, 84, "ENTITY"], [81, 84, "GENE_OR_GENE_PRODUCT"], [0, 29, "ENTITY"], [57, 66, "ENTITY"], [117, 122, "PROTEIN"], [117, 122, "GGP"], [8, 20, "ENTITY"], [117, 122, "ENTITY"], [29, 37, "ENTITY"], [117, 122, "GENE_OR_GENE_PRODUCT"], [103, 114, "ENTITY"], [84, 95, "ENTITY"], [81, 84, "DISEASE"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "In contrast to 3a-WT , the 3a-CS mutant protein lost the plasma membrane localization and became more concentrated in the cytoplasm and the perinuclear region ( Fig. 1C and F ) .", "labels": [[57, 64, "ENTITY"], [33, 40, "SO"], [140, 152, "ENTITY"], [33, 40, "ENTITY"], [57, 64, "GO"], [140, 152, "GO"], [57, 64, "CELLULAR_COMPONENT"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Fig. 1C reveals a high density of the 3a protein at the cell membrane and also in the cytoplasm and the nucleus of the infected cells .", "labels": [[56, 70, "CELLULAR_COMPONENT"], [41, 49, "CHEBI"], [38, 49, "ENTITY"], [86, 96, "ORGANISM_SUBSTANCE"], [18, 31, "ENTITY"], [119, 134, "CELL_TYPE"], [0, 8, "GENE_OR_GENE_PRODUCT"], [104, 112, "ENTITY"], [128, 134, "CELL"], [56, 70, "ENTITY"], [56, 70, "GO"], [104, 112, "CELLULAR_COMPONENT"], [128, 134, "ENTITY"], [128, 134, "CL"], [86, 96, "GO"], [119, 128, "ENTITY"], [86, 96, "ENTITY"], [104, 112, "GO"]]}
{"text": "The 3a protein expression for both wild-type and M6 mutant was revealed on the oocyte cell membranes by anti-LH21 Ab and confocal microscopy ( Fig. 4 B and C ) .", "labels": [[104, 117, "ENTITY"], [52, 59, "SO"], [79, 101, "CL"], [121, 141, "ENTITY"], [86, 101, "ENTITY"], [79, 101, "CELL"], [79, 86, "ENTITY"], [104, 117, "PROTEIN"], [114, 117, "TAXON"], [15, 26, "ENTITY"], [7, 15, "CHEBI"], [35, 45, "ENTITY"], [52, 59, "ENTITY"], [4, 15, "ENTITY"]]}
{"text": "We found that wild type 3a ( 3a-WT ) protein localized to the plasma membrane ( Fig. 1B and F ) , and also displayed a punctate cytoplasmic staining pattern ( Fig. 1B and F ) .", "labels": [[58, 69, "ENTITY"], [85, 88, "CELL"], [85, 88, "ENTITY"], [119, 128, "ORGANISM_SUBSTANCE"], [58, 69, "GO"], [14, 27, "ENTITY"], [119, 128, "GO"], [107, 140, "ENTITY"], [58, 69, "CELLULAR_COMPONENT"], [14, 27, "SO"]]}
{"text": "The 3a protein expression for both wild-type and M6 mutant was revealed on the oocyte cell membranes by anti-LH21 Ab and confocal microscopy ( Fig. 4 B and C ) .", "labels": [[104, 117, "ENTITY"], [52, 59, "SO"], [79, 101, "CL"], [121, 141, "ENTITY"], [86, 101, "ENTITY"], [79, 101, "CELL"], [79, 86, "ENTITY"], [104, 117, "PROTEIN"], [114, 117, "TAXON"], [15, 26, "ENTITY"], [7, 15, "CHEBI"], [35, 45, "ENTITY"], [52, 59, "ENTITY"], [4, 15, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Importantly , virus inclusion bodies can still be detected in type II alveolar epithelia and macrophages , despite that the PCR test was negative in blood or throat swabs [ 10 , 12 , 14 ] .", "labels": [[14, 30, "TAXON"], [62, 79, "ENTITY"], [62, 79, "CANCER"], [155, 165, "ENTITY"], [120, 128, "ENTITY"], [155, 165, "CANCER"]]}
{"text": "Fig. 1C reveals a high density of the 3a protein at the cell membrane and also in the cytoplasm and the nucleus of the infected cells .", "labels": [[41, 49, "CHEBI"], [38, 49, "ENTITY"], [18, 31, "ENTITY"], [86, 96, "ENTITY"], [119, 134, "CELL_TYPE"], [104, 112, "ENTITY"], [0, 8, "GENE_OR_GENE_PRODUCT"], [128, 134, "CELL"], [56, 70, "CELLULAR_COMPONENT"], [104, 112, "CELLULAR_COMPONENT"], [56, 70, "ENTITY"], [128, 134, "CL"], [86, 96, "ORGANISM_SUBSTANCE"], [86, 96, "GO"], [119, 128, "ENTITY"], [128, 134, "ENTITY"], [56, 70, "GO"], [104, 112, "GO"]]}
{"text": "We found that wild type 3a ( 3a-WT ) protein localized to the plasma membrane ( Fig. 1B and F ) , and also displayed a punctate cytoplasmic staining pattern ( Fig. 1B and F ) .", "labels": [[58, 69, "ENTITY"], [85, 88, "CELL"], [107, 140, "ENTITY"], [85, 88, "ENTITY"], [119, 128, "ORGANISM_SUBSTANCE"], [14, 27, "ENTITY"], [119, 128, "GO"], [58, 69, "GO"], [58, 69, "CELLULAR_COMPONENT"], [14, 27, "SO"]]}
{"text": "In contrast to 3a-WT , the 3a-CS mutant protein lost the plasma membrane localization and became more concentrated in the cytoplasm and the perinuclear region ( Fig. 1C and F ) .", "labels": [[57, 64, "ENTITY"], [33, 40, "SO"], [140, 152, "ENTITY"], [140, 152, "GO"], [33, 40, "ENTITY"], [57, 64, "GO"], [57, 64, "CELLULAR_COMPONENT"]]}
{"text": "Similarly , the plasma membrane localization of 3a-YA ( Fig. 1D and F ) and 3a-DE ( Fig. 1E and F ) mutants was partially reduced with a concomitant increase in cytoplasmic signals .", "labels": [[149, 173, "ENTITY"], [112, 122, "ENTITY"], [68, 72, "SO"], [16, 23, "GO"], [16, 23, "CELLULAR_COMPONENT"], [149, 161, "ORGANISM_SUBSTANCE"], [149, 161, "GO"], [68, 72, "ENTITY"], [130, 137, "ENTITY"], [137, 149, "ENTITY"]]}
{"text": "Similarly , the plasma membrane localization of 3a-YA ( Fig. 1D and F ) and 3a-DE ( Fig. 1E and F ) mutants was partially reduced with a concomitant increase in cytoplasmic signals .", "labels": [[149, 173, "ENTITY"], [112, 122, "ENTITY"], [68, 72, "SO"], [16, 23, "GO"], [16, 23, "CELLULAR_COMPONENT"], [149, 161, "ORGANISM_SUBSTANCE"], [149, 161, "GO"], [68, 72, "ENTITY"], [130, 137, "ENTITY"], [137, 149, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Fig. 1C reveals a high density of the 3a protein at the cell membrane and also in the cytoplasm and the nucleus of the infected cells .", "labels": [[41, 49, "CHEBI"], [38, 49, "ENTITY"], [86, 96, "ORGANISM_SUBSTANCE"], [18, 31, "ENTITY"], [119, 134, "CELL_TYPE"], [0, 8, "GENE_OR_GENE_PRODUCT"], [104, 112, "GO"], [104, 112, "CELLULAR_COMPONENT"], [128, 134, "CELL"], [56, 70, "CELLULAR_COMPONENT"], [128, 134, "ENTITY"], [56, 70, "ENTITY"], [128, 134, "CL"], [86, 96, "GO"], [119, 128, "ENTITY"], [86, 96, "ENTITY"], [104, 112, "ENTITY"], [56, 70, "GO"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "From our data of more than 600 NCP patients in Jiangsu Province , age , lymphocyte count , oxygen supplementation and aggressive pulmonary radiographic infiltrations are independent risk factors for NCP progressing to a critical condition .", "labels": [[218, 229, "ENTITY"], [31, 35, "CHEMICAL"], [89, 98, "ENTITY"], [35, 44, "ENTITY"], [114, 152, "DISEASE"], [9, 14, "ENTITY"], [70, 83, "ENTITY"], [118, 152, "ENTITY"], [170, 187, "ENTITY"], [47, 64, "ENTITY"], [31, 35, "ENTITY"], [118, 129, "ORGAN"], [47, 64, "ORGANISM"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [300, 315, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [236, 242, "ENTITY"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "Multivariate regression further suggests that age and D-dimer levels ( > 1 mg/L ) are two 92 independent risk factors for mortality ( 89 , 101 ) .", "labels": [[0, 24, "ENTITY"], [93, 110, "ENTITY"], [54, 62, "PROTEIN"], [54, 62, "GENE_OR_GENE_PRODUCT"], [54, 62, "GGP"], [46, 50, "ENTITY"], [54, 69, "ENTITY"]]}
{"text": "As shown by Table 1 , < 40 years or > 60 years group was related to higher risk of reaching the composite endpoint ( R2 = 0.203 , P4 = 0.049 ) .", "labels": [[72, 79, "ENTITY"], [100, 110, "ENTITY"], [-1, 8, "ENTITY"]]}
{"text": "As shown by Table 1 , < 40 years or > 60 years group was related to higher risk of reaching the composite endpoint ( R2 = 0.203 , P4 = 0.049 ) .", "labels": [[72, 79, "ENTITY"], [100, 110, "ENTITY"], [-1, 8, "ENTITY"]]}
{"text": "Using normal lung tissue from eight adult donors , Zhao et al. [ 14 ] demonstrated that 83 % of ACE2-expressing cells were alveolar epithelial type II cells ( ACE2-expressing cells were alveolar epithelial type II cells ) , suggesting that these cells can serve as a reservoir for viral invasion .", "labels": [[13, 25, "ENTITY"], [151, 159, "PROTEIN"], [143, 151, "ENTITY"], [93, 112, "GENE_OR_GENE_PRODUCT"], [151, 159, "ENTITY"], [93, 112, "CELL_LINE"], [42, 49, "ENTITY"], [118, 151, "CELL_TYPE"], [13, 25, "TISSUE"], [42, 49, "ORGANISM"], [93, 112, "ENTITY"], [36, 42, "ENTITY"], [118, 151, "ENTITY"], [6, 13, "ENTITY"], [118, 151, "CELL"], [151, 159, "CELL"], [93, 112, "GGP"]]}
{"text": "As expected from prior literature , the AT2 cells showed highest ACE2 expression in the lung both in terms of their CPM values ( Fig. 1D , further referred to as ACE2 + cells ) and the percentage of positive cells ( Supp . Fig. 3 ) .", "labels": [[159, 169, "CELL_TYPE"], [185, 208, "ENTITY"], [199, 208, "CL"], [40, 44, "ENTITY"], [185, 208, "CELL_TYPE"], [159, 169, "GENE_OR_GENE_PRODUCT"], [159, 169, "ENTITY"], [208, 223, "CELL"], [40, 44, "CELL"], [17, 23, "ENTITY"], [199, 208, "CELL"], [159, 169, "GGP"], [40, 44, "CELL_TYPE"], [23, 34, "ENTITY"]]}
{"text": "The expression of TMPRSS2 across cell types of the lung ( further referred to as TMPRSS2 + cells ) was much stronger with a certain specificity for AT2 cells ( Fig. 1E ) , which is in agreement with previous studies .", "labels": [[18, 26, "PROTEIN"], [18, 26, "GENE_OR_GENE_PRODUCT"], [51, 56, "ORGAN"], [144, 152, "CELL"], [51, 56, "ENTITY"], [144, 152, "ENTITY"], [148, 152, "CL"], [33, 38, "CL"], [81, 91, "CELL_TYPE"], [81, 91, "ENTITY"], [152, 160, "CELL"], [18, 26, "GGP"], [33, 44, "ENTITY"], [81, 91, "GGP"], [81, 91, "GENE_OR_GENE_PRODUCT"], [199, 208, "ENTITY"], [18, 26, "ENTITY"], [4, 15, "ENTITY"], [33, 38, "CELL"], [144, 152, "CELL_TYPE"]]}
{"text": "In lung tissue , AT2 , endothelial , and immune cells were most strongly positive for FURIN expression ( Fig. 3A ) .", "labels": [[37, 48, "CELL"], [86, 92, "ENTITY"], [3, 15, "TISSUE"], [41, 48, "CL"], [64, 73, "ENTITY"], [3, 15, "ENTITY"], [37, 48, "CELL_TYPE"], [37, 48, "ENTITY"]]}
{"text": "Furthermore , the lesions occurred mainly in the lung confirmed by the HE staining and anti-spike protein of SARS-CoV-2 staining , with mild to moderate interstitial pneumonia characterized by thickened alveolar septa , accumulation of alveolar macrophages in the alveoli , degeneration of the alveolar epithelia , and infiltration of inflammatory cells ( Figure 3a ) .", "labels": [[319, 348, "ENTITY"], [233, 245, "CELL"], [290, 303, "TISSUE"], [233, 245, "ENTITY"], [264, 274, "ENTITY"], [109, 120, "ENTITY"], [144, 166, "DISEASE"], [87, 98, "ENTITY"], [335, 348, "CELL"], [144, 166, "ENTITY"], [290, 303, "ENTITY"], [319, 348, "CELL_TYPE"], [193, 212, "MULTI-TISSUE_STRUCTURE"], [233, 245, "CL"], [348, 356, "ENTITY"], [166, 176, "ENTITY"], [233, 245, "CELL_TYPE"], [190, 212, "ENTITY"], [335, 348, "CL"], [87, 98, "PROTEIN"], [348, 356, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Notably , the use of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers ( ARBs ) was higher in patients with elevated TnT levels ( 11 [ 21.1 % ] vs 8 [ 5.9 % ] ; Table 1 ) , reflecting the higher rates ofCVD .", "labels": [[21, 91, "PROTEIN"], [146, 150, "ENTITY"], [202, 217, "ENTITY"], [62, 91, "ENTITY"], [21, 91, "GENE_OR_GENE_PRODUCT"], [44, 51, "SO"], [137, 146, "PROTEIN"], [137, 146, "GENE_OR_GENE_PRODUCT"], [137, 146, "ENTITY"], [21, 51, "ENTITY"]]}
{"text": "Notably , the use of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers ( ARBs ) was higher in patients with elevated TnT levels ( 11 [ 21.1 % ] vs 8 [ 5.9 % ] ; Table 1 ) , reflecting the higher rates ofCVD .", "labels": [[21, 91, "PROTEIN"], [146, 150, "ENTITY"], [202, 217, "ENTITY"], [62, 91, "ENTITY"], [21, 91, "GENE_OR_GENE_PRODUCT"], [44, 51, "SO"], [137, 146, "PROTEIN"], [137, 146, "GENE_OR_GENE_PRODUCT"], [137, 146, "ENTITY"], [21, 51, "ENTITY"]]}
{"text": "Similarly , animal models have had inconsistent findings with respect to the effects of ARBs on ACE2 , with some showing that ARBs may increase messenger RNA expression or protein levels of ACE2 in tissue21,26 - 34 and others showing no effect.23", "labels": [[169, 180, "ENTITY"], [12, 19, "ENTITY"], [135, 154, "ENTITY"], [195, 210, "GENE_OR_GENE_PRODUCT"], [154, 158, "ENTITY"], [135, 154, "SO"], [195, 210, "CELL_LINE"], [135, 154, "RNA"], [77, 85, "ENTITY"]]}
{"text": "Similarly , animal models have had inconsistent findings with respect to the effects of ARBs on ACE2 , with some showing that ARBs may increase messenger RNA expression or protein levels of ACE2 in tissue21,26 - 34 and others showing no effect.23", "labels": [[169, 180, "ENTITY"], [12, 19, "ENTITY"], [135, 154, "ENTITY"], [195, 210, "GENE_OR_GENE_PRODUCT"], [154, 158, "ENTITY"], [135, 154, "SO"], [195, 210, "CELL_LINE"], [135, 154, "RNA"], [77, 85, "ENTITY"]]}
{"text": "Angiotensin-converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) are highly recommended medications for patients with cardiovascular diseases , such as refractory hypertension , coronary artery disease , heart failure , and post-myocardial infarction status . 1 , 2", "labels": [[192, 223, "ENTITY"], [162, 170, "ORGAN"], [239, 269, "DISEASE"], [23, 41, "SO"], [173, 192, "ENTITY"], [51, 76, "ENTITY"], [239, 269, "ENTITY"], [105, 117, "ENTITY"], [223, 239, "DISEASE"], [142, 162, "ENTITY"], [0, 41, "GENE_OR_GENE_PRODUCT"], [51, 76, "PROTEIN"], [192, 216, "MULTI-TISSUE_STRUCTURE"], [223, 239, "ENTITY"], [181, 192, "DISEASE"], [51, 76, "GENE_OR_GENE_PRODUCT"], [192, 223, "DISEASE"], [0, 41, "ENTITY"], [51, 76, "GGP"], [142, 162, "DISEASE"], [239, 253, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "Angiotensin-converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) are highly recommended medications for patients with cardiovascular diseases , such as refractory hypertension , coronary artery disease , heart failure , and post-myocardial infarction status . 1 , 2", "labels": [[192, 223, "ENTITY"], [162, 170, "ORGAN"], [239, 269, "DISEASE"], [23, 41, "SO"], [192, 216, "MULTI-TISSUE_STRUCTURE"], [173, 192, "ENTITY"], [51, 76, "ENTITY"], [239, 269, "ENTITY"], [105, 117, "ENTITY"], [223, 239, "DISEASE"], [142, 162, "ENTITY"], [0, 41, "GENE_OR_GENE_PRODUCT"], [51, 76, "PROTEIN"], [223, 239, "ENTITY"], [181, 192, "DISEASE"], [192, 223, "DISEASE"], [51, 76, "GENE_OR_GENE_PRODUCT"], [0, 41, "ENTITY"], [51, 76, "GGP"], [142, 162, "DISEASE"], [239, 253, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "Angiotensin-converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) are highly recommended medications for patients with cardiovascular diseases , such as refractory hypertension , coronary artery disease , heart failure , and post-myocardial infarction status . 1 , 2", "labels": [[192, 223, "ENTITY"], [162, 170, "ORGAN"], [239, 269, "DISEASE"], [23, 41, "SO"], [192, 216, "MULTI-TISSUE_STRUCTURE"], [173, 192, "ENTITY"], [51, 76, "ENTITY"], [239, 269, "ENTITY"], [105, 117, "ENTITY"], [223, 239, "DISEASE"], [142, 162, "ENTITY"], [0, 41, "GENE_OR_GENE_PRODUCT"], [51, 76, "PROTEIN"], [223, 239, "ENTITY"], [181, 192, "DISEASE"], [192, 223, "DISEASE"], [51, 76, "GENE_OR_GENE_PRODUCT"], [0, 41, "ENTITY"], [51, 76, "GGP"], [142, 162, "DISEASE"], [239, 253, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "Angiotensin-converting enzyme inhibitors ( ACEIs ) and angiotensin receptor blockers ( ARBs ) are highly recommended medications for patients with cardiovascular diseases , such as refractory hypertension , coronary artery disease , heart failure , and post-myocardial infarction status . 1 , 2", "labels": [[192, 223, "ENTITY"], [162, 170, "ORGAN"], [239, 269, "DISEASE"], [23, 41, "SO"], [192, 216, "MULTI-TISSUE_STRUCTURE"], [173, 192, "ENTITY"], [51, 76, "ENTITY"], [239, 269, "ENTITY"], [105, 117, "ENTITY"], [223, 239, "DISEASE"], [142, 162, "ENTITY"], [0, 41, "GENE_OR_GENE_PRODUCT"], [51, 76, "PROTEIN"], [223, 239, "ENTITY"], [181, 192, "DISEASE"], [192, 223, "DISEASE"], [51, 76, "GENE_OR_GENE_PRODUCT"], [0, 41, "ENTITY"], [51, 76, "GGP"], [142, 162, "DISEASE"], [239, 253, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "Intravenous infusions of ACEIs and ARBs in experimental animals increase the numbers of angiotensin converting enzyme 2 ( ACE2 ) receptors in the cardiopulmonary circulation . 4", "labels": [[88, 100, "CHEMICAL"], [35, 40, "ENTITY"], [88, 120, "GGP"], [88, 129, "PROTEIN"], [25, 31, "CHEMICAL"], [25, 31, "ENTITY"], [142, 162, "ENTITY"], [43, 64, "ENTITY"], [88, 120, "GENE_OR_GENE_PRODUCT"], [88, 120, "ENTITY"], [35, 40, "CHEMICAL"], [64, 73, "ENTITY"], [0, 12, "IMMATERIAL_ANATOMICAL_ENTITY"], [35, 40, "SIMPLE_CHEMICAL"], [0, 12, "ENTITY"], [56, 64, "TAXON"], [25, 31, "SIMPLE_CHEMICAL"], [12, 22, "ENTITY"]]}
{"text": "Patients taking ACEIs or ARBs chronically for cardiovascular diseases are assumed to have increased numbers of ACE2 receptors throughout their cardiopulmonary circulations as observed in experimental animal models .", "labels": [[111, 126, "PROTEIN"], [90, 100, "ENTITY"], [143, 172, "MULTI-TISSUE_STRUCTURE"], [30, 42, "ENTITY"], [0, 9, "ORGANISM"], [16, 22, "CHEMICAL"], [25, 30, "SIMPLE_CHEMICAL"], [16, 22, "ENTITY"], [46, 70, "DISEASE"], [46, 61, "ORGAN"], [111, 116, "GENE_OR_GENE_PRODUCT"], [200, 207, "TAXON"], [187, 200, "ENTITY"], [111, 116, "GGP"], [0, 9, "ENTITY"], [25, 30, "CHEMICAL"], [25, 30, "ENTITY"], [46, 70, "ENTITY"], [143, 172, "ENTITY"], [16, 22, "SIMPLE_CHEMICAL"], [111, 126, "ENTITY"], [100, 108, "ENTITY"], [200, 214, "ENTITY"]]}
{"text": "Since patients treated with ACEIs and ARBS will have increased numbers of ACE2 receptors in their lungs for coronavirus S proteins to bind to , they may be at increased risk of severe disease outcomes due to SARS-CoV-2 infections .", "labels": [[6, 15, "ENTITY"], [53, 63, "ENTITY"], [74, 89, "PROTEIN"], [74, 79, "GGP"], [98, 104, "ENTITY"], [6, 15, "ORGANISM"], [38, 43, "CHEMICAL"], [208, 219, "DISEASE"], [122, 131, "CHEBI"], [134, 139, "ENTITY"], [28, 34, "CHEMICAL"], [15, 28, "ENTITY"], [208, 219, "ENTITY"], [38, 43, "ENTITY"], [74, 89, "ENTITY"], [108, 131, "ENTITY"], [38, 43, "SIMPLE_CHEMICAL"], [28, 34, "SIMPLE_CHEMICAL"], [98, 104, "ORGAN"], [28, 34, "ENTITY"], [74, 79, "GENE_OR_GENE_PRODUCT"], [108, 131, "PROTEIN"], [108, 131, "ORGANISM"], [184, 192, "ENTITY"], [38, 43, "PROTEIN"]]}
{"text": "The generation of Ang II by ACE is pharmacologically inhibited by angiotensin converting enzyme inhibitors ( ACEi ) , and angiotensin receptor blockers ( ARBs ) function by blocking the downstream interaction of Ang II with the AT1 receptor [ 16 ] .", "labels": [[18, 25, "GGP"], [18, 25, "GENE_OR_GENE_PRODUCT"], [118, 143, "ENTITY"], [143, 154, "CHEMICAL"], [53, 63, "ENTITY"], [4, 15, "ENTITY"], [118, 143, "GGP"], [197, 212, "GGP"], [118, 143, "GENE_OR_GENE_PRODUCT"], [66, 78, "CHEMICAL"], [66, 107, "GGP"], [118, 143, "PROTEIN"], [28, 32, "GENE_OR_GENE_PRODUCT"], [66, 107, "ENTITY"], [186, 197, "ENTITY"], [197, 212, "ENTITY"], [28, 32, "ENTITY"], [143, 154, "ENTITY"], [28, 32, "GGP"], [18, 25, "PROTEIN"], [18, 25, "ENTITY"], [161, 173, "ENTITY"], [197, 212, "GENE_OR_GENE_PRODUCT"], [143, 154, "SIMPLE_CHEMICAL"], [224, 232, "GGP"], [35, 53, "ENTITY"], [66, 107, "PROTEIN"], [197, 212, "CHEMICAL"], [224, 232, "GENE_OR_GENE_PRODUCT"], [28, 32, "CHEMICAL"], [224, 232, "PROTEIN"], [224, 232, "ENTITY"], [197, 212, "PROTEIN"], [66, 109, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Notably , the use of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers ( ARBs ) was higher in patients with elevated TnT levels ( 11 [ 21.1 % ] vs 8 [ 5.9 % ] ; Table 1 ) , reflecting the higher rates ofCVD .", "labels": [[146, 150, "ENTITY"], [202, 217, "ENTITY"], [62, 91, "ENTITY"], [21, 91, "GENE_OR_GENE_PRODUCT"], [137, 146, "GENE_OR_GENE_PRODUCT"], [137, 146, "PROTEIN"], [21, 91, "PROTEIN"], [137, 146, "ENTITY"], [21, 51, "ENTITY"], [44, 51, "SO"]]}
{"text": "Two mechanisms may protect children from COVID-19 infections : ( 1 ) cross-protective antibodies from multiple upper respiratory tract infections caused by the common cold-causing alpha coronaviruses , and ( 2 ) fewer ACE2 receptors in their lower respiratory tracts to attract the binding S proteins of the beta coronaviruses .", "labels": [[41, 61, "DISEASE"], [212, 223, "ENTITY"], [102, 117, "PATHOLOGICAL_FORMATION"], [212, 223, "PROTEIN"], [27, 36, "ENTITY"], [27, 36, "ORGANISM"], [301, 313, "GENE_OR_GENE_PRODUCT"], [160, 186, "PROTEIN"], [301, 313, "ENTITY"], [282, 292, "CHEBI"], [41, 61, "ENTITY"], [270, 292, "PROTEIN"], [69, 86, "GO"], [97, 135, "ENTITY"], [301, 313, "PROTEIN"], [242, 260, "ENTITY"], [67, 86, "ENTITY"], [41, 50, "SIMPLE_CHEMICAL"], [4, 15, "ENTITY"], [160, 186, "ENTITY"], [67, 86, "PROTEIN"], [270, 292, "ENTITY"]]}
{"text": "Ribavirin is a nucleoside analogue with a broad-spectrum of antiviral effects . A study compared 111 patients with severe acute respiratory syndrome ( severe acute respiratory syndrome ) treated with ribavirin monotherapy and 41 patients with severe acute respiratory syndrome treated with lopinavir/ritonavir and ribavirin ; patients treated with the combined therapy had a lower risk of acute respiratory distress syndrome ( acute respiratory distress syndrome ) and death ( 6 ) .", "labels": [[180, 189, "ENTITY"], [90, 100, "ENTITY"], [21, 32, "CHEMICAL"], [0, 10, "PROTEIN"], [0, 10, "CHEMICAL"], [21, 32, "CHEBI"], [343, 356, "CHEMICAL"], [0, 10, "SIMPLE_CHEMICAL"], [-1, 23, "DISEASE"], [-1, 20, "ENTITY"], [149, 156, "ENTITY"], [0, 10, "GGP"], [21, 32, "SIMPLE_CHEMICAL"], [149, 156, "ORGANISM"], [343, 356, "SIMPLE_CHEMICAL"], [131, 140, "ENTITY"], [-1, 20, "SIMPLE_CHEMICAL"], [-1, 19, "ENTITY"], [149, 156, "ENTITY"], [180, 189, "DISEASE"], [219, 229, "ENTITY"], [0, 10, "ENTITY"], [-1, 20, "CHEMICAL"], [298, 322, "ENTITY"]]}
{"text": "Chloroquine is a widely used antimalarial that was found to be a potential broad-spectrum antiviral in 2006 ( 7 ) . Chloroquine was found to block SARS-CoV-2 infection at low-micromolar concentration , with a half-maximal effective concentration ( EC50 ) of 1.13 \u03bcM and a half-cytotoxic concentration ( CC50 ) greater than 100 \u03bcM ( 8) .", "labels": [[-1, 12, "ENTITY"], [186, 196, "ORGANISM"], [-1, 15, "SIMPLE_CHEMICAL"], [-1, 37, "PROTEIN"], [0, 12, "CHEMICAL"], [-1, 37, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [203, 218, "SIMPLE_CHEMICAL"], [232, 241, "ENTITY"], [203, 218, "ENTITY"], [254, 264, "ENTITY"], [35, 48, "ENTITY"], [81, 96, "ENTITY"], [0, 12, "CHEBI"], [-1, 15, "CHEMICAL"], [-1, 15, "CHEBI"], [203, 218, "CHEBI"], [346, 354, "ENTITY"], [0, 12, "ENTITY"], [-1, 25, "ENTITY"], [-1, 15, "ENTITY"], [-1, 12, "ENTITY"]]}
{"text": "Adverse reactions include nausea , diarrhea , dizziness , elevated serum aminotransferase , etc .", "labels": [[26, 33, "DISEASE"], [58, 73, "PROTEIN"], [26, 33, "ENTITY"], [58, 73, "ENTITY"], [58, 73, "ORGANISM_SUBSTANCE"], [0, 18, "ENTITY"]]}
{"text": "DPP4 inhibitors target the enzymatic activity of DPP4 and consequently block the breakdown of GLP-1 . This increase insulin secretion and decrease blood glucose levels in patients with type 2 diabetes .", "labels": [[147, 161, "ENTITY"], [94, 100, "PROTEIN"], [27, 37, "SO"], [81, 91, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [5, 16, "ENTITY"], [185, 192, "ENTITY"], [94, 100, "CHEBI"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [185, 192, "DISEASE"], [16, 23, "ENTITY"], [0, 5, "PROTEIN"], [71, 77, "ENTITY"], [94, 100, "SIMPLE_CHEMICAL"], [147, 153, "ORGANISM_SUBSTANCE"], [27, 46, "ENTITY"], [0, 5, "ENTITY"], [0, 5, "ENTITY"], [116, 124, "ENTITY"], [0, 5, "PROTEIN"], [94, 100, "ENTITY"], [0, 16, "GGP"]]}
{"text": "Lower total protein level correlated with severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = \u2212 0.340 , P3 = 0.001 , R2 = \u2212 0.252 , P4 = 0.015 ) .", "labels": [[0, 20, "ENTITY"], [60, 72, "ORGANISM"], [60, 82, "DISEASE"], [26, 37, "ENTITY"], [42, 49, "ENTITY"], [12, 20, "CHEBI"], [86, 105, "ENTITY"], [60, 82, "ENTITY"]]}
{"text": "In terms of inflammation indicators , patients on admission showed increase in lactate dehydrogenase ( 25 [ 41 % ] of 61 patients ) , c reactive protein ( 42 [ 67 % ] of 63 patients ) , and erythrocyte sedimentation rate ( 30 [ 52 % ] of 58 patients ) , but not procalcitonin .", "labels": [[132, 147, "ENTITY"], [81, 103, "GGP"], [81, 89, "CHEMICAL"], [243, 260, "GENE_OR_GENE_PRODUCT"], [25, 36, "ENTITY"], [12, 25, "DISEASE"], [81, 103, "PROTEIN"], [81, 103, "ENTITY"], [123, 147, "PROTEIN"], [12, 25, "ENTITY"], [243, 260, "ENTITY"], [123, 147, "GENE_OR_GENE_PRODUCT"], [175, 192, "CL"], [69, 78, "ENTITY"], [113, 120, "ORGANISM"], [175, 204, "ENTITY"], [52, 62, "ENTITY"], [113, 120, "ENTITY"], [138, 147, "CHEBI"], [243, 260, "PROTEIN"], [175, 192, "CELL"], [81, 103, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In terms of inflammation indicators , patients on admission showed increase in lactate dehydrogenase ( 25 [ 41 % ] of 61 patients ) , c reactive protein ( 42 [ 67 % ] of 63 patients ) , and erythrocyte sedimentation rate ( 30 [ 52 % ] of 58 patients ) , but not procalcitonin .", "labels": [[132, 147, "ENTITY"], [81, 103, "GGP"], [81, 89, "CHEMICAL"], [243, 260, "GENE_OR_GENE_PRODUCT"], [25, 36, "ENTITY"], [81, 103, "PROTEIN"], [81, 103, "ENTITY"], [123, 147, "PROTEIN"], [243, 260, "ENTITY"], [123, 147, "GENE_OR_GENE_PRODUCT"], [175, 192, "CL"], [69, 78, "ENTITY"], [12, 25, "ENTITY"], [113, 120, "ORGANISM"], [175, 204, "ENTITY"], [52, 62, "ENTITY"], [113, 120, "ENTITY"], [138, 147, "CHEBI"], [243, 260, "PROTEIN"], [12, 25, "DISEASE"], [175, 192, "CELL"], [81, 103, "GENE_OR_GENE_PRODUCT"]]}
{"text": "But in the severe patients , the neutrophil count , D-dimer , blood urea , and creatinine levels were higher significantly , and the lymphocyte counts continued to decrease .", "labels": [[11, 18, "ENTITY"], [33, 44, "ENTITY"], [60, 68, "ENTITY"], [18, 27, "ENTITY"], [60, 68, "GGP"], [18, 27, "ORGANISM"], [79, 90, "ENTITY"], [151, 164, "ENTITY"], [60, 68, "ORGANISM_SUBSTANCE"], [60, 68, "DISEASE"], [133, 144, "ENTITY"]]}
{"text": "Higher C-reactive protein level was strongly related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.572 , P3<0.001 , R2 = 0.503 , P4<0.001 ) .", "labels": [[74, 96, "DISEASE"], [26, 32, "ENTITY"], [7, 26, "ENTITY"], [7, 18, "GENE_OR_GENE_PRODUCT"], [74, 96, "ENTITY"], [7, 26, "PROTEIN"], [74, 86, "ORGANISM"], [56, 63, "ENTITY"], [100, 119, "ENTITY"], [0, 7, "ENTITY"], [7, 26, "GGP"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer .", "labels": [[126, 138, "PROTEIN"], [34, 41, "ENTITY"], [44, 63, "GGP"], [44, 63, "ENTITY"], [12, 21, "ENTITY"], [44, 63, "PROTEIN"], [155, 166, "ENTITY"], [101, 109, "PROTEIN"], [25, 34, "ENTITY"], [155, 166, "PROTEIN"], [12, 21, "ORGANISM"], [44, 55, "GENE_OR_GENE_PRODUCT"], [126, 138, "GENE_OR_GENE_PRODUCT"], [101, 109, "GGP"], [101, 109, "GENE_OR_GENE_PRODUCT"], [126, 138, "CHEBI"], [101, 109, "ENTITY"], [126, 138, "ENTITY"]]}
{"text": "The mice depleted of CD8 + T cells cleared the virus from the lungs as well as the isotype control-treated animals did and exhibited a near complete clearance of virus by day 9 p.i . However , depletion of CD4 + T cells resulted in delayed viral clearance from the lungs .", "labels": [[203, 214, "ENTITY"], [21, 29, "ENTITY"], [4, 9, "ENTITY"], [21, 29, "CELL_TYPE"], [203, 214, "GGP"], [203, 214, "CELL_TYPE"], [21, 25, "GENE_OR_GENE_PRODUCT"], [232, 246, "ENTITY"], [9, 18, "ENTITY"], [21, 29, "GGP"], [4, 9, "ORGANISM"], [232, 240, "TAXON"], [4, 9, "TAXON"]]}
{"text": "Compared to the isotype-treated controls , levels of cytokines IFN-\u03b3 , IL-2 , IL-4 , and IL-5 and chemokine MIP-2/CXCL2 were lower in mice depleted of CD4 + T cells ( P < 0.05 by Student 's t test ) , and IL-2 , IL-4 , and MIP-2/CXCL2 levels were lower in mice depleted of both CD4 + and CD8 + T cells ( P < 0.05 by Student 's t test ) .", "labels": [[134, 139, "ENTITY"], [139, 148, "GGP"], [273, 288, "GGP"], [78, 89, "CHEMICAL"], [148, 159, "CELL_TYPE"], [0, 9, "ENTITY"], [273, 288, "ENTITY"], [16, 41, "ENTITY"], [98, 108, "ENTITY"], [53, 63, "PROTEIN"], [78, 89, "ENTITY"], [171, 190, "ENTITY"], [261, 288, "CELL_TYPE"], [148, 159, "ENTITY"], [139, 148, "GENE_OR_GENE_PRODUCT"], [94, 108, "PROTEIN"], [148, 159, "GENE_OR_GENE_PRODUCT"], [139, 148, "ENTITY"], [125, 134, "ENTITY"], [165, 179, "ENTITY"], [148, 159, "GGP"]]}
{"text": "Compared to the isotype-treated controls , levels of cytokines IFN-\u03b3 , IL-2 , IL-4 , and IL-5 and chemokine MIP-2/CXCL2 were lower in mice depleted of CD4 + T cells ( P < 0.05 by Student 's t test ) , and IL-2 , IL-4 , and MIP-2/CXCL2 levels were lower in mice depleted of both CD4 + and CD8 + T cells ( P < 0.05 by Student 's t test ) .", "labels": [[134, 139, "ENTITY"], [139, 148, "GGP"], [273, 288, "GGP"], [78, 89, "CHEMICAL"], [148, 159, "CELL_TYPE"], [0, 9, "ENTITY"], [273, 288, "ENTITY"], [16, 41, "ENTITY"], [98, 108, "ENTITY"], [53, 63, "PROTEIN"], [78, 89, "ENTITY"], [171, 190, "ENTITY"], [261, 288, "CELL_TYPE"], [148, 159, "ENTITY"], [139, 148, "GENE_OR_GENE_PRODUCT"], [94, 108, "PROTEIN"], [148, 159, "GENE_OR_GENE_PRODUCT"], [139, 148, "ENTITY"], [125, 134, "ENTITY"], [165, 179, "ENTITY"], [148, 159, "GGP"]]}
{"text": "Compared to the isotype-treated controls , levels of cytokines IFN-\u03b3 , IL-2 , IL-4 , and IL-5 and chemokine MIP-2/CXCL2 were lower in mice depleted of CD4 + T cells ( P < 0.05 by Student 's t test ) , and IL-2 , IL-4 , and MIP-2/CXCL2 levels were lower in mice depleted of both CD4 + and CD8 + T cells ( P < 0.05 by Student 's t test ) .", "labels": [[134, 139, "ENTITY"], [139, 148, "GGP"], [273, 288, "GGP"], [78, 89, "CHEMICAL"], [148, 159, "CELL_TYPE"], [0, 9, "ENTITY"], [273, 288, "ENTITY"], [16, 41, "ENTITY"], [98, 108, "ENTITY"], [53, 63, "PROTEIN"], [78, 89, "ENTITY"], [171, 190, "ENTITY"], [261, 288, "CELL_TYPE"], [148, 159, "ENTITY"], [139, 148, "GENE_OR_GENE_PRODUCT"], [94, 108, "PROTEIN"], [148, 159, "GENE_OR_GENE_PRODUCT"], [139, 148, "ENTITY"], [125, 134, "ENTITY"], [165, 179, "ENTITY"], [148, 159, "GGP"]]}
{"text": "Compared to the isotype-treated controls , levels of cytokines IFN-\u03b3 , IL-2 , IL-4 , and IL-5 and chemokine MIP-2/CXCL2 were lower in mice depleted of CD4 + T cells ( P < 0.05 by Student 's t test ) , and IL-2 , IL-4 , and MIP-2/CXCL2 levels were lower in mice depleted of both CD4 + and CD8 + T cells ( P < 0.05 by Student 's t test ) .", "labels": [[134, 139, "ENTITY"], [139, 148, "GGP"], [273, 288, "GGP"], [78, 89, "CHEMICAL"], [148, 159, "CELL_TYPE"], [0, 9, "ENTITY"], [273, 288, "ENTITY"], [16, 41, "ENTITY"], [98, 108, "ENTITY"], [53, 63, "PROTEIN"], [78, 89, "ENTITY"], [171, 190, "ENTITY"], [261, 288, "CELL_TYPE"], [148, 159, "ENTITY"], [139, 148, "GENE_OR_GENE_PRODUCT"], [94, 108, "PROTEIN"], [148, 159, "GENE_OR_GENE_PRODUCT"], [139, 148, "ENTITY"], [125, 134, "ENTITY"], [165, 179, "ENTITY"], [148, 159, "GGP"]]}
{"text": "Compared to the isotype-treated controls , levels of cytokines IFN-\u03b3 , IL-2 , IL-4 , and IL-5 and chemokine MIP-2/CXCL2 were lower in mice depleted of CD4 + T cells ( P < 0.05 by Student 's t test ) , and IL-2 , IL-4 , and MIP-2/CXCL2 levels were lower in mice depleted of both CD4 + and CD8 + T cells ( P < 0.05 by Student 's t test ) .", "labels": [[134, 139, "ENTITY"], [139, 148, "GGP"], [273, 288, "GGP"], [78, 89, "CHEMICAL"], [148, 159, "CELL_TYPE"], [0, 9, "ENTITY"], [273, 288, "ENTITY"], [16, 41, "ENTITY"], [98, 108, "ENTITY"], [53, 63, "PROTEIN"], [78, 89, "ENTITY"], [171, 190, "ENTITY"], [261, 288, "CELL_TYPE"], [148, 159, "ENTITY"], [139, 148, "GENE_OR_GENE_PRODUCT"], [94, 108, "PROTEIN"], [148, 159, "GENE_OR_GENE_PRODUCT"], [139, 148, "ENTITY"], [125, 134, "ENTITY"], [165, 179, "ENTITY"], [148, 159, "GGP"]]}
{"text": "FACS analysis revealed that depletion of CD4 + T cells resulted in decreased number of leukocytes infiltrating into the lungs on day 9 p.i . ( Fig. 5B),consistent with the decreased chemokine production .", "labels": [[67, 77, "PROTEIN"], [182, 192, "ENTITY"], [41, 49, "CELL_TYPE"], [0, 5, "CELL"], [41, 45, "GENE_OR_GENE_PRODUCT"], [0, 5, "ENTITY"], [5, 14, "ENTITY"], [28, 38, "ENTITY"], [41, 49, "GGP"], [67, 77, "ENTITY"], [41, 49, "ENTITY"]]}
{"text": "Depletion of CD4 + T cells results in enhanced interstitial pneumonitis .", "labels": [[13, 21, "GGP"], [0, 10, "ENTITY"], [13, 21, "ENTITY"], [47, 60, "ENTITY"], [47, 60, "DISEASE"], [13, 21, "CELL_TYPE"], [13, 17, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Interestingly , the concentration of these three cytokines was negatively correlated with total T cell counts , CD4 + counts , and CD8 + counts , respectively ( Figure 2B ) .", "labels": [[146, 161, "ENTITY"], [110, 118, "ENTITY"], [90, 98, "ENTITY"], [127, 137, "ENTITY"], [110, 116, "GGP"]]}
{"text": "Interestingly , serum levels of IFN-\u03b3 , IL-10 , IL-6 and TNF-\u03b1 were significantly decreased in these patients in the decline period as compared with illness period , while counts of total T cells , CD4 + , and CD8 + T cell subsets recovered during the decline period ( Figure 2C ) .", "labels": [[117, 125, "ENTITY"], [182, 190, "CL"], [68, 82, "ENTITY"], [182, 190, "CELL"], [16, 22, "ENTITY"], [260, 269, "ENTITY"], [206, 218, "GGP"], [149, 157, "ENTITY"], [206, 223, "ENTITY"], [117, 125, "ENTITY"], [190, 198, "ENTITY"], [179, 190, "CELL_TYPE"], [179, 190, "ENTITY"], [190, 223, "CELL_TYPE"], [190, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [40, 59, "ENTITY"], [26, 38, "SIMPLE_CHEMICAL"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GGP"], [253, 271, "ENTITY"], [26, 40, "CHEBI"], [170, 179, "GGP"], [26, 38, "CHEMICAL"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [144, 154, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [26, 38, "ENTITY"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "FACs showed that these patients have very low level of PD-1 and Tim-3 on CD8 + and CD4 + T cells in the prodromal stage , however , their levels on CD8 + T cells was increased in overtly symptomatic stages , and highest levels were seen in ICU period ( Figure 3C , D ) .", "labels": [[23, 32, "ORGANISM"], [83, 97, "GGP"], [73, 79, "GGP"], [73, 97, "CELL_TYPE"], [55, 60, "ENTITY"], [64, 70, "ENTITY"], [104, 120, "ENTITY"], [64, 70, "GGP"], [55, 60, "PROTEIN"], [187, 199, "ENTITY"], [64, 70, "GENE_OR_GENE_PRODUCT"], [83, 97, "ENTITY"], [0, 5, "ENTITY"], [83, 87, "GENE_OR_GENE_PRODUCT"], [55, 60, "GENE_OR_GENE_PRODUCT"], [240, 244, "ENTITY"], [0, 5, "CELL"], [244, 253, "ENTITY"], [23, 32, "ENTITY"], [145, 156, "GGP"], [73, 77, "GENE_OR_GENE_PRODUCT"], [46, 52, "ENTITY"], [145, 156, "ENTITY"], [145, 156, "CELL_TYPE"], [73, 79, "ENTITY"], [212, 220, "ENTITY"], [64, 70, "PROTEIN"], [179, 187, "ENTITY"]]}
{"text": "Similarly , higher levels of Tim-3 was observed on CD4 + T cells from patients who are in ICU stage , although enhancing the expression of PD-1 on CD4 + T cells was not obviously during disease progress ( Figure 3C , D ) .", "labels": [[90, 94, "ENTITY"], [203, 212, "ENTITY"], [51, 59, "CELL_TYPE"], [48, 59, "GGP"], [51, 59, "GGP"], [212, 215, "ENTITY"], [51, 59, "ENTITY"], [179, 194, "ENTITY"], [48, 59, "ENTITY"], [48, 59, "CELL_TYPE"]]}
{"text": "However , lymphocyte counts ( difference,\u2212 0.34 \u00d7 109/mL;95%CI,\u22120.47 to\u22120.22 \u00d7 109/mL;P < .001 ) and CD8 T cells ( difference , \u221266.00 cells/\u03bcL ; 95%CI , \u2212129.00 to \u22127.00 cells/\u03bcL ; P = .03 ) were significantly decreased .", "labels": [[95, 105, "CELL_TYPE"], [115, 135, "CHEMICAL"], [144, 154, "ENTITY"], [107, 115, "ENTITY"], [95, 105, "GGP"], [95, 105, "GENE_OR_GENE_PRODUCT"], [154, 165, "DNA"], [154, 165, "GENE_OR_GENE_PRODUCT"], [154, 165, "CHEMICAL"], [95, 105, "ENTITY"], [115, 135, "GENE_OR_GENE_PRODUCT"], [30, 41, "ENTITY"]]}
{"text": "Because functional blockade of PD-1 , CTLA-4 , and TIGIT is beneficial for CD8 + T cells to maintain lasting antigen-specific immunity and antiviral effects,10,11 the excessive exhaustion of CD8 + T cells in severe patients may reduce their cellular immune response to SARS- CoV-2 .", "labels": [[188, 199, "GGP"], [208, 215, "ORGANISM"], [266, 275, "PROTEIN"], [71, 83, "CELL_TYPE"], [266, 275, "ENTITY"], [31, 36, "ENTITY"], [135, 149, "ENTITY"], [235, 257, "ENTITY"], [71, 83, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [101, 126, "ENTITY"], [19, 28, "ENTITY"], [188, 199, "ENTITY"], [188, 199, "CELL_TYPE"], [266, 275, "ORGANISM"], [71, 83, "GGP"], [8, 19, "ENTITY"], [208, 215, "ENTITY"], [31, 36, "PROTEIN"], [167, 177, "ENTITY"]]}
{"text": "Interestingly , serum levels of IFN-\u03b3 , IL-10 , IL-6 and TNF-\u03b1 were significantly decreased in these patients in the decline period as compared with illness period , while counts of total T cells , CD4 + , and CD8 + T cell subsets recovered during the decline period ( Figure 2C ) .", "labels": [[117, 125, "ENTITY"], [182, 190, "CL"], [68, 82, "ENTITY"], [182, 190, "CELL"], [16, 22, "ENTITY"], [260, 269, "ENTITY"], [206, 218, "GGP"], [149, 157, "ENTITY"], [206, 223, "ENTITY"], [117, 125, "ENTITY"], [190, 198, "ENTITY"], [179, 190, "CELL_TYPE"], [179, 190, "ENTITY"], [190, 223, "CELL_TYPE"], [190, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [40, 59, "ENTITY"], [26, 38, "SIMPLE_CHEMICAL"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GGP"], [253, 271, "ENTITY"], [26, 40, "CHEBI"], [170, 179, "GGP"], [26, 38, "CHEMICAL"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [144, 154, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [26, 38, "ENTITY"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "Because functional blockade of PD-1 , CTLA-4 , and TIGIT is beneficial for CD8 + T cells to maintain lasting antigen-specific immunity and antiviral effects,10,11 the excessive exhaustion of CD8 + T cells in severe patients may reduce their cellular immune response to SARS- CoV-2 .", "labels": [[188, 199, "GGP"], [208, 215, "ORGANISM"], [266, 275, "PROTEIN"], [71, 83, "CELL_TYPE"], [266, 275, "ENTITY"], [31, 36, "ENTITY"], [135, 149, "ENTITY"], [235, 257, "ENTITY"], [71, 83, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [101, 126, "ENTITY"], [19, 28, "ENTITY"], [188, 199, "ENTITY"], [188, 199, "CELL_TYPE"], [266, 275, "ORGANISM"], [71, 83, "GGP"], [8, 19, "ENTITY"], [208, 215, "ENTITY"], [31, 36, "PROTEIN"], [167, 177, "ENTITY"]]}
{"text": "Interestingly , the concentration of these three cytokines was negatively correlated with total T cell counts , CD4 + counts , and CD8 + counts , respectively ( Figure 2B ) .", "labels": [[146, 161, "ENTITY"], [110, 118, "ENTITY"], [90, 98, "ENTITY"], [127, 137, "ENTITY"], [110, 116, "GGP"]]}
{"text": "Furthermore , statistical analysis showed that the percentage of PD-1 + CD8 + T cells from ICU patients was significantly higher than from both Non-ICU cases and healthy controls ( Figure 3B ) , indicating that SARS-CoV-2 viruses induce T cell exhaustion in COVID-19 patients , particularly in those requiring ICU care .", "labels": [[230, 239, "CELL"], [65, 80, "CELL_LINE"], [255, 267, "ORGANISM"], [258, 267, "ENTITY"], [72, 80, "ENTITY"], [206, 222, "ENTITY"], [162, 170, "ENTITY"], [144, 152, "ENTITY"], [179, 188, "ENTITY"], [222, 230, "ENTITY"], [230, 239, "ENTITY"], [300, 314, "ENTITY"], [211, 222, "TAXON"], [14, 26, "ENTITY"], [230, 239, "CL"], [80, 85, "ENTITY"], [65, 80, "GGP"]]}
{"text": "FACs showed that these patients have very low level of PD-1 and Tim-3 on CD8 + and CD4 + T cells in the prodromal stage , however , their levels on CD8 + T cells was increased in overtly symptomatic stages , and highest levels were seen in ICU period ( Figure 3C , D ) .", "labels": [[23, 32, "ORGANISM"], [83, 97, "GGP"], [73, 79, "GGP"], [73, 97, "CELL_TYPE"], [104, 120, "ENTITY"], [187, 199, "ENTITY"], [55, 60, "ENTITY"], [83, 97, "ENTITY"], [0, 5, "ENTITY"], [83, 87, "GENE_OR_GENE_PRODUCT"], [55, 60, "PROTEIN"], [64, 70, "GENE_OR_GENE_PRODUCT"], [240, 244, "ENTITY"], [64, 70, "ENTITY"], [0, 5, "CELL"], [244, 253, "ENTITY"], [23, 32, "ENTITY"], [145, 156, "GGP"], [55, 60, "GENE_OR_GENE_PRODUCT"], [73, 77, "GENE_OR_GENE_PRODUCT"], [46, 52, "ENTITY"], [145, 156, "ENTITY"], [179, 187, "ENTITY"], [145, 156, "CELL_TYPE"], [73, 79, "ENTITY"], [212, 220, "ENTITY"], [64, 70, "PROTEIN"], [64, 70, "GGP"]]}
{"text": "NK cells highly expressed KLRF1 , KLRC1 and KLRD1 . CD8 + T cells expressed CD8A and CD8B .", "labels": [[26, 32, "GGP"], [16, 26, "GENE_OR_GENE_PRODUCT"], [50, 60, "GGP"], [50, 60, "ENTITY"], [26, 32, "PROTEIN"], [16, 26, "PROTEIN"], [26, 32, "ENTITY"], [0, 9, "CELL_TYPE"], [0, 9, "CELL"], [16, 26, "ENTITY"], [0, 9, "CL"], [26, 32, "GENE_OR_GENE_PRODUCT"], [50, 60, "CELL_TYPE"], [16, 26, "ENTITY"], [3, 9, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "NK cells highly expressed KLRF1 , KLRC1 and KLRD1 . CD8 + T cells expressed CD8A and CD8B .", "labels": [[26, 32, "GGP"], [26, 32, "PROTEIN"], [16, 26, "PROTEIN"], [26, 32, "ENTITY"], [0, 9, "CELL_TYPE"], [50, 60, "GGP"], [50, 60, "ENTITY"], [50, 60, "CELL_TYPE"], [0, 9, "CELL"], [16, 26, "ENTITY"], [0, 9, "CL"], [26, 32, "GENE_OR_GENE_PRODUCT"], [16, 26, "GENE_OR_GENE_PRODUCT"], [16, 26, "ENTITY"], [3, 9, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "GEX analysis showed that CD8 + T cells expressed high levels of effector molecules , including GZMA , GZMK , FASLG , CCL5 , etc . , and resident T cell markers ITGA1 , CXCR6 , JAML , etc . , likely played crucial roles in immune defense ( Figure S4 ) .", "labels": [[128, 136, "ENTITY"], [25, 33, "CELL_TYPE"], [85, 95, "ENTITY"], [25, 33, "ENTITY"], [109, 117, "GENE_OR_GENE_PRODUCT"], [102, 109, "PROTEIN"], [25, 33, "GGP"], [128, 152, "PROTEIN"], [102, 109, "CHEMICAL"], [64, 73, "CHEBI"], [109, 117, "GGP"], [102, 109, "GENE_OR_GENE_PRODUCT"], [85, 95, "GGP"], [109, 117, "ENTITY"], [85, 95, "PROTEIN"], [205, 222, "ENTITY"], [0, 13, "ENTITY"], [102, 109, "ENTITY"], [205, 229, "CELL"], [25, 29, "GENE_OR_GENE_PRODUCT"], [109, 117, "PROTEIN"], [64, 73, "PROTEIN"], [102, 109, "GGP"], [85, 95, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"], [222, 229, "ENTITY"]]}
{"text": "GEX analysis showed that CD8 + T cells expressed high levels of effector molecules , including GZMA , GZMK , FASLG , CCL5 , etc . , and resident T cell markers ITGA1 , CXCR6 , JAML , etc . , likely played crucial roles in immune defense ( Figure S4 ) .", "labels": [[128, 136, "ENTITY"], [25, 33, "CELL_TYPE"], [85, 95, "ENTITY"], [25, 33, "ENTITY"], [109, 117, "GENE_OR_GENE_PRODUCT"], [25, 33, "GGP"], [128, 152, "PROTEIN"], [102, 109, "GENE_OR_GENE_PRODUCT"], [64, 73, "CHEBI"], [109, 117, "GGP"], [85, 95, "GGP"], [102, 109, "PROTEIN"], [102, 109, "GGP"], [109, 117, "ENTITY"], [85, 95, "PROTEIN"], [205, 222, "ENTITY"], [0, 13, "ENTITY"], [205, 229, "CELL"], [25, 29, "GENE_OR_GENE_PRODUCT"], [109, 117, "PROTEIN"], [64, 73, "PROTEIN"], [85, 95, "GENE_OR_GENE_PRODUCT"], [102, 109, "ENTITY"], [102, 109, "CHEMICAL"], [64, 73, "ENTITY"], [222, 229, "ENTITY"]]}
{"text": "GEX analysis showed that CD8 + T cells expressed high levels of effector molecules , including GZMA , GZMK , FASLG , CCL5 , etc . , and resident T cell markers ITGA1 , CXCR6 , JAML , etc . , likely played crucial roles in immune defense ( Figure S4 ) .", "labels": [[128, 136, "ENTITY"], [25, 33, "CELL_TYPE"], [85, 95, "ENTITY"], [25, 33, "ENTITY"], [102, 109, "PROTEIN"], [25, 33, "GGP"], [128, 152, "PROTEIN"], [64, 73, "CHEBI"], [85, 95, "GGP"], [109, 117, "ENTITY"], [109, 117, "GGP"], [85, 95, "PROTEIN"], [205, 222, "ENTITY"], [0, 13, "ENTITY"], [102, 109, "ENTITY"], [205, 229, "CELL"], [25, 29, "GENE_OR_GENE_PRODUCT"], [102, 109, "CHEMICAL"], [64, 73, "PROTEIN"], [102, 109, "GENE_OR_GENE_PRODUCT"], [102, 109, "GGP"], [85, 95, "GENE_OR_GENE_PRODUCT"], [109, 117, "PROTEIN"], [109, 117, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"], [222, 229, "ENTITY"]]}
{"text": "GEX analysis showed that CD8 + T cells expressed high levels of effector molecules , including GZMA , GZMK , FASLG , CCL5 , etc . , and resident T cell markers ITGA1 , CXCR6 , JAML , etc . , likely played crucial roles in immune defense ( Figure S4 ) .", "labels": [[128, 136, "ENTITY"], [25, 33, "CELL_TYPE"], [85, 95, "ENTITY"], [25, 33, "ENTITY"], [102, 109, "PROTEIN"], [109, 117, "GENE_OR_GENE_PRODUCT"], [25, 33, "GGP"], [128, 152, "PROTEIN"], [64, 73, "CHEBI"], [109, 117, "GGP"], [85, 95, "GGP"], [109, 117, "ENTITY"], [85, 95, "PROTEIN"], [205, 222, "ENTITY"], [0, 13, "ENTITY"], [102, 109, "ENTITY"], [205, 229, "CELL"], [25, 29, "GENE_OR_GENE_PRODUCT"], [102, 109, "CHEMICAL"], [109, 117, "PROTEIN"], [64, 73, "PROTEIN"], [102, 109, "GENE_OR_GENE_PRODUCT"], [102, 109, "GGP"], [85, 95, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"], [222, 229, "ENTITY"]]}
{"text": "GEX analysis showed that CD8 + T cells expressed high levels of effector molecules , including GZMA , GZMK , FASLG , CCL5 , etc . , and resident T cell markers ITGA1 , CXCR6 , JAML , etc . , likely played crucial roles in immune defense ( Figure S4 ) .", "labels": [[128, 136, "ENTITY"], [25, 33, "CELL_TYPE"], [85, 95, "ENTITY"], [25, 33, "ENTITY"], [102, 109, "PROTEIN"], [109, 117, "GENE_OR_GENE_PRODUCT"], [25, 33, "GGP"], [128, 152, "PROTEIN"], [64, 73, "CHEBI"], [109, 117, "GGP"], [85, 95, "GGP"], [109, 117, "ENTITY"], [85, 95, "PROTEIN"], [205, 222, "ENTITY"], [0, 13, "ENTITY"], [102, 109, "ENTITY"], [205, 229, "CELL"], [25, 29, "GENE_OR_GENE_PRODUCT"], [102, 109, "CHEMICAL"], [109, 117, "PROTEIN"], [64, 73, "PROTEIN"], [102, 109, "GENE_OR_GENE_PRODUCT"], [102, 109, "GGP"], [85, 95, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"], [222, 229, "ENTITY"]]}
{"text": "GEX analysis showed that CD8 + T cells expressed high levels of effector molecules , including GZMA , GZMK , FASLG , CCL5 , etc . , and resident T cell markers ITGA1 , CXCR6 , JAML , etc . , likely played crucial roles in immune defense ( Figure S4 ) .", "labels": [[128, 136, "ENTITY"], [25, 33, "CELL_TYPE"], [85, 95, "ENTITY"], [25, 33, "ENTITY"], [102, 109, "PROTEIN"], [109, 117, "GENE_OR_GENE_PRODUCT"], [25, 33, "GGP"], [128, 152, "PROTEIN"], [64, 73, "CHEBI"], [109, 117, "GGP"], [85, 95, "GGP"], [109, 117, "ENTITY"], [85, 95, "PROTEIN"], [205, 222, "ENTITY"], [0, 13, "ENTITY"], [102, 109, "ENTITY"], [205, 229, "CELL"], [25, 29, "GENE_OR_GENE_PRODUCT"], [102, 109, "CHEMICAL"], [109, 117, "PROTEIN"], [64, 73, "PROTEIN"], [102, 109, "GENE_OR_GENE_PRODUCT"], [102, 109, "GGP"], [85, 95, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"], [222, 229, "ENTITY"]]}
{"text": "We found increased expression of signaling and tissue resident genes including XCL1 , XCL2 , ZNF683 , HOPX , CXCR6 and ITGAE , etc . , which further supports a superior effector functions of those expanded CD8 + T cells ( Figure 4E ) .", "labels": [[160, 169, "CHEBI"], [197, 212, "ENTITY"], [47, 69, "ENTITY"], [160, 178, "ENTITY"], [9, 19, "ENTITY"], [19, 30, "ENTITY"], [63, 69, "SO"], [102, 109, "GENE_OR_GENE_PRODUCT"], [197, 212, "GGP"], [102, 109, "ENTITY"], [197, 212, "CELL_TYPE"], [214, 222, "ENTITY"], [79, 84, "GENE_OR_GENE_PRODUCT"], [214, 222, "GENE_OR_GENE_PRODUCT"], [33, 43, "ENTITY"], [102, 109, "PROTEIN"], [47, 54, "TISSUE"], [79, 84, "ENTITY"], [102, 109, "GGP"], [79, 84, "PROTEIN"], [79, 84, "GGP"]]}
{"text": "GEX analysis showed that CD8 + T cells expressed high levels of effector molecules , including GZMA , GZMK , FASLG , CCL5 , etc . , and resident T cell markers ITGA1 , CXCR6 , JAML , etc . , likely played crucial roles in immune defense ( Figure S4 ) .", "labels": [[128, 136, "ENTITY"], [25, 33, "CELL_TYPE"], [85, 95, "ENTITY"], [25, 33, "ENTITY"], [102, 109, "PROTEIN"], [109, 117, "GENE_OR_GENE_PRODUCT"], [25, 33, "GGP"], [128, 152, "PROTEIN"], [64, 73, "CHEBI"], [109, 117, "GGP"], [85, 95, "GGP"], [109, 117, "ENTITY"], [85, 95, "PROTEIN"], [205, 222, "ENTITY"], [0, 13, "ENTITY"], [102, 109, "ENTITY"], [205, 229, "CELL"], [25, 29, "GENE_OR_GENE_PRODUCT"], [102, 109, "CHEMICAL"], [109, 117, "PROTEIN"], [64, 73, "PROTEIN"], [102, 109, "GENE_OR_GENE_PRODUCT"], [102, 109, "GGP"], [85, 95, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"], [222, 229, "ENTITY"]]}
{"text": "We found T cell activation , migration , calcium ion signaling molecules were upregulated in CD8 + T cells from mild cases , but the virus responses , metabolites and energy generation , and translation initiation molecules was upregulated in CD8 + T cells from severe cases ( Figure 3E and 3F ) .", "labels": [[185, 214, "ENTITY"], [203, 214, "CHEBI"], [163, 174, "ENTITY"], [9, 16, "CELL"], [78, 99, "CELL_TYPE"], [101, 112, "ENTITY"], [53, 63, "CHEBI"], [39, 63, "ENTITY"], [39, 49, "CHEBI"], [107, 117, "ENTITY"], [90, 101, "ENTITY"], [214, 228, "ENTITY"], [78, 99, "ENTITY"], [90, 101, "GGP"], [129, 139, "ENTITY"], [139, 151, "ENTITY"], [9, 27, "ENTITY"], [185, 214, "PROTEIN"], [139, 151, "CHEBI"], [78, 90, "GENE_OR_GENE_PRODUCT"], [78, 99, "GGP"], [269, 277, "ENTITY"], [90, 101, "CELL_TYPE"], [9, 16, "CL"]]}
{"text": "We found T cell activation , migration , calcium ion signaling molecules were upregulated in CD8 + T cells from mild cases , but the virus responses , metabolites and energy generation , and translation initiation molecules was upregulated in CD8 + T cells from severe cases ( Figure 3E and 3F ) .", "labels": [[185, 214, "ENTITY"], [203, 214, "CHEBI"], [163, 174, "ENTITY"], [78, 99, "CELL_TYPE"], [9, 16, "CELL"], [101, 112, "ENTITY"], [53, 63, "CHEBI"], [39, 63, "ENTITY"], [39, 49, "CHEBI"], [107, 117, "ENTITY"], [90, 101, "ENTITY"], [214, 228, "ENTITY"], [78, 99, "ENTITY"], [9, 16, "CL"], [90, 101, "GGP"], [129, 139, "ENTITY"], [139, 151, "ENTITY"], [185, 214, "PROTEIN"], [139, 151, "CHEBI"], [9, 27, "ENTITY"], [78, 90, "GENE_OR_GENE_PRODUCT"], [78, 99, "GGP"], [269, 277, "ENTITY"], [90, 101, "CELL_TYPE"]]}
{"text": "We found T cell activation , migration , calcium ion signaling molecules were upregulated in CD8 + T cells from mild cases , but the virus responses , metabolites and energy generation , and translation initiation molecules was upregulated in CD8 + T cells from severe cases ( Figure 3E and 3F ) .", "labels": [[185, 214, "ENTITY"], [203, 214, "CHEBI"], [163, 174, "ENTITY"], [9, 16, "CELL"], [78, 99, "CELL_TYPE"], [101, 112, "ENTITY"], [53, 63, "CHEBI"], [39, 63, "ENTITY"], [107, 117, "ENTITY"], [90, 101, "ENTITY"], [214, 228, "ENTITY"], [78, 99, "ENTITY"], [9, 16, "CL"], [39, 49, "CHEBI"], [90, 101, "GGP"], [129, 139, "ENTITY"], [139, 151, "ENTITY"], [185, 214, "PROTEIN"], [139, 151, "CHEBI"], [9, 27, "ENTITY"], [78, 90, "GENE_OR_GENE_PRODUCT"], [78, 99, "GGP"], [269, 277, "ENTITY"], [90, 101, "CELL_TYPE"]]}
{"text": "We found T cell activation , migration , calcium ion signaling molecules were upregulated in CD8 + T cells from mild cases , but the virus responses , metabolites and energy generation , and translation initiation molecules was upregulated in CD8 + T cells from severe cases ( Figure 3E and 3F ) .", "labels": [[185, 214, "ENTITY"], [203, 214, "CHEBI"], [163, 174, "ENTITY"], [9, 16, "CELL"], [129, 139, "ENTITY"], [78, 99, "CELL_TYPE"], [101, 112, "ENTITY"], [53, 63, "CHEBI"], [39, 63, "ENTITY"], [39, 49, "CHEBI"], [107, 117, "ENTITY"], [90, 101, "ENTITY"], [214, 228, "ENTITY"], [78, 99, "ENTITY"], [9, 16, "CL"], [90, 101, "GGP"], [139, 151, "CHEBI"], [139, 151, "ENTITY"], [185, 214, "PROTEIN"], [9, 27, "ENTITY"], [78, 90, "GENE_OR_GENE_PRODUCT"], [78, 99, "GGP"], [269, 277, "ENTITY"], [90, 101, "CELL_TYPE"]]}
{"text": "We found T cell activation , migration , calcium ion signaling molecules were upregulated in CD8 + T cells from mild cases , but the virus responses , metabolites and energy generation , and translation initiation molecules was upregulated in CD8 + T cells from severe cases ( Figure 3E and 3F ) .", "labels": [[185, 214, "ENTITY"], [203, 214, "CHEBI"], [163, 174, "ENTITY"], [9, 16, "CELL"], [78, 99, "CELL_TYPE"], [101, 112, "ENTITY"], [53, 63, "CHEBI"], [39, 63, "ENTITY"], [39, 49, "CHEBI"], [107, 117, "ENTITY"], [90, 101, "ENTITY"], [214, 228, "ENTITY"], [78, 99, "ENTITY"], [9, 16, "CL"], [90, 101, "GGP"], [129, 139, "ENTITY"], [139, 151, "ENTITY"], [185, 214, "PROTEIN"], [139, 151, "CHEBI"], [9, 27, "ENTITY"], [78, 90, "GENE_OR_GENE_PRODUCT"], [78, 99, "GGP"], [269, 277, "ENTITY"], [90, 101, "CELL_TYPE"]]}
{"text": "We found increased expression of signaling and tissue resident genes including XCL1 , XCL2 , ZNF683 , HOPX , CXCR6 and ITGAE , etc . , which further supports a superior effector functions of those expanded CD8 + T cells ( Figure 4E ) .", "labels": [[160, 169, "CHEBI"], [197, 212, "ENTITY"], [47, 69, "ENTITY"], [160, 178, "ENTITY"], [79, 84, "GGP"], [9, 19, "ENTITY"], [19, 30, "ENTITY"], [63, 69, "SO"], [102, 109, "GENE_OR_GENE_PRODUCT"], [197, 212, "GGP"], [102, 109, "ENTITY"], [197, 212, "CELL_TYPE"], [214, 222, "ENTITY"], [79, 84, "ENTITY"], [214, 222, "GENE_OR_GENE_PRODUCT"], [33, 43, "ENTITY"], [79, 84, "PROTEIN"], [102, 109, "PROTEIN"], [47, 54, "TISSUE"], [102, 109, "GGP"], [79, 84, "GENE_OR_GENE_PRODUCT"]]}
{"text": "We found increased expression of signaling and tissue resident genes including XCL1 , XCL2 , ZNF683 , HOPX , CXCR6 and ITGAE , etc . , which further supports a superior effector functions of those expanded CD8 + T cells ( Figure 4E ) .", "labels": [[160, 169, "CHEBI"], [197, 212, "ENTITY"], [47, 69, "ENTITY"], [160, 178, "ENTITY"], [9, 19, "ENTITY"], [19, 30, "ENTITY"], [63, 69, "SO"], [102, 109, "GENE_OR_GENE_PRODUCT"], [197, 212, "GGP"], [102, 109, "ENTITY"], [197, 212, "CELL_TYPE"], [214, 222, "ENTITY"], [79, 84, "GENE_OR_GENE_PRODUCT"], [214, 222, "GENE_OR_GENE_PRODUCT"], [33, 43, "ENTITY"], [102, 109, "PROTEIN"], [47, 54, "TISSUE"], [79, 84, "ENTITY"], [102, 109, "GGP"], [79, 84, "PROTEIN"], [79, 84, "GGP"]]}
{"text": "We found increased expression of signaling and tissue resident genes including XCL1 , XCL2 , ZNF683 , HOPX , CXCR6 and ITGAE , etc . , which further supports a superior effector functions of those expanded CD8 + T cells ( Figure 4E ) .", "labels": [[160, 169, "CHEBI"], [197, 212, "ENTITY"], [47, 69, "ENTITY"], [160, 178, "ENTITY"], [9, 19, "ENTITY"], [19, 30, "ENTITY"], [63, 69, "SO"], [102, 109, "GENE_OR_GENE_PRODUCT"], [197, 212, "GGP"], [102, 109, "ENTITY"], [197, 212, "CELL_TYPE"], [214, 222, "ENTITY"], [79, 84, "GENE_OR_GENE_PRODUCT"], [214, 222, "GENE_OR_GENE_PRODUCT"], [33, 43, "ENTITY"], [102, 109, "PROTEIN"], [47, 54, "TISSUE"], [79, 84, "ENTITY"], [102, 109, "GGP"], [79, 84, "PROTEIN"], [79, 84, "GGP"]]}
{"text": "We found increased expression of signaling and tissue resident genes including XCL1 , XCL2 , ZNF683 , HOPX , CXCR6 and ITGAE , etc . , which further supports a superior effector functions of those expanded CD8 + T cells ( Figure 4E ) .", "labels": [[160, 169, "CHEBI"], [197, 212, "ENTITY"], [47, 69, "ENTITY"], [160, 178, "ENTITY"], [9, 19, "ENTITY"], [19, 30, "ENTITY"], [63, 69, "SO"], [102, 109, "GGP"], [197, 212, "GGP"], [102, 109, "PROTEIN"], [102, 109, "GENE_OR_GENE_PRODUCT"], [102, 109, "ENTITY"], [197, 212, "CELL_TYPE"], [214, 222, "ENTITY"], [79, 84, "GENE_OR_GENE_PRODUCT"], [214, 222, "GENE_OR_GENE_PRODUCT"], [33, 43, "ENTITY"], [47, 54, "TISSUE"], [79, 84, "ENTITY"], [79, 84, "PROTEIN"], [79, 84, "GGP"]]}
{"text": "We found increased expression of signaling and tissue resident genes including XCL1 , XCL2 , ZNF683 , HOPX , CXCR6 and ITGAE , etc . , which further supports a superior effector functions of those expanded CD8 + T cells ( Figure 4E ) .", "labels": [[160, 169, "CHEBI"], [197, 212, "ENTITY"], [47, 69, "ENTITY"], [160, 178, "ENTITY"], [9, 19, "ENTITY"], [19, 30, "ENTITY"], [63, 69, "SO"], [102, 109, "GENE_OR_GENE_PRODUCT"], [197, 212, "GGP"], [102, 109, "ENTITY"], [197, 212, "CELL_TYPE"], [214, 222, "ENTITY"], [79, 84, "GENE_OR_GENE_PRODUCT"], [214, 222, "GENE_OR_GENE_PRODUCT"], [33, 43, "ENTITY"], [102, 109, "PROTEIN"], [47, 54, "TISSUE"], [79, 84, "ENTITY"], [102, 109, "GGP"], [79, 84, "PROTEIN"], [79, 84, "GGP"]]}
{"text": "As per reports for Ebola and influenza1,4 , co-expression of CD38 and HLA-DR on CD8 + T cells ( assessed as the frequency of CD38+HLA-DR+ CD8 + T cells ) rapidly increased in this patient from day 7 ( 3.57 % ) to day 8 ( 5.32 % ) and day 9 ( 11.8 % ) , then decreased at day 20 ( 7.05 % ) ( Fig. 1e ) .", "labels": [[80, 88, "GGP"], [29, 42, "PROTEIN"], [19, 25, "ENTITY"], [122, 146, "ENTITY"], [154, 162, "ENTITY"], [80, 88, "CELL_TYPE"], [122, 146, "CELL_LINE"], [125, 138, "GENE_OR_GENE_PRODUCT"], [29, 42, "ENTITY"], [125, 146, "GGP"], [7, 15, "ENTITY"], [80, 88, "ENTITY"]]}
{"text": "As per reports for Ebola and influenza1,4 , co-expression of CD38 and HLA-DR on CD8 + T cells ( assessed as the frequency of CD38+HLA-DR+ CD8 + T cells ) rapidly increased in this patient from day 7 ( 3.57 % ) to day 8 ( 5.32 % ) and day 9 ( 11.8 % ) , then decreased at day 20 ( 7.05 % ) ( Fig. 1e ) .", "labels": [[80, 88, "GGP"], [29, 42, "PROTEIN"], [19, 25, "ENTITY"], [122, 146, "ENTITY"], [154, 162, "ENTITY"], [80, 88, "CELL_TYPE"], [122, 146, "CELL_LINE"], [125, 138, "GENE_OR_GENE_PRODUCT"], [29, 42, "ENTITY"], [125, 146, "GGP"], [7, 15, "ENTITY"], [80, 88, "ENTITY"]]}
{"text": "As per reports for Ebola and influenza1,4 , co-expression of CD38 and HLA-DR on CD8 + T cells ( assessed as the frequency of CD38+HLA-DR+ CD8 + T cells ) rapidly increased in this patient from day 7 ( 3.57 % ) to day 8 ( 5.32 % ) and day 9 ( 11.8 % ) , then decreased at day 20 ( 7.05 % ) ( Fig. 1e ) .", "labels": [[80, 88, "CELL_TYPE"], [80, 88, "ENTITY"], [29, 42, "PROTEIN"], [19, 25, "ENTITY"], [80, 88, "GGP"], [122, 146, "ENTITY"], [154, 162, "ENTITY"], [29, 42, "ENTITY"], [7, 15, "ENTITY"], [125, 146, "GGP"], [122, 146, "CELL_LINE"], [125, 138, "GENE_OR_GENE_PRODUCT"]]}
{"text": "As per reports for Ebola and influenza1,4 , co-expression of CD38 and HLA-DR on CD8 + T cells ( assessed as the frequency of CD38+HLA-DR+ CD8 + T cells ) rapidly increased in this patient from day 7 ( 3.57 % ) to day 8 ( 5.32 % ) and day 9 ( 11.8 % ) , then decreased at day 20 ( 7.05 % ) ( Fig. 1e ) .", "labels": [[80, 88, "CELL_TYPE"], [80, 88, "ENTITY"], [29, 42, "PROTEIN"], [19, 25, "ENTITY"], [80, 88, "GGP"], [122, 146, "ENTITY"], [154, 162, "ENTITY"], [29, 42, "ENTITY"], [7, 15, "ENTITY"], [125, 146, "GGP"], [122, 146, "CELL_LINE"], [125, 138, "GENE_OR_GENE_PRODUCT"]]}
{"text": "CD38+HLA-DR+ T cells , especially CD8+T cells , produced larger amounts of granzymes A and B and perforin ( ~34\u201354 % higher ) than did their parent cells ( CD8 + or CD4 + populations ; Fig. 1e ) .", "labels": [[141, 148, "CELL"], [72, 85, "ENTITY"], [15, 21, "GENE_OR_GENE_PRODUCT"], [156, 162, "GENE_OR_GENE_PRODUCT"], [34, 40, "CELL"], [72, 85, "GGP"], [15, 21, "GGP"], [156, 171, "ENTITY"], [72, 85, "PROTEIN"], [135, 148, "CELL_TYPE"], [0, 21, "CELL_LINE"], [15, 21, "ENTITY"], [72, 85, "GENE_OR_GENE_PRODUCT"], [34, 40, "ENTITY"], [171, 183, "GENE_OR_GENE_PRODUCT"], [34, 40, "CL"], [34, 40, "CELL_TYPE"], [135, 148, "ENTITY"], [0, 21, "ENTITY"], [13, 21, "CELL"], [148, 171, "CELL_TYPE"], [13, 21, "CL"], [141, 148, "CL"]]}
{"text": "CD38+HLA-DR+ T cells , especially CD8+T cells , produced larger amounts of granzymes A and B and perforin ( ~34\u201354 % higher ) than did their parent cells ( CD8 + or CD4 + populations ; Fig. 1e ) .", "labels": [[141, 148, "CELL"], [72, 85, "ENTITY"], [15, 21, "GENE_OR_GENE_PRODUCT"], [156, 162, "GENE_OR_GENE_PRODUCT"], [34, 40, "CELL"], [72, 85, "GGP"], [15, 21, "GGP"], [156, 171, "ENTITY"], [72, 85, "PROTEIN"], [135, 148, "CELL_TYPE"], [0, 21, "CELL_LINE"], [15, 21, "ENTITY"], [72, 85, "GENE_OR_GENE_PRODUCT"], [34, 40, "ENTITY"], [171, 183, "GENE_OR_GENE_PRODUCT"], [34, 40, "CL"], [34, 40, "CELL_TYPE"], [135, 148, "ENTITY"], [0, 21, "ENTITY"], [13, 21, "CELL"], [148, 171, "CELL_TYPE"], [13, 21, "CL"], [141, 148, "CL"]]}
{"text": "CD38+HLA-DR+ T cells , especially CD8+T cells , produced larger amounts of granzymes A and B and perforin ( ~34\u201354 % higher ) than did their parent cells ( CD8 + or CD4 + populations ; Fig. 1e ) .", "labels": [[141, 148, "CELL"], [72, 85, "ENTITY"], [15, 21, "GENE_OR_GENE_PRODUCT"], [156, 162, "GENE_OR_GENE_PRODUCT"], [34, 40, "CELL"], [72, 85, "GGP"], [15, 21, "GGP"], [156, 171, "ENTITY"], [72, 85, "PROTEIN"], [135, 148, "CELL_TYPE"], [0, 21, "CELL_LINE"], [15, 21, "ENTITY"], [72, 85, "GENE_OR_GENE_PRODUCT"], [34, 40, "ENTITY"], [171, 183, "GENE_OR_GENE_PRODUCT"], [34, 40, "CL"], [34, 40, "CELL_TYPE"], [135, 148, "ENTITY"], [0, 21, "ENTITY"], [13, 21, "CELL"], [148, 171, "CELL_TYPE"], [13, 21, "CL"], [141, 148, "CL"]]}
{"text": "C3 activation products ( C3 fragments C3a , C3b , iC3b , C3dg , and C3c ) were detected by Western blotting in lung tissue of SARS-CoV MA15-infected mice , but not in control mice , as early as 1 day postinfection ( dpi ) ( Fig. 1B ) , confirming that SARS-CoV MA15 infection activates the complement pathway .", "labels": [[25, 38, "ENTITY"], [0, 23, "PROTEIN"], [160, 167, "ENTITY"], [25, 38, "PROTEIN"], [99, 116, "ENTITY"], [135, 140, "ENTITY"], [50, 57, "GGP"], [247, 261, "ENTITY"], [236, 252, "ORGANISM"], [50, 57, "PROTEIN"], [236, 247, "ENTITY"], [50, 57, "ENTITY"], [116, 135, "ENTITY"], [191, 200, "ENTITY"], [116, 126, "ORGANISM"], [0, 3, "GGP"], [185, 191, "ENTITY"], [79, 99, "ENTITY"], [50, 57, "GENE_OR_GENE_PRODUCT"], [0, 23, "ENTITY"], [276, 290, "ENTITY"], [116, 126, "GGP"], [25, 38, "GGP"], [25, 38, "GENE_OR_GENE_PRODUCT"], [99, 116, "TISSUE"], [14, 23, "SO"]]}
{"text": "Western blot analysis showed increased levels of C3a-derived fragments in the serum , indicating systemic complement activation in SARS-CoV MA15-infected mice at 2 dpi ( Fig. 7A ) .", "labels": [[61, 71, "SO"], [78, 84, "ENTITY"], [78, 84, "ORGANISM_SUBSTANCE"], [49, 71, "DNA"], [61, 71, "ENTITY"], [0, 22, "ENTITY"], [49, 61, "ENTITY"], [29, 39, "ENTITY"], [97, 117, "ENTITY"], [39, 46, "ENTITY"]]}
{"text": "C3 activation products ( C3 fragments C3a , C3b , iC3b , C3dg , and C3c ) were detected by Western blotting in lung tissue of SARS-CoV MA15-infected mice , but not in control mice , as early as 1 day postinfection ( dpi ) ( Fig. 1B ) , confirming that SARS-CoV MA15 infection activates the complement pathway .", "labels": [[25, 38, "ENTITY"], [0, 23, "PROTEIN"], [160, 167, "ENTITY"], [25, 38, "PROTEIN"], [99, 116, "ENTITY"], [135, 140, "ENTITY"], [50, 57, "GGP"], [247, 261, "ENTITY"], [236, 252, "ORGANISM"], [50, 57, "PROTEIN"], [236, 247, "ENTITY"], [50, 57, "ENTITY"], [116, 135, "ENTITY"], [191, 200, "ENTITY"], [116, 126, "ORGANISM"], [0, 3, "GGP"], [185, 191, "ENTITY"], [79, 99, "ENTITY"], [50, 57, "GENE_OR_GENE_PRODUCT"], [0, 23, "ENTITY"], [276, 290, "ENTITY"], [116, 126, "GGP"], [25, 38, "GGP"], [25, 38, "GENE_OR_GENE_PRODUCT"], [99, 116, "TISSUE"], [14, 23, "SO"]]}
{"text": "C3 activation products ( C3 fragments C3a , C3b , iC3b , C3dg , and C3c ) were detected by Western blotting in lung tissue of SARS-CoV MA15-infected mice , but not in control mice , as early as 1 day postinfection ( dpi ) ( Fig. 1B ) , confirming that SARS-CoV MA15 infection activates the complement pathway .", "labels": [[25, 38, "ENTITY"], [0, 23, "PROTEIN"], [160, 167, "ENTITY"], [25, 38, "PROTEIN"], [99, 116, "ENTITY"], [135, 140, "ENTITY"], [50, 57, "GGP"], [247, 261, "ENTITY"], [236, 252, "ORGANISM"], [50, 57, "PROTEIN"], [236, 247, "ENTITY"], [50, 57, "ENTITY"], [116, 135, "ENTITY"], [191, 200, "ENTITY"], [116, 126, "ORGANISM"], [0, 3, "GGP"], [185, 191, "ENTITY"], [79, 99, "ENTITY"], [50, 57, "GENE_OR_GENE_PRODUCT"], [0, 23, "ENTITY"], [276, 290, "ENTITY"], [116, 126, "GGP"], [25, 38, "GGP"], [25, 38, "GENE_OR_GENE_PRODUCT"], [99, 116, "TISSUE"], [14, 23, "SO"]]}
{"text": "Until today , six different strains of Human coronaviruses ( HCoVs ) have been reported , in addition to the newly emerged COVID-19 [ 2,12 ] . 229E and NL63 strains of HCoVs belong to Alphacoronaviruses while OC43 , HKU1 , SARS , MERS , and COVID-19 HCoVs belong to Betacoronaviruses [ 2,11 ] .", "labels": [[28, 36, "ORGANISM"], [39, 45, "ORGANISM"], [39, 45, "ENTITY"], [39, 45, "PROTEIN"], [28, 36, "PROTEIN"], [174, 184, "GENE_OR_GENE_PRODUCT"], [230, 241, "ENTITY"], [230, 241, "GENE_OR_GENE_PRODUCT"], [143, 157, "ORGANISM"], [115, 123, "ENTITY"], [174, 184, "ORGANISM"], [28, 36, "ENTITY"], [174, 184, "ENTITY"], [143, 157, "ENTITY"], [28, 36, "DISEASE"], [230, 241, "PROTEIN"], [174, 184, "ENTITY"], [115, 134, "GENE_OR_GENE_PRODUCT"], [203, 214, "PROTEIN"]]}
{"text": "Until today , six different strains of Human coronaviruses ( HCoVs ) have been reported , in addition to the newly emerged COVID-19 [ 2,12 ] . 229E and NL63 strains of HCoVs belong to Alphacoronaviruses while OC43 , HKU1 , SARS , MERS , and COVID-19 HCoVs belong to Betacoronaviruses [ 2,11 ] .", "labels": [[28, 36, "ORGANISM"], [39, 45, "ORGANISM"], [39, 45, "ENTITY"], [39, 45, "PROTEIN"], [28, 36, "PROTEIN"], [174, 184, "GENE_OR_GENE_PRODUCT"], [230, 241, "ENTITY"], [230, 241, "GENE_OR_GENE_PRODUCT"], [143, 157, "ORGANISM"], [115, 123, "ENTITY"], [174, 184, "ORGANISM"], [28, 36, "ENTITY"], [174, 184, "ENTITY"], [143, 157, "ENTITY"], [28, 36, "DISEASE"], [230, 241, "PROTEIN"], [174, 184, "ENTITY"], [115, 134, "GENE_OR_GENE_PRODUCT"], [203, 214, "PROTEIN"]]}
{"text": "Until today , six different strains of Human coronaviruses ( HCoVs ) have been reported , in addition to the newly emerged COVID-19 [ 2,12 ] . 229E and NL63 strains of HCoVs belong to Alphacoronaviruses while OC43 , HKU1 , SARS , MERS , and COVID-19 HCoVs belong to Betacoronaviruses [ 2,11 ] .", "labels": [[28, 36, "ORGANISM"], [39, 45, "ORGANISM"], [39, 45, "ENTITY"], [39, 45, "PROTEIN"], [28, 36, "PROTEIN"], [174, 184, "GENE_OR_GENE_PRODUCT"], [230, 241, "ENTITY"], [230, 241, "GENE_OR_GENE_PRODUCT"], [143, 157, "ORGANISM"], [115, 123, "ENTITY"], [174, 184, "ORGANISM"], [28, 36, "ENTITY"], [174, 184, "ENTITY"], [143, 157, "ENTITY"], [28, 36, "DISEASE"], [230, 241, "PROTEIN"], [174, 184, "ENTITY"], [115, 134, "GENE_OR_GENE_PRODUCT"], [203, 214, "PROTEIN"]]}
{"text": "Infection of HCoV-OC43 , VR-1558 , was inhibited only by EST and not by camostat ( Fig. 2b ) . This indicates that VR-1558 enters cells via the late endosome pathway using cysteine proteases and it does not use TMRPSS2 for cell entry in HBTE-ALI culture .", "labels": [[140, 149, "CELLULAR_COMPONENT"], [13, 23, "ENTITY"], [81, 88, "SIMPLE_CHEMICAL"], [228, 237, "CELL"], [123, 130, "CELL"], [123, 130, "ENTITY"], [140, 149, "GO"], [140, 158, "ENTITY"], [228, 246, "ENTITY"], [123, 130, "CL"], [166, 181, "ENTITY"], [228, 237, "CHEMICAL"], [219, 228, "ENTITY"], [228, 246, "CELL_LINE"], [13, 23, "TAXON"], [13, 23, "ORGANISM"], [0, 10, "ENTITY"], [110, 130, "CELL_LINE"], [166, 181, "PROTEIN"]]}
{"text": "Beside affecting the virus maturation process , pH modulation by chloroquine can impair the proper maturation of viral protein [ 32 ] and the recognition of viral antigen by dendritic cells , which occurs through a Toll-like receptor-dependent pathway that requires endosomal acidification [ 69 ] .", "labels": [[257, 266, "ENTITY"], [21, 27, "TAXON"], [113, 119, "PROTEIN"], [110, 119, "PROTEIN"], [257, 266, "GO"], [21, 46, "ENTITY"], [266, 276, "ENTITY"], [257, 266, "CELLULAR_COMPONENT"], [113, 119, "ENTITY"], [171, 184, "CL"], [7, 17, "ENTITY"], [110, 119, "ENTITY"], [113, 119, "TAXON"], [171, 184, "CELL"], [171, 184, "CELL_TYPE"], [205, 244, "ENTITY"], [205, 215, "GENE_OR_GENE_PRODUCT"], [171, 184, "ENTITY"]]}
{"text": "ECs showed extensive linkages with pericytes , with dominant role of angiopoietin ligands (ANGPT1/2)\u2013Tie receptor ( TIE2 ) interaction in normal heart , which could promote vascular EC survival and reduced vascular leakage .", "labels": [[11, 21, "ENTITY"], [0, 4, "ENTITY"], [69, 82, "ENTITY"], [138, 145, "ORGAN"], [198, 215, "ENTITY"], [35, 45, "ENTITY"], [0, 4, "CELL"], [69, 105, "GENE_OR_GENE_PRODUCT"], [0, 3, "ENTITY"], [198, 215, "DISEASE"], [165, 173, "CELL"], [165, 173, "ENTITY"], [0, 4, "CELL_TYPE"], [198, 206, "MULTI-TISSUE_STRUCTURE"], [35, 45, "CELL_TYPE"], [0, 4, "CL"], [135, 145, "ENTITY"], [35, 45, "CL"], [69, 105, "GGP"], [21, 30, "ENTITY"], [35, 45, "CELL"], [69, 105, "PROTEIN"]]}
{"text": "The entry of SARS-CoV into human host cells is mediated mainly by a cellular receptor angiotensin-converting enzyme 2 ( ACE2 ) , which is expressed in human airway epithelia , lung parenchyma , vascular endothelia , kidney cells , and small intestine cells 23 - 25 .", "labels": [[13, 22, "ORGANISM"], [27, 44, "TAXON"], [27, 33, "ENTITY"], [27, 44, "CELL_TYPE"], [203, 223, "CELL_TYPE"], [148, 164, "ORGANISM"], [181, 203, "ENTITY"], [4, 10, "ENTITY"], [229, 251, "CELL_TYPE"], [13, 22, "PROTEIN"], [68, 118, "ENTITY"], [27, 33, "ENTITY"], [203, 223, "ENTITY"], [13, 22, "GGP"], [68, 118, "GENE_OR_GENE_PRODUCT"], [68, 77, "CL"], [164, 181, "ENTITY"], [13, 22, "ENTITY"], [181, 203, "CELL_TYPE"], [164, 181, "MULTI-TISSUE_STRUCTURE"], [27, 44, "ORGANISM"], [68, 118, "PROTEIN"], [229, 241, "CELL"], [33, 44, "ENTITY"], [203, 223, "CELL"], [157, 164, "ENTITY"], [216, 223, "CL"], [181, 203, "TISSUE"], [229, 241, "ENTITY"]]}
{"text": "For those patients with most severe ARDS , extracorporeal membrane oxygenation or prone position is recommended .", "labels": [[82, 88, "ENTITY"], [29, 36, "ENTITY"], [10, 19, "ENTITY"], [43, 67, "ENTITY"], [36, 41, "ENTITY"], [10, 19, "ORGANISM"], [36, 41, "DISEASE"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 176, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [167, 174, "ENTITY"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 174, "GGP"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [167, 174, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [167, 176, "GENE_OR_GENE_PRODUCT"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [167, 176, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [167, 176, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "PROTEIN"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [354, 400, "PROTEIN"]]}
{"text": "Consistent with previous reports , 20mM NH4Cl and 100 nM bafilomycin A decreased entry of SARS-CoV S and VSV-G pseudovirions by over 99 % , compared to no treatment control .", "labels": [[105, 111, "ORGANISM"], [0, 16, "ENTITY"], [90, 99, "PROTEIN"], [35, 40, "SIMPLE_CHEMICAL"], [25, 33, "ENTITY"], [57, 69, "GGP"], [90, 99, "ENTITY"], [152, 165, "ENTITY"], [90, 99, "ORGANISM"]]}
{"text": "Consistent with previous reports , 20mM NH4Cl and 100 nM bafilomycin A decreased entry of SARS-CoV S and VSV-G pseudovirions by over 99 % , compared to no treatment control .", "labels": [[105, 111, "ORGANISM"], [0, 16, "ENTITY"], [90, 99, "PROTEIN"], [35, 40, "SIMPLE_CHEMICAL"], [25, 33, "ENTITY"], [90, 99, "ENTITY"], [152, 165, "ENTITY"], [57, 69, "GGP"], [90, 99, "ORGANISM"]]}
{"text": "In the herpes simplex virus ( HSV ) model , chloroquine inhibited budding with accumulation of non-infectious HSV-1 particles in the trans-Golgi network [ 66 ] .", "labels": [[133, 145, "ENTITY"], [56, 66, "ENTITY"], [7, 22, "DISEASE"], [7, 28, "ENTITY"], [22, 28, "TAXON"], [44, 56, "ENTITY"], [7, 28, "ORGANISM"], [92, 116, "ENTITY"], [129, 145, "TISSUE"], [95, 116, "ORGANISM"]]}
{"text": "All 74 patients with COVID-19 with GI symptoms were treated in isolation with supportive and empiric medication , while 66 ( 89.19 % ) patients received antiviral treatment , including interferon-\u03b1 sprays , arbidol hydrochloride capsules ( two tablets three times daily ) , lopinavir and ritonavir two tablets ( 500 mg ) twice daily , via the oral route .", "labels": [[175, 198, "ENTITY"], [7, 16, "ENTITY"], [52, 60, "ENTITY"], [7, 16, "ORGANISM"], [316, 321, "ENTITY"], [63, 73, "ENTITY"], [274, 288, "SIMPLE_CHEMICAL"], [327, 339, "ENTITY"], [35, 38, "ORGAN"], [144, 163, "ENTITY"], [274, 288, "CHEMICAL"], [198, 229, "ENTITY"], [207, 229, "CHEBI"], [274, 288, "ENTITY"], [93, 112, "ENTITY"], [264, 274, "SIMPLE_CHEMICAL"], [21, 30, "ENTITY"], [35, 47, "ENTITY"], [207, 229, "SIMPLE_CHEMICAL"], [78, 89, "ENTITY"], [264, 274, "CHEMICAL"], [21, 30, "GENE_OR_GENE_PRODUCT"], [207, 215, "CHEMICAL"], [288, 298, "ENTITY"], [264, 274, "ENTITY"], [238, 244, "ENTITY"], [327, 335, "ORGAN"]]}
{"text": "Both anti-N and anti-S3 anti-bodies were positive in all the serum samples , whereas anti-3a and anti-9b antibodies were only positive in part of these samples .", "labels": [[16, 36, "PROTEIN"], [5, 12, "ENTITY"], [61, 75, "ENTITY"], [41, 50, "ENTITY"], [16, 36, "ENTITY"], [97, 105, "PROTEIN"], [5, 12, "GENE_OR_GENE_PRODUCT"], [61, 75, "ORGANISM_SUBSTANCE"], [97, 105, "GENE_OR_GENE_PRODUCT"], [16, 24, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Early intravenous infusion of human immunoglobulin is recommended for critically ill patients , based on their clinical condition , at 0.25\u20130.5 g/(kg\u00b7d ) , for 3\u20135 days [ 6\u20137 ] .", "labels": [[30, 51, "ORGANISM"], [6, 18, "IMMATERIAL_ANATOMICAL_ENTITY"], [70, 85, "ENTITY"], [30, 51, "PROTEIN"], [85, 94, "ENTITY"], [36, 51, "ENTITY"], [85, 94, "ORGANISM"], [111, 120, "ENTITY"], [30, 51, "GGP"], [30, 36, "ENTITY"], [6, 27, "ENTITY"], [0, 6, "ENTITY"]]}
{"text": "Previous study done by this group has shown that infection of IBV induced the production of IL-6 and IL-8 , which was dependent on the phosphorylation of MAP kinase p38 ( Liao et al.,2011 ) .", "labels": [[92, 97, "ENTITY"], [78, 89, "ENTITY"], [28, 34, "ENTITY"], [62, 66, "PROTEIN"], [92, 97, "PROTEIN"], [49, 59, "DISEASE"], [92, 97, "GGP"], [154, 165, "GGP"], [49, 59, "ENTITY"], [62, 66, "ENTITY"], [101, 106, "PROTEIN"], [101, 106, "GGP"], [62, 66, "ORGANISM"], [101, 106, "ENTITY"], [154, 165, "PROTEIN"], [9, 15, "ENTITY"], [66, 74, "ENTITY"], [154, 165, "ENTITY"], [62, 66, "CHEMICAL"], [154, 165, "GENE_OR_GENE_PRODUCT"], [101, 106, "GENE_OR_GENE_PRODUCT"], [92, 97, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Previous study done by this group has shown that infection of IBV induced the production of IL-6 and IL-8 , which was dependent on the phosphorylation of MAP kinase p38 ( Liao et al.,2011 ) .", "labels": [[92, 97, "PROTEIN"], [101, 106, "ENTITY"], [78, 89, "ENTITY"], [28, 34, "ENTITY"], [62, 66, "PROTEIN"], [101, 106, "PROTEIN"], [101, 106, "GGP"], [49, 59, "DISEASE"], [92, 97, "GENE_OR_GENE_PRODUCT"], [101, 106, "GENE_OR_GENE_PRODUCT"], [154, 165, "GGP"], [49, 59, "ENTITY"], [92, 97, "GGP"], [92, 97, "ENTITY"], [62, 66, "ENTITY"], [62, 66, "ORGANISM"], [154, 165, "PROTEIN"], [9, 15, "ENTITY"], [66, 74, "ENTITY"], [154, 165, "ENTITY"], [62, 66, "CHEMICAL"], [154, 165, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Interestingly , a protein phosphatase called dual-specificity phosphatase 1 ( DUSP1 ) was also up-regulated in IBV-infected cells and dephosphorylated p38 to modulate pro-inflammatory cytokine production ( Liao et al. , 2011 ) .", "labels": [[108, 124, "ENTITY"], [134, 151, "GGP"], [108, 124, "CELL_TYPE"], [158, 184, "PROTEIN"], [134, 151, "PROTEIN"], [18, 26, "PROTEIN"], [45, 74, "PROTEIN"], [45, 74, "GENE_OR_GENE_PRODUCT"], [130, 151, "ENTITY"], [18, 26, "ENTITY"], [111, 124, "CL"], [134, 151, "GENE_OR_GENE_PRODUCT"], [111, 124, "CELL"], [167, 184, "ENTITY"], [158, 167, "ENTITY"], [45, 74, "ENTITY"]]}
{"text": "Interestingly , a protein phosphatase called dual-specificity phosphatase 1 ( DUSP1 ) was also up-regulated in IBV-infected cells and dephosphorylated p38 to modulate pro-inflammatory cytokine production ( Liao et al. , 2011 ) .", "labels": [[108, 124, "ENTITY"], [134, 151, "GGP"], [108, 124, "CELL_TYPE"], [158, 184, "PROTEIN"], [134, 151, "PROTEIN"], [18, 26, "PROTEIN"], [45, 74, "PROTEIN"], [45, 74, "GENE_OR_GENE_PRODUCT"], [130, 151, "ENTITY"], [18, 26, "ENTITY"], [111, 124, "CL"], [134, 151, "GENE_OR_GENE_PRODUCT"], [111, 124, "CELL"], [167, 184, "ENTITY"], [158, 167, "ENTITY"], [45, 74, "ENTITY"]]}
{"text": "In IBV-infected Vero cells , significant splicing of XBP1 mRNA was detected starting from 12 to 16 h post-infection till the late stage of infection . The mRNA levels of XBP1 effector genes ( EDEM1 , ERdj4 , and p58IPK ) were up-regulated in IBV-infected Vero cells", "labels": [[167, 184, "GGP"], [192, 200, "ENTITY"], [53, 58, "GGP"], [226, 242, "ENTITY"], [192, 200, "GGP"], [3, 21, "CELL"], [192, 200, "GENE_OR_GENE_PRODUCT"], [3, 16, "ENTITY"], [167, 184, "ENTITY"], [3, 27, "CELL_LINE"], [125, 130, "ENTITY"], [226, 260, "CELL_LINE"], [167, 184, "DNA"], [53, 58, "RNA"], [16, 21, "CL"], [3, 21, "ENTITY"], [16, 27, "ENTITY"], [21, 27, "CL"], [192, 200, "PROTEIN"], [16, 27, "CELL"]]}
{"text": "In IBV-infected Vero cells , significant splicing of XBP1 mRNA was detected starting from 12 to 16 h post-infection till the late stage of infection . The mRNA levels of XBP1 effector genes ( EDEM1 , ERdj4 , and p58IPK ) were up-regulated in IBV-infected Vero cells", "labels": [[167, 184, "GGP"], [53, 58, "RNA"], [226, 242, "ENTITY"], [3, 21, "CELL"], [3, 16, "ENTITY"], [3, 27, "CELL_LINE"], [125, 130, "ENTITY"], [53, 58, "GGP"], [226, 260, "CELL_LINE"], [167, 184, "DNA"], [192, 200, "GENE_OR_GENE_PRODUCT"], [192, 200, "ENTITY"], [16, 21, "CL"], [192, 200, "PROTEIN"], [3, 21, "ENTITY"], [16, 27, "ENTITY"], [21, 27, "CL"], [16, 27, "CELL"], [192, 200, "GGP"], [167, 184, "ENTITY"]]}
{"text": "In IBV-infected Vero cells , significant splicing of XBP1 mRNA was detected starting from 12 to 16 h post-infection till the late stage of infection . The mRNA levels of XBP1 effector genes ( EDEM1 , ERdj4 , and p58IPK ) were up-regulated in IBV-infected Vero cells", "labels": [[192, 200, "ENTITY"], [167, 184, "GGP"], [53, 58, "RNA"], [226, 242, "ENTITY"], [192, 200, "GGP"], [3, 21, "CELL"], [192, 200, "GENE_OR_GENE_PRODUCT"], [3, 16, "ENTITY"], [3, 27, "CELL_LINE"], [125, 130, "ENTITY"], [53, 58, "GGP"], [226, 260, "CELL_LINE"], [167, 184, "DNA"], [16, 21, "CL"], [3, 21, "ENTITY"], [16, 27, "ENTITY"], [21, 27, "CL"], [192, 200, "PROTEIN"], [16, 27, "CELL"], [167, 184, "ENTITY"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [111, 121, "CHEMICAL"], [30, 39, "ENTITY"], [0, 8, "DISEASE"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "ENTITY"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [0, 8, "ENTITY"], [111, 121, "CHEMICAL"], [30, 39, "ENTITY"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "DISEASE"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [0, 8, "ENTITY"], [111, 121, "CHEMICAL"], [30, 39, "ENTITY"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "DISEASE"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [0, 8, "ENTITY"], [111, 121, "CHEMICAL"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "DISEASE"], [30, 39, "ENTITY"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "Symptoms were relieved after inhalation of interferon-\u03b1 and supportive care", "labels": [[43, 56, "GENE_OR_GENE_PRODUCT"], [43, 56, "ENTITY"], [29, 40, "ENTITY"], [0, 9, "ENTITY"], [14, 23, "ENTITY"]]}
{"text": "The patient was treated with interferon\u2010\u03b1 inhalation and supportive care .", "labels": [[57, 73, "ENTITY"], [16, 29, "ENTITY"], [42, 53, "ENTITY"], [4, 12, "ENTITY"], [4, 12, "ORGANISM"]]}
{"text": "Fewer deceased patients ( 25 ; 22 % ) than recovered patients ( 64 ; 40 % ) received interferon \u03b1 inhalation treatment .", "labels": [[76, 85, "ENTITY"], [6, 15, "ENTITY"], [76, 85, "PROTEIN"], [43, 53, "ENTITY"], [15, 24, "ORGANISM"], [85, 98, "ENTITY"], [15, 24, "ENTITY"], [43, 53, "ORGANISM"], [98, 109, "ENTITY"]]}
{"text": "Vero E6 lack the capacity to produce IFN-I , but are able to respond to exogenous treatment Following pretreatment with IFN-I , SARS-CoV infection has a modest reduction in viral titer ( 1.5 log plaque forming units ( PFU ) as compared to untreated control 24 hours post infection ( Fig. 1B ) .", "labels": [[5, 8, "ENTITY"], [37, 43, "GGP"], [37, 43, "ENTITY"], [210, 218, "ENTITY"], [120, 137, "CHEMICAL"], [153, 179, "DISEASE"], [227, 239, "ENTITY"], [37, 43, "GENE_OR_GENE_PRODUCT"], [0, 8, "ORGANISM"], [170, 179, "ENTITY"], [266, 271, "DISEASE"], [260, 271, "ENTITY"], [17, 26, "ENTITY"], [0, 5, "ENTITY"], [153, 160, "ENTITY"], [249, 260, "ENTITY"], [187, 210, "ENTITY"], [37, 43, "PROTEIN"], [126, 137, "ENTITY"]]}
{"text": "Examining Vero cell protein lysates , we found that IFN-I treated cells infected with SARS-C oV-2 induced phosphorylated STAT-1 by 48 hours post infection ( Fig. 2 ) .", "labels": [[86, 93, "GENE_OR_GENE_PRODUCT"], [15, 28, "CL"], [10, 28, "PROTEIN"], [140, 145, "ENTITY"], [10, 20, "CELL"], [52, 66, "CELL_LINE"], [10, 36, "ENTITY"]]}
{"text": "Examining further , STAT1 , IFIT2 , and TRIM25 , known ISGs 17 , had increased protein expression in the context of SARS-CoV-2 infection following IFN SARS-CoV-2 infection relative to control likely due to the mRNA targeting activity of nonstructural protein 1 ( NSP1 ) 24 .", "labels": [[69, 87, "ENTITY"], [215, 225, "ENTITY"], [234, 251, "ENTITY"], [234, 251, "GENE_OR_GENE_PRODUCT"], [113, 127, "ENTITY"], [147, 162, "ENTITY"], [113, 127, "CHEMICAL"], [210, 215, "ENTITY"], [69, 79, "CHEBI"], [237, 251, "CHEBI"], [147, 162, "DISEASE"], [137, 151, "GGP"], [40, 49, "SO"], [234, 251, "PROTEIN"]]}
{"text": "Examining further , STAT1 , IFIT2 , and TRIM25 , known ISGs 17 , had increased protein expression in the context of SARS-CoV-2 infection following IFN SARS-CoV-2 infection relative to control likely due to the mRNA targeting activity of nonstructural protein 1 ( NSP1 ) 24 .", "labels": [[69, 87, "ENTITY"], [215, 225, "ENTITY"], [234, 251, "ENTITY"], [234, 251, "GENE_OR_GENE_PRODUCT"], [113, 127, "ENTITY"], [147, 162, "ENTITY"], [113, 127, "CHEMICAL"], [210, 215, "ENTITY"], [69, 79, "CHEBI"], [237, 251, "CHEBI"], [147, 162, "DISEASE"], [137, 151, "GGP"], [40, 49, "SO"], [234, 251, "PROTEIN"]]}
{"text": "NK cells highly expressed KLRF1 , KLRC1 and KLRD1 . CD8 + T cells expressed CD8A and CD8B .", "labels": [[16, 26, "GENE_OR_GENE_PRODUCT"], [50, 60, "GGP"], [26, 32, "PROTEIN"], [50, 60, "ENTITY"], [16, 26, "PROTEIN"], [26, 32, "ENTITY"], [0, 9, "CELL"], [26, 32, "GENE_OR_GENE_PRODUCT"], [0, 9, "CELL_TYPE"], [16, 26, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "CL"], [50, 60, "CELL_TYPE"], [16, 26, "ENTITY"], [26, 32, "GGP"], [3, 9, "ENTITY"]]}
{"text": "NK cells highly expressed KLRF1 , KLRC1 and KLRD1 . CD8 + T cells expressed CD8A and CD8B .", "labels": [[26, 32, "GGP"], [16, 26, "GENE_OR_GENE_PRODUCT"], [50, 60, "GGP"], [50, 60, "ENTITY"], [26, 32, "PROTEIN"], [16, 26, "PROTEIN"], [0, 9, "CELL"], [26, 32, "ENTITY"], [0, 9, "CELL_TYPE"], [16, 26, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "CL"], [50, 60, "CELL_TYPE"], [16, 26, "ENTITY"], [26, 32, "GENE_OR_GENE_PRODUCT"], [3, 9, "ENTITY"]]}
{"text": "NK cells highly expressed KLRF1 , KLRC1 and KLRD1 . CD8 + T cells expressed CD8A and CD8B .", "labels": [[26, 32, "GGP"], [16, 26, "GENE_OR_GENE_PRODUCT"], [50, 60, "GGP"], [50, 60, "ENTITY"], [26, 32, "PROTEIN"], [16, 26, "PROTEIN"], [0, 9, "CELL"], [26, 32, "ENTITY"], [0, 9, "CELL_TYPE"], [16, 26, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "CL"], [50, 60, "CELL_TYPE"], [16, 26, "ENTITY"], [26, 32, "GENE_OR_GENE_PRODUCT"], [3, 9, "ENTITY"]]}
{"text": "Considering the immunologic differences between adults and children , the IFN-\u03b3 induction by NK cells are higher in adults but has a lower threshold in children ( 11,37 ) .", "labels": [[59, 68, "ENTITY"], [59, 68, "ORGANISM"], [93, 96, "CELL_TYPE"], [16, 28, "ENTITY"], [48, 55, "ENTITY"], [93, 96, "CELL"], [93, 96, "CL"], [93, 96, "ENTITY"]]}
{"text": "Other commonly measured blood measures that may lead to altered ACE2 expression also included red cell distribution width ( often associated with iron-deficiency , folate or B12 deficiency anemia ) , basophil percentage ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) , calcium level , urate level , HDL-cholesterol and LDL cholesterol ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) .", "labels": [[-1, 14, "ENTITY"], [277, 293, "CHEMICAL"], [64, 69, "GGP"], [247, 255, "CHEBI"], [-1, 13, "CHEMICAL"], [247, 255, "SIMPLE_CHEMICAL"], [15, 24, "ENTITY"], [247, 255, "ENTITY"], [263, 269, "CHEBI"], [247, 255, "CHEMICAL"], [94, 103, "CELL"], [209, 222, "ENTITY"], [64, 69, "PROTEIN"], [-1, 13, "SIMPLE_CHEMICAL"], [171, 189, "ENTITY"], [263, 269, "CHEMICAL"], [-1, 13, "ENTITY"], [24, 30, "ORGANISM_SUBSTANCE"], [200, 209, "ENTITY"], [277, 293, "SIMPLE_CHEMICAL"], [94, 122, "ENTITY"], [-1, 14, "ENTITY"], [24, 39, "ENTITY"], [64, 69, "GENE_OR_GENE_PRODUCT"], [94, 103, "CL"], [277, 293, "ENTITY"], [171, 189, "CHEMICAL"], [-1, 13, "CHEBI"], [263, 269, "SIMPLE_CHEMICAL"], [-1, 12, "ENTITY"], [64, 69, "ENTITY"], [69, 80, "ENTITY"], [255, 263, "ENTITY"]]}
{"text": "Other commonly measured blood measures that may lead to altered ACE2 expression also included red cell distribution width ( often associated with iron-deficiency , folate or B12 deficiency anemia ) , basophil percentage ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) , calcium level , urate level , HDL-cholesterol and LDL cholesterol ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) .", "labels": [[-1, 14, "ENTITY"], [277, 293, "CHEMICAL"], [64, 69, "GGP"], [247, 255, "CHEBI"], [-1, 13, "CHEMICAL"], [247, 255, "SIMPLE_CHEMICAL"], [15, 24, "ENTITY"], [247, 255, "ENTITY"], [263, 269, "CHEBI"], [247, 255, "CHEMICAL"], [94, 103, "CELL"], [209, 222, "ENTITY"], [64, 69, "PROTEIN"], [-1, 13, "SIMPLE_CHEMICAL"], [171, 189, "ENTITY"], [263, 269, "CHEMICAL"], [-1, 13, "ENTITY"], [24, 30, "ORGANISM_SUBSTANCE"], [200, 209, "ENTITY"], [277, 293, "SIMPLE_CHEMICAL"], [94, 122, "ENTITY"], [-1, 14, "ENTITY"], [24, 39, "ENTITY"], [64, 69, "GENE_OR_GENE_PRODUCT"], [94, 103, "CL"], [277, 293, "ENTITY"], [171, 189, "CHEMICAL"], [-1, 13, "CHEBI"], [263, 269, "SIMPLE_CHEMICAL"], [-1, 12, "ENTITY"], [64, 69, "ENTITY"], [69, 80, "ENTITY"], [255, 263, "ENTITY"]]}
{"text": "Furthermore , the lesions occurred mainly in the lung confirmed by the HE staining and anti-spike protein of SARS-CoV-2 staining , with mild to moderate interstitial pneumonia characterized by thickened alveolar septa , accumulation of alveolar macrophages in the alveoli , degeneration of the alveolar epithelia , and infiltration of inflammatory cells ( Figure 3a ) .", "labels": [[233, 245, "CL"], [319, 348, "ENTITY"], [233, 245, "CELL_TYPE"], [348, 356, "ENTITY"], [290, 303, "TISSUE"], [109, 120, "ENTITY"], [144, 166, "DISEASE"], [87, 98, "ENTITY"], [335, 348, "CELL"], [233, 245, "ENTITY"], [264, 274, "ENTITY"], [144, 166, "ENTITY"], [319, 348, "CELL_TYPE"], [193, 212, "MULTI-TISSUE_STRUCTURE"], [290, 303, "ENTITY"], [348, 356, "GENE_OR_GENE_PRODUCT"], [166, 176, "ENTITY"], [190, 212, "ENTITY"], [233, 245, "CELL"], [335, 348, "CL"], [87, 98, "PROTEIN"]]}
{"text": "In comparison , one integrative therapy , Chinese herbal medicine ( CHM ) , is widely used in the treatment of COVID-19 , and was shown to be quite effective in preliminary clinical practice .", "labels": [[98, 111, "PROTEIN"], [98, 111, "ENTITY"], [20, 32, "ENTITY"], [98, 111, "DISEASE"], [161, 182, "ENTITY"], [40, 57, "ENTITY"], [98, 111, "SIMPLE_CHEMICAL"], [3, 14, "ENTITY"]]}
{"text": "Thus , cancer patients diagnosed with mild or medium COVID-19 should be encouraged to receive CHM therapies .", "labels": [[7, 14, "CANCER"]]}
{"text": "Other reported therapeutic agents that are used for the treatment of seriously ill patients have been noted in Table 1 .", "labels": [[79, 83, "ENTITY"], [83, 92, "ENTITY"], [83, 92, "ORGANISM"], [15, 34, "ENTITY"], [56, 66, "ENTITY"]]}
{"text": "Furthermore , RNA synthesis inhibitors ( like 3TC , TDF ) , remdesivir , neuraminidase inhibitors , peptide ( EK1 ) , anti-inflammatory drugs , abidol , Chinese traditional medicine , such as Lianhuaqingwen and ShuFengJieDu Capsules , could be the promising COVID-19 treatments.2", "labels": [[14, 18, "ENTITY"], [87, 100, "ENTITY"], [108, 118, "ENTITY"], [87, 100, "SO"], [118, 136, "ENTITY"], [248, 258, "CHEMICAL"], [244, 258, "PROTEIN"], [192, 211, "ORGANISM"], [60, 100, "SIMPLE_CHEMICAL"], [60, 87, "ENTITY"], [60, 87, "CHEBI"], [173, 192, "ENTITY"], [192, 211, "ENTITY"]]}
{"text": "Antibiotics , traditional Chinese medicine , intravenous glucocorticoids and immunoglobulin were also used dependent on patients \u2019 conditions .", "labels": [[45, 57, "CHEMICAL"], [0, 12, "ENTITY"], [0, 12, "CHEBI"], [43, 57, "ENTITY"], [45, 57, "CHEBI"], [43, 57, "ORGANISM_SUBSTANCE"], [26, 34, "ENTITY"]]}
{"text": "Also , according to Jian-ya et al. , treatment of 51 COVID-19 patients with traditional Chinese medicine , interferon , Lopinavir , Ritonavir and short-term ( 3 to 5 days ) corticosteroids was successful and resulted in recovery and discharge of 50 patients ( 3 ) .", "labels": [[166, 173, "ENTITY"], [220, 233, "ENTITY"], [53, 62, "ENTITY"], [50, 62, "ORGANISM"], [243, 249, "ENTITY"], [107, 120, "SIMPLE_CHEMICAL"], [120, 132, "SIMPLE_CHEMICAL"], [120, 132, "ENTITY"], [120, 132, "CHEMICAL"], [107, 120, "CHEMICAL"], [208, 220, "ENTITY"], [107, 120, "ENTITY"], [76, 96, "ENTITY"], [243, 249, "ORGANISM"], [166, 173, "SIMPLE_CHEMICAL"]]}
{"text": "Until today , six different strains of Human coronaviruses ( HCoVs ) have been reported , in addition to the newly emerged COVID-19 [ 2,12 ] . 229E and NL63 strains of HCoVs belong to Alphacoronaviruses while OC43 , HKU1 , SARS , MERS , and COVID-19 HCoVs belong to Betacoronaviruses [ 2,11 ] .", "labels": [[28, 36, "ORGANISM"], [39, 45, "ORGANISM"], [39, 45, "ENTITY"], [39, 45, "PROTEIN"], [28, 36, "PROTEIN"], [174, 184, "GENE_OR_GENE_PRODUCT"], [230, 241, "ENTITY"], [230, 241, "GENE_OR_GENE_PRODUCT"], [143, 157, "ORGANISM"], [115, 123, "ENTITY"], [174, 184, "ORGANISM"], [28, 36, "ENTITY"], [174, 184, "ENTITY"], [143, 157, "ENTITY"], [28, 36, "DISEASE"], [230, 241, "PROTEIN"], [174, 184, "ENTITY"], [115, 134, "GENE_OR_GENE_PRODUCT"], [203, 214, "PROTEIN"]]}
{"text": "Upon infection with MERS-CoV , diabetic DPP4H/M mice developed weight loss , and had a prolonged phase of severe disease and delayed recovery .", "labels": [[40, 48, "ENTITY"], [20, 29, "PROTEIN"], [20, 29, "GGP"], [63, 70, "ENTITY"], [31, 40, "DISEASE"], [63, 70, "DISEASE"], [125, 133, "ENTITY"], [20, 29, "ENTITY"], [5, 15, "ENTITY"], [5, 15, "DISEASE"], [87, 97, "ENTITY"]]}
{"text": "Consistently , the mRNA level of homocysteine-inducible , ER stress-inducible , ubiquitin-like domain member 1 ( HERPUD1 ) , an ER stress marker , was up-regulated in L cells infected with mouse hepatitis virus ( MHV ) or SARS-CoV ( Versteeg et al. , 2007 ) .", "labels": [[0, 13, "ENTITY"], [175, 195, "ORGANISM"], [151, 167, "CL"], [213, 219, "ORGANISM"], [151, 167, "CELL"], [175, 184, "TAXON"], [167, 175, "ENTITY"], [175, 195, "ENTITY"], [58, 61, "ENTITY"], [213, 219, "GGP"], [61, 102, "ENTITY"], [184, 195, "DISEASE"], [151, 167, "CELL_TYPE"], [121, 138, "PROTEIN"], [213, 219, "PROTEIN"], [61, 102, "PROTEIN"], [213, 219, "ENTITY"], [121, 138, "ENTITY"], [138, 151, "ENTITY"], [151, 167, "ENTITY"], [80, 95, "SO"]]}
{"text": "The EDEMosomes are COPII-independent vesicles that export from the ER , which are normally used to fine-tune the level of ER degradation enhancer , mannosidase alpha-like 1 ( degradation enhancer, mannosidase alpha-like 1 ) , a regulator of ER-associated degradation ( ERAD;Cal\u00ec et al. , 2008 ) . It has been demonstrated that MHV infection causes accumulation of degradation enhancer, mannosidase alpha-like 1 and osteosarcoma amplified 9 ( OS-9 , another EDEMosome cargo),and that both degradation enhancer, mannosidase alpha-like 1 and OS-9 co-localize with the RTCs of MHV ( Reggiori et al. , 2010 ) .", "labels": [[281, 290, "ENTITY"], [228, 247, "DISEASE"], [67, 70, "GENE_OR_GENE_PRODUCT"], [160, 171, "GGP"], [148, 160, "GENE_OR_GENE_PRODUCT"], [125, 137, "ENTITY"], [160, 171, "ENTITY"], [19, 46, "ENTITY"], [125, 137, "ENTITY"], [4, 15, "ENTITY"], [51, 58, "ENTITY"], [37, 46, "CELLULAR_COMPONENT"], [256, 268, "ENTITY"], [146, 171, "GGP"], [148, 160, "ENTITY"], [148, 160, "PROTEIN"], [-1, 21, "GENE_OR_GENE_PRODUCT"], [-1, 21, "ENTITY"], [67, 70, "ENTITY"], [241, 247, "ENTITY"], [181, 187, "GENE_OR_GENE_PRODUCT"], [160, 171, "PROTEIN"], [146, 171, "GENE_OR_GENE_PRODUCT"], [146, 171, "PROTEIN"], [148, 160, "GGP"], [-1, 21, "GO"], [281, 307, "GENE_OR_GENE_PRODUCT"], [228, 238, "TAXON"], [160, 171, "GENE_OR_GENE_PRODUCT"], [281, 290, "DISEASE"], [146, 171, "ENTITY"], [125, 137, "DNA"], [228, 238, "ORGANISM"], [160, 171, "ENTITY"], [4, 15, "PROTEIN"], [67, 70, "PROTEIN"], [4, 15, "GENE_OR_GENE_PRODUCT"], [181, 187, "ENTITY"], [360, 367, "SIMPLE_CHEMICAL"], [122, 137, "DNA"], [228, 238, "ENTITY"]]}
{"text": "The EDEMosomes are COPII-independent vesicles that export from the ER , which are normally used to fine-tune the level of ER degradation enhancer , mannosidase alpha-like 1 ( degradation enhancer, mannosidase alpha-like 1 ) , a regulator of ER-associated degradation ( ERAD;Cal\u00ec et al. , 2008 ) . It has been demonstrated that MHV infection causes accumulation of degradation enhancer, mannosidase alpha-like 1 and osteosarcoma amplified 9 ( OS-9 , another EDEMosome cargo),and that both degradation enhancer, mannosidase alpha-like 1 and OS-9 co-localize with the RTCs of MHV ( Reggiori et al. , 2010 ) .", "labels": [[281, 290, "ENTITY"], [228, 247, "DISEASE"], [67, 70, "GENE_OR_GENE_PRODUCT"], [160, 171, "GGP"], [148, 160, "GENE_OR_GENE_PRODUCT"], [125, 137, "ENTITY"], [160, 171, "ENTITY"], [19, 46, "ENTITY"], [125, 137, "ENTITY"], [4, 15, "ENTITY"], [37, 46, "CELLULAR_COMPONENT"], [51, 58, "ENTITY"], [256, 268, "ENTITY"], [146, 171, "GGP"], [148, 160, "ENTITY"], [148, 160, "PROTEIN"], [-1, 21, "GENE_OR_GENE_PRODUCT"], [-1, 21, "ENTITY"], [67, 70, "ENTITY"], [241, 247, "ENTITY"], [181, 187, "GENE_OR_GENE_PRODUCT"], [160, 171, "PROTEIN"], [146, 171, "GENE_OR_GENE_PRODUCT"], [146, 171, "PROTEIN"], [148, 160, "GGP"], [-1, 21, "GO"], [281, 307, "GENE_OR_GENE_PRODUCT"], [228, 238, "TAXON"], [160, 171, "GENE_OR_GENE_PRODUCT"], [281, 290, "DISEASE"], [146, 171, "ENTITY"], [4, 15, "GENE_OR_GENE_PRODUCT"], [125, 137, "DNA"], [228, 238, "ORGANISM"], [4, 15, "PROTEIN"], [160, 171, "ENTITY"], [67, 70, "PROTEIN"], [181, 187, "ENTITY"], [360, 367, "SIMPLE_CHEMICAL"], [122, 137, "DNA"], [228, 238, "ENTITY"]]}
{"text": "\u03b2-Hydroxcytidine was the most potent inhibitor of the nonIFNs evaluated , with IC50=0.1 \u00b5M , but it was not as potent in reducing virus yields ( IC90=6 \u00b5M ) .", "labels": [[79, 88, "PROTEIN"], [0, 17, "SIMPLE_CHEMICAL"], [37, 47, "ENTITY"], [62, 72, "ENTITY"], [143, 152, "PROTEIN"], [0, 17, "CHEMICAL"], [0, 17, "ENTITY"], [121, 130, "TAXON"], [37, 47, "CHEBI"], [54, 62, "ENTITY"], [54, 62, "DNA"], [121, 130, "ENTITY"]]}
{"text": "The reduced expressions of interferon-\u03b3 ( IFN-\u03b3 ) by CD4+T , CD8+T and NK cells below LLN were observed in some patients with severe ( 50 % , 16.7 % and 16.7 % ) or moderate COVID-19 ( 14.3 % , 0 % and 14.3 % ) .", "labels": [[27, 40, "ENTITY"], [165, 174, "ENTITY"], [27, 40, "GENE_OR_GENE_PRODUCT"], [4, 12, "ENTITY"], [27, 40, "PROTEIN"], [165, 174, "GENE_OR_GENE_PRODUCT"], [67, 74, "ENTITY"], [67, 74, "CELL"], [12, 24, "ENTITY"], [67, 74, "CL"], [153, 165, "ENTITY"]]}
{"text": "Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation , caffeine , and antibiotics .", "labels": [[137, 147, "ENTITY"], [66, 72, "MULTI-TISSUE_STRUCTURE"], [66, 91, "ENTITY"], [9, 39, "DISEASE"], [9, 39, "ENTITY"], [126, 131, "ENTITY"], [43, 53, "ENTITY"], [0, 9, "ENTITY"], [43, 53, "DISEASE"], [116, 120, "ENTITY"], [152, 176, "ENTITY"], [94, 104, "ENTITY"]]}
{"text": "Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation , caffeine , and antibiotics .", "labels": [[137, 147, "ENTITY"], [66, 72, "MULTI-TISSUE_STRUCTURE"], [66, 91, "ENTITY"], [9, 39, "DISEASE"], [43, 53, "DISEASE"], [126, 131, "ENTITY"], [0, 9, "ENTITY"], [116, 120, "ENTITY"], [9, 39, "ENTITY"], [152, 176, "ENTITY"], [43, 53, "ENTITY"], [94, 104, "ENTITY"]]}
{"text": "Patients with hypoxemia should be given oxygen therapy immediately and maintain a blood oxygen saturation level to no less than 90 % in man and non-pregnant women , and between 92 % and 95 % in pregnant women .", "labels": [[40, 47, "CHEMICAL"], [40, 47, "CHEBI"], [14, 24, "DISEASE"], [148, 157, "ORGANISM"], [40, 47, "SIMPLE_CHEMICAL"], [144, 157, "ORGANISM"], [191, 203, "ENTITY"], [40, 55, "ENTITY"], [40, 47, "CHEMICAL"], [0, 9, "ENTITY"], [0, 9, "ORGANISM"], [40, 47, "CHEBI"], [82, 95, "ORGANISM_SUBSTANCE"], [106, 112, "ENTITY"], [82, 106, "ENTITY"], [14, 24, "ENTITY"]]}
{"text": "The patient recovered after treatment with antiviral 50 therapy ( Arbidol ) and supportive care .", "labels": [[43, 64, "ENTITY"], [4, 12, "ENTITY"], [4, 12, "ORGANISM"], [28, 38, "ENTITY"], [12, 22, "ENTITY"], [76, 91, "ENTITY"]]}
{"text": "Symptoms were relieved after inhalation of interferon-\u03b1 and supportive care", "labels": [[29, 40, "ENTITY"], [0, 9, "ENTITY"], [43, 56, "GENE_OR_GENE_PRODUCT"], [14, 23, "ENTITY"], [43, 56, "ENTITY"]]}
{"text": "The patient was treated with interferon\u2010\u03b1 inhalation and supportive care .", "labels": [[16, 29, "ENTITY"], [42, 53, "ENTITY"], [57, 73, "ENTITY"], [4, 12, "ENTITY"], [4, 12, "ORGANISM"]]}
{"text": "Symptoms improved after antiviral treatment ( Arbidol ) and supportive care", "labels": [[56, 71, "ENTITY"], [0, 9, "ENTITY"], [9, 18, "ENTITY"], [24, 44, "ENTITY"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [111, 121, "CHEMICAL"], [30, 39, "ENTITY"], [0, 8, "DISEASE"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "ENTITY"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [0, 8, "ENTITY"], [111, 121, "CHEMICAL"], [30, 39, "ENTITY"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "DISEASE"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [0, 8, "ENTITY"], [111, 121, "CHEMICAL"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "DISEASE"], [30, 39, "ENTITY"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "All 74 patients with COVID-19 with GI symptoms were treated in isolation with supportive and empiric medication , while 66 ( 89.19 % ) patients received antiviral treatment , including interferon-\u03b1 sprays , arbidol hydrochloride capsules ( two tablets three times daily ) , lopinavir and ritonavir two tablets ( 500 mg ) twice daily , via the oral route .", "labels": [[175, 198, "ENTITY"], [7, 16, "ENTITY"], [52, 60, "ENTITY"], [7, 16, "ORGANISM"], [316, 321, "ENTITY"], [274, 288, "SIMPLE_CHEMICAL"], [327, 339, "ENTITY"], [35, 38, "ORGAN"], [144, 163, "ENTITY"], [274, 288, "CHEMICAL"], [198, 229, "ENTITY"], [207, 229, "CHEBI"], [274, 288, "ENTITY"], [63, 73, "ENTITY"], [93, 112, "ENTITY"], [264, 274, "SIMPLE_CHEMICAL"], [21, 30, "ENTITY"], [35, 47, "ENTITY"], [207, 229, "SIMPLE_CHEMICAL"], [78, 89, "ENTITY"], [264, 274, "CHEMICAL"], [21, 30, "GENE_OR_GENE_PRODUCT"], [207, 215, "CHEMICAL"], [288, 298, "ENTITY"], [264, 274, "ENTITY"], [238, 244, "ENTITY"], [327, 335, "ORGAN"]]}
{"text": "However , the viral RNA copies in the VeroE6/TMPRSS2 cell culture supernatants were > 100 times greater than those from VeroE6 cells ( Fig. 1 D and E ) .", "labels": [[14, 20, "RNA"], [115, 127, "ENTITY"], [38, 58, "ENTITY"], [133, 140, "CELL"], [14, 20, "TAXON"], [115, 127, "CELL_LINE"], [115, 127, "CELL"], [38, 53, "CELL"], [38, 45, "CL"], [38, 58, "CELL_LINE"], [14, 24, "ENTITY"]]}
{"text": "Three deceased patients received continuous renal replacement therapy .", "labels": [[6, 15, "ENTITY"], [33, 70, "ENTITY"], [15, 24, "ORGANISM"], [44, 50, "ORGAN"], [15, 24, "ENTITY"]]}
{"text": "Until today , six different strains of Human coronaviruses ( HCoVs ) have been reported , in addition to the newly emerged COVID-19 [ 2,12 ] . 229E and NL63 strains of HCoVs belong to Alphacoronaviruses while OC43 , HKU1 , SARS , MERS , and COVID-19 HCoVs belong to Betacoronaviruses [ 2,11 ] .", "labels": [[28, 36, "ORGANISM"], [39, 45, "ORGANISM"], [39, 45, "ENTITY"], [39, 45, "PROTEIN"], [28, 36, "PROTEIN"], [174, 184, "GENE_OR_GENE_PRODUCT"], [230, 241, "ENTITY"], [230, 241, "GENE_OR_GENE_PRODUCT"], [143, 157, "ORGANISM"], [115, 123, "ENTITY"], [174, 184, "ORGANISM"], [28, 36, "ENTITY"], [174, 184, "ENTITY"], [143, 157, "ENTITY"], [28, 36, "DISEASE"], [230, 241, "PROTEIN"], [174, 184, "ENTITY"], [115, 134, "GENE_OR_GENE_PRODUCT"], [203, 214, "PROTEIN"]]}
{"text": "According to Zhou and colleagues , in coronaviruses , teicoplanin acts on the early step of the viral life cycle by inhibiting the low pH cleavage of the viral spike protein by cathepsin L in the late endosomes thereby preventing the release of genomic viral RNA and the continuation of virus replication cycle .", "labels": [[150, 166, "ENTITY"], [92, 107, "ENTITY"], [13, 18, "ENTITY"], [160, 166, "CHEBI"], [174, 187, "GENE_OR_GENE_PRODUCT"], [22, 33, "ENTITY"], [242, 259, "ENTITY"], [192, 201, "CELLULAR_COMPONENT"], [174, 187, "ENTITY"], [174, 187, "GGP"], [174, 187, "PROTEIN"], [150, 166, "PROTEIN"], [192, 201, "GO"], [135, 138, "ENTITY"], [131, 135, "ENTITY"], [242, 259, "SO"], [284, 305, "ENTITY"], [242, 259, "RNA"], [192, 201, "ENTITY"]]}
{"text": "For coronaviruses , their receptor binding and subsequent internalization mainly depend on the spike protein ( S protein ) anchored in the viral envelope .", "labels": [[135, 145, "ENTITY"], [109, 113, "ENTITY"], [95, 101, "ENTITY"], [95, 101, "PROTEIN"], [4, 18, "PROTEIN"], [26, 35, "ENTITY"], [109, 113, "PROTEIN"], [135, 145, "TAXON"], [4, 18, "ORGANISM"], [4, 18, "ENTITY"]]}
{"text": "According to Zhou and colleagues , in coronaviruses , teicoplanin acts on the early step of the viral life cycle by inhibiting the low pH cleavage of the viral spike protein by cathepsin L in the late endosomes thereby preventing the release of genomic viral RNA and the continuation of virus replication cycle .", "labels": [[150, 166, "ENTITY"], [13, 18, "ENTITY"], [160, 166, "CHEBI"], [174, 187, "GENE_OR_GENE_PRODUCT"], [22, 33, "ENTITY"], [242, 259, "ENTITY"], [192, 201, "CELLULAR_COMPONENT"], [174, 187, "ENTITY"], [174, 187, "GGP"], [174, 187, "PROTEIN"], [150, 166, "PROTEIN"], [192, 201, "GO"], [135, 138, "ENTITY"], [131, 135, "ENTITY"], [242, 259, "SO"], [284, 305, "ENTITY"], [92, 107, "ENTITY"], [242, 259, "RNA"], [192, 201, "ENTITY"]]}
{"text": "Since lymphocytopenia is often seen in severe COVID-19 patients , the CRS caused by SARS-CoV-2 virus has to be mediated by leukocytes other than T cells , as in patients receiving CAR-T therapy ; a high WBC-count is common , suggesting it , in association with lymphocytopenia , as a differential diagnostic criterion for COVID-19 .", "labels": [[55, 64, "ENTITY"], [239, 244, "ENTITY"], [170, 180, "CHEMICAL"], [84, 95, "GENE_OR_GENE_PRODUCT"], [198, 203, "ENTITY"], [46, 64, "SIMPLE_CHEMICAL"], [6, 22, "ENTITY"], [308, 322, "PROTEIN"], [84, 95, "ENTITY"], [39, 46, "ENTITY"], [46, 55, "ENTITY"], [308, 322, "GENE_OR_GENE_PRODUCT"], [284, 308, "ENTITY"], [6, 22, "DISEASE"], [170, 186, "ENTITY"], [170, 180, "CELL_TYPE"], [170, 180, "CELL"], [198, 203, "GENE_OR_GENE_PRODUCT"], [46, 55, "DISEASE"], [308, 322, "ENTITY"]]}
{"text": "One caveat is that MSCs need to be activated by IFN\u03b3 to exert their anti-inflammatory effects , which may be absent in severely affected patients as T cells are not well activated by SARS-CoV-2 infection .", "labels": [[48, 53, "PROTEIN"], [19, 24, "CHEMICAL"], [19, 24, "TAXON"], [19, 24, "ENTITY"], [48, 53, "GENE_OR_GENE_PRODUCT"], [68, 94, "ENTITY"], [48, 53, "ENTITY"], [35, 45, "ENTITY"], [183, 194, "DISEASE"], [183, 194, "ENTITY"], [19, 24, "CELL"], [19, 24, "CELL_TYPE"]]}
{"text": "DPP4 plays also an important role in immune regulation by activating T cells and upregulating CD86 expression and NF-\u03baB pathway .", "labels": [[94, 99, "GENE_OR_GENE_PRODUCT"], [69, 77, "CELL"], [69, 77, "CL"], [94, 99, "ENTITY"], [99, 110, "ENTITY"], [37, 55, "ENTITY"], [58, 77, "ENTITY"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [0, 5, "PROTEIN"], [81, 94, "ENTITY"], [0, 5, "ENTITY"], [69, 77, "CELL_TYPE"], [94, 99, "PROTEIN"], [114, 120, "DNA"], [114, 120, "CHEMICAL"], [114, 120, "GENE_OR_GENE_PRODUCT"], [114, 128, "ENTITY"]]}
{"text": "Studies have shown that IL-6 levels significantly correlated with the severity of COVID-19 , C-reactive protein ( CRP ) , lactate dehydrogenase ( LDH ) , and D-dimer levels and T cell counts , and it has been suggested that Tocilizumab , with its inhibitory effect on IL-6 , may be effective in treatment of COVID-19 ( 10 , 11 ) .", "labels": [[152, 158, "GGP"], [295, 305, "GENE_OR_GENE_PRODUCT"], [238, 247, "ENTITY"], [82, 91, "ENTITY"], [24, 29, "GGP"], [152, 166, "ENTITY"], [118, 130, "GGP"], [70, 79, "ENTITY"], [152, 158, "PROTEIN"], [93, 104, "GGP"], [118, 130, "PROTEIN"], [166, 177, "ENTITY"], [130, 144, "GENE_OR_GENE_PRODUCT"], [50, 61, "ENTITY"], [24, 29, "GENE_OR_GENE_PRODUCT"], [282, 295, "ENTITY"], [130, 144, "PROTEIN"], [24, 29, "ENTITY"], [82, 91, "PROTEIN"], [295, 305, "ENTITY"], [177, 184, "ENTITY"], [152, 158, "GENE_OR_GENE_PRODUCT"], [0, 8, "ENTITY"], [130, 144, "ENTITY"], [118, 130, "ENTITY"], [118, 130, "GENE_OR_GENE_PRODUCT"], [166, 177, "CL"], [24, 29, "PROTEIN"], [166, 177, "CELL"], [273, 282, "ENTITY"], [93, 104, "ENTITY"], [209, 224, "ENTITY"], [209, 224, "SIMPLE_CHEMICAL"], [82, 91, "GENE_OR_GENE_PRODUCT"], [93, 104, "PROTEIN"], [29, 36, "ENTITY"]]}
{"text": "Interestingly , the concentration of these three cytokines was negatively correlated with total T cell counts , CD4 + counts , and CD8 + counts , respectively ( Figure 2B ) .", "labels": [[146, 161, "ENTITY"], [110, 118, "ENTITY"], [90, 98, "ENTITY"], [127, 137, "ENTITY"], [110, 116, "GGP"]]}
{"text": "Interestingly , serum levels of IFN-\u03b3 , IL-10 , IL-6 and TNF-\u03b1 were significantly decreased in these patients in the decline period as compared with illness period , while counts of total T cells , CD4 + , and CD8 + T cell subsets recovered during the decline period ( Figure 2C ) .", "labels": [[117, 125, "ENTITY"], [182, 190, "CL"], [68, 82, "ENTITY"], [182, 190, "CELL"], [16, 22, "ENTITY"], [260, 269, "ENTITY"], [206, 218, "GGP"], [149, 157, "ENTITY"], [206, 223, "ENTITY"], [117, 125, "ENTITY"], [190, 198, "ENTITY"], [179, 190, "CELL_TYPE"], [179, 190, "ENTITY"], [190, 223, "CELL_TYPE"], [190, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "FACs analysis illustrated that , T cells from COVID-19 patients have markedly higher levels of PD-1 compared to healthy controls ( Figure 3A ) .", "labels": [[0, 5, "CELL"], [129, 138, "ENTITY"], [0, 5, "ENTITY"], [5, 14, "ENTITY"], [46, 55, "ORGANISM"], [112, 120, "ENTITY"]]}
{"text": "As demonstrated in vitro , TMPRSS2 , a serine protease inhibitor blocks SARS-CoV-2 S protein-driven entry into cells ( 30 ) .", "labels": [[65, 72, "CHEMICAL"], [39, 55, "CHEBI"], [37, 46, "GENE_OR_GENE_PRODUCT"], [16, 25, "ENTITY"], [65, 83, "ENTITY"], [37, 46, "ENTITY"], [65, 83, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Interestingly , ZDHHC5 also has a published role in allowing anthrax toxin to enter cells , suggesting that inhibition of this enzyme could have broad utility [ 37 ] .", "labels": [[61, 69, "DISEASE"], [61, 69, "ENTITY"], [61, 69, "ORGANISM"]]}
{"text": "Invasive mechanical ventilation was needed in 17 ( 15 % ) deceased patients , one of whom received extracorporeal membrane pulmonary oxygenation as rescue therapy .", "labels": [[145, 155, "ENTITY"], [9, 32, "ENTITY"], [0, 9, "ENTITY"], [90, 133, "ENTITY"], [58, 67, "ORGANISM"], [58, 67, "ENTITY"]]}
{"text": "Antiviral ( oseltamivir , 75 mg twice a day ; ribavirin , 0.5 g twice a day ; umifenovir , 0.2 g 3 times a day ) , antibacterial ( moxifloxacin , 0.4 g every day ) , glucocorticoid ( methylprednisolone , 40 - 80 mg every day ) , and respiratory support were the main treatment approaches for the hospitalized patients ( Table 1 ) .", "labels": [[166, 183, "CHEBI"], [99, 105, "ENTITY"], [115, 131, "SIMPLE_CHEMICAL"], [0, 10, "ENTITY"], [166, 183, "ENTITY"], [166, 183, "CHEMICAL"], [166, 183, "SIMPLE_CHEMICAL"], [32, 40, "ENTITY"], [115, 131, "CHEMICAL"], [146, 152, "ENTITY"], [152, 166, "ENTITY"], [215, 233, "ENTITY"], [245, 267, "ENTITY"], [152, 166, "SIMPLE_CHEMICAL"], [277, 288, "ENTITY"], [107, 115, "ENTITY"], [115, 131, "ENTITY"]]}
{"text": "All patients received antiviral treatments ( virazole , oseltamivir and interferon ) .", "labels": [[22, 43, "ENTITY"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "On the contrary , other proposed effects of chloroquine on the immune system include increasing the export of soluble antigens into the cytosol of dendritic cells and the enhancement of human cytotoxic CD8 + T-cell responses against viral antigens [ 70 ] .", "labels": [[225, 239, "ENTITY"], [186, 208, "CELL_TYPE"], [33, 41, "ENTITY"], [110, 118, "PROTEIN"], [147, 157, "CELL"], [147, 157, "CELL_TYPE"], [202, 208, "ENTITY"], [147, 157, "ENTITY"], [63, 70, "ENTITY"], [147, 157, "CL"], [225, 239, "PROTEIN"], [208, 215, "ENTITY"]]}
{"text": "Actual bicarbonate and total carbon dioxide concentration were markedly lower in deceased patients than in recovered patients .", "labels": [[29, 44, "CHEMICAL"], [81, 90, "ENTITY"], [44, 58, "ENTITY"], [0, 7, "ENTITY"], [107, 117, "ENTITY"], [7, 19, "CHEBI"], [90, 99, "ORGANISM"], [29, 44, "CHEBI"], [90, 99, "ORGANISM"], [90, 99, "ENTITY"], [72, 78, "ENTITY"], [9, 16, "ENTITY"], [7, 19, "CHEMICAL"], [7, 19, "ENTITY"], [7, 19, "SIMPLE_CHEMICAL"], [90, 99, "ENTITY"]]}
{"text": "Compared with patients without ARDS , for patients with ARDS , the value of liver damage indices ( total bilirubin [ difference , 1.90mg/dL ; 95%CI , 0.60 - 3.30 mg/dL ; P = .004 ] ) , renal dysfunction indices ( urea [ difference , 1.69 mM ; 95 % CI , 1.10 - 2.29mM;P < .001 ] ) , inflammation-related indices ( interleukin- 6 [ IL-6 ] [ difference , 0.93 pg/L ; 95%CI , 0.07 - 1.98 pg/L ; P = .03 ] ) , and coagulation function indices ( D-dimer [ difference , 0.52 \u03bcg/mL ; 95 % CI , 0.21 - 0.94 \u03bcg/mL ; P < .001 ] ) were significantly elevated .", "labels": [[99, 105, "GGP"], [403, 409, "ENTITY"], [258, 282, "ENTITY"], [31, 36, "ENTITY"], [194, 203, "CHEMICAL"], [14, 23, "ENTITY"], [403, 409, "PROTEIN"], [0, 9, "ENTITY"], [73, 89, "ENTITY"], [409, 421, "ENTITY"], [73, 82, "DISEASE"], [191, 203, "CHEMICAL"], [99, 105, "SIMPLE_CHEMICAL"], [172, 191, "ENTITY"], [191, 203, "CHEBI"], [31, 36, "DISEASE"], [89, 99, "ENTITY"], [130, 142, "CHEMICAL"], [191, 203, "ENTITY"], [105, 117, "ENTITY"], [14, 23, "ORGANISM"], [372, 401, "ENTITY"], [99, 105, "CHEMICAL"], [97, 105, "ENTITY"], [403, 409, "GGP"]]}
{"text": "For patients with ARDS who died , the value of liver damage indices ( total bilirubin [ difference , 2.60 mg/dL ; 95 % CI , 0.30 - 5.20mg/dL;P = .03 ] ) , renal dysfunction indices ( urea [ difference , 1.50 mM ; 95%CI , 0.50 - 2.70 mM ; P = .004 ] ) , inflammation- related indices ( IL-6 [ difference , 3.88 pg/L ; 95 % CI , 2.20 - 6.13pg/L;P < .001 ] ) , and coagulation function indices ( Ddimer [ difference , 2.10 \u03bcg/mL ; 95 % CI , 0.89 - 5.27 \u03bcg/mL ; P = .001 ] ) were significantly elevated compared with patients with ARDS who survived .", "labels": [[60, 70, "ENTITY"], [47, 60, "ENTITY"], [161, 173, "ENTITY"], [292, 310, "SIMPLE_CHEMICAL"], [469, 476, "ENTITY"], [68, 76, "ENTITY"], [327, 356, "ENTITY"], [70, 76, "CHEMICAL"], [161, 173, "CHEBI"], [469, 476, "ORGANISM"], [70, 76, "SIMPLE_CHEMICAL"], [4, 13, "ENTITY"], [267, 275, "ENTITY"], [88, 99, "CHEMICAL"], [18, 23, "ENTITY"], [47, 53, "DISEASE"], [88, 101, "CHEMICAL"], [143, 161, "ENTITY"], [18, 23, "DISEASE"], [143, 161, "DISEASE"], [70, 76, "GGP"], [161, 173, "CHEMICAL"], [27, 32, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Concentrations of alanine aminotransferase , aspartate aminotransferase , total bilirubin , alkaline phosphatase , and \u03b3-glutamyl transpeptidase were markedly higher in deceased patients than in recovered patients", "labels": [[115, 130, "PROTEIN"], [45, 55, "CHEBI"], [90, 101, "PROTEIN"], [18, 43, "PROTEIN"], [195, 205, "ENTITY"], [18, 43, "ENTITY"], [0, 15, "ENTITY"], [115, 130, "ENTITY"], [18, 43, "GENE_OR_GENE_PRODUCT"], [115, 130, "GENE_OR_GENE_PRODUCT"], [74, 80, "CHEMICAL"], [74, 80, "PROTEIN"], [18, 26, "CHEBI"], [45, 55, "GENE_OR_GENE_PRODUCT"], [169, 178, "ORGANISM"], [90, 101, "SIMPLE_CHEMICAL"], [74, 80, "GGP"], [195, 205, "ORGANISM"], [74, 80, "SIMPLE_CHEMICAL"], [72, 80, "ENTITY"], [169, 178, "ENTITY"], [45, 55, "PROTEIN"], [18, 26, "CHEMICAL"], [90, 101, "ENTITY"], [45, 55, "ENTITY"]]}
{"text": "Other commonly measured blood measures that may lead to altered ACE2 expression also included red cell distribution width ( often associated with iron-deficiency , folate or B12 deficiency anemia ) , basophil percentage ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) , calcium level , urate level , HDL-cholesterol and LDL cholesterol ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) .", "labels": [[-1, 14, "ENTITY"], [277, 293, "CHEMICAL"], [64, 69, "GGP"], [-1, 13, "CHEMICAL"], [15, 24, "ENTITY"], [263, 269, "CHEBI"], [247, 255, "ENTITY"], [247, 255, "SIMPLE_CHEMICAL"], [247, 255, "CHEBI"], [94, 103, "CELL"], [209, 222, "ENTITY"], [64, 69, "PROTEIN"], [-1, 13, "SIMPLE_CHEMICAL"], [171, 189, "ENTITY"], [263, 269, "CHEMICAL"], [-1, 13, "ENTITY"], [24, 30, "ORGANISM_SUBSTANCE"], [200, 209, "ENTITY"], [277, 293, "SIMPLE_CHEMICAL"], [247, 255, "CHEMICAL"], [94, 122, "ENTITY"], [-1, 14, "ENTITY"], [24, 39, "ENTITY"], [64, 69, "GENE_OR_GENE_PRODUCT"], [94, 103, "CL"], [277, 293, "ENTITY"], [171, 189, "CHEMICAL"], [-1, 13, "CHEBI"], [263, 269, "SIMPLE_CHEMICAL"], [-1, 12, "ENTITY"], [64, 69, "ENTITY"], [69, 80, "ENTITY"], [255, 263, "ENTITY"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "Patients infected with COVID-19 showed higher leukocyte numbers , abnormal respiratory findings , and increased levels of plasma pro-inflammatory cytokines .", "labels": [[23, 32, "GENE_OR_GENE_PRODUCT"], [46, 56, "CELL"], [39, 46, "ENTITY"], [102, 112, "ENTITY"], [46, 56, "CL"], [119, 146, "PROTEIN"], [129, 146, "ENTITY"], [122, 129, "ENTITY"], [23, 32, "PROTEIN"], [23, 32, "DISEASE"], [46, 56, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "ORGANISM"], [75, 87, "ENTITY"], [23, 32, "ENTITY"], [9, 18, "ENTITY"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [164, 171, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "SIMPLE_CHEMICAL"], [362, 377, "GENE_OR_GENE_PRODUCT"], [164, 171, "PROTEIN"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [102, 108, "PROTEIN"], [164, 171, "GGP"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [133, 164, "GENE_OR_GENE_PRODUCT"], [133, 164, "PROTEIN"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [33, 41, "DNA"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [299, 330, "GGP"], [377, 389, "PROTEIN"], [164, 171, "ENTITY"], [33, 41, "CHEMICAL"], [33, 41, "ENTITY"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Additionally , in severe cases , a reduction of CD4 + and CD8 + T cells and a decrease of regulatory T cells has been found , likely due to high expression of proinflammatory cytokines in COVID-19 patients [ 3 ] .", "labels": [[145, 175, "ENTITY"], [87, 103, "CL"], [72, 78, "ENTITY"], [87, 103, "CELL_TYPE"], [175, 197, "GENE_OR_GENE_PRODUCT"], [90, 103, "CELL"], [87, 103, "ENTITY"], [54, 66, "ENTITY"], [175, 188, "ENTITY"], [54, 66, "GGP"], [145, 175, "PROTEIN"], [140, 145, "ENTITY"], [188, 197, "ENTITY"], [45, 66, "CELL_TYPE"]]}
{"text": "Additionally , in severe cases , a reduction of CD4 + and CD8 + T cells and a decrease of regulatory T cells has been found , likely due to high expression of proinflammatory cytokines in COVID-19 patients [ 3 ] .", "labels": [[145, 175, "ENTITY"], [87, 103, "CL"], [72, 78, "ENTITY"], [87, 103, "CELL_TYPE"], [175, 197, "GENE_OR_GENE_PRODUCT"], [90, 103, "CELL"], [87, 103, "ENTITY"], [54, 66, "ENTITY"], [175, 188, "ENTITY"], [54, 66, "GGP"], [145, 175, "PROTEIN"], [140, 145, "ENTITY"], [188, 197, "ENTITY"], [45, 66, "CELL_TYPE"]]}
{"text": "Additionally , in severe cases , a reduction of CD4 + and CD8 + T cells and a decrease of regulatory T cells has been found , likely due to high expression of proinflammatory cytokines in COVID-19 patients [ 3 ] .", "labels": [[87, 103, "ENTITY"], [145, 175, "ENTITY"], [72, 78, "ENTITY"], [87, 103, "CELL_TYPE"], [175, 197, "GENE_OR_GENE_PRODUCT"], [87, 103, "CL"], [54, 66, "ENTITY"], [90, 103, "CELL"], [175, 188, "ENTITY"], [54, 66, "GGP"], [145, 175, "PROTEIN"], [140, 145, "ENTITY"], [188, 197, "ENTITY"], [45, 66, "CELL_TYPE"]]}
{"text": "Specifically , sirolimus and dactinomycin may inhibit both mTOR signaling and RNA synthesis pathway ( including DNA topoisomerase 2-alpha ( TOP2A ) and DNA topoisomerase 2-beta ( TOP2B ) ) in HCoV-infected cells ( Fig. 6b ) .", "labels": [[148, 170, "ENTITY"], [148, 170, "GENE_OR_GENE_PRODUCT"], [170, 179, "GGP"], [170, 179, "ENTITY"], [185, 192, "ENTITY"], [78, 92, "ENTITY"], [102, 112, "SO"], [102, 130, "PROTEIN"], [170, 179, "PROTEIN"], [185, 192, "CELL_LINE"], [170, 179, "GENE_OR_GENE_PRODUCT"], [102, 130, "GENE_OR_GENE_PRODUCT"], [185, 192, "CELL"], [102, 130, "ENTITY"], [148, 170, "PROTEIN"]]}
{"text": "Specifically , sirolimus and dactinomycin may inhibit both mTOR signaling and RNA synthesis pathway ( including DNA topoisomerase 2-alpha ( TOP2A ) and DNA topoisomerase 2-beta ( TOP2B ) ) in HCoV-infected cells ( Fig. 6b ) .", "labels": [[148, 170, "ENTITY"], [148, 170, "GENE_OR_GENE_PRODUCT"], [170, 179, "GGP"], [170, 179, "ENTITY"], [185, 192, "ENTITY"], [78, 92, "ENTITY"], [102, 112, "SO"], [102, 130, "PROTEIN"], [170, 179, "PROTEIN"], [185, 192, "CELL_LINE"], [102, 130, "GENE_OR_GENE_PRODUCT"], [170, 179, "GENE_OR_GENE_PRODUCT"], [185, 192, "CELL"], [102, 130, "ENTITY"], [148, 170, "PROTEIN"]]}
{"text": "Specifically , sirolimus and dactinomycin may inhibit both mTOR signaling and RNA synthesis pathway ( including DNA topoisomerase 2-alpha ( TOP2A ) and DNA topoisomerase 2-beta ( TOP2B ) ) in HCoV-infected cells ( Fig. 6b ) .", "labels": [[148, 170, "ENTITY"], [148, 170, "GENE_OR_GENE_PRODUCT"], [170, 179, "GGP"], [170, 179, "ENTITY"], [185, 192, "ENTITY"], [78, 92, "ENTITY"], [102, 112, "SO"], [102, 130, "PROTEIN"], [170, 179, "PROTEIN"], [185, 192, "CELL_LINE"], [102, 130, "GENE_OR_GENE_PRODUCT"], [170, 179, "GENE_OR_GENE_PRODUCT"], [185, 192, "CELL"], [102, 130, "ENTITY"], [148, 170, "PROTEIN"]]}
{"text": "Specifically , sirolimus and dactinomycin may inhibit both mTOR signaling and RNA synthesis pathway ( including DNA topoisomerase 2-alpha ( TOP2A ) and DNA topoisomerase 2-beta ( TOP2B ) ) in HCoV-infected cells ( Fig. 6b ) .", "labels": [[148, 170, "ENTITY"], [148, 170, "GENE_OR_GENE_PRODUCT"], [170, 179, "GGP"], [170, 179, "ENTITY"], [185, 192, "ENTITY"], [78, 92, "ENTITY"], [102, 112, "SO"], [102, 130, "PROTEIN"], [170, 179, "PROTEIN"], [185, 192, "CELL_LINE"], [102, 130, "GENE_OR_GENE_PRODUCT"], [170, 179, "GENE_OR_GENE_PRODUCT"], [185, 192, "CELL"], [102, 130, "ENTITY"], [148, 170, "PROTEIN"]]}
{"text": "The eosinophil values of patients 1 , 2 and 3 were all less than the lower bound of normal range before they were transferred to the First Affiliated Hospital of Zhejiang University ( Figure 4 ) .", "labels": [[15, 22, "ENTITY"], [4, 15, "CL"], [25, 34, "ORGANISM"], [4, 15, "ENTITY"], [84, 91, "ENTITY"], [4, 15, "CELL_TYPE"], [4, 15, "CELL"], [25, 36, "ENTITY"], [182, 191, "ENTITY"]]}
{"text": "The blood counts of patients on admission showed decrease in neutrophils ( 26 [ 39 % ] of 67 patients ) , lymphocytes ( 28 [ 42 % ] of 67 patients ) , and eosinophils ( 48 [ 72 % ] of 67 patients ) , among which , the number of eosinophils in 31 patients was zero .", "labels": [[179, 191, "CELL"], [-1, 11, "ENTITY"], [130, 147, "CELL_TYPE"], [264, 270, "ENTITY"], [117, 128, "ENTITY"], [-1, 18, "ENTITY"], [130, 147, "CL"], [14, 21, "ENTITY"], [264, 270, "ORGANISM"], [-1, 18, "CELL"], [179, 191, "CELL_TYPE"], [130, 147, "CELL"], [179, 191, "ENTITY"], [-1, 18, "CL"], [130, 147, "ENTITY"], [242, 252, "ENTITY"], [242, 252, "CELL"], [-1, 18, "CELL_TYPE"], [242, 252, "CELL_TYPE"], [-1, 11, "ORGANISM"], [6, 12, "ORGANISM_SUBSTANCE"], [117, 128, "ORGANISM"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [126, 150, "DISEASE"], [219, 230, "DISEASE"], [126, 150, "ENTITY"], [7, 14, "ENTITY"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "The inflammatory biomarkers , including high sensitivity C-reactive protein ( median [ IQR ] , 8.55 [ 4.87- 15.165 ] vs 3.13 [1.24 - 5.75]mg/dL [ to convert to milligrams per liter , multiply by 10 ] ) , procalcitonin ( median [ IQR ] , 0.21 [ 0.11- 0.45 ] vs 0.05 [ 0.04 - 0.11 ] ng/mL ) , and globulin ( median [IQR],29.7 [ 27.0 - 34.6 ] vs 27.4 [ 25.6 - 29.6 ] grams per liter ) were significantly higher in patientswith elevated TnT levels ( P < .001 for all ) .", "labels": [[117, 133, "CHEMICAL"], [4, 17, "ENTITY"], [287, 295, "SIMPLE_CHEMICAL"], [183, 204, "ENTITY"], [387, 401, "PROTEIN"], [57, 68, "PROTEIN"], [183, 204, "GENE_OR_GENE_PRODUCT"], [40, 45, "ENTITY"], [183, 204, "GGP"], [387, 401, "GENE_OR_GENE_PRODUCT"], [287, 306, "CHEMICAL"], [374, 387, "ENTITY"], [57, 68, "ENTITY"], [401, 408, "ENTITY"], [387, 401, "ENTITY"], [149, 160, "ENTITY"], [17, 28, "ENTITY"], [117, 133, "SIMPLE_CHEMICAL"], [287, 295, "ENTITY"], [57, 68, "GGP"]]}
{"text": "The damaged cells induce innate inflammation in the lungs that is largely mediated by pro-inflammatory macrophages and granulocytes . Lung inflammation is the main cause of life-threatening respiratory disorders at the severe stage [ 4 ] .", "labels": [[4, 18, "CELL_TYPE"], [103, 115, "CELL"], [86, 115, "CELL_TYPE"], [119, 132, "CELL_TYPE"], [134, 139, "ENTITY"], [190, 202, "DISEASE"], [219, 226, "ENTITY"], [4, 18, "ENTITY"], [119, 132, "CELL"], [12, 18, "CELL"], [18, 25, "ENTITY"], [52, 58, "ENTITY"], [52, 58, "ORGAN"], [86, 115, "ENTITY"], [190, 202, "ENTITY"], [119, 132, "CL"], [119, 132, "ENTITY"], [25, 45, "ENTITY"], [12, 18, "CL"], [32, 45, "DISEASE"], [86, 115, "CL"]]}
{"text": "Therapeutic options include steroids , intravenous immunoglobulin , selective cytokine blockade ( eg , anakinra or tocilizumab ) and JAK inhibition .", "labels": [[68, 78, "PROTEIN"], [28, 37, "CHEMICAL"], [39, 51, "ENTITY"], [68, 78, "ENTITY"], [39, 51, "PROTEIN"], [98, 103, "CHEMICAL"], [12, 20, "ENTITY"], [28, 37, "ENTITY"], [28, 37, "CHEBI"], [0, 12, "ENTITY"], [78, 87, "ENTITY"], [98, 103, "SIMPLE_CHEMICAL"], [28, 37, "SIMPLE_CHEMICAL"], [39, 51, "ORGANISM_SUBSTANCE"], [133, 137, "ENTITY"], [98, 103, "ENTITY"]]}
{"text": "We also observed that starting insulin within one year of diagnosis , which was only assessed within diabetic subjects , was casually associated with increased ACE2 expression .", "labels": [[8, 17, "ENTITY"], [150, 160, "ENTITY"], [31, 39, "GGP"], [58, 68, "ENTITY"], [160, 165, "ENTITY"], [31, 39, "PROTEIN"], [31, 39, "ENTITY"], [50, 55, "ENTITY"], [150, 160, "GENE_OR_GENE_PRODUCT"], [31, 39, "GENE_OR_GENE_PRODUCT"], [150, 160, "PROTEIN"], [150, 160, "GGP"], [125, 145, "ENTITY"]]}
{"text": "Integrins are heterodimeric cell surface receptors that play roles in cell adhesion , cell migration , and cell signaling processes ( Hynes , 2002 ) .", "labels": [[0, 10, "PROTEIN"], [0, 10, "TAXON"], [28, 41, "CELLULAR_COMPONENT"], [0, 10, "ENTITY"], [70, 84, "ENTITY"], [28, 33, "CELL"], [14, 51, "PROTEIN"], [28, 33, "ENTITY"], [0, 10, "GENE_OR_GENE_PRODUCT"], [28, 33, "CL"], [14, 51, "ENTITY"], [28, 33, "CL"], [103, 122, "ENTITY"]]}
{"text": "Integrins are heterodimeric cell surface receptors that play roles in cell adhesion , cell migration , and cell signaling processes ( Hynes , 2002 ) .", "labels": [[0, 10, "PROTEIN"], [70, 84, "ENTITY"], [0, 10, "ENTITY"], [28, 41, "CELLULAR_COMPONENT"], [28, 33, "CELL"], [14, 51, "PROTEIN"], [103, 122, "ENTITY"], [28, 33, "ENTITY"], [0, 10, "GENE_OR_GENE_PRODUCT"], [28, 33, "CL"], [14, 51, "ENTITY"], [28, 33, "CL"], [0, 10, "TAXON"]]}
{"text": "Integrins are heterodimeric cell surface receptors that play roles in cell adhesion , cell migration , and cell signaling processes ( Hynes , 2002 ) .", "labels": [[0, 10, "PROTEIN"], [70, 84, "ENTITY"], [0, 10, "ENTITY"], [28, 41, "CELLULAR_COMPONENT"], [28, 33, "CELL"], [14, 51, "PROTEIN"], [28, 33, "ENTITY"], [103, 122, "ENTITY"], [0, 10, "GENE_OR_GENE_PRODUCT"], [28, 33, "CL"], [14, 51, "ENTITY"], [28, 33, "CL"], [0, 10, "TAXON"]]}
{"text": "> 10 * 10 ^ 9/L group were strongly related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.604 , P3<0.001 , R2 = 0.543 , P4<0.001 ) .", "labels": [[61, 79, "DISEASE"], [14, 18, "ENTITY"], [61, 79, "ENTITY"], [89, 103, "ENTITY"]]}
{"text": "Compared with normal range , the whole blood count on admission of three ( 30 % ) moderatevcases showed mild leucopenia , while white blood cell ( WBC ) counts were normal or slightly increased above the upper limit of normal ( ULN ) in all the severe cases ( Table 2 ) .", "labels": [[140, 145, "ENTITY"], [14, 27, "ENTITY"], [128, 140, "CELL"], [140, 145, "PROTEIN"], [97, 109, "ENTITY"], [122, 140, "ENTITY"], [104, 109, "DISEASE"], [140, 145, "SIMPLE_CHEMICAL"], [33, 45, "ENTITY"], [175, 184, "ENTITY"], [0, 9, "ENTITY"], [122, 140, "CELL_TYPE"], [128, 140, "CL"], [147, 153, "ENTITY"]]}
{"text": "Compared with normal range , the whole blood count on admission of three ( 30 % ) moderatevcases showed mild leucopenia , while white blood cell ( WBC ) counts were normal or slightly increased above the upper limit of normal ( ULN ) in all the severe cases ( Table 2 ) .", "labels": [[140, 145, "ENTITY"], [14, 27, "ENTITY"], [128, 140, "CELL"], [140, 145, "PROTEIN"], [97, 109, "ENTITY"], [122, 140, "ENTITY"], [104, 109, "DISEASE"], [140, 145, "SIMPLE_CHEMICAL"], [33, 45, "ENTITY"], [175, 184, "ENTITY"], [0, 9, "ENTITY"], [122, 140, "CELL_TYPE"], [128, 140, "CL"], [147, 153, "ENTITY"]]}
{"text": "Patients with elevated TnT levels presented with significantly higher white blood cell count(median[IQR],4640[6170- 3740 ] vs 7390 [ 4890 - 11 630 ] /\u03bcL [ to convert to \u00d7109 per liter , multiply by0.001])and neutrophil counts ( median [IQR],3070 [ 2350 - 4870 ] vs 6010 [ 3540 - 10 120 ] /\u03bcL [ to convert to \u00d7109 per liter , multiply by 0.001 ] ) ( P < .001 for both ) and lower lymphocyte counts ( median [ IQR ] , 840 [ 630 - 1130 ] vs 690 [ 340- 1010 ] /\u03bcL [ toconvert to \u00d7 109 per liter , multiplyby0.001;P = .01 ) than those with normal TnT levels ( Table 2 ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [27, 34, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [195, 208, "CELL"], [456, 475, "PROTEIN"], [195, 208, "CELL_TYPE"], [76, 121, "CELL"], [158, 166, "PROTEIN"], [373, 379, "ENTITY"], [358, 367, "CL"], [23, 27, "PROTEIN"], [93, 100, "PROTEIN"], [0, 9, "ORGANISM"], [76, 87, "CL"], [70, 87, "ENTITY"], [93, 100, "ENTITY"], [228, 248, "CHEMICAL"], [0, 9, "ENTITY"], [351, 367, "CELL"], [456, 475, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"], [358, 367, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"], [195, 208, "CL"]]}
{"text": "Remarkably , in SJIA patients , the pulmonary involvement triggers a hyper-inflammatory reaction and occurrence of secondary haemophagocytic lymphohistiocytosis ( sHLH ) , since the up-regulation of IFN-signature , IL-1\u03b2 and IL-6 may be observed [ 5,8 ] .", "labels": [[141, 163, "ENTITY"], [115, 141, "DISEASE"], [172, 182, "ENTITY"], [67, 88, "ENTITY"], [112, 141, "ENTITY"], [199, 213, "CHEMICAL"], [115, 125, "CHEBI"], [182, 199, "PROTEIN"], [215, 221, "GGP"], [36, 46, "ENTITY"], [215, 221, "PROTEIN"], [199, 213, "PROTEIN"], [141, 163, "GENE_OR_GENE_PRODUCT"], [215, 221, "ENTITY"], [199, 213, "ENTITY"], [215, 221, "GENE_OR_GENE_PRODUCT"], [199, 213, "GENE_OR_GENE_PRODUCT"], [182, 199, "ENTITY"], [182, 199, "GENE_OR_GENE_PRODUCT"], [199, 213, "GGP"]]}
{"text": "Remarkably , in SJIA patients , the pulmonary involvement triggers a hyper-inflammatory reaction and occurrence of secondary haemophagocytic lymphohistiocytosis ( sHLH ) , since the up-regulation of IFN-signature , IL-1\u03b2 and IL-6 may be observed [ 5,8 ] .", "labels": [[141, 163, "ENTITY"], [115, 141, "DISEASE"], [172, 182, "ENTITY"], [141, 163, "GENE_OR_GENE_PRODUCT"], [67, 88, "ENTITY"], [112, 141, "ENTITY"], [199, 213, "CHEMICAL"], [115, 125, "CHEBI"], [182, 199, "PROTEIN"], [215, 221, "GGP"], [36, 46, "ENTITY"], [215, 221, "PROTEIN"], [199, 213, "PROTEIN"], [215, 221, "ENTITY"], [199, 213, "ENTITY"], [215, 221, "GENE_OR_GENE_PRODUCT"], [199, 213, "GENE_OR_GENE_PRODUCT"], [182, 199, "ENTITY"], [182, 199, "GENE_OR_GENE_PRODUCT"], [199, 213, "GGP"]]}
{"text": "The blood counts of patients on admission showed decrease in neutrophils ( 26 [ 39 % ] of 67 patients ) , lymphocytes ( 28 [ 42 % ] of 67 patients ) , and eosinophils ( 48 [ 72 % ] of 67 patients ) , among which , the number of eosinophils in 31 patients was zero .", "labels": [[179, 191, "CELL_TYPE"], [-1, 11, "ENTITY"], [130, 147, "ENTITY"], [264, 270, "ENTITY"], [117, 128, "ENTITY"], [-1, 18, "ENTITY"], [14, 21, "ENTITY"], [264, 270, "ORGANISM"], [-1, 18, "CELL"], [130, 147, "CL"], [-1, 18, "CL"], [179, 191, "CELL"], [242, 252, "ENTITY"], [242, 252, "CELL"], [-1, 18, "CELL_TYPE"], [242, 252, "CELL_TYPE"], [130, 147, "CELL_TYPE"], [179, 191, "ENTITY"], [-1, 11, "ORGANISM"], [6, 12, "ORGANISM_SUBSTANCE"], [117, 128, "ORGANISM"], [130, 147, "CELL"]]}
{"text": "From our data of more than 600 NCP patients in Jiangsu Province , age , lymphocyte count , oxygen supplementation and aggressive pulmonary radiographic infiltrations are independent risk factors for NCP progressing to a critical condition .", "labels": [[218, 229, "ENTITY"], [31, 35, "CHEMICAL"], [70, 83, "ENTITY"], [89, 98, "ENTITY"], [35, 44, "ENTITY"], [114, 152, "DISEASE"], [9, 14, "ENTITY"], [170, 187, "ENTITY"], [118, 152, "ENTITY"], [47, 64, "ENTITY"], [31, 35, "ENTITY"], [118, 129, "ORGAN"], [47, 64, "ORGANISM"]]}
{"text": "The lymphocyte numbers of the patients were estimated from the routine blood test data at the time of admission or initial diagnosis . Spearman \u2019s correlation statistical analysis was performed on lymphocyte numbers and CT staging with results of p<0.05 and r\u00bc\u00010.780 , suggesting a moderate negative correlation between the two .", "labels": [[123, 133, "ENTITY"], [4, 15, "ENTITY"], [115, 123, "ENTITY"], [71, 82, "ENTITY"], [291, 300, "ENTITY"], [135, 171, "ENTITY"], [63, 71, "ENTITY"], [30, 39, "ENTITY"], [94, 102, "ENTITY"], [102, 112, "ENTITY"], [30, 39, "ORGANISM"], [82, 87, "ENTITY"], [282, 291, "ENTITY"], [135, 144, "GENE_OR_GENE_PRODUCT"], [4, 15, "ENTITY"], [4, 15, "CL"], [216, 223, "ENTITY"], [4, 15, "CELL"], [71, 77, "ORGANISM_SUBSTANCE"], [15, 23, "ENTITY"]]}
{"text": "Laboratory findings of the 3 patients ( Supplementary Table 3 ) indicated cell count reduction of various types of immune cells including lymphocytes in patients \u2019 blood .", "labels": [[29, 38, "ORGANISM"], [153, 164, "ENTITY"], [128, 138, "CELL"], [0, 11, "ENTITY"], [64, 79, "ENTITY"], [112, 122, "CELL_TYPE"], [112, 122, "CELL"], [79, 85, "ENTITY"], [40, 60, "ENTITY"], [112, 122, "ENTITY"], [128, 138, "ENTITY"], [128, 138, "CELL_TYPE"], [128, 138, "CL"], [112, 122, "CL"], [29, 38, "ENTITY"], [11, 20, "ENTITY"]]}
{"text": "Lower lymphocyte count was strongly related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = -0.451 , P3<0.001 , R2 = -0.415 , P4<0.001 ) .", "labels": [[65, 87, "DISEASE"], [0, 17, "CELL"], [47, 54, "ENTITY"], [6, 17, "CL"], [6, 17, "ENTITY"], [65, 77, "ORGANISM"], [91, 110, "ENTITY"], [65, 87, "ENTITY"], [0, 6, "ENTITY"], [17, 23, "ENTITY"]]}
{"text": "All immune cell types , including dendritic cells , were decreased significantly ( P < 0.01 ) , and CD68 positive macrophages , which were decreased in number , were noticeably ( P < 0.01 ) increased in size and gave the impression of macrophage activation ( Fig. 2 , D and E ) .", "labels": [[4, 22, "ENTITY"], [34, 44, "CL"], [221, 235, "CELL"], [105, 114, "CL"], [11, 16, "CL"], [94, 114, "CELL_TYPE"], [212, 221, "ENTITY"], [259, 264, "ENTITY"], [105, 114, "CELL"], [4, 16, "CELL"], [34, 44, "CELL"], [221, 246, "ENTITY"], [100, 105, "ENTITY"], [34, 44, "CELL_TYPE"], [128, 139, "ENTITY"], [221, 235, "GGP"], [34, 44, "ENTITY"]]}
{"text": "The damaged cells induce innate inflammation in the lungs that is largely mediated by pro-inflammatory macrophages and granulocytes . Lung inflammation is the main cause of life-threatening respiratory disorders at the severe stage [ 4 ] .", "labels": [[86, 115, "ENTITY"], [4, 18, "CELL_TYPE"], [103, 115, "CELL"], [119, 132, "ENTITY"], [134, 139, "ENTITY"], [190, 202, "DISEASE"], [219, 226, "ENTITY"], [4, 18, "ENTITY"], [12, 18, "CELL"], [119, 132, "CELL"], [18, 25, "ENTITY"], [52, 58, "ENTITY"], [52, 58, "ORGAN"], [190, 202, "ENTITY"], [119, 132, "CELL_TYPE"], [25, 45, "ENTITY"], [12, 18, "CL"], [32, 45, "DISEASE"], [86, 115, "CL"], [119, 132, "CL"], [86, 115, "CELL_TYPE"]]}
{"text": "The expression of TMPRSS2 across cell types of the lung ( further referred to as TMPRSS2 + cells ) was much stronger with a certain specificity for AT2 cells ( Fig. 1E ) , which is in agreement with previous studies .", "labels": [[18, 26, "PROTEIN"], [152, 160, "CELL"], [18, 26, "GENE_OR_GENE_PRODUCT"], [51, 56, "ORGAN"], [144, 152, "CELL"], [51, 56, "ENTITY"], [144, 152, "ENTITY"], [148, 152, "CL"], [33, 38, "CL"], [81, 91, "CELL_TYPE"], [81, 91, "ENTITY"], [18, 26, "GGP"], [33, 44, "ENTITY"], [81, 91, "GGP"], [81, 91, "GENE_OR_GENE_PRODUCT"], [199, 208, "ENTITY"], [18, 26, "ENTITY"], [4, 15, "ENTITY"], [33, 38, "CELL"], [144, 152, "CELL_TYPE"]]}
{"text": "In lung tissue , AT2 , endothelial , and immune cells were most strongly positive for FURIN expression ( Fig. 3A ) .", "labels": [[37, 48, "CELL"], [86, 92, "ENTITY"], [3, 15, "TISSUE"], [41, 48, "CL"], [64, 73, "ENTITY"], [3, 15, "ENTITY"], [37, 48, "CELL_TYPE"], [37, 48, "ENTITY"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Mortality was markedly higher in patients with elevated plasma TnT levels than in patients with normal TnT levels ( 31 [59.6%]vs 12 [ 8.9 % ] ) ( Table 1 ) .", "labels": [[47, 56, "ENTITY"], [63, 67, "ENTITY"], [67, 74, "ENTITY"], [33, 42, "ENTITY"], [67, 74, "ENTITY"], [63, 67, "PROTEIN"], [0, 10, "ENTITY"], [56, 63, "ENTITY"], [33, 42, "ENTITY"], [56, 67, "ORGANISM_SUBSTANCE"], [33, 42, "ORGANISM"], [63, 67, "GENE_OR_GENE_PRODUCT"], [63, 67, "PROTEIN"], [23, 30, "ENTITY"], [63, 67, "ENTITY"], [33, 42, "ORGANISM"]]}
{"text": "Both TnT and NT-proBNP levels increased significantly during the course of hospitalization in those who ultimately died , but no such dynamic changes of TnT or NT-proBNP levels were evident in survivors .", "labels": [[5, 9, "GENE_OR_GENE_PRODUCT"], [13, 23, "ENTITY"], [115, 120, "ENTITY"], [5, 9, "PROTEIN"], [75, 91, "ENTITY"], [13, 23, "GENE_OR_GENE_PRODUCT"], [13, 23, "GGP"], [5, 9, "ENTITY"], [30, 40, "ENTITY"], [23, 30, "ENTITY"]]}
{"text": "Both TnT and NT-proBNP levels increased significantly during the course of hospitalization in those who ultimately died , but no such dynamic changes of TnT or NT-proBNP levels were evident in survivors .", "labels": [[5, 9, "GENE_OR_GENE_PRODUCT"], [13, 23, "ENTITY"], [115, 120, "ENTITY"], [5, 9, "PROTEIN"], [75, 91, "ENTITY"], [13, 23, "GENE_OR_GENE_PRODUCT"], [13, 23, "GGP"], [5, 9, "ENTITY"], [30, 40, "ENTITY"], [23, 30, "ENTITY"]]}
{"text": "But in the severe patients , the neutrophil count , D-dimer , blood urea , and creatinine levels were higher significantly , and the lymphocyte counts continued to decrease .", "labels": [[11, 18, "ENTITY"], [60, 68, "GGP"], [60, 68, "DISEASE"], [33, 44, "ENTITY"], [18, 27, "ENTITY"], [60, 68, "ENTITY"], [18, 27, "ORGANISM"], [79, 90, "ENTITY"], [60, 68, "ORGANISM_SUBSTANCE"], [151, 164, "ENTITY"], [133, 144, "ENTITY"]]}
{"text": "The blood counts of patients on admission showed decrease in neutrophils ( 26 [ 39 % ] of 67 patients ) , lymphocytes ( 28 [ 42 % ] of 67 patients ) , and eosinophils ( 48 [ 72 % ] of 67 patients ) , among which , the number of eosinophils in 31 patients was zero .", "labels": [[179, 191, "CELL_TYPE"], [-1, 18, "CELL_TYPE"], [-1, 11, "ENTITY"], [130, 147, "CELL_TYPE"], [264, 270, "ENTITY"], [117, 128, "ENTITY"], [-1, 18, "ENTITY"], [130, 147, "CL"], [-1, 18, "CL"], [14, 21, "ENTITY"], [264, 270, "ORGANISM"], [130, 147, "CELL"], [179, 191, "CELL"], [130, 147, "ENTITY"], [242, 252, "ENTITY"], [242, 252, "CELL"], [242, 252, "CELL_TYPE"], [179, 191, "ENTITY"], [-1, 11, "ORGANISM"], [6, 12, "ORGANISM_SUBSTANCE"], [117, 128, "ORGANISM"], [-1, 18, "CELL"]]}
{"text": "Both WBC and neutrophil counts were significantly higher in severe cases than moderate cases . Whereas lymphocyte counts were significantly lower in severe cases ( 0.7 \u00d7 109/L ) than moderate cases ( 1.1 \u00d7 109/L ) .", "labels": [[62, 69, "ENTITY"], [105, 116, "CL"], [5, 9, "PROTEIN"], [5, 9, "GO"], [80, 89, "ENTITY"], [26, 33, "ENTITY"], [15, 26, "ENTITY"], [105, 116, "CELL"], [62, 69, "ENTITY"], [105, 116, "ENTITY"], [69, 75, "ENTITY"], [69, 75, "ENTITY"], [26, 33, "ENTITY"], [15, 26, "CL"], [5, 9, "ENTITY"], [80, 89, "ENTITY"], [5, 9, "SIMPLE_CHEMICAL"], [15, 26, "CELL_TYPE"], [69, 75, "ENTITY"], [15, 26, "CELL"]]}
{"text": "Higher neutrophil percentage was strongly related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.641 , P3<0.001 , R2 = 0.492 , P4<0.001 ) .", "labels": [[97, 116, "ENTITY"], [0, 7, "ENTITY"], [7, 18, "CELL"], [18, 29, "ENTITY"], [71, 83, "ORGANISM"], [71, 93, "DISEASE"], [53, 60, "ENTITY"], [7, 18, "CL"], [71, 93, "ENTITY"], [7, 18, "ENTITY"], [7, 18, "CELL_TYPE"]]}
{"text": "Patients with elevated TnT levels presented with significantly higher white blood cell count(median[IQR],4640[6170- 3740 ] vs 7390 [ 4890 - 11 630 ] /\u03bcL [ to convert to \u00d7109 per liter , multiply by0.001])and neutrophil counts ( median [IQR],3070 [ 2350 - 4870 ] vs 6010 [ 3540 - 10 120 ] /\u03bcL [ to convert to \u00d7109 per liter , multiply by 0.001 ] ) ( P < .001 for both ) and lower lymphocyte counts ( median [ IQR ] , 840 [ 630 - 1130 ] vs 690 [ 340- 1010 ] /\u03bcL [ toconvert to \u00d7 109 per liter , multiplyby0.001;P = .01 ) than those with normal TnT levels ( Table 2 ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [27, 34, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [195, 208, "CELL"], [456, 475, "PROTEIN"], [195, 208, "CELL_TYPE"], [76, 121, "CELL"], [158, 166, "PROTEIN"], [373, 379, "ENTITY"], [358, 367, "CL"], [23, 27, "PROTEIN"], [93, 100, "PROTEIN"], [0, 9, "ORGANISM"], [76, 87, "CL"], [93, 100, "ENTITY"], [228, 248, "CHEMICAL"], [0, 9, "ENTITY"], [70, 87, "ENTITY"], [351, 367, "CELL"], [456, 475, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"], [358, 367, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"], [195, 208, "CL"]]}
{"text": "ECs showed extensive linkages with pericytes , with dominant role of angiopoietin ligands (ANGPT1/2)\u2013Tie receptor ( TIE2 ) interaction in normal heart , which could promote vascular EC survival and reduced vascular leakage .", "labels": [[11, 21, "ENTITY"], [35, 45, "CELL"], [0, 4, "ENTITY"], [69, 105, "PROTEIN"], [69, 82, "ENTITY"], [138, 145, "ORGAN"], [198, 215, "ENTITY"], [35, 45, "CL"], [0, 4, "CELL"], [165, 173, "ENTITY"], [0, 3, "ENTITY"], [198, 215, "DISEASE"], [69, 105, "GGP"], [0, 4, "CELL_TYPE"], [198, 206, "MULTI-TISSUE_STRUCTURE"], [35, 45, "CELL_TYPE"], [0, 4, "CL"], [135, 145, "ENTITY"], [165, 173, "CELL"], [35, 45, "ENTITY"], [21, 30, "ENTITY"], [69, 105, "GENE_OR_GENE_PRODUCT"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [939, 948, "ORGANISM"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [236, 242, "ENTITY"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [300, 315, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "The virions budded into the ERGIC are exported through secretory pathway in smooth-wall vesicles , which ultimately fuse with the plasma membrane and release the mature virus particles ( Krijnse-Locker et al. , 1994 ) .", "labels": [[55, 65, "CELLULAR_COMPONENT"], [28, 34, "PROTEIN"], [130, 137, "CELLULAR_COMPONENT"], [88, 97, "GO"], [130, 137, "ENTITY"], [12, 19, "ENTITY"], [4, 19, "CELLULAR_COMPONENT"], [4, 12, "ENTITY"], [169, 175, "ORGANISM"], [76, 97, "MULTI-TISSUE_STRUCTURE"], [28, 34, "CELLULAR_COMPONENT"], [169, 175, "ENTITY"], [55, 73, "ENTITY"], [76, 97, "ENTITY"], [130, 137, "GO"], [28, 34, "ENTITY"]]}
{"text": "For HIV , the antiretroviral effect of chloroquine is attributable to a post-transcriptional inhibition of glycosylation of the gp120 envelope glycoprotein , and the neosynthesised virus particles are non-infectious [ 19,65 ] .", "labels": [[166, 181, "TAXON"], [14, 29, "ENTITY"], [4, 8, "TAXON"], [4, 8, "ENTITY"], [72, 93, "ENTITY"], [162, 187, "ENTITY"], [128, 143, "PROTEIN"], [128, 143, "ORGANISM"], [128, 143, "ENTITY"]]}
{"text": "Furthermore , RNA synthesis inhibitors ( like 3TC , TDF ) , remdesivir , neuraminidase inhibitors , peptide ( EK1 ) , anti-inflammatory drugs , abidol , Chinese traditional medicine , such as Lianhuaqingwen and ShuFengJieDu Capsules , could be the promising COVID-19 treatments.2", "labels": [[14, 18, "ENTITY"], [87, 100, "ENTITY"], [108, 118, "ENTITY"], [87, 100, "SO"], [118, 136, "ENTITY"], [173, 192, "ENTITY"], [244, 258, "PROTEIN"], [248, 258, "CHEMICAL"], [60, 100, "SIMPLE_CHEMICAL"], [192, 211, "ORGANISM"], [60, 87, "ENTITY"], [60, 87, "CHEBI"], [192, 211, "ENTITY"]]}
{"text": "PKR is induced by IFN and activated by the binding of double-stranded RNA ( dsRNA ) after virus infection ( Clemens and Elia , 1997 ) . HRI is activated in red blood cells and hepatocytes by low levels of heme ( McEwenet al. , 2005 ) . GCN2 senses amino acid deficiency and is activated via binding to uncharged transfer RNAs ( Sood et al. , 2000 ) .", "labels": [[236, 248, "CHEMICAL"], [312, 321, "ORGANISM"], [291, 312, "ENTITY"], [195, 202, "GENE_OR_GENE_PRODUCT"], [166, 176, "ENTITY"], [205, 212, "PROTEIN"], [236, 248, "CHEBI"], [18, 22, "GENE_OR_GENE_PRODUCT"], [84, 96, "DISEASE"], [54, 74, "ENTITY"], [166, 176, "CELL_TYPE"], [7, 15, "ENTITY"], [143, 166, "CELL"], [166, 176, "CELL"], [195, 202, "PROTEIN"], [18, 22, "GGP"], [54, 74, "RNA"], [312, 321, "CHEMICAL"], [0, 4, "PROTEIN"], [0, 4, "GENE_OR_GENE_PRODUCT"], [195, 202, "CHEBI"], [43, 51, "ENTITY"], [26, 36, "ENTITY"], [143, 166, "CELL_TYPE"], [143, 166, "CL"], [166, 176, "CL"], [70, 74, "SO"], [176, 195, "ENTITY"], [236, 259, "ENTITY"], [195, 202, "ENTITY"], [143, 166, "ENTITY"], [18, 22, "ENTITY"], [136, 143, "ENTITY"], [18, 22, "CHEMICAL"], [259, 277, "ENTITY"], [26, 36, "ENTITY"], [0, 4, "ENTITY"], [18, 22, "PROTEIN"], [205, 212, "ENTITY"], [236, 248, "AMINO_ACID"], [84, 96, "ENTITY"]]}
{"text": "Until today , six different strains of Human coronaviruses ( HCoVs ) have been reported , in addition to the newly emerged COVID-19 [ 2,12 ] . 229E and NL63 strains of HCoVs belong to Alphacoronaviruses while OC43 , HKU1 , SARS , MERS , and COVID-19 HCoVs belong to Betacoronaviruses [ 2,11 ] .", "labels": [[28, 36, "ORGANISM"], [28, 36, "PROTEIN"], [39, 45, "PROTEIN"], [174, 184, "GENE_OR_GENE_PRODUCT"], [230, 241, "ENTITY"], [230, 241, "GENE_OR_GENE_PRODUCT"], [39, 45, "ORGANISM"], [143, 157, "ORGANISM"], [115, 123, "ENTITY"], [174, 184, "ORGANISM"], [28, 36, "ENTITY"], [174, 184, "ENTITY"], [143, 157, "ENTITY"], [28, 36, "DISEASE"], [230, 241, "PROTEIN"], [39, 45, "ENTITY"], [174, 184, "ENTITY"], [115, 134, "GENE_OR_GENE_PRODUCT"], [203, 214, "PROTEIN"]]}
{"text": "Most human CoVs , such as hCoV-229E , OC43 , NL63 , and HKU1 , cause mild respiratory diseases , but the worldwide spread of two previously unrecognized coronaviruses , the severe acute respiratory syndrome CoV ( SARS-CoV ) and Middle East respiratory syndrome CoV ( MERS-CoV ) , has called global attention to the lethal potential of human CoVs 2 .", "labels": [[63, 86, "ENTITY"], [173, 198, "ENTITY"], [173, 198, "DISEASE"], [140, 153, "PROTEIN"], [322, 335, "ORGANISM"], [5, 11, "ENTITY"], [298, 308, "ENTITY"], [322, 335, "ENTITY"], [140, 153, "ORGANISM"], [140, 153, "ENTITY"], [69, 86, "DISEASE"], [280, 291, "ENTITY"], [322, 335, "PROTEIN"], [5, 16, "ORGANISM"], [213, 252, "ENTITY"], [11, 16, "ENTITY"], [5, 11, "TAXON"], [198, 213, "ORGANISM"], [322, 332, "TAXON"], [167, 173, "ENTITY"], [198, 211, "ENTITY"], [198, 213, "ENTITY"], [228, 252, "DISEASE"]]}
{"text": "Infections with human strains HCoV-229E , HCoV-OC43 , HCoV-NL63 , and HCoV-HKU1 usually cause mild , self-limiting respiratory infections such as the common cold.2,24", "labels": [[30, 40, "ENTITY"], [0, 11, "ENTITY"], [0, 11, "DISEASE"], [150, 157, "ENTITY"], [16, 22, "TAXON"], [94, 101, "ENTITY"], [22, 30, "ENTITY"], [101, 127, "ENTITY"], [101, 127, "DISEASE"], [16, 40, "ORGANISM"], [16, 22, "ENTITY"]]}
{"text": "Two mechanisms may protect children from COVID-19 infections : ( 1 ) cross-protective antibodies from multiple upper respiratory tract infections caused by the common cold-causing alpha coronaviruses , and ( 2 ) fewer ACE2 receptors in their lower respiratory tracts to attract the binding S proteins of the beta coronaviruses .", "labels": [[212, 223, "ENTITY"], [102, 117, "PATHOLOGICAL_FORMATION"], [212, 223, "PROTEIN"], [27, 36, "ENTITY"], [27, 36, "ORGANISM"], [242, 260, "ENTITY"], [301, 313, "GENE_OR_GENE_PRODUCT"], [160, 186, "PROTEIN"], [97, 135, "ENTITY"], [301, 313, "ENTITY"], [282, 292, "CHEBI"], [41, 50, "SIMPLE_CHEMICAL"], [270, 292, "PROTEIN"], [69, 86, "GO"], [301, 313, "PROTEIN"], [67, 86, "ENTITY"], [41, 61, "DISEASE"], [41, 61, "ENTITY"], [4, 15, "ENTITY"], [160, 186, "ENTITY"], [67, 86, "PROTEIN"], [270, 292, "ENTITY"]]}
{"text": "We previously demonstrated that the influenza virus M2 protein ( a proton-selective ion channel ) , its H37 G mutant ( which has lost its proton selectivity and enables the transport of other cations such as Na + and K + ) , and the EMCV 2B protein ( a Ca 2 + channel ) stimulates NLRP3 inflammasome-mediated IL-1\u03b2 secretion ( Ichinohe et al. , 2010 ; Ito et al. , 2012 ) .", "labels": [[241, 260, "PROTEIN"], [200, 208, "SIMPLE_CHEMICAL"], [233, 241, "CHEBI"], [67, 88, "ENTITY"], [55, 63, "CHEBI"], [88, 98, "ENTITY"], [200, 208, "ENTITY"], [100, 110, "ENTITY"], [104, 110, "SO"], [225, 241, "ENTITY"], [36, 63, "PROTEIN"], [225, 233, "ORGANISM"], [67, 88, "PROTEIN"], [100, 110, "PROTEIN"], [46, 52, "TAXON"], [200, 213, "PROTEIN"], [55, 63, "CHEMICAL"], [270, 287, "ENTITY"], [225, 241, "PROTEIN"], [200, 208, "CHEBI"], [36, 63, "ENTITY"], [287, 315, "ENTITY"], [241, 260, "ENTITY"], [134, 145, "ENTITY"]]}
{"text": "Unlike HCoV-OC43 , HCoV-229E infection of Huh7 causes CPE .", "labels": [[7, 17, "DISEASE"], [7, 17, "ORGANISM"], [19, 29, "DISEASE"], [19, 29, "ENTITY"], [7, 17, "ENTITY"]]}
{"text": "Most human CoVs , such as hCoV-229E , OC43 , NL63 , and HKU1 , cause mild respiratory diseases , but the worldwide spread of two previously unrecognized coronaviruses , the severe acute respiratory syndrome CoV ( SARS-CoV ) and Middle East respiratory syndrome CoV ( MERS-CoV ) , has called global attention to the lethal potential of human CoVs 2 .", "labels": [[63, 86, "ENTITY"], [173, 198, "ENTITY"], [173, 198, "DISEASE"], [5, 16, "ORGANISM"], [140, 153, "PROTEIN"], [322, 335, "ORGANISM"], [298, 308, "ENTITY"], [322, 335, "ENTITY"], [140, 153, "ORGANISM"], [140, 153, "ENTITY"], [69, 86, "DISEASE"], [280, 291, "ENTITY"], [322, 335, "PROTEIN"], [213, 252, "ENTITY"], [5, 11, "ENTITY"], [5, 11, "TAXON"], [11, 16, "ENTITY"], [198, 213, "ORGANISM"], [322, 332, "TAXON"], [167, 173, "ENTITY"], [198, 211, "ENTITY"], [198, 213, "ENTITY"], [228, 252, "DISEASE"]]}
{"text": "Such neuroinvasive propensity of CoVs has been documented almost for all the betacoronaviruses , including SARS-CoV 1 , MERS-CoV 11 , HCoV-229E 16 , HCoV-OC43 12 , mouse hepatitis virus ( MHV ) 17 , and porcine hemagglutinating encephalomyelitis coronavirus ( HEV ) 9 - 10 , 18 - 19 .", "labels": [[118, 129, "ENTITY"], [203, 246, "ENTITY"], [107, 116, "ENTITY"], [132, 144, "ORGANISM"], [170, 180, "TAXON"], [194, 246, "ORGANISM"], [33, 38, "ENTITY"], [159, 180, "ORGANISM"], [87, 93, "TAXON"], [19, 30, "ENTITY"], [164, 180, "DISEASE"], [107, 116, "ORGANISM"], [77, 95, "GENE_OR_GENE_PRODUCT"], [5, 19, "ENTITY"], [107, 116, "PROTEIN"], [47, 58, "ENTITY"], [118, 129, "PROTEIN"], [194, 203, "TAXON"], [87, 93, "ENTITY"], [77, 95, "ENTITY"], [132, 144, "ENTITY"], [194, 203, "ENTITY"], [159, 180, "ENTITY"]]}
{"text": "Infections with human strains HCoV-229E , HCoV-OC43 , HCoV-NL63 , and HCoV-HKU1 usually cause mild , self-limiting respiratory infections such as the common cold.2,24", "labels": [[30, 40, "ENTITY"], [16, 22, "ENTITY"], [0, 11, "ENTITY"], [150, 157, "ENTITY"], [0, 11, "DISEASE"], [16, 22, "TAXON"], [94, 101, "ENTITY"], [22, 30, "ENTITY"], [101, 127, "ENTITY"], [101, 127, "DISEASE"], [16, 40, "ORGANISM"]]}
{"text": "Most human CoVs , such as hCoV-229E , OC43 , NL63 , and HKU1 , cause mild respiratory diseases , but the worldwide spread of two previously unrecognized coronaviruses , the severe acute respiratory syndrome CoV ( SARS-CoV ) and Middle East respiratory syndrome CoV ( MERS-CoV ) , has called global attention to the lethal potential of human CoVs 2 .", "labels": [[63, 86, "ENTITY"], [173, 198, "ENTITY"], [173, 198, "DISEASE"], [140, 153, "PROTEIN"], [322, 335, "ORGANISM"], [298, 308, "ENTITY"], [322, 335, "ENTITY"], [140, 153, "ORGANISM"], [140, 153, "ENTITY"], [69, 86, "DISEASE"], [280, 291, "ENTITY"], [322, 335, "PROTEIN"], [213, 252, "ENTITY"], [5, 11, "ENTITY"], [5, 11, "TAXON"], [11, 16, "ENTITY"], [198, 213, "ORGANISM"], [322, 332, "TAXON"], [5, 16, "ORGANISM"], [167, 173, "ENTITY"], [198, 211, "ENTITY"], [198, 213, "ENTITY"], [228, 252, "DISEASE"]]}
{"text": "The S. cusia leaf methanol extract reduced HCoV\u2010NL63\u2010induced CPE in LLC\u2010MK2 cells in a concentration\u2010dependent manner ( Figure 1A ) .", "labels": [[43, 61, "ENTITY"], [68, 82, "CELL"], [4, 35, "CHEMICAL"], [4, 7, "TAXON"], [68, 82, "ENTITY"], [43, 65, "CELL"], [4, 35, "ENTITY"], [13, 27, "CHEBI"], [68, 82, "CELL_TYPE"], [43, 65, "CHEMICAL"], [120, 127, "ENTITY"], [4, 35, "TISSUE"], [76, 82, "CL"], [87, 111, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Among them , tryptanthrin at 40 \u03bcM exhibited the strongest antiviral activity with a significant reduction in HCoV\u2010NL63\u2010induced CPE in LLC\u2010MK2 cells 36 and 48 h post\u2010infection ( Figure 3A ) .", "labels": [[135, 143, "ENTITY"], [135, 143, "CELL"], [110, 128, "CELL"], [59, 69, "ENTITY"], [176, 185, "ENTITY"], [135, 143, "CELL_TYPE"]]}
{"text": "Indigodole B ( 5aR\u2010ethyltryptanthrin ) at 40 \u03bcM concentration was ranked the second highest in terms of anti\u2010HCoV\u2010NL63 activity in reducing virus induced CPE 36 and 48 h post\u2010infection ( Figure 3A ) .", "labels": [[0, 13, "ENTITY"], [131, 140, "ENTITY"], [140, 146, "ENTITY"], [131, 140, "TAXON"], [146, 154, "ENTITY"], [0, 13, "CHEMICAL"], [146, 154, "CHEMICAL"], [101, 119, "ENTITY"], [185, 194, "ENTITY"], [45, 48, "ENTITY"]]}
{"text": "Infections with human strains HCoV-229E , HCoV-OC43 , HCoV-NL63 , and HCoV-HKU1 usually cause mild , self-limiting respiratory infections such as the common cold.2,24", "labels": [[30, 40, "ENTITY"], [16, 22, "ENTITY"], [0, 11, "ENTITY"], [150, 157, "ENTITY"], [0, 11, "DISEASE"], [16, 22, "TAXON"], [94, 101, "ENTITY"], [22, 30, "ENTITY"], [101, 127, "ENTITY"], [101, 127, "DISEASE"], [16, 40, "ORGANISM"]]}
{"text": "Most human CoVs , such as hCoV-229E , OC43 , NL63 , and HKU1 , cause mild respiratory diseases , but the worldwide spread of two previously unrecognized coronaviruses , the severe acute respiratory syndrome CoV ( SARS-CoV ) and Middle East respiratory syndrome CoV ( MERS-CoV ) , has called global attention to the lethal potential of human CoVs 2 .", "labels": [[63, 86, "ENTITY"], [173, 198, "ENTITY"], [173, 198, "DISEASE"], [140, 153, "PROTEIN"], [5, 16, "ORGANISM"], [322, 335, "ORGANISM"], [298, 308, "ENTITY"], [322, 335, "ENTITY"], [140, 153, "ORGANISM"], [140, 153, "ENTITY"], [69, 86, "DISEASE"], [280, 291, "ENTITY"], [322, 335, "PROTEIN"], [213, 252, "ENTITY"], [5, 11, "ENTITY"], [5, 11, "TAXON"], [11, 16, "ENTITY"], [198, 213, "ORGANISM"], [322, 332, "TAXON"], [167, 173, "ENTITY"], [198, 211, "ENTITY"], [198, 213, "ENTITY"], [228, 252, "DISEASE"]]}
{"text": "Such neuroinvasive propensity of CoVs has been documented almost for all the betacoronaviruses , including SARS-CoV 1 , MERS-CoV 11 , HCoV-229E 16 , HCoV-OC43 12 , mouse hepatitis virus ( MHV ) 17 , and porcine hemagglutinating encephalomyelitis coronavirus ( HEV ) 9 - 10 , 18 - 19 .", "labels": [[118, 129, "ENTITY"], [203, 246, "ENTITY"], [107, 116, "ENTITY"], [132, 144, "ORGANISM"], [170, 180, "TAXON"], [194, 246, "ORGANISM"], [33, 38, "ENTITY"], [159, 180, "ORGANISM"], [87, 93, "TAXON"], [19, 30, "ENTITY"], [164, 180, "DISEASE"], [107, 116, "ORGANISM"], [77, 95, "GENE_OR_GENE_PRODUCT"], [5, 19, "ENTITY"], [107, 116, "PROTEIN"], [47, 58, "ENTITY"], [118, 129, "PROTEIN"], [194, 203, "TAXON"], [87, 93, "ENTITY"], [77, 95, "ENTITY"], [132, 144, "ENTITY"], [194, 203, "ENTITY"], [159, 180, "ENTITY"]]}
{"text": "Infections with human strains HCoV-229E , HCoV-OC43 , HCoV-NL63 , and HCoV-HKU1 usually cause mild , self-limiting respiratory infections such as the common cold.2,24", "labels": [[30, 40, "ENTITY"], [16, 22, "ENTITY"], [0, 11, "ENTITY"], [150, 157, "ENTITY"], [0, 11, "DISEASE"], [16, 22, "TAXON"], [94, 101, "ENTITY"], [22, 30, "ENTITY"], [101, 127, "ENTITY"], [101, 127, "DISEASE"], [16, 40, "ORGANISM"]]}
{"text": "We previously demonstrated that the influenza virus M2 protein ( a proton-selective ion channel ) , its H37 G mutant ( which has lost its proton selectivity and enables the transport of other cations such as Na + and K + ) , and the EMCV 2B protein ( a Ca 2 + channel ) stimulates NLRP3 inflammasome-mediated IL-1\u03b2 secretion ( Ichinohe et al. , 2010 ; Ito et al. , 2012 ) .", "labels": [[241, 260, "PROTEIN"], [36, 63, "PROTEIN"], [200, 208, "SIMPLE_CHEMICAL"], [233, 241, "CHEBI"], [67, 88, "ENTITY"], [55, 63, "CHEBI"], [88, 98, "ENTITY"], [200, 208, "ENTITY"], [100, 110, "ENTITY"], [104, 110, "SO"], [225, 241, "ENTITY"], [225, 233, "ORGANISM"], [67, 88, "PROTEIN"], [100, 110, "PROTEIN"], [200, 213, "PROTEIN"], [55, 63, "CHEMICAL"], [270, 287, "ENTITY"], [225, 241, "PROTEIN"], [200, 208, "CHEBI"], [36, 63, "ENTITY"], [287, 315, "ENTITY"], [241, 260, "ENTITY"], [46, 52, "TAXON"], [134, 145, "ENTITY"]]}
{"text": "In agreement with a previous result ( Ichinohe et al. , 2010 ) , we found that IL-1\u03b2 secretion caused by influenza virus was completely blocked when the extracellular K + concentration was increased to 130 mM ( Figure 5A ) .", "labels": [[102, 115, "ENTITY"], [105, 115, "TAXON"], [125, 136, "ENTITY"], [167, 171, "ENTITY"], [149, 167, "GO"], [206, 211, "ENTITY"], [79, 85, "ENTITY"], [149, 167, "ENTITY"], [3, 13, "ENTITY"]]}
{"text": "Intranasal inoculation in mice with avian influenza virus was reported to cause neural infection besides bronchitis or pneumonia 36 .", "labels": [[105, 116, "ENTITY"], [0, 23, "ENTITY"], [26, 31, "TAXON"], [119, 129, "DISEASE"], [119, 129, "ENTITY"], [26, 31, "ORGANISM"], [80, 97, "ENTITY"], [26, 31, "ENTITY"], [80, 97, "DISEASE"], [105, 116, "DISEASE"], [52, 58, "TAXON"], [36, 42, "TAXON"], [36, 58, "ENTITY"], [36, 58, "ORGANISM"]]}
{"text": "Intranasal inoculation in mice with avian influenza virus was reported to cause neural infection besides bronchitis or pneumonia 36 .", "labels": [[0, 23, "ENTITY"], [26, 31, "TAXON"], [119, 129, "DISEASE"], [119, 129, "ENTITY"], [26, 31, "ORGANISM"], [80, 97, "ENTITY"], [26, 31, "ENTITY"], [80, 97, "DISEASE"], [36, 58, "ORGANISM"], [105, 116, "ENTITY"], [52, 58, "TAXON"], [36, 42, "TAXON"], [36, 58, "ENTITY"], [105, 116, "DISEASE"]]}
{"text": "Intranasal inoculation in mice with avian influenza virus was reported to cause neural infection besides bronchitis or pneumonia 36 .", "labels": [[105, 116, "ENTITY"], [0, 23, "ENTITY"], [26, 31, "TAXON"], [26, 31, "ORGANISM"], [80, 97, "ENTITY"], [26, 31, "ENTITY"], [80, 97, "DISEASE"], [119, 129, "ENTITY"], [105, 116, "DISEASE"], [119, 129, "DISEASE"], [52, 58, "TAXON"], [36, 42, "TAXON"], [36, 58, "ENTITY"], [36, 58, "ORGANISM"]]}
{"text": "Most human CoVs , such as hCoV-229E , OC43 , NL63 , and HKU1 , cause mild respiratory diseases , but the worldwide spread of two previously unrecognized coronaviruses , the severe acute respiratory syndrome CoV ( SARS-CoV ) and Middle East respiratory syndrome CoV ( MERS-CoV ) , has called global attention to the lethal potential of human CoVs 2 .", "labels": [[63, 86, "ENTITY"], [173, 198, "ENTITY"], [173, 198, "DISEASE"], [140, 153, "PROTEIN"], [322, 335, "ORGANISM"], [298, 308, "ENTITY"], [322, 335, "ENTITY"], [140, 153, "ORGANISM"], [140, 153, "ENTITY"], [228, 252, "DISEASE"], [280, 291, "ENTITY"], [322, 335, "PROTEIN"], [213, 252, "ENTITY"], [5, 11, "ENTITY"], [69, 86, "DISEASE"], [5, 11, "TAXON"], [11, 16, "ENTITY"], [198, 213, "ORGANISM"], [322, 332, "TAXON"], [167, 173, "ENTITY"], [5, 16, "ORGANISM"], [198, 211, "ENTITY"], [198, 213, "ENTITY"]]}
{"text": "Such neuroinvasive propensity of CoVs has been documented almost for all the betacoronaviruses , including SARS-CoV 1 , MERS-CoV 11 , HCoV-229E 16 , HCoV-OC43 12 , mouse hepatitis virus ( MHV ) 17 , and porcine hemagglutinating encephalomyelitis coronavirus ( HEV ) 9 - 10 , 18 - 19 .", "labels": [[118, 129, "ENTITY"], [203, 246, "ENTITY"], [107, 116, "ENTITY"], [132, 144, "ORGANISM"], [170, 180, "TAXON"], [194, 246, "ORGANISM"], [33, 38, "ENTITY"], [159, 180, "ORGANISM"], [87, 93, "TAXON"], [19, 30, "ENTITY"], [164, 180, "DISEASE"], [107, 116, "ORGANISM"], [77, 95, "GENE_OR_GENE_PRODUCT"], [5, 19, "ENTITY"], [107, 116, "PROTEIN"], [47, 58, "ENTITY"], [118, 129, "PROTEIN"], [194, 203, "TAXON"], [87, 93, "ENTITY"], [77, 95, "ENTITY"], [132, 144, "ENTITY"], [194, 203, "ENTITY"], [159, 180, "ENTITY"]]}
{"text": "Experimental studies using transgenic mice further revealed that either SARS-CoV 30 or MERS-COV 11 , when given intranasally , could enter the brain , possibly via the olfactory nerves , and there after rapidly spread to some specific brain areas including thalamus and brainstem .", "labels": [[87, 99, "PROTEIN"], [72, 84, "PROTEIN"], [87, 99, "ENTITY"], [0, 21, "ENTITY"], [226, 241, "ENTITY"], [72, 84, "ORGANISM"], [247, 257, "PATHOLOGICAL_FORMATION"], [27, 43, "SO"], [38, 43, "ORGANISM"], [72, 81, "ENTITY"], [226, 235, "ORGAN"], [27, 43, "ENTITY"], [247, 257, "ENTITY"], [164, 178, "TISSUE"], [164, 178, "ENTITY"]]}
{"text": "A study involving MERS-CoV described that ORF 8b strongly antagonizes the INF-beta ( \u03b2 ) promoter and ORF4b and 8b significantly suppress IFN induction ( Lee et al. , 2019b ) .", "labels": [[129, 138, "ENTITY"], [74, 83, "ENTITY"], [74, 83, "GENE_OR_GENE_PRODUCT"], [74, 89, "DNA"], [129, 138, "GENE_OR_GENE_PRODUCT"], [18, 27, "GGP"], [58, 70, "ENTITY"], [18, 27, "PROTEIN"], [42, 49, "ENTITY"], [2, 8, "ENTITY"], [42, 49, "PROTEIN"], [115, 129, "ENTITY"], [129, 138, "CHEMICAL"], [42, 46, "SO"], [138, 142, "ENTITY"], [129, 138, "PROTEIN"], [18, 27, "ENTITY"], [129, 138, "GGP"]]}
{"text": "A study involving MERS-CoV described that ORF 8b strongly antagonizes the INF-beta ( \u03b2 ) promoter and ORF4b and 8b significantly suppress IFN induction ( Lee et al. , 2019b ) .", "labels": [[129, 138, "ENTITY"], [74, 83, "ENTITY"], [74, 83, "GENE_OR_GENE_PRODUCT"], [74, 89, "DNA"], [129, 138, "GENE_OR_GENE_PRODUCT"], [18, 27, "GGP"], [58, 70, "ENTITY"], [18, 27, "PROTEIN"], [42, 49, "ENTITY"], [2, 8, "ENTITY"], [42, 49, "PROTEIN"], [115, 129, "ENTITY"], [129, 138, "CHEMICAL"], [42, 46, "SO"], [138, 142, "ENTITY"], [129, 138, "PROTEIN"], [18, 27, "ENTITY"], [129, 138, "GGP"]]}
{"text": "SARS-CoV and Middle East respiratory syndrome (MERS)-CoV can enter cells via endocytosis and use cathepsin in endosomes for activation ( 12\u201314 ) . However , TMPRSS2 expression greatly promotes replication and syncytium formation in these viruses in vitro and in vivo ( 5 , 6 , 11 , 12 , 15 ) .", "labels": [[67, 73, "ENTITY"], [97, 120, "GGP"], [97, 107, "GENE_OR_GENE_PRODUCT"], [209, 219, "ENTITY"], [238, 249, "ENTITY"], [184, 193, "ENTITY"], [157, 165, "ENTITY"], [46, 57, "GENE_OR_GENE_PRODUCT"], [0, 9, "ORGANISM"], [46, 57, "ENTITY"], [13, 46, "ENTITY"], [77, 89, "ENTITY"], [124, 135, "ENTITY"], [147, 157, "GGP"], [67, 73, "CELL"], [97, 107, "PROTEIN"], [147, 157, "GENE_OR_GENE_PRODUCT"], [97, 107, "ENTITY"], [67, 73, "CL"], [176, 184, "ENTITY"], [147, 157, "PROTEIN"], [255, 262, "ENTITY"], [0, 9, "ENTITY"], [110, 120, "ENTITY"], [147, 157, "ENTITY"], [110, 120, "CELLULAR_COMPONENT"], [25, 46, "DISEASE"]]}
{"text": "The mTOR signaling plays an essential role for MERS-CoV infection66 .", "labels": [[4, 9, "ENTITY"], [9, 19, "ENTITY"], [4, 9, "GENE_OR_GENE_PRODUCT"], [4, 9, "PROTEIN"], [47, 56, "GGP"], [47, 68, "PROTEIN"], [56, 68, "ENTITY"], [4, 9, "GGP"], [47, 56, "ENTITY"]]}
{"text": "Based on our analyses of differential gene expression , we report significant transcriptional upregulation of multiple genes associated with activation of ER sensors IRE1 , ATF6 , and PERK , such as Edem1 , Hspa5 ( encoding BiP protein ) , and Ddit3 ( encoding CHOP ) , in response to virus replication , with the most robust response detected in cells infected with the wild-type or DUBmut virus infection ( Fig. 5B , C , and D ) .", "labels": [[199, 207, "PROTEIN"], [244, 252, "ENTITY"], [319, 326, "ENTITY"], [155, 158, "ENTITY"], [215, 228, "PROTEIN"], [273, 291, "ENTITY"], [371, 391, "DISEASE"], [38, 54, "ENTITY"], [397, 407, "GENE_OR_GENE_PRODUCT"], [199, 207, "GENE_OR_GENE_PRODUCT"], [335, 347, "ENTITY"], [371, 391, "ENTITY"], [38, 43, "SO"], [305, 314, "ENTITY"], [215, 228, "ENTITY"], [110, 119, "ENTITY"], [397, 407, "ENTITY"], [199, 207, "ENTITY"], [199, 207, "GGP"], [371, 384, "TAXON"], [409, 414, "ENTITY"], [261, 270, "ENTITY"], [215, 228, "GGP"], [25, 38, "ENTITY"], [207, 215, "ENTITY"], [353, 367, "ENTITY"], [13, 22, "ENTITY"]]}
{"text": "Based on our analyses of differential gene expression , we report significant transcriptional upregulation of multiple genes associated with activation of ER sensors IRE1 , ATF6 , and PERK , such as Edem1 , Hspa5 ( encoding BiP protein ) , and Ddit3 ( encoding CHOP ) , in response to virus replication , with the most robust response detected in cells infected with the wild-type or DUBmut virus infection ( Fig. 5B , C , and D ) .", "labels": [[244, 252, "ENTITY"], [319, 326, "ENTITY"], [155, 158, "ENTITY"], [215, 228, "PROTEIN"], [273, 291, "ENTITY"], [371, 391, "DISEASE"], [38, 54, "ENTITY"], [397, 407, "GENE_OR_GENE_PRODUCT"], [199, 207, "ENTITY"], [199, 207, "GENE_OR_GENE_PRODUCT"], [335, 347, "ENTITY"], [199, 207, "PROTEIN"], [207, 215, "ENTITY"], [371, 391, "ENTITY"], [38, 43, "SO"], [305, 314, "ENTITY"], [215, 228, "ENTITY"], [110, 119, "ENTITY"], [397, 407, "ENTITY"], [371, 384, "TAXON"], [409, 414, "ENTITY"], [261, 270, "ENTITY"], [199, 207, "GGP"], [215, 228, "GGP"], [25, 38, "ENTITY"], [353, 367, "ENTITY"], [13, 22, "ENTITY"]]}
{"text": "Based on our analyses of differential gene expression , we report significant transcriptional upregulation of multiple genes associated with activation of ER sensors IRE1 , ATF6 , and PERK , such as Edem1 , Hspa5 ( encoding BiP protein ) , and Ddit3 ( encoding CHOP ) , in response to virus replication , with the most robust response detected in cells infected with the wild-type or DUBmut virus infection ( Fig. 5B , C , and D ) .", "labels": [[319, 326, "ENTITY"], [155, 158, "ENTITY"], [244, 252, "ENTITY"], [215, 228, "PROTEIN"], [273, 291, "ENTITY"], [371, 391, "DISEASE"], [38, 54, "ENTITY"], [397, 407, "GENE_OR_GENE_PRODUCT"], [199, 207, "ENTITY"], [199, 207, "GENE_OR_GENE_PRODUCT"], [335, 347, "ENTITY"], [199, 207, "PROTEIN"], [371, 391, "ENTITY"], [38, 43, "SO"], [305, 314, "ENTITY"], [215, 228, "ENTITY"], [110, 119, "ENTITY"], [397, 407, "ENTITY"], [371, 384, "TAXON"], [409, 414, "ENTITY"], [261, 270, "ENTITY"], [199, 207, "GGP"], [215, 228, "GGP"], [25, 38, "ENTITY"], [207, 215, "ENTITY"], [353, 367, "ENTITY"], [13, 22, "ENTITY"]]}
{"text": "We found that the WT- and DUBmut-viruses exhibit higher proportions of spliced XBP-1 mRNA at 9 hpi and 12 hpi compared to EndoUmut infected cells ( Fig. 5E ) , consistent with activation of the IRE-1 arm of the unfolded protein response .", "labels": [[211, 220, "CHEBI"], [26, 41, "ENTITY"], [71, 79, "ENTITY"], [79, 85, "ENTITY"], [95, 99, "ENTITY"], [148, 153, "GENE_OR_GENE_PRODUCT"], [190, 200, "ENTITY"], [18, 22, "ENTITY"], [85, 90, "ENTITY"], [190, 200, "PROTEIN"], [140, 146, "CL"], [79, 90, "RNA"], [56, 68, "ENTITY"], [122, 146, "ENTITY"], [79, 85, "GENE_OR_GENE_PRODUCT"], [26, 41, "GENE_OR_GENE_PRODUCT"], [140, 146, "CELL"], [158, 171, "ENTITY"], [207, 220, "PROTEIN"], [207, 228, "ENTITY"], [122, 146, "CELL_LINE"], [85, 90, "CHEBI"], [95, 99, "ENTITY"], [18, 41, "PROTEIN"]]}
{"text": "Such neuroinvasive propensity of CoVs has been documented almost for all the betacoronaviruses , including SARS-CoV 1 , MERS-CoV 11 , HCoV-229E 16 , HCoV-OC43 12 , mouse hepatitis virus ( MHV ) 17 , and porcine hemagglutinating encephalomyelitis coronavirus ( HEV ) 9 - 10 , 18 - 19 .", "labels": [[164, 180, "DISEASE"], [118, 129, "ENTITY"], [203, 246, "ENTITY"], [107, 116, "ENTITY"], [132, 144, "ORGANISM"], [170, 180, "TAXON"], [194, 246, "ORGANISM"], [33, 38, "ENTITY"], [159, 180, "ORGANISM"], [87, 93, "TAXON"], [19, 30, "ENTITY"], [107, 116, "ORGANISM"], [77, 95, "GENE_OR_GENE_PRODUCT"], [5, 19, "ENTITY"], [107, 116, "PROTEIN"], [47, 58, "ENTITY"], [118, 129, "PROTEIN"], [194, 203, "TAXON"], [87, 93, "ENTITY"], [77, 95, "ENTITY"], [132, 144, "ENTITY"], [194, 203, "ENTITY"], [159, 180, "ENTITY"]]}
{"text": "Further analysis showed that SARS-CoV nsp 1 suppressed Sendai virus- induced IFN-\u03b2 mRNA accumulation , and suppressed reporter mRNA accumulation in cells .", "labels": [[83, 88, "ENTITY"], [88, 101, "ENTITY"], [118, 127, "RNA"], [29, 44, "ENTITY"], [55, 69, "ENTITY"], [69, 77, "ENTITY"], [83, 88, "CHEBI"], [29, 44, "PROTEIN"], [55, 69, "ORGANISM"], [29, 44, "ORGANISM"], [77, 83, "GENE_OR_GENE_PRODUCT"], [8, 17, "ENTITY"], [44, 55, "ENTITY"], [77, 83, "ENTITY"]]}
{"text": "HEV 67N is the first coronavirus found to invade the porcine brain , and it shares > 91 % homology with HCoV-OC43 38 - 39 .", "labels": [[53, 67, "ORGANISM"], [21, 33, "TAXON"], [21, 33, "ENTITY"], [53, 61, "ENTITY"], [0, 8, "DNA"], [42, 49, "ENTITY"], [0, 8, "ORGANISM"], [61, 67, "ENTITY"], [0, 4, "ENTITY"], [21, 33, "ORGANISM"], [99, 117, "ENTITY"], [99, 117, "ORGANISM"], [53, 61, "TAXON"]]}
{"text": "The transfer of HEV67N between neurons has been demonstrated by our previous ultrastructural studies to use the clathrin-coating-mediated endo-/exocytotic pathway 10 .", "labels": [[16, 23, "GGP"], [4, 13, "ENTITY"], [16, 23, "CELL"], [31, 39, "CL"], [112, 163, "ENTITY"], [16, 23, "DNA"], [31, 39, "ENTITY"], [31, 39, "CELL"], [16, 23, "ENTITY"], [77, 101, "ENTITY"]]}
{"text": "The transfer of HEV67N between neurons has been demonstrated by our previous ultrastructural studies to use the clathrin-coating-mediated endo-/exocytotic pathway 10 .", "labels": [[16, 23, "GGP"], [4, 13, "ENTITY"], [16, 23, "CELL"], [31, 39, "CL"], [112, 163, "ENTITY"], [16, 23, "DNA"], [31, 39, "ENTITY"], [31, 39, "CELL"], [16, 23, "ENTITY"], [77, 101, "ENTITY"]]}
{"text": "Such neuroinvasive propensity of CoVs has been documented almost for all the betacoronaviruses , including SARS-CoV 1 , MERS-CoV 11 , HCoV-229E 16 , HCoV-OC43 12 , mouse hepatitis virus ( MHV ) 17 , and porcine hemagglutinating encephalomyelitis coronavirus ( HEV ) 9 - 10 , 18 - 19 .", "labels": [[118, 129, "ENTITY"], [107, 116, "ENTITY"], [132, 144, "ORGANISM"], [170, 180, "TAXON"], [33, 38, "ENTITY"], [159, 180, "ORGANISM"], [194, 246, "ORGANISM"], [19, 30, "ENTITY"], [164, 180, "DISEASE"], [107, 116, "ORGANISM"], [203, 246, "ENTITY"], [77, 95, "GENE_OR_GENE_PRODUCT"], [87, 93, "ENTITY"], [5, 19, "ENTITY"], [107, 116, "PROTEIN"], [47, 58, "ENTITY"], [118, 129, "PROTEIN"], [194, 203, "TAXON"], [77, 95, "ENTITY"], [132, 144, "ENTITY"], [194, 203, "ENTITY"], [87, 93, "TAXON"], [159, 180, "ENTITY"]]}
{"text": "After 24 hpi , the RNA synthesis of all strains was predominantly suppressed by TAT-Nb6 ( Fig. 7B to D ) , and the relative RNA levels for strains SD16 , GD-HD , and VR2332 were significantly reduced compared to levels for the TAT-Nb53 group and no nanobody group ( Fig. 7C and D ) .", "labels": [[115, 124, "SO"], [9, 13, "ENTITY"], [249, 258, "ENTITY"], [242, 249, "ENTITY"], [19, 23, "ENTITY"], [147, 154, "ENTITY"], [242, 258, "PROTEIN"], [40, 48, "GENE_OR_GENE_PRODUCT"], [105, 111, "ORGANISM"], [105, 111, "ENTITY"], [135, 147, "ENTITY"], [147, 154, "PROTEIN"], [147, 154, "GENE_OR_GENE_PRODUCT"], [219, 236, "PROTEIN"], [200, 212, "ENTITY"], [115, 124, "ENTITY"], [219, 236, "ENTITY"], [40, 48, "PROTEIN"], [147, 154, "GGP"]]}
{"text": "Titration of the viruses released in the cell culture revealed that TAT-Nb6 treatment suppressed progeny virus production for all strains at 48 hpi ( Fig. 7E ) .", "labels": [[17, 25, "TAXON"], [68, 76, "ENTITY"], [17, 23, "ENTITY"], [0, 10, "ENTITY"], [17, 23, "TAXON"], [111, 122, "ENTITY"], [130, 138, "ENTITY"], [41, 46, "CELL"], [41, 46, "CL"], [25, 34, "ENTITY"], [17, 25, "ENTITY"], [97, 105, "ENTITY"], [41, 54, "ENTITY"], [76, 86, "ENTITY"], [144, 148, "ENTITY"], [68, 76, "PROTEIN"], [86, 97, "ENTITY"]]}
{"text": "After 24 hpi , the RNA synthesis of all strains was predominantly suppressed by TAT-Nb6 ( Fig. 7B to D ) , and the relative RNA levels for strains SD16 , GD-HD , and VR2332 were significantly reduced compared to levels for the TAT-Nb53 group and no nanobody group ( Fig. 7C and D ) .", "labels": [[115, 124, "SO"], [9, 13, "ENTITY"], [105, 111, "ORGANISM"], [249, 258, "ENTITY"], [242, 249, "ENTITY"], [19, 23, "ENTITY"], [105, 111, "ENTITY"], [147, 154, "ENTITY"], [242, 258, "PROTEIN"], [40, 48, "GENE_OR_GENE_PRODUCT"], [135, 147, "ENTITY"], [147, 154, "PROTEIN"], [147, 154, "GENE_OR_GENE_PRODUCT"], [219, 236, "PROTEIN"], [200, 212, "ENTITY"], [115, 124, "ENTITY"], [219, 236, "ENTITY"], [40, 48, "PROTEIN"], [147, 154, "GGP"]]}
{"text": "Titration of the viruses released in the cell culture revealed that TAT-Nb6 treatment suppressed progeny virus production for all strains at 48 hpi ( Fig. 7E ) .", "labels": [[68, 76, "ENTITY"], [111, 122, "ENTITY"], [0, 10, "ENTITY"], [17, 25, "ENTITY"], [41, 46, "CELL"], [130, 138, "ENTITY"], [17, 25, "TAXON"], [41, 46, "CL"], [25, 34, "ENTITY"], [97, 105, "ENTITY"], [41, 54, "ENTITY"], [76, 86, "ENTITY"], [17, 23, "ENTITY"], [144, 148, "ENTITY"], [68, 76, "PROTEIN"], [17, 23, "TAXON"], [86, 97, "ENTITY"]]}
{"text": "As expected , Nsp9 was pulled down by TAT-Nb6-His but not by the control nanobody , TAT-Nb53-His ( Fig. 4 ) .", "labels": [[65, 73, "ENTITY"]]}
{"text": "Consistent with the Nsp9 expression results , titration of progeny viruses in the cell medium also demonstrated that TAT-Nb6 suppressed the virus replication in a dose-dependent manner", "labels": [[0, 16, "ENTITY"], [25, 36, "ENTITY"], [36, 44, "ENTITY"], [20, 25, "PROTEIN"], [20, 25, "GGP"], [67, 73, "ENTITY"], [20, 25, "ENTITY"], [20, 25, "GENE_OR_GENE_PRODUCT"], [82, 87, "ENTITY"]]}
{"text": "Indirect immunofluorescence showed that U274 is localized to the perinuclear region , as well as to the plasma membrane of transfected and infected cells ( see Fig. \u200bFig.3,3 , where cells have been permeabilized with Triton X-100 ) .", "labels": [[104, 111, "GO"], [48, 58, "ENTITY"], [212, 224, "ENTITY"], [104, 111, "CELLULAR_COMPONENT"], [65, 84, "ENTITY"], [212, 224, "SIMPLE_CHEMICAL"], [123, 148, "CELL_LINE"], [40, 45, "PROTEIN"], [65, 77, "CELLULAR_COMPONENT"], [40, 45, "ENTITY"], [65, 84, "GO"], [0, 28, "ENTITY"], [104, 111, "ENTITY"]]}
{"text": "Again , HeLa cells transfected with myc-U274 were able to internalize anti-myc antibodies ( Fig. \u200b(Fig.5,5 , upper panel , lanes 11 and 12 ) just like endogenous TfR ( Fig. \u200b(Fig.5,5 , upper panel , lanes 15 and 16 ) , whereas CD81 did not undergo efficient internalization ( Fig. \u200b(Fig.5,5 , upper panel , lanes 13 and 14 ) .", "labels": [[99, 117, "ENTITY"], [250, 260, "ENTITY"], [38, 47, "ENTITY"], [111, 117, "ENTITY"], [38, 47, "SIMPLE_CHEMICAL"], [164, 175, "SIMPLE_CHEMICAL"], [123, 131, "ENTITY"], [260, 283, "ENTITY"], [153, 164, "GENE_OR_GENE_PRODUCT"], [153, 164, "PROTEIN"], [99, 111, "ENTITY"], [72, 92, "ENTITY"], [94, 99, "PROTEIN"], [94, 109, "SIMPLE_CHEMICAL"], [117, 123, "ENTITY"], [81, 92, "GO"], [109, 117, "ENTITY"], [94, 99, "ENTITY"], [153, 164, "GGP"], [72, 92, "PROTEIN"], [10, 21, "ENTITY"], [10, 21, "CELL_LINE"], [60, 72, "ENTITY"], [10, 21, "CELL"], [15, 21, "CL"], [21, 33, "ENTITY"], [153, 164, "ENTITY"], [242, 250, "ENTITY"]]}
{"text": "A 37-kDa protein ( 3a protein ) was recognized by the anti-LH21 Ab in virus-infected cell lysate but not in uninfected cell lysate ( Fig. 1B ) , which indicates an active expression of 3a protein in the virus-infected cells .", "labels": [[70, 85, "CL"], [171, 188, "PROTEIN"], [70, 85, "CELL"], [50, 64, "PROTEIN"], [67, 85, "TAXON"], [108, 124, "ENTITY"], [9, 17, "CHEBI"], [54, 64, "TAXON"], [19, 22, "ENTITY"], [70, 85, "CELL"], [2, 17, "ENTITY"], [199, 218, "ENTITY"], [19, 22, "PROTEIN"], [108, 119, "CELL"], [2, 17, "PROTEIN"], [151, 171, "ENTITY"], [108, 119, "CL"], [50, 64, "ENTITY"], [199, 218, "CELL_TYPE"], [67, 90, "ENTITY"], [182, 188, "CHEBI"], [171, 188, "ENTITY"]]}
{"text": "IL-1\u03b2 was released from LPS-primed BMMs transduced with the M2- and 2B-expressing lentivirus ( Figure 1D ) . Similarly , the lentiviruses expressing the SARS-CoV E or 3a proteins stimulated IL-1\u03b2 release from LPS-primed BMMs ( Figure 1D ) .", "labels": [[60, 64, "ENTITY"], [125, 138, "ENTITY"], [82, 93, "TAXON"], [82, 93, "ENTITY"], [24, 40, "CELL_LINE"], [19, 35, "CELL_LINE"], [82, 93, "ORGANISM"], [167, 170, "CHEBI"], [35, 40, "CELL"], [0, 6, "CHEMICAL"], [164, 170, "ENTITY"], [0, 6, "ENTITY"], [0, 6, "GGP"], [95, 102, "ENTITY"], [60, 64, "GENE_OR_GENE_PRODUCT"], [179, 190, "GENE_OR_GENE_PRODUCT"], [60, 64, "CHEMICAL"], [220, 227, "ENTITY"], [179, 190, "GGP"], [170, 179, "ENTITY"], [10, 19, "ENTITY"], [24, 35, "ENTITY"], [24, 35, "CELL"], [24, 35, "ENTITY"], [40, 51, "ENTITY"], [179, 190, "PROTEIN"], [149, 162, "ORGANISM"], [35, 40, "ENTITY"], [149, 170, "PROTEIN"], [179, 190, "ENTITY"], [0, 6, "ENTITY"], [24, 35, "TAXON"], [0, 6, "PROTEIN"], [0, 6, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Specifically , emdoin inhibited SARS-CoV-associated 3a protein70 , and blocked an interaction between the SARS-CoV spike protein and ACE2 ( ref . 71 ) .", "labels": [[32, 55, "PROTEIN"], [102, 121, "ENTITY"], [102, 121, "PROTEIN"], [32, 55, "CHEMICAL"], [32, 55, "ENTITY"], [115, 121, "CHEBI"]]}
{"text": "Coimmunoprecipitation experiments were performed to determine whether U274 could interact with the SARS-CoV structural proteins M , E , and N. As shown in Fig. \u200bFig.6A6A ( upper panel ) , myc-U274 specifically coimmunoprecipitated E-HA ( lane 6 ) and M-HA ( lane 8) , and neither of these showed any nonspecific binding to myc-GST ( lanes 5 and 7 ) .", "labels": [[99, 108, "ORGANISM"], [312, 320, "PROTEIN"], [210, 231, "CHEMICAL"], [0, 22, "ENTITY"], [155, 160, "GENE_OR_GENE_PRODUCT"], [70, 75, "PROTEIN"], [70, 75, "ENTITY"], [289, 300, "ENTITY"], [155, 160, "ENTITY"], [245, 251, "ENTITY"], [119, 128, "CHEBI"], [312, 331, "GENE_OR_GENE_PRODUCT"], [99, 132, "PROTEIN"], [197, 210, "ENTITY"], [312, 323, "ENTITY"], [81, 90, "ENTITY"], [210, 231, "GENE_OR_GENE_PRODUCT"], [99, 130, "ENTITY"], [22, 34, "ENTITY"], [155, 160, "CHEMICAL"]]}
{"text": "Coimmunoprecipitation experiments were performed to determine whether U274 could interact with the SARS-CoV structural proteins M , E , and N. As shown in Fig. \u200bFig.6A6A ( upper panel ) , myc-U274 specifically coimmunoprecipitated E-HA ( lane 6 ) and M-HA ( lane 8) , and neither of these showed any nonspecific binding to myc-GST ( lanes 5 and 7 ) .", "labels": [[99, 108, "ORGANISM"], [312, 320, "PROTEIN"], [210, 231, "CHEMICAL"], [0, 22, "ENTITY"], [155, 160, "GENE_OR_GENE_PRODUCT"], [70, 75, "PROTEIN"], [70, 75, "ENTITY"], [289, 300, "ENTITY"], [155, 160, "ENTITY"], [245, 251, "ENTITY"], [119, 128, "CHEBI"], [312, 331, "GENE_OR_GENE_PRODUCT"], [99, 132, "PROTEIN"], [197, 210, "ENTITY"], [312, 323, "ENTITY"], [81, 90, "ENTITY"], [210, 231, "GENE_OR_GENE_PRODUCT"], [99, 130, "ENTITY"], [22, 34, "ENTITY"], [155, 160, "CHEMICAL"]]}
{"text": "As shown in Fig. \u200bFig.6B6B ( upper panel ) , the S protein of \u223c180-kDa interacts specifically with myc-U274 but not with myc-GST .", "labels": [[17, 27, "ENTITY"], [45, 51, "PROTEIN"], [12, 27, "CANCER"], [45, 51, "ENTITY"]]}
{"text": "These results indicated that the persistently infected Vero E6 cells produce infectious viruses .", "labels": [[6, 14, "ENTITY"], [63, 69, "CL"], [55, 60, "ENTITY"], [46, 55, "ENTITY"], [55, 69, "CELL_LINE"], [55, 69, "CELL"], [60, 69, "ENTITY"], [88, 96, "TAXON"], [77, 96, "ENTITY"]]}
{"text": "These results indicated that the persistently infected Vero E6 cells produce infectious viruses .", "labels": [[6, 14, "ENTITY"], [63, 69, "CL"], [46, 55, "ENTITY"], [55, 69, "CELL_LINE"], [55, 69, "CELL"], [60, 69, "ENTITY"], [88, 96, "TAXON"], [77, 96, "ENTITY"], [55, 60, "ENTITY"]]}
{"text": "The amount of mRNA8 and 9 of the persistent cells are 81.4 % of the acute infected cells .", "labels": [[44, 50, "CELL"], [33, 50, "ENTITY"], [14, 20, "ENTITY"], [44, 50, "CL"], [33, 50, "CELL_TYPE"], [68, 83, "ENTITY"], [14, 26, "PROTEIN"], [4, 11, "ENTITY"], [68, 83, "CELL_TYPE"], [14, 20, "GGP"]]}
{"text": "Interestingly , ACE-2 was also decreased in the acute infection of SARS-CoV.", "labels": [[48, 54, "ENTITY"], [48, 54, "DISEASE"]]}
{"text": "The majority of the virus in a seed could induce the apoptotic cell death of Vero E6 cells [ 13 ]", "labels": [[42, 49, "ENTITY"], [53, 68, "CL"], [20, 26, "ENTITY"], [77, 91, "CELL"], [68, 74, "DISEASE"], [77, 91, "ENTITY"], [85, 91, "CL"], [20, 26, "TAXON"], [77, 91, "CELL_LINE"], [31, 36, "ENTITY"], [53, 74, "ENTITY"], [63, 68, "CELL"]]}
{"text": "Fig 6 . In contrast , mice deficient in either CCR1 , CCR2 , or CCR5 exhibited more prominent airway epithelial cell apoptosis , a severe denuding bronchiolitis with an accumulation of cohesive apoptotic debris within the airway ( empty arrowhead ) , and perivenular/periarterial cuffing ( filled arrowhead ) but there was a distinct lack of cuffing around the affected airways .", "labels": [[325, 339, "ENTITY"], [247, 255, "CHEMICAL"], [84, 112, "CELL"], [84, 94, "ENTITY"], [138, 147, "DISEASE"], [94, 112, "CL"], [112, 117, "ENTITY"], [94, 112, "ENTITY"], [161, 169, "ENTITY"], [325, 339, "CELLULAR_COMPONENT"], [247, 280, "TISSUE"], [131, 138, "ENTITY"], [185, 194, "ENTITY"], [222, 237, "ENTITY"], [247, 280, "ENTITY"], [22, 27, "ENTITY"], [280, 297, "ENTITY"], [138, 147, "ENTITY"], [127, 131, "ENTITY"]]}
{"text": "This result suggested that , at least , the phosphorylation of Akt in viral infected cells were necessary to establish persistence .", "labels": [[109, 119, "ENTITY"], [76, 85, "CL"], [76, 85, "CELL"], [67, 85, "ENTITY"], [5, 12, "ENTITY"], [67, 85, "CELL_TYPE"]]}
{"text": "Among the 22 SARS blood samples that were obtained from the early stages of the disease , EM detected SARS-like viral particles in monocytes and lymphocytes of six patients . These round viral particles , with diameters of 80\u2013120 nm , were located in the cytoplasm .", "labels": [[102, 118, "ENTITY"], [13, 18, "DISEASE"], [60, 73, "ENTITY"], [13, 18, "ENTITY"], [18, 32, "ENTITY"], [181, 193, "ENTITY"], [80, 88, "ENTITY"], [181, 187, "TAXON"]]}
{"text": "Most of the infected cells were T cells . Some B cells and NK cells also were infected by the virus . By EM , the viral particles tended to form clusters and were located within or near the endoplasmic reticulum .", "labels": [[32, 40, "CELL_TYPE"], [110, 120, "ENTITY"], [59, 62, "CL"], [12, 27, "CELL_TYPE"], [21, 27, "ENTITY"], [140, 145, "ENTITY"], [186, 202, "ENTITY"], [32, 40, "CELL"], [32, 40, "CL"], [32, 40, "ENTITY"], [59, 62, "CELL_TYPE"], [21, 27, "CELL"], [59, 62, "CELL"], [186, 202, "CELLULAR_COMPONENT"], [21, 27, "CL"], [186, 202, "GO"], [12, 21, "ENTITY"], [59, 62, "ENTITY"]]}
{"text": "A large proportion of lymphocytes in the circulation and lymphoid organs contained the virus ( Fig. 2 , A and B ) .", "labels": [[87, 93, "ENTITY"], [22, 34, "CL"], [57, 73, "ENTITY"], [22, 34, "CELL_TYPE"], [8, 19, "ENTITY"], [57, 73, "TISSUE"], [22, 34, "ENTITY"], [87, 93, "TAXON"], [22, 34, "CELL"], [41, 53, "ENTITY"]]}
{"text": "In addition , the epithelial cells of mucosa of the small and large intestines were found to be infected by the virus by in situ hybridization and EM ( Fig. 3 G ) .", "labels": [[18, 29, "CELL_TYPE"], [18, 29, "CELL"], [121, 129, "ENTITY"], [18, 29, "CL"], [18, 29, "ENTITY"]]}
{"text": "Clusters of SARS viral particles also were detected in the cytoplasm of the distal tubular epithelium by EM ( Fig. 3 , M and N ) .", "labels": [[17, 33, "ENTITY"], [83, 102, "ENTITY"], [105, 108, "ENTITY"], [83, 102, "TISSUE"], [43, 52, "ENTITY"], [59, 69, "GO"], [0, 9, "ENTITY"], [105, 108, "PROTEIN"], [12, 17, "ENTITY"], [17, 23, "TAXON"], [59, 69, "ENTITY"], [76, 83, "ENTITY"], [12, 17, "DISEASE"], [59, 69, "ORGANISM_SUBSTANCE"]]}
{"text": "Results show that SARS patients \u2019 sera contain high levels of IgG recognizing 3a protein ( Fig. 1A ) .", "labels": [[0, 8, "ENTITY"], [23, 32, "ORGANISM"], [78, 81, "ENTITY"], [23, 32, "ENTITY"], [18, 23, "ENTITY"], [18, 23, "DISEASE"]]}
{"text": "First , a modest increase in the levels of IFN-\u03b1 and IFN-\u03b2 was detected in the lungs early ( on day 3 ) following SARS-CoV infection , but no statistical difference was found compared to mock-infected control samples ( P > 0.05 ) .", "labels": [[187, 209, "ENTITY"], [104, 123, "ENTITY"], [104, 123, "DISEASE"], [139, 154, "ENTITY"]]}
{"text": "When the variability between nsp 3 isolates of the SARS epidemic are compared , the results suggest that nsps 1 - 3 perform cell- and host- specific roles in replication and/or virulence . Additionally , they have demonstrated high capacity for adaptation to new environments and selective pressures .", "labels": [[35, 44, "ENTITY"], [276, 290, "ENTITY"], [29, 35, "GENE_OR_GENE_PRODUCT"], [69, 78, "ENTITY"], [51, 56, "ENTITY"], [170, 177, "ENTITY"], [227, 232, "ENTITY"], [29, 35, "ENTITY"], [56, 65, "ENTITY"], [29, 35, "PROTEIN"], [9, 21, "ENTITY"], [105, 112, "PROTEIN"], [105, 110, "ENTITY"], [105, 112, "ORGANISM"], [51, 56, "DISEASE"]]}
{"text": "PLpro alone induced mRNA expression of TGF-b1 ( greater than four fold ) , IL-1a ( approximately three fold),and RANTES ( approximately two fold ) ( Fig. 2A , D , and E ) , yet no signifi- ca nt rise in TNF-a and IFN-a compared to vector controls ( Fig. 2B and C ) .", "labels": [[219, 231, "ENTITY"], [0, 6, "ENTITY"], [39, 46, "GGP"], [103, 113, "GGP"], [103, 113, "PROTEIN"], [20, 25, "ENTITY"], [103, 113, "ENTITY"], [39, 46, "ENTITY"], [25, 36, "ENTITY"], [192, 195, "PROTEIN"], [39, 46, "GENE_OR_GENE_PRODUCT"], [103, 113, "GENE_OR_GENE_PRODUCT"], [12, 20, "ENTITY"], [39, 46, "PROTEIN"], [192, 195, "ENTITY"], [192, 195, "GENE_OR_GENE_PRODUCT"], [192, 195, "GGP"], [103, 113, "CHEMICAL"], [0, 6, "GENE_OR_GENE_PRODUCT"], [20, 25, "CHEBI"]]}
{"text": "Irbesartan can inhibit NTCP , thus inhibiting viral entry45,46 . SLC10A1 interacts with C11orf74 , a potential transcriptional repressor that interacts with nsp-10 of SARS-CoV47 . There are several other ARBs ( such as eletriptan , frovatriptan , and zolmitriptan ) in which their targets are potentially associated with HCoV-associated host proteins in the human interactome .", "labels": [[245, 251, "ENTITY"], [211, 219, "SIMPLE_CHEMICAL"], [293, 305, "ENTITY"], [245, 251, "CHEMICAL"], [219, 232, "ENTITY"], [0, 11, "CHEMICAL"], [46, 52, "ENTITY"], [219, 232, "SIMPLE_CHEMICAL"], [269, 281, "ENTITY"], [211, 219, "CHEBI"], [245, 251, "CHEBI"], [219, 232, "CHEMICAL"], [101, 127, "ENTITY"], [101, 127, "PROTEIN"], [46, 52, "DISEASE"], [0, 11, "SIMPLE_CHEMICAL"], [15, 23, "ENTITY"], [23, 28, "SIMPLE_CHEMICAL"], [305, 342, "PROTEIN"], [211, 219, "ENTITY"], [46, 52, "PROTEIN"], [245, 251, "SIMPLE_CHEMICAL"], [321, 342, "CHEBI"], [354, 364, "ENTITY"], [0, 11, "ENTITY"], [305, 342, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"], [211, 219, "CHEMICAL"], [305, 342, "ENTITY"]]}
{"text": "Kamitami et al. observed that SARS-CoV replication in human 293 cells suppresses IFN-\u03b2 mRNA accumulation ( Kamitani et al. , 2006 ) . Plasmid- based overexpression of nsp 1 resulted in the inhibition of host gene expression by promoting degradation of host mRNA , and that IFN-\u03b2 mRNA accumulation was decreased without alteration of IRF-3 phosphorylation , dimerization , or translocation .", "labels": [[200, 208, "RNA"], [203, 208, "ENTITY"], [81, 92, "RNA"], [81, 87, "CHEBI"], [30, 39, "ORGANISM"], [319, 333, "PROTEIN"], [39, 51, "ENTITY"], [143, 149, "ENTITY"], [200, 208, "TAXON"], [203, 213, "ENTITY"], [87, 92, "ENTITY"], [54, 70, "ORGANISM"], [64, 70, "CL"], [200, 208, "TAXON"], [92, 105, "ENTITY"], [87, 92, "CHEBI"], [339, 357, "ENTITY"], [87, 92, "ENTITY"], [30, 39, "ENTITY"], [319, 333, "GGP"], [54, 70, "CELL_TYPE"], [54, 64, "ENTITY"], [54, 60, "TAXON"], [319, 333, "GENE_OR_GENE_PRODUCT"], [319, 339, "ENTITY"], [268, 279, "RNA"], [227, 237, "ENTITY"], [81, 87, "ENTITY"], [357, 375, "ENTITY"], [81, 87, "GENE_OR_GENE_PRODUCT"], [0, 9, "ENTITY"], [70, 81, "ENTITY"], [81, 87, "ENTITY"]]}
{"text": "The Appr-1\u2033-p domain of nsp 3 is proposed to have functions in viral RNA synthesis ( Snijder et al. , 2003 ) .", "labels": [[63, 83, "ENTITY"], [24, 30, "GENE_OR_GENE_PRODUCT"], [4, 21, "GGP"], [63, 73, "TAXON"], [4, 21, "ENTITY"], [4, 14, "GENE_OR_GENE_PRODUCT"], [24, 30, "PROTEIN"], [24, 30, "ENTITY"], [50, 60, "ENTITY"], [4, 21, "PROTEIN"]]}
{"text": "Infection of WT , RAG-1-/- , or MyD88-/- mice resulted in weight loss beginning at day 2 post-infection ( Fig. 1A ) .", "labels": [[13, 16, "SO"], [13, 16, "ENTITY"], [55, 65, "ENTITY"], [29, 41, "ENTITY"], [55, 65, "DISEASE"], [32, 41, "ORGANISM"], [0, 10, "ENTITY"], [13, 16, "CELL"], [32, 41, "TAXON"]]}
{"text": "Control mice exhibited approximately 15 % transient weight loss , with peak weight loss at day 3 postinfection ( Fig. 2A ) . In contrast , the C3 \u2013/\u2013 mice were significantly protected from infection , with no significant weight loss evident at any time point .", "labels": [[71, 83, "DISEASE"], [0, 13, "ENTITY"], [241, 248, "ENTITY"], [160, 172, "DISEASE"], [143, 146, "TAXON"], [52, 59, "DISEASE"], [137, 146, "GENE_OR_GENE_PRODUCT"], [137, 146, "ENTITY"], [160, 172, "ENTITY"], [8, 13, "TAXON"], [8, 13, "ORGANISM"], [42, 59, "ENTITY"], [199, 209, "ENTITY"], [66, 83, "ENTITY"]]}
{"text": "ii ) the genetic absence of MyD88 significantly enhances SARS CoV- induced morbidity and mortality , and iii ) MyD88-dependent signaling through a receptor(s ) other than IL-1R1 or IL-18R1 is responsible for protection from rMA15 .", "labels": [[111, 127, "ENTITY"], [57, 62, "PROTEIN"], [9, 17, "ENTITY"]]}
{"text": "ii ) the genetic absence of MyD88 significantly enhances SARS CoV- induced morbidity and mortality , and iii ) MyD88-dependent signaling through a receptor(s ) other than IL-1R1 or IL-18R1 is responsible for protection from rMA15 .", "labels": [[111, 127, "ENTITY"], [57, 62, "PROTEIN"], [9, 17, "ENTITY"]]}
{"text": "Interestingly , SARS-CoV infection of either WT or MyD88-/- mice resulted in similar induction of type III IFN over mock-infected mice which peaked at 2 dpi and declined thereafter ( Fig 3A ) .", "labels": [[98, 107, "PROTEIN"], [181, 187, "CELL"], [98, 107, "GENE_OR_GENE_PRODUCT"], [51, 60, "ENTITY"], [51, 60, "ORGANISM"], [16, 25, "DISEASE"], [98, 107, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "Infection of WT mice with rMA15 resulted in a significant induction of proinflammatory chemokines including CCL2 ( MCP-1 ) , CCL3 ( MIP-1a ) , and CCL5 ( RANTES ) as compared to mockinfected control mice ( Fig. 3B ) .", "labels": [[178, 191, "ENTITY"], [13, 21, "ENTITY"], [26, 32, "GENE_OR_GENE_PRODUCT"], [125, 132, "PROTEIN"], [108, 113, "GENE_OR_GENE_PRODUCT"], [147, 154, "GGP"], [147, 154, "GENE_OR_GENE_PRODUCT"], [13, 21, "SO"], [125, 132, "GENE_OR_GENE_PRODUCT"], [71, 87, "ENTITY"], [58, 68, "ENTITY"], [71, 98, "PROTEIN"], [108, 113, "GGP"], [147, 154, "ENTITY"], [125, 132, "GGP"], [26, 32, "GGP"], [26, 32, "ENTITY"], [147, 154, "PROTEIN"], [0, 10, "ENTITY"], [125, 132, "ENTITY"], [147, 154, "CHEMICAL"], [108, 113, "PROTEIN"], [108, 113, "ENTITY"], [26, 32, "PROTEIN"], [13, 21, "ORGANISM"], [87, 98, "ENTITY"]]}
{"text": "In contrast to type I and type III IFNs , induction of CCL2 was dramatically reduced in rMA15-infected MyD88-/- mice compared to WT mice at 2 dpi ( 14 fold difference , P,0.005 ) .", "labels": [[129, 132, "ENTITY"], [15, 22, "ENTITY"], [26, 40, "ENTITY"], [26, 40, "GENE_OR_GENE_PRODUCT"], [129, 132, "SO"], [15, 40, "PROTEIN"], [129, 132, "ORGANISM"], [103, 112, "ENTITY"]]}
{"text": "hird , a biphasic pattern of significantly increased production of proinflammatory cytokines TNF-\u03b1 and IL-6 and chemokines CCL2/MCP-1 , CCL3/MIP-1\u03b1 , and CXCL10/IP-10 was seen both early and late following infection ( P < 0.05 ) .", "labels": [[112, 123, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [9, 18, "ENTITY"], [67, 93, "PROTEIN"], [0, 5, "ENTITY"], [187, 206, "ENTITY"], [112, 123, "GGP"]]}
{"text": "MIP1a , MIP1b , and MCP1 are all highly expressed in the lung following SARS-CoV MA15 infection of both C57BL/6J and C3 \u2013/\u2013 mice ( following SARS-CoV MA15 infection of both C57BL/6J and C3 \u2013/\u2013 mice ) , indicating that some inflammatory signaling remains intact in the absence of C3 .", "labels": [[0, 6, "CHEMICAL"], [0, 6, "GGP"], [0, 6, "PROTEIN"], [72, 86, "ENTITY"], [0, 6, "GENE_OR_GENE_PRODUCT"], [113, 124, "ENTITY"], [33, 40, "ENTITY"], [113, 124, "GENE_OR_GENE_PRODUCT"], [62, 81, "ORGANISM"], [0, 6, "ENTITY"], [86, 113, "ENTITY"]]}
{"text": "Both MCP-1 and RANTES levels were elevated in the serum following infection , regardless of mouse genetic background ( Fig. 7B ) .", "labels": [[22, 29, "ENTITY"], [92, 98, "TAXON"], [66, 76, "DISEASE"], [15, 22, "GGP"], [50, 56, "ENTITY"], [50, 56, "ORGANISM_SUBSTANCE"], [15, 22, "PROTEIN"], [5, 11, "PROTEIN"], [15, 22, "GENE_OR_GENE_PRODUCT"], [34, 43, "ENTITY"], [66, 76, "ENTITY"], [15, 22, "ENTITY"], [5, 11, "ENTITY"], [5, 11, "GENE_OR_GENE_PRODUCT"], [98, 106, "ENTITY"], [5, 11, "GGP"]]}
{"text": "Infection of WT mice with rMA15 resulted in a significant induction of proinflammatory chemokines including CCL2 ( MCP-1 ) , CCL3 ( MIP-1a ) , and CCL5 ( RANTES ) as compared to mockinfected control mice ( Fig. 3B ) .", "labels": [[178, 191, "ENTITY"], [13, 21, "ENTITY"], [26, 32, "GENE_OR_GENE_PRODUCT"], [147, 154, "CHEMICAL"], [147, 154, "PROTEIN"], [13, 21, "SO"], [108, 113, "GGP"], [71, 87, "ENTITY"], [58, 68, "ENTITY"], [108, 113, "PROTEIN"], [147, 154, "GENE_OR_GENE_PRODUCT"], [71, 98, "PROTEIN"], [147, 154, "ENTITY"], [108, 113, "GENE_OR_GENE_PRODUCT"], [125, 132, "PROTEIN"], [147, 154, "GGP"], [26, 32, "GGP"], [26, 32, "ENTITY"], [0, 10, "ENTITY"], [125, 132, "GENE_OR_GENE_PRODUCT"], [125, 132, "GGP"], [108, 113, "ENTITY"], [26, 32, "PROTEIN"], [13, 21, "ORGANISM"], [87, 98, "ENTITY"], [125, 132, "ENTITY"]]}
{"text": "Similarly , the induction of CCL3 ( 22 fold difference at 2 dpi , P,0.005 ; 5 fold difference at 4 dpi , p,0.005 ) and CCL5 ( 8 fold difference at 2 dpi , P,0.005 ; 8 fold difference at 4 dpi , P,0.01 ) were dramatically reduced in infected MyD88-/- compared to infected WT mice ( Fig. 3B ) .", "labels": [[250, 259, "ENTITY"], [58, 66, "GENE_OR_GENE_PRODUCT"], [58, 66, "ENTITY"], [44, 55, "ENTITY"], [60, 66, "CANCER"], [60, 66, "PROTEIN"], [44, 55, "ENTITY"], [94, 99, "ENTITY"], [60, 66, "ENTITY"], [262, 274, "CELL"], [94, 99, "ENTITY"], [221, 229, "ENTITY"]]}
{"text": "hird , a biphasic pattern of significantly increased production of proinflammatory cytokines TNF-\u03b1 and IL-6 and chemokines CCL2/MCP-1 , CCL3/MIP-1\u03b1 , and CXCL10/IP-10 was seen both early and late following infection ( P < 0.05 ) .", "labels": [[112, 123, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [9, 18, "ENTITY"], [67, 93, "PROTEIN"], [0, 5, "ENTITY"], [187, 206, "ENTITY"], [112, 123, "GGP"]]}
{"text": "MIP1a , MIP1b , and MCP1 are all highly expressed in the lung following SARS-CoV MA15 infection of both C57BL/6J and C3 \u2013/\u2013 mice ( following SARS-CoV MA15 infection of both C57BL/6J and C3 \u2013/\u2013 mice ) , indicating that some inflammatory signaling remains intact in the absence of C3 .", "labels": [[0, 6, "CHEMICAL"], [0, 6, "GGP"], [0, 6, "PROTEIN"], [72, 86, "ENTITY"], [0, 6, "GENE_OR_GENE_PRODUCT"], [113, 124, "ENTITY"], [33, 40, "ENTITY"], [113, 124, "GENE_OR_GENE_PRODUCT"], [62, 81, "ORGANISM"], [0, 6, "ENTITY"], [86, 113, "ENTITY"]]}
{"text": "Infection of WT mice with rMA15 resulted in a significant induction of proinflammatory chemokines including CCL2 ( MCP-1 ) , CCL3 ( MIP-1a ) , and CCL5 ( RANTES ) as compared to mockinfected control mice ( Fig. 3B ) .", "labels": [[125, 132, "ENTITY"], [178, 191, "ENTITY"], [13, 21, "ENTITY"], [26, 32, "GENE_OR_GENE_PRODUCT"], [13, 21, "SO"], [125, 132, "PROTEIN"], [108, 113, "GGP"], [71, 87, "ENTITY"], [58, 68, "ENTITY"], [108, 113, "PROTEIN"], [71, 98, "PROTEIN"], [108, 113, "GENE_OR_GENE_PRODUCT"], [125, 132, "GGP"], [125, 132, "GENE_OR_GENE_PRODUCT"], [26, 32, "GGP"], [147, 154, "ENTITY"], [26, 32, "ENTITY"], [0, 10, "ENTITY"], [147, 154, "GENE_OR_GENE_PRODUCT"], [147, 154, "CHEMICAL"], [108, 113, "ENTITY"], [26, 32, "PROTEIN"], [13, 21, "ORGANISM"], [147, 154, "PROTEIN"], [87, 98, "ENTITY"], [147, 154, "GGP"]]}
{"text": "Similarly , the induction of CCL3 ( 22 fold difference at 2 dpi , P,0.005 ; 5 fold difference at 4 dpi , p,0.005 ) and CCL5 ( 8 fold difference at 2 dpi , P,0.005 ; 8 fold difference at 4 dpi , P,0.01 ) were dramatically reduced in infected MyD88-/- compared to infected WT mice ( Fig. 3B ) .", "labels": [[250, 259, "ENTITY"], [58, 66, "GENE_OR_GENE_PRODUCT"], [58, 66, "ENTITY"], [44, 55, "ENTITY"], [60, 66, "CANCER"], [60, 66, "PROTEIN"], [44, 55, "ENTITY"], [94, 99, "ENTITY"], [60, 66, "ENTITY"], [262, 274, "CELL"], [94, 99, "ENTITY"], [221, 229, "ENTITY"]]}
{"text": "Second , a marked increase in inflammatory chemokines CCL5/RANTES and CXCL9/MIG , accompanied by an increase of inflammatory cytokines IFN-\u03b3 , IL-2 , and IL-5 , was detected in the lungs predominantly at day 7 , the late stage of infection ( P < 0.05 ) .", "labels": [[221, 230, "DISEASE"], [125, 135, "ENTITY"], [125, 135, "GENE_OR_GENE_PRODUCT"], [30, 54, "PROTEIN"], [109, 125, "ENTITY"], [210, 230, "ENTITY"], [109, 135, "PROTEIN"], [125, 135, "CHEMICAL"], [187, 201, "ENTITY"]]}
{"text": "Both MCP-1 and RANTES levels were elevated in the serum following infection , regardless of mouse genetic background ( Fig. 7B ) .", "labels": [[22, 29, "ENTITY"], [92, 98, "TAXON"], [15, 22, "PROTEIN"], [66, 76, "DISEASE"], [15, 22, "ENTITY"], [50, 56, "ENTITY"], [50, 56, "ORGANISM_SUBSTANCE"], [15, 22, "GGP"], [15, 22, "GENE_OR_GENE_PRODUCT"], [5, 11, "PROTEIN"], [34, 43, "ENTITY"], [66, 76, "ENTITY"], [5, 11, "ENTITY"], [5, 11, "GENE_OR_GENE_PRODUCT"], [98, 106, "ENTITY"], [5, 11, "GGP"]]}
{"text": "In addition to proinflammatory chemokines , virus-induced expression of several proinflammatory cytokines , including TNF-a ( 9 fold difference at 2 dpi , P,0.005 ; 3 fold difference at 4 dpi , p,0.005 ) , IL-1b ( 3.8 fold difference at 2 dpi , P,0.01 ) , and IL-6 ( 11 fold difference at 2 dpi , P,0.005 ) ; , was severely impaired in rMA15-infected MyD88-/- mice compared to infected WT mice ( Fig. 3C ) .", "labels": [[15, 31, "PROTEIN"], [194, 204, "GGP"], [144, 149, "ENTITY"], [194, 204, "ENTITY"], [149, 155, "ENTITY"], [315, 333, "ENTITY"], [149, 155, "CANCER"], [31, 42, "ENTITY"], [44, 58, "ENTITY"], [108, 118, "PROTEIN"], [194, 204, "PROTEIN"], [133, 147, "GENE_OR_GENE_PRODUCT"], [194, 204, "GENE_OR_GENE_PRODUCT"], [108, 118, "ENTITY"], [133, 147, "ENTITY"], [342, 351, "CELL"], [15, 42, "PROTEIN"], [15, 31, "ENTITY"], [133, 147, "PROTEIN"], [245, 252, "ENTITY"], [365, 377, "SO"], [108, 118, "GGP"], [149, 155, "PROTEIN"], [108, 118, "GENE_OR_GENE_PRODUCT"], [365, 377, "ENTITY"], [365, 377, "ORGANISM"], [245, 252, "GGP"], [245, 252, "GENE_OR_GENE_PRODUCT"], [194, 204, "CHEMICAL"], [133, 144, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [149, 155, "ENTITY"], [360, 365, "ENTITY"], [307, 315, "ENTITY"], [307, 336, "DISEASE"], [245, 252, "PROTEIN"]]}
{"text": "hird , a biphasic pattern of significantly increased production of proinflammatory cytokines TNF-\u03b1 and IL-6 and chemokines CCL2/MCP-1 , CCL3/MIP-1\u03b1 , and CXCL10/IP-10 was seen both early and late following infection ( P < 0.05 ) .", "labels": [[112, 123, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [9, 18, "ENTITY"], [67, 93, "PROTEIN"], [0, 5, "ENTITY"], [187, 206, "ENTITY"], [112, 123, "GGP"]]}
{"text": "Granulocyte colony-stimulating factor ( G-CSF ) , interleukin 6 ( IL-6 ) , tumor necrosis factor alpha ( TNF-a ) , and IL-1a comprised a group of cytokines and chemokines that were more highly produced in the lungs of C57BL/6J mice than in C3 \u2013/\u2013 mice ( Fig. 6B ) , all peaking at 2 days postinfection .", "labels": [[0, 38, "GENE_OR_GENE_PRODUCT"], [97, 103, "GGP"], [243, 252, "CELL"], [0, 38, "GGP"], [97, 103, "ENTITY"], [237, 243, "TAXON"], [66, 97, "GGP"], [137, 146, "PROTEIN"], [66, 75, "DISEASE"], [0, 38, "ENTITY"], [66, 97, "GENE_OR_GENE_PRODUCT"], [193, 205, "ENTITY"], [97, 103, "PROTEIN"], [270, 288, "ENTITY"], [209, 218, "ORGANISM"], [0, 38, "PROTEIN"], [137, 146, "ENTITY"], [146, 160, "ENTITY"], [97, 103, "GENE_OR_GENE_PRODUCT"], [66, 97, "PROTEIN"], [232, 243, "GENE_OR_GENE_PRODUCT"], [146, 160, "PROTEIN"], [232, 243, "ENTITY"], [193, 205, "ORGAN"], [209, 218, "ENTITY"], [66, 97, "ENTITY"]]}
{"text": "In addition to proinflammatory chemokines , virus-induced expression of several proinflammatory cytokines , including TNF-a ( 9 fold difference at 2 dpi , P,0.005 ; 3 fold difference at 4 dpi , p,0.005 ) , IL-1b ( 3.8 fold difference at 2 dpi , P,0.01 ) , and IL-6 ( 11 fold difference at 2 dpi , P,0.005 ) ; , was severely impaired in rMA15-infected MyD88-/- mice compared to infected WT mice ( Fig. 3C ) .", "labels": [[15, 31, "PROTEIN"], [194, 204, "GGP"], [144, 149, "ENTITY"], [194, 204, "ENTITY"], [149, 155, "ENTITY"], [315, 333, "ENTITY"], [149, 155, "CANCER"], [31, 42, "ENTITY"], [44, 58, "ENTITY"], [108, 118, "PROTEIN"], [194, 204, "PROTEIN"], [133, 147, "GENE_OR_GENE_PRODUCT"], [194, 204, "GENE_OR_GENE_PRODUCT"], [108, 118, "ENTITY"], [133, 147, "ENTITY"], [342, 351, "CELL"], [15, 42, "PROTEIN"], [15, 31, "ENTITY"], [133, 147, "PROTEIN"], [245, 252, "ENTITY"], [365, 377, "SO"], [108, 118, "GGP"], [149, 155, "PROTEIN"], [108, 118, "GENE_OR_GENE_PRODUCT"], [365, 377, "ENTITY"], [365, 377, "ORGANISM"], [245, 252, "GGP"], [245, 252, "GENE_OR_GENE_PRODUCT"], [194, 204, "CHEMICAL"], [133, 144, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [149, 155, "ENTITY"], [360, 365, "ENTITY"], [307, 315, "ENTITY"], [307, 336, "DISEASE"], [245, 252, "PROTEIN"]]}
{"text": "In addition to proinflammatory chemokines , virus-induced expression of several proinflammatory cytokines , including TNF-a ( 9 fold difference at 2 dpi , P,0.005 ; 3 fold difference at 4 dpi , p,0.005 ) , IL-1b ( 3.8 fold difference at 2 dpi , P,0.01 ) , and IL-6 ( 11 fold difference at 2 dpi , P,0.005 ) ; , was severely impaired in rMA15-infected MyD88-/- mice compared to infected WT mice ( Fig. 3C ) .", "labels": [[15, 31, "PROTEIN"], [194, 204, "GGP"], [144, 149, "ENTITY"], [194, 204, "ENTITY"], [149, 155, "ENTITY"], [315, 333, "ENTITY"], [149, 155, "CANCER"], [31, 42, "ENTITY"], [44, 58, "ENTITY"], [108, 118, "PROTEIN"], [194, 204, "PROTEIN"], [133, 147, "GENE_OR_GENE_PRODUCT"], [194, 204, "GENE_OR_GENE_PRODUCT"], [108, 118, "ENTITY"], [133, 147, "ENTITY"], [342, 351, "CELL"], [15, 42, "PROTEIN"], [15, 31, "ENTITY"], [133, 147, "PROTEIN"], [245, 252, "ENTITY"], [365, 377, "SO"], [108, 118, "GGP"], [149, 155, "PROTEIN"], [108, 118, "GENE_OR_GENE_PRODUCT"], [365, 377, "ENTITY"], [365, 377, "ORGANISM"], [245, 252, "GGP"], [245, 252, "GENE_OR_GENE_PRODUCT"], [194, 204, "CHEMICAL"], [133, 144, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [149, 155, "ENTITY"], [360, 365, "ENTITY"], [307, 315, "ENTITY"], [307, 336, "DISEASE"], [245, 252, "PROTEIN"]]}
{"text": "hird , a biphasic pattern of significantly increased production of proinflammatory cytokines TNF-\u03b1 and IL-6 and chemokines CCL2/MCP-1 , CCL3/MIP-1\u03b1 , and CXCL10/IP-10 was seen both early and late following infection ( P < 0.05 ) .", "labels": [[112, 123, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [9, 18, "ENTITY"], [67, 93, "PROTEIN"], [0, 5, "ENTITY"], [187, 206, "ENTITY"], [112, 123, "GGP"]]}
{"text": "Granulocyte colony-stimulating factor ( G-CSF ) , interleukin 6 ( IL-6 ) , tumor necrosis factor alpha ( TNF-a ) , and IL-1a comprised a group of cytokines and chemokines that were more highly produced in the lungs of C57BL/6J mice than in C3 \u2013/\u2013 mice ( Fig. 6B ) , all peaking at 2 days postinfection .", "labels": [[0, 38, "GENE_OR_GENE_PRODUCT"], [97, 103, "GGP"], [243, 252, "CELL"], [0, 38, "GGP"], [97, 103, "ENTITY"], [237, 243, "TAXON"], [66, 97, "GGP"], [137, 146, "PROTEIN"], [66, 75, "DISEASE"], [0, 38, "ENTITY"], [66, 97, "GENE_OR_GENE_PRODUCT"], [193, 205, "ENTITY"], [97, 103, "PROTEIN"], [270, 288, "ENTITY"], [209, 218, "ORGANISM"], [0, 38, "PROTEIN"], [137, 146, "ENTITY"], [146, 160, "ENTITY"], [97, 103, "GENE_OR_GENE_PRODUCT"], [66, 97, "PROTEIN"], [232, 243, "GENE_OR_GENE_PRODUCT"], [146, 160, "PROTEIN"], [232, 243, "ENTITY"], [193, 205, "ORGAN"], [209, 218, "ENTITY"], [66, 97, "ENTITY"]]}
{"text": "At 2 dpi , MyD88-/- mice exhibited a denuding bronchiolitis characterized by an extrusion of airway epithelial cells into the lumen of the airway and epithelial/endothelial atypia ( vacuolization and disruption of normal epithelium and endothelium ) but did not exhibit any obvious signs of inflammatory cell infiltration including peribronchivascular ( PBV ) or peri-venular immune cell infiltration ( \u2018 \u2018 cuffing \u2019 \u2019 ) .", "labels": [[150, 173, "ENTITY"], [214, 221, "ENTITY"], [388, 407, "ENTITY"], [358, 388, "ENTITY"], [214, 221, "TISSUE"], [100, 111, "ENTITY"], [388, 407, "CELLULAR_COMPONENT"], [322, 332, "CELLULAR_COMPONENT"], [5, 9, "ENTITY"], [358, 383, "CELL"], [322, 332, "ENTITY"], [93, 111, "CELL_TYPE"], [93, 111, "CELL"], [274, 282, "ENTITY"], [11, 20, "ENTITY"], [100, 111, "CL"], [291, 304, "CL"], [291, 304, "CELL"], [332, 354, "ENTITY"], [363, 383, "CL"], [288, 309, "ENTITY"]]}
{"text": "At 4 dpi , MyD88-/- mice continued to exhibit a denuding bronchiolitis , epithelial/endothelial atypia , and the added phenotype of PBV edema without immune cell infiltration around the airway though perivascular infiltration of immune cells was observed ( Fig. 4 ) .", "labels": [[142, 157, "CL"], [226, 236, "ENTITY"], [113, 119, "ENTITY"], [132, 136, "ENTITY"], [132, 136, "ORGAN"], [193, 213, "ENTITY"], [226, 236, "CELL"], [142, 157, "CELL"], [226, 236, "CL"], [11, 20, "ENTITY"], [132, 136, "DISEASE"], [226, 236, "CELL_TYPE"], [142, 162, "ENTITY"], [71, 96, "ENTITY"], [5, 9, "ENTITY"]]}
{"text": "Interestingly , by 6 dpi , the severity of PBV edema and denuding bronchiolitis in MyD88-/- mice had waned , and signs of lung inflammation were evident , with marked PBV infiltrates and perivascular cuffing even more severe than that seen in WT mice at similar times post infection .", "labels": [[57, 66, "DISEASE"], [83, 92, "ORGANISM"], [240, 246, "SO"], [43, 47, "ENTITY"], [268, 273, "ENTITY"], [160, 167, "ENTITY"], [183, 200, "ENTITY"], [119, 127, "DISEASE"], [43, 47, "PATHOLOGICAL_FORMATION"], [80, 92, "ENTITY"], [240, 246, "ENTITY"], [268, 273, "DISEASE"], [83, 92, "TAXON"], [119, 127, "ENTITY"], [40, 47, "ENTITY"], [57, 66, "ENTITY"], [43, 47, "DISEASE"], [183, 200, "TISSUE"], [160, 171, "CELL_TYPE"], [43, 47, "TISSUE"], [240, 246, "ORGANISM"], [262, 268, "ENTITY"]]}
{"text": "Fig 6 . In contrast , mice deficient in either CCR1 , CCR2 , or CCR5 exhibited more prominent airway epithelial cell apoptosis , a severe denuding bronchiolitis with an accumulation of cohesive apoptotic debris within the airway ( empty arrowhead ) , and perivenular/periarterial cuffing ( filled arrowhead ) but there was a distinct lack of cuffing around the affected airways .", "labels": [[325, 339, "ENTITY"], [247, 255, "CHEMICAL"], [84, 112, "CELL"], [84, 94, "ENTITY"], [138, 147, "DISEASE"], [94, 112, "CL"], [112, 117, "ENTITY"], [94, 112, "ENTITY"], [161, 169, "ENTITY"], [325, 339, "CELLULAR_COMPONENT"], [247, 280, "TISSUE"], [131, 138, "ENTITY"], [185, 194, "ENTITY"], [222, 237, "ENTITY"], [247, 280, "ENTITY"], [22, 27, "ENTITY"], [280, 297, "ENTITY"], [138, 147, "ENTITY"], [127, 131, "ENTITY"]]}
{"text": "In contrast , WT mice at 2 dpi exhibited pronounced lung inflammation characterized by perivascular cuffing , endothelial and epithelial atypia , and peribronchivascular immune cell infiltration , without the severe denuding bronchiolitis seen in MyD88-/- mice ( Fig. 4 ) .", "labels": [[14, 17, "ENTITY"], [146, 182, "ENTITY"], [3, 12, "ENTITY"], [14, 17, "SO"], [244, 256, "ENTITY"], [52, 57, "ENTITY"], [209, 216, "ENTITY"], [216, 225, "DISEASE"], [247, 256, "TAXON"], [146, 177, "CELL"], [87, 100, "TISSUE"], [122, 137, "ENTITY"], [52, 57, "DISEASE"], [122, 137, "TISSUE"], [216, 225, "ENTITY"], [247, 256, "ORGANISM"], [87, 100, "ENTITY"], [170, 177, "CL"], [14, 17, "ORGANISM"]]}
{"text": "Interestingly , by 6 dpi , the severity of PBV edema and denuding bronchiolitis in MyD88-/- mice had waned , and signs of lung inflammation were evident , with marked PBV infiltrates and perivascular cuffing even more severe than that seen in WT mice at similar times post infection .", "labels": [[57, 66, "DISEASE"], [83, 92, "ORGANISM"], [240, 246, "SO"], [43, 47, "ENTITY"], [268, 273, "ENTITY"], [160, 167, "ENTITY"], [183, 200, "ENTITY"], [119, 127, "DISEASE"], [43, 47, "PATHOLOGICAL_FORMATION"], [80, 92, "ENTITY"], [240, 246, "ENTITY"], [268, 273, "DISEASE"], [83, 92, "TAXON"], [119, 127, "ENTITY"], [40, 47, "ENTITY"], [57, 66, "ENTITY"], [43, 47, "DISEASE"], [183, 200, "TISSUE"], [160, 171, "CELL_TYPE"], [43, 47, "TISSUE"], [240, 246, "ORGANISM"], [262, 268, "ENTITY"]]}
{"text": "What is puzzling is that SARS-CoV infection leads to highly lethal pneumonia compared to other common cold symptoms after other coronavirus infections .", "labels": [[102, 116, "ENTITY"], [128, 151, "ENTITY"], [25, 34, "ORGANISM"], [128, 140, "ORGANISM"], [67, 77, "ENTITY"], [60, 77, "ORGANISM"], [128, 151, "DISEASE"], [67, 77, "DISEASE"], [25, 44, "ENTITY"], [60, 67, "ENTITY"], [25, 44, "DISEASE"]]}
{"text": "At 4 dpi , MyD88-/- mice continued to exhibit a denuding bronchiolitis , epithelial/endothelial atypia , and the added phenotype of PBV edema without immune cell infiltration around the airway though perivascular infiltration of immune cells was observed ( Fig. 4 ) .", "labels": [[142, 157, "CL"], [226, 236, "ENTITY"], [113, 119, "ENTITY"], [132, 136, "ENTITY"], [132, 136, "ORGAN"], [193, 213, "ENTITY"], [226, 236, "CELL"], [142, 157, "CELL"], [226, 236, "CL"], [11, 20, "ENTITY"], [132, 136, "DISEASE"], [226, 236, "CELL_TYPE"], [142, 162, "ENTITY"], [71, 96, "ENTITY"], [5, 9, "ENTITY"]]}
{"text": "Interestingly , by 6 dpi , the severity of PBV edema and denuding bronchiolitis in MyD88-/- mice had waned , and signs of lung inflammation were evident , with marked PBV infiltrates and perivascular cuffing even more severe than that seen in WT mice at similar times post infection .", "labels": [[57, 66, "DISEASE"], [83, 92, "ORGANISM"], [240, 246, "SO"], [43, 47, "ENTITY"], [268, 273, "ENTITY"], [160, 167, "ENTITY"], [183, 200, "ENTITY"], [119, 127, "DISEASE"], [43, 47, "PATHOLOGICAL_FORMATION"], [80, 92, "ENTITY"], [240, 246, "ENTITY"], [268, 273, "DISEASE"], [83, 92, "TAXON"], [119, 127, "ENTITY"], [40, 47, "ENTITY"], [57, 66, "ENTITY"], [43, 47, "DISEASE"], [183, 200, "TISSUE"], [160, 171, "CELL_TYPE"], [43, 47, "TISSUE"], [240, 246, "ORGANISM"], [262, 268, "ENTITY"]]}
{"text": "At 4 dpi , C57BL/6J mice displayed pronounced lung pathology , including inflammatory cells in the large airway and parenchyma , perivascular cuffing , thickening of the interstitial membrane , and low levels of intra-alveolar edema .", "labels": [[11, 20, "ENTITY"], [73, 86, "CELL"], [202, 227, "ENTITY"], [142, 152, "ENTITY"], [99, 105, "ENTITY"], [11, 20, "ORGANISM"], [46, 51, "ENTITY"], [166, 183, "ENTITY"], [170, 183, "GO"], [73, 86, "CL"], [99, 105, "MULTI-TISSUE_STRUCTURE"], [5, 9, "ENTITY"], [202, 227, "TISSUE"], [63, 86, "ENTITY"], [127, 142, "ENTITY"], [166, 183, "CELLULAR_COMPONENT"], [63, 86, "CELL_TYPE"], [127, 142, "MULTI-TISSUE_STRUCTURE"], [198, 202, "ENTITY"], [202, 227, "DISEASE"]]}
{"text": "The histological and flow cytometric analyses outlined above suggested that monocytes/macrophages are i ) the major cell population increased in the SARS-infected lung at early times post-infection , ii ) increased in the lung by a MyD88-dependent mechanism , and iii ) critical for protection against severe rMA15-induced disease .", "labels": [[116, 121, "ENTITY"], [149, 163, "ENTITY"], [21, 46, "ENTITY"], [302, 323, "ENTITY"], [76, 98, "CELL_TYPE"], [171, 177, "ENTITY"], [4, 17, "ENTITY"], [76, 98, "CL"], [76, 98, "CELL"], [232, 248, "ENTITY"], [76, 98, "ENTITY"]]}
{"text": "Furthermore , inflammatory monocytes , which have previously been associated with increased SARS-CoV MA15 pathogenesis ( 26 ) , were significantly increased in the lungs of wild-type mice but not C3 \u2013/\u2013 mice ( Fig. 5B ) .", "labels": [[173, 183, "TAXON"], [14, 27, "CELL_TYPE"], [101, 106, "ENTITY"], [14, 27, "ENTITY"], [82, 92, "ENTITY"], [164, 173, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [133, 147, "ENTITY"], [82, 101, "ORGANISM"], [192, 203, "ENTITY"], [61, 77, "ENTITY"], [92, 101, "ENTITY"], [173, 183, "ORGANISM"], [173, 183, "ENTITY"], [203, 210, "CELL"]]}
{"text": "The histological and flow cytometric analyses outlined above suggested that monocytes/macrophages are i ) the major cell population increased in the SARS-infected lung at early times post-infection , ii ) increased in the lung by a MyD88-dependent mechanism , and iii ) critical for protection against severe rMA15-induced disease .", "labels": [[116, 121, "ENTITY"], [149, 163, "ENTITY"], [76, 98, "CL"], [76, 98, "CELL"], [21, 46, "ENTITY"], [76, 98, "ENTITY"], [302, 323, "ENTITY"], [171, 177, "ENTITY"], [4, 17, "ENTITY"], [232, 248, "ENTITY"], [76, 98, "CELL_TYPE"]]}
{"text": "Second , the pulmonary migration of inflammatory cells ( such as NK T cells , NK cells , macrophages , and CD4 + T cells ) began on day 2 , increased rapidly to reach a peak on day 7 and/or 9 ( P < 0.01 ) , and declined thereafter .", "labels": [[62, 70, "CL"], [76, 81, "CELL_TYPE"], [103, 115, "CELL_TYPE"], [70, 78, "CELL_TYPE"], [70, 78, "ENTITY"], [76, 81, "ENTITY"], [70, 78, "CELL"], [76, 81, "CELL"], [36, 49, "CELL_TYPE"], [62, 70, "CELL"], [132, 140, "ENTITY"], [76, 81, "CL"], [123, 129, "ENTITY"], [13, 23, "ENTITY"], [62, 70, "ENTITY"], [103, 115, "GGP"], [36, 49, "ENTITY"], [70, 78, "CL"], [103, 115, "ENTITY"], [62, 70, "CELL_TYPE"]]}
{"text": "Finally , we observed significantly more dendritic cells and alveolar macrophages in the lungs of SARS-CoV MA15-infected C3 \u2013/\u2013 mice than in the lungs of infected C57BL/6J mice .", "labels": [[163, 172, "ORGANISM"], [41, 51, "ENTITY"], [107, 124, "CHEMICAL"], [61, 70, "ENTITY"], [163, 172, "ENTITY"], [61, 70, "CL"], [98, 121, "PROTEIN"], [98, 121, "GGP"], [41, 51, "CELL_TYPE"], [61, 70, "CELL_TYPE"], [98, 124, "ENTITY"], [41, 51, "CL"], [98, 128, "ORGANISM"], [41, 51, "CELL"], [61, 70, "CELL"]]}
{"text": "Fig 6 . In contrast , mice deficient in either CCR1 , CCR2 , or CCR5 exhibited more prominent airway epithelial cell apoptosis , a severe denuding bronchiolitis with an accumulation of cohesive apoptotic debris within the airway ( empty arrowhead ) , and perivenular/periarterial cuffing ( filled arrowhead ) but there was a distinct lack of cuffing around the affected airways .", "labels": [[325, 339, "ENTITY"], [247, 255, "CHEMICAL"], [84, 112, "CELL"], [84, 94, "ENTITY"], [138, 147, "DISEASE"], [94, 112, "CL"], [112, 117, "ENTITY"], [94, 112, "ENTITY"], [161, 169, "ENTITY"], [325, 339, "CELLULAR_COMPONENT"], [247, 280, "TISSUE"], [131, 138, "ENTITY"], [185, 194, "ENTITY"], [222, 237, "ENTITY"], [247, 280, "ENTITY"], [22, 27, "ENTITY"], [280, 297, "ENTITY"], [138, 147, "ENTITY"], [127, 131, "ENTITY"]]}
{"text": "Fig 6 . In contrast , mice deficient in either CCR1 , CCR2 , or CCR5 exhibited more prominent airway epithelial cell apoptosis , a severe denuding bronchiolitis with an accumulation of cohesive apoptotic debris within the airway ( empty arrowhead ) , and perivenular/periarterial cuffing ( filled arrowhead ) but there was a distinct lack of cuffing around the affected airways .", "labels": [[325, 339, "ENTITY"], [247, 255, "CHEMICAL"], [84, 112, "CELL"], [84, 94, "ENTITY"], [138, 147, "DISEASE"], [94, 112, "CL"], [112, 117, "ENTITY"], [94, 112, "ENTITY"], [161, 169, "ENTITY"], [325, 339, "CELLULAR_COMPONENT"], [247, 280, "TISSUE"], [131, 138, "ENTITY"], [185, 194, "ENTITY"], [222, 237, "ENTITY"], [247, 280, "ENTITY"], [22, 27, "ENTITY"], [280, 297, "ENTITY"], [138, 147, "ENTITY"], [127, 131, "ENTITY"]]}
{"text": "Fig 6 . In contrast , mice deficient in either CCR1 , CCR2 , or CCR5 exhibited more prominent airway epithelial cell apoptosis , a severe denuding bronchiolitis with an accumulation of cohesive apoptotic debris within the airway ( empty arrowhead ) , and perivenular/periarterial cuffing ( filled arrowhead ) but there was a distinct lack of cuffing around the affected airways .", "labels": [[325, 339, "ENTITY"], [247, 255, "CHEMICAL"], [84, 112, "CELL"], [84, 94, "ENTITY"], [138, 147, "DISEASE"], [94, 112, "CL"], [112, 117, "ENTITY"], [94, 112, "ENTITY"], [161, 169, "ENTITY"], [325, 339, "CELLULAR_COMPONENT"], [247, 280, "TISSUE"], [131, 138, "ENTITY"], [185, 194, "ENTITY"], [222, 237, "ENTITY"], [247, 280, "ENTITY"], [22, 27, "ENTITY"], [280, 297, "ENTITY"], [138, 147, "ENTITY"], [127, 131, "ENTITY"]]}
{"text": "The expression of 9b protein in SARS-CoV infected cells was confirmed by Western blot analysis with anti-9b monoclonal antibody .", "labels": [[18, 21, "GENE_OR_GENE_PRODUCT"], [119, 128, "GO"], [100, 128, "GENE_OR_GENE_PRODUCT"], [4, 15, "ENTITY"], [32, 56, "CELL_TYPE"], [32, 41, "ORGANISM"], [100, 128, "PROTEIN"], [50, 56, "CL"], [32, 41, "ENTITY"], [73, 95, "ENTITY"], [41, 50, "ENTITY"], [108, 128, "ENTITY"], [21, 29, "CHEBI"], [32, 41, "GGP"], [50, 56, "CELL"], [18, 29, "ENTITY"]]}
{"text": "First , a modest increase in the levels of IFN-\u03b1 and IFN-\u03b2 was detected in the lungs early ( on day 3 ) following SARS-CoV infection , but no statistical difference was found compared to mock-infected control samples ( P > 0.05 ) .", "labels": [[187, 209, "ENTITY"], [104, 123, "ENTITY"], [104, 123, "DISEASE"], [139, 154, "ENTITY"]]}
{"text": "First , a modest increase in the levels of IFN-\u03b1 and IFN-\u03b2 was detected in the lungs early ( on day 3 ) following SARS-CoV infection , but no statistical difference was found compared to mock-infected control samples ( P > 0.05 ) .", "labels": [[187, 209, "ENTITY"], [104, 123, "ENTITY"], [104, 123, "DISEASE"], [139, 154, "ENTITY"]]}
{"text": "Second , a marked increase in inflammatory chemokines CCL5/RANTES and CXCL9/MIG , accompanied by an increase of inflammatory cytokines IFN-\u03b3 , IL-2 , and IL-5 , was detected in the lungs predominantly at day 7 , the late stage of infection ( P < 0.05 ) .", "labels": [[221, 230, "DISEASE"], [125, 135, "ENTITY"], [125, 135, "GENE_OR_GENE_PRODUCT"], [30, 54, "PROTEIN"], [109, 125, "ENTITY"], [210, 230, "ENTITY"], [109, 135, "PROTEIN"], [125, 135, "CHEMICAL"], [187, 201, "ENTITY"]]}
{"text": "Second , a marked increase in inflammatory chemokines CCL5/RANTES and CXCL9/MIG , accompanied by an increase of inflammatory cytokines IFN-\u03b3 , IL-2 , and IL-5 , was detected in the lungs predominantly at day 7 , the late stage of infection ( P < 0.05 ) .", "labels": [[221, 230, "DISEASE"], [125, 135, "ENTITY"], [125, 135, "GENE_OR_GENE_PRODUCT"], [30, 54, "PROTEIN"], [109, 125, "ENTITY"], [210, 230, "ENTITY"], [109, 135, "PROTEIN"], [125, 135, "CHEMICAL"], [187, 201, "ENTITY"]]}
{"text": "Second , a marked increase in inflammatory chemokines CCL5/RANTES and CXCL9/MIG , accompanied by an increase of inflammatory cytokines IFN-\u03b3 , IL-2 , and IL-5 , was detected in the lungs predominantly at day 7 , the late stage of infection ( P < 0.05 ) .", "labels": [[221, 230, "DISEASE"], [125, 135, "ENTITY"], [125, 135, "GENE_OR_GENE_PRODUCT"], [30, 54, "PROTEIN"], [109, 125, "ENTITY"], [210, 230, "ENTITY"], [109, 135, "PROTEIN"], [125, 135, "CHEMICAL"], [187, 201, "ENTITY"]]}
{"text": "Second , a marked increase in inflammatory chemokines CCL5/RANTES and CXCL9/MIG , accompanied by an increase of inflammatory cytokines IFN-\u03b3 , IL-2 , and IL-5 , was detected in the lungs predominantly at day 7 , the late stage of infection ( P < 0.05 ) .", "labels": [[221, 230, "DISEASE"], [125, 135, "ENTITY"], [125, 135, "GENE_OR_GENE_PRODUCT"], [30, 54, "PROTEIN"], [109, 125, "ENTITY"], [210, 230, "ENTITY"], [109, 135, "PROTEIN"], [125, 135, "CHEMICAL"], [187, 201, "ENTITY"]]}
{"text": "However , numerous cytokines and chemokines , such as IL-5 , G-CSF , and KC ( keratinocyte chemoattractant or CXCL1 ) were present in significantly higher abundance in the lungs of C57BL/6J mice than in those of C3 knockout mice ( Fig. 7C ) .", "labels": [[73, 78, "CELL"], [203, 215, "GENE_OR_GENE_PRODUCT"], [73, 91, "PROTEIN"], [172, 181, "ORGANISM"], [91, 110, "GENE_OR_GENE_PRODUCT"], [203, 215, "ENTITY"], [91, 110, "GGP"], [91, 110, "PROTEIN"], [73, 78, "ENTITY"], [73, 78, "CL"], [148, 155, "ENTITY"], [165, 172, "ORGAN"], [224, 231, "GENE_OR_GENE_PRODUCT"], [91, 110, "ENTITY"], [172, 181, "ENTITY"], [78, 91, "ENTITY"], [165, 172, "ENTITY"]]}
{"text": "hird , a biphasic pattern of significantly increased production of proinflammatory cytokines TNF-\u03b1 and IL-6 and chemokines CCL2/MCP-1 , CCL3/MIP-1\u03b1 , and CXCL10/IP-10 was seen both early and late following infection ( P < 0.05 ) .", "labels": [[112, 123, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [9, 18, "ENTITY"], [67, 93, "PROTEIN"], [0, 5, "ENTITY"], [187, 206, "ENTITY"], [112, 123, "GGP"]]}
{"text": "An increase in mRNA transcripts for CCL2/MCP-1 , CCL3/MIP-1\u03b1 , and CXCL10/IP-10 was detected in the lung early on days 2 and 3 p.i . , when peak viral replication occurred .", "labels": [[140, 145, "TAXON"], [20, 32, "ENTITY"], [15, 32, "CHEBI"], [36, 47, "ENTITY"], [15, 20, "ENTITY"], [100, 105, "ENTITY"], [36, 47, "GGP"], [36, 47, "GENE_OR_GENE_PRODUCT"], [36, 47, "PROTEIN"], [140, 151, "ENTITY"], [3, 12, "ENTITY"], [15, 32, "RNA"]]}
{"text": "An increase in mRNA transcripts for CCL2/MCP-1 , CCL3/MIP-1\u03b1 , and CXCL10/IP-10 was detected in the lung early on days 2 and 3 p.i . , when peak viral replication occurred .", "labels": [[140, 145, "TAXON"], [20, 32, "ENTITY"], [15, 32, "CHEBI"], [15, 20, "ENTITY"], [100, 105, "ENTITY"], [36, 47, "GGP"], [36, 47, "PROTEIN"], [140, 151, "ENTITY"], [3, 12, "ENTITY"], [36, 47, "GENE_OR_GENE_PRODUCT"], [15, 32, "RNA"], [36, 47, "ENTITY"]]}
{"text": "An increase in mRNA transcripts for CCL2/MCP-1 , CCL3/MIP-1\u03b1 , and CXCL10/IP-10 was detected in the lung early on days 2 and 3 p.i . , when peak viral replication occurred .", "labels": [[36, 47, "ENTITY"], [140, 145, "TAXON"], [36, 47, "PROTEIN"], [20, 32, "ENTITY"], [15, 32, "CHEBI"], [15, 20, "ENTITY"], [100, 105, "ENTITY"], [36, 47, "GENE_OR_GENE_PRODUCT"], [140, 151, "ENTITY"], [3, 12, "ENTITY"], [15, 32, "RNA"], [36, 47, "GGP"]]}
{"text": "In contrast , mRNA transcripts for CCL5/RANTES and CXCL9/MIG increased predominantly late in infection on days 5 and 7 , when histopathologic evidence of pneumonitis was seen in the infected lungs .", "labels": [[126, 142, "ENTITY"], [182, 191, "ORGAN"], [182, 191, "ENTITY"], [14, 19, "CHEBI"], [14, 19, "RNA"]]}
{"text": "In contrast , mRNA transcripts for CCL5/RANTES and CXCL9/MIG increased predominantly late in infection on days 5 and 7 , when histopathologic evidence of pneumonitis was seen in the infected lungs .", "labels": [[126, 142, "ENTITY"], [182, 191, "ORGAN"], [182, 191, "ENTITY"], [14, 19, "CHEBI"], [14, 19, "RNA"]]}
{"text": "An increase in mRNA transcripts for CCR2 , CCR5 , and CXCR3 , which are receptors for the upregulated chemokines ( CCR2 for CCL2/MCP-1 , CCR5 for CCL3/MIP-1a and CCL5/RANTES , and CXCR3 for CXCL9/MIG and CXCL10/IP-10 ) , was also found in the lungs after infection with SARS-CoV ( Fig. 1C ) .", "labels": [[124, 137, "GGP"], [255, 270, "PROTEIN"], [243, 255, "DISEASE"], [180, 190, "GENE_OR_GENE_PRODUCT"], [102, 115, "ENTITY"], [180, 190, "CHEMICAL"], [255, 270, "ORGANISM"], [3, 12, "ENTITY"], [243, 255, "ENTITY"], [15, 32, "RNA"], [90, 102, "PROTEIN"], [255, 270, "ENTITY"], [255, 270, "GGP"], [180, 190, "PROTEIN"], [48, 54, "ENTITY"], [36, 41, "PROTEIN"], [36, 41, "GGP"], [190, 204, "PROTEIN"], [124, 137, "GENE_OR_GENE_PRODUCT"], [48, 54, "PROTEIN"], [36, 41, "ENTITY"], [124, 137, "ENTITY"], [20, 32, "ENTITY"], [190, 204, "GENE_OR_GENE_PRODUCT"], [48, 54, "GENE_OR_GENE_PRODUCT"], [180, 190, "ENTITY"], [36, 41, "GENE_OR_GENE_PRODUCT"], [102, 115, "PROTEIN"], [124, 137, "PROTEIN"], [102, 115, "GENE_OR_GENE_PRODUCT"], [190, 204, "ENTITY"], [102, 115, "GGP"], [15, 32, "CHEBI"], [15, 20, "ENTITY"], [190, 204, "GGP"], [48, 54, "GGP"], [90, 102, "ENTITY"]]}
{"text": "An increase in mRNA transcripts for CCR2 , CCR5 , and CXCR3 , which are receptors for the upregulated chemokines ( CCR2 for CCL2/MCP-1 , CCR5 for CCL3/MIP-1a and CCL5/RANTES , and CXCR3 for CXCL9/MIG and CXCL10/IP-10 ) , was also found in the lungs after infection with SARS-CoV ( Fig. 1C ) .", "labels": [[255, 270, "PROTEIN"], [243, 255, "DISEASE"], [102, 115, "ENTITY"], [255, 270, "ORGANISM"], [124, 137, "ENTITY"], [36, 41, "PROTEIN"], [3, 12, "ENTITY"], [243, 255, "ENTITY"], [15, 32, "RNA"], [90, 102, "PROTEIN"], [180, 190, "GENE_OR_GENE_PRODUCT"], [255, 270, "ENTITY"], [255, 270, "GGP"], [36, 41, "GENE_OR_GENE_PRODUCT"], [48, 54, "ENTITY"], [190, 204, "PROTEIN"], [48, 54, "PROTEIN"], [36, 41, "GGP"], [190, 204, "GENE_OR_GENE_PRODUCT"], [20, 32, "ENTITY"], [180, 190, "PROTEIN"], [124, 137, "GENE_OR_GENE_PRODUCT"], [48, 54, "GENE_OR_GENE_PRODUCT"], [102, 115, "PROTEIN"], [180, 190, "CHEMICAL"], [102, 115, "GENE_OR_GENE_PRODUCT"], [190, 204, "ENTITY"], [102, 115, "GGP"], [15, 32, "CHEBI"], [36, 41, "ENTITY"], [124, 137, "PROTEIN"], [180, 190, "ENTITY"], [15, 20, "ENTITY"], [190, 204, "GGP"], [48, 54, "GGP"], [124, 137, "GGP"], [90, 102, "ENTITY"]]}
{"text": "An increase in mRNA transcripts for CCR2 , CCR5 , and CXCR3 , which are receptors for the upregulated chemokines ( CCR2 for CCL2/MCP-1 , CCR5 for CCL3/MIP-1a and CCL5/RANTES , and CXCR3 for CXCL9/MIG and CXCL10/IP-10 ) , was also found in the lungs after infection with SARS-CoV ( Fig. 1C ) .", "labels": [[255, 270, "PROTEIN"], [243, 255, "DISEASE"], [180, 190, "CHEMICAL"], [102, 115, "ENTITY"], [255, 270, "ORGANISM"], [124, 137, "ENTITY"], [36, 41, "PROTEIN"], [3, 12, "ENTITY"], [243, 255, "ENTITY"], [15, 32, "RNA"], [90, 102, "PROTEIN"], [255, 270, "ENTITY"], [255, 270, "GGP"], [36, 41, "GENE_OR_GENE_PRODUCT"], [48, 54, "ENTITY"], [180, 190, "PROTEIN"], [180, 190, "ENTITY"], [190, 204, "PROTEIN"], [48, 54, "PROTEIN"], [36, 41, "GGP"], [190, 204, "GENE_OR_GENE_PRODUCT"], [20, 32, "ENTITY"], [180, 190, "GENE_OR_GENE_PRODUCT"], [124, 137, "GENE_OR_GENE_PRODUCT"], [48, 54, "GENE_OR_GENE_PRODUCT"], [102, 115, "PROTEIN"], [102, 115, "GENE_OR_GENE_PRODUCT"], [190, 204, "ENTITY"], [102, 115, "GGP"], [15, 32, "CHEBI"], [36, 41, "ENTITY"], [124, 137, "PROTEIN"], [15, 20, "ENTITY"], [190, 204, "GGP"], [48, 54, "GGP"], [124, 137, "GGP"], [90, 102, "ENTITY"]]}
{"text": "Second , the pulmonary migration of inflammatory cells ( such as NK T cells , NK cells , macrophages , and CD4 + T cells ) began on day 2 , increased rapidly to reach a peak on day 7 and/or 9 ( P < 0.01 ) , and declined thereafter .", "labels": [[76, 81, "ENTITY"], [62, 70, "CL"], [76, 81, "CELL"], [103, 115, "CELL_TYPE"], [76, 81, "CELL_TYPE"], [70, 78, "CL"], [70, 78, "CELL_TYPE"], [36, 49, "CELL_TYPE"], [62, 70, "CELL"], [132, 140, "ENTITY"], [70, 78, "ENTITY"], [123, 129, "ENTITY"], [13, 23, "ENTITY"], [70, 78, "CELL"], [62, 70, "ENTITY"], [103, 115, "GGP"], [36, 49, "ENTITY"], [103, 115, "ENTITY"], [76, 81, "CL"], [62, 70, "CELL_TYPE"]]}
{"text": "Second , the pulmonary migration of inflammatory cells ( such as NK T cells , NK cells , macrophages , and CD4 + T cells ) began on day 2 , increased rapidly to reach a peak on day 7 and/or 9 ( P < 0.01 ) , and declined thereafter .", "labels": [[62, 70, "CL"], [76, 81, "CELL_TYPE"], [103, 115, "CELL_TYPE"], [70, 78, "CELL_TYPE"], [70, 78, "ENTITY"], [76, 81, "ENTITY"], [70, 78, "CELL"], [76, 81, "CELL"], [36, 49, "CELL_TYPE"], [62, 70, "CELL"], [132, 140, "ENTITY"], [76, 81, "CL"], [123, 129, "ENTITY"], [13, 23, "ENTITY"], [62, 70, "ENTITY"], [103, 115, "GGP"], [36, 49, "ENTITY"], [70, 78, "CL"], [103, 115, "ENTITY"], [62, 70, "CELL_TYPE"]]}
{"text": "Consistently with what was observed in human SARS-CoV patients ( 25 ) , lymphopenia was observed in the lungs of both SARS-CoV MA15-infected C57BL/6J and C3 \u2013/\u2013 mice with reduced percentages of B cells ( Fig. 5A ) and CD4 T cells relative to those in mock-infected mice following infection .", "labels": [[113, 141, "PROTEIN"], [0, 13, "ENTITY"], [214, 224, "CELL_TYPE"], [251, 265, "ENTITY"], [251, 265, "ORGANISM"], [150, 161, "GENE_OR_GENE_PRODUCT"], [218, 224, "CL"], [45, 54, "ENTITY"], [214, 224, "GENE_OR_GENE_PRODUCT"], [39, 45, "ENTITY"], [251, 265, "TAXON"], [150, 157, "ENTITY"], [242, 251, "ENTITY"], [27, 36, "ENTITY"], [191, 196, "CELL"], [214, 224, "ENTITY"], [113, 127, "ENTITY"], [196, 204, "CELL"], [191, 196, "ENTITY"], [191, 196, "CELL_TYPE"], [39, 63, "ORGANISM"], [54, 63, "ENTITY"], [39, 54, "GGP"], [127, 141, "ORGANISM"]]}
{"text": "The number of CD8 + T cells increased sharply on days 7 and 9 ( P < 0.05 )", "labels": [[14, 22, "ENTITY"], [14, 22, "CELL_TYPE"], [14, 22, "GGP"], [14, 18, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Therefore , we suggest that emodin may contribute to reduced virus release from the SARS-CoV-infected cell through inhibition of the current medi-ated by 3a protein .", "labels": [[154, 157, "ENTITY"], [141, 157, "PROTEIN"], [84, 102, "ENTITY"]]}
{"text": "Particularly , ORF3 and ORF8 in SARS-CoV-2 are highly divergent from ORF3a and ORF8b in SARS-CoV that are known to induce NLRP3 inflammasome activation .", "labels": []}
{"text": "We found that LY294002 ( PI kinase inhibitor ) significantly inhibited the entry of SARS pseudovirions into VeroE6 cells , whereas entry of VSV-G pseudovirus was not affected ( Fig. 1A ) .", "labels": [[25, 35, "GENE_OR_GENE_PRODUCT"], [14, 23, "SIMPLE_CHEMICAL"], [81, 89, "ORGANISM"], [103, 115, "ENTITY"], [47, 61, "ENTITY"], [137, 146, "ORGANISM"], [14, 23, "ENTITY"], [103, 115, "CELL"], [25, 35, "ENTITY"], [84, 89, "ENTITY"], [137, 146, "ENTITY"], [14, 23, "CHEMICAL"], [25, 28, "PROTEIN"], [103, 115, "CELL_LINE"], [108, 115, "CL"], [140, 146, "TAXON"]]}
{"text": "Another PI kinase inhibitor , wortmannin , also inhibited SARS-CoV S-mediated entry into VeroE6 cells with no effect on VSV-G pseudovirus entry ( Fig. 1E ) .", "labels": [[8, 28, "GGP"], [58, 67, "ENTITY"], [117, 126, "ORGANISM"], [84, 96, "CELL"], [89, 96, "CL"], [84, 96, "ENTITY"], [48, 67, "ORGANISM"], [102, 110, "ENTITY"], [120, 126, "TAXON"], [8, 18, "PROTEIN"], [117, 126, "ENTITY"], [48, 58, "GGP"], [48, 58, "ENTITY"], [8, 28, "ENTITY"], [8, 18, "SIMPLE_CHEMICAL"], [84, 96, "CELL_LINE"]]}
{"text": "From these results , we conclude that LY294002 and wortmannin inhibit SARS pseudovirus entry by targeting PI4 KB and that PI4 KB is involved in SARS-CoV S-mediated entry into VeroE6 cells .", "labels": [[141, 153, "ORGANISM"], [144, 153, "ENTITY"], [170, 182, "CELL_LINE"], [170, 182, "CELL"], [170, 182, "ENTITY"], [175, 182, "CL"], [70, 75, "ORGANISM"], [11, 19, "ENTITY"], [106, 110, "GENE_OR_GENE_PRODUCT"], [117, 126, "GENE_OR_GENE_PRODUCT"], [106, 110, "ENTITY"], [117, 126, "ENTITY"]]}
{"text": "injecting SARS-CoV spike into mice worsened lung injury .", "labels": [[44, 56, "DISEASE"], [0, 10, "ENTITY"], [30, 35, "ORGANISM"], [19, 25, "ENTITY"], [44, 56, "ENTITY"], [10, 19, "ENTITY"], [30, 35, "ENTITY"], [10, 19, "ORGANISM"], [30, 35, "TAXON"], [44, 49, "ORGAN"]]}
{"text": "These tentative suggestions were based on the observation that SARS-CoV-2 uses angiotensin-converting enzyme 2 ( ACE2 ) as the receptor binding domain for its spike protein ( Lu et al. , 2020 ; Wan , Shang , Graham , Baric , & Li , 2020 ) , similarly to the coronavirus strain implicated in the 2002\u20132003 SARS epidemic ( Dimitrov , 2003 ; Ge et al. , 2013 ; Li et al. , 2003 ; Prabakaran et al 2004 ; Turner , Hiscox , & Hooper , 2004 ) .", "labels": [[63, 74, "SIMPLE_CHEMICAL"], [208, 215, "ENTITY"], [123, 144, "PROTEIN"], [358, 368, "CHEMICAL"], [155, 165, "ENTITY"], [63, 74, "ENTITY"], [79, 111, "PROTEIN"], [16, 28, "ENTITY"], [46, 58, "ENTITY"], [241, 258, "TAXON"], [377, 388, "DISEASE"], [102, 109, "SO"], [136, 144, "SO"], [63, 74, "CHEMICAL"], [377, 388, "ENTITY"], [79, 111, "GENE_OR_GENE_PRODUCT"], [358, 368, "ENTITY"], [159, 165, "CHEBI"], [194, 200, "ENTITY"], [241, 258, "ENTITY"], [123, 144, "ENTITY"], [178, 184, "ENTITY"], [155, 165, "PROTEIN"], [79, 111, "ENTITY"], [241, 258, "ORGANISM"]]}
{"text": "The researchers found that SARS-CoV-infected or recombinant SARS-spike protein-treated wild-type mice exhibited significantly reduced ACE2 expression in the lungs .", "labels": [[134, 139, "ENTITY"], [97, 102, "ENTITY"], [97, 102, "TAXON"], [48, 60, "ENTITY"], [97, 102, "ORGANISM"], [134, 139, "GGP"], [60, 71, "ENTITY"], [134, 139, "PROTEIN"], [157, 163, "ORGAN"], [87, 97, "ENTITY"], [4, 16, "ENTITY"], [139, 150, "ENTITY"], [71, 87, "ENTITY"], [27, 45, "ENTITY"], [134, 139, "GENE_OR_GENE_PRODUCT"], [157, 163, "ENTITY"]]}
{"text": "The angiotensin-converting enzyme 2 ( ACE2 ) was identified as the critical receptor for mediating SARS-2002 entry into host cells ( 7 , 8) .", "labels": [[89, 109, "ENTITY"], [115, 125, "CELL"], [115, 125, "ENTITY"], [4, 36, "ENTITY"], [89, 99, "CHEMICAL"], [27, 34, "SO"], [115, 125, "CELL_TYPE"], [4, 36, "PROTEIN"], [115, 125, "CL"], [4, 36, "GENE_OR_GENE_PRODUCT"], [89, 99, "PROTEIN"], [63, 76, "ENTITY"]]}
{"text": "C4b , CfB , and C3 all had significantly higher abundances in the lungs of mice infected with a lethal dose of SARS-CoV MA15 than in those of mice infected with a sublethal dose ( Fig. 1A ) .", "labels": [[96, 103, "ENTITY"], [161, 173, "ENTITY"], [111, 120, "ENTITY"], [0, 4, "PROTEIN"], [75, 80, "ENTITY"], [0, 4, "GGP"], [75, 80, "ENTITY"], [108, 120, "ORGANISM"], [41, 48, "ENTITY"], [0, 4, "ENTITY"], [0, 4, "GENE_OR_GENE_PRODUCT"]]}
{"text": "C4b , CfB , and C3 all had significantly higher abundances in the lungs of mice infected with a lethal dose of SARS-CoV MA15 than in those of mice infected with a sublethal dose ( Fig. 1A ) .", "labels": [[96, 103, "ENTITY"], [161, 173, "ENTITY"], [111, 120, "ENTITY"], [0, 4, "ENTITY"], [75, 80, "ENTITY"], [0, 4, "GENE_OR_GENE_PRODUCT"], [75, 80, "ENTITY"], [0, 4, "PROTEIN"], [108, 120, "ORGANISM"], [41, 48, "ENTITY"], [0, 4, "GGP"]]}
{"text": "C4b , CfB , and C3 all had significantly higher abundances in the lungs of mice infected with a lethal dose of SARS-CoV MA15 than in those of mice infected with a sublethal dose ( Fig. 1A ) .", "labels": [[96, 103, "ENTITY"], [161, 173, "ENTITY"], [111, 120, "ENTITY"], [0, 4, "ENTITY"], [75, 80, "ENTITY"], [0, 4, "GENE_OR_GENE_PRODUCT"], [75, 80, "ENTITY"], [0, 4, "PROTEIN"], [108, 120, "ORGANISM"], [41, 48, "ENTITY"], [0, 4, "GGP"]]}
{"text": "C3 activation products ( C3 fragments C3a , C3b , iC3b , C3dg , and C3c ) were detected by Western blotting in lung tissue of SARS-CoV MA15-infected mice , but not in control mice , as early as 1 day postinfection ( dpi ) ( Fig. 1B ) , confirming that SARS-CoV MA15 infection activates the complement pathway .", "labels": [[25, 38, "ENTITY"], [0, 23, "PROTEIN"], [160, 167, "ENTITY"], [25, 38, "PROTEIN"], [99, 116, "ENTITY"], [135, 140, "ENTITY"], [50, 57, "GGP"], [247, 261, "ENTITY"], [236, 252, "ORGANISM"], [50, 57, "PROTEIN"], [236, 247, "ENTITY"], [50, 57, "ENTITY"], [116, 135, "ENTITY"], [191, 200, "ENTITY"], [116, 126, "ORGANISM"], [0, 3, "GGP"], [185, 191, "ENTITY"], [79, 99, "ENTITY"], [50, 57, "GENE_OR_GENE_PRODUCT"], [0, 23, "ENTITY"], [276, 290, "ENTITY"], [116, 126, "GGP"], [25, 38, "GGP"], [25, 38, "GENE_OR_GENE_PRODUCT"], [99, 116, "TISSUE"], [14, 23, "SO"]]}
{"text": "Western blot analysis showed increased levels of C3a-derived fragments in the serum , indicating systemic complement activation in SARS-CoV MA15-infected mice at 2 dpi ( Fig. 7A ) .", "labels": [[61, 71, "SO"], [78, 84, "ENTITY"], [78, 84, "ORGANISM_SUBSTANCE"], [49, 71, "DNA"], [61, 71, "ENTITY"], [0, 22, "ENTITY"], [49, 61, "ENTITY"], [29, 39, "ENTITY"], [97, 117, "ENTITY"], [39, 46, "ENTITY"]]}
{"text": "C3 activation products ( C3 fragments C3a , C3b , iC3b , C3dg , and C3c ) were detected by Western blotting in lung tissue of SARS-CoV MA15-infected mice , but not in control mice , as early as 1 day postinfection ( dpi ) ( Fig. 1B ) , confirming that SARS-CoV MA15 infection activates the complement pathway .", "labels": [[25, 38, "ENTITY"], [0, 23, "PROTEIN"], [160, 167, "ENTITY"], [25, 38, "PROTEIN"], [99, 116, "ENTITY"], [135, 140, "ENTITY"], [50, 57, "GGP"], [247, 261, "ENTITY"], [236, 252, "ORGANISM"], [50, 57, "PROTEIN"], [236, 247, "ENTITY"], [50, 57, "ENTITY"], [116, 135, "ENTITY"], [191, 200, "ENTITY"], [116, 126, "ORGANISM"], [0, 3, "GGP"], [185, 191, "ENTITY"], [79, 99, "ENTITY"], [50, 57, "GENE_OR_GENE_PRODUCT"], [0, 23, "ENTITY"], [276, 290, "ENTITY"], [116, 126, "GGP"], [25, 38, "GGP"], [25, 38, "GENE_OR_GENE_PRODUCT"], [99, 116, "TISSUE"], [14, 23, "SO"]]}
{"text": "C3 activation products ( C3 fragments C3a , C3b , iC3b , C3dg , and C3c ) were detected by Western blotting in lung tissue of SARS-CoV MA15-infected mice , but not in control mice , as early as 1 day postinfection ( dpi ) ( Fig. 1B ) , confirming that SARS-CoV MA15 infection activates the complement pathway .", "labels": [[25, 38, "ENTITY"], [0, 23, "PROTEIN"], [160, 167, "ENTITY"], [25, 38, "PROTEIN"], [99, 116, "ENTITY"], [135, 140, "ENTITY"], [50, 57, "GGP"], [247, 261, "ENTITY"], [236, 252, "ORGANISM"], [50, 57, "PROTEIN"], [236, 247, "ENTITY"], [50, 57, "ENTITY"], [116, 135, "ENTITY"], [191, 200, "ENTITY"], [116, 126, "ORGANISM"], [0, 3, "GGP"], [185, 191, "ENTITY"], [79, 99, "ENTITY"], [50, 57, "GENE_OR_GENE_PRODUCT"], [0, 23, "ENTITY"], [276, 290, "ENTITY"], [116, 126, "GGP"], [25, 38, "GGP"], [25, 38, "GENE_OR_GENE_PRODUCT"], [99, 116, "TISSUE"], [14, 23, "SO"]]}
{"text": "C3 activation products ( C3 fragments C3a , C3b , iC3b , C3dg , and C3c ) were detected by Western blotting in lung tissue of SARS-CoV MA15-infected mice , but not in control mice , as early as 1 day postinfection ( dpi ) ( Fig. 1B ) , confirming that SARS-CoV MA15 infection activates the complement pathway .", "labels": [[25, 38, "ENTITY"], [0, 23, "PROTEIN"], [160, 167, "ENTITY"], [25, 38, "PROTEIN"], [99, 116, "ENTITY"], [135, 140, "ENTITY"], [50, 57, "GGP"], [247, 261, "ENTITY"], [236, 252, "ORGANISM"], [50, 57, "PROTEIN"], [236, 247, "ENTITY"], [50, 57, "ENTITY"], [116, 135, "ENTITY"], [191, 200, "ENTITY"], [116, 126, "ORGANISM"], [0, 3, "GGP"], [185, 191, "ENTITY"], [79, 99, "ENTITY"], [50, 57, "GENE_OR_GENE_PRODUCT"], [0, 23, "ENTITY"], [276, 290, "ENTITY"], [116, 126, "GGP"], [25, 38, "GGP"], [25, 38, "GENE_OR_GENE_PRODUCT"], [99, 116, "TISSUE"], [14, 23, "SO"]]}
{"text": "All three metrics have been shown to change significantly following SARS-CoV MA15 infection , with Penh and EF50 increasing following infection and RPEF decreasing . Combined , these measurements show that SARS-CoV MA15-infected animals have altered exhalation patterns in their breathing .", "labels": [[77, 92, "ENTITY"], [242, 250, "ENTITY"], [215, 229, "TAXON"], [201, 215, "PROTEIN"], [215, 229, "ENTITY"], [68, 77, "ENTITY"], [68, 82, "ORGANISM"], [10, 18, "ENTITY"]]}
{"text": "C3 \u2013/\u2013 mice exhibit a decreased change in Penh and EF50 levels following SARS-CoV MA15 infection relative to those of infected C57BL/6J control mice ; however , RPEF values were similar between infection conditions ( Fig. 2C to E ) .", "labels": [[73, 82, "ENTITY"], [87, 97, "ENTITY"], [127, 136, "ORGANISM"], [32, 39, "ENTITY"], [7, 12, "ENTITY"], [7, 12, "TAXON"], [22, 32, "ENTITY"], [7, 12, "ORGANISM"], [51, 56, "ENTITY"], [51, 56, "GENE_OR_GENE_PRODUCT"], [7, 12, "TAXON"], [0, 7, "ENTITY"], [118, 127, "ENTITY"], [82, 97, "ENTITY"], [42, 47, "GENE_OR_GENE_PRODUCT"], [42, 47, "ENTITY"], [127, 149, "ENTITY"], [73, 87, "ORGANISM"], [56, 63, "ENTITY"], [0, 12, "GENE_OR_GENE_PRODUCT"], [161, 166, "ENTITY"]]}
{"text": "All three metrics have been shown to change significantly following SARS-CoV MA15 infection , with Penh and EF50 increasing following infection and RPEF decreasing . Combined , these measurements show that SARS-CoV MA15-infected animals have altered exhalation patterns in their breathing .", "labels": [[77, 92, "ENTITY"], [242, 250, "ENTITY"], [215, 229, "TAXON"], [201, 215, "PROTEIN"], [215, 229, "ENTITY"], [68, 77, "ENTITY"], [68, 82, "ORGANISM"], [10, 18, "ENTITY"]]}
{"text": "C3 \u2013/\u2013 mice exhibit a decreased change in Penh and EF50 levels following SARS-CoV MA15 infection relative to those of infected C57BL/6J control mice ; however , RPEF values were similar between infection conditions ( Fig. 2C to E ) .", "labels": [[73, 82, "ENTITY"], [87, 97, "ENTITY"], [127, 136, "ORGANISM"], [32, 39, "ENTITY"], [7, 12, "ENTITY"], [7, 12, "TAXON"], [22, 32, "ENTITY"], [7, 12, "ORGANISM"], [51, 56, "ENTITY"], [51, 56, "GENE_OR_GENE_PRODUCT"], [7, 12, "TAXON"], [0, 7, "ENTITY"], [118, 127, "ENTITY"], [82, 97, "ENTITY"], [42, 47, "GENE_OR_GENE_PRODUCT"], [42, 47, "ENTITY"], [127, 149, "ENTITY"], [73, 87, "ORGANISM"], [56, 63, "ENTITY"], [0, 12, "GENE_OR_GENE_PRODUCT"], [161, 166, "ENTITY"]]}
{"text": "All three metrics have been shown to change significantly following SARS-CoV MA15 infection , with Penh and EF50 increasing following infection and RPEF decreasing . Combined , these measurements show that SARS-CoV MA15-infected animals have altered exhalation patterns in their breathing .", "labels": [[77, 92, "ENTITY"], [242, 250, "ENTITY"], [215, 229, "TAXON"], [201, 215, "PROTEIN"], [215, 229, "ENTITY"], [68, 77, "ENTITY"], [68, 82, "ORGANISM"], [10, 18, "ENTITY"]]}
{"text": "C3 \u2013/\u2013 mice exhibit a decreased change in Penh and EF50 levels following SARS-CoV MA15 infection relative to those of infected C57BL/6J control mice ; however , RPEF values were similar between infection conditions ( Fig. 2C to E ) .", "labels": [[73, 82, "ENTITY"], [87, 97, "ENTITY"], [127, 136, "ORGANISM"], [32, 39, "ENTITY"], [7, 12, "ENTITY"], [7, 12, "TAXON"], [22, 32, "ENTITY"], [7, 12, "ORGANISM"], [51, 56, "ENTITY"], [51, 56, "GENE_OR_GENE_PRODUCT"], [7, 12, "TAXON"], [0, 7, "ENTITY"], [118, 127, "ENTITY"], [82, 97, "ENTITY"], [42, 47, "GENE_OR_GENE_PRODUCT"], [42, 47, "ENTITY"], [127, 149, "ENTITY"], [73, 87, "ORGANISM"], [56, 63, "ENTITY"], [0, 12, "GENE_OR_GENE_PRODUCT"], [161, 166, "ENTITY"]]}
{"text": "C3 \u2013/\u2013 mice exhibited more airspace inflammation , including eosinophils , at 2 dpi than their wild-type controls , although this relationship was reversed later in infection .", "labels": [[27, 49, "ENTITY"], [0, 7, "ENTITY"], [89, 105, "ENTITY"], [27, 36, "TISSUE"], [0, 12, "GENE_OR_GENE_PRODUCT"], [7, 12, "ENTITY"], [7, 12, "TAXON"], [27, 49, "DISEASE"]]}
{"text": "At 4 dpi , C57BL/6J mice displayed pronounced lung pathology , including inflammatory cells in the large airway and parenchyma , perivascular cuffing , thickening of the interstitial membrane , and low levels of intra-alveolar edema .", "labels": [[11, 20, "ENTITY"], [202, 227, "ENTITY"], [142, 152, "ENTITY"], [99, 105, "ENTITY"], [11, 20, "ORGANISM"], [46, 51, "ENTITY"], [166, 183, "ENTITY"], [170, 183, "GO"], [99, 105, "MULTI-TISSUE_STRUCTURE"], [5, 9, "ENTITY"], [202, 227, "TISSUE"], [63, 86, "ENTITY"], [127, 142, "ENTITY"], [73, 86, "CELL"], [73, 86, "CL"], [166, 183, "CELLULAR_COMPONENT"], [63, 86, "CELL_TYPE"], [127, 142, "MULTI-TISSUE_STRUCTURE"], [198, 202, "ENTITY"], [202, 227, "DISEASE"]]}
{"text": "C3 \u2013/\u2013 mice exhibited more airspace inflammation , including eosinophils , at 2 dpi than their wild-type controls , although this relationship was reversed later in infection .", "labels": [[27, 49, "ENTITY"], [0, 7, "ENTITY"], [89, 105, "ENTITY"], [27, 36, "TISSUE"], [0, 12, "GENE_OR_GENE_PRODUCT"], [7, 12, "ENTITY"], [7, 12, "TAXON"], [27, 49, "DISEASE"]]}
{"text": "In parallel with humans exhibiting lung pathology , C3 \u2013/\u2013 mice exhibited significant pulmonary infiltration following SARS-CoV MA15 infection , but this inflammation was reduced relative to that observed in wild-type mice .", "labels": [[52, 59, "GENE_OR_GENE_PRODUCT"], [17, 24, "ENTITY"], [208, 218, "ENTITY"], [35, 40, "ORGAN"], [208, 218, "TAXON"], [17, 24, "TAXON"], [52, 55, "ENTITY"], [17, 24, "ORGANISM"], [86, 96, "ENTITY"], [86, 96, "DISEASE"], [119, 133, "DISEASE"], [35, 50, "ENTITY"], [119, 128, "ORGANISM"], [208, 218, "ORGANISM"], [128, 133, "ENTITY"]]}
{"text": "At 4 dpi , C57BL/6J mice displayed pronounced lung pathology , including inflammatory cells in the large airway and parenchyma , perivascular cuffing , thickening of the interstitial membrane , and low levels of intra-alveolar edema .", "labels": [[11, 20, "ENTITY"], [73, 86, "CELL"], [202, 227, "ENTITY"], [142, 152, "ENTITY"], [99, 105, "ENTITY"], [11, 20, "ORGANISM"], [46, 51, "ENTITY"], [166, 183, "ENTITY"], [170, 183, "GO"], [73, 86, "CL"], [99, 105, "MULTI-TISSUE_STRUCTURE"], [5, 9, "ENTITY"], [202, 227, "TISSUE"], [63, 86, "ENTITY"], [127, 142, "ENTITY"], [166, 183, "CELLULAR_COMPONENT"], [63, 86, "CELL_TYPE"], [127, 142, "MULTI-TISSUE_STRUCTURE"], [198, 202, "ENTITY"], [202, 227, "DISEASE"]]}
{"text": "At both 2 and 4 dpi , we observed scattered positive staining for complement in the lungs of SARS-CoV MA15-infected mice , suggesting that local tissue damage might contribute to SARS-CoV pathogenesis ( Fig. 4 )", "labels": [[139, 152, "ENTITY"], [139, 145, "TISSUE"], [139, 152, "DISEASE"], [93, 102, "ENTITY"], [16, 20, "ENTITY"], [93, 102, "ENTITY"]]}
{"text": "Consistently with what was observed in human SARS-CoV patients ( 25 ) , lymphopenia was observed in the lungs of both SARS-CoV MA15-infected C57BL/6J and C3 \u2013/\u2013 mice with reduced percentages of B cells ( Fig. 5A ) and CD4 T cells relative to those in mock-infected mice following infection .", "labels": [[113, 141, "PROTEIN"], [0, 13, "ENTITY"], [214, 224, "CELL_TYPE"], [251, 265, "ENTITY"], [251, 265, "ORGANISM"], [150, 161, "GENE_OR_GENE_PRODUCT"], [218, 224, "CL"], [45, 54, "ENTITY"], [214, 224, "GENE_OR_GENE_PRODUCT"], [39, 45, "ENTITY"], [251, 265, "TAXON"], [150, 157, "ENTITY"], [242, 251, "ENTITY"], [27, 36, "ENTITY"], [191, 196, "CELL"], [214, 224, "ENTITY"], [113, 127, "ENTITY"], [196, 204, "CELL"], [191, 196, "ENTITY"], [191, 196, "CELL_TYPE"], [39, 63, "ORGANISM"], [54, 63, "ENTITY"], [39, 54, "GGP"], [127, 141, "ORGANISM"]]}
{"text": "Consistently with what was observed in human SARS-CoV patients ( 25 ) , lymphopenia was observed in the lungs of both SARS-CoV MA15-infected C57BL/6J and C3 \u2013/\u2013 mice with reduced percentages of B cells ( Fig. 5A ) and CD4 T cells relative to those in mock-infected mice following infection .", "labels": [[113, 141, "PROTEIN"], [0, 13, "ENTITY"], [214, 224, "CELL_TYPE"], [251, 265, "ENTITY"], [251, 265, "ORGANISM"], [150, 161, "GENE_OR_GENE_PRODUCT"], [218, 224, "CL"], [45, 54, "ENTITY"], [214, 224, "GENE_OR_GENE_PRODUCT"], [39, 45, "ENTITY"], [251, 265, "TAXON"], [150, 157, "ENTITY"], [242, 251, "ENTITY"], [27, 36, "ENTITY"], [191, 196, "CELL"], [214, 224, "ENTITY"], [113, 127, "ENTITY"], [196, 204, "CELL"], [191, 196, "ENTITY"], [191, 196, "CELL_TYPE"], [39, 63, "ORGANISM"], [54, 63, "ENTITY"], [39, 54, "GGP"], [127, 141, "ORGANISM"]]}
{"text": "Despite similar overall lymphocyte levels , small but significant differences were observed in levels of T cell activation between infected C57BL/6J and C3 \u2013/\u2013 mice ; both CD4 and CD8 T cells in C3 \u2013/\u2013 mice expressed more Ki-67 ( Fig. 5C and D ) , an intracellular marker of proliferation , than those in C57BL/6J controls .", "labels": [[153, 160, "ENTITY"], [24, 35, "ENTITY"], [192, 202, "GENE_OR_GENE_PRODUCT"], [296, 314, "ENTITY"], [176, 186, "GENE_OR_GENE_PRODUCT"], [24, 35, "CELL"], [296, 305, "ORGANISM"], [192, 198, "ENTITY"], [24, 35, "CL"], [35, 42, "ENTITY"], [160, 165, "ENTITY"], [176, 186, "GGP"], [153, 160, "GENE_OR_GENE_PRODUCT"], [265, 275, "ENTITY"], [176, 186, "ENTITY"], [251, 265, "ENTITY"], [246, 251, "IMMATERIAL_ANATOMICAL_ENTITY"], [246, 251, "ENTITY"], [167, 186, "CELL_TYPE"], [246, 251, "GO"]]}
{"text": "Analysis of myeloid cells in the lung showed that infected C56BL/6J mice had significantly higher levels of neutrophils , particularly nonactivated neutrophils , in the lung than infected C3 \u2013/\u2013 mice ( Fig. 5B and E ) .", "labels": [[179, 195, "GENE_OR_GENE_PRODUCT"], [108, 120, "ENTITY"], [50, 59, "ENTITY"], [179, 195, "ENTITY"], [33, 38, "ENTITY"], [108, 120, "CELL"], [59, 73, "ORGANISM"], [59, 73, "ENTITY"], [108, 120, "CL"], [68, 73, "TAXON"], [98, 105, "ENTITY"], [200, 207, "CELL"], [12, 26, "CELL_TYPE"], [12, 26, "ENTITY"], [108, 120, "CELL_TYPE"], [135, 148, "CELL_TYPE"], [12, 26, "CL"], [12, 26, "CELL"], [0, 9, "ENTITY"], [33, 38, "ORGAN"]]}
{"text": "Finally , we observed significantly more dendritic cells and alveolar macrophages in the lungs of SARS-CoV MA15-infected C3 \u2013/\u2013 mice than in the lungs of infected C57BL/6J mice .", "labels": [[163, 172, "ORGANISM"], [41, 51, "CELL_TYPE"], [41, 51, "CELL"], [107, 124, "CHEMICAL"], [41, 51, "ENTITY"], [163, 172, "ENTITY"], [61, 70, "CL"], [98, 121, "PROTEIN"], [98, 128, "ORGANISM"], [98, 121, "GGP"], [61, 70, "CELL_TYPE"], [98, 124, "ENTITY"], [61, 70, "ENTITY"], [41, 51, "CL"], [61, 70, "CELL"]]}
{"text": "MIP1a , MIP1b , and MCP1 are all highly expressed in the lung following SARS-CoV MA15 infection of both C57BL/6J and C3 \u2013/\u2013 mice ( following SARS-CoV MA15 infection of both C57BL/6J and C3 \u2013/\u2013 mice ) , indicating that some inflammatory signaling remains intact in the absence of C3 .", "labels": [[0, 6, "CHEMICAL"], [0, 6, "GGP"], [0, 6, "PROTEIN"], [72, 86, "ENTITY"], [0, 6, "GENE_OR_GENE_PRODUCT"], [113, 124, "ENTITY"], [33, 40, "ENTITY"], [113, 124, "GENE_OR_GENE_PRODUCT"], [62, 81, "ORGANISM"], [0, 6, "ENTITY"], [86, 113, "ENTITY"]]}
{"text": "Granulocyte colony-stimulating factor ( G-CSF ) , interleukin 6 ( IL-6 ) , tumor necrosis factor alpha ( TNF-a ) , and IL-1a comprised a group of cytokines and chemokines that were more highly produced in the lungs of C57BL/6J mice than in C3 \u2013/\u2013 mice ( Fig. 6B ) , all peaking at 2 days postinfection .", "labels": [[0, 38, "GENE_OR_GENE_PRODUCT"], [97, 103, "GGP"], [243, 252, "CELL"], [0, 38, "GGP"], [97, 103, "ENTITY"], [237, 243, "TAXON"], [66, 97, "GGP"], [137, 146, "PROTEIN"], [66, 75, "DISEASE"], [0, 38, "ENTITY"], [66, 97, "GENE_OR_GENE_PRODUCT"], [193, 205, "ENTITY"], [97, 103, "PROTEIN"], [270, 288, "ENTITY"], [209, 218, "ORGANISM"], [0, 38, "PROTEIN"], [137, 146, "ENTITY"], [146, 160, "ENTITY"], [97, 103, "GENE_OR_GENE_PRODUCT"], [66, 97, "PROTEIN"], [232, 243, "GENE_OR_GENE_PRODUCT"], [146, 160, "PROTEIN"], [232, 243, "ENTITY"], [193, 205, "ORGAN"], [209, 218, "ENTITY"], [66, 97, "ENTITY"]]}
{"text": "However , numerous cytokines and chemokines , such as IL-5 , G-CSF , and KC ( keratinocyte chemoattractant or CXCL1 ) were present in significantly higher abundance in the lungs of C57BL/6J mice than in those of C3 knockout mice ( Fig. 7C ) .", "labels": [[73, 78, "CELL"], [203, 215, "GENE_OR_GENE_PRODUCT"], [73, 91, "PROTEIN"], [172, 181, "ORGANISM"], [91, 110, "GENE_OR_GENE_PRODUCT"], [203, 215, "ENTITY"], [91, 110, "GGP"], [91, 110, "PROTEIN"], [73, 78, "ENTITY"], [73, 78, "CL"], [148, 155, "ENTITY"], [165, 172, "ORGAN"], [224, 231, "GENE_OR_GENE_PRODUCT"], [91, 110, "ENTITY"], [172, 181, "ENTITY"], [78, 91, "ENTITY"], [165, 172, "ENTITY"]]}
{"text": "Granulocyte colony-stimulating factor ( G-CSF ) , interleukin 6 ( IL-6 ) , tumor necrosis factor alpha ( TNF-a ) , and IL-1a comprised a group of cytokines and chemokines that were more highly produced in the lungs of C57BL/6J mice than in C3 \u2013/\u2013 mice ( Fig. 6B ) , all peaking at 2 days postinfection .", "labels": [[0, 38, "GENE_OR_GENE_PRODUCT"], [97, 103, "GGP"], [243, 252, "CELL"], [0, 38, "GGP"], [97, 103, "ENTITY"], [237, 243, "TAXON"], [66, 97, "GGP"], [137, 146, "PROTEIN"], [66, 75, "DISEASE"], [0, 38, "ENTITY"], [66, 97, "GENE_OR_GENE_PRODUCT"], [193, 205, "ENTITY"], [97, 103, "PROTEIN"], [270, 288, "ENTITY"], [209, 218, "ORGANISM"], [0, 38, "PROTEIN"], [137, 146, "ENTITY"], [146, 160, "ENTITY"], [97, 103, "GENE_OR_GENE_PRODUCT"], [66, 97, "PROTEIN"], [232, 243, "GENE_OR_GENE_PRODUCT"], [146, 160, "PROTEIN"], [232, 243, "ENTITY"], [193, 205, "ORGAN"], [209, 218, "ENTITY"], [66, 97, "ENTITY"]]}
{"text": "However , numerous cytokines and chemokines , such as IL-5 , G-CSF , and KC ( keratinocyte chemoattractant or CXCL1 ) were present in significantly higher abundance in the lungs of C57BL/6J mice than in those of C3 knockout mice ( Fig. 7C ) .", "labels": [[73, 78, "CELL"], [203, 215, "GENE_OR_GENE_PRODUCT"], [73, 91, "PROTEIN"], [172, 181, "ORGANISM"], [91, 110, "GENE_OR_GENE_PRODUCT"], [203, 215, "ENTITY"], [91, 110, "GGP"], [91, 110, "PROTEIN"], [73, 78, "ENTITY"], [73, 78, "CL"], [148, 155, "ENTITY"], [165, 172, "ORGAN"], [224, 231, "GENE_OR_GENE_PRODUCT"], [91, 110, "ENTITY"], [172, 181, "ENTITY"], [78, 91, "ENTITY"], [165, 172, "ENTITY"]]}
{"text": "In addition , the SARS-CoV E protein acts as a Ca 2 + -permeable ion channels that activates the NLRP3 inflammasome ( Nieto-Torres et al. , 2015 ) .", "labels": [[47, 54, "ENTITY"], [18, 27, "ORGANISM"], [18, 29, "ENTITY"], [93, 103, "PROTEIN"], [54, 69, "ENTITY"], [18, 29, "GGP"], [47, 69, "PROTEIN"], [18, 29, "PROTEIN"], [54, 65, "CHEBI"], [97, 103, "ENTITY"]]}
{"text": "Most human CoVs , such as hCoV-229E , OC43 , NL63 , and HKU1 , cause mild respiratory diseases , but the worldwide spread of two previously unrecognized coronaviruses , the severe acute respiratory syndrome CoV ( SARS-CoV ) and Middle East respiratory syndrome CoV ( MERS-CoV ) , has called global attention to the lethal potential of human CoVs 2 .", "labels": [[63, 86, "ENTITY"], [140, 153, "PROTEIN"], [173, 198, "DISEASE"], [322, 335, "ORGANISM"], [298, 308, "ENTITY"], [322, 335, "ENTITY"], [140, 153, "ORGANISM"], [140, 153, "ENTITY"], [280, 291, "ENTITY"], [173, 198, "ENTITY"], [322, 335, "PROTEIN"], [213, 252, "ENTITY"], [5, 11, "ENTITY"], [5, 11, "TAXON"], [11, 16, "ENTITY"], [69, 86, "DISEASE"], [198, 213, "ORGANISM"], [322, 332, "TAXON"], [167, 173, "ENTITY"], [5, 16, "ORGANISM"], [198, 211, "ENTITY"], [198, 213, "ENTITY"], [228, 252, "DISEASE"]]}
{"text": "Such neuroinvasive propensity of CoVs has been documented almost for all the betacoronaviruses , including SARS-CoV 1 , MERS-CoV 11 , HCoV-229E 16 , HCoV-OC43 12 , mouse hepatitis virus ( MHV ) 17 , and porcine hemagglutinating encephalomyelitis coronavirus ( HEV ) 9 - 10 , 18 - 19 .", "labels": [[107, 116, "PROTEIN"], [107, 116, "ORGANISM"], [118, 129, "ENTITY"], [203, 246, "ENTITY"], [132, 144, "ORGANISM"], [170, 180, "TAXON"], [194, 246, "ORGANISM"], [33, 38, "ENTITY"], [159, 180, "ORGANISM"], [87, 93, "TAXON"], [19, 30, "ENTITY"], [164, 180, "DISEASE"], [107, 116, "ENTITY"], [77, 95, "GENE_OR_GENE_PRODUCT"], [5, 19, "ENTITY"], [47, 58, "ENTITY"], [118, 129, "PROTEIN"], [194, 203, "TAXON"], [87, 93, "ENTITY"], [77, 95, "ENTITY"], [132, 144, "ENTITY"], [194, 203, "ENTITY"], [159, 180, "ENTITY"]]}
{"text": "Experimental studies using transgenic mice further revealed that either SARS-CoV 30 or MERS-COV 11 , when given intranasally , could enter the brain , possibly via the olfactory nerves , and there after rapidly spread to some specific brain areas including thalamus and brainstem .", "labels": [[87, 99, "PROTEIN"], [72, 84, "PROTEIN"], [87, 99, "ENTITY"], [0, 21, "ENTITY"], [226, 241, "ENTITY"], [72, 84, "ORGANISM"], [72, 81, "ENTITY"], [27, 43, "SO"], [38, 43, "ORGANISM"], [247, 257, "ENTITY"], [226, 235, "ORGAN"], [27, 43, "ENTITY"], [247, 257, "PATHOLOGICAL_FORMATION"], [164, 178, "TISSUE"], [164, 178, "ENTITY"]]}
{"text": "Niclosamide suppressed the cytopathic effect ( CPE ) of SARS-CoV at a concentration of as low as 1 \u03bcM and inhibited SARS-CoV replication with an EC50 value of less than 0.1 \u03bcM in Vero E6 cells .", "labels": [[12, 23, "ENTITY"], [184, 187, "CL"], [106, 116, "ENTITY"], [176, 187, "CELL_LINE"], [106, 116, "ORGANISM"], [0, 12, "CHEBI"], [0, 12, "ENTITY"], [27, 45, "ENTITY"], [176, 187, "ENTITY"], [56, 65, "ENTITY"], [176, 187, "CELL"], [106, 116, "GGP"], [0, 12, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"]]}
{"text": "We therefore previously suggested that in contrast to most other coronaviruses , SARS-CoV became highly lethal because the virus deregulates a lung protective pathway [ 10 , 12 ] .", "labels": [[65, 79, "ENTITY"], [143, 159, "ENTITY"], [65, 79, "PROTEIN"], [65, 79, "ORGANISM"]]}
{"text": "Similarly , the existence of 29 nucleotide deletions in ORF 8b has been described in SARS-CoV ( Oostra et al. , 2007 ) .", "labels": [[32, 43, "ENTITY"], [32, 43, "SO"], [29, 43, "DNA"], [56, 60, "ENTITY"], [56, 60, "DNA"]]}
{"text": "Accessory proteins 8b and 8ab of SARS-CoV can suppress the INF-\u03b2 signaling pathway ( and thus interferon production ) by their participation in the ubiquitin-mediated rapid degradation of INF regulatory factor 3 ( IRF3 ) ( Wong et al. , 2018 ) .", "labels": [[59, 65, "ENTITY"], [33, 42, "ORGANISM"], [59, 65, "PROTEIN"], [26, 30, "GENE_OR_GENE_PRODUCT"], [26, 30, "PROTEIN"], [188, 210, "ENTITY"], [46, 55, "ENTITY"], [167, 173, "ENTITY"], [26, 30, "ENTITY"], [185, 210, "PROTEIN"], [33, 42, "PROTEIN"], [65, 83, "ENTITY"], [0, 22, "PROTEIN"], [33, 42, "ENTITY"], [185, 210, "GENE_OR_GENE_PRODUCT"], [94, 105, "ENTITY"], [10, 19, "CHEBI"], [59, 65, "GENE_OR_GENE_PRODUCT"], [0, 22, "GENE_OR_GENE_PRODUCT"], [33, 42, "GGP"], [185, 210, "GGP"], [0, 22, "ENTITY"]]}
{"text": "Particularly , ORF3 and ORF8 in SARS-CoV-2 are highly divergent from ORF3a and ORF8b in SARS-CoV that are known to induce NLRP3 inflammasome activation .", "labels": []}
{"text": "Accessory proteins 8b and 8ab of SARS-CoV can suppress the INF-\u03b2 signaling pathway ( and thus interferon production ) by their participation in the ubiquitin-mediated rapid degradation of INF regulatory factor 3 ( IRF3 ) ( Wong et al. , 2018 ) .", "labels": [[59, 65, "ENTITY"], [33, 42, "ORGANISM"], [59, 65, "PROTEIN"], [26, 30, "GENE_OR_GENE_PRODUCT"], [26, 30, "PROTEIN"], [188, 210, "ENTITY"], [46, 55, "ENTITY"], [167, 173, "ENTITY"], [26, 30, "ENTITY"], [185, 210, "PROTEIN"], [33, 42, "PROTEIN"], [65, 83, "ENTITY"], [0, 22, "PROTEIN"], [33, 42, "ENTITY"], [185, 210, "GENE_OR_GENE_PRODUCT"], [94, 105, "ENTITY"], [10, 19, "CHEBI"], [59, 65, "GENE_OR_GENE_PRODUCT"], [0, 22, "GENE_OR_GENE_PRODUCT"], [33, 42, "GGP"], [185, 210, "GGP"], [0, 22, "ENTITY"]]}
{"text": "SARS-CoV and Middle East respiratory syndrome (MERS)-CoV can enter cells via endocytosis and use cathepsin in endosomes for activation ( 12\u201314 ) . However , TMPRSS2 expression greatly promotes replication and syncytium formation in these viruses in vitro and in vivo ( 5 , 6 , 11 , 12 , 15 ) .", "labels": [[67, 73, "ENTITY"], [97, 120, "GGP"], [97, 107, "GENE_OR_GENE_PRODUCT"], [209, 219, "ENTITY"], [238, 249, "ENTITY"], [184, 193, "ENTITY"], [157, 165, "ENTITY"], [0, 9, "ENTITY"], [46, 57, "GENE_OR_GENE_PRODUCT"], [46, 57, "ENTITY"], [13, 46, "ENTITY"], [77, 89, "ENTITY"], [124, 135, "ENTITY"], [147, 157, "GGP"], [67, 73, "CELL"], [97, 107, "PROTEIN"], [147, 157, "GENE_OR_GENE_PRODUCT"], [97, 107, "ENTITY"], [67, 73, "CL"], [25, 46, "DISEASE"], [176, 184, "ENTITY"], [147, 157, "PROTEIN"], [0, 9, "ORGANISM"], [255, 262, "ENTITY"], [110, 120, "CELLULAR_COMPONENT"], [110, 120, "ENTITY"], [147, 157, "ENTITY"]]}
{"text": "With SARS-CoV , animal models showed that infection with the virus downregulated ACE2 expression , generating an inflammatory response correlated with acute lung injury and impaired cardiac contractility [ 26\u201328 ] .", "labels": [[5, 14, "ENTITY"], [16, 23, "ENTITY"], [173, 190, "ENTITY"], [146, 162, "DISEASE"], [5, 14, "ORGANISM"], [110, 126, "ENTITY"], [126, 135, "ENTITY"], [151, 157, "ORGAN"], [173, 182, "ORGAN"], [146, 162, "ENTITY"]]}
{"text": "Not only has ACE2 facilitated the invasion of SARS virus for rapid replication , but also ACE2 is depleted from the cell membrane and therefore the damaging effects of Ang II are enhanced , resulting in acute deterioration of lung tissues [ 5 ] .", "labels": [[51, 57, "TAXON"], [223, 231, "TISSUE"], [223, 231, "ENTITY"], [148, 157, "ENTITY"], [168, 172, "GGP"], [13, 18, "ENTITY"], [116, 121, "CL"], [46, 51, "DISEASE"], [13, 18, "PROTEIN"], [46, 57, "ORGANISM"], [61, 67, "ENTITY"], [168, 172, "PROTEIN"], [168, 172, "CHEMICAL"], [34, 43, "ENTITY"], [46, 57, "ENTITY"], [67, 79, "ENTITY"], [168, 172, "GENE_OR_GENE_PRODUCT"], [116, 121, "CELLULAR_COMPONENT"], [13, 18, "GGP"], [13, 18, "GENE_OR_GENE_PRODUCT"], [116, 121, "ENTITY"], [200, 209, "ENTITY"], [168, 172, "ENTITY"]]}
{"text": "Not only has ACE2 facilitated the invasion of SARS virus for rapid replication , but also ACE2 is depleted from the cell membrane and therefore the damaging effects of Ang II are enhanced , resulting in acute deterioration of lung tissues [ 5 ] .", "labels": [[51, 57, "TAXON"], [223, 231, "TISSUE"], [223, 231, "ENTITY"], [148, 157, "ENTITY"], [168, 172, "GGP"], [116, 121, "CL"], [46, 51, "DISEASE"], [13, 18, "GENE_OR_GENE_PRODUCT"], [46, 57, "ORGANISM"], [61, 67, "ENTITY"], [168, 172, "PROTEIN"], [168, 172, "CHEMICAL"], [34, 43, "ENTITY"], [46, 57, "ENTITY"], [67, 79, "ENTITY"], [13, 18, "GGP"], [168, 172, "GENE_OR_GENE_PRODUCT"], [116, 121, "CELLULAR_COMPONENT"], [13, 18, "PROTEIN"], [13, 18, "ENTITY"], [116, 121, "ENTITY"], [200, 209, "ENTITY"], [168, 172, "ENTITY"]]}
{"text": "The researchers found that SARS-CoV-infected or recombinant SARS-spike protein-treated wild-type mice exhibited significantly reduced ACE2 expression in the lungs .", "labels": [[97, 102, "TAXON"], [97, 102, "ENTITY"], [48, 60, "ENTITY"], [97, 102, "ORGANISM"], [60, 71, "ENTITY"], [157, 163, "ORGAN"], [134, 139, "ENTITY"], [87, 97, "ENTITY"], [4, 16, "ENTITY"], [134, 139, "GGP"], [139, 150, "ENTITY"], [134, 139, "PROTEIN"], [71, 87, "ENTITY"], [27, 45, "ENTITY"], [134, 139, "GENE_OR_GENE_PRODUCT"], [157, 163, "ENTITY"]]}
{"text": "Several studies revealed that CoV implements some strategies to evade the immune response by antagonizing the arms of IFN signaling pathway (32).In this regard , Frieman et al. indicated that SARS-CoV ORF6 protein blocks the expression of STAT1-activated genes and finally acts as an IFN antagonist ( 33 ) .", "labels": [[118, 122, "ENTITY"], [239, 255, "SO"], [118, 122, "GGP"], [192, 206, "PROTEIN"], [118, 140, "ENTITY"], [8, 16, "ENTITY"], [118, 122, "GENE_OR_GENE_PRODUCT"], [239, 255, "ENTITY"], [192, 214, "ENTITY"], [30, 34, "PROTEIN"], [239, 255, "DNA"], [74, 90, "ENTITY"], [118, 122, "GGP"], [118, 122, "PROTEIN"], [140, 148, "GENE_OR_GENE_PRODUCT"], [192, 206, "GGP"], [30, 34, "ENTITY"], [192, 201, "ORGANISM"]]}
{"text": "It was concluded that the immune response of SARS-affected patients is mainly innate immune response rather than specific antiviral responses .", "labels": [[26, 42, "ENTITY"], [45, 59, "GGP"], [45, 59, "ENTITY"], [45, 59, "CHEMICAL"], [78, 101, "ENTITY"], [59, 68, "ORGANISM"], [59, 68, "ENTITY"], [122, 142, "ENTITY"]]}
{"text": "At 24 h p.i . , rSCV8full grew to titers 30 times higher than rSCVdel8 ( Fig. 2b )", "labels": [[8, 12, "ENTITY"]]}
{"text": "For coronaviruses , their receptor binding and subsequent internalization mainly depend on the spike protein ( S protein ) anchored in the viral envelope .", "labels": [[135, 145, "ENTITY"], [109, 113, "ENTITY"], [95, 101, "ENTITY"], [95, 101, "PROTEIN"], [4, 18, "PROTEIN"], [26, 35, "ENTITY"], [109, 113, "PROTEIN"], [135, 145, "TAXON"], [4, 18, "ORGANISM"], [4, 18, "ENTITY"]]}
{"text": "Moreover , antiserum raised against human ACE2 blocked SARS-S- and SARS-2-S- but not VSV-G- or MERS-S-driven entry ( Figure 3B ) .", "labels": [[115, 124, "ENTITY"], [36, 42, "ORGANISM"], [36, 42, "PROTEIN"], [36, 42, "GGP"]]}
{"text": "Two patients ( 2/5 ) had high D-dimer level .", "labels": [[30, 38, "ENTITY"], [25, 30, "PROTEIN"], [25, 30, "GGP"], [25, 30, "ENTITY"], [25, 30, "GENE_OR_GENE_PRODUCT"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Measurements of plasmin(ogen ) levels and its enzymatic activity may be important biomarkers of disease severity in addition to resultant D-dimer .", "labels": [[96, 104, "ENTITY"], [0, 13, "ENTITY"], [46, 56, "ENTITY"], [16, 29, "PROTEIN"], [16, 29, "ENTITY"]]}
{"text": "Levels of lactate dehydrogenase ( LDH ) , concentrations of serum high-sensitivity C-reactive protein ( hsCRP ) , ferritin and D-dimer levels were markedly higher in severe cases than moderate cases .", "labels": [[10, 18, "CHEMICAL"], [129, 137, "ENTITY"], [59, 96, "PROTEIN"], [149, 158, "ENTITY"], [0, 7, "ENTITY"], [10, 32, "GGP"], [10, 32, "PROTEIN"], [158, 168, "ENTITY"], [62, 96, "ENTITY"], [10, 32, "ENTITY"], [68, 96, "GGP"], [168, 175, "ENTITY"], [10, 32, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer .", "labels": [[126, 138, "PROTEIN"], [34, 41, "ENTITY"], [126, 138, "GENE_OR_GENE_PRODUCT"], [12, 21, "ENTITY"], [101, 109, "PROTEIN"], [155, 166, "ENTITY"], [44, 63, "PROTEIN"], [25, 34, "ENTITY"], [155, 166, "PROTEIN"], [44, 63, "GGP"], [12, 21, "ORGANISM"], [101, 109, "GENE_OR_GENE_PRODUCT"], [126, 138, "ENTITY"], [101, 109, "GGP"], [44, 55, "GENE_OR_GENE_PRODUCT"], [126, 138, "CHEBI"], [101, 109, "ENTITY"], [44, 63, "ENTITY"]]}
{"text": "Multivariate regression further suggests that age and D-dimer levels ( > 1 mg/L ) are two 92 independent risk factors for mortality ( 89 , 101 ) .", "labels": [[0, 24, "ENTITY"], [93, 110, "ENTITY"], [54, 62, "PROTEIN"], [54, 62, "GENE_OR_GENE_PRODUCT"], [54, 62, "GGP"], [46, 50, "ENTITY"], [54, 69, "ENTITY"]]}
{"text": "Higher D-dimer level was strongly related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.717 , P3<0.001,R2 = 0.737,P4<0.001 ) .", "labels": [[7, 15, "ENTITY"], [0, 7, "ENTITY"], [63, 75, "ORGANISM"], [45, 52, "ENTITY"], [63, 85, "DISEASE"], [7, 15, "PROTEIN"], [89, 108, "ENTITY"], [63, 85, "ENTITY"], [7, 15, "GENE_OR_GENE_PRODUCT"], [7, 15, "GGP"], [15, 21, "ENTITY"]]}
{"text": "Once SpO2 < 93 % , RR > 30/min , HR > 120/min or any signs of organ failure were observed , patients would be transferred to intensive care unit ( ICU ) and ICU physicians and nurses would take over their treatment .", "labels": [[5, 10, "ENTITY"], [134, 152, "ENTITY"], [152, 157, "ENTITY"], [71, 80, "ENTITY"], [71, 80, "DISEASE"], [93, 104, "ORGANISM"], [163, 173, "ENTITY"], [39, 44, "ENTITY"], [173, 188, "ENTITY"], [93, 104, "ENTITY"]]}
{"text": "The range of SPO2 under the natural breathing conditions of the patients in this study was 70e99 % . Spearman \u2019s correlation statistical analysis was performed on SPO2 and CT staging with results of p<0.05 and r\u00bce0.446 , suggesting a weak negative correlation between the two .", "labels": [[64, 73, "ENTITY"], [234, 239, "ENTITY"], [13, 18, "ENTITY"], [64, 73, "ORGANISM"], [239, 248, "ENTITY"], [81, 87, "ENTITY"], [99, 137, "ENTITY"], [168, 175, "ENTITY"], [101, 110, "GENE_OR_GENE_PRODUCT"], [28, 46, "ENTITY"], [4, 10, "ENTITY"], [221, 234, "ENTITY"]]}
{"text": "Based on our analyses of differential gene expression , we report significant transcriptional upregulation of multiple genes associated with activation of ER sensors IRE1 , ATF6 , and PERK , such as Edem1 , Hspa5 ( encoding BiP protein ) , and Ddit3 ( encoding CHOP ) , in response to virus replication , with the most robust response detected in cells infected with the wild-type or DUBmut virus infection ( Fig. 5B , C , and D ) .", "labels": [[244, 252, "ENTITY"], [319, 326, "ENTITY"], [155, 158, "ENTITY"], [215, 228, "PROTEIN"], [273, 291, "ENTITY"], [371, 391, "DISEASE"], [38, 54, "ENTITY"], [397, 407, "GENE_OR_GENE_PRODUCT"], [199, 207, "ENTITY"], [199, 207, "GENE_OR_GENE_PRODUCT"], [335, 347, "ENTITY"], [199, 207, "PROTEIN"], [207, 215, "ENTITY"], [371, 391, "ENTITY"], [38, 43, "SO"], [305, 314, "ENTITY"], [215, 228, "ENTITY"], [110, 119, "ENTITY"], [397, 407, "ENTITY"], [371, 384, "TAXON"], [409, 414, "ENTITY"], [261, 270, "ENTITY"], [199, 207, "GGP"], [215, 228, "GGP"], [25, 38, "ENTITY"], [353, 367, "ENTITY"], [13, 22, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Studies have shown that multi-functional T cells can better control human immunodeficiency virus in natural infection and are correlated with better outcomes during vaccination ; thus , the functional damage of CD4 + T cells may have predisposed COVID-19 patients to severe disease.8", "labels": [[68, 74, "ENTITY"], [41, 49, "CELL"], [41, 49, "CL"], [234, 255, "ORGANISM"], [149, 158, "ENTITY"], [208, 219, "CELL_TYPE"], [68, 97, "ORGANISM"], [208, 219, "GENE_OR_GENE_PRODUCT"], [165, 177, "ENTITY"], [24, 49, "ENTITY"], [246, 255, "ENTITY"], [68, 97, "DISEASE"], [267, 274, "CHEMICAL"], [100, 118, "ENTITY"], [126, 137, "ENTITY"], [208, 219, "GGP"], [234, 246, "ENTITY"], [0, 8, "ENTITY"], [91, 97, "TAXON"], [30, 41, "ENTITY"], [208, 219, "ENTITY"], [100, 118, "DISEASE"], [234, 246, "DISEASE"], [24, 49, "CELL_TYPE"], [74, 97, "ENTITY"], [68, 74, "TAXON"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "These data indicate that COVID-19 , similar to some chronic infections , damages the function of CD4 + T cells and promotes excessive activation and possibly subsequent exhaustion of CD8 + T cells .", "labels": [[94, 105, "GGP"], [115, 124, "ENTITY"], [25, 34, "GENE_OR_GENE_PRODUCT"], [94, 105, "ENTITY"], [94, 105, "CELL_TYPE"], [180, 191, "GGP"], [52, 60, "ENTITY"], [52, 60, "DISEASE"], [158, 169, "ENTITY"], [124, 134, "ENTITY"], [25, 34, "ENTITY"], [180, 191, "CELL_TYPE"], [180, 191, "ENTITY"], [25, 34, "PROTEIN"], [6, 11, "ENTITY"]]}
{"text": "Because functional blockade of PD-1 , CTLA-4 , and TIGIT is beneficial for CD8 + T cells to maintain lasting antigen-specific immunity and antiviral effects,10,11 the excessive exhaustion of CD8 + T cells in severe patients may reduce their cellular immune response to SARS- CoV-2 .", "labels": [[188, 199, "GGP"], [208, 215, "ORGANISM"], [266, 275, "PROTEIN"], [71, 83, "CELL_TYPE"], [266, 275, "ENTITY"], [31, 36, "ENTITY"], [135, 149, "ENTITY"], [235, 257, "ENTITY"], [71, 83, "ENTITY"], [101, 126, "ENTITY"], [19, 28, "ENTITY"], [188, 199, "ENTITY"], [188, 199, "CELL_TYPE"], [31, 36, "GENE_OR_GENE_PRODUCT"], [31, 36, "PROTEIN"], [266, 275, "ORGANISM"], [71, 83, "GGP"], [8, 19, "ENTITY"], [208, 215, "ENTITY"], [167, 177, "ENTITY"]]}
{"text": "Because functional blockade of PD-1 , CTLA-4 , and TIGIT is beneficial for CD8 + T cells to maintain lasting antigen-specific immunity and antiviral effects,10,11 the excessive exhaustion of CD8 + T cells in severe patients may reduce their cellular immune response to SARS- CoV-2 .", "labels": [[188, 199, "GGP"], [208, 215, "ORGANISM"], [266, 275, "PROTEIN"], [71, 83, "CELL_TYPE"], [266, 275, "ENTITY"], [31, 36, "ENTITY"], [135, 149, "ENTITY"], [235, 257, "ENTITY"], [71, 83, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [101, 126, "ENTITY"], [19, 28, "ENTITY"], [188, 199, "ENTITY"], [188, 199, "CELL_TYPE"], [266, 275, "ORGANISM"], [71, 83, "GGP"], [8, 19, "ENTITY"], [208, 215, "ENTITY"], [31, 36, "PROTEIN"], [167, 177, "ENTITY"]]}
{"text": "Because functional blockade of PD-1 , CTLA-4 , and TIGIT is beneficial for CD8 + T cells to maintain lasting antigen-specific immunity and antiviral effects,10,11 the excessive exhaustion of CD8 + T cells in severe patients may reduce their cellular immune response to SARS- CoV-2 .", "labels": [[188, 199, "GGP"], [208, 215, "ORGANISM"], [266, 275, "PROTEIN"], [71, 83, "CELL_TYPE"], [266, 275, "ENTITY"], [31, 36, "ENTITY"], [135, 149, "ENTITY"], [235, 257, "ENTITY"], [71, 83, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [101, 126, "ENTITY"], [19, 28, "ENTITY"], [188, 199, "ENTITY"], [188, 199, "CELL_TYPE"], [266, 275, "ORGANISM"], [71, 83, "GGP"], [8, 19, "ENTITY"], [208, 215, "ENTITY"], [31, 36, "PROTEIN"], [167, 177, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Results indicated the activation of p38 MAPK- and ERK1/2-mediated signaling linking with induction of TGF-?1 and upregulation of vimentin by PLpro .", "labels": [[102, 109, "CHEMICAL"], [141, 147, "ENTITY"], [113, 126, "ENTITY"], [22, 33, "ENTITY"], [141, 147, "GENE_OR_GENE_PRODUCT"], [66, 76, "ENTITY"], [89, 99, "ENTITY"], [36, 46, "GGP"], [36, 46, "ENTITY"], [102, 109, "PROTEIN"], [40, 46, "CHEMICAL"], [129, 138, "ENTITY"], [36, 46, "GENE_OR_GENE_PRODUCT"], [129, 138, "GGP"], [0, 8, "ENTITY"], [129, 138, "PROTEIN"], [141, 147, "PROTEIN"], [36, 46, "PROTEIN"], [129, 138, "GENE_OR_GENE_PRODUCT"], [102, 109, "ENTITY"], [50, 66, "GENE_OR_GENE_PRODUCT"], [50, 66, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Based on our analyses of differential gene expression , we report significant transcriptional upregulation of multiple genes associated with activation of ER sensors IRE1 , ATF6 , and PERK , such as Edem1 , Hspa5 ( encoding BiP protein ) , and Ddit3 ( encoding CHOP ) , in response to virus replication , with the most robust response detected in cells infected with the wild-type or DUBmut virus infection ( Fig. 5B , C , and D ) .", "labels": [[199, 207, "PROTEIN"], [244, 252, "ENTITY"], [319, 326, "ENTITY"], [155, 158, "ENTITY"], [215, 228, "PROTEIN"], [273, 291, "ENTITY"], [371, 391, "DISEASE"], [38, 54, "ENTITY"], [397, 407, "GENE_OR_GENE_PRODUCT"], [199, 207, "GENE_OR_GENE_PRODUCT"], [335, 347, "ENTITY"], [371, 391, "ENTITY"], [38, 43, "SO"], [305, 314, "ENTITY"], [215, 228, "ENTITY"], [110, 119, "ENTITY"], [397, 407, "ENTITY"], [199, 207, "ENTITY"], [199, 207, "GGP"], [371, 384, "TAXON"], [409, 414, "ENTITY"], [261, 270, "ENTITY"], [215, 228, "GGP"], [25, 38, "ENTITY"], [207, 215, "ENTITY"], [353, 367, "ENTITY"], [13, 22, "ENTITY"]]}
{"text": "We found that the WT- and DUBmut-viruses exhibit higher proportions of spliced XBP-1 mRNA at 9 hpi and 12 hpi compared to EndoUmut infected cells ( Fig. 5E ) , consistent with activation of the IRE-1 arm of the unfolded protein response .", "labels": [[26, 41, "ENTITY"], [71, 79, "ENTITY"], [79, 85, "ENTITY"], [95, 99, "ENTITY"], [148, 153, "GENE_OR_GENE_PRODUCT"], [190, 200, "ENTITY"], [18, 22, "ENTITY"], [85, 90, "ENTITY"], [190, 200, "PROTEIN"], [140, 146, "CL"], [207, 220, "PROTEIN"], [79, 90, "RNA"], [56, 68, "ENTITY"], [122, 146, "ENTITY"], [79, 85, "GENE_OR_GENE_PRODUCT"], [26, 41, "GENE_OR_GENE_PRODUCT"], [140, 146, "CELL"], [158, 171, "ENTITY"], [122, 146, "CELL_LINE"], [207, 228, "ENTITY"], [85, 90, "CHEBI"], [95, 99, "ENTITY"], [211, 220, "CHEBI"], [18, 41, "PROTEIN"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Viral proteins with RGD motifs promote infection by binding integrin heterodimers such as \u03b1V\u03b21 , \u03b1V\u03b23 , \u03b1V\u03b25 , \u03b1V\u03b26 , \u03b1V\u03b28 , \u03b15\u03b21 , \u03b18\u03b21 and \u03b1IIb\u03b23 ( Hussein et al. , 2015 ) , activating transducing pathways involving phosphatidylinositol-3 kinase ( PI\u20133 K ) or mitogen-activate protein kinase ( MAPK ) , which promote virus entry and infection of the host cell .", "labels": [[39, 49, "CELL"], [118, 125, "CHEMICAL"], [208, 218, "GGP"], [218, 241, "PROTEIN"], [218, 241, "GENE_OR_GENE_PRODUCT"], [208, 218, "PROTEIN"], [250, 279, "PROTEIN"], [6, 14, "PROTEIN"], [250, 279, "GENE_OR_GENE_PRODUCT"], [319, 325, "ENTITY"], [111, 118, "ENTITY"], [132, 141, "GENE_OR_GENE_PRODUCT"], [90, 95, "GGP"], [111, 118, "PROTEIN"], [39, 49, "ENTITY"], [111, 118, "GGP"], [0, 15, "PROTEIN"], [39, 49, "ENTITY"], [52, 82, "ENTITY"], [208, 218, "GENE_OR_GENE_PRODUCT"], [90, 95, "PROTEIN"], [0, 15, "ENTITY"], [0, 15, "TAXON"], [132, 141, "ENTITY"], [118, 125, "PROTEIN"], [118, 125, "ENTITY"], [250, 262, "CHEMICAL"], [6, 14, "GENE_OR_GENE_PRODUCT"], [218, 241, "ENTITY"], [39, 49, "DISEASE"], [250, 279, "ENTITY"], [31, 39, "ENTITY"], [24, 31, "SO"], [20, 24, "ENTITY"], [90, 95, "CHEMICAL"], [90, 95, "ENTITY"], [208, 218, "ENTITY"], [60, 69, "GO"], [167, 187, "ENTITY"], [39, 49, "CL"], [60, 69, "GENE_OR_GENE_PRODUCT"], [6, 14, "ENTITY"], [319, 325, "DISEASE"], [24, 31, "ENTITY"], [52, 82, "PROTEIN"], [303, 311, "ENTITY"], [20, 31, "PROTEIN"]]}
{"text": "Chloroquine is known to inhibit phosphorylation ( activation ) of the p38 mitogen-activated protein kinase ( MAPK ) in THP-1 cells as well as caspase-1 [ 72 ] . Activation of cells via MAPK signalling is frequently required by viruses to achieve their replication cycle [ 73 ] . In the model of HCoV-229 coronavirus , chloroquine-induced virus inhibition occurs through inhibition of p38 MAPK [ 44 ] .", "labels": [[181, 190, "ENTITY"], [0, 12, "CHEBI"], [125, 131, "PROTEIN"], [66, 100, "GENE_OR_GENE_PRODUCT"], [116, 125, "CELL"], [66, 100, "PROTEIN"], [286, 304, "ENTITY"], [304, 318, "ENTITY"], [125, 131, "ENTITY"], [161, 172, "CELL"], [355, 370, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [318, 344, "ENTITY"], [277, 282, "ENTITY"], [32, 48, "ENTITY"], [66, 100, "GGP"], [344, 355, "PROTEIN"], [116, 125, "ENTITY"], [0, 12, "CHEMICAL"], [344, 355, "ENTITY"], [66, 100, "ENTITY"], [161, 172, "ENTITY"], [116, 125, "CELL_LINE"], [161, 172, "CL"], [116, 125, "CL"], [304, 318, "GENE_OR_GENE_PRODUCT"], [286, 304, "GENE_OR_GENE_PRODUCT"], [344, 355, "GENE_OR_GENE_PRODUCT"], [215, 227, "TAXON"], [24, 32, "ENTITY"], [215, 227, "ENTITY"], [125, 131, "GENE_OR_GENE_PRODUCT"], [0, 12, "ENTITY"], [344, 355, "GGP"]]}
{"text": "ii ) the genetic absence of MyD88 significantly enhances SARS CoV- induced morbidity and mortality , and iii ) MyD88-dependent signaling through a receptor(s ) other than IL-1R1 or IL-18R1 is responsible for protection from rMA15 .", "labels": [[111, 127, "ENTITY"], [57, 62, "PROTEIN"], [9, 17, "ENTITY"]]}
{"text": "The histological and flow cytometric analyses outlined above suggested that monocytes/macrophages are i ) the major cell population increased in the SARS-infected lung at early times post-infection , ii ) increased in the lung by a MyD88-dependent mechanism , and iii ) critical for protection against severe rMA15-induced disease .", "labels": [[116, 121, "ENTITY"], [149, 163, "ENTITY"], [21, 46, "ENTITY"], [302, 323, "ENTITY"], [76, 98, "CELL_TYPE"], [171, 177, "ENTITY"], [4, 17, "ENTITY"], [232, 248, "ENTITY"], [76, 98, "CL"], [76, 98, "CELL"], [76, 98, "ENTITY"]]}
{"text": "The histological and flow cytometric analyses outlined above suggested that monocytes/macrophages are i ) the major cell population increased in the SARS-infected lung at early times post-infection , ii ) increased in the lung by a MyD88-dependent mechanism , and iii ) critical for protection against severe rMA15-induced disease .", "labels": [[116, 121, "ENTITY"], [149, 163, "ENTITY"], [76, 98, "CL"], [76, 98, "CELL"], [21, 46, "ENTITY"], [76, 98, "ENTITY"], [302, 323, "ENTITY"], [171, 177, "ENTITY"], [4, 17, "ENTITY"], [232, 248, "ENTITY"], [76, 98, "CELL_TYPE"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[542, 550, "ENTITY"], [416, 427, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [301, 311, "TAXON"], [139, 151, "PROTEIN"], [439, 444, "ENTITY"], [125, 135, "SO"], [162, 193, "ENTITY"], [408, 416, "ENTITY"], [477, 487, "ENTITY"], [320, 326, "ENTITY"], [115, 125, "DISEASE"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [162, 187, "ORGANISM"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [487, 507, "ENTITY"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "Interestingly , induction of TNF-\u03b1 , IL-6 , and IL-8 has been detected in cells overexpressing the spike protein of SARS-CoV via the NF-\u03baB pathway(Wang et al. , 2007;Dosch et al. , 2009 ) .", "labels": [[99, 105, "CHEBI"], [95, 105, "ENTITY"], [74, 80, "ENTITY"], [129, 139, "ORGANISM"], [155, 161, "SIMPLE_CHEMICAL"], [95, 105, "PROTEIN"], [129, 139, "DNA"]]}
{"text": "Interestingly , induction of TNF-\u03b1 , IL-6 , and IL-8 has been detected in cells overexpressing the spike protein of SARS-CoV via the NF-\u03baB pathway(Wang et al. , 2007;Dosch et al. , 2009 ) .", "labels": [[99, 105, "CHEBI"], [95, 105, "ENTITY"], [74, 80, "ENTITY"], [129, 139, "ORGANISM"], [155, 161, "SIMPLE_CHEMICAL"], [95, 105, "PROTEIN"], [129, 139, "DNA"]]}
{"text": "Interestingly , induction of TNF-\u03b1 , IL-6 , and IL-8 has been detected in cells overexpressing the spike protein of SARS-CoV via the NF-\u03baB pathway(Wang et al. , 2007;Dosch et al. , 2009 ) .", "labels": [[99, 105, "CHEBI"], [95, 105, "ENTITY"], [74, 80, "ENTITY"], [129, 139, "ORGANISM"], [155, 161, "SIMPLE_CHEMICAL"], [95, 105, "PROTEIN"], [129, 139, "DNA"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Based on our analyses of differential gene expression , we report significant transcriptional upregulation of multiple genes associated with activation of ER sensors IRE1 , ATF6 , and PERK , such as Edem1 , Hspa5 ( encoding BiP protein ) , and Ddit3 ( encoding CHOP ) , in response to virus replication , with the most robust response detected in cells infected with the wild-type or DUBmut virus infection ( Fig. 5B , C , and D ) .", "labels": [[319, 326, "ENTITY"], [155, 158, "ENTITY"], [244, 252, "ENTITY"], [215, 228, "PROTEIN"], [273, 291, "ENTITY"], [371, 391, "DISEASE"], [38, 54, "ENTITY"], [397, 407, "GENE_OR_GENE_PRODUCT"], [199, 207, "ENTITY"], [199, 207, "GENE_OR_GENE_PRODUCT"], [335, 347, "ENTITY"], [199, 207, "PROTEIN"], [371, 391, "ENTITY"], [38, 43, "SO"], [305, 314, "ENTITY"], [215, 228, "ENTITY"], [110, 119, "ENTITY"], [397, 407, "ENTITY"], [371, 384, "TAXON"], [409, 414, "ENTITY"], [261, 270, "ENTITY"], [199, 207, "GGP"], [215, 228, "GGP"], [25, 38, "ENTITY"], [207, 215, "ENTITY"], [353, 367, "ENTITY"], [13, 22, "ENTITY"]]}
{"text": "The Appr-1\u2033-p domain of nsp 3 is proposed to have functions in viral RNA synthesis ( Snijder et al. , 2003 ) .", "labels": [[63, 83, "ENTITY"], [24, 30, "GENE_OR_GENE_PRODUCT"], [4, 21, "GGP"], [63, 73, "TAXON"], [4, 21, "ENTITY"], [4, 14, "GENE_OR_GENE_PRODUCT"], [24, 30, "PROTEIN"], [24, 30, "ENTITY"], [50, 60, "ENTITY"], [4, 21, "PROTEIN"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[542, 550, "ENTITY"], [416, 427, "ENTITY"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [301, 311, "TAXON"], [439, 444, "ENTITY"], [125, 135, "SO"], [162, 193, "ENTITY"], [408, 416, "ENTITY"], [477, 487, "ENTITY"], [320, 326, "ENTITY"], [115, 125, "DISEASE"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [162, 187, "ORGANISM"], [139, 151, "PROTEIN"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [487, 507, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "The host CD26 receptor cleaves amino-terminal dipeptides from polypeptides with either L-proline or L-alanine in the penultimate position , leading to T-cell activation and thus acting as a key immunoregulatory factor in viral infections [ 9 ] .", "labels": [[87, 97, "CHEMICAL"], [100, 110, "CHEBI"], [87, 97, "CHEBI"], [9, 14, "GENE_OR_GENE_PRODUCT"], [129, 138, "SO"], [9, 57, "GGP"], [87, 97, "SIMPLE_CHEMICAL"], [4, 9, "ENTITY"], [100, 110, "CHEMICAL"], [31, 57, "ENTITY"], [87, 97, "ENTITY"], [194, 211, "ENTITY"], [117, 138, "ENTITY"], [151, 158, "ENTITY"], [9, 23, "ENTITY"], [221, 227, "ENTITY"], [221, 227, "DISEASE"], [62, 75, "ENTITY"], [100, 110, "SIMPLE_CHEMICAL"], [100, 110, "ENTITY"], [4, 23, "PROTEIN"], [194, 211, "PROTEIN"]]}
{"text": "Studies have shown that multi-functional T cells can better control human immunodeficiency virus in natural infection and are correlated with better outcomes during vaccination ; thus , the functional damage of CD4 + T cells may have predisposed COVID-19 patients to severe disease.8", "labels": [[68, 74, "ENTITY"], [41, 49, "CELL"], [68, 97, "DISEASE"], [41, 49, "CL"], [149, 158, "ENTITY"], [208, 219, "CELL_TYPE"], [208, 219, "GENE_OR_GENE_PRODUCT"], [246, 255, "ENTITY"], [165, 177, "ENTITY"], [24, 49, "ENTITY"], [267, 274, "CHEMICAL"], [74, 97, "ENTITY"], [234, 255, "ORGANISM"], [100, 118, "ENTITY"], [126, 137, "ENTITY"], [208, 219, "GGP"], [234, 246, "ENTITY"], [0, 8, "ENTITY"], [91, 97, "TAXON"], [30, 41, "ENTITY"], [208, 219, "ENTITY"], [100, 118, "DISEASE"], [68, 97, "ORGANISM"], [234, 246, "DISEASE"], [24, 49, "CELL_TYPE"], [68, 74, "TAXON"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [19, 26, "CL"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate ( AMP ) kinase .", "labels": [[19, 46, "ENTITY"], [59, 64, "PROTEIN"], [83, 107, "CHEMICAL"], [0, 6, "GENE_OR_GENE_PRODUCT"], [59, 64, "GENE_OR_GENE_PRODUCT"], [0, 6, "CHEMICAL"], [59, 64, "ENTITY"], [0, 6, "GGP"], [59, 64, "GGP"], [83, 93, "CHEBI"], [83, 107, "SIMPLE_CHEMICAL"], [83, 107, "ENTITY"], [68, 79, "ENTITY"], [0, 6, "PROTEIN"], [0, 6, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Functional analysis by DAVID and Cluster Profiler revealed that these genes were enriched in specific cellular biological processes , including positive regulation of neutrophil chemotaxis , neutrophil activation , type I interferon signaling pathway , inflammatory response , and antigen processing and presentation ( Fig.3b and Extended Data Fig.5c-d ) , suggesting an active innate immune response against SARS-CoV-2 infection .", "labels": [[102, 132, "ENTITY"], [304, 319, "GENE_OR_GENE_PRODUCT"], [277, 289, "ENTITY"], [102, 111, "CL"], [23, 29, "CHEMICAL"], [401, 420, "DISEASE"], [70, 76, "SO"], [0, 20, "ENTITY"], [357, 368, "ENTITY"], [339, 344, "SIMPLE_CHEMICAL"], [304, 319, "ENTITY"], [102, 111, "CELL"], [213, 222, "GGP"], [70, 76, "ENTITY"], [213, 222, "GENE_OR_GENE_PRODUCT"], [243, 266, "ENTITY"], [319, 344, "ENTITY"], [213, 222, "PROTEIN"], [23, 29, "ENTITY"], [213, 243, "ENTITY"], [339, 344, "CHEMICAL"], [33, 50, "ENTITY"], [189, 202, "ENTITY"], [371, 392, "ENTITY"], [167, 178, "ENTITY"], [401, 420, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Fig 6 . In contrast , mice deficient in either CCR1 , CCR2 , or CCR5 exhibited more prominent airway epithelial cell apoptosis , a severe denuding bronchiolitis with an accumulation of cohesive apoptotic debris within the airway ( empty arrowhead ) , and perivenular/periarterial cuffing ( filled arrowhead ) but there was a distinct lack of cuffing around the affected airways .", "labels": [[325, 339, "ENTITY"], [247, 255, "CHEMICAL"], [84, 112, "CELL"], [84, 94, "ENTITY"], [138, 147, "DISEASE"], [94, 112, "CL"], [112, 117, "ENTITY"], [94, 112, "ENTITY"], [161, 169, "ENTITY"], [325, 339, "CELLULAR_COMPONENT"], [247, 280, "TISSUE"], [131, 138, "ENTITY"], [185, 194, "ENTITY"], [222, 237, "ENTITY"], [247, 280, "ENTITY"], [22, 27, "ENTITY"], [280, 297, "ENTITY"], [138, 147, "ENTITY"], [127, 131, "ENTITY"]]}
{"text": "Interestingly , an earlier onset and more significant apoptosis induction in IRE1-knockdown IBV-infected cells was observed , which is associated with hyperphosphorylation of pro-apoptotic kinase JNK and hypophosphorylation of pro-survival kinase RAC-alpha serine/threonine-protein kinase ( Akt ) .", "labels": [[224, 282, "PROTEIN"], [92, 105, "ENTITY"], [172, 196, "GGP"], [224, 282, "GENE_OR_GENE_PRODUCT"], [224, 282, "ENTITY"], [240, 257, "CHEMICAL"], [172, 196, "PROTEIN"], [172, 196, "ENTITY"], [77, 105, "CELL_LINE"], [132, 146, "ENTITY"], [224, 282, "GGP"], [172, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "This scenario could occur in stressed cells when GRP78 is overexpressed and translocated from the Endoplasmic Reticulum ( ER ) to the cell membrane ( M ) .", "labels": [[98, 120, "GO"], [5, 14, "ENTITY"], [98, 120, "ENTITY"], [98, 120, "PROTEIN"], [29, 44, "ENTITY"], [49, 55, "GENE_OR_GENE_PRODUCT"], [130, 139, "GO"], [49, 55, "PROTEIN"], [49, 55, "GGP"], [58, 72, "ENTITY"], [130, 139, "CELLULAR_COMPONENT"], [38, 44, "CELL"], [130, 139, "ENTITY"], [49, 55, "ENTITY"], [38, 44, "CL"], [76, 89, "ENTITY"]]}
{"text": "This scenario could occur in stressed cells when GRP78 is overexpressed and translocated from the Endoplasmic Reticulum ( ER ) to the cell membrane ( M ) .", "labels": [[98, 120, "GO"], [5, 14, "ENTITY"], [98, 120, "ENTITY"], [98, 120, "PROTEIN"], [29, 44, "ENTITY"], [49, 55, "GENE_OR_GENE_PRODUCT"], [130, 139, "GO"], [49, 55, "PROTEIN"], [49, 55, "GGP"], [58, 72, "ENTITY"], [130, 139, "CELLULAR_COMPONENT"], [38, 44, "CELL"], [130, 139, "ENTITY"], [49, 55, "ENTITY"], [38, 44, "CL"], [76, 89, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "The transfer of HEV67N between neurons has been demonstrated by our previous ultrastructural studies to use the clathrin-coating-mediated endo-/exocytotic pathway 10 .", "labels": [[16, 23, "GGP"], [4, 13, "ENTITY"], [16, 23, "CELL"], [31, 39, "CL"], [112, 163, "ENTITY"], [16, 23, "DNA"], [31, 39, "ENTITY"], [31, 39, "CELL"], [16, 23, "ENTITY"], [77, 101, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "C3 activation products ( C3 fragments C3a , C3b , iC3b , C3dg , and C3c ) were detected by Western blotting in lung tissue of SARS-CoV MA15-infected mice , but not in control mice , as early as 1 day postinfection ( dpi ) ( Fig. 1B ) , confirming that SARS-CoV MA15 infection activates the complement pathway .", "labels": [[25, 38, "ENTITY"], [0, 23, "PROTEIN"], [160, 167, "ENTITY"], [25, 38, "PROTEIN"], [99, 116, "ENTITY"], [135, 140, "ENTITY"], [50, 57, "GGP"], [247, 261, "ENTITY"], [236, 252, "ORGANISM"], [50, 57, "PROTEIN"], [236, 247, "ENTITY"], [50, 57, "ENTITY"], [116, 135, "ENTITY"], [191, 200, "ENTITY"], [116, 126, "ORGANISM"], [0, 3, "GGP"], [185, 191, "ENTITY"], [79, 99, "ENTITY"], [50, 57, "GENE_OR_GENE_PRODUCT"], [0, 23, "ENTITY"], [276, 290, "ENTITY"], [116, 126, "GGP"], [25, 38, "GGP"], [25, 38, "GENE_OR_GENE_PRODUCT"], [99, 116, "TISSUE"], [14, 23, "SO"]]}
{"text": "C3 activation products ( C3 fragments C3a , C3b , iC3b , C3dg , and C3c ) were detected by Western blotting in lung tissue of SARS-CoV MA15-infected mice , but not in control mice , as early as 1 day postinfection ( dpi ) ( Fig. 1B ) , confirming that SARS-CoV MA15 infection activates the complement pathway .", "labels": [[25, 38, "ENTITY"], [0, 23, "PROTEIN"], [160, 167, "ENTITY"], [25, 38, "PROTEIN"], [99, 116, "ENTITY"], [135, 140, "ENTITY"], [50, 57, "GGP"], [247, 261, "ENTITY"], [236, 252, "ORGANISM"], [50, 57, "PROTEIN"], [236, 247, "ENTITY"], [50, 57, "ENTITY"], [116, 135, "ENTITY"], [191, 200, "ENTITY"], [116, 126, "ORGANISM"], [0, 3, "GGP"], [185, 191, "ENTITY"], [79, 99, "ENTITY"], [50, 57, "GENE_OR_GENE_PRODUCT"], [0, 23, "ENTITY"], [276, 290, "ENTITY"], [116, 126, "GGP"], [25, 38, "GGP"], [25, 38, "GENE_OR_GENE_PRODUCT"], [99, 116, "TISSUE"], [14, 23, "SO"]]}
{"text": "C3 activation products ( C3 fragments C3a , C3b , iC3b , C3dg , and C3c ) were detected by Western blotting in lung tissue of SARS-CoV MA15-infected mice , but not in control mice , as early as 1 day postinfection ( dpi ) ( Fig. 1B ) , confirming that SARS-CoV MA15 infection activates the complement pathway .", "labels": [[25, 38, "ENTITY"], [0, 23, "PROTEIN"], [160, 167, "ENTITY"], [25, 38, "PROTEIN"], [99, 116, "ENTITY"], [135, 140, "ENTITY"], [50, 57, "GGP"], [247, 261, "ENTITY"], [236, 252, "ORGANISM"], [50, 57, "PROTEIN"], [236, 247, "ENTITY"], [50, 57, "ENTITY"], [116, 135, "ENTITY"], [191, 200, "ENTITY"], [116, 126, "ORGANISM"], [0, 3, "GGP"], [185, 191, "ENTITY"], [79, 99, "ENTITY"], [50, 57, "GENE_OR_GENE_PRODUCT"], [0, 23, "ENTITY"], [276, 290, "ENTITY"], [116, 126, "GGP"], [25, 38, "GGP"], [25, 38, "GENE_OR_GENE_PRODUCT"], [99, 116, "TISSUE"], [14, 23, "SO"]]}
{"text": "C3 activation products ( C3 fragments C3a , C3b , iC3b , C3dg , and C3c ) were detected by Western blotting in lung tissue of SARS-CoV MA15-infected mice , but not in control mice , as early as 1 day postinfection ( dpi ) ( Fig. 1B ) , confirming that SARS-CoV MA15 infection activates the complement pathway .", "labels": [[25, 38, "ENTITY"], [0, 23, "PROTEIN"], [160, 167, "ENTITY"], [25, 38, "PROTEIN"], [99, 116, "ENTITY"], [135, 140, "ENTITY"], [50, 57, "GGP"], [247, 261, "ENTITY"], [236, 252, "ORGANISM"], [50, 57, "PROTEIN"], [236, 247, "ENTITY"], [50, 57, "ENTITY"], [116, 135, "ENTITY"], [191, 200, "ENTITY"], [116, 126, "ORGANISM"], [0, 3, "GGP"], [185, 191, "ENTITY"], [79, 99, "ENTITY"], [50, 57, "GENE_OR_GENE_PRODUCT"], [0, 23, "ENTITY"], [276, 290, "ENTITY"], [116, 126, "GGP"], [25, 38, "GGP"], [25, 38, "GENE_OR_GENE_PRODUCT"], [99, 116, "TISSUE"], [14, 23, "SO"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Accumulating evidence revealed that a part of severe COVID-19 patients have a elevated cytokine profile resembling CS in SARS and MERS .", "labels": [[13, 22, "ENTITY"], [87, 96, "PROTEIN"], [53, 62, "ENTITY"], [53, 71, "ORGANISM"], [87, 104, "ENTITY"], [0, 13, "ENTITY"], [53, 62, "DISEASE"], [46, 53, "ENTITY"], [115, 118, "ENTITY"], [121, 126, "DISEASE"], [121, 126, "ENTITY"], [62, 71, "ENTITY"], [78, 87, "ENTITY"], [130, 135, "DISEASE"], [130, 135, "ENTITY"]]}
{"text": "Some of top pathways include cytokine and cytokine receptor interaction , VEGFA-VEGF2 signaling pathway , JAS-STAT signaling pathway etc", "labels": [[60, 72, "ENTITY"], [8, 21, "ENTITY"], [29, 38, "PROTEIN"], [104, 125, "ENTITY"], [29, 38, "ENTITY"], [42, 60, "PROTEIN"], [42, 60, "ENTITY"], [74, 96, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Chloroquine was shown to inhibit quinone reductase 2 [ 56 ] , a structural neighbour of UDP-N-acetylglucosamine 2-epimerases [ 57 ] that are involved in the biosynthesis of sialic acids . The sialic acids are acidic monosaccharides found at the extremity of sugar chains present on cell transmembrane proteins and are critical components of ligand recognition . The possible interference of chloroquine with sialic acid biosynthesis could account for the broad antiviral spectrum of that drug since viruses such as the human coronavirus HCoV-O43 and the orthomyxoviruses use sialic acid moieties as receptors [ 58 ] .", "labels": [[0, 12, "CHEBI"], [271, 301, "GO"], [245, 264, "ENTITY"], [587, 599, "ENTITY"], [199, 216, "CHEBI"], [157, 180, "CHEMICAL"], [546, 554, "ENTITY"], [391, 408, "CHEBI"], [245, 264, "PROTEIN"], [512, 525, "ORGANISM"], [375, 391, "SIMPLE_CHEMICAL"], [391, 420, "ENTITY"], [554, 587, "PROTEIN"], [391, 408, "CHEMICAL"], [554, 575, "CHEMICAL"], [271, 301, "PROTEIN"], [245, 258, "SIMPLE_CHEMICAL"], [512, 537, "PROTEIN"], [519, 525, "ENTITY"], [519, 537, "CHEMICAL"], [157, 180, "ENTITY"], [62, 75, "ENTITY"], [375, 391, "ENTITY"], [391, 408, "SIMPLE_CHEMICAL"], [186, 199, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [238, 245, "PATHOLOGICAL_FORMATION"], [33, 53, "ENTITY"], [85, 112, "GENE_OR_GENE_PRODUCT"], [157, 180, "SIMPLE_CHEMICAL"], [209, 216, "SIMPLE_CHEMICAL"], [554, 587, "SIMPLE_CHEMICAL"], [0, 12, "CHEMICAL"], [157, 180, "CHEBI"], [186, 199, "ENTITY"], [327, 348, "ENTITY"], [33, 53, "PROTEIN"], [271, 301, "ENTITY"], [455, 471, "ENTITY"], [186, 199, "CHEBI"], [85, 112, "ENTITY"], [271, 287, "CELLULAR_COMPONENT"], [199, 216, "ENTITY"], [375, 391, "CHEBI"], [554, 587, "ENTITY"], [33, 53, "GENE_OR_GENE_PRODUCT"], [33, 41, "CHEMICAL"], [25, 33, "ENTITY"], [375, 391, "CHEMICAL"], [238, 245, "ENTITY"], [554, 575, "CHEBI"], [186, 199, "SIMPLE_CHEMICAL"], [33, 53, "GGP"], [0, 12, "ENTITY"], [525, 537, "ENTITY"], [546, 554, "TAXON"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Interestingly , the mRNA level of CSPG2 , which is involved in the extracellular matrix assembly ( 32 ) , was also specifically up- regulated , with four different transcripts giving similar results ( Table \u200b(Table1).1 ) .", "labels": [[63, 81, "CELLULAR_COMPONENT"], [128, 132, "ENTITY"], [201, 207, "GENE_OR_GENE_PRODUCT"], [183, 191, "ENTITY"], [63, 88, "GO"], [63, 88, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "It acts by binding host receptors on target cells , inducing endocytosis of virion particle , and then catalyzes the fusion between host and viral membranes , allowing penetration of the virus genome into host cytoplasm .", "labels": [[159, 168, "ENTITY"], [44, 50, "CL"], [76, 83, "ENTITY"], [19, 34, "ENTITY"], [183, 193, "TAXON"], [11, 34, "PROTEIN"], [19, 24, "GO"], [183, 193, "DNA"], [19, 24, "TAXON"], [19, 24, "ENTITY"], [37, 50, "CELL_TYPE"], [37, 50, "ENTITY"], [137, 147, "TAXON"], [44, 50, "CELL"], [183, 193, "ENTITY"], [137, 147, "ENTITY"], [11, 19, "ENTITY"], [200, 210, "CELLULAR_COMPONENT"]]}
{"text": "Interestingly , the Spike protein ( S ) interacts with the GOLGA7-ZDHHC5 acyl-transferase complex , which likely mediates palmitoylation on its cytosolic tail ( see also Appendix ) [ 35 ] . Palmitoylation has been reported to facilitate membrane fusion by SARS-CoV Spike and suggests a potential target for therapeutic inhibition [ 36 ] .", "labels": [[20, 26, "ENTITY"], [140, 154, "PROTEIN"], [307, 319, "ENTITY"], [55, 90, "ENTITY"], [246, 256, "ENTITY"], [296, 307, "ENTITY"], [20, 36, "PROTEIN"], [140, 154, "ENTITY"], [226, 237, "GO"], [226, 237, "ENTITY"], [113, 122, "ENTITY"], [246, 256, "GGP"], [246, 256, "PROTEIN"], [140, 154, "CELLULAR_COMPONENT"], [246, 256, "ORGANISM"], [226, 237, "CELLULAR_COMPONENT"], [55, 90, "PROTEIN"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "This suggests that homeostasis of the immune system plays an important role in the development of COVID-19 pneumonia .", "labels": [[107, 117, "DISEASE"], [19, 31, "ENTITY"], [38, 52, "ENTITY"], [83, 95, "ENTITY"], [98, 107, "SIMPLE_CHEMICAL"], [98, 117, "ENTITY"]]}
{"text": "Accordingly , findings from multiple studies in humans and animals indicate that corticosteroid immunosuppression ( both inhaled and systemic ) impairs induction of anti-viral type-I interferon responses to a range of respiratory viruses,3,4 effects that are likely to also occur in the context of COVID-19 .", "labels": [[218, 230, "GENE_OR_GENE_PRODUCT"], [162, 194, "ENTITY"], [144, 152, "ENTITY"], [81, 96, "ENTITY"], [28, 37, "ENTITY"], [162, 183, "PROTEIN"]]}
{"text": "Chloroquine-induced inhibition of tumour necrosis factor-alpha ( TNF\u03b1 ) production by immune cells was reported to occur either through disruption of cellular iron metabolism [ 80 ] , blockade of the conversion of pro-TNF into soluble mature TNF\u03b1 molecules [ 81 ] and/or inhibition of TNF\u03b1 mRNA expression [ 72,82,83 ] .", "labels": [[0, 20, "CELLULAR_COMPONENT"], [222, 247, "PROTEIN"], [83, 93, "ENTITY"], [285, 295, "ENTITY"], [65, 70, "CHEBI"], [20, 34, "RNA"], [200, 214, "PROTEIN"], [34, 63, "GGP"], [147, 164, "ENTITY"], [227, 235, "ENTITY"], [34, 50, "DISEASE"], [34, 63, "PROTEIN"], [150, 159, "CHEMICAL"], [83, 93, "CELL_TYPE"], [65, 70, "ENTITY"], [83, 93, "CL"], [20, 31, "GENE_OR_GENE_PRODUCT"], [264, 271, "ENTITY"], [34, 63, "GENE_OR_GENE_PRODUCT"], [235, 242, "ENTITY"], [200, 214, "ENTITY"], [20, 31, "ENTITY"], [200, 214, "GENE_OR_GENE_PRODUCT"], [0, 31, "ENTITY"], [34, 63, "ENTITY"], [20, 31, "DISEASE"], [235, 242, "GENE_OR_GENE_PRODUCT"], [83, 93, "CELL"], [295, 308, "PROTEIN"], [147, 159, "CL"], [147, 159, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Here , we further systematically evaluated the broad-spectrum surface-fusion inhibitory activity of EK1C4 on cell \u2013 cell fusion mediated by S proteins of divergent coronaviruses , including SARS-CoV , MERS-CoV , HCoV-OC43 , HCoV-NL63 and HCoV-229E.Among them , SARS-CoV has the closest relative to SARS-CoV-2 , and its S protein-mediated cell \u2013 cell fusion could be effectively inhibited by EK1C4 with IC50 of 4.3 nM , which is about 94-fold more active than that of EK1 ( IC50 = 409.3 nM ) ( Fig. 5a ) .", "labels": [[254, 261, "PROTEIN"], [190, 201, "ENTITY"], [180, 190, "GGP"], [286, 298, "SIMPLE_CHEMICAL"], [154, 164, "ENTITY"], [311, 321, "ENTITY"], [201, 212, "ENTITY"], [224, 238, "ORGANISM"], [190, 201, "GGP"], [436, 444, "ENTITY"], [224, 238, "DNA"], [224, 238, "ENTITY"], [190, 201, "ORGANISM"], [286, 298, "CHEMICAL"], [137, 142, "ENTITY"], [201, 212, "TAXON"], [180, 190, "PROTEIN"], [154, 164, "PROTEIN"], [321, 345, "ENTITY"], [286, 298, "ENTITY"], [180, 190, "ORGANISM"], [311, 338, "CELL_LINE"], [201, 212, "ORGANISM"], [154, 164, "TAXON"], [254, 261, "ENTITY"], [254, 261, "GGP"], [321, 338, "CL"], [254, 261, "ORGANISM"], [190, 201, "PROTEIN"], [180, 190, "ENTITY"], [137, 142, "PROTEIN"], [114, 121, "ENTITY"], [212, 224, "ORGANISM"], [109, 116, "CELL"], [212, 224, "ENTITY"]]}
{"text": "The clinical features include fever , dry cough , shortness of breath , normal or low levels of peripheral white blood cells , and inflammatory changes on chest X-ray .", "labels": [[48, 63, "ENTITY"], [38, 42, "ENTITY"], [107, 119, "CELL"], [4, 22, "ENTITY"], [107, 119, "CL"], [82, 86, "ENTITY"], [127, 144, "ENTITY"], [30, 36, "ENTITY"], [38, 42, "DISEASE"], [48, 63, "DISEASE"], [152, 161, "ENTITY"], [93, 119, "ENTITY"], [93, 119, "CELL_TYPE"], [30, 36, "DISEASE"]]}
{"text": "Functional analysis by DAVID and Cluster Profiler revealed that these genes were enriched in specific cellular biological processes , including positive regulation of neutrophil chemotaxis , neutrophil activation , type I interferon signaling pathway , inflammatory response , and antigen processing and presentation ( Fig.3b and Extended Data Fig.5c-d ) , suggesting an active innate immune response against SARS-CoV-2 infection .", "labels": [[102, 132, "ENTITY"], [277, 289, "ENTITY"], [304, 319, "GENE_OR_GENE_PRODUCT"], [102, 111, "CL"], [23, 29, "CHEMICAL"], [401, 420, "DISEASE"], [70, 76, "SO"], [0, 20, "ENTITY"], [357, 368, "ENTITY"], [304, 319, "ENTITY"], [339, 344, "SIMPLE_CHEMICAL"], [102, 111, "CELL"], [213, 222, "GGP"], [243, 266, "ENTITY"], [70, 76, "ENTITY"], [213, 222, "GENE_OR_GENE_PRODUCT"], [319, 344, "ENTITY"], [213, 222, "PROTEIN"], [23, 29, "ENTITY"], [213, 243, "ENTITY"], [339, 344, "CHEMICAL"], [33, 50, "ENTITY"], [189, 202, "ENTITY"], [371, 392, "ENTITY"], [167, 178, "ENTITY"], [401, 420, "ENTITY"]]}
{"text": "The innate immune response to tissue damage caused by the virus could lead to acute respiratory distress syndrome ( ARDS ) , in which respiratory failure is characterized by the rapid onset of widespread inflammation in the lungs and subsequent fatality [ 4 ] .", "labels": [[234, 245, "ENTITY"], [58, 64, "TAXON"], [128, 146, "ENTITY"], [78, 114, "ENTITY"], [30, 44, "DISEASE"], [84, 114, "DISEASE"], [30, 44, "ENTITY"], [30, 37, "TISSUE"], [128, 146, "DISEASE"], [193, 204, "DISEASE"], [193, 204, "ENTITY"], [58, 64, "ENTITY"], [4, 27, "ENTITY"]]}
{"text": "Mechanistic evidence suggests two competing hypotheses : 1 ) RAS blockade decreases proinflammatory activity of Ang II , decreasing the risk of ARDS , myocarditis , or mortality in COVID-19 , or 2 ) RAS blockade increases ACE2 expression , promoting SARS-CoV-2 virulence in the lungs and heart that leads to ARDS , myocarditis , and death .", "labels": [[144, 151, "ENTITY"], [144, 151, "DISEASE"], [0, 12, "ENTITY"], [240, 261, "ENTITY"], [305, 315, "DISEASE"], [109, 116, "ENTITY"], [168, 181, "ENTITY"], [59, 65, "ENTITY"], [65, 74, "ENTITY"], [109, 116, "PROTEIN"], [151, 165, "ENTITY"], [305, 315, "ENTITY"], [109, 116, "GENE_OR_GENE_PRODUCT"], [74, 100, "ENTITY"], [278, 284, "ORGAN"], [44, 55, "ENTITY"], [240, 250, "SIMPLE_CHEMICAL"], [65, 74, "ENTITY"], [61, 65, "ENTITY"], [212, 227, "ENTITY"], [163, 168, "ENTITY"], [168, 181, "GENE_OR_GENE_PRODUCT"], [299, 305, "ENTITY"], [109, 116, "CHEMICAL"], [240, 250, "CHEMICAL"], [299, 305, "DISEASE"], [168, 195, "CELL_LINE"], [278, 284, "ENTITY"], [109, 116, "GGP"], [12, 21, "ENTITY"], [151, 165, "DISEASE"]]}
{"text": "With SARS-CoV , animal models showed that infection with the virus downregulated ACE2 expression , generating an inflammatory response correlated with acute lung injury and impaired cardiac contractility [ 26\u201328 ] .", "labels": [[16, 23, "ENTITY"], [126, 135, "ENTITY"], [173, 190, "ENTITY"], [146, 162, "DISEASE"], [110, 126, "ENTITY"], [5, 14, "ORGANISM"], [173, 182, "ORGAN"], [5, 14, "ENTITY"], [151, 157, "ORGAN"], [146, 162, "ENTITY"]]}
{"text": "With SARS-CoV , animal models showed that infection with the virus downregulated ACE2 expression , generating an inflammatory response correlated with acute lung injury and impaired cardiac contractility [ 26\u201328 ] .", "labels": [[16, 23, "ENTITY"], [126, 135, "ENTITY"], [146, 162, "DISEASE"], [110, 126, "ENTITY"], [5, 14, "ORGANISM"], [5, 14, "ENTITY"], [151, 157, "ORGAN"], [173, 190, "ENTITY"], [146, 162, "ENTITY"], [173, 182, "ORGAN"]]}
{"text": "Mechanistic evidence suggests two competing hypotheses : 1 ) RAS blockade decreases proinflammatory activity of Ang II , decreasing the risk of ARDS , myocarditis , or mortality in COVID-19 , or 2 ) RAS blockade increases ACE2 expression , promoting SARS-CoV-2 virulence in the lungs and heart that leads to ARDS , myocarditis , and death .", "labels": [[151, 165, "ENTITY"], [144, 151, "ENTITY"], [144, 151, "DISEASE"], [0, 12, "ENTITY"], [240, 261, "ENTITY"], [305, 315, "DISEASE"], [109, 116, "ENTITY"], [168, 181, "ENTITY"], [59, 65, "ENTITY"], [65, 74, "ENTITY"], [109, 116, "PROTEIN"], [305, 315, "ENTITY"], [109, 116, "GENE_OR_GENE_PRODUCT"], [74, 100, "ENTITY"], [278, 284, "ORGAN"], [44, 55, "ENTITY"], [240, 250, "SIMPLE_CHEMICAL"], [65, 74, "ENTITY"], [61, 65, "ENTITY"], [212, 227, "ENTITY"], [163, 168, "ENTITY"], [168, 181, "GENE_OR_GENE_PRODUCT"], [299, 305, "ENTITY"], [109, 116, "CHEMICAL"], [240, 250, "CHEMICAL"], [299, 305, "DISEASE"], [151, 165, "DISEASE"], [168, 195, "CELL_LINE"], [278, 284, "ENTITY"], [109, 116, "GGP"], [12, 21, "ENTITY"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [164, 171, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "SIMPLE_CHEMICAL"], [362, 377, "GENE_OR_GENE_PRODUCT"], [164, 171, "PROTEIN"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [102, 108, "PROTEIN"], [164, 171, "GGP"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [133, 164, "GENE_OR_GENE_PRODUCT"], [133, 164, "PROTEIN"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [33, 41, "DNA"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [299, 330, "GGP"], [377, 389, "PROTEIN"], [164, 171, "ENTITY"], [33, 41, "CHEMICAL"], [33, 41, "ENTITY"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In terms of inflammation indicators , patients on admission showed increase in lactate dehydrogenase ( 25 [ 41 % ] of 61 patients ) , c reactive protein ( 42 [ 67 % ] of 63 patients ) , and erythrocyte sedimentation rate ( 30 [ 52 % ] of 58 patients ) , but not procalcitonin .", "labels": [[132, 147, "ENTITY"], [81, 89, "CHEMICAL"], [81, 103, "GENE_OR_GENE_PRODUCT"], [243, 260, "GENE_OR_GENE_PRODUCT"], [25, 36, "ENTITY"], [123, 147, "PROTEIN"], [81, 103, "PROTEIN"], [81, 103, "ENTITY"], [243, 260, "ENTITY"], [123, 147, "GENE_OR_GENE_PRODUCT"], [69, 78, "ENTITY"], [12, 25, "ENTITY"], [113, 120, "ORGANISM"], [175, 204, "ENTITY"], [52, 62, "ENTITY"], [81, 103, "GGP"], [113, 120, "ENTITY"], [138, 147, "CHEBI"], [243, 260, "PROTEIN"], [12, 25, "DISEASE"], [175, 192, "CELL"], [175, 192, "CL"]]}
{"text": "In terms of inflammation indicators , patients on admission showed increase in lactate dehydrogenase ( 25 [ 41 % ] of 61 patients ) , c reactive protein ( 42 [ 67 % ] of 63 patients ) , and erythrocyte sedimentation rate ( 30 [ 52 % ] of 58 patients ) , but not procalcitonin .", "labels": [[132, 147, "ENTITY"], [81, 103, "GGP"], [81, 89, "CHEMICAL"], [243, 260, "GENE_OR_GENE_PRODUCT"], [25, 36, "ENTITY"], [81, 103, "PROTEIN"], [81, 103, "ENTITY"], [123, 147, "PROTEIN"], [243, 260, "ENTITY"], [123, 147, "GENE_OR_GENE_PRODUCT"], [175, 192, "CL"], [69, 78, "ENTITY"], [12, 25, "ENTITY"], [113, 120, "ORGANISM"], [175, 204, "ENTITY"], [52, 62, "ENTITY"], [113, 120, "ENTITY"], [138, 147, "CHEBI"], [243, 260, "PROTEIN"], [12, 25, "DISEASE"], [175, 192, "CELL"], [81, 103, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In terms of inflammation indicators , patients on admission showed increase in lactate dehydrogenase ( 25 [ 41 % ] of 61 patients ) , c reactive protein ( 42 [ 67 % ] of 63 patients ) , and erythrocyte sedimentation rate ( 30 [ 52 % ] of 58 patients ) , but not procalcitonin .", "labels": [[132, 147, "ENTITY"], [81, 103, "GGP"], [81, 89, "CHEMICAL"], [243, 260, "GENE_OR_GENE_PRODUCT"], [25, 36, "ENTITY"], [81, 103, "PROTEIN"], [81, 103, "ENTITY"], [123, 147, "PROTEIN"], [243, 260, "ENTITY"], [123, 147, "GENE_OR_GENE_PRODUCT"], [175, 192, "CL"], [69, 78, "ENTITY"], [12, 25, "ENTITY"], [113, 120, "ORGANISM"], [175, 204, "ENTITY"], [52, 62, "ENTITY"], [113, 120, "ENTITY"], [138, 147, "CHEBI"], [243, 260, "PROTEIN"], [12, 25, "DISEASE"], [175, 192, "CELL"], [81, 103, "GENE_OR_GENE_PRODUCT"]]}
{"text": "A multicentre , randomised controlled trial of tocilizumab ( IL-6 receptor blockade , licensed for cytokine release syndrome ) , has been approved in patients with COVID-19 pneumonia and elevated IL-6 in China ( ChiCTR2000029765 ) [ 9 ] . Janus kinase ( JAK ) inhibition could affect both inflammation and cellular viral entry in COVID-19 [ 10 ] .", "labels": [[66, 75, "ENTITY"], [187, 196, "GENE_OR_GENE_PRODUCT"], [245, 258, "ENTITY"], [277, 289, "DISEASE"], [187, 196, "PROTEIN"], [164, 173, "DISEASE"], [138, 150, "ORGANISM"], [289, 306, "CL"], [239, 245, "GENE_OR_GENE_PRODUCT"], [315, 330, "GENE_OR_GENE_PRODUCT"], [289, 315, "ENTITY"], [315, 327, "ENTITY"], [59, 66, "GENE_OR_GENE_PRODUCT"], [289, 302, "CELL"], [2, 14, "ENTITY"], [196, 204, "ENTITY"], [59, 66, "ENTITY"], [204, 212, "PROTEIN"], [159, 173, "ENTITY"], [277, 289, "ENTITY"], [16, 38, "ENTITY"], [59, 66, "GGP"], [187, 196, "ENTITY"], [138, 150, "ENTITY"], [239, 245, "GGP"], [239, 245, "PROTEIN"], [187, 196, "GGP"], [95, 116, "ENTITY"]]}
{"text": "For wild-type Nsp5 , we identified one high-confidence interaction , the epigenetic regulator histone deacetylase 2 ( HDAC2 ) , and predicted a cleavage site between the HDAC domain and the nuclear localization sequence , suggesting that Nsp5 may inhibit HDAC2 transport into the nucleus ( Extended Data Fig. 7 ) , potentially impacting the published functions of HDAC2 in mediating inflammation and interferon response [ 38,39 ] .", "labels": [[132, 153, "ENTITY"], [271, 280, "CELLULAR_COMPONENT"], [198, 211, "SO"], [351, 361, "PROTEIN"], [351, 361, "GGP"], [186, 211, "DNA"], [84, 114, "GGP"], [186, 211, "ENTITY"], [14, 19, "GENE_OR_GENE_PRODUCT"], [383, 411, "ENTITY"], [351, 361, "GENE_OR_GENE_PRODUCT"], [247, 255, "ENTITY"], [39, 55, "ENTITY"], [69, 84, "ENTITY"], [351, 361, "ENTITY"], [14, 19, "GGP"], [247, 255, "GENE_OR_GENE_PRODUCT"], [373, 383, "DISEASE"], [247, 255, "GGP"], [280, 290, "ENTITY"], [84, 114, "ENTITY"], [383, 400, "PROTEIN"], [14, 19, "ENTITY"], [238, 247, "ENTITY"], [327, 351, "ENTITY"], [4, 14, "ENTITY"], [271, 280, "ENTITY"], [166, 175, "ENTITY"], [118, 124, "ENTITY"], [373, 383, "ENTITY"], [144, 153, "SO"], [247, 255, "PROTEIN"], [383, 411, "SIMPLE_CHEMICAL"], [69, 114, "PROTEIN"], [166, 175, "PROTEIN"], [271, 280, "GO"], [84, 114, "GENE_OR_GENE_PRODUCT"], [118, 123, "SO"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "The damaged cells induce innate inflammation in the lungs that is largely mediated by pro-inflammatory macrophages and granulocytes . Lung inflammation is the main cause of life-threatening respiratory disorders at the severe stage [ 4 ] .", "labels": [[4, 18, "CELL_TYPE"], [103, 115, "CELL"], [86, 115, "CELL_TYPE"], [119, 132, "ENTITY"], [190, 202, "DISEASE"], [134, 139, "ENTITY"], [219, 226, "ENTITY"], [4, 18, "ENTITY"], [12, 18, "CELL"], [119, 132, "CELL"], [18, 25, "ENTITY"], [52, 58, "ENTITY"], [190, 202, "ENTITY"], [52, 58, "ORGAN"], [86, 115, "ENTITY"], [119, 132, "CELL_TYPE"], [25, 45, "ENTITY"], [12, 18, "CL"], [32, 45, "DISEASE"], [119, 132, "CL"], [86, 115, "CL"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "DPP4 degrades incretins such as glucagon like peptide 1 ( GLP-1 ) and glucose-dependent insulinotropic polypeptide , ultimately leading to reduced insulin secretion and abnormal visceral adipose tissue metabolism .", "labels": [[66, 88, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [5, 14, "ENTITY"], [46, 56, "ENTITY"], [139, 155, "ENTITY"], [66, 103, "GGP"], [70, 88, "CHEMICAL"], [169, 195, "TISSUE"], [0, 5, "GENE_OR_GENE_PRODUCT"], [169, 178, "ENTITY"], [66, 103, "ENTITY"], [32, 41, "GGP"], [46, 54, "SO"], [32, 56, "GENE_OR_GENE_PRODUCT"], [195, 202, "ENTITY"], [32, 41, "ENTITY"], [139, 147, "GENE_OR_GENE_PRODUCT"], [139, 147, "PROTEIN"], [0, 5, "ENTITY"], [14, 24, "PROTEIN"], [178, 195, "ENTITY"], [14, 24, "CHEBI"], [14, 24, "ENTITY"], [0, 5, "PROTEIN"], [139, 147, "GGP"], [14, 24, "SIMPLE_CHEMICAL"]]}
{"text": "DPP4 inhibitors target the enzymatic activity of DPP4 and consequently block the breakdown of GLP-1 . This increase insulin secretion and decrease blood glucose levels in patients with type 2 diabetes .", "labels": [[94, 100, "PROTEIN"], [27, 37, "SO"], [81, 91, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [5, 16, "ENTITY"], [185, 192, "ENTITY"], [94, 100, "CHEBI"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [185, 192, "DISEASE"], [16, 23, "ENTITY"], [0, 5, "PROTEIN"], [71, 77, "ENTITY"], [94, 100, "SIMPLE_CHEMICAL"], [147, 153, "ORGANISM_SUBSTANCE"], [27, 46, "ENTITY"], [0, 5, "ENTITY"], [0, 5, "ENTITY"], [147, 161, "ENTITY"], [116, 124, "ENTITY"], [0, 5, "PROTEIN"], [94, 100, "ENTITY"], [0, 16, "GGP"]]}
{"text": "This result supported further our hypothesis that N-induced cell death was due to interference with the integrin signalling pathway , and that serum factors inhibited this phenomenon dominantly by maintaining the activity of FAK through alternative pathways .", "labels": [[143, 149, "PROTEIN"], [104, 113, "GENE_OR_GENE_PRODUCT"], [34, 45, "ENTITY"], [143, 149, "ENTITY"], [5, 12, "ENTITY"], [50, 71, "ENTITY"], [50, 65, "GENE_OR_GENE_PRODUCT"], [237, 249, "ENTITY"], [104, 132, "ENTITY"], [104, 113, "GO"], [65, 71, "DISEASE"], [104, 113, "PROTEIN"], [50, 65, "CL"], [82, 95, "ENTITY"]]}
{"text": "From these experiments , we conclude that the N protein of SARS-CoV induces apoptosis and actin reorganization by interfering with the integrin signalling pathway during cellular stress induced by the absence of growth factors .", "labels": [[170, 179, "ENTITY"], [212, 219, "PROTEIN"], [90, 96, "ENTITY"], [11, 23, "ENTITY"], [212, 219, "ENTITY"], [135, 155, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "To intervene the ion channel function we treated 3a-WT-transfected Vero E6 cells with ion channel blockers , 4-aminopyridine ( AP ) or Ba , and found that both inhibitors were able to suppress 3a-WT-induced nuclear condensation ( Fig. 6F ) .", "labels": [[41, 49, "ENTITY"], [86, 107, "ENTITY"], [17, 29, "CHEBI"], [67, 72, "ENTITY"], [41, 81, "CELL_LINE"], [72, 81, "ENTITY"], [193, 207, "GO"], [184, 207, "GENE_OR_GENE_PRODUCT"], [67, 81, "CELL"], [17, 29, "CHEBI"], [193, 215, "ENTITY"], [75, 81, "CL"], [17, 38, "ENTITY"]]}
{"text": "We found that the number of AO positive cells was largely reduced in 3a-WT-expressing larvae that were treated with Ba ( Fig. 7C ) when compared to the untreated control ( Fig. 7B ) .", "labels": [[58, 66, "ENTITY"], [28, 31, "ENTITY"], [116, 119, "ENTITY"], [28, 46, "CELL_TYPE"], [40, 46, "CL"], [86, 93, "ORGANISM"], [86, 93, "ENTITY"], [148, 162, "ENTITY"], [103, 116, "ENTITY"], [116, 126, "GENE_OR_GENE_PRODUCT"], [40, 46, "CELL"], [116, 119, "PROTEIN"]]}
{"text": "Notably , the 3a-CS mutant completely abrogated IL-1\u03b2 secretion ( Figure 2B ) , suggesting that the ion channel activity of the 3a protein is required for SARS-CoV 3a-induced IL-1\u03b2 secretion .", "labels": [[14, 20, "ENTITY"], [64, 73, "ENTITY"], [14, 20, "SO"], [164, 175, "GGP"], [38, 48, "PROTEIN"], [10, 17, "CHEBI"], [10, 17, "PROTEIN"], [38, 48, "GGP"], [48, 54, "ENTITY"], [164, 175, "PROTEIN"], [151, 175, "ORGANISM"], [48, 54, "ENTITY"], [38, 48, "ENTITY"], [96, 104, "ENTITY"], [164, 175, "ENTITY"], [27, 38, "ENTITY"], [38, 48, "GENE_OR_GENE_PRODUCT"], [10, 17, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Infection of HCoV-OC43 , VR-1558 , was inhibited only by EST and not by camostat ( Fig. 2b ) . This indicates that VR-1558 enters cells via the late endosome pathway using cysteine proteases and it does not use TMRPSS2 for cell entry in HBTE-ALI culture .", "labels": [[140, 149, "CELLULAR_COMPONENT"], [13, 23, "ENTITY"], [81, 88, "SIMPLE_CHEMICAL"], [228, 237, "CELL"], [123, 130, "CELL"], [123, 130, "ENTITY"], [140, 149, "GO"], [140, 158, "ENTITY"], [228, 246, "ENTITY"], [123, 130, "CL"], [166, 181, "ENTITY"], [228, 237, "CHEMICAL"], [219, 228, "ENTITY"], [228, 246, "CELL_LINE"], [13, 23, "TAXON"], [13, 23, "ORGANISM"], [0, 10, "ENTITY"], [110, 130, "CELL_LINE"], [166, 181, "PROTEIN"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "This in turn contributes to lung injury , as angiotensin-stimulated AT1R results in increased pulmonary vascular permeability , thereby mediating increased lung pathology ( Imai et al. , 2005 ; Kuba et al. , 2005 ) .", "labels": [[136, 146, "ENTITY"], [28, 40, "ENTITY"], [94, 113, "ENTITY"], [28, 40, "DISEASE"], [28, 33, "ORGAN"], [94, 104, "MULTI-TISSUE_STRUCTURE"], [146, 161, "ENTITY"], [84, 94, "ORGAN"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Spleen atrophy was observed in all reported cases with decreased numbers of lymphocyte , and significant cell degeneration , focal hemorrhagic necrosis , macrophage proliferation and macrophage phagocytosis were found in spleen .", "labels": [[76, 87, "CELL"], [65, 73, "ENTITY"], [123, 143, "ENTITY"], [0, 15, "DISEASE"], [0, 7, "ORGAN"], [55, 65, "ENTITY"], [76, 87, "CELL_TYPE"], [0, 15, "ENTITY"], [123, 143, "DISEASE"], [105, 110, "ENTITY"], [154, 165, "ENTITY"], [76, 87, "CL"], [105, 110, "DISEASE"], [152, 165, "ENTITY"], [44, 50, "ENTITY"], [76, 87, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "It is characterized mainly by increased pulmonary vascular permeability and pulmonary edema .", "labels": [[40, 72, "ENTITY"], [6, 20, "ENTITY"], [76, 92, "DISEASE"], [40, 59, "MULTI-TISSUE_STRUCTURE"], [76, 92, "CANCER"], [76, 92, "ENTITY"], [30, 40, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Functional analysis by DAVID and Cluster Profiler revealed that these genes were enriched in specific cellular biological processes , including positive regulation of neutrophil chemotaxis , neutrophil activation , type I interferon signaling pathway , inflammatory response , and antigen processing and presentation ( Fig.3b and Extended Data Fig.5c-d ) , suggesting an active innate immune response against SARS-CoV-2 infection .", "labels": [[102, 132, "ENTITY"], [277, 289, "ENTITY"], [304, 319, "GENE_OR_GENE_PRODUCT"], [102, 111, "CL"], [23, 29, "CHEMICAL"], [401, 420, "DISEASE"], [70, 76, "SO"], [0, 20, "ENTITY"], [357, 368, "ENTITY"], [304, 319, "ENTITY"], [339, 344, "SIMPLE_CHEMICAL"], [102, 111, "CELL"], [213, 222, "GGP"], [70, 76, "ENTITY"], [213, 222, "GENE_OR_GENE_PRODUCT"], [243, 266, "ENTITY"], [319, 344, "ENTITY"], [213, 222, "PROTEIN"], [23, 29, "ENTITY"], [213, 243, "ENTITY"], [339, 344, "CHEMICAL"], [33, 50, "ENTITY"], [189, 202, "ENTITY"], [371, 392, "ENTITY"], [167, 178, "ENTITY"], [401, 420, "ENTITY"]]}
{"text": "Chemical signals such as Interleukin-8 ( IL-8 ) and IL-6 stimulate neutrophil chemotaxis and recruitment to the site of infection where they congregate and cause the release of more proinflammatory mediators that in turn activate additional inflammatory signals , leading to cytokine storms that may progress to vital organ failure 13 .", "labels": [[25, 39, "ENTITY"], [57, 78, "ENTITY"], [57, 67, "CELL"], [177, 198, "ENTITY"], [312, 318, "ORGAN"], [216, 221, "ENTITY"], [0, 9, "CHEBI"], [0, 17, "ENTITY"], [312, 324, "ENTITY"], [57, 67, "CL"], [230, 254, "ENTITY"], [312, 324, "DISEASE"], [177, 198, "PROTEIN"], [25, 39, "GENE_OR_GENE_PRODUCT"], [272, 284, "ENTITY"], [25, 39, "PROTEIN"], [57, 67, "CELL_TYPE"]]}
{"text": "Functional analysis by DAVID and Cluster Profiler revealed that these genes were enriched in specific cellular biological processes , including positive regulation of neutrophil chemotaxis , neutrophil activation , type I interferon signaling pathway , inflammatory response , and antigen processing and presentation ( Fig.3b and Extended Data Fig.5c-d ) , suggesting an active innate immune response against SARS-CoV-2 infection .", "labels": [[102, 132, "ENTITY"], [277, 289, "ENTITY"], [304, 319, "GENE_OR_GENE_PRODUCT"], [102, 111, "CL"], [23, 29, "CHEMICAL"], [401, 420, "DISEASE"], [70, 76, "SO"], [0, 20, "ENTITY"], [357, 368, "ENTITY"], [304, 319, "ENTITY"], [339, 344, "SIMPLE_CHEMICAL"], [189, 202, "ENTITY"], [102, 111, "CELL"], [213, 222, "GGP"], [70, 76, "ENTITY"], [213, 222, "GENE_OR_GENE_PRODUCT"], [243, 266, "ENTITY"], [319, 344, "ENTITY"], [213, 222, "PROTEIN"], [23, 29, "ENTITY"], [213, 243, "ENTITY"], [339, 344, "CHEMICAL"], [33, 50, "ENTITY"], [371, 392, "ENTITY"], [167, 178, "ENTITY"], [401, 420, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Results indicated the activation of p38 MAPK- and ERK1/2-mediated signaling linking with induction of TGF-?1 and upregulation of vimentin by PLpro .", "labels": [[102, 109, "CHEMICAL"], [141, 147, "ENTITY"], [113, 126, "ENTITY"], [22, 33, "ENTITY"], [141, 147, "GENE_OR_GENE_PRODUCT"], [66, 76, "ENTITY"], [89, 99, "ENTITY"], [36, 46, "GGP"], [36, 46, "ENTITY"], [102, 109, "PROTEIN"], [40, 46, "CHEMICAL"], [129, 138, "ENTITY"], [36, 46, "GENE_OR_GENE_PRODUCT"], [129, 138, "GGP"], [0, 8, "ENTITY"], [129, 138, "PROTEIN"], [141, 147, "PROTEIN"], [36, 46, "PROTEIN"], [129, 138, "GENE_OR_GENE_PRODUCT"], [102, 109, "ENTITY"], [50, 66, "GENE_OR_GENE_PRODUCT"], [50, 66, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Viral proteins with RGD motifs promote infection by binding integrin heterodimers such as \u03b1V\u03b21 , \u03b1V\u03b23 , \u03b1V\u03b25 , \u03b1V\u03b26 , \u03b1V\u03b28 , \u03b15\u03b21 , \u03b18\u03b21 and \u03b1IIb\u03b23 ( Hussein et al. , 2015 ) , activating transducing pathways involving phosphatidylinositol-3 kinase ( PI\u20133 K ) or mitogen-activate protein kinase ( MAPK ) , which promote virus entry and infection of the host cell .", "labels": [[39, 49, "CELL"], [118, 125, "CHEMICAL"], [208, 218, "GGP"], [218, 241, "GENE_OR_GENE_PRODUCT"], [208, 218, "PROTEIN"], [250, 279, "PROTEIN"], [6, 14, "PROTEIN"], [250, 279, "GENE_OR_GENE_PRODUCT"], [319, 325, "ENTITY"], [218, 241, "ENTITY"], [111, 118, "ENTITY"], [132, 141, "GENE_OR_GENE_PRODUCT"], [90, 95, "GGP"], [111, 118, "PROTEIN"], [39, 49, "ENTITY"], [111, 118, "GGP"], [0, 15, "PROTEIN"], [218, 241, "PROTEIN"], [39, 49, "ENTITY"], [52, 82, "ENTITY"], [208, 218, "GENE_OR_GENE_PRODUCT"], [90, 95, "PROTEIN"], [0, 15, "ENTITY"], [0, 15, "TAXON"], [132, 141, "ENTITY"], [118, 125, "PROTEIN"], [118, 125, "ENTITY"], [250, 262, "CHEMICAL"], [6, 14, "GENE_OR_GENE_PRODUCT"], [39, 49, "DISEASE"], [250, 279, "ENTITY"], [31, 39, "ENTITY"], [24, 31, "SO"], [20, 24, "ENTITY"], [90, 95, "CHEMICAL"], [90, 95, "ENTITY"], [208, 218, "ENTITY"], [60, 69, "GO"], [167, 187, "ENTITY"], [39, 49, "CL"], [60, 69, "GENE_OR_GENE_PRODUCT"], [6, 14, "ENTITY"], [319, 325, "DISEASE"], [24, 31, "ENTITY"], [52, 82, "PROTEIN"], [303, 311, "ENTITY"], [20, 31, "PROTEIN"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "The 3a-mediated potassium-sensitive current could be completely blocked by 10 mM barium in the bath solution ( Fig. 4F ) .", "labels": [[81, 88, "SIMPLE_CHEMICAL"], [16, 36, "ENTITY"], [64, 72, "ENTITY"], [81, 88, "ENTITY"], [81, 88, "CHEMICAL"], [95, 109, "ENTITY"]]}
{"text": "The 3a-mediated potassium-sensitive current could be completely blocked by 10 mM barium in the bath solution ( Fig. 4F ) .", "labels": [[81, 88, "SIMPLE_CHEMICAL"], [16, 36, "ENTITY"], [64, 72, "ENTITY"], [81, 88, "ENTITY"], [81, 88, "CHEMICAL"], [95, 109, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "The sensitivity to proteasome inhibition suggested that DRP1 underwent ubiquitination . Consistent with that possibility the immunoblotting of DRP1 immunoprecipitates revealed the presence of K48-linked ubiquitin ( Fig. 1F ) .", "labels": [[56, 61, "PROTEIN"], [71, 86, "ENTITY"], [88, 99, "ENTITY"], [19, 30, "PROTEIN"], [56, 61, "GGP"], [4, 16, "ENTITY"], [192, 203, "PROTEIN"], [192, 203, "GENE_OR_GENE_PRODUCT"], [56, 61, "ENTITY"], [19, 30, "GO"], [56, 61, "PROTEIN"], [192, 203, "GGP"], [56, 61, "GENE_OR_GENE_PRODUCT"], [19, 30, "ENTITY"], [192, 203, "ENTITY"], [30, 41, "ENTITY"]]}
{"text": "Finally , in the THP-1 cells permanently transfected with 9b-GFP we also found a marked reduction in the endogenous level of MAVS ( Fig. 5E ) .", "labels": [[17, 23, "ENTITY"], [130, 137, "GENE_OR_GENE_PRODUCT"], [17, 23, "CELL"], [17, 23, "CELL_LINE"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "It acts by binding host receptors on target cells , inducing endocytosis of virion particle , and then catalyzes the fusion between host and viral membranes , allowing penetration of the virus genome into host cytoplasm .", "labels": [[159, 168, "ENTITY"], [44, 50, "CL"], [76, 83, "ENTITY"], [19, 34, "ENTITY"], [11, 34, "PROTEIN"], [19, 24, "GO"], [19, 24, "TAXON"], [137, 147, "ENTITY"], [19, 24, "ENTITY"], [137, 147, "TAXON"], [37, 50, "ENTITY"], [37, 50, "CELL_TYPE"], [200, 210, "CELLULAR_COMPONENT"], [183, 193, "DNA"], [44, 50, "CELL"], [183, 193, "ENTITY"], [183, 193, "TAXON"], [11, 19, "ENTITY"]]}
{"text": "It acts by binding host receptors on target cells , inducing endocytosis of virion particle , and then catalyzes the fusion between host and viral membranes , allowing penetration of the virus genome into host cytoplasm .", "labels": [[159, 168, "ENTITY"], [44, 50, "CL"], [76, 83, "ENTITY"], [19, 34, "ENTITY"], [183, 193, "TAXON"], [11, 34, "PROTEIN"], [19, 24, "GO"], [183, 193, "DNA"], [19, 24, "TAXON"], [19, 24, "ENTITY"], [37, 50, "CELL_TYPE"], [37, 50, "ENTITY"], [137, 147, "TAXON"], [44, 50, "CELL"], [183, 193, "ENTITY"], [137, 147, "ENTITY"], [11, 19, "ENTITY"], [200, 210, "CELLULAR_COMPONENT"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "According to WHO guidelines , infected patients will receive supportive care including oxygen therapy , fluid therapy , and antibiotics for treating secondary bacterial infections .", "labels": [[17, 28, "ENTITY"], [102, 110, "ENTITY"], [149, 159, "TAXON"], [61, 72, "ENTITY"], [149, 169, "DISEASE"], [140, 149, "ENTITY"], [149, 169, "ENTITY"], [87, 94, "ENTITY"]]}
{"text": "Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation , caffeine , and antibiotics .", "labels": [[137, 147, "ENTITY"], [152, 176, "ENTITY"], [66, 72, "MULTI-TISSUE_STRUCTURE"], [66, 91, "ENTITY"], [9, 39, "DISEASE"], [9, 39, "ENTITY"], [126, 131, "ENTITY"], [43, 53, "ENTITY"], [0, 9, "ENTITY"], [43, 53, "DISEASE"], [116, 120, "ENTITY"], [94, 104, "ENTITY"]]}
{"text": "Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation , caffeine , and antibiotics .", "labels": [[137, 147, "ENTITY"], [152, 176, "ENTITY"], [66, 72, "MULTI-TISSUE_STRUCTURE"], [66, 91, "ENTITY"], [9, 39, "DISEASE"], [43, 53, "DISEASE"], [126, 131, "ENTITY"], [0, 9, "ENTITY"], [116, 120, "ENTITY"], [9, 39, "ENTITY"], [43, 53, "ENTITY"], [94, 104, "ENTITY"]]}
{"text": "He also had suspected sepsis , with an Enterobacter agglomerates\u2013 positive blood culture , leukocytosis , thrombocytopenia ( 11 cells \u00d7 103/\u03bcL ; to convert to cells \u00d7 109/L , multiply by 1.0 ) , and coagulopathy ( prothrombin time , 21 seconds ; activated partial thromboplastin time , 81.9 seconds ) , which improved with antibiotic treatment .", "labels": [[246, 264, "PROTEIN"], [191, 199, "ENTITY"], [148, 159, "CELL"], [148, 159, "CL"], [246, 264, "GENE_OR_GENE_PRODUCT"], [309, 323, "ENTITY"], [22, 29, "ENTITY"], [148, 159, "ENTITY"], [309, 318, "CHEBI"], [39, 52, "ENTITY"], [22, 29, "DISEASE"], [199, 214, "ENTITY"], [199, 214, "GENE_OR_GENE_PRODUCT"], [12, 22, "ENTITY"], [236, 264, "ENTITY"], [191, 199, "DISEASE"]]}
{"text": "He also had suspected sepsis , with an Enterobacter agglomerates\u2013 positive blood culture , leukocytosis , thrombocytopenia ( 11 cells \u00d7 103/\u03bcL ; to convert to cells \u00d7 109/L , multiply by 1.0 ) , and coagulopathy ( prothrombin time , 21 seconds ; activated partial thromboplastin time , 81.9 seconds ) , which improved with antibiotic treatment .", "labels": [[246, 264, "PROTEIN"], [191, 199, "ENTITY"], [148, 159, "CELL"], [148, 159, "CL"], [246, 264, "GENE_OR_GENE_PRODUCT"], [309, 323, "ENTITY"], [22, 29, "ENTITY"], [148, 159, "ENTITY"], [309, 318, "CHEBI"], [39, 52, "ENTITY"], [22, 29, "DISEASE"], [199, 214, "ENTITY"], [199, 214, "GENE_OR_GENE_PRODUCT"], [12, 22, "ENTITY"], [236, 264, "ENTITY"], [191, 199, "DISEASE"]]}
{"text": "He also had suspected sepsis , with an Enterobacter agglomerates\u2013 positive blood culture , leukocytosis , thrombocytopenia ( 11 cells \u00d7 103/\u03bcL ; to convert to cells \u00d7 109/L , multiply by 1.0 ) , and coagulopathy ( prothrombin time , 21 seconds ; activated partial thromboplastin time , 81.9 seconds ) , which improved with antibiotic treatment .", "labels": [[246, 264, "PROTEIN"], [191, 199, "ENTITY"], [148, 159, "CELL"], [148, 159, "CL"], [246, 264, "GENE_OR_GENE_PRODUCT"], [309, 323, "ENTITY"], [22, 29, "ENTITY"], [148, 159, "ENTITY"], [309, 318, "CHEBI"], [39, 52, "ENTITY"], [22, 29, "DISEASE"], [199, 214, "ENTITY"], [199, 214, "GENE_OR_GENE_PRODUCT"], [12, 22, "ENTITY"], [236, 264, "ENTITY"], [191, 199, "DISEASE"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Antibiotics , traditional Chinese medicine , intravenous glucocorticoids and immunoglobulin were also used dependent on patients \u2019 conditions .", "labels": [[45, 57, "CHEMICAL"], [0, 12, "ENTITY"], [0, 12, "CHEBI"], [43, 57, "ENTITY"], [45, 57, "CHEBI"], [26, 34, "ENTITY"], [43, 57, "ORGANISM_SUBSTANCE"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "In response to unfolded proteins , IRE1 undergoes oligomerization ( Bertolotti et al. , 2000 ) . This results in trans-autophosphorylation of the kinase domain and the activation of IRE1 \u2019s RNase domain .", "labels": [[24, 33, "CHEBI"], [146, 153, "SO"], [15, 33, "PROTEIN"], [15, 33, "ENTITY"], [142, 153, "PROTEIN"], [142, 153, "ENTITY"], [168, 196, "ENTITY"], [102, 113, "ENTITY"], [168, 196, "GGP"], [3, 12, "ENTITY"], [168, 196, "PROTEIN"], [168, 190, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[416, 427, "ENTITY"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [301, 311, "TAXON"], [439, 444, "ENTITY"], [125, 135, "SO"], [162, 193, "ENTITY"], [408, 416, "ENTITY"], [477, 487, "ENTITY"], [320, 326, "ENTITY"], [115, 125, "DISEASE"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [162, 187, "ORGANISM"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [139, 151, "PROTEIN"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [542, 550, "ENTITY"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [487, 507, "ENTITY"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "Accessory proteins 8b and 8ab of SARS-CoV can suppress the INF-\u03b2 signaling pathway ( and thus interferon production ) by their participation in the ubiquitin-mediated rapid degradation of INF regulatory factor 3 ( IRF3 ) ( Wong et al. , 2018 ) .", "labels": [[33, 42, "GGP"], [59, 65, "ENTITY"], [33, 42, "ORGANISM"], [59, 65, "PROTEIN"], [26, 30, "GENE_OR_GENE_PRODUCT"], [26, 30, "PROTEIN"], [188, 210, "ENTITY"], [46, 55, "ENTITY"], [167, 173, "ENTITY"], [26, 30, "ENTITY"], [94, 105, "ENTITY"], [185, 210, "PROTEIN"], [33, 42, "ENTITY"], [0, 22, "PROTEIN"], [65, 83, "ENTITY"], [33, 42, "PROTEIN"], [185, 210, "GENE_OR_GENE_PRODUCT"], [10, 19, "CHEBI"], [59, 65, "GENE_OR_GENE_PRODUCT"], [0, 22, "GENE_OR_GENE_PRODUCT"], [185, 210, "GGP"], [0, 22, "ENTITY"]]}
{"text": "Functional analysis by DAVID and Cluster Profiler revealed that these genes were enriched in specific cellular biological processes , including positive regulation of neutrophil chemotaxis , neutrophil activation , type I interferon signaling pathway , inflammatory response , and antigen processing and presentation ( Fig.3b and Extended Data Fig.5c-d ) , suggesting an active innate immune response against SARS-CoV-2 infection .", "labels": [[102, 132, "ENTITY"], [277, 289, "ENTITY"], [213, 243, "ENTITY"], [304, 319, "GENE_OR_GENE_PRODUCT"], [102, 111, "CL"], [23, 29, "CHEMICAL"], [401, 420, "DISEASE"], [70, 76, "SO"], [0, 20, "ENTITY"], [357, 368, "ENTITY"], [304, 319, "ENTITY"], [339, 344, "SIMPLE_CHEMICAL"], [102, 111, "CELL"], [213, 222, "GGP"], [70, 76, "ENTITY"], [213, 222, "GENE_OR_GENE_PRODUCT"], [243, 266, "ENTITY"], [319, 344, "ENTITY"], [213, 222, "PROTEIN"], [23, 29, "ENTITY"], [339, 344, "CHEMICAL"], [33, 50, "ENTITY"], [189, 202, "ENTITY"], [371, 392, "ENTITY"], [167, 178, "ENTITY"], [401, 420, "ENTITY"]]}
{"text": "Thus , it can be concluded that a delayed IFN-related antiviral response could debilitate the host immunity to inhibit rapid virus replication at the early stages of infection .", "labels": [[150, 156, "ENTITY"], [54, 64, "ENTITY"], [125, 131, "ENTITY"]]}
{"text": "A combination of type I IFN and either IFN-\u03b3 or IFN-\u03bb , was shown to synergistically inhibit the virus replication in vitro ( 40,53,54 ) .", "labels": [[2, 14, "ENTITY"], [48, 54, "GENE_OR_GENE_PRODUCT"], [17, 28, "PROTEIN"], [48, 54, "PROTEIN"], [39, 45, "CHEMICAL"], [17, 28, "GENE_OR_GENE_PRODUCT"], [48, 54, "ENTITY"], [17, 28, "ENTITY"], [39, 45, "PROTEIN"], [17, 28, "GGP"], [39, 45, "GENE_OR_GENE_PRODUCT"], [39, 45, "ENTITY"], [97, 103, "ENTITY"]]}
{"text": "For WNV , it has been shown that ATF6 activation promotes efficient WNV replication by suppressing signal transducer and activator of transcription 1 ( signal transducer and activator of transcription 1 ) phosphorylation and late-phase IFN signaling ( Ambrose and Mackenzie , 2013 ) .", "labels": [[87, 148, "PROTEIN"], [4, 8, "PROTEIN"], [49, 58, "ENTITY"], [33, 38, "ENTITY"], [58, 68, "TAXON"], [58, 68, "ENTITY"], [117, 148, "ENTITY"], [58, 68, "ORGANISM"], [4, 8, "ENTITY"], [4, 8, "ENTITY"], [4, 8, "ORGANISM"], [58, 68, "PROTEIN"], [121, 134, "GENE_OR_GENE_PRODUCT"], [4, 8, "TAXON"], [87, 106, "ENTITY"], [4, 8, "DISEASE"], [99, 117, "ENTITY"], [121, 134, "ENTITY"]]}
{"text": "This immune system inhibition might happen through affecting STAT1 and other important discussed proteins or some other strategies that CoV implement to antagonize IFN signaling ( 31 ) , which finally compromises effective IFN mediated antiviral immune responses .", "labels": [[5, 19, "ENTITY"], [153, 164, "ENTITY"], [61, 67, "PROTEIN"], [201, 213, "ENTITY"], [213, 223, "GGP"], [164, 178, "ENTITY"], [97, 106, "ENTITY"], [61, 67, "GENE_OR_GENE_PRODUCT"], [61, 67, "GGP"], [97, 106, "CHEBI"], [213, 223, "GENE_OR_GENE_PRODUCT"], [136, 140, "PROTEIN"], [136, 140, "ENTITY"], [164, 168, "GGP"], [164, 168, "GENE_OR_GENE_PRODUCT"], [213, 223, "PROTEIN"], [164, 168, "PROTEIN"], [61, 67, "ENTITY"], [213, 223, "ENTITY"], [227, 253, "ENTITY"], [136, 140, "SIMPLE_CHEMICAL"], [19, 30, "ENTITY"]]}
{"text": "Interestingly , we found that Nsp13 interacts with two key players of IFN signaling pathway including TANK-binding kinase 1 ( TBK1 ) and TANK-binding kinase 1-binding protein 1 (TBKBP1/SINTBAD).SINTBAD acts as a critical adaptor protein between TBK1 and IKKi and therefore mediates induction of IRF-dependent transcription [ 41 ] .", "labels": [[70, 84, "ENTITY"], [102, 122, "GGP"], [221, 229, "CHEBI"], [133, 167, "GGP"], [133, 167, "ENTITY"], [102, 122, "ENTITY"], [273, 282, "ENTITY"], [102, 122, "GENE_OR_GENE_PRODUCT"], [292, 309, "ENTITY"], [102, 122, "PROTEIN"], [133, 177, "PROTEIN"], [212, 229, "PROTEIN"], [133, 167, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Interestingly , we found that Nsp13 interacts with two key players of IFN signaling pathway including TANK-binding kinase 1 ( TBK1 ) and TANK-binding kinase 1-binding protein 1 (TBKBP1/SINTBAD).SINTBAD acts as a critical adaptor protein between TBK1 and IKKi and therefore mediates induction of IRF-dependent transcription [ 41 ] .", "labels": [[70, 84, "ENTITY"], [102, 122, "GGP"], [221, 229, "CHEBI"], [133, 167, "GGP"], [133, 167, "ENTITY"], [102, 122, "ENTITY"], [273, 282, "ENTITY"], [102, 122, "GENE_OR_GENE_PRODUCT"], [292, 309, "ENTITY"], [102, 122, "PROTEIN"], [133, 177, "PROTEIN"], [212, 229, "PROTEIN"], [133, 167, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Some of top pathways include cytokine and cytokine receptor interaction , VEGFA-VEGF2 signaling pathway , JAS-STAT signaling pathway etc", "labels": [[60, 72, "ENTITY"], [8, 21, "ENTITY"], [29, 38, "PROTEIN"], [104, 125, "ENTITY"], [29, 38, "ENTITY"], [42, 60, "PROTEIN"], [42, 60, "ENTITY"], [74, 96, "ENTITY"]]}
{"text": "Overexpression of human ACE2 enhanced disease severity in a mouse model of SARS-CoV infection , demonstrating that viral entry into cells is a critical step [ 11 ]", "labels": [[60, 66, "ORGANISM"], [29, 38, "ENTITY"], [18, 24, "ENTITY"], [38, 55, "ENTITY"], [60, 72, "ENTITY"], [24, 29, "ENTITY"], [18, 29, "GGP"], [115, 121, "ENTITY"], [60, 66, "TAXON"], [18, 29, "PROTEIN"], [18, 29, "ORGANISM"], [75, 94, "ENTITY"], [0, 15, "ENTITY"], [75, 84, "ORGANISM"], [75, 94, "DISEASE"]]}
{"text": "The angiotensin-converting enzyme 2 ( ACE2 ) was identified as the critical receptor for mediating SARS-2002 entry into host cells ( 7 , 8) .", "labels": [[115, 125, "ENTITY"], [89, 109, "ENTITY"], [4, 36, "ENTITY"], [89, 99, "CHEMICAL"], [27, 34, "SO"], [4, 36, "PROTEIN"], [115, 125, "CELL"], [115, 125, "CL"], [4, 36, "GENE_OR_GENE_PRODUCT"], [89, 99, "PROTEIN"], [63, 76, "ENTITY"], [115, 125, "CELL_TYPE"]]}
{"text": "Using normal lung tissue from eight adult donors , Zhao et al. [ 14 ] demonstrated that 83 % of ACE2-expressing cells were alveolar epithelial type II cells ( ACE2-expressing cells were alveolar epithelial type II cells ) , suggesting that these cells can serve as a reservoir for viral invasion .", "labels": [[13, 25, "ENTITY"], [151, 159, "PROTEIN"], [143, 151, "ENTITY"], [93, 112, "GENE_OR_GENE_PRODUCT"], [151, 159, "ENTITY"], [93, 112, "CELL_LINE"], [42, 49, "ENTITY"], [118, 151, "CELL_TYPE"], [13, 25, "TISSUE"], [42, 49, "ORGANISM"], [93, 112, "ENTITY"], [36, 42, "ENTITY"], [118, 151, "ENTITY"], [6, 13, "ENTITY"], [118, 151, "CELL"], [151, 159, "CELL"], [93, 112, "GGP"]]}
{"text": "Thus , treatment with a soluble form of ACE2 itself may exert dual functions : ( 1 ) slow viral entry into cells and hence viral spread [ 7 , 9 ] and ( 2 ) protect the lung from injury [ 10 , 12 , 31 , 32 ]", "labels": [[85, 90, "TAXON"], [168, 173, "ENTITY"], [117, 129, "ENTITY"], [156, 164, "ENTITY"], [156, 164, "ORGAN"], [62, 67, "ENTITY"], [85, 96, "ENTITY"]]}
{"text": "Interestingly , the respiratory epithelial cells from the respiratory track sample contained approximately 2 % ACE2 positive cells , and the respiratory track is thus regarded as high risk ( Fig. 1 ) .", "labels": [[20, 43, "CELL"], [116, 125, "CELL"], [58, 76, "ENTITY"], [176, 184, "ENTITY"], [109, 125, "ENTITY"], [109, 125, "CELL_TYPE"], [20, 43, "ENTITY"], [16, 32, "ENTITY"], [20, 43, "CELL_TYPE"], [116, 125, "CL"], [32, 43, "CL"]]}
{"text": "The scRNA-seq data from human heart showed that more than 7.5 % myocardial cells have positive ACE2 expression ( Fig. 2 ) , thereby implying that heart could be in high risk of 2019-nCoV infection , especially in the presence of the virus in blood or viremia .", "labels": [[174, 187, "ENTITY"], [24, 30, "TAXON"], [233, 242, "ORGANISM_SUBSTANCE"], [174, 187, "DISEASE"], [64, 75, "CELL_TYPE"], [4, 14, "ENTITY"], [233, 242, "ENTITY"], [64, 75, "CELL"], [14, 19, "ENTITY"], [24, 36, "ORGANISM"], [242, 251, "ENTITY"], [24, 30, "ENTITY"], [242, 251, "DISEASE"], [30, 36, "ENTITY"], [64, 75, "ENTITY"], [161, 169, "ENTITY"]]}
{"text": "Interestingly , extremely high ACE2 expression was found in ileal epithelial cells ( ~30 % ACE2-positive cells , Fig. 3 ) ; thus , ileum could be at high risk .", "labels": [[89, 105, "CELL_TYPE"], [66, 77, "CL"], [91, 105, "CELL"], [89, 105, "ENTITY"], [60, 77, "CELL_TYPE"], [105, 113, "CELL"], [60, 77, "CELL"], [60, 77, "ENTITY"], [143, 149, "ENTITY"], [91, 105, "CL"]]}
{"text": "More than 1 % ACE2 positive esophagus epithelial cells were found , and esophagus can thus be regarded as high risk ( Fig. 4 ) .", "labels": [[103, 111, "ENTITY"], [28, 49, "CELL"], [19, 28, "ENTITY"], [38, 49, "CL"], [14, 49, "CELL_LINE"]]}
{"text": "Significantly high ACE2 expression was found in kidney proximal tubule ( PT ) cells with the proportion of ACE2-positive cells at approximately 4 % ( Fig. 5 ) . Furthermore , the proportion of ACE2-positive cells in the bladder urothelial cells was 2.4 % ( Fig. 6).Therefore , kidney and bladder were considered high risk , especially in viremia .", "labels": [[48, 55, "ENTITY"], [19, 24, "GENE_OR_GENE_PRODUCT"], [213, 228, "ENTITY"], [19, 24, "GGP"], [48, 55, "ORGAN"], [213, 228, "CELL_TYPE"], [93, 107, "CELL_TYPE"], [104, 121, "CELL_TYPE"], [213, 228, "CL"], [301, 312, "ENTITY"], [107, 121, "CL"], [173, 179, "ENTITY"], [48, 71, "ENTITY"], [19, 24, "ENTITY"], [48, 78, "CELL"], [14, 19, "ENTITY"], [19, 24, "PROTEIN"], [104, 121, "CELL"], [93, 107, "CELL"], [93, 107, "ENTITY"], [24, 35, "ENTITY"], [213, 228, "CELL"], [104, 121, "ENTITY"]]}
{"text": "With the furin cleavage site on the S protein , 2019-nCoV probably gains ability to infect organs or tissues insensitive to other coronaviruses , leading to systematic infection of 2019-nCoV in the body", "labels": [[24, 29, "SO"], [9, 29, "DNA"], [9, 15, "ENTITY"], [38, 46, "CHEBI"], [36, 46, "PROTEIN"], [154, 168, "ENTITY"], [36, 46, "ENTITY"], [9, 15, "GGP"], [9, 15, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Elbasvir is predicted to bind stably ( \u0394G \u2264 \u201210.5 ) to RdRP , helicase , guanine-N7 methyltransferase , papain-like proteinase , proteinase SCL-PRO , and surface glycoprotein S , alone or in a complex with ACE2 ( angiotensin converting enzyme 2 ) , a host-cell protein exploited by SARS- CoV-2 for cell entry .", "labels": [[148, 162, "ENTITY"], [25, 37, "ENTITY"], [0, 9, "CHEMICAL"], [269, 282, "ENTITY"], [84, 116, "ENTITY"], [84, 104, "SO"], [193, 201, "GENE_OR_GENE_PRODUCT"], [193, 201, "PROTEIN"], [84, 116, "GENE_OR_GENE_PRODUCT"], [269, 282, "CHEMICAL"], [148, 162, "GENE_OR_GENE_PRODUCT"], [0, 9, "ENTITY"], [193, 201, "ENTITY"], [148, 162, "PROTEIN"], [185, 193, "ENTITY"], [201, 225, "GGP"], [116, 140, "ENTITY"], [269, 282, "PROTEIN"], [236, 251, "ENTITY"], [288, 298, "ENTITY"], [84, 116, "PROTEIN"], [201, 236, "PROTEIN"], [116, 127, "CHEMICAL"], [201, 236, "ENTITY"], [62, 84, "PROTEIN"], [62, 84, "ENTITY"], [201, 213, "CHEMICAL"], [201, 236, "GENE_OR_GENE_PRODUCT"], [269, 282, "ORGANISM"], [193, 201, "GGP"], [116, 127, "GENE_OR_GENE_PRODUCT"], [236, 251, "PROTEIN"], [116, 140, "PROTEIN"]]}
{"text": "Similar to the SARS-2002 virus , the COVID-19 virus enters the host cell by RBD binding to the host cell ACE2 receptor ( 7 , 11 , 12 ) .", "labels": [[63, 68, "CL"], [37, 46, "ENTITY"], [15, 31, "ENTITY"], [95, 110, "PROTEIN"], [63, 68, "CELL"], [95, 110, "CELL"], [63, 68, "ENTITY"], [105, 110, "ENTITY"], [63, 73, "TAXON"], [63, 68, "ENTITY"], [15, 25, "CHEMICAL"], [37, 46, "GENE_OR_GENE_PRODUCT"], [25, 31, "TAXON"], [15, 25, "PROTEIN"]]}
{"text": "As RHO GTPases have been implicated in membrane remodeling and the viral replication cycle , especially entry , replication , and spread [ Van den Broeke et al. ( 2014 ) ] , transient secretory cells may be more permissive to SARS-CoV-2 infection adding to a potential vulnerability caused by considerably high co-expression levels of ACE2 and TMPRSS2 .", "labels": [[212, 226, "IMMATERIAL_ANATOMICAL_ENTITY"], [212, 237, "DISEASE"], [67, 73, "TAXON"], [130, 147, "SIMPLE_CHEMICAL"], [39, 48, "CELLULAR_COMPONENT"], [174, 184, "CL"], [335, 344, "GENE_OR_GENE_PRODUCT"], [335, 344, "PROTEIN"], [174, 184, "CELL_TYPE"], [174, 184, "CELL"], [7, 15, "ENTITY"], [247, 259, "ENTITY"], [3, 7, "GENE_OR_GENE_PRODUCT"], [293, 311, "ENTITY"], [325, 332, "ENTITY"], [212, 237, "ENTITY"], [3, 15, "GGP"], [3, 7, "DISEASE"], [39, 48, "GO"], [335, 344, "GGP"], [325, 332, "GGP"], [39, 59, "ENTITY"], [67, 91, "ENTITY"], [325, 332, "PROTEIN"], [174, 184, "ENTITY"], [335, 344, "ENTITY"], [325, 332, "GENE_OR_GENE_PRODUCT"], [3, 15, "PROTEIN"], [259, 269, "ENTITY"], [3, 7, "ENTITY"]]}
{"text": "The potent anti-SARS-CoV-1 effects of chloroquine in vitro were considered attributable to a deficit in the glycosylation of a virus cell surface receptor , the angiotensin-converting enzyme 2 ( ACE2 ) on Vero cells [ 59 ] .", "labels": [[38, 50, "CHEBI"], [93, 101, "ENTITY"], [27, 35, "ENTITY"], [202, 210, "ENTITY"], [161, 191, "ENTITY"], [50, 59, "ENTITY"], [205, 210, "CL"], [161, 191, "PROTEIN"], [108, 122, "ENTITY"], [38, 50, "SIMPLE_CHEMICAL"], [202, 210, "CELL_LINE"], [127, 138, "TAXON"], [11, 27, "ENTITY"], [38, 50, "CHEMICAL"], [38, 50, "ENTITY"], [202, 210, "CELL"], [127, 155, "ENTITY"], [161, 191, "GENE_OR_GENE_PRODUCT"], [127, 155, "PROTEIN"]]}
{"text": "A multicentre , randomised controlled trial of tocilizumab ( IL-6 receptor blockade , licensed for cytokine release syndrome ) , has been approved in patients with COVID-19 pneumonia and elevated IL-6 in China ( ChiCTR2000029765 ) [ 9 ] . Janus kinase ( JAK ) inhibition could affect both inflammation and cellular viral entry in COVID-19 [ 10 ] .", "labels": [[66, 75, "ENTITY"], [187, 196, "GENE_OR_GENE_PRODUCT"], [245, 258, "ENTITY"], [315, 327, "ENTITY"], [315, 330, "GENE_OR_GENE_PRODUCT"], [277, 289, "DISEASE"], [187, 196, "PROTEIN"], [164, 173, "DISEASE"], [138, 150, "ORGANISM"], [289, 306, "CL"], [239, 245, "GENE_OR_GENE_PRODUCT"], [289, 315, "ENTITY"], [59, 66, "GENE_OR_GENE_PRODUCT"], [2, 14, "ENTITY"], [196, 204, "ENTITY"], [59, 66, "ENTITY"], [204, 212, "PROTEIN"], [159, 173, "ENTITY"], [277, 289, "ENTITY"], [16, 38, "ENTITY"], [59, 66, "GGP"], [289, 302, "CELL"], [187, 196, "ENTITY"], [138, 150, "ENTITY"], [239, 245, "GGP"], [239, 245, "PROTEIN"], [187, 196, "GGP"], [95, 116, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "These results show that blocking CD147 on the host cells has an inhibitory effect on SARS-CoV-2 , suggesting an essential role of CD147 in facilitating SARS-CoV-2 invasion for host cells .", "labels": [[85, 96, "ENTITY"], [85, 96, "ENTITY"], [46, 51, "CL"], [64, 75, "ENTITY"], [46, 57, "CELL_TYPE"], [6, 14, "ENTITY"], [33, 39, "GGP"], [33, 39, "GENE_OR_GENE_PRODUCT"], [46, 51, "CELL_TYPE"], [46, 51, "CELL"], [46, 57, "CL"], [46, 57, "CELL"], [33, 39, "ENTITY"], [24, 33, "ENTITY"], [85, 96, "CHEMICAL"], [46, 57, "ENTITY"], [46, 51, "ENTITY"], [85, 96, "SIMPLE_CHEMICAL"], [33, 39, "PROTEIN"]]}
{"text": "Accordingly , we infected the cells with SARS-CoV- , or 2019-nCoV-S-pseudotyped HIV-1 viruses after siRNA-mediated knockdown of the expression of cathepsin L and TMPRSS2 and found that both cathepsin L and TMPRSS2 depletion impaired the cell entry of pseudoviruses ( Figure 1C ) , indicating that both cathepsin L and TMPRSS2 are required for 2019-nCoV cell entry .", "labels": [[265, 274, "ENTITY"], [80, 86, "TAXON"], [339, 353, "CELL"], [214, 224, "ENTITY"], [143, 156, "GENE_OR_GENE_PRODUCT"], [339, 358, "ENTITY"], [56, 66, "CL"], [162, 170, "ENTITY"], [56, 80, "ORGANISM"], [26, 35, "ENTITY"], [143, 156, "PROTEIN"], [185, 200, "ENTITY"], [53, 86, "ENTITY"], [143, 156, "GGP"], [185, 200, "GGP"], [100, 115, "ENTITY"], [143, 156, "ENTITY"], [185, 200, "GENE_OR_GENE_PRODUCT"], [185, 200, "PROTEIN"]]}
{"text": "Accordingly , we infected the cells with SARS-CoV- , or 2019-nCoV-S-pseudotyped HIV-1 viruses after siRNA-mediated knockdown of the expression of cathepsin L and TMPRSS2 and found that both cathepsin L and TMPRSS2 depletion impaired the cell entry of pseudoviruses ( Figure 1C ) , indicating that both cathepsin L and TMPRSS2 are required for 2019-nCoV cell entry .", "labels": [[265, 274, "ENTITY"], [80, 86, "TAXON"], [339, 353, "CELL"], [214, 224, "ENTITY"], [143, 156, "GENE_OR_GENE_PRODUCT"], [339, 358, "ENTITY"], [56, 66, "CL"], [56, 80, "ORGANISM"], [26, 35, "ENTITY"], [143, 156, "PROTEIN"], [185, 200, "ENTITY"], [53, 86, "ENTITY"], [143, 156, "GGP"], [185, 200, "GGP"], [162, 170, "ENTITY"], [100, 115, "ENTITY"], [143, 156, "ENTITY"], [185, 200, "GENE_OR_GENE_PRODUCT"], [185, 200, "PROTEIN"]]}
{"text": "The transfer of HEV67N between neurons has been demonstrated by our previous ultrastructural studies to use the clathrin-coating-mediated endo-/exocytotic pathway 10 .", "labels": [[16, 23, "GGP"], [4, 13, "ENTITY"], [16, 23, "CELL"], [31, 39, "CL"], [112, 163, "ENTITY"], [16, 23, "DNA"], [31, 39, "ENTITY"], [31, 39, "CELL"], [16, 23, "ENTITY"], [77, 101, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [99, 108, "ORGANISM"], [63, 73, "DNA"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "The amount of mRNA8 and 9 of the persistent cells are 81.4 % of the acute infected cells .", "labels": [[44, 50, "CELL"], [33, 50, "ENTITY"], [14, 20, "ENTITY"], [44, 50, "CL"], [33, 50, "CELL_TYPE"], [68, 83, "ENTITY"], [14, 26, "PROTEIN"], [4, 11, "ENTITY"], [68, 83, "CELL_TYPE"], [14, 20, "GGP"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Translation attenuation has been widely observed as a defensive mechanism of the host cells against viral infection . By reducing the translation of viral proteins , virus replication is hampered and the spread of infection is limited , giving enough time for the immune system to initiate effective antiviral responses", "labels": [[12, 24, "ENTITY"], [100, 106, "TAXON"], [281, 290, "ENTITY"], [0, 12, "ENTITY"], [100, 106, "PROTEIN"], [290, 310, "ENTITY"], [100, 106, "TAXON"], [81, 92, "CELL"], [164, 172, "ENTITY"], [260, 271, "ENTITY"], [81, 92, "CL"], [100, 116, "ENTITY"], [54, 74, "ENTITY"], [100, 106, "ENTITY"], [81, 92, "ENTITY"], [100, 116, "DISEASE"], [81, 92, "CELL_TYPE"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[542, 550, "ENTITY"], [416, 427, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [301, 311, "TAXON"], [139, 151, "PROTEIN"], [469, 477, "ENTITY"], [439, 444, "ENTITY"], [125, 135, "SO"], [162, 193, "ENTITY"], [477, 487, "ENTITY"], [115, 125, "DISEASE"], [162, 187, "ORGANISM"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [408, 416, "ENTITY"], [554, 561, "CL"], [408, 416, "TAXON"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [320, 326, "ENTITY"], [397, 408, "ENTITY"], [554, 561, "CELL"], [487, 507, "ENTITY"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "As RHO GTPases have been implicated in membrane remodeling and the viral replication cycle , especially entry , replication , and spread [ Van den Broeke et al. ( 2014 ) ] , transient secretory cells may be more permissive to SARS-CoV-2 infection adding to a potential vulnerability caused by considerably high co-expression levels of ACE2 and TMPRSS2 .", "labels": [[212, 226, "IMMATERIAL_ANATOMICAL_ENTITY"], [212, 237, "DISEASE"], [130, 147, "SIMPLE_CHEMICAL"], [39, 48, "CELLULAR_COMPONENT"], [174, 184, "CL"], [335, 344, "GENE_OR_GENE_PRODUCT"], [335, 344, "PROTEIN"], [174, 184, "CELL_TYPE"], [174, 184, "CELL"], [7, 15, "ENTITY"], [247, 259, "ENTITY"], [3, 7, "GENE_OR_GENE_PRODUCT"], [293, 311, "ENTITY"], [325, 332, "ENTITY"], [212, 237, "ENTITY"], [3, 15, "GGP"], [3, 7, "DISEASE"], [39, 48, "GO"], [335, 344, "GGP"], [325, 332, "GGP"], [67, 73, "TAXON"], [39, 59, "ENTITY"], [67, 91, "ENTITY"], [325, 332, "PROTEIN"], [174, 184, "ENTITY"], [335, 344, "ENTITY"], [325, 332, "GENE_OR_GENE_PRODUCT"], [3, 15, "PROTEIN"], [259, 269, "ENTITY"], [3, 7, "ENTITY"]]}
{"text": "SARS-CoV and Middle East respiratory syndrome (MERS)-CoV can enter cells via endocytosis and use cathepsin in endosomes for activation ( 12\u201314 ) . However , TMPRSS2 expression greatly promotes replication and syncytium formation in these viruses in vitro and in vivo ( 5 , 6 , 11 , 12 , 15 ) .", "labels": [[67, 73, "ENTITY"], [97, 120, "GGP"], [97, 107, "GENE_OR_GENE_PRODUCT"], [209, 219, "ENTITY"], [238, 249, "ENTITY"], [184, 193, "ENTITY"], [157, 165, "ENTITY"], [0, 9, "ENTITY"], [46, 57, "GENE_OR_GENE_PRODUCT"], [46, 57, "ENTITY"], [13, 46, "ENTITY"], [77, 89, "ENTITY"], [124, 135, "ENTITY"], [147, 157, "GGP"], [67, 73, "CELL"], [97, 107, "PROTEIN"], [147, 157, "GENE_OR_GENE_PRODUCT"], [97, 107, "ENTITY"], [67, 73, "CL"], [25, 46, "DISEASE"], [176, 184, "ENTITY"], [147, 157, "PROTEIN"], [0, 9, "ORGANISM"], [255, 262, "ENTITY"], [110, 120, "CELLULAR_COMPONENT"], [110, 120, "ENTITY"], [147, 157, "ENTITY"]]}
{"text": "SARS-CoV and Middle East respiratory syndrome (MERS)-CoV can enter cells via endocytosis and use cathepsin in endosomes for activation ( 12\u201314 ) . However , TMPRSS2 expression greatly promotes replication and syncytium formation in these viruses in vitro and in vivo ( 5 , 6 , 11 , 12 , 15 ) .", "labels": [[67, 73, "ENTITY"], [97, 120, "GGP"], [97, 107, "GENE_OR_GENE_PRODUCT"], [209, 219, "ENTITY"], [238, 249, "ENTITY"], [184, 193, "ENTITY"], [157, 165, "ENTITY"], [46, 57, "GENE_OR_GENE_PRODUCT"], [0, 9, "ORGANISM"], [46, 57, "ENTITY"], [13, 46, "ENTITY"], [77, 89, "ENTITY"], [124, 135, "ENTITY"], [147, 157, "GGP"], [67, 73, "CELL"], [97, 107, "PROTEIN"], [147, 157, "GENE_OR_GENE_PRODUCT"], [97, 107, "ENTITY"], [67, 73, "CL"], [176, 184, "ENTITY"], [147, 157, "PROTEIN"], [255, 262, "ENTITY"], [0, 9, "ENTITY"], [110, 120, "ENTITY"], [147, 157, "ENTITY"], [110, 120, "CELLULAR_COMPONENT"], [25, 46, "DISEASE"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[542, 550, "ENTITY"], [416, 427, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [301, 311, "TAXON"], [139, 151, "PROTEIN"], [439, 444, "ENTITY"], [125, 135, "SO"], [162, 193, "ENTITY"], [408, 416, "ENTITY"], [115, 125, "DISEASE"], [162, 187, "ORGANISM"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [477, 487, "ENTITY"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [320, 326, "ENTITY"], [487, 507, "ENTITY"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "As RHO GTPases have been implicated in membrane remodeling and the viral replication cycle , especially entry , replication , and spread [ Van den Broeke et al. ( 2014 ) ] , transient secretory cells may be more permissive to SARS-CoV-2 infection adding to a potential vulnerability caused by considerably high co-expression levels of ACE2 and TMPRSS2 .", "labels": [[212, 226, "IMMATERIAL_ANATOMICAL_ENTITY"], [212, 237, "DISEASE"], [130, 147, "SIMPLE_CHEMICAL"], [39, 48, "CELLULAR_COMPONENT"], [174, 184, "CL"], [67, 73, "TAXON"], [335, 344, "GENE_OR_GENE_PRODUCT"], [335, 344, "PROTEIN"], [174, 184, "CELL_TYPE"], [174, 184, "CELL"], [7, 15, "ENTITY"], [247, 259, "ENTITY"], [3, 7, "GENE_OR_GENE_PRODUCT"], [293, 311, "ENTITY"], [325, 332, "ENTITY"], [212, 237, "ENTITY"], [3, 15, "GGP"], [3, 7, "DISEASE"], [39, 48, "GO"], [335, 344, "GGP"], [325, 332, "GGP"], [39, 59, "ENTITY"], [67, 91, "ENTITY"], [325, 332, "PROTEIN"], [174, 184, "ENTITY"], [335, 344, "ENTITY"], [325, 332, "GENE_OR_GENE_PRODUCT"], [3, 15, "PROTEIN"], [259, 269, "ENTITY"], [3, 7, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "One of the best characterized drug targets among coronaviruses is the main protease ( Mpro , also called 3CLpro ) ( 4 ) . Along with the papain- like protease(s ) , this enzyme is essential for processing the polyproteins that are translated from the viral RNA ( 5 ) .", "labels": [[75, 84, "PROTEIN"], [242, 251, "ENTITY"], [242, 251, "TAXON"], [49, 63, "ENTITY"], [49, 63, "PROTEIN"], [98, 105, "PROTEIN"], [49, 63, "ORGANISM"], [30, 35, "CHEBI"], [194, 209, "ENTITY"], [16, 30, "ENTITY"], [242, 251, "RNA"], [128, 150, "PROTEIN"], [194, 209, "SO"], [128, 137, "DISEASE"], [75, 84, "ENTITY"], [98, 105, "ENTITY"], [180, 194, "ENTITY"], [30, 43, "ENTITY"], [128, 137, "GENE_OR_GENE_PRODUCT"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[542, 550, "ENTITY"], [416, 427, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [301, 311, "TAXON"], [139, 151, "PROTEIN"], [439, 444, "ENTITY"], [125, 135, "SO"], [162, 193, "ENTITY"], [408, 416, "ENTITY"], [477, 487, "ENTITY"], [320, 326, "ENTITY"], [115, 125, "DISEASE"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [162, 187, "ORGANISM"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [487, 507, "ENTITY"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expression of ACE2 decreases with increasing age .", "labels": [[49, 53, "ENTITY"], [23, 33, "ENTITY"], [4, 15, "ENTITY"], [18, 23, "GGP"], [18, 23, "GENE_OR_GENE_PRODUCT"], [18, 23, "ENTITY"], [18, 23, "PROTEIN"], [38, 49, "ENTITY"]]}
{"text": "Therefore , the IRE1 branch of UPR is closely associated with the JNK pathway and involved in JNK-mediated apoptosis and autophagy signaling .", "labels": [[16, 21, "ENTITY"], [66, 70, "ENTITY"], [16, 21, "PROTEIN"], [16, 21, "GGP"]]}
{"text": "Moreover , chloroquine has immunomodulatory effects , suppressing the production/release of TNF-\u03b1 and IL-6 . It also works as a novel class of autophagy inhibitor [ 81 ] , which may interfere with viral infection and replication .", "labels": [[143, 153, "ENTITY"], [203, 217, "ENTITY"], [192, 203, "DISEASE"], [27, 44, "ENTITY"], [140, 153, "CHEBI"], [192, 203, "ENTITY"]]}
{"text": "Moreover , chloroquine has immunomodulatory effects , suppressing the production/release of TNF-\u03b1 and IL-6 . It also works as a novel class of autophagy inhibitor [ 81 ] , which may interfere with viral infection and replication .", "labels": [[143, 153, "ENTITY"], [203, 217, "ENTITY"], [192, 203, "DISEASE"], [27, 44, "ENTITY"], [140, 153, "CHEBI"], [192, 203, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "SARS-CoV and Middle East respiratory syndrome (MERS)-CoV can enter cells via endocytosis and use cathepsin in endosomes for activation ( 12\u201314 ) . However , TMPRSS2 expression greatly promotes replication and syncytium formation in these viruses in vitro and in vivo ( 5 , 6 , 11 , 12 , 15 ) .", "labels": [[67, 73, "ENTITY"], [77, 89, "ENTITY"], [97, 120, "GGP"], [97, 107, "GENE_OR_GENE_PRODUCT"], [209, 219, "ENTITY"], [238, 249, "ENTITY"], [184, 193, "ENTITY"], [157, 165, "ENTITY"], [0, 9, "ENTITY"], [46, 57, "GENE_OR_GENE_PRODUCT"], [46, 57, "ENTITY"], [13, 46, "ENTITY"], [124, 135, "ENTITY"], [147, 157, "GGP"], [67, 73, "CELL"], [97, 107, "PROTEIN"], [147, 157, "GENE_OR_GENE_PRODUCT"], [97, 107, "ENTITY"], [67, 73, "CL"], [25, 46, "DISEASE"], [176, 184, "ENTITY"], [147, 157, "PROTEIN"], [0, 9, "ORGANISM"], [255, 262, "ENTITY"], [110, 120, "CELLULAR_COMPONENT"], [110, 120, "ENTITY"], [147, 157, "ENTITY"]]}
{"text": "SARS-CoV and Middle East respiratory syndrome (MERS)-CoV can enter cells via endocytosis and use cathepsin in endosomes for activation ( 12\u201314 ) . However , TMPRSS2 expression greatly promotes replication and syncytium formation in these viruses in vitro and in vivo ( 5 , 6 , 11 , 12 , 15 ) .", "labels": [[67, 73, "ENTITY"], [77, 89, "ENTITY"], [97, 120, "GGP"], [97, 107, "GENE_OR_GENE_PRODUCT"], [209, 219, "ENTITY"], [238, 249, "ENTITY"], [184, 193, "ENTITY"], [157, 165, "ENTITY"], [46, 57, "GENE_OR_GENE_PRODUCT"], [0, 9, "ORGANISM"], [46, 57, "ENTITY"], [13, 46, "ENTITY"], [124, 135, "ENTITY"], [147, 157, "GGP"], [67, 73, "CELL"], [97, 107, "PROTEIN"], [147, 157, "GENE_OR_GENE_PRODUCT"], [97, 107, "ENTITY"], [67, 73, "CL"], [176, 184, "ENTITY"], [147, 157, "PROTEIN"], [255, 262, "ENTITY"], [0, 9, "ENTITY"], [110, 120, "ENTITY"], [147, 157, "ENTITY"], [110, 120, "CELLULAR_COMPONENT"], [25, 46, "DISEASE"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Mesalazine ( an approved drug for inflammatory bowel disease ) , sirolimus ( an approved immunosuppressive drug ) , and equilin ( an approved agonist of the estrogen receptor for menopausal symptoms ) achieved the highest GSEA scores of 3 , followed by paroxetine and melatonin with GSEA scores of 2 .", "labels": [[0, 11, "CHEBI"], [114, 120, "SIMPLE_CHEMICAL"], [166, 190, "ENTITY"], [268, 278, "ENTITY"], [268, 278, "GENE_OR_GENE_PRODUCT"], [150, 166, "GENE_OR_GENE_PRODUCT"], [89, 107, "CHEBI"], [16, 25, "ENTITY"], [214, 222, "ENTITY"], [16, 25, "CHEBI"], [253, 268, "SIMPLE_CHEMICAL"], [150, 166, "PROTEIN"], [150, 157, "CHEMICAL"], [80, 107, "ENTITY"], [150, 166, "ENTITY"], [0, 11, "ENTITY"], [34, 53, "DISEASE"], [114, 120, "ENTITY"], [253, 268, "CHEMICAL"], [150, 166, "GGP"], [241, 253, "SIMPLE_CHEMICAL"], [114, 120, "PROTEIN"], [241, 253, "CHEBI"], [253, 268, "ENTITY"], [114, 120, "DISEASE"], [34, 53, "ENTITY"], [241, 253, "ENTITY"], [241, 253, "CHEMICAL"], [0, 11, "SIMPLE_CHEMICAL"], [0, 11, "CHEMICAL"]]}
{"text": "Spleen atrophy was observed in all reported cases with decreased numbers of lymphocyte , and significant cell degeneration , focal hemorrhagic necrosis , macrophage proliferation and macrophage phagocytosis were found in spleen .", "labels": [[76, 87, "CELL"], [65, 73, "ENTITY"], [123, 143, "ENTITY"], [0, 15, "DISEASE"], [0, 7, "ORGAN"], [55, 65, "ENTITY"], [76, 87, "CELL_TYPE"], [0, 15, "ENTITY"], [105, 110, "ENTITY"], [154, 165, "ENTITY"], [76, 87, "CL"], [105, 110, "DISEASE"], [123, 143, "DISEASE"], [44, 50, "ENTITY"], [152, 165, "ENTITY"], [76, 87, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "ACE cleaves angiotensin I to generate angiotensin II , the peptide which binds to and activates AT1R to constrict blood vessels , thereby elevating blood pressure .", "labels": [[114, 120, "MULTI-TISSUE_STRUCTURE"], [12, 26, "GGP"], [38, 53, "PROTEIN"], [38, 53, "GGP"], [0, 26, "GENE_OR_GENE_PRODUCT"], [38, 53, "ENTITY"], [12, 26, "CHEMICAL"], [38, 53, "GENE_OR_GENE_PRODUCT"], [138, 148, "ORGANISM_SUBSTANCE"], [12, 26, "ENTITY"], [38, 53, "CHEMICAL"], [4, 12, "ENTITY"], [0, 4, "ENTITY"], [138, 154, "ENTITY"], [12, 26, "PROTEIN"], [114, 120, "ENTITY"]]}
{"text": "For example , the nsp16 has been shown to utilize the 2\u2032-O-methyltransferase activity to modify coronavirus mRNAs , so as to evade from the cytosolic RNA sensor melanoma differentiation-associated protein 5 ( MDA5 ) and type I IFN induction ( Roth-Cross et al. , 2008;Z\u00fcst et al. , 2011 ) .", "labels": [[231, 243, "GENE_OR_GENE_PRODUCT"], [154, 161, "CANCER"], [231, 243, "DNA"], [154, 161, "DISEASE"], [161, 205, "ENTITY"], [216, 227, "GGP"], [136, 161, "ENTITY"], [216, 227, "PROTEIN"], [136, 150, "GO"], [96, 108, "RNA"], [154, 205, "GGP"], [216, 231, "ENTITY"], [154, 205, "PROTEIN"], [216, 227, "GENE_OR_GENE_PRODUCT"], [136, 150, "CELLULAR_COMPONENT"]]}
{"text": "For example , the nsp16 has been shown to utilize the 2\u2032-O-methyltransferase activity to modify coronavirus mRNAs , so as to evade from the cytosolic RNA sensor melanoma differentiation-associated protein 5 ( MDA5 ) and type I IFN induction ( Roth-Cross et al. , 2008;Z\u00fcst et al. , 2011 ) .", "labels": [[231, 243, "GENE_OR_GENE_PRODUCT"], [154, 161, "CANCER"], [231, 243, "DNA"], [154, 161, "DISEASE"], [161, 205, "ENTITY"], [216, 227, "GGP"], [136, 161, "ENTITY"], [216, 227, "PROTEIN"], [136, 150, "GO"], [96, 108, "RNA"], [154, 205, "GGP"], [216, 231, "ENTITY"], [154, 205, "PROTEIN"], [216, 227, "GENE_OR_GENE_PRODUCT"], [136, 150, "CELLULAR_COMPONENT"]]}
{"text": "A multicentre , randomised controlled trial of tocilizumab ( IL-6 receptor blockade , licensed for cytokine release syndrome ) , has been approved in patients with COVID-19 pneumonia and elevated IL-6 in China ( ChiCTR2000029765 ) [ 9 ] . Janus kinase ( JAK ) inhibition could affect both inflammation and cellular viral entry in COVID-19 [ 10 ] .", "labels": [[66, 75, "ENTITY"], [187, 196, "GENE_OR_GENE_PRODUCT"], [245, 258, "ENTITY"], [277, 289, "DISEASE"], [187, 196, "PROTEIN"], [164, 173, "DISEASE"], [138, 150, "ORGANISM"], [289, 306, "CL"], [239, 245, "GENE_OR_GENE_PRODUCT"], [315, 330, "GENE_OR_GENE_PRODUCT"], [289, 315, "ENTITY"], [315, 327, "ENTITY"], [59, 66, "GENE_OR_GENE_PRODUCT"], [289, 302, "CELL"], [2, 14, "ENTITY"], [196, 204, "ENTITY"], [59, 66, "ENTITY"], [204, 212, "PROTEIN"], [159, 173, "ENTITY"], [277, 289, "ENTITY"], [16, 38, "ENTITY"], [59, 66, "GGP"], [187, 196, "ENTITY"], [138, 150, "ENTITY"], [239, 245, "GGP"], [239, 245, "PROTEIN"], [187, 196, "GGP"], [95, 116, "ENTITY"]]}
{"text": "A multicentre , randomised controlled trial of tocilizumab ( IL-6 receptor blockade , licensed for cytokine release syndrome ) , has been approved in patients with COVID-19 pneumonia and elevated IL-6 in China ( ChiCTR2000029765 ) [ 9 ] . Janus kinase ( JAK ) inhibition could affect both inflammation and cellular viral entry in COVID-19 [ 10 ] .", "labels": [[66, 75, "ENTITY"], [187, 196, "GENE_OR_GENE_PRODUCT"], [245, 258, "ENTITY"], [315, 327, "ENTITY"], [315, 330, "GENE_OR_GENE_PRODUCT"], [277, 289, "DISEASE"], [187, 196, "PROTEIN"], [164, 173, "DISEASE"], [138, 150, "ORGANISM"], [289, 306, "CL"], [239, 245, "GENE_OR_GENE_PRODUCT"], [289, 315, "ENTITY"], [59, 66, "GENE_OR_GENE_PRODUCT"], [2, 14, "ENTITY"], [196, 204, "ENTITY"], [59, 66, "ENTITY"], [204, 212, "PROTEIN"], [159, 173, "ENTITY"], [277, 289, "ENTITY"], [16, 38, "ENTITY"], [59, 66, "GGP"], [289, 302, "CELL"], [187, 196, "ENTITY"], [138, 150, "ENTITY"], [239, 245, "GGP"], [239, 245, "PROTEIN"], [187, 196, "GGP"], [95, 116, "ENTITY"]]}
{"text": "Chloroquine-induced inhibition of tumour necrosis factor-alpha ( TNF\u03b1 ) production by immune cells was reported to occur either through disruption of cellular iron metabolism [ 80 ] , blockade of the conversion of pro-TNF into soluble mature TNF\u03b1 molecules [ 81 ] and/or inhibition of TNF\u03b1 mRNA expression [ 72,82,83 ] .", "labels": [[0, 20, "CELLULAR_COMPONENT"], [222, 247, "PROTEIN"], [83, 93, "ENTITY"], [285, 295, "ENTITY"], [65, 70, "CHEBI"], [20, 34, "RNA"], [200, 214, "PROTEIN"], [34, 63, "GGP"], [227, 235, "ENTITY"], [147, 159, "CL"], [34, 50, "DISEASE"], [34, 63, "PROTEIN"], [83, 93, "CELL_TYPE"], [65, 70, "ENTITY"], [83, 93, "CL"], [20, 31, "GENE_OR_GENE_PRODUCT"], [264, 271, "ENTITY"], [34, 63, "GENE_OR_GENE_PRODUCT"], [147, 159, "GENE_OR_GENE_PRODUCT"], [235, 242, "ENTITY"], [200, 214, "ENTITY"], [147, 164, "ENTITY"], [20, 31, "ENTITY"], [150, 159, "CHEMICAL"], [200, 214, "GENE_OR_GENE_PRODUCT"], [0, 31, "ENTITY"], [34, 63, "ENTITY"], [20, 31, "DISEASE"], [235, 242, "GENE_OR_GENE_PRODUCT"], [83, 93, "CELL"], [295, 308, "PROTEIN"]]}
{"text": "Chloroquine-induced inhibition of tumour necrosis factor-alpha ( TNF\u03b1 ) production by immune cells was reported to occur either through disruption of cellular iron metabolism [ 80 ] , blockade of the conversion of pro-TNF into soluble mature TNF\u03b1 molecules [ 81 ] and/or inhibition of TNF\u03b1 mRNA expression [ 72,82,83 ] .", "labels": [[65, 70, "ENTITY"], [83, 93, "ENTITY"], [20, 34, "RNA"], [200, 214, "PROTEIN"], [34, 63, "GGP"], [0, 20, "CELLULAR_COMPONENT"], [227, 235, "ENTITY"], [147, 159, "CL"], [0, 31, "ENTITY"], [34, 50, "DISEASE"], [34, 63, "PROTEIN"], [83, 93, "CELL_TYPE"], [83, 93, "CL"], [20, 31, "GENE_OR_GENE_PRODUCT"], [264, 271, "ENTITY"], [222, 247, "PROTEIN"], [34, 63, "GENE_OR_GENE_PRODUCT"], [147, 159, "GENE_OR_GENE_PRODUCT"], [65, 70, "CHEBI"], [235, 242, "ENTITY"], [200, 214, "ENTITY"], [147, 164, "ENTITY"], [20, 31, "ENTITY"], [150, 159, "CHEMICAL"], [200, 214, "GENE_OR_GENE_PRODUCT"], [34, 63, "ENTITY"], [20, 31, "DISEASE"], [235, 242, "GENE_OR_GENE_PRODUCT"], [83, 93, "CELL"], [295, 308, "PROTEIN"], [285, 295, "ENTITY"]]}
{"text": "However , in hyperinflammation , immunosuppression is likely to be beneficial . Re-analysis of data from a phase 3 randomised controlled trial of IL-1 blockade ( anakinra ) in sepsis , showed significant survival benefit in patients with hyperinflammation , without increased adverse events.[8 ]", "labels": [[213, 224, "ENTITY"], [266, 284, "ENTITY"], [151, 162, "ENTITY"], [204, 213, "ENTITY"], [171, 176, "DISEASE"], [192, 204, "ENTITY"], [171, 176, "ENTITY"], [143, 151, "ENTITY"], [151, 162, "CHEMICAL"], [143, 151, "GGP"], [213, 224, "ORGANISM"], [151, 162, "SIMPLE_CHEMICAL"], [105, 137, "ENTITY"], [185, 192, "ENTITY"]]}
{"text": "All patients with severe COVID-19 should be screened for hyperinflammation using laboratory trends ( eg , increasing ferritin , decreasing platelet counts , or erythrocyte sedimentation rate ) and the HScore [ 11 ] ( table ) to identify the subgroup of patients for whom immunosuppression could improve mortality .", "labels": [[25, 34, "GENE_OR_GENE_PRODUCT"], [18, 25, "ENTITY"], [106, 117, "CHEBI"], [25, 34, "DISEASE"], [81, 99, "ENTITY"], [157, 186, "ENTITY"], [57, 75, "DISEASE"], [262, 271, "ENTITY"], [128, 139, "CELL"], [241, 253, "ORGANISM"], [271, 289, "ENTITY"], [4, 13, "ENTITY"], [106, 117, "ENTITY"], [128, 148, "ENTITY"], [128, 139, "CL"], [106, 117, "PROTEIN"], [106, 117, "GENE_OR_GENE_PRODUCT"], [25, 34, "ENTITY"], [228, 241, "ENTITY"], [295, 303, "ENTITY"], [57, 75, "ENTITY"], [241, 253, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "All patients with severe COVID-19 should be screened for hyperinflammation using laboratory trends ( eg , increasing ferritin , decreasing platelet counts , or erythrocyte sedimentation rate ) and the HScore [ 11 ] ( table ) to identify the subgroup of patients for whom immunosuppression could improve mortality .", "labels": [[25, 34, "GENE_OR_GENE_PRODUCT"], [18, 25, "ENTITY"], [106, 117, "CHEBI"], [25, 34, "DISEASE"], [81, 99, "ENTITY"], [157, 186, "ENTITY"], [57, 75, "DISEASE"], [262, 271, "ENTITY"], [128, 139, "CELL"], [241, 253, "ORGANISM"], [271, 289, "ENTITY"], [4, 13, "ENTITY"], [106, 117, "ENTITY"], [128, 148, "ENTITY"], [128, 139, "CL"], [106, 117, "PROTEIN"], [106, 117, "GENE_OR_GENE_PRODUCT"], [25, 34, "ENTITY"], [228, 241, "ENTITY"], [295, 303, "ENTITY"], [57, 75, "ENTITY"], [241, 253, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "All patients with severe COVID-19 should be screened for hyperinflammation using laboratory trends ( eg , increasing ferritin , decreasing platelet counts , or erythrocyte sedimentation rate ) and the HScore [ 11 ] ( table ) to identify the subgroup of patients for whom immunosuppression could improve mortality .", "labels": [[25, 34, "GENE_OR_GENE_PRODUCT"], [18, 25, "ENTITY"], [106, 117, "CHEBI"], [25, 34, "DISEASE"], [81, 99, "ENTITY"], [57, 75, "DISEASE"], [262, 271, "ENTITY"], [128, 139, "CELL"], [241, 253, "ORGANISM"], [271, 289, "ENTITY"], [4, 13, "ENTITY"], [106, 117, "ENTITY"], [128, 148, "ENTITY"], [128, 139, "CL"], [106, 117, "PROTEIN"], [106, 117, "GENE_OR_GENE_PRODUCT"], [25, 34, "ENTITY"], [228, 241, "ENTITY"], [157, 186, "ENTITY"], [295, 303, "ENTITY"], [57, 75, "ENTITY"], [241, 253, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "In the influenza virus model , it was reported that chloroquine improve the cross-presentation of non-replicating virus antigen by dendritic cells to CD8 + T-cells recruited to lymph nodes draining the site of infection , eliciting a broadly protective immune response [ 71 ] .", "labels": [[98, 120, "PROTEIN"], [174, 183, "ENTITY"], [174, 183, "MULTI-TISSUE_STRUCTURE"], [131, 141, "CL"], [150, 156, "CELL_TYPE"], [131, 141, "CELL_TYPE"], [131, 141, "ENTITY"], [17, 23, "ORGANISM"], [7, 29, "ENTITY"], [98, 120, "ENTITY"], [17, 23, "TAXON"], [131, 141, "CELL"], [234, 260, "ENTITY"], [150, 154, "GGP"], [183, 189, "ENTITY"], [150, 156, "ENTITY"]]}
{"text": "Usually , Toll-like receptor ( TLR ) 3 , TLR7 , TLR8 , and TLR9 sense viral RNA and DNA in the endosome [ 60 , 61 ] . The viral RNA receptor retinoic-acid inducible gene I ( RIG-I ) [ 62 ] , cytosolic receptor melanoma differentiation-associated gene 5 ( MDA5 ) and nucleotidyl transferase cyclic GMP-AMP synthase ( cGAS ) [ 63 ] are responsible for the recognition of viral RNA and DNA in the cytoplasm .", "labels": [[111, 122, "TAXON"], [155, 165, "PROTEIN"], [354, 366, "CELLULAR_COMPONENT"], [174, 201, "ENTITY"], [41, 48, "GGP"], [346, 354, "ENTITY"], [10, 35, "PROTEIN"], [201, 219, "ENTITY"], [354, 366, "ENTITY"], [346, 354, "RNA"], [70, 84, "ENTITY"], [10, 20, "ENTITY"], [41, 48, "GENE_OR_GENE_PRODUCT"], [88, 95, "CELLULAR_COMPONENT"], [191, 201, "DISEASE"], [64, 70, "TAXON"], [88, 95, "ENTITY"], [111, 141, "PROTEIN"], [246, 297, "PROTEIN"], [76, 80, "ENTITY"], [155, 165, "ENTITY"], [354, 366, "SO"], [64, 70, "ENTITY"], [88, 95, "GO"], [10, 20, "GENE_OR_GENE_PRODUCT"], [174, 219, "PROTEIN"], [346, 354, "TAXON"], [111, 155, "ENTITY"], [70, 84, "ORGANISM_SUBSTANCE"], [76, 80, "SO"], [246, 297, "GENE_OR_GENE_PRODUCT"], [41, 48, "PROTEIN"], [10, 20, "GGP"], [155, 165, "GGP"], [262, 297, "GGP"], [246, 297, "ENTITY"], [174, 184, "GO"], [70, 84, "GO"], [59, 64, "ENTITY"], [174, 219, "GENE_OR_GENE_PRODUCT"], [41, 48, "ENTITY"], [76, 80, "CELLULAR_COMPONENT"]]}
{"text": "Usually , Toll-like receptor ( TLR ) 3 , TLR7 , TLR8 , and TLR9 sense viral RNA and DNA in the endosome [ 60 , 61 ] . The viral RNA receptor retinoic-acid inducible gene I ( RIG-I ) [ 62 ] , cytosolic receptor melanoma differentiation-associated gene 5 ( MDA5 ) and nucleotidyl transferase cyclic GMP-AMP synthase ( cGAS ) [ 63 ] are responsible for the recognition of viral RNA and DNA in the cytoplasm .", "labels": [[111, 122, "TAXON"], [155, 165, "PROTEIN"], [354, 366, "CELLULAR_COMPONENT"], [174, 201, "ENTITY"], [346, 354, "ENTITY"], [201, 219, "ENTITY"], [354, 366, "ENTITY"], [346, 354, "RNA"], [70, 84, "ENTITY"], [10, 20, "ENTITY"], [88, 95, "CELLULAR_COMPONENT"], [191, 201, "DISEASE"], [64, 70, "TAXON"], [88, 95, "ENTITY"], [111, 141, "PROTEIN"], [246, 297, "PROTEIN"], [41, 48, "GENE_OR_GENE_PRODUCT"], [76, 80, "ENTITY"], [155, 165, "ENTITY"], [354, 366, "SO"], [64, 70, "ENTITY"], [41, 48, "ENTITY"], [88, 95, "GO"], [10, 20, "GENE_OR_GENE_PRODUCT"], [174, 219, "PROTEIN"], [346, 354, "TAXON"], [111, 155, "ENTITY"], [70, 84, "ORGANISM_SUBSTANCE"], [76, 80, "SO"], [41, 48, "GGP"], [246, 297, "GENE_OR_GENE_PRODUCT"], [10, 20, "GGP"], [155, 165, "GGP"], [262, 297, "GGP"], [246, 297, "ENTITY"], [174, 184, "GO"], [70, 84, "GO"], [59, 64, "ENTITY"], [10, 35, "PROTEIN"], [174, 219, "GENE_OR_GENE_PRODUCT"], [41, 48, "PROTEIN"], [76, 80, "CELLULAR_COMPONENT"]]}
{"text": "Usually , Toll-like receptor ( TLR ) 3 , TLR7 , TLR8 , and TLR9 sense viral RNA and DNA in the endosome [ 60 , 61 ] . The viral RNA receptor retinoic-acid inducible gene I ( RIG-I ) [ 62 ] , cytosolic receptor melanoma differentiation-associated gene 5 ( MDA5 ) and nucleotidyl transferase cyclic GMP-AMP synthase ( cGAS ) [ 63 ] are responsible for the recognition of viral RNA and DNA in the cytoplasm .", "labels": [[111, 122, "TAXON"], [41, 48, "PROTEIN"], [155, 165, "PROTEIN"], [354, 366, "CELLULAR_COMPONENT"], [174, 201, "ENTITY"], [41, 48, "ENTITY"], [346, 354, "ENTITY"], [201, 219, "ENTITY"], [354, 366, "ENTITY"], [346, 354, "RNA"], [70, 84, "ENTITY"], [10, 20, "ENTITY"], [88, 95, "CELLULAR_COMPONENT"], [191, 201, "DISEASE"], [64, 70, "TAXON"], [88, 95, "ENTITY"], [111, 141, "PROTEIN"], [246, 297, "PROTEIN"], [76, 80, "ENTITY"], [155, 165, "ENTITY"], [354, 366, "SO"], [64, 70, "ENTITY"], [88, 95, "GO"], [10, 20, "GENE_OR_GENE_PRODUCT"], [174, 219, "PROTEIN"], [346, 354, "TAXON"], [111, 155, "ENTITY"], [70, 84, "ORGANISM_SUBSTANCE"], [41, 48, "GGP"], [76, 80, "SO"], [246, 297, "GENE_OR_GENE_PRODUCT"], [10, 20, "GGP"], [155, 165, "GGP"], [262, 297, "GGP"], [246, 297, "ENTITY"], [174, 184, "GO"], [70, 84, "GO"], [59, 64, "ENTITY"], [41, 48, "GENE_OR_GENE_PRODUCT"], [174, 219, "GENE_OR_GENE_PRODUCT"], [10, 35, "PROTEIN"], [76, 80, "CELLULAR_COMPONENT"]]}
{"text": "Usually , Toll-like receptor ( TLR ) 3 , TLR7 , TLR8 , and TLR9 sense viral RNA and DNA in the endosome [ 60 , 61 ] . The viral RNA receptor retinoic-acid inducible gene I ( RIG-I ) [ 62 ] , cytosolic receptor melanoma differentiation-associated gene 5 ( MDA5 ) and nucleotidyl transferase cyclic GMP-AMP synthase ( cGAS ) [ 63 ] are responsible for the recognition of viral RNA and DNA in the cytoplasm .", "labels": [[111, 122, "TAXON"], [10, 35, "PROTEIN"], [155, 165, "PROTEIN"], [354, 366, "CELLULAR_COMPONENT"], [174, 201, "ENTITY"], [346, 354, "ENTITY"], [201, 219, "ENTITY"], [354, 366, "ENTITY"], [346, 354, "RNA"], [70, 84, "ENTITY"], [10, 20, "ENTITY"], [88, 95, "CELLULAR_COMPONENT"], [191, 201, "DISEASE"], [64, 70, "TAXON"], [88, 95, "ENTITY"], [59, 64, "ENTITY"], [41, 48, "PROTEIN"], [111, 141, "PROTEIN"], [246, 297, "PROTEIN"], [76, 80, "ENTITY"], [41, 48, "GGP"], [155, 165, "ENTITY"], [354, 366, "SO"], [64, 70, "ENTITY"], [41, 48, "ENTITY"], [88, 95, "GO"], [10, 20, "GENE_OR_GENE_PRODUCT"], [174, 219, "PROTEIN"], [346, 354, "TAXON"], [111, 155, "ENTITY"], [70, 84, "ORGANISM_SUBSTANCE"], [76, 80, "SO"], [246, 297, "GENE_OR_GENE_PRODUCT"], [10, 20, "GGP"], [155, 165, "GGP"], [262, 297, "GGP"], [246, 297, "ENTITY"], [174, 184, "GO"], [41, 48, "GENE_OR_GENE_PRODUCT"], [70, 84, "GO"], [174, 219, "GENE_OR_GENE_PRODUCT"], [76, 80, "CELLULAR_COMPONENT"]]}
{"text": "Usually , Toll-like receptor ( TLR ) 3 , TLR7 , TLR8 , and TLR9 sense viral RNA and DNA in the endosome [ 60 , 61 ] . The viral RNA receptor retinoic-acid inducible gene I ( RIG-I ) [ 62 ] , cytosolic receptor melanoma differentiation-associated gene 5 ( MDA5 ) and nucleotidyl transferase cyclic GMP-AMP synthase ( cGAS ) [ 63 ] are responsible for the recognition of viral RNA and DNA in the cytoplasm .", "labels": [[111, 122, "TAXON"], [41, 48, "ENTITY"], [155, 165, "PROTEIN"], [174, 201, "ENTITY"], [354, 366, "CELLULAR_COMPONENT"], [346, 354, "ENTITY"], [201, 219, "ENTITY"], [354, 366, "ENTITY"], [346, 354, "RNA"], [70, 84, "ENTITY"], [10, 20, "ENTITY"], [88, 95, "CELLULAR_COMPONENT"], [191, 201, "DISEASE"], [64, 70, "TAXON"], [88, 95, "ENTITY"], [10, 35, "PROTEIN"], [111, 141, "PROTEIN"], [246, 297, "PROTEIN"], [76, 80, "ENTITY"], [155, 165, "ENTITY"], [354, 366, "SO"], [64, 70, "ENTITY"], [88, 95, "GO"], [10, 20, "GENE_OR_GENE_PRODUCT"], [41, 48, "GGP"], [41, 48, "PROTEIN"], [174, 219, "PROTEIN"], [346, 354, "TAXON"], [111, 155, "ENTITY"], [41, 48, "GENE_OR_GENE_PRODUCT"], [76, 80, "SO"], [70, 84, "ORGANISM_SUBSTANCE"], [246, 297, "GENE_OR_GENE_PRODUCT"], [10, 20, "GGP"], [155, 165, "GGP"], [262, 297, "GGP"], [246, 297, "ENTITY"], [174, 184, "GO"], [70, 84, "GO"], [59, 64, "ENTITY"], [174, 219, "GENE_OR_GENE_PRODUCT"], [76, 80, "CELLULAR_COMPONENT"]]}
{"text": "Usually , Toll-like receptor ( TLR ) 3 , TLR7 , TLR8 , and TLR9 sense viral RNA and DNA in the endosome [ 60 , 61 ] . The viral RNA receptor retinoic-acid inducible gene I ( RIG-I ) [ 62 ] , cytosolic receptor melanoma differentiation-associated gene 5 ( MDA5 ) and nucleotidyl transferase cyclic GMP-AMP synthase ( cGAS ) [ 63 ] are responsible for the recognition of viral RNA and DNA in the cytoplasm .", "labels": [[111, 122, "TAXON"], [41, 48, "ENTITY"], [155, 165, "PROTEIN"], [174, 201, "ENTITY"], [354, 366, "CELLULAR_COMPONENT"], [346, 354, "ENTITY"], [201, 219, "ENTITY"], [354, 366, "ENTITY"], [346, 354, "RNA"], [70, 84, "ENTITY"], [10, 20, "ENTITY"], [88, 95, "CELLULAR_COMPONENT"], [191, 201, "DISEASE"], [64, 70, "TAXON"], [88, 95, "ENTITY"], [10, 35, "PROTEIN"], [111, 141, "PROTEIN"], [246, 297, "PROTEIN"], [76, 80, "ENTITY"], [155, 165, "ENTITY"], [354, 366, "SO"], [64, 70, "ENTITY"], [88, 95, "GO"], [10, 20, "GENE_OR_GENE_PRODUCT"], [41, 48, "GGP"], [41, 48, "PROTEIN"], [174, 219, "PROTEIN"], [346, 354, "TAXON"], [111, 155, "ENTITY"], [41, 48, "GENE_OR_GENE_PRODUCT"], [76, 80, "SO"], [70, 84, "ORGANISM_SUBSTANCE"], [246, 297, "GENE_OR_GENE_PRODUCT"], [10, 20, "GGP"], [155, 165, "GGP"], [262, 297, "GGP"], [246, 297, "ENTITY"], [174, 184, "GO"], [70, 84, "GO"], [59, 64, "ENTITY"], [174, 219, "GENE_OR_GENE_PRODUCT"], [76, 80, "CELLULAR_COMPONENT"]]}
{"text": "Usually , Toll-like receptor ( TLR ) 3 , TLR7 , TLR8 , and TLR9 sense viral RNA and DNA in the endosome [ 60 , 61 ] . The viral RNA receptor retinoic-acid inducible gene I ( RIG-I ) [ 62 ] , cytosolic receptor melanoma differentiation-associated gene 5 ( MDA5 ) and nucleotidyl transferase cyclic GMP-AMP synthase ( cGAS ) [ 63 ] are responsible for the recognition of viral RNA and DNA in the cytoplasm .", "labels": [[111, 122, "TAXON"], [41, 48, "ENTITY"], [155, 165, "PROTEIN"], [174, 201, "ENTITY"], [354, 366, "CELLULAR_COMPONENT"], [346, 354, "ENTITY"], [201, 219, "ENTITY"], [354, 366, "ENTITY"], [346, 354, "RNA"], [70, 84, "ENTITY"], [10, 20, "ENTITY"], [88, 95, "CELLULAR_COMPONENT"], [191, 201, "DISEASE"], [64, 70, "TAXON"], [88, 95, "ENTITY"], [10, 35, "PROTEIN"], [111, 141, "PROTEIN"], [246, 297, "PROTEIN"], [76, 80, "ENTITY"], [155, 165, "ENTITY"], [354, 366, "SO"], [64, 70, "ENTITY"], [88, 95, "GO"], [10, 20, "GENE_OR_GENE_PRODUCT"], [41, 48, "GGP"], [41, 48, "PROTEIN"], [174, 219, "PROTEIN"], [346, 354, "TAXON"], [111, 155, "ENTITY"], [41, 48, "GENE_OR_GENE_PRODUCT"], [76, 80, "SO"], [70, 84, "ORGANISM_SUBSTANCE"], [246, 297, "GENE_OR_GENE_PRODUCT"], [10, 20, "GGP"], [155, 165, "GGP"], [262, 297, "GGP"], [246, 297, "ENTITY"], [174, 184, "GO"], [70, 84, "GO"], [59, 64, "ENTITY"], [174, 219, "GENE_OR_GENE_PRODUCT"], [76, 80, "CELLULAR_COMPONENT"]]}
{"text": "SGs are induced by protein kinase R (PKR)-mediated phosphorylation of eIF2\u03b1 upon viral dsRNA recognition [ 57 ] . Promoting G3BP aggregation via the eIF4A inhibitor Zotatafin [ 58,59 ] or reducing SG disassembly by Silmitasertib inhibition of CK2 [ 60 ] warrant investigation for treatment of SARS-CoV-2 . The mTOR inhibitor rapamycin disrupts the binding of LARP1 to mTORC1 [ 61 ] and has been shown to reduce MERS infection by \u223c60 % in vitro [ 62 ] , another drug that could be tested for repurposing .", "labels": [[51, 67, "ENTITY"], [254, 262, "ENTITY"], [70, 76, "PROTEIN"], [293, 306, "ENTITY"], [293, 325, "GGP"], [114, 124, "PROTEIN"], [155, 165, "SIMPLE_CHEMICAL"], [70, 76, "ENTITY"], [145, 155, "CHEBI"], [145, 165, "PROTEIN"], [229, 240, "ENTITY"], [280, 293, "CHEMICAL"], [0, 4, "ENTITY"], [200, 215, "CHEMICAL"], [401, 416, "DISEASE"], [335, 348, "ENTITY"], [114, 124, "ENTITY"], [306, 315, "ENTITY"], [395, 401, "ENTITY"], [81, 93, "TAXON"], [124, 129, "ENTITY"], [200, 215, "ORGANISM"], [293, 306, "GENE_OR_GENE_PRODUCT"], [348, 356, "GENE_OR_GENE_PRODUCT"], [0, 4, "GO"], [262, 280, "ENTITY"], [8, 16, "ENTITY"], [229, 243, "GENE_OR_GENE_PRODUCT"], [348, 356, "PROTEIN"], [0, 4, "GENE_OR_GENE_PRODUCT"], [145, 155, "ENTITY"], [19, 36, "ENTITY"], [416, 433, "ENTITY"], [188, 200, "ENTITY"], [348, 356, "ENTITY"], [19, 27, "CHEBI"], [477, 487, "ENTITY"], [155, 165, "CHEMICAL"], [280, 293, "ENTITY"], [19, 36, "GENE_OR_GENE_PRODUCT"], [280, 293, "SIMPLE_CHEMICAL"], [359, 368, "GENE_OR_GENE_PRODUCT"], [70, 76, "GENE_OR_GENE_PRODUCT"], [200, 229, "ENTITY"], [155, 165, "ENTITY"], [404, 416, "ENTITY"], [114, 124, "GENE_OR_GENE_PRODUCT"], [229, 240, "PROTEIN"], [19, 36, "PROTEIN"], [359, 365, "PROTEIN"], [81, 105, "ENTITY"], [114, 124, "GGP"], [325, 335, "ENTITY"], [348, 356, "GGP"], [359, 365, "ENTITY"], [0, 4, "PROTEIN"]]}
{"text": "Beside affecting the virus maturation process , pH modulation by chloroquine can impair the proper maturation of viral protein [ 32 ] and the recognition of viral antigen by dendritic cells , which occurs through a Toll-like receptor-dependent pathway that requires endosomal acidification [ 69 ] .", "labels": [[21, 27, "TAXON"], [171, 184, "CL"], [113, 119, "PROTEIN"], [257, 266, "GO"], [21, 46, "ENTITY"], [171, 184, "CELL_TYPE"], [257, 266, "CELLULAR_COMPONENT"], [113, 119, "ENTITY"], [7, 17, "ENTITY"], [110, 119, "PROTEIN"], [171, 184, "CELL"], [113, 119, "TAXON"], [205, 244, "ENTITY"], [171, 184, "ENTITY"], [110, 119, "ENTITY"], [257, 266, "ENTITY"], [266, 276, "ENTITY"], [205, 215, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The infection of SARS virus is initiated by the attachment of S protein to the receptor ACE2 [ 19 ] , followed by cleavage with host cell protease TMPRSS2 [ 20 - 22 ] . The viruses are then transported through the early and late endosomes , subsequently endo/lysosomes , during which host protein extracellular proteases including cathepsin L mediates the further cleavage of S protein in endocytic vesicles [ 23 - 26 ] . The activated S protein will then activate the fusion between viral and cell membranes and release the genome of SARS-CoV into cytoplasm .", "labels": [[88, 95, "GENE_OR_GENE_PRODUCT"], [181, 190, "ENTITY"], [64, 72, "ENTITY"], [4, 14, "DISEASE"], [271, 297, "TAXON"], [321, 331, "ENTITY"], [535, 544, "ENTITY"], [48, 59, "ENTITY"], [214, 229, "ENTITY"], [62, 72, "ENTITY"], [364, 376, "CHEBI"], [64, 72, "CHEBI"], [476, 494, "CELLULAR_COMPONENT"], [138, 147, "GGP"], [123, 147, "CELL"], [364, 376, "ENTITY"], [535, 544, "ORGANISM_SUBSTANCE"], [271, 311, "PROTEIN"], [17, 28, "ORGANISM"], [364, 376, "PROTEIN"], [321, 331, "GGP"], [4, 14, "ENTITY"], [88, 93, "GGP"], [123, 133, "CL"], [17, 28, "ENTITY"], [284, 311, "CELLULAR_COMPONENT"], [535, 544, "GO"], [476, 494, "GO"], [476, 494, "ENTITY"], [378, 389, "GO"], [62, 72, "PROTEIN"], [278, 311, "ENTITY"], [321, 331, "PROTEIN"], [123, 147, "ENTITY"], [321, 331, "GENE_OR_GENE_PRODUCT"], [378, 389, "CELLULAR_COMPONENT"], [214, 229, "CELLULAR_COMPONENT"], [123, 157, "PROTEIN"], [22, 28, "TAXON"], [165, 173, "ENTITY"], [79, 93, "ENTITY"], [241, 254, "ENTITY"], [378, 389, "ENTITY"], [17, 22, "DISEASE"], [165, 173, "TAXON"]]}
{"text": "Chloroquine can also impair another early stage of virus replication by interfering with the pH-dependent endosome-mediated viral entry of enveloped viruses such as Dengue virus or Chikungunya virus [ 60,61 ] .", "labels": [[0, 12, "CHEBI"], [181, 199, "ENTITY"], [165, 178, "TAXON"], [51, 57, "TAXON"], [21, 28, "ENTITY"], [72, 84, "ENTITY"], [124, 136, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [165, 178, "ORGANISM"], [165, 178, "ENTITY"], [139, 157, "ENTITY"], [93, 106, "ENTITY"], [106, 124, "ENTITY"], [0, 12, "CHEMICAL"], [181, 201, "ORGANISM"], [124, 130, "TAXON"], [51, 69, "ENTITY"], [36, 48, "ENTITY"], [149, 157, "TAXON"], [51, 57, "TAXON"], [0, 12, "ENTITY"]]}
{"text": "A pH-dependant mechanism of entry of coronavirus into target cells was also reported for SARS-CoV-1 after binding of the DC-SIGN receptor [ 62 ] . The activation step that occurs in endosomes at acidic pH results in fusion of the viral and endosomal membranes leading to the release of the viral SARS-CoV-1 genome into the cytosol [63].In the absence of antiviral drug , the virus is targeted to the lysosomal compartment where the low pH , along with the action of enzymes , disrupts the viral particle , thus liberating the infectious nucleic acid and , in several cases , enzymes necessary for its replication [ 64 ] .", "labels": [[15, 25, "ENTITY"], [351, 364, "ENTITY"], [106, 114, "ENTITY"], [319, 331, "PROTEIN"], [526, 537, "CHEMICAL"], [121, 138, "ENTITY"], [61, 67, "CELL"], [476, 495, "ENTITY"], [121, 138, "PROTEIN"], [121, 129, "GGP"], [466, 476, "ENTITY"], [354, 364, "CHEBI"], [511, 537, "ENTITY"], [37, 49, "ENTITY"], [476, 489, "TAXON"], [567, 573, "SO"], [286, 307, "DNA"], [121, 138, "GENE_OR_GENE_PRODUCT"], [526, 537, "CHEBI"], [593, 601, "ENTITY"], [61, 67, "CL"], [54, 67, "CELL_TYPE"], [456, 466, "PROTEIN"], [319, 331, "CELLULAR_COMPONENT"], [236, 250, "ENTITY"], [54, 61, "ENTITY"], [28, 34, "ENTITY"], [37, 49, "TAXON"], [236, 250, "GO"], [567, 573, "ENTITY"], [456, 466, "SO"], [456, 466, "ENTITY"], [61, 67, "ENTITY"], [89, 100, "ENTITY"], [192, 202, "ENTITY"], [37, 49, "ORGANISM"], [89, 100, "SO"], [286, 307, "ENTITY"], [396, 410, "ENTITY"], [236, 250, "CELLULAR_COMPONENT"]]}
{"text": "The infection of SARS virus is initiated by the attachment of S protein to the receptor ACE2 [ 19 ] , followed by cleavage with host cell protease TMPRSS2 [ 20 - 22 ] . The viruses are then transported through the early and late endosomes , subsequently endo/lysosomes , during which host protein extracellular proteases including cathepsin L mediates the further cleavage of S protein in endocytic vesicles [ 23 - 26 ] . The activated S protein will then activate the fusion between viral and cell membranes and release the genome of SARS-CoV into cytoplasm .", "labels": [[88, 95, "GENE_OR_GENE_PRODUCT"], [181, 190, "ENTITY"], [64, 72, "ENTITY"], [4, 14, "DISEASE"], [271, 297, "TAXON"], [321, 331, "ENTITY"], [535, 544, "ENTITY"], [48, 59, "ENTITY"], [214, 229, "ENTITY"], [62, 72, "ENTITY"], [364, 376, "CHEBI"], [64, 72, "CHEBI"], [476, 494, "CELLULAR_COMPONENT"], [138, 147, "GGP"], [123, 147, "CELL"], [364, 376, "ENTITY"], [535, 544, "ORGANISM_SUBSTANCE"], [271, 311, "PROTEIN"], [17, 28, "ORGANISM"], [364, 376, "PROTEIN"], [321, 331, "GGP"], [4, 14, "ENTITY"], [88, 93, "GGP"], [123, 133, "CL"], [17, 28, "ENTITY"], [284, 311, "CELLULAR_COMPONENT"], [535, 544, "GO"], [476, 494, "GO"], [476, 494, "ENTITY"], [378, 389, "GO"], [62, 72, "PROTEIN"], [278, 311, "ENTITY"], [321, 331, "PROTEIN"], [123, 147, "ENTITY"], [321, 331, "GENE_OR_GENE_PRODUCT"], [378, 389, "CELLULAR_COMPONENT"], [214, 229, "CELLULAR_COMPONENT"], [123, 157, "PROTEIN"], [22, 28, "TAXON"], [165, 173, "ENTITY"], [79, 93, "ENTITY"], [241, 254, "ENTITY"], [378, 389, "ENTITY"], [17, 22, "DISEASE"], [165, 173, "TAXON"]]}
{"text": "The S proteins of most coronaviruses are cleaved by host protease into two functional subunits : an N-terminal receptor binding domain ( S1 ) and a C-terminal domain(S2 ) responsible for membrane fusion ( Huang et al. , 2006;Qiuet al. , 2006;Yamada et al. , 2009 ) .", "labels": [[23, 37, "PROTEIN"], [100, 128, "ENTITY"], [4, 15, "ENTITY"], [23, 37, "TAXON"], [100, 128, "PROTEIN"], [4, 15, "PROTEIN"], [23, 37, "ORGANISM"], [52, 66, "ENTITY"], [75, 95, "ENTITY"], [183, 196, "ENTITY"], [23, 37, "ENTITY"], [146, 159, "ENTITY"], [52, 66, "PROTEIN"], [6, 15, "CHEBI"]]}
{"text": "The glycosylation of M protein is proposed to play a certain function in alpha interferon ( IFN ) induction and in vivo tissue tropism ( Charley and Laude , 1988;Laude et al.,1992;de Haan et al. , 2003 ) .", "labels": [[115, 127, "ENTITY"], [73, 90, "GENE_OR_GENE_PRODUCT"], [4, 18, "ENTITY"], [115, 120, "TISSUE"], [108, 115, "ENTITY"], [61, 70, "ENTITY"], [73, 90, "ENTITY"], [21, 31, "ENTITY"], [73, 90, "PROTEIN"], [21, 31, "PROTEIN"], [73, 92, "CHEMICAL"], [73, 90, "GGP"], [23, 31, "CHEBI"]]}
{"text": "A pH-dependant mechanism of entry of coronavirus into target cells was also reported for SARS-CoV-1 after binding of the DC-SIGN receptor [ 62 ] . The activation step that occurs in endosomes at acidic pH results in fusion of the viral and endosomal membranes leading to the release of the viral SARS-CoV-1 genome into the cytosol [63].In the absence of antiviral drug , the virus is targeted to the lysosomal compartment where the low pH , along with the action of enzymes , disrupts the viral particle , thus liberating the infectious nucleic acid and , in several cases , enzymes necessary for its replication [ 64 ] .", "labels": [[15, 25, "ENTITY"], [351, 364, "ENTITY"], [106, 114, "ENTITY"], [319, 331, "PROTEIN"], [526, 537, "CHEMICAL"], [121, 138, "ENTITY"], [61, 67, "CELL"], [476, 495, "ENTITY"], [121, 138, "PROTEIN"], [121, 129, "GGP"], [466, 476, "ENTITY"], [354, 364, "CHEBI"], [511, 537, "ENTITY"], [192, 202, "ENTITY"], [37, 49, "ENTITY"], [476, 489, "TAXON"], [567, 573, "SO"], [286, 307, "DNA"], [121, 138, "GENE_OR_GENE_PRODUCT"], [526, 537, "CHEBI"], [593, 601, "ENTITY"], [61, 67, "CL"], [54, 67, "CELL_TYPE"], [456, 466, "PROTEIN"], [319, 331, "CELLULAR_COMPONENT"], [236, 250, "ENTITY"], [28, 34, "ENTITY"], [54, 61, "ENTITY"], [37, 49, "TAXON"], [236, 250, "GO"], [567, 573, "ENTITY"], [456, 466, "SO"], [456, 466, "ENTITY"], [61, 67, "ENTITY"], [89, 100, "ENTITY"], [37, 49, "ORGANISM"], [89, 100, "SO"], [286, 307, "ENTITY"], [396, 410, "ENTITY"], [236, 250, "CELLULAR_COMPONENT"]]}
{"text": "The other antiviral drugs include nitazoxanide , favipiravir , nafamostat , and so on ( See Table 1 for details ) .", "labels": [[34, 47, "ENTITY"], [34, 47, "CHEMICAL"], [10, 26, "ENTITY"], [34, 47, "CHEBI"], [34, 47, "SIMPLE_CHEMICAL"]]}
{"text": "The other antiviral drugs include nitazoxanide , favipiravir , nafamostat , and so on ( See Table 1 for details ) .", "labels": [[34, 47, "ENTITY"], [34, 47, "CHEMICAL"], [10, 26, "ENTITY"], [34, 47, "CHEBI"], [34, 47, "SIMPLE_CHEMICAL"]]}
{"text": "The infection of SARS virus is initiated by the attachment of S protein to the receptor ACE2 [ 19 ] , followed by cleavage with host cell protease TMPRSS2 [ 20 - 22 ] . The viruses are then transported through the early and late endosomes , subsequently endo/lysosomes , during which host protein extracellular proteases including cathepsin L mediates the further cleavage of S protein in endocytic vesicles [ 23 - 26 ] . The activated S protein will then activate the fusion between viral and cell membranes and release the genome of SARS-CoV into cytoplasm .", "labels": [[88, 95, "GENE_OR_GENE_PRODUCT"], [181, 190, "ENTITY"], [64, 72, "ENTITY"], [4, 14, "DISEASE"], [271, 297, "TAXON"], [321, 331, "ENTITY"], [535, 544, "ENTITY"], [48, 59, "ENTITY"], [214, 229, "ENTITY"], [62, 72, "ENTITY"], [364, 376, "CHEBI"], [64, 72, "CHEBI"], [476, 494, "CELLULAR_COMPONENT"], [138, 147, "GGP"], [123, 147, "CELL"], [364, 376, "ENTITY"], [535, 544, "ORGANISM_SUBSTANCE"], [123, 133, "CL"], [271, 311, "PROTEIN"], [17, 28, "ORGANISM"], [364, 376, "PROTEIN"], [321, 331, "GGP"], [4, 14, "ENTITY"], [88, 93, "GGP"], [17, 28, "ENTITY"], [284, 311, "CELLULAR_COMPONENT"], [535, 544, "GO"], [476, 494, "GO"], [476, 494, "ENTITY"], [378, 389, "GO"], [62, 72, "PROTEIN"], [278, 311, "ENTITY"], [321, 331, "PROTEIN"], [123, 147, "ENTITY"], [321, 331, "GENE_OR_GENE_PRODUCT"], [378, 389, "CELLULAR_COMPONENT"], [214, 229, "CELLULAR_COMPONENT"], [123, 157, "PROTEIN"], [22, 28, "TAXON"], [165, 173, "ENTITY"], [79, 93, "ENTITY"], [241, 254, "ENTITY"], [378, 389, "ENTITY"], [17, 22, "DISEASE"], [165, 173, "TAXON"]]}
{"text": "Due to the alkalisation of endosomes , chloroquine was an effective in vitro treatment against Chikungunya virus when added to Vero cells prior to virus exposure [ 30 ] .", "labels": [[127, 132, "CELL"], [127, 132, "ENTITY"], [95, 107, "ENTITY"], [27, 37, "GO"], [27, 37, "ENTITY"], [95, 107, "ORGANISM"], [11, 24, "ENTITY"], [27, 37, "CELLULAR_COMPONENT"], [127, 132, "CELL_LINE"]]}
{"text": "A pH-dependant mechanism of entry of coronavirus into target cells was also reported for SARS-CoV-1 after binding of the DC-SIGN receptor [ 62 ] . The activation step that occurs in endosomes at acidic pH results in fusion of the viral and endosomal membranes leading to the release of the viral SARS-CoV-1 genome into the cytosol [63].In the absence of antiviral drug , the virus is targeted to the lysosomal compartment where the low pH , along with the action of enzymes , disrupts the viral particle , thus liberating the infectious nucleic acid and , in several cases , enzymes necessary for its replication [ 64 ] .", "labels": [[15, 25, "ENTITY"], [351, 364, "ENTITY"], [106, 114, "ENTITY"], [319, 331, "PROTEIN"], [526, 537, "CHEMICAL"], [121, 138, "ENTITY"], [61, 67, "CELL"], [476, 495, "ENTITY"], [121, 138, "PROTEIN"], [121, 129, "GGP"], [466, 476, "ENTITY"], [354, 364, "CHEBI"], [511, 537, "ENTITY"], [37, 49, "ENTITY"], [476, 489, "TAXON"], [567, 573, "SO"], [286, 307, "DNA"], [121, 138, "GENE_OR_GENE_PRODUCT"], [526, 537, "CHEBI"], [593, 601, "ENTITY"], [61, 67, "CL"], [54, 67, "CELL_TYPE"], [456, 466, "PROTEIN"], [319, 331, "CELLULAR_COMPONENT"], [236, 250, "ENTITY"], [54, 61, "ENTITY"], [28, 34, "ENTITY"], [37, 49, "TAXON"], [236, 250, "GO"], [567, 573, "ENTITY"], [456, 466, "SO"], [456, 466, "ENTITY"], [61, 67, "ENTITY"], [89, 100, "ENTITY"], [192, 202, "ENTITY"], [37, 49, "ORGANISM"], [89, 100, "SO"], [286, 307, "ENTITY"], [396, 410, "ENTITY"], [236, 250, "CELLULAR_COMPONENT"]]}
{"text": "Interestingly , the Spike protein ( S ) interacts with the GOLGA7-ZDHHC5 acyl-transferase complex , which likely mediates palmitoylation on its cytosolic tail ( see also Appendix ) [ 35 ] . Palmitoylation has been reported to facilitate membrane fusion by SARS-CoV Spike and suggests a potential target for therapeutic inhibition [ 36 ] .", "labels": [[20, 26, "ENTITY"], [140, 154, "PROTEIN"], [307, 319, "ENTITY"], [55, 90, "ENTITY"], [246, 256, "ENTITY"], [296, 307, "ENTITY"], [20, 36, "PROTEIN"], [140, 154, "ENTITY"], [226, 237, "GO"], [226, 237, "ENTITY"], [113, 122, "ENTITY"], [246, 256, "GGP"], [246, 256, "PROTEIN"], [140, 154, "CELLULAR_COMPONENT"], [246, 256, "ORGANISM"], [226, 237, "CELLULAR_COMPONENT"], [55, 90, "PROTEIN"]]}
{"text": "The abundant membrane ( M ) proteins give the virion its shape , whereas the small envelope(E ) proteins play an essential role during assembly ( Sturmanetal.,1980 ; Liu and Inglis , 1991 ) . Inside the envelope , the helical nucleocapsid is formed by binding of the nucleocapsid(N ) proteins on the genomicRNA in a beads-on-a-string fashion .", "labels": [[83, 96, "CHEBI"], [135, 146, "ENTITY"], [252, 267, "ENTITY"], [252, 267, "PROTEIN"], [146, 174, "ENTITY"], [284, 296, "ENTITY"], [284, 296, "CHEBI"], [203, 226, "PROTEIN"], [4, 13, "ENTITY"], [13, 22, "CELLULAR_COMPONENT"], [83, 96, "ENTITY"], [135, 146, "GENE_OR_GENE_PRODUCT"], [203, 226, "ENTITY"], [192, 199, "ENTITY"], [13, 22, "GO"], [300, 316, "ENTITY"], [13, 22, "ENTITY"]]}
{"text": "ATF4 in turn transactivates genes involved in amino acid metabolism , redox reactions , and stress response .", "labels": [[0, 5, "GGP"], [46, 57, "CHEBI"], [28, 34, "ENTITY"], [70, 76, "ENTITY"], [46, 57, "CHEMICAL"], [0, 5, "ENTITY"], [0, 5, "PROTEIN"], [46, 57, "AMINO_ACID"], [46, 68, "ENTITY"], [88, 99, "ENTITY"], [13, 28, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [28, 34, "SO"]]}
{"text": "Chloroquine can also impair another early stage of virus replication by interfering with the pH-dependent endosome-mediated viral entry of enveloped viruses such as Dengue virus or Chikungunya virus [ 60,61 ] .", "labels": [[0, 12, "CHEBI"], [181, 199, "ENTITY"], [165, 178, "TAXON"], [51, 57, "TAXON"], [21, 28, "ENTITY"], [72, 84, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [165, 178, "ORGANISM"], [165, 178, "ENTITY"], [139, 157, "ENTITY"], [93, 106, "ENTITY"], [106, 124, "ENTITY"], [0, 12, "CHEMICAL"], [181, 201, "ORGANISM"], [124, 136, "ENTITY"], [51, 69, "ENTITY"], [36, 48, "ENTITY"], [149, 157, "TAXON"], [51, 57, "TAXON"], [124, 130, "TAXON"], [0, 12, "ENTITY"]]}
{"text": "Beside affecting the virus maturation process , pH modulation by chloroquine can impair the proper maturation of viral protein [ 32 ] and the recognition of viral antigen by dendritic cells , which occurs through a Toll-like receptor-dependent pathway that requires endosomal acidification [ 69 ] .", "labels": [[21, 27, "TAXON"], [171, 184, "CL"], [113, 119, "PROTEIN"], [257, 266, "GO"], [266, 276, "ENTITY"], [171, 184, "CELL_TYPE"], [257, 266, "CELLULAR_COMPONENT"], [113, 119, "ENTITY"], [7, 17, "ENTITY"], [110, 119, "PROTEIN"], [171, 184, "CELL"], [21, 46, "ENTITY"], [113, 119, "TAXON"], [171, 184, "ENTITY"], [110, 119, "ENTITY"], [257, 266, "ENTITY"], [205, 215, "GENE_OR_GENE_PRODUCT"], [205, 244, "ENTITY"]]}
{"text": "According to Zhou and colleagues , in coronaviruses , teicoplanin acts on the early step of the viral life cycle by inhibiting the low pH cleavage of the viral spike protein by cathepsin L in the late endosomes thereby preventing the release of genomic viral RNA and the continuation of virus replication cycle .", "labels": [[150, 166, "ENTITY"], [92, 107, "ENTITY"], [13, 18, "ENTITY"], [160, 166, "CHEBI"], [174, 187, "GENE_OR_GENE_PRODUCT"], [22, 33, "ENTITY"], [242, 259, "ENTITY"], [192, 201, "CELLULAR_COMPONENT"], [174, 187, "ENTITY"], [174, 187, "GGP"], [174, 187, "PROTEIN"], [150, 166, "PROTEIN"], [192, 201, "GO"], [135, 138, "ENTITY"], [131, 135, "ENTITY"], [242, 259, "SO"], [284, 305, "ENTITY"], [242, 259, "RNA"], [192, 201, "ENTITY"]]}
{"text": "ATF4 in turn transactivates genes involved in amino acid metabolism , redox reactions , and stress response .", "labels": [[0, 5, "GGP"], [46, 57, "CHEBI"], [28, 34, "ENTITY"], [70, 76, "ENTITY"], [46, 57, "CHEMICAL"], [0, 5, "ENTITY"], [0, 5, "PROTEIN"], [46, 57, "AMINO_ACID"], [88, 99, "ENTITY"], [13, 28, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [28, 34, "SO"], [46, 68, "ENTITY"]]}
{"text": "In contrast , GADD34 has also been shown to specify PP1 to dephosphorylate the TGF-\u03b2-activated kinase 1 ( TAK1 ) , thus negatively regulating the toll-like receptor ( TLR ) signal-ing and pro-inflammatory cytokines [ IL-6 and TNF-\u03b1 ( Tumornecrosis factor alpha ) ] production in macrophages ( Gu et al.,2014 ) .", "labels": [[205, 215, "GGP"], [79, 102, "GENE_OR_GENE_PRODUCT"], [79, 102, "ENTITY"], [217, 222, "GENE_OR_GENE_PRODUCT"], [226, 234, "DISEASE"], [226, 248, "PROTEIN"], [279, 296, "PROTEIN"], [205, 215, "GENE_OR_GENE_PRODUCT"], [142, 173, "PROTEIN"], [217, 222, "ENTITY"], [156, 165, "ENTITY"], [142, 156, "ENTITY"], [265, 279, "CELL"], [173, 205, "PROTEIN"], [142, 156, "GENE_OR_GENE_PRODUCT"], [205, 215, "PROTEIN"], [265, 279, "CELL_TYPE"], [217, 222, "CHEMICAL"], [205, 215, "ENTITY"], [265, 279, "CL"], [142, 156, "GGP"], [217, 222, "PROTEIN"], [173, 188, "ENTITY"], [226, 248, "ENTITY"], [255, 265, "ENTITY"], [188, 205, "ENTITY"], [156, 165, "GENE_OR_GENE_PRODUCT"], [79, 102, "PROTEIN"], [265, 279, "ENTITY"], [79, 102, "GGP"]]}
{"text": "In contrast , GADD34 has also been shown to specify PP1 to dephosphorylate the TGF-\u03b2-activated kinase 1 ( TAK1 ) , thus negatively regulating the toll-like receptor ( TLR ) signal-ing and pro-inflammatory cytokines [ IL-6 and TNF-\u03b1 ( Tumornecrosis factor alpha ) ] production in macrophages ( Gu et al.,2014 ) .", "labels": [[205, 215, "GGP"], [79, 102, "GENE_OR_GENE_PRODUCT"], [79, 102, "ENTITY"], [217, 222, "GENE_OR_GENE_PRODUCT"], [226, 234, "DISEASE"], [226, 248, "PROTEIN"], [279, 296, "PROTEIN"], [205, 215, "GENE_OR_GENE_PRODUCT"], [142, 173, "PROTEIN"], [217, 222, "ENTITY"], [156, 165, "ENTITY"], [142, 156, "ENTITY"], [265, 279, "CELL"], [173, 205, "PROTEIN"], [142, 156, "GENE_OR_GENE_PRODUCT"], [205, 215, "PROTEIN"], [265, 279, "CELL_TYPE"], [217, 222, "CHEMICAL"], [205, 215, "ENTITY"], [265, 279, "CL"], [142, 156, "GGP"], [217, 222, "PROTEIN"], [173, 188, "ENTITY"], [226, 248, "ENTITY"], [255, 265, "ENTITY"], [188, 205, "ENTITY"], [156, 165, "GENE_OR_GENE_PRODUCT"], [79, 102, "PROTEIN"], [265, 279, "ENTITY"], [79, 102, "GGP"]]}
{"text": "Interestingly , the ER stress and TLR activation synergistically activate IRE1 and induce the production of pro-inflammatory cytokines such as IL-1\u03b2 and IL-6 ( Martinon et al. , 2010 ) .", "labels": [[20, 23, "ENTITY"], [108, 125, "PROTEIN"]]}
{"text": "Translation attenuation has been widely observed as a defensive mechanism of the host cells against viral infection . By reducing the translation of viral proteins , virus replication is hampered and the spread of infection is limited , giving enough time for the immune system to initiate effective antiviral responses", "labels": [[12, 24, "ENTITY"], [100, 106, "ENTITY"], [281, 290, "ENTITY"], [0, 12, "ENTITY"], [290, 310, "ENTITY"], [100, 106, "TAXON"], [100, 106, "PROTEIN"], [164, 172, "ENTITY"], [260, 271, "ENTITY"], [81, 92, "CL"], [100, 116, "ENTITY"], [54, 74, "ENTITY"], [100, 106, "TAXON"], [81, 92, "CELL"], [81, 92, "ENTITY"], [100, 116, "DISEASE"], [81, 92, "CELL_TYPE"]]}
{"text": "Translation attenuation has been widely observed as a defensive mechanism of the host cells against viral infection . By reducing the translation of viral proteins , virus replication is hampered and the spread of infection is limited , giving enough time for the immune system to initiate effective antiviral responses", "labels": [[12, 24, "ENTITY"], [100, 106, "TAXON"], [281, 290, "ENTITY"], [0, 12, "ENTITY"], [100, 106, "PROTEIN"], [290, 310, "ENTITY"], [100, 106, "TAXON"], [81, 92, "CELL"], [164, 172, "ENTITY"], [260, 271, "ENTITY"], [81, 92, "CL"], [100, 116, "ENTITY"], [54, 74, "ENTITY"], [100, 106, "ENTITY"], [81, 92, "ENTITY"], [100, 116, "DISEASE"], [81, 92, "CELL_TYPE"]]}
{"text": "For example , the nsp16 has been shown to utilize the 2\u2032-O-methyltransferase activity to modify coronavirus mRNAs , so as to evade from the cytosolic RNA sensor melanoma differentiation-associated protein 5 ( MDA5 ) and type I IFN induction ( Roth-Cross et al. , 2008;Z\u00fcst et al. , 2011 ) .", "labels": [[231, 243, "GENE_OR_GENE_PRODUCT"], [154, 161, "CANCER"], [231, 243, "DNA"], [154, 161, "DISEASE"], [161, 205, "ENTITY"], [216, 227, "GGP"], [136, 161, "ENTITY"], [216, 227, "PROTEIN"], [136, 150, "GO"], [96, 108, "RNA"], [154, 205, "GGP"], [216, 231, "ENTITY"], [154, 205, "PROTEIN"], [216, 227, "GENE_OR_GENE_PRODUCT"], [136, 150, "CELLULAR_COMPONENT"]]}
{"text": "Chloroquine-mediated inhibition of hepatitis A virus was found to be associated with uncoating , thus blocking its entire replication cycle [ 22 ] .", "labels": [[35, 47, "DISEASE"], [21, 32, "ENTITY"], [122, 134, "ENTITY"], [0, 21, "ENTITY"], [69, 85, "ENTITY"], [35, 53, "ENTITY"], [85, 95, "ENTITY"], [47, 53, "TAXON"], [35, 53, "ORGANISM"]]}
{"text": "The virions budded into the ERGIC are exported through secretory pathway in smooth-wall vesicles , which ultimately fuse with the plasma membrane and release the mature virus particles ( Krijnse-Locker et al. , 1994 ) .", "labels": [[55, 65, "CELLULAR_COMPONENT"], [28, 34, "PROTEIN"], [4, 19, "CELLULAR_COMPONENT"], [130, 137, "CELLULAR_COMPONENT"], [88, 97, "GO"], [130, 137, "ENTITY"], [12, 19, "ENTITY"], [169, 175, "ORGANISM"], [4, 12, "ENTITY"], [76, 97, "MULTI-TISSUE_STRUCTURE"], [28, 34, "CELLULAR_COMPONENT"], [169, 175, "ENTITY"], [55, 73, "ENTITY"], [76, 97, "ENTITY"], [130, 137, "GO"], [28, 34, "ENTITY"]]}
{"text": "Beside affecting the virus maturation process , pH modulation by chloroquine can impair the proper maturation of viral protein [ 32 ] and the recognition of viral antigen by dendritic cells , which occurs through a Toll-like receptor-dependent pathway that requires endosomal acidification [ 69 ] .", "labels": [[21, 27, "TAXON"], [171, 184, "CL"], [113, 119, "PROTEIN"], [257, 266, "GO"], [266, 276, "ENTITY"], [171, 184, "CELL_TYPE"], [257, 266, "CELLULAR_COMPONENT"], [113, 119, "ENTITY"], [7, 17, "ENTITY"], [110, 119, "PROTEIN"], [171, 184, "CELL"], [21, 46, "ENTITY"], [113, 119, "TAXON"], [171, 184, "ENTITY"], [110, 119, "ENTITY"], [257, 266, "ENTITY"], [205, 215, "GENE_OR_GENE_PRODUCT"], [205, 244, "ENTITY"]]}
{"text": "The glycosylation of M protein is proposed to play a certain function in alpha interferon ( IFN ) induction and in vivo tissue tropism ( Charley and Laude , 1988;Laude et al.,1992;de Haan et al. , 2003 ) .", "labels": [[115, 127, "ENTITY"], [61, 70, "ENTITY"], [73, 90, "GENE_OR_GENE_PRODUCT"], [4, 18, "ENTITY"], [115, 120, "TISSUE"], [108, 115, "ENTITY"], [73, 92, "CHEMICAL"], [73, 90, "ENTITY"], [21, 31, "ENTITY"], [73, 90, "PROTEIN"], [21, 31, "PROTEIN"], [73, 90, "GGP"], [23, 31, "CHEBI"]]}
{"text": "More patients who died than who recovered had arterial pressure of 140 mm Hg or higher ( 50 ( 44 % ) v 33 ( 20 % ) )", "labels": [[80, 87, "ENTITY"], [46, 55, "MULTI-TISSUE_STRUCTURE"], [5, 14, "ENTITY"], [46, 64, "ENTITY"], [5, 14, "ORGANISM"], [18, 23, "ENTITY"], [32, 42, "ENTITY"], [74, 77, "CHEBI"]]}
{"text": "71.4 % of non-survivors meet the criteria of the International Society on Thrombosis and Haemostasis ( International Society on Thrombosis and Haemostasis ) for disseminated intravascular coagulation ( DIC ) , suggesting the coexistence of coagulation activation and hyper-fibrinolysis in patients with severe COVID-19 infection ( 78 , 85 ) .", "labels": [[114, 127, "ENTITY"], [89, 101, "DISEASE"], [49, 89, "ENTITY"], [163, 178, "ENTITY"], [205, 220, "ENTITY"], [141, 153, "ENTITY"], [71, 89, "DISEASE"], [141, 163, "ENTITY"], [205, 216, "SIMPLE_CHEMICAL"], [89, 101, "ENTITY"], [205, 220, "DISEASE"], [49, 71, "ENTITY"]]}
{"text": "Higher temperature was related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.362 , R2 = 0.383 , P3<0.001 , P4<0.001 ) .", "labels": [[34, 41, "ENTITY"], [52, 74, "DISEASE"], [52, 64, "ORGANISM"], [7, 19, "ENTITY"], [78, 97, "ENTITY"], [52, 74, "ENTITY"], [0, 7, "ENTITY"]]}
{"text": "Besides p38 , DUSP1 has also been shown to dephosphorylate c-Jun N-terminal kinase ( JNK ) and ERK ( Sun et al.,1993;Franklin and Kraft , 1997 ) . It has been long proposed that ERK phosphorylation promotes cell survival , whereas prolonged JNK and p38 phosphorylation is linked to the induction of apoptosis ( Xia et al. , 1995 ) .", "labels": [[8, 12, "ENTITY"], [164, 173, "GENE_OR_GENE_PRODUCT"], [164, 173, "GGP"], [8, 12, "GGP"], [126, 138, "GENE_OR_GENE_PRODUCT"], [164, 173, "PROTEIN"], [198, 212, "ENTITY"], [85, 89, "ENTITY"], [164, 173, "ENTITY"], [182, 198, "ENTITY"], [85, 89, "PROTEIN"], [85, 89, "GGP"], [286, 299, "ENTITY"], [59, 76, "GENE_OR_GENE_PRODUCT"], [8, 12, "PROTEIN"], [59, 76, "GGP"], [279, 286, "ENTITY"], [59, 76, "PROTEIN"], [245, 253, "ENTITY"], [85, 89, "GENE_OR_GENE_PRODUCT"], [59, 76, "ENTITY"], [8, 12, "GENE_OR_GENE_PRODUCT"], [173, 182, "ENTITY"]]}
{"text": "Spleen atrophy was observed in all reported cases with decreased numbers of lymphocyte , and significant cell degeneration , focal hemorrhagic necrosis , macrophage proliferation and macrophage phagocytosis were found in spleen .", "labels": [[76, 87, "CELL"], [65, 73, "ENTITY"], [123, 143, "ENTITY"], [0, 15, "DISEASE"], [0, 7, "ORGAN"], [55, 65, "ENTITY"], [76, 87, "CELL_TYPE"], [0, 15, "ENTITY"], [105, 110, "ENTITY"], [154, 165, "ENTITY"], [76, 87, "CL"], [105, 110, "DISEASE"], [123, 143, "DISEASE"], [44, 50, "ENTITY"], [152, 165, "ENTITY"], [76, 87, "ENTITY"]]}
{"text": "The S. cusia leaf methanol extract reduced HCoV\u2010NL63\u2010induced CPE in LLC\u2010MK2 cells in a concentration\u2010dependent manner ( Figure 1A ) .", "labels": [[43, 61, "ENTITY"], [68, 82, "CELL"], [4, 35, "CHEMICAL"], [4, 7, "TAXON"], [68, 82, "ENTITY"], [43, 65, "CELL"], [4, 35, "ENTITY"], [13, 27, "CHEBI"], [68, 82, "CELL_TYPE"], [43, 65, "CHEMICAL"], [120, 127, "ENTITY"], [4, 35, "TISSUE"], [76, 82, "CL"], [87, 111, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Among them , tryptanthrin at 40 \u03bcM exhibited the strongest antiviral activity with a significant reduction in HCoV\u2010NL63\u2010induced CPE in LLC\u2010MK2 cells 36 and 48 h post\u2010infection ( Figure 3A ) .", "labels": [[135, 143, "ENTITY"], [135, 143, "CELL"], [110, 128, "CELL"], [59, 69, "ENTITY"], [176, 185, "ENTITY"], [135, 143, "CELL_TYPE"]]}
{"text": "Indigodole B ( 5aR\u2010ethyltryptanthrin ) at 40 \u03bcM concentration was ranked the second highest in terms of anti\u2010HCoV\u2010NL63 activity in reducing virus induced CPE 36 and 48 h post\u2010infection ( Figure 3A ) .", "labels": [[0, 13, "ENTITY"], [131, 140, "ENTITY"], [140, 146, "ENTITY"], [131, 140, "TAXON"], [146, 154, "ENTITY"], [0, 13, "CHEMICAL"], [146, 154, "CHEMICAL"], [101, 119, "ENTITY"], [185, 194, "ENTITY"], [45, 48, "ENTITY"]]}
{"text": "Among them , tryptanthrin at 40 \u03bcM exhibited the strongest antiviral activity with a significant reduction in HCoV\u2010NL63\u2010induced CPE in LLC\u2010MK2 cells 36 and 48 h post\u2010infection ( Figure 3A ) .", "labels": [[135, 143, "ENTITY"], [135, 143, "CELL"], [110, 128, "CELL"], [59, 69, "ENTITY"], [176, 185, "ENTITY"], [135, 143, "CELL_TYPE"]]}
{"text": "The management of patients mainly focuses on the provision of supportive care , e.g. , oxygenation , ventilation , and fluid management .", "labels": [[4, 15, "ENTITY"], [18, 27, "ENTITY"], [18, 27, "ORGANISM"], [49, 59, "ENTITY"], [115, 125, "ENTITY"], [62, 78, "ENTITY"]]}
{"text": "According to WHO guidelines , infected patients will receive supportive care including oxygen therapy , fluid therapy , and antibiotics for treating secondary bacterial infections .", "labels": [[17, 28, "ENTITY"], [149, 159, "TAXON"], [61, 72, "ENTITY"], [149, 169, "DISEASE"], [140, 149, "ENTITY"], [149, 169, "ENTITY"], [102, 110, "ENTITY"], [87, 94, "ENTITY"]]}
{"text": "( 2 ) Restrictive fluid resuscitation under the premise of adequate tissue perfusion is performed to relieve pulmonary edema .", "labels": [[101, 119, "ENTITY"], [6, 24, "ENTITY"], [59, 75, "ENTITY"], [101, 119, "CANCER"], [101, 119, "DISEASE"], [59, 68, "TISSUE"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Growth and development inhibition is more common when combining IFN-\u03b1 with ribavirin . Suicidal ideation is more common in children ( mainly adolescents ) compared with adults ( 2.4%vs . 1 % ) [ 12 ] .", "labels": [[87, 96, "DISEASE"], [64, 70, "GENE_OR_GENE_PRODUCT"], [11, 23, "ENTITY"], [64, 70, "ENTITY"], [64, 70, "PROTEIN"], [75, 85, "SIMPLE_CHEMICAL"], [0, 7, "ENTITY"], [75, 85, "CHEMICAL"], [23, 34, "ENTITY"], [75, 85, "ENTITY"], [87, 96, "ENTITY"]]}
{"text": "Once SpO2 < 93 % , RR > 30/min , HR > 120/min or any signs of organ failure were observed , patients would be transferred to intensive care unit ( ICU ) and ICU physicians and nurses would take over their treatment .", "labels": [[5, 10, "ENTITY"], [134, 152, "ENTITY"], [152, 157, "ENTITY"], [71, 80, "ENTITY"], [71, 80, "DISEASE"], [93, 104, "ORGANISM"], [163, 173, "ENTITY"], [39, 44, "ENTITY"], [173, 188, "ENTITY"], [93, 104, "ENTITY"]]}
{"text": "Heart rates were much higher in deceased patients ( 101.0 beats per minute ) than in recovered patients ( 91.0 beats per minute ) .", "labels": [[32, 41, "ENTITY"], [85, 95, "ENTITY"], [0, 12, "ENTITY"], [85, 95, "ORGANISM"], [0, 6, "ORGAN"], [22, 29, "ENTITY"], [41, 50, "ENTITY"], [41, 50, "ORGANISM"]]}
{"text": "Losartan was exhibited four hydrogen binds with Asn1487 , Arg1433 and Ser1382 residues within the range of 1.8 \u20132.8 \u00c5.", "labels": [[48, 56, "ENTITY"], [28, 37, "CHEMICAL"], [28, 37, "ENTITY"], [28, 37, "CHEBI"], [0, 9, "CHEMICAL"], [48, 56, "GGP"], [70, 78, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "SIMPLE_CHEMICAL"], [37, 43, "ENTITY"]]}
{"text": "A total of 13 hydrophobic bonds were found with Pro1388 , Val1377 , Leu1379 , Ser1382 , Ala1386 , His1348 , and Tyr1349 in the range of 3.1 - 3.9 \u00c5.", "labels": [[78, 88, "SIMPLE_CHEMICAL"], [88, 98, "SIMPLE_CHEMICAL"], [88, 98, "CELL_LINE"], [88, 98, "ENTITY"], [48, 56, "PROTEIN"], [106, 112, "ENTITY"], [48, 56, "GENE_OR_GENE_PRODUCT"], [78, 88, "ENTITY"], [26, 32, "CHEBI"], [48, 56, "ENTITY"], [106, 112, "DNA"], [14, 32, "ENTITY"], [78, 88, "CHEMICAL"]]}
{"text": "Different from SARS-CoV , MERS-CoV enters human host cells mainly via dipeptidyl peptidase 4 ( DPP4 ) , which is present in the lower respiratory tract , kidney , small intestine , liver , and the cells of the immune system 26 - 27 .", "labels": [[48, 53, "ENTITY"], [15, 24, "PROTEIN"], [42, 53, "CELL_TYPE"], [42, 53, "TAXON"], [70, 91, "GENE_OR_GENE_PRODUCT"], [70, 91, "PROTEIN"], [70, 91, "GGP"], [42, 53, "ORGANISM"], [15, 24, "ENTITY"], [15, 24, "ORGANISM"], [70, 91, "ENTITY"], [124, 146, "ENTITY"], [146, 154, "ORGAN"], [169, 179, "ORGAN"], [154, 169, "ENTITY"], [169, 179, "ENTITY"], [146, 154, "ENTITY"], [203, 210, "ENTITY"]]}
{"text": "More than half ( 126of197[64.0 % ] ) of this cohort had lymphocytopenia .", "labels": [[10, 15, "ENTITY"]]}
{"text": "Laboratory tests showed leukocytosis , lymphocytopenia , and an elevated creatine kinase \u2013 MB fraction .", "labels": [[0, 17, "ENTITY"], [91, 94, "ENTITY"], [24, 37, "ENTITY"], [24, 37, "DISEASE"], [64, 89, "GENE_OR_GENE_PRODUCT"], [64, 73, "CHEBI"], [82, 89, "ENTITY"], [64, 73, "CHEMICAL"], [64, 82, "ENTITY"]]}
{"text": "One study analyzed the lymphocyte subsets and cytokines in 123 patients , all patients had lymphcytopenia", "labels": [[10, 19, "ENTITY"], [23, 34, "CELL"], [23, 34, "CL"], [63, 72, "ORGANISM"], [46, 56, "ENTITY"], [63, 72, "ENTITY"], [46, 56, "PROTEIN"], [23, 34, "ENTITY"], [4, 10, "ENTITY"], [23, 42, "CELL_TYPE"]]}
{"text": "Spleen atrophy was observed in all reported cases with decreased numbers of lymphocyte , and significant cell degeneration , focal hemorrhagic necrosis , macrophage proliferation and macrophage phagocytosis were found in spleen .", "labels": [[76, 87, "CELL"], [65, 73, "ENTITY"], [123, 143, "ENTITY"], [0, 15, "DISEASE"], [0, 7, "ORGAN"], [55, 65, "ENTITY"], [76, 87, "CELL_TYPE"], [0, 15, "ENTITY"], [105, 110, "ENTITY"], [154, 165, "ENTITY"], [76, 87, "CL"], [105, 110, "DISEASE"], [123, 143, "DISEASE"], [44, 50, "ENTITY"], [152, 165, "ENTITY"], [76, 87, "ENTITY"]]}
{"text": "However , lymphocyte counts ( difference,\u2212 0.34 \u00d7 109/mL;95%CI,\u22120.47 to\u22120.22 \u00d7 109/mL;P < .001 ) and CD8 T cells ( difference , \u221266.00 cells/\u03bcL ; 95%CI , \u2212129.00 to \u22127.00 cells/\u03bcL ; P = .03 ) were significantly decreased .", "labels": [[95, 105, "CELL_TYPE"], [115, 135, "CHEMICAL"], [144, 154, "ENTITY"], [107, 115, "ENTITY"], [95, 105, "GGP"], [95, 105, "GENE_OR_GENE_PRODUCT"], [154, 165, "DNA"], [154, 165, "GENE_OR_GENE_PRODUCT"], [154, 165, "CHEMICAL"], [95, 105, "ENTITY"], [115, 135, "GENE_OR_GENE_PRODUCT"], [30, 41, "ENTITY"]]}
{"text": "Patients with elevated TnT levels presented with significantly higher white blood cell count(median[IQR],4640[6170- 3740 ] vs 7390 [ 4890 - 11 630 ] /\u03bcL [ to convert to \u00d7109 per liter , multiply by0.001])and neutrophil counts ( median [IQR],3070 [ 2350 - 4870 ] vs 6010 [ 3540 - 10 120 ] /\u03bcL [ to convert to \u00d7109 per liter , multiply by 0.001 ] ) ( P < .001 for both ) and lower lymphocyte counts ( median [ IQR ] , 840 [ 630 - 1130 ] vs 690 [ 340- 1010 ] /\u03bcL [ toconvert to \u00d7 109 per liter , multiplyby0.001;P = .01 ) than those with normal TnT levels ( Table 2 ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [27, 34, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [195, 208, "CELL"], [456, 475, "PROTEIN"], [195, 208, "CELL_TYPE"], [76, 121, "CELL"], [158, 166, "PROTEIN"], [373, 379, "ENTITY"], [358, 367, "CL"], [23, 27, "PROTEIN"], [93, 100, "PROTEIN"], [0, 9, "ORGANISM"], [76, 87, "CL"], [93, 100, "ENTITY"], [228, 248, "CHEMICAL"], [0, 9, "ENTITY"], [70, 87, "ENTITY"], [351, 367, "CELL"], [456, 475, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"], [358, 367, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"], [195, 208, "CL"]]}
{"text": "This reinforces that high levels of D-dimer and low lymphocyte counts are 306 associated with poor prognosis and suggest that that DIP treatment should be initiated before the progression to critical illness ( Figure 3B ) .", "labels": [[131, 135, "ENTITY"], [63, 70, "ENTITY"], [36, 44, "GGP"], [78, 94, "ENTITY"], [48, 52, "ENTITY"], [52, 63, "ENTITY"], [210, 217, "ENTITY"], [52, 63, "CELL"], [176, 188, "ENTITY"], [131, 135, "CHEMICAL"], [21, 26, "ENTITY"], [36, 44, "GENE_OR_GENE_PRODUCT"], [94, 109, "ENTITY"], [26, 33, "ENTITY"], [135, 145, "ENTITY"], [191, 208, "ENTITY"], [52, 63, "CL"], [36, 44, "PROTEIN"], [36, 44, "ENTITY"], [131, 135, "SIMPLE_CHEMICAL"]]}
{"text": "For patients with ARDS or pulmonary extensive effusion in CT scan , high-flow nasal cannula oxygen therapy ( high-flow nasal cannula oxygen therapy ) or non-invasive mechanical ventilation ( NIV ) was used to maintain positive end expiratory pressure ( PEEP ) to prevent alveolar collapse even if some of these patients did not have refractory hypoxemia .", "labels": [[268, 277, "ENTITY"], [18, 23, "ENTITY"], [268, 277, "DISEASE"], [58, 61, "PROTEIN"], [184, 193, "ENTITY"], [26, 55, "ENTITY"], [4, 13, "ENTITY"], [197, 208, "ENTITY"], [26, 36, "ORGAN"], [68, 84, "ENTITY"], [68, 99, "ENTITY"], [18, 23, "DISEASE"], [255, 268, "ENTITY"], [4, 13, "ORGANISM"], [58, 66, "ENTITY"], [175, 184, "ENTITY"]]}
{"text": "The management of patients mainly focuses on the provision of supportive care , e.g. , oxygenation , ventilation , and fluid management .", "labels": [[4, 15, "ENTITY"], [18, 27, "ENTITY"], [18, 27, "ORGANISM"], [49, 59, "ENTITY"], [115, 125, "ENTITY"], [62, 78, "ENTITY"]]}
{"text": "According to WHO guidelines , infected patients will receive supportive care including oxygen therapy , fluid therapy , and antibiotics for treating secondary bacterial infections .", "labels": [[17, 28, "ENTITY"], [102, 110, "ENTITY"], [149, 159, "TAXON"], [61, 72, "ENTITY"], [149, 169, "DISEASE"], [140, 149, "ENTITY"], [149, 169, "ENTITY"], [87, 94, "ENTITY"]]}
{"text": "From our data of more than 600 NCP patients in Jiangsu Province , age , lymphocyte count , oxygen supplementation and aggressive pulmonary radiographic infiltrations are independent risk factors for NCP progressing to a critical condition .", "labels": [[89, 98, "ENTITY"], [218, 229, "ENTITY"], [31, 35, "CHEMICAL"], [35, 44, "ENTITY"], [114, 152, "DISEASE"], [9, 14, "ENTITY"], [70, 83, "ENTITY"], [118, 152, "ENTITY"], [170, 187, "ENTITY"], [47, 64, "ENTITY"], [31, 35, "ENTITY"], [118, 129, "ORGAN"], [47, 64, "ORGANISM"]]}
{"text": "Among the eight patients , six ( 6/8 ) received high-flow oxygen therapy and two critically ill ( 2/8 ) patients received mechanical ventilation .", "labels": [[48, 58, "CHEMICAL"], [113, 133, "ENTITY"], [16, 25, "ORGANISM"], [77, 92, "ENTITY"], [39, 65, "ENTITY"], [48, 58, "SIMPLE_CHEMICAL"], [48, 58, "CHEBI"], [16, 25, "ENTITY"]]}
{"text": "A majority of the patients ( 58.0 % ) received intravenous antibiotic therapy , and 35.8 % received oseltamivir therapy ; oxygen therapy was administered in 41.3 % and mechanical ventilation in 6.1 % ; higher percentages of patients with severe disease received these therapies ( Table 3 ) .", "labels": [[112, 129, "ENTITY"], [129, 141, "ENTITY"], [47, 59, "CHEBI"], [112, 122, "CHEMICAL"], [209, 224, "ORGANISM"], [18, 27, "ENTITY"], [18, 27, "ORGANISM"], [224, 238, "ENTITY"], [209, 224, "ENTITY"], [162, 179, "ENTITY"], [38, 47, "IMMATERIAL_ANATOMICAL_ENTITY"], [112, 122, "CHEBI"], [91, 112, "ENTITY"], [253, 268, "ENTITY"], [38, 70, "ENTITY"], [38, 47, "CHEMICAL"], [112, 122, "SIMPLE_CHEMICAL"]]}
{"text": "For patients with ARDS or pulmonary extensive effusion in CT scan , high-flow nasal cannula oxygen therapy ( high-flow nasal cannula oxygen therapy ) or non-invasive mechanical ventilation ( NIV ) was used to maintain positive end expiratory pressure ( PEEP ) to prevent alveolar collapse even if some of these patients did not have refractory hypoxemia .", "labels": [[268, 277, "ENTITY"], [18, 23, "ENTITY"], [268, 277, "DISEASE"], [58, 61, "PROTEIN"], [184, 193, "ENTITY"], [26, 55, "ENTITY"], [4, 13, "ENTITY"], [197, 208, "ENTITY"], [26, 36, "ORGAN"], [68, 84, "ENTITY"], [68, 99, "ENTITY"], [18, 23, "DISEASE"], [255, 268, "ENTITY"], [4, 13, "ORGANISM"], [58, 66, "ENTITY"], [175, 184, "ENTITY"]]}
{"text": "Median prothrombin time was significantly longer in deceased patients than in recovered patients , whereas activated partial thromboplastin time was comparable between the two groups .", "labels": [[0, 7, "ENTITY"], [61, 70, "ENTITY"], [52, 61, "ENTITY"], [61, 70, "ORGANISM"], [61, 70, "ENTITY"], [61, 70, "ORGANISM"], [7, 24, "ENTITY"], [7, 19, "PROTEIN"], [7, 19, "GENE_OR_GENE_PRODUCT"], [78, 88, "ENTITY"]]}
{"text": "Patients with elevated TnT levels also had significantly longer prothrombin time ( median [ IQR ] , 12.4 [ 12.0 - 13.0 ] vs 13.3 [ 12.2 - 15.3 ] seconds ; P = .005 ) , shorter activated partial thromboplastin time ( median [ IQR ] , 31.2 [ 27.5 - 33.2 ] vs 32.7 [ 31.0 - 35.8 ] seconds ; P = .003 ) , and a significant higher level of D-dimer ( median [ IQR ] , 0.29 [ 0.17 - 0.60 ] vs 3.85 [ 0.51 - 25.58 ] \u03bcg/mL[to convert to nanomoles per liter , multiply by 5.476 ] ; P < .001 ) .", "labels": [[176, 194, "GENE_OR_GENE_PRODUCT"], [23, 27, "ENTITY"], [14, 23, "ENTITY"], [145, 155, "ENTITY"], [23, 27, "PROTEIN"], [319, 326, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"], [27, 34, "ENTITY"], [0, 9, "ENTITY"], [64, 76, "PROTEIN"], [0, 9, "ORGANISM"], [64, 76, "GENE_OR_GENE_PRODUCT"], [176, 194, "PROTEIN"], [417, 425, "GENE_OR_GENE_PRODUCT"], [64, 81, "ENTITY"], [43, 55, "ENTITY"]]}
{"text": "The existence of significantly increased fibrin-degraded products and reduced platelets in severe COVID-19 patients is consistent with the presence of hyper-fibrinolysis .", "labels": [[139, 148, "ENTITY"], [31, 41, "ENTITY"], [41, 57, "CHEMICAL"], [78, 88, "CELL_TYPE"], [91, 98, "ENTITY"], [98, 107, "ENTITY"], [41, 66, "ENTITY"], [151, 170, "CHEMICAL"], [57, 66, "SO"], [70, 78, "ENTITY"], [4, 14, "ENTITY"], [98, 107, "DISEASE"], [107, 116, "ENTITY"], [78, 88, "CELL"], [78, 88, "CL"], [98, 116, "ORGANISM"], [151, 170, "ENTITY"], [78, 88, "ENTITY"], [41, 66, "PROTEIN"], [119, 135, "ENTITY"]]}
{"text": "Platelet counts were decreased significantly in severe and dead patients ( 79 , 97 , 101 )", "labels": [[64, 73, "ORGANISM"], [0, 16, "ENTITY"], [59, 64, "ENTITY"], [0, 9, "CL"], [64, 73, "ENTITY"], [21, 31, "ENTITY"], [48, 55, "ENTITY"], [0, 9, "CELL"]]}
{"text": "Median platelet counts were significantly lower in deceased patients", "labels": [[7, 16, "CL"], [0, 7, "ENTITY"], [51, 60, "ENTITY"], [7, 16, "CELL"], [7, 23, "ENTITY"]]}
{"text": "Decreased platelet counts were observed in 25 ( 20.2 % ) patients , prolonged prothrombin time ( PT ) was observed in 77 ( 62.1 % ) patients , fibrinogen ( FIB ) levels were increased in 27 ( 21.8 % ) patients , and D-dimer levels were increased in 26 ( 21.0 % ) patients .", "labels": [[216, 224, "ENTITY"], [57, 68, "ENTITY"], [10, 19, "CL"], [57, 68, "ENTITY"], [68, 78, "GENE_OR_GENE_PRODUCT"], [236, 252, "ORGANISM"], [162, 169, "ENTITY"], [68, 90, "ENTITY"], [10, 26, "ENTITY"], [143, 156, "ENTITY"], [90, 95, "ENTITY"], [57, 68, "PROTEIN"], [236, 252, "ENTITY"], [10, 19, "CELL"], [57, 68, "GENE_OR_GENE_PRODUCT"], [57, 68, "ENTITY"], [0, 10, "ENTITY"], [68, 78, "PROTEIN"]]}
{"text": "For those patients with most severe ARDS , extracorporeal membrane oxygenation or prone position is recommended .", "labels": [[29, 36, "ENTITY"], [10, 19, "ENTITY"], [82, 88, "ENTITY"], [36, 41, "ENTITY"], [43, 67, "ENTITY"], [10, 19, "ORGANISM"], [36, 41, "DISEASE"]]}
{"text": "This is accompanied by a prolonged prothrombin time particularly in non-- survivors ( 31 , 79 , 97 , 101 ) .", "labels": [[35, 52, "ENTITY"], [35, 47, "PROTEIN"], [68, 74, "ENTITY"], [35, 47, "GENE_OR_GENE_PRODUCT"], [74, 84, "ENTITY"], [25, 35, "ENTITY"]]}
{"text": "Although previous study proved prone position \u2019s benefit in moderate-to-severe ARDS patients with invasive mechanical ventilation ( IMV ) [ 11 ] , we attempted awake prone position in NCP patients which showed significant effects in improving oxygenation and pulmonary heterogeneity ( Fig. \u200b(Fig.2).2 ) .", "labels": [[283, 290, "ENTITY"], [150, 160, "ENTITY"], [210, 222, "ENTITY"], [37, 46, "PROTEIN"], [243, 259, "ORGAN"], [181, 188, "ENTITY"], [37, 46, "ENTITY"], [222, 233, "ENTITY"], [37, 46, "SO"], [37, 46, "GGP"], [233, 243, "ENTITY"], [37, 46, "CHEMICAL"], [243, 269, "ENTITY"], [283, 290, "PROTEIN"], [31, 37, "SO"], [18, 24, "ENTITY"]]}
{"text": "Although previous study proved prone position \u2019s benefit in moderate-to-severe ARDS patients with invasive mechanical ventilation ( IMV ) [ 11 ] , we attempted awake prone position in NCP patients which showed significant effects in improving oxygenation and pulmonary heterogeneity ( Fig. \u200b(Fig.2).2 ) .", "labels": [[283, 290, "ENTITY"], [150, 160, "ENTITY"], [210, 222, "ENTITY"], [37, 46, "PROTEIN"], [243, 259, "ORGAN"], [181, 188, "ENTITY"], [37, 46, "ENTITY"], [222, 233, "ENTITY"], [37, 46, "SO"], [37, 46, "GGP"], [233, 243, "ENTITY"], [37, 46, "CHEMICAL"], [243, 269, "ENTITY"], [283, 290, "PROTEIN"], [31, 37, "SO"], [18, 24, "ENTITY"]]}
{"text": "Critically , this injury was attenuated by blocking the renin- angiotensin pathway and depended on ACE2 expression [ 12 ] .", "labels": [[0, 11, "ENTITY"], [56, 75, "ENTITY"], [56, 63, "GENE_OR_GENE_PRODUCT"]]}
{"text": "This suggests that excessive ACE2 may competitively bind with SARS- CoV-2 not only to neutralize the virus but also rescue cellular ACE2 activity which negatively regulates the renin-angiotensin system ( RAS ) to protect the lung from injury [ 12 , 30 ] .", "labels": [[62, 74, "ENTITY"], [123, 137, "CELL"], [116, 123, "ENTITY"], [29, 34, "ENTITY"], [86, 97, "ENTITY"], [101, 107, "TAXON"], [177, 202, "GENE_OR_GENE_PRODUCT"], [177, 202, "ENTITY"], [137, 146, "ENTITY"], [123, 132, "ENTITY"], [29, 34, "PROTEIN"], [38, 52, "ENTITY"], [101, 107, "ENTITY"], [62, 74, "PROTEIN"], [163, 173, "ENTITY"], [62, 74, "ORGANISM"], [19, 29, "ENTITY"], [29, 34, "GENE_OR_GENE_PRODUCT"], [52, 57, "ENTITY"], [29, 34, "PROTEIN"], [29, 34, "ENTITY"], [29, 34, "GGP"], [123, 137, "CL"]]}
{"text": "This suggests that excessive ACE2 may competitively bind with SARS- CoV-2 not only to neutralize the virus but also rescue cellular ACE2 activity which negatively regulates the renin-angiotensin system ( RAS ) to protect the lung from injury [ 12 , 30 ] .", "labels": [[29, 34, "GENE_OR_GENE_PRODUCT"], [62, 74, "ENTITY"], [116, 123, "ENTITY"], [29, 34, "GGP"], [86, 97, "ENTITY"], [101, 107, "TAXON"], [177, 202, "GENE_OR_GENE_PRODUCT"], [177, 202, "ENTITY"], [137, 146, "ENTITY"], [123, 132, "ENTITY"], [38, 52, "ENTITY"], [101, 107, "ENTITY"], [62, 74, "PROTEIN"], [123, 137, "CL"], [29, 34, "PROTEIN"], [163, 173, "ENTITY"], [29, 34, "ENTITY"], [62, 74, "ORGANISM"], [19, 29, "ENTITY"], [29, 34, "ENTITY"], [52, 57, "ENTITY"], [123, 137, "CELL"], [29, 34, "PROTEIN"]]}
{"text": "Paradoxically , pharmacologic RAS blockade has also been associated with increased ACE2 expression in mouse models [ 20 ] .", "labels": [[102, 108, "ENTITY"]]}
{"text": "By contract , ACE2 inactivates angiotensin II while generating angiotensin 1\u20137 , a heptapeptide having a potent vasodilator function via activation of its Mas receptor ( Santos et al. , 2003 ) , and thus serving as a negative regulator of the renin \u2013 angiotensin system .", "labels": [[151, 159, "ENTITY"], [31, 43, "ENTITY"], [31, 43, "PROTEIN"], [31, 43, "CHEMICAL"], [31, 43, "CHEMICAL"], [217, 226, "ENTITY"], [236, 243, "ENTITY"], [212, 217, "ENTITY"], [31, 43, "ENTITY"], [31, 43, "GGP"], [151, 159, "PROTEIN"], [105, 124, "ENTITY"], [3, 12, "ENTITY"], [31, 43, "GENE_OR_GENE_PRODUCT"], [236, 251, "GENE_OR_GENE_PRODUCT"], [31, 43, "SIMPLE_CHEMICAL"], [31, 43, "PROTEIN"], [151, 159, "GENE_OR_GENE_PRODUCT"], [243, 251, "CHEMICAL"]]}
{"text": "Mechanistic evidence suggests two competing hypotheses : 1 ) RAS blockade decreases proinflammatory activity of Ang II , decreasing the risk of ARDS , myocarditis , or mortality in COVID-19 , or 2 ) RAS blockade increases ACE2 expression , promoting SARS-CoV-2 virulence in the lungs and heart that leads to ARDS , myocarditis , and death .", "labels": [[144, 151, "ENTITY"], [144, 151, "DISEASE"], [0, 12, "ENTITY"], [240, 261, "ENTITY"], [74, 100, "ENTITY"], [305, 315, "DISEASE"], [109, 116, "ENTITY"], [168, 181, "ENTITY"], [59, 65, "ENTITY"], [65, 74, "ENTITY"], [109, 116, "PROTEIN"], [151, 165, "ENTITY"], [305, 315, "ENTITY"], [109, 116, "GENE_OR_GENE_PRODUCT"], [278, 284, "ORGAN"], [44, 55, "ENTITY"], [240, 250, "SIMPLE_CHEMICAL"], [65, 74, "ENTITY"], [61, 65, "ENTITY"], [163, 168, "ENTITY"], [168, 181, "GENE_OR_GENE_PRODUCT"], [299, 305, "ENTITY"], [109, 116, "CHEMICAL"], [240, 250, "CHEMICAL"], [299, 305, "DISEASE"], [212, 227, "ENTITY"], [168, 195, "CELL_LINE"], [278, 284, "ENTITY"], [109, 116, "GGP"], [12, 21, "ENTITY"], [151, 165, "DISEASE"]]}
{"text": "In humans the renin-angiotensin system is the hormone system which regulates blood pressure and vascular resistances , as well as electrolytic balance ; within this important system , the angiotensin-converting enzyme ( ACE ) , present on the surface of vascular endothelial cells , in particular those of the lungs , is deputed to the conversion of angiotensin I to angiotensin II ( AII ) , a potent vasoconstrictive peptide [ 1 ] .", "labels": [[184, 211, "PROTEIN"], [350, 367, "ENTITY"], [20, 32, "ENTITY"], [336, 350, "CHEMICAL"], [336, 350, "GENE_OR_GENE_PRODUCT"], [130, 143, "ENTITY"], [243, 275, "CELL_TYPE"], [243, 275, "CELL"], [211, 220, "ENTITY"], [211, 220, "GENE_OR_GENE_PRODUCT"], [3, 10, "TAXON"], [336, 350, "GGP"], [243, 275, "ENTITY"], [336, 350, "ENTITY"], [165, 175, "ENTITY"], [184, 211, "GENE_OR_GENE_PRODUCT"], [188, 211, "SO"], [77, 92, "ENTITY"], [336, 367, "PROTEIN"], [390, 401, "ENTITY"], [390, 401, "CHEBI"], [77, 83, "ORGANISM_SUBSTANCE"], [350, 367, "GGP"], [184, 211, "ENTITY"], [20, 32, "GENE_OR_GENE_PRODUCT"], [329, 336, "ENTITY"], [96, 117, "ENTITY"], [243, 275, "CL"], [350, 367, "CHEMICAL"], [3, 10, "ORGANISM"], [14, 39, "ENTITY"], [236, 243, "CELLULAR_COMPONENT"], [3, 10, "ENTITY"], [350, 367, "GENE_OR_GENE_PRODUCT"], [67, 77, "ENTITY"], [46, 61, "ENTITY"], [96, 105, "MULTI-TISSUE_STRUCTURE"], [236, 243, "ENTITY"]]}
{"text": "Angiotensin-converting enzyme 2 ( ACE2 ) is a crucial component of the renin-angiotensin system ( RAS ) .", "labels": [[23, 30, "SO"], [67, 89, "ENTITY"], [67, 89, "GENE_OR_GENE_PRODUCT"], [0, 32, "GENE_OR_GENE_PRODUCT"], [0, 32, "PROTEIN"], [0, 32, "ENTITY"]]}
{"text": "In the RAS cascade , ACE is responsible for the conversion of Angiotensin ( Ang ) I to Ang II , and Ang II is the vasoactive peptide principally responsible for systemic vasoconstriction and stimulation of aldosterone release ( Figure 1 ) [ 16 ]", "labels": [[7, 19, "ENTITY"], [84, 91, "ENTITY"], [206, 218, "ENTITY"], [110, 125, "CHEBI"], [7, 11, "GENE_OR_GENE_PRODUCT"], [84, 91, "CHEMICAL"], [110, 125, "ENTITY"], [62, 80, "GENE_OR_GENE_PRODUCT"], [218, 228, "ENTITY"], [84, 91, "GENE_OR_GENE_PRODUCT"], [157, 170, "ENTITY"]]}
{"text": "RAS activity in patients with CVD or cardiovascular comorbidities could increase the likelihood and severity of SARS-CoV-2 infection in the lung or heart and may explain heterogeneity in the clinical course of COVID-19 , but in what direction ? ?", "labels": [[112, 133, "DISEASE"], [37, 52, "ORGANISM_SUBDIVISION"], [16, 25, "ORGANISM"], [4, 13, "ENTITY"], [85, 96, "ENTITY"], [100, 109, "ENTITY"], [30, 66, "DISEASE"], [148, 154, "ENTITY"], [210, 219, "GENE_OR_GENE_PRODUCT"], [140, 145, "ENTITY"], [30, 34, "ENTITY"], [16, 25, "ENTITY"], [191, 207, "ENTITY"], [0, 4, "ENTITY"], [72, 81, "ENTITY"], [140, 145, "ORGAN"], [112, 123, "SIMPLE_CHEMICAL"], [210, 219, "ENTITY"], [112, 133, "ENTITY"], [148, 154, "ORGAN"], [210, 219, "PROTEIN"], [170, 184, "ENTITY"], [37, 66, "ENTITY"], [0, 4, "GENE_OR_GENE_PRODUCT"]]}
{"text": "RAS activity in patients with CVD or cardiovascular comorbidities could increase the likelihood and severity of SARS-CoV-2 infection in the lung or heart and may explain heterogeneity in the clinical course of COVID-19 , but in what direction ? ?", "labels": [[112, 133, "ENTITY"], [16, 25, "ORGANISM"], [4, 13, "ENTITY"], [85, 96, "ENTITY"], [100, 109, "ENTITY"], [30, 66, "DISEASE"], [148, 154, "ENTITY"], [112, 133, "DISEASE"], [210, 219, "GENE_OR_GENE_PRODUCT"], [210, 219, "ENTITY"], [30, 34, "ENTITY"], [140, 145, "ENTITY"], [37, 52, "ORGANISM_SUBDIVISION"], [16, 25, "ENTITY"], [191, 207, "ENTITY"], [0, 4, "ENTITY"], [72, 81, "ENTITY"], [140, 145, "ORGAN"], [210, 219, "PROTEIN"], [37, 66, "ENTITY"], [112, 123, "SIMPLE_CHEMICAL"], [148, 154, "ORGAN"], [170, 184, "ENTITY"], [0, 4, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Mechanistic evidence suggests two competing hypotheses : 1 ) RAS blockade decreases proinflammatory activity of Ang II , decreasing the risk of ARDS , myocarditis , or mortality in COVID-19 , or 2 ) RAS blockade increases ACE2 expression , promoting SARS-CoV-2 virulence in the lungs and heart that leads to ARDS , myocarditis , and death .", "labels": [[144, 151, "ENTITY"], [144, 151, "DISEASE"], [0, 12, "ENTITY"], [240, 261, "ENTITY"], [305, 315, "DISEASE"], [109, 116, "ENTITY"], [168, 181, "ENTITY"], [59, 65, "ENTITY"], [65, 74, "ENTITY"], [109, 116, "PROTEIN"], [151, 165, "ENTITY"], [305, 315, "ENTITY"], [109, 116, "GENE_OR_GENE_PRODUCT"], [74, 100, "ENTITY"], [278, 284, "ORGAN"], [44, 55, "ENTITY"], [240, 250, "SIMPLE_CHEMICAL"], [65, 74, "ENTITY"], [61, 65, "ENTITY"], [212, 227, "ENTITY"], [163, 168, "ENTITY"], [168, 181, "GENE_OR_GENE_PRODUCT"], [299, 305, "ENTITY"], [109, 116, "CHEMICAL"], [240, 250, "CHEMICAL"], [299, 305, "DISEASE"], [168, 195, "CELL_LINE"], [278, 284, "ENTITY"], [109, 116, "GGP"], [12, 21, "ENTITY"], [151, 165, "DISEASE"]]}
{"text": "In humans the renin-angiotensin system is the hormone system which regulates blood pressure and vascular resistances , as well as electrolytic balance ; within this important system , the angiotensin-converting enzyme ( ACE ) , present on the surface of vascular endothelial cells , in particular those of the lungs , is deputed to the conversion of angiotensin I to angiotensin II ( AII ) , a potent vasoconstrictive peptide [ 1 ] .", "labels": [[184, 211, "PROTEIN"], [350, 367, "ENTITY"], [20, 32, "ENTITY"], [336, 350, "CHEMICAL"], [336, 350, "GENE_OR_GENE_PRODUCT"], [130, 143, "ENTITY"], [77, 92, "ENTITY"], [211, 220, "ENTITY"], [211, 220, "GENE_OR_GENE_PRODUCT"], [3, 10, "TAXON"], [243, 275, "CELL_TYPE"], [243, 275, "ENTITY"], [336, 350, "GGP"], [336, 350, "ENTITY"], [165, 175, "ENTITY"], [243, 275, "CELL"], [184, 211, "GENE_OR_GENE_PRODUCT"], [188, 211, "SO"], [243, 275, "CL"], [336, 367, "PROTEIN"], [390, 401, "ENTITY"], [390, 401, "CHEBI"], [77, 83, "ORGANISM_SUBSTANCE"], [350, 367, "GGP"], [184, 211, "ENTITY"], [20, 32, "GENE_OR_GENE_PRODUCT"], [329, 336, "ENTITY"], [96, 117, "ENTITY"], [350, 367, "CHEMICAL"], [3, 10, "ORGANISM"], [14, 39, "ENTITY"], [236, 243, "CELLULAR_COMPONENT"], [3, 10, "ENTITY"], [350, 367, "GENE_OR_GENE_PRODUCT"], [67, 77, "ENTITY"], [46, 61, "ENTITY"], [96, 105, "MULTI-TISSUE_STRUCTURE"], [236, 243, "ENTITY"]]}
{"text": "In humans the renin-angiotensin system is the hormone system which regulates blood pressure and vascular resistances , as well as electrolytic balance ; within this important system , the angiotensin-converting enzyme ( ACE ) , present on the surface of vascular endothelial cells , in particular those of the lungs , is deputed to the conversion of angiotensin I to angiotensin II ( AII ) , a potent vasoconstrictive peptide [ 1 ] .", "labels": [[130, 143, "ENTITY"], [184, 211, "PROTEIN"], [350, 367, "ENTITY"], [20, 32, "ENTITY"], [336, 350, "CHEMICAL"], [336, 350, "GENE_OR_GENE_PRODUCT"], [211, 220, "ENTITY"], [211, 220, "GENE_OR_GENE_PRODUCT"], [3, 10, "TAXON"], [243, 275, "CELL_TYPE"], [243, 275, "ENTITY"], [336, 350, "GGP"], [336, 350, "ENTITY"], [165, 175, "ENTITY"], [243, 275, "CELL"], [184, 211, "GENE_OR_GENE_PRODUCT"], [188, 211, "SO"], [243, 275, "CL"], [77, 92, "ENTITY"], [336, 367, "PROTEIN"], [390, 401, "ENTITY"], [390, 401, "CHEBI"], [77, 83, "ORGANISM_SUBSTANCE"], [350, 367, "GGP"], [184, 211, "ENTITY"], [20, 32, "GENE_OR_GENE_PRODUCT"], [329, 336, "ENTITY"], [96, 117, "ENTITY"], [350, 367, "CHEMICAL"], [3, 10, "ORGANISM"], [14, 39, "ENTITY"], [236, 243, "CELLULAR_COMPONENT"], [3, 10, "ENTITY"], [350, 367, "GENE_OR_GENE_PRODUCT"], [67, 77, "ENTITY"], [46, 61, "ENTITY"], [96, 105, "MULTI-TISSUE_STRUCTURE"], [236, 243, "ENTITY"]]}
{"text": "In humans the renin-angiotensin system is the hormone system which regulates blood pressure and vascular resistances , as well as electrolytic balance ; within this important system , the angiotensin-converting enzyme ( ACE ) , present on the surface of vascular endothelial cells , in particular those of the lungs , is deputed to the conversion of angiotensin I to angiotensin II ( AII ) , a potent vasoconstrictive peptide [ 1 ] .", "labels": [[184, 211, "PROTEIN"], [350, 367, "ENTITY"], [20, 32, "ENTITY"], [336, 350, "CHEMICAL"], [336, 350, "GENE_OR_GENE_PRODUCT"], [130, 143, "ENTITY"], [96, 117, "ENTITY"], [211, 220, "ENTITY"], [211, 220, "GENE_OR_GENE_PRODUCT"], [3, 10, "TAXON"], [243, 275, "CELL_TYPE"], [243, 275, "ENTITY"], [336, 350, "GGP"], [336, 350, "ENTITY"], [165, 175, "ENTITY"], [243, 275, "CELL"], [184, 211, "GENE_OR_GENE_PRODUCT"], [188, 211, "SO"], [243, 275, "CL"], [96, 105, "MULTI-TISSUE_STRUCTURE"], [77, 92, "ENTITY"], [336, 367, "PROTEIN"], [390, 401, "ENTITY"], [390, 401, "CHEBI"], [77, 83, "ORGANISM_SUBSTANCE"], [350, 367, "GGP"], [184, 211, "ENTITY"], [20, 32, "GENE_OR_GENE_PRODUCT"], [329, 336, "ENTITY"], [350, 367, "CHEMICAL"], [3, 10, "ORGANISM"], [14, 39, "ENTITY"], [236, 243, "CELLULAR_COMPONENT"], [3, 10, "ENTITY"], [350, 367, "GENE_OR_GENE_PRODUCT"], [67, 77, "ENTITY"], [46, 61, "ENTITY"], [236, 243, "ENTITY"]]}
{"text": "Once SpO2 < 93 % , RR > 30/min , HR > 120/min or any signs of organ failure were observed , patients would be transferred to intensive care unit ( ICU ) and ICU physicians and nurses would take over their treatment .", "labels": [[5, 10, "ENTITY"], [134, 152, "ENTITY"], [152, 157, "ENTITY"], [71, 80, "ENTITY"], [71, 80, "DISEASE"], [93, 104, "ORGANISM"], [163, 173, "ENTITY"], [39, 44, "ENTITY"], [173, 188, "ENTITY"], [93, 104, "ENTITY"]]}
{"text": "Respiratory rates were significantly higher in deceased patients ( 24.0 breaths per minute ) than in recovered patients ( 20.0 breaths per minute ) .", "labels": [[0, 18, "ENTITY"], [101, 111, "ENTITY"], [101, 111, "ORGANISM"], [23, 44, "ENTITY"], [56, 65, "ORGANISM"], [56, 65, "ENTITY"], [47, 56, "ENTITY"]]}
{"text": "These results indicated that the persistently infected Vero E6 cells produce infectious viruses .", "labels": [[6, 14, "ENTITY"], [63, 69, "CL"], [46, 55, "ENTITY"], [55, 69, "CELL_LINE"], [55, 69, "CELL"], [60, 69, "ENTITY"], [88, 96, "TAXON"], [77, 96, "ENTITY"], [55, 60, "ENTITY"]]}
{"text": "When the variability between nsp 3 isolates of the SARS epidemic are compared , the results suggest that nsps 1 - 3 perform cell- and host- specific roles in replication and/or virulence . Additionally , they have demonstrated high capacity for adaptation to new environments and selective pressures .", "labels": [[35, 44, "ENTITY"], [276, 290, "ENTITY"], [29, 35, "GENE_OR_GENE_PRODUCT"], [69, 78, "ENTITY"], [51, 56, "ENTITY"], [170, 177, "ENTITY"], [227, 232, "ENTITY"], [29, 35, "ENTITY"], [56, 65, "ENTITY"], [29, 35, "PROTEIN"], [9, 21, "ENTITY"], [105, 112, "PROTEIN"], [105, 110, "ENTITY"], [105, 112, "ORGANISM"], [51, 56, "DISEASE"]]}
{"text": "When the variability between nsp 3 isolates of the SARS epidemic are compared , the results suggest that nsps 1 - 3 perform cell- and host- specific roles in replication and/or virulence . Additionally , they have demonstrated high capacity for adaptation to new environments and selective pressures .", "labels": [[35, 44, "ENTITY"], [276, 290, "ENTITY"], [29, 35, "GENE_OR_GENE_PRODUCT"], [69, 78, "ENTITY"], [51, 56, "ENTITY"], [170, 177, "ENTITY"], [227, 232, "ENTITY"], [29, 35, "ENTITY"], [56, 65, "ENTITY"], [29, 35, "PROTEIN"], [9, 21, "ENTITY"], [105, 112, "PROTEIN"], [105, 110, "ENTITY"], [105, 112, "ORGANISM"], [51, 56, "DISEASE"]]}
{"text": "When the variability between nsp 3 isolates of the SARS epidemic are compared , the results suggest that nsps 1 - 3 perform cell- and host- specific roles in replication and/or virulence . Additionally , they have demonstrated high capacity for adaptation to new environments and selective pressures .", "labels": [[35, 44, "ENTITY"], [276, 290, "ENTITY"], [29, 35, "GENE_OR_GENE_PRODUCT"], [69, 78, "ENTITY"], [51, 56, "ENTITY"], [170, 177, "ENTITY"], [227, 232, "ENTITY"], [29, 35, "ENTITY"], [56, 65, "ENTITY"], [29, 35, "PROTEIN"], [9, 21, "ENTITY"], [105, 112, "PROTEIN"], [105, 110, "ENTITY"], [105, 112, "ORGANISM"], [51, 56, "DISEASE"]]}
{"text": "Consistent with the Nsp9 expression results , titration of progeny viruses in the cell medium also demonstrated that TAT-Nb6 suppressed the virus replication in a dose-dependent manner", "labels": [[0, 16, "ENTITY"], [25, 36, "ENTITY"], [36, 44, "ENTITY"], [20, 25, "PROTEIN"], [20, 25, "GGP"], [67, 73, "ENTITY"], [20, 25, "ENTITY"], [20, 25, "GENE_OR_GENE_PRODUCT"], [82, 87, "ENTITY"]]}
{"text": "Titration of the viruses released in the cell culture revealed that TAT-Nb6 treatment suppressed progeny virus production for all strains at 48 hpi ( Fig. 7E ) .", "labels": [[17, 25, "TAXON"], [68, 76, "ENTITY"], [17, 23, "ENTITY"], [0, 10, "ENTITY"], [17, 23, "TAXON"], [111, 122, "ENTITY"], [130, 138, "ENTITY"], [41, 46, "CELL"], [41, 46, "CL"], [25, 34, "ENTITY"], [17, 25, "ENTITY"], [97, 105, "ENTITY"], [41, 54, "ENTITY"], [76, 86, "ENTITY"], [144, 148, "ENTITY"], [68, 76, "PROTEIN"], [86, 97, "ENTITY"]]}
{"text": "Titration of the viruses released in the cell culture revealed that TAT-Nb6 treatment suppressed progeny virus production for all strains at 48 hpi ( Fig. 7E ) .", "labels": [[68, 76, "ENTITY"], [111, 122, "ENTITY"], [0, 10, "ENTITY"], [17, 25, "ENTITY"], [41, 46, "CELL"], [130, 138, "ENTITY"], [17, 25, "TAXON"], [41, 46, "CL"], [25, 34, "ENTITY"], [97, 105, "ENTITY"], [41, 54, "ENTITY"], [76, 86, "ENTITY"], [17, 23, "ENTITY"], [144, 148, "ENTITY"], [68, 76, "PROTEIN"], [17, 23, "TAXON"], [86, 97, "ENTITY"]]}
{"text": "Not only has ACE2 facilitated the invasion of SARS virus for rapid replication , but also ACE2 is depleted from the cell membrane and therefore the damaging effects of Ang II are enhanced , resulting in acute deterioration of lung tissues [ 5 ] .", "labels": [[51, 57, "TAXON"], [223, 231, "TISSUE"], [223, 231, "ENTITY"], [148, 157, "ENTITY"], [168, 172, "GGP"], [13, 18, "ENTITY"], [116, 121, "CL"], [46, 51, "DISEASE"], [13, 18, "PROTEIN"], [46, 57, "ORGANISM"], [61, 67, "ENTITY"], [168, 172, "PROTEIN"], [168, 172, "CHEMICAL"], [34, 43, "ENTITY"], [46, 57, "ENTITY"], [67, 79, "ENTITY"], [168, 172, "GENE_OR_GENE_PRODUCT"], [116, 121, "CELLULAR_COMPONENT"], [13, 18, "GGP"], [13, 18, "GENE_OR_GENE_PRODUCT"], [116, 121, "ENTITY"], [200, 209, "ENTITY"], [168, 172, "ENTITY"]]}
{"text": "Through a literature review , we identified a list of important symptoms and mechanisms linked to SARS-CoV-2 , including fever , fatigue , cough 17 , breathing difficulty , septic shock , viral proliferation , immunodeficiency and pulmonary fibrosis 18 ( Figure 4 ) .", "labels": [[145, 160, "ENTITY"], [180, 194, "ENTITY"], [180, 186, "TAXON"], [160, 180, "ENTITY"], [129, 139, "DISEASE"], [231, 241, "DISEASE"], [194, 210, "ORGANISM"], [210, 241, "ENTITY"], [194, 210, "ENTITY"], [241, 255, "ENTITY"], [210, 231, "ORGAN"], [160, 180, "DISEASE"], [129, 139, "ENTITY"], [111, 121, "DISEASE"], [111, 121, "ENTITY"], [10, 28, "ENTITY"]]}
{"text": "A previous attempt to predict drugs for the Mpro of SARS-CoV has identified two HIV-1 protease inhibitors , namely lopinavir and ritonavir , as potential candidates , both of which bind to the same target site of Mpro ( Nukoolkarn et al. , 2008 ) . The conserved amino acids Thr24-Asn28 and Asn119 ( numbered according to positions in SARS-CoV Mpro because the present sequence of 2019-nCoV Mpro in GenBank is in polypeptide form ) formed the binding pockets for lopinavir/ritonavir in the spatial structure of both SARS-CoV Mpro and 2019-nCoV Mpro , whereas the nearby non-conserved amino acids locate far away from the binding pocket , thus would not affect its structural conservation ( Fig. 1B ) .", "labels": [[361, 369, "SO"], [22, 30, "ENTITY"], [247, 263, "SO"], [144, 154, "ENTITY"], [570, 584, "CHEBI"], [322, 335, "ENTITY"], [309, 322, "SO"], [52, 61, "GGP"], [451, 463, "CHEMICAL"], [451, 463, "SIMPLE_CHEMICAL"], [44, 49, "ENTITY"], [269, 275, "ENTITY"], [80, 106, "GGP"], [361, 369, "ENTITY"], [322, 335, "ORGANISM"], [253, 263, "ENTITY"], [612, 621, "ENTITY"], [247, 291, "PROTEIN"], [213, 220, "SIMPLE_CHEMICAL"], [198, 205, "SO"], [275, 291, "ENTITY"], [508, 516, "GGP"], [664, 675, "SO"], [508, 534, "PROTEIN"], [570, 584, "CHEMICAL"], [559, 584, "PROTEIN"], [80, 95, "ORGANISM"], [275, 291, "GENE_OR_GENE_PRODUCT"], [653, 675, "ENTITY"], [391, 399, "GENE_OR_GENE_PRODUCT"], [391, 399, "ENTITY"], [570, 584, "AMINO_ACID"], [30, 36, "ENTITY"], [432, 439, "ENTITY"], [508, 516, "ORGANISM"], [451, 463, "ENTITY"], [52, 61, "ORGANISM"], [52, 61, "ENTITY"], [369, 381, "ENTITY"], [80, 106, "ENTITY"], [463, 498, "ENTITY"], [612, 621, "PROTEIN"], [508, 516, "ENTITY"], [525, 534, "ENTITY"], [253, 275, "CHEMICAL"], [399, 413, "ENTITY"], [322, 335, "PROTEIN"], [44, 61, "PROTEIN"], [559, 584, "ENTITY"]]}
{"text": "A previous attempt to predict drugs for the Mpro of SARS-CoV has identified two HIV-1 protease inhibitors , namely lopinavir and ritonavir , as potential candidates , both of which bind to the same target site of Mpro ( Nukoolkarn et al. , 2008 ) . The conserved amino acids Thr24-Asn28 and Asn119 ( numbered according to positions in SARS-CoV Mpro because the present sequence of 2019-nCoV Mpro in GenBank is in polypeptide form ) formed the binding pockets for lopinavir/ritonavir in the spatial structure of both SARS-CoV Mpro and 2019-nCoV Mpro , whereas the nearby non-conserved amino acids locate far away from the binding pocket , thus would not affect its structural conservation ( Fig. 1B ) .", "labels": [[361, 369, "SO"], [22, 30, "ENTITY"], [247, 263, "SO"], [144, 154, "ENTITY"], [570, 584, "CHEBI"], [322, 335, "ENTITY"], [309, 322, "SO"], [52, 61, "GGP"], [451, 463, "CHEMICAL"], [451, 463, "SIMPLE_CHEMICAL"], [44, 49, "ENTITY"], [269, 275, "ENTITY"], [80, 106, "GGP"], [361, 369, "ENTITY"], [322, 335, "ORGANISM"], [253, 263, "ENTITY"], [612, 621, "ENTITY"], [247, 291, "PROTEIN"], [213, 220, "SIMPLE_CHEMICAL"], [198, 205, "SO"], [275, 291, "ENTITY"], [508, 516, "GGP"], [664, 675, "SO"], [508, 534, "PROTEIN"], [570, 584, "CHEMICAL"], [559, 584, "PROTEIN"], [80, 95, "ORGANISM"], [275, 291, "GENE_OR_GENE_PRODUCT"], [653, 675, "ENTITY"], [391, 399, "GENE_OR_GENE_PRODUCT"], [391, 399, "ENTITY"], [570, 584, "AMINO_ACID"], [30, 36, "ENTITY"], [432, 439, "ENTITY"], [508, 516, "ORGANISM"], [451, 463, "ENTITY"], [52, 61, "ORGANISM"], [52, 61, "ENTITY"], [369, 381, "ENTITY"], [80, 106, "ENTITY"], [463, 498, "ENTITY"], [612, 621, "PROTEIN"], [508, 516, "ENTITY"], [525, 534, "ENTITY"], [253, 275, "CHEMICAL"], [399, 413, "ENTITY"], [322, 335, "PROTEIN"], [44, 61, "PROTEIN"], [559, 584, "ENTITY"]]}
{"text": "A previous attempt to predict drugs for the Mpro of SARS-CoV has identified two HIV-1 protease inhibitors , namely lopinavir and ritonavir , as potential candidates , both of which bind to the same target site of Mpro ( Nukoolkarn et al. , 2008 ) . The conserved amino acids Thr24-Asn28 and Asn119 ( numbered according to positions in SARS-CoV Mpro because the present sequence of 2019-nCoV Mpro in GenBank is in polypeptide form ) formed the binding pockets for lopinavir/ritonavir in the spatial structure of both SARS-CoV Mpro and 2019-nCoV Mpro , whereas the nearby non-conserved amino acids locate far away from the binding pocket , thus would not affect its structural conservation ( Fig. 1B ) .", "labels": [[361, 369, "SO"], [22, 30, "ENTITY"], [247, 263, "SO"], [144, 154, "ENTITY"], [570, 584, "CHEBI"], [322, 335, "ENTITY"], [309, 322, "SO"], [52, 61, "GGP"], [451, 463, "CHEMICAL"], [451, 463, "SIMPLE_CHEMICAL"], [44, 49, "ENTITY"], [269, 275, "ENTITY"], [80, 106, "GGP"], [361, 369, "ENTITY"], [322, 335, "ORGANISM"], [253, 263, "ENTITY"], [612, 621, "ENTITY"], [247, 291, "PROTEIN"], [213, 220, "SIMPLE_CHEMICAL"], [198, 205, "SO"], [275, 291, "ENTITY"], [508, 516, "GGP"], [664, 675, "SO"], [508, 534, "PROTEIN"], [570, 584, "CHEMICAL"], [559, 584, "PROTEIN"], [80, 95, "ORGANISM"], [275, 291, "GENE_OR_GENE_PRODUCT"], [653, 675, "ENTITY"], [391, 399, "GENE_OR_GENE_PRODUCT"], [463, 498, "ENTITY"], [391, 399, "ENTITY"], [570, 584, "AMINO_ACID"], [30, 36, "ENTITY"], [432, 439, "ENTITY"], [508, 516, "ORGANISM"], [451, 463, "ENTITY"], [52, 61, "ORGANISM"], [52, 61, "ENTITY"], [369, 381, "ENTITY"], [80, 106, "ENTITY"], [612, 621, "PROTEIN"], [508, 516, "ENTITY"], [525, 534, "ENTITY"], [253, 275, "CHEMICAL"], [399, 413, "ENTITY"], [322, 335, "PROTEIN"], [44, 61, "PROTEIN"], [559, 584, "ENTITY"]]}
{"text": "A previous attempt to predict drugs for the Mpro of SARS-CoV has identified two HIV-1 protease inhibitors , namely lopinavir and ritonavir , as potential candidates , both of which bind to the same target site of Mpro ( Nukoolkarn et al. , 2008 ) . The conserved amino acids Thr24-Asn28 and Asn119 ( numbered according to positions in SARS-CoV Mpro because the present sequence of 2019-nCoV Mpro in GenBank is in polypeptide form ) formed the binding pockets for lopinavir/ritonavir in the spatial structure of both SARS-CoV Mpro and 2019-nCoV Mpro , whereas the nearby non-conserved amino acids locate far away from the binding pocket , thus would not affect its structural conservation ( Fig. 1B ) .", "labels": [[361, 369, "SO"], [22, 30, "ENTITY"], [247, 263, "SO"], [144, 154, "ENTITY"], [570, 584, "CHEBI"], [322, 335, "ENTITY"], [309, 322, "SO"], [52, 61, "GGP"], [451, 463, "CHEMICAL"], [451, 463, "SIMPLE_CHEMICAL"], [44, 49, "ENTITY"], [269, 275, "ENTITY"], [80, 106, "GGP"], [361, 369, "ENTITY"], [322, 335, "ORGANISM"], [253, 263, "ENTITY"], [612, 621, "ENTITY"], [247, 291, "PROTEIN"], [213, 220, "SIMPLE_CHEMICAL"], [198, 205, "SO"], [275, 291, "ENTITY"], [508, 516, "GGP"], [664, 675, "SO"], [508, 534, "PROTEIN"], [570, 584, "CHEMICAL"], [559, 584, "PROTEIN"], [80, 95, "ORGANISM"], [275, 291, "GENE_OR_GENE_PRODUCT"], [653, 675, "ENTITY"], [391, 399, "GENE_OR_GENE_PRODUCT"], [463, 498, "ENTITY"], [391, 399, "ENTITY"], [570, 584, "AMINO_ACID"], [30, 36, "ENTITY"], [432, 439, "ENTITY"], [508, 516, "ORGANISM"], [451, 463, "ENTITY"], [52, 61, "ORGANISM"], [52, 61, "ENTITY"], [369, 381, "ENTITY"], [80, 106, "ENTITY"], [612, 621, "PROTEIN"], [508, 516, "ENTITY"], [525, 534, "ENTITY"], [253, 275, "CHEMICAL"], [399, 413, "ENTITY"], [322, 335, "PROTEIN"], [44, 61, "PROTEIN"], [559, 584, "ENTITY"]]}
{"text": "This reinforces that high levels of D-dimer and low lymphocyte counts are 306 associated with poor prognosis and suggest that that DIP treatment should be initiated before the progression to critical illness ( Figure 3B ) .", "labels": [[131, 135, "ENTITY"], [36, 44, "ENTITY"], [78, 94, "ENTITY"], [48, 52, "ENTITY"], [52, 63, "ENTITY"], [210, 217, "ENTITY"], [52, 63, "CELL"], [176, 188, "ENTITY"], [131, 135, "CHEMICAL"], [36, 44, "GGP"], [21, 26, "ENTITY"], [36, 44, "PROTEIN"], [94, 109, "ENTITY"], [26, 33, "ENTITY"], [36, 44, "GENE_OR_GENE_PRODUCT"], [63, 70, "ENTITY"], [52, 63, "CL"], [191, 208, "ENTITY"], [135, 145, "ENTITY"], [131, 135, "SIMPLE_CHEMICAL"]]}
{"text": "This reinforces that high levels of D-dimer and low lymphocyte counts are 306 associated with poor prognosis and suggest that that DIP treatment should be initiated before the progression to critical illness ( Figure 3B ) .", "labels": [[131, 135, "ENTITY"], [63, 70, "ENTITY"], [36, 44, "GGP"], [78, 94, "ENTITY"], [48, 52, "ENTITY"], [52, 63, "ENTITY"], [210, 217, "ENTITY"], [52, 63, "CELL"], [176, 188, "ENTITY"], [131, 135, "CHEMICAL"], [21, 26, "ENTITY"], [36, 44, "GENE_OR_GENE_PRODUCT"], [94, 109, "ENTITY"], [26, 33, "ENTITY"], [135, 145, "ENTITY"], [191, 208, "ENTITY"], [52, 63, "CL"], [36, 44, "PROTEIN"], [36, 44, "ENTITY"], [131, 135, "SIMPLE_CHEMICAL"]]}
{"text": "The management of patients mainly focuses on the provision of supportive care , e.g. , oxygenation , ventilation , and fluid management .", "labels": [[4, 15, "ENTITY"], [18, 27, "ENTITY"], [18, 27, "ORGANISM"], [49, 59, "ENTITY"], [115, 125, "ENTITY"], [62, 78, "ENTITY"]]}
{"text": "Among the eight patients , six ( 6/8 ) received high-flow oxygen therapy and two critically ill ( 2/8 ) patients received mechanical ventilation .", "labels": [[48, 58, "CHEMICAL"], [113, 133, "ENTITY"], [16, 25, "ORGANISM"], [77, 92, "ENTITY"], [39, 65, "ENTITY"], [48, 58, "SIMPLE_CHEMICAL"], [48, 58, "CHEBI"], [16, 25, "ENTITY"]]}
{"text": "A majority of the patients ( 58.0 % ) received intravenous antibiotic therapy , and 35.8 % received oseltamivir therapy ; oxygen therapy was administered in 41.3 % and mechanical ventilation in 6.1 % ; higher percentages of patients with severe disease received these therapies ( Table 3 ) .", "labels": [[112, 129, "ENTITY"], [129, 141, "ENTITY"], [47, 59, "CHEBI"], [209, 224, "ORGANISM"], [18, 27, "ENTITY"], [18, 27, "ORGANISM"], [224, 238, "ENTITY"], [209, 224, "ENTITY"], [162, 179, "ENTITY"], [112, 122, "CHEBI"], [38, 47, "IMMATERIAL_ANATOMICAL_ENTITY"], [112, 122, "CHEMICAL"], [112, 122, "SIMPLE_CHEMICAL"], [91, 112, "ENTITY"], [253, 268, "ENTITY"], [38, 70, "ENTITY"], [38, 47, "CHEMICAL"]]}
{"text": "On the other hand , the kinase but not the RNAse activity of IRE1 has been associated with ER-stress-induced NF-kB activation ( Tam et al. , 2012 ) . Under ER stress , IRE1 has been shown to phosphorylate TRAF2 , which activates the I\u03baB kinase ( IKK ) and contributes to its basal activity ( Figure 4 ) . IKK inturn phosphorylates I\u03baB\u03b1 and promotes its proteasomal degradation , releasing NF-\u03baB to activate downstream genes ( Tam et al.,2012 ) .", "labels": [[256, 281, "ENTITY"], [43, 49, "ENTITY"], [94, 101, "GENE_OR_GENE_PRODUCT"], [219, 237, "ENTITY"], [49, 58, "ENTITY"], [91, 115, "ENTITY"], [191, 205, "PROTEIN"], [94, 101, "ENTITY"], [191, 205, "GENE_OR_GENE_PRODUCT"], [182, 191, "ENTITY"], [219, 237, "PROTEIN"], [150, 159, "ENTITY"], [94, 101, "PROTEIN"], [94, 101, "GGP"], [191, 205, "ENTITY"], [395, 407, "ENTITY"], [191, 205, "GGP"], [395, 407, "DNA"], [340, 365, "ENTITY"], [340, 353, "GO"], [219, 228, "SO"], [292, 303, "ENTITY"], [379, 389, "ENTITY"]]}
{"text": "Under ER stress , ATF6 is translocated from the ER to the Golgi apparatus and cleaved by protease S1P and S2P ( Haze et al. , 1999 ) .", "labels": [[6, 9, "PROTEIN"], [89, 98, "PROTEIN"], [6, 9, "GENE_OR_GENE_PRODUCT"], [58, 64, "GO"], [6, 16, "ENTITY"], [58, 64, "ENTITY"]]}
{"text": "ATF4 in turn transactivates genes involved in amino acid metabolism , redox reactions , and stress response .", "labels": [[0, 5, "GGP"], [46, 57, "CHEBI"], [28, 34, "ENTITY"], [46, 57, "CHEMICAL"], [0, 5, "ENTITY"], [0, 5, "PROTEIN"], [46, 57, "AMINO_ACID"], [88, 99, "ENTITY"], [70, 76, "ENTITY"], [13, 28, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [28, 34, "SO"], [46, 68, "ENTITY"]]}
{"text": "The virions budded into the ERGIC are exported through secretory pathway in smooth-wall vesicles , which ultimately fuse with the plasma membrane and release the mature virus particles ( Krijnse-Locker et al. , 1994 ) .", "labels": [[28, 34, "PROTEIN"], [55, 65, "CELLULAR_COMPONENT"], [130, 137, "CELLULAR_COMPONENT"], [88, 97, "GO"], [130, 137, "ENTITY"], [55, 73, "ENTITY"], [12, 19, "ENTITY"], [4, 12, "ENTITY"], [4, 19, "CELLULAR_COMPONENT"], [76, 97, "MULTI-TISSUE_STRUCTURE"], [28, 34, "CELLULAR_COMPONENT"], [169, 175, "ORGANISM"], [169, 175, "ENTITY"], [76, 97, "ENTITY"], [130, 137, "GO"], [28, 34, "ENTITY"]]}
{"text": "The late endosomes , autophagosomes , and the early secretary pathway have all been implicated as the membrane source of DMVs ( vander Meer et al. , 1999;Prentice et al. , 2004;Verheije et al. , 2008 ) .", "labels": [[4, 19, "CELLULAR_COMPONENT"], [143, 149, "CHEMICAL"], [4, 19, "ENTITY"], [143, 149, "SIMPLE_CHEMICAL"], [4, 19, "GO"], [42, 52, "ENTITY"]]}
{"text": "The abundant membrane ( M ) proteins give the virion its shape , whereas the small envelope(E ) proteins play an essential role during assembly ( Sturmanetal.,1980 ; Liu and Inglis , 1991 ) . Inside the envelope , the helical nucleocapsid is formed by binding of the nucleocapsid(N ) proteins on the genomicRNA in a beads-on-a-string fashion .", "labels": [[13, 22, "GO"], [135, 146, "GENE_OR_GENE_PRODUCT"], [252, 267, "ENTITY"], [284, 296, "CHEBI"], [252, 267, "PROTEIN"], [146, 174, "ENTITY"], [284, 296, "ENTITY"], [135, 146, "ENTITY"], [83, 96, "CHEBI"], [203, 226, "PROTEIN"], [4, 13, "ENTITY"], [13, 22, "CELLULAR_COMPONENT"], [203, 226, "ENTITY"], [192, 199, "ENTITY"], [83, 96, "ENTITY"], [300, 316, "ENTITY"], [13, 22, "ENTITY"]]}
{"text": "Coronavirus infection starts with receptor binding via the S protein ( Figure1 ) .", "labels": [[0, 12, "TAXON"], [0, 12, "ORGANISM"], [61, 69, "CHEBI"], [59, 69, "ENTITY"], [59, 69, "PROTEIN"], [0, 22, "ENTITY"], [0, 22, "DISEASE"], [34, 51, "ENTITY"]]}
{"text": "The S proteins of most coronaviruses are cleaved by host protease into two functional subunits : an N-terminal receptor binding domain ( S1 ) and a C-terminal domain(S2 ) responsible for membrane fusion ( Huang et al. , 2006;Qiuet al. , 2006;Yamada et al. , 2009 ) .", "labels": [[23, 37, "PROTEIN"], [100, 128, "ENTITY"], [4, 15, "ENTITY"], [183, 196, "ENTITY"], [23, 37, "TAXON"], [100, 128, "PROTEIN"], [4, 15, "PROTEIN"], [23, 37, "ORGANISM"], [52, 66, "ENTITY"], [75, 95, "ENTITY"], [23, 37, "ENTITY"], [146, 159, "ENTITY"], [52, 66, "PROTEIN"], [6, 15, "CHEBI"]]}
{"text": "This close juxtaposition of the viral and cellular membrane enables fusion of the lipid bilayers , and the viral nucleocapsid is thus delivered into the cytoplasm ( Masters,2006 ) .", "labels": [[68, 75, "ENTITY"], [11, 25, "ENTITY"], [42, 60, "CELLULAR_COMPONENT"], [32, 38, "ENTITY"], [82, 97, "CELLULAR_COMPONENT"], [32, 38, "TAXON"], [82, 88, "CHEBI"], [32, 38, "ENTITY"], [42, 60, "CL"], [42, 60, "ENTITY"], [32, 38, "PROTEIN"], [82, 97, "ENTITY"]]}
{"text": "After uncoating , the genomic RNA first acts as an mRNA for translation of the replicase polyprotein .", "labels": [[79, 89, "PROTEIN"], [6, 16, "ENTITY"], [22, 30, "SO"], [22, 30, "RNA"], [22, 30, "ENTITY"], [79, 89, "ENTITY"]]}
{"text": "GICA possessed a relatively higher positive rate in serum IgM detection ( 5/10 , 5/13 , and 9/14 in the early , middle , and late stages , respectively ) and ELISA exhibited a comparatively higher positive rate in serum IgG testing ( 4/10 , 8/13 , and 12/14 in the early , middle , and late stages , respectively )", "labels": [[44, 52, "PROTEIN"], [44, 52, "ORGANISM_SUBSTANCE"], [206, 224, "ENTITY"], [104, 112, "ENTITY"], [52, 62, "ENTITY"], [28, 35, "ENTITY"], [112, 125, "ENTITY"], [28, 35, "ENTITY"], [0, 5, "GGP"], [58, 62, "PROTEIN"], [35, 49, "ENTITY"], [0, 5, "ENTITY"], [252, 261, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [52, 62, "ORGANISM_SUBSTANCE"], [62, 72, "ENTITY"], [121, 130, "ENTITY"], [0, 5, "PROTEIN"]]}
{"text": "As shown in Table 1 , at the early , middle and late stages of infection , the serum IgM antibody was detected in 6/10 , 7/13 , and 11/14 of cases , respectively ( at least one immunoassay was positive ) . Meanwhile , at the early and middle stages of infection , 5/10 and 10/13 cases demonstrated positive serum IgG results , whereas the serum IgG was detected in all cases ( 14/14 ) when it came to the late stage of infection", "labels": [[225, 235, "ENTITY"], [79, 85, "ENTITY"], [75, 89, "PROTEIN"], [20, 25, "ENTITY"], [132, 141, "ENTITY"], [307, 317, "ENTITY"], [102, 111, "ENTITY"], [48, 53, "DISEASE"], [53, 63, "ENTITY"], [75, 89, "ENTITY"], [85, 89, "GO"], [167, 177, "ENTITY"], [177, 193, "ENTITY"], [44, 53, "ENTITY"], [48, 53, "ENTITY"], [53, 63, "DISEASE"], [390, 401, "ENTITY"], [285, 298, "ENTITY"], [285, 298, "PROTEIN"], [285, 298, "ORGANISM_SUBSTANCE"], [75, 89, "ORGANISM_SUBSTANCE"]]}
{"text": "GICA possessed a relatively higher positive rate in serum IgM detection ( 5/10 , 5/13 , and 9/14 in the early , middle , and late stages , respectively ) and ELISA exhibited a comparatively higher positive rate in serum IgG testing ( 4/10 , 8/13 , and 12/14 in the early , middle , and late stages , respectively )", "labels": [[44, 52, "PROTEIN"], [44, 52, "ORGANISM_SUBSTANCE"], [206, 224, "ENTITY"], [104, 112, "ENTITY"], [52, 62, "ENTITY"], [28, 35, "ENTITY"], [112, 125, "ENTITY"], [28, 35, "ENTITY"], [0, 5, "GGP"], [58, 62, "PROTEIN"], [35, 49, "ENTITY"], [0, 5, "ENTITY"], [252, 261, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [52, 62, "ORGANISM_SUBSTANCE"], [62, 72, "ENTITY"], [121, 130, "ENTITY"], [0, 5, "PROTEIN"]]}
{"text": "It has been well established that NF-\u03baB is required for the induction of pro-inflammatory cytokines ( such as IL-6 and IL-8 ) and the early expression of IFN-\u03b2 during RNA virus infection ( Libermann and Baltimore,1990 ; Kunsch and Rosen,1993 ; Wang et al.,2010 ; Balachandran and Beg,2011 ; Basagoudanavar et al. , 2011 ) .", "labels": [[160, 177, "ENTITY"], [73, 90, "ENTITY"], [73, 100, "PROTEIN"], [34, 40, "DNA"], [160, 171, "SO"], [167, 177, "DISEASE"], [231, 244, "ORGANISM"], [263, 280, "CHEMICAL"], [280, 291, "GENE_OR_GENE_PRODUCT"], [252, 263, "ENTITY"], [60, 70, "ENTITY"], [90, 100, "ENTITY"], [263, 280, "GENE_OR_GENE_PRODUCT"], [203, 220, "ENTITY"], [34, 40, "ENTITY"], [34, 40, "GENE_OR_GENE_PRODUCT"], [134, 140, "ENTITY"], [34, 40, "CHEMICAL"], [263, 280, "ENTITY"]]}
{"text": "It has been well established that NF-\u03baB is required for the induction of pro-inflammatory cytokines ( such as IL-6 and IL-8 ) and the early expression of IFN-\u03b2 during RNA virus infection ( Libermann and Baltimore,1990 ; Kunsch and Rosen,1993 ; Wang et al.,2010 ; Balachandran and Beg,2011 ; Basagoudanavar et al. , 2011 ) .", "labels": [[160, 177, "ENTITY"], [73, 90, "ENTITY"], [73, 100, "PROTEIN"], [34, 40, "DNA"], [160, 171, "SO"], [167, 177, "DISEASE"], [231, 244, "ORGANISM"], [263, 280, "CHEMICAL"], [280, 291, "GENE_OR_GENE_PRODUCT"], [252, 263, "ENTITY"], [60, 70, "ENTITY"], [90, 100, "ENTITY"], [263, 280, "GENE_OR_GENE_PRODUCT"], [203, 220, "ENTITY"], [34, 40, "ENTITY"], [34, 40, "GENE_OR_GENE_PRODUCT"], [134, 140, "ENTITY"], [34, 40, "CHEMICAL"], [263, 280, "ENTITY"]]}
{"text": "In its inactive form , NF-\u03baB is sequestered in the cytoplasm by inhibitor of NF-\u03baB alpha ( I\u03baB\u03b1 ) , which masks the nuclear localization signal of NF-\u03baB(Karin and Ben-Neriah , 2000 ) .", "labels": [[114, 126, "ENTITY"], [53, 63, "GO"], [34, 46, "ENTITY"], [25, 31, "DNA"], [25, 31, "ENTITY"], [66, 76, "CHEBI"], [79, 91, "DNA"], [79, 91, "GGP"], [25, 31, "GGP"], [161, 178, "GENE_OR_GENE_PRODUCT"], [25, 31, "CHEMICAL"], [79, 91, "GENE_OR_GENE_PRODUCT"], [79, 91, "ENTITY"], [25, 31, "SIMPLE_CHEMICAL"], [53, 63, "ORGANISM_SUBSTANCE"], [53, 63, "ENTITY"], [9, 18, "ENTITY"], [79, 91, "CHEMICAL"], [66, 76, "ENTITY"]]}
{"text": "DPP4 plays also an important role in immune regulation by activating T cells and upregulating CD86 expression and NF-\u03baB pathway .", "labels": [[94, 99, "GENE_OR_GENE_PRODUCT"], [69, 77, "CL"], [94, 99, "ENTITY"], [99, 110, "ENTITY"], [37, 55, "ENTITY"], [58, 77, "ENTITY"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [69, 77, "CELL_TYPE"], [69, 77, "CELL"], [0, 5, "PROTEIN"], [81, 94, "ENTITY"], [0, 5, "ENTITY"], [94, 99, "PROTEIN"], [114, 120, "DNA"], [114, 120, "CHEMICAL"], [114, 120, "GENE_OR_GENE_PRODUCT"], [114, 128, "ENTITY"]]}
{"text": "We previously demonstrated that the influenza virus M2 protein ( a proton-selective ion channel ) , its H37 G mutant ( which has lost its proton selectivity and enables the transport of other cations such as Na + and K + ) , and the EMCV 2B protein ( a Ca 2 + channel ) stimulates NLRP3 inflammasome-mediated IL-1\u03b2 secretion ( Ichinohe et al. , 2010 ; Ito et al. , 2012 ) .", "labels": [[241, 260, "PROTEIN"], [200, 208, "SIMPLE_CHEMICAL"], [46, 52, "TAXON"], [233, 241, "CHEBI"], [67, 88, "ENTITY"], [55, 63, "CHEBI"], [88, 98, "ENTITY"], [200, 208, "ENTITY"], [100, 110, "ENTITY"], [104, 110, "SO"], [225, 241, "ENTITY"], [36, 63, "PROTEIN"], [225, 233, "ORGANISM"], [67, 88, "PROTEIN"], [100, 110, "PROTEIN"], [200, 213, "PROTEIN"], [55, 63, "CHEMICAL"], [270, 287, "ENTITY"], [225, 241, "PROTEIN"], [200, 208, "CHEBI"], [36, 63, "ENTITY"], [287, 315, "ENTITY"], [241, 260, "ENTITY"], [134, 145, "ENTITY"]]}
{"text": "Key viral-cellular PPIs that may influence the pathogenesis of SARS-CoV-2 include interaction between NKRF ( an endogenous repressor of IL-8/IL-6 synthesis ) and nsp9/nsp10/nsp12/nsp13/nsp15 20,21 , C1QBP ( involved in complement C1 activation ) and nsp9/nsp10 22 , G3BP2 ( anti-viral stress granule protein ) and N 23 , and RAE1 ( an interferon-inducible mRNA nuclear export protein ) and ORF6 24 .", "labels": [[158, 191, "DNA"], [300, 310, "GENE_OR_GENE_PRODUCT"], [4, 19, "ENTITY"], [335, 361, "CHEBI"], [369, 376, "CHEBI"], [102, 107, "ENTITY"], [63, 74, "GENE_OR_GENE_PRODUCT"], [47, 60, "ENTITY"], [63, 74, "ENTITY"], [33, 43, "ENTITY"], [158, 191, "ENTITY"], [266, 300, "PROTEIN"], [325, 335, "GENE_OR_GENE_PRODUCT"], [102, 107, "GENE_OR_GENE_PRODUCT"], [266, 300, "CL"], [19, 24, "ENTITY"], [300, 314, "ENTITY"], [325, 335, "ENTITY"], [63, 74, "CHEMICAL"], [300, 310, "DNA"], [82, 94, "ENTITY"], [266, 300, "ENTITY"], [216, 233, "ENTITY"], [335, 361, "CELLULAR_COMPONENT"], [325, 376, "PROTEIN"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "It was previously shown that thalidomide enhances TCR-mediated T cells activation by by-passing T cell need for co-stimulation by accessory molecules , such as the B7 protein together with the CD28 protein , and therefore can overcome T cell deficiency 25 .", "labels": [[226, 237, "CL"], [29, 41, "ENTITY"], [226, 237, "CELL"], [63, 71, "CL"], [140, 150, "CHEBI"], [63, 70, "CL"], [50, 71, "CELL_TYPE"], [63, 70, "CELL_TYPE"], [71, 82, "ENTITY"], [112, 127, "ENTITY"], [130, 150, "ENTITY"], [193, 198, "PROTEIN"], [193, 198, "ENTITY"], [164, 167, "PROTEIN"], [130, 150, "PROTEIN"], [29, 41, "CHEMICAL"], [63, 71, "CELL"], [29, 41, "SIMPLE_CHEMICAL"], [50, 71, "ENTITY"], [85, 103, "ENTITY"], [29, 41, "CHEBI"], [63, 70, "CELL"], [164, 167, "ENTITY"], [226, 242, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "The late endosomes , autophagosomes , and the early secretary pathway have all been implicated as the membrane source of DMVs ( vander Meer et al. , 1999;Prentice et al. , 2004;Verheije et al. , 2008 ) .", "labels": [[4, 19, "CELLULAR_COMPONENT"], [143, 149, "CHEMICAL"], [4, 19, "GO"], [4, 19, "ENTITY"], [143, 149, "SIMPLE_CHEMICAL"], [42, 52, "ENTITY"]]}
{"text": "The late endosomes , autophagosomes , and the early secretary pathway have all been implicated as the membrane source of DMVs ( vander Meer et al. , 1999;Prentice et al. , 2004;Verheije et al. , 2008 ) .", "labels": [[4, 19, "CELLULAR_COMPONENT"], [143, 149, "CHEMICAL"], [4, 19, "ENTITY"], [143, 149, "SIMPLE_CHEMICAL"], [4, 19, "GO"], [42, 52, "ENTITY"]]}
{"text": "The late endosomes , autophagosomes , and the early secretary pathway have all been implicated as the membrane source of DMVs ( vander Meer et al. , 1999;Prentice et al. , 2004;Verheije et al. , 2008 ) .", "labels": [[4, 19, "CELLULAR_COMPONENT"], [143, 149, "CHEMICAL"], [4, 19, "ENTITY"], [143, 149, "SIMPLE_CHEMICAL"], [4, 19, "GO"], [42, 52, "ENTITY"]]}
{"text": "The EDEMosomes are COPII-independent vesicles that export from the ER , which are normally used to fine-tune the level of ER degradation enhancer , mannosidase alpha-like 1 ( degradation enhancer, mannosidase alpha-like 1 ) , a regulator of ER-associated degradation ( ERAD;Cal\u00ec et al. , 2008 ) . It has been demonstrated that MHV infection causes accumulation of degradation enhancer, mannosidase alpha-like 1 and osteosarcoma amplified 9 ( OS-9 , another EDEMosome cargo),and that both degradation enhancer, mannosidase alpha-like 1 and OS-9 co-localize with the RTCs of MHV ( Reggiori et al. , 2010 ) .", "labels": [[281, 290, "ENTITY"], [228, 247, "DISEASE"], [67, 70, "GENE_OR_GENE_PRODUCT"], [160, 171, "GGP"], [148, 160, "GENE_OR_GENE_PRODUCT"], [125, 137, "ENTITY"], [160, 171, "ENTITY"], [19, 46, "ENTITY"], [125, 137, "ENTITY"], [4, 15, "ENTITY"], [51, 58, "ENTITY"], [37, 46, "CELLULAR_COMPONENT"], [256, 268, "ENTITY"], [146, 171, "GGP"], [148, 160, "ENTITY"], [148, 160, "PROTEIN"], [-1, 21, "GENE_OR_GENE_PRODUCT"], [-1, 21, "ENTITY"], [67, 70, "ENTITY"], [241, 247, "ENTITY"], [181, 187, "GENE_OR_GENE_PRODUCT"], [160, 171, "PROTEIN"], [146, 171, "GENE_OR_GENE_PRODUCT"], [146, 171, "PROTEIN"], [148, 160, "GGP"], [-1, 21, "GO"], [281, 307, "GENE_OR_GENE_PRODUCT"], [228, 238, "TAXON"], [160, 171, "GENE_OR_GENE_PRODUCT"], [281, 290, "DISEASE"], [146, 171, "ENTITY"], [125, 137, "DNA"], [228, 238, "ORGANISM"], [160, 171, "ENTITY"], [4, 15, "PROTEIN"], [67, 70, "PROTEIN"], [4, 15, "GENE_OR_GENE_PRODUCT"], [181, 187, "ENTITY"], [360, 367, "SIMPLE_CHEMICAL"], [122, 137, "DNA"], [228, 238, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "The binding of COVI-19 to the Toll Like Receptor ( TLR ) causes the release of pro-IL-1\u03b2 which is cleaved by caspase-1 , followed by inflammasome activation and production of active mature IL-1\u03b2 which is a mediator of lung inflammation , fever and fibrosis .", "labels": [[15, 23, "ENTITY"], [223, 238, "ENTITY"], [30, 49, "ENTITY"], [130, 146, "ENTITY"], [215, 223, "DISEASE"], [182, 189, "PROTEIN"], [4, 12, "ENTITY"], [182, 189, "ENTITY"], [182, 189, "GENE_OR_GENE_PRODUCT"], [15, 23, "DNA"], [182, 189, "GGP"], [30, 49, "GENE_OR_GENE_PRODUCT"], [172, 182, "ENTITY"], [30, 49, "PROTEIN"], [223, 238, "DISEASE"], [215, 223, "ENTITY"], [15, 23, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "The late endosomes , autophagosomes , and the early secretary pathway have all been implicated as the membrane source of DMVs ( vander Meer et al. , 1999;Prentice et al. , 2004;Verheije et al. , 2008 ) .", "labels": [[4, 19, "CELLULAR_COMPONENT"], [143, 149, "CHEMICAL"], [4, 19, "GO"], [4, 19, "ENTITY"], [143, 149, "SIMPLE_CHEMICAL"], [42, 52, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "According to Zhou and colleagues , in coronaviruses , teicoplanin acts on the early step of the viral life cycle by inhibiting the low pH cleavage of the viral spike protein by cathepsin L in the late endosomes thereby preventing the release of genomic viral RNA and the continuation of virus replication cycle .", "labels": [[150, 166, "ENTITY"], [13, 18, "ENTITY"], [160, 166, "CHEBI"], [174, 187, "GENE_OR_GENE_PRODUCT"], [22, 33, "ENTITY"], [242, 259, "ENTITY"], [192, 201, "CELLULAR_COMPONENT"], [174, 187, "ENTITY"], [174, 187, "GGP"], [174, 187, "PROTEIN"], [150, 166, "PROTEIN"], [192, 201, "GO"], [135, 138, "ENTITY"], [131, 135, "ENTITY"], [242, 259, "SO"], [92, 107, "ENTITY"], [242, 259, "RNA"], [284, 305, "ENTITY"], [192, 201, "ENTITY"]]}
{"text": "The late endosomes , autophagosomes , and the early secretary pathway have all been implicated as the membrane source of DMVs ( vander Meer et al. , 1999;Prentice et al. , 2004;Verheije et al. , 2008 ) .", "labels": [[4, 19, "CELLULAR_COMPONENT"], [143, 149, "CHEMICAL"], [4, 19, "ENTITY"], [143, 149, "SIMPLE_CHEMICAL"], [4, 19, "GO"], [42, 52, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "The entry of SARS-CoV into human host cells is mediated mainly by a cellular receptor angiotensin-converting enzyme 2 ( ACE2 ) , which is expressed in human airway epithelia , lung parenchyma , vascular endothelia , kidney cells , and small intestine cells 23 - 25 .", "labels": [[13, 22, "ORGANISM"], [27, 44, "TAXON"], [27, 33, "ENTITY"], [27, 44, "CELL_TYPE"], [203, 223, "CELL_TYPE"], [148, 164, "ORGANISM"], [181, 203, "ENTITY"], [4, 10, "ENTITY"], [229, 251, "CELL_TYPE"], [13, 22, "PROTEIN"], [68, 118, "ENTITY"], [27, 33, "ENTITY"], [203, 223, "ENTITY"], [13, 22, "GGP"], [68, 118, "GENE_OR_GENE_PRODUCT"], [68, 77, "CL"], [164, 181, "ENTITY"], [13, 22, "ENTITY"], [181, 203, "CELL_TYPE"], [164, 181, "MULTI-TISSUE_STRUCTURE"], [27, 44, "ORGANISM"], [68, 118, "PROTEIN"], [229, 241, "CELL"], [33, 44, "ENTITY"], [203, 223, "CELL"], [157, 164, "ENTITY"], [216, 223, "CL"], [181, 203, "TISSUE"], [229, 241, "ENTITY"]]}
{"text": "Thus , for SARS-CoV pathogenesis , ACE2 is not only the entry receptor of the virus but also protects from lung injury .", "labels": [[52, 62, "ENTITY"], [102, 112, "ENTITY"], [102, 112, "DISEASE"]]}
{"text": "Thus , treatment with a soluble form of ACE2 itself may exert dual functions : ( 1 ) slow viral entry into cells and hence viral spread [ 7 , 9 ] and ( 2 ) protect the lung from injury [ 10 , 12 , 31 , 32 ]", "labels": [[85, 90, "TAXON"], [168, 173, "ENTITY"], [117, 129, "ENTITY"], [156, 164, "ENTITY"], [156, 164, "ORGAN"], [62, 67, "ENTITY"], [85, 96, "ENTITY"]]}
{"text": "Thus , for SARS-CoV pathogenesis , ACE2 is not only the entry receptor of the virus but also protects from lung injury .", "labels": [[52, 62, "ENTITY"], [102, 112, "ENTITY"], [102, 112, "DISEASE"]]}
{"text": "Indeed , enhanced ACE activity and decreased ACE2 availability contribute to lung injury during acid- and ventilator-induced lung injury [ 12 , 31 , 32 ] .", "labels": [[106, 130, "ENTITY"], [96, 102, "ENTITY"], [77, 82, "DISEASE"], [77, 82, "ENTITY"], [106, 130, "DISEASE"]]}
{"text": "Thus , treatment with a soluble form of ACE2 itself may exert dual functions : ( 1 ) slow viral entry into cells and hence viral spread [ 7 , 9 ] and ( 2 ) protect the lung from injury [ 10 , 12 , 31 , 32 ]", "labels": [[85, 90, "TAXON"], [168, 173, "ENTITY"], [117, 129, "ENTITY"], [156, 164, "ENTITY"], [156, 164, "ORGAN"], [62, 67, "ENTITY"], [85, 96, "ENTITY"]]}
{"text": "Therefore , higher ACE2 expression following chronically medicating SARS-CoV-2 infected patients with AT1R blockers , while seemingly paradoxical , may protect them against acute lung injury rather than putting them at higher risk to develop SARS .", "labels": [[234, 242, "ENTITY"], [234, 242, "DISEASE"], [124, 134, "ENTITY"], [102, 107, "GGP"], [165, 184, "DISEASE"], [102, 107, "ENTITY"], [12, 19, "ENTITY"], [45, 57, "ENTITY"], [173, 179, "ORGAN"], [102, 107, "GENE_OR_GENE_PRODUCT"], [165, 184, "ENTITY"]]}
{"text": "By contract , ACE2 inactivates angiotensin II while generating angiotensin 1\u20137 , a heptapeptide having a potent vasodilator function via activation of its Mas receptor ( Santos et al. , 2003 ) , and thus serving as a negative regulator of the renin \u2013 angiotensin system .", "labels": [[151, 159, "ENTITY"], [31, 43, "ENTITY"], [31, 43, "PROTEIN"], [31, 43, "CHEMICAL"], [31, 43, "CHEMICAL"], [217, 226, "ENTITY"], [236, 243, "ENTITY"], [212, 217, "ENTITY"], [31, 43, "ENTITY"], [31, 43, "GGP"], [151, 159, "PROTEIN"], [105, 124, "ENTITY"], [3, 12, "ENTITY"], [31, 43, "GENE_OR_GENE_PRODUCT"], [236, 251, "GENE_OR_GENE_PRODUCT"], [31, 43, "SIMPLE_CHEMICAL"], [31, 43, "PROTEIN"], [151, 159, "GENE_OR_GENE_PRODUCT"], [243, 251, "CHEMICAL"]]}
{"text": "It has been demonstrated that the binding of the coronavirus spike protein to ACE2 , its cellular binding site , leads to ACE2 downregulation , which in turn results in excessive production of angiotensin by the related enzyme ACE , while less ACE2 is capable of converting it to the vasodilator heptapeptide angiotensin 1\u20137 .", "labels": [[49, 61, "TAXON"], [49, 75, "PROTEIN"], [78, 83, "PROTEIN"], [78, 83, "ENTITY"], [296, 321, "CHEMICAL"], [212, 227, "ENTITY"], [169, 179, "ENTITY"], [153, 158, "ENTITY"], [280, 321, "ENTITY"], [49, 75, "ENTITY"], [67, 75, "CHEBI"], [78, 83, "ENTITY"], [78, 83, "GENE_OR_GENE_PRODUCT"], [49, 61, "ORGANISM"], [212, 220, "SO"], [34, 42, "ENTITY"], [78, 83, "GGP"], [280, 321, "GENE_OR_GENE_PRODUCT"], [220, 227, "GENE_OR_GENE_PRODUCT"], [89, 106, "ENTITY"], [89, 106, "DNA"]]}
{"text": "This may be accounted for by two complementary mechanisms : blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection , as well as upregulating ACE2 , thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1\u20137 .", "labels": [[134, 140, "ENTITY"], [191, 200, "GGP"], [163, 176, "GGP"], [163, 176, "GENE_OR_GENE_PRODUCT"], [83, 95, "ENTITY"], [47, 58, "ENTITY"], [263, 291, "ENTITY"], [163, 176, "PROTEIN"], [191, 200, "ENTITY"], [163, 176, "ENTITY"], [267, 291, "CHEMICAL"], [134, 140, "DISEASE"], [191, 200, "CHEMICAL"], [263, 291, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In contrast , ACE2 counteracts the RAS cascade by providing inhibitory control over Ang II . It does this via two primary mechanisms . First , ACE2 directly catalyzes Ang I and Ang II , depleting their levels [ 17 ] .", "labels": [[135, 143, "GGP"], [114, 122, "ENTITY"], [84, 88, "ENTITY"], [84, 88, "GENE_OR_GENE_PRODUCT"], [157, 167, "GENE_OR_GENE_PRODUCT"], [60, 71, "ENTITY"], [181, 186, "ENTITY"], [135, 143, "PROTEIN"], [157, 167, "GGP"], [135, 143, "ENTITY"], [157, 167, "ENTITY"], [84, 88, "PROTEIN"], [157, 177, "PROTEIN"], [135, 143, "GENE_OR_GENE_PRODUCT"]]}
{"text": "This could lead to toxic Ang II overaccumulation , and several pathologic sequelae such as ARDS or fulminant myocarditis may follow .", "labels": [[19, 25, "ENTITY"], [63, 74, "ENTITY"], [32, 49, "ENTITY"], [25, 32, "GENE_OR_GENE_PRODUCT"], [25, 32, "ENTITY"], [19, 25, "CHEBI"], [99, 109, "ENTITY"]]}
{"text": "The inhalation of acidic gas significantly increased the levels of Ang II in the lung and plasma of wild-type mice , and the levels of Ang II in the lung and plasma of acid-induced ACE2 knockout ( ACE2 KO ) mice were further increased .", "labels": [[90, 97, "ORGANISM_SUBSTANCE"], [67, 74, "ENTITY"], [67, 71, "PROTEIN"], [110, 115, "TAXON"], [18, 29, "ENTITY"], [90, 97, "ENTITY"], [67, 71, "CHEMICAL"], [67, 71, "GGP"], [100, 115, "ENTITY"], [67, 74, "GENE_OR_GENE_PRODUCT"], [4, 15, "ENTITY"], [110, 115, "ORGANISM"], [168, 186, "ENTITY"], [67, 74, "GGP"], [67, 74, "CHEMICAL"], [81, 86, "ORGAN"], [43, 53, "ENTITY"], [57, 64, "ENTITY"], [67, 71, "ENTITY"], [81, 86, "ENTITY"], [18, 25, "CHEBI"], [67, 71, "GENE_OR_GENE_PRODUCT"], [67, 74, "PROTEIN"]]}
{"text": "ACE2 has a protective effect on many diseases with reduced expression of ACE2 , such as hypertension , diabetes , and cardiovascular diseases , because it antagonizes the role of Ang II .", "labels": [[0, 5, "GGP"], [59, 70, "ENTITY"], [0, 5, "PROTEIN"], [37, 46, "ENTITY"], [0, 5, "ENTITY"], [114, 133, "DISEASE"], [114, 133, "ENTITY"], [0, 5, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [0, 5, "PROTEIN"], [11, 29, "ENTITY"], [51, 59, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Studies have shown that the protective mechanism of ACE2 against hypertension is most likely achieved by degradation of Ang II26 .", "labels": [[0, 8, "ENTITY"], [52, 57, "ENTITY"], [120, 129, "ENTITY"], [52, 57, "PROTEIN"], [120, 129, "GENE_OR_GENE_PRODUCT"], [28, 49, "ENTITY"], [52, 57, "GGP"], [65, 78, "ENTITY"], [120, 129, "PROTEIN"], [105, 117, "ENTITY"], [52, 57, "GENE_OR_GENE_PRODUCT"], [65, 78, "DISEASE"]]}
{"text": "By contract , ACE2 inactivates angiotensin II while generating angiotensin 1\u20137 , a heptapeptide having a potent vasodilator function via activation of its Mas receptor ( Santos et al. , 2003 ) , and thus serving as a negative regulator of the renin \u2013 angiotensin system .", "labels": [[151, 159, "ENTITY"], [31, 43, "ENTITY"], [31, 43, "PROTEIN"], [31, 43, "CHEMICAL"], [31, 43, "CHEMICAL"], [217, 226, "ENTITY"], [236, 243, "ENTITY"], [212, 217, "ENTITY"], [31, 43, "ENTITY"], [31, 43, "GGP"], [151, 159, "PROTEIN"], [105, 124, "ENTITY"], [3, 12, "ENTITY"], [31, 43, "GENE_OR_GENE_PRODUCT"], [236, 251, "GENE_OR_GENE_PRODUCT"], [31, 43, "SIMPLE_CHEMICAL"], [31, 43, "PROTEIN"], [151, 159, "GENE_OR_GENE_PRODUCT"], [243, 251, "CHEMICAL"]]}
{"text": "In humans the renin-angiotensin system is the hormone system which regulates blood pressure and vascular resistances , as well as electrolytic balance ; within this important system , the angiotensin-converting enzyme ( ACE ) , present on the surface of vascular endothelial cells , in particular those of the lungs , is deputed to the conversion of angiotensin I to angiotensin II ( AII ) , a potent vasoconstrictive peptide [ 1 ] .", "labels": [[184, 211, "PROTEIN"], [350, 367, "ENTITY"], [20, 32, "ENTITY"], [336, 350, "CHEMICAL"], [336, 350, "GENE_OR_GENE_PRODUCT"], [130, 143, "ENTITY"], [243, 275, "CELL_TYPE"], [243, 275, "CELL"], [211, 220, "ENTITY"], [211, 220, "GENE_OR_GENE_PRODUCT"], [3, 10, "TAXON"], [336, 350, "GGP"], [243, 275, "ENTITY"], [336, 350, "ENTITY"], [165, 175, "ENTITY"], [184, 211, "GENE_OR_GENE_PRODUCT"], [188, 211, "SO"], [77, 92, "ENTITY"], [336, 367, "PROTEIN"], [390, 401, "ENTITY"], [390, 401, "CHEBI"], [77, 83, "ORGANISM_SUBSTANCE"], [350, 367, "GGP"], [184, 211, "ENTITY"], [20, 32, "GENE_OR_GENE_PRODUCT"], [329, 336, "ENTITY"], [96, 117, "ENTITY"], [243, 275, "CL"], [350, 367, "CHEMICAL"], [3, 10, "ORGANISM"], [14, 39, "ENTITY"], [236, 243, "CELLULAR_COMPONENT"], [3, 10, "ENTITY"], [350, 367, "GENE_OR_GENE_PRODUCT"], [67, 77, "ENTITY"], [46, 61, "ENTITY"], [96, 105, "MULTI-TISSUE_STRUCTURE"], [236, 243, "ENTITY"]]}
{"text": "Angiotensin-converting enzyme 2 ( ACE2 ) is a crucial component of the renin-angiotensin system ( RAS ) .", "labels": [[23, 30, "SO"], [67, 89, "ENTITY"], [67, 89, "GENE_OR_GENE_PRODUCT"], [0, 32, "GENE_OR_GENE_PRODUCT"], [0, 32, "PROTEIN"], [0, 32, "ENTITY"]]}
{"text": "Taken together , these observations suggest that chronic AT1R blockade results in ACE2 upregulation in both rats and humans .", "labels": [[57, 62, "ENTITY"]]}
{"text": "It has been demonstrated that the binding of the coronavirus spike protein to ACE2 , its cellular binding site , leads to ACE2 downregulation , which in turn results in excessive production of angiotensin by the related enzyme ACE , while less ACE2 is capable of converting it to the vasodilator heptapeptide angiotensin 1\u20137 .", "labels": [[49, 61, "TAXON"], [49, 75, "PROTEIN"], [78, 83, "PROTEIN"], [78, 83, "ENTITY"], [212, 227, "ENTITY"], [169, 179, "ENTITY"], [153, 158, "ENTITY"], [280, 321, "GENE_OR_GENE_PRODUCT"], [49, 75, "ENTITY"], [67, 75, "CHEBI"], [78, 83, "ENTITY"], [78, 83, "GENE_OR_GENE_PRODUCT"], [49, 61, "ORGANISM"], [212, 220, "SO"], [34, 42, "ENTITY"], [78, 83, "GGP"], [220, 227, "GENE_OR_GENE_PRODUCT"], [296, 321, "CHEMICAL"], [89, 106, "ENTITY"], [280, 321, "ENTITY"], [89, 106, "DNA"]]}
{"text": "This may be accounted for by two complementary mechanisms : blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection , as well as upregulating ACE2 , thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1\u20137 .", "labels": [[134, 140, "ENTITY"], [191, 200, "GGP"], [263, 291, "GENE_OR_GENE_PRODUCT"], [163, 176, "GGP"], [163, 176, "GENE_OR_GENE_PRODUCT"], [83, 95, "ENTITY"], [47, 58, "ENTITY"], [263, 291, "ENTITY"], [267, 291, "CHEMICAL"], [163, 176, "PROTEIN"], [191, 200, "ENTITY"], [163, 176, "ENTITY"], [134, 140, "DISEASE"], [191, 200, "CHEMICAL"]]}
{"text": "Moreover , antiserum raised against human ACE2 blocked SARS-S- and SARS-2-S- but not VSV-G- or MERS-S-driven entry ( Figure 3B ) .", "labels": [[115, 124, "ENTITY"], [36, 42, "ORGANISM"], [36, 42, "PROTEIN"], [36, 42, "GGP"]]}
{"text": "ACE2 in the gastrointestinal tract may underly early gastrointestinal symptoms such as nausea , vomiting , and diarrhea , and ACE2 in the heart may be related to cardiac damage and fulminant myocarditis that have been reported in COVID-19 [ 14,15 ] .", "labels": [[12, 35, "ORGAN"], [12, 29, "ORGAN"], [0, 5, "PROTEIN"], [177, 191, "ENTITY"], [12, 35, "DISEASE"], [159, 170, "ENTITY"], [12, 35, "ENTITY"], [0, 5, "ENTITY"], [159, 170, "DISEASE"], [177, 191, "DISEASE"], [227, 241, "GENE_OR_GENE_PRODUCT"], [87, 94, "ENTITY"], [0, 5, "GGP"], [87, 94, "DISEASE"], [53, 79, "ENTITY"], [53, 79, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "ACE2 in the gastrointestinal tract may underly early gastrointestinal symptoms such as nausea , vomiting , and diarrhea , and ACE2 in the heart may be related to cardiac damage and fulminant myocarditis that have been reported in COVID-19 [ 14,15 ] .", "labels": [[12, 35, "ORGAN"], [87, 94, "DISEASE"], [12, 29, "ORGAN"], [87, 94, "ENTITY"], [0, 5, "PROTEIN"], [177, 191, "ENTITY"], [12, 35, "DISEASE"], [159, 170, "ENTITY"], [12, 35, "ENTITY"], [0, 5, "ENTITY"], [159, 170, "DISEASE"], [177, 191, "DISEASE"], [227, 241, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [53, 79, "ENTITY"], [53, 79, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "ACE2 in the gastrointestinal tract may underly early gastrointestinal symptoms such as nausea , vomiting , and diarrhea , and ACE2 in the heart may be related to cardiac damage and fulminant myocarditis that have been reported in COVID-19 [ 14,15 ] .", "labels": [[12, 35, "ORGAN"], [87, 94, "DISEASE"], [12, 29, "ORGAN"], [87, 94, "ENTITY"], [0, 5, "PROTEIN"], [177, 191, "ENTITY"], [12, 35, "DISEASE"], [159, 170, "ENTITY"], [12, 35, "ENTITY"], [0, 5, "ENTITY"], [159, 170, "DISEASE"], [177, 191, "DISEASE"], [227, 241, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [53, 79, "ENTITY"], [53, 79, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "ACE2 in the gastrointestinal tract may underly early gastrointestinal symptoms such as nausea , vomiting , and diarrhea , and ACE2 in the heart may be related to cardiac damage and fulminant myocarditis that have been reported in COVID-19 [ 14,15 ] .", "labels": [[12, 35, "ORGAN"], [87, 94, "DISEASE"], [12, 29, "ORGAN"], [87, 94, "ENTITY"], [0, 5, "PROTEIN"], [177, 191, "ENTITY"], [12, 35, "DISEASE"], [159, 170, "ENTITY"], [12, 35, "ENTITY"], [0, 5, "ENTITY"], [159, 170, "DISEASE"], [177, 191, "DISEASE"], [227, 241, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [53, 79, "ENTITY"], [53, 79, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In contrast , ACE2 counteracts the RAS cascade by providing inhibitory control over Ang II . It does this via two primary mechanisms . First , ACE2 directly catalyzes Ang I and Ang II , depleting their levels [ 17 ] .", "labels": [[135, 143, "GGP"], [114, 122, "ENTITY"], [84, 88, "ENTITY"], [84, 88, "GENE_OR_GENE_PRODUCT"], [157, 167, "GENE_OR_GENE_PRODUCT"], [60, 71, "ENTITY"], [181, 186, "ENTITY"], [135, 143, "PROTEIN"], [157, 167, "GGP"], [135, 143, "ENTITY"], [157, 167, "ENTITY"], [84, 88, "PROTEIN"], [157, 177, "PROTEIN"], [135, 143, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Indeed , increased ACE2 levels are seen in multiple cardiovascular conditions and related comorbidities such as diabetes and hypertension [ 8,18,25 ] .", "labels": []}
{"text": "Indeed , increased ACE2 levels are seen in multiple cardiovascular conditions and related comorbidities such as diabetes and hypertension [ 8,18,25 ] .", "labels": []}
{"text": "Indeed , increased ACE2 levels are seen in multiple cardiovascular conditions and related comorbidities such as diabetes and hypertension [ 8,18,25 ] .", "labels": []}
{"text": "For this , both ACE and AII have been widely exploited as pharmacological targets in the treatment of hypertension , heart failure or diabetic nephropathy by means of ACE inhibitors and AII receptor antagonists , respectively [ 1 ] .", "labels": [[182, 199, "GENE_OR_GENE_PRODUCT"], [16, 20, "CHEBI"], [115, 123, "DISEASE"], [164, 171, "ENTITY"], [131, 143, "DISEASE"], [131, 143, "ENTITY"], [115, 123, "ENTITY"], [20, 28, "GGP"], [182, 199, "ENTITY"]]}
{"text": "Not only has ACE2 facilitated the invasion of SARS virus for rapid replication , but also ACE2 is depleted from the cell membrane and therefore the damaging effects of Ang II are enhanced , resulting in acute deterioration of lung tissues [ 5 ] .", "labels": [[51, 57, "TAXON"], [223, 231, "TISSUE"], [223, 231, "ENTITY"], [148, 157, "ENTITY"], [168, 172, "GGP"], [13, 18, "ENTITY"], [116, 121, "CL"], [46, 51, "DISEASE"], [13, 18, "PROTEIN"], [46, 57, "ORGANISM"], [61, 67, "ENTITY"], [168, 172, "PROTEIN"], [168, 172, "CHEMICAL"], [34, 43, "ENTITY"], [46, 57, "ENTITY"], [67, 79, "ENTITY"], [168, 172, "GENE_OR_GENE_PRODUCT"], [116, 121, "CELLULAR_COMPONENT"], [13, 18, "GGP"], [13, 18, "GENE_OR_GENE_PRODUCT"], [116, 121, "ENTITY"], [200, 209, "ENTITY"], [168, 172, "ENTITY"]]}
{"text": "The angiotensin-converting 1 ( ACE1 ) enzyme is characterized by a genetic deletion/insertion ( D/I ) polymorphism in intron 16 , which is associated with alterations in circulating and tissue concentrations of ACE . The D allele is associated with a reduced expression of ACE2 .", "labels": [[259, 270, "GGP"], [259, 270, "GENE_OR_GENE_PRODUCT"], [65, 75, "ENTITY"], [215, 223, "ENTITY"], [4, 38, "DNA"], [223, 233, "ENTITY"], [155, 170, "ENTITY"], [251, 259, "ENTITY"], [4, 29, "GENE_OR_GENE_PRODUCT"], [259, 270, "ENTITY"], [193, 208, "GENE_OR_GENE_PRODUCT"], [96, 102, "ENTITY"], [193, 208, "ENTITY"], [65, 75, "SO"], [215, 223, "DNA"], [4, 29, "ENTITY"], [217, 223, "SO"], [130, 150, "ENTITY"], [259, 270, "PROTEIN"], [150, 157, "ENTITY"], [182, 193, "ENTITY"]]}
{"text": "For this , both ACE and AII have been widely exploited as pharmacological targets in the treatment of hypertension , heart failure or diabetic nephropathy by means of ACE inhibitors and AII receptor antagonists , respectively [ 1 ] .", "labels": [[182, 199, "GENE_OR_GENE_PRODUCT"], [16, 20, "CHEBI"], [164, 171, "ENTITY"], [115, 123, "DISEASE"], [131, 143, "ENTITY"], [20, 28, "GGP"], [131, 143, "DISEASE"], [115, 123, "ENTITY"], [182, 199, "ENTITY"]]}
{"text": "For this , both ACE and AII have been widely exploited as pharmacological targets in the treatment of hypertension , heart failure or diabetic nephropathy by means of ACE inhibitors and AII receptor antagonists , respectively [ 1 ] .", "labels": [[182, 199, "GENE_OR_GENE_PRODUCT"], [16, 20, "CHEBI"], [115, 123, "DISEASE"], [164, 171, "ENTITY"], [131, 143, "DISEASE"], [20, 28, "GGP"], [115, 123, "ENTITY"], [131, 143, "ENTITY"], [182, 199, "ENTITY"]]}
{"text": "ACE2 antagonizes the activation of the classical RAS system and protects against organ damage , protecting against hypertension , diabetes , and cardiovascular disease .", "labels": [[21, 32, "ENTITY"], [39, 60, "ENTITY"], [81, 94, "ENTITY"], [0, 5, "PROTEIN"], [5, 17, "ENTITY"], [64, 73, "ENTITY"], [0, 5, "ENTITY"], [49, 53, "GENE_OR_GENE_PRODUCT"], [81, 94, "DISEASE"], [81, 87, "ORGAN"], [141, 160, "ENTITY"], [0, 5, "GGP"], [141, 160, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "ARDS is a clinical high-mortality disease , and ACE2 has a protective effect on this type of acute lung injury .", "labels": [[93, 104, "DISEASE"], [10, 42, "ENTITY"], [0, 5, "DISEASE"], [93, 104, "ENTITY"], [0, 5, "ENTITY"], [59, 70, "ENTITY"]]}
{"text": "ACE2 is highly expressed in the lung , and Imai14 et al. confirmed the protective effect of ACE2 in acute lung injury .", "labels": [[0, 5, "PROTEIN"], [15, 25, "ENTITY"], [71, 82, "ENTITY"], [100, 111, "ENTITY"], [100, 111, "DISEASE"], [0, 5, "ENTITY"], [32, 37, "ENTITY"], [0, 5, "GGP"], [32, 37, "ORGAN"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Therefore , the downregulation of ACE2 expression in SARS-CoV infection may play a causal role in the pathogenesis of SARS , which provides a reasonable explanation for the progression of SARS patients into ARDS .", "labels": [[53, 62, "DISEASE"], [53, 58, "ENTITY"], [115, 123, "ORGANISM"], [53, 62, "ENTITY"]]}
{"text": "In diabetic nephropathy , downregulation of renal tubular ACE2 is associated with proteinuria and tubular damage32 , and further inhibition of ACE2 aggravates renal damage33 .", "labels": [[148, 165, "ENTITY"], [50, 58, "MULTI-TISSUE_STRUCTURE"], [44, 58, "ENTITY"], [50, 58, "ENTITY"], [148, 165, "PROTEIN"], [44, 58, "MULTI-TISSUE_STRUCTURE"], [3, 24, "DISEASE"], [148, 159, "MULTI-TISSUE_STRUCTURE"], [50, 58, "PROTEIN"], [3, 24, "ENTITY"]]}
{"text": "In diabetic nephropathy , downregulation of renal tubular ACE2 is associated with proteinuria and tubular damage32 , and further inhibition of ACE2 aggravates renal damage33 .", "labels": [[148, 165, "ENTITY"], [50, 58, "MULTI-TISSUE_STRUCTURE"], [44, 58, "ENTITY"], [50, 58, "ENTITY"], [148, 165, "PROTEIN"], [44, 58, "MULTI-TISSUE_STRUCTURE"], [3, 24, "DISEASE"], [148, 159, "MULTI-TISSUE_STRUCTURE"], [50, 58, "PROTEIN"], [3, 24, "ENTITY"]]}
{"text": "The expression of ACE2 decreases with increasing age .", "labels": [[49, 53, "ENTITY"], [23, 33, "ENTITY"], [4, 15, "ENTITY"], [18, 23, "GGP"], [18, 23, "GENE_OR_GENE_PRODUCT"], [18, 23, "ENTITY"], [18, 23, "PROTEIN"], [38, 49, "ENTITY"]]}
{"text": "RNA sequencing revealed that myocardial ACE2 expression was significantly increased in patients with heart failure ( Figure 1J , fold change = 3.00 , P<0.0001 ) , which was further validated at the protein level by proteomics profiling ( Figure 1 K , fold change=1.82 , P<0.0001 ) .", "labels": [[194, 206, "ENTITY"], [29, 45, "MULTI-TISSUE_STRUCTURE"], [101, 115, "ENTITY"], [101, 115, "DISEASE"], [249, 270, "CHEMICAL"], [127, 134, "GENE_OR_GENE_PRODUCT"], [40, 45, "ENTITY"], [40, 45, "PROTEIN"], [45, 56, "ENTITY"], [117, 124, "ENTITY"], [87, 96, "ORGANISM"], [101, 107, "ORGAN"], [29, 40, "ENTITY"], [0, 4, "SO"], [74, 84, "ENTITY"], [87, 96, "ENTITY"], [206, 226, "ENTITY"], [0, 15, "ENTITY"], [226, 238, "ENTITY"], [40, 45, "GGP"]]}
{"text": "ACE2 is a key counterregulatory enzyme that degrades angiotensin II to angiotensin-(1\u20137 ) , thereby attenuating its effects on vasoconstriction , sodium retention , and fibrosis . Although angiotensin II is the primary substrate of ACE2 , that enzyme also cleaves angiotensin I to angiotensin-(1\u20139 ) and participates in the hydrolysis of other peptides.16", "labels": [[256, 264, "ENTITY"], [53, 68, "PROTEIN"], [0, 5, "PROTEIN"], [256, 264, "GENE_OR_GENE_PRODUCT"], [207, 219, "ENTITY"], [14, 39, "ENTITY"], [53, 68, "ENTITY"], [14, 32, "GENE_OR_GENE_PRODUCT"], [219, 232, "ENTITY"], [44, 53, "ENTITY"], [53, 68, "CHEMICAL"], [219, 232, "PROTEIN"], [219, 232, "GGP"], [219, 232, "GENE_OR_GENE_PRODUCT"], [66, 71, "GENE_OR_GENE_PRODUCT"], [66, 71, "PROTEIN"], [32, 39, "SO"], [66, 71, "ENTITY"], [144, 153, "ENTITY"], [14, 39, "PROTEIN"], [53, 68, "GENE_OR_GENE_PRODUCT"], [256, 264, "PROTEIN"], [256, 264, "CHEMICAL"], [71, 88, "ENTITY"], [71, 88, "GENE_OR_GENE_PRODUCT"], [256, 264, "GGP"], [0, 5, "ENTITY"], [317, 324, "ENTITY"], [71, 88, "PROTEIN"], [0, 5, "GGP"], [53, 68, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "ACE2 is a key counterregulatory enzyme that degrades angiotensin II to angiotensin-(1\u20137 ) , thereby attenuating its effects on vasoconstriction , sodium retention , and fibrosis . Although angiotensin II is the primary substrate of ACE2 , that enzyme also cleaves angiotensin I to angiotensin-(1\u20139 ) and participates in the hydrolysis of other peptides.16", "labels": [[256, 264, "ENTITY"], [53, 68, "PROTEIN"], [0, 5, "PROTEIN"], [256, 264, "GENE_OR_GENE_PRODUCT"], [207, 219, "ENTITY"], [14, 39, "ENTITY"], [53, 68, "ENTITY"], [14, 32, "GENE_OR_GENE_PRODUCT"], [219, 232, "ENTITY"], [44, 53, "ENTITY"], [53, 68, "CHEMICAL"], [219, 232, "PROTEIN"], [219, 232, "GGP"], [219, 232, "GENE_OR_GENE_PRODUCT"], [66, 71, "GENE_OR_GENE_PRODUCT"], [66, 71, "PROTEIN"], [32, 39, "SO"], [66, 71, "ENTITY"], [144, 153, "ENTITY"], [14, 39, "PROTEIN"], [53, 68, "GENE_OR_GENE_PRODUCT"], [256, 264, "PROTEIN"], [256, 264, "CHEMICAL"], [71, 88, "ENTITY"], [71, 88, "GENE_OR_GENE_PRODUCT"], [256, 264, "GGP"], [0, 5, "ENTITY"], [317, 324, "ENTITY"], [71, 88, "PROTEIN"], [0, 5, "GGP"], [53, 68, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "As expected from prior literature , the AT2 cells showed highest ACE2 expression in the lung both in terms of their CPM values ( Fig. 1D , further referred to as ACE2 + cells ) and the percentage of positive cells ( Supp . Fig. 3 ) .", "labels": [[159, 169, "CELL_TYPE"], [185, 208, "ENTITY"], [199, 208, "CL"], [40, 44, "ENTITY"], [185, 208, "CELL_TYPE"], [159, 169, "GENE_OR_GENE_PRODUCT"], [159, 169, "ENTITY"], [208, 223, "CELL"], [40, 44, "CELL"], [17, 23, "ENTITY"], [199, 208, "CELL"], [159, 169, "GGP"], [40, 44, "CELL_TYPE"], [23, 34, "ENTITY"]]}
{"text": "We observed totally five diabetes-related traits that showed nominally significant MR results , and they were all positively associated with ACE2 expression .", "labels": [[83, 86, "PROTEIN"], [25, 42, "ENTITY"], [61, 83, "ENTITY"], [3, 12, "ENTITY"], [86, 94, "ENTITY"], [42, 49, "ENTITY"], [83, 86, "ENTITY"]]}
{"text": "We observed totally five diabetes-related traits that showed nominally significant MR results , and they were all positively associated with ACE2 expression .", "labels": [[83, 86, "PROTEIN"], [25, 42, "ENTITY"], [61, 83, "ENTITY"], [3, 12, "ENTITY"], [86, 94, "ENTITY"], [42, 49, "ENTITY"], [83, 86, "ENTITY"]]}
{"text": "Several neoplasms , such as breast and lung cancer , may be associated with increased ACE2 expression .", "labels": [[76, 86, "GENE_OR_GENE_PRODUCT"], [39, 44, "ENTITY"], [8, 18, "ENTITY"], [76, 86, "ENTITY"], [86, 91, "ENTITY"], [8, 18, "CANCER"], [76, 86, "GGP"], [39, 44, "CANCER"], [8, 18, "DISEASE"], [28, 44, "DISEASE"], [57, 71, "ENTITY"], [76, 86, "PROTEIN"]]}
{"text": "Several neoplasms , such as breast and lung cancer , may be associated with increased ACE2 expression .", "labels": [[76, 86, "GENE_OR_GENE_PRODUCT"], [39, 44, "ENTITY"], [8, 18, "ENTITY"], [76, 86, "ENTITY"], [86, 91, "ENTITY"], [8, 18, "CANCER"], [76, 86, "GGP"], [39, 44, "CANCER"], [8, 18, "DISEASE"], [28, 44, "DISEASE"], [57, 71, "ENTITY"], [76, 86, "PROTEIN"]]}
{"text": "We also observed that several autoimmune disorders , especially inflammatory bowel diseases may be casually associated with ACE2 expression .", "labels": [[8, 17, "ENTITY"], [64, 83, "ENTITY"], [30, 51, "DISEASE"], [30, 51, "ENTITY"], [64, 83, "DISEASE"]]}
{"text": "Interestingly , asthma and tobacco use also showed nominal significant associations with higher ACE2 expression .", "labels": []}
{"text": "Interestingly , asthma and tobacco use also showed nominal significant associations with higher ACE2 expression .", "labels": []}
{"text": "Other commonly measured blood measures that may lead to altered ACE2 expression also included red cell distribution width ( often associated with iron-deficiency , folate or B12 deficiency anemia ) , basophil percentage ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) , calcium level , urate level , HDL-cholesterol and LDL cholesterol ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) .", "labels": [[-1, 14, "ENTITY"], [277, 293, "CHEMICAL"], [94, 103, "CL"], [64, 69, "GGP"], [247, 255, "CHEBI"], [-1, 13, "CHEMICAL"], [247, 255, "SIMPLE_CHEMICAL"], [15, 24, "ENTITY"], [247, 255, "ENTITY"], [263, 269, "CHEBI"], [247, 255, "CHEMICAL"], [209, 222, "ENTITY"], [64, 69, "PROTEIN"], [-1, 13, "SIMPLE_CHEMICAL"], [171, 189, "ENTITY"], [263, 269, "CHEMICAL"], [-1, 13, "ENTITY"], [24, 30, "ORGANISM_SUBSTANCE"], [200, 209, "ENTITY"], [277, 293, "SIMPLE_CHEMICAL"], [94, 122, "ENTITY"], [-1, 14, "ENTITY"], [24, 39, "ENTITY"], [64, 69, "GENE_OR_GENE_PRODUCT"], [277, 293, "ENTITY"], [171, 189, "CHEMICAL"], [-1, 13, "CHEBI"], [263, 269, "SIMPLE_CHEMICAL"], [-1, 12, "ENTITY"], [64, 69, "ENTITY"], [69, 80, "ENTITY"], [255, 263, "ENTITY"], [94, 103, "CELL"]]}
{"text": "Other commonly measured blood measures that may lead to altered ACE2 expression also included red cell distribution width ( often associated with iron-deficiency , folate or B12 deficiency anemia ) , basophil percentage ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) , calcium level , urate level , HDL-cholesterol and LDL cholesterol ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) .", "labels": [[-1, 14, "ENTITY"], [277, 293, "CHEMICAL"], [64, 69, "GGP"], [-1, 13, "CHEMICAL"], [15, 24, "ENTITY"], [263, 269, "CHEBI"], [247, 255, "ENTITY"], [247, 255, "SIMPLE_CHEMICAL"], [247, 255, "CHEBI"], [94, 103, "CELL"], [209, 222, "ENTITY"], [64, 69, "PROTEIN"], [-1, 13, "SIMPLE_CHEMICAL"], [171, 189, "ENTITY"], [263, 269, "CHEMICAL"], [-1, 13, "ENTITY"], [24, 30, "ORGANISM_SUBSTANCE"], [200, 209, "ENTITY"], [277, 293, "SIMPLE_CHEMICAL"], [247, 255, "CHEMICAL"], [94, 122, "ENTITY"], [-1, 14, "ENTITY"], [24, 39, "ENTITY"], [64, 69, "GENE_OR_GENE_PRODUCT"], [94, 103, "CL"], [277, 293, "ENTITY"], [171, 189, "CHEMICAL"], [-1, 13, "CHEBI"], [263, 269, "SIMPLE_CHEMICAL"], [-1, 12, "ENTITY"], [64, 69, "ENTITY"], [69, 80, "ENTITY"], [255, 263, "ENTITY"]]}
{"text": "Other commonly measured blood measures that may lead to altered ACE2 expression also included red cell distribution width ( often associated with iron-deficiency , folate or B12 deficiency anemia ) , basophil percentage ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) , calcium level , urate level , HDL-cholesterol and LDL cholesterol ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) .", "labels": [[-1, 14, "ENTITY"], [277, 293, "CHEMICAL"], [64, 69, "GGP"], [247, 255, "CHEBI"], [-1, 13, "CHEMICAL"], [247, 255, "SIMPLE_CHEMICAL"], [15, 24, "ENTITY"], [247, 255, "ENTITY"], [263, 269, "CHEBI"], [247, 255, "CHEMICAL"], [94, 103, "CELL"], [209, 222, "ENTITY"], [64, 69, "PROTEIN"], [-1, 13, "SIMPLE_CHEMICAL"], [171, 189, "ENTITY"], [263, 269, "CHEMICAL"], [-1, 13, "ENTITY"], [24, 30, "ORGANISM_SUBSTANCE"], [200, 209, "ENTITY"], [277, 293, "SIMPLE_CHEMICAL"], [94, 122, "ENTITY"], [-1, 14, "ENTITY"], [24, 39, "ENTITY"], [64, 69, "GENE_OR_GENE_PRODUCT"], [94, 103, "CL"], [277, 293, "ENTITY"], [171, 189, "CHEMICAL"], [-1, 13, "CHEBI"], [263, 269, "SIMPLE_CHEMICAL"], [-1, 12, "ENTITY"], [64, 69, "ENTITY"], [69, 80, "ENTITY"], [255, 263, "ENTITY"]]}
{"text": "Other commonly measured blood measures that may lead to altered ACE2 expression also included red cell distribution width ( often associated with iron-deficiency , folate or B12 deficiency anemia ) , basophil percentage ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) , calcium level , urate level , HDL-cholesterol and LDL cholesterol ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) .", "labels": [[-1, 14, "ENTITY"], [277, 293, "CHEMICAL"], [64, 69, "GGP"], [247, 255, "CHEBI"], [-1, 13, "CHEMICAL"], [247, 255, "SIMPLE_CHEMICAL"], [15, 24, "ENTITY"], [247, 255, "ENTITY"], [263, 269, "CHEBI"], [247, 255, "CHEMICAL"], [94, 103, "CELL"], [209, 222, "ENTITY"], [64, 69, "PROTEIN"], [-1, 13, "SIMPLE_CHEMICAL"], [171, 189, "ENTITY"], [263, 269, "CHEMICAL"], [-1, 13, "ENTITY"], [24, 30, "ORGANISM_SUBSTANCE"], [200, 209, "ENTITY"], [277, 293, "SIMPLE_CHEMICAL"], [94, 122, "ENTITY"], [-1, 14, "ENTITY"], [24, 39, "ENTITY"], [64, 69, "GENE_OR_GENE_PRODUCT"], [94, 103, "CL"], [277, 293, "ENTITY"], [171, 189, "CHEMICAL"], [-1, 13, "CHEBI"], [263, 269, "SIMPLE_CHEMICAL"], [-1, 12, "ENTITY"], [64, 69, "ENTITY"], [69, 80, "ENTITY"], [255, 263, "ENTITY"]]}
{"text": "Other commonly measured blood measures that may lead to altered ACE2 expression also included red cell distribution width ( often associated with iron-deficiency , folate or B12 deficiency anemia ) , basophil percentage ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) , calcium level , urate level , HDL-cholesterol and LDL cholesterol ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) .", "labels": [[-1, 14, "ENTITY"], [277, 293, "CHEMICAL"], [64, 69, "GGP"], [247, 255, "CHEBI"], [-1, 13, "CHEMICAL"], [247, 255, "SIMPLE_CHEMICAL"], [15, 24, "ENTITY"], [247, 255, "ENTITY"], [263, 269, "CHEBI"], [247, 255, "CHEMICAL"], [94, 103, "CELL"], [209, 222, "ENTITY"], [64, 69, "PROTEIN"], [-1, 13, "SIMPLE_CHEMICAL"], [171, 189, "ENTITY"], [263, 269, "CHEMICAL"], [-1, 13, "ENTITY"], [24, 30, "ORGANISM_SUBSTANCE"], [200, 209, "ENTITY"], [277, 293, "SIMPLE_CHEMICAL"], [94, 122, "ENTITY"], [-1, 14, "ENTITY"], [24, 39, "ENTITY"], [64, 69, "GENE_OR_GENE_PRODUCT"], [94, 103, "CL"], [277, 293, "ENTITY"], [171, 189, "CHEMICAL"], [-1, 13, "CHEBI"], [263, 269, "SIMPLE_CHEMICAL"], [-1, 12, "ENTITY"], [64, 69, "ENTITY"], [69, 80, "ENTITY"], [255, 263, "ENTITY"]]}
{"text": "Some of top pathways include cytokine and cytokine receptor interaction , VEGFA-VEGF2 signaling pathway , JAS-STAT signaling pathway etc", "labels": [[60, 72, "ENTITY"], [8, 21, "ENTITY"], [29, 38, "PROTEIN"], [104, 125, "ENTITY"], [29, 38, "ENTITY"], [42, 60, "PROTEIN"], [42, 60, "ENTITY"], [74, 96, "ENTITY"]]}
{"text": "Some of top pathways include cytokine and cytokine receptor interaction , VEGFA-VEGF2 signaling pathway , JAS-STAT signaling pathway etc", "labels": [[60, 72, "ENTITY"], [8, 21, "ENTITY"], [29, 38, "PROTEIN"], [104, 125, "ENTITY"], [29, 38, "ENTITY"], [42, 60, "PROTEIN"], [42, 60, "ENTITY"], [74, 96, "ENTITY"]]}
{"text": "The model describing the docking molecules indicated that all of the 17 compounds in the garlic essential oil from T1-ACE2 to T17-ACE2 have the binding ability toward the areas affected by the ACE2 protein .", "labels": [[89, 96, "ORGANISM_SUBSTANCE"], [72, 82, "CHEBI"], [4, 10, "ENTITY"], [126, 135, "DNA"], [106, 110, "ORGANISM_SUBSTANCE"], [115, 123, "DNA"], [193, 206, "PROTEIN"], [33, 43, "CHEBI"], [144, 152, "ENTITY"], [89, 96, "ENTITY"], [72, 82, "ENTITY"], [193, 206, "ENTITY"], [126, 135, "ENTITY"], [118, 123, "GENE_OR_GENE_PRODUCT"], [115, 123, "CHEMICAL"], [193, 206, "GGP"], [171, 177, "ENTITY"], [115, 123, "ENTITY"], [25, 43, "ENTITY"], [126, 135, "GENE_OR_GENE_PRODUCT"], [177, 186, "ENTITY"], [25, 43, "PROTEIN"]]}
{"text": "ACE cleaves angiotensin I to generate angiotensin II , the peptide which binds to and activates AT1R to constrict blood vessels , thereby elevating blood pressure .", "labels": [[38, 53, "GENE_OR_GENE_PRODUCT"], [114, 120, "MULTI-TISSUE_STRUCTURE"], [12, 26, "GGP"], [38, 53, "ENTITY"], [38, 53, "CHEMICAL"], [12, 26, "CHEMICAL"], [138, 148, "ORGANISM_SUBSTANCE"], [0, 26, "GENE_OR_GENE_PRODUCT"], [38, 53, "GGP"], [12, 26, "ENTITY"], [38, 53, "PROTEIN"], [4, 12, "ENTITY"], [0, 4, "ENTITY"], [138, 154, "ENTITY"], [12, 26, "PROTEIN"], [114, 120, "ENTITY"]]}
{"text": "The generation of Ang II by ACE is pharmacologically inhibited by angiotensin converting enzyme inhibitors ( ACEi ) , and angiotensin receptor blockers ( ARBs ) function by blocking the downstream interaction of Ang II with the AT1 receptor [ 16 ] .", "labels": [[18, 25, "GGP"], [18, 25, "GENE_OR_GENE_PRODUCT"], [118, 143, "ENTITY"], [143, 154, "CHEMICAL"], [118, 143, "GGP"], [4, 15, "ENTITY"], [197, 212, "GGP"], [118, 143, "GENE_OR_GENE_PRODUCT"], [66, 78, "CHEMICAL"], [28, 32, "GGP"], [118, 143, "PROTEIN"], [28, 32, "GENE_OR_GENE_PRODUCT"], [186, 197, "ENTITY"], [66, 107, "GGP"], [197, 212, "ENTITY"], [143, 154, "ENTITY"], [18, 25, "PROTEIN"], [18, 25, "ENTITY"], [161, 173, "ENTITY"], [197, 212, "GENE_OR_GENE_PRODUCT"], [143, 154, "SIMPLE_CHEMICAL"], [224, 232, "GGP"], [35, 53, "ENTITY"], [66, 107, "PROTEIN"], [66, 107, "ENTITY"], [197, 212, "CHEMICAL"], [224, 232, "GENE_OR_GENE_PRODUCT"], [224, 232, "PROTEIN"], [224, 232, "ENTITY"], [197, 212, "PROTEIN"], [28, 32, "CHEMICAL"], [53, 63, "ENTITY"], [28, 32, "ENTITY"], [66, 109, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Studies have further demonstrated that Ang II plays a role in acute lung injury via AT1R .", "labels": [[84, 89, "ENTITY"], [62, 73, "CANCER"], [0, 8, "ENTITY"], [62, 80, "ENTITY"], [39, 46, "PROTEIN"], [84, 89, "PROTEIN"], [39, 46, "GENE_OR_GENE_PRODUCT"], [84, 89, "GENE_OR_GENE_PRODUCT"], [39, 46, "ENTITY"], [62, 80, "DISEASE"], [39, 46, "GGP"]]}
{"text": "A tentative suggestion based on existing therapeutics , which would likely be resistant to new coronavirus mutations , is to use available angiotensin receptor 1 ( AT1R ) blockers , such as losartan , as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections .", "labels": [[95, 107, "ENTITY"], [182, 190, "ENTITY"], [129, 160, "GENE_OR_GENE_PRODUCT"], [95, 107, "DISEASE"], [182, 190, "SIMPLE_CHEMICAL"], [221, 234, "DISEASE"], [234, 253, "ENTITY"], [221, 234, "ENTITY"], [263, 285, "ENTITY"], [268, 279, "TAXON"], [263, 279, "ORGANISM"], [199, 204, "ENTITY"], [129, 160, "GGP"], [204, 221, "ENTITY"], [129, 171, "PROTEIN"], [41, 54, "ENTITY"], [12, 23, "ENTITY"], [129, 160, "ENTITY"], [182, 190, "CHEMICAL"]]}
{"text": "ACE cleaves angiotensin I to generate angiotensin II , the peptide which binds to and activates AT1R to constrict blood vessels , thereby elevating blood pressure .", "labels": [[114, 120, "MULTI-TISSUE_STRUCTURE"], [12, 26, "GGP"], [38, 53, "PROTEIN"], [38, 53, "GGP"], [0, 26, "GENE_OR_GENE_PRODUCT"], [38, 53, "ENTITY"], [12, 26, "CHEMICAL"], [38, 53, "GENE_OR_GENE_PRODUCT"], [138, 148, "ORGANISM_SUBSTANCE"], [12, 26, "ENTITY"], [38, 53, "CHEMICAL"], [4, 12, "ENTITY"], [0, 4, "ENTITY"], [138, 154, "ENTITY"], [12, 26, "PROTEIN"], [114, 120, "ENTITY"]]}
{"text": "Taken together , these observations suggest that chronic AT1R blockade results in ACE2 upregulation in both rats and humans .", "labels": [[57, 62, "ENTITY"]]}
{"text": "This in turn contributes to lung injury , as angiotensin-stimulated AT1R results in increased pulmonary vascular permeability , thereby mediating increased lung pathology ( Imai et al. , 2005 ; Kuba et al. , 2005 ) .", "labels": [[136, 146, "ENTITY"], [94, 113, "ENTITY"], [28, 40, "DISEASE"], [28, 40, "ENTITY"], [28, 33, "ORGAN"], [94, 104, "MULTI-TISSUE_STRUCTURE"], [146, 161, "ENTITY"], [84, 94, "ORGAN"]]}
{"text": "The results shown that 13 representative drugs got higher docking scores than intrinsic ligand , which may be potential AKK1 inhibitor .", "labels": [[51, 58, "ENTITY"], [120, 125, "GGP"], [41, 47, "ENTITY"], [58, 73, "ENTITY"], [88, 95, "ENTITY"], [4, 12, "ENTITY"], [78, 88, "ENTITY"]]}
{"text": "The drug targets are members of the numb-associated kinase ( NAK ) family \u2014 including AAK1 and GAK \u2014 the inhibition of which has been shown to reduce viral infection in vitro.5,6 Baricitinib was identified as a NAK inhibitor , with a particularly high affinity for AAK1 , a pivotal regulator of clathrinmediated endocytosis . We suggested that this drug could be of use in countering SARS-CoV-2 infections , subject to appropriate clinical testing .", "labels": [[21, 29, "ENTITY"], [252, 261, "GENE_OR_GENE_PRODUCT"], [76, 86, "PROTEIN"], [234, 252, "ENTITY"], [206, 215, "GGP"], [252, 261, "PROTEIN"], [252, 261, "ENTITY"], [143, 150, "TAXON"], [156, 169, "ENTITY"], [209, 215, "ENTITY"], [4, 17, "ENTITY"], [373, 395, "DISEASE"], [373, 395, "ENTITY"], [76, 86, "ENTITY"], [282, 295, "CHEMICAL"], [4, 9, "CHEBI"], [76, 86, "GGP"], [274, 282, "ENTITY"], [76, 86, "GENE_OR_GENE_PRODUCT"], [36, 59, "ENTITY"], [143, 156, "DISEASE"], [252, 261, "GGP"], [282, 312, "ENTITY"], [143, 156, "ENTITY"], [99, 105, "ENTITY"], [169, 179, "ENTITY"], [169, 179, "GENE_OR_GENE_PRODUCT"], [373, 384, "SIMPLE_CHEMICAL"], [36, 67, "PROTEIN"]]}
{"text": "The model describing the docking molecules indicated that all of the 17 compounds in the garlic essential oil from T1-ACE2 to T17-ACE2 have the binding ability toward the areas affected by the ACE2 protein .", "labels": [[89, 96, "ORGANISM_SUBSTANCE"], [72, 82, "CHEBI"], [4, 10, "ENTITY"], [126, 135, "DNA"], [106, 110, "ORGANISM_SUBSTANCE"], [115, 123, "DNA"], [193, 206, "PROTEIN"], [33, 43, "CHEBI"], [144, 152, "ENTITY"], [89, 96, "ENTITY"], [72, 82, "ENTITY"], [193, 206, "ENTITY"], [126, 135, "ENTITY"], [118, 123, "GENE_OR_GENE_PRODUCT"], [115, 123, "CHEMICAL"], [193, 206, "GGP"], [171, 177, "ENTITY"], [115, 123, "ENTITY"], [25, 43, "ENTITY"], [126, 135, "GENE_OR_GENE_PRODUCT"], [177, 186, "ENTITY"], [25, 43, "PROTEIN"]]}
{"text": "The model describing the docking molecules indicated that all of the 17 compounds in the garlic essential oil from T1-ACE2 to T17-ACE2 have the binding ability toward the areas affected by the ACE2 protein .", "labels": [[89, 96, "ORGANISM_SUBSTANCE"], [72, 82, "CHEBI"], [4, 10, "ENTITY"], [126, 135, "DNA"], [106, 110, "ORGANISM_SUBSTANCE"], [115, 123, "DNA"], [193, 206, "PROTEIN"], [33, 43, "CHEBI"], [144, 152, "ENTITY"], [89, 96, "ENTITY"], [72, 82, "ENTITY"], [193, 206, "ENTITY"], [126, 135, "ENTITY"], [118, 123, "GENE_OR_GENE_PRODUCT"], [115, 123, "CHEMICAL"], [193, 206, "GGP"], [171, 177, "ENTITY"], [115, 123, "ENTITY"], [25, 43, "ENTITY"], [126, 135, "GENE_OR_GENE_PRODUCT"], [177, 186, "ENTITY"], [25, 43, "PROTEIN"]]}
{"text": "The compounds T1 and T2 indicated the highest content in the garlic essential oil ( 51.3 % ) and gave the best anti-SARS-CoV-2 activity , followed by the three compounds T5 , T4 , and T11 .", "labels": [[170, 173, "PROTEIN"], [21, 24, "ENTITY"], [21, 24, "DNA"], [170, 173, "ENTITY"], [78, 82, "ORGANISM_SUBSTANCE"], [61, 68, "ENTITY"], [14, 17, "DNA"], [4, 17, "ENTITY"], [111, 127, "ENTITY"], [46, 54, "ENTITY"], [21, 24, "CANCER"], [61, 68, "ORGANISM_SUBSTANCE"], [4, 14, "CHEBI"]]}
{"text": "The model describing the docking molecules indicated that all of the 17 compounds in the garlic essential oil from T1-ACE2 to T17-ACE2 have the binding ability toward the areas affected by the ACE2 protein .", "labels": [[89, 96, "ORGANISM_SUBSTANCE"], [72, 82, "CHEBI"], [4, 10, "ENTITY"], [126, 135, "DNA"], [106, 110, "ORGANISM_SUBSTANCE"], [115, 123, "DNA"], [193, 206, "PROTEIN"], [33, 43, "CHEBI"], [144, 152, "ENTITY"], [89, 96, "ENTITY"], [72, 82, "ENTITY"], [193, 206, "ENTITY"], [126, 135, "ENTITY"], [118, 123, "GENE_OR_GENE_PRODUCT"], [115, 123, "CHEMICAL"], [193, 206, "GGP"], [171, 177, "ENTITY"], [115, 123, "ENTITY"], [25, 43, "ENTITY"], [126, 135, "GENE_OR_GENE_PRODUCT"], [177, 186, "ENTITY"], [25, 43, "PROTEIN"]]}
{"text": "The compounds T1 and T2 indicated the highest content in the garlic essential oil ( 51.3 % ) and gave the best anti-SARS-CoV-2 activity , followed by the three compounds T5 , T4 , and T11 .", "labels": [[170, 173, "PROTEIN"], [21, 24, "ENTITY"], [21, 24, "DNA"], [170, 173, "ENTITY"], [78, 82, "ORGANISM_SUBSTANCE"], [61, 68, "ENTITY"], [14, 17, "DNA"], [4, 17, "ENTITY"], [111, 127, "ENTITY"], [46, 54, "ENTITY"], [21, 24, "CANCER"], [61, 68, "ORGANISM_SUBSTANCE"], [4, 14, "CHEBI"]]}
{"text": "On the other hand , IDX-184 and Sofosbuvir both form metal interaction through the Mg+2 with D652 ( two interactions ) and E702 , respectively .", "labels": []}
{"text": "On the other hand , IDX-184 and Sofosbuvir both form metal interaction through the Mg+2 with D652 ( two interactions ) and E702 , respectively .", "labels": []}
{"text": "As reflected from the docking scores , the eight compounds , including the physiological GTP and UTP and the four drugs IDX-184 , Sofosbuvir , Ribavirin , and Remidisvir can bind to both COVID-19 and SARS HCoV RdRps with good binding energy ( \u22126.5 up to \u22129.0 kcal/mol ) .", "labels": [[196, 205, "ORGANISM"], [130, 143, "ENTITY"], [75, 89, "CHEBI"], [114, 120, "PROTEIN"], [234, 241, "PROTEIN"], [75, 89, "SIMPLE_CHEMICAL"], [114, 120, "GENE_OR_GENE_PRODUCT"], [248, 259, "ENTITY"], [130, 143, "SIMPLE_CHEMICAL"], [234, 241, "CELLULAR_COMPONENT"], [114, 120, "ENTITY"], [130, 143, "CHEMICAL"], [75, 89, "ENTITY"], [200, 210, "ENTITY"], [22, 37, "ENTITY"], [221, 234, "ENTITY"], [114, 120, "CHEMICAL"], [234, 241, "ENTITY"]]}
{"text": "Previous studies ( 5 , 6 ) have shown that the phylogenetically related SARS-CoV is proteolytically activated by TMPRSS2 in vitro and in vivo .", "labels": [[9, 17, "ENTITY"], [64, 72, "ORGANISM"], [64, 72, "ENTITY"], [64, 72, "PROTEIN"], [130, 137, "ENTITY"], [81, 100, "ENTITY"], [113, 124, "ENTITY"], [64, 72, "TAXON"]]}
{"text": "However , the viral RNA copies in the VeroE6/TMPRSS2 cell culture supernatants were > 100 times greater than those from VeroE6 cells ( Fig. 1 D and E ) .", "labels": [[14, 20, "RNA"], [115, 127, "ENTITY"], [38, 58, "ENTITY"], [133, 140, "CELL"], [14, 20, "TAXON"], [115, 127, "CELL_LINE"], [115, 127, "CELL"], [38, 53, "CELL"], [38, 45, "CL"], [38, 58, "CELL_LINE"], [14, 24, "ENTITY"]]}
{"text": "SARS-CoV and Middle East respiratory syndrome (MERS)-CoV can enter cells via endocytosis and use cathepsin in endosomes for activation ( 12\u201314 ) . However , TMPRSS2 expression greatly promotes replication and syncytium formation in these viruses in vitro and in vivo ( 5 , 6 , 11 , 12 , 15 ) .", "labels": [[67, 73, "ENTITY"], [157, 165, "ENTITY"], [97, 120, "GGP"], [97, 107, "GENE_OR_GENE_PRODUCT"], [209, 219, "ENTITY"], [238, 249, "ENTITY"], [184, 193, "ENTITY"], [46, 57, "GENE_OR_GENE_PRODUCT"], [0, 9, "ORGANISM"], [46, 57, "ENTITY"], [13, 46, "ENTITY"], [77, 89, "ENTITY"], [124, 135, "ENTITY"], [147, 157, "GGP"], [67, 73, "CELL"], [97, 107, "PROTEIN"], [25, 46, "DISEASE"], [147, 157, "GENE_OR_GENE_PRODUCT"], [97, 107, "ENTITY"], [67, 73, "CL"], [176, 184, "ENTITY"], [147, 157, "PROTEIN"], [255, 262, "ENTITY"], [0, 9, "ENTITY"], [110, 120, "ENTITY"], [147, 157, "ENTITY"], [110, 120, "CELLULAR_COMPONENT"]]}
{"text": "Our findings suggest that TMPRSS2 is also likely to be a key protease for SARS-CoV-2 replication .", "labels": [[61, 70, "ENTITY"], [26, 34, "PROTEIN"], [26, 34, "ENTITY"], [26, 34, "GGP"], [4, 13, "ENTITY"], [74, 85, "CHEMICAL"], [26, 34, "GENE_OR_GENE_PRODUCT"], [74, 97, "ENTITY"], [74, 85, "SIMPLE_CHEMICAL"]]}
{"text": "For instance , a variety of human proteases , such as trypsin , tryptase Clara , human airway trypsin-like protease ( HAT ) and transmembrane protease serine 2 ( TMPRSS2 ) , are known to cleave and activate the S protein of SARS-CoV ( Bosch et al. 2008 ; Bertram et al. 2011 ) .", "labels": [[198, 211, "PROTEIN"], [213, 224, "GGP"], [34, 43, "ENTITY"], [34, 43, "ORGANISM"], [213, 224, "ENTITY"], [151, 162, "GENE_OR_GENE_PRODUCT"], [73, 81, "TAXON"], [122, 151, "GGP"], [73, 107, "ORGANISM"], [34, 43, "DISEASE"], [187, 198, "ENTITY"], [62, 73, "ENTITY"], [62, 73, "PROTEIN"], [198, 211, "CHEBI"], [213, 224, "ORGANISM"], [122, 151, "PROTEIN"], [122, 151, "GENE_OR_GENE_PRODUCT"], [151, 162, "GGP"], [34, 43, "PROTEIN"], [151, 162, "PROTEIN"], [122, 151, "ENTITY"], [62, 73, "GENE_OR_GENE_PRODUCT"], [198, 211, "ENTITY"], [28, 34, "PROTEIN"], [73, 107, "PROTEIN"], [151, 162, "ENTITY"], [73, 81, "ENTITY"]]}
{"text": "The expression of TMPRSS2 across cell types of the lung ( further referred to as TMPRSS2 + cells ) was much stronger with a certain specificity for AT2 cells ( Fig. 1E ) , which is in agreement with previous studies .", "labels": [[18, 26, "PROTEIN"], [18, 26, "GENE_OR_GENE_PRODUCT"], [51, 56, "ORGAN"], [144, 152, "CELL"], [51, 56, "ENTITY"], [144, 152, "ENTITY"], [148, 152, "CL"], [33, 38, "CL"], [81, 91, "CELL_TYPE"], [81, 91, "ENTITY"], [152, 160, "CELL"], [18, 26, "GGP"], [33, 44, "ENTITY"], [81, 91, "GGP"], [81, 91, "GENE_OR_GENE_PRODUCT"], [199, 208, "ENTITY"], [18, 26, "ENTITY"], [4, 15, "ENTITY"], [33, 38, "CELL"], [144, 152, "CELL_TYPE"]]}
{"text": "The expression of TMPRSS2 across cell types of the lung ( further referred to as TMPRSS2 + cells ) was much stronger with a certain specificity for AT2 cells ( Fig. 1E ) , which is in agreement with previous studies .", "labels": [[18, 26, "PROTEIN"], [152, 160, "CELL"], [18, 26, "GENE_OR_GENE_PRODUCT"], [51, 56, "ORGAN"], [144, 152, "CELL"], [51, 56, "ENTITY"], [144, 152, "ENTITY"], [148, 152, "CL"], [33, 38, "CL"], [81, 91, "CELL_TYPE"], [81, 91, "ENTITY"], [18, 26, "GGP"], [33, 44, "ENTITY"], [81, 91, "GGP"], [81, 91, "GENE_OR_GENE_PRODUCT"], [199, 208, "ENTITY"], [18, 26, "ENTITY"], [4, 15, "ENTITY"], [33, 38, "CELL"], [144, 152, "CELL_TYPE"]]}
{"text": "Then it is cleaved by TMPRSS2 at the S1/S2 boundary or within S2 subunit , which removes the structural constraint of S1 on S2 , and releases the internal fusion peptide combined with the Spike TM domain for the fusion of viral and cellular membranes . Finally , the viral genomes enter into the host cells .", "labels": [[263, 273, "ENTITY"], [22, 30, "ENTITY"], [37, 52, "CELLULAR_COMPONENT"], [22, 30, "PROTEIN"], [184, 197, "PROTEIN"], [184, 197, "ENTITY"], [37, 52, "ENTITY"], [37, 43, "PROTEIN"], [22, 25, "SO"], [263, 273, "DNA"], [62, 73, "ENTITY"], [93, 104, "ENTITY"], [292, 301, "CL"], [292, 301, "CELL_TYPE"], [292, 301, "CELL"], [228, 241, "ENTITY"], [22, 30, "GENE_OR_GENE_PRODUCT"], [62, 73, "PROTEIN"], [142, 162, "ENTITY"], [263, 273, "TAXON"], [22, 30, "GGP"], [292, 301, "ENTITY"], [11, 19, "ENTITY"], [188, 194, "GENE_OR_GENE_PRODUCT"], [228, 241, "CELLULAR_COMPONENT"], [142, 162, "SO"], [228, 241, "CL"]]}
{"text": "ACE2 cleaving by TMPRSSs : TMPRSS2 can also cleave ACE2 amino acids 697 to 716 , resulting in the shedding of 13kD ACE2 fragment in culture supernatants and augmented viral infectivity .", "labels": [[51, 62, "GGP"], [0, 5, "PROTEIN"], [129, 140, "ENTITY"], [17, 25, "PROTEIN"], [110, 120, "ENTITY"], [51, 62, "ENTITY"], [51, 68, "GENE_OR_GENE_PRODUCT"], [5, 14, "ENTITY"], [157, 173, "ENTITY"], [107, 120, "DNA"], [110, 120, "GGP"], [157, 167, "TAXON"], [56, 62, "CHEMICAL"], [110, 115, "GENE_OR_GENE_PRODUCT"], [51, 75, "PROTEIN"], [17, 25, "ENTITY"], [0, 5, "ENTITY"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Accordingly , we infected the cells with SARS-CoV- , or 2019- nCoV -S- pseudotyped HIV-1 viruses after siRNA-mediated knockdown of the expression of cathepsin L and TMPRSS2 and found that both cathepsin L and TMPRSS2 depletion impaired the cell entry of pseudoviruses ( Figure 1C ) , indicating that both cathepsin L and TMPRSS2 are required for 2019- nCoV cell entry .", "labels": [[146, 159, "ENTITY"], [268, 277, "ENTITY"], [146, 159, "GENE_OR_GENE_PRODUCT"], [83, 89, "TAXON"], [67, 89, "ORGANISM"], [62, 67, "CL"], [188, 203, "ENTITY"], [146, 159, "GGP"], [103, 118, "ENTITY"], [67, 71, "ENTITY"], [71, 89, "ENTITY"], [188, 203, "GGP"], [346, 362, "ENTITY"], [165, 173, "ENTITY"], [146, 159, "PROTEIN"], [188, 203, "GENE_OR_GENE_PRODUCT"], [62, 67, "CELL"], [56, 67, "ENTITY"], [26, 35, "ENTITY"], [188, 203, "PROTEIN"], [217, 227, "ENTITY"]]}
{"text": "Accordingly , we infected the cells with SARS-CoV- , or 2019-nCoV-S-pseudotyped HIV-1 viruses after siRNA-mediated knockdown of the expression of cathepsin L and TMPRSS2 and found that both cathepsin L and TMPRSS2 depletion impaired the cell entry of pseudoviruses ( Figure 1C ) , indicating that both cathepsin L and TMPRSS2 are required for 2019-nCoV cell entry .", "labels": [[265, 274, "ENTITY"], [80, 86, "TAXON"], [339, 353, "CELL"], [214, 224, "ENTITY"], [143, 156, "GENE_OR_GENE_PRODUCT"], [339, 358, "ENTITY"], [56, 66, "CL"], [56, 80, "ORGANISM"], [26, 35, "ENTITY"], [143, 156, "PROTEIN"], [185, 200, "ENTITY"], [53, 86, "ENTITY"], [143, 156, "GGP"], [185, 200, "GGP"], [162, 170, "ENTITY"], [100, 115, "ENTITY"], [143, 156, "ENTITY"], [185, 200, "GENE_OR_GENE_PRODUCT"], [185, 200, "PROTEIN"]]}
{"text": "The results shown that 13 representative drugs got higher docking scores than intrinsic ligand , which may be potential AKK1 inhibitor .", "labels": [[51, 58, "ENTITY"], [120, 125, "GGP"], [41, 47, "ENTITY"], [58, 73, "ENTITY"], [88, 95, "ENTITY"], [4, 12, "ENTITY"], [78, 88, "ENTITY"]]}
{"text": "The model describing the docking molecules indicated that all of the 17 compounds in the garlic essential oil from T1-ACE2 to T17-ACE2 have the binding ability toward the areas affected by the ACE2 protein .", "labels": [[89, 96, "ORGANISM_SUBSTANCE"], [72, 82, "CHEBI"], [4, 10, "ENTITY"], [126, 135, "DNA"], [106, 110, "ORGANISM_SUBSTANCE"], [115, 123, "DNA"], [193, 206, "PROTEIN"], [33, 43, "CHEBI"], [144, 152, "ENTITY"], [89, 96, "ENTITY"], [72, 82, "ENTITY"], [193, 206, "ENTITY"], [126, 135, "ENTITY"], [118, 123, "GENE_OR_GENE_PRODUCT"], [115, 123, "CHEMICAL"], [193, 206, "GGP"], [171, 177, "ENTITY"], [115, 123, "ENTITY"], [25, 43, "ENTITY"], [126, 135, "GENE_OR_GENE_PRODUCT"], [177, 186, "ENTITY"], [25, 43, "PROTEIN"]]}
{"text": "The results shown that 13 representative drugs got higher docking scores than intrinsic ligand , which may be potential AKK1 inhibitor .", "labels": [[51, 58, "ENTITY"], [120, 125, "GGP"], [41, 47, "ENTITY"], [58, 73, "ENTITY"], [88, 95, "ENTITY"], [4, 12, "ENTITY"], [78, 88, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "As a final example , we were intrigued to observe that the SARS-CoV-2 Nsp6 protein interacts with the Sigma receptor , which is thought to regulate ER stress response [ 71 ] .", "labels": [[139, 151, "GENE_OR_GENE_PRODUCT"], [59, 75, "ENTITY"], [59, 70, "ORGANISM"], [139, 158, "ENTITY"], [102, 108, "PROTEIN"], [139, 148, "PROTEIN"], [59, 75, "GGP"], [59, 75, "PROTEIN"], [102, 108, "ENTITY"]]}
{"text": "The results shown that 13 representative drugs got higher docking scores than intrinsic ligand , which may be potential AKK1 inhibitor .", "labels": [[51, 58, "ENTITY"], [120, 125, "GGP"], [41, 47, "ENTITY"], [58, 73, "ENTITY"], [88, 95, "ENTITY"], [4, 12, "ENTITY"], [78, 88, "ENTITY"]]}
{"text": "The results shown that 13 representative drugs got higher docking scores than intrinsic ligand , which may be potential AKK1 inhibitor .", "labels": [[51, 58, "ENTITY"], [120, 125, "GGP"], [41, 47, "ENTITY"], [58, 73, "ENTITY"], [88, 95, "ENTITY"], [4, 12, "ENTITY"], [78, 88, "ENTITY"]]}
{"text": "Favipiravir is converted into an active phosphoribosylated form ( Favipiravir is converted into an active phosphoribosylated form ) in cells and is recognized as a substrate by viral RNA polymerase , thus inhibiting RNA polymerase activity ( 11 ) .", "labels": [[0, 12, "ENTITY"], [-1, 4, "ENTITY"], [-1, 22, "PROTEIN"], [-1, 6, "TAXON"], [148, 161, "ENTITY"], [161, 167, "SO"], [161, 189, "ENTITY"], [-1, 14, "SIMPLE_CHEMICAL"], [161, 171, "PROTEIN"], [-1, 22, "ENTITY"]]}
{"text": "The results shown that 13 representative drugs got higher docking scores than intrinsic ligand , which may be potential AKK1 inhibitor .", "labels": [[51, 58, "ENTITY"], [120, 125, "GGP"], [41, 47, "ENTITY"], [58, 73, "ENTITY"], [88, 95, "ENTITY"], [4, 12, "ENTITY"], [78, 88, "ENTITY"]]}
{"text": "A previous attempt to predict drugs for the Mpro of SARS-CoV has identified two HIV-1 protease inhibitors , namely lopinavir and ritonavir , as potential candidates , both of which bind to the same target site of Mpro ( Nukoolkarn et al. , 2008 ) . The conserved amino acids Thr24-Asn28 and Asn119 ( numbered according to positions in SARS-CoV Mpro because the present sequence of 2019-nCoV Mpro in GenBank is in polypeptide form ) formed the binding pockets for lopinavir/ritonavir in the spatial structure of both SARS-CoV Mpro and 2019-nCoV Mpro , whereas the nearby non-conserved amino acids locate far away from the binding pocket , thus would not affect its structural conservation ( Fig. 1B ) .", "labels": [[361, 369, "SO"], [22, 30, "ENTITY"], [247, 263, "SO"], [144, 154, "ENTITY"], [570, 584, "CHEBI"], [322, 335, "ENTITY"], [309, 322, "SO"], [52, 61, "GGP"], [451, 463, "CHEMICAL"], [451, 463, "SIMPLE_CHEMICAL"], [44, 49, "ENTITY"], [269, 275, "ENTITY"], [80, 106, "GGP"], [361, 369, "ENTITY"], [322, 335, "ORGANISM"], [253, 263, "ENTITY"], [612, 621, "ENTITY"], [247, 291, "PROTEIN"], [213, 220, "SIMPLE_CHEMICAL"], [198, 205, "SO"], [275, 291, "ENTITY"], [508, 516, "GGP"], [664, 675, "SO"], [508, 534, "PROTEIN"], [570, 584, "CHEMICAL"], [559, 584, "PROTEIN"], [80, 95, "ORGANISM"], [275, 291, "GENE_OR_GENE_PRODUCT"], [653, 675, "ENTITY"], [391, 399, "GENE_OR_GENE_PRODUCT"], [391, 399, "ENTITY"], [570, 584, "AMINO_ACID"], [30, 36, "ENTITY"], [432, 439, "ENTITY"], [508, 516, "ORGANISM"], [451, 463, "ENTITY"], [52, 61, "ORGANISM"], [52, 61, "ENTITY"], [369, 381, "ENTITY"], [80, 106, "ENTITY"], [463, 498, "ENTITY"], [612, 621, "PROTEIN"], [508, 516, "ENTITY"], [525, 534, "ENTITY"], [253, 275, "CHEMICAL"], [399, 413, "ENTITY"], [322, 335, "PROTEIN"], [44, 61, "PROTEIN"], [559, 584, "ENTITY"]]}
{"text": "The ~306 aa long main protease ( Mpro ) , a key enzyme for coronavirus replication , is also encoded by the polypeptide and responsible for processing the polypeptide into functional proteins ( Lai and Holmes , 2001 ) .", "labels": [[44, 48, "ENTITY"], [167, 183, "ENTITY"], [4, 17, "PROTEIN"], [55, 71, "ENTITY"], [9, 12, "CHEBI"], [167, 183, "PROTEIN"], [44, 48, "SO"], [4, 31, "ENTITY"], [183, 192, "ENTITY"], [172, 183, "CHEBI"]]}
{"text": "Amino acids Thr24 , Thr26 , and Asn119 were predicted to be the key residues for binding to the drugs ( Figs. 1C and S2 ) , forming 2 hydrogen bonds with lopinavir and 3 hydrogen bonds with ritonavir , respectively .", "labels": [[164, 179, "SIMPLE_CHEMICAL"], [164, 179, "CHEBI"], [0, 18, "CHEMICAL"], [64, 68, "ENTITY"], [0, 12, "CHEBI"], [12, 18, "GGP"], [164, 179, "ENTITY"], [0, 18, "ENTITY"], [64, 68, "CHEBI"], [124, 143, "CHEBI"], [102, 110, "ENTITY"], [0, 18, "SIMPLE_CHEMICAL"], [120, 143, "ENTITY"]]}
{"text": "Amino acids Thr24 , Thr26 , and Asn119 were predicted to be the key residues for binding to the drugs ( Figs. 1C and S2 ) , forming 2 hydrogen bonds with lopinavir and 3 hydrogen bonds with ritonavir , respectively .", "labels": [[164, 179, "SIMPLE_CHEMICAL"], [164, 179, "CHEBI"], [0, 18, "CHEMICAL"], [64, 68, "ENTITY"], [0, 12, "CHEBI"], [12, 18, "GGP"], [164, 179, "ENTITY"], [0, 18, "ENTITY"], [64, 68, "CHEBI"], [124, 143, "CHEBI"], [102, 110, "ENTITY"], [0, 18, "SIMPLE_CHEMICAL"], [120, 143, "ENTITY"]]}
{"text": "A previous attempt to predict drugs for the Mpro of SARS-CoV has identified two HIV-1 protease inhibitors , namely lopinavir and ritonavir , as potential candidates , both of which bind to the same target site of Mpro ( Nukoolkarn et al. , 2008 ) . The conserved amino acids Thr24-Asn28 and Asn119 ( numbered according to positions in SARS-CoV Mpro because the present sequence of 2019-nCoV Mpro in GenBank is in polypeptide form ) formed the binding pockets for lopinavir/ritonavir in the spatial structure of both SARS-CoV Mpro and 2019-nCoV Mpro , whereas the nearby non-conserved amino acids locate far away from the binding pocket , thus would not affect its structural conservation ( Fig. 1B ) .", "labels": [[361, 369, "SO"], [22, 30, "ENTITY"], [247, 263, "SO"], [144, 154, "ENTITY"], [570, 584, "CHEBI"], [322, 335, "ENTITY"], [309, 322, "SO"], [52, 61, "GGP"], [451, 463, "CHEMICAL"], [451, 463, "SIMPLE_CHEMICAL"], [44, 49, "ENTITY"], [269, 275, "ENTITY"], [80, 106, "GGP"], [361, 369, "ENTITY"], [322, 335, "ORGANISM"], [253, 263, "ENTITY"], [612, 621, "ENTITY"], [247, 291, "PROTEIN"], [213, 220, "SIMPLE_CHEMICAL"], [198, 205, "SO"], [275, 291, "ENTITY"], [508, 516, "GGP"], [664, 675, "SO"], [508, 534, "PROTEIN"], [570, 584, "CHEMICAL"], [559, 584, "PROTEIN"], [80, 95, "ORGANISM"], [275, 291, "GENE_OR_GENE_PRODUCT"], [653, 675, "ENTITY"], [391, 399, "GENE_OR_GENE_PRODUCT"], [391, 399, "ENTITY"], [570, 584, "AMINO_ACID"], [30, 36, "ENTITY"], [432, 439, "ENTITY"], [508, 516, "ORGANISM"], [451, 463, "ENTITY"], [52, 61, "ORGANISM"], [52, 61, "ENTITY"], [369, 381, "ENTITY"], [80, 106, "ENTITY"], [463, 498, "ENTITY"], [612, 621, "PROTEIN"], [508, 516, "ENTITY"], [525, 534, "ENTITY"], [253, 275, "CHEMICAL"], [399, 413, "ENTITY"], [322, 335, "PROTEIN"], [44, 61, "PROTEIN"], [559, 584, "ENTITY"]]}
{"text": "Amino acids Thr24 , Thr26 , and Asn119 were predicted to be the key residues for binding to the drugs ( Figs. 1C and S2 ) , forming 2 hydrogen bonds with lopinavir and 3 hydrogen bonds with ritonavir , respectively .", "labels": [[164, 179, "SIMPLE_CHEMICAL"], [164, 179, "CHEBI"], [0, 18, "CHEMICAL"], [64, 68, "ENTITY"], [0, 12, "CHEBI"], [12, 18, "GGP"], [164, 179, "ENTITY"], [0, 18, "ENTITY"], [64, 68, "CHEBI"], [124, 143, "CHEBI"], [102, 110, "ENTITY"], [0, 18, "SIMPLE_CHEMICAL"], [120, 143, "ENTITY"]]}
{"text": "Amino acids Thr24 , Thr26 , and Asn119 were predicted to be the key residues for binding to the drugs ( Figs. 1C and S2 ) , forming 2 hydrogen bonds with lopinavir and 3 hydrogen bonds with ritonavir , respectively .", "labels": [[164, 179, "SIMPLE_CHEMICAL"], [164, 179, "CHEBI"], [0, 18, "CHEMICAL"], [64, 68, "ENTITY"], [0, 12, "CHEBI"], [12, 18, "GGP"], [164, 179, "ENTITY"], [0, 18, "ENTITY"], [64, 68, "CHEBI"], [124, 143, "CHEBI"], [102, 110, "ENTITY"], [0, 18, "SIMPLE_CHEMICAL"], [120, 143, "ENTITY"]]}
{"text": "The results shown that 13 representative drugs got higher docking scores than intrinsic ligand , which may be potential AKK1 inhibitor .", "labels": [[51, 58, "ENTITY"], [120, 125, "GGP"], [41, 47, "ENTITY"], [58, 73, "ENTITY"], [88, 95, "ENTITY"], [4, 12, "ENTITY"], [78, 88, "ENTITY"]]}
{"text": "As reflected from the docking scores , the eight compounds , including the physiological GTP and UTP and the four drugs IDX-184 , Sofosbuvir , Ribavirin , and Remidisvir can bind to both COVID-19 and SARS HCoV RdRps with good binding energy ( \u22126.5 up to \u22129.0 kcal/mol ) .", "labels": [[196, 205, "ORGANISM"], [130, 143, "ENTITY"], [75, 89, "CHEBI"], [114, 120, "PROTEIN"], [234, 241, "PROTEIN"], [75, 89, "SIMPLE_CHEMICAL"], [114, 120, "GENE_OR_GENE_PRODUCT"], [248, 259, "ENTITY"], [130, 143, "SIMPLE_CHEMICAL"], [234, 241, "CELLULAR_COMPONENT"], [114, 120, "ENTITY"], [130, 143, "CHEMICAL"], [75, 89, "ENTITY"], [200, 210, "ENTITY"], [22, 37, "ENTITY"], [221, 234, "ENTITY"], [114, 120, "CHEMICAL"], [234, 241, "ENTITY"]]}
{"text": "A previous attempt to predict drugs for the Mpro of SARS-CoV has identified two HIV-1 protease inhibitors , namely lopinavir and ritonavir , as potential candidates , both of which bind to the same target site of Mpro ( Nukoolkarn et al. , 2008 ) . The conserved amino acids Thr24-Asn28 and Asn119 ( numbered according to positions in SARS-CoV Mpro because the present sequence of 2019-nCoV Mpro in GenBank is in polypeptide form ) formed the binding pockets for lopinavir/ritonavir in the spatial structure of both SARS-CoV Mpro and 2019-nCoV Mpro , whereas the nearby non-conserved amino acids locate far away from the binding pocket , thus would not affect its structural conservation ( Fig. 1B ) .", "labels": [[361, 369, "SO"], [22, 30, "ENTITY"], [247, 263, "SO"], [144, 154, "ENTITY"], [570, 584, "CHEBI"], [322, 335, "ENTITY"], [309, 322, "SO"], [52, 61, "GGP"], [451, 463, "CHEMICAL"], [451, 463, "SIMPLE_CHEMICAL"], [44, 49, "ENTITY"], [269, 275, "ENTITY"], [80, 106, "GGP"], [361, 369, "ENTITY"], [322, 335, "ORGANISM"], [253, 263, "ENTITY"], [612, 621, "ENTITY"], [247, 291, "PROTEIN"], [213, 220, "SIMPLE_CHEMICAL"], [198, 205, "SO"], [275, 291, "ENTITY"], [508, 516, "GGP"], [664, 675, "SO"], [508, 534, "PROTEIN"], [570, 584, "CHEMICAL"], [559, 584, "PROTEIN"], [80, 95, "ORGANISM"], [275, 291, "GENE_OR_GENE_PRODUCT"], [653, 675, "ENTITY"], [391, 399, "GENE_OR_GENE_PRODUCT"], [463, 498, "ENTITY"], [391, 399, "ENTITY"], [570, 584, "AMINO_ACID"], [30, 36, "ENTITY"], [432, 439, "ENTITY"], [508, 516, "ORGANISM"], [451, 463, "ENTITY"], [52, 61, "ORGANISM"], [52, 61, "ENTITY"], [369, 381, "ENTITY"], [80, 106, "ENTITY"], [612, 621, "PROTEIN"], [508, 516, "ENTITY"], [525, 534, "ENTITY"], [253, 275, "CHEMICAL"], [399, 413, "ENTITY"], [322, 335, "PROTEIN"], [44, 61, "PROTEIN"], [559, 584, "ENTITY"]]}
{"text": "A previous attempt to predict drugs for the Mpro of SARS-CoV has identified two HIV-1 protease inhibitors , namely lopinavir and ritonavir , as potential candidates , both of which bind to the same target site of Mpro ( Nukoolkarn et al. , 2008 ) . The conserved amino acids Thr24-Asn28 and Asn119 ( numbered according to positions in SARS-CoV Mpro because the present sequence of 2019-nCoV Mpro in GenBank is in polypeptide form ) formed the binding pockets for lopinavir/ritonavir in the spatial structure of both SARS-CoV Mpro and 2019-nCoV Mpro , whereas the nearby non-conserved amino acids locate far away from the binding pocket , thus would not affect its structural conservation ( Fig. 1B ) .", "labels": [[361, 369, "SO"], [22, 30, "ENTITY"], [247, 263, "SO"], [144, 154, "ENTITY"], [570, 584, "CHEBI"], [322, 335, "ENTITY"], [309, 322, "SO"], [52, 61, "GGP"], [451, 463, "CHEMICAL"], [451, 463, "SIMPLE_CHEMICAL"], [44, 49, "ENTITY"], [269, 275, "ENTITY"], [80, 106, "GGP"], [361, 369, "ENTITY"], [322, 335, "ORGANISM"], [253, 263, "ENTITY"], [612, 621, "ENTITY"], [247, 291, "PROTEIN"], [213, 220, "SIMPLE_CHEMICAL"], [198, 205, "SO"], [275, 291, "ENTITY"], [508, 516, "GGP"], [664, 675, "SO"], [508, 534, "PROTEIN"], [570, 584, "CHEMICAL"], [559, 584, "PROTEIN"], [80, 95, "ORGANISM"], [275, 291, "GENE_OR_GENE_PRODUCT"], [653, 675, "ENTITY"], [391, 399, "GENE_OR_GENE_PRODUCT"], [463, 498, "ENTITY"], [391, 399, "ENTITY"], [570, 584, "AMINO_ACID"], [30, 36, "ENTITY"], [432, 439, "ENTITY"], [508, 516, "ORGANISM"], [451, 463, "ENTITY"], [52, 61, "ORGANISM"], [52, 61, "ENTITY"], [369, 381, "ENTITY"], [80, 106, "ENTITY"], [612, 621, "PROTEIN"], [508, 516, "ENTITY"], [525, 534, "ENTITY"], [253, 275, "CHEMICAL"], [399, 413, "ENTITY"], [322, 335, "PROTEIN"], [44, 61, "PROTEIN"], [559, 584, "ENTITY"]]}
{"text": "The results shown that 13 representative drugs got higher docking scores than intrinsic ligand , which may be potential AKK1 inhibitor .", "labels": [[51, 58, "ENTITY"], [120, 125, "GGP"], [41, 47, "ENTITY"], [58, 73, "ENTITY"], [88, 95, "ENTITY"], [4, 12, "ENTITY"], [78, 88, "ENTITY"]]}
{"text": "As reflected from the docking scores , the eight compounds , including the physiological GTP and UTP and the four drugs IDX-184 , Sofosbuvir , Ribavirin , and Remidisvir can bind to both COVID-19 and SARS HCoV RdRps with good binding energy ( \u22126.5 up to \u22129.0 kcal/mol ) .", "labels": [[196, 205, "ORGANISM"], [234, 241, "PROTEIN"], [75, 89, "CHEBI"], [114, 120, "PROTEIN"], [130, 143, "CHEMICAL"], [75, 89, "SIMPLE_CHEMICAL"], [114, 120, "GENE_OR_GENE_PRODUCT"], [248, 259, "ENTITY"], [234, 241, "CELLULAR_COMPONENT"], [114, 120, "ENTITY"], [75, 89, "ENTITY"], [200, 210, "ENTITY"], [22, 37, "ENTITY"], [221, 234, "ENTITY"], [130, 143, "ENTITY"], [130, 143, "SIMPLE_CHEMICAL"], [114, 120, "CHEMICAL"], [234, 241, "ENTITY"]]}
{"text": "Additionally , Sofosbuvir formed two hydrophobic interactions with Y510 and D651 of the COVID-19 RdRp .", "labels": [[88, 97, "DNA"], [88, 97, "ENTITY"], [88, 97, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Additionally , Sofosbuvir formed two hydrophobic interactions with Y510 and D651 of the COVID-19 RdRp .", "labels": [[88, 97, "DNA"], [88, 97, "ENTITY"], [88, 97, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The results shown that 13 representative drugs got higher docking scores than intrinsic ligand , which may be potential AKK1 inhibitor .", "labels": [[51, 58, "ENTITY"], [120, 125, "GGP"], [41, 47, "ENTITY"], [58, 73, "ENTITY"], [88, 95, "ENTITY"], [4, 12, "ENTITY"], [78, 88, "ENTITY"]]}
{"text": "The results shown that 13 representative drugs got higher docking scores than intrinsic ligand , which may be potential AKK1 inhibitor .", "labels": [[51, 58, "ENTITY"], [120, 125, "GGP"], [41, 47, "ENTITY"], [58, 73, "ENTITY"], [88, 95, "ENTITY"], [4, 12, "ENTITY"], [78, 88, "ENTITY"]]}
{"text": "A multicentre , randomised controlled trial of tocilizumab ( IL-6 receptor blockade , licensed for cytokine release syndrome ) , has been approved in patients with COVID-19 pneumonia and elevated IL-6 in China ( ChiCTR2000029765 ) [ 9 ] . Janus kinase ( JAK ) inhibition could affect both inflammation and cellular viral entry in COVID-19 [ 10 ] .", "labels": [[66, 75, "ENTITY"], [187, 196, "GENE_OR_GENE_PRODUCT"], [245, 258, "ENTITY"], [59, 66, "ENTITY"], [277, 289, "DISEASE"], [187, 196, "PROTEIN"], [164, 173, "DISEASE"], [239, 245, "GGP"], [289, 306, "CL"], [138, 150, "ORGANISM"], [315, 330, "GENE_OR_GENE_PRODUCT"], [289, 315, "ENTITY"], [239, 245, "GENE_OR_GENE_PRODUCT"], [315, 327, "ENTITY"], [2, 14, "ENTITY"], [59, 66, "GENE_OR_GENE_PRODUCT"], [204, 212, "PROTEIN"], [159, 173, "ENTITY"], [277, 289, "ENTITY"], [16, 38, "ENTITY"], [289, 302, "CELL"], [187, 196, "ENTITY"], [138, 150, "ENTITY"], [196, 204, "ENTITY"], [59, 66, "GGP"], [239, 245, "PROTEIN"], [187, 196, "GGP"], [95, 116, "ENTITY"]]}
{"text": "From these results , we conclude that LY294002 and wortmannin inhibit SARS pseudovirus entry by targeting PI4 KB and that PI4 KB is involved in SARS-CoV S-mediated entry into VeroE6 cells .", "labels": [[141, 153, "ORGANISM"], [144, 153, "ENTITY"], [170, 182, "CELL_LINE"], [170, 182, "CELL"], [170, 182, "ENTITY"], [175, 182, "CL"], [70, 75, "ORGANISM"], [106, 110, "ENTITY"], [11, 19, "ENTITY"], [106, 110, "GENE_OR_GENE_PRODUCT"], [117, 126, "GENE_OR_GENE_PRODUCT"], [117, 126, "ENTITY"]]}
{"text": "From these results , we conclude that LY294002 and wortmannin inhibit SARS pseudovirus entry by targeting PI4 KB and that PI4 KB is involved in SARS-CoV S-mediated entry into VeroE6 cells .", "labels": [[141, 153, "ORGANISM"], [170, 182, "CELL_LINE"], [170, 182, "CELL"], [170, 182, "ENTITY"], [175, 182, "CL"], [70, 75, "ORGANISM"], [144, 153, "ENTITY"], [106, 110, "ENTITY"], [11, 19, "ENTITY"], [106, 110, "GENE_OR_GENE_PRODUCT"], [117, 126, "GENE_OR_GENE_PRODUCT"], [117, 126, "ENTITY"]]}
{"text": "FIGURE 7 . Model of the PI kinases and PI4P involved in SARS-CoV S-mediated entry . After SARS-CoV binds to ACE2 , PI4P , the catalytic product of PI4 KB , creates a lipid microenvironment or PI4P-enriched organelle required for the steps leading to fusion . Pharmacological inhibitors of PI4 KB , such as LY294002 or wortmannin , suppress PI4 KB activity and thereby inhibit SARSCoV S-mediated entry . Cellular factors , such as PI3Ks or Sac1 , that negatively regulate PI4P generation can also inhibit SARS-CoV S-mediated entry .", "labels": [[412, 422, "ENTITY"], [65, 76, "CL"], [24, 27, "ENTITY"], [122, 136, "ENTITY"], [298, 306, "SIMPLE_CHEMICAL"], [156, 166, "SIMPLE_CHEMICAL"], [0, 7, "ENTITY"], [275, 286, "GENE_OR_GENE_PRODUCT"], [412, 422, "CHEBI"], [24, 27, "PROTEIN"], [318, 329, "ENTITY"], [56, 65, "ENTITY"], [259, 275, "CHEBI"], [65, 84, "PROTEIN"], [451, 462, "PROTEIN"], [298, 306, "ENTITY"], [331, 344, "ENTITY"], [56, 65, "ORGANISM"], [172, 192, "CELL"], [275, 286, "PROTEIN"], [491, 504, "ORGANISM"], [306, 318, "CHEBI"], [122, 136, "PROTEIN"], [451, 462, "GENE_OR_GENE_PRODUCT"], [65, 76, "CELL"], [298, 306, "CHEMICAL"], [412, 422, "PROTEIN"], [462, 471, "ENTITY"], [172, 206, "ENTITY"], [65, 84, "ENTITY"], [451, 462, "ENTITY"], [476, 487, "ENTITY"], [24, 27, "GENE_OR_GENE_PRODUCT"], [368, 384, "ENTITY"], [275, 286, "ENTITY"], [275, 283, "ENTITY"], [156, 172, "ENTITY"], [192, 206, "GO"], [239, 250, "ENTITY"], [306, 318, "SIMPLE_CHEMICAL"], [306, 318, "ENTITY"], [156, 166, "CHEBI"], [250, 275, "ENTITY"], [306, 318, "CHEMICAL"], [412, 422, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The results shown that 13 representative drugs got higher docking scores than intrinsic ligand , which may be potential AKK1 inhibitor .", "labels": [[51, 58, "ENTITY"], [120, 125, "GGP"], [41, 47, "ENTITY"], [58, 73, "ENTITY"], [88, 95, "ENTITY"], [4, 12, "ENTITY"], [78, 88, "ENTITY"]]}
{"text": "In agreement with these findings , directed expression of human and bat ( Rhinolophus alcyone ) ACE2 but not human DPP4 , the entry receptor used by MERS-CoV ( Raj et al. , 2013 ) , or human APN , the entry receptor used by HCoV-229E ( Yeager et al.,1992 ) , allowed SARS-2-S- and SARS-S-driven entry into otherwise non-susceptible BHK-21 cells ( Figure 3A ) .", "labels": [[301, 332, "CELL_LINE"], [141, 149, "ENTITY"], [122, 132, "ENTITY"], [301, 332, "CL"], [301, 316, "ENTITY"], [332, 339, "ENTITY"], [332, 339, "GENE_OR_GENE_PRODUCT"], [72, 86, "ENTITY"], [301, 332, "CELL"], [105, 115, "GGP"], [191, 207, "ENTITY"], [58, 64, "ENTITY"], [105, 115, "ORGANISM"], [24, 33, "ENTITY"], [316, 332, "ENTITY"], [178, 185, "ORGANISM"], [267, 281, "SIMPLE_CHEMICAL"], [141, 149, "ORGANISM"], [301, 316, "CHEMICAL"], [105, 115, "PROTEIN"], [267, 281, "CHEMICAL"], [267, 281, "ENTITY"], [178, 185, "PROTEIN"], [3, 13, "ENTITY"]]}
{"text": "Human DPP4\u2014a receptor for the lineage C betacoronaviruses \u2014 only mediated entry of MERS-CoV , whereas APN only mediated entry of the alphacoronavirus HCoV-229E ( Fig. 2b ) .", "labels": [[0, 22, "PROTEIN"], [129, 150, "ORGANISM"], [6, 13, "CHEMICAL"], [0, 6, "TAXON"], [0, 22, "ORGANISM"], [30, 58, "PROTEIN"], [30, 58, "ENTITY"], [0, 6, "ENTITY"], [6, 22, "ENTITY"], [129, 150, "ENTITY"]]}
{"text": "Different from SARS-CoV , MERS-CoV enters human host cells mainly via dipeptidyl peptidase 4 ( DPP4 ) , which is present in the lower respiratory tract , kidney , small intestine , liver , and the cells of the immune system 26 - 27 .", "labels": [[48, 53, "ENTITY"], [15, 24, "PROTEIN"], [42, 53, "CELL_TYPE"], [42, 53, "TAXON"], [70, 91, "GENE_OR_GENE_PRODUCT"], [70, 91, "PROTEIN"], [70, 91, "GGP"], [42, 53, "ORGANISM"], [15, 24, "ENTITY"], [15, 24, "ORGANISM"], [70, 91, "ENTITY"], [124, 146, "ENTITY"], [146, 154, "ORGAN"], [169, 179, "ORGAN"], [154, 169, "ENTITY"], [169, 179, "ENTITY"], [146, 154, "ENTITY"], [203, 210, "ENTITY"]]}
{"text": "The host CD26 receptor cleaves amino-terminal dipeptides from polypeptides with either L-proline or L-alanine in the penultimate position , leading to T-cell activation and thus acting as a key immunoregulatory factor in viral infections [ 9 ] .", "labels": [[87, 97, "CHEMICAL"], [100, 110, "CHEBI"], [87, 97, "CHEBI"], [129, 138, "SO"], [9, 57, "GGP"], [87, 97, "SIMPLE_CHEMICAL"], [4, 9, "ENTITY"], [100, 110, "CHEMICAL"], [9, 14, "GENE_OR_GENE_PRODUCT"], [31, 57, "ENTITY"], [87, 97, "ENTITY"], [194, 211, "ENTITY"], [117, 138, "ENTITY"], [151, 158, "ENTITY"], [9, 23, "ENTITY"], [221, 227, "ENTITY"], [221, 227, "DISEASE"], [62, 75, "ENTITY"], [100, 110, "SIMPLE_CHEMICAL"], [100, 110, "ENTITY"], [4, 23, "PROTEIN"], [194, 211, "PROTEIN"]]}
{"text": "Although its functions are not fully understood yet , DPP4 plays a major role in glucose and insulin metabolism .", "labels": [[13, 23, "ENTITY"], [93, 101, "ENTITY"]]}
{"text": "Although its functions are not fully understood yet , DPP4 plays a major role in glucose and insulin metabolism .", "labels": [[13, 23, "ENTITY"], [93, 101, "ENTITY"]]}
{"text": "DPP4 degrades incretins such as glucagon like peptide 1 ( GLP-1 ) and glucose-dependent insulinotropic polypeptide , ultimately leading to reduced insulin secretion and abnormal visceral adipose tissue metabolism .", "labels": [[66, 88, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [5, 14, "ENTITY"], [46, 56, "ENTITY"], [139, 155, "ENTITY"], [66, 103, "GGP"], [70, 88, "CHEMICAL"], [169, 195, "TISSUE"], [0, 5, "GENE_OR_GENE_PRODUCT"], [169, 178, "ENTITY"], [66, 103, "ENTITY"], [32, 41, "GGP"], [46, 54, "SO"], [32, 56, "GENE_OR_GENE_PRODUCT"], [195, 202, "ENTITY"], [32, 41, "ENTITY"], [139, 147, "GENE_OR_GENE_PRODUCT"], [139, 147, "PROTEIN"], [0, 5, "ENTITY"], [14, 24, "PROTEIN"], [178, 195, "ENTITY"], [14, 24, "CHEBI"], [14, 24, "ENTITY"], [0, 5, "PROTEIN"], [139, 147, "GGP"], [14, 24, "SIMPLE_CHEMICAL"]]}
{"text": "DPP4 regulates postprandial glucose via degradation of GLP-1 .", "labels": [[5, 15, "ENTITY"], [28, 36, "CHEBI"], [28, 36, "ENTITY"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [55, 61, "CHEBI"], [55, 61, "SIMPLE_CHEMICAL"], [28, 36, "CHEMICAL"], [0, 5, "PROTEIN"], [0, 5, "ENTITY"], [40, 52, "ENTITY"], [28, 36, "SIMPLE_CHEMICAL"], [55, 61, "PROTEIN"], [55, 61, "ENTITY"], [15, 28, "ENTITY"]]}
{"text": "DPP4 inhibitors target the enzymatic activity of DPP4 and consequently block the breakdown of GLP-1 . This increase insulin secretion and decrease blood glucose levels in patients with type 2 diabetes .", "labels": [[94, 100, "PROTEIN"], [27, 37, "SO"], [81, 91, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [5, 16, "ENTITY"], [185, 192, "ENTITY"], [94, 100, "CHEBI"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [185, 192, "DISEASE"], [16, 23, "ENTITY"], [0, 5, "PROTEIN"], [71, 77, "ENTITY"], [94, 100, "SIMPLE_CHEMICAL"], [147, 153, "ORGANISM_SUBSTANCE"], [27, 46, "ENTITY"], [0, 5, "ENTITY"], [0, 5, "ENTITY"], [147, 161, "ENTITY"], [116, 124, "ENTITY"], [0, 5, "PROTEIN"], [94, 100, "ENTITY"], [0, 16, "GGP"]]}
{"text": "DPP4 degrades incretins such as glucagon like peptide 1 ( GLP-1 ) and glucose-dependent insulinotropic polypeptide , ultimately leading to reduced insulin secretion and abnormal visceral adipose tissue metabolism .", "labels": [[66, 88, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [5, 14, "ENTITY"], [46, 56, "ENTITY"], [139, 155, "ENTITY"], [66, 103, "GGP"], [70, 88, "CHEMICAL"], [169, 195, "TISSUE"], [0, 5, "GENE_OR_GENE_PRODUCT"], [169, 178, "ENTITY"], [66, 103, "ENTITY"], [32, 41, "GGP"], [46, 54, "SO"], [32, 56, "GENE_OR_GENE_PRODUCT"], [195, 202, "ENTITY"], [32, 41, "ENTITY"], [139, 147, "GENE_OR_GENE_PRODUCT"], [139, 147, "PROTEIN"], [0, 5, "ENTITY"], [14, 24, "PROTEIN"], [178, 195, "ENTITY"], [14, 24, "CHEBI"], [14, 24, "ENTITY"], [0, 5, "PROTEIN"], [139, 147, "GGP"], [14, 24, "SIMPLE_CHEMICAL"]]}
{"text": "DPP4 degrades incretins such as glucagon like peptide 1 ( GLP-1 ) and glucose-dependent insulinotropic polypeptide , ultimately leading to reduced insulin secretion and abnormal visceral adipose tissue metabolism .", "labels": [[66, 88, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [5, 14, "ENTITY"], [46, 56, "ENTITY"], [139, 155, "ENTITY"], [66, 103, "GGP"], [70, 88, "CHEMICAL"], [169, 195, "TISSUE"], [0, 5, "GENE_OR_GENE_PRODUCT"], [169, 178, "ENTITY"], [66, 103, "ENTITY"], [32, 41, "GGP"], [46, 54, "SO"], [32, 56, "GENE_OR_GENE_PRODUCT"], [195, 202, "ENTITY"], [32, 41, "ENTITY"], [139, 147, "GENE_OR_GENE_PRODUCT"], [139, 147, "PROTEIN"], [0, 5, "ENTITY"], [14, 24, "PROTEIN"], [178, 195, "ENTITY"], [14, 24, "CHEBI"], [14, 24, "ENTITY"], [0, 5, "PROTEIN"], [139, 147, "GGP"], [14, 24, "SIMPLE_CHEMICAL"]]}
{"text": "DPP4 inhibitors target the enzymatic activity of DPP4 and consequently block the breakdown of GLP-1 . This increase insulin secretion and decrease blood glucose levels in patients with type 2 diabetes .", "labels": [[94, 100, "PROTEIN"], [27, 37, "SO"], [81, 91, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [5, 16, "ENTITY"], [185, 192, "ENTITY"], [94, 100, "CHEBI"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [185, 192, "DISEASE"], [16, 23, "ENTITY"], [0, 5, "PROTEIN"], [71, 77, "ENTITY"], [94, 100, "SIMPLE_CHEMICAL"], [147, 153, "ORGANISM_SUBSTANCE"], [27, 46, "ENTITY"], [0, 5, "ENTITY"], [0, 5, "ENTITY"], [147, 161, "ENTITY"], [116, 124, "ENTITY"], [0, 5, "PROTEIN"], [94, 100, "ENTITY"], [0, 16, "GGP"]]}
{"text": "DPP4 regulates postprandial glucose via degradation of GLP-1 .", "labels": [[5, 15, "ENTITY"], [28, 36, "CHEBI"], [0, 5, "GGP"], [28, 36, "CHEMICAL"], [0, 5, "GENE_OR_GENE_PRODUCT"], [55, 61, "CHEBI"], [55, 61, "SIMPLE_CHEMICAL"], [28, 36, "SIMPLE_CHEMICAL"], [28, 36, "ENTITY"], [0, 5, "ENTITY"], [0, 5, "PROTEIN"], [40, 52, "ENTITY"], [55, 61, "PROTEIN"], [55, 61, "ENTITY"], [15, 28, "ENTITY"]]}
{"text": "DPP4 plays also an important role in immune regulation by activating T cells and upregulating CD86 expression and NF-\u03baB pathway .", "labels": [[94, 99, "GENE_OR_GENE_PRODUCT"], [69, 77, "CELL"], [69, 77, "CL"], [94, 99, "ENTITY"], [99, 110, "ENTITY"], [37, 55, "ENTITY"], [58, 77, "ENTITY"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [0, 5, "PROTEIN"], [81, 94, "ENTITY"], [0, 5, "ENTITY"], [69, 77, "CELL_TYPE"], [94, 99, "PROTEIN"], [114, 120, "DNA"], [114, 120, "CHEMICAL"], [114, 120, "GENE_OR_GENE_PRODUCT"], [114, 128, "ENTITY"]]}
{"text": "DPP4 plays also an important role in immune regulation by activating T cells and upregulating CD86 expression and NF-\u03baB pathway .", "labels": [[69, 77, "CL"], [99, 110, "ENTITY"], [94, 99, "ENTITY"], [37, 55, "ENTITY"], [58, 77, "ENTITY"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [69, 77, "CELL_TYPE"], [94, 99, "PROTEIN"], [69, 77, "CELL"], [0, 5, "PROTEIN"], [81, 94, "ENTITY"], [0, 5, "ENTITY"], [114, 120, "DNA"], [114, 120, "CHEMICAL"], [114, 120, "GENE_OR_GENE_PRODUCT"], [94, 99, "GENE_OR_GENE_PRODUCT"], [114, 128, "ENTITY"]]}
{"text": "DPP4 plays also an important role in immune regulation by activating T cells and upregulating CD86 expression and NF-\u03baB pathway .", "labels": [[94, 99, "GENE_OR_GENE_PRODUCT"], [69, 77, "CL"], [94, 99, "ENTITY"], [99, 110, "ENTITY"], [37, 55, "ENTITY"], [58, 77, "ENTITY"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [69, 77, "CELL_TYPE"], [69, 77, "CELL"], [0, 5, "PROTEIN"], [81, 94, "ENTITY"], [0, 5, "ENTITY"], [94, 99, "PROTEIN"], [114, 120, "DNA"], [114, 120, "CHEMICAL"], [114, 120, "GENE_OR_GENE_PRODUCT"], [114, 128, "ENTITY"]]}
{"text": "DPP4 plays also an important role in immune regulation by activating T cells and upregulating CD86 expression and NF-\u03baB pathway .", "labels": [[94, 99, "GENE_OR_GENE_PRODUCT"], [69, 77, "CL"], [94, 99, "ENTITY"], [99, 110, "ENTITY"], [37, 55, "ENTITY"], [58, 77, "ENTITY"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [69, 77, "CELL_TYPE"], [69, 77, "CELL"], [0, 5, "PROTEIN"], [81, 94, "ENTITY"], [0, 5, "ENTITY"], [94, 99, "PROTEIN"], [114, 120, "DNA"], [114, 120, "CHEMICAL"], [114, 120, "GENE_OR_GENE_PRODUCT"], [114, 128, "ENTITY"]]}
{"text": "Individuals with type 2 diabetes and obesity are commonly prescribed with DPP-4 inhibitors and/or GLP-1 receptor analogs .", "labels": [[37, 45, "DISEASE"], [98, 104, "SIMPLE_CHEMICAL"], [80, 91, "CHEBI"], [98, 113, "GGP"], [17, 33, "DISEASE"], [58, 69, "ENTITY"], [113, 121, "ENTITY"], [0, 12, "ENTITY"], [98, 113, "PROTEIN"], [74, 91, "ENTITY"], [98, 113, "ENTITY"], [17, 33, "ENTITY"], [37, 45, "ENTITY"], [0, 12, "TAXON"], [74, 80, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Individuals with type 2 diabetes and obesity are commonly prescribed with DPP-4 inhibitors and/or GLP-1 receptor analogs .", "labels": [[98, 104, "SIMPLE_CHEMICAL"], [80, 91, "CHEBI"], [98, 113, "GGP"], [58, 69, "ENTITY"], [17, 33, "DISEASE"], [37, 45, "ENTITY"], [113, 121, "ENTITY"], [0, 12, "ENTITY"], [98, 113, "PROTEIN"], [74, 91, "ENTITY"], [37, 45, "DISEASE"], [98, 113, "ENTITY"], [17, 33, "ENTITY"], [0, 12, "TAXON"], [74, 80, "GENE_OR_GENE_PRODUCT"]]}
{"text": "DPP4 inhibitors target the enzymatic activity of DPP4 and consequently block the breakdown of GLP-1 . This increase insulin secretion and decrease blood glucose levels in patients with type 2 diabetes .", "labels": [[147, 161, "ENTITY"], [94, 100, "PROTEIN"], [27, 37, "SO"], [81, 91, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [5, 16, "ENTITY"], [185, 192, "ENTITY"], [94, 100, "CHEBI"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [185, 192, "DISEASE"], [16, 23, "ENTITY"], [0, 5, "PROTEIN"], [71, 77, "ENTITY"], [94, 100, "SIMPLE_CHEMICAL"], [147, 153, "ORGANISM_SUBSTANCE"], [27, 46, "ENTITY"], [0, 5, "ENTITY"], [0, 5, "ENTITY"], [116, 124, "ENTITY"], [0, 5, "PROTEIN"], [94, 100, "ENTITY"], [0, 16, "GGP"]]}
{"text": "PKR is induced by IFN and activated by the binding of double-stranded RNA ( dsRNA ) after virus infection ( Clemens and Elia , 1997 ) . HRI is activated in red blood cells and hepatocytes by low levels of heme ( McEwenet al. , 2005 ) . GCN2 senses amino acid deficiency and is activated via binding to uncharged transfer RNAs ( Sood et al. , 2000 ) .", "labels": [[236, 248, "CHEMICAL"], [291, 312, "ENTITY"], [195, 202, "GENE_OR_GENE_PRODUCT"], [166, 176, "ENTITY"], [205, 212, "PROTEIN"], [18, 22, "GGP"], [236, 248, "CHEBI"], [312, 321, "ORGANISM"], [84, 96, "DISEASE"], [54, 74, "ENTITY"], [166, 176, "CELL_TYPE"], [7, 15, "ENTITY"], [143, 166, "CELL"], [166, 176, "CELL"], [18, 22, "CHEMICAL"], [312, 321, "CHEMICAL"], [195, 202, "PROTEIN"], [54, 74, "RNA"], [195, 202, "CHEBI"], [43, 51, "ENTITY"], [26, 36, "ENTITY"], [0, 4, "ENTITY"], [143, 166, "CELL_TYPE"], [18, 22, "ENTITY"], [143, 166, "CL"], [166, 176, "CL"], [70, 74, "SO"], [176, 195, "ENTITY"], [236, 259, "ENTITY"], [195, 202, "ENTITY"], [143, 166, "ENTITY"], [0, 4, "PROTEIN"], [136, 143, "ENTITY"], [0, 4, "GENE_OR_GENE_PRODUCT"], [259, 277, "ENTITY"], [26, 36, "ENTITY"], [205, 212, "ENTITY"], [18, 22, "GENE_OR_GENE_PRODUCT"], [236, 248, "AMINO_ACID"], [18, 22, "PROTEIN"], [84, 96, "ENTITY"]]}
{"text": "In agreement with these findings , directed expression of human and bat ( Rhinolophus alcyone ) ACE2 but not human DPP4 , the entry receptor used by MERS-CoV ( Raj et al. , 2013 ) , or human APN , the entry receptor used by HCoV-229E ( Yeager et al.,1992 ) , allowed SARS-2-S- and SARS-S-driven entry into otherwise non-susceptible BHK-21 cells ( Figure 3A ) .", "labels": [[301, 332, "CELL_LINE"], [141, 149, "ENTITY"], [122, 132, "ENTITY"], [301, 332, "CL"], [301, 316, "ENTITY"], [332, 339, "ENTITY"], [332, 339, "GENE_OR_GENE_PRODUCT"], [72, 86, "ENTITY"], [301, 332, "CELL"], [105, 115, "GGP"], [191, 207, "ENTITY"], [58, 64, "ENTITY"], [105, 115, "ORGANISM"], [24, 33, "ENTITY"], [316, 332, "ENTITY"], [178, 185, "ORGANISM"], [267, 281, "SIMPLE_CHEMICAL"], [141, 149, "ORGANISM"], [301, 316, "CHEMICAL"], [105, 115, "PROTEIN"], [267, 281, "CHEMICAL"], [267, 281, "ENTITY"], [178, 185, "PROTEIN"], [3, 13, "ENTITY"]]}
{"text": "Human DPP4\u2014a receptor for the lineage C betacoronaviruses \u2014 only mediated entry of MERS-CoV , whereas APN only mediated entry of the alphacoronavirus HCoV-229E ( Fig. 2b ) .", "labels": [[0, 22, "ORGANISM"], [129, 150, "ORGANISM"], [6, 22, "ENTITY"], [0, 22, "PROTEIN"], [0, 6, "TAXON"], [30, 58, "PROTEIN"], [30, 58, "ENTITY"], [0, 6, "ENTITY"], [6, 13, "CHEMICAL"], [129, 150, "ENTITY"]]}
{"text": "That cathepsins use HCoV-OC43 for entry into HCT-8 cells was confirmed by an entry inhibition assay similar to that in HBTE-ALI cultures ( Fig. 3b and c ) .", "labels": [[83, 100, "ENTITY"], [5, 16, "GENE_OR_GENE_PRODUCT"], [5, 16, "PROTEIN"], [119, 137, "CELL_LINE"], [34, 40, "ENTITY"], [20, 30, "ORGANISM"], [119, 128, "CHEMICAL"], [45, 57, "CL"], [139, 144, "CELL"], [45, 57, "ENTITY"], [34, 40, "ENTITY"], [119, 137, "ENTITY"], [5, 16, "ENTITY"], [45, 57, "CELL"], [119, 137, "CELL"], [45, 57, "CELL_LINE"]]}
{"text": "SARS-CoV and Middle East respiratory syndrome (MERS)-CoV can enter cells via endocytosis and use cathepsin in endosomes for activation ( 12\u201314 ) . However , TMPRSS2 expression greatly promotes replication and syncytium formation in these viruses in vitro and in vivo ( 5 , 6 , 11 , 12 , 15 ) .", "labels": [[67, 73, "ENTITY"], [97, 107, "PROTEIN"], [209, 219, "ENTITY"], [238, 249, "ENTITY"], [97, 107, "ENTITY"], [184, 193, "ENTITY"], [97, 107, "GENE_OR_GENE_PRODUCT"], [157, 165, "ENTITY"], [46, 57, "GENE_OR_GENE_PRODUCT"], [0, 9, "ORGANISM"], [46, 57, "ENTITY"], [13, 46, "ENTITY"], [77, 89, "ENTITY"], [124, 135, "ENTITY"], [97, 120, "GGP"], [147, 157, "GGP"], [67, 73, "CELL"], [25, 46, "DISEASE"], [147, 157, "GENE_OR_GENE_PRODUCT"], [67, 73, "CL"], [176, 184, "ENTITY"], [147, 157, "PROTEIN"], [255, 262, "ENTITY"], [0, 9, "ENTITY"], [110, 120, "ENTITY"], [147, 157, "ENTITY"], [110, 120, "CELLULAR_COMPONENT"]]}
{"text": "This idea is based on observations that the angiotensin-converting enzyme 2 ( ACE2 ) very likely serves as the binding site for SARS-CoV-2 , the strain implicated in the current COVID-19 epidemic , similarly to strain SARS-CoV implicated in the 2002\u20132003 SARS epidemic .", "labels": [[170, 178, "GENE_OR_GENE_PRODUCT"], [170, 178, "ENTITY"], [107, 119, "ENTITY"], [107, 119, "SO"], [128, 133, "ENTITY"], [67, 74, "SO"], [44, 76, "ENTITY"], [178, 187, "ENTITY"], [107, 119, "DNA"], [22, 35, "ENTITY"], [44, 76, "GENE_OR_GENE_PRODUCT"], [44, 76, "PROTEIN"], [208, 218, "ENTITY"]]}
{"text": "Human ACE2 is the receptor for both SARS-CoV and SARS-CoV-2 .", "labels": [[0, 11, "GGP"], [49, 60, "ORGANISM"], [36, 45, "GGP"], [0, 11, "ORGANISM"], [6, 11, "ENTITY"], [18, 27, "ENTITY"], [49, 60, "ENTITY"], [0, 11, "PROTEIN"], [0, 6, "ENTITY"], [36, 45, "ORGANISM"], [49, 60, "CHEMICAL"], [36, 45, "ENTITY"]]}
{"text": "Not only has ACE2 facilitated the invasion of SARS virus for rapid replication , but also ACE2 is depleted from the cell membrane and therefore the damaging effects of Ang II are enhanced , resulting in acute deterioration of lung tissues [ 5 ] .", "labels": [[51, 57, "TAXON"], [223, 231, "TISSUE"], [223, 231, "ENTITY"], [148, 157, "ENTITY"], [168, 172, "GGP"], [13, 18, "ENTITY"], [116, 121, "CL"], [46, 51, "DISEASE"], [13, 18, "PROTEIN"], [46, 57, "ORGANISM"], [61, 67, "ENTITY"], [168, 172, "PROTEIN"], [168, 172, "CHEMICAL"], [34, 43, "ENTITY"], [46, 57, "ENTITY"], [67, 79, "ENTITY"], [168, 172, "GENE_OR_GENE_PRODUCT"], [116, 121, "CELLULAR_COMPONENT"], [13, 18, "GGP"], [13, 18, "GENE_OR_GENE_PRODUCT"], [116, 121, "ENTITY"], [200, 209, "ENTITY"], [168, 172, "ENTITY"]]}
{"text": "Similar to SARS-CoV , SARS-CoV-2 also uses the ACE2 receptor to invade human alveolar epithelial cells .", "labels": [[47, 52, "ENTITY"], [11, 20, "ORGANISM"], [71, 97, "CELL_TYPE"], [77, 97, "ENTITY"], [47, 52, "PROTEIN"], [11, 20, "ENTITY"], [71, 97, "ORGANISM"], [11, 20, "PROTEIN"], [71, 97, "TAXON"]]}
{"text": "ACE2 is also one of the primary receptors for SARS-CoV invasion into the human body.15", "labels": [[46, 64, "ENTITY"], [0, 5, "PROTEIN"], [46, 55, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [46, 55, "ORGANISM"], [73, 79, "ENTITY"], [0, 5, "ENTITY"], [24, 42, "PROTEIN"], [0, 5, "GGP"], [73, 79, "TAXON"], [24, 42, "ENTITY"]]}
{"text": "Daczkowski et al. demonstrated that CoV could interact with IFNstimulated gene 15 ( ISG15 ) and antagonize the IFN-mediated antiviral response ( 36 ) .", "labels": [[0, 11, "ENTITY"], [60, 82, "DNA"], [0, 11, "CHEMICAL"], [74, 79, "SO"], [36, 40, "PROTEIN"], [107, 134, "ENTITY"], [36, 40, "ORGANISM_SUBSTANCE"], [46, 55, "ENTITY"], [36, 40, "ENTITY"], [60, 82, "ENTITY"]]}
{"text": "FIGURE 7 . Model of the PI kinases and PI4P involved in SARS-CoV S-mediated entry . After SARS-CoV binds to ACE2 , PI4P , the catalytic product of PI4 KB , creates a lipid microenvironment or PI4P-enriched organelle required for the steps leading to fusion . Pharmacological inhibitors of PI4 KB , such as LY294002 or wortmannin , suppress PI4 KB activity and thereby inhibit SARSCoV S-mediated entry . Cellular factors , such as PI3Ks or Sac1 , that negatively regulate PI4P generation can also inhibit SARS-CoV S-mediated entry .", "labels": [[412, 422, "ENTITY"], [65, 76, "CL"], [122, 136, "ENTITY"], [298, 306, "SIMPLE_CHEMICAL"], [156, 166, "SIMPLE_CHEMICAL"], [0, 7, "ENTITY"], [275, 286, "GENE_OR_GENE_PRODUCT"], [412, 422, "CHEBI"], [318, 329, "ENTITY"], [24, 27, "PROTEIN"], [56, 65, "ENTITY"], [24, 27, "GENE_OR_GENE_PRODUCT"], [259, 275, "CHEBI"], [65, 84, "PROTEIN"], [451, 462, "PROTEIN"], [298, 306, "ENTITY"], [331, 344, "ENTITY"], [56, 65, "ORGANISM"], [172, 192, "CELL"], [275, 286, "PROTEIN"], [491, 504, "ORGANISM"], [306, 318, "CHEBI"], [122, 136, "PROTEIN"], [451, 462, "GENE_OR_GENE_PRODUCT"], [65, 76, "CELL"], [298, 306, "CHEMICAL"], [24, 27, "ENTITY"], [412, 422, "PROTEIN"], [462, 471, "ENTITY"], [172, 206, "ENTITY"], [65, 84, "ENTITY"], [451, 462, "ENTITY"], [476, 487, "ENTITY"], [368, 384, "ENTITY"], [275, 286, "ENTITY"], [275, 283, "ENTITY"], [156, 172, "ENTITY"], [192, 206, "GO"], [239, 250, "ENTITY"], [306, 318, "SIMPLE_CHEMICAL"], [306, 318, "ENTITY"], [156, 166, "CHEBI"], [250, 275, "ENTITY"], [306, 318, "CHEMICAL"], [412, 422, "GENE_OR_GENE_PRODUCT"]]}
{"text": "SARS-CoV-2 uses the same receptor , ACE2 , as SARS-CoV ( 2 ) , and ACE2 expression is very high in VeroE6 cells ( 7 ) .", "labels": [[0, 11, "CHEMICAL"], [43, 57, "PROTEIN"], [99, 106, "CL"], [91, 106, "CELL"], [0, 11, "SIMPLE_CHEMICAL"], [0, 11, "ENTITY"], [91, 106, "CELL_LINE"], [43, 55, "ORGANISM"], [36, 41, "ENTITY"], [25, 34, "ENTITY"], [91, 106, "ENTITY"]]}
{"text": "FIGURE 7 . Model of the PI kinases and PI4P involved in SARS-CoV S-mediated entry . After SARS-CoV binds to ACE2 , PI4P , the catalytic product of PI4 KB , creates a lipid microenvironment or PI4P-enriched organelle required for the steps leading to fusion . Pharmacological inhibitors of PI4 KB , such as LY294002 or wortmannin , suppress PI4 KB activity and thereby inhibit SARSCoV S-mediated entry . Cellular factors , such as PI3Ks or Sac1 , that negatively regulate PI4P generation can also inhibit SARS-CoV S-mediated entry .", "labels": [[412, 422, "ENTITY"], [65, 76, "CL"], [24, 27, "ENTITY"], [122, 136, "ENTITY"], [298, 306, "SIMPLE_CHEMICAL"], [156, 166, "SIMPLE_CHEMICAL"], [0, 7, "ENTITY"], [275, 286, "GENE_OR_GENE_PRODUCT"], [412, 422, "CHEBI"], [24, 27, "PROTEIN"], [318, 329, "ENTITY"], [56, 65, "ENTITY"], [259, 275, "CHEBI"], [65, 84, "PROTEIN"], [451, 462, "PROTEIN"], [298, 306, "ENTITY"], [331, 344, "ENTITY"], [56, 65, "ORGANISM"], [172, 192, "CELL"], [275, 286, "PROTEIN"], [491, 504, "ORGANISM"], [306, 318, "CHEBI"], [122, 136, "PROTEIN"], [451, 462, "GENE_OR_GENE_PRODUCT"], [65, 76, "CELL"], [298, 306, "CHEMICAL"], [412, 422, "PROTEIN"], [462, 471, "ENTITY"], [172, 206, "ENTITY"], [65, 84, "ENTITY"], [451, 462, "ENTITY"], [476, 487, "ENTITY"], [24, 27, "GENE_OR_GENE_PRODUCT"], [368, 384, "ENTITY"], [275, 286, "ENTITY"], [275, 283, "ENTITY"], [156, 172, "ENTITY"], [192, 206, "GO"], [239, 250, "ENTITY"], [306, 318, "SIMPLE_CHEMICAL"], [306, 318, "ENTITY"], [156, 166, "CHEBI"], [250, 275, "ENTITY"], [306, 318, "CHEMICAL"], [412, 422, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In agreement with these findings , directed expression of human and bat ( Rhinolophus alcyone ) ACE2 but not human DPP4 , the entry receptor used by MERS-CoV ( Raj et al. , 2013 ) , or human APN , the entry receptor used by HCoV-229E ( Yeager et al.,1992 ) , allowed SARS-2-S- and SARS-S-driven entry into otherwise non-susceptible BHK-21 cells ( Figure 3A ) .", "labels": [[301, 332, "CELL_LINE"], [141, 149, "ENTITY"], [122, 132, "ENTITY"], [301, 332, "CL"], [301, 316, "ENTITY"], [332, 339, "ENTITY"], [332, 339, "GENE_OR_GENE_PRODUCT"], [72, 86, "ENTITY"], [301, 332, "CELL"], [105, 115, "GGP"], [191, 207, "ENTITY"], [58, 64, "ENTITY"], [105, 115, "ORGANISM"], [24, 33, "ENTITY"], [316, 332, "ENTITY"], [178, 185, "ORGANISM"], [267, 281, "SIMPLE_CHEMICAL"], [141, 149, "ORGANISM"], [301, 316, "CHEMICAL"], [105, 115, "PROTEIN"], [267, 281, "CHEMICAL"], [267, 281, "ENTITY"], [178, 185, "PROTEIN"], [3, 13, "ENTITY"]]}
{"text": "Interestingly , we found that Nsp13 interacts with two key players of IFN signaling pathway including TANK-binding kinase 1 ( TBK1 ) and TANK-binding kinase 1-binding protein 1 (TBKBP1/SINTBAD).SINTBAD acts as a critical adaptor protein between TBK1 and IKKi and therefore mediates induction of IRF-dependent transcription [ 41 ] .", "labels": [[102, 122, "GGP"], [221, 229, "CHEBI"], [133, 167, "GGP"], [133, 167, "ENTITY"], [292, 309, "ENTITY"], [102, 122, "ENTITY"], [273, 282, "ENTITY"], [102, 122, "GENE_OR_GENE_PRODUCT"], [102, 122, "PROTEIN"], [133, 177, "PROTEIN"], [70, 84, "ENTITY"], [212, 229, "PROTEIN"], [133, 167, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Interestingly , we found that Nsp13 interacts with two key players of IFN signaling pathway including TANK-binding kinase 1 ( TBK1 ) and TANK-binding kinase 1-binding protein 1 (TBKBP1/SINTBAD).SINTBAD acts as a critical adaptor protein between TBK1 and IKKi and therefore mediates induction of IRF-dependent transcription [ 41 ] .", "labels": [[102, 122, "GGP"], [221, 229, "CHEBI"], [133, 167, "GGP"], [133, 167, "ENTITY"], [102, 122, "ENTITY"], [273, 282, "ENTITY"], [102, 122, "GENE_OR_GENE_PRODUCT"], [292, 309, "ENTITY"], [102, 122, "PROTEIN"], [133, 177, "PROTEIN"], [70, 84, "ENTITY"], [212, 229, "PROTEIN"], [133, 167, "GENE_OR_GENE_PRODUCT"]]}
{"text": "ORF 8b strongly inhibited TANK-binding kinase 1-mediated induction of NF-\u03baB signaling , but not I\u03baB kinase epsilon and IRF3-mediated activations ( Lee et al. , 2019a ) .", "labels": [[70, 86, "ENTITY"], [0, 4, "SO"], [26, 46, "PROTEIN"], [96, 107, "PROTEIN"], [26, 57, "ENTITY"], [70, 76, "GENE_OR_GENE_PRODUCT"], [70, 76, "CHEMICAL"], [26, 57, "GGP"], [70, 76, "DNA"], [57, 67, "ENTITY"], [0, 7, "PROTEIN"], [0, 7, "ENTITY"], [16, 26, "ENTITY"], [96, 107, "ENTITY"], [26, 57, "GENE_OR_GENE_PRODUCT"]]}
{"text": "RNF41/Nrdp1 , an E3 ubiquitin ligase is targeted by Nsp15 protein which promotes activation of TBK1 and IRF3 and therefore increases type I interferon production 45 .", "labels": [[0, 12, "GENE_OR_GENE_PRODUCT"], [133, 140, "GENE_OR_GENE_PRODUCT"], [52, 58, "ENTITY"], [0, 12, "PROTEIN"], [0, 12, "ENTITY"], [17, 30, "PROTEIN"], [52, 58, "GGP"], [133, 140, "GGP"], [0, 12, "CHEMICAL"], [133, 162, "PROTEIN"], [52, 58, "PROTEIN"], [17, 30, "ENTITY"], [133, 140, "ENTITY"]]}
{"text": "Interestingly , we found that Nsp13 interacts with two key players of IFN signaling pathway including TANK-binding kinase 1 ( TBK1 ) and TANK-binding kinase 1-binding protein 1 (TBKBP1/SINTBAD).SINTBAD acts as a critical adaptor protein between TBK1 and IKKi and therefore mediates induction of IRF-dependent transcription [ 41 ] .", "labels": [[70, 84, "ENTITY"], [102, 122, "GGP"], [221, 229, "CHEBI"], [133, 167, "GGP"], [133, 167, "ENTITY"], [102, 122, "ENTITY"], [273, 282, "ENTITY"], [102, 122, "GENE_OR_GENE_PRODUCT"], [292, 309, "ENTITY"], [102, 122, "PROTEIN"], [133, 177, "PROTEIN"], [212, 229, "PROTEIN"], [133, 167, "GENE_OR_GENE_PRODUCT"]]}
{"text": "RNF41/Nrdp1 , an E3 ubiquitin ligase is targeted by Nsp15 protein which promotes activation of TBK1 and IRF3 and therefore increases type I interferon production [ 45 ] .", "labels": [[133, 140, "GGP"], [0, 12, "GENE_OR_GENE_PRODUCT"], [52, 58, "ENTITY"], [0, 12, "PROTEIN"], [0, 12, "ENTITY"], [17, 30, "PROTEIN"], [52, 58, "GGP"], [133, 140, "PROTEIN"], [133, 140, "GENE_OR_GENE_PRODUCT"], [0, 12, "CHEMICAL"], [133, 140, "ENTITY"], [52, 58, "PROTEIN"], [17, 30, "ENTITY"]]}
{"text": "Interestingly , we found that Nsp13 interacts with two key players of IFN signaling pathway including TANK-binding kinase 1 ( TBK1 ) and TANK-binding kinase 1-binding protein 1 (TBKBP1/SINTBAD).SINTBAD acts as a critical adaptor protein between TBK1 and IKKi and therefore mediates induction of IRF-dependent transcription [ 41 ] .", "labels": [[70, 84, "ENTITY"], [102, 122, "GGP"], [221, 229, "CHEBI"], [133, 167, "GGP"], [133, 167, "ENTITY"], [102, 122, "ENTITY"], [273, 282, "ENTITY"], [102, 122, "GENE_OR_GENE_PRODUCT"], [292, 309, "ENTITY"], [102, 122, "PROTEIN"], [133, 177, "PROTEIN"], [212, 229, "PROTEIN"], [133, 167, "GENE_OR_GENE_PRODUCT"]]}
{"text": "When the variability between nsp 3 isolates of the SARS epidemic are compared , the results suggest that nsps 1 - 3 perform cell- and host- specific roles in replication and/or virulence . Additionally , they have demonstrated high capacity for adaptation to new environments and selective pressures .", "labels": [[35, 44, "ENTITY"], [276, 290, "ENTITY"], [29, 35, "GENE_OR_GENE_PRODUCT"], [69, 78, "ENTITY"], [51, 56, "ENTITY"], [170, 177, "ENTITY"], [227, 232, "ENTITY"], [29, 35, "ENTITY"], [56, 65, "ENTITY"], [29, 35, "PROTEIN"], [9, 21, "ENTITY"], [105, 112, "PROTEIN"], [105, 110, "ENTITY"], [105, 112, "ORGANISM"], [51, 56, "DISEASE"]]}
{"text": "At 12 h post-infection ( p.i . ) , wildtype nsps 1 and 2 both displayed bright , punctate perinuclear localization , similar to that observed in MHV infection ( Fig. 4A ) .", "labels": [[133, 149, "ENTITY"], [72, 90, "CELLULAR_COMPONENT"], [133, 149, "DISEASE"], [35, 44, "GENE_OR_GENE_PRODUCT"], [81, 90, "GO"], [8, 23, "ENTITY"], [133, 142, "TAXON"], [133, 142, "ORGANISM"], [72, 102, "ENTITY"], [62, 72, "ENTITY"], [31, 51, "PROTEIN"]]}
{"text": "When the variability between nsp 3 isolates of the SARS epidemic are compared , the results suggest that nsps 1 - 3 perform cell- and host- specific roles in replication and/or virulence . Additionally , they have demonstrated high capacity for adaptation to new environments and selective pressures .", "labels": [[35, 44, "ENTITY"], [276, 290, "ENTITY"], [29, 35, "GENE_OR_GENE_PRODUCT"], [69, 78, "ENTITY"], [51, 56, "ENTITY"], [170, 177, "ENTITY"], [227, 232, "ENTITY"], [29, 35, "ENTITY"], [56, 65, "ENTITY"], [29, 35, "PROTEIN"], [9, 21, "ENTITY"], [105, 112, "PROTEIN"], [105, 110, "ENTITY"], [105, 112, "ORGANISM"], [51, 56, "DISEASE"]]}
{"text": "PLpro alone induced mRNA expression of TGF-b1 ( greater than four fold ) , IL-1a ( approximately three fold),and RANTES ( approximately two fold ) ( Fig. 2A , D , and E ) , yet no signifi- ca nt rise in TNF-a and IFN-a compared to vector controls ( Fig. 2B and C ) .", "labels": [[219, 231, "ENTITY"], [0, 6, "ENTITY"], [39, 46, "GGP"], [103, 113, "GGP"], [103, 113, "PROTEIN"], [20, 25, "ENTITY"], [103, 113, "ENTITY"], [39, 46, "ENTITY"], [25, 36, "ENTITY"], [192, 195, "PROTEIN"], [39, 46, "GENE_OR_GENE_PRODUCT"], [103, 113, "GENE_OR_GENE_PRODUCT"], [12, 20, "ENTITY"], [39, 46, "PROTEIN"], [192, 195, "ENTITY"], [192, 195, "GENE_OR_GENE_PRODUCT"], [192, 195, "GGP"], [103, 113, "CHEMICAL"], [0, 6, "GENE_OR_GENE_PRODUCT"], [20, 25, "CHEBI"]]}
{"text": "Irbesartan can inhibit NTCP , thus inhibiting viral entry45,46 . SLC10A1 interacts with C11orf74 , a potential transcriptional repressor that interacts with nsp-10 of SARS-CoV47 . There are several other ARBs ( such as eletriptan , frovatriptan , and zolmitriptan ) in which their targets are potentially associated with HCoV-associated host proteins in the human interactome .", "labels": [[245, 251, "ENTITY"], [211, 219, "SIMPLE_CHEMICAL"], [293, 305, "ENTITY"], [245, 251, "CHEMICAL"], [219, 232, "ENTITY"], [0, 11, "CHEMICAL"], [46, 52, "ENTITY"], [219, 232, "SIMPLE_CHEMICAL"], [269, 281, "ENTITY"], [211, 219, "CHEBI"], [245, 251, "CHEBI"], [219, 232, "CHEMICAL"], [101, 127, "ENTITY"], [101, 127, "PROTEIN"], [46, 52, "DISEASE"], [0, 11, "SIMPLE_CHEMICAL"], [15, 23, "ENTITY"], [23, 28, "SIMPLE_CHEMICAL"], [305, 342, "PROTEIN"], [211, 219, "ENTITY"], [46, 52, "PROTEIN"], [245, 251, "SIMPLE_CHEMICAL"], [321, 342, "CHEBI"], [354, 364, "ENTITY"], [0, 11, "ENTITY"], [305, 342, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"], [211, 219, "CHEMICAL"], [305, 342, "ENTITY"]]}
{"text": "Orf10 may bind to the CUL2-ZYG11B complex and hijack it for ubiquitination and degradation of restriction factors . The ubiquitin transfer to a substrate requires neddylation of CUL2 via NEDD8-activating enzyme ( NAE ) , a druggable target that can be inhibited by the small molecule Pevonedistat [ 68 ] ( Fig. 4c ) .", "labels": [[223, 233, "ENTITY"], [79, 91, "ENTITY"], [94, 114, "ENTITY"], [269, 275, "CHEBI"], [60, 70, "ENTITY"], [22, 42, "PROTEIN"], [10, 15, "ENTITY"], [46, 53, "ENTITY"], [265, 284, "ENTITY"], [34, 42, "ENTITY"], [0, 6, "ENTITY"], [0, 6, "PROTEIN"], [94, 114, "PROTEIN"], [187, 204, "PROTEIN"], [0, 6, "GGP"], [0, 6, "SIMPLE_CHEMICAL"], [0, 6, "CHEMICAL"], [187, 204, "ENTITY"], [60, 75, "ENTITY"]]}
{"text": "For wild-type Nsp5 , we identified one high-confidence interaction , the epigenetic regulator histone deacetylase 2 ( HDAC2 ) , and predicted a cleavage site between the HDAC domain and the nuclear localization sequence , suggesting that Nsp5 may inhibit HDAC2 transport into the nucleus ( Extended Data Fig. 7 ) , potentially impacting the published functions of HDAC2 in mediating inflammation and interferon response 38,39 .", "labels": [[132, 153, "ENTITY"], [271, 280, "CELLULAR_COMPONENT"], [198, 211, "SO"], [351, 361, "PROTEIN"], [351, 361, "GGP"], [186, 211, "DNA"], [84, 114, "GGP"], [186, 211, "ENTITY"], [14, 19, "GENE_OR_GENE_PRODUCT"], [351, 361, "GENE_OR_GENE_PRODUCT"], [247, 255, "ENTITY"], [39, 55, "ENTITY"], [69, 84, "ENTITY"], [351, 361, "ENTITY"], [14, 19, "GGP"], [247, 255, "GENE_OR_GENE_PRODUCT"], [373, 383, "DISEASE"], [247, 255, "GGP"], [280, 290, "ENTITY"], [383, 411, "ENTITY"], [84, 114, "ENTITY"], [14, 19, "ENTITY"], [238, 247, "ENTITY"], [383, 411, "PROTEIN"], [327, 351, "ENTITY"], [4, 14, "ENTITY"], [271, 280, "ENTITY"], [166, 175, "ENTITY"], [118, 124, "ENTITY"], [383, 411, "GENE_OR_GENE_PRODUCT"], [373, 383, "ENTITY"], [144, 153, "SO"], [247, 255, "PROTEIN"], [69, 114, "PROTEIN"], [166, 175, "PROTEIN"], [271, 280, "GO"], [84, 114, "GENE_OR_GENE_PRODUCT"], [118, 123, "SO"]]}
{"text": "For wild-type Nsp5 , we identified one high-confidence interaction , the epigenetic regulator histone deacetylase 2 ( HDAC2 ) , and predicted a cleavage site between the HDAC domain and the nuclear localization sequence , suggesting that Nsp5 may inhibit HDAC2 transport into the nucleus ( Extended Data Fig. 7 ) , potentially impacting the published functions of HDAC2 in mediating inflammation and interferon response 38,39 .", "labels": [[132, 153, "ENTITY"], [271, 280, "CELLULAR_COMPONENT"], [198, 211, "SO"], [351, 361, "PROTEIN"], [351, 361, "GGP"], [186, 211, "DNA"], [84, 114, "GGP"], [186, 211, "ENTITY"], [14, 19, "GENE_OR_GENE_PRODUCT"], [351, 361, "GENE_OR_GENE_PRODUCT"], [247, 255, "ENTITY"], [39, 55, "ENTITY"], [69, 84, "ENTITY"], [351, 361, "ENTITY"], [14, 19, "GGP"], [247, 255, "GENE_OR_GENE_PRODUCT"], [373, 383, "DISEASE"], [247, 255, "GGP"], [280, 290, "ENTITY"], [383, 411, "ENTITY"], [84, 114, "ENTITY"], [14, 19, "ENTITY"], [238, 247, "ENTITY"], [383, 411, "PROTEIN"], [327, 351, "ENTITY"], [4, 14, "ENTITY"], [271, 280, "ENTITY"], [166, 175, "ENTITY"], [118, 124, "ENTITY"], [383, 411, "GENE_OR_GENE_PRODUCT"], [373, 383, "ENTITY"], [144, 153, "SO"], [247, 255, "PROTEIN"], [69, 114, "PROTEIN"], [166, 175, "PROTEIN"], [271, 280, "GO"], [84, 114, "GENE_OR_GENE_PRODUCT"], [118, 123, "SO"]]}
{"text": "For wild-type Nsp5 , we identified one high-confidence interaction , the epigenetic regulator histone deacetylase 2 ( HDAC2 ) , and predicted a cleavage site between the HDAC domain and the nuclear localization sequence , suggesting that Nsp5 may inhibit HDAC2 transport into the nucleus ( Extended Data Fig. 7 ) , potentially impacting the published functions of HDAC2 in mediating inflammation and interferon response [ 38,39 ] .", "labels": [[132, 153, "ENTITY"], [271, 280, "CELLULAR_COMPONENT"], [198, 211, "SO"], [351, 361, "PROTEIN"], [351, 361, "GGP"], [186, 211, "DNA"], [84, 114, "GGP"], [186, 211, "ENTITY"], [14, 19, "GENE_OR_GENE_PRODUCT"], [383, 411, "ENTITY"], [351, 361, "GENE_OR_GENE_PRODUCT"], [247, 255, "ENTITY"], [39, 55, "ENTITY"], [69, 84, "ENTITY"], [351, 361, "ENTITY"], [14, 19, "GGP"], [247, 255, "GENE_OR_GENE_PRODUCT"], [373, 383, "DISEASE"], [247, 255, "GGP"], [280, 290, "ENTITY"], [84, 114, "ENTITY"], [383, 400, "PROTEIN"], [14, 19, "ENTITY"], [238, 247, "ENTITY"], [327, 351, "ENTITY"], [4, 14, "ENTITY"], [271, 280, "ENTITY"], [166, 175, "ENTITY"], [118, 124, "ENTITY"], [373, 383, "ENTITY"], [144, 153, "SO"], [247, 255, "PROTEIN"], [383, 411, "SIMPLE_CHEMICAL"], [69, 114, "PROTEIN"], [166, 175, "PROTEIN"], [271, 280, "GO"], [84, 114, "GENE_OR_GENE_PRODUCT"], [118, 123, "SO"]]}
{"text": "For wild-type Nsp5 , we identified one high-confidence interaction , the epigenetic regulator histone deacetylase 2 ( HDAC2 ) , and predicted a cleavage site between the HDAC domain and the nuclear localization sequence , suggesting that Nsp5 may inhibit HDAC2 transport into the nucleus ( Extended Data Fig. 7 ) , potentially impacting the published functions of HDAC2 in mediating inflammation and interferon response 38,39 .", "labels": [[132, 153, "ENTITY"], [271, 280, "CELLULAR_COMPONENT"], [198, 211, "SO"], [351, 361, "PROTEIN"], [351, 361, "GGP"], [186, 211, "DNA"], [84, 114, "GGP"], [186, 211, "ENTITY"], [14, 19, "GENE_OR_GENE_PRODUCT"], [351, 361, "GENE_OR_GENE_PRODUCT"], [247, 255, "ENTITY"], [39, 55, "ENTITY"], [69, 84, "ENTITY"], [351, 361, "ENTITY"], [14, 19, "GGP"], [247, 255, "GENE_OR_GENE_PRODUCT"], [373, 383, "DISEASE"], [247, 255, "GGP"], [280, 290, "ENTITY"], [383, 411, "ENTITY"], [84, 114, "ENTITY"], [14, 19, "ENTITY"], [238, 247, "ENTITY"], [383, 411, "PROTEIN"], [327, 351, "ENTITY"], [4, 14, "ENTITY"], [271, 280, "ENTITY"], [166, 175, "ENTITY"], [118, 124, "ENTITY"], [383, 411, "GENE_OR_GENE_PRODUCT"], [373, 383, "ENTITY"], [144, 153, "SO"], [247, 255, "PROTEIN"], [69, 114, "PROTEIN"], [166, 175, "PROTEIN"], [271, 280, "GO"], [84, 114, "GENE_OR_GENE_PRODUCT"], [118, 123, "SO"]]}
{"text": "For wild-type Nsp5 , we identified one high-confidence interaction , the epigenetic regulator histone deacetylase 2 ( HDAC2 ) , and predicted a cleavage site between the HDAC domain and the nuclear localization sequence , suggesting that Nsp5 may inhibit HDAC2 transport into the nucleus ( Extended Data Fig. 7 ) , potentially impacting the published functions of HDAC2 in mediating inflammation and interferon response [ 38,39 ] .", "labels": [[132, 153, "ENTITY"], [383, 411, "ENTITY"], [271, 280, "CELLULAR_COMPONENT"], [198, 211, "SO"], [351, 361, "PROTEIN"], [351, 361, "GGP"], [186, 211, "DNA"], [84, 114, "GGP"], [186, 211, "ENTITY"], [14, 19, "GENE_OR_GENE_PRODUCT"], [351, 361, "GENE_OR_GENE_PRODUCT"], [247, 255, "ENTITY"], [39, 55, "ENTITY"], [69, 84, "ENTITY"], [351, 361, "ENTITY"], [14, 19, "GGP"], [247, 255, "GENE_OR_GENE_PRODUCT"], [373, 383, "DISEASE"], [247, 255, "GGP"], [383, 411, "SIMPLE_CHEMICAL"], [280, 290, "ENTITY"], [84, 114, "ENTITY"], [383, 400, "PROTEIN"], [14, 19, "ENTITY"], [238, 247, "ENTITY"], [327, 351, "ENTITY"], [4, 14, "ENTITY"], [271, 280, "ENTITY"], [166, 175, "ENTITY"], [118, 124, "ENTITY"], [373, 383, "ENTITY"], [144, 153, "SO"], [247, 255, "PROTEIN"], [69, 114, "PROTEIN"], [166, 175, "PROTEIN"], [271, 280, "GO"], [84, 114, "GENE_OR_GENE_PRODUCT"], [118, 123, "SO"]]}
{"text": "Key viral-cellular PPIs that may influence the pathogenesis of SARS-CoV-2 include interaction between NKRF ( an endogenous repressor of IL-8/IL-6 synthesis ) and nsp9/nsp10/nsp12/nsp13/nsp15 20,21 , C1QBP ( involved in complement C1 activation ) and nsp9/nsp10 22 , G3BP2 ( anti-viral stress granule protein ) and N 23 , and RAE1 ( an interferon-inducible mRNA nuclear export protein ) and ORF6 24 .", "labels": [[158, 191, "DNA"], [300, 310, "GENE_OR_GENE_PRODUCT"], [4, 19, "ENTITY"], [335, 361, "CHEBI"], [216, 233, "ENTITY"], [102, 107, "ENTITY"], [63, 74, "GENE_OR_GENE_PRODUCT"], [47, 60, "ENTITY"], [325, 335, "ENTITY"], [63, 74, "ENTITY"], [33, 43, "ENTITY"], [158, 191, "ENTITY"], [266, 300, "PROTEIN"], [102, 107, "GENE_OR_GENE_PRODUCT"], [266, 300, "CL"], [19, 24, "ENTITY"], [325, 335, "GENE_OR_GENE_PRODUCT"], [300, 314, "ENTITY"], [63, 74, "CHEMICAL"], [300, 310, "DNA"], [82, 94, "ENTITY"], [266, 300, "ENTITY"], [325, 376, "PROTEIN"], [369, 376, "CHEBI"], [335, 361, "CELLULAR_COMPONENT"]]}
{"text": "Key viral-cellular PPIs that may influence the pathogenesis of SARS-CoV-2 include interaction between NKRF ( an endogenous repressor of IL-8/IL-6 synthesis ) and nsp9/nsp10/nsp12/nsp13/nsp15 20,21 , C1QBP ( involved in complement C1 activation ) and nsp9/nsp10 22 , G3BP2 ( anti-viral stress granule protein ) and N 23 , and RAE1 ( an interferon-inducible mRNA nuclear export protein ) and ORF6 24 .", "labels": [[158, 191, "DNA"], [300, 310, "GENE_OR_GENE_PRODUCT"], [4, 19, "ENTITY"], [102, 107, "ENTITY"], [335, 361, "CHEBI"], [63, 74, "GENE_OR_GENE_PRODUCT"], [47, 60, "ENTITY"], [325, 335, "ENTITY"], [63, 74, "ENTITY"], [33, 43, "ENTITY"], [158, 191, "ENTITY"], [266, 300, "PROTEIN"], [266, 300, "CL"], [102, 107, "GENE_OR_GENE_PRODUCT"], [19, 24, "ENTITY"], [325, 335, "GENE_OR_GENE_PRODUCT"], [300, 314, "ENTITY"], [63, 74, "CHEMICAL"], [300, 310, "DNA"], [82, 94, "ENTITY"], [266, 300, "ENTITY"], [216, 233, "ENTITY"], [325, 376, "PROTEIN"], [369, 376, "CHEBI"], [335, 361, "CELLULAR_COMPONENT"]]}
{"text": "Key viral-cellular PPIs that may influence the pathogenesis of SARS-CoV-2 include interaction between NKRF ( an endogenous repressor of IL-8/IL-6 synthesis ) and nsp9/nsp10/nsp12/nsp13/nsp15 20,21 , C1QBP ( involved in complement C1 activation ) and nsp9/nsp10 22 , G3BP2 ( anti-viral stress granule protein ) and N 23 , and RAE1 ( an interferon-inducible mRNA nuclear export protein ) and ORF6 24 .", "labels": [[158, 191, "DNA"], [300, 310, "GENE_OR_GENE_PRODUCT"], [4, 19, "ENTITY"], [102, 107, "ENTITY"], [335, 361, "CHEBI"], [63, 74, "GENE_OR_GENE_PRODUCT"], [47, 60, "ENTITY"], [325, 335, "ENTITY"], [63, 74, "ENTITY"], [33, 43, "ENTITY"], [158, 191, "ENTITY"], [266, 300, "PROTEIN"], [266, 300, "CL"], [102, 107, "GENE_OR_GENE_PRODUCT"], [19, 24, "ENTITY"], [325, 335, "GENE_OR_GENE_PRODUCT"], [300, 314, "ENTITY"], [63, 74, "CHEMICAL"], [300, 310, "DNA"], [82, 94, "ENTITY"], [266, 300, "ENTITY"], [216, 233, "ENTITY"], [325, 376, "PROTEIN"], [369, 376, "CHEBI"], [335, 361, "CELLULAR_COMPONENT"]]}
{"text": "The human purine biosynthesis enzyme Inosine-5\u2032-monophosphate dehydrogenase ( IMPDH2 ) interacts with the viral protein nsp14 . Several chemically diverse compounds inhibit IMPDH2 , including the clinically approved mycophenolic acid ( 20 nM ) , the approved antiviral drug ribavirin ( 200 nM ) , and the investigational new drug Merimepodib ( 10 nM ) ( Table 1a ) .", "labels": [[4, 76, "PROTEIN"], [102, 120, "PROTEIN"], [30, 37, "SO"], [37, 62, "CHEMICAL"], [259, 274, "CHEMICAL"], [165, 173, "PROTEIN"], [295, 305, "ENTITY"], [10, 17, "CHEMICAL"], [102, 112, "TAXON"], [10, 30, "ENTITY"], [207, 229, "ENTITY"], [4, 17, "TAXON"], [207, 229, "CHEMICAL"], [147, 155, "ENTITY"], [165, 173, "GENE_OR_GENE_PRODUCT"], [4, 10, "ENTITY"], [250, 274, "ENTITY"], [128, 147, "ENTITY"], [30, 76, "ENTITY"], [165, 173, "GGP"], [147, 155, "CHEBI"], [37, 76, "GENE_OR_GENE_PRODUCT"], [207, 229, "CHEBI"], [102, 120, "ENTITY"], [207, 229, "SIMPLE_CHEMICAL"], [155, 165, "ENTITY"], [165, 173, "ENTITY"], [4, 17, "ORGANISM"], [259, 274, "SIMPLE_CHEMICAL"]]}
{"text": "RNF41/Nrdp1 , an E3 ubiquitin ligase is targeted by Nsp15 protein which promotes activation of TBK1 and IRF3 and therefore increases type I interferon production [ 45 ] .", "labels": [[52, 58, "ENTITY"], [0, 12, "ENTITY"], [133, 140, "GGP"], [133, 140, "PROTEIN"], [17, 30, "PROTEIN"], [0, 12, "CHEMICAL"], [52, 58, "GGP"], [0, 12, "GENE_OR_GENE_PRODUCT"], [0, 12, "PROTEIN"], [133, 140, "GENE_OR_GENE_PRODUCT"], [52, 58, "PROTEIN"], [17, 30, "ENTITY"], [133, 140, "ENTITY"]]}
{"text": "RNF41/Nrdp1 , an E3 ubiquitin ligase is targeted by Nsp15 protein which promotes activation of TBK1 and IRF3 and therefore increases type I interferon production [ 45 ] .", "labels": [[52, 58, "ENTITY"], [0, 12, "ENTITY"], [133, 140, "GGP"], [133, 140, "PROTEIN"], [17, 30, "PROTEIN"], [0, 12, "CHEMICAL"], [52, 58, "GGP"], [0, 12, "GENE_OR_GENE_PRODUCT"], [0, 12, "PROTEIN"], [133, 140, "GENE_OR_GENE_PRODUCT"], [52, 58, "PROTEIN"], [17, 30, "ENTITY"], [133, 140, "ENTITY"]]}
{"text": "RNF41/Nrdp1 , an E3 ubiquitin ligase is targeted by Nsp15 protein which promotes activation of TBK1 and IRF3 and therefore increases type I interferon production [ 45 ] .", "labels": [[133, 140, "GGP"], [52, 58, "ENTITY"], [0, 12, "ENTITY"], [17, 30, "PROTEIN"], [0, 12, "CHEMICAL"], [52, 58, "GGP"], [0, 12, "GENE_OR_GENE_PRODUCT"], [0, 12, "PROTEIN"], [133, 140, "PROTEIN"], [133, 140, "GENE_OR_GENE_PRODUCT"], [133, 140, "ENTITY"], [52, 58, "PROTEIN"], [17, 30, "ENTITY"]]}
{"text": "Key viral-cellular PPIs that may influence the pathogenesis of SARS-CoV-2 include interaction between NKRF ( an endogenous repressor of IL-8/IL-6 synthesis ) and nsp9/nsp10/nsp12/nsp13/nsp15 20,21 , C1QBP ( involved in complement C1 activation ) and nsp9/nsp10 22 , G3BP2 ( anti-viral stress granule protein ) and N 23 , and RAE1 ( an interferon-inducible mRNA nuclear export protein ) and ORF6 24 .", "labels": [[158, 191, "DNA"], [300, 310, "GENE_OR_GENE_PRODUCT"], [4, 19, "ENTITY"], [335, 361, "CHEBI"], [369, 376, "CHEBI"], [102, 107, "ENTITY"], [63, 74, "GENE_OR_GENE_PRODUCT"], [47, 60, "ENTITY"], [63, 74, "ENTITY"], [33, 43, "ENTITY"], [158, 191, "ENTITY"], [266, 300, "PROTEIN"], [325, 335, "GENE_OR_GENE_PRODUCT"], [102, 107, "GENE_OR_GENE_PRODUCT"], [266, 300, "CL"], [19, 24, "ENTITY"], [300, 314, "ENTITY"], [325, 335, "ENTITY"], [63, 74, "CHEMICAL"], [300, 310, "DNA"], [82, 94, "ENTITY"], [266, 300, "ENTITY"], [216, 233, "ENTITY"], [335, 361, "CELLULAR_COMPONENT"], [325, 376, "PROTEIN"]]}
{"text": "The other antiviral drugs include nitazoxanide , favipiravir , nafamostat , and so on ( See Table 1 for details ) .", "labels": [[34, 47, "ENTITY"], [34, 47, "CHEMICAL"], [10, 26, "ENTITY"], [34, 47, "CHEBI"], [34, 47, "SIMPLE_CHEMICAL"]]}
{"text": "According to Zhou and colleagues , in coronaviruses , teicoplanin acts on the early step of the viral life cycle by inhibiting the low pH cleavage of the viral spike protein by cathepsin L in the late endosomes thereby preventing the release of genomic viral RNA and the continuation of virus replication cycle .", "labels": [[150, 166, "ENTITY"], [92, 107, "ENTITY"], [13, 18, "ENTITY"], [160, 166, "CHEBI"], [174, 187, "GENE_OR_GENE_PRODUCT"], [22, 33, "ENTITY"], [242, 259, "ENTITY"], [192, 201, "CELLULAR_COMPONENT"], [174, 187, "ENTITY"], [174, 187, "GGP"], [174, 187, "PROTEIN"], [150, 166, "PROTEIN"], [192, 201, "GO"], [135, 138, "ENTITY"], [131, 135, "ENTITY"], [242, 259, "SO"], [284, 305, "ENTITY"], [242, 259, "RNA"], [192, 201, "ENTITY"]]}
{"text": "According to Zhou and colleagues , in coronaviruses , teicoplanin acts on the early step of the viral life cycle by inhibiting the low pH cleavage of the viral spike protein by cathepsin L in the late endosomes thereby preventing the release of genomic viral RNA and the continuation of virus replication cycle .", "labels": [[150, 166, "ENTITY"], [92, 107, "ENTITY"], [13, 18, "ENTITY"], [160, 166, "CHEBI"], [174, 187, "GENE_OR_GENE_PRODUCT"], [22, 33, "ENTITY"], [242, 259, "ENTITY"], [192, 201, "CELLULAR_COMPONENT"], [174, 187, "ENTITY"], [174, 187, "GGP"], [174, 187, "PROTEIN"], [150, 166, "PROTEIN"], [192, 201, "GO"], [135, 138, "ENTITY"], [131, 135, "ENTITY"], [242, 259, "SO"], [284, 305, "ENTITY"], [242, 259, "RNA"], [192, 201, "ENTITY"]]}
{"text": "Accordingly , we infected the cells with SARS-CoV- , or 2019- nCoV -S- pseudotyped HIV-1 viruses after siRNA-mediated knockdown of the expression of cathepsin L and TMPRSS2 and found that both cathepsin L and TMPRSS2 depletion impaired the cell entry of pseudoviruses ( Figure 1C ) , indicating that both cathepsin L and TMPRSS2 are required for 2019- nCoV cell entry .", "labels": [[146, 159, "ENTITY"], [268, 277, "ENTITY"], [146, 159, "GENE_OR_GENE_PRODUCT"], [83, 89, "TAXON"], [67, 89, "ORGANISM"], [62, 67, "CL"], [188, 203, "ENTITY"], [146, 159, "GGP"], [103, 118, "ENTITY"], [67, 71, "ENTITY"], [71, 89, "ENTITY"], [188, 203, "GGP"], [346, 362, "ENTITY"], [146, 159, "PROTEIN"], [188, 203, "GENE_OR_GENE_PRODUCT"], [165, 173, "ENTITY"], [62, 67, "CELL"], [56, 67, "ENTITY"], [26, 35, "ENTITY"], [188, 203, "PROTEIN"], [217, 227, "ENTITY"]]}
{"text": "Accordingly , we infected the cells with SARS-CoV- , or 2019-nCoV-S-pseudotyped HIV-1 viruses after siRNA-mediated knockdown of the expression of cathepsin L and TMPRSS2 and found that both cathepsin L and TMPRSS2 depletion impaired the cell entry of pseudoviruses ( Figure 1C ) , indicating that both cathepsin L and TMPRSS2 are required for 2019-nCoV cell entry .", "labels": [[265, 274, "ENTITY"], [80, 86, "TAXON"], [339, 353, "CELL"], [214, 224, "ENTITY"], [143, 156, "GENE_OR_GENE_PRODUCT"], [339, 358, "ENTITY"], [56, 66, "CL"], [162, 170, "ENTITY"], [56, 80, "ORGANISM"], [26, 35, "ENTITY"], [143, 156, "PROTEIN"], [185, 200, "ENTITY"], [53, 86, "ENTITY"], [143, 156, "GGP"], [185, 200, "GGP"], [100, 115, "ENTITY"], [143, 156, "ENTITY"], [185, 200, "GENE_OR_GENE_PRODUCT"], [185, 200, "PROTEIN"]]}
{"text": "We observed about 3 to 4 fold increase in luciferase activity in 3a expressing cells as compared to the vector control cells .", "labels": [[104, 125, "ENTITY"], [79, 85, "CL"], [42, 62, "ENTITY"], [42, 53, "GENE_OR_GENE_PRODUCT"], [104, 111, "SO"], [68, 79, "ENTITY"], [79, 85, "CELL"], [79, 85, "CELL"], [3, 12, "ENTITY"], [79, 85, "CL"], [42, 53, "PROTEIN"], [30, 39, "ENTITY"], [104, 125, "CELL_LINE"], [79, 85, "ENTITY"]]}
{"text": "The identified target genes of ATF6 include ER chaperones ( such as GRP78 , GRP94 ) , PDI , and the UPR transcription factors GADD153 and XBP1 ( Szegezdi et al. , 2006 ) .", "labels": [[22, 28, "SO"], [44, 58, "ENTITY"], [44, 58, "PROTEIN"], [138, 145, "PROTEIN"], [31, 36, "ENTITY"], [44, 47, "GENE_OR_GENE_PRODUCT"], [31, 36, "GGP"], [15, 22, "ENTITY"], [118, 126, "ENTITY"], [118, 126, "GENE_OR_GENE_PRODUCT"], [96, 126, "PROTEIN"], [138, 145, "GENE_OR_GENE_PRODUCT"], [44, 58, "GGP"], [31, 36, "PROTEIN"], [4, 15, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [118, 126, "GGP"], [22, 28, "ENTITY"]]}
{"text": "These results show that blocking CD147 on the host cells has an inhibitory effect on SARS-CoV-2 , suggesting an essential role of CD147 in facilitating SARS-CoV-2 invasion for host cells .", "labels": [[85, 96, "ENTITY"], [85, 96, "ENTITY"], [33, 39, "ENTITY"], [46, 51, "CL"], [64, 75, "ENTITY"], [46, 57, "CELL_TYPE"], [6, 14, "ENTITY"], [46, 51, "CELL_TYPE"], [46, 51, "CELL"], [46, 57, "CL"], [46, 57, "CELL"], [24, 33, "ENTITY"], [85, 96, "CHEMICAL"], [33, 39, "GGP"], [33, 39, "PROTEIN"], [46, 57, "ENTITY"], [46, 51, "ENTITY"], [33, 39, "GENE_OR_GENE_PRODUCT"], [85, 96, "SIMPLE_CHEMICAL"]]}
{"text": "As expected , Nsp9 was pulled down by TAT-Nb6-His but not by the control nanobody , TAT-Nb53-His ( Fig. 4 ) .", "labels": [[65, 73, "ENTITY"]]}
{"text": "After 24 hpi , the RNA synthesis of all strains was predominantly suppressed by TAT-Nb6 ( Fig. 7B to D ) , and the relative RNA levels for strains SD16 , GD-HD , and VR2332 were significantly reduced compared to levels for the TAT-Nb53 group and no nanobody group ( Fig. 7C and D ) .", "labels": [[115, 124, "SO"], [9, 13, "ENTITY"], [249, 258, "ENTITY"], [242, 249, "ENTITY"], [19, 23, "ENTITY"], [147, 154, "ENTITY"], [242, 258, "PROTEIN"], [40, 48, "GENE_OR_GENE_PRODUCT"], [105, 111, "ORGANISM"], [105, 111, "ENTITY"], [135, 147, "ENTITY"], [147, 154, "PROTEIN"], [147, 154, "GENE_OR_GENE_PRODUCT"], [219, 236, "PROTEIN"], [200, 212, "ENTITY"], [115, 124, "ENTITY"], [219, 236, "ENTITY"], [40, 48, "PROTEIN"], [147, 154, "GGP"]]}
{"text": "After 24 hpi , the RNA synthesis of all strains was predominantly suppressed by TAT-Nb6 ( Fig. 7B to D ) , and the relative RNA levels for strains SD16 , GD-HD , and VR2332 were significantly reduced compared to levels for the TAT-Nb53 group and no nanobody group ( Fig. 7C and D ) .", "labels": [[115, 124, "SO"], [9, 13, "ENTITY"], [105, 111, "ORGANISM"], [249, 258, "ENTITY"], [242, 249, "ENTITY"], [19, 23, "ENTITY"], [105, 111, "ENTITY"], [147, 154, "ENTITY"], [242, 258, "PROTEIN"], [40, 48, "GENE_OR_GENE_PRODUCT"], [135, 147, "ENTITY"], [147, 154, "PROTEIN"], [147, 154, "GENE_OR_GENE_PRODUCT"], [219, 236, "PROTEIN"], [200, 212, "ENTITY"], [115, 124, "ENTITY"], [219, 236, "ENTITY"], [40, 48, "PROTEIN"], [147, 154, "GGP"]]}
{"text": "Besides PERK , three other kinases are known to phosphorylate eIF2\u03b1 , namely the protein kinase RNA-activated ( PKR ) , heme-regulated inhibitor kinase ( HRI ) , and general control non-derepressible-2 ( GCN2;Ron and Walter , 2007 ) .", "labels": [[174, 182, "PROTEIN"], [77, 96, "ENTITY"], [116, 145, "ENTITY"], [8, 13, "GENE_OR_GENE_PRODUCT"], [116, 135, "CHEBI"], [116, 145, "PROTEIN"], [77, 96, "PROTEIN"], [27, 34, "GGP"], [182, 204, "PROTEIN"], [8, 13, "ENTITY"], [27, 34, "GENE_OR_GENE_PRODUCT"], [27, 34, "PROTEIN"], [158, 174, "ENTITY"], [77, 96, "GENE_OR_GENE_PRODUCT"], [182, 204, "GENE_OR_GENE_PRODUCT"], [27, 34, "ENTITY"], [8, 13, "GGP"], [116, 145, "GENE_OR_GENE_PRODUCT"], [8, 13, "PROTEIN"], [174, 182, "ENTITY"]]}
{"text": "However , knock-down of PKR using specific morpholino oligomers did not affect SARS-CoV-induced eIF2\u03b1 phosphorylation but significantly inhibited SARS-CoV-induced apoptosis ( Kr\u00e4hling et al. , 2009 ) .", "labels": [[43, 54, "ENTITY"], [79, 96, "ENTITY"], [79, 96, "GENE_OR_GENE_PRODUCT"], [79, 96, "ENTITY"]]}
{"text": "The up-regulation of GADD153 was likely mediated by both PKR and PERK , since knock-down of either PKR or PERK by siRNA reduces IBV-induced GADD153 ( Liaoet al. , 2013 ) .", "labels": [[21, 29, "GGP"], [21, 29, "PROTEIN"], [128, 140, "GENE_OR_GENE_PRODUCT"], [21, 29, "ENTITY"], [65, 70, "ENTITY"], [65, 70, "GGP"], [57, 61, "GENE_OR_GENE_PRODUCT"], [65, 70, "GENE_OR_GENE_PRODUCT"], [4, 18, "ENTITY"], [57, 61, "PROTEIN"], [65, 70, "PROTEIN"], [57, 61, "ENTITY"], [128, 140, "ENTITY"], [57, 61, "GGP"], [21, 29, "GENE_OR_GENE_PRODUCT"]]}
{"text": "SGs are induced by protein kinase R (PKR)-mediated phosphorylation of eIF2\u03b1 upon viral dsRNA recognition [ 57 ] . Promoting G3BP aggregation via the eIF4A inhibitor Zotatafin [ 58,59 ] or reducing SG disassembly by Silmitasertib inhibition of CK2 [ 60 ] warrant investigation for treatment of SARS-CoV-2 . The mTOR inhibitor rapamycin disrupts the binding of LARP1 to mTORC1 [ 61 ] and has been shown to reduce MERS infection by \u223c60 % in vitro [ 62 ] , another drug that could be tested for repurposing .", "labels": [[51, 67, "ENTITY"], [254, 262, "ENTITY"], [70, 76, "PROTEIN"], [293, 306, "ENTITY"], [293, 325, "GGP"], [114, 124, "PROTEIN"], [155, 165, "SIMPLE_CHEMICAL"], [70, 76, "ENTITY"], [229, 240, "ENTITY"], [280, 293, "CHEMICAL"], [145, 155, "ENTITY"], [0, 4, "ENTITY"], [200, 215, "CHEMICAL"], [401, 416, "DISEASE"], [335, 348, "ENTITY"], [114, 124, "ENTITY"], [306, 315, "ENTITY"], [395, 401, "ENTITY"], [81, 93, "TAXON"], [124, 129, "ENTITY"], [200, 215, "ORGANISM"], [293, 306, "GENE_OR_GENE_PRODUCT"], [348, 356, "GENE_OR_GENE_PRODUCT"], [0, 4, "GO"], [262, 280, "ENTITY"], [8, 16, "ENTITY"], [229, 243, "GENE_OR_GENE_PRODUCT"], [348, 356, "PROTEIN"], [0, 4, "GENE_OR_GENE_PRODUCT"], [19, 36, "ENTITY"], [416, 433, "ENTITY"], [188, 200, "ENTITY"], [348, 356, "ENTITY"], [19, 27, "CHEBI"], [477, 487, "ENTITY"], [155, 165, "CHEMICAL"], [280, 293, "ENTITY"], [19, 36, "GENE_OR_GENE_PRODUCT"], [280, 293, "SIMPLE_CHEMICAL"], [359, 368, "GENE_OR_GENE_PRODUCT"], [145, 155, "CHEBI"], [70, 76, "GENE_OR_GENE_PRODUCT"], [200, 229, "ENTITY"], [155, 165, "ENTITY"], [404, 416, "ENTITY"], [114, 124, "GENE_OR_GENE_PRODUCT"], [229, 240, "PROTEIN"], [19, 36, "PROTEIN"], [359, 365, "PROTEIN"], [81, 105, "ENTITY"], [114, 124, "GGP"], [325, 335, "ENTITY"], [348, 356, "GGP"], [359, 365, "ENTITY"], [145, 165, "PROTEIN"], [0, 4, "PROTEIN"]]}
{"text": "The SARS-CoV-2 nucleocapsid ( N ) interactome includes many host mRNA binding proteins , including the SG related factors G3BP1/2 , the mTOR translational repressors LARP1 , and the protein kinases CK2 ( Fig. 4a ) .", "labels": [[4, 32, "PROTEIN"], [132, 166, "GGP"], [60, 78, "ENTITY"], [178, 190, "ENTITY"], [60, 65, "CHEBI"], [114, 122, "GGP"], [4, 28, "ENTITY"], [178, 190, "GENE_OR_GENE_PRODUCT"], [114, 122, "CHEMICAL"], [114, 122, "ENTITY"], [178, 190, "PROTEIN"], [132, 166, "PROTEIN"], [155, 166, "ENTITY"], [136, 155, "ENTITY"], [99, 122, "PROTEIN"], [55, 78, "PROTEIN"], [106, 114, "ENTITY"], [4, 15, "CHEMICAL"], [99, 114, "GENE_OR_GENE_PRODUCT"], [114, 122, "GENE_OR_GENE_PRODUCT"], [155, 166, "GENE_OR_GENE_PRODUCT"], [4, 28, "ORGANISM"], [70, 78, "CHEBI"]]}
{"text": "Finally , it was also reported that thalidomide prevents NF-kB from binding to the promoters of its target genes , including TNF-alpha and IFN-Gamma thereby reducing excessive inflammatory response 27,28 .", "labels": [[115, 125, "GGP"], [166, 198, "ENTITY"], [100, 107, "DNA"], [115, 125, "GENE_OR_GENE_PRODUCT"], [115, 125, "CHEMICAL"], [157, 166, "ENTITY"], [166, 198, "PROTEIN"], [115, 125, "ENTITY"], [115, 125, "PROTEIN"]]}
{"text": "Remarkably , human dipeptidyl peptidase 4 ( DPP4 was identified as a functional receptor for the spike protein of the MERS-Co-V [ 4 ] . MERS-CoV binds to the receptor-binding domain and interacts with T cells and nuclear factors , such as NF-\u03baB , highly involved in the pathogenesis of inflammatory disorders .", "labels": [[93, 103, "ENTITY"], [154, 175, "ENTITY"], [67, 80, "ENTITY"], [136, 145, "ENTITY"], [154, 175, "PROTEIN"], [97, 103, "CHEBI"], [93, 103, "PROTEIN"], [263, 270, "ENTITY"], [196, 203, "ENTITY"], [209, 221, "PROTEIN"], [231, 239, "DNA"], [19, 40, "ENTITY"], [196, 203, "CL"], [13, 40, "GENE_OR_GENE_PRODUCT"], [231, 239, "CHEMICAL"], [196, 203, "CELL_TYPE"], [209, 221, "ENTITY"], [270, 299, "ENTITY"], [270, 299, "DISEASE"], [231, 239, "ENTITY"], [158, 175, "SO"], [13, 40, "GGP"], [13, 40, "PROTEIN"], [231, 239, "SIMPLE_CHEMICAL"], [196, 203, "CELL"]]}
{"text": "Remarkably , human dipeptidyl peptidase 4 ( DPP4 was identified as a functional receptor for the spike protein of the MERS-Co-V [ 4 ] . MERS-CoV binds to the receptor-binding domain and interacts with T cells and nuclear factors , such as NF-\u03baB , highly involved in the pathogenesis of inflammatory disorders .", "labels": [[93, 103, "ENTITY"], [154, 175, "ENTITY"], [67, 80, "ENTITY"], [136, 145, "ENTITY"], [154, 175, "PROTEIN"], [270, 299, "ENTITY"], [97, 103, "CHEBI"], [93, 103, "PROTEIN"], [263, 270, "ENTITY"], [196, 203, "ENTITY"], [209, 221, "PROTEIN"], [231, 239, "DNA"], [19, 40, "ENTITY"], [196, 203, "CL"], [13, 40, "GENE_OR_GENE_PRODUCT"], [231, 239, "CHEMICAL"], [196, 203, "CELL_TYPE"], [270, 299, "DISEASE"], [209, 221, "ENTITY"], [231, 239, "ENTITY"], [158, 175, "SO"], [13, 40, "GGP"], [13, 40, "PROTEIN"], [231, 239, "SIMPLE_CHEMICAL"], [196, 203, "CELL"]]}
{"text": "Baricitinib , fedratinib , and ruxolitinib are potent and selective JAK inhibitors approved for indications such as rheumatoid arthritis and myelofibrosis . All three are powerful antiinflammatories that , as JAK \u2013 STAT signalling inhibitors , are likely to be effective against the consequences of the elevated levels of cytokines ( including interferon-\u03b3 ) typically observed in people with COVID-19\u00b72", "labels": [[58, 72, "GGP"], [68, 72, "ENTITY"], [248, 261, "ENTITY"], [296, 303, "ENTITY"], [113, 127, "ENTITY"], [271, 283, "ENTITY"], [312, 322, "ENTITY"], [220, 231, "CHEBI"], [204, 213, "GENE_OR_GENE_PRODUCT"], [113, 127, "DISEASE"], [0, 12, "ENTITY"], [334, 344, "PROTEIN"], [58, 68, "GENE_OR_GENE_PRODUCT"], [369, 378, "ENTITY"], [334, 344, "ENTITY"], [381, 393, "ENTITY"], [68, 72, "PROTEIN"], [381, 393, "PROTEIN"], [0, 12, "CHEMICAL"], [68, 72, "GGP"], [0, 12, "GENE_OR_GENE_PRODUCT"], [369, 378, "ORGANISM"], [381, 393, "CHEMICAL"], [171, 180, "ENTITY"], [312, 322, "PROTEIN"], [58, 72, "ENTITY"], [334, 344, "GENE_OR_GENE_PRODUCT"]]}
{"text": "TBNK lymphocyte subset analysis revealed decreased percentage of CD16 + CD56 + lymphocytes ( 4/8 ) and Th/Ts ( 1/8 ) , and increased percentage of CD3 + ( 2/8 ) , CD4 + ( 4/8 ) and CD8 + ( 1/8 ) lymphocytes . Cytokine detection assays showed increased levels of IL-6 ( 2/8 ) , IL-10 ( 5/8 ) and IFN-\u03b3 ( 2/8 ) .", "labels": [[-1, 25, "ENTITY"], [281, 287, "GENE_OR_GENE_PRODUCT"], [199, 222, "ENTITY"], [127, 137, "ENTITY"], [127, 137, "GENE_OR_GENE_PRODUCT"], [41, 51, "ENTITY"], [5, 16, "CELL"], [266, 271, "ENTITY"], [281, 293, "PROTEIN"], [127, 137, "ENTITY"], [5, 16, "ENTITY"], [0, 5, "ENTITY"], [281, 287, "ENTITY"], [159, 199, "CELL_TYPE"], [239, 246, "ENTITY"], [175, 199, "ENTITY"], [127, 137, "PROTEIN"], [51, 65, "GGP"], [65, 70, "GENE_OR_GENE_PRODUCT"], [232, 239, "ENTITY"], [281, 287, "CHEMICAL"], [127, 137, "GGP"], [5, 16, "CL"], [51, 62, "GENE_OR_GENE_PRODUCT"], [137, 157, "ENTITY"], [-1, 25, "CELL_LINE"], [137, 157, "CELL_TYPE"], [266, 271, "PROTEIN"], [185, 199, "CL"], [266, 271, "GGP"], [0, 23, "CELL_LINE"], [266, 271, "GENE_OR_GENE_PRODUCT"], [51, 62, "ENTITY"], [83, 95, "CL"]]}
{"text": "The reduced expressions of interferon-\u03b3 ( IFN-\u03b3 ) by CD4+T , CD8+T and NK cells below LLN were observed in some patients with severe ( 50 % , 16.7 % and 16.7 % ) or moderate COVID-19 ( 14.3 % , 0 % and 14.3 % ) .", "labels": [[27, 40, "ENTITY"], [165, 174, "ENTITY"], [27, 40, "GENE_OR_GENE_PRODUCT"], [4, 12, "ENTITY"], [27, 40, "PROTEIN"], [165, 174, "GENE_OR_GENE_PRODUCT"], [67, 74, "ENTITY"], [67, 74, "CELL"], [12, 24, "ENTITY"], [67, 74, "CL"], [153, 165, "ENTITY"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[214, 226, "PROTEIN"], [303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [235, 253, "CHEMICAL"], [127, 132, "CHEMICAL"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [235, 272, "GENE_OR_GENE_PRODUCT"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [214, 226, "GGP"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [235, 272, "GGP"], [235, 272, "PROTEIN"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [214, 226, "ENTITY"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [214, 226, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [235, 272, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Interestingly , serum levels of IFN-\u03b3 , IL-10 , IL-6 and TNF-\u03b1 were significantly decreased in these patients in the decline period as compared with illness period , while counts of total T cells , CD4 + , and CD8 + T cell subsets recovered during the decline period ( Figure 2C ) .", "labels": [[117, 125, "ENTITY"], [182, 190, "CL"], [68, 82, "ENTITY"], [182, 190, "CELL"], [16, 22, "ENTITY"], [260, 269, "ENTITY"], [206, 218, "GGP"], [149, 157, "ENTITY"], [206, 223, "ENTITY"], [117, 125, "ENTITY"], [190, 198, "ENTITY"], [179, 190, "CELL_TYPE"], [179, 190, "ENTITY"], [190, 223, "CELL_TYPE"], [190, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [144, 154, "GGP"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [208, 227, "GENE_OR_GENE_PRODUCT"], [40, 59, "ENTITY"], [26, 38, "SIMPLE_CHEMICAL"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GENE_OR_GENE_PRODUCT"], [253, 271, "ENTITY"], [26, 40, "CHEBI"], [170, 179, "GGP"], [26, 38, "CHEMICAL"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [144, 154, "PROTEIN"], [40, 59, "SIMPLE_CHEMICAL"], [144, 154, "ENTITY"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [26, 38, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "Remarkably , in SJIA patients , the pulmonary involvement triggers a hyper-inflammatory reaction and occurrence of secondary haemophagocytic lymphohistiocytosis ( sHLH ) , since the up-regulation of IFN-signature , IL-1\u03b2 and IL-6 may be observed [ 5,8 ] .", "labels": [[141, 163, "ENTITY"], [115, 141, "DISEASE"], [172, 182, "ENTITY"], [67, 88, "ENTITY"], [112, 141, "ENTITY"], [199, 213, "GENE_OR_GENE_PRODUCT"], [115, 125, "CHEBI"], [182, 199, "PROTEIN"], [215, 221, "GGP"], [36, 46, "ENTITY"], [199, 213, "ENTITY"], [215, 221, "PROTEIN"], [141, 163, "GENE_OR_GENE_PRODUCT"], [199, 213, "CHEMICAL"], [215, 221, "ENTITY"], [215, 221, "GENE_OR_GENE_PRODUCT"], [182, 199, "ENTITY"], [182, 199, "GENE_OR_GENE_PRODUCT"], [199, 213, "GGP"], [199, 213, "PROTEIN"]]}
{"text": "A combination of type I IFN and either IFN-\u03b3 or IFN-\u03bb , was shown to synergistically inhibit the virus replication in vitro ( 40,53,54 ) .", "labels": [[2, 14, "ENTITY"], [48, 54, "ENTITY"], [39, 45, "PROTEIN"], [48, 54, "PROTEIN"], [48, 54, "GENE_OR_GENE_PRODUCT"], [17, 28, "GGP"], [39, 45, "ENTITY"], [17, 28, "GENE_OR_GENE_PRODUCT"], [39, 45, "GENE_OR_GENE_PRODUCT"], [39, 45, "CHEMICAL"], [17, 28, "PROTEIN"], [17, 28, "ENTITY"], [97, 103, "ENTITY"]]}
{"text": "Finally , it was also reported that thalidomide prevents NF-kB from binding to the promoters of its target genes , including TNF-alpha and IFN-Gamma thereby reducing excessive inflammatory response 27,28 .", "labels": [[115, 125, "PROTEIN"], [157, 166, "ENTITY"], [166, 198, "ENTITY"], [100, 107, "DNA"], [115, 125, "GGP"], [115, 125, "CHEMICAL"], [115, 125, "GENE_OR_GENE_PRODUCT"], [115, 125, "ENTITY"], [166, 198, "PROTEIN"]]}
{"text": "In contrast , GADD34 has also been shown to specify PP1 to dephosphorylate the TGF-\u03b2-activated kinase 1 ( TAK1 ) , thus negatively regulating the toll-like receptor ( TLR ) signal-ing and pro-inflammatory cytokines [ IL-6 and TNF-\u03b1 ( Tumornecrosis factor alpha ) ] production in macrophages ( Gu et al.,2014 ) .", "labels": [[205, 215, "GGP"], [79, 102, "GENE_OR_GENE_PRODUCT"], [79, 102, "ENTITY"], [217, 222, "GENE_OR_GENE_PRODUCT"], [188, 205, "ENTITY"], [279, 296, "PROTEIN"], [205, 215, "GENE_OR_GENE_PRODUCT"], [226, 248, "PROTEIN"], [142, 173, "PROTEIN"], [217, 222, "ENTITY"], [156, 165, "ENTITY"], [142, 156, "ENTITY"], [265, 279, "CELL"], [173, 205, "PROTEIN"], [142, 156, "GENE_OR_GENE_PRODUCT"], [205, 215, "PROTEIN"], [265, 279, "CELL_TYPE"], [217, 222, "CHEMICAL"], [205, 215, "ENTITY"], [265, 279, "CL"], [142, 156, "GGP"], [217, 222, "PROTEIN"], [226, 234, "DISEASE"], [255, 265, "ENTITY"], [156, 165, "GENE_OR_GENE_PRODUCT"], [173, 188, "ENTITY"], [226, 248, "ENTITY"], [79, 102, "PROTEIN"], [265, 279, "ENTITY"], [79, 102, "GGP"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "In any case , blocking IL-6 may be effective . Blocking IL-1 and TNF may also benefit patients .", "labels": [[47, 56, "PROTEIN"], [47, 56, "GENE_OR_GENE_PRODUCT"], [78, 86, "ORGANISM"], [78, 86, "ENTITY"], [7, 12, "ENTITY"], [47, 56, "ENTITY"], [47, 56, "GGP"]]}
{"text": "Of patients with available data , concentrations of interleukin 2 receptor , interleukin 6 , interleukin 8 , interleukin 10 , and tumour necrosis factor \u03b1 were significantly higher in deceased patients than in recovered patients .", "labels": [[126, 146, "PROTEIN"], [75, 89, "GENE_OR_GENE_PRODUCT"], [3, 12, "ENTITY"], [52, 66, "PROTEIN"], [75, 89, "PROTEIN"], [184, 193, "ORGANISM"], [75, 89, "ENTITY"], [27, 32, "ENTITY"], [52, 66, "GGP"], [52, 66, "GENE_OR_GENE_PRODUCT"], [75, 89, "GGP"], [202, 210, "ENTITY"], [52, 66, "ENTITY"], [126, 146, "ENTITY"], [184, 193, "ENTITY"], [126, 146, "GENE_OR_GENE_PRODUCT"], [210, 220, "ENTITY"], [210, 220, "ORGANISM"], [174, 184, "ENTITY"], [126, 146, "GGP"], [126, 137, "DISEASE"], [3, 12, "ORGANISM"]]}
{"text": "Evaluation of serum cytokines on admission revealed that levels of interleukin (IL)- 2R , IL-6 , IL-10 , and tumor necrosis factor-\u03b1 ( TNF-\u03b1 ) were markedly higher in severe cases than in moderate cases ( Figure 2 , Supplementary Table 1 ) .", "labels": [[205, 230, "GENE_OR_GENE_PRODUCT"], [105, 115, "DISEASE"], [157, 167, "ENTITY"], [33, 43, "ENTITY"], [124, 135, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [0, 11, "ENTITY"], [14, 20, "ENTITY"], [105, 124, "PROTEIN"], [14, 20, "ORGANISM_SUBSTANCE"], [124, 135, "PROTEIN"], [105, 124, "ENTITY"], [105, 124, "GENE_OR_GENE_PRODUCT"], [67, 88, "ENTITY"], [197, 205, "ENTITY"], [180, 188, "ENTITY"], [67, 88, "GGP"], [124, 135, "ENTITY"], [20, 30, "ENTITY"], [205, 230, "ENTITY"], [57, 64, "ENTITY"], [67, 88, "GENE_OR_GENE_PRODUCT"], [188, 197, "ENTITY"], [67, 88, "PROTEIN"], [14, 30, "PROTEIN"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "We only found the levels of TNF-\u03b1 , IL-6 and IL-10 were significantly increased in infected patients , and statistical analysis illustrated that their levels in ICU patients are significantly higher than in Non-ICU patients ( Figure 2A ) .", "labels": [[161, 165, "ENTITY"], [207, 215, "ORGANISM"], [207, 215, "ENTITY"], [28, 34, "ENTITY"], [103, 119, "ENTITY"], [224, 233, "ENTITY"], [28, 34, "CHEMICAL"], [28, 34, "GENE_OR_GENE_PRODUCT"], [28, 34, "PROTEIN"], [161, 165, "ORGANISM"], [18, 25, "ENTITY"]]}
{"text": "Interestingly , serum levels of IFN-\u03b3 , IL-10 , IL-6 and TNF-\u03b1 were significantly decreased in these patients in the decline period as compared with illness period , while counts of total T cells , CD4 + , and CD8 + T cell subsets recovered during the decline period ( Figure 2C ) .", "labels": [[117, 125, "ENTITY"], [182, 190, "CL"], [68, 82, "ENTITY"], [182, 190, "CELL"], [16, 22, "ENTITY"], [260, 269, "ENTITY"], [206, 218, "GGP"], [149, 157, "ENTITY"], [206, 223, "ENTITY"], [117, 125, "ENTITY"], [190, 198, "ENTITY"], [179, 190, "CELL_TYPE"], [179, 190, "ENTITY"], [190, 223, "CELL_TYPE"], [190, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Another biomarker of uncontrolled pro-inflammatory cytokine response , TNF-\u03b1 , was up-regulated 40-fold during virus infection ( Figure 7D ) . Only the combination of ATV/RTV could significantly prevent the induction of TNF-\u03b1 release ( Figure 7D ) .", "labels": [[207, 220, "CHEMICAL"], [152, 167, "PROTEIN"], [34, 51, "ENTITY"], [207, 220, "GENE_OR_GENE_PRODUCT"], [152, 167, "ENTITY"], [8, 18, "ENTITY"], [71, 77, "ENTITY"], [207, 220, "PROTEIN"], [226, 236, "ENTITY"], [104, 117, "ENTITY"], [34, 60, "PROTEIN"], [152, 167, "CHEMICAL"], [104, 117, "DISEASE"], [152, 167, "GENE_OR_GENE_PRODUCT"], [207, 220, "ENTITY"], [127, 136, "ENTITY"], [21, 34, "ENTITY"]]}
{"text": "The levels of inflammatory cytokines ( IL-1 , TNF ) are high in the lungs of COVID-19 patients and these cytokines are strong inducers of HA-synthase-2 ( HAS2 ) in CD31 + endothelium , EpCAM + lung alveolar epithelial cells , and fibroblasts [ 13 ] .", "labels": [[14, 37, "ENTITY"], [138, 154, "ENTITY"], [164, 171, "ENTITY"], [14, 37, "PROTEIN"], [159, 164, "PROTEIN"], [224, 230, "CL"], [224, 230, "ENTITY"], [171, 218, "CELL_TYPE"], [4, 11, "ENTITY"], [224, 230, "CELL_TYPE"], [138, 154, "GENE_OR_GENE_PRODUCT"], [77, 86, "ENTITY"], [159, 164, "GGP"], [159, 164, "GENE_OR_GENE_PRODUCT"], [185, 218, "CELL"], [171, 185, "ENTITY"], [171, 185, "GGP"], [185, 218, "ENTITY"], [74, 86, "ORGANISM"], [119, 126, "ENTITY"], [138, 154, "PROTEIN"], [138, 154, "GGP"], [198, 218, "CL"], [159, 164, "ENTITY"], [171, 185, "GENE_OR_GENE_PRODUCT"], [224, 230, "CELL"]]}
{"text": "Interestingly , the concentration of these three cytokines was negatively correlated with total T cell counts , CD4 + counts , and CD8 + counts , respectively ( Figure 2B ) .", "labels": [[146, 161, "ENTITY"], [110, 118, "ENTITY"], [90, 98, "ENTITY"], [127, 137, "ENTITY"], [110, 116, "GGP"]]}
{"text": "Moreover , the glycans on SARS-CoV S proteins have been shown to bind C-type lectins DC-SIGN ( dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin ) and L-SIGN ( liver lymph node-specific intercellular adhesion molecule-3-grabbing non-integrin ) , which can serve as alternative receptors for SARS-CoV independent of the major receptor ACE2 ( Han et al. , 2007 ) .", "labels": [[26, 37, "ORGANISM"], [181, 196, "ENTITY"], [196, 259, "ENTITY"], [142, 162, "GGP"], [181, 230, "MULTI-TISSUE_STRUCTURE"], [142, 162, "GENE_OR_GENE_PRODUCT"], [26, 37, "ENTITY"], [286, 307, "ENTITY"], [307, 321, "GGP"], [70, 85, "GENE_OR_GENE_PRODUCT"], [142, 162, "GGP"], [307, 321, "PROTEIN"], [342, 355, "ENTITY"], [26, 37, "PROTEIN"], [342, 355, "PROTEIN"], [142, 162, "GENE_OR_GENE_PRODUCT"], [307, 321, "ENTITY"], [70, 77, "ENTITY"], [93, 162, "PROTEIN"], [307, 321, "ORGANISM"], [70, 85, "PROTEIN"]]}
{"text": "The folding , maturation , and assembly of the gigantic S trimeric glycoprotein rely heavily on the protein chaperons inside the ER , such as calnexin . In fact , the N-terminal part of the S2 domain of SARS-CoV S protein has been found to interact with calnexin , and knock-down of calnexin decreases the infectivity of pseudotyped lentivirus carrying the SARS-CoV S protein ( Fukushi et al. , 2012 ) .", "labels": [[43, 67, "ENTITY"], [231, 240, "ENTITY"], [186, 193, "ENTITY"], [193, 203, "ORGANISM"], [306, 333, "ORGANISM"], [292, 306, "ENTITY"], [344, 368, "ENTITY"], [96, 108, "ENTITY"], [269, 283, "GENE_OR_GENE_PRODUCT"], [269, 283, "GGP"], [344, 368, "PROTEIN"], [163, 178, "ENTITY"], [368, 378, "SIMPLE_CHEMICAL"], [193, 214, "GGP"], [96, 108, "PROTEIN"], [321, 333, "TAXON"], [193, 214, "PROTEIN"], [186, 193, "SO"], [269, 283, "PROTEIN"], [269, 283, "ENTITY"], [43, 67, "PROTEIN"], [344, 368, "ORGANISM"], [186, 193, "PROTEIN"], [193, 214, "ENTITY"], [142, 151, "ENTITY"], [306, 333, "ENTITY"], [25, 31, "ENTITY"], [344, 368, "GGP"], [163, 178, "PROTEIN"], [4, 12, "ENTITY"], [43, 67, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Moreover , the glycans on SARS-CoV S proteins have been shown to bind C-type lectins DC-SIGN ( dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin ) and L-SIGN ( liver lymph node-specific intercellular adhesion molecule-3-grabbing non-integrin ) , which can serve as alternative receptors for SARS-CoV independent of the major receptor ACE2 ( Han et al. , 2007 ) .", "labels": [[26, 37, "ORGANISM"], [181, 196, "ENTITY"], [196, 259, "ENTITY"], [142, 162, "GGP"], [181, 230, "MULTI-TISSUE_STRUCTURE"], [142, 162, "GENE_OR_GENE_PRODUCT"], [26, 37, "ENTITY"], [286, 307, "ENTITY"], [307, 321, "GGP"], [70, 85, "GENE_OR_GENE_PRODUCT"], [142, 162, "GGP"], [307, 321, "PROTEIN"], [342, 355, "ENTITY"], [26, 37, "PROTEIN"], [342, 355, "PROTEIN"], [142, 162, "GENE_OR_GENE_PRODUCT"], [307, 321, "ENTITY"], [70, 77, "ENTITY"], [93, 162, "PROTEIN"], [307, 321, "ORGANISM"], [70, 85, "PROTEIN"]]}
{"text": "Moreover , the glycans on SARS-CoV S proteins have been shown to bind C-type lectins DC-SIGN ( dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin ) and L-SIGN ( liver lymph node-specific intercellular adhesion molecule-3-grabbing non-integrin ) , which can serve as alternative receptors for SARS-CoV independent of the major receptor ACE2 ( Han et al. , 2007 ) .", "labels": [[26, 37, "ORGANISM"], [181, 196, "ENTITY"], [196, 259, "ENTITY"], [142, 162, "GGP"], [181, 230, "MULTI-TISSUE_STRUCTURE"], [142, 162, "GENE_OR_GENE_PRODUCT"], [26, 37, "ENTITY"], [286, 307, "ENTITY"], [307, 321, "GGP"], [70, 85, "GENE_OR_GENE_PRODUCT"], [142, 162, "GGP"], [307, 321, "PROTEIN"], [342, 355, "ENTITY"], [26, 37, "PROTEIN"], [342, 355, "PROTEIN"], [142, 162, "GENE_OR_GENE_PRODUCT"], [307, 321, "ENTITY"], [70, 77, "ENTITY"], [93, 162, "PROTEIN"], [307, 321, "ORGANISM"], [70, 85, "PROTEIN"]]}
{"text": "Coronavirus infection starts with receptor binding via the S protein ( Figure1 ) .", "labels": [[0, 12, "TAXON"], [0, 12, "ORGANISM"], [61, 69, "CHEBI"], [59, 69, "ENTITY"], [59, 69, "PROTEIN"], [0, 22, "ENTITY"], [0, 22, "DISEASE"], [34, 51, "ENTITY"]]}
{"text": "Transmembrane structural proteins ( S , M , and E ) are synthesized , inserted , and folded in the endoplasmic reticulum ( ER ) and transported to the ER \u2013 Golgi intermediate compartment ( ERGIC ) .", "labels": [[0, 34, "PROTEIN"], [147, 175, "ENTITY"], [0, 14, "GO"], [25, 34, "CHEBI"], [123, 132, "ENTITY"], [92, 111, "PROTEIN"], [0, 14, "CELLULAR_COMPONENT"], [14, 34, "ENTITY"], [42, 48, "ENTITY"], [162, 175, "GO"], [0, 14, "ENTITY"], [92, 111, "ENTITY"], [92, 111, "CELLULAR_COMPONENT"], [56, 70, "SO"], [56, 70, "ENTITY"], [92, 111, "GO"]]}
{"text": "These S proteins cause fusion of the infected cell with neighboring uninfected cells , resulting in the formation of a large , multinucleated cell known as a syncytium , which enablesthe virus to spread without being released into the extracellular space ( Masters , 2006 ) .", "labels": [[176, 187, "TAXON"], [79, 85, "CL"], [125, 142, "ENTITY"], [79, 85, "CELL"], [125, 142, "CL"], [37, 46, "ENTITY"], [249, 257, "ENTITY"], [125, 142, "CELL"], [6, 17, "PROTEIN"], [231, 249, "GO"], [231, 249, "CELLULAR_COMPONENT"], [46, 51, "ENTITY"], [8, 17, "CHEBI"], [46, 51, "CELL"], [176, 187, "ENTITY"], [6, 17, "ENTITY"], [68, 85, "ENTITY"], [231, 249, "ENTITY"], [46, 51, "CL"], [23, 30, "ENTITY"]]}
{"text": "For coronaviruses , their receptor binding and subsequent internalization mainly depend on the spike protein ( S protein ) anchored in the viral envelope .", "labels": [[135, 145, "ENTITY"], [109, 113, "ENTITY"], [95, 101, "ENTITY"], [95, 101, "PROTEIN"], [4, 18, "PROTEIN"], [26, 35, "ENTITY"], [109, 113, "PROTEIN"], [135, 145, "TAXON"], [4, 18, "ORGANISM"], [4, 18, "ENTITY"]]}
{"text": "These tentative suggestions were based on the observation that SARS-CoV-2 uses angiotensin-converting enzyme 2 ( ACE2 ) as the receptor binding domain for its spike protein ( Lu et al. , 2020 ; Wan , Shang , Graham , Baric , & Li , 2020 ) , similarly to the coronavirus strain implicated in the 2002\u20132003 SARS epidemic ( Dimitrov , 2003 ; Ge et al. , 2013 ; Li et al. , 2003 ; Prabakaran et al 2004 ; Turner , Hiscox , & Hooper , 2004 ) .", "labels": [[63, 74, "SIMPLE_CHEMICAL"], [208, 215, "ENTITY"], [123, 144, "PROTEIN"], [358, 368, "CHEMICAL"], [155, 165, "ENTITY"], [63, 74, "ENTITY"], [79, 111, "PROTEIN"], [16, 28, "ENTITY"], [46, 58, "ENTITY"], [241, 258, "TAXON"], [377, 388, "DISEASE"], [102, 109, "SO"], [136, 144, "SO"], [63, 74, "CHEMICAL"], [377, 388, "ENTITY"], [79, 111, "GENE_OR_GENE_PRODUCT"], [358, 368, "ENTITY"], [159, 165, "CHEBI"], [194, 200, "ENTITY"], [241, 258, "ENTITY"], [123, 144, "ENTITY"], [178, 184, "ENTITY"], [155, 165, "PROTEIN"], [79, 111, "ENTITY"], [241, 258, "ORGANISM"]]}
{"text": "Experimental affinity measurements ( e.g. surface plasmon resonance , SPR ) confirm the high affinity of SARS-2002 RBD \u2014 ACE2 binding , with an equilibrium dissociation constant ( K D ) of ~15 mM ( 18 - 21 ) , similar to the binding affinity of ACE2 and the COVID-19 RBD ( 22 , 23 ) .", "labels": [[115, 121, "GENE_OR_GENE_PRODUCT"], [0, 22, "ENTITY"], [22, 35, "ENTITY"], [102, 115, "PROTEIN"], [245, 254, "GENE_OR_GENE_PRODUCT"], [115, 121, "GGP"], [245, 258, "ENTITY"], [210, 221, "ENTITY"], [245, 267, "PROTEIN"], [115, 121, "ENTITY"], [121, 126, "ENTITY"], [115, 121, "PROTEIN"], [105, 115, "ENTITY"], [136, 169, "ENTITY"], [88, 93, "ENTITY"], [42, 58, "ENTITY"]]}
{"text": "Similarly , SARS-CoV RBD protein blocked the entry of both SARS-CoV pseudovirus and SARS-CoV-2 pseudovirus into hACE2-expressing 293 T cells with IC50 of 4.1 and 11.63 \u03bcg/ml , respectively ( Fig. 4b ) .", "labels": [[12, 25, "ENTITY"], [112, 135, "GENE_OR_GENE_PRODUCT"], [112, 135, "CELL_LINE"], [12, 21, "ENTITY"], [129, 135, "CL"], [84, 95, "ENTITY"], [12, 25, "GGP"], [12, 25, "PROTEIN"], [112, 135, "ENTITY"], [12, 21, "ORGANISM"], [84, 95, "ORGANISM"]]}
{"text": "The angiotensin-converting enzyme 2 ( ACE2 ) was identified as the critical receptor for mediating SARS-2002 entry into host cells ( 7 , 8) .", "labels": [[115, 125, "ENTITY"], [89, 109, "ENTITY"], [4, 36, "ENTITY"], [89, 99, "CHEMICAL"], [27, 34, "SO"], [4, 36, "PROTEIN"], [115, 125, "CELL"], [115, 125, "CL"], [4, 36, "GENE_OR_GENE_PRODUCT"], [89, 99, "PROTEIN"], [63, 76, "ENTITY"], [115, 125, "CELL_TYPE"]]}
{"text": "We found that LY294002 ( PI kinase inhibitor ) significantly inhibited the entry of SARS pseudovirions into VeroE6 cells , whereas entry of VSV-G pseudovirus was not affected ( Fig. 1A ) .", "labels": [[25, 35, "GENE_OR_GENE_PRODUCT"], [14, 23, "SIMPLE_CHEMICAL"], [81, 89, "ORGANISM"], [103, 115, "ENTITY"], [47, 61, "ENTITY"], [137, 146, "ORGANISM"], [14, 23, "ENTITY"], [103, 115, "CELL"], [25, 35, "ENTITY"], [84, 89, "ENTITY"], [137, 146, "ENTITY"], [14, 23, "CHEMICAL"], [25, 28, "PROTEIN"], [103, 115, "CELL_LINE"], [108, 115, "CL"], [140, 146, "TAXON"]]}
{"text": "Another PI kinase inhibitor , wortmannin , also inhibited SARS-CoV S-mediated entry into VeroE6 cells with no effect on VSV-G pseudovirus entry ( Fig. 1E ) .", "labels": [[8, 28, "GGP"], [58, 67, "ENTITY"], [117, 126, "ORGANISM"], [84, 96, "CELL"], [89, 96, "CL"], [84, 96, "ENTITY"], [48, 67, "ORGANISM"], [102, 110, "ENTITY"], [120, 126, "TAXON"], [8, 18, "PROTEIN"], [117, 126, "ENTITY"], [48, 58, "GGP"], [48, 58, "ENTITY"], [8, 28, "ENTITY"], [8, 18, "SIMPLE_CHEMICAL"], [84, 96, "CELL_LINE"]]}
{"text": "From these results , we conclude that LY294002 and wortmannin inhibit SARS pseudovirus entry by targeting PI4 KB and that PI4 KB is involved in SARS-CoV S-mediated entry into VeroE6 cells .", "labels": [[141, 153, "ORGANISM"], [144, 153, "ENTITY"], [170, 182, "CELL_LINE"], [170, 182, "CELL"], [170, 182, "ENTITY"], [175, 182, "CL"], [70, 75, "ORGANISM"], [11, 19, "ENTITY"], [106, 110, "GENE_OR_GENE_PRODUCT"], [117, 126, "GENE_OR_GENE_PRODUCT"], [106, 110, "ENTITY"], [117, 126, "ENTITY"]]}
{"text": "injecting SARS-CoV spike into mice worsened lung injury .", "labels": [[44, 56, "DISEASE"], [0, 10, "ENTITY"], [30, 35, "ORGANISM"], [19, 25, "ENTITY"], [44, 56, "ENTITY"], [10, 19, "ENTITY"], [30, 35, "ENTITY"], [10, 19, "ORGANISM"], [30, 35, "TAXON"], [44, 49, "ORGAN"]]}
{"text": "These tentative suggestions were based on the observation that SARS-CoV-2 uses angiotensin-converting enzyme 2 ( ACE2 ) as the receptor binding domain for its spike protein ( Lu et al. , 2020 ; Wan , Shang , Graham , Baric , & Li , 2020 ) , similarly to the coronavirus strain implicated in the 2002\u20132003 SARS epidemic ( Dimitrov , 2003 ; Ge et al. , 2013 ; Li et al. , 2003 ; Prabakaran et al 2004 ; Turner , Hiscox , & Hooper , 2004 ) .", "labels": [[63, 74, "SIMPLE_CHEMICAL"], [208, 215, "ENTITY"], [123, 144, "PROTEIN"], [358, 368, "CHEMICAL"], [155, 165, "ENTITY"], [63, 74, "ENTITY"], [79, 111, "PROTEIN"], [16, 28, "ENTITY"], [46, 58, "ENTITY"], [241, 258, "TAXON"], [377, 388, "DISEASE"], [102, 109, "SO"], [136, 144, "SO"], [63, 74, "CHEMICAL"], [377, 388, "ENTITY"], [79, 111, "GENE_OR_GENE_PRODUCT"], [358, 368, "ENTITY"], [159, 165, "CHEBI"], [194, 200, "ENTITY"], [241, 258, "ENTITY"], [123, 144, "ENTITY"], [178, 184, "ENTITY"], [155, 165, "PROTEIN"], [79, 111, "ENTITY"], [241, 258, "ORGANISM"]]}
{"text": "The researchers found that SARS-CoV-infected or recombinant SARS-spike protein-treated wild-type mice exhibited significantly reduced ACE2 expression in the lungs .", "labels": [[134, 139, "ENTITY"], [97, 102, "ENTITY"], [97, 102, "TAXON"], [48, 60, "ENTITY"], [97, 102, "ORGANISM"], [134, 139, "GGP"], [60, 71, "ENTITY"], [134, 139, "PROTEIN"], [157, 163, "ORGAN"], [87, 97, "ENTITY"], [4, 16, "ENTITY"], [139, 150, "ENTITY"], [71, 87, "ENTITY"], [27, 45, "ENTITY"], [134, 139, "GENE_OR_GENE_PRODUCT"], [157, 163, "ENTITY"]]}
{"text": "The angiotensin-converting enzyme 2 ( ACE2 ) was identified as the critical receptor for mediating SARS-2002 entry into host cells ( 7 , 8) .", "labels": [[89, 109, "ENTITY"], [115, 125, "CELL"], [115, 125, "ENTITY"], [4, 36, "ENTITY"], [89, 99, "CHEMICAL"], [27, 34, "SO"], [115, 125, "CELL_TYPE"], [4, 36, "PROTEIN"], [115, 125, "CL"], [4, 36, "GENE_OR_GENE_PRODUCT"], [89, 99, "PROTEIN"], [63, 76, "ENTITY"]]}
{"text": "From these results , we conclude that LY294002 and wortmannin inhibit SARS pseudovirus entry by targeting PI4 KB and that PI4 KB is involved in SARS-CoV S-mediated entry into VeroE6 cells .", "labels": [[141, 153, "ORGANISM"], [170, 182, "CELL_LINE"], [170, 182, "CELL"], [170, 182, "ENTITY"], [175, 182, "CL"], [70, 75, "ORGANISM"], [144, 153, "ENTITY"], [106, 110, "ENTITY"], [11, 19, "ENTITY"], [106, 110, "GENE_OR_GENE_PRODUCT"], [117, 126, "GENE_OR_GENE_PRODUCT"], [117, 126, "ENTITY"]]}
{"text": "injecting SARS-CoV spike into mice worsened lung injury .", "labels": [[44, 56, "DISEASE"], [44, 49, "ORGAN"], [0, 10, "ENTITY"], [30, 35, "ORGANISM"], [19, 25, "ENTITY"], [30, 35, "ENTITY"], [10, 19, "ORGANISM"], [30, 35, "TAXON"], [44, 56, "ENTITY"], [10, 19, "ENTITY"]]}
{"text": "We therefore investigated the ability of plasma from four mice immunized with a stabilized SARS-CoV S to inhibit SARS-CoV-2 S- and SARS-CoV S-mediated entry into target cells . All sera tested completely inhibited transduction of SARS-CoV S-MLV and reduced SARS-CoV-2 S-MLV transduction to \u000110 % of control in VeroE6 cells ( Figure 5C )", "labels": [[80, 91, "ENTITY"], [113, 124, "ORGANISM"], [63, 73, "ENTITY"], [169, 175, "ENTITY"], [91, 100, "PROTEIN"], [91, 100, "ORGANISM"], [13, 26, "ENTITY"], [91, 100, "ENTITY"], [113, 131, "PROTEIN"], [113, 127, "ENTITY"], [113, 124, "CHEMICAL"], [58, 63, "ENTITY"], [91, 102, "PROTEIN"], [91, 100, "GGP"], [105, 113, "ENTITY"], [323, 332, "ENTITY"], [91, 102, "ENTITY"], [310, 317, "CL"], [41, 48, "ENTITY"], [58, 63, "ORGANISM"], [307, 317, "CELL"], [131, 151, "ORGANISM"], [91, 102, "ORGANISM"], [307, 317, "ENTITY"], [323, 332, "CELL"], [162, 169, "ENTITY"], [140, 151, "ENTITY"], [113, 127, "GENE_OR_GENE_PRODUCT"], [162, 175, "CELL_TYPE"], [307, 317, "CELL_LINE"], [169, 175, "CELL"], [169, 175, "CL"], [58, 63, "TAXON"], [41, 48, "ORGANISM_SUBSTANCE"]]}
{"text": "Strikingly , LY6E significantly inhibited VSVpp entry mediated by S proteins from HCoV-229E ( Fig. 2a ) , MERS-CoV ( Fig. 2b ) , SARS-CoV ( Fig. 2c ) , and SARS-CoV-2 ( 2c), and SARS-CoV-2 ) .", "labels": [[0, 11, "ENTITY"], [145, 156, "CHEMICAL"], [122, 129, "GGP"], [122, 129, "PROTEIN"], [122, 129, "ORGANISM"], [122, 129, "ENTITY"], [145, 156, "ENTITY"], [145, 156, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The researchers found that SARS-CoV-infected or recombinant SARS-spike protein-treated wild-type mice exhibited significantly reduced ACE2 expression in the lungs .", "labels": [[97, 102, "TAXON"], [97, 102, "ENTITY"], [48, 60, "ENTITY"], [97, 102, "ORGANISM"], [60, 71, "ENTITY"], [157, 163, "ORGAN"], [134, 139, "ENTITY"], [87, 97, "ENTITY"], [4, 16, "ENTITY"], [134, 139, "GGP"], [139, 150, "ENTITY"], [134, 139, "PROTEIN"], [71, 87, "ENTITY"], [27, 45, "ENTITY"], [134, 139, "GENE_OR_GENE_PRODUCT"], [157, 163, "ENTITY"]]}
{"text": "LY6E potently inhibited CoV S protein-mediated syncytia formation ( Fig. 2e-f ) .", "labels": [[30, 56, "ENTITY"], [0, 5, "ENTITY"], [5, 14, "ENTITY"], [24, 30, "ENTITY"], [14, 24, "ENTITY"], [68, 73, "SIMPLE_CHEMICAL"], [0, 5, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [24, 56, "ORGANISM"], [24, 30, "PROTEIN"]]}
{"text": "ECs showed extensive linkages with pericytes , with dominant role of angiopoietin ligands (ANGPT1/2)\u2013Tie receptor ( TIE2 ) interaction in normal heart , which could promote vascular EC survival and reduced vascular leakage .", "labels": [[11, 21, "ENTITY"], [0, 4, "ENTITY"], [69, 82, "ENTITY"], [138, 145, "ORGAN"], [198, 215, "ENTITY"], [35, 45, "ENTITY"], [0, 4, "CELL"], [69, 105, "GENE_OR_GENE_PRODUCT"], [165, 173, "ENTITY"], [0, 3, "ENTITY"], [198, 215, "DISEASE"], [0, 4, "CELL_TYPE"], [198, 206, "MULTI-TISSUE_STRUCTURE"], [35, 45, "CELL_TYPE"], [0, 4, "CL"], [135, 145, "ENTITY"], [35, 45, "CL"], [69, 105, "GGP"], [165, 173, "CELL"], [21, 30, "ENTITY"], [35, 45, "CELL"], [69, 105, "PROTEIN"]]}
{"text": "ECs showed extensive linkages with pericytes , with dominant role of angiopoietin ligands (ANGPT1/2)\u2013Tie receptor ( TIE2 ) interaction in normal heart , which could promote vascular EC survival and reduced vascular leakage .", "labels": [[11, 21, "ENTITY"], [0, 4, "ENTITY"], [69, 82, "ENTITY"], [138, 145, "ORGAN"], [198, 215, "ENTITY"], [35, 45, "ENTITY"], [0, 4, "CELL"], [69, 105, "GENE_OR_GENE_PRODUCT"], [165, 173, "ENTITY"], [0, 3, "ENTITY"], [198, 215, "DISEASE"], [0, 4, "CELL_TYPE"], [198, 206, "MULTI-TISSUE_STRUCTURE"], [35, 45, "CELL_TYPE"], [0, 4, "CL"], [135, 145, "ENTITY"], [35, 45, "CL"], [69, 105, "GGP"], [165, 173, "CELL"], [21, 30, "ENTITY"], [35, 45, "CELL"], [69, 105, "PROTEIN"]]}
{"text": "ECs showed extensive linkages with pericytes , with dominant role of angiopoietin ligands (ANGPT1/2)\u2013Tie receptor ( TIE2 ) interaction in normal heart , which could promote vascular EC survival and reduced vascular leakage .", "labels": [[11, 21, "ENTITY"], [35, 45, "CELL"], [0, 4, "ENTITY"], [69, 105, "PROTEIN"], [69, 82, "ENTITY"], [138, 145, "ORGAN"], [198, 215, "ENTITY"], [35, 45, "CL"], [0, 4, "CELL"], [165, 173, "ENTITY"], [0, 3, "ENTITY"], [198, 215, "DISEASE"], [69, 105, "GGP"], [0, 4, "CELL_TYPE"], [198, 206, "MULTI-TISSUE_STRUCTURE"], [35, 45, "CELL_TYPE"], [0, 4, "CL"], [135, 145, "ENTITY"], [165, 173, "CELL"], [35, 45, "ENTITY"], [21, 30, "ENTITY"], [69, 105, "GENE_OR_GENE_PRODUCT"]]}
{"text": "ECs showed extensive linkages with pericytes , with dominant role of angiopoietin ligands (ANGPT1/2)\u2013Tie receptor ( TIE2 ) interaction in normal heart , which could promote vascular EC survival and reduced vascular leakage .", "labels": [[11, 21, "ENTITY"], [0, 4, "ENTITY"], [69, 82, "ENTITY"], [138, 145, "ORGAN"], [198, 215, "ENTITY"], [35, 45, "ENTITY"], [0, 4, "CELL"], [69, 105, "GENE_OR_GENE_PRODUCT"], [0, 3, "ENTITY"], [198, 215, "DISEASE"], [165, 173, "CELL"], [165, 173, "ENTITY"], [0, 4, "CELL_TYPE"], [198, 206, "MULTI-TISSUE_STRUCTURE"], [35, 45, "CELL_TYPE"], [0, 4, "CL"], [135, 145, "ENTITY"], [35, 45, "CL"], [69, 105, "GGP"], [21, 30, "ENTITY"], [35, 45, "CELL"], [69, 105, "PROTEIN"]]}
{"text": "ECs showed extensive linkages with pericytes , with dominant role of angiopoietin ligands (ANGPT1/2)\u2013Tie receptor ( TIE2 ) interaction in normal heart , which could promote vascular EC survival and reduced vascular leakage .", "labels": [[11, 21, "ENTITY"], [0, 4, "ENTITY"], [69, 105, "PROTEIN"], [69, 82, "ENTITY"], [138, 145, "ORGAN"], [198, 215, "ENTITY"], [35, 45, "ENTITY"], [0, 4, "CELL"], [165, 173, "ENTITY"], [0, 3, "ENTITY"], [198, 215, "DISEASE"], [69, 105, "GGP"], [0, 4, "CELL_TYPE"], [198, 206, "MULTI-TISSUE_STRUCTURE"], [35, 45, "CELL_TYPE"], [0, 4, "CL"], [135, 145, "ENTITY"], [35, 45, "CL"], [165, 173, "CELL"], [21, 30, "ENTITY"], [35, 45, "CELL"], [69, 105, "GENE_OR_GENE_PRODUCT"]]}
{"text": "ECs showed extensive linkages with pericytes , with dominant role of angiopoietin ligands (ANGPT1/2)\u2013Tie receptor ( TIE2 ) interaction in normal heart , which could promote vascular EC survival and reduced vascular leakage .", "labels": [[11, 21, "ENTITY"], [0, 4, "ENTITY"], [69, 105, "PROTEIN"], [69, 82, "ENTITY"], [138, 145, "ORGAN"], [198, 215, "ENTITY"], [35, 45, "ENTITY"], [0, 4, "CELL"], [165, 173, "ENTITY"], [0, 3, "ENTITY"], [198, 215, "DISEASE"], [69, 105, "GGP"], [0, 4, "CELL_TYPE"], [198, 206, "MULTI-TISSUE_STRUCTURE"], [35, 45, "CELL_TYPE"], [0, 4, "CL"], [135, 145, "ENTITY"], [35, 45, "CL"], [165, 173, "CELL"], [21, 30, "ENTITY"], [35, 45, "CELL"], [69, 105, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Surprisingly , we find that the transmembrane protein E binds to the bromodomain-containing proteins BRD2 and BRD4 ( Fig. 4d , Extended Data Fig. 9 ) , potentially disrupting BRD-histone binding by mimicking histone structure . BRD2 is a member of the bromodomain and extra-terminal ( BET ) domain family whose members bind acetylated histones to regulate gene transcription [ 69 ] .", "labels": [[175, 187, "ENTITY"], [324, 335, "SO"], [32, 54, "PROTEIN"], [216, 226, "ENTITY"], [245, 252, "ENTITY"], [311, 335, "ENTITY"], [245, 252, "PROTEIN"], [198, 216, "ENTITY"], [311, 335, "PROTEIN"], [245, 252, "GENE_OR_GENE_PRODUCT"], [216, 226, "PROTEIN"], [245, 252, "GGP"], [32, 46, "GO"], [216, 226, "GENE_OR_GENE_PRODUCT"], [198, 208, "GENE_OR_GENE_PRODUCT"], [298, 305, "ENTITY"], [32, 54, "GENE_OR_GENE_PRODUCT"], [69, 92, "ENTITY"], [164, 175, "SIMPLE_CHEMICAL"], [164, 175, "ENTITY"], [252, 268, "GENE_OR_GENE_PRODUCT"], [216, 226, "GGP"], [69, 101, "PROTEIN"], [164, 175, "CHEMICAL"], [347, 361, "ENTITY"], [252, 268, "ENTITY"], [152, 164, "ENTITY"], [125, 136, "ENTITY"], [32, 54, "ENTITY"], [115, 122, "GENE_OR_GENE_PRODUCT"], [335, 347, "ENTITY"], [69, 101, "GGP"], [252, 291, "PROTEIN"], [283, 291, "ENTITY"], [283, 289, "SO"], [198, 208, "CHEBI"]]}
{"text": "These results show that blocking CD147 on the host cells has an inhibitory effect on SARS-CoV-2 , suggesting an essential role of CD147 in facilitating SARS-CoV-2 invasion for host cells .", "labels": [[85, 96, "ENTITY"], [85, 96, "ENTITY"], [46, 51, "CL"], [64, 75, "ENTITY"], [46, 57, "CELL_TYPE"], [6, 14, "ENTITY"], [33, 39, "GGP"], [33, 39, "GENE_OR_GENE_PRODUCT"], [46, 51, "CELL_TYPE"], [46, 51, "CELL"], [46, 57, "CL"], [46, 57, "CELL"], [33, 39, "ENTITY"], [24, 33, "ENTITY"], [85, 96, "CHEMICAL"], [46, 57, "ENTITY"], [46, 51, "ENTITY"], [85, 96, "SIMPLE_CHEMICAL"], [33, 39, "PROTEIN"]]}
{"text": "These results show that blocking CD147 on the host cells has an inhibitory effect on SARS-CoV-2 , suggesting an essential role of CD147 in facilitating SARS-CoV-2 invasion for host cells .", "labels": [[85, 96, "ENTITY"], [85, 96, "ENTITY"], [46, 51, "CL"], [64, 75, "ENTITY"], [46, 57, "CELL_TYPE"], [6, 14, "ENTITY"], [33, 39, "GGP"], [33, 39, "GENE_OR_GENE_PRODUCT"], [46, 51, "CELL_TYPE"], [46, 51, "CELL"], [46, 57, "CL"], [46, 57, "CELL"], [33, 39, "ENTITY"], [24, 33, "ENTITY"], [85, 96, "CHEMICAL"], [46, 57, "ENTITY"], [46, 51, "ENTITY"], [85, 96, "SIMPLE_CHEMICAL"], [33, 39, "PROTEIN"]]}
{"text": "The folding , maturation , and assembly of the gigantic S trimeric glycoprotein rely heavily on the protein chaperons inside the ER , such as calnexin . In fact , the N-terminal part of the S2 domain of SARS-CoV S protein has been found to interact with calnexin , and knock-down of calnexin decreases the infectivity of pseudotyped lentivirus carrying the SARS-CoV S protein ( Fukushi et al. , 2012 ) .", "labels": [[43, 67, "ENTITY"], [231, 240, "ENTITY"], [186, 193, "ENTITY"], [193, 203, "ORGANISM"], [306, 333, "ORGANISM"], [292, 306, "ENTITY"], [344, 368, "ENTITY"], [96, 108, "ENTITY"], [269, 283, "GENE_OR_GENE_PRODUCT"], [269, 283, "GGP"], [344, 368, "PROTEIN"], [163, 178, "ENTITY"], [368, 378, "SIMPLE_CHEMICAL"], [193, 214, "GGP"], [96, 108, "PROTEIN"], [321, 333, "TAXON"], [193, 214, "PROTEIN"], [186, 193, "SO"], [269, 283, "PROTEIN"], [269, 283, "ENTITY"], [43, 67, "PROTEIN"], [344, 368, "ORGANISM"], [186, 193, "PROTEIN"], [193, 214, "ENTITY"], [142, 151, "ENTITY"], [306, 333, "ENTITY"], [25, 31, "ENTITY"], [344, 368, "GGP"], [163, 178, "PROTEIN"], [4, 12, "ENTITY"], [43, 67, "GENE_OR_GENE_PRODUCT"]]}
{"text": "MERS-CoV RBD did not bind to hACE2-expressing 293 T cells ( Fig. 2b ( right panel ) ) , but rather bound to hDPP4-expressing 293 T cells ( Fig. 2c ( right panel ) ) .", "labels": [[29, 52, "ENTITY"], [68, 76, "ENTITY"], [21, 26, "ENTITY"], [0, 9, "GGP"], [0, 13, "PROTEIN"], [29, 52, "CELL_LINE"], [99, 129, "CELL_LINE"], [29, 52, "GENE_OR_GENE_PRODUCT"], [99, 129, "GENE_OR_GENE_PRODUCT"], [58, 65, "CELL"], [139, 149, "ENTITY"], [108, 129, "CL"], [131, 149, "CELL"], [99, 129, "ENTITY"], [9, 13, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "MERS-CoV RBD did not block the entry of SARS-CoV-2 pseudovirus or SARS-CoV pseudovirus into hACE2-expressing 293 T cells , but it did block the entry of MERS-CoV pseudovirus into hDPP4-expressing 293 T cells ( IC50 : 22.25 \u03bcg/ml ) ( Fig. 4a \u2013 c ) .", "labels": [[202, 210, "ENTITY"], [109, 115, "CL"], [92, 115, "GENE_OR_GENE_PRODUCT"], [9, 13, "ENTITY"], [150, 162, "GGP"], [223, 233, "CELL"], [92, 115, "CELL_LINE"], [66, 87, "ENTITY"], [51, 63, "TAXON"], [150, 162, "ORGANISM"], [40, 51, "CHEMICAL"], [66, 87, "ORGANISM"], [0, 9, "ENTITY"], [0, 13, "PROTEIN"], [92, 115, "ENTITY"], [150, 162, "ENTITY"], [174, 202, "GENE_OR_GENE_PRODUCT"], [174, 202, "CELL_LINE"], [0, 9, "GGP"], [174, 202, "ENTITY"], [31, 37, "ENTITY"], [40, 63, "ORGANISM"], [40, 63, "ENTITY"]]}
{"text": "Remarkably , human dipeptidyl peptidase 4 ( DPP4 was identified as a functional receptor for the spike protein of the MERS-Co-V [ 4 ] . MERS-CoV binds to the receptor-binding domain and interacts with T cells and nuclear factors , such as NF-\u03baB , highly involved in the pathogenesis of inflammatory disorders .", "labels": [[93, 103, "ENTITY"], [154, 175, "ENTITY"], [67, 80, "ENTITY"], [136, 145, "ENTITY"], [154, 175, "PROTEIN"], [97, 103, "CHEBI"], [93, 103, "PROTEIN"], [263, 270, "ENTITY"], [196, 203, "ENTITY"], [209, 221, "PROTEIN"], [231, 239, "DNA"], [19, 40, "ENTITY"], [196, 203, "CL"], [13, 40, "GENE_OR_GENE_PRODUCT"], [231, 239, "CHEMICAL"], [196, 203, "CELL_TYPE"], [209, 221, "ENTITY"], [270, 299, "ENTITY"], [270, 299, "DISEASE"], [231, 239, "ENTITY"], [158, 175, "SO"], [13, 40, "GGP"], [13, 40, "PROTEIN"], [231, 239, "SIMPLE_CHEMICAL"], [196, 203, "CELL"]]}
{"text": "PKR is induced by IFN and activated by the binding of double-stranded RNA ( dsRNA ) after virus infection ( Clemens and Elia , 1997 ) . HRI is activated in red blood cells and hepatocytes by low levels of heme ( McEwenet al. , 2005 ) . GCN2 senses amino acid deficiency and is activated via binding to uncharged transfer RNAs ( Sood et al. , 2000 ) .", "labels": [[236, 248, "CHEMICAL"], [312, 321, "ORGANISM"], [291, 312, "ENTITY"], [195, 202, "GENE_OR_GENE_PRODUCT"], [166, 176, "ENTITY"], [54, 74, "ENTITY"], [205, 212, "PROTEIN"], [18, 22, "GGP"], [236, 248, "CHEBI"], [84, 96, "DISEASE"], [54, 74, "RNA"], [143, 166, "CELL"], [166, 176, "CELL_TYPE"], [7, 15, "ENTITY"], [166, 176, "CELL"], [18, 22, "CHEMICAL"], [195, 202, "PROTEIN"], [312, 321, "CHEMICAL"], [0, 4, "PROTEIN"], [0, 4, "GENE_OR_GENE_PRODUCT"], [195, 202, "CHEBI"], [43, 51, "ENTITY"], [26, 36, "ENTITY"], [143, 166, "CELL_TYPE"], [18, 22, "ENTITY"], [143, 166, "CL"], [166, 176, "CL"], [70, 74, "SO"], [176, 195, "ENTITY"], [236, 259, "ENTITY"], [195, 202, "ENTITY"], [143, 166, "ENTITY"], [136, 143, "ENTITY"], [259, 277, "ENTITY"], [26, 36, "ENTITY"], [0, 4, "ENTITY"], [205, 212, "ENTITY"], [18, 22, "GENE_OR_GENE_PRODUCT"], [236, 248, "AMINO_ACID"], [18, 22, "PROTEIN"], [84, 96, "ENTITY"]]}
{"text": "Interestingly , ZDHHC5 also has a published role in allowing anthrax toxin to enter cells , suggesting that inhibition of this enzyme could have broad utility [ 37 ] .", "labels": [[61, 69, "DISEASE"], [61, 69, "ENTITY"], [61, 69, "ORGANISM"]]}
{"text": "IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate ( AMP ) kinase .", "labels": [[0, 6, "ENTITY"], [19, 46, "ENTITY"], [83, 107, "CHEMICAL"], [0, 6, "GENE_OR_GENE_PRODUCT"], [59, 64, "GENE_OR_GENE_PRODUCT"], [0, 6, "GGP"], [59, 64, "ENTITY"], [59, 64, "GGP"], [83, 93, "CHEBI"], [0, 6, "PROTEIN"], [83, 107, "SIMPLE_CHEMICAL"], [83, 107, "ENTITY"], [68, 79, "ENTITY"], [0, 6, "CHEMICAL"], [59, 64, "PROTEIN"]]}
{"text": "This cytokine inhibits class II histocompatibility complex ( MHC ) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1\u03b2 , IL-6 , TNF and CCL2 .", "labels": [[122, 134, "PROTEIN"], [122, 134, "GGP"], [165, 172, "ENTITY"], [144, 157, "CHEMICAL"], [144, 157, "GENE_OR_GENE_PRODUCT"], [94, 110, "DISEASE"], [165, 172, "GENE_OR_GENE_PRODUCT"], [165, 172, "GGP"], [5, 14, "ENTITY"], [23, 67, "PROTEIN"], [23, 59, "GENE_OR_GENE_PRODUCT"], [165, 172, "CHEMICAL"], [14, 23, "ENTITY"], [122, 134, "GENE_OR_GENE_PRODUCT"], [23, 59, "ENTITY"], [144, 157, "ENTITY"], [144, 157, "GGP"], [5, 14, "PROTEIN"], [144, 157, "PROTEIN"], [122, 134, "ENTITY"], [94, 110, "ENTITY"], [165, 172, "PROTEIN"]]}
{"text": "This cytokine inhibits class II histocompatibility complex ( MHC ) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1\u03b2 , IL-6 , TNF and CCL2 .", "labels": [[122, 134, "PROTEIN"], [122, 134, "GGP"], [165, 172, "ENTITY"], [144, 157, "CHEMICAL"], [144, 157, "GENE_OR_GENE_PRODUCT"], [94, 110, "DISEASE"], [165, 172, "GENE_OR_GENE_PRODUCT"], [165, 172, "GGP"], [5, 14, "ENTITY"], [23, 67, "PROTEIN"], [23, 59, "GENE_OR_GENE_PRODUCT"], [165, 172, "CHEMICAL"], [14, 23, "ENTITY"], [122, 134, "GENE_OR_GENE_PRODUCT"], [23, 59, "ENTITY"], [144, 157, "ENTITY"], [144, 157, "GGP"], [5, 14, "PROTEIN"], [144, 157, "PROTEIN"], [122, 134, "ENTITY"], [94, 110, "ENTITY"], [165, 172, "PROTEIN"]]}
{"text": "This cytokine inhibits class II histocompatibility complex ( MHC ) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1\u03b2 , IL-6 , TNF and CCL2 .", "labels": [[122, 134, "PROTEIN"], [122, 134, "GGP"], [165, 172, "ENTITY"], [144, 157, "CHEMICAL"], [144, 157, "GENE_OR_GENE_PRODUCT"], [94, 110, "DISEASE"], [165, 172, "GENE_OR_GENE_PRODUCT"], [165, 172, "GGP"], [5, 14, "ENTITY"], [23, 67, "PROTEIN"], [23, 59, "GENE_OR_GENE_PRODUCT"], [165, 172, "CHEMICAL"], [14, 23, "ENTITY"], [122, 134, "GENE_OR_GENE_PRODUCT"], [23, 59, "ENTITY"], [144, 157, "ENTITY"], [144, 157, "GGP"], [5, 14, "PROTEIN"], [144, 157, "PROTEIN"], [122, 134, "ENTITY"], [94, 110, "ENTITY"], [165, 172, "PROTEIN"]]}
{"text": "This cytokine inhibits class II histocompatibility complex ( MHC ) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1\u03b2 , IL-6 , TNF and CCL2 .", "labels": [[122, 134, "PROTEIN"], [122, 134, "GGP"], [165, 172, "ENTITY"], [144, 157, "CHEMICAL"], [144, 157, "GENE_OR_GENE_PRODUCT"], [94, 110, "DISEASE"], [165, 172, "GENE_OR_GENE_PRODUCT"], [165, 172, "GGP"], [5, 14, "ENTITY"], [23, 67, "PROTEIN"], [23, 59, "GENE_OR_GENE_PRODUCT"], [165, 172, "CHEMICAL"], [14, 23, "ENTITY"], [122, 134, "GENE_OR_GENE_PRODUCT"], [23, 59, "ENTITY"], [144, 157, "ENTITY"], [144, 157, "GGP"], [5, 14, "PROTEIN"], [144, 157, "PROTEIN"], [122, 134, "ENTITY"], [94, 110, "ENTITY"], [165, 172, "PROTEIN"]]}
{"text": "This cytokine inhibits class II histocompatibility complex ( MHC ) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1\u03b2 , IL-6 , TNF and CCL2 .", "labels": [[122, 134, "PROTEIN"], [122, 134, "GGP"], [165, 172, "ENTITY"], [144, 157, "CHEMICAL"], [144, 157, "GENE_OR_GENE_PRODUCT"], [94, 110, "DISEASE"], [165, 172, "GENE_OR_GENE_PRODUCT"], [165, 172, "GGP"], [5, 14, "ENTITY"], [23, 67, "PROTEIN"], [23, 59, "GENE_OR_GENE_PRODUCT"], [165, 172, "CHEMICAL"], [14, 23, "ENTITY"], [122, 134, "GENE_OR_GENE_PRODUCT"], [23, 59, "ENTITY"], [144, 157, "ENTITY"], [144, 157, "GGP"], [5, 14, "PROTEIN"], [144, 157, "PROTEIN"], [122, 134, "ENTITY"], [94, 110, "ENTITY"], [165, 172, "PROTEIN"]]}
{"text": "This cytokine inhibits class II histocompatibility complex ( MHC ) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1\u03b2 , IL-6 , TNF and CCL2 .", "labels": [[122, 134, "PROTEIN"], [122, 134, "GGP"], [165, 172, "ENTITY"], [144, 157, "CHEMICAL"], [144, 157, "GENE_OR_GENE_PRODUCT"], [94, 110, "DISEASE"], [165, 172, "GENE_OR_GENE_PRODUCT"], [165, 172, "GGP"], [5, 14, "ENTITY"], [23, 67, "PROTEIN"], [23, 59, "GENE_OR_GENE_PRODUCT"], [165, 172, "CHEMICAL"], [14, 23, "ENTITY"], [122, 134, "GENE_OR_GENE_PRODUCT"], [23, 59, "ENTITY"], [144, 157, "ENTITY"], [144, 157, "GGP"], [5, 14, "PROTEIN"], [144, 157, "PROTEIN"], [122, 134, "ENTITY"], [94, 110, "ENTITY"], [165, 172, "PROTEIN"]]}
{"text": "Intriguingly , the preclinical molecule Sanglifehrin A ( Table 1b ) is known to act as a molecular glue linking IMPDH with cyclophilin A ( Fig. 5b)73 , which itself is implicated in viral capsid packaging , even though it itself is not a human \u201c prey \u201d in the viral-human protein interactome .", "labels": [[253, 280, "ENTITY"], [232, 238, "ENTITY"], [232, 238, "ORGANISM"], [104, 112, "SIMPLE_CHEMICAL"], [40, 53, "CHEMICAL"], [238, 244, "ENTITY"], [260, 272, "CHEBI"], [87, 99, "ENTITY"], [232, 238, "TAXON"], [104, 112, "ENTITY"], [168, 188, "TAXON"], [19, 31, "ENTITY"], [104, 112, "CHEMICAL"], [168, 195, "ENTITY"], [253, 260, "GENE_OR_GENE_PRODUCT"], [40, 53, "GENE_OR_GENE_PRODUCT"], [40, 53, "ENTITY"], [232, 244, "PROTEIN"]]}
{"text": "Since MAVS is required for the phosphorylation of IRF3 in the RIG-I mediated anti-viral response , we checked whether 9b-GFP expression reduced IRF3 phosphorylation , which it did ( Fig. 3C ) .", "labels": [[62, 68, "PROTEIN"], [62, 68, "GGP"], [77, 97, "ENTITY"], [6, 11, "GENE_OR_GENE_PRODUCT"], [6, 11, "GGP"], [50, 55, "PROTEIN"], [50, 55, "GENE_OR_GENE_PRODUCT"], [6, 11, "PROTEIN"], [6, 11, "ENTITY"], [50, 55, "GGP"], [31, 47, "ENTITY"], [62, 68, "ENTITY"], [50, 55, "ENTITY"]]}
{"text": "Lowered DRP1 levels impaired the MAVS-induced increase IFN-\u03b2 reporter activity although not nearly as effectively as did the 9b-FLAG construct ( Fig. 3I ) .", "labels": [[8, 13, "PROTEIN"], [55, 61, "GENE_OR_GENE_PRODUCT"], [46, 55, "ENTITY"], [13, 20, "ENTITY"], [0, 8, "ENTITY"], [55, 61, "ENTITY"], [133, 143, "SO"], [20, 29, "ENTITY"], [8, 13, "ENTITY"], [33, 46, "CHEMICAL"], [33, 46, "ENTITY"], [8, 13, "GENE_OR_GENE_PRODUCT"], [8, 13, "GGP"]]}
{"text": "Indicating that ORF-9b likely triggers K48-linked ubiquitination of MAVS immunoblotting Myc-MAVS immunoprecipitates revealed the presence of K48-linked ubiquitin ( Fig. 5C ) .", "labels": [[39, 60, "GGP"], [16, 23, "ENTITY"], [97, 116, "ENTITY"], [39, 60, "CHEMICAL"], [39, 60, "ENTITY"], [68, 88, "ENTITY"], [39, 50, "PROTEIN"], [68, 73, "GENE_OR_GENE_PRODUCT"], [68, 73, "GGP"], [0, 11, "ENTITY"], [16, 23, "PROTEIN"], [39, 60, "GENE_OR_GENE_PRODUCT"], [16, 23, "SIMPLE_CHEMICAL"], [39, 65, "ENTITY"], [39, 50, "GENE_OR_GENE_PRODUCT"], [39, 60, "PROTEIN"], [68, 73, "PROTEIN"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [362, 377, "GGP"], [330, 341, "ENTITY"], [299, 330, "ENTITY"], [299, 330, "PROTEIN"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [164, 171, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [362, 377, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [164, 171, "GGP"], [102, 108, "PROTEIN"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [164, 171, "ENTITY"], [133, 164, "PROTEIN"], [133, 164, "GENE_OR_GENE_PRODUCT"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [423, 434, "ENTITY"], [299, 330, "GGP"], [33, 41, "ENTITY"], [164, 171, "PROTEIN"], [377, 389, "PROTEIN"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expression of 9b protein in SARS-CoV infected cells was confirmed by Western blot analysis with anti-9b monoclonal antibody .", "labels": [[18, 21, "GENE_OR_GENE_PRODUCT"], [119, 128, "GO"], [100, 128, "GENE_OR_GENE_PRODUCT"], [4, 15, "ENTITY"], [32, 56, "CELL_TYPE"], [32, 41, "ORGANISM"], [100, 128, "PROTEIN"], [50, 56, "CL"], [32, 41, "ENTITY"], [73, 95, "ENTITY"], [41, 50, "ENTITY"], [108, 128, "ENTITY"], [21, 29, "CHEBI"], [32, 41, "GGP"], [50, 56, "CELL"], [18, 29, "ENTITY"]]}
{"text": "Western blot analysis of the pellets demonstrated that 9b protein was not released into the culture medium of 9b-expressing cells , while 3a protein was released as previously described ( Huang et al. , 2006b ) . The abundant host protein , actin , was not detectable in the supernatants from any group of cells ( Fig. 2 ) .", "labels": [[124, 130, "CELL"], [297, 303, "CELL"], [0, 22, "ENTITY"], [58, 66, "CHEBI"], [124, 130, "CL"], [110, 130, "ENTITY"], [29, 37, "ENTITY"], [213, 231, "PROTEIN"], [55, 66, "ENTITY"], [217, 231, "TAXON"], [66, 74, "ENTITY"], [217, 231, "ENTITY"], [231, 241, "GO"], [138, 141, "ENTITY"], [92, 107, "ENTITY"], [268, 275, "ENTITY"], [297, 303, "CL"], [231, 241, "GENE_OR_GENE_PRODUCT"], [297, 303, "ENTITY"], [231, 241, "ENTITY"], [110, 130, "CELL_TYPE"], [55, 58, "GENE_OR_GENE_PRODUCT"], [231, 241, "PROTEIN"]]}
{"text": "Expression of 9b-GFP in HEK 293 cells reduced DRP1 levels by approximately 70 % via a mechanism sensitive to proteasome inhibition , but not autophagic degradation inhibition ( Fig. 1D ) .", "labels": [[152, 164, "ENTITY"], [46, 51, "GENE_OR_GENE_PRODUCT"], [46, 51, "GGP"], [32, 38, "CL"], [24, 38, "CELL_LINE"], [46, 51, "PROTEIN"], [24, 38, "CELL"], [24, 38, "ENTITY"], [0, 11, "ENTITY"], [51, 58, "ENTITY"], [137, 152, "ENTITY"], [14, 21, "GENE_OR_GENE_PRODUCT"], [38, 46, "ENTITY"], [46, 51, "ENTITY"]]}
{"text": "We also examined DRP1 levels in the permanently transfected THP-1 cells and again found a marked decrease in DRP1 levels ( Fig. 1 G ) .", "labels": [[22, 29, "ENTITY"], [60, 72, "CELL_LINE"], [17, 22, "ENTITY"], [60, 72, "ENTITY"], [60, 72, "CELL"], [8, 17, "ENTITY"], [17, 22, "ENTITY"], [48, 60, "ENTITY"], [17, 22, "GENE_OR_GENE_PRODUCT"], [17, 22, "GENE_OR_GENE_PRODUCT"], [17, 22, "PROTEIN"], [17, 22, "GGP"], [66, 72, "CL"], [97, 106, "ENTITY"], [123, 130, "GENE_OR_GENE_PRODUCT"], [36, 48, "ENTITY"], [22, 29, "ENTITY"], [17, 22, "PROTEIN"], [17, 22, "GGP"]]}
{"text": "The DRP1 shRNA appropriately decreased DRP1 expression , but did not impact endogenous MAVS expression ( Fig. 3J ) . This indicates that the ORF-9b mediated reduction in DRP1 may contributes to the decrease in type I interferon signaling , however other mechanisms must be operant .", "labels": [[265, 273, "ENTITY"], [4, 9, "ENTITY"], [207, 217, "GGP"], [44, 55, "ENTITY"], [4, 9, "PROTEIN"], [4, 9, "GENE_OR_GENE_PRODUCT"], [207, 217, "PROTEIN"], [207, 228, "ENTITY"], [9, 15, "ENTITY"], [4, 9, "GENE_OR_GENE_PRODUCT"], [148, 157, "ENTITY"], [4, 9, "GGP"], [29, 39, "ENTITY"], [207, 217, "GENE_OR_GENE_PRODUCT"], [4, 9, "GGP"], [4, 9, "ENTITY"], [4, 15, "RNA"]]}
{"text": "These data show that ORF-9b localizes to mitochondria and likely causes mitochondrial elongation by triggering DRP1 ubiquitination and its proteasomal destruction .", "labels": [[41, 54, "ENTITY"], [41, 54, "CELLULAR_COMPONENT"], [72, 86, "GO"], [116, 131, "ENTITY"], [28, 38, "ENTITY"], [139, 151, "GO"], [72, 86, "CELLULAR_COMPONENT"], [111, 116, "GGP"], [139, 163, "ENTITY"], [21, 28, "PROTEIN"], [21, 28, "ENTITY"], [21, 28, "SIMPLE_CHEMICAL"], [111, 116, "PROTEIN"], [111, 116, "ENTITY"], [41, 54, "GO"], [72, 97, "ENTITY"], [111, 116, "GENE_OR_GENE_PRODUCT"], [6, 11, "ENTITY"]]}
{"text": "We expressed 9b-GFP in the presence of either an IFN-\u03b2 or a NF-\u03baB reporter construct and simulated an intracellular viral infection by cotransfecting Poly(I : C ) . As expected Poly(I : C ) induced both reporter constructs , but the presence of ORF-9b significantly inhibited this response ( Fig. 3A ) .", "labels": [[157, 163, "ENTITY"], [102, 116, "IMMATERIAL_ANATOMICAL_ENTITY"], [27, 36, "ENTITY"], [60, 85, "DNA"], [49, 55, "ENTITY"], [102, 122, "GO"], [27, 36, "ENTITY"], [60, 66, "CHEMICAL"], [150, 157, "CHEMICAL"], [13, 20, "GENE_OR_GENE_PRODUCT"], [252, 266, "ENTITY"], [168, 177, "GENE_OR_GENE_PRODUCT"], [49, 55, "GENE_OR_GENE_PRODUCT"], [27, 36, "SIMPLE_CHEMICAL"], [150, 157, "GENE_OR_GENE_PRODUCT"], [27, 36, "PROTEIN"], [116, 132, "ENTITY"], [266, 281, "ENTITY"], [116, 132, "DISEASE"], [168, 177, "CHEMICAL"], [60, 85, "ENTITY"], [102, 116, "ENTITY"], [60, 66, "GENE_OR_GENE_PRODUCT"], [66, 75, "SO"], [190, 212, "ENTITY"], [135, 150, "ENTITY"], [190, 212, "DNA"], [75, 85, "SO"], [3, 13, "ENTITY"]]}
{"text": "As expected the amount of interferon-\u03b2 decreased in the cell supernatant in the presence of 9b-Flag ( Fig. 3D ) .", "labels": [[26, 39, "ENTITY"], [56, 61, "CELL"], [16, 23, "ENTITY"], [56, 73, "ENTITY"], [56, 61, "CL"], [39, 49, "ENTITY"]]}
{"text": "We expressed 9b-GFP in the presence of either an IFN-\u03b2 or a NF-\u03baB reporter construct and simulated an intracellular viral infection by cotransfecting Poly(I : C ) . As expected Poly(I : C ) induced both reporter constructs , but the presence of ORF-9b significantly inhibited this response ( Fig. 3A ) .", "labels": [[157, 163, "ENTITY"], [102, 116, "IMMATERIAL_ANATOMICAL_ENTITY"], [27, 36, "ENTITY"], [60, 85, "DNA"], [49, 55, "ENTITY"], [102, 122, "GO"], [27, 36, "ENTITY"], [60, 66, "CHEMICAL"], [150, 157, "CHEMICAL"], [13, 20, "GENE_OR_GENE_PRODUCT"], [252, 266, "ENTITY"], [168, 177, "GENE_OR_GENE_PRODUCT"], [49, 55, "GENE_OR_GENE_PRODUCT"], [27, 36, "SIMPLE_CHEMICAL"], [150, 157, "GENE_OR_GENE_PRODUCT"], [27, 36, "PROTEIN"], [116, 132, "ENTITY"], [266, 281, "ENTITY"], [116, 132, "DISEASE"], [168, 177, "CHEMICAL"], [60, 85, "ENTITY"], [102, 116, "ENTITY"], [60, 66, "GENE_OR_GENE_PRODUCT"], [66, 75, "SO"], [190, 212, "ENTITY"], [135, 150, "ENTITY"], [190, 212, "DNA"], [75, 85, "SO"], [3, 13, "ENTITY"]]}
{"text": "Since MAVS is required for the phosphorylation of IRF3 in the RIG-I mediated anti-viral response , we checked whether 9b-GFP expression reduced IRF3 phosphorylation , which it did ( Fig. 3C ) .", "labels": [[6, 11, "PROTEIN"], [62, 68, "PROTEIN"], [62, 68, "GGP"], [77, 97, "ENTITY"], [50, 55, "PROTEIN"], [6, 11, "GENE_OR_GENE_PRODUCT"], [50, 55, "GENE_OR_GENE_PRODUCT"], [6, 11, "ENTITY"], [50, 55, "GGP"], [31, 47, "ENTITY"], [62, 68, "ENTITY"], [50, 55, "ENTITY"], [6, 11, "GGP"]]}
{"text": "Indicating that ORF-9b likely triggers K48-linked ubiquitination of MAVS immunoblotting Myc-MAVS immunoprecipitates revealed the presence of K48-linked ubiquitin ( Fig. 5C ) .", "labels": [[16, 23, "PROTEIN"], [39, 60, "GGP"], [16, 23, "ENTITY"], [39, 60, "CHEMICAL"], [97, 116, "ENTITY"], [39, 60, "PROTEIN"], [68, 88, "ENTITY"], [39, 60, "ENTITY"], [39, 50, "PROTEIN"], [68, 73, "GENE_OR_GENE_PRODUCT"], [0, 11, "ENTITY"], [39, 60, "GENE_OR_GENE_PRODUCT"], [39, 65, "ENTITY"], [39, 50, "GENE_OR_GENE_PRODUCT"], [16, 23, "SIMPLE_CHEMICAL"], [68, 73, "PROTEIN"], [68, 73, "GGP"]]}
{"text": "Finally , in the THP-1 cells permanently transfected with 9b-GFP we also found a marked reduction in the endogenous level of MAVS ( Fig. 5E ) .", "labels": [[17, 23, "ENTITY"], [130, 137, "GENE_OR_GENE_PRODUCT"], [17, 23, "CELL"], [17, 23, "CELL_LINE"]]}
{"text": "Finally , in the THP-1 cells permanently transfected with 9b-GFP we also found a marked reduction in the endogenous level of MAVS ( Fig. 5E ) .", "labels": [[17, 23, "ENTITY"], [130, 137, "GENE_OR_GENE_PRODUCT"], [17, 23, "CELL"], [17, 23, "CELL_LINE"]]}
{"text": "Interestingly , 9b-GFP expression potently induced autophagosome formation in A549 cells ( Fig. 7A , Video 2 ) .", "labels": [[89, 96, "CELL"], [78, 83, "ENTITY"], [78, 83, "CELL"], [78, 83, "CELL_LINE"]]}
{"text": "Similarly , 9b-Flag triggered autophagy in the same cells ( Fig. 7B ) .", "labels": []}
{"text": "The induction of autophagy by ORF-9b depended upon ATG5 , an important regulator of autophagosome formation , as reducing its expression decreased 9b-GFP triggered LC3 processing ( Fig. 7F ) .", "labels": [[137, 147, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [30, 37, "PROTEIN"], [51, 56, "ENTITY"], [30, 37, "SIMPLE_CHEMICAL"], [154, 164, "GENE_OR_GENE_PRODUCT"], [51, 56, "PROTEIN"], [51, 56, "GGP"], [4, 14, "ENTITY"], [51, 56, "GENE_OR_GENE_PRODUCT"], [154, 168, "ENTITY"], [154, 164, "GGP"], [30, 37, "ENTITY"], [154, 164, "PROTEIN"], [17, 27, "ENTITY"]]}
{"text": "The results showed that SARS-CoV-2 RBD reacted strongly with anti-SARS-CoV RBD IgG with antibody titer of 1:2.4 \u00d7 104 ( Fig. 4d ) , but it did not react with anti-MERS-CoV RBD IgG ( Fig. 4d),but not with anti-MERS-CoV RBD IgG ) . As expected , SARS-CoV RBD reacted strongly with anti-SARS-CoV RBD IgG ( antibody titer : 1:1.4 \u00d7 105 ) ( Fig. 4d),but not with anti-MERS-CoV RBD IgG ( Fig. 4d),but not with anti-MERS-CoV RBD IgG ) .", "labels": [[24, 35, "ENTITY"], [118, 125, "CELL"], [197, 221, "ENTITY"], [79, 83, "ENTITY"], [61, 83, "PROTEIN"], [61, 75, "ENTITY"], [197, 217, "DISEASE"], [24, 35, "CHEMICAL"], [24, 39, "PROTEIN"], [4, 12, "ENTITY"], [88, 97, "ENTITY"], [39, 47, "GO"], [35, 39, "ENTITY"], [35, 39, "SIMPLE_CHEMICAL"], [88, 97, "GO"], [35, 39, "ENTITY"], [153, 176, "PROTEIN"], [39, 47, "ENTITY"], [61, 79, "DISEASE"], [79, 83, "SIMPLE_CHEMICAL"], [276, 296, "PROTEIN"], [97, 103, "ENTITY"], [153, 176, "ENTITY"], [24, 35, "GENE_OR_GENE_PRODUCT"], [47, 56, "ENTITY"], [176, 182, "CELL"], [276, 296, "ENTITY"], [197, 221, "PROTEIN"], [35, 39, "ORGANISM"]]}
{"text": "Kuba et al. [ 10 ] demonstrated in mice that SARS-CoV downregulates ACE2 protein ( but not ACE ) by binding its spike protein , contributing to severe lung injury .", "labels": [[54, 73, "PROTEIN"], [108, 118, "PROTEIN"], [144, 156, "ENTITY"], [54, 73, "GGP"], [45, 54, "ENTITY"], [112, 118, "CHEBI"], [144, 156, "DISEASE"], [54, 73, "ENTITY"], [128, 144, "ENTITY"], [144, 151, "ORGAN"], [54, 68, "GENE_OR_GENE_PRODUCT"], [108, 118, "ENTITY"]]}
{"text": "Overexpression of human ACE2 enhanced disease severity in a mouse model of SARS-CoV infection , demonstrating that viral entry into cells is a critical step [ 11 ]", "labels": [[18, 29, "ORGANISM"], [60, 66, "ORGANISM"], [24, 29, "ENTITY"], [18, 24, "ENTITY"], [38, 55, "ENTITY"], [60, 72, "ENTITY"], [29, 38, "ENTITY"], [18, 29, "PROTEIN"], [60, 66, "TAXON"], [18, 29, "GGP"], [75, 94, "ENTITY"], [115, 121, "ENTITY"], [0, 15, "ENTITY"], [75, 84, "ORGANISM"], [75, 94, "DISEASE"]]}
{"text": "Critically , this injury was attenuated by blocking the renin- angiotensin pathway and depended on ACE2 expression [ 12 ] .", "labels": [[0, 11, "ENTITY"], [56, 63, "GENE_OR_GENE_PRODUCT"], [56, 75, "ENTITY"]]}
{"text": "Kuba et al. [ 10 ] demonstrated in mice that SARS-CoV downregulates ACE2 protein ( but not ACE ) by binding its spike protein , contributing to severe lung injury .", "labels": [[54, 73, "PROTEIN"], [108, 118, "PROTEIN"], [144, 156, "ENTITY"], [54, 73, "GGP"], [45, 54, "ENTITY"], [112, 118, "CHEBI"], [144, 156, "DISEASE"], [54, 73, "ENTITY"], [128, 144, "ENTITY"], [144, 151, "ORGAN"], [54, 68, "GENE_OR_GENE_PRODUCT"], [108, 118, "ENTITY"]]}
{"text": "This suggests that excessive ACE2 may competitively bind with SARS- CoV-2 not only to neutralize the virus but also rescue cellular ACE2 activity which negatively regulates the renin-angiotensin system ( RAS ) to protect the lung from injury [ 12 , 30 ] .", "labels": [[29, 34, "GENE_OR_GENE_PRODUCT"], [62, 74, "ENTITY"], [116, 123, "ENTITY"], [29, 34, "GGP"], [86, 97, "ENTITY"], [101, 107, "TAXON"], [177, 202, "GENE_OR_GENE_PRODUCT"], [177, 202, "ENTITY"], [137, 146, "ENTITY"], [123, 132, "ENTITY"], [38, 52, "ENTITY"], [101, 107, "ENTITY"], [62, 74, "PROTEIN"], [123, 137, "CL"], [29, 34, "PROTEIN"], [163, 173, "ENTITY"], [29, 34, "ENTITY"], [62, 74, "ORGANISM"], [19, 29, "ENTITY"], [29, 34, "ENTITY"], [52, 57, "ENTITY"], [123, 137, "CELL"], [29, 34, "PROTEIN"]]}
{"text": "With SARS-CoV , animal models showed that infection with the virus downregulated ACE2 expression , generating an inflammatory response correlated with acute lung injury and impaired cardiac contractility [ 26\u201328 ] .", "labels": [[16, 23, "ENTITY"], [126, 135, "ENTITY"], [173, 190, "ENTITY"], [146, 162, "DISEASE"], [110, 126, "ENTITY"], [5, 14, "ORGANISM"], [173, 182, "ORGAN"], [5, 14, "ENTITY"], [151, 157, "ORGAN"], [146, 162, "ENTITY"]]}
{"text": "These mice showed increased severity of pathological conditions in acute lung injury .", "labels": [[28, 37, "ENTITY"], [67, 85, "DISEASE"], [18, 28, "ENTITY"], [67, 85, "ENTITY"], [6, 11, "ORGANISM"], [6, 11, "TAXON"], [73, 78, "ORGAN"], [40, 53, "ENTITY"], [6, 11, "ENTITY"]]}
{"text": "Other mouse models have suggested that dysregulation of ACE2 may mediate acute lung injury that is secondary to virulent strains of influenza48,49 and respiratory syncytial virus.50", "labels": [[6, 12, "TAXON"], [73, 91, "DISEASE"], [6, 12, "ORGANISM"], [56, 61, "ENTITY"], [121, 129, "ENTITY"], [39, 53, "ENTITY"], [112, 121, "TAXON"], [79, 84, "ORGAN"], [56, 61, "PROTEIN"], [56, 61, "GENE_OR_GENE_PRODUCT"], [6, 19, "ENTITY"], [132, 147, "CHEMICAL"], [99, 112, "ENTITY"], [151, 173, "ENTITY"], [132, 147, "ENTITY"], [112, 121, "ENTITY"], [73, 91, "ENTITY"], [56, 61, "GGP"]]}
{"text": "ACE2 has a well-recognized role in myocardial recovery and injury response ; in one study , ACE2 knockout in animal models contributed to adverse left ventricular remodeling in response to acute injury driven by angiotensin II.55", "labels": [[35, 46, "ENTITY"], [106, 116, "ENTITY"], [0, 5, "PROTEIN"], [59, 66, "ENTITY"], [186, 195, "DISEASE"], [135, 163, "ENTITY"], [0, 5, "ENTITY"], [138, 151, "MULTI-TISSUE_STRUCTURE"], [35, 46, "MULTI-TISSUE_STRUCTURE"], [46, 55, "ENTITY"], [0, 5, "ENTITY"], [0, 5, "GGP"], [209, 224, "TISSUE"], [66, 75, "ENTITY"], [186, 195, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "As shown in Figure 1(B ) , serum starvation induced approx . 30 % cell death in the presence of N ( lane 4 ) .", "labels": [[25, 33, "ENTITY"], [66, 71, "DISEASE"], [33, 44, "ENTITY"], [12, 23, "ENTITY"], [61, 71, "ENTITY"], [93, 100, "ENTITY"], [12, 23, "GENE_OR_GENE_PRODUCT"], [93, 100, "CHEMICAL"]]}
{"text": "This result supported further our hypothesis that N-induced cell death was due to interference with the integrin signalling pathway , and that serum factors inhibited this phenomenon dominantly by maintaining the activity of FAK through alternative pathways .", "labels": [[143, 149, "PROTEIN"], [104, 113, "GENE_OR_GENE_PRODUCT"], [34, 45, "ENTITY"], [143, 149, "ENTITY"], [5, 12, "ENTITY"], [50, 71, "ENTITY"], [50, 65, "GENE_OR_GENE_PRODUCT"], [237, 249, "ENTITY"], [104, 113, "GO"], [65, 71, "DISEASE"], [104, 113, "PROTEIN"], [104, 132, "ENTITY"], [50, 65, "CL"], [82, 95, "ENTITY"]]}
{"text": "From these experiments , we conclude that the N protein of SARS-CoV induces apoptosis and actin reorganization by interfering with the integrin signalling pathway during cellular stress induced by the absence of growth factors .", "labels": [[170, 179, "ENTITY"], [212, 219, "PROTEIN"], [90, 96, "ENTITY"], [11, 23, "ENTITY"], [212, 219, "ENTITY"], [135, 155, "ENTITY"]]}
{"text": "N expression clearly down-regulated the level of extracellular fibronectin in the absence of serum ( Figure 2A , upper panel ) .", "labels": [[21, 36, "ENTITY"], [49, 75, "ENTITY"], [93, 99, "ORGANISM_SUBSTANCE"], [49, 75, "CELLULAR_COMPONENT"], [0, 13, "ENTITY"], [40, 46, "ENTITY"], [93, 99, "ENTITY"], [111, 119, "ENTITY"], [49, 75, "PROTEIN"], [101, 108, "ENTITY"], [49, 75, "GO"], [82, 90, "ENTITY"]]}
{"text": "As expected , fibronectin levels were found to be lower in N-expressing cells irrespective of the presence or absence of serum ( Figure 2A , lower panel ) , suggesting that N down-regulated fibronectin gene expression .", "labels": [[59, 72, "ENTITY"], [168, 175, "ENTITY"], [59, 72, "CELL_TYPE"], [127, 136, "ENTITY"], [175, 202, "ENTITY"], [14, 26, "ENTITY"], [175, 190, "GENE_OR_GENE_PRODUCT"], [139, 147, "ENTITY"], [202, 207, "ENTITY"]]}
{"text": "The level of phosphorylated FAK was significantly down-regulated in N-expressing cells in the absence of growth factors ( Figure 2C ) .", "labels": [[68, 87, "ENTITY"], [81, 87, "CELL"], [81, 87, "CL"], [94, 102, "ENTITY"], [122, 129, "ENTITY"], [28, 32, "GGP"], [68, 87, "CELL_TYPE"], [28, 32, "ENTITY"], [4, 10, "ENTITY"], [13, 28, "ENTITY"], [105, 120, "ENTITY"], [105, 120, "PROTEIN"], [28, 32, "GENE_OR_GENE_PRODUCT"], [13, 32, "PROTEIN"], [50, 65, "ENTITY"]]}
{"text": "This result supported further our hypothesis that N-induced cell death was due to interference with the integrin signalling pathway , and that serum factors inhibited this phenomenon dominantly by maintaining the activity of FAK through alternative pathways .", "labels": [[143, 149, "PROTEIN"], [104, 113, "GENE_OR_GENE_PRODUCT"], [34, 45, "ENTITY"], [143, 149, "ENTITY"], [5, 12, "ENTITY"], [50, 71, "ENTITY"], [50, 65, "GENE_OR_GENE_PRODUCT"], [237, 249, "ENTITY"], [104, 132, "ENTITY"], [104, 113, "GO"], [65, 71, "DISEASE"], [104, 113, "PROTEIN"], [50, 65, "CL"], [82, 95, "ENTITY"]]}
{"text": "From these experiments , we conclude that the N protein of SARS-CoV induces apoptosis and actin reorganization by interfering with the integrin signalling pathway during cellular stress induced by the absence of growth factors .", "labels": [[170, 179, "ENTITY"], [212, 219, "PROTEIN"], [90, 96, "ENTITY"], [11, 23, "ENTITY"], [212, 219, "ENTITY"], [135, 155, "ENTITY"]]}
{"text": "In the absence of serum , N expression down-regulated the activity of p-ERK ( Figure 3A , lanes 4\u20136 )", "labels": [[18, 24, "ENTITY"], [7, 15, "ENTITY"], [76, 85, "GENE_OR_GENE_PRODUCT"], [18, 24, "ORGANISM_SUBSTANCE"], [76, 85, "ENTITY"]]}
{"text": "Furthermore , N expression up-regulated the activity of stress activated protein kinases , namely the JNK and p38 MAPK pathways . The activity was significantly high in the absence of serum ( Figure 3B , top panel , lanes 5 and 6 ) .", "labels": [[56, 81, "ENTITY"], [106, 119, "ENTITY"], [184, 192, "ENTITY"], [106, 114, "PROTEIN"], [106, 114, "GGP"], [199, 208, "ENTITY"], [208, 216, "ENTITY"], [106, 114, "GENE_OR_GENE_PRODUCT"], [56, 81, "PROTEIN"]]}
{"text": "Furthermore , N expression up-regulated the activity of stress activated protein kinases , namely the JNK and p38 MAPK pathways . The activity was significantly high in the absence of serum ( Figure 3B , top panel , lanes 5 and 6 ) .", "labels": [[56, 81, "ENTITY"], [106, 119, "ENTITY"], [184, 192, "ENTITY"], [106, 114, "PROTEIN"], [106, 114, "GGP"], [199, 208, "ENTITY"], [208, 216, "ENTITY"], [106, 114, "GENE_OR_GENE_PRODUCT"], [56, 81, "PROTEIN"]]}
{"text": "Thus we conclude that N-induced activation of the p38 MAPK pathway in the absence of growth factors leads to actin reorganization .", "labels": [[109, 115, "GENE_OR_GENE_PRODUCT"], [109, 115, "PROTEIN"], [74, 82, "ENTITY"], [109, 130, "ENTITY"], [32, 43, "ENTITY"], [109, 115, "GO"], [50, 59, "PROTEIN"], [50, 67, "ENTITY"], [50, 59, "GGP"], [50, 59, "GENE_OR_GENE_PRODUCT"], [85, 100, "ENTITY"], [85, 100, "PROTEIN"]]}
{"text": "The level of p-Akt was found to be significantly down-regulated in the absence of serum ( Figure 5A , lanes 4\u20136 ) .", "labels": [[71, 79, "ENTITY"], [13, 19, "PROTEIN"], [13, 19, "ENTITY"], [4, 10, "ENTITY"], [82, 88, "ENTITY"], [13, 19, "GGP"], [82, 88, "ORGANISM_SUBSTANCE"], [90, 97, "ENTITY"], [49, 64, "ENTITY"], [13, 19, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Immunoprecipitation of Bcl-2 showed strong down-regulation in the absence of serum ( Figure 5B , lanes 4\u20136 ) .", "labels": [[23, 29, "ENTITY"], [77, 83, "ORGANISM_SUBSTANCE"], [23, 29, "PROTEIN"], [23, 29, "GENE_OR_GENE_PRODUCT"], [85, 92, "ENTITY"], [66, 74, "ENTITY"], [43, 59, "ENTITY"], [0, 20, "ENTITY"], [77, 83, "ENTITY"], [23, 29, "GGP"]]}
{"text": "From these experiments , we conclude that the N protein of SARS-CoV induces apoptosis and actin reorganization by interfering with the integrin signalling pathway during cellular stress induced by the absence of growth factors .", "labels": [[170, 179, "ENTITY"], [212, 219, "PROTEIN"], [90, 96, "ENTITY"], [11, 23, "ENTITY"], [212, 219, "ENTITY"], [135, 155, "ENTITY"]]}
{"text": "The results showed that all three subunits , A\u03b1 , B\u03b2 , and \u03b3 , of fibrinogen ( Table \u200b(Table1)1 ) were strongly up-regulated in the 3a-expressing clones .", "labels": [[34, 43, "ENTITY"], [125, 146, "CELL_LINE"], [103, 112, "ENTITY"], [79, 85, "PROTEIN"], [4, 12, "ENTITY"], [132, 146, "SO"], [132, 146, "ENTITY"]]}
{"text": "The results showed that all three subunits , A\u03b1 , B\u03b2 , and \u03b3 , of fibrinogen ( Table \u200b(Table1)1 ) were strongly up-regulated in the 3a-expressing clones .", "labels": [[34, 43, "ENTITY"], [125, 146, "CELL_LINE"], [103, 112, "ENTITY"], [79, 85, "PROTEIN"], [4, 12, "ENTITY"], [132, 146, "SO"], [132, 146, "ENTITY"]]}
{"text": "The results showed that all three subunits , A\u03b1 , B\u03b2 , and \u03b3 , of fibrinogen ( Table \u200b(Table1)1 ) were strongly up-regulated in the 3a-expressing clones .", "labels": [[34, 43, "ENTITY"], [125, 146, "CELL_LINE"], [103, 112, "ENTITY"], [79, 85, "PROTEIN"], [4, 12, "ENTITY"], [132, 146, "SO"], [132, 146, "ENTITY"]]}
{"text": "The only other fibrinogen-related gene that showed an increase in the mRNA level in the 3a-expressing clones was Fgl-1 ( Table \u200b(Table1,1 , Fig. \u200bFig.1B),1B ) , but the degree of up-regulation was less .", "labels": [[113, 119, "PROTEIN"], [113, 119, "CHEMICAL"], [54, 63, "ENTITY"], [113, 119, "ENTITY"], [15, 39, "SO"], [75, 81, "ENTITY"], [138, 145, "SIMPLE_CHEMICAL"], [15, 39, "DNA"], [102, 109, "SO"], [88, 109, "CELL_LINE"], [70, 75, "ENTITY"], [15, 39, "ENTITY"], [70, 75, "CHEBI"], [102, 109, "ENTITY"]]}
{"text": "The only other fibrinogen-related gene that showed an increase in the mRNA level in the 3a-expressing clones was Fgl-1 ( Table \u200b(Table1,1 , Fig. \u200bFig.1B),1B ) , but the degree of up-regulation was less .", "labels": [[113, 119, "CHEMICAL"], [54, 63, "ENTITY"], [15, 39, "SO"], [113, 119, "PROTEIN"], [75, 81, "ENTITY"], [138, 145, "SIMPLE_CHEMICAL"], [15, 39, "DNA"], [102, 109, "SO"], [88, 109, "CELL_LINE"], [70, 75, "ENTITY"], [15, 39, "ENTITY"], [113, 119, "ENTITY"], [70, 75, "CHEBI"], [102, 109, "ENTITY"]]}
{"text": "Interestingly , the mRNA level of CSPG2 , which is involved in the extracellular matrix assembly ( 32 ) , was also specifically up- regulated , with four different transcripts giving similar results ( Table \u200b(Table1).1 ) .", "labels": [[63, 81, "CELLULAR_COMPONENT"], [63, 88, "GO"], [128, 132, "ENTITY"], [201, 207, "GENE_OR_GENE_PRODUCT"], [183, 191, "ENTITY"], [63, 88, "ENTITY"]]}
{"text": "Consistent with the increase in the mRNA , the A\u03b1 protein levels in the 3a-expressing clones were significantly higher than in the vector control ( Fig. \u200b(Fig.2A,2A , panel b , lanes 4 to 6 ) .", "labels": [[0, 16, "ENTITY"], [72, 86, "CELL_LINE"], [131, 138, "ENTITY"], [36, 41, "RNA"], [36, 41, "ENTITY"], [148, 153, "CHEMICAL"], [47, 50, "PROTEIN"], [20, 29, "ENTITY"], [148, 153, "PROTEIN"], [47, 50, "GGP"], [47, 50, "ENTITY"], [36, 41, "CHEBI"]]}
{"text": "Consistently , the levels of both B\u03b2 and \u03b3 proteins in the 3a-expressing clones were also higher than that in the vector control ( Fig. \u200b(Fig.2A,2A , panels c and a , lanes 4 to 6 ) .", "labels": [[0, 13, "ENTITY"], [131, 136, "PROTEIN"], [114, 121, "ENTITY"], [163, 167, "ENTITY"], [34, 43, "PROTEIN"], [59, 73, "CELL_LINE"], [131, 136, "CHEMICAL"]]}
{"text": "Consistently , the levels of both B\u03b2 and \u03b3 proteins in the 3a-expressing clones were also higher than that in the vector control ( Fig. \u200b(Fig.2A,2A , panels c and a , lanes 4 to 6 ) .", "labels": [[0, 13, "ENTITY"], [131, 136, "PROTEIN"], [114, 121, "ENTITY"], [163, 167, "ENTITY"], [34, 43, "PROTEIN"], [59, 73, "CELL_LINE"], [131, 136, "CHEMICAL"]]}
{"text": "As shown in Fig.2B,2B , high levels of fibrinogen ( \u224830 ng per 106 cells ) were secreted from the 3a-expressing clones", "labels": [[98, 112, "SO"], [12, 22, "SIMPLE_CHEMICAL"], [12, 22, "ENTITY"], [98, 112, "ENTITY"], [94, 112, "CELL_LINE"]]}
{"text": "The level of fibrinogen in the culture supernatant from infected Vero E6 cells was also significantly higher than that from mock-infected cells ( Fig. \u200b(Fig.3B,3B , P < 0.005 ) , but we could not determine the concentration , as the assay was designed for measuring human fibrinogen and no standard from the African green monkeys was available", "labels": [[56, 65, "ENTITY"], [73, 79, "CELL"], [73, 79, "CL"], [70, 79, "ENTITY"], [124, 144, "ENTITY"], [13, 24, "PROTEIN"], [13, 24, "ENTITY"], [31, 51, "ENTITY"], [256, 272, "ORGANISM"], [65, 70, "ENTITY"], [266, 272, "ENTITY"], [4, 10, "ENTITY"], [256, 272, "GGP"], [304, 316, "ENTITY"], [283, 290, "ENTITY"], [13, 24, "GGP"], [256, 266, "ENTITY"], [316, 322, "ENTITY"], [13, 24, "GENE_OR_GENE_PRODUCT"], [256, 272, "PROTEIN"], [124, 144, "CELL_TYPE"], [65, 79, "CELL"], [146, 151, "SIMPLE_CHEMICAL"], [73, 79, "CL"], [56, 79, "CELL_LINE"]]}
{"text": "The expression of fibrinogen \u03b3 was higher in infected cells than mock- infected cells ( Fig. \u200b(Fig.3A).3A ) .", "labels": [[4, 15, "ENTITY"], [45, 54, "ENTITY"], [45, 54, "ENTITY"], [54, 60, "CL"], [18, 31, "GGP"], [54, 60, "CELL"], [54, 60, "CELL"], [45, 60, "CELL_TYPE"], [65, 86, "CELL_TYPE"], [18, 29, "PROTEIN"], [18, 31, "ENTITY"], [54, 60, "ENTITY"], [54, 60, "ENTITY"], [18, 29, "GENE_OR_GENE_PRODUCT"], [54, 60, "CL"]]}
{"text": "Results show that SARS patients \u2019 sera contain high levels of IgG recognizing 3a protein ( Fig. 1A ) .", "labels": [[0, 8, "ENTITY"], [23, 32, "ORGANISM"], [23, 32, "ENTITY"], [78, 81, "ENTITY"], [18, 23, "ENTITY"], [18, 23, "DISEASE"]]}
{"text": "Fig. 1C reveals a high density of the 3a protein at the cell membrane and also in the cytoplasm and the nucleus of the infected cells .", "labels": [[56, 70, "CELLULAR_COMPONENT"], [41, 49, "CHEBI"], [38, 49, "ENTITY"], [86, 96, "ORGANISM_SUBSTANCE"], [18, 31, "ENTITY"], [119, 134, "CELL_TYPE"], [0, 8, "GENE_OR_GENE_PRODUCT"], [104, 112, "ENTITY"], [128, 134, "CELL"], [56, 70, "ENTITY"], [56, 70, "GO"], [104, 112, "CELLULAR_COMPONENT"], [128, 134, "ENTITY"], [128, 134, "CL"], [86, 96, "GO"], [119, 128, "ENTITY"], [86, 96, "ENTITY"], [104, 112, "GO"]]}
{"text": "The 3a protein expression for both wild-type and M6 mutant was revealed on the oocyte cell membranes by anti-LH21 Ab and confocal microscopy ( Fig. 4 B and C ) .", "labels": [[104, 117, "ENTITY"], [52, 59, "SO"], [79, 101, "CL"], [121, 141, "ENTITY"], [86, 101, "ENTITY"], [79, 101, "CELL"], [79, 86, "ENTITY"], [104, 117, "PROTEIN"], [114, 117, "TAXON"], [15, 26, "ENTITY"], [7, 15, "CHEBI"], [35, 45, "ENTITY"], [52, 59, "ENTITY"], [4, 15, "ENTITY"]]}
{"text": "We found that wild type 3a ( 3a-WT ) protein localized to the plasma membrane ( Fig. 1B and F ) , and also displayed a punctate cytoplasmic staining pattern ( Fig. 1B and F ) .", "labels": [[58, 69, "ENTITY"], [85, 88, "CELL"], [85, 88, "ENTITY"], [119, 128, "ORGANISM_SUBSTANCE"], [58, 69, "GO"], [14, 27, "ENTITY"], [119, 128, "GO"], [107, 140, "ENTITY"], [58, 69, "CELLULAR_COMPONENT"], [14, 27, "SO"]]}
{"text": "Fig. 1C reveals a high density of the 3a protein at the cell membrane and also in the cytoplasm and the nucleus of the infected cells .", "labels": [[41, 49, "CHEBI"], [38, 49, "ENTITY"], [18, 31, "ENTITY"], [86, 96, "ENTITY"], [119, 134, "CELL_TYPE"], [104, 112, "ENTITY"], [0, 8, "GENE_OR_GENE_PRODUCT"], [128, 134, "CELL"], [56, 70, "CELLULAR_COMPONENT"], [104, 112, "CELLULAR_COMPONENT"], [56, 70, "ENTITY"], [128, 134, "CL"], [86, 96, "ORGANISM_SUBSTANCE"], [86, 96, "GO"], [119, 128, "ENTITY"], [128, 134, "ENTITY"], [56, 70, "GO"], [104, 112, "GO"]]}
{"text": "We found that wild type 3a ( 3a-WT ) protein localized to the plasma membrane ( Fig. 1B and F ) , and also displayed a punctate cytoplasmic staining pattern ( Fig. 1B and F ) .", "labels": [[58, 69, "ENTITY"], [85, 88, "CELL"], [107, 140, "ENTITY"], [85, 88, "ENTITY"], [119, 128, "ORGANISM_SUBSTANCE"], [14, 27, "ENTITY"], [119, 128, "GO"], [58, 69, "GO"], [58, 69, "CELLULAR_COMPONENT"], [14, 27, "SO"]]}
{"text": "Fig. 1C reveals a high density of the 3a protein at the cell membrane and also in the cytoplasm and the nucleus of the infected cells .", "labels": [[41, 49, "CHEBI"], [38, 49, "ENTITY"], [86, 96, "ORGANISM_SUBSTANCE"], [18, 31, "ENTITY"], [119, 134, "CELL_TYPE"], [0, 8, "GENE_OR_GENE_PRODUCT"], [104, 112, "GO"], [104, 112, "CELLULAR_COMPONENT"], [128, 134, "CELL"], [56, 70, "CELLULAR_COMPONENT"], [128, 134, "ENTITY"], [56, 70, "ENTITY"], [128, 134, "CL"], [86, 96, "GO"], [119, 128, "ENTITY"], [86, 96, "ENTITY"], [104, 112, "ENTITY"], [56, 70, "GO"]]}
{"text": "These findings demonstrate that 3a protein is a transmembrane protein with an extracellular N terminus and an intracellular C terminus ( Fig. 2C ) .", "labels": [[78, 103, "GO"], [78, 103, "ENTITY"], [110, 124, "IMMATERIAL_ANATOMICAL_ENTITY"], [124, 135, "ENTITY"], [110, 135, "GO"], [6, 15, "ENTITY"], [48, 70, "PROTEIN"], [78, 103, "PROTEIN"], [35, 43, "CHEBI"], [32, 43, "ENTITY"], [48, 70, "GO"], [48, 62, "CELLULAR_COMPONENT"], [110, 135, "PROTEIN"], [48, 70, "ENTITY"], [78, 94, "CELLULAR_COMPONENT"], [110, 124, "ENTITY"]]}
{"text": "We observed that oocytes expressing 3a protein at their membrane surface led to a dramatic increase of membrane current over the entire potential range in 100 mM potassium solution ( Fig. 4E ) .", "labels": [[36, 47, "ENTITY"], [162, 172, "SIMPLE_CHEMICAL"], [56, 73, "GO"], [39, 47, "CHEBI"], [25, 36, "ENTITY"], [91, 100, "ENTITY"], [56, 65, "CELLULAR_COMPONENT"], [17, 25, "CL"], [56, 65, "GO"], [56, 65, "CELLULAR_COMPONENT"], [56, 65, "ENTITY"], [162, 181, "ENTITY"], [162, 172, "CHEBI"], [3, 12, "ENTITY"], [136, 146, "ENTITY"], [162, 172, "CHEMICAL"], [56, 73, "ENTITY"], [17, 25, "ENTITY"]]}
{"text": "The 3a-mediated potassium-sensitive current could be completely blocked by 10 mM barium in the bath solution ( Fig. 4F ) .", "labels": [[81, 88, "SIMPLE_CHEMICAL"], [16, 36, "ENTITY"], [64, 72, "ENTITY"], [81, 88, "ENTITY"], [81, 88, "CHEMICAL"], [95, 109, "ENTITY"]]}
{"text": "The results suggest that the viral 3a protein function may contribute to the release of the virus from infected cells .", "labels": [[92, 98, "ENTITY"], [112, 118, "ENTITY"], [29, 46, "PROTEIN"], [103, 112, "ENTITY"], [92, 98, "TAXON"], [77, 85, "ENTITY"], [38, 46, "CHEBI"], [29, 55, "ENTITY"], [4, 12, "ENTITY"], [112, 118, "CELL"], [29, 35, "TAXON"], [103, 118, "CELL_TYPE"], [112, 118, "CL"]]}
{"text": "Consistent with previous findings ( Lawet al. , 2005),we showed that up to 60 % of 3a-WT-expressing Vero E6 cells displayed nuclear condensation ( Fig. 2A ) .", "labels": [[114, 124, "CELLULAR_COMPONENT"], [0, 16, "ENTITY"], [100, 108, "ENTITY"], [114, 132, "ENTITY"], [114, 124, "GO"], [80, 108, "CELL_LINE"], [83, 108, "CELL"], [105, 108, "CL"], [25, 34, "ENTITY"], [83, 100, "ENTITY"]]}
{"text": "Here , we found that both caspase-8- and -9-specific inhibitors significantly suppressed nuclear condensation induced by 3a-WT in Vero E6 cells ( Fig. 2C ) .", "labels": [[130, 138, "CELL_LINE"], [89, 97, "ENTITY"], [130, 138, "ENTITY"], [130, 138, "CELL"], [144, 151, "CELL"]]}
{"text": "Here , we found that both caspase-8- and -9-specific inhibitors significantly suppressed nuclear condensation induced by 3a-WT in Vero E6 cells ( Fig. 2C ) .", "labels": [[130, 138, "CELL_LINE"], [89, 97, "ENTITY"], [130, 138, "ENTITY"], [130, 138, "CELL"], [144, 151, "CELL"]]}
{"text": "This indicates 3a triggers apoptosis through both the death receptor- and mitochondria-mediated pathways .", "labels": [[54, 60, "DISEASE"], [27, 37, "ENTITY"], [74, 105, "ENTITY"], [15, 18, "ENTITY"], [54, 60, "ENTITY"]]}
{"text": "This indicates 3a triggers apoptosis through both the death receptor- and mitochondria-mediated pathways .", "labels": [[54, 60, "DISEASE"], [27, 37, "ENTITY"], [74, 105, "ENTITY"], [15, 18, "ENTITY"], [54, 60, "ENTITY"]]}
{"text": "When we treated 3a-WT-expressing Vero E6 cells with a broad-spectrum caspase inhibitor z-VAD-fmk ( Van Noorden , 2001 ) which blocks caspase-dependent apoptosis in general , a similar level of inhibition was again observed ( Fig. 2D ) .", "labels": [[69, 97, "GGP"], [33, 47, "CELL"], [41, 47, "CL"], [8, 16, "ENTITY"], [54, 87, "ENTITY"], [126, 151, "ENTITY"], [87, 97, "SIMPLE_CHEMICAL"], [176, 184, "ENTITY"], [38, 47, "ENTITY"], [69, 77, "GENE_OR_GENE_PRODUCT"], [33, 38, "ENTITY"], [87, 97, "ENTITY"], [87, 97, "CHEMICAL"]]}
{"text": "As previously reported ( Wong et al. , 2005 ) , 3a-WT-expressing transgenic animals displayed an increased number of AO-positive cells ( Fig. 5B ) when compared to the gmr-GAL4 driver control ( Fig. 5B) when compared to the gmr-GAL4 driver control ) .", "labels": [[161, 184, "ENTITY"], [117, 129, "CELL"], [117, 129, "CL"], [114, 129, "CELL_TYPE"], [129, 137, "CELL"], [48, 65, "ENTITY"], [114, 129, "ENTITY"], [161, 168, "GENE_OR_GENE_PRODUCT"], [161, 168, "DNA"], [48, 76, "SO"]]}
{"text": "Here , we show that 3a-WT protein induced Bid cleavage ( Fig. 3A ) and mitochondrial cytochrome c release ( Fig. 3B ) .", "labels": [[42, 46, "ENTITY"], [67, 85, "PROTEIN"], [67, 85, "GO"], [67, 98, "ENTITY"], [67, 85, "CELLULAR_COMPONENT"]]}
{"text": "Here , we show that 3a-WT protein induced Bid cleavage ( Fig. 3A ) and mitochondrial cytochrome c release ( Fig. 3B ) .", "labels": [[42, 46, "ENTITY"], [67, 85, "PROTEIN"], [67, 85, "GO"], [67, 98, "ENTITY"], [67, 85, "CELLULAR_COMPONENT"]]}
{"text": "We previously reported that overexpression of 3a- WT protein caused a rough-eye phenotype , and the eye size was also reduced due to excessive cell death ( Wong et al. , 2005 ; Fig. 4B ) .", "labels": [[76, 80, "ENTITY"], [70, 80, "ENTITY"], [80, 90, "ENTITY"], [50, 61, "SO"], [28, 43, "ENTITY"], [133, 148, "DISEASE"], [46, 61, "PROTEIN"], [46, 53, "GENE_OR_GENE_PRODUCT"], [50, 61, "ENTITY"], [143, 148, "ENTITY"]]}
{"text": "Nevertheless , we found that both 3a-WT ( Fig. 4 G ) and 3a mutants ( Fig. 4H \u2013 J ) caused disruption of external eye morphology by scanning electron microscopy .", "labels": [[34, 37, "SO"], [84, 91, "ENTITY"], [118, 150, "ENTITY"], [53, 60, "ENTITY"], [132, 141, "CHEBI"], [91, 105, "ENTITY"], [105, 118, "ENTITY"], [60, 75, "GENE_OR_GENE_PRODUCT"]]}
{"text": "We previously reported that overexpression of 3a- WT protein caused a rough-eye phenotype , and the eye size was also reduced due to excessive cell death ( Wong et al. , 2005 ; Fig. 4B ) .", "labels": [[76, 80, "ENTITY"], [70, 80, "ENTITY"], [80, 90, "ENTITY"], [50, 61, "SO"], [28, 43, "ENTITY"], [133, 148, "DISEASE"], [46, 61, "PROTEIN"], [46, 53, "GENE_OR_GENE_PRODUCT"], [50, 61, "ENTITY"], [143, 148, "ENTITY"]]}
{"text": "Cells expressing 3a-WT-EGFP displayed a larger membrane current over the potential range ( Fig. 6B ) when compared to the mock transfected cells ( Fig. 6B) when compared to the mock transfected cells ) .", "labels": [[127, 139, "CL"], [0, 6, "ENTITY"], [6, 17, "ENTITY"], [0, 6, "CL"], [47, 56, "GO"], [47, 56, "CELLULAR_COMPONENT"], [118, 139, "ENTITY"], [0, 6, "CELL"], [17, 28, "DNA"], [127, 139, "CELL"], [73, 83, "ENTITY"], [118, 139, "CELL_LINE"], [47, 56, "ENTITY"]]}
{"text": "To intervene the ion channel function we treated 3a-WT-transfected Vero E6 cells with ion channel blockers , 4-aminopyridine ( AP ) or Ba , and found that both inhibitors were able to suppress 3a-WT-induced nuclear condensation ( Fig. 6F ) .", "labels": [[41, 49, "ENTITY"], [86, 107, "ENTITY"], [67, 72, "ENTITY"], [41, 81, "CELL_LINE"], [72, 81, "ENTITY"], [193, 207, "GO"], [17, 38, "ENTITY"], [184, 207, "GENE_OR_GENE_PRODUCT"], [67, 81, "CELL"], [17, 29, "CHEBI"], [193, 215, "ENTITY"], [75, 81, "CL"], [17, 29, "CHEBI"]]}
{"text": "We found that the number of AO positive cells was largely reduced in 3a-WT-expressing larvae that were treated with Ba ( Fig. 7C ) when compared to the untreated control ( Fig. 7B ) .", "labels": [[58, 66, "ENTITY"], [28, 31, "ENTITY"], [116, 119, "ENTITY"], [28, 46, "CELL_TYPE"], [40, 46, "CL"], [86, 93, "ORGANISM"], [86, 93, "ENTITY"], [148, 162, "ENTITY"], [103, 116, "ENTITY"], [116, 126, "GENE_OR_GENE_PRODUCT"], [40, 46, "CELL"], [116, 119, "PROTEIN"]]}
{"text": "Cells expressing 3a-WT-EGFP displayed a larger membrane current over the potential range ( Fig. 6B ) when compared to the mock transfected cells ( Fig. 6B) when compared to the mock transfected cells ) .", "labels": [[127, 139, "CL"], [0, 6, "ENTITY"], [6, 17, "ENTITY"], [0, 6, "CL"], [47, 56, "GO"], [47, 56, "CELLULAR_COMPONENT"], [118, 139, "ENTITY"], [0, 6, "CELL"], [17, 28, "DNA"], [127, 139, "CELL"], [73, 83, "ENTITY"], [118, 139, "CELL_LINE"], [47, 56, "ENTITY"]]}
{"text": "To intervene the ion channel function we treated 3a-WT-transfected Vero E6 cells with ion channel blockers , 4-aminopyridine ( AP ) or Ba , and found that both inhibitors were able to suppress 3a-WT-induced nuclear condensation ( Fig. 6F ) .", "labels": [[41, 49, "ENTITY"], [86, 107, "ENTITY"], [17, 29, "CHEBI"], [67, 72, "ENTITY"], [41, 81, "CELL_LINE"], [72, 81, "ENTITY"], [193, 207, "GO"], [184, 207, "GENE_OR_GENE_PRODUCT"], [67, 81, "CELL"], [17, 29, "CHEBI"], [193, 215, "ENTITY"], [75, 81, "CL"], [17, 38, "ENTITY"]]}
{"text": "We found that the number of AO positive cells was largely reduced in 3a-WT-expressing larvae that were treated with Ba ( Fig. 7C ) when compared to the untreated control ( Fig. 7B ) .", "labels": [[58, 66, "ENTITY"], [28, 31, "ENTITY"], [116, 119, "ENTITY"], [28, 46, "CELL_TYPE"], [40, 46, "CL"], [86, 93, "ORGANISM"], [86, 93, "ENTITY"], [148, 162, "ENTITY"], [103, 116, "ENTITY"], [116, 126, "GENE_OR_GENE_PRODUCT"], [40, 46, "CELL"], [116, 119, "PROTEIN"]]}
{"text": "We further found that addition of ion channel blocker barium chloride ( Ba ) altered the cell membrane current mediated by 3a-WT-EGFP , 3a-YA-EGFP and 3a-DE-EGFP proteins ( Fig. 6B \u2013 D ) .", "labels": [[54, 70, "CHEMICAL"], [147, 162, "ENTITY"], [85, 94, "GO"], [61, 70, "CHEBI"], [134, 162, "PROTEIN"], [34, 54, "CHEBI"], [85, 94, "CELLULAR_COMPONENT"], [34, 70, "ENTITY"], [151, 162, "CHEBI"], [85, 94, "ENTITY"]]}
{"text": "We observed about 3 to 4 fold increase in luciferase activity in 3a expressing cells as compared to the vector control cells .", "labels": [[104, 125, "ENTITY"], [79, 85, "CL"], [42, 62, "ENTITY"], [42, 53, "GENE_OR_GENE_PRODUCT"], [104, 111, "SO"], [68, 79, "ENTITY"], [79, 85, "CELL"], [79, 85, "CELL"], [3, 12, "ENTITY"], [79, 85, "CL"], [42, 53, "PROTEIN"], [30, 39, "ENTITY"], [104, 125, "CELL_LINE"], [79, 85, "ENTITY"]]}
{"text": "We observed about 3 to 4 fold increase in luciferase activity in 3a expressing cells as compared to the vector control cells .", "labels": [[104, 125, "ENTITY"], [79, 85, "CL"], [42, 62, "ENTITY"], [42, 53, "GENE_OR_GENE_PRODUCT"], [104, 111, "SO"], [68, 79, "ENTITY"], [79, 85, "CELL"], [79, 85, "CELL"], [3, 12, "ENTITY"], [79, 85, "CL"], [42, 53, "PROTEIN"], [30, 39, "ENTITY"], [104, 125, "CELL_LINE"], [79, 85, "ENTITY"]]}
{"text": "Compared to control cells , the 3a-expressing cells showed increased levels of phospho-eIF2\u03b1 ( peIF2\u03b1 ) without a concomitant increase in total eIF2\u03b1 levels ( Fig. 2B ) .", "labels": [[20, 26, "CELL"], [32, 46, "ENTITY"], [20, 26, "CL"], [138, 144, "GENE_OR_GENE_PRODUCT"], [32, 46, "CELL_LINE"], [87, 93, "ENTITY"], [114, 126, "ENTITY"], [12, 26, "ENTITY"], [12, 26, "CELL_TYPE"], [0, 9, "ENTITY"]]}
{"text": "Compared to control cells , the 3a-expressing cells showed increased levels of phospho-eIF2\u03b1 ( peIF2\u03b1 ) without a concomitant increase in total eIF2\u03b1 levels ( Fig. 2B ) .", "labels": [[20, 26, "CELL"], [32, 46, "ENTITY"], [20, 26, "CL"], [138, 144, "GENE_OR_GENE_PRODUCT"], [87, 93, "ENTITY"], [32, 46, "CELL_LINE"], [114, 126, "ENTITY"], [12, 26, "ENTITY"], [12, 26, "CELL_TYPE"], [0, 9, "ENTITY"]]}
{"text": "There was about 17-fold increase in ATF4 expression in 3a-expressing cells compared to control cells ; the other viral proteins did not show any significant effect on ATF4 translation", "labels": [[113, 119, "TAXON"], [36, 41, "GENE_OR_GENE_PRODUCT"], [41, 52, "ENTITY"], [69, 75, "ENTITY"], [36, 41, "ENTITY"], [36, 41, "GGP"], [113, 119, "ENTITY"], [69, 75, "CL"], [55, 75, "CELL_LINE"], [36, 41, "PROTEIN"], [69, 75, "CELL"], [87, 101, "ENTITY"], [55, 75, "CELL"], [113, 119, "PROTEIN"], [69, 75, "CL"], [87, 101, "CELL_TYPE"], [24, 33, "ENTITY"]]}
{"text": "There was an \u223c4-fold increase in CHOP promoter activity in 3a-expressing cells ( Fig. 3B ) ; the other viral proteins showed variable results .", "labels": [[97, 109, "TAXON"], [33, 47, "DNA"], [97, 109, "PROTEIN"], [33, 38, "GENE_OR_GENE_PRODUCT"], [125, 134, "ENTITY"], [13, 21, "GENE_OR_GENE_PRODUCT"], [118, 125, "ENTITY"], [21, 30, "ENTITY"], [97, 109, "ENTITY"], [33, 47, "GGP"], [73, 79, "CELL"], [73, 79, "CL"], [38, 56, "ENTITY"], [33, 38, "ENTITY"], [59, 79, "ENTITY"], [59, 79, "CELL_LINE"], [33, 38, "CHEMICAL"]]}
{"text": "Increased IFNAR1 phosphorylation was observed in 3a expressing cells , compared to control cells ( Fig. 4A ) .", "labels": [[85, 99, "ENTITY"], [19, 35, "ENTITY"], [12, 19, "PROTEIN"], [12, 19, "GENE_OR_GENE_PRODUCT"], [54, 65, "ENTITY"], [65, 71, "CL"], [65, 71, "CL"], [65, 71, "CELL"], [65, 71, "ENTITY"], [101, 106, "CELL"], [2, 12, "ENTITY"], [85, 99, "CELL_TYPE"], [12, 19, "ENTITY"], [65, 71, "CELL"], [12, 19, "GGP"]]}
{"text": "Compared to control cells , the 3a expressing cells showed increased ubiquitination of the IFNAR1 protein ( Fig. 4B ) .", "labels": [[20, 26, "CELL"], [91, 98, "GGP"], [20, 26, "CL"], [91, 98, "PROTEIN"], [32, 35, "ENTITY"], [91, 98, "ENTITY"], [12, 26, "ENTITY"], [12, 26, "CELL_TYPE"], [0, 9, "ENTITY"]]}
{"text": "There was increased localization of IFNAR1 in the lysosomal compartment in 3a expressing cells compared to control cells ( Fig. 5 ) .", "labels": [[50, 72, "ENTITY"], [89, 95, "CL"], [107, 121, "ENTITY"], [89, 95, "ENTITY"], [89, 95, "CELL"], [36, 43, "GENE_OR_GENE_PRODUCT"], [50, 60, "CELLULAR_COMPONENT"], [20, 33, "ENTITY"], [89, 95, "CELL"], [36, 43, "ENTITY"], [78, 89, "ENTITY"], [89, 95, "CL"], [107, 121, "CELL_TYPE"], [36, 43, "PROTEIN"], [10, 20, "ENTITY"], [36, 43, "GGP"], [50, 60, "GO"], [95, 104, "ENTITY"]]}
{"text": "As shown in Fig. 6 , there was a significant decrease in the equilibrium levels of IFNAR1 in 3a-ECFP expressing cells compared to control cells .", "labels": [[130, 138, "CELL_TYPE"], [130, 138, "ENTITY"], [61, 73, "ENTITY"]]}
{"text": "IL-1\u03b2 was released from LPS-primed BMMs transduced with the M2- and 2B-expressing lentivirus ( Figure 1D ) . Similarly , the lentiviruses expressing the SARS-CoV E or 3a proteins stimulated IL-1\u03b2 release from LPS-primed BMMs ( Figure 1D ) .", "labels": [[60, 64, "ENTITY"], [125, 138, "ENTITY"], [82, 93, "TAXON"], [82, 93, "ENTITY"], [24, 40, "CELL_LINE"], [19, 35, "CELL_LINE"], [82, 93, "ORGANISM"], [167, 170, "CHEBI"], [35, 40, "CELL"], [164, 170, "ENTITY"], [0, 6, "GENE_OR_GENE_PRODUCT"], [95, 102, "ENTITY"], [0, 6, "CHEMICAL"], [60, 64, "GENE_OR_GENE_PRODUCT"], [0, 6, "PROTEIN"], [0, 6, "ENTITY"], [179, 190, "GENE_OR_GENE_PRODUCT"], [0, 6, "GGP"], [60, 64, "CHEMICAL"], [220, 227, "ENTITY"], [179, 190, "GGP"], [170, 179, "ENTITY"], [0, 6, "ENTITY"], [10, 19, "ENTITY"], [24, 35, "ENTITY"], [24, 35, "CELL"], [24, 35, "ENTITY"], [40, 51, "ENTITY"], [179, 190, "PROTEIN"], [149, 162, "ORGANISM"], [35, 40, "ENTITY"], [149, 170, "PROTEIN"], [179, 190, "ENTITY"], [24, 35, "TAXON"]]}
{"text": "Furthermore , IL-1\u03b2 secretion from LPS-primed BMMs co-infected with E- and 3a-expressing lentiviruses was significantly higher than that from SARS-CoV E-expressing lentivirus-infected cells ( Figure 1E ) . These data indicated that the expression of SARS-CoV viroporin 3a is sufficient to stimulate IL-1\u03b2 secretion by LPS-primed BMMs .", "labels": [[142, 151, "CHEMICAL"], [190, 199, "GENE_OR_GENE_PRODUCT"], [289, 299, "ENTITY"], [315, 329, "CELL_LINE"], [142, 184, "CELL_TYPE"], [142, 184, "ORGANISM"], [247, 259, "PROTEIN"], [190, 199, "ENTITY"], [142, 151, "ENTITY"], [289, 299, "GENE_OR_GENE_PRODUCT"], [289, 299, "GGP"], [247, 259, "GGP"], [164, 184, "ENTITY"], [289, 299, "PROTEIN"], [35, 46, "CELL"], [164, 184, "CL"], [247, 259, "ORGANISM"], [14, 20, "ENTITY"], [35, 46, "ENTITY"]]}
{"text": "As reported previously ( Nakahira et al. , 2011 ; Ito et al. , 2012 ) , treatment of BMMs with Mito-TEMPO completely blocked IL-1\u03b2 secretion in response to ATP ( Figure 6A ) . Similarly , IL-1\u03b2 release induced by the SARS-CoV E and 3a proteins was significantly inhibited by Mito-TEMPO ( Figure 6B ) .", "labels": [[72, 82, "TAXON"], [72, 82, "CELL"], [202, 217, "ENTITY"], [117, 125, "GGP"], [72, 82, "CELL_LINE"], [117, 125, "ENTITY"], [226, 232, "CHEBI"], [117, 125, "PROTEIN"], [144, 153, "ENTITY"], [217, 232, "ENTITY"], [262, 275, "CHEMICAL"], [262, 275, "ENTITY"], [176, 188, "ENTITY"], [106, 117, "ENTITY"], [117, 125, "GENE_OR_GENE_PRODUCT"], [262, 275, "SIMPLE_CHEMICAL"], [202, 217, "ORGANISM"], [156, 162, "ENTITY"], [117, 125, "CHEMICAL"], [144, 153, "CHEMICAL"], [131, 144, "ENTITY"], [144, 153, "SIMPLE_CHEMICAL"], [125, 131, "ENTITY"], [144, 153, "CHEBI"], [202, 232, "PROTEIN"], [125, 131, "ENTITY"], [72, 82, "ENTITY"], [95, 106, "ENTITY"], [248, 262, "ENTITY"]]}
{"text": "IL-1\u03b2 was released from LPS-primed BMMs transduced with the M2- and 2B-expressing lentivirus ( Figure 1D ) . Similarly , the lentiviruses expressing the SARS-CoV E or 3a proteins stimulated IL-1\u03b2 release from LPS-primed BMMs ( Figure 1D ) .", "labels": [[60, 64, "ENTITY"], [125, 138, "ENTITY"], [82, 93, "TAXON"], [82, 93, "ENTITY"], [24, 40, "CELL_LINE"], [19, 35, "CELL_LINE"], [82, 93, "ORGANISM"], [167, 170, "CHEBI"], [35, 40, "CELL"], [0, 6, "CHEMICAL"], [164, 170, "ENTITY"], [0, 6, "ENTITY"], [0, 6, "GGP"], [95, 102, "ENTITY"], [60, 64, "GENE_OR_GENE_PRODUCT"], [179, 190, "GENE_OR_GENE_PRODUCT"], [60, 64, "CHEMICAL"], [220, 227, "ENTITY"], [179, 190, "GGP"], [170, 179, "ENTITY"], [10, 19, "ENTITY"], [24, 35, "ENTITY"], [24, 35, "CELL"], [24, 35, "ENTITY"], [40, 51, "ENTITY"], [179, 190, "PROTEIN"], [149, 162, "ORGANISM"], [35, 40, "ENTITY"], [149, 170, "PROTEIN"], [179, 190, "ENTITY"], [0, 6, "ENTITY"], [24, 35, "TAXON"], [0, 6, "PROTEIN"], [0, 6, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Specifically , emdoin inhibited SARS-CoV-associated 3a protein70 , and blocked an interaction between the SARS-CoV spike protein and ACE2 ( ref . 71 ) .", "labels": [[32, 55, "PROTEIN"], [102, 121, "ENTITY"], [102, 121, "PROTEIN"], [32, 55, "CHEMICAL"], [32, 55, "ENTITY"], [115, 121, "CHEBI"]]}
{"text": "Although cells expressing the ion channel activity-loss mutants 3a-CS or V25F uniformly expressed NLRP3 throughout the cytoplasm , it was redistributed to the perinuclear region in SARS-CoV 3a- or E-expressing cells ( Figure 4 ) .", "labels": [[119, 129, "ORGANISM_SUBSTANCE"], [181, 190, "PROTEIN"], [181, 190, "ENTITY"], [98, 104, "ENTITY"], [30, 56, "ENTITY"], [119, 129, "GO"], [159, 171, "GO"], [9, 15, "CELL"], [98, 104, "CHEMICAL"], [9, 15, "ENTITY"], [73, 78, "ENTITY"], [88, 98, "ENTITY"], [119, 129, "ENTITY"], [181, 190, "ORGANISM"], [98, 104, "GGP"], [197, 210, "CELL_LINE"], [98, 104, "PROTEIN"], [15, 26, "ENTITY"], [216, 225, "ENTITY"], [30, 64, "PROTEIN"], [159, 171, "ENTITY"], [98, 104, "GENE_OR_GENE_PRODUCT"], [30, 42, "CHEBI"], [197, 210, "ENTITY"], [9, 15, "CL"], [56, 64, "SO"], [42, 56, "CHEMICAL"]]}
{"text": "In addition , the SARS-CoV E protein acts as a Ca 2 + -permeable ion channels that activates the NLRP3 inflammasome ( Nieto-Torres et al. , 2015 ) .", "labels": [[47, 54, "ENTITY"], [18, 29, "ENTITY"], [18, 27, "ORGANISM"], [93, 103, "PROTEIN"], [54, 69, "ENTITY"], [18, 29, "GGP"], [47, 69, "PROTEIN"], [18, 29, "PROTEIN"], [54, 65, "CHEBI"], [97, 103, "ENTITY"]]}
{"text": "Although cells expressing the ion channel activity-loss mutants 3a-CS or V25F uniformly expressed NLRP3 throughout the cytoplasm , it was redistributed to the perinuclear region in SARS-CoV 3a- or E-expressing cells ( Figure 4 ) .", "labels": [[119, 129, "ORGANISM_SUBSTANCE"], [181, 190, "PROTEIN"], [181, 190, "ENTITY"], [98, 104, "ENTITY"], [30, 56, "ENTITY"], [119, 129, "GO"], [159, 171, "GO"], [9, 15, "CELL"], [98, 104, "CHEMICAL"], [9, 15, "ENTITY"], [73, 78, "ENTITY"], [88, 98, "ENTITY"], [119, 129, "ENTITY"], [181, 190, "ORGANISM"], [98, 104, "GGP"], [197, 210, "CELL_LINE"], [98, 104, "PROTEIN"], [15, 26, "ENTITY"], [216, 225, "ENTITY"], [30, 64, "PROTEIN"], [159, 171, "ENTITY"], [98, 104, "GENE_OR_GENE_PRODUCT"], [30, 42, "CHEBI"], [197, 210, "ENTITY"], [9, 15, "CL"], [56, 64, "SO"], [42, 56, "CHEMICAL"]]}
{"text": "In addition , the SARS-CoV E protein acts as a Ca 2 + -permeable ion channels that activates the NLRP3 inflammasome ( Nieto-Torres et al. , 2015 ) .", "labels": [[47, 54, "ENTITY"], [18, 27, "ORGANISM"], [18, 29, "ENTITY"], [93, 103, "PROTEIN"], [54, 69, "ENTITY"], [18, 29, "GGP"], [47, 69, "PROTEIN"], [18, 29, "PROTEIN"], [54, 65, "CHEBI"], [97, 103, "ENTITY"]]}
{"text": "IL-1\u03b2 was released from LPS-primed BMMs transduced with the M2- and 2B-expressing lentivirus ( Figure 1D ) . Similarly , the lentiviruses expressing the SARS-CoV E or 3a proteins stimulated IL-1\u03b2 release from LPS-primed BMMs ( Figure 1D ) .", "labels": [[125, 138, "ENTITY"], [82, 93, "TAXON"], [24, 40, "CELL_LINE"], [82, 93, "ENTITY"], [19, 35, "CELL_LINE"], [82, 93, "ORGANISM"], [60, 64, "CHEMICAL"], [60, 64, "GENE_OR_GENE_PRODUCT"], [35, 40, "CELL"], [164, 170, "ENTITY"], [0, 6, "GENE_OR_GENE_PRODUCT"], [60, 64, "ENTITY"], [95, 102, "ENTITY"], [0, 6, "CHEMICAL"], [0, 6, "PROTEIN"], [0, 6, "ENTITY"], [179, 190, "GENE_OR_GENE_PRODUCT"], [0, 6, "GGP"], [220, 227, "ENTITY"], [179, 190, "GGP"], [170, 179, "ENTITY"], [0, 6, "ENTITY"], [10, 19, "ENTITY"], [24, 35, "ENTITY"], [167, 170, "CHEBI"], [24, 35, "CELL"], [24, 35, "ENTITY"], [40, 51, "ENTITY"], [179, 190, "PROTEIN"], [149, 162, "ORGANISM"], [35, 40, "ENTITY"], [149, 170, "PROTEIN"], [179, 190, "ENTITY"], [24, 35, "TAXON"]]}
{"text": "Furthermore , IL-1\u03b2 secretion from LPS-primed BMMs co-infected with E- and 3a-expressing lentiviruses was significantly higher than that from SARS-CoV E-expressing lentivirus-infected cells ( Figure 1E ) . These data indicated that the expression of SARS-CoV viroporin 3a is sufficient to stimulate IL-1\u03b2 secretion by LPS-primed BMMs .", "labels": [[142, 151, "CHEMICAL"], [190, 199, "GENE_OR_GENE_PRODUCT"], [289, 299, "ENTITY"], [315, 329, "CELL_LINE"], [142, 184, "CELL_TYPE"], [142, 184, "ORGANISM"], [247, 259, "PROTEIN"], [190, 199, "ENTITY"], [142, 151, "ENTITY"], [289, 299, "GENE_OR_GENE_PRODUCT"], [289, 299, "GGP"], [247, 259, "GGP"], [164, 184, "ENTITY"], [289, 299, "PROTEIN"], [35, 46, "CELL"], [164, 184, "CL"], [247, 259, "ORGANISM"], [14, 20, "ENTITY"], [35, 46, "ENTITY"]]}
{"text": "As reported previously ( Nakahira et al. , 2011 ; Ito et al. , 2012 ) , treatment of BMMs with Mito-TEMPO completely blocked IL-1\u03b2 secretion in response to ATP ( Figure 6A ) . Similarly , IL-1\u03b2 release induced by the SARS-CoV E and 3a proteins was significantly inhibited by Mito-TEMPO ( Figure 6B ) .", "labels": [[72, 82, "TAXON"], [72, 82, "CELL"], [202, 217, "ENTITY"], [117, 125, "GGP"], [72, 82, "CELL_LINE"], [117, 125, "ENTITY"], [226, 232, "CHEBI"], [117, 125, "PROTEIN"], [144, 153, "ENTITY"], [217, 232, "ENTITY"], [262, 275, "CHEMICAL"], [262, 275, "ENTITY"], [176, 188, "ENTITY"], [106, 117, "ENTITY"], [117, 125, "GENE_OR_GENE_PRODUCT"], [262, 275, "SIMPLE_CHEMICAL"], [202, 217, "ORGANISM"], [156, 162, "ENTITY"], [117, 125, "CHEMICAL"], [144, 153, "CHEMICAL"], [131, 144, "ENTITY"], [144, 153, "SIMPLE_CHEMICAL"], [125, 131, "ENTITY"], [144, 153, "CHEBI"], [202, 232, "PROTEIN"], [125, 131, "ENTITY"], [72, 82, "ENTITY"], [95, 106, "ENTITY"], [248, 262, "ENTITY"]]}
{"text": "Qin et al. also reported that administration of moxifloxacin , lopinavir , and interferon to non-ICU patients and the addition of methylprednisolone to the above treatment for ICU patients resulted in 26 patients being discharged from intensive care unit ( ICU ) and 16 patients being discharged from hospital ( 4 ) .", "labels": [[48, 61, "ENTITY"], [48, 61, "SIMPLE_CHEMICAL"], [230, 250, "ENTITY"], [97, 101, "ORGANISM"], [93, 101, "ENTITY"], [48, 61, "CHEMICAL"], [97, 101, "ENTITY"], [30, 45, "ENTITY"], [93, 101, "ORGANISM"]]}
{"text": "Qin et al. also reported that administration of moxifloxacin , lopinavir , and interferon to non-ICU patients and the addition of methylprednisolone to the above treatment for ICU patients resulted in 26 patients being discharged from intensive care unit ( ICU ) and 16 patients being discharged from hospital ( 4 ) .", "labels": [[48, 61, "ENTITY"], [230, 250, "ENTITY"], [48, 61, "CHEMICAL"], [93, 101, "ENTITY"], [48, 61, "SIMPLE_CHEMICAL"], [97, 101, "ORGANISM"], [97, 101, "ENTITY"], [30, 45, "ENTITY"], [93, 101, "ORGANISM"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [26, 38, "CHEMICAL"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [26, 38, "SIMPLE_CHEMICAL"], [40, 59, "ENTITY"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GGP"], [253, 271, "ENTITY"], [170, 179, "GGP"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [26, 40, "CHEBI"], [144, 154, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [26, 38, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[26, 38, "CHEMICAL"], [179, 194, "ENTITY"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [196, 208, "GGP"], [208, 227, "CHEMICAL"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [26, 38, "SIMPLE_CHEMICAL"], [40, 59, "ENTITY"], [170, 179, "ENTITY"], [179, 194, "GGP"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "ENTITY"], [144, 154, "GGP"], [253, 271, "ENTITY"], [170, 179, "GGP"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [26, 40, "CHEBI"], [144, 154, "GENE_OR_GENE_PRODUCT"], [196, 208, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [179, 194, "GENE_OR_GENE_PRODUCT"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [196, 208, "CHEMICAL"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [196, 208, "PROTEIN"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [26, 38, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [26, 38, "CHEMICAL"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [26, 38, "SIMPLE_CHEMICAL"], [40, 59, "ENTITY"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GGP"], [253, 271, "ENTITY"], [170, 179, "GGP"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [26, 40, "CHEBI"], [144, 154, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [26, 38, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [144, 154, "GGP"], [26, 38, "CHEMICAL"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [208, 227, "GENE_OR_GENE_PRODUCT"], [26, 38, "SIMPLE_CHEMICAL"], [40, 59, "ENTITY"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GENE_OR_GENE_PRODUCT"], [253, 271, "ENTITY"], [170, 179, "GGP"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [26, 40, "CHEBI"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [144, 154, "PROTEIN"], [40, 59, "SIMPLE_CHEMICAL"], [144, 154, "ENTITY"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [26, 38, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [26, 38, "CHEMICAL"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [26, 38, "SIMPLE_CHEMICAL"], [40, 59, "ENTITY"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GGP"], [253, 271, "ENTITY"], [170, 179, "GGP"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [26, 40, "CHEBI"], [144, 154, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [26, 38, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [26, 38, "CHEMICAL"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [26, 38, "SIMPLE_CHEMICAL"], [40, 59, "ENTITY"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GGP"], [253, 271, "ENTITY"], [170, 179, "GGP"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [26, 40, "CHEBI"], [144, 154, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [26, 38, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "IFN-\u03b1 , combined with ribavirin , which could reduce viral replication , moderated the host response and improved clinical outcome in MERS-CoV infected rhesus macaques [ 2 ] .", "labels": [[143, 159, "ENTITY"], [0, 6, "GENE_OR_GENE_PRODUCT"], [134, 143, "ENTITY"], [46, 53, "TAXON"], [105, 123, "ENTITY"], [0, 6, "ENTITY"], [0, 6, "PROTEIN"], [143, 152, "TAXON"], [46, 59, "ENTITY"], [143, 168, "ORGANISM"]]}
{"text": "IFN-\u03b1 , combined with ribavirin , which could reduce viral replication , moderated the host response and improved clinical outcome in MERS-CoV infected rhesus macaques [ 2 ] .", "labels": [[143, 159, "ENTITY"], [0, 6, "GENE_OR_GENE_PRODUCT"], [134, 143, "ENTITY"], [46, 53, "TAXON"], [105, 123, "ENTITY"], [0, 6, "ENTITY"], [0, 6, "PROTEIN"], [143, 152, "TAXON"], [46, 59, "ENTITY"], [143, 168, "ORGANISM"]]}
{"text": "Growth and development inhibition is more common when combining IFN-\u03b1 with ribavirin . Suicidal ideation is more common in children ( mainly adolescents ) compared with adults ( 2.4%vs . 1 % ) [ 12 ] .", "labels": [[87, 96, "DISEASE"], [64, 70, "GENE_OR_GENE_PRODUCT"], [11, 23, "ENTITY"], [64, 70, "ENTITY"], [64, 70, "PROTEIN"], [75, 85, "SIMPLE_CHEMICAL"], [0, 7, "ENTITY"], [75, 85, "CHEMICAL"], [23, 34, "ENTITY"], [75, 85, "ENTITY"], [87, 96, "ENTITY"]]}
{"text": "Growth and development inhibition is more common when combining IFN-\u03b1 with ribavirin . Suicidal ideation is more common in children ( mainly adolescents ) compared with adults ( 2.4%vs . 1 % ) [ 12 ] .", "labels": [[64, 70, "GENE_OR_GENE_PRODUCT"], [64, 70, "ENTITY"], [64, 70, "PROTEIN"], [75, 85, "SIMPLE_CHEMICAL"], [87, 96, "DISEASE"], [11, 23, "ENTITY"], [0, 7, "ENTITY"], [87, 96, "ENTITY"], [75, 85, "CHEMICAL"], [23, 34, "ENTITY"], [75, 85, "ENTITY"]]}
{"text": "Quantitative real-time PCR assay indicated MG-132 causing more than a twofold decrease of TGF-?1 and vimentin mRNA in PLpro-expressing versus control cells ( Fig. 6A ) .", "labels": [[90, 97, "SIMPLE_CHEMICAL"], [118, 156, "CELL_LINE"], [101, 115, "RNA"], [90, 97, "CHEMICAL"], [118, 135, "ENTITY"], [142, 156, "ENTITY"], [43, 50, "SIMPLE_CHEMICAL"], [43, 50, "GGP"], [78, 87, "ENTITY"], [90, 97, "ENTITY"], [118, 135, "GGP"], [118, 135, "GENE_OR_GENE_PRODUCT"], [150, 156, "CL"], [101, 110, "ENTITY"], [0, 33, "ENTITY"], [150, 156, "CELL"], [101, 115, "GGP"], [43, 50, "CHEMICAL"], [101, 110, "GENE_OR_GENE_PRODUCT"], [43, 50, "ENTITY"], [110, 115, "ENTITY"], [90, 97, "PROTEIN"]]}
{"text": "Quantitative real-time PCR assay indicated MG-132 causing more than a twofold decrease of TGF-?1 and vimentin mRNA in PLpro-expressing versus control cells ( Fig. 6A ) .", "labels": [[90, 97, "SIMPLE_CHEMICAL"], [118, 156, "CELL_LINE"], [101, 115, "RNA"], [90, 97, "CHEMICAL"], [118, 135, "ENTITY"], [142, 156, "ENTITY"], [43, 50, "SIMPLE_CHEMICAL"], [43, 50, "GGP"], [78, 87, "ENTITY"], [90, 97, "ENTITY"], [118, 135, "GGP"], [118, 135, "GENE_OR_GENE_PRODUCT"], [150, 156, "CL"], [101, 110, "ENTITY"], [0, 33, "ENTITY"], [150, 156, "CELL"], [43, 50, "CHEMICAL"], [101, 115, "GGP"], [43, 50, "ENTITY"], [110, 115, "ENTITY"], [101, 110, "GENE_OR_GENE_PRODUCT"], [90, 97, "PROTEIN"]]}
{"text": "ELISA assays indicated MG-132 reducing TGF-?1 protein in lysates of PLpro-expressing cells by twofold and no effect on controls ( Fig. 6B ) , proving ubiquitin \u2013 proteasomal system involvement in PLpro-induced expression of TGF-?1 and vimentin .", "labels": [[210, 224, "ENTITY"], [181, 196, "GGP"], [181, 196, "GENE_OR_GENE_PRODUCT"], [39, 46, "SIMPLE_CHEMICAL"], [210, 224, "SIMPLE_CHEMICAL"], [68, 91, "CELL_TYPE"], [119, 128, "ENTITY"], [142, 150, "ENTITY"], [210, 224, "CHEMICAL"], [210, 224, "PROTEIN"], [39, 54, "ENTITY"], [23, 30, "GGP"], [85, 91, "CL"], [46, 54, "CHEBI"], [181, 210, "ENTITY"], [23, 30, "SIMPLE_CHEMICAL"], [106, 116, "ENTITY"], [39, 46, "CHEMICAL"], [0, 13, "ENTITY"], [150, 174, "ENTITY"], [85, 91, "CELL"], [174, 181, "ENTITY"], [23, 30, "ENTITY"], [142, 150, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [39, 54, "PROTEIN"], [150, 162, "GO"], [57, 65, "ENTITY"], [23, 30, "CHEMICAL"], [68, 91, "ENTITY"]]}
{"text": "When the variability between nsp 3 isolates of the SARS epidemic are compared , the results suggest that nsps 1 - 3 perform cell- and host- specific roles in replication and/or virulence . Additionally , they have demonstrated high capacity for adaptation to new environments and selective pressures .", "labels": [[35, 44, "ENTITY"], [276, 290, "ENTITY"], [29, 35, "GENE_OR_GENE_PRODUCT"], [69, 78, "ENTITY"], [51, 56, "ENTITY"], [170, 177, "ENTITY"], [227, 232, "ENTITY"], [29, 35, "ENTITY"], [56, 65, "ENTITY"], [29, 35, "PROTEIN"], [9, 21, "ENTITY"], [105, 112, "PROTEIN"], [105, 110, "ENTITY"], [105, 112, "ORGANISM"], [51, 56, "DISEASE"]]}
{"text": "The Appr-1\u2033-p domain of nsp 3 is proposed to have functions in viral RNA synthesis ( Snijder et al. , 2003 ) .", "labels": [[63, 83, "ENTITY"], [24, 30, "GENE_OR_GENE_PRODUCT"], [4, 21, "GGP"], [63, 73, "TAXON"], [4, 21, "ENTITY"], [4, 14, "GENE_OR_GENE_PRODUCT"], [24, 30, "PROTEIN"], [24, 30, "ENTITY"], [50, 60, "ENTITY"], [4, 21, "PROTEIN"]]}
{"text": "Two groups subsequently demonstrated that expressed and purified SARS PLP possesses deubiquitinating activity ( Barretto et al. , 2005 ; Lindner et al. , 2005 ) .", "labels": [[56, 65, "ENTITY"], [4, 11, "ENTITY"], [42, 52, "ENTITY"], [65, 70, "ENTITY"], [70, 74, "ENTITY"], [84, 110, "ENTITY"], [65, 70, "DISEASE"]]}
{"text": "It was discovered that SARS-CoV nsp 4 is cleaved first at its amino terminus by the PLP ( PLP2 for MHV ) and at its carboxy terminus by 3CLPro ( Harcourt et al. , 2004;Kanjanahaluethai et al. , 2003;Prentice et al. , 2004b ) .", "labels": [[112, 124, "ENTITY"], [62, 68, "CHEMICAL"], [23, 38, "ORGANISM"], [23, 38, "ENTITY"], [23, 38, "PROTEIN"], [62, 77, "ENTITY"], [84, 88, "PROTEIN"], [62, 77, "PROTEIN"], [112, 124, "GO"], [84, 88, "GGP"], [84, 88, "GENE_OR_GENE_PRODUCT"], [62, 77, "SO"], [112, 124, "PROTEIN"], [84, 88, "ENTITY"]]}
{"text": "PLpro alone induced mRNA expression of TGF-b1 ( greater than four fold ) , IL-1a ( approximately three fold),and RANTES ( approximately two fold ) ( Fig. 2A , D , and E ) , yet no signifi- ca nt rise in TNF-a and IFN-a compared to vector controls ( Fig. 2B and C ) .", "labels": [[219, 231, "ENTITY"], [39, 46, "PROTEIN"], [39, 46, "ENTITY"], [0, 6, "ENTITY"], [103, 113, "GGP"], [103, 113, "PROTEIN"], [20, 25, "ENTITY"], [39, 46, "GENE_OR_GENE_PRODUCT"], [103, 113, "ENTITY"], [25, 36, "ENTITY"], [192, 195, "PROTEIN"], [103, 113, "GENE_OR_GENE_PRODUCT"], [12, 20, "ENTITY"], [192, 195, "ENTITY"], [192, 195, "GENE_OR_GENE_PRODUCT"], [192, 195, "GGP"], [103, 113, "CHEMICAL"], [0, 6, "GENE_OR_GENE_PRODUCT"], [39, 46, "GGP"], [20, 25, "CHEBI"]]}
{"text": "PLpro alone induced mRNA expression of TGF-b1 ( greater than four fold ) , IL-1a ( approximately three fold),and RANTES ( approximately two fold ) ( Fig. 2A , D , and E ) , yet no signifi- ca nt rise in TNF-a and IFN-a compared to vector controls ( Fig. 2B and C ) .", "labels": [[219, 231, "ENTITY"], [0, 6, "ENTITY"], [39, 46, "GGP"], [103, 113, "GGP"], [103, 113, "PROTEIN"], [20, 25, "ENTITY"], [103, 113, "ENTITY"], [39, 46, "ENTITY"], [25, 36, "ENTITY"], [192, 195, "PROTEIN"], [39, 46, "GENE_OR_GENE_PRODUCT"], [103, 113, "GENE_OR_GENE_PRODUCT"], [12, 20, "ENTITY"], [39, 46, "PROTEIN"], [192, 195, "ENTITY"], [192, 195, "GENE_OR_GENE_PRODUCT"], [192, 195, "GGP"], [103, 113, "CHEMICAL"], [0, 6, "GENE_OR_GENE_PRODUCT"], [20, 25, "CHEBI"]]}
{"text": "PLpro alone induced mRNA expression of TGF-b1 ( greater than four fold ) , IL-1a ( approximately three fold),and RANTES ( approximately two fold ) ( Fig. 2A , D , and E ) , yet no signifi- ca nt rise in TNF-a and IFN-a compared to vector controls ( Fig. 2B and C ) .", "labels": [[219, 231, "ENTITY"], [0, 6, "ENTITY"], [39, 46, "GGP"], [103, 113, "GGP"], [103, 113, "PROTEIN"], [20, 25, "ENTITY"], [103, 113, "ENTITY"], [39, 46, "ENTITY"], [25, 36, "ENTITY"], [192, 195, "PROTEIN"], [39, 46, "GENE_OR_GENE_PRODUCT"], [103, 113, "GENE_OR_GENE_PRODUCT"], [12, 20, "ENTITY"], [39, 46, "PROTEIN"], [192, 195, "ENTITY"], [192, 195, "GENE_OR_GENE_PRODUCT"], [192, 195, "GGP"], [103, 113, "CHEMICAL"], [0, 6, "GENE_OR_GENE_PRODUCT"], [20, 25, "CHEBI"]]}
{"text": "TGF-b1 in cultured media and cell lysates of PLpro-expressing cells were twice as high as in vector controls , indicating that PLpro plays a unique role in upregulating TGF-b1 production .", "labels": [[0, 7, "ENTITY"], [45, 68, "ENTITY"], [0, 7, "GENE_OR_GENE_PRODUCT"], [29, 42, "CELL"], [93, 100, "SO"], [10, 25, "ENTITY"], [0, 7, "GGP"], [62, 68, "CL"], [0, 7, "PROTEIN"], [93, 109, "ENTITY"], [62, 68, "CELL"], [29, 34, "CL"], [45, 68, "CELL_TYPE"], [29, 42, "ENTITY"]]}
{"text": "Results indicated the activation of p38 MAPK- and ERK1/2-mediated signaling linking with induction of TGF-?1 and upregulation of vimentin by PLpro .", "labels": [[102, 109, "CHEMICAL"], [141, 147, "ENTITY"], [113, 126, "ENTITY"], [22, 33, "ENTITY"], [141, 147, "GENE_OR_GENE_PRODUCT"], [66, 76, "ENTITY"], [89, 99, "ENTITY"], [36, 46, "GGP"], [36, 46, "ENTITY"], [102, 109, "PROTEIN"], [40, 46, "CHEMICAL"], [129, 138, "ENTITY"], [36, 46, "GENE_OR_GENE_PRODUCT"], [129, 138, "GGP"], [0, 8, "ENTITY"], [129, 138, "PROTEIN"], [141, 147, "PROTEIN"], [36, 46, "PROTEIN"], [129, 138, "GENE_OR_GENE_PRODUCT"], [102, 109, "ENTITY"], [50, 66, "GENE_OR_GENE_PRODUCT"], [50, 66, "ENTITY"]]}
{"text": "MS analysis of HSP27 ( Spot ID 1 ) showed a Mascot score of 161 , five matched peptides , and sequence coverage of 37 % ; vimentin ( Spot ID 7 ) showed a Mascot score of 1420 , sequence coverage of 71 % , and 14 matched peptides", "labels": [[167, 186, "ENTITY"], [122, 133, "ENTITY"], [167, 177, "SO"], [0, 3, "ENTITY"], [23, 31, "ENTITY"], [122, 133, "GENE_OR_GENE_PRODUCT"], [71, 79, "ENTITY"], [122, 133, "PROTEIN"], [23, 31, "GENE_OR_GENE_PRODUCT"], [42, 51, "ENTITY"], [94, 103, "ENTITY"], [15, 21, "PROTEIN"], [15, 21, "GENE_OR_GENE_PRODUCT"], [15, 21, "ENTITY"], [35, 44, "ENTITY"], [15, 21, "GGP"], [71, 79, "SO"], [3, 12, "ENTITY"]]}
{"text": "Peptide peaks from Q-TOF MS analysis from three representative spots of interest , vimentin ( Spot ID 7 ) , glial fibrillary acidic protein ( ID 17), and HSP277 ) , and HSP27 ( ID 17), and HSP27 ) appear in Supporting Information Fig. S1A \u2013 C.", "labels": [[0, 8, "SO"], [104, 125, "GENE_OR_GENE_PRODUCT"], [104, 132, "ENTITY"], [-1, 12, "PROTEIN"], [19, 37, "ENTITY"], [-1, 26, "ENTITY"], [104, 132, "GGP"], [92, 102, "GENE_OR_GENE_PRODUCT"], [153, 161, "ENTITY"], [92, 102, "PROTEIN"], [-1, 17, "GENE_OR_GENE_PRODUCT"], [0, 8, "ENTITY"], [104, 132, "PROTEIN"], [92, 102, "ENTITY"], [-1, 12, "ENTITY"], [153, 161, "GENE_OR_GENE_PRODUCT"], [63, 69, "ENTITY"]]}
{"text": "Analyzing cell lysates by Western blot confirms protein profiling induced by PLpro ( Fig. 5 ) , i.e. significant rise of vimentin and HSP27 coupled with substantial decline of ERK1 in PLpro- expressing cells compared to vector controls , consistent with 2DE/Q-TOF MS/MS analysis in Fig. 4 , Tables 1 and 2 .", "labels": [[181, 202, "CELL_TYPE"], [227, 249, "ENTITY"], [184, 191, "ENTITY"], [153, 165, "ENTITY"], [191, 202, "ENTITY"], [77, 83, "GENE_OR_GENE_PRODUCT"], [48, 66, "ENTITY"], [10, 15, "CL"], [10, 23, "ENTITY"], [10, 23, "CELL"], [191, 202, "CL"], [279, 300, "SIMPLE_CHEMICAL"], [26, 39, "ENTITY"], [48, 56, "CHEBI"], [254, 270, "ENTITY"], [217, 227, "ENTITY"], [191, 202, "CELL"], [77, 90, "ENTITY"], [66, 74, "ENTITY"]]}
{"text": "MS analysis of HSP27 ( Spot ID 1 ) showed a Mascot score of 161 , five matched peptides , and sequence coverage of 37 % ; vimentin ( Spot ID 7 ) showed a Mascot score of 1420 , sequence coverage of 71 % , and 14 matched peptides", "labels": [[15, 21, "GGP"], [167, 186, "ENTITY"], [167, 177, "SO"], [0, 3, "ENTITY"], [23, 31, "ENTITY"], [15, 21, "GENE_OR_GENE_PRODUCT"], [71, 79, "ENTITY"], [15, 21, "ENTITY"], [42, 51, "ENTITY"], [15, 21, "PROTEIN"], [122, 133, "PROTEIN"], [94, 103, "ENTITY"], [122, 133, "ENTITY"], [23, 31, "GENE_OR_GENE_PRODUCT"], [122, 133, "GENE_OR_GENE_PRODUCT"], [35, 44, "ENTITY"], [71, 79, "SO"], [3, 12, "ENTITY"]]}
{"text": "Peptide peaks from Q-TOF MS analysis from three representative spots of interest , vimentin ( Spot ID 7 ) , glial fibrillary acidic protein ( ID 17), and HSP277 ) , and HSP27 ( ID 17), and HSP27 ) appear in Supporting Information Fig. S1A \u2013 C.", "labels": [[0, 8, "SO"], [104, 125, "GENE_OR_GENE_PRODUCT"], [104, 132, "ENTITY"], [-1, 12, "PROTEIN"], [19, 37, "ENTITY"], [-1, 26, "ENTITY"], [104, 132, "GGP"], [92, 102, "GENE_OR_GENE_PRODUCT"], [153, 161, "ENTITY"], [92, 102, "PROTEIN"], [-1, 17, "GENE_OR_GENE_PRODUCT"], [0, 8, "ENTITY"], [104, 132, "PROTEIN"], [92, 102, "ENTITY"], [-1, 12, "ENTITY"], [153, 161, "GENE_OR_GENE_PRODUCT"], [63, 69, "ENTITY"]]}
{"text": "Analyzing cell lysates by Western blot confirms protein profiling induced by PLpro ( Fig. 5 ) , i.e. significant rise of vimentin and HSP27 coupled with substantial decline of ERK1 in PLpro- expressing cells compared to vector controls , consistent with 2DE/Q-TOF MS/MS analysis in Fig. 4 , Tables 1 and 2 .", "labels": [[181, 202, "CELL_TYPE"], [227, 249, "ENTITY"], [184, 191, "ENTITY"], [153, 165, "ENTITY"], [191, 202, "ENTITY"], [77, 83, "GENE_OR_GENE_PRODUCT"], [48, 66, "ENTITY"], [10, 15, "CL"], [10, 23, "ENTITY"], [10, 23, "CELL"], [191, 202, "CL"], [279, 300, "SIMPLE_CHEMICAL"], [26, 39, "ENTITY"], [48, 56, "CHEBI"], [254, 270, "ENTITY"], [217, 227, "ENTITY"], [191, 202, "CELL"], [77, 90, "ENTITY"], [66, 74, "ENTITY"]]}
{"text": "Results indicated the activation of p38 MAPK- and ERK1/2-mediated signaling linking with induction of TGF-?1 and upregulation of vimentin by PLpro .", "labels": [[102, 109, "CHEMICAL"], [129, 138, "PROTEIN"], [129, 138, "GGP"], [141, 147, "ENTITY"], [129, 138, "ENTITY"], [113, 126, "ENTITY"], [22, 33, "ENTITY"], [141, 147, "GENE_OR_GENE_PRODUCT"], [66, 76, "ENTITY"], [89, 99, "ENTITY"], [36, 46, "GGP"], [36, 46, "ENTITY"], [129, 138, "GENE_OR_GENE_PRODUCT"], [102, 109, "PROTEIN"], [40, 46, "CHEMICAL"], [36, 46, "GENE_OR_GENE_PRODUCT"], [0, 8, "ENTITY"], [141, 147, "PROTEIN"], [36, 46, "PROTEIN"], [102, 109, "ENTITY"], [50, 66, "GENE_OR_GENE_PRODUCT"], [50, 66, "ENTITY"]]}
{"text": "Peptide peaks from Q-TOF MS analysis from three representative spots of interest , vimentin ( Spot ID 7 ) , glial fibrillary acidic protein ( ID 17), and HSP277 ) , and HSP27 ( ID 17), and HSP27 ) appear in Supporting Information Fig. S1A \u2013 C.", "labels": [[0, 8, "SO"], [104, 125, "GENE_OR_GENE_PRODUCT"], [104, 132, "ENTITY"], [-1, 12, "PROTEIN"], [19, 37, "ENTITY"], [-1, 26, "ENTITY"], [104, 132, "GGP"], [92, 102, "GENE_OR_GENE_PRODUCT"], [153, 161, "ENTITY"], [92, 102, "PROTEIN"], [-1, 17, "GENE_OR_GENE_PRODUCT"], [0, 8, "ENTITY"], [104, 132, "PROTEIN"], [92, 102, "ENTITY"], [-1, 12, "ENTITY"], [153, 161, "GENE_OR_GENE_PRODUCT"], [63, 69, "ENTITY"]]}
{"text": "Analyzing cell lysates by Western blot confirms protein profiling induced by PLpro ( Fig. 5 ) , i.e. significant rise of vimentin and HSP27 coupled with substantial decline of ERK1 in PLpro- expressing cells compared to vector controls , consistent with 2DE/Q-TOF MS/MS analysis in Fig. 4 , Tables 1 and 2 .", "labels": [[181, 202, "CELL_TYPE"], [227, 249, "ENTITY"], [184, 191, "ENTITY"], [153, 165, "ENTITY"], [191, 202, "ENTITY"], [77, 83, "GENE_OR_GENE_PRODUCT"], [48, 66, "ENTITY"], [10, 15, "CL"], [10, 23, "ENTITY"], [10, 23, "CELL"], [191, 202, "CL"], [279, 300, "SIMPLE_CHEMICAL"], [26, 39, "ENTITY"], [48, 56, "CHEBI"], [254, 270, "ENTITY"], [217, 227, "ENTITY"], [191, 202, "CELL"], [77, 90, "ENTITY"], [66, 74, "ENTITY"]]}
{"text": "Moreover , quantitative real-time PCR indicated mRNA expression of ubiquitin-conjugating enzyme E2\u201325 kDa ( Spot ID 3 ) and protein disulfide isomerase A3 precursor ( Spot ID 11 ) upregulated two fold in PLpro-expressing cells , but no change in controls ( Supporting Information Fig. S2 ) , supporting 2D/MS data ( Fig. 4 and Table 1 ) .", "labels": [[106, 116, "PROTEIN"], [67, 102, "PROTEIN"], [196, 221, "ENTITY"], [204, 221, "CL"], [11, 34, "ENTITY"], [67, 102, "ENTITY"], [196, 221, "CELL_TYPE"], [120, 155, "ENTITY"], [106, 116, "ENTITY"], [246, 280, "ENTITY"], [120, 152, "GGP"], [67, 102, "GENE_OR_GENE_PRODUCT"], [106, 116, "ORGANISM"], [292, 303, "ENTITY"], [120, 152, "GENE_OR_GENE_PRODUCT"], [155, 172, "ENTITY"], [120, 155, "PROTEIN"], [236, 246, "ENTITY"]]}
{"text": "Moreover , quantitative real-time PCR indicated mRNA expression of ubiquitin-conjugating enzyme E2\u201325 kDa ( Spot ID 3 ) and protein disulfide isomerase A3 precursor ( Spot ID 11 ) upregulated two fold in PLpro-expressing cells , but no change in controls ( Supporting Information Fig. S2 ) , supporting 2D/MS data ( Fig. 4 and Table 1 ) .", "labels": [[106, 116, "PROTEIN"], [67, 102, "PROTEIN"], [196, 221, "ENTITY"], [204, 221, "CL"], [11, 34, "ENTITY"], [67, 102, "ENTITY"], [196, 221, "CELL_TYPE"], [120, 155, "ENTITY"], [106, 116, "ENTITY"], [246, 280, "ENTITY"], [120, 152, "GGP"], [67, 102, "GENE_OR_GENE_PRODUCT"], [106, 116, "ORGANISM"], [292, 303, "ENTITY"], [120, 152, "GENE_OR_GENE_PRODUCT"], [155, 172, "ENTITY"], [120, 155, "PROTEIN"], [236, 246, "ENTITY"]]}
{"text": "Results indicated the activation of p38 MAPK- and ERK1/2-mediated signaling linking with induction of TGF-?1 and upregulation of vimentin by PLpro .", "labels": [[102, 109, "CHEMICAL"], [141, 147, "ENTITY"], [113, 126, "ENTITY"], [22, 33, "ENTITY"], [141, 147, "GENE_OR_GENE_PRODUCT"], [66, 76, "ENTITY"], [89, 99, "ENTITY"], [36, 46, "GGP"], [36, 46, "ENTITY"], [102, 109, "PROTEIN"], [40, 46, "CHEMICAL"], [129, 138, "ENTITY"], [36, 46, "GENE_OR_GENE_PRODUCT"], [129, 138, "GGP"], [0, 8, "ENTITY"], [129, 138, "PROTEIN"], [141, 147, "PROTEIN"], [36, 46, "PROTEIN"], [129, 138, "GENE_OR_GENE_PRODUCT"], [102, 109, "ENTITY"], [50, 66, "GENE_OR_GENE_PRODUCT"], [50, 66, "ENTITY"]]}
{"text": "Results indicated the activation of p38 MAPK- and ERK1/2-mediated signaling linking with induction of TGF-?1 and upregulation of vimentin by PLpro .", "labels": [[102, 109, "CHEMICAL"], [141, 147, "ENTITY"], [113, 126, "ENTITY"], [22, 33, "ENTITY"], [141, 147, "GENE_OR_GENE_PRODUCT"], [66, 76, "ENTITY"], [89, 99, "ENTITY"], [36, 46, "GGP"], [36, 46, "ENTITY"], [102, 109, "PROTEIN"], [40, 46, "CHEMICAL"], [129, 138, "ENTITY"], [36, 46, "GENE_OR_GENE_PRODUCT"], [129, 138, "GGP"], [0, 8, "ENTITY"], [129, 138, "PROTEIN"], [141, 147, "PROTEIN"], [36, 46, "PROTEIN"], [129, 138, "GENE_OR_GENE_PRODUCT"], [102, 109, "ENTITY"], [50, 66, "GENE_OR_GENE_PRODUCT"], [50, 66, "ENTITY"]]}
{"text": "ELISA assay showed less PLpro-induced TGF-?1 production by SB203580 ( 1.5-fold ) and U0126 ( 3.3-fold ) ( Fig. 7A and B ) .", "labels": [[38, 45, "CHEMICAL"], [0, 12, "ENTITY"], [59, 68, "SIMPLE_CHEMICAL"], [59, 68, "ENTITY"], [59, 68, "CHEMICAL"], [24, 45, "ENTITY"], [38, 45, "PROTEIN"], [45, 56, "ENTITY"]]}
{"text": "NF\u03ba-B expression increased 10 - 14 h post-nsp 1 transfection , suggesting that cytokine induction occurred via an NF\u03ba-B-dependent pathway . In support of this hypothesis , expression of CCL5 , CCL3 and CXCL10 was reduced up to 60 % in nsp 1-expressing cells in the presence of the IKK-\u03b2 inhibitor , sodium salicylate .", "labels": [[193, 202, "ENTITY"], [17, 27, "ENTITY"], [186, 191, "GGP"], [0, 6, "ENTITY"], [287, 306, "CHEBI"], [0, 6, "PROTEIN"], [186, 191, "PROTEIN"], [287, 306, "SIMPLE_CHEMICAL"], [74, 88, "ENTITY"], [35, 46, "GENE_OR_GENE_PRODUCT"], [111, 130, "ENTITY"], [193, 202, "GGP"], [193, 202, "PROTEIN"], [186, 191, "GENE_OR_GENE_PRODUCT"], [35, 48, "ENTITY"], [186, 191, "ENTITY"], [274, 287, "ENTITY"], [6, 17, "ENTITY"], [274, 287, "GGP"], [287, 306, "CHEMICAL"], [159, 172, "ENTITY"], [186, 191, "CHEMICAL"], [227, 239, "ENTITY"], [172, 186, "PROTEIN"], [172, 186, "GENE_OR_GENE_PRODUCT"], [227, 239, "GENE_OR_GENE_PRODUCT"], [172, 186, "GGP"], [172, 186, "ENTITY"], [287, 306, "ENTITY"], [193, 202, "GENE_OR_GENE_PRODUCT"], [227, 239, "CELL_TYPE"], [202, 213, "ENTITY"]]}
{"text": "NF\u03ba-B expression increased 10 - 14 h post-nsp 1 transfection , suggesting that cytokine induction occurred via an NF\u03ba-B-dependent pathway . In support of this hypothesis , expression of CCL5 , CCL3 and CXCL10 was reduced up to 60 % in nsp 1-expressing cells in the presence of the IKK-\u03b2 inhibitor , sodium salicylate .", "labels": [[17, 27, "ENTITY"], [193, 202, "GENE_OR_GENE_PRODUCT"], [0, 6, "ENTITY"], [287, 306, "CHEBI"], [186, 191, "PROTEIN"], [0, 6, "PROTEIN"], [287, 306, "SIMPLE_CHEMICAL"], [74, 88, "ENTITY"], [35, 46, "GENE_OR_GENE_PRODUCT"], [111, 130, "ENTITY"], [186, 191, "CHEMICAL"], [193, 202, "PROTEIN"], [193, 202, "ENTITY"], [193, 202, "GGP"], [35, 48, "ENTITY"], [274, 287, "ENTITY"], [186, 191, "GENE_OR_GENE_PRODUCT"], [202, 213, "ENTITY"], [6, 17, "ENTITY"], [274, 287, "GGP"], [287, 306, "CHEMICAL"], [159, 172, "ENTITY"], [227, 239, "ENTITY"], [172, 186, "PROTEIN"], [172, 186, "GENE_OR_GENE_PRODUCT"], [227, 239, "GENE_OR_GENE_PRODUCT"], [172, 186, "GGP"], [172, 186, "ENTITY"], [287, 306, "ENTITY"], [186, 191, "ENTITY"], [227, 239, "CELL_TYPE"], [186, 191, "GGP"]]}
{"text": "NF\u03ba-B expression increased 10 - 14 h post-nsp 1 transfection , suggesting that cytokine induction occurred via an NF\u03ba-B-dependent pathway . In support of this hypothesis , expression of CCL5 , CCL3 and CXCL10 was reduced up to 60 % in nsp 1-expressing cells in the presence of the IKK-\u03b2 inhibitor , sodium salicylate .", "labels": [[17, 27, "ENTITY"], [0, 6, "ENTITY"], [193, 202, "PROTEIN"], [287, 306, "CHEBI"], [186, 191, "PROTEIN"], [0, 6, "PROTEIN"], [287, 306, "SIMPLE_CHEMICAL"], [74, 88, "ENTITY"], [193, 202, "GENE_OR_GENE_PRODUCT"], [35, 46, "GENE_OR_GENE_PRODUCT"], [111, 130, "ENTITY"], [193, 202, "ENTITY"], [186, 191, "CHEMICAL"], [202, 213, "ENTITY"], [35, 48, "ENTITY"], [274, 287, "ENTITY"], [186, 191, "GENE_OR_GENE_PRODUCT"], [6, 17, "ENTITY"], [274, 287, "GGP"], [287, 306, "CHEMICAL"], [159, 172, "ENTITY"], [227, 239, "ENTITY"], [172, 186, "PROTEIN"], [172, 186, "GENE_OR_GENE_PRODUCT"], [227, 239, "GENE_OR_GENE_PRODUCT"], [172, 186, "GGP"], [172, 186, "ENTITY"], [193, 202, "GGP"], [287, 306, "ENTITY"], [186, 191, "ENTITY"], [227, 239, "CELL_TYPE"], [186, 191, "GGP"]]}
{"text": "When the variability between nsp 3 isolates of the SARS epidemic are compared , the results suggest that nsps 1 - 3 perform cell- and host- specific roles in replication and/or virulence . Additionally , they have demonstrated high capacity for adaptation to new environments and selective pressures .", "labels": [[35, 44, "ENTITY"], [276, 290, "ENTITY"], [29, 35, "GENE_OR_GENE_PRODUCT"], [69, 78, "ENTITY"], [51, 56, "ENTITY"], [170, 177, "ENTITY"], [227, 232, "ENTITY"], [29, 35, "ENTITY"], [56, 65, "ENTITY"], [29, 35, "PROTEIN"], [9, 21, "ENTITY"], [105, 112, "PROTEIN"], [105, 110, "ENTITY"], [105, 112, "ORGANISM"], [51, 56, "DISEASE"]]}
{"text": "Kamitami et al. observed that SARS-CoV replication in human 293 cells suppresses IFN-\u03b2 mRNA accumulation ( Kamitani et al. , 2006 ) . Plasmid- based overexpression of nsp 1 resulted in the inhibition of host gene expression by promoting degradation of host mRNA , and that IFN-\u03b2 mRNA accumulation was decreased without alteration of IRF-3 phosphorylation , dimerization , or translocation .", "labels": [[200, 208, "RNA"], [203, 208, "ENTITY"], [81, 92, "RNA"], [81, 87, "CHEBI"], [319, 333, "PROTEIN"], [39, 51, "ENTITY"], [143, 149, "ENTITY"], [200, 208, "TAXON"], [203, 213, "ENTITY"], [87, 92, "ENTITY"], [54, 70, "ORGANISM"], [64, 70, "CL"], [200, 208, "TAXON"], [92, 105, "ENTITY"], [87, 92, "CHEBI"], [339, 357, "ENTITY"], [30, 39, "ORGANISM"], [87, 92, "ENTITY"], [319, 333, "GGP"], [54, 70, "CELL_TYPE"], [54, 64, "ENTITY"], [54, 60, "TAXON"], [319, 333, "GENE_OR_GENE_PRODUCT"], [319, 339, "ENTITY"], [268, 279, "RNA"], [227, 237, "ENTITY"], [30, 39, "ENTITY"], [81, 87, "ENTITY"], [357, 375, "ENTITY"], [81, 87, "GENE_OR_GENE_PRODUCT"], [0, 9, "ENTITY"], [70, 81, "ENTITY"], [81, 87, "ENTITY"]]}
{"text": "Further analysis showed that SARS-CoV nsp 1 suppressed Sendai virus- induced IFN-\u03b2 mRNA accumulation , and suppressed reporter mRNA accumulation in cells .", "labels": [[83, 88, "ENTITY"], [88, 101, "ENTITY"], [118, 127, "RNA"], [29, 44, "ENTITY"], [55, 69, "ENTITY"], [69, 77, "ENTITY"], [83, 88, "CHEBI"], [29, 44, "PROTEIN"], [55, 69, "ORGANISM"], [29, 44, "ORGANISM"], [77, 83, "GENE_OR_GENE_PRODUCT"], [8, 17, "ENTITY"], [44, 55, "ENTITY"], [77, 83, "ENTITY"]]}
{"text": "Overexpression of nsp 1 in the lung epithelial cell line A549 increases the production of CCL5 , CXCL10 and CCL3 cytokines 30 - 200-fold compared with mock-transfected cells or cells expressing nsp 5 ( Law et al. , 2006 ) . Similar results were detected with CCL5 and CXCL10 in HepG2 cells , suggesting that this was not a cell line- specific induction .", "labels": [[183, 194, "PROTEIN"], [245, 254, "GGP"], [62, 72, "ENTITY"], [151, 168, "CELL"], [232, 245, "ENTITY"], [268, 278, "ENTITY"], [90, 95, "GENE_OR_GENE_PRODUCT"], [259, 268, "GENE_OR_GENE_PRODUCT"], [268, 278, "CELL"], [334, 343, "ENTITY"], [224, 232, "ENTITY"], [18, 24, "PROTEIN"], [18, 24, "ENTITY"], [245, 254, "GENE_OR_GENE_PRODUCT"], [151, 168, "CL"], [31, 62, "CELL"], [90, 95, "PROTEIN"], [259, 268, "PROTEIN"], [90, 95, "ENTITY"], [146, 168, "CELL_LINE"], [168, 174, "ENTITY"], [18, 24, "GENE_OR_GENE_PRODUCT"], [259, 268, "GGP"], [36, 52, "CL"], [108, 128, "GENE_OR_GENE_PRODUCT"], [128, 137, "ENTITY"], [245, 254, "ENTITY"], [76, 87, "ENTITY"], [31, 62, "CELL_LINE"], [245, 254, "PROTEIN"], [259, 268, "ENTITY"], [313, 323, "CELL"], [108, 113, "PROTEIN"], [183, 194, "ENTITY"], [268, 278, "CELL_LINE"], [268, 278, "GGP"], [31, 62, "ENTITY"], [146, 168, "ENTITY"], [183, 194, "GENE_OR_GENE_PRODUCT"], [0, 15, "ENTITY"], [90, 95, "GGP"]]}
{"text": "Overexpression of nsp 1 in the lung epithelial cell line A549 increases the production of CCL5 , CXCL10 and CCL3 cytokines 30 - 200-fold compared with mock-transfected cells or cells expressing nsp 5 ( Law et al. , 2006 ) . Similar results were detected with CCL5 and CXCL10 in HepG2 cells , suggesting that this was not a cell line- specific induction .", "labels": [[90, 95, "ENTITY"], [183, 194, "PROTEIN"], [245, 254, "GGP"], [62, 72, "ENTITY"], [268, 278, "CELL_LINE"], [151, 168, "CELL"], [232, 245, "ENTITY"], [268, 278, "ENTITY"], [90, 95, "GGP"], [334, 343, "ENTITY"], [224, 232, "ENTITY"], [18, 24, "ENTITY"], [268, 278, "GGP"], [245, 254, "GENE_OR_GENE_PRODUCT"], [151, 168, "CL"], [31, 62, "CELL"], [259, 268, "GENE_OR_GENE_PRODUCT"], [90, 95, "PROTEIN"], [146, 168, "CELL_LINE"], [168, 174, "ENTITY"], [90, 95, "GENE_OR_GENE_PRODUCT"], [18, 24, "GENE_OR_GENE_PRODUCT"], [36, 52, "CL"], [128, 137, "ENTITY"], [245, 254, "ENTITY"], [76, 87, "ENTITY"], [31, 62, "CELL_LINE"], [245, 254, "PROTEIN"], [259, 268, "GGP"], [108, 128, "GENE_OR_GENE_PRODUCT"], [313, 323, "CELL"], [108, 113, "PROTEIN"], [183, 194, "ENTITY"], [268, 278, "CELL"], [31, 62, "ENTITY"], [146, 168, "ENTITY"], [259, 268, "ENTITY"], [259, 268, "PROTEIN"], [183, 194, "GENE_OR_GENE_PRODUCT"], [0, 15, "ENTITY"], [18, 24, "PROTEIN"]]}
{"text": "Overexpression of nsp 1 in the lung epithelial cell line A549 increases the production of CCL5 , CXCL10 and CCL3 cytokines 30 - 200-fold compared with mock-transfected cells or cells expressing nsp 5 ( Law et al. , 2006 ) . Similar results were detected with CCL5 and CXCL10 in HepG2 cells , suggesting that this was not a cell line- specific induction .", "labels": [[90, 95, "ENTITY"], [183, 194, "PROTEIN"], [245, 254, "GGP"], [62, 72, "ENTITY"], [151, 168, "CELL"], [232, 245, "ENTITY"], [90, 95, "GGP"], [268, 278, "GGP"], [259, 268, "PROTEIN"], [334, 343, "ENTITY"], [224, 232, "ENTITY"], [18, 24, "ENTITY"], [245, 254, "GENE_OR_GENE_PRODUCT"], [151, 168, "CL"], [31, 62, "CELL"], [90, 95, "PROTEIN"], [268, 278, "ENTITY"], [146, 168, "CELL_LINE"], [168, 174, "ENTITY"], [90, 95, "GENE_OR_GENE_PRODUCT"], [18, 24, "GENE_OR_GENE_PRODUCT"], [36, 52, "CL"], [128, 137, "ENTITY"], [245, 254, "ENTITY"], [259, 268, "GENE_OR_GENE_PRODUCT"], [76, 87, "ENTITY"], [31, 62, "CELL_LINE"], [108, 113, "PROTEIN"], [245, 254, "PROTEIN"], [259, 268, "GGP"], [268, 278, "CELL_LINE"], [313, 323, "CELL"], [183, 194, "ENTITY"], [108, 128, "GENE_OR_GENE_PRODUCT"], [31, 62, "ENTITY"], [146, 168, "ENTITY"], [183, 194, "GENE_OR_GENE_PRODUCT"], [0, 15, "ENTITY"], [18, 24, "PROTEIN"], [259, 268, "ENTITY"], [268, 278, "CELL"]]}
{"text": "NF\u03ba-B expression increased 10 - 14 h post-nsp 1 transfection , suggesting that cytokine induction occurred via an NF\u03ba-B-dependent pathway . In support of this hypothesis , expression of CCL5 , CCL3 and CXCL10 was reduced up to 60 % in nsp 1-expressing cells in the presence of the IKK-\u03b2 inhibitor , sodium salicylate .", "labels": [[17, 27, "ENTITY"], [193, 202, "GENE_OR_GENE_PRODUCT"], [0, 6, "ENTITY"], [287, 306, "CHEBI"], [186, 191, "PROTEIN"], [0, 6, "PROTEIN"], [287, 306, "SIMPLE_CHEMICAL"], [74, 88, "ENTITY"], [202, 213, "ENTITY"], [35, 46, "GENE_OR_GENE_PRODUCT"], [111, 130, "ENTITY"], [186, 191, "CHEMICAL"], [193, 202, "PROTEIN"], [193, 202, "ENTITY"], [193, 202, "GGP"], [35, 48, "ENTITY"], [274, 287, "ENTITY"], [186, 191, "GENE_OR_GENE_PRODUCT"], [6, 17, "ENTITY"], [274, 287, "GGP"], [287, 306, "CHEMICAL"], [159, 172, "ENTITY"], [227, 239, "ENTITY"], [172, 186, "PROTEIN"], [172, 186, "GENE_OR_GENE_PRODUCT"], [227, 239, "GENE_OR_GENE_PRODUCT"], [172, 186, "GGP"], [172, 186, "ENTITY"], [287, 306, "ENTITY"], [186, 191, "ENTITY"], [227, 239, "CELL_TYPE"], [186, 191, "GGP"]]}
{"text": "At 12 h post-infection ( p.i . ) , wildtype nsps 1 and 2 both displayed bright , punctate perinuclear localization , similar to that observed in MHV infection ( Fig. 4A ) .", "labels": [[133, 149, "ENTITY"], [72, 90, "CELLULAR_COMPONENT"], [133, 149, "DISEASE"], [35, 44, "GENE_OR_GENE_PRODUCT"], [81, 90, "GO"], [8, 23, "ENTITY"], [133, 142, "TAXON"], [133, 142, "ORGANISM"], [72, 102, "ENTITY"], [62, 72, "ENTITY"], [31, 51, "PROTEIN"]]}
{"text": "Chloroquine was shown to inhibit quinone reductase 2 [ 56 ] , a structural neighbour of UDP-N-acetylglucosamine 2-epimerases [ 57 ] that are involved in the biosynthesis of sialic acids . The sialic acids are acidic monosaccharides found at the extremity of sugar chains present on cell transmembrane proteins and are critical components of ligand recognition . The possible interference of chloroquine with sialic acid biosynthesis could account for the broad antiviral spectrum of that drug since viruses such as the human coronavirus HCoV-O43 and the orthomyxoviruses use sialic acid moieties as receptors [ 58 ] .", "labels": [[0, 12, "CHEBI"], [271, 301, "GO"], [245, 264, "ENTITY"], [587, 599, "ENTITY"], [199, 216, "CHEBI"], [157, 180, "CHEMICAL"], [546, 554, "ENTITY"], [554, 587, "ENTITY"], [391, 408, "CHEBI"], [245, 264, "PROTEIN"], [375, 391, "SIMPLE_CHEMICAL"], [512, 525, "ORGANISM"], [391, 420, "ENTITY"], [391, 408, "CHEMICAL"], [271, 301, "PROTEIN"], [245, 258, "SIMPLE_CHEMICAL"], [512, 537, "PROTEIN"], [519, 525, "ENTITY"], [519, 537, "CHEMICAL"], [157, 180, "ENTITY"], [62, 75, "ENTITY"], [375, 391, "ENTITY"], [391, 408, "SIMPLE_CHEMICAL"], [186, 199, "CHEMICAL"], [554, 575, "CHEBI"], [0, 12, "SIMPLE_CHEMICAL"], [238, 245, "PATHOLOGICAL_FORMATION"], [33, 53, "ENTITY"], [85, 112, "GENE_OR_GENE_PRODUCT"], [157, 180, "SIMPLE_CHEMICAL"], [554, 587, "SIMPLE_CHEMICAL"], [209, 216, "SIMPLE_CHEMICAL"], [0, 12, "CHEMICAL"], [157, 180, "CHEBI"], [186, 199, "ENTITY"], [327, 348, "ENTITY"], [33, 53, "PROTEIN"], [554, 587, "PROTEIN"], [554, 575, "CHEMICAL"], [271, 301, "ENTITY"], [455, 471, "ENTITY"], [186, 199, "CHEBI"], [85, 112, "ENTITY"], [271, 287, "CELLULAR_COMPONENT"], [199, 216, "ENTITY"], [375, 391, "CHEBI"], [33, 53, "GENE_OR_GENE_PRODUCT"], [33, 41, "CHEMICAL"], [25, 33, "ENTITY"], [375, 391, "CHEMICAL"], [238, 245, "ENTITY"], [186, 199, "SIMPLE_CHEMICAL"], [33, 53, "GGP"], [0, 12, "ENTITY"], [525, 537, "ENTITY"], [546, 554, "TAXON"]]}
{"text": "ELISA assay showed less PLpro-induced TGF-?1 production by SB203580 ( 1.5-fold ) and U0126 ( 3.3-fold ) ( Fig. 7A and B ) .", "labels": [[38, 45, "CHEMICAL"], [59, 68, "SIMPLE_CHEMICAL"], [0, 12, "ENTITY"], [24, 45, "ENTITY"], [38, 45, "PROTEIN"], [59, 68, "ENTITY"], [59, 68, "CHEMICAL"], [45, 56, "ENTITY"]]}
{"text": "Quantitative real-time PCR assay indicated U0126 raising PLpro-induced mRNA expression of TGF-?1 ( sixfold ) , vimentin ( 3.3-fold ) , and type I collagen ( 8.4-fold ) ( Fig. 7C ) .", "labels": [[133, 146, "GENE_OR_GENE_PRODUCT"], [133, 146, "ENTITY"], [90, 97, "CHEMICAL"], [43, 49, "ENTITY"], [43, 49, "SIMPLE_CHEMICAL"], [71, 76, "ENTITY"], [90, 97, "ENTITY"], [71, 76, "CHEBI"], [90, 97, "PROTEIN"], [133, 146, "PROTEIN"], [43, 49, "CHEMICAL"], [133, 146, "GGP"], [90, 97, "SIMPLE_CHEMICAL"], [76, 87, "ENTITY"], [57, 76, "RNA"], [0, 33, "ENTITY"], [57, 71, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Quantitative real-time PCR assay indicated U0126 raising PLpro-induced mRNA expression of TGF-?1 ( sixfold ) , vimentin ( 3.3-fold ) , and type I collagen ( 8.4-fold ) ( Fig. 7C ) .", "labels": [[133, 146, "GENE_OR_GENE_PRODUCT"], [133, 146, "ENTITY"], [90, 97, "CHEMICAL"], [43, 49, "ENTITY"], [43, 49, "SIMPLE_CHEMICAL"], [71, 76, "ENTITY"], [90, 97, "ENTITY"], [71, 76, "CHEBI"], [90, 97, "PROTEIN"], [133, 146, "PROTEIN"], [43, 49, "CHEMICAL"], [133, 146, "GGP"], [90, 97, "SIMPLE_CHEMICAL"], [76, 87, "ENTITY"], [57, 76, "RNA"], [0, 33, "ENTITY"], [57, 71, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Quantitative real-time PCR assay indicated U0126 raising PLpro-induced mRNA expression of TGF-?1 ( sixfold ) , vimentin ( 3.3-fold ) , and type I collagen ( 8.4-fold ) ( Fig. 7C ) .", "labels": [[133, 146, "GENE_OR_GENE_PRODUCT"], [133, 146, "ENTITY"], [90, 97, "CHEMICAL"], [43, 49, "ENTITY"], [43, 49, "SIMPLE_CHEMICAL"], [71, 76, "ENTITY"], [90, 97, "ENTITY"], [71, 76, "CHEBI"], [90, 97, "PROTEIN"], [133, 146, "PROTEIN"], [43, 49, "CHEMICAL"], [133, 146, "GGP"], [90, 97, "SIMPLE_CHEMICAL"], [76, 87, "ENTITY"], [57, 76, "RNA"], [0, 33, "ENTITY"], [57, 71, "GENE_OR_GENE_PRODUCT"]]}
{"text": "ATV alone showed a nearly 10-fold increase in potency for inhibiting SARS-CoV-2 replication in A549 ( Figure 6C ) compared to Vero cells ( Figure 6B ) . ATV/RTV and CQ were similarly potent in inhibiting virus replication in both cell types ( Figure 6B and C ) .", "labels": [[0, 4, "ENTITY"], [95, 100, "CELL"], [100, 109, "CELL"], [225, 235, "ENTITY"], [123, 131, "CELL_LINE"], [146, 149, "ENTITY"], [69, 80, "CHEMICAL"], [0, 4, "PROTEIN"], [235, 243, "ENTITY"], [95, 100, "ENTITY"], [123, 131, "ENTITY"], [183, 193, "ENTITY"], [46, 54, "ENTITY"], [102, 109, "ENTITY"], [126, 131, "CL"], [69, 92, "ENTITY"], [100, 109, "ENTITY"], [58, 69, "TAXON"], [193, 210, "ENTITY"], [58, 69, "ENTITY"], [34, 43, "ENTITY"], [69, 80, "SIMPLE_CHEMICAL"], [123, 131, "CELL"], [0, 4, "SIMPLE_CHEMICAL"], [0, 4, "CHEMICAL"]]}
{"text": "ATV/RTV and CQ were similarly efficient to inhibit viral replication in the human monocytes ( Figure 7A ) .", "labels": [[0, 8, "SIMPLE_CHEMICAL"], [43, 51, "ENTITY"], [76, 82, "ENTITY"], [30, 40, "ENTITY"], [76, 92, "CELL_TYPE"], [0, 8, "CHEMICAL"], [12, 15, "SIMPLE_CHEMICAL"], [76, 92, "ORGANISM"], [12, 15, "CHEMICAL"], [12, 15, "ENTITY"], [51, 69, "ENTITY"], [82, 92, "ENTITY"], [51, 57, "TAXON"], [0, 8, "PROTEIN"], [76, 92, "TAXON"], [0, 8, "ENTITY"], [94, 101, "GENE_OR_GENE_PRODUCT"], [94, 101, "ENTITY"]]}
{"text": "Moreover , we observed that infections by SARS-CoV-2 triggered the expected increase in the IL-6 levels in the culture supernatant , which ranged from 20- to 60-fold depending on the cell donor ( Figure 7C , open circles in nil-treated cells ) . The virus-induced enhancement of IL-6 levels were significantly prevented by treatment with ATV at 10 \u00b5M , ATV/RTV at both 1 and 10 \u00b5M and CQ at 10 \u00b5M ( Figure 7C ) .", "labels": [[244, 264, "ENTITY"], [179, 188, "ENTITY"], [203, 213, "ENTITY"], [348, 351, "ENTITY"], [224, 236, "CL"], [194, 203, "ENTITY"], [348, 351, "SIMPLE_CHEMICAL"], [345, 353, "CHEMICAL"], [264, 276, "PROTEIN"], [348, 351, "CHEMICAL"], [310, 323, "ENTITY"], [221, 236, "CELL_LINE"], [224, 236, "CELL"], [264, 276, "GENE_OR_GENE_PRODUCT"], [264, 276, "GGP"], [221, 236, "ENTITY"], [345, 353, "ENTITY"], [111, 119, "ENTITY"], [92, 97, "ENTITY"], [264, 276, "ENTITY"], [345, 353, "SIMPLE_CHEMICAL"], [391, 399, "ENTITY"], [345, 353, "PROTEIN"]]}
{"text": "Another biomarker of uncontrolled pro-inflammatory cytokine response , TNF-\u03b1 , was up-regulated 40-fold during virus infection ( Figure 7D ) . Only the combination of ATV/RTV could significantly prevent the induction of TNF-\u03b1 release ( Figure 7D ) .", "labels": [[207, 220, "CHEMICAL"], [152, 167, "PROTEIN"], [34, 51, "ENTITY"], [207, 220, "GENE_OR_GENE_PRODUCT"], [152, 167, "ENTITY"], [8, 18, "ENTITY"], [71, 77, "ENTITY"], [207, 220, "PROTEIN"], [226, 236, "ENTITY"], [104, 117, "ENTITY"], [34, 60, "PROTEIN"], [152, 167, "CHEMICAL"], [104, 117, "DISEASE"], [152, 167, "GENE_OR_GENE_PRODUCT"], [207, 220, "ENTITY"], [127, 136, "ENTITY"], [21, 34, "ENTITY"]]}
{"text": "Also , Zhou et al. reported that short-term moderate-dose corticosteroid ( 160 mg/day ) plus immunoglobulin ( 20 g/day ) significantly reduced lung injury , normalized lymphocyte counts , body temperature , C-reactive protein levels , and oxygenation index in 10 COVID-19 patients ( 5 ) .", "labels": [[157, 168, "ENTITY"], [135, 148, "DISEASE"], [193, 218, "GGP"], [193, 207, "GENE_OR_GENE_PRODUCT"], [44, 58, "SIMPLE_CHEMICAL"], [179, 186, "ORGANISM_SUBDIVISION"], [263, 272, "ENTITY"], [157, 168, "CELL"], [193, 218, "ENTITY"], [168, 179, "ENTITY"], [251, 272, "CANCER"], [135, 143, "ORGAN"], [44, 58, "ENTITY"], [251, 263, "DISEASE"], [226, 239, "ENTITY"], [157, 168, "CL"], [135, 148, "ENTITY"], [193, 218, "PROTEIN"], [179, 193, "ENTITY"], [121, 135, "ENTITY"], [251, 263, "ENTITY"]]}
{"text": "Also , Zhou et al. reported that short-term moderate-dose corticosteroid ( 160 mg/day ) plus immunoglobulin ( 20 g/day ) significantly reduced lung injury , normalized lymphocyte counts , body temperature , C-reactive protein levels , and oxygenation index in 10 COVID-19 patients ( 5 ) .", "labels": [[157, 168, "ENTITY"], [135, 148, "DISEASE"], [193, 218, "GGP"], [193, 207, "GENE_OR_GENE_PRODUCT"], [44, 58, "SIMPLE_CHEMICAL"], [179, 186, "ORGANISM_SUBDIVISION"], [263, 272, "ENTITY"], [157, 168, "CELL"], [193, 218, "ENTITY"], [168, 179, "ENTITY"], [251, 272, "CANCER"], [135, 143, "ORGAN"], [44, 58, "ENTITY"], [251, 263, "DISEASE"], [226, 239, "ENTITY"], [157, 168, "CL"], [135, 148, "ENTITY"], [193, 218, "PROTEIN"], [179, 193, "ENTITY"], [121, 135, "ENTITY"], [251, 263, "ENTITY"]]}
{"text": "Also , Zhou et al. reported that short-term moderate-dose corticosteroid ( 160 mg/day ) plus immunoglobulin ( 20 g/day ) significantly reduced lung injury , normalized lymphocyte counts , body temperature , C-reactive protein levels , and oxygenation index in 10 COVID-19 patients ( 5 ) .", "labels": [[157, 168, "ENTITY"], [135, 148, "DISEASE"], [193, 218, "GGP"], [193, 207, "GENE_OR_GENE_PRODUCT"], [44, 58, "SIMPLE_CHEMICAL"], [179, 186, "ORGANISM_SUBDIVISION"], [263, 272, "ENTITY"], [157, 168, "CELL"], [193, 218, "ENTITY"], [168, 179, "ENTITY"], [251, 272, "CANCER"], [135, 143, "ORGAN"], [44, 58, "ENTITY"], [251, 263, "DISEASE"], [226, 239, "ENTITY"], [157, 168, "CL"], [135, 148, "ENTITY"], [193, 218, "PROTEIN"], [179, 193, "ENTITY"], [121, 135, "ENTITY"], [251, 263, "ENTITY"]]}
{"text": "A study compared 111 patients with severe acute respiratory syndrome ( SARS ) treated with ribavirin monotherapy and 41 patients with SARS treated with lopinavir/ ritonavir and ribavirin ; patients treated with the combined therapy had a lower risk of acute respiratory distress syndrome ( ARDS ) and death ( 6 ) .", "labels": [[76, 86, "ENTITY"], [2, 8, "ENTITY"], [91, 101, "ENTITY"], [211, 224, "ENTITY"], [134, 147, "ENTITY"], [249, 279, "ENTITY"], [21, 30, "ORGANISM"], [60, 71, "DISEASE"], [42, 69, "DISEASE"], [152, 163, "ENTITY"], [60, 71, "ENTITY"], [147, 163, "GENE_OR_GENE_PRODUCT"], [35, 42, "ENTITY"], [147, 163, "CHEMICAL"], [249, 279, "DISEASE"], [21, 30, "ENTITY"], [236, 244, "ENTITY"], [189, 206, "ENTITY"], [42, 69, "ENTITY"]]}
{"text": "Lopinavir/ritonavir is a medication for the human immunodeficiency virus ( human immunodeficiency virus ) used in combination with other medications to treat adults and children over 14 days of age who are infected with human immunodeficiency virus -1 ( 5 ) . Chu et al. found that lopinavir/ritonavir has anti-SARS-CoV activity in vitro and in clinical studies ( 6 ) .", "labels": [[257, 274, "ENTITY"], [235, 244, "ENTITY"], [257, 274, "SIMPLE_CHEMICAL"], [54, 60, "ENTITY"], [-1, 7, "ENTITY"], [280, 305, "ENTITY"], [-1, 16, "ENTITY"], [-1, 7, "ENTITY"], [-1, 24, "ORGANISM"], [-1, 10, "ORGANISM"], [29, 40, "ENTITY"], [54, 60, "ORGANISM"], [-1, 21, "ENTITY"], [-1, 16, "SO"], [-1, 10, "ENTITY"], [0, 20, "ENTITY"], [257, 274, "CHEMICAL"]]}
{"text": "Lopinavir/ritonavir is a medication for the human immunodeficiency virus ( human immunodeficiency virus ) used in combination with other medications to treat adults and children over 14 days of age who are infected with human immunodeficiency virus -1 ( 5 ) . Chu et al. found that lopinavir/ritonavir has anti-SARS-CoV activity in vitro and in clinical studies ( 6 ) .", "labels": [[257, 274, "ENTITY"], [257, 274, "SIMPLE_CHEMICAL"], [-1, 24, "ORGANISM"], [54, 60, "ENTITY"], [280, 305, "ENTITY"], [-1, 10, "ORGANISM"], [-1, 16, "ENTITY"], [-1, 7, "ENTITY"], [29, 40, "ENTITY"], [235, 244, "ENTITY"], [-1, 21, "ENTITY"], [54, 60, "ORGANISM"], [-1, 16, "SO"], [-1, 10, "ENTITY"], [-1, 7, "ENTITY"], [0, 20, "ENTITY"], [257, 274, "CHEMICAL"]]}
{"text": "Ribavirin is a nucleoside analogue with a broad-spectrum of antiviral effects . A study compared 111 patients with severe acute respiratory syndrome ( severe acute respiratory syndrome ) treated with ribavirin monotherapy and 41 patients with severe acute respiratory syndrome treated with lopinavir/ritonavir and ribavirin ; patients treated with the combined therapy had a lower risk of acute respiratory distress syndrome ( acute respiratory distress syndrome ) and death ( 6 ) .", "labels": [[180, 189, "ENTITY"], [90, 100, "ENTITY"], [21, 32, "CHEMICAL"], [0, 10, "PROTEIN"], [21, 32, "CHEBI"], [343, 356, "CHEMICAL"], [0, 10, "SIMPLE_CHEMICAL"], [-1, 23, "DISEASE"], [149, 156, "ENTITY"], [21, 32, "SIMPLE_CHEMICAL"], [149, 156, "ORGANISM"], [0, 10, "ENTITY"], [-1, 20, "ENTITY"], [343, 356, "SIMPLE_CHEMICAL"], [219, 229, "ENTITY"], [131, 140, "ENTITY"], [0, 10, "CHEMICAL"], [-1, 19, "ENTITY"], [149, 156, "ENTITY"], [-1, 20, "SIMPLE_CHEMICAL"], [-1, 20, "CHEMICAL"], [180, 189, "DISEASE"], [0, 10, "GGP"], [298, 322, "ENTITY"]]}
{"text": "Ribavirin is a nucleoside analogue with a broad-spectrum of antiviral effects . A study compared 111 patients with severe acute respiratory syndrome ( severe acute respiratory syndrome ) treated with ribavirin monotherapy and 41 patients with severe acute respiratory syndrome treated with lopinavir/ritonavir and ribavirin ; patients treated with the combined therapy had a lower risk of acute respiratory distress syndrome ( acute respiratory distress syndrome ) and death ( 6 ) .", "labels": [[180, 189, "ENTITY"], [90, 100, "ENTITY"], [21, 32, "CHEMICAL"], [0, 10, "PROTEIN"], [21, 32, "CHEBI"], [343, 356, "CHEMICAL"], [0, 10, "SIMPLE_CHEMICAL"], [-1, 23, "DISEASE"], [-1, 20, "ENTITY"], [149, 156, "ENTITY"], [21, 32, "SIMPLE_CHEMICAL"], [149, 156, "ORGANISM"], [0, 10, "ENTITY"], [343, 356, "SIMPLE_CHEMICAL"], [219, 229, "ENTITY"], [131, 140, "ENTITY"], [0, 10, "CHEMICAL"], [-1, 20, "SIMPLE_CHEMICAL"], [-1, 19, "ENTITY"], [149, 156, "ENTITY"], [298, 322, "ENTITY"], [180, 189, "DISEASE"], [0, 10, "GGP"], [-1, 20, "CHEMICAL"]]}
{"text": "The major therapeutic drugs that might be effective in managing COVID-19 include remdesivir , lopinavir/ritonavir alone or in combination with interferon-\u03b2 , convalescent plasma , and mAbs.17", "labels": [[10, 28, "ENTITY"], [42, 52, "ENTITY"], [156, 171, "ORGANISM"], [81, 92, "ENTITY"], [158, 171, "ENTITY"], [64, 73, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"]]}
{"text": "In the modified intention to-treat population , the median time to clinical improvement was 15 days in the lopinavir \u2013 ritonavir group , as compared with 16 days in the standard-care group ( hazard ratio , 1.39 ; 95 % CI , 1.00 to 1.91 ) ( Table S1 and Fig. S1 in the Supplementary Appendix ) .", "labels": [[16, 26, "ENTITY"], [7, 26, "SO"], [26, 35, "SIMPLE_CHEMICAL"], [183, 198, "ENTITY"], [67, 76, "ENTITY"], [107, 119, "CHEMICAL"], [26, 46, "ENTITY"], [7, 16, "ENTITY"], [258, 268, "ENTITY"], [240, 249, "GENE_OR_GENE_PRODUCT"], [119, 129, "ENTITY"], [165, 183, "ENTITY"]]}
{"text": "The 28-day mortality was numerically lower in the lopinavir \u2013 ritonavir group than in the standardcare group for either the intention-to-treat population ( 19.2 % vs. 25.0 % ; difference , \u22125.8 percentage points ; 95 % CI , \u221217.3 to 5.7 ) .", "labels": [[120, 143, "ENTITY"], [205, 212, "ENTITY"], [62, 72, "ENTITY"], [50, 60, "ENTITY"], [11, 21, "ENTITY"], [50, 60, "SIMPLE_CHEMICAL"], [25, 43, "ENTITY"], [176, 187, "ENTITY"], [214, 224, "ENTITY"], [90, 103, "ENTITY"], [176, 187, "GENE_OR_GENE_PRODUCT"], [50, 62, "CHEMICAL"]]}
{"text": "The patient received antiviral drugs including Arbidol and Kaletra ( Lopinavir and Ritonavir tablets ) and was discharged on February 13 when chest CT images showed that the bilateral lesions were mostly absorbed .", "labels": [[59, 67, "ENTITY"], [142, 148, "ENTITY"], [47, 55, "CHEMICAL"], [21, 37, "ENTITY"], [59, 67, "CHEMICAL"], [59, 67, "SIMPLE_CHEMICAL"], [83, 93, "ENTITY"], [148, 151, "ENTITY"], [174, 184, "ENTITY"], [170, 184, "ORGAN"], [4, 12, "ENTITY"], [47, 55, "ENTITY"], [4, 12, "ORGANISM"], [31, 37, "CHEBI"], [142, 148, "PROTEIN"]]}
{"text": "One antiviral-drug candidate is a combination of the HIV protease inhibitors lopinavir and ritonavir .", "labels": [[53, 77, "GO"], [91, 101, "SIMPLE_CHEMICAL"], [34, 46, "ENTITY"], [91, 101, "ENTITY"], [57, 87, "SIMPLE_CHEMICAL"], [53, 66, "ENTITY"], [77, 87, "CHEMICAL"], [4, 19, "ENTITY"], [91, 101, "CHEMICAL"], [77, 87, "ENTITY"]]}
{"text": "The number of deaths was somewhat lower in the group that received lopinavir \u2013 ritonavir .", "labels": [[4, 14, "ENTITY"], [67, 79, "CHEMICAL"], [67, 77, "SIMPLE_CHEMICAL"], [14, 21, "DISEASE"], [67, 77, "ENTITY"], [47, 53, "ENTITY"], [14, 21, "ENTITY"]]}
{"text": "The 28-day mortality was numerically lower in the lopinavir \u2013 ritonavir group than in the standardcare group for either the intention-to-treat population ( 19.2 % vs. 25.0 % ; difference , \u22125.8 percentage points ; 95 % CI , \u221217.3 to 5.7 ) .", "labels": [[120, 143, "ENTITY"], [205, 212, "ENTITY"], [62, 72, "ENTITY"], [50, 60, "ENTITY"], [50, 60, "SIMPLE_CHEMICAL"], [25, 43, "ENTITY"], [11, 21, "ENTITY"], [176, 187, "ENTITY"], [214, 224, "ENTITY"], [90, 103, "ENTITY"], [176, 187, "GENE_OR_GENE_PRODUCT"], [50, 62, "CHEMICAL"]]}
{"text": "Gastrointestinal adverse events including nausea , vomiting , and diarrhea were more common in lopinavir \u2013 ritonavir group than in the standard-care group ( Table 4 ) .", "labels": [[107, 117, "ENTITY"], [42, 49, "DISEASE"], [131, 149, "ENTITY"], [42, 49, "ENTITY"], [92, 107, "CHEMICAL"], [95, 107, "ENTITY"], [0, 32, "ENTITY"], [95, 107, "SIMPLE_CHEMICAL"]]}
{"text": "Gastrointestinal adverse events including nausea , vomiting , and diarrhea were more common in lopinavir \u2013 ritonavir group than in the standard-care group ( Table 4 ) .", "labels": [[107, 117, "ENTITY"], [42, 49, "DISEASE"], [131, 149, "ENTITY"], [42, 49, "ENTITY"], [92, 107, "CHEMICAL"], [95, 107, "ENTITY"], [0, 32, "ENTITY"], [95, 107, "SIMPLE_CHEMICAL"]]}
{"text": "Gastrointestinal adverse events including nausea , vomiting , and diarrhea were more common in lopinavir \u2013 ritonavir group than in the standard-care group ( Table 4 ) .", "labels": [[107, 117, "ENTITY"], [42, 49, "DISEASE"], [131, 149, "ENTITY"], [42, 49, "ENTITY"], [92, 107, "CHEMICAL"], [95, 107, "ENTITY"], [0, 32, "ENTITY"], [95, 107, "SIMPLE_CHEMICAL"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [111, 121, "CHEMICAL"], [30, 39, "ENTITY"], [0, 8, "DISEASE"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "ENTITY"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [0, 8, "ENTITY"], [111, 121, "CHEMICAL"], [30, 39, "ENTITY"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "DISEASE"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [0, 8, "ENTITY"], [111, 121, "CHEMICAL"], [30, 39, "ENTITY"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "DISEASE"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "Fatigue , cough , fever , and diarrhea symptoms gradually improved after treatment with antiviral medication ( Arbidol , Kaletra and inhalation of interferon-\u03b1 ) and supportive care .", "labels": [[98, 111, "CHEMICAL"], [83, 98, "ENTITY"], [111, 121, "ENTITY"], [160, 166, "ENTITY"], [0, 8, "ENTITY"], [111, 121, "CHEMICAL"], [133, 147, "GENE_OR_GENE_PRODUCT"], [111, 121, "SIMPLE_CHEMICAL"], [0, 8, "DISEASE"], [30, 39, "ENTITY"], [133, 147, "ENTITY"], [98, 111, "ENTITY"], [48, 58, "ENTITY"]]}
{"text": "The major therapeutic drugs that might be effective in managing COVID-19 include remdesivir , lopinavir/ritonavir alone or in combination with interferon-\u03b2 , convalescent plasma , and mAbs.17", "labels": [[10, 28, "ENTITY"], [42, 52, "ENTITY"], [156, 171, "ORGANISM"], [81, 92, "ENTITY"], [158, 171, "ENTITY"], [64, 73, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [0, 10, "CHEMICAL"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [0, 10, "ENTITY"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [198, 232, "ENTITY"], [0, 10, "SIMPLE_CHEMICAL"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "In summary , combination of mercaptopurine and melatonin may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by synergistically targeting papain-like protease , ACE2 , c-Jun signaling , and anti-inflammatory pathways ( Fig. 6d ) .", "labels": [[13, 25, "ENTITY"], [153, 165, "PROTEIN"], [201, 223, "ENTITY"], [181, 189, "ENTITY"], [153, 165, "ENTITY"], [153, 165, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In summary , combination of mercaptopurine and melatonin may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by synergistically targeting papain-like protease , ACE2 , c-Jun signaling , and anti-inflammatory pathways ( Fig. 6d ) .", "labels": [[13, 25, "ENTITY"], [153, 165, "PROTEIN"], [201, 223, "ENTITY"], [181, 189, "ENTITY"], [153, 165, "ENTITY"], [153, 165, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In summary , combination of mercaptopurine and melatonin may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by synergistically targeting papain-like protease , ACE2 , c-Jun signaling , and anti-inflammatory pathways ( Fig. 6d ) .", "labels": [[13, 25, "ENTITY"], [153, 165, "PROTEIN"], [181, 189, "ENTITY"], [201, 223, "ENTITY"], [153, 165, "ENTITY"], [153, 165, "GENE_OR_GENE_PRODUCT"]]}
{"text": "A study compared 111 patients with severe acute respiratory syndrome ( SARS ) treated with ribavirin monotherapy and 41 patients with SARS treated with lopinavir/ ritonavir and ribavirin ; patients treated with the combined therapy had a lower risk of acute respiratory distress syndrome ( ARDS ) and death ( 6 ) .", "labels": [[76, 86, "ENTITY"], [2, 8, "ENTITY"], [91, 101, "ENTITY"], [211, 224, "ENTITY"], [134, 147, "ENTITY"], [249, 279, "ENTITY"], [21, 30, "ORGANISM"], [60, 71, "DISEASE"], [42, 69, "DISEASE"], [147, 163, "GENE_OR_GENE_PRODUCT"], [147, 163, "CHEMICAL"], [60, 71, "ENTITY"], [35, 42, "ENTITY"], [152, 163, "ENTITY"], [249, 279, "DISEASE"], [21, 30, "ENTITY"], [236, 244, "ENTITY"], [189, 206, "ENTITY"], [42, 69, "ENTITY"]]}
{"text": "A pH-dependant mechanism of entry of coronavirus into target cells was also reported for SARS-CoV-1 after binding of the DC-SIGN receptor [ 62 ] . The activation step that occurs in endosomes at acidic pH results in fusion of the viral and endosomal membranes leading to the release of the viral SARS-CoV-1 genome into the cytosol [63].In the absence of antiviral drug , the virus is targeted to the lysosomal compartment where the low pH , along with the action of enzymes , disrupts the viral particle , thus liberating the infectious nucleic acid and , in several cases , enzymes necessary for its replication [ 64 ] .", "labels": [[15, 25, "ENTITY"], [351, 364, "ENTITY"], [106, 114, "ENTITY"], [319, 331, "PROTEIN"], [526, 537, "CHEMICAL"], [121, 138, "ENTITY"], [61, 67, "CELL"], [476, 495, "ENTITY"], [121, 138, "PROTEIN"], [354, 364, "CHEBI"], [466, 476, "ENTITY"], [511, 537, "ENTITY"], [37, 49, "ENTITY"], [476, 489, "TAXON"], [567, 573, "SO"], [286, 307, "DNA"], [121, 138, "GENE_OR_GENE_PRODUCT"], [526, 537, "CHEBI"], [593, 601, "ENTITY"], [61, 67, "CL"], [54, 67, "CELL_TYPE"], [456, 466, "PROTEIN"], [319, 331, "CELLULAR_COMPONENT"], [236, 250, "ENTITY"], [28, 34, "ENTITY"], [54, 61, "ENTITY"], [37, 49, "TAXON"], [236, 250, "GO"], [567, 573, "ENTITY"], [456, 466, "SO"], [456, 466, "ENTITY"], [61, 67, "ENTITY"], [89, 100, "ENTITY"], [121, 129, "GGP"], [192, 202, "ENTITY"], [37, 49, "ORGANISM"], [89, 100, "SO"], [286, 307, "ENTITY"], [396, 410, "ENTITY"], [236, 250, "CELLULAR_COMPONENT"]]}
{"text": "The EDEMosomes are COPII-independent vesicles that export from the ER , which are normally used to fine-tune the level of ER degradation enhancer , mannosidase alpha-like 1 ( degradation enhancer, mannosidase alpha-like 1 ) , a regulator of ER-associated degradation ( ERAD;Cal\u00ec et al. , 2008 ) . It has been demonstrated that MHV infection causes accumulation of degradation enhancer, mannosidase alpha-like 1 and osteosarcoma amplified 9 ( OS-9 , another EDEMosome cargo),and that both degradation enhancer, mannosidase alpha-like 1 and OS-9 co-localize with the RTCs of MHV ( Reggiori et al. , 2010 ) .", "labels": [[281, 290, "ENTITY"], [228, 247, "DISEASE"], [67, 70, "GENE_OR_GENE_PRODUCT"], [160, 171, "GGP"], [148, 160, "GENE_OR_GENE_PRODUCT"], [125, 137, "ENTITY"], [160, 171, "ENTITY"], [19, 46, "ENTITY"], [125, 137, "ENTITY"], [4, 15, "ENTITY"], [51, 58, "ENTITY"], [37, 46, "CELLULAR_COMPONENT"], [256, 268, "ENTITY"], [146, 171, "GGP"], [148, 160, "ENTITY"], [148, 160, "PROTEIN"], [-1, 21, "GENE_OR_GENE_PRODUCT"], [-1, 21, "ENTITY"], [67, 70, "ENTITY"], [241, 247, "ENTITY"], [181, 187, "GENE_OR_GENE_PRODUCT"], [160, 171, "PROTEIN"], [146, 171, "GENE_OR_GENE_PRODUCT"], [146, 171, "PROTEIN"], [148, 160, "GGP"], [-1, 21, "GO"], [281, 307, "GENE_OR_GENE_PRODUCT"], [228, 238, "TAXON"], [160, 171, "GENE_OR_GENE_PRODUCT"], [281, 290, "DISEASE"], [146, 171, "ENTITY"], [125, 137, "DNA"], [228, 238, "ORGANISM"], [160, 171, "ENTITY"], [4, 15, "PROTEIN"], [67, 70, "PROTEIN"], [4, 15, "GENE_OR_GENE_PRODUCT"], [181, 187, "ENTITY"], [360, 367, "SIMPLE_CHEMICAL"], [122, 137, "DNA"], [228, 238, "ENTITY"]]}
{"text": "In lung tissue , AT2 , endothelial , and immune cells were most strongly positive for FURIN expression ( Fig. 3A ) .", "labels": [[37, 48, "CELL"], [86, 92, "ENTITY"], [3, 15, "TISSUE"], [41, 48, "CL"], [64, 73, "ENTITY"], [3, 15, "ENTITY"], [37, 48, "CELL_TYPE"], [37, 48, "ENTITY"]]}
{"text": "In lung tissue , AT2 , endothelial , and immune cells were most strongly positive for FURIN expression ( Fig. 3A ) .", "labels": [[37, 48, "CELL"], [86, 92, "ENTITY"], [3, 15, "TISSUE"], [41, 48, "CL"], [64, 73, "ENTITY"], [3, 15, "ENTITY"], [37, 48, "CELL_TYPE"], [37, 48, "ENTITY"]]}
{"text": "The induction of autophagy by ORF-9b depended upon ATG5 , an important regulator of autophagosome formation , as reducing its expression decreased 9b-GFP triggered LC3 processing ( Fig. 7F ) .", "labels": [[137, 147, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [17, 27, "ENTITY"], [30, 37, "PROTEIN"], [51, 56, "ENTITY"], [30, 37, "SIMPLE_CHEMICAL"], [154, 164, "GENE_OR_GENE_PRODUCT"], [4, 14, "ENTITY"], [154, 168, "ENTITY"], [154, 164, "GGP"], [51, 56, "GENE_OR_GENE_PRODUCT"], [30, 37, "ENTITY"], [154, 164, "PROTEIN"], [51, 56, "PROTEIN"], [51, 56, "GGP"]]}
{"text": "The induction of autophagy by ORF-9b depended upon ATG5 , an important regulator of autophagosome formation , as reducing its expression decreased 9b-GFP triggered LC3 processing ( Fig. 7F ) .", "labels": [[137, 147, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [51, 56, "ENTITY"], [154, 164, "GENE_OR_GENE_PRODUCT"], [30, 37, "SIMPLE_CHEMICAL"], [4, 14, "ENTITY"], [154, 164, "GGP"], [30, 37, "PROTEIN"], [154, 168, "ENTITY"], [154, 164, "PROTEIN"], [51, 56, "GENE_OR_GENE_PRODUCT"], [51, 56, "PROTEIN"], [51, 56, "GGP"], [17, 27, "ENTITY"], [30, 37, "ENTITY"]]}
{"text": "The induction of autophagy by ORF-9b depended upon ATG5 , an important regulator of autophagosome formation , as reducing its expression decreased 9b-GFP triggered LC3 processing ( Fig. 7F ) .", "labels": [[137, 147, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [30, 37, "PROTEIN"], [51, 56, "ENTITY"], [30, 37, "SIMPLE_CHEMICAL"], [154, 164, "GENE_OR_GENE_PRODUCT"], [4, 14, "ENTITY"], [154, 168, "ENTITY"], [154, 164, "GGP"], [51, 56, "GENE_OR_GENE_PRODUCT"], [30, 37, "ENTITY"], [154, 164, "PROTEIN"], [51, 56, "PROTEIN"], [51, 56, "GGP"], [17, 27, "ENTITY"]]}
{"text": "Another study , demonstrated that IFN-\u03b1 and -\u03b3 co-administration caused hyper-activated IRF-1 and STAT1 , which finally led to a more robust antiviral symphony against virus replication ( 59 ) .", "labels": [[160, 174, "ENTITY"], [72, 88, "PROTEIN"], [8, 14, "ENTITY"], [134, 151, "ENTITY"]]}
{"text": "Another study , demonstrated that IFN-\u03b1 and -\u03b3 co-administration caused hyper-activated IRF-1 and STAT1 , which finally led to a more robust antiviral symphony against virus replication ( 59 ) .", "labels": [[160, 174, "ENTITY"], [72, 88, "PROTEIN"], [8, 14, "ENTITY"], [134, 151, "ENTITY"]]}
{"text": "A combination of type I IFN and either IFN-\u03b3 or IFN-\u03bb , was shown to synergistically inhibit the virus replication in vitro ( 40,53,54 ) .", "labels": [[2, 14, "ENTITY"], [48, 54, "GENE_OR_GENE_PRODUCT"], [17, 28, "GGP"], [48, 54, "PROTEIN"], [39, 45, "CHEMICAL"], [48, 54, "ENTITY"], [17, 28, "GENE_OR_GENE_PRODUCT"], [17, 28, "ENTITY"], [39, 45, "PROTEIN"], [39, 45, "GENE_OR_GENE_PRODUCT"], [17, 28, "PROTEIN"], [39, 45, "ENTITY"], [97, 103, "ENTITY"]]}
{"text": "IFN-a treatment stimulated higher transcriptional levels of TNF-a and IFN-b , but not TGF-b1 , IL-1a , and RANTES in vector controls than in PLpro-expressing cells ( Fig. 2 ) .", "labels": [[70, 76, "PROTEIN"], [60, 66, "PROTEIN"], [138, 158, "CELL_TYPE"], [16, 27, "ENTITY"], [34, 57, "ENTITY"], [60, 66, "GGP"], [27, 34, "ENTITY"], [141, 158, "CL"], [70, 76, "ENTITY"], [6, 16, "ENTITY"], [0, 6, "ENTITY"], [60, 66, "GENE_OR_GENE_PRODUCT"], [0, 6, "SIMPLE_CHEMICAL"], [70, 76, "GENE_OR_GENE_PRODUCT"], [114, 124, "ENTITY"], [141, 158, "CELL"], [60, 66, "ENTITY"], [138, 158, "ENTITY"], [0, 6, "PROTEIN"], [60, 66, "CHEMICAL"], [0, 6, "CHEMICAL"]]}
{"text": "IFN-a treatment stimulated higher transcriptional levels of TNF-a and IFN-b , but not TGF-b1 , IL-1a , and RANTES in vector controls than in PLpro-expressing cells ( Fig. 2 ) .", "labels": [[60, 66, "CHEMICAL"], [70, 76, "PROTEIN"], [138, 158, "CELL_TYPE"], [16, 27, "ENTITY"], [34, 57, "ENTITY"], [27, 34, "ENTITY"], [141, 158, "CL"], [6, 16, "ENTITY"], [0, 6, "ENTITY"], [60, 66, "PROTEIN"], [70, 76, "ENTITY"], [70, 76, "GENE_OR_GENE_PRODUCT"], [0, 6, "SIMPLE_CHEMICAL"], [60, 66, "GENE_OR_GENE_PRODUCT"], [60, 66, "ENTITY"], [114, 124, "ENTITY"], [141, 158, "CELL"], [60, 66, "GGP"], [138, 158, "ENTITY"], [0, 6, "PROTEIN"], [0, 6, "CHEMICAL"]]}
{"text": "Interestingly , we found that Nsp13 interacts with two key players of IFN signaling pathway including TANK-binding kinase 1 ( TBK1 ) and TANK-binding kinase 1-binding protein 1 (TBKBP1/SINTBAD).SINTBAD acts as a critical adaptor protein between TBK1 and IKKi and therefore mediates induction of IRF-dependent transcription [ 41 ] .", "labels": [[102, 122, "GGP"], [221, 229, "CHEBI"], [133, 167, "GGP"], [133, 167, "ENTITY"], [102, 122, "ENTITY"], [273, 282, "ENTITY"], [102, 122, "GENE_OR_GENE_PRODUCT"], [292, 309, "ENTITY"], [102, 122, "PROTEIN"], [133, 177, "PROTEIN"], [70, 84, "ENTITY"], [212, 229, "PROTEIN"], [133, 167, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Together , nsps 3 , 4 , and 6 are predicted to function to nucleate and anchor viral replication complexes on double-membrane vesicles in the cytoplasm ( Gosert et al. , 2002;Prentice et al. , 2004a;van der Meer et al. , 1999 ) .", "labels": [[107, 126, "CELLULAR_COMPONENT"], [107, 126, "GO"], [68, 97, "ENTITY"], [11, 24, "PROTEIN"], [11, 16, "ENTITY"], [72, 79, "TAXON"], [68, 97, "PROTEIN"], [85, 97, "GO"], [11, 16, "GENE_OR_GENE_PRODUCT"], [107, 126, "ENTITY"]]}
{"text": "Together , nsps 3 , 4 , and 6 are predicted to function to nucleate and anchor viral replication complexes on double-membrane vesicles in the cytoplasm ( Gosert et al. , 2002;Prentice et al. , 2004a;van der Meer et al. , 1999 ) .", "labels": [[107, 126, "CELLULAR_COMPONENT"], [107, 126, "GO"], [68, 97, "ENTITY"], [11, 24, "PROTEIN"], [11, 16, "ENTITY"], [85, 97, "GO"], [72, 79, "TAXON"], [68, 97, "PROTEIN"], [11, 16, "GENE_OR_GENE_PRODUCT"], [107, 126, "ENTITY"]]}
{"text": "It was discovered that SARS-CoV nsp 4 is cleaved first at its amino terminus by the PLP ( PLP2 for MHV ) and at its carboxy terminus by 3CLPro ( Harcourt et al. , 2004;Kanjanahaluethai et al. , 2003;Prentice et al. , 2004b ) .", "labels": [[112, 124, "ENTITY"], [62, 68, "CHEMICAL"], [23, 38, "ORGANISM"], [23, 38, "ENTITY"], [23, 38, "PROTEIN"], [62, 77, "ENTITY"], [84, 88, "PROTEIN"], [62, 77, "PROTEIN"], [112, 124, "GO"], [84, 88, "GGP"], [84, 88, "GENE_OR_GENE_PRODUCT"], [62, 77, "SO"], [112, 124, "PROTEIN"], [84, 88, "ENTITY"]]}
{"text": "Nsp 14 likely functions coordinately with nsps 15 and 16 in processing and modification of viral or cellular RNAs .", "labels": [[75, 88, "ENTITY"], [0, 7, "ENTITY"], [91, 97, "TAXON"], [42, 47, "ENTITY"], [14, 24, "ENTITY"], [100, 109, "CELL"], [91, 114, "DNA"], [91, 97, "ENTITY"], [100, 114, "CL"], [42, 47, "ORGANISM"], [100, 114, "ENTITY"], [42, 57, "PROTEIN"], [60, 71, "ENTITY"]]}
{"text": "However , the Y414 virus was virulent in mice , whereas the Y414H mutant was completely attenuated , even in the absence of the mutation in the 2a protein ( Sperry et al. , 2005 ) .", "labels": [[77, 88, "ENTITY"], [144, 147, "CHEBI"], [140, 147, "PROTEIN"], [140, 147, "ENTITY"], [14, 19, "ENTITY"], [60, 66, "SO"], [56, 66, "PROTEIN"], [56, 66, "ENTITY"]]}
{"text": "Nsp 14 likely functions coordinately with nsps 15 and 16 in processing and modification of viral or cellular RNAs .", "labels": [[75, 88, "ENTITY"], [0, 7, "ENTITY"], [91, 97, "TAXON"], [42, 47, "ENTITY"], [14, 24, "ENTITY"], [100, 109, "CELL"], [91, 114, "DNA"], [91, 97, "ENTITY"], [100, 114, "CL"], [42, 47, "ORGANISM"], [100, 114, "ENTITY"], [42, 57, "PROTEIN"], [60, 71, "ENTITY"]]}
{"text": "Concentrations of procalcitonin , high sensitivity C-reactive protein , and ferritin , as well as erythrocyte sedimentation rate , were significantly higher in deceased patients than in recovered patients .", "labels": [[186, 196, "ENTITY"], [51, 62, "PROTEIN"], [160, 169, "ENTITY"], [18, 32, "ENTITY"], [0, 15, "ENTITY"], [186, 196, "ORGANISM"], [18, 32, "PROTEIN"], [18, 32, "GGP"], [18, 32, "GENE_OR_GENE_PRODUCT"], [160, 169, "ORGANISM"], [51, 62, "ENTITY"], [51, 62, "GGP"], [34, 39, "ENTITY"]]}
{"text": "Concentrations of alanine aminotransferase , aspartate aminotransferase , total bilirubin , alkaline phosphatase , and \u03b3-glutamyl transpeptidase were markedly higher in deceased patients than in recovered patients", "labels": [[115, 130, "ENTITY"], [45, 55, "CHEBI"], [115, 130, "GENE_OR_GENE_PRODUCT"], [90, 101, "PROTEIN"], [18, 43, "PROTEIN"], [115, 130, "PROTEIN"], [195, 205, "ENTITY"], [18, 43, "ENTITY"], [0, 15, "ENTITY"], [18, 43, "GENE_OR_GENE_PRODUCT"], [74, 80, "CHEMICAL"], [74, 80, "PROTEIN"], [18, 26, "CHEBI"], [45, 55, "GENE_OR_GENE_PRODUCT"], [169, 178, "ORGANISM"], [90, 101, "SIMPLE_CHEMICAL"], [74, 80, "GGP"], [195, 205, "ORGANISM"], [74, 80, "SIMPLE_CHEMICAL"], [72, 80, "ENTITY"], [169, 178, "ENTITY"], [45, 55, "PROTEIN"], [18, 26, "CHEMICAL"], [90, 101, "ENTITY"], [45, 55, "ENTITY"]]}
{"text": "As RHO GTPases have been implicated in membrane remodeling and the viral replication cycle , especially entry , replication , and spread [ Van den Broeke et al. ( 2014 ) ] , transient secretory cells may be more permissive to SARS-CoV-2 infection adding to a potential vulnerability caused by considerably high co-expression levels of ACE2 and TMPRSS2 .", "labels": [[212, 226, "IMMATERIAL_ANATOMICAL_ENTITY"], [212, 237, "DISEASE"], [130, 147, "SIMPLE_CHEMICAL"], [39, 48, "CELLULAR_COMPONENT"], [174, 184, "CL"], [335, 344, "GENE_OR_GENE_PRODUCT"], [335, 344, "PROTEIN"], [174, 184, "CELL_TYPE"], [174, 184, "CELL"], [7, 15, "ENTITY"], [247, 259, "ENTITY"], [3, 7, "GENE_OR_GENE_PRODUCT"], [293, 311, "ENTITY"], [325, 332, "ENTITY"], [212, 237, "ENTITY"], [3, 15, "GGP"], [3, 7, "DISEASE"], [39, 48, "GO"], [335, 344, "GGP"], [325, 332, "GGP"], [67, 73, "TAXON"], [39, 59, "ENTITY"], [67, 91, "ENTITY"], [325, 332, "PROTEIN"], [174, 184, "ENTITY"], [335, 344, "ENTITY"], [325, 332, "GENE_OR_GENE_PRODUCT"], [3, 15, "PROTEIN"], [259, 269, "ENTITY"], [3, 7, "ENTITY"]]}
{"text": "As RHO GTPases have been implicated in membrane remodeling and the viral replication cycle , especially entry , replication , and spread [ Van den Broeke et al. ( 2014 ) ] , transient secretory cells may be more permissive to SARS-CoV-2 infection adding to a potential vulnerability caused by considerably high co-expression levels of ACE2 and TMPRSS2 .", "labels": [[212, 226, "IMMATERIAL_ANATOMICAL_ENTITY"], [212, 237, "DISEASE"], [67, 73, "TAXON"], [130, 147, "SIMPLE_CHEMICAL"], [39, 48, "CELLULAR_COMPONENT"], [174, 184, "CL"], [335, 344, "GENE_OR_GENE_PRODUCT"], [335, 344, "PROTEIN"], [174, 184, "CELL_TYPE"], [174, 184, "CELL"], [7, 15, "ENTITY"], [247, 259, "ENTITY"], [3, 7, "GENE_OR_GENE_PRODUCT"], [293, 311, "ENTITY"], [325, 332, "ENTITY"], [212, 237, "ENTITY"], [3, 15, "GGP"], [3, 7, "DISEASE"], [39, 48, "GO"], [335, 344, "GGP"], [325, 332, "GGP"], [39, 59, "ENTITY"], [67, 91, "ENTITY"], [325, 332, "PROTEIN"], [174, 184, "ENTITY"], [335, 344, "ENTITY"], [325, 332, "GENE_OR_GENE_PRODUCT"], [3, 15, "PROTEIN"], [259, 269, "ENTITY"], [3, 7, "ENTITY"]]}
{"text": "As RHO GTPases have been implicated in membrane remodeling and the viral replication cycle , especially entry , replication , and spread [ Van den Broeke et al. ( 2014 ) ] , transient secretory cells may be more permissive to SARS-CoV-2 infection adding to a potential vulnerability caused by considerably high co-expression levels of ACE2 and TMPRSS2 .", "labels": [[212, 226, "IMMATERIAL_ANATOMICAL_ENTITY"], [212, 237, "DISEASE"], [130, 147, "SIMPLE_CHEMICAL"], [39, 48, "CELLULAR_COMPONENT"], [174, 184, "CL"], [335, 344, "GENE_OR_GENE_PRODUCT"], [335, 344, "PROTEIN"], [174, 184, "CELL_TYPE"], [174, 184, "CELL"], [7, 15, "ENTITY"], [247, 259, "ENTITY"], [3, 7, "GENE_OR_GENE_PRODUCT"], [293, 311, "ENTITY"], [325, 332, "ENTITY"], [212, 237, "ENTITY"], [3, 15, "GGP"], [3, 7, "DISEASE"], [39, 48, "GO"], [335, 344, "GGP"], [325, 332, "GGP"], [39, 59, "ENTITY"], [325, 332, "PROTEIN"], [174, 184, "ENTITY"], [335, 344, "ENTITY"], [67, 73, "TAXON"], [325, 332, "GENE_OR_GENE_PRODUCT"], [3, 15, "PROTEIN"], [67, 91, "ENTITY"], [259, 269, "ENTITY"], [3, 7, "ENTITY"]]}
{"text": "As RHO GTPases have been implicated in membrane remodeling and the viral replication cycle , especially entry , replication , and spread [ Van den Broeke et al. ( 2014 ) ] , transient secretory cells may be more permissive to SARS-CoV-2 infection adding to a potential vulnerability caused by considerably high co-expression levels of ACE2 and TMPRSS2 .", "labels": [[212, 226, "IMMATERIAL_ANATOMICAL_ENTITY"], [212, 237, "DISEASE"], [130, 147, "SIMPLE_CHEMICAL"], [39, 48, "CELLULAR_COMPONENT"], [174, 184, "CL"], [67, 73, "TAXON"], [335, 344, "GENE_OR_GENE_PRODUCT"], [335, 344, "PROTEIN"], [174, 184, "CELL_TYPE"], [174, 184, "CELL"], [7, 15, "ENTITY"], [247, 259, "ENTITY"], [3, 7, "GENE_OR_GENE_PRODUCT"], [293, 311, "ENTITY"], [325, 332, "ENTITY"], [212, 237, "ENTITY"], [3, 15, "GGP"], [3, 7, "DISEASE"], [39, 48, "GO"], [335, 344, "GGP"], [325, 332, "GGP"], [39, 59, "ENTITY"], [67, 91, "ENTITY"], [325, 332, "PROTEIN"], [174, 184, "ENTITY"], [335, 344, "ENTITY"], [325, 332, "GENE_OR_GENE_PRODUCT"], [3, 15, "PROTEIN"], [259, 269, "ENTITY"], [3, 7, "ENTITY"]]}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [271, 279, "PROTEIN"], [77, 84, "GGP"], [113, 125, "DNA"], [88, 113, "CELL"], [54, 61, "PROTEIN"], [77, 84, "GENE_OR_GENE_PRODUCT"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [77, 84, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [77, 84, "PROTEIN"], [54, 61, "ENTITY"], [161, 170, "PROTEIN"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [88, 113, "ENTITY"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [396, 409, "CELL_TYPE"], [88, 113, "PROTEIN"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [88, 94, "CL"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [88, 113, "ENTITY"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [88, 113, "CELL"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "From https://doi.org/10.1101/2020.03.22.002386", "labels": []}
{"text": "As the single-nucleotide polymorphism rs12252-C/C in the gene IFITM3 ( which encodes interferon-induced transmembrane protein 3 ) is linked to severe influenza6,7 , we analyzed IFITM3-rs12252 in the patient with COVID-19 and found the \u2018 risk \u2019 IFITM3-rs12252-C/C variant ( Extended Data Fig. 2b ) .", "labels": [[7, 38, "SO"], [7, 38, "ENTITY"], [143, 150, "ENTITY"], [168, 177, "DISEASE"], [62, 69, "GENE_OR_GENE_PRODUCT"], [143, 150, "PROTEIN"], [85, 126, "GENE_OR_GENE_PRODUCT"], [7, 50, "DNA"], [168, 177, "PROTEIN"], [38, 50, "GENE_OR_GENE_PRODUCT"], [85, 126, "ENTITY"], [237, 244, "CHEMICAL"], [57, 69, "ENTITY"], [244, 263, "SO"], [237, 263, "PROTEIN"], [57, 69, "SO"], [237, 263, "ENTITY"], [263, 273, "ENTITY"], [62, 69, "PROTEIN"], [231, 237, "ENTITY"], [85, 126, "PROTEIN"]]}
{"text": "As the single-nucleotide polymorphism rs12252-C/C in the gene IFITM3 ( which encodes interferon-induced transmembrane protein 3 ) is linked to severe influenza6,7 , we analyzed IFITM3-rs12252 in the patient with COVID-19 and found the \u2018 risk \u2019 IFITM3-rs12252-C/C variant ( Extended Data Fig. 2b ) .", "labels": [[7, 38, "SO"], [7, 38, "ENTITY"], [57, 69, "ENTITY"], [143, 150, "ENTITY"], [244, 263, "SO"], [168, 177, "DISEASE"], [143, 150, "PROTEIN"], [85, 126, "GENE_OR_GENE_PRODUCT"], [7, 50, "DNA"], [62, 69, "GENE_OR_GENE_PRODUCT"], [168, 177, "PROTEIN"], [38, 50, "GENE_OR_GENE_PRODUCT"], [237, 263, "PROTEIN"], [85, 126, "ENTITY"], [57, 69, "SO"], [237, 244, "CHEMICAL"], [237, 263, "ENTITY"], [263, 273, "ENTITY"], [85, 126, "PROTEIN"], [231, 237, "ENTITY"], [62, 69, "PROTEIN"]]}
{"text": "The enrolled patients showed increase in alanine aminotransferase ( 23 [ 33 % ] of 69 patients ) and aspartate aminotransferase ( 19 [ 28 % ] of 69 patients ) , most of which count less than 100 U/L.", "labels": [[13, 22, "ENTITY"], [78, 86, "ENTITY"], [29, 38, "ENTITY"], [161, 169, "ENTITY"], [41, 49, "CHEMICAL"], [97, 111, "GGP"], [13, 22, "ORGANISM"], [41, 66, "ENTITY"], [78, 86, "ORGANISM"], [97, 111, "ENTITY"], [41, 66, "GENE_OR_GENE_PRODUCT"], [97, 128, "PROTEIN"], [41, 71, "PROTEIN"], [97, 111, "GENE_OR_GENE_PRODUCT"], [41, 49, "CHEBI"]]}
{"text": "The enrolled patients showed increase in alanine aminotransferase ( 23 [ 33 % ] of 69 patients ) and aspartate aminotransferase ( 19 [ 28 % ] of 69 patients ) , most of which count less than 100 U/L.", "labels": [[13, 22, "ENTITY"], [78, 86, "ENTITY"], [29, 38, "ENTITY"], [161, 169, "ENTITY"], [41, 49, "CHEMICAL"], [97, 111, "GGP"], [13, 22, "ORGANISM"], [41, 66, "ENTITY"], [78, 86, "ORGANISM"], [97, 111, "ENTITY"], [41, 66, "GENE_OR_GENE_PRODUCT"], [41, 71, "PROTEIN"], [97, 128, "PROTEIN"], [97, 111, "GENE_OR_GENE_PRODUCT"], [41, 49, "CHEBI"]]}
{"text": "Also , treatment of \u03b1-glucosidase inhibitors , which inhibit the interactions of calnexin with its substrates , dose dependently inhibits the incorporationof S into pseudovirus and suppresses SARS-CoV replication in cell cultures ( Fukushi et al. , 2012 ) .", "labels": [[181, 192, "ORGANISM"], [213, 221, "ENTITY"], [20, 34, "ENTITY"], [221, 232, "SIMPLE_CHEMICAL"], [20, 34, "GGP"], [117, 129, "ENTITY"], [192, 201, "ENTITY"], [181, 192, "TAXON"], [181, 192, "ENTITY"], [213, 221, "CELL_LINE"], [213, 221, "CELL"]]}
{"text": "We know that angiotensin converting enzyme is involved in corona virus infection . Pathogenic coronaviruses ( severe acute respiratory syndrome coronavirus [ SARS-CoV ] and SARS-CoV-2 ) bind to their target cells through angiotensin-converting enzyme 2 ( ACE2 ) , [ 3,4 ] .", "labels": [[221, 244, "SO"], [244, 253, "GENE_OR_GENE_PRODUCT"], [36, 43, "ENTITY"], [200, 207, "CELL"], [244, 253, "PROTEIN"], [58, 71, "SIMPLE_CHEMICAL"], [200, 207, "ENTITY"], [213, 244, "ENTITY"], [13, 43, "PROTEIN"], [13, 25, "CHEMICAL"], [65, 81, "DISEASE"], [213, 244, "GENE_OR_GENE_PRODUCT"], [65, 71, "TAXON"], [200, 207, "CL"], [244, 253, "ENTITY"], [244, 253, "GGP"], [13, 43, "GGP"], [194, 207, "CELL_TYPE"], [117, 135, "DISEASE"], [135, 144, "ORGANISM"], [13, 25, "ENTITY"], [58, 81, "ENTITY"], [213, 244, "PROTEIN"], [173, 186, "ENTITY"], [83, 94, "ENTITY"], [25, 36, "ENTITY"], [110, 144, "ENTITY"]]}
{"text": "The authors hypothesise that approaches such as corticosteroids or Janus kinase ( JAK ) inhibitors could be considered if hyperinflammation is present .", "labels": [[29, 40, "ENTITY"], [67, 80, "PROTEIN"], [48, 64, "SIMPLE_CHEMICAL"], [67, 80, "ENTITY"], [67, 80, "GENE_OR_GENE_PRODUCT"], [48, 64, "ENTITY"], [4, 12, "ENTITY"], [48, 64, "CHEBI"]]}
{"text": "The identified target genes of ATF6 include ER chaperones ( such as GRP78 , GRP94 ) , PDI , and the UPR transcription factors GADD153 and XBP1 ( Szegezdi et al. , 2006 ) .", "labels": [[22, 28, "SO"], [44, 58, "ENTITY"], [44, 58, "PROTEIN"], [138, 145, "PROTEIN"], [31, 36, "ENTITY"], [44, 47, "GENE_OR_GENE_PRODUCT"], [31, 36, "GGP"], [15, 22, "ENTITY"], [118, 126, "ENTITY"], [118, 126, "GENE_OR_GENE_PRODUCT"], [96, 126, "PROTEIN"], [138, 145, "GENE_OR_GENE_PRODUCT"], [44, 58, "GGP"], [31, 36, "PROTEIN"], [4, 15, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [118, 126, "GGP"], [22, 28, "ENTITY"]]}
{"text": "One of ATF4 \u2019s target genes is the growth arrest and DNA damage-inducible protein 153 ( GADD153 , also knownas C/EBP homologous protein , or CHOP ) . GADD153 induces the growth arrest and DNA damage-inducible protein 34 ( growth arrest and DNA damage-inducible protein 34 ) , which recruits protein phosphatase 1 ( PP1 ) to dephosphorylate eIF2\u03b1 and release the translation block .", "labels": [[53, 82, "ENTITY"], [239, 248, "GENE_OR_GENE_PRODUCT"], [256, 281, "ENTITY"], [88, 96, "ENTITY"], [53, 82, "GENE_OR_GENE_PRODUCT"], [42, 49, "SO"], [35, 42, "ENTITY"], [141, 150, "ENTITY"], [57, 74, "CHEBI"], [141, 150, "GGP"], [74, 82, "ENTITY"], [141, 150, "GENE_OR_GENE_PRODUCT"], [7, 12, "GGP"], [209, 222, "GGP"], [53, 74, "GGP"], [42, 74, "GENE_OR_GENE_PRODUCT"], [209, 222, "ENTITY"], [42, 74, "ENTITY"], [53, 74, "GENE_OR_GENE_PRODUCT"], [53, 74, "PROTEIN"], [209, 222, "PROTEIN"], [209, 222, "GENE_OR_GENE_PRODUCT"], [98, 128, "ENTITY"], [7, 22, "DNA"], [141, 150, "PROTEIN"], [103, 128, "PROTEIN"], [239, 248, "PROTEIN"], [53, 74, "ENTITY"], [226, 239, "ENTITY"], [103, 111, "GENE_OR_GENE_PRODUCT"], [7, 12, "ENTITY"], [117, 128, "CHEBI"], [7, 12, "GENE_OR_GENE_PRODUCT"], [158, 177, "ENTITY"]]}
{"text": "Beside affecting the virus maturation process , pH modulation by chloroquine can impair the proper maturation of viral protein [ 32 ] and the recognition of viral antigen by dendritic cells , which occurs through a Toll-like receptor-dependent pathway that requires endosomal acidification [ 69 ] .", "labels": [[21, 27, "TAXON"], [113, 119, "PROTEIN"], [257, 266, "GO"], [21, 46, "ENTITY"], [266, 276, "ENTITY"], [257, 266, "CELLULAR_COMPONENT"], [113, 119, "ENTITY"], [171, 184, "CELL_TYPE"], [171, 184, "CL"], [7, 17, "ENTITY"], [110, 119, "PROTEIN"], [113, 119, "TAXON"], [205, 244, "ENTITY"], [171, 184, "CELL"], [110, 119, "ENTITY"], [257, 266, "ENTITY"], [205, 215, "GENE_OR_GENE_PRODUCT"], [171, 184, "ENTITY"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [192, 203, "ENTITY"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [271, 279, "PROTEIN"], [182, 192, "ENTITY"], [88, 113, "ENTITY"], [203, 214, "CL"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "DNA"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [382, 411, "DISEASE"], [271, 279, "GGP"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "DNA"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [203, 238, "ENTITY"], [192, 203, "CHEMICAL"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [203, 214, "CELL"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [77, 84, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [182, 192, "ENTITY"], [113, 123, "PROTEIN"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [182, 192, "DNA"], [54, 61, "PROTEIN"], [203, 238, "ENTITY"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [192, 203, "DNA"], [382, 411, "DISEASE"], [271, 279, "GGP"], [192, 203, "GENE_OR_GENE_PRODUCT"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [192, 203, "ENTITY"], [125, 129, "PROTEIN"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [192, 203, "CHEMICAL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [182, 192, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [77, 84, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"], [203, 214, "CL"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [203, 238, "ENTITY"], [396, 409, "ENTITY"], [88, 113, "PROTEIN"], [113, 123, "ENTITY"], [271, 279, "ENTITY"], [203, 214, "CL"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [192, 203, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [192, 203, "DNA"], [125, 129, "ENTITY"], [77, 84, "GENE_OR_GENE_PRODUCT"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [248, 271, "ENTITY"], [182, 192, "DNA"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [77, 84, "ENTITY"], [203, 214, "CELL"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [203, 214, "CL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [113, 123, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [182, 192, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "CELL"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [203, 214, "CELL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [192, 203, "DNA"], [125, 129, "ENTITY"], [77, 84, "GENE_OR_GENE_PRODUCT"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [182, 192, "DNA"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [203, 238, "ENTITY"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [248, 271, "ENTITY"], [192, 203, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [182, 192, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [192, 203, "CHEMICAL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [77, 84, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "Indeed , enhanced ACE activity and decreased ACE2 availability contribute to lung injury during acid- and ventilator-induced lung injury [ 12 , 31 , 32 ] .", "labels": [[106, 130, "ENTITY"], [96, 102, "ENTITY"], [77, 82, "DISEASE"], [77, 82, "ENTITY"], [106, 130, "DISEASE"]]}
{"text": "ACE cleaves angiotensin I to generate angiotensin II , the peptide which binds to and activates AT1R to constrict blood vessels , thereby elevating blood pressure .", "labels": [[12, 26, "CHEMICAL"], [114, 120, "MULTI-TISSUE_STRUCTURE"], [38, 53, "PROTEIN"], [38, 53, "GGP"], [12, 26, "ENTITY"], [38, 53, "ENTITY"], [38, 53, "GENE_OR_GENE_PRODUCT"], [0, 26, "GENE_OR_GENE_PRODUCT"], [12, 26, "PROTEIN"], [138, 148, "ORGANISM_SUBSTANCE"], [38, 53, "CHEMICAL"], [12, 26, "GGP"], [4, 12, "ENTITY"], [138, 154, "ENTITY"], [0, 4, "ENTITY"], [114, 120, "ENTITY"]]}
{"text": "In the RAS cascade , ACE is responsible for the conversion of Angiotensin ( Ang ) I to Ang II , and Ang II is the vasoactive peptide principally responsible for systemic vasoconstriction and stimulation of aldosterone release ( Figure 1 ) [ 16 ]", "labels": [[7, 19, "ENTITY"], [84, 91, "ENTITY"], [206, 218, "ENTITY"], [110, 125, "CHEBI"], [7, 11, "GENE_OR_GENE_PRODUCT"], [84, 91, "CHEMICAL"], [110, 125, "ENTITY"], [218, 228, "ENTITY"], [62, 80, "GENE_OR_GENE_PRODUCT"], [84, 91, "GENE_OR_GENE_PRODUCT"], [157, 170, "ENTITY"]]}
{"text": "It has been demonstrated that the binding of the coronavirus spike protein to ACE2 , its cellular binding site , leads to ACE2 downregulation , which in turn results in excessive production of angiotensin by the related enzyme ACE , while less ACE2 is capable of converting it to the vasodilator heptapeptide angiotensin 1\u20137 .", "labels": [[49, 61, "TAXON"], [49, 75, "PROTEIN"], [78, 83, "PROTEIN"], [78, 83, "ENTITY"], [212, 227, "ENTITY"], [169, 179, "ENTITY"], [153, 158, "ENTITY"], [280, 321, "GENE_OR_GENE_PRODUCT"], [49, 75, "ENTITY"], [67, 75, "CHEBI"], [78, 83, "ENTITY"], [78, 83, "GENE_OR_GENE_PRODUCT"], [49, 61, "ORGANISM"], [212, 220, "SO"], [34, 42, "ENTITY"], [78, 83, "GGP"], [220, 227, "GENE_OR_GENE_PRODUCT"], [296, 321, "CHEMICAL"], [89, 106, "ENTITY"], [280, 321, "ENTITY"], [89, 106, "DNA"]]}
{"text": "This may be accounted for by two complementary mechanisms : blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection , as well as upregulating ACE2 , thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1\u20137 .", "labels": [[134, 140, "ENTITY"], [191, 200, "GGP"], [263, 291, "GENE_OR_GENE_PRODUCT"], [163, 176, "GGP"], [163, 176, "GENE_OR_GENE_PRODUCT"], [83, 95, "ENTITY"], [47, 58, "ENTITY"], [263, 291, "ENTITY"], [267, 291, "CHEMICAL"], [163, 176, "PROTEIN"], [191, 200, "ENTITY"], [163, 176, "ENTITY"], [134, 140, "DISEASE"], [191, 200, "CHEMICAL"]]}
{"text": "This may be accounted for by two complementary mechanisms : blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection , as well as upregulating ACE2 , thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1\u20137 .", "labels": [[134, 140, "ENTITY"], [191, 200, "GGP"], [163, 176, "GGP"], [163, 176, "GENE_OR_GENE_PRODUCT"], [83, 95, "ENTITY"], [267, 291, "CHEMICAL"], [47, 58, "ENTITY"], [263, 291, "ENTITY"], [263, 291, "GENE_OR_GENE_PRODUCT"], [163, 176, "PROTEIN"], [191, 200, "ENTITY"], [163, 176, "ENTITY"], [134, 140, "DISEASE"], [191, 200, "CHEMICAL"]]}
{"text": "In the RAS cascade , ACE is responsible for the conversion of Angiotensin ( Ang ) I to Ang II , and Ang II is the vasoactive peptide principally responsible for systemic vasoconstriction and stimulation of aldosterone release ( Figure 1 ) [ 16 ]", "labels": [[7, 19, "ENTITY"], [84, 91, "ENTITY"], [206, 218, "ENTITY"], [110, 125, "CHEBI"], [7, 11, "GENE_OR_GENE_PRODUCT"], [84, 91, "CHEMICAL"], [110, 125, "ENTITY"], [62, 80, "GENE_OR_GENE_PRODUCT"], [218, 228, "ENTITY"], [84, 91, "GENE_OR_GENE_PRODUCT"], [157, 170, "ENTITY"]]}
{"text": "The generation of Ang II by ACE is pharmacologically inhibited by angiotensin converting enzyme inhibitors ( ACEi ) , and angiotensin receptor blockers ( ARBs ) function by blocking the downstream interaction of Ang II with the AT1 receptor [ 16 ] .", "labels": [[18, 25, "GGP"], [18, 25, "GENE_OR_GENE_PRODUCT"], [118, 143, "ENTITY"], [143, 154, "CHEMICAL"], [118, 143, "GGP"], [4, 15, "ENTITY"], [197, 212, "GGP"], [118, 143, "GENE_OR_GENE_PRODUCT"], [66, 78, "CHEMICAL"], [28, 32, "GGP"], [118, 143, "PROTEIN"], [28, 32, "GENE_OR_GENE_PRODUCT"], [186, 197, "ENTITY"], [66, 107, "GGP"], [197, 212, "ENTITY"], [143, 154, "ENTITY"], [18, 25, "PROTEIN"], [18, 25, "ENTITY"], [161, 173, "ENTITY"], [197, 212, "GENE_OR_GENE_PRODUCT"], [143, 154, "SIMPLE_CHEMICAL"], [224, 232, "GGP"], [35, 53, "ENTITY"], [66, 107, "PROTEIN"], [66, 107, "ENTITY"], [197, 212, "CHEMICAL"], [224, 232, "GENE_OR_GENE_PRODUCT"], [224, 232, "PROTEIN"], [224, 232, "ENTITY"], [197, 212, "PROTEIN"], [28, 32, "CHEMICAL"], [53, 63, "ENTITY"], [28, 32, "ENTITY"], [66, 109, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The angiotensin-converting 1 ( ACE1 ) enzyme is characterized by a genetic deletion/insertion ( D/I ) polymorphism in intron 16 , which is associated with alterations in circulating and tissue concentrations of ACE . The D allele is associated with a reduced expression of ACE2 .", "labels": [[259, 270, "GGP"], [259, 270, "GENE_OR_GENE_PRODUCT"], [65, 75, "ENTITY"], [215, 223, "ENTITY"], [4, 38, "DNA"], [223, 233, "ENTITY"], [155, 170, "ENTITY"], [251, 259, "ENTITY"], [4, 29, "GENE_OR_GENE_PRODUCT"], [259, 270, "ENTITY"], [193, 208, "GENE_OR_GENE_PRODUCT"], [96, 102, "ENTITY"], [193, 208, "ENTITY"], [65, 75, "SO"], [215, 223, "DNA"], [4, 29, "ENTITY"], [217, 223, "SO"], [130, 150, "ENTITY"], [259, 270, "PROTEIN"], [150, 157, "ENTITY"], [182, 193, "ENTITY"]]}
{"text": "It should also be noted that the two Asian countries which were initially severely hit by the virus , China and Korea , are also characterized by low D allele frequencies .", "labels": [[143, 159, "ENTITY"], [94, 100, "TAXON"], [74, 83, "ENTITY"], [37, 43, "ENTITY"], [43, 53, "ENTITY"], [94, 100, "ENTITY"]]}
{"text": "These data suggest that ACE1 D/I polymorphism may be regarded as a confounder in the spread of COVID-19 and the outcome of the infection in various European populations . These findings are in agreement with the role of ACE in pulmonary infections caused by coronaviruses [ 4 ] .", "labels": [[24, 33, "ENTITY"], [29, 33, "CHEMICAL"], [67, 78, "ENTITY"], [148, 169, "ENTITY"], [6, 11, "ENTITY"], [112, 120, "ENTITY"], [127, 137, "ENTITY"], [85, 92, "ENTITY"], [95, 104, "PROTEIN"], [95, 104, "ENTITY"], [148, 169, "CELL_LINE"], [95, 104, "DISEASE"], [33, 46, "ENTITY"], [227, 237, "ENTITY"], [227, 237, "DISEASE"], [95, 104, "GENE_OR_GENE_PRODUCT"], [258, 274, "ORGANISM"], [24, 29, "GENE_OR_GENE_PRODUCT"], [127, 137, "DISEASE"]]}
{"text": "ACE2 cleaving by TMPRSSs : TMPRSS2 can also cleave ACE2 amino acids 697 to 716 , resulting in the shedding of 13kD ACE2 fragment in culture supernatants and augmented viral infectivity .", "labels": [[17, 25, "PROTEIN"], [51, 62, "GGP"], [0, 5, "PROTEIN"], [17, 25, "ENTITY"], [129, 140, "ENTITY"], [110, 120, "ENTITY"], [51, 62, "ENTITY"], [51, 68, "GENE_OR_GENE_PRODUCT"], [5, 14, "ENTITY"], [157, 173, "ENTITY"], [107, 120, "DNA"], [110, 120, "GGP"], [157, 167, "TAXON"], [56, 62, "CHEMICAL"], [110, 115, "GENE_OR_GENE_PRODUCT"], [51, 75, "PROTEIN"], [0, 5, "ENTITY"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Then it is cleaved by TMPRSS2 at the S1/S2 boundary or within S2 subunit , which removes the structural constraint of S1 on S2 , and releases the internal fusion peptide combined with the Spike TM domain for the fusion of viral and cellular membranes . Finally , the viral genomes enter into the host cells .", "labels": [[263, 273, "ENTITY"], [22, 30, "ENTITY"], [37, 52, "CELLULAR_COMPONENT"], [184, 197, "PROTEIN"], [184, 197, "ENTITY"], [37, 52, "ENTITY"], [37, 43, "PROTEIN"], [22, 25, "SO"], [22, 30, "GENE_OR_GENE_PRODUCT"], [292, 301, "CELL"], [263, 273, "DNA"], [62, 73, "ENTITY"], [93, 104, "ENTITY"], [292, 301, "CELL_TYPE"], [228, 241, "ENTITY"], [292, 301, "ENTITY"], [292, 301, "CL"], [62, 73, "PROTEIN"], [142, 162, "ENTITY"], [263, 273, "TAXON"], [22, 30, "GGP"], [11, 19, "ENTITY"], [22, 30, "PROTEIN"], [188, 194, "GENE_OR_GENE_PRODUCT"], [228, 241, "CELLULAR_COMPONENT"], [142, 162, "SO"], [228, 241, "CL"]]}
{"text": "The potent anti-SARS-CoV-1 effects of chloroquine in vitro were considered attributable to a deficit in the glycosylation of a virus cell surface receptor , the angiotensin-converting enzyme 2 ( ACE2 ) on Vero cells [ 59 ] .", "labels": [[38, 50, "CHEBI"], [93, 101, "ENTITY"], [27, 35, "ENTITY"], [202, 210, "ENTITY"], [161, 191, "ENTITY"], [50, 59, "ENTITY"], [205, 210, "CL"], [161, 191, "PROTEIN"], [108, 122, "ENTITY"], [38, 50, "SIMPLE_CHEMICAL"], [202, 210, "CELL_LINE"], [127, 138, "TAXON"], [11, 27, "ENTITY"], [38, 50, "CHEMICAL"], [38, 50, "ENTITY"], [202, 210, "CELL"], [127, 155, "ENTITY"], [161, 191, "GENE_OR_GENE_PRODUCT"], [127, 155, "PROTEIN"]]}
{"text": "Albumin concentrations were significantly lower in deceased patients than in recovered patients .", "labels": [[0, 8, "ENTITY"], [60, 69, "ORGANISM"], [0, 8, "SIMPLE_CHEMICAL"], [8, 23, "ENTITY"], [60, 69, "ENTITY"], [0, 8, "GGP"], [60, 69, "ENTITY"], [77, 87, "ENTITY"], [51, 60, "ENTITY"], [60, 69, "ORGANISM"]]}
{"text": "Albumin concentrations were significantly lower in severe cases than moderate cases , and hypoalbuminemia ( albumin<32g/L ) was more frequent in severe cases ( Table 2 ) .", "labels": [[0, 8, "ENTITY"], [0, 8, "SIMPLE_CHEMICAL"], [8, 23, "ENTITY"], [58, 64, "ENTITY"], [58, 64, "ENTITY"], [69, 78, "ENTITY"], [0, 8, "GGP"], [51, 58, "ENTITY"], [51, 58, "ENTITY"]]}
{"text": "Concentrations of alanine aminotransferase , aspartate aminotransferase , total bilirubin , alkaline phosphatase , and \u03b3-glutamyl transpeptidase were markedly higher in deceased patients than in recovered patients", "labels": [[115, 130, "PROTEIN"], [45, 55, "CHEBI"], [90, 101, "PROTEIN"], [18, 43, "PROTEIN"], [195, 205, "ENTITY"], [18, 43, "ENTITY"], [0, 15, "ENTITY"], [115, 130, "ENTITY"], [18, 43, "GENE_OR_GENE_PRODUCT"], [115, 130, "GENE_OR_GENE_PRODUCT"], [74, 80, "CHEMICAL"], [74, 80, "PROTEIN"], [18, 26, "CHEBI"], [45, 55, "GENE_OR_GENE_PRODUCT"], [169, 178, "ORGANISM"], [90, 101, "SIMPLE_CHEMICAL"], [74, 80, "GGP"], [195, 205, "ORGANISM"], [74, 80, "SIMPLE_CHEMICAL"], [72, 80, "ENTITY"], [169, 178, "ENTITY"], [45, 55, "PROTEIN"], [18, 26, "CHEMICAL"], [90, 101, "ENTITY"], [45, 55, "ENTITY"]]}
{"text": "Previous studies have shown that the mRNA and protein levels of DUSP1 are modulated by ER stress ( Boutros et al. , 2008;Li et al. , 2011 ) . ER stress-induced DUSP1 up-regulation is likely to be mediated by ATF3 in the PERK pathway , since knock-down of ATF3 significantly reduced DUSP1 induction in cells under ER stress ( Gora et al. , 2010 ) .", "labels": [[145, 160, "ENTITY"], [288, 301, "ENTITY"], [64, 70, "ENTITY"], [288, 301, "CELL"], [145, 160, "PROTEIN"], [241, 252, "PROTEIN"], [274, 282, "PROTEIN"], [196, 208, "GGP"], [37, 42, "CHEBI"], [196, 208, "GENE_OR_GENE_PRODUCT"], [64, 70, "GGP"], [274, 282, "GENE_OR_GENE_PRODUCT"], [87, 90, "GENE_OR_GENE_PRODUCT"], [87, 90, "PROTEIN"], [274, 282, "GGP"], [241, 252, "ENTITY"], [37, 42, "RNA"], [145, 160, "GENE_OR_GENE_PRODUCT"], [64, 70, "ENTITY"], [274, 282, "ENTITY"], [288, 301, "CL"], [216, 225, "ENTITY"], [87, 97, "ENTITY"], [46, 61, "ENTITY"], [241, 252, "GENE_OR_GENE_PRODUCT"], [307, 316, "ENTITY"], [37, 42, "ENTITY"], [64, 70, "PROTEIN"], [196, 208, "ENTITY"], [64, 70, "ENTITY"], [196, 208, "PROTEIN"], [260, 274, "ENTITY"], [145, 160, "GGP"], [9, 17, "ENTITY"], [46, 54, "CHEBI"], [241, 252, "GGP"], [64, 70, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Previous studies have shown that the mRNA and protein levels of DUSP1 are modulated by ER stress ( Boutros et al. , 2008;Li et al. , 2011 ) . ER stress-induced DUSP1 up-regulation is likely to be mediated by ATF3 in the PERK pathway , since knock-down of ATF3 significantly reduced DUSP1 induction in cells under ER stress ( Gora et al. , 2010 ) .", "labels": [[145, 160, "ENTITY"], [64, 70, "ENTITY"], [288, 301, "ENTITY"], [288, 301, "CELL"], [145, 160, "PROTEIN"], [241, 252, "PROTEIN"], [64, 70, "GGP"], [274, 282, "PROTEIN"], [196, 208, "GGP"], [37, 42, "CHEBI"], [196, 208, "GENE_OR_GENE_PRODUCT"], [274, 282, "GENE_OR_GENE_PRODUCT"], [87, 90, "GENE_OR_GENE_PRODUCT"], [87, 90, "PROTEIN"], [274, 282, "GGP"], [241, 252, "ENTITY"], [37, 42, "RNA"], [145, 160, "GENE_OR_GENE_PRODUCT"], [64, 70, "ENTITY"], [274, 282, "ENTITY"], [288, 301, "CL"], [216, 225, "ENTITY"], [46, 61, "ENTITY"], [241, 252, "GENE_OR_GENE_PRODUCT"], [307, 316, "ENTITY"], [64, 70, "GENE_OR_GENE_PRODUCT"], [37, 42, "ENTITY"], [196, 208, "ENTITY"], [64, 70, "ENTITY"], [196, 208, "PROTEIN"], [64, 70, "PROTEIN"], [260, 274, "ENTITY"], [145, 160, "GGP"], [9, 17, "ENTITY"], [46, 54, "CHEBI"], [87, 97, "ENTITY"], [241, 252, "GGP"]]}
{"text": "ATF4 in turn transactivates genes involved in amino acid metabolism , redox reactions , and stress response .", "labels": [[0, 5, "GGP"], [46, 57, "CHEBI"], [28, 34, "ENTITY"], [70, 76, "ENTITY"], [46, 57, "CHEMICAL"], [0, 5, "ENTITY"], [0, 5, "PROTEIN"], [46, 57, "AMINO_ACID"], [46, 68, "ENTITY"], [88, 99, "ENTITY"], [13, 28, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [28, 34, "SO"]]}
{"text": "ATF4 in turn transactivates genes involved in amino acid metabolism , redox reactions , and stress response .", "labels": [[0, 5, "GGP"], [46, 57, "CHEBI"], [28, 34, "ENTITY"], [46, 57, "CHEMICAL"], [0, 5, "ENTITY"], [0, 5, "PROTEIN"], [46, 57, "AMINO_ACID"], [88, 99, "ENTITY"], [70, 76, "ENTITY"], [13, 28, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [28, 34, "SO"], [46, 68, "ENTITY"]]}
{"text": "ATF4 in turn transactivates genes involved in amino acid metabolism , redox reactions , and stress response .", "labels": [[0, 5, "GGP"], [46, 57, "CHEBI"], [28, 34, "ENTITY"], [70, 76, "ENTITY"], [46, 57, "CHEMICAL"], [0, 5, "ENTITY"], [0, 5, "PROTEIN"], [46, 57, "AMINO_ACID"], [88, 99, "ENTITY"], [13, 28, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [28, 34, "SO"], [46, 68, "ENTITY"]]}
{"text": "One of ATF4 \u2019s target genes is the growth arrest and DNA damage-inducible protein 153 ( GADD153 , also knownas C/EBP homologous protein , or CHOP ) . GADD153 induces the growth arrest and DNA damage-inducible protein 34 ( growth arrest and DNA damage-inducible protein 34 ) , which recruits protein phosphatase 1 ( PP1 ) to dephosphorylate eIF2\u03b1 and release the translation block .", "labels": [[74, 82, "ENTITY"], [53, 82, "ENTITY"], [239, 248, "GENE_OR_GENE_PRODUCT"], [256, 281, "ENTITY"], [53, 82, "GENE_OR_GENE_PRODUCT"], [42, 49, "SO"], [35, 42, "ENTITY"], [141, 150, "ENTITY"], [57, 74, "CHEBI"], [141, 150, "GGP"], [7, 12, "GENE_OR_GENE_PRODUCT"], [88, 96, "ENTITY"], [141, 150, "GENE_OR_GENE_PRODUCT"], [209, 222, "GGP"], [53, 74, "GGP"], [42, 74, "GENE_OR_GENE_PRODUCT"], [209, 222, "ENTITY"], [42, 74, "ENTITY"], [53, 74, "GENE_OR_GENE_PRODUCT"], [53, 74, "PROTEIN"], [209, 222, "PROTEIN"], [209, 222, "GENE_OR_GENE_PRODUCT"], [98, 128, "ENTITY"], [141, 150, "PROTEIN"], [7, 12, "GGP"], [103, 128, "PROTEIN"], [239, 248, "PROTEIN"], [7, 22, "DNA"], [53, 74, "ENTITY"], [226, 239, "ENTITY"], [103, 111, "GENE_OR_GENE_PRODUCT"], [7, 12, "ENTITY"], [117, 128, "CHEBI"], [158, 177, "ENTITY"]]}
{"text": "The identified target genes of ATF6 include ER chaperones ( such as GRP78 , GRP94 ) , PDI , and the UPR transcription factors GADD153 and XBP1 ( Szegezdi et al. , 2006 ) .", "labels": [[22, 28, "SO"], [44, 58, "ENTITY"], [44, 58, "PROTEIN"], [138, 145, "PROTEIN"], [31, 36, "ENTITY"], [44, 47, "GENE_OR_GENE_PRODUCT"], [31, 36, "GGP"], [15, 22, "ENTITY"], [118, 126, "ENTITY"], [118, 126, "GENE_OR_GENE_PRODUCT"], [96, 126, "PROTEIN"], [138, 145, "GENE_OR_GENE_PRODUCT"], [44, 58, "GGP"], [31, 36, "PROTEIN"], [4, 15, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [118, 126, "GGP"], [22, 28, "ENTITY"]]}
{"text": "The identified target genes of ATF6 include ER chaperones ( such as GRP78 , GRP94 ) , PDI , and the UPR transcription factors GADD153 and XBP1 ( Szegezdi et al. , 2006 ) .", "labels": [[22, 28, "SO"], [44, 58, "ENTITY"], [44, 58, "PROTEIN"], [138, 145, "PROTEIN"], [31, 36, "ENTITY"], [44, 47, "GENE_OR_GENE_PRODUCT"], [31, 36, "GGP"], [15, 22, "ENTITY"], [118, 126, "ENTITY"], [118, 126, "GENE_OR_GENE_PRODUCT"], [96, 126, "PROTEIN"], [138, 145, "GENE_OR_GENE_PRODUCT"], [44, 58, "GGP"], [31, 36, "PROTEIN"], [4, 15, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [118, 126, "GGP"], [22, 28, "ENTITY"]]}
{"text": "The identified target genes of ATF6 include ER chaperones ( such as GRP78 , GRP94 ) , PDI , and the UPR transcription factors GADD153 and XBP1 ( Szegezdi et al. , 2006 ) .", "labels": [[22, 28, "SO"], [44, 58, "ENTITY"], [44, 58, "PROTEIN"], [138, 145, "PROTEIN"], [31, 36, "ENTITY"], [44, 47, "GENE_OR_GENE_PRODUCT"], [31, 36, "GGP"], [15, 22, "ENTITY"], [118, 126, "ENTITY"], [118, 126, "GENE_OR_GENE_PRODUCT"], [96, 126, "PROTEIN"], [138, 145, "GENE_OR_GENE_PRODUCT"], [44, 58, "GGP"], [31, 36, "PROTEIN"], [4, 15, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [118, 126, "GGP"], [22, 28, "ENTITY"]]}
{"text": "The identified target genes of ATF6 include ER chaperones ( such as GRP78 , GRP94 ) , PDI , and the UPR transcription factors GADD153 and XBP1 ( Szegezdi et al. , 2006 ) .", "labels": [[22, 28, "SO"], [44, 58, "ENTITY"], [44, 58, "PROTEIN"], [138, 145, "PROTEIN"], [31, 36, "ENTITY"], [44, 47, "GENE_OR_GENE_PRODUCT"], [31, 36, "GGP"], [15, 22, "ENTITY"], [118, 126, "ENTITY"], [118, 126, "GENE_OR_GENE_PRODUCT"], [96, 126, "PROTEIN"], [138, 145, "GENE_OR_GENE_PRODUCT"], [44, 58, "GGP"], [31, 36, "PROTEIN"], [4, 15, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [118, 126, "GGP"], [22, 28, "ENTITY"]]}
{"text": "However , recent studies have demonstrated that , under certain circumstances , ATF6-mediated signals may also contribute to ER-stress-induced apoptosis , possibly via activation of CHOP and/or suppression of myeloid cell leukemia sequence 1 ( Mcl-1;Gotoh et al. , 2002;Nakanishi et al. , 2005;Morishima et al.,2011 ) .", "labels": [[259, 265, "CHEMICAL"], [206, 231, "PROTEIN"], [206, 231, "DISEASE"], [206, 231, "CL"], [206, 231, "CELL"], [187, 194, "ENTITY"], [206, 231, "ENTITY"], [125, 143, "ENTITY"], [80, 94, "ENTITY"]]}
{"text": "The identified target genes of ATF6 include ER chaperones ( such as GRP78 , GRP94 ) , PDI , and the UPR transcription factors GADD153 and XBP1 ( Szegezdi et al. , 2006 ) .", "labels": [[22, 28, "SO"], [44, 58, "ENTITY"], [44, 58, "PROTEIN"], [31, 36, "ENTITY"], [44, 47, "GENE_OR_GENE_PRODUCT"], [31, 36, "GGP"], [138, 145, "GENE_OR_GENE_PRODUCT"], [15, 22, "ENTITY"], [118, 126, "ENTITY"], [118, 126, "GENE_OR_GENE_PRODUCT"], [96, 126, "PROTEIN"], [44, 58, "GGP"], [31, 36, "PROTEIN"], [4, 15, "ENTITY"], [138, 145, "PROTEIN"], [31, 36, "GENE_OR_GENE_PRODUCT"], [118, 126, "GGP"], [22, 28, "ENTITY"]]}
{"text": "Previously , it was proposed the ATF6 pathway is mainly pro-survival , as it enhances the ER protein folding capacity to counteract ER stress ( Szegezdiet al. , 2006 ) .", "labels": [[121, 135, "ENTITY"], [86, 93, "ENTITY"], [121, 132, "PROTEIN"], [86, 93, "GGP"], [33, 38, "ENTITY"], [121, 135, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Previously , it was proposed the ATF6 pathway is mainly pro-survival , as it enhances the ER protein folding capacity to counteract ER stress ( Szegezdiet al. , 2006 ) .", "labels": [[121, 135, "ENTITY"], [86, 93, "ENTITY"], [121, 132, "PROTEIN"], [86, 93, "GGP"], [33, 38, "ENTITY"], [121, 135, "GENE_OR_GENE_PRODUCT"]]}
{"text": "However , recent studies have demonstrated that , under certain circumstances , ATF6-mediated signals may also contribute to ER-stress-induced apoptosis , possibly via activation of CHOP and/or suppression of myeloid cell leukemia sequence 1 ( Mcl-1;Gotoh et al. , 2002;Nakanishi et al. , 2005;Morishima et al.,2011 ) .", "labels": [[259, 265, "CHEMICAL"], [206, 231, "PROTEIN"], [206, 231, "DISEASE"], [206, 231, "CL"], [206, 231, "CELL"], [187, 194, "ENTITY"], [206, 231, "ENTITY"], [125, 143, "ENTITY"], [80, 94, "ENTITY"]]}
{"text": "However , recent studies have demonstrated that , under certain circumstances , ATF6-mediated signals may also contribute to ER-stress-induced apoptosis , possibly via activation of CHOP and/or suppression of myeloid cell leukemia sequence 1 ( Mcl-1;Gotoh et al. , 2002;Nakanishi et al. , 2005;Morishima et al.,2011 ) .", "labels": [[259, 265, "CHEMICAL"], [206, 231, "PROTEIN"], [206, 231, "DISEASE"], [206, 231, "CL"], [206, 231, "CELL"], [187, 194, "ENTITY"], [206, 231, "ENTITY"], [125, 143, "ENTITY"], [80, 94, "ENTITY"]]}
{"text": "However , recent studies have demonstrated that , under certain circumstances , ATF6-mediated signals may also contribute to ER-stress-induced apoptosis , possibly via activation of CHOP and/or suppression of myeloid cell leukemia sequence 1 ( Mcl-1;Gotoh et al. , 2002;Nakanishi et al. , 2005;Morishima et al.,2011 ) .", "labels": [[259, 265, "CHEMICAL"], [206, 231, "PROTEIN"], [206, 231, "DISEASE"], [206, 231, "CL"], [206, 231, "CELL"], [187, 194, "ENTITY"], [206, 231, "ENTITY"], [125, 143, "ENTITY"], [80, 94, "ENTITY"]]}
{"text": "In the case of ASFV , ATF6 activation has been shown to modulate ASFV-induced apoptosis and facilitate viral replication ( Galindo et al. , 2012 ) .", "labels": [[103, 109, "ENTITY"], [15, 20, "ENTITY"], [65, 78, "ENTITY"], [7, 12, "ENTITY"], [15, 20, "ORGANISM"]]}
{"text": "In the case of ASFV , ATF6 activation has been shown to modulate ASFV-induced apoptosis and facilitate viral replication ( Galindo et al. , 2012 ) .", "labels": [[15, 20, "ENTITY"], [65, 78, "ENTITY"], [7, 12, "ENTITY"], [15, 20, "ORGANISM"], [103, 109, "ENTITY"]]}
{"text": "For WNV , it has been shown that ATF6 activation promotes efficient WNV replication by suppressing signal transducer and activator of transcription 1 ( signal transducer and activator of transcription 1 ) phosphorylation and late-phase IFN signaling ( Ambrose and Mackenzie , 2013 ) .", "labels": [[87, 148, "PROTEIN"], [4, 8, "PROTEIN"], [49, 58, "ENTITY"], [58, 68, "TAXON"], [58, 68, "ENTITY"], [117, 148, "ENTITY"], [58, 68, "ORGANISM"], [4, 8, "ENTITY"], [4, 8, "ENTITY"], [4, 8, "ORGANISM"], [58, 68, "PROTEIN"], [121, 134, "GENE_OR_GENE_PRODUCT"], [33, 38, "ENTITY"], [87, 106, "ENTITY"], [4, 8, "TAXON"], [4, 8, "DISEASE"], [99, 117, "ENTITY"], [121, 134, "ENTITY"]]}
{"text": "For WNV , it has been shown that ATF6 activation promotes efficient WNV replication by suppressing signal transducer and activator of transcription 1 ( signal transducer and activator of transcription 1 ) phosphorylation and late-phase IFN signaling ( Ambrose and Mackenzie , 2013 ) .", "labels": [[87, 148, "PROTEIN"], [4, 8, "PROTEIN"], [49, 58, "ENTITY"], [58, 68, "TAXON"], [58, 68, "ENTITY"], [117, 148, "ENTITY"], [58, 68, "ORGANISM"], [4, 8, "ENTITY"], [4, 8, "ENTITY"], [4, 8, "ORGANISM"], [58, 68, "PROTEIN"], [121, 134, "GENE_OR_GENE_PRODUCT"], [33, 38, "ENTITY"], [87, 106, "ENTITY"], [4, 8, "TAXON"], [4, 8, "DISEASE"], [99, 117, "ENTITY"], [121, 134, "ENTITY"]]}
{"text": "For WNV , it has been shown that ATF6 activation promotes efficient WNV replication by suppressing signal transducer and activator of transcription 1 ( signal transducer and activator of transcription 1 ) phosphorylation and late-phase IFN signaling ( Ambrose and Mackenzie , 2013 ) .", "labels": [[87, 148, "PROTEIN"], [4, 8, "PROTEIN"], [49, 58, "ENTITY"], [58, 68, "TAXON"], [58, 68, "ENTITY"], [117, 148, "ENTITY"], [58, 68, "ORGANISM"], [4, 8, "ENTITY"], [4, 8, "ENTITY"], [4, 8, "ORGANISM"], [58, 68, "PROTEIN"], [121, 134, "GENE_OR_GENE_PRODUCT"], [33, 38, "ENTITY"], [87, 106, "ENTITY"], [4, 8, "TAXON"], [4, 8, "DISEASE"], [99, 117, "ENTITY"], [121, 134, "ENTITY"]]}
{"text": "However , if ER stress persists , GADD153 can induce apoptosis by suppressing the anti-apoptotic protein B-cell lymphoma 2 ( Bcl-2 ) and inducing the pro-apoptotic proteins such as Bcl-2-interacting mediator of cell death ( Bim;Puthalakath et al. , 2007 ) . GADD153 also activates ER oxidoreductin-1\u03b1 ( ERO1\u03b1 ) , which encodes an ER oxidase . The increase protein influx to a hyperoxidizing ER aggravates ER stress and induces apoptosis ( Marciniak et al. , 2004;Figure 3 ) .", "labels": [[271, 284, "PROTEIN"], [46, 53, "ENTITY"], [271, 284, "GENE_OR_GENE_PRODUCT"], [319, 330, "ENTITY"], [146, 164, "ENTITY"], [333, 343, "ENTITY"], [364, 376, "ENTITY"], [150, 164, "CHEBI"], [178, 199, "PROTEIN"], [13, 16, "ENTITY"], [319, 330, "GGP"], [319, 330, "GENE_OR_GENE_PRODUCT"], [146, 164, "PROTEIN"], [271, 284, "ENTITY"], [343, 356, "ENTITY"], [439, 458, "GENE_OR_GENE_PRODUCT"], [16, 23, "ENTITY"], [319, 330, "PROTEIN"], [78, 121, "ENTITY"], [78, 121, "PROTEIN"], [107, 112, "DISEASE"], [258, 271, "ENTITY"], [208, 216, "ENTITY"], [178, 199, "ENTITY"], [82, 105, "CHEBI"]]}
{"text": "However , if ER stress persists , GADD153 can induce apoptosis by suppressing the anti-apoptotic protein B-cell lymphoma 2 ( Bcl-2 ) and inducing the pro-apoptotic proteins such as Bcl-2-interacting mediator of cell death ( Bim;Puthalakath et al. , 2007 ) . GADD153 also activates ER oxidoreductin-1\u03b1 ( ERO1\u03b1 ) , which encodes an ER oxidase . The increase protein influx to a hyperoxidizing ER aggravates ER stress and induces apoptosis ( Marciniak et al. , 2004;Figure 3 ) .", "labels": [[271, 284, "PROTEIN"], [178, 199, "PROTEIN"], [46, 53, "ENTITY"], [271, 284, "GENE_OR_GENE_PRODUCT"], [319, 330, "ENTITY"], [146, 164, "ENTITY"], [333, 343, "ENTITY"], [364, 376, "ENTITY"], [150, 164, "CHEBI"], [13, 16, "ENTITY"], [319, 330, "GGP"], [319, 330, "GENE_OR_GENE_PRODUCT"], [146, 164, "PROTEIN"], [271, 284, "ENTITY"], [343, 356, "ENTITY"], [439, 458, "GENE_OR_GENE_PRODUCT"], [16, 23, "ENTITY"], [319, 330, "PROTEIN"], [178, 199, "ENTITY"], [78, 121, "ENTITY"], [78, 121, "PROTEIN"], [107, 112, "DISEASE"], [258, 271, "ENTITY"], [208, 216, "ENTITY"], [82, 105, "CHEBI"]]}
{"text": "Higher \u03b1 - hydroxybutyrate dehydrogenase activity correlated strongly with severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.449 , P3<0.001 , R2 = 0.439 , P4<0.001 ) .", "labels": [[7, 27, "CHEMICAL"], [93, 115, "ENTITY"], [119, 138, "ENTITY"], [75, 82, "ENTITY"], [11, 41, "GGP"], [7, 41, "ENTITY"], [50, 61, "ENTITY"], [93, 115, "DISEASE"], [7, 41, "GENE_OR_GENE_PRODUCT"], [41, 50, "ENTITY"], [0, 7, "ENTITY"], [93, 105, "ORGANISM"]]}
{"text": "Serum circulating immunoglobulin A , immunoglobulin G , and immunoglobulin M did not differ significantly between the two groups , whereas complement 3 and complement 4 concentrations were markedly lower in deceased patients than in recovered patients", "labels": [[0, 35, "PROTEIN"], [189, 198, "ENTITY"], [18, 33, "GENE_OR_GENE_PRODUCT"], [0, 6, "ORGANISM_SUBSTANCE"], [18, 35, "ENTITY"], [207, 216, "ENTITY"], [207, 216, "ORGANISM"], [233, 243, "ENTITY"], [18, 33, "PROTEIN"], [18, 33, "ENTITY"], [6, 18, "ENTITY"], [18, 35, "GENE_OR_GENE_PRODUCT"], [0, 6, "ENTITY"], [233, 243, "ORGANISM"], [56, 75, "GENE_OR_GENE_PRODUCT"], [56, 75, "ENTITY"], [56, 75, "PROTEIN"], [18, 35, "GGP"]]}
{"text": "Serum circulating immunoglobulin A , immunoglobulin G , and immunoglobulin M did not differ significantly between the two groups , whereas complement 3 and complement 4 concentrations were markedly lower in deceased patients than in recovered patients", "labels": [[0, 35, "PROTEIN"], [189, 198, "ENTITY"], [18, 33, "GENE_OR_GENE_PRODUCT"], [0, 6, "ORGANISM_SUBSTANCE"], [18, 35, "ENTITY"], [207, 216, "ENTITY"], [207, 216, "ORGANISM"], [233, 243, "ENTITY"], [18, 33, "PROTEIN"], [18, 33, "ENTITY"], [6, 18, "ENTITY"], [18, 35, "GENE_OR_GENE_PRODUCT"], [0, 6, "ENTITY"], [233, 243, "ORGANISM"], [56, 75, "GENE_OR_GENE_PRODUCT"], [56, 75, "ENTITY"], [56, 75, "PROTEIN"], [18, 35, "GGP"]]}
{"text": "A chest radiographic image showed pneumonia , but other laboratory tests ( except procalcitonin ) were normal", "labels": [[2, 8, "ENTITY"], [34, 44, "ENTITY"], [56, 67, "ENTITY"], [34, 44, "DISEASE"]]}
{"text": "Concentrations of procalcitonin , high sensitivity C-reactive protein , and ferritin , as well as erythrocyte sedimentation rate , were significantly higher in deceased patients than in recovered patients .", "labels": [[186, 196, "ENTITY"], [51, 62, "PROTEIN"], [160, 169, "ENTITY"], [18, 32, "ENTITY"], [0, 15, "ENTITY"], [186, 196, "ORGANISM"], [18, 32, "PROTEIN"], [18, 32, "GGP"], [18, 32, "GENE_OR_GENE_PRODUCT"], [160, 169, "ORGANISM"], [51, 62, "ENTITY"], [51, 62, "GGP"], [34, 39, "ENTITY"]]}
{"text": "The inflammatory biomarkers , including high sensitivity C-reactive protein ( median [ IQR ] , 8.55 [ 4.87- 15.165 ] vs 3.13 [1.24 - 5.75]mg/dL [ to convert to milligrams per liter , multiply by 10 ] ) , procalcitonin ( median [ IQR ] , 0.21 [ 0.11- 0.45 ] vs 0.05 [ 0.04 - 0.11 ] ng/mL ) , and globulin ( median [IQR],29.7 [ 27.0 - 34.6 ] vs 27.4 [ 25.6 - 29.6 ] grams per liter ) were significantly higher in patientswith elevated TnT levels ( P < .001 for all ) .", "labels": [[117, 133, "CHEMICAL"], [4, 17, "ENTITY"], [287, 295, "SIMPLE_CHEMICAL"], [183, 204, "ENTITY"], [387, 401, "PROTEIN"], [287, 306, "CHEMICAL"], [57, 68, "PROTEIN"], [183, 204, "GENE_OR_GENE_PRODUCT"], [40, 45, "ENTITY"], [183, 204, "GGP"], [387, 401, "GENE_OR_GENE_PRODUCT"], [374, 387, "ENTITY"], [57, 68, "ENTITY"], [401, 408, "ENTITY"], [387, 401, "ENTITY"], [149, 160, "ENTITY"], [17, 28, "ENTITY"], [117, 133, "SIMPLE_CHEMICAL"], [287, 295, "ENTITY"], [57, 68, "GGP"]]}
{"text": "The binding of COVI-19 to the Toll Like Receptor ( TLR ) causes the release of pro-IL-1\u03b2 which is cleaved by caspase-1 , followed by inflammasome activation and production of active mature IL-1\u03b2 which is a mediator of lung inflammation , fever and fibrosis .", "labels": [[15, 23, "ENTITY"], [30, 49, "ENTITY"], [215, 223, "DISEASE"], [223, 238, "DISEASE"], [182, 189, "PROTEIN"], [4, 12, "ENTITY"], [182, 189, "ENTITY"], [182, 189, "GENE_OR_GENE_PRODUCT"], [223, 238, "ENTITY"], [15, 23, "DNA"], [182, 189, "GGP"], [30, 49, "GENE_OR_GENE_PRODUCT"], [172, 182, "ENTITY"], [30, 49, "PROTEIN"], [215, 223, "ENTITY"], [15, 23, "GENE_OR_GENE_PRODUCT"], [130, 146, "ENTITY"]]}
{"text": "The binding of COVI-19 to the Toll Like Receptor ( TLR ) causes the release of pro-IL-1\u03b2 which is cleaved by caspase-1 , followed by inflammasome activation and production of active mature IL-1\u03b2 which is a mediator of lung inflammation , fever and fibrosis .", "labels": [[15, 23, "ENTITY"], [223, 238, "ENTITY"], [30, 49, "ENTITY"], [130, 146, "ENTITY"], [215, 223, "DISEASE"], [182, 189, "PROTEIN"], [4, 12, "ENTITY"], [182, 189, "ENTITY"], [182, 189, "GENE_OR_GENE_PRODUCT"], [15, 23, "DNA"], [182, 189, "GGP"], [30, 49, "GENE_OR_GENE_PRODUCT"], [172, 182, "ENTITY"], [30, 49, "PROTEIN"], [223, 238, "DISEASE"], [215, 223, "ENTITY"], [15, 23, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Apart from the XBP1 pathway , activated IRE1 has been shown to recruit TNF receptor-associated factor 2 ( TRAF2 ) and induce apoptosis by activating the JNK ( Urano et al. , 2000 ) . This IRE1-JNK pathway is independent of IRE1 \u2019s RNase activity , but it requires IRE1 \u2019s kinase domain and involves TRAF2-dependent activation of caspase-12 ( Yonedaet al.,2001 ) .", "labels": [[315, 329, "PROTEIN"], [71, 102, "PROTEIN"], [208, 228, "GGP"], [223, 237, "ENTITY"], [15, 28, "ENTITY"], [290, 299, "ENTITY"], [208, 228, "GENE_OR_GENE_PRODUCT"], [208, 223, "ENTITY"], [315, 329, "ENTITY"], [299, 315, "ENTITY"], [255, 272, "GENE_OR_GENE_PRODUCT"], [181, 188, "PROTEIN"], [75, 102, "ENTITY"], [15, 20, "GGP"], [255, 272, "ENTITY"], [15, 20, "GENE_OR_GENE_PRODUCT"], [208, 220, "PROTEIN"], [290, 299, "SIMPLE_CHEMICAL"], [181, 197, "ENTITY"], [255, 272, "GGP"], [40, 45, "PROTEIN"], [71, 102, "GENE_OR_GENE_PRODUCT"], [118, 125, "ENTITY"], [71, 102, "GGP"], [255, 272, "PROTEIN"], [315, 329, "GENE_OR_GENE_PRODUCT"], [15, 20, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "GEX analysis showed that CD8 + T cells expressed high levels of effector molecules , including GZMA , GZMK , FASLG , CCL5 , etc . , and resident T cell markers ITGA1 , CXCR6 , JAML , etc . , likely played crucial roles in immune defense ( Figure S4 ) .", "labels": [[128, 136, "ENTITY"], [25, 33, "CELL_TYPE"], [85, 95, "ENTITY"], [25, 33, "ENTITY"], [102, 109, "PROTEIN"], [109, 117, "GENE_OR_GENE_PRODUCT"], [25, 33, "GGP"], [128, 152, "PROTEIN"], [64, 73, "CHEBI"], [109, 117, "GGP"], [85, 95, "GGP"], [109, 117, "ENTITY"], [85, 95, "PROTEIN"], [205, 222, "ENTITY"], [0, 13, "ENTITY"], [102, 109, "ENTITY"], [205, 229, "CELL"], [25, 29, "GENE_OR_GENE_PRODUCT"], [102, 109, "CHEMICAL"], [109, 117, "PROTEIN"], [64, 73, "PROTEIN"], [102, 109, "GENE_OR_GENE_PRODUCT"], [102, 109, "GGP"], [85, 95, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"], [222, 229, "ENTITY"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [138, 161, "ENTITY"], [138, 161, "PROTEIN"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "GENE_OR_GENE_PRODUCT"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [69, 75, "ENTITY"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [61, 69, "GGP"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [54, 61, "PROTEIN"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [54, 61, "ENTITY"], [248, 271, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [61, 69, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [54, 61, "PROTEIN"], [113, 125, "DNA"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [61, 69, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [61, 69, "GENE_OR_GENE_PRODUCT"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [248, 271, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [54, 61, "ENTITY"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [61, 69, "GGP"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"], [54, 61, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "ENTITY"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [125, 129, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [192, 203, "GENE_OR_GENE_PRODUCT"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [125, 129, "PROTEIN"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "All immune cell types , including dendritic cells , were decreased significantly ( P < 0.01 ) , and CD68 positive macrophages , which were decreased in number , were noticeably ( P < 0.01 ) increased in size and gave the impression of macrophage activation ( Fig. 2 , D and E ) .", "labels": [[4, 22, "ENTITY"], [34, 44, "CL"], [221, 235, "CELL"], [105, 114, "CL"], [221, 246, "ENTITY"], [11, 16, "CL"], [94, 114, "CELL_TYPE"], [212, 221, "ENTITY"], [259, 264, "ENTITY"], [105, 114, "CELL"], [4, 16, "CELL"], [34, 44, "CELL"], [100, 105, "ENTITY"], [34, 44, "CELL_TYPE"], [128, 139, "ENTITY"], [221, 235, "GGP"], [34, 44, "ENTITY"]]}
{"text": "All immune cell types , including dendritic cells , were decreased significantly ( P < 0.01 ) , and CD68 positive macrophages , which were decreased in number , were noticeably ( P < 0.01 ) increased in size and gave the impression of macrophage activation ( Fig. 2 , D and E ) .", "labels": [[4, 22, "ENTITY"], [34, 44, "CL"], [221, 235, "CELL"], [105, 114, "CL"], [11, 16, "CL"], [94, 114, "CELL_TYPE"], [212, 221, "ENTITY"], [259, 264, "ENTITY"], [105, 114, "CELL"], [4, 16, "CELL"], [34, 44, "CELL"], [221, 246, "ENTITY"], [100, 105, "ENTITY"], [34, 44, "CELL_TYPE"], [128, 139, "ENTITY"], [221, 235, "GGP"], [34, 44, "ENTITY"]]}
{"text": "DPP4 plays also an important role in immune regulation by activating T cells and upregulating CD86 expression and NF-\u03baB pathway .", "labels": [[69, 77, "CL"], [99, 110, "ENTITY"], [94, 99, "ENTITY"], [37, 55, "ENTITY"], [58, 77, "ENTITY"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [69, 77, "CELL_TYPE"], [94, 99, "PROTEIN"], [69, 77, "CELL"], [0, 5, "PROTEIN"], [81, 94, "ENTITY"], [0, 5, "ENTITY"], [114, 120, "DNA"], [114, 120, "CHEMICAL"], [114, 120, "GENE_OR_GENE_PRODUCT"], [94, 99, "GENE_OR_GENE_PRODUCT"], [114, 128, "ENTITY"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [138, 161, "GENE_OR_GENE_PRODUCT"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [138, 161, "PROTEIN"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [138, 161, "ENTITY"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "NK cells highly expressed KLRF1 , KLRC1 and KLRD1 . CD8 + T cells expressed CD8A and CD8B .", "labels": [[26, 32, "GGP"], [16, 26, "GENE_OR_GENE_PRODUCT"], [50, 60, "GGP"], [50, 60, "ENTITY"], [26, 32, "PROTEIN"], [16, 26, "PROTEIN"], [26, 32, "ENTITY"], [0, 9, "CELL_TYPE"], [0, 9, "CELL"], [16, 26, "ENTITY"], [0, 9, "CL"], [26, 32, "GENE_OR_GENE_PRODUCT"], [50, 60, "CELL_TYPE"], [16, 26, "ENTITY"], [3, 9, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [138, 161, "GENE_OR_GENE_PRODUCT"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "PROTEIN"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"], [138, 161, "ENTITY"]]}
{"text": "NK cells highly expressed KLRF1 , KLRC1 and KLRD1 . CD8 + T cells expressed CD8A and CD8B .", "labels": [[26, 32, "GGP"], [26, 32, "PROTEIN"], [16, 26, "PROTEIN"], [26, 32, "ENTITY"], [0, 9, "CELL_TYPE"], [50, 60, "GGP"], [50, 60, "ENTITY"], [50, 60, "CELL_TYPE"], [0, 9, "CELL"], [16, 26, "ENTITY"], [0, 9, "CL"], [26, 32, "GENE_OR_GENE_PRODUCT"], [16, 26, "GENE_OR_GENE_PRODUCT"], [16, 26, "ENTITY"], [3, 9, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Usually , Toll-like receptor ( TLR ) 3 , TLR7 , TLR8 , and TLR9 sense viral RNA and DNA in the endosome [ 60 , 61 ] . The viral RNA receptor retinoic-acid inducible gene I ( RIG-I ) [ 62 ] , cytosolic receptor melanoma differentiation-associated gene 5 ( MDA5 ) and nucleotidyl transferase cyclic GMP-AMP synthase ( cGAS ) [ 63 ] are responsible for the recognition of viral RNA and DNA in the cytoplasm .", "labels": [[111, 122, "TAXON"], [41, 48, "ENTITY"], [155, 165, "PROTEIN"], [174, 201, "ENTITY"], [354, 366, "CELLULAR_COMPONENT"], [346, 354, "ENTITY"], [201, 219, "ENTITY"], [354, 366, "ENTITY"], [346, 354, "RNA"], [70, 84, "ENTITY"], [10, 20, "ENTITY"], [88, 95, "CELLULAR_COMPONENT"], [191, 201, "DISEASE"], [64, 70, "TAXON"], [88, 95, "ENTITY"], [10, 35, "PROTEIN"], [111, 141, "PROTEIN"], [246, 297, "PROTEIN"], [76, 80, "ENTITY"], [155, 165, "ENTITY"], [354, 366, "SO"], [64, 70, "ENTITY"], [88, 95, "GO"], [10, 20, "GENE_OR_GENE_PRODUCT"], [41, 48, "GGP"], [41, 48, "PROTEIN"], [174, 219, "PROTEIN"], [346, 354, "TAXON"], [111, 155, "ENTITY"], [41, 48, "GENE_OR_GENE_PRODUCT"], [76, 80, "SO"], [70, 84, "ORGANISM_SUBSTANCE"], [246, 297, "GENE_OR_GENE_PRODUCT"], [10, 20, "GGP"], [155, 165, "GGP"], [262, 297, "GGP"], [246, 297, "ENTITY"], [174, 184, "GO"], [70, 84, "GO"], [59, 64, "ENTITY"], [174, 219, "GENE_OR_GENE_PRODUCT"], [76, 80, "CELLULAR_COMPONENT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [249, 291, "PROTEIN"], [119, 133, "ENTITY"], [249, 291, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [164, 171, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [33, 41, "CHEMICAL"], [362, 377, "GENE_OR_GENE_PRODUCT"], [164, 171, "PROTEIN"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [102, 108, "PROTEIN"], [164, 171, "GGP"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [133, 164, "GENE_OR_GENE_PRODUCT"], [133, 164, "PROTEIN"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [33, 41, "ENTITY"], [299, 330, "GGP"], [377, 389, "PROTEIN"], [164, 171, "ENTITY"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [249, 291, "PROTEIN"], [119, 133, "ENTITY"], [249, 291, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [164, 171, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [362, 377, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [33, 41, "CHEMICAL"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [164, 171, "GGP"], [102, 108, "PROTEIN"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [164, 171, "ENTITY"], [133, 164, "PROTEIN"], [133, 164, "GENE_OR_GENE_PRODUCT"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [33, 41, "ENTITY"], [299, 330, "GGP"], [164, 171, "PROTEIN"], [377, 389, "PROTEIN"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Most patients presented with an elevated myocardial indices : 194 of 198 ( 98.0 % ) had elevated lactate dehydrogenase (LDH),and 9 of 198 ( 4.5 % ) had an elevated creatinekinase muscle-brain isoform .", "labels": [[41, 52, "MULTI-TISSUE_STRUCTURE"], [88, 105, "PROTEIN"], [155, 192, "PROTEIN"], [41, 60, "ENTITY"], [155, 179, "GENE_OR_GENE_PRODUCT"], [5, 14, "ENTITY"], [179, 192, "SO"], [5, 14, "ORGANISM"], [88, 105, "GENE_OR_GENE_PRODUCT"], [148, 155, "ENTITY"], [88, 105, "GGP"], [32, 41, "CHEMICAL"], [179, 192, "ENTITY"], [88, 105, "ENTITY"], [32, 41, "ENTITY"]]}
{"text": "Laboratory tests showed leukocytosis , lymphocytopenia , and an elevated creatine kinase \u2013 MB fraction .", "labels": [[0, 17, "ENTITY"], [91, 94, "ENTITY"], [24, 37, "ENTITY"], [24, 37, "DISEASE"], [64, 89, "GENE_OR_GENE_PRODUCT"], [64, 73, "CHEBI"], [82, 89, "ENTITY"], [64, 73, "CHEMICAL"], [64, 82, "ENTITY"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Higher creatine kinase activity correlated strongly with severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.231 , P3 = 0.019 , R2 = 0.289 , P4 = 0.003 ) .", "labels": [[7, 16, "CHEBI"], [7, 23, "PROTEIN"], [32, 43, "ENTITY"], [75, 97, "DISEASE"], [7, 32, "ENTITY"], [101, 120, "ENTITY"], [7, 16, "CHEMICAL"], [7, 16, "SIMPLE_CHEMICAL"], [75, 87, "ORGANISM"], [0, 7, "ENTITY"], [75, 97, "ENTITY"], [57, 64, "ENTITY"]]}
{"text": "Most patients presented with an elevated myocardial indices : 194 of 198 ( 98.0 % ) had elevated lactate dehydrogenase (LDH),and 9 of 198 ( 4.5 % ) had an elevated creatinekinase muscle-brain isoform .", "labels": [[41, 52, "MULTI-TISSUE_STRUCTURE"], [88, 105, "PROTEIN"], [155, 192, "PROTEIN"], [41, 60, "ENTITY"], [155, 179, "GENE_OR_GENE_PRODUCT"], [5, 14, "ENTITY"], [179, 192, "SO"], [5, 14, "ORGANISM"], [88, 105, "GENE_OR_GENE_PRODUCT"], [148, 155, "ENTITY"], [88, 105, "GGP"], [32, 41, "CHEMICAL"], [179, 192, "ENTITY"], [88, 105, "ENTITY"], [32, 41, "ENTITY"]]}
{"text": "Laboratory tests showed leukocytosis , lymphocytopenia , and an elevated creatine kinase \u2013 MB fraction .", "labels": [[0, 17, "ENTITY"], [91, 94, "ENTITY"], [24, 37, "ENTITY"], [24, 37, "DISEASE"], [64, 89, "GENE_OR_GENE_PRODUCT"], [64, 73, "CHEBI"], [82, 89, "ENTITY"], [64, 73, "CHEMICAL"], [64, 82, "ENTITY"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "This may explain the clinical manifestation of CK elevation among 13 % of COVID-19 patients . 2", "labels": [[47, 50, "ENTITY"], [47, 50, "GENE_OR_GENE_PRODUCT"], [21, 44, "ENTITY"], [50, 60, "ENTITY"], [74, 83, "GENE_OR_GENE_PRODUCT"], [47, 50, "PROTEIN"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer .", "labels": [[126, 138, "PROTEIN"], [34, 41, "ENTITY"], [126, 138, "GENE_OR_GENE_PRODUCT"], [12, 21, "ENTITY"], [101, 109, "PROTEIN"], [155, 166, "ENTITY"], [44, 63, "PROTEIN"], [25, 34, "ENTITY"], [155, 166, "PROTEIN"], [44, 63, "GGP"], [12, 21, "ORGANISM"], [101, 109, "GENE_OR_GENE_PRODUCT"], [126, 138, "ENTITY"], [101, 109, "GGP"], [44, 55, "GENE_OR_GENE_PRODUCT"], [126, 138, "CHEBI"], [101, 109, "ENTITY"], [44, 63, "ENTITY"]]}
{"text": "Those with elevated TnT levels had significantly higher levels of other biomarkers of cardiac injury , specifically creatine kinase\u2013 myocardial band test ( median [ IQR ] , 3.34 [ 2.11 - 5.80 ] vs 0.81 [ 0.54 - 1.38 ] , ng/mL [ to convert to micrograms per liter , multiply by 1 ] ) and myoglobin ( median [ IQR ] , 128.7 [ 65.8 - 206.9 ] vs 27.2 [ 21.0 - 49.8 ] \u03bcg/L [ to convert to nanomoles per liter , multiply by 0.05814 ] ) ( P < .001 , for all ) and also had higher levels of N-terminal pro \u2013 brain natriuretic peptide ( N-terminal pro\u2013brain natriuretic peptide ) ( median [ IQR ] , 817.4 ( 336.0 - 1944.0 ] vs 141.4 [ 39.3 - 303.6 ] pg/mL [ to convert to nanograms per liter , multiply by 1 ] ) .", "labels": [[462, 483, "ENTITY"], [11, 20, "ENTITY"], [24, 31, "ENTITY"], [20, 24, "ENTITY"], [156, 171, "ENTITY"], [20, 24, "PROTEIN"], [116, 125, "ENTITY"], [265, 279, "GGP"], [86, 101, "DISEASE"], [116, 125, "SIMPLE_CHEMICAL"], [20, 24, "GENE_OR_GENE_PRODUCT"], [265, 279, "GENE_OR_GENE_PRODUCT"], [430, 436, "ENTITY"], [72, 83, "ENTITY"], [86, 101, "ENTITY"], [281, 287, "ENTITY"], [86, 94, "ORGAN"], [447, 500, "PROTEIN"], [24, 31, "ENTITY"], [447, 457, "ENTITY"], [265, 279, "ENTITY"], [483, 498, "GGP"], [133, 149, "ENTITY"], [483, 498, "ENTITY"], [265, 279, "PROTEIN"], [500, 506, "ENTITY"]]}
{"text": "Of 194 patients,166(85.6%)demonstrated increased high sensitivity C- reactive protein .", "labels": [[7, 39, "DISEASE"], [66, 86, "ENTITY"], [49, 66, "ENTITY"], [39, 49, "ENTITY"], [78, 86, "CHEBI"], [7, 39, "ENTITY"]]}
{"text": "Most values of C-reactive protein ( CRP , normal range : 0\u201310 mg/L ) were above the upper bound of normal range , and over half of the fibrinogen levels ( FIB , normal range : 1.8\u20133.5 g/L ) were high during the observed period ( Figure 3 ) .", "labels": [[155, 161, "ENTITY"], [200, 211, "ENTITY"], [15, 34, "PROTEIN"], [146, 153, "ENTITY"], [15, 34, "GGP"], [220, 227, "ENTITY"], [146, 153, "SIMPLE_CHEMICAL"], [40, 49, "ENTITY"], [5, 12, "ENTITY"], [96, 106, "ENTITY"], [15, 34, "ENTITY"], [131, 146, "ENTITY"], [146, 153, "DNA"]]}
{"text": "In terms of inflammation indicators , patients on admission showed increase in lactate dehydrogenase ( 25 [ 41 % ] of 61 patients ) , c reactive protein ( 42 [ 67 % ] of 63 patients ) , and erythrocyte sedimentation rate ( 30 [ 52 % ] of 58 patients ) , but not procalcitonin .", "labels": [[132, 147, "ENTITY"], [81, 103, "GGP"], [81, 89, "CHEMICAL"], [243, 260, "GENE_OR_GENE_PRODUCT"], [25, 36, "ENTITY"], [12, 25, "DISEASE"], [81, 103, "PROTEIN"], [81, 103, "ENTITY"], [123, 147, "PROTEIN"], [12, 25, "ENTITY"], [243, 260, "ENTITY"], [123, 147, "GENE_OR_GENE_PRODUCT"], [175, 192, "CL"], [69, 78, "ENTITY"], [113, 120, "ORGANISM"], [175, 204, "ENTITY"], [52, 62, "ENTITY"], [113, 120, "ENTITY"], [138, 147, "CHEBI"], [243, 260, "PROTEIN"], [175, 192, "CELL"], [81, 103, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Increased C-reactive protein , procalcitonin and lactate dehydrogenase were found in five patients ( 5/8 ) , and increased alanine aminotransferase ( ALT ) in four ( 4/8 ) .", "labels": [[113, 123, "CHEBI"], [49, 57, "GENE_OR_GENE_PRODUCT"], [49, 57, "PROTEIN"], [49, 57, "GGP"], [10, 21, "GENE_OR_GENE_PRODUCT"], [10, 29, "PROTEIN"], [49, 57, "ENTITY"], [10, 29, "ENTITY"], [0, 10, "ENTITY"], [113, 123, "CHEMICAL"], [113, 131, "GENE_OR_GENE_PRODUCT"], [131, 148, "ENTITY"], [113, 131, "ENTITY"], [131, 148, "PROTEIN"], [131, 148, "GENE_OR_GENE_PRODUCT"], [10, 29, "GGP"], [113, 131, "PROTEIN"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [236, 242, "ENTITY"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [300, 315, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "Concentrations of procalcitonin , high sensitivity C-reactive protein , and ferritin , as well as erythrocyte sedimentation rate , were significantly higher in deceased patients than in recovered patients .", "labels": [[186, 196, "ENTITY"], [51, 62, "PROTEIN"], [160, 169, "ENTITY"], [18, 32, "ENTITY"], [0, 15, "ENTITY"], [186, 196, "ORGANISM"], [18, 32, "PROTEIN"], [18, 32, "GGP"], [18, 32, "GENE_OR_GENE_PRODUCT"], [160, 169, "ORGANISM"], [51, 62, "ENTITY"], [51, 62, "GGP"], [34, 39, "ENTITY"]]}
{"text": "Levels of lactate dehydrogenase ( LDH ) , concentrations of serum high-sensitivity C-reactive protein ( hsCRP ) , ferritin and D-dimer levels were markedly higher in severe cases than moderate cases .", "labels": [[10, 18, "CHEMICAL"], [129, 137, "ENTITY"], [59, 96, "PROTEIN"], [149, 158, "ENTITY"], [0, 7, "ENTITY"], [10, 32, "GGP"], [10, 32, "PROTEIN"], [158, 168, "ENTITY"], [62, 96, "ENTITY"], [10, 32, "ENTITY"], [68, 96, "GGP"], [168, 175, "ENTITY"], [10, 32, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"]]}
{"text": "Consistent with others , most of severe COVID-19 patients in our ICU ward had persistent very high level of erythematosus sedimentation rate ( ESR ) , CRP , and high level of IL-6,TNFa , IL-1B , IL-8 , IL2R , etc , and were associated with ARDS , hypercoagulation and disseminated intravascular coagulation ( DIC ) , manifested as thrombosis , thrombocytopenia , gangrene of extremities .", "labels": [[0, 16, "ENTITY"], [175, 187, "GENE_OR_GENE_PRODUCT"], [328, 344, "ENTITY"], [175, 187, "ENTITY"], [175, 187, "DNA"], [328, 344, "DISEASE"], [99, 108, "GGP"], [65, 69, "ENTITY"], [235, 247, "DISEASE"], [108, 136, "ENTITY"], [344, 363, "ENTITY"], [235, 247, "ENTITY"], [187, 193, "ENTITY"], [99, 108, "DNA"], [187, 193, "GENE_OR_GENE_PRODUCT"], [268, 281, "IMMATERIAL_ANATOMICAL_ENTITY"], [268, 295, "DISEASE"], [99, 108, "ENTITY"], [344, 363, "ORGAN"], [175, 187, "GGP"], [317, 328, "DISEASE"], [94, 99, "ENTITY"], [187, 193, "PROTEIN"], [247, 295, "ENTITY"], [40, 49, "GENE_OR_GENE_PRODUCT"], [215, 224, "ENTITY"], [187, 193, "GGP"], [99, 108, "GENE_OR_GENE_PRODUCT"], [317, 328, "ENTITY"]]}
{"text": "Analysis of the global proteomic changes reveal significant upregulation of CXCR2 , PRG3 , LBP , MMP25 , CRP , NLRP1 in the COVID-19-MS PBMC cohort ( Fig.3c ) .", "labels": [[76, 82, "GENE_OR_GENE_PRODUCT"], [23, 33, "ENTITY"], [97, 105, "GENE_OR_GENE_PRODUCT"], [105, 111, "GENE_OR_GENE_PRODUCT"], [105, 111, "GGP"], [76, 82, "PROTEIN"], [105, 111, "ENTITY"], [141, 150, "SIMPLE_CHEMICAL"], [124, 136, "ENTITY"], [16, 23, "ENTITY"], [97, 105, "PROTEIN"], [89, 97, "GENE_OR_GENE_PRODUCT"], [97, 105, "GGP"], [60, 73, "ENTITY"], [76, 82, "GGP"], [105, 111, "PROTEIN"], [97, 105, "ENTITY"], [136, 141, "ENTITY"], [76, 82, "ENTITY"], [0, 9, "ENTITY"], [120, 136, "CELL"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [40, 59, "ENTITY"], [26, 38, "SIMPLE_CHEMICAL"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GGP"], [253, 271, "ENTITY"], [26, 40, "CHEBI"], [170, 179, "GGP"], [26, 38, "CHEMICAL"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [144, 154, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [26, 38, "ENTITY"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "In terms of inflammation indicators , patients on admission showed increase in lactate dehydrogenase ( 25 [ 41 % ] of 61 patients ) , c reactive protein ( 42 [ 67 % ] of 63 patients ) , and erythrocyte sedimentation rate ( 30 [ 52 % ] of 58 patients ) , but not procalcitonin .", "labels": [[132, 147, "ENTITY"], [81, 103, "GGP"], [81, 89, "CHEMICAL"], [243, 260, "GENE_OR_GENE_PRODUCT"], [25, 36, "ENTITY"], [81, 103, "PROTEIN"], [81, 103, "ENTITY"], [123, 147, "PROTEIN"], [243, 260, "ENTITY"], [123, 147, "GENE_OR_GENE_PRODUCT"], [175, 192, "CL"], [69, 78, "ENTITY"], [12, 25, "ENTITY"], [113, 120, "ORGANISM"], [175, 204, "ENTITY"], [52, 62, "ENTITY"], [113, 120, "ENTITY"], [138, 147, "CHEBI"], [243, 260, "PROTEIN"], [12, 25, "DISEASE"], [175, 192, "CELL"], [81, 103, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The inflammatory biomarkers , including high sensitivity C-reactive protein ( median [ IQR ] , 8.55 [ 4.87- 15.165 ] vs 3.13 [1.24 - 5.75]mg/dL [ to convert to milligrams per liter , multiply by 10 ] ) , procalcitonin ( median [ IQR ] , 0.21 [ 0.11- 0.45 ] vs 0.05 [ 0.04 - 0.11 ] ng/mL ) , and globulin ( median [IQR],29.7 [ 27.0 - 34.6 ] vs 27.4 [ 25.6 - 29.6 ] grams per liter ) were significantly higher in patientswith elevated TnT levels ( P < .001 for all ) .", "labels": [[117, 133, "CHEMICAL"], [4, 17, "ENTITY"], [287, 295, "SIMPLE_CHEMICAL"], [183, 204, "ENTITY"], [387, 401, "PROTEIN"], [287, 306, "CHEMICAL"], [57, 68, "PROTEIN"], [183, 204, "GENE_OR_GENE_PRODUCT"], [40, 45, "ENTITY"], [183, 204, "GGP"], [387, 401, "GENE_OR_GENE_PRODUCT"], [374, 387, "ENTITY"], [57, 68, "ENTITY"], [401, 408, "ENTITY"], [387, 401, "ENTITY"], [149, 160, "ENTITY"], [17, 28, "ENTITY"], [117, 133, "SIMPLE_CHEMICAL"], [287, 295, "ENTITY"], [57, 68, "GGP"]]}
{"text": "Studies have shown that IL-6 levels significantly correlated with the severity of COVID-19 , C-reactive protein ( CRP ) , lactate dehydrogenase ( LDH ) , and D-dimer levels and T cell counts , and it has been suggested that Tocilizumab , with its inhibitory effect on IL-6 , may be effective in treatment of COVID-19 ( 10 , 11 ) .", "labels": [[152, 158, "GGP"], [295, 305, "GENE_OR_GENE_PRODUCT"], [238, 247, "ENTITY"], [82, 91, "ENTITY"], [24, 29, "GGP"], [152, 166, "ENTITY"], [118, 130, "GGP"], [70, 79, "ENTITY"], [152, 158, "PROTEIN"], [93, 104, "GGP"], [118, 130, "PROTEIN"], [166, 177, "ENTITY"], [130, 144, "GENE_OR_GENE_PRODUCT"], [50, 61, "ENTITY"], [24, 29, "GENE_OR_GENE_PRODUCT"], [282, 295, "ENTITY"], [130, 144, "PROTEIN"], [24, 29, "ENTITY"], [82, 91, "PROTEIN"], [295, 305, "ENTITY"], [177, 184, "ENTITY"], [152, 158, "GENE_OR_GENE_PRODUCT"], [0, 8, "ENTITY"], [130, 144, "ENTITY"], [118, 130, "ENTITY"], [118, 130, "GENE_OR_GENE_PRODUCT"], [166, 177, "CL"], [24, 29, "PROTEIN"], [166, 177, "CELL"], [273, 282, "ENTITY"], [93, 104, "ENTITY"], [209, 224, "ENTITY"], [209, 224, "SIMPLE_CHEMICAL"], [82, 91, "GENE_OR_GENE_PRODUCT"], [93, 104, "PROTEIN"], [29, 36, "ENTITY"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [284, 303, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [284, 303, "PROTEIN"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [235, 272, "ENTITY"], [141, 160, "PROTEIN"], [235, 272, "GENE_OR_GENE_PRODUCT"], [214, 226, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [235, 253, "CHEMICAL"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [235, 272, "GGP"], [284, 303, "GENE_OR_GENE_PRODUCT"], [167, 174, "GENE_OR_GENE_PRODUCT"], [235, 272, "PROTEIN"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [175, 180, "GENE_OR_GENE_PRODUCT"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "GGP"], [211, 219, "GGP"], [384, 388, "GENE_OR_GENE_PRODUCT"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [175, 180, "CHEMICAL"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [254, 262, "ENTITY"], [143, 149, "ENTITY"], [175, 180, "ENTITY"], [155, 162, "PROTEIN"], [143, 149, "GENE_OR_GENE_PRODUCT"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [175, 180, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [277, 292, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [292, 317, "GGP"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [235, 272, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [235, 253, "CHEMICAL"], [167, 176, "ENTITY"], [284, 303, "GENE_OR_GENE_PRODUCT"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [235, 272, "GGP"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "PROTEIN"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [284, 303, "ENTITY"], [235, 272, "GENE_OR_GENE_PRODUCT"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Because functional blockade of PD-1 , CTLA-4 , and TIGIT is beneficial for CD8 + T cells to maintain lasting antigen-specific immunity and antiviral effects,10,11 the excessive exhaustion of CD8 + T cells in severe patients may reduce their cellular immune response to SARS- CoV-2 .", "labels": [[188, 199, "GGP"], [208, 215, "ORGANISM"], [266, 275, "PROTEIN"], [71, 83, "CELL_TYPE"], [266, 275, "ENTITY"], [31, 36, "ENTITY"], [135, 149, "ENTITY"], [235, 257, "ENTITY"], [71, 83, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [101, 126, "ENTITY"], [19, 28, "ENTITY"], [188, 199, "ENTITY"], [188, 199, "CELL_TYPE"], [266, 275, "ORGANISM"], [71, 83, "GGP"], [8, 19, "ENTITY"], [208, 215, "ENTITY"], [31, 36, "PROTEIN"], [167, 177, "ENTITY"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Previous study done by this group has shown that infection of IBV induced the production of IL-6 and IL-8 , which was dependent on the phosphorylation of MAP kinase p38 ( Liao et al.,2011 ) .", "labels": [[92, 97, "PROTEIN"], [101, 106, "ENTITY"], [78, 89, "ENTITY"], [28, 34, "ENTITY"], [62, 66, "PROTEIN"], [101, 106, "PROTEIN"], [101, 106, "GGP"], [49, 59, "DISEASE"], [92, 97, "GENE_OR_GENE_PRODUCT"], [101, 106, "GENE_OR_GENE_PRODUCT"], [154, 165, "GGP"], [49, 59, "ENTITY"], [92, 97, "GGP"], [92, 97, "ENTITY"], [62, 66, "ENTITY"], [62, 66, "ORGANISM"], [154, 165, "PROTEIN"], [9, 15, "ENTITY"], [66, 74, "ENTITY"], [154, 165, "ENTITY"], [62, 66, "CHEMICAL"], [154, 165, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Of patients with available data , concentrations of interleukin 2 receptor , interleukin 6 , interleukin 8 , interleukin 10 , and tumour necrosis factor \u03b1 were significantly higher in deceased patients than in recovered patients .", "labels": [[126, 146, "PROTEIN"], [75, 89, "GENE_OR_GENE_PRODUCT"], [3, 12, "ENTITY"], [52, 66, "PROTEIN"], [75, 89, "PROTEIN"], [184, 193, "ORGANISM"], [75, 89, "ENTITY"], [27, 32, "ENTITY"], [52, 66, "GGP"], [52, 66, "GENE_OR_GENE_PRODUCT"], [75, 89, "GGP"], [202, 210, "ENTITY"], [52, 66, "ENTITY"], [126, 146, "ENTITY"], [184, 193, "ENTITY"], [126, 146, "GENE_OR_GENE_PRODUCT"], [210, 220, "ENTITY"], [210, 220, "ORGANISM"], [174, 184, "ENTITY"], [126, 146, "GGP"], [126, 137, "DISEASE"], [3, 12, "ORGANISM"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "GENE_OR_GENE_PRODUCT"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [127, 132, "CHEMICAL"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "GGP"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [127, 132, "PROTEIN"], [120, 125, "ENTITY"], [127, 132, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "The expression of IL-6 , IL-8 and IL-10 in the serum of patients with COVID-19 increased significantly compared with the control group ( P<0.05 ) .", "labels": [[18, 23, "GGP"], [4, 15, "ENTITY"], [121, 129, "ENTITY"], [18, 23, "GENE_OR_GENE_PRODUCT"], [18, 23, "PROTEIN"], [18, 23, "ENTITY"]]}
{"text": "Chemical signals such as Interleukin-8 ( IL-8 ) and IL-6 stimulate neutrophil chemotaxis and recruitment to the site of infection where they congregate and cause the release of more proinflammatory mediators that in turn activate additional inflammatory signals , leading to cytokine storms that may progress to vital organ failure 13 .", "labels": [[57, 78, "ENTITY"], [25, 39, "ENTITY"], [57, 67, "CELL"], [177, 198, "ENTITY"], [312, 318, "ORGAN"], [25, 39, "GENE_OR_GENE_PRODUCT"], [230, 254, "ENTITY"], [216, 221, "ENTITY"], [0, 9, "CHEBI"], [0, 17, "ENTITY"], [312, 324, "ENTITY"], [57, 67, "CL"], [312, 324, "DISEASE"], [272, 284, "ENTITY"], [25, 39, "PROTEIN"], [177, 198, "PROTEIN"], [57, 67, "CELL_TYPE"]]}
{"text": "The elevation of IL-8 and IL-6 but not IL-17 in PMBCs collected from COVID-19 patients indicates possible roles for IL-8/IL-6 in the severe inflammatory response induced by SARS-CoV-2 ( Fig.3d-e and Extended Data Fig.5e ) .", "labels": [[162, 170, "ENTITY"], [26, 31, "GENE_OR_GENE_PRODUCT"], [17, 22, "GGP"], [39, 45, "GENE_OR_GENE_PRODUCT"], [17, 22, "PROTEIN"], [133, 140, "ENTITY"], [116, 126, "ENTITY"], [173, 184, "GGP"], [39, 45, "ENTITY"], [116, 126, "GENE_OR_GENE_PRODUCT"], [26, 31, "ENTITY"], [26, 31, "PROTEIN"], [116, 126, "GGP"], [116, 126, "PROTEIN"], [26, 31, "GGP"], [4, 14, "ENTITY"], [48, 54, "CELL"], [69, 78, "ENTITY"], [39, 45, "PROTEIN"], [173, 184, "ENTITY"], [140, 162, "ENTITY"], [69, 87, "ORGANISM"], [78, 87, "ENTITY"], [48, 54, "CELL_TYPE"], [48, 54, "ENTITY"], [17, 22, "GENE_OR_GENE_PRODUCT"], [17, 22, "ENTITY"], [173, 184, "CHEMICAL"], [199, 213, "ENTITY"], [39, 45, "GGP"]]}
{"text": "Pearson correlation analysis results showed a remarkably positive correlation of MP production and the expression of IL-6 , IL-8 and IL-10 with the severity of COVID-19 ( Table 4 ) .", "labels": [[81, 84, "ENTITY"], [81, 84, "GENE_OR_GENE_PRODUCT"], [0, 29, "ENTITY"], [57, 66, "ENTITY"], [117, 122, "PROTEIN"], [117, 122, "GGP"], [8, 20, "ENTITY"], [117, 122, "ENTITY"], [29, 37, "ENTITY"], [117, 122, "GENE_OR_GENE_PRODUCT"], [103, 114, "ENTITY"], [84, 95, "ENTITY"], [81, 84, "DISEASE"]]}
{"text": "Chemical signals such as Interleukin-8 ( IL-8 ) and IL-6 stimulate neutrophil chemotaxis and recruitment to the site of infection where they congregate and cause the release of more proinflammatory mediators that in turn activate additional inflammatory signals , leading to cytokine storms that may progress to vital organ failure 13 .", "labels": [[57, 78, "ENTITY"], [25, 39, "ENTITY"], [57, 67, "CELL"], [177, 198, "ENTITY"], [312, 318, "ORGAN"], [25, 39, "GENE_OR_GENE_PRODUCT"], [230, 254, "ENTITY"], [216, 221, "ENTITY"], [0, 9, "CHEBI"], [0, 17, "ENTITY"], [312, 324, "ENTITY"], [57, 67, "CL"], [312, 324, "DISEASE"], [272, 284, "ENTITY"], [25, 39, "PROTEIN"], [177, 198, "PROTEIN"], [57, 67, "CELL_TYPE"]]}
{"text": "Analysis of the global proteomic changes reveal significant upregulation of CXCR2 , PRG3 , LBP , MMP25 , CRP , NLRP1 in the COVID-19-MS PBMC cohort ( Fig.3c ) .", "labels": [[23, 33, "ENTITY"], [97, 105, "GENE_OR_GENE_PRODUCT"], [105, 111, "GENE_OR_GENE_PRODUCT"], [76, 82, "PROTEIN"], [105, 111, "ENTITY"], [76, 82, "ENTITY"], [141, 150, "SIMPLE_CHEMICAL"], [76, 82, "GGP"], [124, 136, "ENTITY"], [16, 23, "ENTITY"], [97, 105, "PROTEIN"], [89, 97, "GENE_OR_GENE_PRODUCT"], [97, 105, "GGP"], [105, 111, "GGP"], [105, 111, "PROTEIN"], [60, 73, "ENTITY"], [76, 82, "GENE_OR_GENE_PRODUCT"], [97, 105, "ENTITY"], [136, 141, "ENTITY"], [0, 9, "ENTITY"], [120, 136, "CELL"]]}
{"text": "GEX analysis showed that CD8 + T cells expressed high levels of effector molecules , including GZMA , GZMK , FASLG , CCL5 , etc . , and resident T cell markers ITGA1 , CXCR6 , JAML , etc . , likely played crucial roles in immune defense ( Figure S4 ) .", "labels": [[128, 136, "ENTITY"], [25, 33, "CELL_TYPE"], [85, 95, "ENTITY"], [25, 33, "ENTITY"], [102, 109, "PROTEIN"], [109, 117, "GENE_OR_GENE_PRODUCT"], [25, 33, "GGP"], [128, 152, "PROTEIN"], [64, 73, "CHEBI"], [109, 117, "GGP"], [85, 95, "GGP"], [109, 117, "ENTITY"], [85, 95, "PROTEIN"], [205, 222, "ENTITY"], [0, 13, "ENTITY"], [102, 109, "ENTITY"], [205, 229, "CELL"], [25, 29, "GENE_OR_GENE_PRODUCT"], [102, 109, "CHEMICAL"], [109, 117, "PROTEIN"], [64, 73, "PROTEIN"], [102, 109, "GENE_OR_GENE_PRODUCT"], [102, 109, "GGP"], [85, 95, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"], [222, 229, "ENTITY"]]}
{"text": "One of ATF4 \u2019s target genes is the growth arrest and DNA damage-inducible protein 153 ( GADD153 , also knownas C/EBP homologous protein , or CHOP ) . GADD153 induces the growth arrest and DNA damage-inducible protein 34 ( growth arrest and DNA damage-inducible protein 34 ) , which recruits protein phosphatase 1 ( PP1 ) to dephosphorylate eIF2\u03b1 and release the translation block .", "labels": [[74, 82, "ENTITY"], [53, 82, "ENTITY"], [239, 248, "GENE_OR_GENE_PRODUCT"], [256, 281, "ENTITY"], [53, 82, "GENE_OR_GENE_PRODUCT"], [42, 49, "SO"], [35, 42, "ENTITY"], [141, 150, "ENTITY"], [57, 74, "CHEBI"], [141, 150, "GGP"], [88, 96, "ENTITY"], [141, 150, "GENE_OR_GENE_PRODUCT"], [7, 12, "GGP"], [209, 222, "GGP"], [53, 74, "GGP"], [42, 74, "GENE_OR_GENE_PRODUCT"], [209, 222, "ENTITY"], [42, 74, "ENTITY"], [53, 74, "GENE_OR_GENE_PRODUCT"], [53, 74, "PROTEIN"], [209, 222, "PROTEIN"], [209, 222, "GENE_OR_GENE_PRODUCT"], [98, 128, "ENTITY"], [7, 22, "DNA"], [141, 150, "PROTEIN"], [103, 128, "PROTEIN"], [239, 248, "PROTEIN"], [53, 74, "ENTITY"], [226, 239, "ENTITY"], [103, 111, "GENE_OR_GENE_PRODUCT"], [7, 12, "ENTITY"], [117, 128, "CHEBI"], [7, 12, "GENE_OR_GENE_PRODUCT"], [158, 177, "ENTITY"]]}
{"text": "However , if ER stress persists , GADD153 can induce apoptosis by suppressing the anti-apoptotic protein B-cell lymphoma 2 ( Bcl-2 ) and inducing the pro-apoptotic proteins such as Bcl-2-interacting mediator of cell death ( Bim;Puthalakath et al. , 2007 ) . GADD153 also activates ER oxidoreductin-1\u03b1 ( ERO1\u03b1 ) , which encodes an ER oxidase . The increase protein influx to a hyperoxidizing ER aggravates ER stress and induces apoptosis ( Marciniak et al. , 2004;Figure 3 ) .", "labels": [[271, 284, "PROTEIN"], [46, 53, "ENTITY"], [271, 284, "GENE_OR_GENE_PRODUCT"], [78, 121, "PROTEIN"], [319, 330, "ENTITY"], [146, 164, "ENTITY"], [333, 343, "ENTITY"], [364, 376, "ENTITY"], [82, 105, "CHEBI"], [150, 164, "CHEBI"], [178, 199, "PROTEIN"], [13, 16, "ENTITY"], [319, 330, "GGP"], [319, 330, "GENE_OR_GENE_PRODUCT"], [146, 164, "PROTEIN"], [78, 121, "ENTITY"], [271, 284, "ENTITY"], [343, 356, "ENTITY"], [439, 458, "GENE_OR_GENE_PRODUCT"], [16, 23, "ENTITY"], [319, 330, "PROTEIN"], [107, 112, "DISEASE"], [258, 271, "ENTITY"], [208, 216, "ENTITY"], [178, 199, "ENTITY"]]}
{"text": "However , if ER stress persists , GADD153 can induce apoptosis by suppressing the anti-apoptotic protein B-cell lymphoma 2 ( Bcl-2 ) and inducing the pro-apoptotic proteins such as Bcl-2-interacting mediator of cell death ( Bim;Puthalakath et al. , 2007 ) . GADD153 also activates ER oxidoreductin-1\u03b1 ( ERO1\u03b1 ) , which encodes an ER oxidase . The increase protein influx to a hyperoxidizing ER aggravates ER stress and induces apoptosis ( Marciniak et al. , 2004;Figure 3 ) .", "labels": [[271, 284, "PROTEIN"], [178, 199, "PROTEIN"], [46, 53, "ENTITY"], [271, 284, "GENE_OR_GENE_PRODUCT"], [78, 121, "PROTEIN"], [319, 330, "ENTITY"], [146, 164, "ENTITY"], [333, 343, "ENTITY"], [364, 376, "ENTITY"], [82, 105, "CHEBI"], [150, 164, "CHEBI"], [13, 16, "ENTITY"], [319, 330, "GGP"], [319, 330, "GENE_OR_GENE_PRODUCT"], [146, 164, "PROTEIN"], [78, 121, "ENTITY"], [271, 284, "ENTITY"], [343, 356, "ENTITY"], [439, 458, "GENE_OR_GENE_PRODUCT"], [16, 23, "ENTITY"], [319, 330, "PROTEIN"], [178, 199, "ENTITY"], [107, 112, "DISEASE"], [258, 271, "ENTITY"], [208, 216, "ENTITY"]]}
{"text": "However , if ER stress persists , GADD153 can induce apoptosis by suppressing the anti-apoptotic protein B-cell lymphoma 2 ( Bcl-2 ) and inducing the pro-apoptotic proteins such as Bcl-2-interacting mediator of cell death ( Bim;Puthalakath et al. , 2007 ) . GADD153 also activates ER oxidoreductin-1\u03b1 ( ERO1\u03b1 ) , which encodes an ER oxidase . The increase protein influx to a hyperoxidizing ER aggravates ER stress and induces apoptosis ( Marciniak et al. , 2004;Figure 3 ) .", "labels": [[271, 284, "PROTEIN"], [178, 199, "PROTEIN"], [46, 53, "ENTITY"], [271, 284, "GENE_OR_GENE_PRODUCT"], [319, 330, "ENTITY"], [146, 164, "ENTITY"], [333, 343, "ENTITY"], [364, 376, "ENTITY"], [150, 164, "CHEBI"], [13, 16, "ENTITY"], [319, 330, "GGP"], [319, 330, "GENE_OR_GENE_PRODUCT"], [146, 164, "PROTEIN"], [271, 284, "ENTITY"], [343, 356, "ENTITY"], [439, 458, "GENE_OR_GENE_PRODUCT"], [16, 23, "ENTITY"], [319, 330, "PROTEIN"], [178, 199, "ENTITY"], [78, 121, "ENTITY"], [78, 121, "PROTEIN"], [107, 112, "DISEASE"], [258, 271, "ENTITY"], [208, 216, "ENTITY"], [82, 105, "CHEBI"]]}
{"text": "However , recent studies have demonstrated that , under certain circumstances , ATF6-mediated signals may also contribute to ER-stress-induced apoptosis , possibly via activation of CHOP and/or suppression of myeloid cell leukemia sequence 1 ( Mcl-1;Gotoh et al. , 2002;Nakanishi et al. , 2005;Morishima et al.,2011 ) .", "labels": [[259, 265, "CHEMICAL"], [80, 94, "ENTITY"], [206, 231, "PROTEIN"], [206, 231, "DISEASE"], [206, 231, "CL"], [206, 231, "CELL"], [187, 194, "ENTITY"], [206, 231, "ENTITY"], [125, 143, "ENTITY"]]}
{"text": "However , if ER stress persists , GADD153 can induce apoptosis by suppressing the anti-apoptotic protein B-cell lymphoma 2 ( Bcl-2 ) and inducing the pro-apoptotic proteins such as Bcl-2-interacting mediator of cell death ( Bim;Puthalakath et al. , 2007 ) . GADD153 also activates ER oxidoreductin-1\u03b1 ( ERO1\u03b1 ) , which encodes an ER oxidase . The increase protein influx to a hyperoxidizing ER aggravates ER stress and induces apoptosis ( Marciniak et al. , 2004;Figure 3 ) .", "labels": [[271, 284, "PROTEIN"], [178, 199, "PROTEIN"], [46, 53, "ENTITY"], [271, 284, "GENE_OR_GENE_PRODUCT"], [78, 121, "PROTEIN"], [319, 330, "ENTITY"], [146, 164, "ENTITY"], [333, 343, "ENTITY"], [364, 376, "ENTITY"], [82, 105, "CHEBI"], [150, 164, "CHEBI"], [13, 16, "ENTITY"], [319, 330, "GGP"], [319, 330, "GENE_OR_GENE_PRODUCT"], [146, 164, "PROTEIN"], [78, 121, "ENTITY"], [271, 284, "ENTITY"], [343, 356, "ENTITY"], [439, 458, "GENE_OR_GENE_PRODUCT"], [16, 23, "ENTITY"], [319, 330, "PROTEIN"], [178, 199, "ENTITY"], [107, 112, "DISEASE"], [258, 271, "ENTITY"], [208, 216, "ENTITY"]]}
{"text": "The up-regulation of GADD153 promotes apoptosis in IBV-infected cells , possibly via inducing the pro-apoptotic protein tribbles-related protein 3 ( TRIB3 ) and suppressing the pro-survival kinase extracellular signal-related kinase ( ERK;Liaoet al. , 2013 ) .", "labels": [[173, 226, "ENTITY"], [4, 18, "ENTITY"], [64, 70, "CL"], [98, 145, "PROTEIN"], [21, 29, "ENTITY"], [38, 48, "ENTITY"], [226, 235, "CHEMICAL"], [64, 70, "CELL"], [21, 29, "GENE_OR_GENE_PRODUCT"], [21, 29, "PROTEIN"], [226, 235, "PROTEIN"], [173, 226, "PROTEIN"], [98, 145, "ENTITY"], [51, 70, "CELL_TYPE"], [173, 226, "GENE_OR_GENE_PRODUCT"], [98, 112, "GGP"], [173, 226, "GGP"], [51, 70, "ENTITY"], [21, 29, "GGP"]]}
{"text": "The up-regulation of GADD153 promotes apoptosis in IBV-infected cells , possibly via inducing the pro-apoptotic protein tribbles-related protein 3 ( TRIB3 ) and suppressing the pro-survival kinase extracellular signal-related kinase ( ERK;Liaoet al. , 2013 ) .", "labels": [[173, 226, "ENTITY"], [4, 18, "ENTITY"], [98, 145, "ENTITY"], [64, 70, "CL"], [21, 29, "ENTITY"], [38, 48, "ENTITY"], [226, 235, "CHEMICAL"], [64, 70, "CELL"], [98, 145, "PROTEIN"], [21, 29, "GENE_OR_GENE_PRODUCT"], [21, 29, "PROTEIN"], [226, 235, "PROTEIN"], [173, 226, "PROTEIN"], [51, 70, "CELL_TYPE"], [173, 226, "GENE_OR_GENE_PRODUCT"], [98, 112, "GGP"], [173, 226, "GGP"], [51, 70, "ENTITY"], [21, 29, "GGP"]]}
{"text": "The identified target genes of ATF6 include ER chaperones ( such as GRP78 , GRP94 ) , PDI , and the UPR transcription factors GADD153 and XBP1 ( Szegezdi et al. , 2006 ) .", "labels": [[22, 28, "SO"], [44, 58, "ENTITY"], [44, 58, "PROTEIN"], [138, 145, "PROTEIN"], [31, 36, "ENTITY"], [44, 47, "GENE_OR_GENE_PRODUCT"], [31, 36, "GGP"], [15, 22, "ENTITY"], [118, 126, "ENTITY"], [118, 126, "GENE_OR_GENE_PRODUCT"], [96, 126, "PROTEIN"], [138, 145, "GENE_OR_GENE_PRODUCT"], [44, 58, "GGP"], [31, 36, "PROTEIN"], [4, 15, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [118, 126, "GGP"], [22, 28, "ENTITY"]]}
{"text": "Usually , Toll-like receptor ( TLR ) 3 , TLR7 , TLR8 , and TLR9 sense viral RNA and DNA in the endosome [ 60 , 61 ] . The viral RNA receptor retinoic-acid inducible gene I ( RIG-I ) [ 62 ] , cytosolic receptor melanoma differentiation-associated gene 5 ( MDA5 ) and nucleotidyl transferase cyclic GMP-AMP synthase ( cGAS ) [ 63 ] are responsible for the recognition of viral RNA and DNA in the cytoplasm .", "labels": [[111, 122, "TAXON"], [41, 48, "ENTITY"], [155, 165, "PROTEIN"], [174, 201, "ENTITY"], [354, 366, "CELLULAR_COMPONENT"], [346, 354, "ENTITY"], [201, 219, "ENTITY"], [354, 366, "ENTITY"], [346, 354, "RNA"], [70, 84, "ENTITY"], [10, 20, "ENTITY"], [88, 95, "CELLULAR_COMPONENT"], [191, 201, "DISEASE"], [64, 70, "TAXON"], [88, 95, "ENTITY"], [10, 35, "PROTEIN"], [111, 141, "PROTEIN"], [246, 297, "PROTEIN"], [76, 80, "ENTITY"], [155, 165, "ENTITY"], [354, 366, "SO"], [64, 70, "ENTITY"], [88, 95, "GO"], [10, 20, "GENE_OR_GENE_PRODUCT"], [41, 48, "GGP"], [41, 48, "PROTEIN"], [174, 219, "PROTEIN"], [346, 354, "TAXON"], [111, 155, "ENTITY"], [41, 48, "GENE_OR_GENE_PRODUCT"], [76, 80, "SO"], [70, 84, "ORGANISM_SUBSTANCE"], [246, 297, "GENE_OR_GENE_PRODUCT"], [10, 20, "GGP"], [155, 165, "GGP"], [262, 297, "GGP"], [246, 297, "ENTITY"], [174, 184, "GO"], [70, 84, "GO"], [59, 64, "ENTITY"], [174, 219, "GENE_OR_GENE_PRODUCT"], [76, 80, "CELLULAR_COMPONENT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [164, 171, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [362, 377, "GENE_OR_GENE_PRODUCT"], [164, 171, "PROTEIN"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [102, 108, "PROTEIN"], [164, 171, "GGP"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [133, 164, "GENE_OR_GENE_PRODUCT"], [133, 164, "PROTEIN"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [33, 41, "ENTITY"], [299, 330, "GGP"], [377, 389, "PROTEIN"], [164, 171, "ENTITY"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [164, 171, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [362, 377, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [164, 171, "GGP"], [102, 108, "PROTEIN"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [164, 171, "ENTITY"], [133, 164, "PROTEIN"], [133, 164, "GENE_OR_GENE_PRODUCT"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [33, 41, "ENTITY"], [299, 330, "GGP"], [164, 171, "PROTEIN"], [377, 389, "PROTEIN"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Lowered DRP1 levels impaired the MAVS-induced increase IFN-\u03b2 reporter activity although not nearly as effectively as did the 9b-FLAG construct ( Fig. 3I ) .", "labels": [[8, 13, "GGP"], [55, 61, "GENE_OR_GENE_PRODUCT"], [46, 55, "ENTITY"], [13, 20, "ENTITY"], [0, 8, "ENTITY"], [33, 46, "ENTITY"], [8, 13, "ENTITY"], [55, 61, "ENTITY"], [133, 143, "SO"], [33, 46, "CHEMICAL"], [8, 13, "GENE_OR_GENE_PRODUCT"], [20, 29, "ENTITY"], [8, 13, "PROTEIN"]]}
{"text": "The DRP1 shRNA appropriately decreased DRP1 expression , but did not impact endogenous MAVS expression ( Fig. 3J ) . This indicates that the ORF-9b mediated reduction in DRP1 may contributes to the decrease in type I interferon signaling , however other mechanisms must be operant .", "labels": [[265, 273, "ENTITY"], [4, 9, "ENTITY"], [207, 217, "GGP"], [44, 55, "ENTITY"], [4, 9, "PROTEIN"], [4, 9, "GENE_OR_GENE_PRODUCT"], [207, 217, "PROTEIN"], [9, 15, "ENTITY"], [4, 9, "GENE_OR_GENE_PRODUCT"], [148, 157, "ENTITY"], [4, 9, "GGP"], [29, 39, "ENTITY"], [207, 217, "GENE_OR_GENE_PRODUCT"], [207, 228, "ENTITY"], [4, 9, "GGP"], [4, 9, "ENTITY"], [4, 15, "RNA"]]}
{"text": "These data show that ORF-9b localizes to mitochondria and likely causes mitochondrial elongation by triggering DRP1 ubiquitination and its proteasomal destruction .", "labels": [[41, 54, "ENTITY"], [41, 54, "CELLULAR_COMPONENT"], [72, 86, "GO"], [116, 131, "ENTITY"], [111, 116, "ENTITY"], [21, 28, "SIMPLE_CHEMICAL"], [28, 38, "ENTITY"], [21, 28, "PROTEIN"], [139, 151, "GO"], [72, 97, "ENTITY"], [72, 86, "CELLULAR_COMPONENT"], [111, 116, "GGP"], [139, 163, "ENTITY"], [111, 116, "PROTEIN"], [21, 28, "ENTITY"], [41, 54, "GO"], [111, 116, "GENE_OR_GENE_PRODUCT"], [6, 11, "ENTITY"]]}
{"text": "Besides p38 , DUSP1 has also been shown to dephosphorylate c-Jun N-terminal kinase ( JNK ) and ERK ( Sun et al.,1993;Franklin and Kraft , 1997 ) . It has been long proposed that ERK phosphorylation promotes cell survival , whereas prolonged JNK and p38 phosphorylation is linked to the induction of apoptosis ( Xia et al. , 1995 ) .", "labels": [[8, 12, "ENTITY"], [164, 173, "GENE_OR_GENE_PRODUCT"], [164, 173, "GGP"], [8, 12, "GGP"], [126, 138, "GENE_OR_GENE_PRODUCT"], [164, 173, "PROTEIN"], [198, 212, "ENTITY"], [85, 89, "ENTITY"], [164, 173, "ENTITY"], [182, 198, "ENTITY"], [85, 89, "PROTEIN"], [85, 89, "GGP"], [286, 299, "ENTITY"], [59, 76, "GENE_OR_GENE_PRODUCT"], [8, 12, "PROTEIN"], [59, 76, "GGP"], [279, 286, "ENTITY"], [59, 76, "PROTEIN"], [245, 253, "ENTITY"], [85, 89, "GENE_OR_GENE_PRODUCT"], [59, 76, "ENTITY"], [8, 12, "GENE_OR_GENE_PRODUCT"], [173, 182, "ENTITY"]]}
{"text": "Besides p38 , DUSP1 has also been shown to dephosphorylate c-Jun N-terminal kinase ( JNK ) and ERK ( Sun et al.,1993;Franklin and Kraft , 1997 ) . It has been long proposed that ERK phosphorylation promotes cell survival , whereas prolonged JNK and p38 phosphorylation is linked to the induction of apoptosis ( Xia et al. , 1995 ) .", "labels": [[8, 12, "ENTITY"], [164, 173, "GENE_OR_GENE_PRODUCT"], [164, 173, "GGP"], [8, 12, "GGP"], [126, 138, "GENE_OR_GENE_PRODUCT"], [164, 173, "PROTEIN"], [198, 212, "ENTITY"], [85, 89, "ENTITY"], [164, 173, "ENTITY"], [182, 198, "ENTITY"], [85, 89, "PROTEIN"], [85, 89, "GGP"], [286, 299, "ENTITY"], [59, 76, "GENE_OR_GENE_PRODUCT"], [8, 12, "PROTEIN"], [59, 76, "GGP"], [279, 286, "ENTITY"], [59, 76, "PROTEIN"], [245, 253, "ENTITY"], [85, 89, "GENE_OR_GENE_PRODUCT"], [59, 76, "ENTITY"], [8, 12, "GENE_OR_GENE_PRODUCT"], [173, 182, "ENTITY"]]}
{"text": "SGs are induced by protein kinase R (PKR)-mediated phosphorylation of eIF2\u03b1 upon viral dsRNA recognition [ 57 ] . Promoting G3BP aggregation via the eIF4A inhibitor Zotatafin [ 58,59 ] or reducing SG disassembly by Silmitasertib inhibition of CK2 [ 60 ] warrant investigation for treatment of SARS-CoV-2 . The mTOR inhibitor rapamycin disrupts the binding of LARP1 to mTORC1 [ 61 ] and has been shown to reduce MERS infection by \u223c60 % in vitro [ 62 ] , another drug that could be tested for repurposing .", "labels": [[51, 67, "ENTITY"], [19, 36, "GENE_OR_GENE_PRODUCT"], [254, 262, "ENTITY"], [70, 76, "PROTEIN"], [293, 306, "ENTITY"], [293, 325, "GGP"], [114, 124, "PROTEIN"], [155, 165, "SIMPLE_CHEMICAL"], [70, 76, "ENTITY"], [19, 36, "PROTEIN"], [229, 240, "ENTITY"], [280, 293, "CHEMICAL"], [145, 155, "ENTITY"], [0, 4, "ENTITY"], [200, 215, "CHEMICAL"], [401, 416, "DISEASE"], [335, 348, "ENTITY"], [114, 124, "ENTITY"], [306, 315, "ENTITY"], [395, 401, "ENTITY"], [81, 93, "TAXON"], [124, 129, "ENTITY"], [200, 215, "ORGANISM"], [19, 36, "ENTITY"], [293, 306, "GENE_OR_GENE_PRODUCT"], [348, 356, "GENE_OR_GENE_PRODUCT"], [0, 4, "GO"], [262, 280, "ENTITY"], [8, 16, "ENTITY"], [229, 243, "GENE_OR_GENE_PRODUCT"], [348, 356, "PROTEIN"], [0, 4, "GENE_OR_GENE_PRODUCT"], [416, 433, "ENTITY"], [188, 200, "ENTITY"], [348, 356, "ENTITY"], [19, 27, "CHEBI"], [477, 487, "ENTITY"], [155, 165, "CHEMICAL"], [280, 293, "ENTITY"], [280, 293, "SIMPLE_CHEMICAL"], [359, 368, "GENE_OR_GENE_PRODUCT"], [145, 155, "CHEBI"], [70, 76, "GENE_OR_GENE_PRODUCT"], [200, 229, "ENTITY"], [155, 165, "ENTITY"], [404, 416, "ENTITY"], [114, 124, "GENE_OR_GENE_PRODUCT"], [229, 240, "PROTEIN"], [359, 365, "PROTEIN"], [81, 105, "ENTITY"], [114, 124, "GGP"], [325, 335, "ENTITY"], [348, 356, "GGP"], [359, 365, "ENTITY"], [145, 165, "PROTEIN"], [0, 4, "PROTEIN"]]}
{"text": "Besides PERK , three other kinases are known to phosphorylate eIF2\u03b1 , namely the protein kinase RNA-activated ( PKR ) , heme-regulated inhibitor kinase ( HRI ) , and general control non-derepressible-2 ( GCN2;Ron and Walter , 2007 ) .", "labels": [[174, 182, "PROTEIN"], [77, 96, "ENTITY"], [116, 145, "ENTITY"], [8, 13, "GENE_OR_GENE_PRODUCT"], [116, 135, "CHEBI"], [116, 145, "PROTEIN"], [77, 96, "PROTEIN"], [27, 34, "GGP"], [182, 204, "PROTEIN"], [8, 13, "ENTITY"], [27, 34, "GENE_OR_GENE_PRODUCT"], [27, 34, "PROTEIN"], [158, 174, "ENTITY"], [77, 96, "GENE_OR_GENE_PRODUCT"], [182, 204, "GENE_OR_GENE_PRODUCT"], [27, 34, "ENTITY"], [8, 13, "GGP"], [116, 145, "GENE_OR_GENE_PRODUCT"], [8, 13, "PROTEIN"], [174, 182, "ENTITY"]]}
{"text": "Besides PERK , three other kinases are known to phosphorylate eIF2\u03b1 , namely the protein kinase RNA-activated ( PKR ) , heme-regulated inhibitor kinase ( HRI ) , and general control non-derepressible-2 ( GCN2;Ron and Walter , 2007 ) .", "labels": [[8, 13, "GGP"], [174, 182, "PROTEIN"], [8, 13, "ENTITY"], [77, 96, "ENTITY"], [116, 145, "ENTITY"], [116, 135, "CHEBI"], [116, 145, "PROTEIN"], [77, 96, "PROTEIN"], [8, 13, "PROTEIN"], [27, 34, "GGP"], [182, 204, "PROTEIN"], [27, 34, "GENE_OR_GENE_PRODUCT"], [8, 13, "GENE_OR_GENE_PRODUCT"], [27, 34, "PROTEIN"], [158, 174, "ENTITY"], [77, 96, "GENE_OR_GENE_PRODUCT"], [182, 204, "GENE_OR_GENE_PRODUCT"], [27, 34, "ENTITY"], [116, 145, "GENE_OR_GENE_PRODUCT"], [174, 182, "ENTITY"]]}
{"text": "However , similar to PKR , viruses have adopted counter measures to inhibit PERK-mediated translation attenuation .", "labels": [[68, 76, "GENE_OR_GENE_PRODUCT"], [68, 76, "ENTITY"], [48, 56, "ENTITY"], [68, 76, "GGP"], [90, 102, "ENTITY"]]}
{"text": "The up-regulation of GADD153 was likely mediated by both PKR and PERK , since knock-down of either PKR or PERK by siRNA reduces IBV-induced GADD153 ( Liaoet al. , 2013 ) .", "labels": [[57, 61, "GGP"], [21, 29, "GGP"], [21, 29, "PROTEIN"], [57, 61, "GENE_OR_GENE_PRODUCT"], [21, 29, "ENTITY"], [57, 61, "PROTEIN"], [65, 70, "GENE_OR_GENE_PRODUCT"], [65, 70, "ENTITY"], [4, 18, "ENTITY"], [128, 140, "GENE_OR_GENE_PRODUCT"], [65, 70, "GGP"], [65, 70, "PROTEIN"], [57, 61, "ENTITY"], [128, 140, "ENTITY"], [21, 29, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Under various stress conditions , phosphorylation of eIF2\u03b1 leads to global translation repression and a net decrease in I\u03baB\u03b1 protein level ( Jiang et al. , 2003).This then results in the activation of NF-\u03baB and induction of pro-inflammatory response ( Figure 3 ) .", "labels": [[221, 241, "ENTITY"], [241, 252, "ENTITY"], [14, 32, "ENTITY"], [120, 125, "ENTITY"]]}
{"text": "Under various stress conditions , phosphorylation of eIF2\u03b1 leads to global translation repression and a net decrease in I\u03baB\u03b1 protein level ( Jiang et al. , 2003).This then results in the activation of NF-\u03baB and induction of pro-inflammatory response ( Figure 3 ) .", "labels": [[221, 241, "ENTITY"], [241, 252, "ENTITY"], [14, 32, "ENTITY"], [120, 125, "ENTITY"]]}
{"text": "Under various stress conditions , phosphorylation of eIF2\u03b1 leads to global translation repression and a net decrease in I\u03baB\u03b1 protein level ( Jiang et al. , 2003).This then results in the activation of NF-\u03baB and induction of pro-inflammatory response ( Figure 3 ) .", "labels": [[221, 241, "ENTITY"], [241, 252, "ENTITY"], [14, 32, "ENTITY"], [120, 125, "ENTITY"]]}
{"text": "Under various stress conditions , phosphorylation of eIF2\u03b1 leads to global translation repression and a net decrease in I\u03baB\u03b1 protein level ( Jiang et al. , 2003).This then results in the activation of NF-\u03baB and induction of pro-inflammatory response ( Figure 3 ) .", "labels": [[221, 241, "ENTITY"], [14, 32, "ENTITY"], [241, 252, "ENTITY"], [120, 125, "ENTITY"]]}
{"text": "The authors thus conclude that global translation shutdown via eIF2\u03b1 phosphorylation prevents accumulation of ATF6 and activation of ATF6 target genes ( Bechill et al. , 2008 ) .", "labels": [[63, 69, "GENE_OR_GENE_PRODUCT"], [38, 50, "ENTITY"], [69, 85, "ENTITY"], [133, 151, "DNA"], [110, 115, "PROTEIN"], [110, 115, "ENTITY"], [63, 69, "DNA"], [110, 115, "GENE_OR_GENE_PRODUCT"], [145, 151, "SO"], [110, 115, "GGP"], [110, 115, "GGP"], [4, 12, "ENTITY"], [94, 107, "ENTITY"], [31, 38, "ENTITY"], [119, 130, "ENTITY"], [110, 115, "GENE_OR_GENE_PRODUCT"], [110, 115, "ENTITY"]]}
{"text": "The authors thus conclude that global translation shutdown via eIF2\u03b1 phosphorylation prevents accumulation of ATF6 and activation of ATF6 target genes ( Bechill et al. , 2008 ) .", "labels": [[63, 69, "GENE_OR_GENE_PRODUCT"], [38, 50, "ENTITY"], [69, 85, "ENTITY"], [133, 151, "DNA"], [110, 115, "PROTEIN"], [110, 115, "ENTITY"], [63, 69, "DNA"], [110, 115, "GENE_OR_GENE_PRODUCT"], [145, 151, "SO"], [110, 115, "GGP"], [110, 115, "GGP"], [4, 12, "ENTITY"], [94, 107, "ENTITY"], [31, 38, "ENTITY"], [119, 130, "ENTITY"], [110, 115, "GENE_OR_GENE_PRODUCT"], [110, 115, "ENTITY"]]}
{"text": "SGs are induced by protein kinase R (PKR)-mediated phosphorylation of eIF2\u03b1 upon viral dsRNA recognition [ 57 ] . Promoting G3BP aggregation via the eIF4A inhibitor Zotatafin [ 58,59 ] or reducing SG disassembly by Silmitasertib inhibition of CK2 [ 60 ] warrant investigation for treatment of SARS-CoV-2 . The mTOR inhibitor rapamycin disrupts the binding of LARP1 to mTORC1 [ 61 ] and has been shown to reduce MERS infection by \u223c60 % in vitro [ 62 ] , another drug that could be tested for repurposing .", "labels": [[51, 67, "ENTITY"], [19, 36, "GENE_OR_GENE_PRODUCT"], [254, 262, "ENTITY"], [70, 76, "PROTEIN"], [293, 306, "ENTITY"], [293, 325, "GGP"], [114, 124, "PROTEIN"], [155, 165, "SIMPLE_CHEMICAL"], [70, 76, "ENTITY"], [19, 36, "PROTEIN"], [229, 240, "ENTITY"], [280, 293, "CHEMICAL"], [0, 4, "ENTITY"], [200, 215, "CHEMICAL"], [401, 416, "DISEASE"], [335, 348, "ENTITY"], [114, 124, "ENTITY"], [306, 315, "ENTITY"], [395, 401, "ENTITY"], [81, 93, "TAXON"], [145, 155, "CHEBI"], [200, 215, "ORGANISM"], [19, 36, "ENTITY"], [293, 306, "GENE_OR_GENE_PRODUCT"], [348, 356, "GENE_OR_GENE_PRODUCT"], [0, 4, "GO"], [262, 280, "ENTITY"], [8, 16, "ENTITY"], [229, 243, "GENE_OR_GENE_PRODUCT"], [348, 356, "PROTEIN"], [145, 155, "ENTITY"], [0, 4, "GENE_OR_GENE_PRODUCT"], [124, 129, "ENTITY"], [145, 165, "PROTEIN"], [416, 433, "ENTITY"], [188, 200, "ENTITY"], [348, 356, "ENTITY"], [19, 27, "CHEBI"], [477, 487, "ENTITY"], [155, 165, "CHEMICAL"], [280, 293, "ENTITY"], [280, 293, "SIMPLE_CHEMICAL"], [359, 368, "GENE_OR_GENE_PRODUCT"], [70, 76, "GENE_OR_GENE_PRODUCT"], [200, 229, "ENTITY"], [155, 165, "ENTITY"], [404, 416, "ENTITY"], [114, 124, "GENE_OR_GENE_PRODUCT"], [229, 240, "PROTEIN"], [359, 365, "PROTEIN"], [81, 105, "ENTITY"], [114, 124, "GGP"], [325, 335, "ENTITY"], [348, 356, "GGP"], [359, 365, "ENTITY"], [0, 4, "PROTEIN"]]}
{"text": "SGs are induced by protein kinase R (PKR)-mediated phosphorylation of eIF2\u03b1 upon viral dsRNA recognition [ 57 ] . Promoting G3BP aggregation via the eIF4A inhibitor Zotatafin [ 58,59 ] or reducing SG disassembly by Silmitasertib inhibition of CK2 [ 60 ] warrant investigation for treatment of SARS-CoV-2 . The mTOR inhibitor rapamycin disrupts the binding of LARP1 to mTORC1 [ 61 ] and has been shown to reduce MERS infection by \u223c60 % in vitro [ 62 ] , another drug that could be tested for repurposing .", "labels": [[51, 67, "ENTITY"], [19, 36, "GENE_OR_GENE_PRODUCT"], [254, 262, "ENTITY"], [70, 76, "PROTEIN"], [293, 306, "ENTITY"], [293, 325, "GGP"], [114, 124, "PROTEIN"], [155, 165, "SIMPLE_CHEMICAL"], [70, 76, "ENTITY"], [19, 36, "PROTEIN"], [229, 240, "ENTITY"], [280, 293, "CHEMICAL"], [0, 4, "ENTITY"], [200, 215, "CHEMICAL"], [401, 416, "DISEASE"], [335, 348, "ENTITY"], [114, 124, "ENTITY"], [306, 315, "ENTITY"], [395, 401, "ENTITY"], [81, 93, "TAXON"], [124, 129, "ENTITY"], [145, 155, "CHEBI"], [19, 36, "ENTITY"], [200, 215, "ORGANISM"], [293, 306, "GENE_OR_GENE_PRODUCT"], [0, 4, "GO"], [262, 280, "ENTITY"], [8, 16, "ENTITY"], [229, 243, "GENE_OR_GENE_PRODUCT"], [348, 356, "GENE_OR_GENE_PRODUCT"], [348, 356, "PROTEIN"], [145, 155, "ENTITY"], [0, 4, "GENE_OR_GENE_PRODUCT"], [145, 165, "PROTEIN"], [416, 433, "ENTITY"], [188, 200, "ENTITY"], [348, 356, "ENTITY"], [19, 27, "CHEBI"], [477, 487, "ENTITY"], [155, 165, "CHEMICAL"], [280, 293, "ENTITY"], [280, 293, "SIMPLE_CHEMICAL"], [359, 368, "GENE_OR_GENE_PRODUCT"], [70, 76, "GENE_OR_GENE_PRODUCT"], [200, 229, "ENTITY"], [155, 165, "ENTITY"], [404, 416, "ENTITY"], [114, 124, "GENE_OR_GENE_PRODUCT"], [229, 240, "PROTEIN"], [359, 365, "PROTEIN"], [81, 105, "ENTITY"], [114, 124, "GGP"], [325, 335, "ENTITY"], [348, 356, "GGP"], [359, 365, "ENTITY"], [0, 4, "PROTEIN"]]}
{"text": "In response to unfolded proteins , IRE1 undergoes oligomerization ( Bertolotti et al. , 2000 ) . This results in trans-autophosphorylation of the kinase domain and the activation of IRE1 \u2019s RNase domain .", "labels": [[24, 33, "CHEBI"], [168, 190, "GENE_OR_GENE_PRODUCT"], [146, 153, "SO"], [142, 153, "PROTEIN"], [102, 113, "ENTITY"], [168, 196, "ENTITY"], [142, 153, "ENTITY"], [168, 196, "GGP"], [168, 196, "PROTEIN"], [15, 33, "ENTITY"], [3, 12, "ENTITY"], [15, 33, "PROTEIN"]]}
{"text": "Apart from the XBP1 pathway , activated IRE1 has been shown to recruit TNF receptor-associated factor 2 ( TRAF2 ) and induce apoptosis by activating the JNK ( Urano et al. , 2000 ) . This IRE1-JNK pathway is independent of IRE1 \u2019s RNase activity , but it requires IRE1 \u2019s kinase domain and involves TRAF2-dependent activation of caspase-12 ( Yonedaet al.,2001 ) .", "labels": [[315, 329, "PROTEIN"], [71, 102, "PROTEIN"], [208, 228, "GGP"], [223, 237, "ENTITY"], [15, 28, "ENTITY"], [290, 299, "ENTITY"], [208, 228, "GENE_OR_GENE_PRODUCT"], [208, 223, "ENTITY"], [315, 329, "ENTITY"], [255, 272, "GENE_OR_GENE_PRODUCT"], [181, 188, "PROTEIN"], [75, 102, "ENTITY"], [15, 20, "GGP"], [255, 272, "ENTITY"], [15, 20, "GENE_OR_GENE_PRODUCT"], [40, 45, "PROTEIN"], [208, 220, "PROTEIN"], [290, 299, "SIMPLE_CHEMICAL"], [299, 315, "ENTITY"], [181, 197, "ENTITY"], [255, 272, "GGP"], [71, 102, "GENE_OR_GENE_PRODUCT"], [118, 125, "ENTITY"], [71, 102, "GGP"], [255, 272, "PROTEIN"], [315, 329, "GENE_OR_GENE_PRODUCT"], [15, 20, "PROTEIN"]]}
{"text": "Therefore , the IRE1 branch of UPR is closely associated with the JNK pathway and involved in JNK-mediated apoptosis and autophagy signaling .", "labels": [[16, 21, "ENTITY"], [66, 70, "ENTITY"], [16, 21, "PROTEIN"], [16, 21, "GGP"]]}
{"text": "Interestingly , an earlier onset and more significant apoptosis induction in IRE1-knockdown IBV-infected cells was observed , which is associated with hyperphosphorylation of pro-apoptotic kinase JNK and hypophosphorylation of pro-survival kinase RAC-alpha serine/threonine-protein kinase ( Akt ) .", "labels": [[224, 282, "PROTEIN"], [92, 105, "ENTITY"], [172, 196, "GGP"], [224, 282, "GENE_OR_GENE_PRODUCT"], [224, 282, "ENTITY"], [240, 257, "CHEMICAL"], [172, 196, "PROTEIN"], [172, 196, "ENTITY"], [77, 105, "CELL_LINE"], [132, 146, "ENTITY"], [224, 282, "GGP"], [172, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Interestingly , an earlier onset and more significant apoptosis induction in IRE1-knockdown IBV-infected cells was observed , which is associated with hyperphosphorylation of pro-apoptotic kinase JNK and hypophosphorylation of pro-survival kinase RAC-alpha serine/threonine-protein kinase ( Akt ) .", "labels": [[224, 282, "PROTEIN"], [92, 105, "ENTITY"], [172, 196, "GGP"], [224, 282, "GENE_OR_GENE_PRODUCT"], [224, 282, "ENTITY"], [240, 257, "CHEMICAL"], [172, 196, "PROTEIN"], [172, 196, "ENTITY"], [77, 105, "CELL_LINE"], [132, 146, "ENTITY"], [224, 282, "GGP"], [172, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Interestingly , an earlier onset and more significant apoptosis induction in IRE1-knockdown IBV-infected cells was observed , which is associated with hyperphosphorylation of pro-apoptotic kinase JNK and hypophosphorylation of pro-survival kinase RAC-alpha serine/threonine-protein kinase ( Akt ) .", "labels": [[224, 282, "PROTEIN"], [92, 105, "ENTITY"], [172, 196, "GGP"], [224, 282, "GENE_OR_GENE_PRODUCT"], [224, 282, "ENTITY"], [240, 257, "CHEMICAL"], [172, 196, "PROTEIN"], [172, 196, "ENTITY"], [77, 105, "CELL_LINE"], [132, 146, "ENTITY"], [224, 282, "GGP"], [172, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Taken together , IRE1 may modulate IBV-induced apoptosis and serve as a survival factor during coronavirus infection .", "labels": [[88, 107, "ENTITY"], [70, 81, "ENTITY"], [88, 107, "DISEASE"], [26, 47, "ENTITY"], [26, 35, "GENE_OR_GENE_PRODUCT"]]}
{"text": "During prolonged ER stress induced by infection , non-specific RNase activity of IRE1 may decay the membrane associated viral mRNA .", "labels": [[17, 20, "GENE_OR_GENE_PRODUCT"], [63, 69, "ENTITY"], [27, 35, "ENTITY"], [7, 17, "ENTITY"], [17, 20, "PROTEIN"], [120, 126, "TAXON"], [38, 48, "DISEASE"], [38, 48, "ENTITY"], [17, 27, "ENTITY"], [100, 126, "RNA"]]}
{"text": "Interestingly , the ER stress and TLR activation synergistically activate IRE1 and induce the production of pro-inflammatory cytokines such as IL-1\u03b2 and IL-6 ( Martinon et al. , 2010 ) .", "labels": [[20, 23, "ENTITY"], [108, 125, "PROTEIN"]]}
{"text": "Interestingly , the ER stress and TLR activation synergistically activate IRE1 and induce the production of pro-inflammatory cytokines such as IL-1\u03b2 and IL-6 ( Martinon et al. , 2010 ) .", "labels": [[20, 23, "ENTITY"], [108, 125, "PROTEIN"]]}
{"text": "On the other hand , the kinase but not the RNAse activity of IRE1 has been associated with ER-stress-induced NF-kB activation ( Tam et al. , 2012 ) . Under ER stress , IRE1 has been shown to phosphorylate TRAF2 , which activates the I\u03baB kinase ( IKK ) and contributes to its basal activity ( Figure 4 ) . IKK inturn phosphorylates I\u03baB\u03b1 and promotes its proteasomal degradation , releasing NF-\u03baB to activate downstream genes ( Tam et al.,2012 ) .", "labels": [[256, 281, "ENTITY"], [43, 49, "ENTITY"], [94, 101, "GGP"], [219, 237, "ENTITY"], [49, 58, "ENTITY"], [91, 115, "ENTITY"], [191, 205, "PROTEIN"], [94, 101, "ENTITY"], [191, 205, "GENE_OR_GENE_PRODUCT"], [182, 191, "ENTITY"], [94, 101, "GENE_OR_GENE_PRODUCT"], [219, 237, "PROTEIN"], [150, 159, "ENTITY"], [191, 205, "ENTITY"], [395, 407, "ENTITY"], [191, 205, "GGP"], [395, 407, "DNA"], [94, 101, "PROTEIN"], [340, 365, "ENTITY"], [340, 353, "GO"], [219, 228, "SO"], [292, 303, "ENTITY"], [379, 389, "ENTITY"]]}
{"text": "On the other hand , the kinase but not the RNAse activity of IRE1 has been associated with ER-stress-induced NF-kB activation ( Tam et al. , 2012 ) . Under ER stress , IRE1 has been shown to phosphorylate TRAF2 , which activates the I\u03baB kinase ( IKK ) and contributes to its basal activity ( Figure 4 ) . IKK inturn phosphorylates I\u03baB\u03b1 and promotes its proteasomal degradation , releasing NF-\u03baB to activate downstream genes ( Tam et al.,2012 ) .", "labels": [[256, 281, "ENTITY"], [43, 49, "ENTITY"], [94, 101, "GENE_OR_GENE_PRODUCT"], [219, 237, "ENTITY"], [49, 58, "ENTITY"], [91, 115, "ENTITY"], [191, 205, "PROTEIN"], [94, 101, "ENTITY"], [191, 205, "GENE_OR_GENE_PRODUCT"], [182, 191, "ENTITY"], [219, 237, "PROTEIN"], [150, 159, "ENTITY"], [94, 101, "PROTEIN"], [94, 101, "GGP"], [191, 205, "ENTITY"], [395, 407, "ENTITY"], [191, 205, "GGP"], [395, 407, "DNA"], [340, 365, "ENTITY"], [340, 353, "GO"], [219, 228, "SO"], [292, 303, "ENTITY"], [379, 389, "ENTITY"]]}
{"text": "However , if ER stress persists , GADD153 can induce apoptosis by suppressing the anti-apoptotic protein B-cell lymphoma 2 ( Bcl-2 ) and inducing the pro-apoptotic proteins such as Bcl-2-interacting mediator of cell death ( Bim;Puthalakath et al. , 2007 ) . GADD153 also activates ER oxidoreductin-1\u03b1 ( ERO1\u03b1 ) , which encodes an ER oxidase . The increase protein influx to a hyperoxidizing ER aggravates ER stress and induces apoptosis ( Marciniak et al. , 2004;Figure 3 ) .", "labels": [[271, 284, "PROTEIN"], [178, 199, "PROTEIN"], [46, 53, "ENTITY"], [271, 284, "GENE_OR_GENE_PRODUCT"], [78, 121, "PROTEIN"], [319, 330, "ENTITY"], [146, 164, "ENTITY"], [333, 343, "ENTITY"], [364, 376, "ENTITY"], [82, 105, "CHEBI"], [150, 164, "CHEBI"], [13, 16, "ENTITY"], [319, 330, "GGP"], [319, 330, "GENE_OR_GENE_PRODUCT"], [146, 164, "PROTEIN"], [78, 121, "ENTITY"], [271, 284, "ENTITY"], [343, 356, "ENTITY"], [439, 458, "GENE_OR_GENE_PRODUCT"], [319, 330, "PROTEIN"], [178, 199, "ENTITY"], [107, 112, "DISEASE"], [16, 23, "ENTITY"], [258, 271, "ENTITY"], [208, 216, "ENTITY"]]}
{"text": "However , if ER stress persists , GADD153 can induce apoptosis by suppressing the anti-apoptotic protein B-cell lymphoma 2 ( Bcl-2 ) and inducing the pro-apoptotic proteins such as Bcl-2-interacting mediator of cell death ( Bim;Puthalakath et al. , 2007 ) . GADD153 also activates ER oxidoreductin-1\u03b1 ( ERO1\u03b1 ) , which encodes an ER oxidase . The increase protein influx to a hyperoxidizing ER aggravates ER stress and induces apoptosis ( Marciniak et al. , 2004;Figure 3 ) .", "labels": [[271, 284, "PROTEIN"], [178, 199, "PROTEIN"], [46, 53, "ENTITY"], [271, 284, "GENE_OR_GENE_PRODUCT"], [319, 330, "ENTITY"], [146, 164, "ENTITY"], [333, 343, "ENTITY"], [364, 376, "ENTITY"], [150, 164, "CHEBI"], [13, 16, "ENTITY"], [319, 330, "GGP"], [319, 330, "GENE_OR_GENE_PRODUCT"], [146, 164, "PROTEIN"], [271, 284, "ENTITY"], [343, 356, "ENTITY"], [439, 458, "GENE_OR_GENE_PRODUCT"], [16, 23, "ENTITY"], [319, 330, "PROTEIN"], [178, 199, "ENTITY"], [78, 121, "ENTITY"], [78, 121, "PROTEIN"], [107, 112, "DISEASE"], [258, 271, "ENTITY"], [208, 216, "ENTITY"], [82, 105, "CHEBI"]]}
{"text": "Mesalazine ( an approved drug for inflammatory bowel disease ) , sirolimus ( an approved immunosuppressive drug ) , and equilin ( an approved agonist of the estrogen receptor for menopausal symptoms ) achieved the highest GSEA scores of 3 , followed by paroxetine and melatonin with GSEA scores of 2 .", "labels": [[0, 11, "CHEBI"], [114, 120, "SIMPLE_CHEMICAL"], [166, 190, "ENTITY"], [268, 278, "ENTITY"], [268, 278, "GENE_OR_GENE_PRODUCT"], [150, 166, "GENE_OR_GENE_PRODUCT"], [89, 107, "CHEBI"], [16, 25, "ENTITY"], [214, 222, "ENTITY"], [16, 25, "CHEBI"], [253, 268, "SIMPLE_CHEMICAL"], [150, 166, "PROTEIN"], [150, 157, "CHEMICAL"], [80, 107, "ENTITY"], [150, 166, "ENTITY"], [0, 11, "ENTITY"], [34, 53, "DISEASE"], [114, 120, "ENTITY"], [253, 268, "CHEMICAL"], [150, 166, "GGP"], [241, 253, "SIMPLE_CHEMICAL"], [114, 120, "PROTEIN"], [241, 253, "CHEBI"], [253, 268, "ENTITY"], [114, 120, "DISEASE"], [34, 53, "ENTITY"], [241, 253, "ENTITY"], [241, 253, "CHEMICAL"], [0, 11, "SIMPLE_CHEMICAL"], [0, 11, "CHEMICAL"]]}
{"text": "GEX analysis showed that CD8 + T cells expressed high levels of effector molecules , including GZMA , GZMK , FASLG , CCL5 , etc . , and resident T cell markers ITGA1 , CXCR6 , JAML , etc . , likely played crucial roles in immune defense ( Figure S4 ) .", "labels": [[128, 136, "ENTITY"], [25, 33, "CELL_TYPE"], [85, 95, "ENTITY"], [25, 33, "ENTITY"], [102, 109, "PROTEIN"], [25, 33, "GGP"], [128, 152, "PROTEIN"], [64, 73, "CHEBI"], [85, 95, "GGP"], [109, 117, "ENTITY"], [109, 117, "GGP"], [85, 95, "PROTEIN"], [205, 222, "ENTITY"], [0, 13, "ENTITY"], [102, 109, "ENTITY"], [205, 229, "CELL"], [25, 29, "GENE_OR_GENE_PRODUCT"], [102, 109, "CHEMICAL"], [64, 73, "PROTEIN"], [102, 109, "GENE_OR_GENE_PRODUCT"], [102, 109, "GGP"], [85, 95, "GENE_OR_GENE_PRODUCT"], [109, 117, "PROTEIN"], [109, 117, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"], [222, 229, "ENTITY"]]}
{"text": "Levels of lactate dehydrogenase ( LDH ) , concentrations of serum high-sensitivity C-reactive protein ( hsCRP ) , ferritin and D-dimer levels were markedly higher in severe cases than moderate cases .", "labels": [[10, 18, "CHEMICAL"], [129, 137, "ENTITY"], [59, 96, "PROTEIN"], [149, 158, "ENTITY"], [0, 7, "ENTITY"], [10, 32, "GGP"], [10, 32, "PROTEIN"], [158, 168, "ENTITY"], [62, 96, "ENTITY"], [10, 32, "ENTITY"], [68, 96, "GGP"], [168, 175, "ENTITY"], [10, 32, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "DPP4 degrades incretins such as glucagon like peptide 1 ( GLP-1 ) and glucose-dependent insulinotropic polypeptide , ultimately leading to reduced insulin secretion and abnormal visceral adipose tissue metabolism .", "labels": [[66, 88, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [5, 14, "ENTITY"], [46, 56, "ENTITY"], [139, 155, "ENTITY"], [66, 103, "GGP"], [70, 88, "CHEMICAL"], [169, 195, "TISSUE"], [0, 5, "GENE_OR_GENE_PRODUCT"], [169, 178, "ENTITY"], [66, 103, "ENTITY"], [32, 41, "GGP"], [46, 54, "SO"], [32, 56, "GENE_OR_GENE_PRODUCT"], [195, 202, "ENTITY"], [32, 41, "ENTITY"], [139, 147, "GENE_OR_GENE_PRODUCT"], [139, 147, "PROTEIN"], [0, 5, "ENTITY"], [14, 24, "PROTEIN"], [178, 195, "ENTITY"], [14, 24, "CHEBI"], [14, 24, "ENTITY"], [0, 5, "PROTEIN"], [139, 147, "GGP"], [14, 24, "SIMPLE_CHEMICAL"]]}
{"text": "DPP4 degrades incretins such as glucagon like peptide 1 ( GLP-1 ) and glucose-dependent insulinotropic polypeptide , ultimately leading to reduced insulin secretion and abnormal visceral adipose tissue metabolism .", "labels": [[66, 88, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [5, 14, "ENTITY"], [46, 56, "ENTITY"], [139, 155, "ENTITY"], [66, 103, "GGP"], [70, 88, "CHEMICAL"], [169, 195, "TISSUE"], [0, 5, "GENE_OR_GENE_PRODUCT"], [169, 178, "ENTITY"], [66, 103, "ENTITY"], [32, 41, "GGP"], [46, 54, "SO"], [32, 56, "GENE_OR_GENE_PRODUCT"], [195, 202, "ENTITY"], [32, 41, "ENTITY"], [139, 147, "GENE_OR_GENE_PRODUCT"], [139, 147, "PROTEIN"], [0, 5, "ENTITY"], [14, 24, "PROTEIN"], [178, 195, "ENTITY"], [14, 24, "CHEBI"], [14, 24, "ENTITY"], [0, 5, "PROTEIN"], [139, 147, "GGP"], [14, 24, "SIMPLE_CHEMICAL"]]}
{"text": "DPP4 regulates postprandial glucose via degradation of GLP-1 .", "labels": [[5, 15, "ENTITY"], [28, 36, "CHEBI"], [28, 36, "ENTITY"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [55, 61, "CHEBI"], [55, 61, "SIMPLE_CHEMICAL"], [28, 36, "CHEMICAL"], [0, 5, "PROTEIN"], [0, 5, "ENTITY"], [40, 52, "ENTITY"], [28, 36, "SIMPLE_CHEMICAL"], [55, 61, "PROTEIN"], [55, 61, "ENTITY"], [15, 28, "ENTITY"]]}
{"text": "DPP4 inhibitors target the enzymatic activity of DPP4 and consequently block the breakdown of GLP-1 . This increase insulin secretion and decrease blood glucose levels in patients with type 2 diabetes .", "labels": [[94, 100, "PROTEIN"], [27, 37, "SO"], [81, 91, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [5, 16, "ENTITY"], [185, 192, "ENTITY"], [94, 100, "CHEBI"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [185, 192, "DISEASE"], [16, 23, "ENTITY"], [0, 5, "PROTEIN"], [71, 77, "ENTITY"], [94, 100, "SIMPLE_CHEMICAL"], [147, 153, "ORGANISM_SUBSTANCE"], [27, 46, "ENTITY"], [0, 5, "ENTITY"], [0, 5, "ENTITY"], [147, 161, "ENTITY"], [116, 124, "ENTITY"], [0, 5, "PROTEIN"], [94, 100, "ENTITY"], [0, 16, "GGP"]]}
{"text": "Some patients demonstrated liver injury with elevated aspartate aminotransferase(AST;59 of 198[29.8%])and alanine aminotransferase(ALT ; 43of198[21.7 % ] )", "labels": [[27, 33, "ORGAN"], [45, 54, "ENTITY"], [54, 88, "GENE_OR_GENE_PRODUCT"], [54, 64, "CHEBI"], [106, 114, "CHEBI"], [54, 64, "CHEMICAL"], [106, 114, "CHEMICAL"], [5, 14, "ENTITY"], [106, 114, "ENTITY"], [5, 14, "ORGANISM"], [27, 40, "ENTITY"], [54, 88, "ENTITY"], [27, 40, "DISEASE"], [106, 114, "AMINO_ACID"]]}
{"text": "Concentrations of alanine aminotransferase , aspartate aminotransferase , total bilirubin , alkaline phosphatase , and \u03b3-glutamyl transpeptidase were markedly higher in deceased patients than in recovered patients", "labels": [[115, 130, "PROTEIN"], [45, 55, "CHEBI"], [90, 101, "PROTEIN"], [18, 43, "PROTEIN"], [195, 205, "ENTITY"], [18, 43, "ENTITY"], [0, 15, "ENTITY"], [115, 130, "ENTITY"], [18, 43, "GENE_OR_GENE_PRODUCT"], [115, 130, "GENE_OR_GENE_PRODUCT"], [74, 80, "CHEMICAL"], [74, 80, "PROTEIN"], [18, 26, "CHEBI"], [45, 55, "GENE_OR_GENE_PRODUCT"], [169, 178, "ORGANISM"], [90, 101, "SIMPLE_CHEMICAL"], [74, 80, "GGP"], [195, 205, "ORGANISM"], [74, 80, "SIMPLE_CHEMICAL"], [72, 80, "ENTITY"], [169, 178, "ENTITY"], [45, 55, "PROTEIN"], [18, 26, "CHEMICAL"], [90, 101, "ENTITY"], [45, 55, "ENTITY"]]}
{"text": "Alanine aminotransferase ( ALT ) and aspartate aminotransferase ( AST ) levels were significantly higher in severe cases than moderate cases .", "labels": [[108, 115, "ENTITY"], [66, 72, "ENTITY"], [33, 47, "ENTITY"], [0, 25, "ENTITY"], [126, 135, "ENTITY"], [33, 47, "PROTEIN"], [33, 47, "GENE_OR_GENE_PRODUCT"], [33, 47, "GGP"], [0, 25, "GGP"], [0, 25, "GENE_OR_GENE_PRODUCT"], [0, 8, "CHEMICAL"], [0, 25, "PROTEIN"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer .", "labels": [[126, 138, "PROTEIN"], [34, 41, "ENTITY"], [126, 138, "GENE_OR_GENE_PRODUCT"], [12, 21, "ENTITY"], [101, 109, "PROTEIN"], [155, 166, "ENTITY"], [44, 63, "PROTEIN"], [25, 34, "ENTITY"], [155, 166, "PROTEIN"], [44, 63, "GGP"], [12, 21, "ORGANISM"], [101, 109, "GENE_OR_GENE_PRODUCT"], [126, 138, "ENTITY"], [101, 109, "GGP"], [44, 55, "GENE_OR_GENE_PRODUCT"], [126, 138, "CHEBI"], [101, 109, "ENTITY"], [44, 63, "ENTITY"]]}
{"text": "Higher aspartate aminotransferase activity was related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.202 , P3 = 0.042 , R2 = 0.325 , P4 = 0.001 ) .", "labels": [[58, 65, "ENTITY"], [7, 34, "ENTITY"], [34, 43, "ENTITY"], [76, 98, "ENTITY"], [7, 17, "CHEMICAL"], [7, 34, "PROTEIN"], [76, 98, "DISEASE"], [76, 88, "ORGANISM"], [7, 34, "GENE_OR_GENE_PRODUCT"], [7, 34, "GGP"], [0, 7, "ENTITY"], [102, 121, "ENTITY"]]}
{"text": "Those with elevated TnT levels also had higher levels of creatinine ( median [ IQR ] , 0.79 [ 0.71 - 1.17 ] vs 0.63 [ 0.55 - 0.79 ] mg/dL [ to convert to micromoles per liter , multiply by 88.4 ] ) and aspartate aminotransferase ( median [ IQR ] , 39.5 [ 27.2 - 57.8 ] vs 29.0 [21.0 - 39.0]U/L [ to convert to microkatal per liter , multiply by 0.0167 ] ) ( P < .001 , both ) , but alanine aminotransferase did not differ between the 2 groups .", "labels": [[57, 68, "ENTITY"], [186, 212, "GENE_OR_GENE_PRODUCT"], [11, 20, "ENTITY"], [24, 31, "ENTITY"], [186, 212, "GGP"], [20, 24, "ENTITY"], [20, 24, "PROTEIN"], [186, 196, "CHEMICAL"], [345, 369, "PROTEIN"], [57, 68, "CHEBI"], [345, 369, "ENTITY"], [57, 68, "SIMPLE_CHEMICAL"], [186, 212, "PROTEIN"], [212, 229, "ENTITY"], [24, 31, "ENTITY"], [186, 212, "ENTITY"], [57, 68, "CHEMICAL"], [345, 369, "GENE_OR_GENE_PRODUCT"], [20, 24, "GENE_OR_GENE_PRODUCT"], [283, 294, "ENTITY"]]}
{"text": "Some patients demonstrated liver injury with elevated aspartate aminotransferase(AST;59 of 198[29.8%])and alanine aminotransferase(ALT ; 43of198[21.7 % ] )", "labels": [[27, 33, "ORGAN"], [45, 54, "ENTITY"], [54, 88, "GENE_OR_GENE_PRODUCT"], [54, 64, "CHEBI"], [106, 114, "CHEBI"], [54, 64, "CHEMICAL"], [106, 114, "CHEMICAL"], [5, 14, "ENTITY"], [106, 114, "ENTITY"], [5, 14, "ORGANISM"], [27, 40, "ENTITY"], [54, 88, "ENTITY"], [27, 40, "DISEASE"], [106, 114, "AMINO_ACID"]]}
{"text": "Concentrations of alanine aminotransferase , aspartate aminotransferase , total bilirubin , alkaline phosphatase , and \u03b3-glutamyl transpeptidase were markedly higher in deceased patients than in recovered patients", "labels": [[115, 130, "PROTEIN"], [45, 55, "CHEBI"], [90, 101, "PROTEIN"], [18, 43, "PROTEIN"], [195, 205, "ENTITY"], [18, 43, "ENTITY"], [0, 15, "ENTITY"], [115, 130, "ENTITY"], [18, 43, "GENE_OR_GENE_PRODUCT"], [115, 130, "GENE_OR_GENE_PRODUCT"], [74, 80, "CHEMICAL"], [74, 80, "PROTEIN"], [18, 26, "CHEBI"], [45, 55, "GENE_OR_GENE_PRODUCT"], [169, 178, "ORGANISM"], [90, 101, "SIMPLE_CHEMICAL"], [74, 80, "GGP"], [195, 205, "ORGANISM"], [74, 80, "SIMPLE_CHEMICAL"], [72, 80, "ENTITY"], [169, 178, "ENTITY"], [45, 55, "PROTEIN"], [18, 26, "CHEMICAL"], [90, 101, "ENTITY"], [45, 55, "ENTITY"]]}
{"text": "Alanine aminotransferase ( ALT ) and aspartate aminotransferase ( AST ) levels were significantly higher in severe cases than moderate cases .", "labels": [[108, 115, "ENTITY"], [66, 72, "ENTITY"], [33, 47, "ENTITY"], [0, 25, "ENTITY"], [126, 135, "ENTITY"], [33, 47, "PROTEIN"], [33, 47, "GENE_OR_GENE_PRODUCT"], [33, 47, "GGP"], [0, 25, "GGP"], [0, 25, "GENE_OR_GENE_PRODUCT"], [0, 8, "CHEMICAL"], [0, 25, "PROTEIN"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer .", "labels": [[126, 138, "PROTEIN"], [34, 41, "ENTITY"], [126, 138, "GENE_OR_GENE_PRODUCT"], [12, 21, "ENTITY"], [101, 109, "PROTEIN"], [155, 166, "ENTITY"], [44, 63, "PROTEIN"], [25, 34, "ENTITY"], [155, 166, "PROTEIN"], [44, 63, "GGP"], [12, 21, "ORGANISM"], [101, 109, "GENE_OR_GENE_PRODUCT"], [126, 138, "ENTITY"], [101, 109, "GGP"], [44, 55, "GENE_OR_GENE_PRODUCT"], [126, 138, "CHEBI"], [101, 109, "ENTITY"], [44, 63, "ENTITY"]]}
{"text": "Higher aspartate aminotransferase activity was related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.202 , P3 = 0.042 , R2 = 0.325 , P4 = 0.001 ) .", "labels": [[58, 65, "ENTITY"], [7, 34, "ENTITY"], [34, 43, "ENTITY"], [76, 98, "ENTITY"], [7, 17, "CHEMICAL"], [7, 34, "PROTEIN"], [76, 98, "DISEASE"], [76, 88, "ORGANISM"], [7, 34, "GENE_OR_GENE_PRODUCT"], [7, 34, "GGP"], [0, 7, "ENTITY"], [102, 121, "ENTITY"]]}
{"text": "Those with elevated TnT levels also had higher levels of creatinine ( median [ IQR ] , 0.79 [ 0.71 - 1.17 ] vs 0.63 [ 0.55 - 0.79 ] mg/dL [ to convert to micromoles per liter , multiply by 88.4 ] ) and aspartate aminotransferase ( median [ IQR ] , 39.5 [ 27.2 - 57.8 ] vs 29.0 [21.0 - 39.0]U/L [ to convert to microkatal per liter , multiply by 0.0167 ] ) ( P < .001 , both ) , but alanine aminotransferase did not differ between the 2 groups .", "labels": [[57, 68, "ENTITY"], [186, 212, "GENE_OR_GENE_PRODUCT"], [11, 20, "ENTITY"], [24, 31, "ENTITY"], [186, 212, "GGP"], [20, 24, "ENTITY"], [20, 24, "PROTEIN"], [186, 196, "CHEMICAL"], [345, 369, "PROTEIN"], [57, 68, "CHEBI"], [345, 369, "ENTITY"], [57, 68, "SIMPLE_CHEMICAL"], [186, 212, "PROTEIN"], [212, 229, "ENTITY"], [24, 31, "ENTITY"], [186, 212, "ENTITY"], [57, 68, "CHEMICAL"], [345, 369, "GENE_OR_GENE_PRODUCT"], [20, 24, "GENE_OR_GENE_PRODUCT"], [283, 294, "ENTITY"]]}
{"text": "Some patients demonstrated liver injury with elevated aspartate aminotransferase(AST;59 of 198[29.8%])and alanine aminotransferase(ALT ; 43of198[21.7 % ] )", "labels": [[27, 33, "ORGAN"], [45, 54, "ENTITY"], [54, 88, "GENE_OR_GENE_PRODUCT"], [54, 64, "CHEBI"], [106, 114, "CHEBI"], [54, 64, "CHEMICAL"], [106, 114, "CHEMICAL"], [5, 14, "ENTITY"], [106, 114, "ENTITY"], [5, 14, "ORGANISM"], [27, 40, "ENTITY"], [54, 88, "ENTITY"], [27, 40, "DISEASE"], [106, 114, "AMINO_ACID"]]}
{"text": "Increased C-reactive protein , procalcitonin and lactate dehydrogenase were found in five patients ( 5/8 ) , and increased alanine aminotransferase ( ALT ) in four ( 4/8 ) .", "labels": [[113, 123, "CHEBI"], [49, 57, "GENE_OR_GENE_PRODUCT"], [10, 29, "ENTITY"], [49, 57, "PROTEIN"], [49, 57, "GGP"], [10, 21, "GENE_OR_GENE_PRODUCT"], [10, 29, "GGP"], [49, 57, "ENTITY"], [113, 123, "CHEMICAL"], [0, 10, "ENTITY"], [113, 131, "GENE_OR_GENE_PRODUCT"], [131, 148, "ENTITY"], [10, 29, "PROTEIN"], [113, 131, "ENTITY"], [131, 148, "PROTEIN"], [131, 148, "GENE_OR_GENE_PRODUCT"], [113, 131, "PROTEIN"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [236, 242, "ENTITY"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [300, 315, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "Concentrations of alanine aminotransferase , aspartate aminotransferase , total bilirubin , alkaline phosphatase , and \u03b3-glutamyl transpeptidase were markedly higher in deceased patients than in recovered patients", "labels": [[115, 130, "PROTEIN"], [45, 55, "CHEBI"], [90, 101, "PROTEIN"], [18, 43, "PROTEIN"], [195, 205, "ENTITY"], [0, 15, "ENTITY"], [115, 130, "ENTITY"], [115, 130, "GENE_OR_GENE_PRODUCT"], [74, 80, "CHEMICAL"], [74, 80, "PROTEIN"], [18, 26, "CHEBI"], [45, 55, "GENE_OR_GENE_PRODUCT"], [169, 178, "ORGANISM"], [90, 101, "SIMPLE_CHEMICAL"], [74, 80, "GGP"], [18, 43, "GENE_OR_GENE_PRODUCT"], [195, 205, "ORGANISM"], [74, 80, "SIMPLE_CHEMICAL"], [72, 80, "ENTITY"], [18, 43, "ENTITY"], [169, 178, "ENTITY"], [45, 55, "PROTEIN"], [18, 26, "CHEMICAL"], [90, 101, "ENTITY"], [45, 55, "ENTITY"]]}
{"text": "Alanine aminotransferase ( ALT ) and aspartate aminotransferase ( AST ) levels were significantly higher in severe cases than moderate cases .", "labels": [[0, 25, "GGP"], [108, 115, "ENTITY"], [0, 25, "PROTEIN"], [66, 72, "ENTITY"], [33, 47, "ENTITY"], [0, 25, "GENE_OR_GENE_PRODUCT"], [126, 135, "ENTITY"], [33, 47, "PROTEIN"], [33, 47, "GENE_OR_GENE_PRODUCT"], [0, 25, "ENTITY"], [33, 47, "GGP"], [0, 8, "CHEMICAL"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer .", "labels": [[126, 138, "PROTEIN"], [34, 41, "ENTITY"], [126, 138, "GENE_OR_GENE_PRODUCT"], [12, 21, "ENTITY"], [101, 109, "PROTEIN"], [155, 166, "ENTITY"], [44, 63, "PROTEIN"], [25, 34, "ENTITY"], [155, 166, "PROTEIN"], [44, 63, "GGP"], [12, 21, "ORGANISM"], [101, 109, "GENE_OR_GENE_PRODUCT"], [126, 138, "ENTITY"], [101, 109, "GGP"], [44, 55, "GENE_OR_GENE_PRODUCT"], [126, 138, "CHEBI"], [101, 109, "ENTITY"], [44, 63, "ENTITY"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Higher alanine aminotransferase activity was related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.243 , P3 = 0.013 , R2 = 0.306 , P4 = 0.002 ) .", "labels": [[7, 15, "CHEBI"], [74, 86, "ORGANISM"], [32, 41, "ENTITY"], [56, 63, "ENTITY"], [100, 119, "ENTITY"], [7, 32, "PROTEIN"], [7, 15, "CHEMICAL"], [7, 32, "ENTITY"], [74, 96, "ENTITY"], [0, 7, "ENTITY"], [74, 96, "DISEASE"], [7, 32, "GENE_OR_GENE_PRODUCT"]]}
{"text": "As for other traits , high alanine aminotransferase ( ALT ) , commonly associated with liver diseases , may be related to elevated ACE2 expression .", "labels": [[131, 136, "ENTITY"], [13, 20, "ENTITY"], [62, 82, "ENTITY"], [82, 93, "ENTITY"], [122, 131, "ENTITY"], [22, 35, "ENTITY"], [27, 35, "GENE_OR_GENE_PRODUCT"], [122, 131, "GENE_OR_GENE_PRODUCT"], [122, 131, "GGP"], [82, 93, "DISEASE"], [122, 131, "PROTEIN"], [27, 35, "PROTEIN"], [111, 122, "ENTITY"]]}
{"text": "As for other traits , high alanine aminotransferase ( ALT ) , commonly associated with liver diseases , may be related to elevated ACE2 expression .", "labels": [[13, 20, "ENTITY"], [62, 82, "ENTITY"], [82, 93, "ENTITY"], [122, 131, "ENTITY"], [22, 35, "ENTITY"], [27, 35, "GENE_OR_GENE_PRODUCT"], [122, 131, "GENE_OR_GENE_PRODUCT"], [122, 131, "GGP"], [82, 93, "DISEASE"], [122, 131, "PROTEIN"], [27, 35, "PROTEIN"], [111, 122, "ENTITY"], [131, 136, "ENTITY"]]}
{"text": "GEX analysis showed that CD8 + T cells expressed high levels of effector molecules , including GZMA , GZMK , FASLG , CCL5 , etc . , and resident T cell markers ITGA1 , CXCR6 , JAML , etc . , likely played crucial roles in immune defense ( Figure S4 ) .", "labels": [[128, 136, "ENTITY"], [25, 33, "CELL_TYPE"], [85, 95, "ENTITY"], [25, 33, "ENTITY"], [109, 117, "GENE_OR_GENE_PRODUCT"], [102, 109, "PROTEIN"], [25, 33, "GGP"], [128, 152, "PROTEIN"], [102, 109, "CHEMICAL"], [64, 73, "CHEBI"], [109, 117, "GGP"], [102, 109, "GENE_OR_GENE_PRODUCT"], [85, 95, "GGP"], [109, 117, "ENTITY"], [85, 95, "PROTEIN"], [205, 222, "ENTITY"], [0, 13, "ENTITY"], [102, 109, "ENTITY"], [205, 229, "CELL"], [25, 29, "GENE_OR_GENE_PRODUCT"], [109, 117, "PROTEIN"], [64, 73, "PROTEIN"], [102, 109, "GGP"], [85, 95, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"], [222, 229, "ENTITY"]]}
{"text": "GEX analysis showed that CD8 + T cells expressed high levels of effector molecules , including GZMA , GZMK , FASLG , CCL5 , etc . , and resident T cell markers ITGA1 , CXCR6 , JAML , etc . , likely played crucial roles in immune defense ( Figure S4 ) .", "labels": [[128, 136, "ENTITY"], [25, 33, "CELL_TYPE"], [85, 95, "ENTITY"], [25, 33, "ENTITY"], [109, 117, "GENE_OR_GENE_PRODUCT"], [25, 33, "GGP"], [128, 152, "PROTEIN"], [102, 109, "GENE_OR_GENE_PRODUCT"], [64, 73, "CHEBI"], [109, 117, "GGP"], [85, 95, "GGP"], [102, 109, "PROTEIN"], [102, 109, "GGP"], [109, 117, "ENTITY"], [85, 95, "PROTEIN"], [205, 222, "ENTITY"], [0, 13, "ENTITY"], [205, 229, "CELL"], [25, 29, "GENE_OR_GENE_PRODUCT"], [109, 117, "PROTEIN"], [64, 73, "PROTEIN"], [85, 95, "GENE_OR_GENE_PRODUCT"], [102, 109, "ENTITY"], [102, 109, "CHEMICAL"], [64, 73, "ENTITY"], [222, 229, "ENTITY"]]}
{"text": "FACs showed that these patients have very low level of PD-1 and Tim-3 on CD8 + and CD4 + T cells in the prodromal stage , however , their levels on CD8 + T cells was increased in overtly symptomatic stages , and highest levels were seen in ICU period ( Figure 3C , D ) .", "labels": [[23, 32, "ORGANISM"], [83, 97, "GGP"], [73, 79, "GGP"], [73, 97, "CELL_TYPE"], [55, 60, "ENTITY"], [64, 70, "ENTITY"], [104, 120, "ENTITY"], [179, 187, "ENTITY"], [64, 70, "GGP"], [187, 199, "ENTITY"], [55, 60, "PROTEIN"], [64, 70, "GENE_OR_GENE_PRODUCT"], [83, 97, "ENTITY"], [0, 5, "ENTITY"], [83, 87, "GENE_OR_GENE_PRODUCT"], [55, 60, "GENE_OR_GENE_PRODUCT"], [240, 244, "ENTITY"], [0, 5, "CELL"], [244, 253, "ENTITY"], [23, 32, "ENTITY"], [145, 156, "GGP"], [73, 77, "GENE_OR_GENE_PRODUCT"], [46, 52, "ENTITY"], [145, 156, "ENTITY"], [145, 156, "CELL_TYPE"], [73, 79, "ENTITY"], [212, 220, "ENTITY"], [64, 70, "PROTEIN"]]}
{"text": "Similarly , higher levels of Tim-3 was observed on CD4 + T cells from patients who are in ICU stage , although enhancing the expression of PD-1 on CD4 + T cells was not obviously during disease progress ( Figure 3C , D ) .", "labels": [[90, 94, "ENTITY"], [203, 212, "ENTITY"], [51, 59, "CELL_TYPE"], [48, 59, "GGP"], [51, 59, "GGP"], [212, 215, "ENTITY"], [51, 59, "ENTITY"], [179, 194, "ENTITY"], [48, 59, "ENTITY"], [48, 59, "CELL_TYPE"]]}
{"text": "FACs showed that these patients have very low level of PD-1 and Tim-3 on CD8 + and CD4 + T cells in the prodromal stage , however , their levels on CD8 + T cells was increased in overtly symptomatic stages , and highest levels were seen in ICU period ( Figure 3C , D ) .", "labels": [[23, 32, "ORGANISM"], [83, 97, "GGP"], [73, 79, "GGP"], [73, 97, "CELL_TYPE"], [55, 60, "ENTITY"], [64, 70, "ENTITY"], [104, 120, "ENTITY"], [64, 70, "GGP"], [55, 60, "PROTEIN"], [187, 199, "ENTITY"], [64, 70, "GENE_OR_GENE_PRODUCT"], [83, 97, "ENTITY"], [0, 5, "ENTITY"], [83, 87, "GENE_OR_GENE_PRODUCT"], [55, 60, "GENE_OR_GENE_PRODUCT"], [240, 244, "ENTITY"], [0, 5, "CELL"], [244, 253, "ENTITY"], [23, 32, "ENTITY"], [145, 156, "GGP"], [73, 77, "GENE_OR_GENE_PRODUCT"], [46, 52, "ENTITY"], [145, 156, "ENTITY"], [145, 156, "CELL_TYPE"], [73, 79, "ENTITY"], [212, 220, "ENTITY"], [64, 70, "PROTEIN"], [179, 187, "ENTITY"]]}
{"text": "Similarly , higher levels of Tim-3 was observed on CD4 + T cells from patients who are in ICU stage , although enhancing the expression of PD-1 on CD4 + T cells was not obviously during disease progress ( Figure 3C , D ) .", "labels": [[90, 94, "ENTITY"], [203, 212, "ENTITY"], [51, 59, "CELL_TYPE"], [48, 59, "GGP"], [51, 59, "GGP"], [212, 215, "ENTITY"], [51, 59, "ENTITY"], [179, 194, "ENTITY"], [48, 59, "ENTITY"], [48, 59, "CELL_TYPE"]]}
{"text": "Consistently , the mRNA level of homocysteine-inducible , ER stress-inducible , ubiquitin-like domain member 1 ( HERPUD1 ) , an ER stress marker , was up-regulated in L cells infected with mouse hepatitis virus ( MHV ) or SARS-CoV ( Versteeg et al. , 2007 ) .", "labels": [[0, 13, "ENTITY"], [175, 195, "ORGANISM"], [151, 167, "CL"], [213, 219, "ORGANISM"], [151, 167, "CELL"], [175, 184, "TAXON"], [167, 175, "ENTITY"], [175, 195, "ENTITY"], [58, 61, "ENTITY"], [213, 219, "GGP"], [61, 102, "ENTITY"], [184, 195, "DISEASE"], [151, 167, "CELL_TYPE"], [121, 138, "PROTEIN"], [213, 219, "PROTEIN"], [61, 102, "PROTEIN"], [213, 219, "ENTITY"], [121, 138, "ENTITY"], [138, 151, "ENTITY"], [151, 167, "ENTITY"], [80, 95, "SO"]]}
{"text": "We observed about 3 to 4 fold increase in luciferase activity in 3a expressing cells as compared to the vector control cells .", "labels": [[104, 125, "ENTITY"], [79, 85, "CL"], [42, 62, "ENTITY"], [42, 53, "GENE_OR_GENE_PRODUCT"], [104, 111, "SO"], [68, 79, "ENTITY"], [79, 85, "CELL"], [79, 85, "CELL"], [3, 12, "ENTITY"], [79, 85, "CL"], [42, 53, "PROTEIN"], [30, 39, "ENTITY"], [104, 125, "CELL_LINE"], [79, 85, "ENTITY"]]}
{"text": "The identified target genes of ATF6 include ER chaperones ( such as GRP78 , GRP94 ) , PDI , and the UPR transcription factors GADD153 and XBP1 ( Szegezdi et al. , 2006 ) .", "labels": [[22, 28, "SO"], [44, 58, "ENTITY"], [44, 58, "PROTEIN"], [138, 145, "PROTEIN"], [31, 36, "ENTITY"], [44, 47, "GENE_OR_GENE_PRODUCT"], [31, 36, "GGP"], [15, 22, "ENTITY"], [118, 126, "ENTITY"], [118, 126, "GENE_OR_GENE_PRODUCT"], [96, 126, "PROTEIN"], [138, 145, "GENE_OR_GENE_PRODUCT"], [44, 58, "GGP"], [31, 36, "PROTEIN"], [4, 15, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [118, 126, "GGP"], [22, 28, "ENTITY"]]}
{"text": "Since Vitamin B3 is highly lung protective , it should be used as soon as coughing begins . When breathing difficulty becomes apparent , hyaluronidase can be used intratracheally and at the same time 4-MU can be given to inhibit HAS2 .", "labels": [[6, 17, "ENTITY"], [195, 200, "SIMPLE_CHEMICAL"], [195, 200, "ENTITY"], [6, 17, "GGP"], [221, 229, "GENE_OR_GENE_PRODUCT"], [27, 32, "ENTITY"], [221, 229, "PROTEIN"], [6, 17, "SIMPLE_CHEMICAL"], [221, 229, "ENTITY"], [195, 200, "PROTEIN"], [92, 107, "ENTITY"], [6, 17, "CHEMICAL"], [27, 32, "ORGAN"], [195, 200, "CHEMICAL"], [221, 229, "GGP"]]}
{"text": "For example , the nsp16 has been shown to utilize the 2\u2032-O-methyltransferase activity to modify coronavirus mRNAs , so as to evade from the cytosolic RNA sensor melanoma differentiation-associated protein 5 ( MDA5 ) and type I IFN induction ( Roth-Cross et al. , 2008;Z\u00fcst et al. , 2011 ) .", "labels": [[231, 243, "GENE_OR_GENE_PRODUCT"], [154, 161, "CANCER"], [231, 243, "DNA"], [154, 161, "DISEASE"], [161, 205, "ENTITY"], [216, 227, "GGP"], [136, 161, "ENTITY"], [216, 227, "PROTEIN"], [136, 150, "GO"], [96, 108, "RNA"], [154, 205, "GGP"], [216, 231, "ENTITY"], [154, 205, "PROTEIN"], [216, 227, "GENE_OR_GENE_PRODUCT"], [136, 150, "CELLULAR_COMPONENT"]]}
{"text": "Usually , Toll-like receptor ( TLR ) 3 , TLR7 , TLR8 , and TLR9 sense viral RNA and DNA in the endosome [ 60 , 61 ] . The viral RNA receptor retinoic-acid inducible gene I ( RIG-I ) [ 62 ] , cytosolic receptor melanoma differentiation-associated gene 5 ( MDA5 ) and nucleotidyl transferase cyclic GMP-AMP synthase ( cGAS ) [ 63 ] are responsible for the recognition of viral RNA and DNA in the cytoplasm .", "labels": [[111, 122, "TAXON"], [41, 48, "ENTITY"], [155, 165, "PROTEIN"], [174, 201, "ENTITY"], [354, 366, "CELLULAR_COMPONENT"], [346, 354, "ENTITY"], [201, 219, "ENTITY"], [354, 366, "ENTITY"], [346, 354, "RNA"], [70, 84, "ENTITY"], [10, 20, "ENTITY"], [88, 95, "CELLULAR_COMPONENT"], [191, 201, "DISEASE"], [64, 70, "TAXON"], [88, 95, "ENTITY"], [10, 35, "PROTEIN"], [111, 141, "PROTEIN"], [246, 297, "PROTEIN"], [76, 80, "ENTITY"], [155, 165, "ENTITY"], [354, 366, "SO"], [64, 70, "ENTITY"], [88, 95, "GO"], [10, 20, "GENE_OR_GENE_PRODUCT"], [41, 48, "GGP"], [41, 48, "PROTEIN"], [174, 219, "PROTEIN"], [346, 354, "TAXON"], [111, 155, "ENTITY"], [41, 48, "GENE_OR_GENE_PRODUCT"], [76, 80, "SO"], [70, 84, "ORGANISM_SUBSTANCE"], [246, 297, "GENE_OR_GENE_PRODUCT"], [10, 20, "GGP"], [155, 165, "GGP"], [262, 297, "GGP"], [246, 297, "ENTITY"], [174, 184, "GO"], [70, 84, "GO"], [59, 64, "ENTITY"], [174, 219, "GENE_OR_GENE_PRODUCT"], [76, 80, "CELLULAR_COMPONENT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [164, 171, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [362, 377, "GENE_OR_GENE_PRODUCT"], [164, 171, "PROTEIN"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [102, 108, "PROTEIN"], [164, 171, "GGP"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [133, 164, "GENE_OR_GENE_PRODUCT"], [133, 164, "PROTEIN"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [33, 41, "ENTITY"], [299, 330, "GGP"], [377, 389, "PROTEIN"], [164, 171, "ENTITY"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [164, 171, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [362, 377, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [164, 171, "GGP"], [102, 108, "PROTEIN"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [164, 171, "ENTITY"], [133, 164, "PROTEIN"], [133, 164, "GENE_OR_GENE_PRODUCT"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [33, 41, "ENTITY"], [299, 330, "GGP"], [164, 171, "PROTEIN"], [377, 389, "PROTEIN"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "As the single-nucleotide polymorphism rs12252-C/C in the gene IFITM3 ( which encodes interferon-induced transmembrane protein 3 ) is linked to severe influenza6,7 , we analyzed IFITM3-rs12252 in the patient with COVID-19 and found the \u2018 risk \u2019 IFITM3-rs12252-C/C variant ( Extended Data Fig. 2b ) .", "labels": [[7, 38, "SO"], [7, 38, "ENTITY"], [143, 150, "ENTITY"], [244, 263, "SO"], [168, 177, "DISEASE"], [62, 69, "GENE_OR_GENE_PRODUCT"], [143, 150, "PROTEIN"], [85, 126, "GENE_OR_GENE_PRODUCT"], [7, 50, "DNA"], [168, 177, "PROTEIN"], [38, 50, "GENE_OR_GENE_PRODUCT"], [237, 263, "PROTEIN"], [85, 126, "ENTITY"], [237, 244, "CHEMICAL"], [57, 69, "ENTITY"], [57, 69, "SO"], [237, 263, "ENTITY"], [263, 273, "ENTITY"], [62, 69, "PROTEIN"], [231, 237, "ENTITY"], [85, 126, "PROTEIN"]]}
{"text": "As the single-nucleotide polymorphism rs12252-C/C in the gene IFITM3 ( which encodes interferon-induced transmembrane protein 3 ) is linked to severe influenza6,7 , we analyzed IFITM3-rs12252 in the patient with COVID-19 and found the \u2018 risk \u2019 IFITM3-rs12252-C/C variant ( Extended Data Fig. 2b ) .", "labels": [[7, 38, "SO"], [7, 38, "ENTITY"], [143, 150, "ENTITY"], [168, 177, "DISEASE"], [62, 69, "GENE_OR_GENE_PRODUCT"], [143, 150, "PROTEIN"], [85, 126, "GENE_OR_GENE_PRODUCT"], [7, 50, "DNA"], [168, 177, "PROTEIN"], [85, 126, "ENTITY"], [237, 244, "CHEMICAL"], [57, 69, "ENTITY"], [244, 263, "SO"], [237, 263, "PROTEIN"], [38, 50, "GENE_OR_GENE_PRODUCT"], [57, 69, "SO"], [237, 263, "ENTITY"], [263, 273, "ENTITY"], [62, 69, "PROTEIN"], [231, 237, "ENTITY"], [85, 126, "PROTEIN"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [0, 10, "CHEMICAL"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [0, 10, "ENTITY"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [198, 232, "ENTITY"], [0, 10, "SIMPLE_CHEMICAL"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [0, 10, "CHEMICAL"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [0, 10, "ENTITY"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [198, 232, "ENTITY"], [0, 10, "SIMPLE_CHEMICAL"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [0, 10, "CHEMICAL"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [0, 10, "ENTITY"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [198, 232, "ENTITY"], [0, 10, "SIMPLE_CHEMICAL"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [0, 10, "CHEMICAL"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [0, 10, "ENTITY"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [198, 232, "ENTITY"], [0, 10, "SIMPLE_CHEMICAL"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "The expressions of immunoglobulin subunits ( IGHG1 , IGHG2 , IGHG4 , IGLC2 , IGLL1 , and IGHE ) were also significant lower in COVID-19-SS ( Fig.3a , h ) , indicating reduced antibody secretion by B cells .", "labels": [[19, 43, "PROTEIN"], [61, 69, "ENTITY"], [167, 175, "ENTITY"], [19, 43, "GGP"], [127, 139, "GENE_OR_GENE_PRODUCT"], [69, 77, "DNA"], [19, 43, "ENTITY"], [69, 77, "ENTITY"], [118, 127, "ENTITY"], [127, 139, "ENTITY"], [69, 77, "GGP"], [61, 69, "DNA"], [61, 69, "GENE_OR_GENE_PRODUCT"], [156, 167, "ENTITY"], [4, 16, "ENTITY"], [69, 77, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [156, 167, "GO"], [19, 34, "GENE_OR_GENE_PRODUCT"], [118, 127, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expressions of immunoglobulin subunits ( IGHG1 , IGHG2 , IGHG4 , IGLC2 , IGLL1 , and IGHE ) were also significant lower in COVID-19-SS ( Fig.3a , h ) , indicating reduced antibody secretion by B cells .", "labels": [[19, 43, "PROTEIN"], [167, 175, "ENTITY"], [61, 69, "GENE_OR_GENE_PRODUCT"], [19, 43, "GGP"], [127, 139, "GENE_OR_GENE_PRODUCT"], [69, 77, "DNA"], [19, 43, "ENTITY"], [69, 77, "ENTITY"], [61, 69, "ENTITY"], [118, 127, "ENTITY"], [61, 69, "GGP"], [127, 139, "ENTITY"], [69, 77, "GGP"], [156, 167, "ENTITY"], [4, 16, "ENTITY"], [69, 77, "GENE_OR_GENE_PRODUCT"], [156, 167, "GO"], [61, 69, "DNA"], [19, 34, "GENE_OR_GENE_PRODUCT"], [118, 127, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expressions of immunoglobulin subunits ( IGHG1 , IGHG2 , IGHG4 , IGLC2 , IGLL1 , and IGHE ) were also significant lower in COVID-19-SS ( Fig.3a , h ) , indicating reduced antibody secretion by B cells .", "labels": [[19, 43, "PROTEIN"], [167, 175, "ENTITY"], [61, 69, "DNA"], [61, 69, "GGP"], [19, 43, "GGP"], [127, 139, "GENE_OR_GENE_PRODUCT"], [69, 77, "DNA"], [19, 43, "ENTITY"], [69, 77, "ENTITY"], [61, 69, "GENE_OR_GENE_PRODUCT"], [118, 127, "ENTITY"], [127, 139, "ENTITY"], [69, 77, "GGP"], [156, 167, "ENTITY"], [4, 16, "ENTITY"], [61, 69, "ENTITY"], [69, 77, "GENE_OR_GENE_PRODUCT"], [156, 167, "GO"], [19, 34, "GENE_OR_GENE_PRODUCT"], [118, 127, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expressions of immunoglobulin subunits ( IGHG1 , IGHG2 , IGHG4 , IGLC2 , IGLL1 , and IGHE ) were also significant lower in COVID-19-SS ( Fig.3a , h ) , indicating reduced antibody secretion by B cells .", "labels": [[61, 69, "ENTITY"], [19, 43, "PROTEIN"], [167, 175, "ENTITY"], [19, 43, "GGP"], [127, 139, "GENE_OR_GENE_PRODUCT"], [69, 77, "DNA"], [19, 43, "ENTITY"], [69, 77, "ENTITY"], [118, 127, "ENTITY"], [127, 139, "ENTITY"], [69, 77, "GGP"], [61, 69, "DNA"], [156, 167, "ENTITY"], [61, 69, "GGP"], [4, 16, "ENTITY"], [69, 77, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [156, 167, "GO"], [19, 34, "GENE_OR_GENE_PRODUCT"], [118, 127, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expressions of immunoglobulin subunits ( IGHG1 , IGHG2 , IGHG4 , IGLC2 , IGLL1 , and IGHE ) were also significant lower in COVID-19-SS ( Fig.3a , h ) , indicating reduced antibody secretion by B cells .", "labels": [[19, 43, "PROTEIN"], [167, 175, "ENTITY"], [61, 69, "DNA"], [69, 77, "DNA"], [19, 43, "GGP"], [127, 139, "GENE_OR_GENE_PRODUCT"], [69, 77, "ENTITY"], [19, 43, "ENTITY"], [61, 69, "GENE_OR_GENE_PRODUCT"], [118, 127, "ENTITY"], [127, 139, "ENTITY"], [61, 69, "GGP"], [156, 167, "ENTITY"], [4, 16, "ENTITY"], [69, 77, "GGP"], [156, 167, "GO"], [69, 77, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [19, 34, "GENE_OR_GENE_PRODUCT"], [118, 127, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expressions of immunoglobulin subunits ( IGHG1 , IGHG2 , IGHG4 , IGLC2 , IGLL1 , and IGHE ) were also significant lower in COVID-19-SS ( Fig.3a , h ) , indicating reduced antibody secretion by B cells .", "labels": [[19, 43, "PROTEIN"], [167, 175, "ENTITY"], [61, 69, "DNA"], [19, 43, "GGP"], [127, 139, "GENE_OR_GENE_PRODUCT"], [69, 77, "DNA"], [19, 43, "ENTITY"], [69, 77, "ENTITY"], [61, 69, "GENE_OR_GENE_PRODUCT"], [118, 127, "ENTITY"], [127, 139, "ENTITY"], [61, 69, "GGP"], [69, 77, "GGP"], [156, 167, "ENTITY"], [4, 16, "ENTITY"], [69, 77, "GENE_OR_GENE_PRODUCT"], [156, 167, "GO"], [61, 69, "ENTITY"], [19, 34, "GENE_OR_GENE_PRODUCT"], [118, 127, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [197, 204, "GENE_OR_GENE_PRODUCT"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [197, 204, "ENTITY"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [197, 204, "PROTEIN"], [446, 462, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [197, 204, "DISEASE"], [197, 204, "ENTITY"], [74, 83, "ORGANISM"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [227, 235, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [155, 162, "PROTEIN"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [197, 204, "CHEMICAL"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [197, 204, "GGP"], [197, 204, "PROTEIN"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [59, 82, "PROTEIN"], [36, 50, "PROTEIN"], [227, 249, "GGP"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [59, 73, "DISEASE"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [36, 50, "ENTITY"], [292, 317, "GENE_OR_GENE_PRODUCT"], [227, 249, "ENTITY"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [132, 142, "ENTITY"], [205, 212, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [59, 82, "ENTITY"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [227, 249, "PROTEIN"], [227, 249, "GENE_OR_GENE_PRODUCT"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "TBNK lymphocyte subset analysis revealed decreased percentage of CD16 + CD56 + lymphocytes ( 4/8 ) and Th/Ts ( 1/8 ) , and increased percentage of CD3 + ( 2/8 ) , CD4 + ( 4/8 ) and CD8 + ( 1/8 ) lymphocytes . Cytokine detection assays showed increased levels of IL-6 ( 2/8 ) , IL-10 ( 5/8 ) and IFN-\u03b3 ( 2/8 ) .", "labels": [[-1, 25, "ENTITY"], [281, 287, "GENE_OR_GENE_PRODUCT"], [199, 222, "ENTITY"], [127, 137, "ENTITY"], [127, 137, "GENE_OR_GENE_PRODUCT"], [41, 51, "ENTITY"], [5, 16, "CELL"], [266, 271, "ENTITY"], [127, 137, "ENTITY"], [5, 16, "ENTITY"], [0, 5, "ENTITY"], [159, 199, "CELL_TYPE"], [239, 246, "ENTITY"], [281, 293, "PROTEIN"], [175, 199, "ENTITY"], [127, 137, "PROTEIN"], [51, 65, "GGP"], [65, 70, "GENE_OR_GENE_PRODUCT"], [281, 287, "CHEMICAL"], [232, 239, "ENTITY"], [127, 137, "GGP"], [5, 16, "CL"], [51, 62, "GENE_OR_GENE_PRODUCT"], [137, 157, "ENTITY"], [-1, 25, "CELL_LINE"], [137, 157, "CELL_TYPE"], [266, 271, "PROTEIN"], [281, 287, "ENTITY"], [185, 199, "CL"], [266, 271, "GGP"], [0, 23, "CELL_LINE"], [266, 271, "GENE_OR_GENE_PRODUCT"], [51, 62, "ENTITY"], [83, 95, "CL"]]}
{"text": "Of patients with available data , concentrations of interleukin 2 receptor , interleukin 6 , interleukin 8 , interleukin 10 , and tumour necrosis factor \u03b1 were significantly higher in deceased patients than in recovered patients .", "labels": [[126, 146, "PROTEIN"], [75, 89, "GENE_OR_GENE_PRODUCT"], [3, 12, "ENTITY"], [52, 66, "PROTEIN"], [75, 89, "PROTEIN"], [184, 193, "ORGANISM"], [75, 89, "ENTITY"], [27, 32, "ENTITY"], [52, 66, "GGP"], [52, 66, "GENE_OR_GENE_PRODUCT"], [75, 89, "GGP"], [202, 210, "ENTITY"], [52, 66, "ENTITY"], [126, 146, "ENTITY"], [184, 193, "ENTITY"], [126, 146, "GENE_OR_GENE_PRODUCT"], [210, 220, "ENTITY"], [210, 220, "ORGANISM"], [174, 184, "ENTITY"], [126, 146, "GGP"], [126, 137, "DISEASE"], [3, 12, "ORGANISM"]]}
{"text": "Evaluation of serum cytokines on admission revealed that levels of interleukin (IL)- 2R , IL-6 , IL-10 , and tumor necrosis factor-\u03b1 ( TNF-\u03b1 ) were markedly higher in severe cases than in moderate cases ( Figure 2 , Supplementary Table 1 ) .", "labels": [[205, 230, "GENE_OR_GENE_PRODUCT"], [105, 115, "DISEASE"], [157, 167, "ENTITY"], [33, 43, "ENTITY"], [124, 135, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [0, 11, "ENTITY"], [14, 20, "ENTITY"], [105, 124, "PROTEIN"], [14, 20, "ORGANISM_SUBSTANCE"], [124, 135, "PROTEIN"], [105, 124, "ENTITY"], [105, 124, "GENE_OR_GENE_PRODUCT"], [67, 88, "ENTITY"], [197, 205, "ENTITY"], [180, 188, "ENTITY"], [67, 88, "GGP"], [124, 135, "ENTITY"], [20, 30, "ENTITY"], [205, 230, "ENTITY"], [57, 64, "ENTITY"], [67, 88, "GENE_OR_GENE_PRODUCT"], [188, 197, "ENTITY"], [67, 88, "PROTEIN"], [14, 30, "PROTEIN"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[134, 139, "ENTITY"], [141, 160, "GGP"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [103, 111, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [111, 120, "GENE_OR_GENE_PRODUCT"], [519, 528, "ENTITY"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [528, 540, "ENTITY"], [127, 132, "GGP"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [303, 354, "CL"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [103, 111, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [303, 354, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [111, 120, "ENTITY"], [141, 160, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [111, 120, "PROTEIN"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [303, 354, "ENTITY"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [103, 111, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [303, 354, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [528, 540, "GGP"], [103, 111, "CHEMICAL"], [167, 176, "ENTITY"], [103, 111, "PROTEIN"], [354, 400, "PROTEIN"]]}
{"text": "We only found the levels of TNF-\u03b1 , IL-6 and IL-10 were significantly increased in infected patients , and statistical analysis illustrated that their levels in ICU patients are significantly higher than in Non-ICU patients ( Figure 2A ) .", "labels": [[161, 165, "ENTITY"], [28, 34, "CHEMICAL"], [207, 215, "ORGANISM"], [207, 215, "ENTITY"], [28, 34, "PROTEIN"], [103, 119, "ENTITY"], [224, 233, "ENTITY"], [28, 34, "ENTITY"], [28, 34, "GENE_OR_GENE_PRODUCT"], [161, 165, "ORGANISM"], [18, 25, "ENTITY"]]}
{"text": "Interestingly , serum levels of IFN-\u03b3 , IL-10 , IL-6 and TNF-\u03b1 were significantly decreased in these patients in the decline period as compared with illness period , while counts of total T cells , CD4 + , and CD8 + T cell subsets recovered during the decline period ( Figure 2C ) .", "labels": [[117, 125, "ENTITY"], [182, 190, "CL"], [68, 82, "ENTITY"], [182, 190, "CELL"], [16, 22, "ENTITY"], [260, 269, "ENTITY"], [206, 218, "GGP"], [149, 157, "ENTITY"], [206, 223, "ENTITY"], [117, 125, "ENTITY"], [190, 198, "ENTITY"], [179, 190, "CELL_TYPE"], [179, 190, "ENTITY"], [190, 223, "CELL_TYPE"], [190, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expression of IL-6 , IL-8 and IL-10 in the serum of patients with COVID-19 increased significantly compared with the control group ( P<0.05 ) .", "labels": [[18, 23, "GGP"], [4, 15, "ENTITY"], [121, 129, "ENTITY"], [18, 23, "GENE_OR_GENE_PRODUCT"], [18, 23, "PROTEIN"], [18, 23, "ENTITY"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "ENTITY"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [196, 208, "GGP"], [208, 227, "CHEMICAL"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [40, 59, "ENTITY"], [26, 38, "SIMPLE_CHEMICAL"], [170, 179, "ENTITY"], [179, 194, "GGP"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "ENTITY"], [144, 154, "GGP"], [253, 271, "ENTITY"], [26, 40, "CHEBI"], [170, 179, "GGP"], [26, 38, "CHEMICAL"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [144, 154, "GENE_OR_GENE_PRODUCT"], [196, 208, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [179, 194, "GENE_OR_GENE_PRODUCT"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [26, 38, "ENTITY"], [196, 208, "CHEMICAL"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [196, 208, "PROTEIN"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "Interestingly , the concentration of these three cytokines was negatively correlated with total T cell counts , CD4 + counts , and CD8 + counts , respectively ( Figure 2B ) .", "labels": [[146, 161, "ENTITY"], [110, 118, "ENTITY"], [90, 98, "ENTITY"], [127, 137, "ENTITY"], [110, 116, "GGP"]]}
{"text": "Pearson correlation analysis results showed a remarkably positive correlation of MP production and the expression of IL-6 , IL-8 and IL-10 with the severity of COVID-19 ( Table 4 ) .", "labels": [[81, 84, "ENTITY"], [81, 84, "GENE_OR_GENE_PRODUCT"], [0, 29, "ENTITY"], [57, 66, "ENTITY"], [117, 122, "PROTEIN"], [117, 122, "GGP"], [8, 20, "ENTITY"], [117, 122, "ENTITY"], [29, 37, "ENTITY"], [117, 122, "GENE_OR_GENE_PRODUCT"], [103, 114, "ENTITY"], [84, 95, "ENTITY"], [81, 84, "DISEASE"]]}
{"text": "Notably , the 3a-CS mutant completely abrogated IL-1\u03b2 secretion ( Figure 2B ) , suggesting that the ion channel activity of the 3a protein is required for SARS-CoV 3a-induced IL-1\u03b2 secretion .", "labels": [[14, 20, "ENTITY"], [64, 73, "ENTITY"], [14, 20, "SO"], [164, 175, "GGP"], [38, 48, "PROTEIN"], [10, 17, "CHEBI"], [10, 17, "PROTEIN"], [38, 48, "GGP"], [48, 54, "ENTITY"], [164, 175, "PROTEIN"], [151, 175, "ORGANISM"], [48, 54, "ENTITY"], [38, 48, "ENTITY"], [96, 104, "ENTITY"], [164, 175, "ENTITY"], [27, 38, "ENTITY"], [38, 48, "GENE_OR_GENE_PRODUCT"], [10, 17, "ENTITY"]]}
{"text": "The binding of COVI-19 to the Toll Like Receptor ( TLR ) causes the release of pro-IL-1\u03b2 which is cleaved by caspase-1 , followed by inflammasome activation and production of active mature IL-1\u03b2 which is a mediator of lung inflammation , fever and fibrosis .", "labels": [[15, 23, "ENTITY"], [30, 49, "ENTITY"], [215, 223, "DISEASE"], [223, 238, "DISEASE"], [182, 189, "PROTEIN"], [4, 12, "ENTITY"], [182, 189, "ENTITY"], [182, 189, "GENE_OR_GENE_PRODUCT"], [223, 238, "ENTITY"], [15, 23, "DNA"], [182, 189, "GGP"], [30, 49, "GENE_OR_GENE_PRODUCT"], [172, 182, "ENTITY"], [30, 49, "PROTEIN"], [215, 223, "ENTITY"], [15, 23, "GENE_OR_GENE_PRODUCT"], [130, 146, "ENTITY"]]}
{"text": "The binding of COVI-19 to the Toll Like Receptor ( TLR ) causes the release of pro-IL-1\u03b2 which is cleaved by caspase-1 , followed by inflammasome activation and production of active mature IL-1\u03b2 which is a mediator of lung inflammation , fever and fibrosis .", "labels": [[15, 23, "ENTITY"], [30, 49, "ENTITY"], [215, 223, "DISEASE"], [223, 238, "DISEASE"], [182, 189, "PROTEIN"], [4, 12, "ENTITY"], [182, 189, "ENTITY"], [182, 189, "GENE_OR_GENE_PRODUCT"], [223, 238, "ENTITY"], [15, 23, "DNA"], [182, 189, "GGP"], [30, 49, "GENE_OR_GENE_PRODUCT"], [172, 182, "ENTITY"], [30, 49, "PROTEIN"], [215, 223, "ENTITY"], [15, 23, "GENE_OR_GENE_PRODUCT"], [130, 146, "ENTITY"]]}
{"text": "The binding of COVI-19 to the Toll Like Receptor ( TLR ) causes the release of pro-IL-1\u03b2 which is cleaved by caspase-1 , followed by inflammasome activation and production of active mature IL-1\u03b2 which is a mediator of lung inflammation , fever and fibrosis .", "labels": [[15, 23, "ENTITY"], [30, 49, "ENTITY"], [215, 223, "DISEASE"], [223, 238, "DISEASE"], [182, 189, "PROTEIN"], [4, 12, "ENTITY"], [182, 189, "ENTITY"], [182, 189, "GENE_OR_GENE_PRODUCT"], [223, 238, "ENTITY"], [15, 23, "DNA"], [182, 189, "GGP"], [30, 49, "GENE_OR_GENE_PRODUCT"], [172, 182, "ENTITY"], [30, 49, "PROTEIN"], [215, 223, "ENTITY"], [15, 23, "GENE_OR_GENE_PRODUCT"], [130, 146, "ENTITY"]]}
{"text": "The levels of inflammatory cytokines ( IL-1 , TNF ) are high in the lungs of COVID-19 patients and these cytokines are strong inducers of HA-synthase-2 ( HAS2 ) in CD31 + endothelium , EpCAM + lung alveolar epithelial cells , and fibroblasts [ 13 ] .", "labels": [[14, 37, "ENTITY"], [138, 154, "ENTITY"], [164, 171, "ENTITY"], [14, 37, "PROTEIN"], [159, 164, "PROTEIN"], [224, 230, "CL"], [224, 230, "ENTITY"], [171, 218, "CELL_TYPE"], [4, 11, "ENTITY"], [224, 230, "CELL_TYPE"], [138, 154, "GENE_OR_GENE_PRODUCT"], [77, 86, "ENTITY"], [159, 164, "GGP"], [159, 164, "GENE_OR_GENE_PRODUCT"], [185, 218, "CELL"], [171, 185, "ENTITY"], [171, 185, "GGP"], [185, 218, "ENTITY"], [74, 86, "ORGANISM"], [119, 126, "ENTITY"], [138, 154, "PROTEIN"], [138, 154, "GGP"], [198, 218, "CL"], [159, 164, "ENTITY"], [171, 185, "GENE_OR_GENE_PRODUCT"], [224, 230, "CELL"]]}
{"text": "Remarkably , in SJIA patients , the pulmonary involvement triggers a hyper-inflammatory reaction and occurrence of secondary haemophagocytic lymphohistiocytosis ( sHLH ) , since the up-regulation of IFN-signature , IL-1\u03b2 and IL-6 may be observed [ 5,8 ] .", "labels": [[215, 221, "GGP"], [141, 163, "ENTITY"], [115, 141, "DISEASE"], [172, 182, "ENTITY"], [67, 88, "ENTITY"], [112, 141, "ENTITY"], [199, 213, "CHEMICAL"], [115, 125, "CHEBI"], [215, 221, "ENTITY"], [182, 199, "PROTEIN"], [36, 46, "ENTITY"], [215, 221, "PROTEIN"], [199, 213, "PROTEIN"], [141, 163, "GENE_OR_GENE_PRODUCT"], [199, 213, "ENTITY"], [199, 213, "GENE_OR_GENE_PRODUCT"], [182, 199, "ENTITY"], [182, 199, "GENE_OR_GENE_PRODUCT"], [215, 221, "GENE_OR_GENE_PRODUCT"], [199, 213, "GGP"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [141, 160, "PROTEIN"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [111, 120, "GENE_OR_GENE_PRODUCT"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [103, 111, "GGP"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [141, 160, "GGP"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [528, 540, "ENTITY"], [127, 132, "GGP"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [141, 160, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "PROTEIN"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [103, 111, "ENTITY"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [103, 111, "CHEMICAL"], [141, 160, "ENTITY"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [528, 540, "GGP"], [167, 176, "ENTITY"], [103, 111, "PROTEIN"], [354, 400, "PROTEIN"]]}
{"text": "IL-38 is also a suppressor cytokine which inhibits IL-1\u03b2 and other pro-inflammatory IL-family members .", "labels": [[0, 6, "GGP"], [0, 6, "PROTEIN"], [67, 102, "PROTEIN"], [51, 57, "GENE_OR_GENE_PRODUCT"], [0, 6, "GENE_OR_GENE_PRODUCT"], [51, 57, "ENTITY"], [51, 57, "GGP"], [16, 36, "ENTITY"], [0, 6, "ENTITY"], [42, 51, "ENTITY"], [51, 57, "PROTEIN"], [51, 57, "CHEMICAL"], [16, 36, "GGP"], [16, 36, "PROTEIN"], [67, 102, "ENTITY"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [111, 120, "PROTEIN"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [111, 120, "GENE_OR_GENE_PRODUCT"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [384, 388, "ENTITY"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [384, 388, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [384, 388, "GGP"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "Evaluation of serum cytokines on admission revealed that levels of interleukin (IL)- 2R , IL-6 , IL-10 , and tumor necrosis factor-\u03b1 ( TNF-\u03b1 ) were markedly higher in severe cases than in moderate cases ( Figure 2 , Supplementary Table 1 ) .", "labels": [[205, 230, "GENE_OR_GENE_PRODUCT"], [105, 115, "DISEASE"], [157, 167, "ENTITY"], [33, 43, "ENTITY"], [124, 135, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [0, 11, "ENTITY"], [14, 20, "ENTITY"], [105, 124, "PROTEIN"], [14, 20, "ORGANISM_SUBSTANCE"], [124, 135, "PROTEIN"], [105, 124, "ENTITY"], [105, 124, "GENE_OR_GENE_PRODUCT"], [67, 88, "ENTITY"], [197, 205, "ENTITY"], [180, 188, "ENTITY"], [67, 88, "GGP"], [124, 135, "ENTITY"], [20, 30, "ENTITY"], [205, 230, "ENTITY"], [57, 64, "ENTITY"], [67, 88, "GENE_OR_GENE_PRODUCT"], [188, 197, "ENTITY"], [67, 88, "PROTEIN"], [14, 30, "PROTEIN"]]}
{"text": "Of patients with available data , concentrations of interleukin 2 receptor , interleukin 6 , interleukin 8 , interleukin 10 , and tumour necrosis factor \u03b1 were significantly higher in deceased patients than in recovered patients .", "labels": [[126, 146, "PROTEIN"], [75, 89, "GENE_OR_GENE_PRODUCT"], [3, 12, "ENTITY"], [52, 66, "PROTEIN"], [75, 89, "PROTEIN"], [184, 193, "ORGANISM"], [75, 89, "ENTITY"], [27, 32, "ENTITY"], [52, 66, "GGP"], [52, 66, "GENE_OR_GENE_PRODUCT"], [75, 89, "GGP"], [202, 210, "ENTITY"], [52, 66, "ENTITY"], [126, 146, "ENTITY"], [184, 193, "ENTITY"], [126, 146, "GENE_OR_GENE_PRODUCT"], [210, 220, "ENTITY"], [210, 220, "ORGANISM"], [174, 184, "ENTITY"], [126, 146, "GGP"], [126, 137, "DISEASE"], [3, 12, "ORGANISM"]]}
{"text": "Consistent with others , most of severe COVID-19 patients in our ICU ward had persistent very high level of erythematosus sedimentation rate ( ESR ) , CRP , and high level of IL-6,TNFa , IL-1B , IL-8 , IL2R , etc , and were associated with ARDS , hypercoagulation and disseminated intravascular coagulation ( DIC ) , manifested as thrombosis , thrombocytopenia , gangrene of extremities .", "labels": [[0, 16, "ENTITY"], [175, 187, "GENE_OR_GENE_PRODUCT"], [328, 344, "ENTITY"], [175, 187, "ENTITY"], [175, 187, "DNA"], [328, 344, "DISEASE"], [99, 108, "GGP"], [65, 69, "ENTITY"], [235, 247, "DISEASE"], [108, 136, "ENTITY"], [344, 363, "ENTITY"], [235, 247, "ENTITY"], [187, 193, "ENTITY"], [99, 108, "DNA"], [187, 193, "GENE_OR_GENE_PRODUCT"], [268, 281, "IMMATERIAL_ANATOMICAL_ENTITY"], [268, 295, "DISEASE"], [99, 108, "ENTITY"], [344, 363, "ORGAN"], [175, 187, "GGP"], [317, 328, "DISEASE"], [94, 99, "ENTITY"], [187, 193, "PROTEIN"], [247, 295, "ENTITY"], [40, 49, "GENE_OR_GENE_PRODUCT"], [215, 224, "ENTITY"], [187, 193, "GGP"], [99, 108, "GENE_OR_GENE_PRODUCT"], [317, 328, "ENTITY"]]}
{"text": "Of patients with available data , concentrations of interleukin 2 receptor , interleukin 6 , interleukin 8 , interleukin 10 , and tumour necrosis factor \u03b1 were significantly higher in deceased patients than in recovered patients .", "labels": [[126, 146, "PROTEIN"], [75, 89, "GENE_OR_GENE_PRODUCT"], [3, 12, "ENTITY"], [52, 66, "PROTEIN"], [75, 89, "PROTEIN"], [184, 193, "ORGANISM"], [75, 89, "ENTITY"], [27, 32, "ENTITY"], [52, 66, "GGP"], [52, 66, "GENE_OR_GENE_PRODUCT"], [75, 89, "GGP"], [202, 210, "ENTITY"], [52, 66, "ENTITY"], [126, 146, "ENTITY"], [184, 193, "ENTITY"], [126, 146, "GENE_OR_GENE_PRODUCT"], [210, 220, "ENTITY"], [210, 220, "ORGANISM"], [174, 184, "ENTITY"], [126, 146, "GGP"], [126, 137, "DISEASE"], [3, 12, "ORGANISM"]]}
{"text": "In contrast , GADD34 has also been shown to specify PP1 to dephosphorylate the TGF-\u03b2-activated kinase 1 ( TAK1 ) , thus negatively regulating the toll-like receptor ( TLR ) signal-ing and pro-inflammatory cytokines [ IL-6 and TNF-\u03b1 ( Tumornecrosis factor alpha ) ] production in macrophages ( Gu et al.,2014 ) .", "labels": [[205, 215, "GGP"], [79, 102, "GENE_OR_GENE_PRODUCT"], [79, 102, "ENTITY"], [226, 234, "DISEASE"], [188, 205, "ENTITY"], [226, 248, "PROTEIN"], [279, 296, "PROTEIN"], [205, 215, "GENE_OR_GENE_PRODUCT"], [217, 222, "ENTITY"], [142, 173, "PROTEIN"], [156, 165, "ENTITY"], [217, 222, "CHEMICAL"], [142, 156, "ENTITY"], [265, 279, "CELL"], [173, 205, "PROTEIN"], [142, 156, "GENE_OR_GENE_PRODUCT"], [205, 215, "PROTEIN"], [265, 279, "CELL_TYPE"], [205, 215, "ENTITY"], [265, 279, "CL"], [217, 222, "PROTEIN"], [142, 156, "GGP"], [217, 222, "GENE_OR_GENE_PRODUCT"], [226, 248, "ENTITY"], [255, 265, "ENTITY"], [156, 165, "GENE_OR_GENE_PRODUCT"], [173, 188, "ENTITY"], [79, 102, "PROTEIN"], [265, 279, "ENTITY"], [79, 102, "GGP"]]}
{"text": "Previous study done by this group has shown that infection of IBV induced the production of IL-6 and IL-8 , which was dependent on the phosphorylation of MAP kinase p38 ( Liao et al.,2011 ) .", "labels": [[92, 97, "ENTITY"], [78, 89, "ENTITY"], [28, 34, "ENTITY"], [62, 66, "PROTEIN"], [92, 97, "PROTEIN"], [49, 59, "DISEASE"], [92, 97, "GGP"], [154, 165, "GGP"], [49, 59, "ENTITY"], [62, 66, "ENTITY"], [101, 106, "PROTEIN"], [101, 106, "GGP"], [62, 66, "ORGANISM"], [101, 106, "ENTITY"], [154, 165, "PROTEIN"], [9, 15, "ENTITY"], [66, 74, "ENTITY"], [154, 165, "ENTITY"], [62, 66, "CHEMICAL"], [154, 165, "GENE_OR_GENE_PRODUCT"], [101, 106, "GENE_OR_GENE_PRODUCT"], [92, 97, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Compared with patients without ARDS , for patients with ARDS , the value of liver damage indices ( total bilirubin [ difference , 1.90mg/dL ; 95%CI , 0.60 - 3.30 mg/dL ; P = .004 ] ) , renal dysfunction indices ( urea [ difference , 1.69 mM ; 95 % CI , 1.10 - 2.29mM;P < .001 ] ) , inflammation-related indices ( interleukin- 6 [ IL-6 ] [ difference , 0.93 pg/L ; 95%CI , 0.07 - 1.98 pg/L ; P = .03 ] ) , and coagulation function indices ( D-dimer [ difference , 0.52 \u03bcg/mL ; 95 % CI , 0.21 - 0.94 \u03bcg/mL ; P < .001 ] ) were significantly elevated .", "labels": [[99, 105, "GGP"], [403, 409, "ENTITY"], [258, 282, "ENTITY"], [31, 36, "ENTITY"], [194, 203, "CHEMICAL"], [14, 23, "ENTITY"], [403, 409, "PROTEIN"], [0, 9, "ENTITY"], [73, 89, "ENTITY"], [409, 421, "ENTITY"], [73, 82, "DISEASE"], [191, 203, "CHEMICAL"], [99, 105, "SIMPLE_CHEMICAL"], [172, 191, "ENTITY"], [191, 203, "CHEBI"], [31, 36, "DISEASE"], [89, 99, "ENTITY"], [130, 142, "CHEMICAL"], [191, 203, "ENTITY"], [105, 117, "ENTITY"], [14, 23, "ORGANISM"], [372, 401, "ENTITY"], [99, 105, "CHEMICAL"], [97, 105, "ENTITY"], [403, 409, "GGP"]]}
{"text": "For patients with ARDS who died , the value of liver damage indices ( total bilirubin [ difference , 2.60 mg/dL ; 95 % CI , 0.30 - 5.20mg/dL;P = .03 ] ) , renal dysfunction indices ( urea [ difference , 1.50 mM ; 95%CI , 0.50 - 2.70 mM ; P = .004 ] ) , inflammation- related indices ( IL-6 [ difference , 3.88 pg/L ; 95 % CI , 2.20 - 6.13pg/L;P < .001 ] ) , and coagulation function indices ( Ddimer [ difference , 2.10 \u03bcg/mL ; 95 % CI , 0.89 - 5.27 \u03bcg/mL ; P = .001 ] ) were significantly elevated compared with patients with ARDS who survived .", "labels": [[60, 70, "ENTITY"], [47, 60, "ENTITY"], [161, 173, "ENTITY"], [292, 310, "SIMPLE_CHEMICAL"], [469, 476, "ENTITY"], [68, 76, "ENTITY"], [327, 356, "ENTITY"], [70, 76, "CHEMICAL"], [161, 173, "CHEBI"], [469, 476, "ORGANISM"], [70, 76, "SIMPLE_CHEMICAL"], [4, 13, "ENTITY"], [267, 275, "ENTITY"], [88, 99, "CHEMICAL"], [18, 23, "ENTITY"], [47, 53, "DISEASE"], [88, 101, "CHEMICAL"], [143, 161, "ENTITY"], [18, 23, "DISEASE"], [143, 161, "DISEASE"], [70, 76, "GGP"], [161, 173, "CHEMICAL"], [27, 32, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "However , IL-6 was statistically significantly associated with death ( Table 4 ) .", "labels": [[19, 33, "ENTITY"]]}
{"text": "However , in another retrospective , multicentre cohort study , the same study group reported a significantly elevation of IL-6 level in non-survival group of patients with COVID-19 , as compared with that of the survivals [ 5 ] .", "labels": [[123, 128, "ENTITY"], [35, 56, "ENTITY"], [137, 150, "ENTITY"], [96, 110, "ENTITY"], [56, 62, "ENTITY"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "TBNK lymphocyte subset analysis revealed decreased percentage of CD16 + CD56 + lymphocytes ( 4/8 ) and Th/Ts ( 1/8 ) , and increased percentage of CD3 + ( 2/8 ) , CD4 + ( 4/8 ) and CD8 + ( 1/8 ) lymphocytes . Cytokine detection assays showed increased levels of IL-6 ( 2/8 ) , IL-10 ( 5/8 ) and IFN-\u03b3 ( 2/8 ) .", "labels": [[-1, 25, "ENTITY"], [281, 287, "GENE_OR_GENE_PRODUCT"], [199, 222, "ENTITY"], [127, 137, "ENTITY"], [266, 271, "PROTEIN"], [41, 51, "ENTITY"], [127, 137, "GENE_OR_GENE_PRODUCT"], [5, 16, "CELL"], [266, 271, "ENTITY"], [281, 293, "PROTEIN"], [127, 137, "ENTITY"], [5, 16, "ENTITY"], [266, 271, "GGP"], [0, 5, "ENTITY"], [266, 271, "GENE_OR_GENE_PRODUCT"], [281, 287, "ENTITY"], [159, 199, "CELL_TYPE"], [239, 246, "ENTITY"], [175, 199, "ENTITY"], [127, 137, "PROTEIN"], [51, 65, "GGP"], [65, 70, "GENE_OR_GENE_PRODUCT"], [232, 239, "ENTITY"], [281, 287, "CHEMICAL"], [127, 137, "GGP"], [5, 16, "CL"], [51, 62, "GENE_OR_GENE_PRODUCT"], [137, 157, "ENTITY"], [-1, 25, "CELL_LINE"], [137, 157, "CELL_TYPE"], [185, 199, "CL"], [0, 23, "CELL_LINE"], [51, 62, "ENTITY"], [83, 95, "CL"]]}
{"text": "In any case , blocking IL-6 may be effective . Blocking IL-1 and TNF may also benefit patients .", "labels": [[47, 56, "PROTEIN"], [47, 56, "GENE_OR_GENE_PRODUCT"], [78, 86, "ORGANISM"], [78, 86, "ENTITY"], [7, 12, "ENTITY"], [47, 56, "ENTITY"], [47, 56, "GGP"]]}
{"text": "Of patients with available data , concentrations of interleukin 2 receptor , interleukin 6 , interleukin 8 , interleukin 10 , and tumour necrosis factor \u03b1 were significantly higher in deceased patients than in recovered patients .", "labels": [[126, 146, "PROTEIN"], [75, 89, "GENE_OR_GENE_PRODUCT"], [3, 12, "ENTITY"], [52, 66, "PROTEIN"], [75, 89, "PROTEIN"], [184, 193, "ORGANISM"], [75, 89, "ENTITY"], [27, 32, "ENTITY"], [52, 66, "GGP"], [52, 66, "GENE_OR_GENE_PRODUCT"], [75, 89, "GGP"], [202, 210, "ENTITY"], [52, 66, "ENTITY"], [126, 146, "ENTITY"], [184, 193, "ENTITY"], [126, 146, "GENE_OR_GENE_PRODUCT"], [210, 220, "ENTITY"], [210, 220, "ORGANISM"], [174, 184, "ENTITY"], [126, 146, "GGP"], [126, 137, "DISEASE"], [3, 12, "ORGANISM"]]}
{"text": "Evaluation of serum cytokines on admission revealed that levels of interleukin (IL)- 2R , IL-6 , IL-10 , and tumor necrosis factor-\u03b1 ( TNF-\u03b1 ) were markedly higher in severe cases than in moderate cases ( Figure 2 , Supplementary Table 1 ) .", "labels": [[205, 230, "GENE_OR_GENE_PRODUCT"], [105, 115, "DISEASE"], [157, 167, "ENTITY"], [33, 43, "ENTITY"], [124, 135, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [0, 11, "ENTITY"], [14, 20, "ENTITY"], [105, 124, "PROTEIN"], [14, 20, "ORGANISM_SUBSTANCE"], [124, 135, "PROTEIN"], [105, 124, "ENTITY"], [105, 124, "GENE_OR_GENE_PRODUCT"], [67, 88, "ENTITY"], [197, 205, "ENTITY"], [180, 188, "ENTITY"], [67, 88, "GGP"], [124, 135, "ENTITY"], [20, 30, "ENTITY"], [205, 230, "ENTITY"], [57, 64, "ENTITY"], [67, 88, "GENE_OR_GENE_PRODUCT"], [188, 197, "ENTITY"], [67, 88, "PROTEIN"], [14, 30, "PROTEIN"]]}
{"text": "Of note , IL-6 levels were increased in both moderate and severe cases .", "labels": []}
{"text": "Consistent with others , most of severe COVID-19 patients in our ICU ward had persistent very high level of erythematosus sedimentation rate ( ESR ) , CRP , and high level of IL-6,TNFa , IL-1B , IL-8 , IL2R , etc , and were associated with ARDS , hypercoagulation and disseminated intravascular coagulation ( DIC ) , manifested as thrombosis , thrombocytopenia , gangrene of extremities .", "labels": [[0, 16, "ENTITY"], [175, 187, "GENE_OR_GENE_PRODUCT"], [328, 344, "ENTITY"], [175, 187, "ENTITY"], [175, 187, "DNA"], [328, 344, "DISEASE"], [99, 108, "GGP"], [65, 69, "ENTITY"], [235, 247, "DISEASE"], [108, 136, "ENTITY"], [344, 363, "ENTITY"], [235, 247, "ENTITY"], [187, 193, "ENTITY"], [99, 108, "DNA"], [187, 193, "GENE_OR_GENE_PRODUCT"], [268, 281, "IMMATERIAL_ANATOMICAL_ENTITY"], [268, 295, "DISEASE"], [99, 108, "ENTITY"], [344, 363, "ORGAN"], [175, 187, "GGP"], [317, 328, "DISEASE"], [94, 99, "ENTITY"], [187, 193, "PROTEIN"], [247, 295, "ENTITY"], [40, 49, "GENE_OR_GENE_PRODUCT"], [215, 224, "ENTITY"], [187, 193, "GGP"], [99, 108, "GENE_OR_GENE_PRODUCT"], [317, 328, "ENTITY"]]}
{"text": "Studies have shown that IL-6 levels significantly correlated with the severity of COVID-19 , C-reactive protein ( CRP ) , lactate dehydrogenase ( LDH ) , and D-dimer levels and T cell counts , and it has been suggested that Tocilizumab , with its inhibitory effect on IL-6 , may be effective in treatment of COVID-19 ( 10 , 11 ) .", "labels": [[152, 158, "GGP"], [295, 305, "GENE_OR_GENE_PRODUCT"], [82, 91, "GENE_OR_GENE_PRODUCT"], [82, 91, "PROTEIN"], [238, 247, "ENTITY"], [24, 29, "GGP"], [152, 166, "ENTITY"], [118, 130, "GGP"], [70, 79, "ENTITY"], [152, 158, "PROTEIN"], [93, 104, "GGP"], [118, 130, "PROTEIN"], [166, 177, "ENTITY"], [130, 144, "GENE_OR_GENE_PRODUCT"], [50, 61, "ENTITY"], [24, 29, "GENE_OR_GENE_PRODUCT"], [82, 91, "ENTITY"], [282, 295, "ENTITY"], [130, 144, "PROTEIN"], [24, 29, "ENTITY"], [295, 305, "ENTITY"], [177, 184, "ENTITY"], [152, 158, "GENE_OR_GENE_PRODUCT"], [0, 8, "ENTITY"], [130, 144, "ENTITY"], [118, 130, "ENTITY"], [118, 130, "GENE_OR_GENE_PRODUCT"], [166, 177, "CL"], [24, 29, "PROTEIN"], [166, 177, "CELL"], [273, 282, "ENTITY"], [93, 104, "ENTITY"], [209, 224, "ENTITY"], [209, 224, "SIMPLE_CHEMICAL"], [93, 104, "PROTEIN"], [29, 36, "ENTITY"]]}
{"text": "We only found the levels of TNF-\u03b1 , IL-6 and IL-10 were significantly increased in infected patients , and statistical analysis illustrated that their levels in ICU patients are significantly higher than in Non-ICU patients ( Figure 2A ) .", "labels": [[161, 165, "ENTITY"], [28, 34, "CHEMICAL"], [207, 215, "ORGANISM"], [207, 215, "ENTITY"], [28, 34, "PROTEIN"], [103, 119, "ENTITY"], [224, 233, "ENTITY"], [28, 34, "ENTITY"], [28, 34, "GENE_OR_GENE_PRODUCT"], [161, 165, "ORGANISM"], [18, 25, "ENTITY"]]}
{"text": "Interestingly , serum levels of IFN-\u03b3 , IL-10 , IL-6 and TNF-\u03b1 were significantly decreased in these patients in the decline period as compared with illness period , while counts of total T cells , CD4 + , and CD8 + T cell subsets recovered during the decline period ( Figure 2C ) .", "labels": [[117, 125, "ENTITY"], [182, 190, "CL"], [68, 82, "ENTITY"], [182, 190, "CELL"], [16, 22, "ENTITY"], [260, 269, "ENTITY"], [206, 218, "GGP"], [149, 157, "ENTITY"], [206, 223, "ENTITY"], [117, 125, "ENTITY"], [190, 198, "ENTITY"], [179, 190, "CELL_TYPE"], [179, 190, "ENTITY"], [190, 223, "CELL_TYPE"], [190, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expression of IL-6 , IL-8 and IL-10 in the serum of patients with COVID-19 increased significantly compared with the control group ( P<0.05 ) .", "labels": [[4, 15, "ENTITY"], [121, 129, "ENTITY"], [18, 23, "GENE_OR_GENE_PRODUCT"], [18, 23, "PROTEIN"], [18, 23, "ENTITY"], [18, 23, "GGP"]]}
{"text": "Chemical signals such as Interleukin-8 ( IL-8 ) and IL-6 stimulate neutrophil chemotaxis and recruitment to the site of infection where they congregate and cause the release of more proinflammatory mediators that in turn activate additional inflammatory signals , leading to cytokine storms that may progress to vital organ failure 13 .", "labels": [[25, 39, "ENTITY"], [57, 78, "ENTITY"], [57, 67, "CELL"], [177, 198, "ENTITY"], [312, 318, "ORGAN"], [230, 254, "ENTITY"], [216, 221, "ENTITY"], [0, 9, "CHEBI"], [0, 17, "ENTITY"], [312, 324, "ENTITY"], [57, 67, "CL"], [312, 324, "DISEASE"], [177, 198, "PROTEIN"], [25, 39, "GENE_OR_GENE_PRODUCT"], [272, 284, "ENTITY"], [25, 39, "PROTEIN"], [57, 67, "CELL_TYPE"]]}
{"text": "The elevation of IL-8 and IL-6 but not IL-17 in PMBCs collected from COVID-19 patients indicates possible roles for IL-8/IL-6 in the severe inflammatory response induced by SARS-CoV-2 ( Fig.3d-e and Extended Data Fig.5e ) .", "labels": [[162, 170, "ENTITY"], [26, 31, "ENTITY"], [17, 22, "ENTITY"], [17, 22, "GENE_OR_GENE_PRODUCT"], [39, 45, "GENE_OR_GENE_PRODUCT"], [133, 140, "ENTITY"], [116, 126, "ENTITY"], [26, 31, "GGP"], [173, 184, "GGP"], [39, 45, "ENTITY"], [26, 31, "GENE_OR_GENE_PRODUCT"], [116, 126, "GENE_OR_GENE_PRODUCT"], [17, 22, "GGP"], [116, 126, "GGP"], [116, 126, "PROTEIN"], [4, 14, "ENTITY"], [48, 54, "CELL"], [69, 78, "ENTITY"], [39, 45, "PROTEIN"], [173, 184, "ENTITY"], [140, 162, "ENTITY"], [26, 31, "PROTEIN"], [78, 87, "ENTITY"], [69, 87, "ORGANISM"], [48, 54, "CELL_TYPE"], [48, 54, "ENTITY"], [173, 184, "CHEMICAL"], [39, 45, "GGP"], [199, 213, "ENTITY"], [17, 22, "PROTEIN"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [40, 59, "ENTITY"], [26, 38, "SIMPLE_CHEMICAL"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GGP"], [253, 271, "ENTITY"], [26, 40, "CHEBI"], [170, 179, "GGP"], [26, 38, "CHEMICAL"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [144, 154, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [26, 38, "ENTITY"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "Moreover , we observed that infections by SARS-CoV-2 triggered the expected increase in the IL-6 levels in the culture supernatant , which ranged from 20- to 60-fold depending on the cell donor ( Figure 7C , open circles in nil-treated cells ) . The virus-induced enhancement of IL-6 levels were significantly prevented by treatment with ATV at 10 \u00b5M , ATV/RTV at both 1 and 10 \u00b5M and CQ at 10 \u00b5M ( Figure 7C ) .", "labels": [[244, 264, "ENTITY"], [179, 188, "ENTITY"], [203, 213, "ENTITY"], [348, 351, "ENTITY"], [224, 236, "CL"], [194, 203, "ENTITY"], [348, 351, "SIMPLE_CHEMICAL"], [345, 353, "CHEMICAL"], [264, 276, "PROTEIN"], [348, 351, "CHEMICAL"], [310, 323, "ENTITY"], [221, 236, "CELL_LINE"], [224, 236, "CELL"], [264, 276, "GENE_OR_GENE_PRODUCT"], [264, 276, "GGP"], [221, 236, "ENTITY"], [345, 353, "ENTITY"], [111, 119, "ENTITY"], [92, 97, "ENTITY"], [264, 276, "ENTITY"], [345, 353, "SIMPLE_CHEMICAL"], [391, 399, "ENTITY"], [345, 353, "PROTEIN"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Tofacitinib has been shown to inhibit interferon\u03b1 production in vitro . Suppression of interferon or other mediators ( eg , interleukin 6 ) could also promote secondary bacterial infection and further complicate the disease course .", "labels": [[30, 38, "ENTITY"], [159, 179, "DISEASE"], [159, 179, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [0, 12, "CHEMICAL"], [151, 159, "ENTITY"], [38, 61, "ENTITY"], [212, 224, "ENTITY"], [38, 50, "CELLULAR_COMPONENT"], [159, 169, "TAXON"], [0, 12, "ENTITY"], [61, 70, "ENTITY"]]}
{"text": "Remarkably , in SJIA patients , the pulmonary involvement triggers a hyper-inflammatory reaction and occurrence of secondary haemophagocytic lymphohistiocytosis ( sHLH ) , since the up-regulation of IFN-signature , IL-1\u03b2 and IL-6 may be observed [ 5,8 ] .", "labels": [[141, 163, "ENTITY"], [115, 141, "DISEASE"], [172, 182, "ENTITY"], [67, 88, "ENTITY"], [112, 141, "ENTITY"], [199, 213, "CHEMICAL"], [115, 125, "CHEBI"], [182, 199, "PROTEIN"], [215, 221, "GGP"], [36, 46, "ENTITY"], [215, 221, "PROTEIN"], [199, 213, "PROTEIN"], [141, 163, "GENE_OR_GENE_PRODUCT"], [215, 221, "ENTITY"], [199, 213, "ENTITY"], [215, 221, "GENE_OR_GENE_PRODUCT"], [199, 213, "GENE_OR_GENE_PRODUCT"], [182, 199, "ENTITY"], [182, 199, "GENE_OR_GENE_PRODUCT"], [199, 213, "GGP"]]}
{"text": "Studies have shown that IL-6 levels significantly correlated with the severity of COVID-19 , C-reactive protein ( CRP ) , lactate dehydrogenase ( LDH ) , and D-dimer levels and T cell counts , and it has been suggested that Tocilizumab , with its inhibitory effect on IL-6 , may be effective in treatment of COVID-19 ( 10 , 11 ) .", "labels": [[152, 158, "GGP"], [295, 305, "GENE_OR_GENE_PRODUCT"], [238, 247, "ENTITY"], [82, 91, "ENTITY"], [24, 29, "GGP"], [152, 166, "ENTITY"], [118, 130, "GGP"], [70, 79, "ENTITY"], [152, 158, "PROTEIN"], [93, 104, "GGP"], [118, 130, "PROTEIN"], [166, 177, "ENTITY"], [130, 144, "GENE_OR_GENE_PRODUCT"], [50, 61, "ENTITY"], [24, 29, "GENE_OR_GENE_PRODUCT"], [282, 295, "ENTITY"], [130, 144, "PROTEIN"], [24, 29, "ENTITY"], [82, 91, "PROTEIN"], [295, 305, "ENTITY"], [177, 184, "ENTITY"], [152, 158, "GENE_OR_GENE_PRODUCT"], [0, 8, "ENTITY"], [130, 144, "ENTITY"], [118, 130, "ENTITY"], [118, 130, "GENE_OR_GENE_PRODUCT"], [166, 177, "CL"], [24, 29, "PROTEIN"], [166, 177, "CELL"], [273, 282, "ENTITY"], [93, 104, "ENTITY"], [209, 224, "ENTITY"], [209, 224, "SIMPLE_CHEMICAL"], [82, 91, "GENE_OR_GENE_PRODUCT"], [93, 104, "PROTEIN"], [29, 36, "ENTITY"]]}
{"text": "Studies have shown that IL-6 levels significantly correlated with the severity of COVID-19 , C-reactive protein ( CRP ) , lactate dehydrogenase ( LDH ) , and D-dimer levels and T cell counts , and it has been suggested that Tocilizumab , with its inhibitory effect on IL-6 , may be effective in treatment of COVID-19 ( 10 , 11 ) .", "labels": [[152, 158, "GGP"], [295, 305, "GENE_OR_GENE_PRODUCT"], [238, 247, "ENTITY"], [82, 91, "ENTITY"], [24, 29, "GGP"], [152, 166, "ENTITY"], [118, 130, "GGP"], [70, 79, "ENTITY"], [152, 158, "PROTEIN"], [93, 104, "GGP"], [118, 130, "PROTEIN"], [166, 177, "ENTITY"], [130, 144, "GENE_OR_GENE_PRODUCT"], [50, 61, "ENTITY"], [24, 29, "GENE_OR_GENE_PRODUCT"], [282, 295, "ENTITY"], [130, 144, "PROTEIN"], [24, 29, "ENTITY"], [82, 91, "PROTEIN"], [295, 305, "ENTITY"], [177, 184, "ENTITY"], [152, 158, "GENE_OR_GENE_PRODUCT"], [0, 8, "ENTITY"], [130, 144, "ENTITY"], [118, 130, "ENTITY"], [118, 130, "GENE_OR_GENE_PRODUCT"], [166, 177, "CL"], [24, 29, "PROTEIN"], [166, 177, "CELL"], [273, 282, "ENTITY"], [93, 104, "ENTITY"], [209, 224, "ENTITY"], [209, 224, "SIMPLE_CHEMICAL"], [82, 91, "GENE_OR_GENE_PRODUCT"], [93, 104, "PROTEIN"], [29, 36, "ENTITY"]]}
{"text": "Studies have shown that IL-6 levels significantly correlated with the severity of COVID-19 , C-reactive protein ( CRP ) , lactate dehydrogenase ( LDH ) , and D-dimer levels and T cell counts , and it has been suggested that Tocilizumab , with its inhibitory effect on IL-6 , may be effective in treatment of COVID-19 ( 10 , 11 ) .", "labels": [[152, 158, "GGP"], [295, 305, "GENE_OR_GENE_PRODUCT"], [238, 247, "ENTITY"], [82, 91, "ENTITY"], [24, 29, "GGP"], [152, 166, "ENTITY"], [118, 130, "GGP"], [70, 79, "ENTITY"], [152, 158, "PROTEIN"], [93, 104, "GGP"], [118, 130, "PROTEIN"], [166, 177, "ENTITY"], [130, 144, "GENE_OR_GENE_PRODUCT"], [50, 61, "ENTITY"], [24, 29, "GENE_OR_GENE_PRODUCT"], [282, 295, "ENTITY"], [130, 144, "PROTEIN"], [24, 29, "ENTITY"], [82, 91, "PROTEIN"], [295, 305, "ENTITY"], [177, 184, "ENTITY"], [152, 158, "GENE_OR_GENE_PRODUCT"], [0, 8, "ENTITY"], [130, 144, "ENTITY"], [118, 130, "ENTITY"], [118, 130, "GENE_OR_GENE_PRODUCT"], [166, 177, "CL"], [24, 29, "PROTEIN"], [166, 177, "CELL"], [273, 282, "ENTITY"], [93, 104, "ENTITY"], [209, 224, "ENTITY"], [209, 224, "SIMPLE_CHEMICAL"], [82, 91, "GENE_OR_GENE_PRODUCT"], [93, 104, "PROTEIN"], [29, 36, "ENTITY"]]}
{"text": "Interestingly , the concentration of these three cytokines was negatively correlated with total T cell counts , CD4 + counts , and CD8 + counts , respectively ( Figure 2B ) .", "labels": [[146, 161, "ENTITY"], [110, 118, "ENTITY"], [90, 98, "ENTITY"], [127, 137, "ENTITY"], [110, 116, "GGP"]]}
{"text": "Pearson correlation analysis results showed a remarkably positive correlation of MP production and the expression of IL-6 , IL-8 and IL-10 with the severity of COVID-19 ( Table 4 ) .", "labels": [[117, 122, "GGP"], [81, 84, "ENTITY"], [81, 84, "GENE_OR_GENE_PRODUCT"], [0, 29, "ENTITY"], [117, 122, "PROTEIN"], [57, 66, "ENTITY"], [117, 122, "ENTITY"], [117, 122, "GENE_OR_GENE_PRODUCT"], [8, 20, "ENTITY"], [29, 37, "ENTITY"], [103, 114, "ENTITY"], [84, 95, "ENTITY"], [81, 84, "DISEASE"]]}
{"text": "Chemical signals such as Interleukin-8 ( IL-8 ) and IL-6 stimulate neutrophil chemotaxis and recruitment to the site of infection where they congregate and cause the release of more proinflammatory mediators that in turn activate additional inflammatory signals , leading to cytokine storms that may progress to vital organ failure 13 .", "labels": [[25, 39, "ENTITY"], [57, 78, "ENTITY"], [57, 67, "CELL"], [177, 198, "ENTITY"], [312, 318, "ORGAN"], [230, 254, "ENTITY"], [216, 221, "ENTITY"], [0, 9, "CHEBI"], [0, 17, "ENTITY"], [312, 324, "ENTITY"], [57, 67, "CL"], [312, 324, "DISEASE"], [177, 198, "PROTEIN"], [25, 39, "GENE_OR_GENE_PRODUCT"], [272, 284, "ENTITY"], [25, 39, "PROTEIN"], [57, 67, "CELL_TYPE"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [137, 141, "GENE_OR_GENE_PRODUCT"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [137, 141, "GGP"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [137, 141, "ENTITY"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "PROTEIN"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [120, 125, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [120, 125, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [120, 125, "ENTITY"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [134, 139, "PROTEIN"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [134, 139, "ENTITY"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [134, 139, "GENE_OR_GENE_PRODUCT"], [134, 139, "GGP"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [303, 354, "CL"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Interestingly , we found that Nsp13 interacts with two key players of IFN signaling pathway including TANK-binding kinase 1 ( TBK1 ) and TANK-binding kinase 1-binding protein 1 (TBKBP1/SINTBAD).SINTBAD acts as a critical adaptor protein between TBK1 and IKKi and therefore mediates induction of IRF-dependent transcription [ 41 ] .", "labels": [[102, 122, "GGP"], [221, 229, "CHEBI"], [133, 167, "GGP"], [133, 167, "ENTITY"], [292, 309, "ENTITY"], [102, 122, "ENTITY"], [273, 282, "ENTITY"], [102, 122, "GENE_OR_GENE_PRODUCT"], [102, 122, "PROTEIN"], [133, 177, "PROTEIN"], [70, 84, "ENTITY"], [212, 229, "PROTEIN"], [133, 167, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Another study , demonstrated that IFN-\u03b1 and -\u03b3 co-administration caused hyper-activated IRF-1 and STAT1 , which finally led to a more robust antiviral symphony against virus replication ( 59 ) .", "labels": [[160, 174, "ENTITY"], [72, 88, "PROTEIN"], [8, 14, "ENTITY"], [134, 151, "ENTITY"]]}
{"text": "Accessory proteins 8b and 8ab of SARS-CoV can suppress the INF-\u03b2 signaling pathway ( and thus interferon production ) by their participation in the ubiquitin-mediated rapid degradation of INF regulatory factor 3 ( IRF3 ) ( Wong et al. , 2018 ) .", "labels": [[33, 42, "GGP"], [59, 65, "ENTITY"], [33, 42, "ORGANISM"], [59, 65, "PROTEIN"], [26, 30, "GENE_OR_GENE_PRODUCT"], [26, 30, "PROTEIN"], [188, 210, "ENTITY"], [46, 55, "ENTITY"], [167, 173, "ENTITY"], [26, 30, "ENTITY"], [185, 210, "PROTEIN"], [33, 42, "ENTITY"], [0, 22, "PROTEIN"], [65, 83, "ENTITY"], [33, 42, "PROTEIN"], [185, 210, "GENE_OR_GENE_PRODUCT"], [94, 105, "ENTITY"], [10, 19, "CHEBI"], [59, 65, "GENE_OR_GENE_PRODUCT"], [0, 22, "GENE_OR_GENE_PRODUCT"], [185, 210, "GGP"], [0, 22, "ENTITY"]]}
{"text": "RNF41/Nrdp1 , an E3 ubiquitin ligase is targeted by Nsp15 protein which promotes activation of TBK1 and IRF3 and therefore increases type I interferon production 45 .", "labels": [[0, 12, "GENE_OR_GENE_PRODUCT"], [133, 140, "GENE_OR_GENE_PRODUCT"], [52, 58, "ENTITY"], [0, 12, "PROTEIN"], [0, 12, "ENTITY"], [17, 30, "PROTEIN"], [52, 58, "GGP"], [133, 140, "GGP"], [0, 12, "CHEMICAL"], [133, 162, "PROTEIN"], [52, 58, "PROTEIN"], [17, 30, "ENTITY"], [133, 140, "ENTITY"]]}
{"text": "RNF41/Nrdp1 , an E3 ubiquitin ligase is targeted by Nsp15 protein which promotes activation of TBK1 and IRF3 and therefore increases type I interferon production [ 45 ] .", "labels": [[133, 140, "GGP"], [0, 12, "GENE_OR_GENE_PRODUCT"], [52, 58, "ENTITY"], [0, 12, "PROTEIN"], [0, 12, "ENTITY"], [17, 30, "PROTEIN"], [52, 58, "GGP"], [133, 140, "PROTEIN"], [133, 140, "GENE_OR_GENE_PRODUCT"], [0, 12, "CHEMICAL"], [133, 140, "ENTITY"], [52, 58, "PROTEIN"], [17, 30, "ENTITY"]]}
{"text": "Yang and colleagues indicated that MERS-CoV ORF4b antagonizes the antiviral IFN-\u03b2 response by inhibiting IRF3 and IRF7 ( 34 ) .", "labels": [[105, 110, "GGP"], [44, 50, "GENE_OR_GENE_PRODUCT"], [50, 62, "ENTITY"], [9, 20, "ENTITY"], [66, 82, "ENTITY"], [114, 119, "PROTEIN"], [35, 50, "PROTEIN"], [105, 110, "GENE_OR_GENE_PRODUCT"], [114, 119, "GGP"], [35, 44, "ENTITY"], [114, 119, "GENE_OR_GENE_PRODUCT"], [94, 105, "ENTITY"], [105, 110, "ENTITY"], [76, 82, "GENE_OR_GENE_PRODUCT"], [35, 44, "GGP"], [105, 110, "PROTEIN"], [44, 50, "ENTITY"], [0, 5, "ENTITY"], [114, 119, "ENTITY"]]}
{"text": "Our results demonstrated that DIP ( 5 \u03bcM ) treatment significantly increased IFNB , IFIT1 , and ISG15 messenger RNA expression and promoted IFN-B secretion ( Figure 2A ) by increasing TBK1 and IRF3 phosphorylation ( Figure 2A) by increasing TBK1 and IRF3 phosphorylation ) .", "labels": [[146, 158, "ENTITY"], [53, 67, "ENTITY"], [184, 189, "GGP"], [67, 77, "GGP"], [198, 216, "ENTITY"], [67, 77, "ENTITY"], [30, 34, "SIMPLE_CHEMICAL"], [102, 112, "SO"], [184, 189, "GENE_OR_GENE_PRODUCT"], [67, 77, "PROTEIN"], [131, 140, "PROTEIN"], [112, 116, "ENTITY"], [4, 12, "ENTITY"], [193, 198, "ENTITY"], [30, 34, "CHEMICAL"], [92, 112, "RNA"], [131, 140, "ENTITY"], [140, 146, "ENTITY"], [184, 189, "ENTITY"], [184, 189, "PROTEIN"], [67, 77, "GENE_OR_GENE_PRODUCT"], [92, 112, "ENTITY"], [30, 34, "ENTITY"]]}
{"text": "Yang and colleagues indicated that MERS-CoV ORF4b antagonizes the antiviral IFN-\u03b2 response by inhibiting IRF3 and IRF7 ( 34 ) .", "labels": [[44, 50, "GENE_OR_GENE_PRODUCT"], [105, 110, "ENTITY"], [50, 62, "ENTITY"], [9, 20, "ENTITY"], [66, 82, "ENTITY"], [114, 119, "GENE_OR_GENE_PRODUCT"], [105, 110, "PROTEIN"], [105, 110, "GGP"], [114, 119, "ENTITY"], [35, 50, "PROTEIN"], [105, 110, "GENE_OR_GENE_PRODUCT"], [35, 44, "ENTITY"], [94, 105, "ENTITY"], [114, 119, "GGP"], [76, 82, "GENE_OR_GENE_PRODUCT"], [35, 44, "GGP"], [114, 119, "PROTEIN"], [44, 50, "ENTITY"], [0, 5, "ENTITY"]]}
{"text": "GEX analysis showed that CD8 + T cells expressed high levels of effector molecules , including GZMA , GZMK , FASLG , CCL5 , etc . , and resident T cell markers ITGA1 , CXCR6 , JAML , etc . , likely played crucial roles in immune defense ( Figure S4 ) .", "labels": [[128, 136, "ENTITY"], [25, 33, "CELL_TYPE"], [85, 95, "ENTITY"], [25, 33, "ENTITY"], [102, 109, "PROTEIN"], [109, 117, "GENE_OR_GENE_PRODUCT"], [25, 33, "GGP"], [128, 152, "PROTEIN"], [64, 73, "CHEBI"], [109, 117, "GGP"], [85, 95, "GGP"], [109, 117, "ENTITY"], [85, 95, "PROTEIN"], [205, 222, "ENTITY"], [0, 13, "ENTITY"], [102, 109, "ENTITY"], [205, 229, "CELL"], [25, 29, "GENE_OR_GENE_PRODUCT"], [102, 109, "CHEMICAL"], [109, 117, "PROTEIN"], [64, 73, "PROTEIN"], [102, 109, "GENE_OR_GENE_PRODUCT"], [102, 109, "GGP"], [85, 95, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"], [222, 229, "ENTITY"]]}
{"text": "GEX analysis showed that CD8 + T cells expressed high levels of effector molecules , including GZMA , GZMK , FASLG , CCL5 , etc . , and resident T cell markers ITGA1 , CXCR6 , JAML , etc . , likely played crucial roles in immune defense ( Figure S4 ) .", "labels": [[128, 136, "ENTITY"], [25, 33, "CELL_TYPE"], [85, 95, "ENTITY"], [25, 33, "ENTITY"], [102, 109, "PROTEIN"], [109, 117, "GENE_OR_GENE_PRODUCT"], [25, 33, "GGP"], [128, 152, "PROTEIN"], [64, 73, "CHEBI"], [109, 117, "GGP"], [85, 95, "GGP"], [109, 117, "ENTITY"], [85, 95, "PROTEIN"], [205, 222, "ENTITY"], [0, 13, "ENTITY"], [102, 109, "ENTITY"], [205, 229, "CELL"], [25, 29, "GENE_OR_GENE_PRODUCT"], [102, 109, "CHEMICAL"], [109, 117, "PROTEIN"], [64, 73, "PROTEIN"], [102, 109, "GENE_OR_GENE_PRODUCT"], [102, 109, "GGP"], [85, 95, "GENE_OR_GENE_PRODUCT"], [64, 73, "ENTITY"], [222, 229, "ENTITY"]]}
{"text": "NK cells highly expressed KLRF1 , KLRC1 and KLRD1 . CD8 + T cells expressed CD8A and CD8B .", "labels": [[26, 32, "GGP"], [16, 26, "GENE_OR_GENE_PRODUCT"], [50, 60, "GGP"], [50, 60, "ENTITY"], [26, 32, "PROTEIN"], [16, 26, "PROTEIN"], [0, 9, "CELL"], [26, 32, "ENTITY"], [0, 9, "CELL_TYPE"], [16, 26, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "CL"], [50, 60, "CELL_TYPE"], [16, 26, "ENTITY"], [26, 32, "GENE_OR_GENE_PRODUCT"], [3, 9, "ENTITY"]]}
{"text": "NK cells highly expressed KLRF1 , KLRC1 and KLRD1 . CD8 + T cells expressed CD8A and CD8B .", "labels": [[26, 32, "GGP"], [16, 26, "GENE_OR_GENE_PRODUCT"], [50, 60, "GGP"], [50, 60, "ENTITY"], [26, 32, "PROTEIN"], [16, 26, "PROTEIN"], [0, 9, "CELL"], [26, 32, "ENTITY"], [0, 9, "CELL_TYPE"], [16, 26, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "CL"], [50, 60, "CELL_TYPE"], [16, 26, "ENTITY"], [26, 32, "GENE_OR_GENE_PRODUCT"], [3, 9, "ENTITY"]]}
{"text": "NK cells highly expressed KLRF1 , KLRC1 and KLRD1 . CD8 + T cells expressed CD8A and CD8B .", "labels": [[16, 26, "GENE_OR_GENE_PRODUCT"], [50, 60, "GGP"], [26, 32, "PROTEIN"], [50, 60, "ENTITY"], [16, 26, "PROTEIN"], [26, 32, "ENTITY"], [0, 9, "CELL"], [26, 32, "GENE_OR_GENE_PRODUCT"], [0, 9, "CELL_TYPE"], [16, 26, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "CL"], [50, 60, "CELL_TYPE"], [16, 26, "ENTITY"], [26, 32, "GGP"], [3, 9, "ENTITY"]]}
{"text": "Analysis of the global proteomic changes reveal significant upregulation of CXCR2 , PRG3 , LBP , MMP25 , CRP , NLRP1 in the COVID-19-MS PBMC cohort ( Fig.3c ) .", "labels": [[76, 82, "GENE_OR_GENE_PRODUCT"], [89, 97, "GENE_OR_GENE_PRODUCT"], [23, 33, "ENTITY"], [97, 105, "GENE_OR_GENE_PRODUCT"], [105, 111, "GENE_OR_GENE_PRODUCT"], [105, 111, "ENTITY"], [76, 82, "PROTEIN"], [141, 150, "SIMPLE_CHEMICAL"], [124, 136, "ENTITY"], [16, 23, "ENTITY"], [97, 105, "PROTEIN"], [97, 105, "GGP"], [105, 111, "GGP"], [105, 111, "PROTEIN"], [60, 73, "ENTITY"], [76, 82, "GGP"], [97, 105, "ENTITY"], [136, 141, "ENTITY"], [76, 82, "ENTITY"], [0, 9, "ENTITY"], [120, 136, "CELL"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "Most patients presented with an elevated myocardial indices : 194 of 198 ( 98.0 % ) had elevated lactate dehydrogenase (LDH),and 9 of 198 ( 4.5 % ) had an elevated creatinekinase muscle-brain isoform .", "labels": [[41, 52, "MULTI-TISSUE_STRUCTURE"], [88, 105, "PROTEIN"], [155, 192, "PROTEIN"], [41, 60, "ENTITY"], [155, 179, "GENE_OR_GENE_PRODUCT"], [5, 14, "ENTITY"], [179, 192, "SO"], [5, 14, "ORGANISM"], [88, 105, "GENE_OR_GENE_PRODUCT"], [148, 155, "ENTITY"], [88, 105, "GGP"], [32, 41, "CHEMICAL"], [179, 192, "ENTITY"], [88, 105, "ENTITY"], [32, 41, "ENTITY"]]}
{"text": "Increased C-reactive protein , procalcitonin and lactate dehydrogenase were found in five patients ( 5/8 ) , and increased alanine aminotransferase ( ALT ) in four ( 4/8 ) .", "labels": [[113, 123, "CHEBI"], [49, 57, "GENE_OR_GENE_PRODUCT"], [10, 29, "ENTITY"], [49, 57, "PROTEIN"], [49, 57, "GGP"], [10, 21, "GENE_OR_GENE_PRODUCT"], [10, 29, "GGP"], [49, 57, "ENTITY"], [113, 123, "CHEMICAL"], [0, 10, "ENTITY"], [113, 131, "GENE_OR_GENE_PRODUCT"], [131, 148, "ENTITY"], [10, 29, "PROTEIN"], [113, 131, "ENTITY"], [131, 148, "PROTEIN"], [131, 148, "GENE_OR_GENE_PRODUCT"], [113, 131, "PROTEIN"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [236, 242, "ENTITY"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [300, 315, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Levels of lactate dehydrogenase ( LDH ) , concentrations of serum high-sensitivity C-reactive protein ( hsCRP ) , ferritin and D-dimer levels were markedly higher in severe cases than moderate cases .", "labels": [[10, 18, "CHEMICAL"], [129, 137, "ENTITY"], [59, 96, "PROTEIN"], [149, 158, "ENTITY"], [0, 7, "ENTITY"], [10, 32, "GGP"], [10, 32, "PROTEIN"], [158, 168, "ENTITY"], [62, 96, "ENTITY"], [10, 32, "ENTITY"], [68, 96, "GGP"], [168, 175, "ENTITY"], [10, 32, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Higher lactate dehydrogenase activity correlated strongly with severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.454 , P3<0.001 , R2 = 0.453 , P4<0.001 ) .", "labels": [[7, 29, "GGP"], [107, 126, "ENTITY"], [38, 49, "ENTITY"], [7, 15, "CHEMICAL"], [7, 29, "PROTEIN"], [63, 70, "ENTITY"], [7, 29, "GENE_OR_GENE_PRODUCT"], [81, 103, "ENTITY"], [81, 93, "ORGANISM"], [7, 29, "ENTITY"], [0, 7, "ENTITY"], [81, 103, "DISEASE"]]}
{"text": "Studies have shown that IL-6 levels significantly correlated with the severity of COVID-19 , C-reactive protein ( CRP ) , lactate dehydrogenase ( LDH ) , and D-dimer levels and T cell counts , and it has been suggested that Tocilizumab , with its inhibitory effect on IL-6 , may be effective in treatment of COVID-19 ( 10 , 11 ) .", "labels": [[152, 158, "GGP"], [295, 305, "GENE_OR_GENE_PRODUCT"], [238, 247, "ENTITY"], [82, 91, "ENTITY"], [24, 29, "GGP"], [152, 166, "ENTITY"], [118, 130, "GGP"], [70, 79, "ENTITY"], [152, 158, "PROTEIN"], [93, 104, "GGP"], [118, 130, "PROTEIN"], [166, 177, "ENTITY"], [130, 144, "GENE_OR_GENE_PRODUCT"], [50, 61, "ENTITY"], [24, 29, "GENE_OR_GENE_PRODUCT"], [282, 295, "ENTITY"], [130, 144, "PROTEIN"], [24, 29, "ENTITY"], [82, 91, "PROTEIN"], [295, 305, "ENTITY"], [177, 184, "ENTITY"], [152, 158, "GENE_OR_GENE_PRODUCT"], [0, 8, "ENTITY"], [130, 144, "ENTITY"], [118, 130, "ENTITY"], [118, 130, "GENE_OR_GENE_PRODUCT"], [166, 177, "CL"], [24, 29, "PROTEIN"], [166, 177, "CELL"], [273, 282, "ENTITY"], [93, 104, "ENTITY"], [209, 224, "ENTITY"], [209, 224, "SIMPLE_CHEMICAL"], [82, 91, "GENE_OR_GENE_PRODUCT"], [93, 104, "PROTEIN"], [29, 36, "ENTITY"]]}
{"text": "Most patients presented with an elevated myocardial indices : 194 of 198 ( 98.0 % ) had elevated lactate dehydrogenase (LDH),and 9 of 198 ( 4.5 % ) had an elevated creatinekinase muscle-brain isoform .", "labels": [[41, 52, "MULTI-TISSUE_STRUCTURE"], [88, 105, "PROTEIN"], [155, 192, "PROTEIN"], [41, 60, "ENTITY"], [155, 179, "GENE_OR_GENE_PRODUCT"], [5, 14, "ENTITY"], [179, 192, "SO"], [5, 14, "ORGANISM"], [88, 105, "GENE_OR_GENE_PRODUCT"], [148, 155, "ENTITY"], [88, 105, "GGP"], [32, 41, "CHEMICAL"], [179, 192, "ENTITY"], [88, 105, "ENTITY"], [32, 41, "ENTITY"]]}
{"text": "Increased C-reactive protein , procalcitonin and lactate dehydrogenase were found in five patients ( 5/8 ) , and increased alanine aminotransferase ( ALT ) in four ( 4/8 ) .", "labels": [[113, 123, "CHEBI"], [49, 57, "GENE_OR_GENE_PRODUCT"], [10, 29, "ENTITY"], [49, 57, "PROTEIN"], [49, 57, "GGP"], [10, 21, "GENE_OR_GENE_PRODUCT"], [10, 29, "GGP"], [49, 57, "ENTITY"], [113, 123, "CHEMICAL"], [0, 10, "ENTITY"], [113, 131, "GENE_OR_GENE_PRODUCT"], [131, 148, "ENTITY"], [10, 29, "PROTEIN"], [113, 131, "ENTITY"], [131, 148, "PROTEIN"], [131, 148, "GENE_OR_GENE_PRODUCT"], [113, 131, "PROTEIN"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Levels of lactate dehydrogenase ( LDH ) , concentrations of serum high-sensitivity C-reactive protein ( hsCRP ) , ferritin and D-dimer levels were markedly higher in severe cases than moderate cases .", "labels": [[10, 18, "CHEMICAL"], [129, 137, "ENTITY"], [59, 96, "PROTEIN"], [149, 158, "ENTITY"], [0, 7, "ENTITY"], [10, 32, "GGP"], [10, 32, "PROTEIN"], [158, 168, "ENTITY"], [62, 96, "ENTITY"], [10, 32, "ENTITY"], [68, 96, "GGP"], [168, 175, "ENTITY"], [10, 32, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"]]}
{"text": "Higher lactate dehydrogenase activity correlated strongly with severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.454 , P3<0.001 , R2 = 0.453 , P4<0.001 ) .", "labels": [[7, 29, "GGP"], [107, 126, "ENTITY"], [38, 49, "ENTITY"], [7, 15, "CHEMICAL"], [7, 29, "PROTEIN"], [63, 70, "ENTITY"], [7, 29, "GENE_OR_GENE_PRODUCT"], [81, 103, "ENTITY"], [81, 93, "ORGANISM"], [7, 29, "ENTITY"], [0, 7, "ENTITY"], [81, 103, "DISEASE"]]}
{"text": "Most patients presented with an elevated myocardial indices : 194 of 198 ( 98.0 % ) had elevated lactate dehydrogenase (LDH),and 9 of 198 ( 4.5 % ) had an elevated creatinekinase muscle-brain isoform .", "labels": [[41, 52, "MULTI-TISSUE_STRUCTURE"], [88, 105, "PROTEIN"], [155, 192, "PROTEIN"], [41, 60, "ENTITY"], [155, 179, "GENE_OR_GENE_PRODUCT"], [5, 14, "ENTITY"], [179, 192, "SO"], [5, 14, "ORGANISM"], [88, 105, "GENE_OR_GENE_PRODUCT"], [148, 155, "ENTITY"], [88, 105, "GGP"], [32, 41, "CHEMICAL"], [179, 192, "ENTITY"], [88, 105, "ENTITY"], [32, 41, "ENTITY"]]}
{"text": "Increased C-reactive protein , procalcitonin and lactate dehydrogenase were found in five patients ( 5/8 ) , and increased alanine aminotransferase ( ALT ) in four ( 4/8 ) .", "labels": [[113, 123, "CHEBI"], [49, 57, "GENE_OR_GENE_PRODUCT"], [10, 29, "ENTITY"], [49, 57, "PROTEIN"], [49, 57, "GGP"], [10, 21, "GENE_OR_GENE_PRODUCT"], [10, 29, "GGP"], [49, 57, "ENTITY"], [113, 123, "CHEMICAL"], [0, 10, "ENTITY"], [113, 131, "GENE_OR_GENE_PRODUCT"], [131, 148, "ENTITY"], [10, 29, "PROTEIN"], [113, 131, "ENTITY"], [131, 148, "PROTEIN"], [131, 148, "GENE_OR_GENE_PRODUCT"], [113, 131, "PROTEIN"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Levels of lactate dehydrogenase ( LDH ) , concentrations of serum high-sensitivity C-reactive protein ( hsCRP ) , ferritin and D-dimer levels were markedly higher in severe cases than moderate cases .", "labels": [[10, 18, "CHEMICAL"], [129, 137, "ENTITY"], [59, 96, "PROTEIN"], [149, 158, "ENTITY"], [0, 7, "ENTITY"], [10, 32, "GGP"], [10, 32, "PROTEIN"], [158, 168, "ENTITY"], [62, 96, "ENTITY"], [10, 32, "ENTITY"], [68, 96, "GGP"], [168, 175, "ENTITY"], [10, 32, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"]]}
{"text": "Most patients presented with an elevated myocardial indices : 194 of 198 ( 98.0 % ) had elevated lactate dehydrogenase (LDH),and 9 of 198 ( 4.5 % ) had an elevated creatinekinase muscle-brain isoform .", "labels": [[41, 52, "MULTI-TISSUE_STRUCTURE"], [88, 105, "PROTEIN"], [155, 192, "PROTEIN"], [41, 60, "ENTITY"], [155, 179, "GENE_OR_GENE_PRODUCT"], [5, 14, "ENTITY"], [179, 192, "SO"], [5, 14, "ORGANISM"], [88, 105, "GENE_OR_GENE_PRODUCT"], [148, 155, "ENTITY"], [88, 105, "GGP"], [32, 41, "CHEMICAL"], [179, 192, "ENTITY"], [88, 105, "ENTITY"], [32, 41, "ENTITY"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "The ISG lymphocyte antigen 6 complex , locus E ( lymphocyte antigen 6 complex, locus E ) strikingly inhibited HCoV-229E infection ( Fig. 1a-b , Extended Data Fig. 1a ) .", "labels": [[-1, 8, "ORGANISM"], [39, 45, "DNA"], [19, 29, "ENTITY"], [4, 8, "ENTITY"], [-1, 18, "ENTITY"], [29, 37, "ENTITY"], [4, 37, "GGP"], [4, 29, "GENE_OR_GENE_PRODUCT"], [67, 87, "ENTITY"], [39, 45, "ENTITY"], [-1, 18, "DISEASE"], [4, 37, "PROTEIN"]]}
{"text": "In addition to HCoV-229E ( Fig. 1c ) , LY6E significantly inhibited infection by HCoV-OC43 , MERS-CoV , SARSCoV , and the recently emerged SARS-CoV-2 ( Fig. 1d-g ) .", "labels": [[15, 25, "ENTITY"], [81, 93, "PROTEIN"], [81, 93, "ENTITY"], [58, 68, "DISEASE"], [93, 104, "ENTITY"], [131, 139, "ORGANISM"], [81, 93, "GGP"], [131, 139, "GGP"], [81, 93, "ORGANISM"], [44, 58, "ENTITY"], [15, 25, "ORGANISM"], [93, 104, "PROTEIN"], [58, 68, "ENTITY"], [93, 104, "GGP"], [131, 139, "CHEMICAL"], [131, 139, "ENTITY"]]}
{"text": "Strikingly , LY6E significantly inhibited VSVpp entry mediated by S proteins from HCoV-229E ( Fig. 2a ) , MERS-CoV ( Fig. 2b ) , SARS-CoV ( Fig. 2c ) , and SARS-CoV-2 ( 2c), and SARS-CoV-2 ) .", "labels": [[0, 11, "ENTITY"], [145, 156, "CHEMICAL"], [122, 129, "GGP"], [122, 129, "PROTEIN"], [122, 129, "ORGANISM"], [122, 129, "ENTITY"], [145, 156, "ENTITY"], [145, 156, "GENE_OR_GENE_PRODUCT"]]}
{"text": "LY6E potently inhibited CoV S protein-mediated syncytia formation ( Fig. 2e-f ) .", "labels": [[30, 56, "ENTITY"], [24, 56, "ORGANISM"], [5, 14, "ENTITY"], [14, 24, "ENTITY"], [24, 30, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [68, 73, "SIMPLE_CHEMICAL"], [0, 5, "PROTEIN"], [0, 5, "ENTITY"], [24, 30, "PROTEIN"]]}
{"text": "In contrast , GADD34 has also been shown to specify PP1 to dephosphorylate the TGF-\u03b2-activated kinase 1 ( TAK1 ) , thus negatively regulating the toll-like receptor ( TLR ) signal-ing and pro-inflammatory cytokines [ IL-6 and TNF-\u03b1 ( Tumornecrosis factor alpha ) ] production in macrophages ( Gu et al.,2014 ) .", "labels": [[205, 215, "GGP"], [79, 102, "GENE_OR_GENE_PRODUCT"], [79, 102, "ENTITY"], [217, 222, "GENE_OR_GENE_PRODUCT"], [226, 234, "DISEASE"], [226, 248, "PROTEIN"], [279, 296, "PROTEIN"], [205, 215, "GENE_OR_GENE_PRODUCT"], [142, 173, "PROTEIN"], [217, 222, "ENTITY"], [156, 165, "ENTITY"], [142, 156, "ENTITY"], [265, 279, "CELL"], [173, 205, "PROTEIN"], [142, 156, "GENE_OR_GENE_PRODUCT"], [205, 215, "PROTEIN"], [265, 279, "CELL_TYPE"], [217, 222, "CHEMICAL"], [205, 215, "ENTITY"], [265, 279, "CL"], [142, 156, "GGP"], [217, 222, "PROTEIN"], [173, 188, "ENTITY"], [226, 248, "ENTITY"], [255, 265, "ENTITY"], [188, 205, "ENTITY"], [156, 165, "GENE_OR_GENE_PRODUCT"], [79, 102, "PROTEIN"], [265, 279, "ENTITY"], [79, 102, "GGP"]]}
{"text": "In contrast , GADD34 has also been shown to specify PP1 to dephosphorylate the TGF-\u03b2-activated kinase 1 ( TAK1 ) , thus negatively regulating the toll-like receptor ( TLR ) signal-ing and pro-inflammatory cytokines [ IL-6 and TNF-\u03b1 ( Tumornecrosis factor alpha ) ] production in macrophages ( Gu et al.,2014 ) .", "labels": [[205, 215, "GGP"], [79, 102, "GENE_OR_GENE_PRODUCT"], [79, 102, "ENTITY"], [226, 234, "DISEASE"], [226, 248, "PROTEIN"], [279, 296, "PROTEIN"], [205, 215, "GENE_OR_GENE_PRODUCT"], [217, 222, "ENTITY"], [142, 173, "PROTEIN"], [156, 165, "ENTITY"], [217, 222, "CHEMICAL"], [142, 156, "ENTITY"], [265, 279, "CELL"], [173, 205, "PROTEIN"], [142, 156, "GENE_OR_GENE_PRODUCT"], [205, 215, "PROTEIN"], [265, 279, "CELL_TYPE"], [205, 215, "ENTITY"], [265, 279, "CL"], [217, 222, "PROTEIN"], [142, 156, "GGP"], [217, 222, "GENE_OR_GENE_PRODUCT"], [226, 248, "ENTITY"], [255, 265, "ENTITY"], [188, 205, "ENTITY"], [156, 165, "GENE_OR_GENE_PRODUCT"], [173, 188, "ENTITY"], [79, 102, "PROTEIN"], [265, 279, "ENTITY"], [79, 102, "GGP"]]}
{"text": "In contrast , GADD34 has also been shown to specify PP1 to dephosphorylate the TGF-\u03b2-activated kinase 1 ( TAK1 ) , thus negatively regulating the toll-like receptor ( TLR ) signal-ing and pro-inflammatory cytokines [ IL-6 and TNF-\u03b1 ( Tumornecrosis factor alpha ) ] production in macrophages ( Gu et al.,2014 ) .", "labels": [[205, 215, "GGP"], [79, 102, "GENE_OR_GENE_PRODUCT"], [79, 102, "ENTITY"], [217, 222, "GENE_OR_GENE_PRODUCT"], [279, 296, "PROTEIN"], [205, 215, "GENE_OR_GENE_PRODUCT"], [226, 248, "PROTEIN"], [142, 173, "PROTEIN"], [217, 222, "ENTITY"], [156, 165, "ENTITY"], [142, 156, "ENTITY"], [265, 279, "CELL"], [173, 205, "PROTEIN"], [142, 156, "GENE_OR_GENE_PRODUCT"], [205, 215, "PROTEIN"], [265, 279, "CELL_TYPE"], [217, 222, "CHEMICAL"], [205, 215, "ENTITY"], [265, 279, "CL"], [142, 156, "GGP"], [217, 222, "PROTEIN"], [226, 234, "DISEASE"], [255, 265, "ENTITY"], [188, 205, "ENTITY"], [156, 165, "GENE_OR_GENE_PRODUCT"], [173, 188, "ENTITY"], [226, 248, "ENTITY"], [79, 102, "PROTEIN"], [265, 279, "ENTITY"], [79, 102, "GGP"]]}
{"text": "The up-regulation of GADD153 promotes apoptosis in IBV-infected cells , possibly via inducing the pro-apoptotic protein tribbles-related protein 3 ( TRIB3 ) and suppressing the pro-survival kinase extracellular signal-related kinase ( ERK;Liaoet al. , 2013 ) .", "labels": [[173, 226, "ENTITY"], [4, 18, "ENTITY"], [64, 70, "CL"], [21, 29, "GGP"], [98, 145, "ENTITY"], [21, 29, "PROTEIN"], [21, 29, "ENTITY"], [98, 145, "PROTEIN"], [226, 235, "CHEMICAL"], [64, 70, "CELL"], [38, 48, "ENTITY"], [226, 235, "PROTEIN"], [173, 226, "PROTEIN"], [51, 70, "CELL_TYPE"], [173, 226, "GENE_OR_GENE_PRODUCT"], [21, 29, "GENE_OR_GENE_PRODUCT"], [98, 112, "GGP"], [173, 226, "GGP"], [51, 70, "ENTITY"]]}
{"text": "Besides p38 , DUSP1 has also been shown to dephosphorylate c-Jun N-terminal kinase ( JNK ) and ERK ( Sun et al.,1993;Franklin and Kraft , 1997 ) . It has been long proposed that ERK phosphorylation promotes cell survival , whereas prolonged JNK and p38 phosphorylation is linked to the induction of apoptosis ( Xia et al. , 1995 ) .", "labels": [[8, 12, "ENTITY"], [164, 173, "GENE_OR_GENE_PRODUCT"], [164, 173, "GGP"], [8, 12, "GGP"], [126, 138, "GENE_OR_GENE_PRODUCT"], [164, 173, "PROTEIN"], [198, 212, "ENTITY"], [85, 89, "ENTITY"], [164, 173, "ENTITY"], [182, 198, "ENTITY"], [85, 89, "PROTEIN"], [85, 89, "GGP"], [286, 299, "ENTITY"], [59, 76, "GENE_OR_GENE_PRODUCT"], [8, 12, "PROTEIN"], [59, 76, "GGP"], [279, 286, "ENTITY"], [59, 76, "PROTEIN"], [245, 253, "ENTITY"], [85, 89, "GENE_OR_GENE_PRODUCT"], [59, 76, "ENTITY"], [8, 12, "GENE_OR_GENE_PRODUCT"], [173, 182, "ENTITY"]]}
{"text": "Besides p38 , DUSP1 has also been shown to dephosphorylate c-Jun N-terminal kinase ( JNK ) and ERK ( Sun et al.,1993;Franklin and Kraft , 1997 ) . It has been long proposed that ERK phosphorylation promotes cell survival , whereas prolonged JNK and p38 phosphorylation is linked to the induction of apoptosis ( Xia et al. , 1995 ) .", "labels": [[8, 12, "ENTITY"], [164, 173, "GENE_OR_GENE_PRODUCT"], [164, 173, "GGP"], [8, 12, "GGP"], [126, 138, "GENE_OR_GENE_PRODUCT"], [164, 173, "PROTEIN"], [198, 212, "ENTITY"], [85, 89, "ENTITY"], [164, 173, "ENTITY"], [182, 198, "ENTITY"], [85, 89, "PROTEIN"], [85, 89, "GGP"], [286, 299, "ENTITY"], [59, 76, "GENE_OR_GENE_PRODUCT"], [8, 12, "PROTEIN"], [59, 76, "GGP"], [279, 286, "ENTITY"], [59, 76, "PROTEIN"], [245, 253, "ENTITY"], [85, 89, "GENE_OR_GENE_PRODUCT"], [59, 76, "ENTITY"], [8, 12, "GENE_OR_GENE_PRODUCT"], [173, 182, "ENTITY"]]}
{"text": "Besides p38 , DUSP1 has also been shown to dephosphorylate c-Jun N-terminal kinase ( JNK ) and ERK ( Sun et al.,1993;Franklin and Kraft , 1997 ) . It has been long proposed that ERK phosphorylation promotes cell survival , whereas prolonged JNK and p38 phosphorylation is linked to the induction of apoptosis ( Xia et al. , 1995 ) .", "labels": [[8, 12, "ENTITY"], [164, 173, "GENE_OR_GENE_PRODUCT"], [164, 173, "GGP"], [8, 12, "GGP"], [126, 138, "GENE_OR_GENE_PRODUCT"], [164, 173, "PROTEIN"], [198, 212, "ENTITY"], [85, 89, "ENTITY"], [164, 173, "ENTITY"], [182, 198, "ENTITY"], [85, 89, "PROTEIN"], [85, 89, "GGP"], [286, 299, "ENTITY"], [59, 76, "GENE_OR_GENE_PRODUCT"], [8, 12, "PROTEIN"], [59, 76, "GGP"], [279, 286, "ENTITY"], [59, 76, "PROTEIN"], [245, 253, "ENTITY"], [85, 89, "GENE_OR_GENE_PRODUCT"], [59, 76, "ENTITY"], [8, 12, "GENE_OR_GENE_PRODUCT"], [173, 182, "ENTITY"]]}
{"text": "Besides p38 , DUSP1 has also been shown to dephosphorylate c-Jun N-terminal kinase ( JNK ) and ERK ( Sun et al.,1993;Franklin and Kraft , 1997 ) . It has been long proposed that ERK phosphorylation promotes cell survival , whereas prolonged JNK and p38 phosphorylation is linked to the induction of apoptosis ( Xia et al. , 1995 ) .", "labels": [[8, 12, "ENTITY"], [164, 173, "GENE_OR_GENE_PRODUCT"], [164, 173, "GGP"], [8, 12, "GGP"], [126, 138, "GENE_OR_GENE_PRODUCT"], [164, 173, "PROTEIN"], [198, 212, "ENTITY"], [85, 89, "ENTITY"], [164, 173, "ENTITY"], [182, 198, "ENTITY"], [85, 89, "PROTEIN"], [85, 89, "GGP"], [286, 299, "ENTITY"], [59, 76, "GENE_OR_GENE_PRODUCT"], [8, 12, "PROTEIN"], [59, 76, "GGP"], [279, 286, "ENTITY"], [59, 76, "PROTEIN"], [245, 253, "ENTITY"], [85, 89, "GENE_OR_GENE_PRODUCT"], [59, 76, "ENTITY"], [8, 12, "GENE_OR_GENE_PRODUCT"], [173, 182, "ENTITY"]]}
{"text": "Previous study done by this group has shown that infection of IBV induced the production of IL-6 and IL-8 , which was dependent on the phosphorylation of MAP kinase p38 ( Liao et al.,2011 ) .", "labels": [[92, 97, "ENTITY"], [78, 89, "ENTITY"], [28, 34, "ENTITY"], [62, 66, "PROTEIN"], [92, 97, "PROTEIN"], [49, 59, "DISEASE"], [92, 97, "GGP"], [154, 165, "GGP"], [49, 59, "ENTITY"], [62, 66, "ENTITY"], [101, 106, "PROTEIN"], [101, 106, "GGP"], [62, 66, "ORGANISM"], [101, 106, "ENTITY"], [154, 165, "PROTEIN"], [9, 15, "ENTITY"], [66, 74, "ENTITY"], [154, 165, "ENTITY"], [62, 66, "CHEMICAL"], [154, 165, "GENE_OR_GENE_PRODUCT"], [101, 106, "GENE_OR_GENE_PRODUCT"], [92, 97, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Previous study done by this group has shown that infection of IBV induced the production of IL-6 and IL-8 , which was dependent on the phosphorylation of MAP kinase p38 ( Liao et al.,2011 ) .", "labels": [[92, 97, "PROTEIN"], [101, 106, "ENTITY"], [78, 89, "ENTITY"], [28, 34, "ENTITY"], [62, 66, "PROTEIN"], [101, 106, "PROTEIN"], [101, 106, "GGP"], [49, 59, "DISEASE"], [92, 97, "GENE_OR_GENE_PRODUCT"], [101, 106, "GENE_OR_GENE_PRODUCT"], [154, 165, "GGP"], [49, 59, "ENTITY"], [92, 97, "GGP"], [92, 97, "ENTITY"], [62, 66, "ENTITY"], [62, 66, "ORGANISM"], [154, 165, "PROTEIN"], [9, 15, "ENTITY"], [66, 74, "ENTITY"], [154, 165, "ENTITY"], [62, 66, "CHEMICAL"], [154, 165, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Chloroquine is known to inhibit phosphorylation ( activation ) of the p38 mitogen-activated protein kinase ( MAPK ) in THP-1 cells as well as caspase-1 [ 72 ] . Activation of cells via MAPK signalling is frequently required by viruses to achieve their replication cycle [ 73 ] . In the model of HCoV-229 coronavirus , chloroquine-induced virus inhibition occurs through inhibition of p38 MAPK [ 44 ] .", "labels": [[0, 12, "CHEBI"], [125, 131, "PROTEIN"], [66, 100, "GENE_OR_GENE_PRODUCT"], [116, 125, "CELL"], [66, 100, "PROTEIN"], [286, 304, "ENTITY"], [304, 318, "ENTITY"], [125, 131, "ENTITY"], [161, 172, "CELL"], [355, 370, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [318, 344, "ENTITY"], [277, 282, "ENTITY"], [32, 48, "ENTITY"], [66, 100, "GGP"], [344, 355, "PROTEIN"], [116, 125, "ENTITY"], [0, 12, "CHEMICAL"], [344, 355, "ENTITY"], [181, 190, "ENTITY"], [66, 100, "ENTITY"], [161, 172, "ENTITY"], [116, 125, "CELL_LINE"], [161, 172, "CL"], [116, 125, "CL"], [304, 318, "GENE_OR_GENE_PRODUCT"], [286, 304, "GENE_OR_GENE_PRODUCT"], [344, 355, "GENE_OR_GENE_PRODUCT"], [215, 227, "TAXON"], [24, 32, "ENTITY"], [215, 227, "ENTITY"], [125, 131, "GENE_OR_GENE_PRODUCT"], [0, 12, "ENTITY"], [344, 355, "GGP"]]}
{"text": "Apart from the XBP1 pathway , activated IRE1 has been shown to recruit TNF receptor-associated factor 2 ( TRAF2 ) and induce apoptosis by activating the JNK ( Urano et al. , 2000 ) . This IRE1-JNK pathway is independent of IRE1 \u2019s RNase activity , but it requires IRE1 \u2019s kinase domain and involves TRAF2-dependent activation of caspase-12 ( Yonedaet al.,2001 ) .", "labels": [[315, 329, "PROTEIN"], [71, 102, "PROTEIN"], [208, 228, "GGP"], [223, 237, "ENTITY"], [15, 28, "ENTITY"], [290, 299, "ENTITY"], [208, 228, "GENE_OR_GENE_PRODUCT"], [208, 223, "ENTITY"], [315, 329, "ENTITY"], [299, 315, "ENTITY"], [255, 272, "GENE_OR_GENE_PRODUCT"], [181, 188, "PROTEIN"], [75, 102, "ENTITY"], [15, 20, "GGP"], [255, 272, "ENTITY"], [15, 20, "GENE_OR_GENE_PRODUCT"], [208, 220, "PROTEIN"], [290, 299, "SIMPLE_CHEMICAL"], [181, 197, "ENTITY"], [255, 272, "GGP"], [40, 45, "PROTEIN"], [71, 102, "GENE_OR_GENE_PRODUCT"], [118, 125, "ENTITY"], [71, 102, "GGP"], [255, 272, "PROTEIN"], [315, 329, "GENE_OR_GENE_PRODUCT"], [15, 20, "PROTEIN"]]}
{"text": "Besides p38 , DUSP1 has also been shown to dephosphorylate c-Jun N-terminal kinase ( JNK ) and ERK ( Sun et al.,1993;Franklin and Kraft , 1997 ) . It has been long proposed that ERK phosphorylation promotes cell survival , whereas prolonged JNK and p38 phosphorylation is linked to the induction of apoptosis ( Xia et al. , 1995 ) .", "labels": [[8, 12, "ENTITY"], [164, 173, "GENE_OR_GENE_PRODUCT"], [164, 173, "GGP"], [8, 12, "GGP"], [126, 138, "GENE_OR_GENE_PRODUCT"], [164, 173, "PROTEIN"], [198, 212, "ENTITY"], [85, 89, "ENTITY"], [164, 173, "ENTITY"], [182, 198, "ENTITY"], [85, 89, "PROTEIN"], [85, 89, "GGP"], [286, 299, "ENTITY"], [59, 76, "GENE_OR_GENE_PRODUCT"], [8, 12, "PROTEIN"], [59, 76, "GGP"], [279, 286, "ENTITY"], [59, 76, "PROTEIN"], [245, 253, "ENTITY"], [85, 89, "GENE_OR_GENE_PRODUCT"], [59, 76, "ENTITY"], [8, 12, "GENE_OR_GENE_PRODUCT"], [173, 182, "ENTITY"]]}
{"text": "By contract , ACE2 inactivates angiotensin II while generating angiotensin 1\u20137 , a heptapeptide having a potent vasodilator function via activation of its Mas receptor ( Santos et al. , 2003 ) , and thus serving as a negative regulator of the renin \u2013 angiotensin system .", "labels": [[31, 43, "ENTITY"], [31, 43, "PROTEIN"], [31, 43, "CHEMICAL"], [31, 43, "CHEMICAL"], [217, 226, "ENTITY"], [212, 217, "ENTITY"], [31, 43, "ENTITY"], [236, 243, "ENTITY"], [31, 43, "GGP"], [151, 159, "ENTITY"], [151, 159, "GENE_OR_GENE_PRODUCT"], [3, 12, "ENTITY"], [151, 159, "PROTEIN"], [31, 43, "GENE_OR_GENE_PRODUCT"], [236, 251, "GENE_OR_GENE_PRODUCT"], [31, 43, "SIMPLE_CHEMICAL"], [31, 43, "PROTEIN"], [243, 251, "CHEMICAL"], [105, 124, "ENTITY"]]}
{"text": "Those with elevated TnT levels had significantly higher levels of other biomarkers of cardiac injury , specifically creatine kinase\u2013 myocardial band test ( median [ IQR ] , 3.34 [ 2.11 - 5.80 ] vs 0.81 [ 0.54 - 1.38 ] , ng/mL [ to convert to micrograms per liter , multiply by 1 ] ) and myoglobin ( median [ IQR ] , 128.7 [ 65.8 - 206.9 ] vs 27.2 [ 21.0 - 49.8 ] \u03bcg/L [ to convert to nanomoles per liter , multiply by 0.05814 ] ) ( P < .001 , for all ) and also had higher levels of N-terminal pro \u2013 brain natriuretic peptide ( N-terminal pro\u2013brain natriuretic peptide ) ( median [ IQR ] , 817.4 ( 336.0 - 1944.0 ] vs 141.4 [ 39.3 - 303.6 ] pg/mL [ to convert to nanograms per liter , multiply by 1 ] ) .", "labels": [[462, 483, "ENTITY"], [11, 20, "ENTITY"], [24, 31, "ENTITY"], [20, 24, "ENTITY"], [156, 171, "ENTITY"], [20, 24, "PROTEIN"], [116, 125, "ENTITY"], [265, 279, "GGP"], [86, 101, "DISEASE"], [116, 125, "SIMPLE_CHEMICAL"], [20, 24, "GENE_OR_GENE_PRODUCT"], [265, 279, "GENE_OR_GENE_PRODUCT"], [430, 436, "ENTITY"], [72, 83, "ENTITY"], [86, 101, "ENTITY"], [281, 287, "ENTITY"], [86, 94, "ORGAN"], [447, 500, "PROTEIN"], [24, 31, "ENTITY"], [447, 457, "ENTITY"], [265, 279, "ENTITY"], [483, 498, "GGP"], [133, 149, "ENTITY"], [483, 498, "ENTITY"], [265, 279, "PROTEIN"], [500, 506, "ENTITY"]]}
{"text": "Under ER stress , ATF6 is translocated from the ER to the Golgi apparatus and cleaved by protease S1P and S2P ( Haze et al. , 1999 ) .", "labels": [[89, 98, "PROTEIN"], [6, 9, "PROTEIN"], [6, 16, "ENTITY"], [58, 64, "GO"], [6, 9, "GENE_OR_GENE_PRODUCT"], [58, 64, "ENTITY"]]}
{"text": "Under ER stress , ATF6 is translocated from the ER to the Golgi apparatus and cleaved by protease S1P and S2P ( Haze et al. , 1999 ) .", "labels": [[89, 98, "PROTEIN"], [6, 9, "PROTEIN"], [6, 16, "ENTITY"], [58, 64, "GO"], [6, 9, "GENE_OR_GENE_PRODUCT"], [58, 64, "ENTITY"]]}
{"text": "However , recent studies have demonstrated that , under certain circumstances , ATF6-mediated signals may also contribute to ER-stress-induced apoptosis , possibly via activation of CHOP and/or suppression of myeloid cell leukemia sequence 1 ( Mcl-1;Gotoh et al. , 2002;Nakanishi et al. , 2005;Morishima et al.,2011 ) .", "labels": [[259, 265, "CHEMICAL"], [80, 94, "ENTITY"], [206, 231, "PROTEIN"], [206, 231, "DISEASE"], [206, 231, "CL"], [206, 231, "CELL"], [187, 194, "ENTITY"], [206, 231, "ENTITY"], [125, 143, "ENTITY"]]}
{"text": "Analysis of the global proteomic changes reveal significant upregulation of CXCR2 , PRG3 , LBP , MMP25 , CRP , NLRP1 in the COVID-19-MS PBMC cohort ( Fig.3c ) .", "labels": [[76, 82, "GENE_OR_GENE_PRODUCT"], [23, 33, "ENTITY"], [97, 105, "PROTEIN"], [105, 111, "GENE_OR_GENE_PRODUCT"], [97, 105, "GENE_OR_GENE_PRODUCT"], [105, 111, "ENTITY"], [76, 82, "PROTEIN"], [141, 150, "SIMPLE_CHEMICAL"], [124, 136, "ENTITY"], [16, 23, "ENTITY"], [97, 105, "GGP"], [89, 97, "GENE_OR_GENE_PRODUCT"], [97, 105, "ENTITY"], [105, 111, "GGP"], [105, 111, "PROTEIN"], [60, 73, "ENTITY"], [76, 82, "GGP"], [136, 141, "ENTITY"], [76, 82, "ENTITY"], [0, 9, "ENTITY"], [120, 136, "CELL"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [362, 377, "GGP"], [330, 341, "ENTITY"], [299, 330, "ENTITY"], [299, 330, "PROTEIN"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [164, 171, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [164, 171, "PROTEIN"], [362, 377, "GENE_OR_GENE_PRODUCT"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [102, 108, "PROTEIN"], [164, 171, "GGP"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [133, 164, "GENE_OR_GENE_PRODUCT"], [133, 164, "PROTEIN"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [423, 434, "ENTITY"], [299, 330, "GGP"], [33, 41, "ENTITY"], [377, 389, "PROTEIN"], [164, 171, "ENTITY"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [362, 377, "GGP"], [330, 341, "ENTITY"], [299, 330, "ENTITY"], [299, 330, "PROTEIN"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [164, 171, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [164, 171, "PROTEIN"], [362, 377, "GENE_OR_GENE_PRODUCT"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [102, 108, "PROTEIN"], [164, 171, "GGP"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [133, 164, "GENE_OR_GENE_PRODUCT"], [133, 164, "PROTEIN"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [423, 434, "ENTITY"], [299, 330, "GGP"], [33, 41, "ENTITY"], [377, 389, "PROTEIN"], [164, 171, "ENTITY"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [362, 377, "GGP"], [330, 341, "ENTITY"], [299, 330, "ENTITY"], [299, 330, "PROTEIN"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [164, 171, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [164, 171, "PROTEIN"], [362, 377, "GENE_OR_GENE_PRODUCT"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "PROTEIN"], [164, 171, "GGP"], [330, 341, "GGP"], [401, 434, "PROTEIN"], [102, 108, "GGP"], [133, 164, "GENE_OR_GENE_PRODUCT"], [133, 164, "PROTEIN"], [14, 25, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [423, 434, "ENTITY"], [299, 330, "GGP"], [33, 41, "ENTITY"], [377, 389, "PROTEIN"], [164, 171, "ENTITY"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [362, 377, "GGP"], [330, 341, "ENTITY"], [299, 330, "ENTITY"], [299, 330, "PROTEIN"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [164, 171, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [164, 171, "PROTEIN"], [362, 377, "GENE_OR_GENE_PRODUCT"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [102, 108, "PROTEIN"], [164, 171, "GGP"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [133, 164, "GENE_OR_GENE_PRODUCT"], [133, 164, "PROTEIN"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [423, 434, "ENTITY"], [299, 330, "GGP"], [33, 41, "ENTITY"], [377, 389, "PROTEIN"], [164, 171, "ENTITY"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Orf10 may bind to the CUL2-ZYG11B complex and hijack it for ubiquitination and degradation of restriction factors . The ubiquitin transfer to a substrate requires neddylation of CUL2 via NEDD8-activating enzyme ( NAE ) , a druggable target that can be inhibited by the small molecule Pevonedistat [ 68 ] ( Fig. 4c ) .", "labels": [[223, 233, "ENTITY"], [79, 91, "ENTITY"], [94, 114, "ENTITY"], [269, 275, "CHEBI"], [60, 70, "ENTITY"], [22, 42, "PROTEIN"], [10, 15, "ENTITY"], [46, 53, "ENTITY"], [265, 284, "ENTITY"], [34, 42, "ENTITY"], [0, 6, "ENTITY"], [0, 6, "PROTEIN"], [94, 114, "PROTEIN"], [187, 204, "PROTEIN"], [0, 6, "GGP"], [0, 6, "SIMPLE_CHEMICAL"], [0, 6, "CHEMICAL"], [187, 204, "ENTITY"], [60, 75, "ENTITY"]]}
{"text": "Furthermore , RNA synthesis inhibitors ( like 3TC , TDF ) , remdesivir , neuraminidase inhibitors , peptide ( EK1 ) , anti-inflammatory drugs , abidol , Chinese traditional medicine , such as Lianhuaqingwen and ShuFengJieDu Capsules , could be the promising COVID-19 treatments.2", "labels": [[14, 18, "ENTITY"], [87, 100, "ENTITY"], [108, 118, "ENTITY"], [60, 87, "CHEBI"], [118, 136, "ENTITY"], [173, 192, "ENTITY"], [87, 100, "SO"], [244, 258, "PROTEIN"], [248, 258, "CHEMICAL"], [192, 211, "ORGANISM"], [60, 87, "ENTITY"], [60, 100, "SIMPLE_CHEMICAL"], [192, 211, "ENTITY"]]}
{"text": "In its inactive form , NF-\u03baB is sequestered in the cytoplasm by inhibitor of NF-\u03baB alpha ( I\u03baB\u03b1 ) , which masks the nuclear localization signal of NF-\u03baB(Karin and Ben-Neriah , 2000 ) .", "labels": [[114, 126, "ENTITY"], [53, 63, "GO"], [34, 46, "ENTITY"], [25, 31, "DNA"], [25, 31, "ENTITY"], [66, 76, "CHEBI"], [79, 91, "DNA"], [79, 91, "GGP"], [25, 31, "GGP"], [161, 178, "GENE_OR_GENE_PRODUCT"], [25, 31, "CHEMICAL"], [79, 91, "GENE_OR_GENE_PRODUCT"], [79, 91, "ENTITY"], [25, 31, "SIMPLE_CHEMICAL"], [53, 63, "ORGANISM_SUBSTANCE"], [53, 63, "ENTITY"], [9, 18, "ENTITY"], [79, 91, "CHEMICAL"], [66, 76, "ENTITY"]]}
{"text": "On the other hand , the kinase but not the RNAse activity of IRE1 has been associated with ER-stress-induced NF-kB activation ( Tam et al. , 2012 ) . Under ER stress , IRE1 has been shown to phosphorylate TRAF2 , which activates the I\u03baB kinase ( IKK ) and contributes to its basal activity ( Figure 4 ) . IKK inturn phosphorylates I\u03baB\u03b1 and promotes its proteasomal degradation , releasing NF-\u03baB to activate downstream genes ( Tam et al.,2012 ) .", "labels": [[256, 281, "ENTITY"], [43, 49, "ENTITY"], [94, 101, "GGP"], [219, 237, "ENTITY"], [49, 58, "ENTITY"], [191, 205, "PROTEIN"], [94, 101, "ENTITY"], [191, 205, "GENE_OR_GENE_PRODUCT"], [182, 191, "ENTITY"], [94, 101, "GENE_OR_GENE_PRODUCT"], [219, 237, "PROTEIN"], [150, 159, "ENTITY"], [191, 205, "ENTITY"], [395, 407, "ENTITY"], [191, 205, "GGP"], [395, 407, "DNA"], [94, 101, "PROTEIN"], [91, 115, "ENTITY"], [340, 365, "ENTITY"], [340, 353, "GO"], [219, 228, "SO"], [292, 303, "ENTITY"], [379, 389, "ENTITY"]]}
{"text": "On the other hand , the kinase but not the RNAse activity of IRE1 has been associated with ER-stress-induced NF-kB activation ( Tam et al. , 2012 ) . Under ER stress , IRE1 has been shown to phosphorylate TRAF2 , which activates the I\u03baB kinase ( IKK ) and contributes to its basal activity ( Figure 4 ) . IKK inturn phosphorylates I\u03baB\u03b1 and promotes its proteasomal degradation , releasing NF-\u03baB to activate downstream genes ( Tam et al.,2012 ) .", "labels": [[256, 281, "ENTITY"], [43, 49, "ENTITY"], [94, 101, "GGP"], [219, 237, "ENTITY"], [49, 58, "ENTITY"], [191, 205, "PROTEIN"], [94, 101, "ENTITY"], [191, 205, "GENE_OR_GENE_PRODUCT"], [182, 191, "ENTITY"], [94, 101, "GENE_OR_GENE_PRODUCT"], [219, 237, "PROTEIN"], [150, 159, "ENTITY"], [191, 205, "ENTITY"], [395, 407, "ENTITY"], [191, 205, "GGP"], [395, 407, "DNA"], [94, 101, "PROTEIN"], [91, 115, "ENTITY"], [340, 365, "ENTITY"], [340, 353, "GO"], [219, 228, "SO"], [292, 303, "ENTITY"], [379, 389, "ENTITY"]]}
{"text": "Analysis of the global proteomic changes reveal significant upregulation of CXCR2 , PRG3 , LBP , MMP25 , CRP , NLRP1 in the COVID-19-MS PBMC cohort ( Fig.3c ) .", "labels": [[76, 82, "GENE_OR_GENE_PRODUCT"], [23, 33, "ENTITY"], [97, 105, "GENE_OR_GENE_PRODUCT"], [105, 111, "GENE_OR_GENE_PRODUCT"], [105, 111, "ENTITY"], [76, 82, "PROTEIN"], [141, 150, "SIMPLE_CHEMICAL"], [124, 136, "ENTITY"], [16, 23, "ENTITY"], [97, 105, "PROTEIN"], [89, 97, "GENE_OR_GENE_PRODUCT"], [97, 105, "GGP"], [105, 111, "GGP"], [105, 111, "PROTEIN"], [60, 73, "ENTITY"], [76, 82, "GGP"], [97, 105, "ENTITY"], [136, 141, "ENTITY"], [76, 82, "ENTITY"], [0, 9, "ENTITY"], [120, 136, "CELL"]]}
{"text": "Concentrations of hypersensitive cardiac troponin I and N-terminal pro-brain natriuretic peptide were markedly higher in deceased patients ( 40.8 pg/mL and 800.0 pg/mL ) than in recovered patients ( 3.3 pg/mL and 72.0 pg/mL ) , with eight deceased patients having cardiac troponin I above 1000 pg/mL and two above 10 000 pg/mL.", "labels": [[67, 97, "GGP"], [33, 41, "PROTEIN"], [41, 52, "GGP"], [67, 97, "GENE_OR_GENE_PRODUCT"], [121, 130, "ENTITY"], [33, 41, "GGP"], [18, 52, "PROTEIN"], [0, 15, "ENTITY"], [33, 52, "GENE_OR_GENE_PRODUCT"], [178, 188, "ORGANISM"], [121, 130, "ENTITY"], [18, 52, "ENTITY"], [121, 130, "ORGANISM"], [257, 272, "ENTITY"], [56, 97, "ENTITY"], [130, 139, "ENTITY"], [178, 188, "ENTITY"], [257, 272, "GENE_OR_GENE_PRODUCT"], [130, 139, "ORGANISM"]]}
{"text": "Those with elevated TnT levels had significantly higher levels of other biomarkers of cardiac injury , specifically creatine kinase\u2013 myocardial band test ( median [ IQR ] , 3.34 [ 2.11 - 5.80 ] vs 0.81 [ 0.54 - 1.38 ] , ng/mL [ to convert to micrograms per liter , multiply by 1 ] ) and myoglobin ( median [ IQR ] , 128.7 [ 65.8 - 206.9 ] vs 27.2 [ 21.0 - 49.8 ] \u03bcg/L [ to convert to nanomoles per liter , multiply by 0.05814 ] ) ( P < .001 , for all ) and also had higher levels of N-terminal pro \u2013 brain natriuretic peptide ( N-terminal pro\u2013brain natriuretic peptide ) ( median [ IQR ] , 817.4 ( 336.0 - 1944.0 ] vs 141.4 [ 39.3 - 303.6 ] pg/mL [ to convert to nanograms per liter , multiply by 1 ] ) .", "labels": [[462, 483, "ENTITY"], [11, 20, "ENTITY"], [24, 31, "ENTITY"], [20, 24, "ENTITY"], [156, 171, "ENTITY"], [20, 24, "PROTEIN"], [116, 125, "ENTITY"], [265, 279, "GGP"], [86, 101, "DISEASE"], [116, 125, "SIMPLE_CHEMICAL"], [20, 24, "GENE_OR_GENE_PRODUCT"], [265, 279, "GENE_OR_GENE_PRODUCT"], [430, 436, "ENTITY"], [72, 83, "ENTITY"], [86, 101, "ENTITY"], [281, 287, "ENTITY"], [86, 94, "ORGAN"], [447, 500, "PROTEIN"], [24, 31, "ENTITY"], [447, 457, "ENTITY"], [265, 279, "ENTITY"], [483, 498, "GGP"], [133, 149, "ENTITY"], [483, 498, "ENTITY"], [265, 279, "PROTEIN"], [500, 506, "ENTITY"]]}
{"text": "Both TnT and NT-proBNP levels increased significantly during the course of hospitalization in those who ultimately died , but no such dynamic changes of TnT or NT-proBNP levels were evident in survivors .", "labels": [[5, 9, "GENE_OR_GENE_PRODUCT"], [13, 23, "ENTITY"], [115, 120, "ENTITY"], [5, 9, "PROTEIN"], [75, 91, "ENTITY"], [13, 23, "GENE_OR_GENE_PRODUCT"], [13, 23, "GGP"], [5, 9, "ENTITY"], [30, 40, "ENTITY"], [23, 30, "ENTITY"]]}
{"text": "Chloroquine was shown to inhibit quinone reductase 2 [ 56 ] , a structural neighbour of UDP-N-acetylglucosamine 2-epimerases [ 57 ] that are involved in the biosynthesis of sialic acids . The sialic acids are acidic monosaccharides found at the extremity of sugar chains present on cell transmembrane proteins and are critical components of ligand recognition . The possible interference of chloroquine with sialic acid biosynthesis could account for the broad antiviral spectrum of that drug since viruses such as the human coronavirus HCoV-O43 and the orthomyxoviruses use sialic acid moieties as receptors [ 58 ] .", "labels": [[0, 12, "CHEBI"], [271, 301, "GO"], [245, 264, "ENTITY"], [587, 599, "ENTITY"], [199, 216, "CHEBI"], [157, 180, "CHEMICAL"], [33, 53, "ENTITY"], [546, 554, "ENTITY"], [391, 408, "CHEBI"], [245, 264, "PROTEIN"], [375, 391, "SIMPLE_CHEMICAL"], [512, 525, "ORGANISM"], [391, 420, "ENTITY"], [554, 587, "PROTEIN"], [391, 408, "CHEMICAL"], [554, 575, "CHEMICAL"], [271, 301, "PROTEIN"], [245, 258, "SIMPLE_CHEMICAL"], [512, 537, "PROTEIN"], [519, 525, "ENTITY"], [519, 537, "CHEMICAL"], [157, 180, "ENTITY"], [62, 75, "ENTITY"], [33, 53, "GENE_OR_GENE_PRODUCT"], [375, 391, "ENTITY"], [391, 408, "SIMPLE_CHEMICAL"], [186, 199, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [238, 245, "PATHOLOGICAL_FORMATION"], [85, 112, "GENE_OR_GENE_PRODUCT"], [157, 180, "SIMPLE_CHEMICAL"], [209, 216, "SIMPLE_CHEMICAL"], [554, 587, "SIMPLE_CHEMICAL"], [0, 12, "CHEMICAL"], [157, 180, "CHEBI"], [186, 199, "ENTITY"], [327, 348, "ENTITY"], [33, 53, "GGP"], [271, 301, "ENTITY"], [455, 471, "ENTITY"], [186, 199, "CHEBI"], [85, 112, "ENTITY"], [271, 287, "CELLULAR_COMPONENT"], [199, 216, "ENTITY"], [375, 391, "CHEBI"], [554, 587, "ENTITY"], [33, 41, "CHEMICAL"], [25, 33, "ENTITY"], [33, 53, "PROTEIN"], [375, 391, "CHEMICAL"], [238, 245, "ENTITY"], [554, 575, "CHEBI"], [186, 199, "SIMPLE_CHEMICAL"], [0, 12, "ENTITY"], [525, 537, "ENTITY"], [546, 554, "TAXON"]]}
{"text": "Because functional blockade of PD-1 , CTLA-4 , and TIGIT is beneficial for CD8 + T cells to maintain lasting antigen-specific immunity and antiviral effects,10,11 the excessive exhaustion of CD8 + T cells in severe patients may reduce their cellular immune response to SARS- CoV-2 .", "labels": [[188, 199, "GGP"], [208, 215, "ORGANISM"], [266, 275, "PROTEIN"], [71, 83, "CELL_TYPE"], [266, 275, "ENTITY"], [31, 36, "ENTITY"], [135, 149, "ENTITY"], [235, 257, "ENTITY"], [71, 83, "ENTITY"], [101, 126, "ENTITY"], [19, 28, "ENTITY"], [188, 199, "ENTITY"], [188, 199, "CELL_TYPE"], [31, 36, "GENE_OR_GENE_PRODUCT"], [31, 36, "PROTEIN"], [266, 275, "ORGANISM"], [71, 83, "GGP"], [8, 19, "ENTITY"], [208, 215, "ENTITY"], [167, 177, "ENTITY"]]}
{"text": "FACs analysis illustrated that , T cells from COVID-19 patients have markedly higher levels of PD-1 compared to healthy controls ( Figure 3A ) .", "labels": [[46, 55, "ORGANISM"], [0, 5, "CELL"], [129, 138, "ENTITY"], [0, 5, "ENTITY"], [5, 14, "ENTITY"], [112, 120, "ENTITY"]]}
{"text": "Furthermore , statistical analysis showed that the percentage of PD-1 + CD8 + T cells from ICU patients was significantly higher than from both Non-ICU cases and healthy controls ( Figure 3B ) , indicating that SARS-CoV-2 viruses induce T cell exhaustion in COVID-19 patients , particularly in those requiring ICU care .", "labels": [[230, 239, "CELL"], [65, 80, "CELL_LINE"], [72, 80, "ENTITY"], [206, 222, "ENTITY"], [162, 170, "ENTITY"], [144, 152, "ENTITY"], [179, 188, "ENTITY"], [222, 230, "ENTITY"], [230, 239, "ENTITY"], [258, 267, "ENTITY"], [300, 314, "ENTITY"], [14, 26, "ENTITY"], [211, 222, "TAXON"], [230, 239, "CL"], [255, 267, "ORGANISM"], [80, 85, "ENTITY"], [65, 80, "GGP"]]}
{"text": "FACs showed that these patients have very low level of PD-1 and Tim-3 on CD8 + and CD4 + T cells in the prodromal stage , however , their levels on CD8 + T cells was increased in overtly symptomatic stages , and highest levels were seen in ICU period ( Figure 3C , D ) .", "labels": [[23, 32, "ORGANISM"], [83, 97, "GGP"], [73, 79, "GGP"], [73, 97, "CELL_TYPE"], [104, 120, "ENTITY"], [179, 187, "ENTITY"], [187, 199, "ENTITY"], [55, 60, "ENTITY"], [83, 97, "ENTITY"], [0, 5, "ENTITY"], [83, 87, "GENE_OR_GENE_PRODUCT"], [55, 60, "PROTEIN"], [64, 70, "GENE_OR_GENE_PRODUCT"], [240, 244, "ENTITY"], [64, 70, "ENTITY"], [0, 5, "CELL"], [244, 253, "ENTITY"], [23, 32, "ENTITY"], [145, 156, "GGP"], [55, 60, "GENE_OR_GENE_PRODUCT"], [73, 77, "GENE_OR_GENE_PRODUCT"], [46, 52, "ENTITY"], [145, 156, "ENTITY"], [145, 156, "CELL_TYPE"], [73, 79, "ENTITY"], [212, 220, "ENTITY"], [64, 70, "PROTEIN"], [64, 70, "GGP"]]}
{"text": "FACs showed that these patients have very low level of PD-1 and Tim-3 on CD8 + and CD4 + T cells in the prodromal stage , however , their levels on CD8 + T cells was increased in overtly symptomatic stages , and highest levels were seen in ICU period ( Figure 3C , D ) .", "labels": [[23, 32, "ORGANISM"], [83, 97, "GGP"], [73, 79, "GGP"], [73, 97, "CELL_TYPE"], [104, 120, "ENTITY"], [179, 187, "ENTITY"], [187, 199, "ENTITY"], [55, 60, "ENTITY"], [83, 97, "ENTITY"], [0, 5, "ENTITY"], [83, 87, "GENE_OR_GENE_PRODUCT"], [55, 60, "PROTEIN"], [64, 70, "GENE_OR_GENE_PRODUCT"], [240, 244, "ENTITY"], [64, 70, "ENTITY"], [0, 5, "CELL"], [244, 253, "ENTITY"], [23, 32, "ENTITY"], [145, 156, "GGP"], [55, 60, "GENE_OR_GENE_PRODUCT"], [73, 77, "GENE_OR_GENE_PRODUCT"], [46, 52, "ENTITY"], [145, 156, "ENTITY"], [145, 156, "CELL_TYPE"], [73, 79, "ENTITY"], [212, 220, "ENTITY"], [64, 70, "PROTEIN"], [64, 70, "GGP"]]}
{"text": "FACs analysis illustrated that , T cells from COVID-19 patients have markedly higher levels of PD-1 compared to healthy controls ( Figure 3A ) .", "labels": [[0, 5, "CELL"], [129, 138, "ENTITY"], [0, 5, "ENTITY"], [5, 14, "ENTITY"], [46, 55, "ORGANISM"], [112, 120, "ENTITY"]]}
{"text": "Furthermore , statistical analysis showed that the percentage of PD-1 + CD8 + T cells from ICU patients was significantly higher than from both Non-ICU cases and healthy controls ( Figure 3B ) , indicating that SARS-CoV-2 viruses induce T cell exhaustion in COVID-19 patients , particularly in those requiring ICU care .", "labels": [[230, 239, "CELL"], [65, 80, "CELL_LINE"], [255, 267, "ORGANISM"], [258, 267, "ENTITY"], [72, 80, "ENTITY"], [206, 222, "ENTITY"], [162, 170, "ENTITY"], [144, 152, "ENTITY"], [179, 188, "ENTITY"], [222, 230, "ENTITY"], [230, 239, "ENTITY"], [300, 314, "ENTITY"], [211, 222, "TAXON"], [14, 26, "ENTITY"], [230, 239, "CL"], [80, 85, "ENTITY"], [65, 80, "GGP"]]}
{"text": "FACs showed that these patients have very low level of PD-1 and Tim-3 on CD8 + and CD4 + T cells in the prodromal stage , however , their levels on CD8 + T cells was increased in overtly symptomatic stages , and highest levels were seen in ICU period ( Figure 3C , D ) .", "labels": [[23, 32, "ORGANISM"], [83, 97, "GGP"], [73, 79, "GGP"], [73, 97, "CELL_TYPE"], [104, 120, "ENTITY"], [187, 199, "ENTITY"], [55, 60, "ENTITY"], [83, 97, "ENTITY"], [0, 5, "ENTITY"], [83, 87, "GENE_OR_GENE_PRODUCT"], [55, 60, "PROTEIN"], [64, 70, "GENE_OR_GENE_PRODUCT"], [240, 244, "ENTITY"], [64, 70, "ENTITY"], [0, 5, "CELL"], [244, 253, "ENTITY"], [23, 32, "ENTITY"], [145, 156, "GGP"], [55, 60, "GENE_OR_GENE_PRODUCT"], [73, 77, "GENE_OR_GENE_PRODUCT"], [46, 52, "ENTITY"], [145, 156, "ENTITY"], [179, 187, "ENTITY"], [145, 156, "CELL_TYPE"], [73, 79, "ENTITY"], [212, 220, "ENTITY"], [64, 70, "PROTEIN"], [64, 70, "GGP"]]}
{"text": "Plasmin , a key player in fibrinolysis , enhances the virulence and pathogenicity of viruses containing a furin site in their envelope proteins , as is the case with the SARS-CoV-2 .", "labels": [[104, 112, "ENTITY"], [104, 112, "DNA"], [104, 112, "GGP"], [0, 8, "ENTITY"], [0, 8, "PROTEIN"], [120, 135, "GO"], [120, 135, "PROTEIN"], [0, 8, "GENE_OR_GENE_PRODUCT"], [0, 8, "GGP"], [120, 135, "ENTITY"]]}
{"text": "One of ATF4 \u2019s target genes is the growth arrest and DNA damage-inducible protein 153 ( GADD153 , also knownas C/EBP homologous protein , or CHOP ) . GADD153 induces the growth arrest and DNA damage-inducible protein 34 ( growth arrest and DNA damage-inducible protein 34 ) , which recruits protein phosphatase 1 ( PP1 ) to dephosphorylate eIF2\u03b1 and release the translation block .", "labels": [[53, 82, "ENTITY"], [239, 248, "GENE_OR_GENE_PRODUCT"], [256, 281, "ENTITY"], [88, 96, "ENTITY"], [53, 82, "GENE_OR_GENE_PRODUCT"], [42, 49, "SO"], [35, 42, "ENTITY"], [141, 150, "ENTITY"], [57, 74, "CHEBI"], [141, 150, "GGP"], [74, 82, "ENTITY"], [141, 150, "GENE_OR_GENE_PRODUCT"], [7, 12, "GGP"], [209, 222, "GGP"], [53, 74, "GGP"], [42, 74, "GENE_OR_GENE_PRODUCT"], [209, 222, "ENTITY"], [42, 74, "ENTITY"], [53, 74, "GENE_OR_GENE_PRODUCT"], [53, 74, "PROTEIN"], [209, 222, "PROTEIN"], [209, 222, "GENE_OR_GENE_PRODUCT"], [98, 128, "ENTITY"], [7, 22, "DNA"], [141, 150, "PROTEIN"], [103, 128, "PROTEIN"], [239, 248, "PROTEIN"], [53, 74, "ENTITY"], [226, 239, "ENTITY"], [103, 111, "GENE_OR_GENE_PRODUCT"], [7, 12, "ENTITY"], [117, 128, "CHEBI"], [7, 12, "GENE_OR_GENE_PRODUCT"], [158, 177, "ENTITY"]]}
{"text": "The rapid dephosphorylation of eIF2\u03b1 is likely due to the accumulation of GADD34 , which is a component of the PP1 complex and a downstream target gene induced by GADD153 ( Wang et al. , 2009 ) .", "labels": [[10, 28, "ENTITY"], [58, 71, "ENTITY"], [111, 115, "PROTEIN"], [4, 10, "ENTITY"], [31, 37, "DNA"], [74, 81, "ENTITY"], [74, 81, "PROTEIN"], [129, 147, "DNA"], [74, 81, "GENE_OR_GENE_PRODUCT"], [74, 81, "GGP"], [31, 37, "GENE_OR_GENE_PRODUCT"], [31, 37, "ENTITY"]]}
{"text": "Interestingly , GADD34 expression did not significantly affect protein synthesis in DCs , but was shown to be crucial for the production of interferon \u03b2 ( IFN-\u03b2 ) and pro-inflammatory cytokines interleukin-6 ( IL-6;Clavarino et al.,2012 ) .", "labels": [[194, 210, "GENE_OR_GENE_PRODUCT"], [194, 210, "ENTITY"], [63, 71, "ENTITY"], [137, 151, "ENTITY"], [194, 210, "PROTEIN"], [163, 194, "PROTEIN"], [163, 194, "GENE_OR_GENE_PRODUCT"], [163, 194, "ENTITY"], [137, 151, "GENE_OR_GENE_PRODUCT"], [137, 163, "PROTEIN"], [163, 194, "GGP"], [137, 151, "GGP"]]}
{"text": "Interestingly , GADD34 expression did not significantly affect protein synthesis in DCs , but was shown to be crucial for the production of interferon \u03b2 ( IFN-\u03b2 ) and pro-inflammatory cytokines interleukin-6 ( IL-6;Clavarino et al.,2012 ) .", "labels": [[194, 210, "GENE_OR_GENE_PRODUCT"], [63, 71, "ENTITY"], [194, 210, "PROTEIN"], [137, 151, "GGP"], [163, 194, "PROTEIN"], [137, 151, "GENE_OR_GENE_PRODUCT"], [163, 194, "GENE_OR_GENE_PRODUCT"], [163, 194, "ENTITY"], [137, 163, "PROTEIN"], [137, 151, "ENTITY"], [163, 194, "GGP"], [194, 210, "ENTITY"]]}
{"text": "Interestingly , GADD34 expression did not significantly affect protein synthesis in DCs , but was shown to be crucial for the production of interferon \u03b2 ( IFN-\u03b2 ) and pro-inflammatory cytokines interleukin-6 ( IL-6;Clavarino et al.,2012 ) .", "labels": [[194, 210, "GENE_OR_GENE_PRODUCT"], [194, 210, "ENTITY"], [63, 71, "ENTITY"], [137, 151, "ENTITY"], [194, 210, "PROTEIN"], [163, 194, "PROTEIN"], [163, 194, "GENE_OR_GENE_PRODUCT"], [163, 194, "ENTITY"], [137, 151, "GENE_OR_GENE_PRODUCT"], [137, 163, "PROTEIN"], [163, 194, "GGP"], [137, 151, "GGP"]]}
{"text": "In contrast , GADD34 has also been shown to specify PP1 to dephosphorylate the TGF-\u03b2-activated kinase 1 ( TAK1 ) , thus negatively regulating the toll-like receptor ( TLR ) signal-ing and pro-inflammatory cytokines [ IL-6 and TNF-\u03b1 ( Tumornecrosis factor alpha ) ] production in macrophages ( Gu et al.,2014 ) .", "labels": [[205, 215, "GGP"], [79, 102, "GENE_OR_GENE_PRODUCT"], [79, 102, "ENTITY"], [217, 222, "GENE_OR_GENE_PRODUCT"], [226, 234, "DISEASE"], [226, 248, "PROTEIN"], [279, 296, "PROTEIN"], [205, 215, "GENE_OR_GENE_PRODUCT"], [142, 173, "PROTEIN"], [217, 222, "ENTITY"], [156, 165, "ENTITY"], [142, 156, "ENTITY"], [265, 279, "CELL"], [173, 205, "PROTEIN"], [142, 156, "GENE_OR_GENE_PRODUCT"], [205, 215, "PROTEIN"], [265, 279, "CELL_TYPE"], [217, 222, "CHEMICAL"], [205, 215, "ENTITY"], [265, 279, "CL"], [142, 156, "GGP"], [217, 222, "PROTEIN"], [226, 248, "ENTITY"], [255, 265, "ENTITY"], [188, 205, "ENTITY"], [156, 165, "GENE_OR_GENE_PRODUCT"], [173, 188, "ENTITY"], [79, 102, "PROTEIN"], [265, 279, "ENTITY"], [79, 102, "GGP"]]}
{"text": "In contrast , GADD34 has also been shown to specify PP1 to dephosphorylate the TGF-\u03b2-activated kinase 1 ( TAK1 ) , thus negatively regulating the toll-like receptor ( TLR ) signal-ing and pro-inflammatory cytokines [ IL-6 and TNF-\u03b1 ( Tumornecrosis factor alpha ) ] production in macrophages ( Gu et al.,2014 ) .", "labels": [[205, 215, "GGP"], [79, 102, "GENE_OR_GENE_PRODUCT"], [79, 102, "ENTITY"], [217, 222, "GENE_OR_GENE_PRODUCT"], [226, 234, "DISEASE"], [226, 248, "PROTEIN"], [279, 296, "PROTEIN"], [205, 215, "GENE_OR_GENE_PRODUCT"], [142, 173, "PROTEIN"], [217, 222, "ENTITY"], [156, 165, "ENTITY"], [142, 156, "ENTITY"], [265, 279, "CELL"], [173, 205, "PROTEIN"], [142, 156, "GENE_OR_GENE_PRODUCT"], [205, 215, "PROTEIN"], [265, 279, "CELL_TYPE"], [217, 222, "CHEMICAL"], [205, 215, "ENTITY"], [265, 279, "CL"], [142, 156, "GGP"], [217, 222, "PROTEIN"], [173, 188, "ENTITY"], [226, 248, "ENTITY"], [255, 265, "ENTITY"], [188, 205, "ENTITY"], [156, 165, "GENE_OR_GENE_PRODUCT"], [79, 102, "PROTEIN"], [265, 279, "ENTITY"], [79, 102, "GGP"]]}
{"text": "In contrast , GADD34 has also been shown to specify PP1 to dephosphorylate the TGF-\u03b2-activated kinase 1 ( TAK1 ) , thus negatively regulating the toll-like receptor ( TLR ) signal-ing and pro-inflammatory cytokines [ IL-6 and TNF-\u03b1 ( Tumornecrosis factor alpha ) ] production in macrophages ( Gu et al.,2014 ) .", "labels": [[205, 215, "GGP"], [79, 102, "GENE_OR_GENE_PRODUCT"], [79, 102, "ENTITY"], [217, 222, "GENE_OR_GENE_PRODUCT"], [279, 296, "PROTEIN"], [205, 215, "GENE_OR_GENE_PRODUCT"], [226, 248, "PROTEIN"], [142, 173, "PROTEIN"], [217, 222, "ENTITY"], [156, 165, "ENTITY"], [142, 156, "ENTITY"], [265, 279, "CELL"], [173, 205, "PROTEIN"], [142, 156, "GENE_OR_GENE_PRODUCT"], [205, 215, "PROTEIN"], [265, 279, "CELL_TYPE"], [217, 222, "CHEMICAL"], [205, 215, "ENTITY"], [265, 279, "CL"], [142, 156, "GGP"], [217, 222, "PROTEIN"], [226, 234, "DISEASE"], [255, 265, "ENTITY"], [188, 205, "ENTITY"], [156, 165, "GENE_OR_GENE_PRODUCT"], [173, 188, "ENTITY"], [226, 248, "ENTITY"], [79, 102, "PROTEIN"], [265, 279, "ENTITY"], [79, 102, "GGP"]]}
{"text": "Analysis of the global proteomic changes reveal significant upregulation of CXCR2 , PRG3 , LBP , MMP25 , CRP , NLRP1 in the COVID-19-MS PBMC cohort ( Fig.3c ) .", "labels": [[76, 82, "GENE_OR_GENE_PRODUCT"], [23, 33, "ENTITY"], [97, 105, "GENE_OR_GENE_PRODUCT"], [105, 111, "GENE_OR_GENE_PRODUCT"], [105, 111, "ENTITY"], [76, 82, "PROTEIN"], [141, 150, "SIMPLE_CHEMICAL"], [124, 136, "ENTITY"], [16, 23, "ENTITY"], [97, 105, "PROTEIN"], [89, 97, "GENE_OR_GENE_PRODUCT"], [97, 105, "GGP"], [105, 111, "GGP"], [105, 111, "PROTEIN"], [60, 73, "ENTITY"], [76, 82, "GGP"], [97, 105, "ENTITY"], [136, 141, "ENTITY"], [76, 82, "ENTITY"], [0, 9, "ENTITY"], [120, 136, "CELL"]]}
{"text": "IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate ( AMP ) kinase .", "labels": [[19, 46, "ENTITY"], [59, 64, "PROTEIN"], [83, 107, "CHEMICAL"], [0, 6, "GENE_OR_GENE_PRODUCT"], [59, 64, "GENE_OR_GENE_PRODUCT"], [0, 6, "CHEMICAL"], [59, 64, "ENTITY"], [0, 6, "GGP"], [59, 64, "GGP"], [83, 93, "CHEBI"], [83, 107, "SIMPLE_CHEMICAL"], [83, 107, "ENTITY"], [68, 79, "ENTITY"], [0, 6, "PROTEIN"], [0, 6, "ENTITY"]]}
{"text": "Gassen et al. revealed that E3 ligase S-phase kinas associated protein 2 ( S-phase kinas associated protein 2 ) executes lysine-48-linked polyubiquitination of Benclin 1 ( BECN1 ) , resulting in its proteasomal degradation . S-phase kinas associated protein 2 inhibition increases the BENC1 level , enhances autophagy , and efficiently reduces MERS-CoV replication.3", "labels": [[91, 108, "ENTITY"], [14, 23, "ENTITY"], [200, 211, "ENTITY"], [28, 46, "GENE_OR_GENE_PRODUCT"], [211, 239, "PROTEIN"], [63, 71, "CHEBI"], [152, 162, "PROTEIN"], [152, 162, "GENE_OR_GENE_PRODUCT"], [152, 162, "ENTITY"], [-1, 20, "ENTITY"], [28, 52, "ENTITY"], [91, 108, "GGP"], [130, 142, "GO"], [91, 108, "PROTEIN"], [181, 195, "GGP"], [91, 108, "GENE_OR_GENE_PRODUCT"], [211, 225, "GGP"], [152, 162, "GGP"], [181, 195, "ENTITY"], [28, 38, "PROTEIN"], [181, 195, "GENE_OR_GENE_PRODUCT"], [211, 239, "ENTITY"], [63, 73, "ENTITY"], [130, 152, "ENTITY"]]}
{"text": "Gassen et al. revealed that E3 ligase S-phase kinas associated protein 2 ( S-phase kinas associated protein 2 ) executes lysine-48-linked polyubiquitination of Benclin 1 ( BECN1 ) , resulting in its proteasomal degradation . S-phase kinas associated protein 2 inhibition increases the BENC1 level , enhances autophagy , and efficiently reduces MERS-CoV replication.3", "labels": [[91, 108, "ENTITY"], [14, 23, "ENTITY"], [200, 211, "ENTITY"], [28, 46, "GENE_OR_GENE_PRODUCT"], [211, 239, "PROTEIN"], [63, 71, "CHEBI"], [152, 162, "PROTEIN"], [152, 162, "GENE_OR_GENE_PRODUCT"], [152, 162, "ENTITY"], [-1, 20, "ENTITY"], [28, 52, "ENTITY"], [91, 108, "GGP"], [130, 142, "GO"], [91, 108, "PROTEIN"], [181, 195, "GGP"], [91, 108, "GENE_OR_GENE_PRODUCT"], [211, 225, "GGP"], [152, 162, "GGP"], [181, 195, "ENTITY"], [28, 38, "PROTEIN"], [181, 195, "GENE_OR_GENE_PRODUCT"], [211, 239, "ENTITY"], [63, 73, "ENTITY"], [130, 152, "ENTITY"]]}
{"text": "Gassen et al. revealed that E3 ligase S-phase kinas associated protein 2 ( S-phase kinas associated protein 2 ) executes lysine-48-linked polyubiquitination of Benclin 1 ( BECN1 ) , resulting in its proteasomal degradation . S-phase kinas associated protein 2 inhibition increases the BENC1 level , enhances autophagy , and efficiently reduces MERS-CoV replication.3", "labels": [[91, 108, "ENTITY"], [14, 23, "ENTITY"], [200, 211, "ENTITY"], [211, 239, "PROTEIN"], [28, 46, "GENE_OR_GENE_PRODUCT"], [211, 239, "ENTITY"], [63, 71, "CHEBI"], [152, 162, "PROTEIN"], [152, 162, "GENE_OR_GENE_PRODUCT"], [152, 162, "ENTITY"], [-1, 20, "ENTITY"], [28, 52, "ENTITY"], [91, 108, "GGP"], [130, 142, "GO"], [91, 108, "PROTEIN"], [181, 195, "GGP"], [91, 108, "GENE_OR_GENE_PRODUCT"], [211, 225, "GGP"], [152, 162, "GGP"], [181, 195, "ENTITY"], [28, 38, "PROTEIN"], [181, 195, "GENE_OR_GENE_PRODUCT"], [63, 73, "ENTITY"], [130, 152, "ENTITY"]]}
{"text": "Gassen et al. revealed that E3 ligase S-phase kinas associated protein 2 ( S-phase kinas associated protein 2 ) executes lysine-48-linked polyubiquitination of Benclin 1 ( BECN1 ) , resulting in its proteasomal degradation . S-phase kinas associated protein 2 inhibition increases the BENC1 level , enhances autophagy , and efficiently reduces MERS-CoV replication.3", "labels": [[91, 108, "ENTITY"], [14, 23, "ENTITY"], [200, 211, "ENTITY"], [211, 239, "PROTEIN"], [28, 46, "GENE_OR_GENE_PRODUCT"], [211, 239, "ENTITY"], [63, 71, "CHEBI"], [152, 162, "PROTEIN"], [152, 162, "GENE_OR_GENE_PRODUCT"], [152, 162, "ENTITY"], [-1, 20, "ENTITY"], [28, 52, "ENTITY"], [91, 108, "GGP"], [130, 142, "GO"], [91, 108, "PROTEIN"], [181, 195, "GGP"], [91, 108, "GENE_OR_GENE_PRODUCT"], [211, 225, "GGP"], [152, 162, "GGP"], [181, 195, "ENTITY"], [28, 38, "PROTEIN"], [181, 195, "GENE_OR_GENE_PRODUCT"], [63, 73, "ENTITY"], [130, 152, "ENTITY"]]}
{"text": "Another study , demonstrated that IFN-\u03b1 and -\u03b3 co-administration caused hyper-activated IRF-1 and STAT1 , which finally led to a more robust antiviral symphony against virus replication ( 59 ) .", "labels": [[160, 174, "ENTITY"], [72, 88, "PROTEIN"], [8, 14, "ENTITY"], [134, 151, "ENTITY"]]}
{"text": "For WNV , it has been shown that ATF6 activation promotes efficient WNV replication by suppressing signal transducer and activator of transcription 1 ( signal transducer and activator of transcription 1 ) phosphorylation and late-phase IFN signaling ( Ambrose and Mackenzie , 2013 ) .", "labels": [[87, 148, "PROTEIN"], [4, 8, "PROTEIN"], [49, 58, "ENTITY"], [33, 38, "ENTITY"], [58, 68, "TAXON"], [58, 68, "ENTITY"], [117, 148, "ENTITY"], [58, 68, "ORGANISM"], [4, 8, "ENTITY"], [4, 8, "ENTITY"], [4, 8, "ORGANISM"], [58, 68, "PROTEIN"], [121, 134, "GENE_OR_GENE_PRODUCT"], [4, 8, "TAXON"], [87, 106, "ENTITY"], [4, 8, "DISEASE"], [99, 117, "ENTITY"], [121, 134, "ENTITY"]]}
{"text": "Our results demonstrated that DIP ( 5 \u03bcM ) treatment significantly increased IFNB , IFIT1 , and ISG15 messenger RNA expression and promoted IFN-B secretion ( Figure 2A ) by increasing TBK1 and IRF3 phosphorylation ( Figure 2A) by increasing TBK1 and IRF3 phosphorylation ) .", "labels": [[146, 158, "ENTITY"], [53, 67, "ENTITY"], [67, 77, "GGP"], [198, 216, "ENTITY"], [67, 77, "ENTITY"], [30, 34, "SIMPLE_CHEMICAL"], [102, 112, "SO"], [184, 189, "GGP"], [67, 77, "PROTEIN"], [131, 140, "PROTEIN"], [112, 116, "ENTITY"], [4, 12, "ENTITY"], [30, 34, "CHEMICAL"], [92, 112, "RNA"], [131, 140, "ENTITY"], [140, 146, "ENTITY"], [184, 189, "PROTEIN"], [184, 189, "ENTITY"], [67, 77, "GENE_OR_GENE_PRODUCT"], [193, 198, "ENTITY"], [92, 112, "ENTITY"], [30, 34, "ENTITY"], [184, 189, "GENE_OR_GENE_PRODUCT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [362, 377, "GGP"], [330, 341, "ENTITY"], [299, 330, "ENTITY"], [299, 330, "PROTEIN"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [164, 171, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [164, 171, "PROTEIN"], [362, 377, "GENE_OR_GENE_PRODUCT"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [102, 108, "PROTEIN"], [164, 171, "GGP"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [133, 164, "GENE_OR_GENE_PRODUCT"], [133, 164, "PROTEIN"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [423, 434, "ENTITY"], [299, 330, "GGP"], [33, 41, "ENTITY"], [377, 389, "PROTEIN"], [164, 171, "ENTITY"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Because functional blockade of PD-1 , CTLA-4 , and TIGIT is beneficial for CD8 + T cells to maintain lasting antigen-specific immunity and antiviral effects,10,11 the excessive exhaustion of CD8 + T cells in severe patients may reduce their cellular immune response to SARS- CoV-2 .", "labels": [[188, 199, "GGP"], [208, 215, "ORGANISM"], [266, 275, "PROTEIN"], [71, 83, "CELL_TYPE"], [266, 275, "ENTITY"], [31, 36, "ENTITY"], [135, 149, "ENTITY"], [235, 257, "ENTITY"], [71, 83, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [101, 126, "ENTITY"], [19, 28, "ENTITY"], [188, 199, "ENTITY"], [188, 199, "CELL_TYPE"], [266, 275, "ORGANISM"], [71, 83, "GGP"], [8, 19, "ENTITY"], [208, 215, "ENTITY"], [31, 36, "PROTEIN"], [167, 177, "ENTITY"]]}
{"text": "Usually , Toll-like receptor ( TLR ) 3 , TLR7 , TLR8 , and TLR9 sense viral RNA and DNA in the endosome [ 60 , 61 ] . The viral RNA receptor retinoic-acid inducible gene I ( RIG-I ) [ 62 ] , cytosolic receptor melanoma differentiation-associated gene 5 ( MDA5 ) and nucleotidyl transferase cyclic GMP-AMP synthase ( cGAS ) [ 63 ] are responsible for the recognition of viral RNA and DNA in the cytoplasm .", "labels": [[111, 122, "TAXON"], [155, 165, "PROTEIN"], [354, 366, "CELLULAR_COMPONENT"], [174, 201, "ENTITY"], [41, 48, "GGP"], [346, 354, "ENTITY"], [10, 35, "PROTEIN"], [201, 219, "ENTITY"], [354, 366, "ENTITY"], [346, 354, "RNA"], [70, 84, "ENTITY"], [10, 20, "ENTITY"], [41, 48, "GENE_OR_GENE_PRODUCT"], [88, 95, "CELLULAR_COMPONENT"], [191, 201, "DISEASE"], [64, 70, "TAXON"], [88, 95, "ENTITY"], [111, 141, "PROTEIN"], [246, 297, "PROTEIN"], [76, 80, "ENTITY"], [155, 165, "ENTITY"], [354, 366, "SO"], [64, 70, "ENTITY"], [88, 95, "GO"], [10, 20, "GENE_OR_GENE_PRODUCT"], [174, 219, "PROTEIN"], [346, 354, "TAXON"], [111, 155, "ENTITY"], [70, 84, "ORGANISM_SUBSTANCE"], [76, 80, "SO"], [246, 297, "GENE_OR_GENE_PRODUCT"], [41, 48, "PROTEIN"], [10, 20, "GGP"], [155, 165, "GGP"], [262, 297, "GGP"], [246, 297, "ENTITY"], [174, 184, "GO"], [70, 84, "GO"], [59, 64, "ENTITY"], [174, 219, "GENE_OR_GENE_PRODUCT"], [41, 48, "ENTITY"], [76, 80, "CELLULAR_COMPONENT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [164, 171, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [362, 377, "GENE_OR_GENE_PRODUCT"], [164, 171, "PROTEIN"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [102, 108, "PROTEIN"], [164, 171, "GGP"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [133, 164, "GENE_OR_GENE_PRODUCT"], [133, 164, "PROTEIN"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [33, 41, "ENTITY"], [299, 330, "GGP"], [377, 389, "PROTEIN"], [164, 171, "ENTITY"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [164, 171, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [362, 377, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [164, 171, "GGP"], [102, 108, "PROTEIN"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [164, 171, "ENTITY"], [133, 164, "PROTEIN"], [133, 164, "GENE_OR_GENE_PRODUCT"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [33, 41, "ENTITY"], [299, 330, "GGP"], [164, 171, "PROTEIN"], [377, 389, "PROTEIN"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "As another approach , the IFN level can be increased indirectly . Noteworthy , toll like receptor (TLR)3 activation , could induce these IFNs ( 61\u201364 ) .", "labels": [[131, 144, "GENE_OR_GENE_PRODUCT"], [98, 105, "ENTITY"]]}
{"text": "As another approach , the IFN level can be increased indirectly . Noteworthy , toll like receptor (TLR)3 activation , could induce these IFNs ( 61\u201364 ) .", "labels": [[131, 144, "GENE_OR_GENE_PRODUCT"], [98, 105, "ENTITY"]]}
{"text": "Usually , Toll-like receptor ( TLR ) 3 , TLR7 , TLR8 , and TLR9 sense viral RNA and DNA in the endosome [ 60 , 61 ] . The viral RNA receptor retinoic-acid inducible gene I ( RIG-I ) [ 62 ] , cytosolic receptor melanoma differentiation-associated gene 5 ( MDA5 ) and nucleotidyl transferase cyclic GMP-AMP synthase ( cGAS ) [ 63 ] are responsible for the recognition of viral RNA and DNA in the cytoplasm .", "labels": [[111, 122, "TAXON"], [155, 165, "PROTEIN"], [354, 366, "CELLULAR_COMPONENT"], [174, 201, "ENTITY"], [346, 354, "ENTITY"], [201, 219, "ENTITY"], [354, 366, "ENTITY"], [346, 354, "RNA"], [70, 84, "ENTITY"], [10, 20, "ENTITY"], [88, 95, "CELLULAR_COMPONENT"], [191, 201, "DISEASE"], [64, 70, "TAXON"], [88, 95, "ENTITY"], [111, 141, "PROTEIN"], [246, 297, "PROTEIN"], [41, 48, "GENE_OR_GENE_PRODUCT"], [76, 80, "ENTITY"], [155, 165, "ENTITY"], [354, 366, "SO"], [64, 70, "ENTITY"], [41, 48, "ENTITY"], [88, 95, "GO"], [10, 20, "GENE_OR_GENE_PRODUCT"], [174, 219, "PROTEIN"], [346, 354, "TAXON"], [111, 155, "ENTITY"], [70, 84, "ORGANISM_SUBSTANCE"], [76, 80, "SO"], [41, 48, "GGP"], [246, 297, "GENE_OR_GENE_PRODUCT"], [10, 20, "GGP"], [155, 165, "GGP"], [262, 297, "GGP"], [246, 297, "ENTITY"], [174, 184, "GO"], [70, 84, "GO"], [59, 64, "ENTITY"], [10, 35, "PROTEIN"], [174, 219, "GENE_OR_GENE_PRODUCT"], [41, 48, "PROTEIN"], [76, 80, "CELLULAR_COMPONENT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [164, 171, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [362, 377, "GENE_OR_GENE_PRODUCT"], [164, 171, "PROTEIN"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [102, 108, "PROTEIN"], [164, 171, "GGP"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [133, 164, "GENE_OR_GENE_PRODUCT"], [133, 164, "PROTEIN"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [33, 41, "ENTITY"], [299, 330, "GGP"], [377, 389, "PROTEIN"], [164, 171, "ENTITY"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [164, 171, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [362, 377, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [164, 171, "GGP"], [102, 108, "PROTEIN"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [164, 171, "ENTITY"], [133, 164, "PROTEIN"], [133, 164, "GENE_OR_GENE_PRODUCT"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [33, 41, "ENTITY"], [299, 330, "GGP"], [164, 171, "PROTEIN"], [377, 389, "PROTEIN"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Usually , Toll-like receptor ( TLR ) 3 , TLR7 , TLR8 , and TLR9 sense viral RNA and DNA in the endosome [ 60 , 61 ] . The viral RNA receptor retinoic-acid inducible gene I ( RIG-I ) [ 62 ] , cytosolic receptor melanoma differentiation-associated gene 5 ( MDA5 ) and nucleotidyl transferase cyclic GMP-AMP synthase ( cGAS ) [ 63 ] are responsible for the recognition of viral RNA and DNA in the cytoplasm .", "labels": [[111, 122, "TAXON"], [41, 48, "PROTEIN"], [155, 165, "PROTEIN"], [354, 366, "CELLULAR_COMPONENT"], [174, 201, "ENTITY"], [41, 48, "ENTITY"], [346, 354, "ENTITY"], [201, 219, "ENTITY"], [354, 366, "ENTITY"], [346, 354, "RNA"], [70, 84, "ENTITY"], [10, 20, "ENTITY"], [88, 95, "CELLULAR_COMPONENT"], [191, 201, "DISEASE"], [64, 70, "TAXON"], [88, 95, "ENTITY"], [111, 141, "PROTEIN"], [246, 297, "PROTEIN"], [76, 80, "ENTITY"], [155, 165, "ENTITY"], [354, 366, "SO"], [64, 70, "ENTITY"], [88, 95, "GO"], [10, 20, "GENE_OR_GENE_PRODUCT"], [174, 219, "PROTEIN"], [346, 354, "TAXON"], [111, 155, "ENTITY"], [70, 84, "ORGANISM_SUBSTANCE"], [41, 48, "GGP"], [76, 80, "SO"], [246, 297, "GENE_OR_GENE_PRODUCT"], [10, 20, "GGP"], [155, 165, "GGP"], [262, 297, "GGP"], [246, 297, "ENTITY"], [174, 184, "GO"], [70, 84, "GO"], [59, 64, "ENTITY"], [41, 48, "GENE_OR_GENE_PRODUCT"], [174, 219, "GENE_OR_GENE_PRODUCT"], [10, 35, "PROTEIN"], [76, 80, "CELLULAR_COMPONENT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [164, 171, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [362, 377, "GENE_OR_GENE_PRODUCT"], [164, 171, "PROTEIN"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [102, 108, "PROTEIN"], [164, 171, "GGP"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [133, 164, "GENE_OR_GENE_PRODUCT"], [133, 164, "PROTEIN"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [33, 41, "ENTITY"], [299, 330, "GGP"], [377, 389, "PROTEIN"], [164, 171, "ENTITY"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [164, 171, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [362, 377, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [164, 171, "GGP"], [102, 108, "PROTEIN"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [164, 171, "ENTITY"], [133, 164, "PROTEIN"], [133, 164, "GENE_OR_GENE_PRODUCT"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [33, 41, "ENTITY"], [299, 330, "GGP"], [164, 171, "PROTEIN"], [377, 389, "PROTEIN"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Usually , Toll-like receptor ( TLR ) 3 , TLR7 , TLR8 , and TLR9 sense viral RNA and DNA in the endosome [ 60 , 61 ] . The viral RNA receptor retinoic-acid inducible gene I ( RIG-I ) [ 62 ] , cytosolic receptor melanoma differentiation-associated gene 5 ( MDA5 ) and nucleotidyl transferase cyclic GMP-AMP synthase ( cGAS ) [ 63 ] are responsible for the recognition of viral RNA and DNA in the cytoplasm .", "labels": [[111, 122, "TAXON"], [10, 35, "PROTEIN"], [155, 165, "PROTEIN"], [354, 366, "CELLULAR_COMPONENT"], [174, 201, "ENTITY"], [346, 354, "ENTITY"], [201, 219, "ENTITY"], [354, 366, "ENTITY"], [346, 354, "RNA"], [70, 84, "ENTITY"], [10, 20, "ENTITY"], [88, 95, "CELLULAR_COMPONENT"], [191, 201, "DISEASE"], [64, 70, "TAXON"], [88, 95, "ENTITY"], [59, 64, "ENTITY"], [41, 48, "PROTEIN"], [111, 141, "PROTEIN"], [246, 297, "PROTEIN"], [76, 80, "ENTITY"], [41, 48, "GGP"], [155, 165, "ENTITY"], [354, 366, "SO"], [64, 70, "ENTITY"], [41, 48, "ENTITY"], [88, 95, "GO"], [10, 20, "GENE_OR_GENE_PRODUCT"], [174, 219, "PROTEIN"], [346, 354, "TAXON"], [111, 155, "ENTITY"], [70, 84, "ORGANISM_SUBSTANCE"], [76, 80, "SO"], [246, 297, "GENE_OR_GENE_PRODUCT"], [10, 20, "GGP"], [155, 165, "GGP"], [262, 297, "GGP"], [246, 297, "ENTITY"], [174, 184, "GO"], [41, 48, "GENE_OR_GENE_PRODUCT"], [70, 84, "GO"], [174, 219, "GENE_OR_GENE_PRODUCT"], [76, 80, "CELLULAR_COMPONENT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [164, 171, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [362, 377, "GENE_OR_GENE_PRODUCT"], [164, 171, "PROTEIN"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [102, 108, "PROTEIN"], [164, 171, "GGP"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [133, 164, "GENE_OR_GENE_PRODUCT"], [133, 164, "PROTEIN"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [33, 41, "ENTITY"], [299, 330, "GGP"], [377, 389, "PROTEIN"], [164, 171, "ENTITY"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "These complex signalling recruit adaptors , including TIR-domain-containing adaptor protein including IFN-\u03b2 ( TIR-domain-containing adaptor protein including IFN-\u03b2 ) , mitochondrial antiviral-signalling protein ( MAVS ) [ 64 ] and stimulator of interferon genes protein ( stimulator of interferon genes protein ) [ 65 ] to trigger downstream cascades molecules , involving adaptor molecule MyD88 and lead to the activation of the transcription factor nuclear factor-\u03baB ( NF-\u03baB ) and interferon regulatory factor 3 ( IRF3 ) and the production of type I Interferons ( IFN-\u03b1 /\u03b2 ) and a series of pro-inflammatory cytokines [ 66 ] .", "labels": [[182, 196, "ENTITY"], [33, 41, "DNA"], [362, 377, "ENTITY"], [54, 102, "PROTEIN"], [133, 164, "GGP"], [33, 41, "SIMPLE_CHEMICAL"], [299, 330, "GENE_OR_GENE_PRODUCT"], [362, 377, "GGP"], [330, 341, "ENTITY"], [119, 133, "ENTITY"], [269, 281, "GO"], [196, 207, "GENE_OR_GENE_PRODUCT"], [164, 171, "GENE_OR_GENE_PRODUCT"], [133, 164, "ENTITY"], [33, 42, "ENTITY"], [236, 241, "ENTITY"], [54, 84, "PROTEIN"], [362, 377, "GENE_OR_GENE_PRODUCT"], [54, 102, "ENTITY"], [102, 108, "ENTITY"], [249, 291, "PROTEIN"], [33, 41, "CHEMICAL"], [6, 14, "ENTITY"], [54, 84, "ENTITY"], [330, 341, "GENE_OR_GENE_PRODUCT"], [182, 207, "PROTEIN"], [207, 213, "CHEBI"], [377, 389, "ENTITY"], [249, 291, "ENTITY"], [164, 171, "GGP"], [102, 108, "PROTEIN"], [401, 434, "PROTEIN"], [330, 341, "GGP"], [102, 108, "GGP"], [164, 171, "ENTITY"], [133, 164, "PROTEIN"], [133, 164, "GENE_OR_GENE_PRODUCT"], [14, 25, "ENTITY"], [401, 423, "ENTITY"], [102, 108, "GENE_OR_GENE_PRODUCT"], [330, 341, "PROTEIN"], [196, 207, "ENTITY"], [362, 377, "PROTEIN"], [299, 330, "ENTITY"], [423, 434, "ENTITY"], [299, 330, "PROTEIN"], [33, 41, "ENTITY"], [299, 330, "GGP"], [164, 171, "PROTEIN"], [377, 389, "PROTEIN"], [182, 207, "ENTITY"], [54, 84, "GGP"], [54, 76, "GENE_OR_GENE_PRODUCT"], [44, 54, "CHEBI"], [377, 389, "GENE_OR_GENE_PRODUCT"]]}
{"text": "For instance , a variety of human proteases , such as trypsin , tryptase Clara , human airway trypsin-like protease ( HAT ) and transmembrane protease serine 2 ( TMPRSS2 ) , are known to cleave and activate the S protein of SARS-CoV ( Bosch et al. 2008 ; Bertram et al. 2011 ) .", "labels": [[198, 211, "PROTEIN"], [213, 224, "GGP"], [34, 43, "ENTITY"], [34, 43, "ORGANISM"], [213, 224, "ENTITY"], [151, 162, "GENE_OR_GENE_PRODUCT"], [73, 81, "TAXON"], [122, 151, "GGP"], [73, 107, "ORGANISM"], [34, 43, "DISEASE"], [187, 198, "ENTITY"], [62, 73, "ENTITY"], [62, 73, "PROTEIN"], [198, 211, "CHEBI"], [213, 224, "ORGANISM"], [122, 151, "PROTEIN"], [122, 151, "GENE_OR_GENE_PRODUCT"], [151, 162, "GGP"], [34, 43, "PROTEIN"], [151, 162, "PROTEIN"], [122, 151, "ENTITY"], [62, 73, "GENE_OR_GENE_PRODUCT"], [198, 211, "ENTITY"], [28, 34, "PROTEIN"], [73, 107, "PROTEIN"], [151, 162, "ENTITY"], [73, 81, "ENTITY"]]}
{"text": "Concentrations of hypersensitive cardiac troponin I and N-terminal pro-brain natriuretic peptide were markedly higher in deceased patients ( 40.8 pg/mL and 800.0 pg/mL ) than in recovered patients ( 3.3 pg/mL and 72.0 pg/mL ) , with eight deceased patients having cardiac troponin I above 1000 pg/mL and two above 10 000 pg/mL.", "labels": [[67, 97, "GGP"], [33, 41, "PROTEIN"], [41, 52, "GGP"], [67, 97, "GENE_OR_GENE_PRODUCT"], [121, 130, "ENTITY"], [33, 41, "GGP"], [18, 52, "PROTEIN"], [0, 15, "ENTITY"], [178, 188, "ORGANISM"], [121, 130, "ENTITY"], [18, 52, "ENTITY"], [121, 130, "ORGANISM"], [257, 272, "ENTITY"], [56, 97, "ENTITY"], [130, 139, "ENTITY"], [33, 52, "GENE_OR_GENE_PRODUCT"], [178, 188, "ENTITY"], [257, 272, "GENE_OR_GENE_PRODUCT"], [130, 139, "ORGANISM"]]}
{"text": "Mortality was markedly higher in patients with elevated plasma TnT levels than in patients with normal TnT levels ( 31 [59.6%]vs 12 [ 8.9 % ] ) ( Table 1 ) .", "labels": [[47, 56, "ENTITY"], [63, 67, "ENTITY"], [67, 74, "ENTITY"], [33, 42, "ENTITY"], [67, 74, "ENTITY"], [63, 67, "PROTEIN"], [0, 10, "ENTITY"], [56, 63, "ENTITY"], [33, 42, "ENTITY"], [56, 67, "ORGANISM_SUBSTANCE"], [33, 42, "ORGANISM"], [63, 67, "GENE_OR_GENE_PRODUCT"], [63, 67, "PROTEIN"], [23, 30, "ENTITY"], [63, 67, "ENTITY"], [33, 42, "ORGANISM"]]}
{"text": "Both TnT and NT-proBNP levels increased significantly during the course of hospitalization in those who ultimately died , but no such dynamic changes of TnT or NT-proBNP levels were evident in survivors .", "labels": [[5, 9, "GENE_OR_GENE_PRODUCT"], [13, 23, "ENTITY"], [115, 120, "ENTITY"], [5, 9, "PROTEIN"], [75, 91, "ENTITY"], [13, 23, "GENE_OR_GENE_PRODUCT"], [13, 23, "GGP"], [5, 9, "ENTITY"], [30, 40, "ENTITY"], [23, 30, "ENTITY"]]}
{"text": "Patients with elevated TnT levels had significantly higher rates of comorbidities including hypertension ( 33 [ 63.5 % ] vs 28 [ 20.7 % ] ) , coronary heart disease ( 17 [ 32.7 % ] vs4[3.0 % ] ) , cardiomyopathy ( 8[15.4%]vs0 ) , diabetes ( 16 [ 30.8 % ] vs 12 [ 8.9 % ] ) , chronic obstructive pulmonary disease ( 4 [ 7.7 % ] vs 0 ) , and chronic kidney disease ( 1 [ 0.7 % ] vs 5 [ 9.6 % ] ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [246, 283, "ENTITY"], [181, 195, "ENTITY"], [27, 34, "ENTITY"], [134, 151, "DISEASE"], [197, 214, "ENTITY"], [68, 82, "ENTITY"], [23, 27, "PROTEIN"], [246, 283, "DISEASE"], [59, 65, "ENTITY"], [0, 9, "ORGANISM"], [134, 151, "ENTITY"], [305, 327, "ENTITY"], [197, 214, "DISEASE"], [0, 9, "ENTITY"], [92, 105, "DISEASE"], [23, 27, "GENE_OR_GENE_PRODUCT"], [92, 105, "ENTITY"], [181, 195, "DISEASE"], [305, 327, "DISEASE"]]}
{"text": "Patients with elevated TnT levels had significantly higher rates of comorbidities including hypertension ( 33 [ 63.5 % ] vs 28 [ 20.7 % ] ) , coronary heart disease ( 17 [ 32.7 % ] vs4[3.0 % ] ) , cardiomyopathy ( 8[15.4%]vs0 ) , diabetes ( 16 [ 30.8 % ] vs 12 [ 8.9 % ] ) , chronic obstructive pulmonary disease ( 4 [ 7.7 % ] vs 0 ) , and chronic kidney disease ( 1 [ 0.7 % ] vs 5 [ 9.6 % ] ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [246, 283, "ENTITY"], [181, 195, "ENTITY"], [27, 34, "ENTITY"], [134, 151, "DISEASE"], [92, 105, "ENTITY"], [197, 214, "ENTITY"], [68, 82, "ENTITY"], [23, 27, "PROTEIN"], [246, 283, "DISEASE"], [0, 9, "ORGANISM"], [134, 151, "ENTITY"], [305, 327, "ENTITY"], [197, 214, "DISEASE"], [59, 65, "ENTITY"], [0, 9, "ENTITY"], [92, 105, "DISEASE"], [23, 27, "GENE_OR_GENE_PRODUCT"], [181, 195, "DISEASE"], [305, 327, "DISEASE"]]}
{"text": "Patients with elevated TnT levels had significantly higher rates of comorbidities including hypertension ( 33 [ 63.5 % ] vs 28 [ 20.7 % ] ) , coronary heart disease ( 17 [ 32.7 % ] vs4[3.0 % ] ) , cardiomyopathy ( 8[15.4%]vs0 ) , diabetes ( 16 [ 30.8 % ] vs 12 [ 8.9 % ] ) , chronic obstructive pulmonary disease ( 4 [ 7.7 % ] vs 0 ) , and chronic kidney disease ( 1 [ 0.7 % ] vs 5 [ 9.6 % ] ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [246, 283, "ENTITY"], [181, 195, "ENTITY"], [27, 34, "ENTITY"], [134, 151, "DISEASE"], [197, 214, "ENTITY"], [92, 105, "ENTITY"], [68, 82, "ENTITY"], [23, 27, "PROTEIN"], [246, 283, "DISEASE"], [0, 9, "ORGANISM"], [134, 151, "ENTITY"], [305, 327, "ENTITY"], [59, 65, "ENTITY"], [0, 9, "ENTITY"], [92, 105, "DISEASE"], [197, 214, "DISEASE"], [23, 27, "GENE_OR_GENE_PRODUCT"], [181, 195, "DISEASE"], [305, 327, "DISEASE"]]}
{"text": "Patients with elevated TnT levels had significantly higher rates of comorbidities including hypertension ( 33 [ 63.5 % ] vs 28 [ 20.7 % ] ) , coronary heart disease ( 17 [ 32.7 % ] vs4[3.0 % ] ) , cardiomyopathy ( 8[15.4%]vs0 ) , diabetes ( 16 [ 30.8 % ] vs 12 [ 8.9 % ] ) , chronic obstructive pulmonary disease ( 4 [ 7.7 % ] vs 0 ) , and chronic kidney disease ( 1 [ 0.7 % ] vs 5 [ 9.6 % ] ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [246, 283, "ENTITY"], [181, 195, "ENTITY"], [27, 34, "ENTITY"], [134, 151, "DISEASE"], [92, 105, "ENTITY"], [197, 214, "ENTITY"], [68, 82, "ENTITY"], [23, 27, "PROTEIN"], [246, 283, "DISEASE"], [0, 9, "ORGANISM"], [134, 151, "ENTITY"], [305, 327, "ENTITY"], [197, 214, "DISEASE"], [59, 65, "ENTITY"], [0, 9, "ENTITY"], [92, 105, "DISEASE"], [23, 27, "GENE_OR_GENE_PRODUCT"], [181, 195, "DISEASE"], [305, 327, "DISEASE"]]}
{"text": "Patients with elevated TnT levels had significantly higher rates of comorbidities including hypertension ( 33 [ 63.5 % ] vs 28 [ 20.7 % ] ) , coronary heart disease ( 17 [ 32.7 % ] vs4[3.0 % ] ) , cardiomyopathy ( 8[15.4%]vs0 ) , diabetes ( 16 [ 30.8 % ] vs 12 [ 8.9 % ] ) , chronic obstructive pulmonary disease ( 4 [ 7.7 % ] vs 0 ) , and chronic kidney disease ( 1 [ 0.7 % ] vs 5 [ 9.6 % ] ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [246, 283, "ENTITY"], [181, 195, "ENTITY"], [27, 34, "ENTITY"], [134, 151, "DISEASE"], [92, 105, "ENTITY"], [197, 214, "ENTITY"], [68, 82, "ENTITY"], [23, 27, "PROTEIN"], [246, 283, "DISEASE"], [0, 9, "ORGANISM"], [134, 151, "ENTITY"], [305, 327, "ENTITY"], [197, 214, "DISEASE"], [59, 65, "ENTITY"], [0, 9, "ENTITY"], [92, 105, "DISEASE"], [23, 27, "GENE_OR_GENE_PRODUCT"], [181, 195, "DISEASE"], [305, 327, "DISEASE"]]}
{"text": "Patients with elevated TnT levels had significantly higher rates of comorbidities including hypertension ( 33 [ 63.5 % ] vs 28 [ 20.7 % ] ) , coronary heart disease ( 17 [ 32.7 % ] vs4[3.0 % ] ) , cardiomyopathy ( 8[15.4%]vs0 ) , diabetes ( 16 [ 30.8 % ] vs 12 [ 8.9 % ] ) , chronic obstructive pulmonary disease ( 4 [ 7.7 % ] vs 0 ) , and chronic kidney disease ( 1 [ 0.7 % ] vs 5 [ 9.6 % ] ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [246, 283, "ENTITY"], [181, 195, "ENTITY"], [27, 34, "ENTITY"], [134, 151, "DISEASE"], [92, 105, "ENTITY"], [197, 214, "ENTITY"], [68, 82, "ENTITY"], [23, 27, "PROTEIN"], [246, 283, "DISEASE"], [0, 9, "ORGANISM"], [134, 151, "ENTITY"], [305, 327, "ENTITY"], [197, 214, "DISEASE"], [59, 65, "ENTITY"], [0, 9, "ENTITY"], [92, 105, "DISEASE"], [23, 27, "GENE_OR_GENE_PRODUCT"], [181, 195, "DISEASE"], [305, 327, "DISEASE"]]}
{"text": "Patients with elevated TnT levels presented with significantly higher white blood cell count(median[IQR],4640[6170- 3740 ] vs 7390 [ 4890 - 11 630 ] /\u03bcL [ to convert to \u00d7109 per liter , multiply by0.001])and neutrophil counts ( median [IQR],3070 [ 2350 - 4870 ] vs 6010 [ 3540 - 10 120 ] /\u03bcL [ to convert to \u00d7109 per liter , multiply by 0.001 ] ) ( P < .001 for both ) and lower lymphocyte counts ( median [ IQR ] , 840 [ 630 - 1130 ] vs 690 [ 340- 1010 ] /\u03bcL [ toconvert to \u00d7 109 per liter , multiplyby0.001;P = .01 ) than those with normal TnT levels ( Table 2 ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [27, 34, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [195, 208, "CELL"], [456, 475, "PROTEIN"], [195, 208, "CELL_TYPE"], [76, 121, "CELL"], [158, 166, "PROTEIN"], [373, 379, "ENTITY"], [358, 367, "CL"], [23, 27, "PROTEIN"], [93, 100, "PROTEIN"], [0, 9, "ORGANISM"], [76, 87, "CL"], [70, 87, "ENTITY"], [93, 100, "ENTITY"], [228, 248, "CHEMICAL"], [0, 9, "ENTITY"], [351, 367, "CELL"], [456, 475, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"], [358, 367, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"], [195, 208, "CL"]]}
{"text": "Patients with elevated TnT levels presented with significantly higher white blood cell count(median[IQR],4640[6170- 3740 ] vs 7390 [ 4890 - 11 630 ] /\u03bcL [ to convert to \u00d7109 per liter , multiply by0.001])and neutrophil counts ( median [IQR],3070 [ 2350 - 4870 ] vs 6010 [ 3540 - 10 120 ] /\u03bcL [ to convert to \u00d7109 per liter , multiply by 0.001 ] ) ( P < .001 for both ) and lower lymphocyte counts ( median [ IQR ] , 840 [ 630 - 1130 ] vs 690 [ 340- 1010 ] /\u03bcL [ toconvert to \u00d7 109 per liter , multiplyby0.001;P = .01 ) than those with normal TnT levels ( Table 2 ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [27, 34, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [195, 208, "CELL"], [456, 475, "PROTEIN"], [195, 208, "CELL_TYPE"], [76, 121, "CELL"], [158, 166, "PROTEIN"], [373, 379, "ENTITY"], [358, 367, "CL"], [23, 27, "PROTEIN"], [93, 100, "PROTEIN"], [0, 9, "ORGANISM"], [76, 87, "CL"], [93, 100, "ENTITY"], [228, 248, "CHEMICAL"], [0, 9, "ENTITY"], [70, 87, "ENTITY"], [351, 367, "CELL"], [456, 475, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"], [358, 367, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"], [195, 208, "CL"]]}
{"text": "Patients with elevated TnT levels presented with significantly higher white blood cell count(median[IQR],4640[6170- 3740 ] vs 7390 [ 4890 - 11 630 ] /\u03bcL [ to convert to \u00d7109 per liter , multiply by0.001])and neutrophil counts ( median [IQR],3070 [ 2350 - 4870 ] vs 6010 [ 3540 - 10 120 ] /\u03bcL [ to convert to \u00d7109 per liter , multiply by 0.001 ] ) ( P < .001 for both ) and lower lymphocyte counts ( median [ IQR ] , 840 [ 630 - 1130 ] vs 690 [ 340- 1010 ] /\u03bcL [ toconvert to \u00d7 109 per liter , multiplyby0.001;P = .01 ) than those with normal TnT levels ( Table 2 ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [27, 34, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [195, 208, "CELL"], [456, 475, "PROTEIN"], [195, 208, "CELL_TYPE"], [76, 121, "CELL"], [158, 166, "PROTEIN"], [373, 379, "ENTITY"], [358, 367, "CL"], [23, 27, "PROTEIN"], [93, 100, "PROTEIN"], [0, 9, "ORGANISM"], [76, 87, "CL"], [93, 100, "ENTITY"], [228, 248, "CHEMICAL"], [0, 9, "ENTITY"], [70, 87, "ENTITY"], [351, 367, "CELL"], [456, 475, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"], [358, 367, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"], [195, 208, "CL"]]}
{"text": "Patients with elevated TnT levels also had significantly longer prothrombin time ( median [ IQR ] , 12.4 [ 12.0 - 13.0 ] vs 13.3 [ 12.2 - 15.3 ] seconds ; P = .005 ) , shorter activated partial thromboplastin time ( median [ IQR ] , 31.2 [ 27.5 - 33.2 ] vs 32.7 [ 31.0 - 35.8 ] seconds ; P = .003 ) , and a significant higher level of D-dimer ( median [ IQR ] , 0.29 [ 0.17 - 0.60 ] vs 3.85 [ 0.51 - 25.58 ] \u03bcg/mL[to convert to nanomoles per liter , multiply by 5.476 ] ; P < .001 ) .", "labels": [[176, 194, "GENE_OR_GENE_PRODUCT"], [23, 27, "ENTITY"], [14, 23, "ENTITY"], [145, 155, "ENTITY"], [23, 27, "PROTEIN"], [319, 326, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"], [27, 34, "ENTITY"], [0, 9, "ENTITY"], [64, 76, "PROTEIN"], [0, 9, "ORGANISM"], [64, 76, "GENE_OR_GENE_PRODUCT"], [176, 194, "PROTEIN"], [417, 425, "GENE_OR_GENE_PRODUCT"], [64, 81, "ENTITY"], [43, 55, "ENTITY"]]}
{"text": "Patients with elevated TnT levels also had significantly longer prothrombin time ( median [ IQR ] , 12.4 [ 12.0 - 13.0 ] vs 13.3 [ 12.2 - 15.3 ] seconds ; P = .005 ) , shorter activated partial thromboplastin time ( median [ IQR ] , 31.2 [ 27.5 - 33.2 ] vs 32.7 [ 31.0 - 35.8 ] seconds ; P = .003 ) , and a significant higher level of D-dimer ( median [ IQR ] , 0.29 [ 0.17 - 0.60 ] vs 3.85 [ 0.51 - 25.58 ] \u03bcg/mL[to convert to nanomoles per liter , multiply by 5.476 ] ; P < .001 ) .", "labels": [[176, 194, "GENE_OR_GENE_PRODUCT"], [23, 27, "ENTITY"], [14, 23, "ENTITY"], [145, 155, "ENTITY"], [23, 27, "PROTEIN"], [319, 326, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"], [27, 34, "ENTITY"], [0, 9, "ENTITY"], [64, 76, "PROTEIN"], [0, 9, "ORGANISM"], [64, 76, "GENE_OR_GENE_PRODUCT"], [176, 194, "PROTEIN"], [417, 425, "GENE_OR_GENE_PRODUCT"], [64, 81, "ENTITY"], [43, 55, "ENTITY"]]}
{"text": "Patients with elevated TnT levels also had significantly longer prothrombin time ( median [ IQR ] , 12.4 [ 12.0 - 13.0 ] vs 13.3 [ 12.2 - 15.3 ] seconds ; P = .005 ) , shorter activated partial thromboplastin time ( median [ IQR ] , 31.2 [ 27.5 - 33.2 ] vs 32.7 [ 31.0 - 35.8 ] seconds ; P = .003 ) , and a significant higher level of D-dimer ( median [ IQR ] , 0.29 [ 0.17 - 0.60 ] vs 3.85 [ 0.51 - 25.58 ] \u03bcg/mL[to convert to nanomoles per liter , multiply by 5.476 ] ; P < .001 ) .", "labels": [[176, 194, "GENE_OR_GENE_PRODUCT"], [23, 27, "ENTITY"], [14, 23, "ENTITY"], [145, 155, "ENTITY"], [23, 27, "PROTEIN"], [319, 326, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"], [27, 34, "ENTITY"], [0, 9, "ENTITY"], [64, 76, "PROTEIN"], [0, 9, "ORGANISM"], [64, 76, "GENE_OR_GENE_PRODUCT"], [176, 194, "PROTEIN"], [417, 425, "GENE_OR_GENE_PRODUCT"], [64, 81, "ENTITY"], [43, 55, "ENTITY"]]}
{"text": "Total , high-density lipoprotein , and low-density lipoprotein cholesterol levels did not differ according to TnT levels , but patients with elevated TnT levels had higher triglyceride levels ( median [ IQR ] , 92.04 [ 69.91 - 159.29 ] vs 82.30 [ 59.29- 115.04]mg/dL [ to convert to millimoles per liter , multiply by 0.0259];P=.04 ) .", "labels": [[21, 33, "CHEMICAL"], [203, 209, "SIMPLE_CHEMICAL"], [185, 194, "ENTITY"], [8, 21, "PROTEIN"], [35, 63, "GGP"], [141, 150, "GENE_OR_GENE_PRODUCT"], [269, 280, "ENTITY"], [165, 172, "SIMPLE_CHEMICAL"], [165, 172, "CHEMICAL"], [165, 185, "ENTITY"], [35, 51, "PROTEIN"], [141, 150, "PROTEIN"], [165, 172, "CHEBI"], [8, 21, "CHEBI"], [203, 209, "PROTEIN"], [141, 150, "ENTITY"], [194, 201, "ENTITY"], [35, 75, "ENTITY"], [35, 63, "SIMPLE_CHEMICAL"], [0, 6, "ENTITY"], [8, 21, "ENTITY"], [110, 114, "ENTITY"], [110, 114, "ENTITY"]]}
{"text": "The inflammatory biomarkers , including high sensitivity C-reactive protein ( median [ IQR ] , 8.55 [ 4.87- 15.165 ] vs 3.13 [1.24 - 5.75]mg/dL [ to convert to milligrams per liter , multiply by 10 ] ) , procalcitonin ( median [ IQR ] , 0.21 [ 0.11- 0.45 ] vs 0.05 [ 0.04 - 0.11 ] ng/mL ) , and globulin ( median [IQR],29.7 [ 27.0 - 34.6 ] vs 27.4 [ 25.6 - 29.6 ] grams per liter ) were significantly higher in patientswith elevated TnT levels ( P < .001 for all ) .", "labels": [[117, 133, "CHEMICAL"], [4, 17, "ENTITY"], [287, 295, "SIMPLE_CHEMICAL"], [183, 204, "ENTITY"], [387, 401, "PROTEIN"], [287, 306, "CHEMICAL"], [57, 68, "PROTEIN"], [183, 204, "GENE_OR_GENE_PRODUCT"], [40, 45, "ENTITY"], [183, 204, "GGP"], [387, 401, "GENE_OR_GENE_PRODUCT"], [374, 387, "ENTITY"], [57, 68, "ENTITY"], [401, 408, "ENTITY"], [387, 401, "ENTITY"], [149, 160, "ENTITY"], [17, 28, "ENTITY"], [117, 133, "SIMPLE_CHEMICAL"], [287, 295, "ENTITY"], [57, 68, "GGP"]]}
{"text": "The inflammatory biomarkers , including high sensitivity C-reactive protein ( median [ IQR ] , 8.55 [ 4.87- 15.165 ] vs 3.13 [1.24 - 5.75]mg/dL [ to convert to milligrams per liter , multiply by 10 ] ) , procalcitonin ( median [ IQR ] , 0.21 [ 0.11- 0.45 ] vs 0.05 [ 0.04 - 0.11 ] ng/mL ) , and globulin ( median [IQR],29.7 [ 27.0 - 34.6 ] vs 27.4 [ 25.6 - 29.6 ] grams per liter ) were significantly higher in patientswith elevated TnT levels ( P < .001 for all ) .", "labels": [[117, 133, "CHEMICAL"], [4, 17, "ENTITY"], [287, 295, "SIMPLE_CHEMICAL"], [183, 204, "ENTITY"], [387, 401, "PROTEIN"], [287, 306, "CHEMICAL"], [57, 68, "PROTEIN"], [183, 204, "GENE_OR_GENE_PRODUCT"], [40, 45, "ENTITY"], [183, 204, "GGP"], [387, 401, "GENE_OR_GENE_PRODUCT"], [374, 387, "ENTITY"], [57, 68, "ENTITY"], [401, 408, "ENTITY"], [387, 401, "ENTITY"], [149, 160, "ENTITY"], [17, 28, "ENTITY"], [117, 133, "SIMPLE_CHEMICAL"], [287, 295, "ENTITY"], [57, 68, "GGP"]]}
{"text": "The inflammatory biomarkers , including high sensitivity C-reactive protein ( median [ IQR ] , 8.55 [ 4.87- 15.165 ] vs 3.13 [1.24 - 5.75]mg/dL [ to convert to milligrams per liter , multiply by 10 ] ) , procalcitonin ( median [ IQR ] , 0.21 [ 0.11- 0.45 ] vs 0.05 [ 0.04 - 0.11 ] ng/mL ) , and globulin ( median [IQR],29.7 [ 27.0 - 34.6 ] vs 27.4 [ 25.6 - 29.6 ] grams per liter ) were significantly higher in patientswith elevated TnT levels ( P < .001 for all ) .", "labels": [[117, 133, "CHEMICAL"], [4, 17, "ENTITY"], [287, 295, "SIMPLE_CHEMICAL"], [183, 204, "ENTITY"], [387, 401, "PROTEIN"], [57, 68, "PROTEIN"], [183, 204, "GENE_OR_GENE_PRODUCT"], [40, 45, "ENTITY"], [183, 204, "GGP"], [387, 401, "GENE_OR_GENE_PRODUCT"], [287, 306, "CHEMICAL"], [374, 387, "ENTITY"], [57, 68, "ENTITY"], [401, 408, "ENTITY"], [387, 401, "ENTITY"], [149, 160, "ENTITY"], [17, 28, "ENTITY"], [117, 133, "SIMPLE_CHEMICAL"], [287, 295, "ENTITY"], [57, 68, "GGP"]]}
{"text": "Those with elevated TnT levels had significantly higher levels of other biomarkers of cardiac injury , specifically creatine kinase\u2013 myocardial band test ( median [ IQR ] , 3.34 [ 2.11 - 5.80 ] vs 0.81 [ 0.54 - 1.38 ] , ng/mL [ to convert to micrograms per liter , multiply by 1 ] ) and myoglobin ( median [ IQR ] , 128.7 [ 65.8 - 206.9 ] vs 27.2 [ 21.0 - 49.8 ] \u03bcg/L [ to convert to nanomoles per liter , multiply by 0.05814 ] ) ( P < .001 , for all ) and also had higher levels of N-terminal pro \u2013 brain natriuretic peptide ( N-terminal pro\u2013brain natriuretic peptide ) ( median [ IQR ] , 817.4 ( 336.0 - 1944.0 ] vs 141.4 [ 39.3 - 303.6 ] pg/mL [ to convert to nanograms per liter , multiply by 1 ] ) .", "labels": [[462, 483, "ENTITY"], [11, 20, "ENTITY"], [24, 31, "ENTITY"], [20, 24, "ENTITY"], [156, 171, "ENTITY"], [20, 24, "PROTEIN"], [116, 125, "ENTITY"], [265, 279, "GGP"], [86, 101, "DISEASE"], [116, 125, "SIMPLE_CHEMICAL"], [20, 24, "GENE_OR_GENE_PRODUCT"], [265, 279, "GENE_OR_GENE_PRODUCT"], [430, 436, "ENTITY"], [72, 83, "ENTITY"], [86, 101, "ENTITY"], [281, 287, "ENTITY"], [86, 94, "ORGAN"], [447, 500, "PROTEIN"], [24, 31, "ENTITY"], [447, 457, "ENTITY"], [265, 279, "ENTITY"], [483, 498, "GGP"], [133, 149, "ENTITY"], [483, 498, "ENTITY"], [265, 279, "PROTEIN"], [500, 506, "ENTITY"]]}
{"text": "Those with elevated TnT levels had significantly higher levels of other biomarkers of cardiac injury , specifically creatine kinase\u2013 myocardial band test ( median [ IQR ] , 3.34 [ 2.11 - 5.80 ] vs 0.81 [ 0.54 - 1.38 ] , ng/mL [ to convert to micrograms per liter , multiply by 1 ] ) and myoglobin ( median [ IQR ] , 128.7 [ 65.8 - 206.9 ] vs 27.2 [ 21.0 - 49.8 ] \u03bcg/L [ to convert to nanomoles per liter , multiply by 0.05814 ] ) ( P < .001 , for all ) and also had higher levels of N-terminal pro \u2013 brain natriuretic peptide ( N-terminal pro\u2013brain natriuretic peptide ) ( median [ IQR ] , 817.4 ( 336.0 - 1944.0 ] vs 141.4 [ 39.3 - 303.6 ] pg/mL [ to convert to nanograms per liter , multiply by 1 ] ) .", "labels": [[462, 483, "ENTITY"], [11, 20, "ENTITY"], [24, 31, "ENTITY"], [20, 24, "ENTITY"], [156, 171, "ENTITY"], [20, 24, "PROTEIN"], [116, 125, "ENTITY"], [265, 279, "GGP"], [86, 101, "DISEASE"], [116, 125, "SIMPLE_CHEMICAL"], [20, 24, "GENE_OR_GENE_PRODUCT"], [265, 279, "GENE_OR_GENE_PRODUCT"], [430, 436, "ENTITY"], [72, 83, "ENTITY"], [86, 101, "ENTITY"], [281, 287, "ENTITY"], [86, 94, "ORGAN"], [447, 500, "PROTEIN"], [24, 31, "ENTITY"], [447, 457, "ENTITY"], [265, 279, "ENTITY"], [483, 498, "GGP"], [133, 149, "ENTITY"], [483, 498, "ENTITY"], [265, 279, "PROTEIN"], [500, 506, "ENTITY"]]}
{"text": "Those with elevated TnT levels had significantly higher levels of other biomarkers of cardiac injury , specifically creatine kinase\u2013 myocardial band test ( median [ IQR ] , 3.34 [ 2.11 - 5.80 ] vs 0.81 [ 0.54 - 1.38 ] , ng/mL [ to convert to micrograms per liter , multiply by 1 ] ) and myoglobin ( median [ IQR ] , 128.7 [ 65.8 - 206.9 ] vs 27.2 [ 21.0 - 49.8 ] \u03bcg/L [ to convert to nanomoles per liter , multiply by 0.05814 ] ) ( P < .001 , for all ) and also had higher levels of N-terminal pro \u2013 brain natriuretic peptide ( N-terminal pro\u2013brain natriuretic peptide ) ( median [ IQR ] , 817.4 ( 336.0 - 1944.0 ] vs 141.4 [ 39.3 - 303.6 ] pg/mL [ to convert to nanograms per liter , multiply by 1 ] ) .", "labels": [[462, 483, "ENTITY"], [11, 20, "ENTITY"], [24, 31, "ENTITY"], [20, 24, "ENTITY"], [156, 171, "ENTITY"], [20, 24, "PROTEIN"], [116, 125, "ENTITY"], [265, 279, "GGP"], [86, 101, "DISEASE"], [116, 125, "SIMPLE_CHEMICAL"], [20, 24, "GENE_OR_GENE_PRODUCT"], [265, 279, "GENE_OR_GENE_PRODUCT"], [430, 436, "ENTITY"], [72, 83, "ENTITY"], [86, 101, "ENTITY"], [281, 287, "ENTITY"], [86, 94, "ORGAN"], [447, 500, "PROTEIN"], [24, 31, "ENTITY"], [447, 457, "ENTITY"], [265, 279, "ENTITY"], [483, 498, "GGP"], [133, 149, "ENTITY"], [483, 498, "ENTITY"], [265, 279, "PROTEIN"], [500, 506, "ENTITY"]]}
{"text": "Patients with elevated TnT levels had evidence of more severe respiratory dysfunction , with lower partial pressure of oxygen ( PaO2 ) ( median [ IQR ] , 64.0[51.0 - 93.0 ] vs 91.0[75.0 - 121.0]mmHg),HCO3 ( median [ IQR ] , 23.3 [ 20.0 - 27.1 ] vs 25.7 [ 23.8 - 27.9 ] mEq/L [ to convert to to millimoles per liter , multiply by 1 ] ) , and PaO2/ fraction of inspired oxygen ( FiO2 ) ( median [ IQR ] , 153.3 [ 103.3- 323.8 ] vs 390.5 [285.7 - 461.9]mmHg ) , and higher levels of lactic acid ( median [ IQR ] , 2.10 [ 1.40 - 3.10 ] vs 1.80 [1.30 - 2.10]mm Hg ) ( P < .001,P < .001,P = .004,P = .001 , respectively ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [309, 317, "GENE_OR_GENE_PRODUCT"], [62, 86, "DISEASE"], [331, 341, "ENTITY"], [27, 34, "ENTITY"], [309, 317, "ENTITY"], [444, 459, "ENTITY"], [146, 150, "CHEBI"], [23, 27, "PROTEIN"], [0, 9, "ORGANISM"], [135, 152, "ENTITY"], [55, 62, "ENTITY"], [137, 144, "ENTITY"], [146, 154, "SIMPLE_CHEMICAL"], [269, 280, "ENTITY"], [38, 47, "ENTITY"], [188, 205, "ENTITY"], [0, 9, "ENTITY"], [93, 119, "ENTITY"], [62, 86, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"], [135, 146, "SIMPLE_CHEMICAL"], [317, 326, "ENTITY"], [347, 359, "ENTITY"], [166, 188, "SIMPLE_CHEMICAL"], [135, 150, "CHEMICAL"]]}
{"text": "Those with elevated TnT levels also had higher levels of creatinine ( median [ IQR ] , 0.79 [ 0.71 - 1.17 ] vs 0.63 [ 0.55 - 0.79 ] mg/dL [ to convert to micromoles per liter , multiply by 88.4 ] ) and aspartate aminotransferase ( median [ IQR ] , 39.5 [ 27.2 - 57.8 ] vs 29.0 [21.0 - 39.0]U/L [ to convert to microkatal per liter , multiply by 0.0167 ] ) ( P < .001 , both ) , but alanine aminotransferase did not differ between the 2 groups .", "labels": [[57, 68, "CHEBI"], [186, 212, "GENE_OR_GENE_PRODUCT"], [11, 20, "ENTITY"], [24, 31, "ENTITY"], [186, 212, "GGP"], [20, 24, "ENTITY"], [57, 68, "SIMPLE_CHEMICAL"], [20, 24, "PROTEIN"], [186, 196, "CHEMICAL"], [345, 369, "PROTEIN"], [345, 369, "ENTITY"], [57, 68, "ENTITY"], [186, 212, "PROTEIN"], [57, 68, "CHEMICAL"], [212, 229, "ENTITY"], [24, 31, "ENTITY"], [186, 212, "ENTITY"], [345, 369, "GENE_OR_GENE_PRODUCT"], [20, 24, "GENE_OR_GENE_PRODUCT"], [283, 294, "ENTITY"]]}
{"text": "Those with elevated TnT levels also had higher levels of creatinine ( median [ IQR ] , 0.79 [ 0.71 - 1.17 ] vs 0.63 [ 0.55 - 0.79 ] mg/dL [ to convert to micromoles per liter , multiply by 88.4 ] ) and aspartate aminotransferase ( median [ IQR ] , 39.5 [ 27.2 - 57.8 ] vs 29.0 [21.0 - 39.0]U/L [ to convert to microkatal per liter , multiply by 0.0167 ] ) ( P < .001 , both ) , but alanine aminotransferase did not differ between the 2 groups .", "labels": [[57, 68, "ENTITY"], [186, 212, "GENE_OR_GENE_PRODUCT"], [11, 20, "ENTITY"], [24, 31, "ENTITY"], [186, 212, "GGP"], [20, 24, "ENTITY"], [20, 24, "PROTEIN"], [186, 196, "CHEMICAL"], [345, 369, "PROTEIN"], [57, 68, "CHEBI"], [345, 369, "ENTITY"], [57, 68, "SIMPLE_CHEMICAL"], [186, 212, "PROTEIN"], [212, 229, "ENTITY"], [24, 31, "ENTITY"], [186, 212, "ENTITY"], [57, 68, "CHEMICAL"], [345, 369, "GENE_OR_GENE_PRODUCT"], [20, 24, "GENE_OR_GENE_PRODUCT"], [283, 294, "ENTITY"]]}
{"text": "Those with elevated TnT levels also had higher levels of creatinine ( median [ IQR ] , 0.79 [ 0.71 - 1.17 ] vs 0.63 [ 0.55 - 0.79 ] mg/dL [ to convert to micromoles per liter , multiply by 88.4 ] ) and aspartate aminotransferase ( median [ IQR ] , 39.5 [ 27.2 - 57.8 ] vs 29.0 [21.0 - 39.0]U/L [ to convert to microkatal per liter , multiply by 0.0167 ] ) ( P < .001 , both ) , but alanine aminotransferase did not differ between the 2 groups .", "labels": [[57, 68, "ENTITY"], [186, 212, "GENE_OR_GENE_PRODUCT"], [11, 20, "ENTITY"], [24, 31, "ENTITY"], [186, 212, "GGP"], [20, 24, "ENTITY"], [20, 24, "PROTEIN"], [186, 196, "CHEMICAL"], [345, 369, "PROTEIN"], [57, 68, "CHEBI"], [345, 369, "ENTITY"], [57, 68, "SIMPLE_CHEMICAL"], [186, 212, "PROTEIN"], [212, 229, "ENTITY"], [24, 31, "ENTITY"], [186, 212, "ENTITY"], [57, 68, "CHEMICAL"], [345, 369, "GENE_OR_GENE_PRODUCT"], [20, 24, "GENE_OR_GENE_PRODUCT"], [283, 294, "ENTITY"]]}
{"text": "Patients with underlying CVD were more likely to exhibit elevation of TnT levels ( 36 [ 54.5 % ] ) compared with patients without CVD ( 16 [ 13.2 % ] ) .", "labels": [[57, 67, "ENTITY"], [25, 29, "ENTITY"], [74, 81, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "ORGANISM"], [70, 74, "GENE_OR_GENE_PRODUCT"], [70, 74, "ENTITY"], [70, 74, "PROTEIN"]]}
{"text": "During hospitalization , patients with elevated TnT levels developed more frequent complications ( Table 1 ) , including acute respiratory distress syndrome ( 30 [ 57.7 % ] vs 16 [ 11.9 % ] ) , malignant arrhythmias ( 6 [ 11.5 % ] vs 7 [ 5.2 % ] ) including ventricular tachycardia/ ventricular fibrillation , acute coagulopathy ( 25 [ 65.8 % ] vs 17 [ 20.0 % ] ) , and acute kidney injury ( 14 [ 36.8 % ] vs 4 [ 4.7 % ] ) , compared with those with normal TnT levels .", "labels": [[336, 358, "DISEASE"], [336, 358, "ENTITY"], [345, 351, "ORGAN"], [238, 283, "ENTITY"], [121, 148, "DISEASE"], [7, 23, "ENTITY"], [258, 270, "DISEASE"], [258, 270, "ENTITY"], [238, 283, "DISEASE"], [111, 148, "ENTITY"], [238, 270, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "During hospitalization , patients with elevated TnT levels developed more frequent complications ( Table 1 ) , including acute respiratory distress syndrome ( 30 [ 57.7 % ] vs 16 [ 11.9 % ] ) , malignant arrhythmias ( 6 [ 11.5 % ] vs 7 [ 5.2 % ] ) including ventricular tachycardia/ ventricular fibrillation , acute coagulopathy ( 25 [ 65.8 % ] vs 17 [ 20.0 % ] ) , and acute kidney injury ( 14 [ 36.8 % ] vs 4 [ 4.7 % ] ) , compared with those with normal TnT levels .", "labels": [[336, 358, "DISEASE"], [336, 358, "ENTITY"], [345, 351, "ORGAN"], [238, 283, "ENTITY"], [7, 23, "ENTITY"], [258, 270, "DISEASE"], [258, 270, "ENTITY"], [121, 148, "DISEASE"], [238, 283, "DISEASE"], [111, 148, "ENTITY"], [238, 270, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "During hospitalization , patients with elevated TnT levels developed more frequent complications ( Table 1 ) , including acute respiratory distress syndrome ( 30 [ 57.7 % ] vs 16 [ 11.9 % ] ) , malignant arrhythmias ( 6 [ 11.5 % ] vs 7 [ 5.2 % ] ) including ventricular tachycardia/ ventricular fibrillation , acute coagulopathy ( 25 [ 65.8 % ] vs 17 [ 20.0 % ] ) , and acute kidney injury ( 14 [ 36.8 % ] vs 4 [ 4.7 % ] ) , compared with those with normal TnT levels .", "labels": [[336, 358, "DISEASE"], [336, 358, "ENTITY"], [345, 351, "ORGAN"], [238, 283, "ENTITY"], [7, 23, "ENTITY"], [258, 270, "DISEASE"], [238, 283, "DISEASE"], [258, 270, "ENTITY"], [121, 148, "DISEASE"], [111, 148, "ENTITY"], [238, 270, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "During hospitalization , patients with elevated TnT levels developed more frequent complications ( Table 1 ) , including acute respiratory distress syndrome ( 30 [ 57.7 % ] vs 16 [ 11.9 % ] ) , malignant arrhythmias ( 6 [ 11.5 % ] vs 7 [ 5.2 % ] ) including ventricular tachycardia/ ventricular fibrillation , acute coagulopathy ( 25 [ 65.8 % ] vs 17 [ 20.0 % ] ) , and acute kidney injury ( 14 [ 36.8 % ] vs 4 [ 4.7 % ] ) , compared with those with normal TnT levels .", "labels": [[336, 358, "DISEASE"], [336, 358, "ENTITY"], [258, 270, "DISEASE"], [238, 283, "ENTITY"], [345, 351, "ORGAN"], [7, 23, "ENTITY"], [258, 270, "ENTITY"], [121, 148, "DISEASE"], [238, 283, "DISEASE"], [111, 148, "ENTITY"], [238, 270, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "During hospitalization , patients with elevated TnT levels developed more frequent complications ( Table 1 ) , including acute respiratory distress syndrome ( 30 [ 57.7 % ] vs 16 [ 11.9 % ] ) , malignant arrhythmias ( 6 [ 11.5 % ] vs 7 [ 5.2 % ] ) including ventricular tachycardia/ ventricular fibrillation , acute coagulopathy ( 25 [ 65.8 % ] vs 17 [ 20.0 % ] ) , and acute kidney injury ( 14 [ 36.8 % ] vs 4 [ 4.7 % ] ) , compared with those with normal TnT levels .", "labels": [[336, 358, "DISEASE"], [336, 358, "ENTITY"], [345, 351, "ORGAN"], [238, 283, "ENTITY"], [7, 23, "ENTITY"], [258, 270, "DISEASE"], [258, 270, "ENTITY"], [121, 148, "DISEASE"], [238, 283, "DISEASE"], [111, 148, "ENTITY"], [238, 270, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "During hospitalization , patients with elevated TnT levels developed more frequent complications ( Table 1 ) , including acute respiratory distress syndrome ( 30 [ 57.7 % ] vs 16 [ 11.9 % ] ) , malignant arrhythmias ( 6 [ 11.5 % ] vs 7 [ 5.2 % ] ) including ventricular tachycardia/ ventricular fibrillation , acute coagulopathy ( 25 [ 65.8 % ] vs 17 [ 20.0 % ] ) , and acute kidney injury ( 14 [ 36.8 % ] vs 4 [ 4.7 % ] ) , compared with those with normal TnT levels .", "labels": [[336, 358, "DISEASE"], [336, 358, "ENTITY"], [345, 351, "ORGAN"], [238, 283, "ENTITY"], [7, 23, "ENTITY"], [258, 270, "DISEASE"], [258, 270, "ENTITY"], [121, 148, "DISEASE"], [238, 283, "DISEASE"], [111, 148, "ENTITY"], [238, 270, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "Notably , the use of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers ( ARBs ) was higher in patients with elevated TnT levels ( 11 [ 21.1 % ] vs 8 [ 5.9 % ] ; Table 1 ) , reflecting the higher rates ofCVD .", "labels": [[146, 150, "ENTITY"], [202, 217, "ENTITY"], [62, 91, "ENTITY"], [21, 91, "GENE_OR_GENE_PRODUCT"], [137, 146, "GENE_OR_GENE_PRODUCT"], [137, 146, "PROTEIN"], [21, 91, "PROTEIN"], [137, 146, "ENTITY"], [21, 51, "ENTITY"], [44, 51, "SO"]]}
{"text": "Notably , the use of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers ( ARBs ) was higher in patients with elevated TnT levels ( 11 [ 21.1 % ] vs 8 [ 5.9 % ] ; Table 1 ) , reflecting the higher rates ofCVD .", "labels": [[21, 91, "PROTEIN"], [146, 150, "ENTITY"], [202, 217, "ENTITY"], [62, 91, "ENTITY"], [21, 91, "GENE_OR_GENE_PRODUCT"], [44, 51, "SO"], [137, 146, "PROTEIN"], [137, 146, "GENE_OR_GENE_PRODUCT"], [137, 146, "ENTITY"], [21, 51, "ENTITY"]]}
{"text": "Notably , the use of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers ( ARBs ) was higher in patients with elevated TnT levels ( 11 [ 21.1 % ] vs 8 [ 5.9 % ] ; Table 1 ) , reflecting the higher rates ofCVD .", "labels": [[21, 91, "PROTEIN"], [146, 150, "ENTITY"], [202, 217, "ENTITY"], [62, 91, "ENTITY"], [21, 91, "GENE_OR_GENE_PRODUCT"], [44, 51, "SO"], [137, 146, "PROTEIN"], [137, 146, "GENE_OR_GENE_PRODUCT"], [137, 146, "ENTITY"], [21, 51, "ENTITY"]]}
{"text": "Apart from the XBP1 pathway , activated IRE1 has been shown to recruit TNF receptor-associated factor 2 ( TRAF2 ) and induce apoptosis by activating the JNK ( Urano et al. , 2000 ) . This IRE1-JNK pathway is independent of IRE1 \u2019s RNase activity , but it requires IRE1 \u2019s kinase domain and involves TRAF2-dependent activation of caspase-12 ( Yonedaet al.,2001 ) .", "labels": [[315, 329, "PROTEIN"], [71, 102, "PROTEIN"], [208, 228, "GGP"], [223, 237, "ENTITY"], [15, 28, "ENTITY"], [290, 299, "ENTITY"], [208, 228, "GENE_OR_GENE_PRODUCT"], [208, 223, "ENTITY"], [315, 329, "ENTITY"], [255, 272, "GENE_OR_GENE_PRODUCT"], [181, 188, "PROTEIN"], [75, 102, "ENTITY"], [15, 20, "GGP"], [255, 272, "ENTITY"], [15, 20, "GENE_OR_GENE_PRODUCT"], [208, 220, "PROTEIN"], [290, 299, "SIMPLE_CHEMICAL"], [299, 315, "ENTITY"], [181, 197, "ENTITY"], [255, 272, "GGP"], [40, 45, "PROTEIN"], [71, 102, "GENE_OR_GENE_PRODUCT"], [118, 125, "ENTITY"], [71, 102, "GGP"], [255, 272, "PROTEIN"], [315, 329, "GENE_OR_GENE_PRODUCT"], [15, 20, "PROTEIN"]]}
{"text": "The up-regulation of GADD153 promotes apoptosis in IBV-infected cells , possibly via inducing the pro-apoptotic protein tribbles-related protein 3 ( TRIB3 ) and suppressing the pro-survival kinase extracellular signal-related kinase ( ERK;Liaoet al. , 2013 ) .", "labels": [[173, 226, "ENTITY"], [4, 18, "ENTITY"], [64, 70, "CL"], [21, 29, "GGP"], [98, 145, "ENTITY"], [21, 29, "PROTEIN"], [21, 29, "ENTITY"], [98, 145, "PROTEIN"], [226, 235, "CHEMICAL"], [64, 70, "CELL"], [38, 48, "ENTITY"], [226, 235, "PROTEIN"], [173, 226, "PROTEIN"], [51, 70, "CELL_TYPE"], [173, 226, "GENE_OR_GENE_PRODUCT"], [21, 29, "GENE_OR_GENE_PRODUCT"], [98, 112, "GGP"], [173, 226, "GGP"], [51, 70, "ENTITY"]]}
{"text": "Interestingly , the mRNA level of CSPG2 , which is involved in the extracellular matrix assembly ( 32 ) , was also specifically up- regulated , with four different transcripts giving similar results ( Table \u200b(Table1).1 ) .", "labels": [[63, 81, "CELLULAR_COMPONENT"], [128, 132, "ENTITY"], [201, 207, "GENE_OR_GENE_PRODUCT"], [183, 191, "ENTITY"], [63, 88, "GO"], [63, 88, "ENTITY"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "The identified target genes of ATF6 include ER chaperones ( such as GRP78 , GRP94 ) , PDI , and the UPR transcription factors GADD153 and XBP1 ( Szegezdi et al. , 2006 ) .", "labels": [[22, 28, "SO"], [44, 58, "ENTITY"], [44, 58, "PROTEIN"], [31, 36, "ENTITY"], [44, 47, "GENE_OR_GENE_PRODUCT"], [31, 36, "GGP"], [138, 145, "GENE_OR_GENE_PRODUCT"], [15, 22, "ENTITY"], [118, 126, "ENTITY"], [118, 126, "GENE_OR_GENE_PRODUCT"], [96, 126, "PROTEIN"], [44, 58, "GGP"], [31, 36, "PROTEIN"], [4, 15, "ENTITY"], [138, 145, "PROTEIN"], [31, 36, "GENE_OR_GENE_PRODUCT"], [118, 126, "GGP"], [22, 28, "ENTITY"]]}
{"text": "Whereas the unspliced XBP1 mRNA ( XBP1u ) encodes an inhibitor of the UPR , XBP1s encode a potent transcriptional activator , which translocates to the nucleus and enhances the expression of many UPR genes , including those encoding molecular chaperones and proteins contributing to ER-associated degradation ( Ng et al. , 2000;Lee et al. , 2003;Figure 4 ) .", "labels": [[91, 114, "ENTITY"], [70, 74, "ENTITY"], [283, 297, "ENTITY"], [267, 283, "ENTITY"], [91, 114, "PROTEIN"], [22, 27, "GENE_OR_GENE_PRODUCT"], [70, 74, "SO"], [22, 32, "GGP"], [12, 22, "ENTITY"], [27, 32, "ENTITY"], [224, 243, "ENTITY"], [224, 233, "CHEBI"], [267, 283, "GENE_OR_GENE_PRODUCT"], [12, 32, "RNA"], [224, 243, "PROTEIN"], [22, 27, "ENTITY"], [191, 200, "DNA"], [267, 283, "GO"]]}
{"text": "Whereas the unspliced XBP1 mRNA ( XBP1u ) encodes an inhibitor of the UPR , XBP1s encode a potent transcriptional activator , which translocates to the nucleus and enhances the expression of many UPR genes , including those encoding molecular chaperones and proteins contributing to ER-associated degradation ( Ng et al. , 2000;Lee et al. , 2003;Figure 4 ) .", "labels": [[91, 114, "ENTITY"], [70, 74, "ENTITY"], [283, 297, "ENTITY"], [267, 283, "ENTITY"], [91, 114, "PROTEIN"], [22, 27, "GENE_OR_GENE_PRODUCT"], [70, 74, "SO"], [22, 32, "GGP"], [12, 22, "ENTITY"], [27, 32, "ENTITY"], [224, 243, "ENTITY"], [224, 233, "CHEBI"], [267, 283, "GENE_OR_GENE_PRODUCT"], [12, 32, "RNA"], [224, 243, "PROTEIN"], [22, 27, "ENTITY"], [191, 200, "DNA"], [267, 283, "GO"]]}
{"text": "Moreover , UPR downstream genes known to be activated by XBP1s , such as ER DNA J domain-containing protein 4 ( DNA J domain-containing protein 4 ) , EDEM1 , and protein kinase inhibitor of 58kDa ( p58IPK ) , are not significantly induced after infection ( Bechillet al. , 2008 ) .", "labels": [[82, 100, "CHEBI"], [128, 142, "CHEMICAL"], [100, 108, "GENE_OR_GENE_PRODUCT"], [70, 108, "ENTITY"], [11, 26, "DNA"], [162, 170, "ENTITY"], [70, 108, "GENE_OR_GENE_PRODUCT"], [181, 189, "ENTITY"], [70, 76, "GGP"], [70, 108, "PROTEIN"], [181, 189, "DISEASE"], [128, 142, "PROTEIN"], [-1, 31, "ENTITY"], [82, 100, "PROTEIN"], [15, 26, "ENTITY"], [-1, 31, "GENE_OR_GENE_PRODUCT"], [82, 100, "CHEBI"]]}
{"text": "Moreover , UPR downstream genes known to be activated by XBP1s , such as ER DNA J domain-containing protein 4 ( DNA J domain-containing protein 4 ) , EDEM1 , and protein kinase inhibitor of 58kDa ( p58IPK ) , are not significantly induced after infection ( Bechillet al. , 2008 ) .", "labels": [[82, 100, "CHEBI"], [128, 142, "CHEMICAL"], [100, 108, "GENE_OR_GENE_PRODUCT"], [70, 108, "ENTITY"], [11, 26, "DNA"], [162, 170, "ENTITY"], [70, 108, "GENE_OR_GENE_PRODUCT"], [181, 189, "ENTITY"], [70, 76, "GGP"], [70, 108, "PROTEIN"], [181, 189, "DISEASE"], [128, 142, "PROTEIN"], [-1, 31, "ENTITY"], [82, 100, "PROTEIN"], [15, 26, "ENTITY"], [-1, 31, "GENE_OR_GENE_PRODUCT"], [82, 100, "CHEBI"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "Of the compounds tested , a human \u03b1-n3 IFN from leukocytes was the most selective inhibitor of virus replication ( Table 1 ) .", "labels": [[28, 39, "PROTEIN"], [95, 101, "ENTITY"], [7, 17, "CHEBI"], [28, 39, "ORGANISM"], [7, 17, "ENTITY"], [17, 24, "ENTITY"], [34, 39, "ENTITY"]]}
{"text": ". Mice were treated with three doses of IFN-\u03b1 B/D , once a day for 3 days beginning 4 h before virus exposure . At day 3 after virus exposure , all doses of the IFN significantly reduced virus lung titres compared with those from the control animals ( Table 7 ) .", "labels": [[12, 25, "ENTITY"], [230, 242, "ENTITY"], [40, 50, "PROTEIN"], [179, 198, "ENTITY"], [2, 7, "ENTITY"], [46, 50, "SIMPLE_CHEMICAL"], [179, 193, "ORGANISM"], [40, 46, "ENTITY"], [2, 7, "ORGANISM"], [165, 179, "ENTITY"], [95, 101, "ENTITY"], [179, 193, "DISEASE"], [234, 242, "TAXON"], [31, 37, "ENTITY"], [46, 50, "ENTITY"], [179, 187, "TAXON"], [2, 7, "TAXON"]]}
{"text": "Therapeutic options include steroids , intravenous immunoglobulin , selective cytokine blockade ( eg , anakinra or tocilizumab ) and JAK inhibition .", "labels": [[68, 78, "PROTEIN"], [28, 37, "CHEMICAL"], [39, 51, "ENTITY"], [68, 78, "ENTITY"], [39, 51, "PROTEIN"], [98, 103, "CHEMICAL"], [12, 20, "ENTITY"], [28, 37, "ENTITY"], [28, 37, "CHEBI"], [0, 12, "ENTITY"], [78, 87, "ENTITY"], [98, 103, "SIMPLE_CHEMICAL"], [28, 37, "SIMPLE_CHEMICAL"], [39, 51, "ORGANISM_SUBSTANCE"], [133, 137, "ENTITY"], [98, 103, "ENTITY"]]}
{"text": "In terms of inflammation indicators , patients on admission showed increase in lactate dehydrogenase ( 25 [ 41 % ] of 61 patients ) , c reactive protein ( 42 [ 67 % ] of 63 patients ) , and erythrocyte sedimentation rate ( 30 [ 52 % ] of 58 patients ) , but not procalcitonin .", "labels": [[132, 147, "ENTITY"], [81, 89, "CHEMICAL"], [81, 103, "GENE_OR_GENE_PRODUCT"], [243, 260, "GENE_OR_GENE_PRODUCT"], [25, 36, "ENTITY"], [12, 25, "DISEASE"], [123, 147, "PROTEIN"], [81, 103, "ENTITY"], [81, 103, "PROTEIN"], [12, 25, "ENTITY"], [243, 260, "ENTITY"], [123, 147, "GENE_OR_GENE_PRODUCT"], [69, 78, "ENTITY"], [113, 120, "ORGANISM"], [175, 204, "ENTITY"], [52, 62, "ENTITY"], [81, 103, "GGP"], [113, 120, "ENTITY"], [138, 147, "CHEBI"], [243, 260, "PROTEIN"], [175, 192, "CELL"], [175, 192, "CL"]]}
{"text": "In terms of inflammation indicators , patients on admission showed increase in lactate dehydrogenase ( 25 [ 41 % ] of 61 patients ) , c reactive protein ( 42 [ 67 % ] of 63 patients ) , and erythrocyte sedimentation rate ( 30 [ 52 % ] of 58 patients ) , but not procalcitonin .", "labels": [[132, 147, "ENTITY"], [81, 89, "CHEMICAL"], [81, 103, "GENE_OR_GENE_PRODUCT"], [243, 260, "GENE_OR_GENE_PRODUCT"], [25, 36, "ENTITY"], [123, 147, "PROTEIN"], [81, 103, "PROTEIN"], [81, 103, "ENTITY"], [243, 260, "ENTITY"], [123, 147, "GENE_OR_GENE_PRODUCT"], [69, 78, "ENTITY"], [12, 25, "ENTITY"], [113, 120, "ORGANISM"], [175, 204, "ENTITY"], [52, 62, "ENTITY"], [81, 103, "GGP"], [113, 120, "ENTITY"], [138, 147, "CHEBI"], [243, 260, "PROTEIN"], [12, 25, "DISEASE"], [175, 192, "CELL"], [175, 192, "CL"]]}
{"text": "The S proteins of most coronaviruses are cleaved by host protease into two functional subunits : an N-terminal receptor binding domain ( S1 ) and a C-terminal domain(S2 ) responsible for membrane fusion ( Huang et al. , 2006;Qiuet al. , 2006;Yamada et al. , 2009 ) .", "labels": [[23, 37, "PROTEIN"], [100, 128, "ENTITY"], [4, 15, "ENTITY"], [183, 196, "ENTITY"], [23, 37, "TAXON"], [100, 128, "PROTEIN"], [4, 15, "PROTEIN"], [23, 37, "ORGANISM"], [52, 66, "ENTITY"], [75, 95, "ENTITY"], [23, 37, "ENTITY"], [146, 159, "ENTITY"], [52, 66, "PROTEIN"], [6, 15, "CHEBI"]]}
{"text": "According to Zhou and colleagues , in coronaviruses , teicoplanin acts on the early step of the viral life cycle by inhibiting the low pH cleavage of the viral spike protein by cathepsin L in the late endosomes thereby preventing the release of genomic viral RNA and the continuation of virus replication cycle .", "labels": [[150, 166, "ENTITY"], [92, 107, "ENTITY"], [13, 18, "ENTITY"], [160, 166, "CHEBI"], [174, 187, "GENE_OR_GENE_PRODUCT"], [22, 33, "ENTITY"], [242, 259, "ENTITY"], [192, 201, "CELLULAR_COMPONENT"], [174, 187, "ENTITY"], [174, 187, "GGP"], [174, 187, "PROTEIN"], [150, 166, "PROTEIN"], [192, 201, "GO"], [135, 138, "ENTITY"], [131, 135, "ENTITY"], [242, 259, "SO"], [242, 259, "RNA"], [284, 305, "ENTITY"], [192, 201, "ENTITY"]]}
{"text": "The S proteins of most coronaviruses are cleaved by host protease into two functional subunits : an N-terminal receptor binding domain ( S1 ) and a C-terminal domain(S2 ) responsible for membrane fusion ( Huang et al. , 2006;Qiuet al. , 2006;Yamada et al. , 2009 ) .", "labels": [[23, 37, "PROTEIN"], [100, 128, "ENTITY"], [4, 15, "ENTITY"], [23, 37, "TAXON"], [100, 128, "PROTEIN"], [4, 15, "PROTEIN"], [23, 37, "ORGANISM"], [52, 66, "ENTITY"], [75, 95, "ENTITY"], [183, 196, "ENTITY"], [23, 37, "ENTITY"], [146, 159, "ENTITY"], [52, 66, "PROTEIN"], [6, 15, "CHEBI"]]}
{"text": "The abundant membrane ( M ) proteins give the virion its shape , whereas the small envelope(E ) proteins play an essential role during assembly ( Sturmanetal.,1980 ; Liu and Inglis , 1991 ) . Inside the envelope , the helical nucleocapsid is formed by binding of the nucleocapsid(N ) proteins on the genomicRNA in a beads-on-a-string fashion .", "labels": [[13, 22, "GO"], [135, 146, "GENE_OR_GENE_PRODUCT"], [252, 267, "ENTITY"], [284, 296, "CHEBI"], [252, 267, "PROTEIN"], [146, 174, "ENTITY"], [284, 296, "ENTITY"], [135, 146, "ENTITY"], [83, 96, "CHEBI"], [203, 226, "PROTEIN"], [4, 13, "ENTITY"], [13, 22, "CELLULAR_COMPONENT"], [203, 226, "ENTITY"], [192, 199, "ENTITY"], [83, 96, "ENTITY"], [300, 316, "ENTITY"], [13, 22, "ENTITY"]]}
{"text": "Transmembrane structural proteins ( S , M , and E ) are synthesized , inserted , and folded in the endoplasmic reticulum ( ER ) and transported to the ER \u2013 Golgi intermediate compartment ( ERGIC ) .", "labels": [[0, 34, "PROTEIN"], [147, 175, "ENTITY"], [0, 14, "GO"], [25, 34, "CHEBI"], [123, 132, "ENTITY"], [92, 111, "PROTEIN"], [0, 14, "CELLULAR_COMPONENT"], [14, 34, "ENTITY"], [42, 48, "ENTITY"], [162, 175, "GO"], [0, 14, "ENTITY"], [92, 111, "ENTITY"], [92, 111, "CELLULAR_COMPONENT"], [56, 70, "SO"], [56, 70, "ENTITY"], [92, 111, "GO"]]}
{"text": "The abundant membrane ( M ) proteins give the virion its shape , whereas the small envelope(E ) proteins play an essential role during assembly ( Sturmanetal.,1980 ; Liu and Inglis , 1991 ) . Inside the envelope , the helical nucleocapsid is formed by binding of the nucleocapsid(N ) proteins on the genomicRNA in a beads-on-a-string fashion .", "labels": [[83, 96, "CHEBI"], [135, 146, "ENTITY"], [252, 267, "ENTITY"], [252, 267, "PROTEIN"], [146, 174, "ENTITY"], [284, 296, "ENTITY"], [284, 296, "CHEBI"], [203, 226, "PROTEIN"], [4, 13, "ENTITY"], [13, 22, "CELLULAR_COMPONENT"], [83, 96, "ENTITY"], [135, 146, "GENE_OR_GENE_PRODUCT"], [203, 226, "ENTITY"], [192, 199, "ENTITY"], [13, 22, "GO"], [300, 316, "ENTITY"], [13, 22, "ENTITY"]]}
{"text": "Transmembrane structural proteins ( S , M , and E ) are synthesized , inserted , and folded in the endoplasmic reticulum ( ER ) and transported to the ER \u2013 Golgi intermediate compartment ( ERGIC ) .", "labels": [[0, 34, "PROTEIN"], [147, 175, "ENTITY"], [0, 14, "GO"], [25, 34, "CHEBI"], [123, 132, "ENTITY"], [92, 111, "PROTEIN"], [0, 14, "CELLULAR_COMPONENT"], [14, 34, "ENTITY"], [42, 48, "ENTITY"], [162, 175, "GO"], [0, 14, "ENTITY"], [92, 111, "ENTITY"], [92, 111, "CELLULAR_COMPONENT"], [56, 70, "SO"], [56, 70, "ENTITY"], [92, 111, "GO"]]}
{"text": "The glycosylation of M protein is proposed to play a certain function in alpha interferon ( IFN ) induction and in vivo tissue tropism ( Charley and Laude , 1988;Laude et al.,1992;de Haan et al. , 2003 ) .", "labels": [[115, 127, "ENTITY"], [73, 90, "GENE_OR_GENE_PRODUCT"], [4, 18, "ENTITY"], [115, 120, "TISSUE"], [108, 115, "ENTITY"], [61, 70, "ENTITY"], [73, 90, "ENTITY"], [21, 31, "ENTITY"], [73, 90, "PROTEIN"], [21, 31, "PROTEIN"], [73, 92, "CHEMICAL"], [73, 90, "GGP"], [23, 31, "CHEBI"]]}
{"text": "The glycosylation of M protein is proposed to play a certain function in alpha interferon ( IFN ) induction and in vivo tissue tropism ( Charley and Laude , 1988;Laude et al.,1992;de Haan et al. , 2003 ) .", "labels": [[115, 127, "ENTITY"], [61, 70, "ENTITY"], [73, 90, "GENE_OR_GENE_PRODUCT"], [4, 18, "ENTITY"], [115, 120, "TISSUE"], [108, 115, "ENTITY"], [73, 92, "CHEMICAL"], [73, 90, "ENTITY"], [21, 31, "ENTITY"], [73, 90, "PROTEIN"], [21, 31, "PROTEIN"], [73, 90, "GGP"], [23, 31, "CHEBI"]]}
{"text": "A pH-dependant mechanism of entry of coronavirus into target cells was also reported for SARS-CoV-1 after binding of the DC-SIGN receptor [ 62 ] . The activation step that occurs in endosomes at acidic pH results in fusion of the viral and endosomal membranes leading to the release of the viral SARS-CoV-1 genome into the cytosol [63].In the absence of antiviral drug , the virus is targeted to the lysosomal compartment where the low pH , along with the action of enzymes , disrupts the viral particle , thus liberating the infectious nucleic acid and , in several cases , enzymes necessary for its replication [ 64 ] .", "labels": [[15, 25, "ENTITY"], [351, 364, "ENTITY"], [106, 114, "ENTITY"], [319, 331, "PROTEIN"], [526, 537, "CHEMICAL"], [121, 138, "ENTITY"], [61, 67, "CELL"], [476, 495, "ENTITY"], [121, 138, "PROTEIN"], [121, 129, "GGP"], [466, 476, "ENTITY"], [354, 364, "CHEBI"], [511, 537, "ENTITY"], [37, 49, "ENTITY"], [476, 489, "TAXON"], [567, 573, "SO"], [286, 307, "DNA"], [121, 138, "GENE_OR_GENE_PRODUCT"], [526, 537, "CHEBI"], [593, 601, "ENTITY"], [61, 67, "CL"], [54, 67, "CELL_TYPE"], [456, 466, "PROTEIN"], [319, 331, "CELLULAR_COMPONENT"], [236, 250, "ENTITY"], [28, 34, "ENTITY"], [54, 61, "ENTITY"], [37, 49, "TAXON"], [236, 250, "GO"], [567, 573, "ENTITY"], [456, 466, "SO"], [456, 466, "ENTITY"], [61, 67, "ENTITY"], [89, 100, "ENTITY"], [192, 202, "ENTITY"], [37, 49, "ORGANISM"], [89, 100, "SO"], [286, 307, "ENTITY"], [396, 410, "ENTITY"], [236, 250, "CELLULAR_COMPONENT"]]}
{"text": "C3 activation products ( C3 fragments C3a , C3b , iC3b , C3dg , and C3c ) were detected by Western blotting in lung tissue of SARS-CoV MA15-infected mice , but not in control mice , as early as 1 day postinfection ( dpi ) ( Fig. 1B ) , confirming that SARS-CoV MA15 infection activates the complement pathway .", "labels": [[25, 38, "ENTITY"], [0, 23, "PROTEIN"], [160, 167, "ENTITY"], [25, 38, "PROTEIN"], [99, 116, "ENTITY"], [135, 140, "ENTITY"], [50, 57, "GGP"], [247, 261, "ENTITY"], [236, 252, "ORGANISM"], [50, 57, "PROTEIN"], [236, 247, "ENTITY"], [50, 57, "ENTITY"], [116, 135, "ENTITY"], [191, 200, "ENTITY"], [116, 126, "ORGANISM"], [0, 3, "GGP"], [185, 191, "ENTITY"], [79, 99, "ENTITY"], [50, 57, "GENE_OR_GENE_PRODUCT"], [0, 23, "ENTITY"], [276, 290, "ENTITY"], [116, 126, "GGP"], [25, 38, "GGP"], [25, 38, "GENE_OR_GENE_PRODUCT"], [99, 116, "TISSUE"], [14, 23, "SO"]]}
{"text": "Compared with patients without ARDS , for patients with ARDS , the value of liver damage indices ( total bilirubin [ difference , 1.90mg/dL ; 95%CI , 0.60 - 3.30 mg/dL ; P = .004 ] ) , renal dysfunction indices ( urea [ difference , 1.69 mM ; 95 % CI , 1.10 - 2.29mM;P < .001 ] ) , inflammation-related indices ( interleukin- 6 [ IL-6 ] [ difference , 0.93 pg/L ; 95%CI , 0.07 - 1.98 pg/L ; P = .03 ] ) , and coagulation function indices ( D-dimer [ difference , 0.52 \u03bcg/mL ; 95 % CI , 0.21 - 0.94 \u03bcg/mL ; P < .001 ] ) were significantly elevated .", "labels": [[99, 105, "GGP"], [403, 409, "ENTITY"], [258, 282, "ENTITY"], [31, 36, "ENTITY"], [194, 203, "CHEMICAL"], [14, 23, "ENTITY"], [403, 409, "PROTEIN"], [0, 9, "ENTITY"], [73, 89, "ENTITY"], [409, 421, "ENTITY"], [73, 82, "DISEASE"], [191, 203, "CHEMICAL"], [99, 105, "SIMPLE_CHEMICAL"], [172, 191, "ENTITY"], [191, 203, "CHEBI"], [31, 36, "DISEASE"], [89, 99, "ENTITY"], [130, 142, "CHEMICAL"], [191, 203, "ENTITY"], [105, 117, "ENTITY"], [14, 23, "ORGANISM"], [372, 401, "ENTITY"], [99, 105, "CHEMICAL"], [97, 105, "ENTITY"], [403, 409, "GGP"]]}
{"text": "For patients with ARDS who died , the value of liver damage indices ( total bilirubin [ difference , 2.60 mg/dL ; 95 % CI , 0.30 - 5.20mg/dL;P = .03 ] ) , renal dysfunction indices ( urea [ difference , 1.50 mM ; 95%CI , 0.50 - 2.70 mM ; P = .004 ] ) , inflammation- related indices ( IL-6 [ difference , 3.88 pg/L ; 95 % CI , 2.20 - 6.13pg/L;P < .001 ] ) , and coagulation function indices ( Ddimer [ difference , 2.10 \u03bcg/mL ; 95 % CI , 0.89 - 5.27 \u03bcg/mL ; P = .001 ] ) were significantly elevated compared with patients with ARDS who survived .", "labels": [[60, 70, "ENTITY"], [47, 60, "ENTITY"], [161, 173, "ENTITY"], [292, 310, "SIMPLE_CHEMICAL"], [469, 476, "ENTITY"], [68, 76, "ENTITY"], [327, 356, "ENTITY"], [70, 76, "CHEMICAL"], [161, 173, "CHEBI"], [469, 476, "ORGANISM"], [70, 76, "SIMPLE_CHEMICAL"], [4, 13, "ENTITY"], [267, 275, "ENTITY"], [88, 99, "CHEMICAL"], [18, 23, "ENTITY"], [47, 53, "DISEASE"], [88, 101, "CHEMICAL"], [143, 161, "ENTITY"], [18, 23, "DISEASE"], [143, 161, "DISEASE"], [70, 76, "GGP"], [161, 173, "CHEMICAL"], [27, 32, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "D-dimer concentrations were markedly greater in deceased patients ( 4.6 \u03bcg/mL ) than in recovered patients ( 0.6 \u03bcg/mL ) .", "labels": [[0, 8, "GGP"], [88, 98, "ENTITY"], [0, 8, "GENE_OR_GENE_PRODUCT"], [48, 57, "ENTITY"], [8, 23, "ENTITY"], [0, 8, "PROTEIN"], [57, 66, "ORGANISM"], [57, 66, "ENTITY"], [88, 98, "ORGANISM"], [0, 8, "ENTITY"]]}
{"text": "Decreased platelet counts were observed in 25 ( 20.2 % ) patients , prolonged prothrombin time ( PT ) was observed in 77 ( 62.1 % ) patients , fibrinogen ( FIB ) levels were increased in 27 ( 21.8 % ) patients , and D-dimer levels were increased in 26 ( 21.0 % ) patients .", "labels": [[57, 68, "ENTITY"], [10, 19, "CL"], [57, 68, "ENTITY"], [10, 26, "ENTITY"], [216, 224, "ENTITY"], [68, 78, "GENE_OR_GENE_PRODUCT"], [236, 252, "ORGANISM"], [162, 169, "ENTITY"], [68, 90, "ENTITY"], [143, 156, "ENTITY"], [57, 68, "PROTEIN"], [90, 95, "ENTITY"], [10, 19, "CELL"], [236, 252, "ENTITY"], [57, 68, "GENE_OR_GENE_PRODUCT"], [57, 68, "ENTITY"], [0, 10, "ENTITY"], [68, 78, "PROTEIN"]]}
{"text": "Patients with elevated TnT levels also had significantly longer prothrombin time ( median [ IQR ] , 12.4 [ 12.0 - 13.0 ] vs 13.3 [ 12.2 - 15.3 ] seconds ; P = .005 ) , shorter activated partial thromboplastin time ( median [ IQR ] , 31.2 [ 27.5 - 33.2 ] vs 32.7 [ 31.0 - 35.8 ] seconds ; P = .003 ) , and a significant higher level of D-dimer ( median [ IQR ] , 0.29 [ 0.17 - 0.60 ] vs 3.85 [ 0.51 - 25.58 ] \u03bcg/mL[to convert to nanomoles per liter , multiply by 5.476 ] ; P < .001 ) .", "labels": [[176, 194, "GENE_OR_GENE_PRODUCT"], [23, 27, "ENTITY"], [14, 23, "ENTITY"], [145, 155, "ENTITY"], [23, 27, "PROTEIN"], [319, 326, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"], [27, 34, "ENTITY"], [0, 9, "ENTITY"], [64, 76, "PROTEIN"], [0, 9, "ORGANISM"], [64, 76, "GENE_OR_GENE_PRODUCT"], [176, 194, "PROTEIN"], [417, 425, "GENE_OR_GENE_PRODUCT"], [64, 81, "ENTITY"], [43, 55, "ENTITY"]]}
{"text": "At present , systemic glucocorticoids administration was empirically used for severe complications in order to suppress CS manifestations in patients with COVID-19 , such as ARDS , acute heart injuries , acute kidney complication , and patients with higher D-dimer levels , et al[3 , 23 , 24 ]", "labels": [[250, 257, "ENTITY"], [181, 187, "ORGAN"], [193, 217, "ENTITY"], [257, 265, "ENTITY"], [250, 257, "PROTEIN"], [250, 257, "GENE_OR_GENE_PRODUCT"], [181, 193, "DISEASE"], [179, 193, "ENTITY"], [250, 257, "GGP"], [181, 187, "ORGAN"]]}
{"text": "This reinforces that high levels of D-dimer and low lymphocyte counts are 306 associated with poor prognosis and suggest that that DIP treatment should be initiated before the progression to critical illness ( Figure 3B ) .", "labels": [[131, 135, "ENTITY"], [36, 44, "ENTITY"], [78, 94, "ENTITY"], [48, 52, "ENTITY"], [52, 63, "ENTITY"], [210, 217, "ENTITY"], [52, 63, "CELL"], [176, 188, "ENTITY"], [131, 135, "CHEMICAL"], [36, 44, "GGP"], [21, 26, "ENTITY"], [36, 44, "PROTEIN"], [94, 109, "ENTITY"], [26, 33, "ENTITY"], [36, 44, "GENE_OR_GENE_PRODUCT"], [63, 70, "ENTITY"], [52, 63, "CL"], [191, 208, "ENTITY"], [135, 145, "ENTITY"], [131, 135, "SIMPLE_CHEMICAL"]]}
{"text": "For instance , a variety of human proteases , such as trypsin , tryptase Clara , human airway trypsin-like protease ( HAT ) and transmembrane protease serine 2 ( TMPRSS2 ) , are known to cleave and activate the S protein of SARS-CoV ( Bosch et al. 2008 ; Bertram et al. 2011 ) .", "labels": [[198, 211, "PROTEIN"], [213, 224, "GGP"], [34, 43, "ENTITY"], [73, 81, "ENTITY"], [34, 43, "ORGANISM"], [213, 224, "ENTITY"], [151, 162, "GENE_OR_GENE_PRODUCT"], [122, 151, "GGP"], [62, 73, "GENE_OR_GENE_PRODUCT"], [73, 107, "ORGANISM"], [34, 43, "DISEASE"], [187, 198, "ENTITY"], [198, 211, "CHEBI"], [213, 224, "ORGANISM"], [122, 151, "PROTEIN"], [122, 151, "GENE_OR_GENE_PRODUCT"], [151, 162, "GGP"], [34, 43, "PROTEIN"], [151, 162, "PROTEIN"], [122, 151, "ENTITY"], [73, 81, "TAXON"], [198, 211, "ENTITY"], [28, 34, "PROTEIN"], [73, 107, "PROTEIN"], [151, 162, "ENTITY"], [62, 73, "PROTEIN"], [62, 73, "ENTITY"]]}
{"text": "For wild-type Nsp5 , we identified one high-confidence interaction , the epigenetic regulator histone deacetylase 2 ( HDAC2 ) , and predicted a cleavage site between the HDAC domain and the nuclear localization sequence , suggesting that Nsp5 may inhibit HDAC2 transport into the nucleus ( Extended Data Fig. 7 ) , potentially impacting the published functions of HDAC2 in mediating inflammation and interferon response [ 38,39 ] .", "labels": [[132, 153, "ENTITY"], [383, 411, "ENTITY"], [271, 280, "CELLULAR_COMPONENT"], [198, 211, "SO"], [351, 361, "PROTEIN"], [351, 361, "GGP"], [186, 211, "DNA"], [84, 114, "GGP"], [186, 211, "ENTITY"], [14, 19, "GENE_OR_GENE_PRODUCT"], [351, 361, "GENE_OR_GENE_PRODUCT"], [247, 255, "ENTITY"], [39, 55, "ENTITY"], [69, 84, "ENTITY"], [351, 361, "ENTITY"], [14, 19, "GGP"], [247, 255, "GENE_OR_GENE_PRODUCT"], [373, 383, "DISEASE"], [247, 255, "GGP"], [383, 411, "SIMPLE_CHEMICAL"], [280, 290, "ENTITY"], [84, 114, "ENTITY"], [383, 400, "PROTEIN"], [14, 19, "ENTITY"], [238, 247, "ENTITY"], [327, 351, "ENTITY"], [4, 14, "ENTITY"], [271, 280, "ENTITY"], [166, 175, "ENTITY"], [118, 124, "ENTITY"], [373, 383, "ENTITY"], [144, 153, "SO"], [247, 255, "PROTEIN"], [69, 114, "PROTEIN"], [166, 175, "PROTEIN"], [271, 280, "GO"], [84, 114, "GENE_OR_GENE_PRODUCT"], [118, 123, "SO"]]}
{"text": "Increased C-reactive protein , procalcitonin and lactate dehydrogenase were found in five patients ( 5/8 ) , and increased alanine aminotransferase ( ALT ) in four ( 4/8 ) .", "labels": [[113, 123, "CHEBI"], [49, 57, "GENE_OR_GENE_PRODUCT"], [10, 29, "ENTITY"], [49, 57, "PROTEIN"], [49, 57, "GGP"], [10, 21, "GENE_OR_GENE_PRODUCT"], [10, 29, "GGP"], [49, 57, "ENTITY"], [113, 123, "CHEMICAL"], [0, 10, "ENTITY"], [113, 131, "GENE_OR_GENE_PRODUCT"], [131, 148, "ENTITY"], [10, 29, "PROTEIN"], [113, 131, "ENTITY"], [131, 148, "PROTEIN"], [131, 148, "GENE_OR_GENE_PRODUCT"], [113, 131, "PROTEIN"]]}
{"text": "Besides , serum levels of procalcitonin tended to be higher in severe cases than in moderate cases .", "labels": []}
{"text": "Fig 6 . In contrast , mice deficient in either CCR1 , CCR2 , or CCR5 exhibited more prominent airway epithelial cell apoptosis , a severe denuding bronchiolitis with an accumulation of cohesive apoptotic debris within the airway ( empty arrowhead ) , and perivenular/periarterial cuffing ( filled arrowhead ) but there was a distinct lack of cuffing around the affected airways .", "labels": [[325, 339, "ENTITY"], [247, 255, "CHEMICAL"], [84, 112, "CELL"], [84, 94, "ENTITY"], [138, 147, "DISEASE"], [94, 112, "CL"], [112, 117, "ENTITY"], [94, 112, "ENTITY"], [161, 169, "ENTITY"], [325, 339, "CELLULAR_COMPONENT"], [247, 280, "TISSUE"], [131, 138, "ENTITY"], [185, 194, "ENTITY"], [222, 237, "ENTITY"], [247, 280, "ENTITY"], [22, 27, "ENTITY"], [280, 297, "ENTITY"], [138, 147, "ENTITY"], [127, 131, "ENTITY"]]}
{"text": "Fig 6 . In contrast , mice deficient in either CCR1 , CCR2 , or CCR5 exhibited more prominent airway epithelial cell apoptosis , a severe denuding bronchiolitis with an accumulation of cohesive apoptotic debris within the airway ( empty arrowhead ) , and perivenular/periarterial cuffing ( filled arrowhead ) but there was a distinct lack of cuffing around the affected airways .", "labels": [[325, 339, "ENTITY"], [247, 255, "CHEMICAL"], [84, 112, "CELL"], [84, 94, "ENTITY"], [138, 147, "DISEASE"], [94, 112, "CL"], [112, 117, "ENTITY"], [94, 112, "ENTITY"], [161, 169, "ENTITY"], [325, 339, "CELLULAR_COMPONENT"], [247, 280, "TISSUE"], [131, 138, "ENTITY"], [185, 194, "ENTITY"], [222, 237, "ENTITY"], [247, 280, "ENTITY"], [22, 27, "ENTITY"], [280, 297, "ENTITY"], [138, 147, "ENTITY"], [127, 131, "ENTITY"]]}
{"text": "Fig 6 . In contrast , mice deficient in either CCR1 , CCR2 , or CCR5 exhibited more prominent airway epithelial cell apoptosis , a severe denuding bronchiolitis with an accumulation of cohesive apoptotic debris within the airway ( empty arrowhead ) , and perivenular/periarterial cuffing ( filled arrowhead ) but there was a distinct lack of cuffing around the affected airways .", "labels": [[325, 339, "ENTITY"], [247, 255, "CHEMICAL"], [84, 112, "CELL"], [84, 94, "ENTITY"], [138, 147, "DISEASE"], [94, 112, "CL"], [112, 117, "ENTITY"], [94, 112, "ENTITY"], [161, 169, "ENTITY"], [325, 339, "CELLULAR_COMPONENT"], [247, 280, "TISSUE"], [131, 138, "ENTITY"], [185, 194, "ENTITY"], [222, 237, "ENTITY"], [247, 280, "ENTITY"], [22, 27, "ENTITY"], [280, 297, "ENTITY"], [138, 147, "ENTITY"], [127, 131, "ENTITY"]]}
{"text": "Male DPP4 H/M mice fed a high-fat diet ( HFD ) for 12 to 17 weeks develop hyperglycemia , and hyperinsulinemia , resembling human type 2 diabetes .", "labels": [[0, 5, "ENTITY"], [25, 39, "ENTITY"], [113, 124, "ENTITY"], [5, 10, "ENTITY"], [10, 19, "ENTITY"], [66, 74, "DISEASE"], [113, 130, "ORGANISM"], [113, 130, "TAXON"], [14, 19, "TAXON"], [124, 137, "ENTITY"], [5, 10, "PROTEIN"], [130, 137, "DISEASE"], [5, 10, "GENE_OR_GENE_PRODUCT"], [66, 74, "ENTITY"], [5, 10, "GGP"]]}
{"text": "Male DPP4 H/M mice fed a high-fat diet ( HFD ) for 12 to 17 weeks develop hyperglycemia , and hyperinsulinemia , resembling human type 2 diabetes .", "labels": [[0, 5, "ENTITY"], [25, 39, "ENTITY"], [113, 124, "ENTITY"], [5, 10, "ENTITY"], [10, 19, "ENTITY"], [66, 74, "DISEASE"], [113, 130, "ORGANISM"], [113, 130, "TAXON"], [14, 19, "TAXON"], [124, 137, "ENTITY"], [5, 10, "PROTEIN"], [130, 137, "DISEASE"], [5, 10, "GENE_OR_GENE_PRODUCT"], [66, 74, "ENTITY"], [5, 10, "GGP"]]}
{"text": "Interestingly , diabetic mice had fewer inflammatory monocyte/macrophages , CD4 + T cells , and lower expression of TNF\u03b1 , IL-6 and Arg1 expression .", "labels": [[116, 123, "ENTITY"], [40, 53, "CELL_TYPE"], [116, 123, "GGP"], [74, 84, "ENTITY"], [16, 25, "ENTITY"], [132, 137, "ENTITY"], [96, 102, "ENTITY"], [80, 84, "CL"], [40, 53, "ENTITY"], [116, 123, "GENE_OR_GENE_PRODUCT"], [74, 84, "CELL_TYPE"], [116, 123, "PROTEIN"]]}
{"text": "Interestingly , diabetic mice had fewer inflammatory monocyte/macrophages , CD4 + T cells , and lower expression of TNF\u03b1 , IL-6 and Arg1 expression .", "labels": [[116, 123, "ENTITY"], [40, 53, "CELL_TYPE"], [116, 123, "GGP"], [74, 84, "ENTITY"], [16, 25, "ENTITY"], [132, 137, "ENTITY"], [96, 102, "ENTITY"], [80, 84, "CL"], [40, 53, "ENTITY"], [116, 123, "GENE_OR_GENE_PRODUCT"], [74, 84, "CELL_TYPE"], [116, 123, "PROTEIN"]]}
{"text": "Interestingly , diabetic mice had fewer inflammatory monocyte/macrophages , CD4 + T cells , and lower expression of TNF\u03b1 , IL-6 and Arg1 expression .", "labels": [[116, 123, "ENTITY"], [40, 53, "CELL_TYPE"], [116, 123, "GGP"], [74, 84, "ENTITY"], [16, 25, "ENTITY"], [132, 137, "ENTITY"], [96, 102, "ENTITY"], [80, 84, "CL"], [40, 53, "ENTITY"], [116, 123, "GENE_OR_GENE_PRODUCT"], [74, 84, "CELL_TYPE"], [116, 123, "PROTEIN"]]}
{"text": "Interestingly , diabetic mice had fewer inflammatory monocyte/macrophages , CD4 + T cells , and lower expression of TNF\u03b1 , IL-6 and Arg1 expression .", "labels": [[40, 53, "CELL_TYPE"], [74, 84, "ENTITY"], [116, 123, "ENTITY"], [16, 25, "ENTITY"], [132, 137, "ENTITY"], [96, 102, "ENTITY"], [80, 84, "CL"], [40, 53, "ENTITY"], [116, 123, "GENE_OR_GENE_PRODUCT"], [74, 84, "CELL_TYPE"], [116, 123, "PROTEIN"], [116, 123, "GGP"]]}
{"text": "Interestingly , diabetic mice had fewer inflammatory monocyte/macrophages , CD4 + T cells , and lower expression of TNF\u03b1 , IL-6 and Arg1 expression .", "labels": [[116, 123, "ENTITY"], [40, 53, "CELL_TYPE"], [116, 123, "GGP"], [74, 84, "ENTITY"], [16, 25, "ENTITY"], [132, 137, "ENTITY"], [96, 102, "ENTITY"], [80, 84, "CL"], [40, 53, "ENTITY"], [116, 123, "GENE_OR_GENE_PRODUCT"], [74, 84, "CELL_TYPE"], [116, 123, "PROTEIN"]]}
{"text": "Interestingly , diabetic mice had fewer inflammatory monocyte/macrophages , CD4 + T cells , and lower expression of TNF\u03b1 , IL-6 and Arg1 expression .", "labels": [[116, 123, "ENTITY"], [40, 53, "CELL_TYPE"], [116, 123, "GGP"], [74, 84, "ENTITY"], [16, 25, "ENTITY"], [96, 102, "ENTITY"], [80, 84, "CL"], [40, 53, "ENTITY"], [116, 123, "GENE_OR_GENE_PRODUCT"], [74, 84, "CELL_TYPE"], [116, 123, "PROTEIN"], [132, 137, "ENTITY"]]}
{"text": "While blocking TPC2 activity by tetrandrine , an inhibitor for TPC237 , decreased entry of SARS-CoV-2 S pseudovirions ( Fig. 3f ) , treatment of cells with 130 , a TRPML1 inhibitor , had no effect ( Supplementary Fig. 1 ) , indicating that TPC2 , not TRPML1 , is important for SARS-CoV-2 entry .", "labels": [[224, 235, "GENE_OR_GENE_PRODUCT"], [32, 44, "ENTITY"], [15, 20, "GENE_OR_GENE_PRODUCT"], [15, 20, "GGP"], [118, 125, "CELL"], [263, 277, "ENTITY"], [32, 44, "CHEBI"], [156, 164, "PROTEIN"], [224, 235, "ENTITY"], [88, 104, "GENE_OR_GENE_PRODUCT"], [156, 164, "GENE_OR_GENE_PRODUCT"], [32, 44, "SIMPLE_CHEMICAL"], [132, 145, "CL"], [224, 235, "PROTEIN"], [132, 145, "ENTITY"], [15, 20, "PROTEIN"], [15, 20, "ENTITY"], [263, 273, "CHEMICAL"], [263, 273, "SIMPLE_CHEMICAL"], [181, 190, "ENTITY"], [72, 82, "ENTITY"], [20, 29, "ENTITY"], [190, 199, "GENE_OR_GENE_PRODUCT"], [240, 247, "PROTEIN"], [156, 164, "ENTITY"], [224, 235, "GGP"], [240, 247, "GGP"], [132, 145, "CELL"], [156, 171, "GGP"], [240, 247, "GENE_OR_GENE_PRODUCT"], [88, 104, "ENTITY"], [6, 15, "ENTITY"], [32, 44, "CHEMICAL"], [164, 171, "ENTITY"], [240, 247, "ENTITY"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Tofacitinib has been shown to inhibit interferon\u03b1 production in vitro . Suppression of interferon or other mediators ( eg , interleukin 6 ) could also promote secondary bacterial infection and further complicate the disease course .", "labels": [[30, 38, "ENTITY"], [159, 179, "DISEASE"], [38, 61, "ENTITY"], [159, 179, "ENTITY"], [0, 12, "SIMPLE_CHEMICAL"], [0, 12, "CHEMICAL"], [151, 159, "ENTITY"], [212, 224, "ENTITY"], [159, 169, "TAXON"], [0, 12, "ENTITY"], [38, 50, "CELLULAR_COMPONENT"], [61, 70, "ENTITY"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [450, 483, "ENTITY"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [450, 483, "CL"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "For instance , a variety of human proteases , such as trypsin , tryptase Clara , human airway trypsin-like protease ( HAT ) and transmembrane protease serine 2 ( TMPRSS2 ) , are known to cleave and activate the S protein of SARS-CoV ( Bosch et al. 2008 ; Bertram et al. 2011 ) .", "labels": [[198, 211, "PROTEIN"], [73, 107, "ORGANISM"], [213, 224, "GGP"], [34, 43, "ENTITY"], [34, 43, "ORGANISM"], [73, 107, "PROTEIN"], [213, 224, "ENTITY"], [151, 162, "GENE_OR_GENE_PRODUCT"], [73, 81, "TAXON"], [122, 151, "GGP"], [34, 43, "DISEASE"], [187, 198, "ENTITY"], [62, 73, "PROTEIN"], [198, 211, "CHEBI"], [213, 224, "ORGANISM"], [122, 151, "PROTEIN"], [62, 73, "GENE_OR_GENE_PRODUCT"], [62, 73, "ENTITY"], [122, 151, "GENE_OR_GENE_PRODUCT"], [151, 162, "GGP"], [34, 43, "PROTEIN"], [151, 162, "PROTEIN"], [122, 151, "ENTITY"], [198, 211, "ENTITY"], [28, 34, "PROTEIN"], [151, 162, "ENTITY"], [73, 81, "ENTITY"]]}
{"text": "Taken together , these observations suggest that chronic AT1R blockade results in ACE2 upregulation in both rats and humans .", "labels": [[57, 62, "ENTITY"]]}
{"text": "Studies by Ferrario27 and others showed that ACE2 levels increased by 4.7 and 2.8 times when blood pressure decreased after applying ACEIs ( lisinopril ) and ARBs ( losartan ) to rats .", "labels": [[11, 22, "SIMPLE_CHEMICAL"], [133, 139, "CHEMICAL"], [45, 50, "ENTITY"], [50, 57, "ENTITY"], [11, 22, "ENTITY"], [45, 50, "GGP"], [0, 8, "ENTITY"], [45, 50, "GENE_OR_GENE_PRODUCT"], [133, 139, "SIMPLE_CHEMICAL"], [108, 118, "ENTITY"], [133, 139, "ENTITY"], [93, 99, "ORGANISM_SUBSTANCE"], [11, 22, "CHEMICAL"], [57, 67, "ENTITY"], [93, 108, "ENTITY"], [45, 50, "PROTEIN"]]}
{"text": "Taken together , these observations suggest that chronic AT1R blockade results in ACE2 upregulation in both rats and humans .", "labels": [[57, 62, "ENTITY"]]}
{"text": "A study involving MERS-CoV described that ORF 8b strongly antagonizes the INF-beta ( \u03b2 ) promoter and ORF4b and 8b significantly suppress IFN induction ( Lee et al. , 2019b ) .", "labels": [[129, 138, "ENTITY"], [74, 83, "ENTITY"], [74, 83, "GENE_OR_GENE_PRODUCT"], [74, 89, "DNA"], [129, 138, "GENE_OR_GENE_PRODUCT"], [18, 27, "GGP"], [58, 70, "ENTITY"], [18, 27, "PROTEIN"], [42, 49, "ENTITY"], [2, 8, "ENTITY"], [42, 49, "PROTEIN"], [115, 129, "ENTITY"], [129, 138, "CHEMICAL"], [42, 46, "SO"], [138, 142, "ENTITY"], [129, 138, "PROTEIN"], [18, 27, "ENTITY"], [129, 138, "GGP"]]}
{"text": "A study involving MERS-CoV described that ORF 8b strongly antagonizes the INF-beta ( \u03b2 ) promoter and ORF4b and 8b significantly suppress IFN induction ( Lee et al. , 2019b ) .", "labels": [[138, 142, "ENTITY"], [74, 83, "ENTITY"], [74, 83, "GENE_OR_GENE_PRODUCT"], [74, 89, "DNA"], [18, 27, "GGP"], [129, 138, "GENE_OR_GENE_PRODUCT"], [18, 27, "PROTEIN"], [58, 70, "ENTITY"], [42, 49, "ENTITY"], [2, 8, "ENTITY"], [42, 49, "PROTEIN"], [115, 129, "ENTITY"], [18, 27, "ENTITY"], [42, 46, "SO"], [129, 138, "CHEMICAL"], [129, 138, "PROTEIN"], [129, 138, "ENTITY"], [129, 138, "GGP"]]}
{"text": "N expression clearly down-regulated the level of extracellular fibronectin in the absence of serum ( Figure 2A , upper panel ) .", "labels": [[21, 36, "ENTITY"], [49, 75, "ENTITY"], [93, 99, "ORGANISM_SUBSTANCE"], [49, 75, "CELLULAR_COMPONENT"], [0, 13, "ENTITY"], [40, 46, "ENTITY"], [93, 99, "ENTITY"], [111, 119, "ENTITY"], [49, 75, "PROTEIN"], [101, 108, "ENTITY"], [49, 75, "GO"], [82, 90, "ENTITY"]]}
{"text": "As expected , fibronectin levels were found to be lower in N-expressing cells irrespective of the presence or absence of serum ( Figure 2A , lower panel ) , suggesting that N down-regulated fibronectin gene expression .", "labels": [[59, 72, "ENTITY"], [168, 175, "ENTITY"], [59, 72, "CELL_TYPE"], [127, 136, "ENTITY"], [175, 202, "ENTITY"], [14, 26, "ENTITY"], [175, 190, "GENE_OR_GENE_PRODUCT"], [139, 147, "ENTITY"], [202, 207, "ENTITY"]]}
{"text": "The level of phosphorylated FAK was significantly down-regulated in N-expressing cells in the absence of growth factors ( Figure 2C ) .", "labels": [[68, 87, "ENTITY"], [81, 87, "CELL"], [81, 87, "CL"], [94, 102, "ENTITY"], [122, 129, "ENTITY"], [28, 32, "GGP"], [68, 87, "CELL_TYPE"], [28, 32, "ENTITY"], [4, 10, "ENTITY"], [13, 28, "ENTITY"], [105, 120, "ENTITY"], [105, 120, "PROTEIN"], [28, 32, "GENE_OR_GENE_PRODUCT"], [13, 32, "PROTEIN"], [50, 65, "ENTITY"]]}
{"text": "As shown in Fig. 6 , SB203580 as an inhibitor of p38 MAPK and PD98059 as an inhibitor of MEK1/2 did not affect the establishment of persistent infection , whereas no surviving cells were observed following treatment with SP600125 , an inhibitor of JNK , or LY294002 , an inhibitor of PI3K/Akt .", "labels": [[49, 53, "ENTITY"], [230, 235, "ENTITY"], [230, 235, "CHEBI"], [166, 176, "ENTITY"], [12, 19, "CELL"], [36, 49, "GENE_OR_GENE_PRODUCT"], [163, 176, "CELL_TYPE"], [36, 49, "ENTITY"], [166, 176, "CL"], [49, 53, "PROTEIN"], [49, 53, "GENE_OR_GENE_PRODUCT"], [166, 176, "CELL"], [49, 53, "GGP"]]}
{"text": "This result suggested that , at least , the phosphorylation of Akt in viral infected cells were necessary to establish persistence .", "labels": [[109, 119, "ENTITY"], [76, 85, "CL"], [76, 85, "CELL"], [67, 85, "ENTITY"], [5, 12, "ENTITY"], [67, 85, "CELL_TYPE"]]}
{"text": "The up-regulation of JNK activity was reflected further by the elevated p-Jun level ( Figure3B , third panel , lanes 5 and 6 ) .", "labels": [[21, 25, "PROTEIN"], [95, 103, "ENTITY"], [72, 78, "PROTEIN"], [72, 84, "ENTITY"], [4, 18, "ENTITY"], [21, 25, "GENE_OR_GENE_PRODUCT"], [63, 72, "ENTITY"], [25, 34, "ENTITY"], [21, 25, "ENTITY"]]}
{"text": "Thus we conclude that N-induced activation of the p38 MAPK pathway in the absence of growth factors leads to actin reorganization .", "labels": [[109, 130, "ENTITY"], [109, 115, "GENE_OR_GENE_PRODUCT"], [109, 115, "PROTEIN"], [74, 82, "ENTITY"], [32, 43, "ENTITY"], [109, 115, "GO"], [50, 59, "PROTEIN"], [50, 67, "ENTITY"], [50, 59, "GGP"], [50, 59, "GENE_OR_GENE_PRODUCT"], [85, 100, "ENTITY"], [85, 100, "PROTEIN"]]}
{"text": "Here , we found that both caspase-8- and -9-specific inhibitors significantly suppressed nuclear condensation induced by 3a-WT in Vero E6 cells ( Fig. 2C ) .", "labels": [[130, 138, "CELL_LINE"], [89, 97, "ENTITY"], [130, 138, "ENTITY"], [130, 138, "CELL"], [144, 151, "CELL"]]}
{"text": "As shown in Fig. 6 , SB203580 as an inhibitor of p38 MAPK and PD98059 as an inhibitor of MEK1/2 did not affect the establishment of persistent infection , whereas no surviving cells were observed following treatment with SP600125 , an inhibitor of JNK , or LY294002 , an inhibitor of PI3K/Akt .", "labels": [[49, 53, "ENTITY"], [230, 235, "ENTITY"], [230, 235, "CHEBI"], [166, 176, "ENTITY"], [12, 19, "CELL"], [36, 49, "GENE_OR_GENE_PRODUCT"], [163, 176, "CELL_TYPE"], [36, 49, "ENTITY"], [166, 176, "CL"], [49, 53, "PROTEIN"], [49, 53, "GENE_OR_GENE_PRODUCT"], [166, 176, "CELL"], [49, 53, "GGP"]]}
{"text": "As demonstrated by the virus entry assay ( Fig. 3 , A and B ) , SARS-CoV S-mediated entry was reduced by \u000480 % in VeroE6 cells that transiently overexpressed recombinant FLAG-Sac1 compared with control VeroE6 cells , whereas VSV-G pseudovirus entry was not affected by recombinant Sac1 expression .", "labels": [[114, 121, "CL"], [217, 231, "ENTITY"], [132, 144, "ENTITY"], [109, 121, "ENTITY"], [144, 158, "ENTITY"], [114, 121, "CL"], [217, 231, "ORGANISM"], [194, 209, "ENTITY"], [23, 29, "TAXON"], [60, 73, "ORGANISM"], [158, 170, "CHEMICAL"], [194, 209, "CELL_LINE"], [109, 121, "CELL"], [158, 170, "SIMPLE_CHEMICAL"], [158, 170, "ENTITY"], [231, 243, "ENTITY"], [257, 269, "ENTITY"], [64, 73, "ENTITY"], [144, 170, "PROTEIN"], [23, 41, "ENTITY"], [225, 231, "TAXON"], [194, 209, "CELL"], [109, 121, "CELL_LINE"], [175, 180, "ENTITY"]]}
{"text": "These results indicate that PI4P is indispensable for SARSCoV S-mediated entry and suggest that PI4 KB mediates SARS-CoV S entry by regulating the level of cellular PI4P .", "labels": [[28, 33, "PROTEIN"], [112, 121, "PROTEIN"], [156, 165, "PROTEIN"], [6, 14, "ENTITY"], [62, 73, "ENTITY"], [156, 165, "CELL"], [28, 33, "GENE_OR_GENE_PRODUCT"], [28, 33, "ENTITY"], [112, 121, "ENTITY"], [28, 32, "GENE_OR_GENE_PRODUCT"], [112, 121, "ORGANISM"], [28, 32, "ENTITY"], [54, 62, "ENTITY"], [28, 32, "PROTEIN"]]}
{"text": "As demonstrated by the virus entry assay ( Fig. 3 , A and B ) , SARS-CoV S-mediated entry was reduced by \u000480 % in VeroE6 cells that transiently overexpressed recombinant FLAG-Sac1 compared with control VeroE6 cells , whereas VSV-G pseudovirus entry was not affected by recombinant Sac1 expression .", "labels": [[114, 121, "CL"], [217, 231, "ENTITY"], [132, 144, "ENTITY"], [109, 121, "ENTITY"], [144, 158, "ENTITY"], [114, 121, "CL"], [217, 231, "ORGANISM"], [194, 209, "ENTITY"], [23, 29, "TAXON"], [60, 73, "ORGANISM"], [158, 170, "CHEMICAL"], [194, 209, "CELL_LINE"], [109, 121, "CELL"], [158, 170, "SIMPLE_CHEMICAL"], [158, 170, "ENTITY"], [231, 243, "ENTITY"], [257, 269, "ENTITY"], [144, 170, "PROTEIN"], [23, 41, "ENTITY"], [225, 231, "TAXON"], [194, 209, "CELL"], [109, 121, "CELL_LINE"], [175, 180, "ENTITY"], [64, 73, "ENTITY"]]}
{"text": "FIGURE 7 . Model of the PI kinases and PI4P involved in SARS-CoV S-mediated entry . After SARS-CoV binds to ACE2 , PI4P , the catalytic product of PI4 KB , creates a lipid microenvironment or PI4P-enriched organelle required for the steps leading to fusion . Pharmacological inhibitors of PI4 KB , such as LY294002 or wortmannin , suppress PI4 KB activity and thereby inhibit SARSCoV S-mediated entry . Cellular factors , such as PI3Ks or Sac1 , that negatively regulate PI4P generation can also inhibit SARS-CoV S-mediated entry .", "labels": [[412, 422, "ENTITY"], [65, 76, "CL"], [122, 136, "ENTITY"], [298, 306, "SIMPLE_CHEMICAL"], [156, 166, "SIMPLE_CHEMICAL"], [0, 7, "ENTITY"], [275, 286, "GENE_OR_GENE_PRODUCT"], [412, 422, "CHEBI"], [318, 329, "ENTITY"], [24, 27, "PROTEIN"], [56, 65, "ENTITY"], [24, 27, "GENE_OR_GENE_PRODUCT"], [259, 275, "CHEBI"], [65, 84, "PROTEIN"], [451, 462, "PROTEIN"], [298, 306, "ENTITY"], [331, 344, "ENTITY"], [56, 65, "ORGANISM"], [172, 192, "CELL"], [275, 286, "PROTEIN"], [491, 504, "ORGANISM"], [306, 318, "CHEBI"], [122, 136, "PROTEIN"], [451, 462, "GENE_OR_GENE_PRODUCT"], [65, 76, "CELL"], [298, 306, "CHEMICAL"], [24, 27, "ENTITY"], [412, 422, "PROTEIN"], [462, 471, "ENTITY"], [172, 206, "ENTITY"], [65, 84, "ENTITY"], [451, 462, "ENTITY"], [476, 487, "ENTITY"], [368, 384, "ENTITY"], [275, 286, "ENTITY"], [275, 283, "ENTITY"], [156, 172, "ENTITY"], [192, 206, "GO"], [239, 250, "ENTITY"], [306, 318, "SIMPLE_CHEMICAL"], [306, 318, "ENTITY"], [156, 166, "CHEBI"], [250, 275, "ENTITY"], [306, 318, "CHEMICAL"], [412, 422, "GENE_OR_GENE_PRODUCT"]]}
{"text": "These results indicate that PI4P is indispensable for SARSCoV S-mediated entry and suggest that PI4 KB mediates SARS-CoV S entry by regulating the level of cellular PI4P .", "labels": [[28, 33, "PROTEIN"], [112, 121, "PROTEIN"], [156, 165, "PROTEIN"], [6, 14, "ENTITY"], [62, 73, "ENTITY"], [156, 165, "CELL"], [28, 33, "GENE_OR_GENE_PRODUCT"], [28, 33, "ENTITY"], [112, 121, "ENTITY"], [28, 32, "GENE_OR_GENE_PRODUCT"], [112, 121, "ORGANISM"], [28, 32, "ENTITY"], [54, 62, "ENTITY"], [28, 32, "PROTEIN"]]}
{"text": "Detection of PI4P from lipid extracts of VeroE6 cells that were transfected with FLAG-Sac1 or a control plasmid revealed that ectopic expression of Sac1 reduced the levels of PI4P in VeroE6 ( Fig. 4 , F and G ) . These results demonstrate that Sac1 phosphatase is a key factor in regulating PI4P levels in VeroE6 cells .", "labels": [[280, 291, "PROTEIN"], [23, 38, "ENTITY"], [81, 91, "CELL_LINE"], [180, 190, "CELL"], [13, 18, "PROTEIN"], [165, 172, "ENTITY"], [81, 91, "SIMPLE_CHEMICAL"], [41, 54, "CELL"], [180, 190, "ENTITY"], [86, 91, "GGP"], [23, 38, "SIMPLE_CHEMICAL"], [134, 145, "ENTITY"], [86, 91, "ENTITY"], [280, 291, "GENE_OR_GENE_PRODUCT"], [199, 207, "GENE_OR_GENE_PRODUCT"], [13, 18, "ENTITY"], [239, 249, "PROTEIN"], [81, 91, "CHEMICAL"], [41, 54, "ENTITY"], [153, 161, "ENTITY"], [180, 190, "CELL_LINE"], [23, 29, "CHEBI"], [239, 249, "ENTITY"], [13, 18, "PROTEIN"], [13, 18, "GENE_OR_GENE_PRODUCT"], [96, 112, "DNA"], [104, 112, "SO"], [64, 76, "ENTITY"], [239, 249, "GGP"], [48, 54, "CL"], [13, 18, "ENTITY"], [41, 48, "CELL_LINE"], [81, 91, "ENTITY"], [13, 18, "GENE_OR_GENE_PRODUCT"], [13, 18, "ENTITY"], [86, 91, "GENE_OR_GENE_PRODUCT"], [41, 54, "CELL_LINE"], [96, 112, "ENTITY"], [126, 134, "ENTITY"], [41, 48, "ENTITY"], [183, 197, "ORGANISM"], [41, 48, "CL"], [280, 291, "ENTITY"], [0, 10, "ENTITY"], [86, 91, "PROTEIN"]]}
{"text": "FIGURE 7 . Model of the PI kinases and PI4P involved in SARS-CoV S-mediated entry . After SARS-CoV binds to ACE2 , PI4P , the catalytic product of PI4 KB , creates a lipid microenvironment or PI4P-enriched organelle required for the steps leading to fusion . Pharmacological inhibitors of PI4 KB , such as LY294002 or wortmannin , suppress PI4 KB activity and thereby inhibit SARSCoV S-mediated entry . Cellular factors , such as PI3Ks or Sac1 , that negatively regulate PI4P generation can also inhibit SARS-CoV S-mediated entry .", "labels": [[412, 422, "ENTITY"], [65, 76, "CL"], [56, 65, "ORGANISM"], [122, 136, "ENTITY"], [298, 306, "SIMPLE_CHEMICAL"], [156, 166, "SIMPLE_CHEMICAL"], [0, 7, "ENTITY"], [275, 286, "GENE_OR_GENE_PRODUCT"], [412, 422, "CHEBI"], [318, 329, "ENTITY"], [24, 27, "PROTEIN"], [24, 27, "GENE_OR_GENE_PRODUCT"], [259, 275, "CHEBI"], [65, 84, "PROTEIN"], [451, 462, "PROTEIN"], [298, 306, "ENTITY"], [331, 344, "ENTITY"], [172, 192, "CELL"], [275, 286, "PROTEIN"], [491, 504, "ORGANISM"], [462, 471, "ENTITY"], [306, 318, "CHEBI"], [122, 136, "PROTEIN"], [451, 462, "GENE_OR_GENE_PRODUCT"], [65, 76, "CELL"], [298, 306, "CHEMICAL"], [24, 27, "ENTITY"], [412, 422, "PROTEIN"], [172, 206, "ENTITY"], [65, 84, "ENTITY"], [451, 462, "ENTITY"], [476, 487, "ENTITY"], [368, 384, "ENTITY"], [275, 286, "ENTITY"], [56, 65, "ENTITY"], [275, 283, "ENTITY"], [156, 172, "ENTITY"], [192, 206, "GO"], [239, 250, "ENTITY"], [306, 318, "SIMPLE_CHEMICAL"], [306, 318, "ENTITY"], [156, 166, "CHEBI"], [250, 275, "ENTITY"], [306, 318, "CHEMICAL"], [412, 422, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Here , we found that both caspase-8- and -9-specific inhibitors significantly suppressed nuclear condensation induced by 3a-WT in Vero E6 cells ( Fig. 2C ) .", "labels": [[130, 138, "CELL_LINE"], [89, 97, "ENTITY"], [130, 138, "ENTITY"], [130, 138, "CELL"], [144, 151, "CELL"]]}
{"text": "As shown in Fig. 6 , SB203580 as an inhibitor of p38 MAPK and PD98059 as an inhibitor of MEK1/2 did not affect the establishment of persistent infection , whereas no surviving cells were observed following treatment with SP600125 , an inhibitor of JNK , or LY294002 , an inhibitor of PI3K/Akt .", "labels": [[49, 53, "ENTITY"], [230, 235, "ENTITY"], [230, 235, "CHEBI"], [166, 176, "ENTITY"], [12, 19, "CELL"], [36, 49, "GENE_OR_GENE_PRODUCT"], [163, 176, "CELL_TYPE"], [36, 49, "ENTITY"], [166, 176, "CL"], [49, 53, "PROTEIN"], [49, 53, "GENE_OR_GENE_PRODUCT"], [166, 176, "CELL"], [49, 53, "GGP"]]}
{"text": "Therefore , we suggest that emodin may contribute to reduced virus release from the SARS-CoV-infected cell through inhibition of the current medi-ated by 3a protein .", "labels": [[154, 157, "ENTITY"], [141, 157, "PROTEIN"], [84, 102, "ENTITY"]]}
{"text": "Particularly , ORF3 and ORF8 in SARS-CoV-2 are highly divergent from ORF3a and ORF8b in SARS-CoV that are known to induce NLRP3 inflammasome activation .", "labels": []}
{"text": "Therefore , we suggest that emodin may contribute to reduced virus release from the SARS-CoV-infected cell through inhibition of the current medi-ated by 3a protein .", "labels": [[154, 157, "ENTITY"], [141, 157, "PROTEIN"], [84, 102, "ENTITY"]]}
{"text": "Yang and colleagues indicated that MERS-CoV ORF4b antagonizes the antiviral IFN-\u03b2 response by inhibiting IRF3 and IRF7 ( 34 ) .", "labels": [[105, 110, "GGP"], [50, 62, "ENTITY"], [9, 20, "ENTITY"], [66, 82, "ENTITY"], [114, 119, "PROTEIN"], [44, 50, "ENTITY"], [35, 50, "PROTEIN"], [105, 110, "GENE_OR_GENE_PRODUCT"], [114, 119, "GGP"], [35, 44, "ENTITY"], [44, 50, "GENE_OR_GENE_PRODUCT"], [114, 119, "GENE_OR_GENE_PRODUCT"], [94, 105, "ENTITY"], [105, 110, "ENTITY"], [76, 82, "GENE_OR_GENE_PRODUCT"], [35, 44, "GGP"], [105, 110, "PROTEIN"], [0, 5, "ENTITY"], [114, 119, "ENTITY"]]}
{"text": "Yang and colleagues indicated that MERS-CoV ORF4b antagonizes the antiviral IFN-\u03b2 response by inhibiting IRF3 and IRF7 ( 34 ) .", "labels": [[105, 110, "ENTITY"], [50, 62, "ENTITY"], [9, 20, "ENTITY"], [66, 82, "ENTITY"], [114, 119, "GENE_OR_GENE_PRODUCT"], [105, 110, "PROTEIN"], [105, 110, "GGP"], [44, 50, "ENTITY"], [114, 119, "ENTITY"], [35, 50, "PROTEIN"], [105, 110, "GENE_OR_GENE_PRODUCT"], [35, 44, "ENTITY"], [44, 50, "GENE_OR_GENE_PRODUCT"], [94, 105, "ENTITY"], [114, 119, "GGP"], [76, 82, "GENE_OR_GENE_PRODUCT"], [35, 44, "GGP"], [114, 119, "PROTEIN"], [0, 5, "ENTITY"]]}
{"text": "We previously demonstrated that the influenza virus M2 protein ( a proton-selective ion channel ) , its H37 G mutant ( which has lost its proton selectivity and enables the transport of other cations such as Na + and K + ) , and the EMCV 2B protein ( a Ca 2 + channel ) stimulates NLRP3 inflammasome-mediated IL-1\u03b2 secretion ( Ichinohe et al. , 2010 ; Ito et al. , 2012 ) .", "labels": [[241, 260, "PROTEIN"], [200, 208, "SIMPLE_CHEMICAL"], [46, 52, "TAXON"], [233, 241, "CHEBI"], [67, 88, "ENTITY"], [55, 63, "CHEBI"], [88, 98, "ENTITY"], [200, 208, "ENTITY"], [100, 110, "ENTITY"], [104, 110, "SO"], [225, 241, "ENTITY"], [36, 63, "PROTEIN"], [225, 233, "ORGANISM"], [67, 88, "PROTEIN"], [100, 110, "PROTEIN"], [200, 213, "PROTEIN"], [55, 63, "CHEMICAL"], [270, 287, "ENTITY"], [225, 241, "PROTEIN"], [200, 208, "CHEBI"], [36, 63, "ENTITY"], [287, 315, "ENTITY"], [241, 260, "ENTITY"], [134, 145, "ENTITY"]]}
{"text": "We previously demonstrated that the influenza virus M2 protein ( a proton-selective ion channel ) , its H37 G mutant ( which has lost its proton selectivity and enables the transport of other cations such as Na + and K + ) , and the EMCV 2B protein ( a Ca 2 + channel ) stimulates NLRP3 inflammasome-mediated IL-1\u03b2 secretion ( Ichinohe et al. , 2010 ; Ito et al. , 2012 ) .", "labels": [[241, 260, "PROTEIN"], [36, 63, "PROTEIN"], [200, 208, "SIMPLE_CHEMICAL"], [233, 241, "CHEBI"], [67, 88, "ENTITY"], [55, 63, "CHEBI"], [88, 98, "ENTITY"], [200, 208, "ENTITY"], [100, 110, "ENTITY"], [104, 110, "SO"], [225, 241, "ENTITY"], [225, 233, "ORGANISM"], [67, 88, "PROTEIN"], [100, 110, "PROTEIN"], [200, 213, "PROTEIN"], [55, 63, "CHEMICAL"], [270, 287, "ENTITY"], [225, 241, "PROTEIN"], [200, 208, "CHEBI"], [36, 63, "ENTITY"], [287, 315, "ENTITY"], [241, 260, "ENTITY"], [46, 52, "TAXON"], [134, 145, "ENTITY"]]}
{"text": "IL-1\u03b2 was released from LPS-primed BMMs transduced with the M2- and 2B-expressing lentivirus ( Figure 1D ) . Similarly , the lentiviruses expressing the SARS-CoV E or 3a proteins stimulated IL-1\u03b2 release from LPS-primed BMMs ( Figure 1D ) .", "labels": [[125, 138, "ENTITY"], [82, 93, "TAXON"], [24, 40, "CELL_LINE"], [82, 93, "ENTITY"], [19, 35, "CELL_LINE"], [60, 64, "GENE_OR_GENE_PRODUCT"], [82, 93, "ORGANISM"], [35, 40, "CELL"], [164, 170, "ENTITY"], [0, 6, "GENE_OR_GENE_PRODUCT"], [95, 102, "ENTITY"], [0, 6, "CHEMICAL"], [0, 6, "PROTEIN"], [0, 6, "ENTITY"], [179, 190, "GENE_OR_GENE_PRODUCT"], [0, 6, "GGP"], [220, 227, "ENTITY"], [60, 64, "CHEMICAL"], [60, 64, "ENTITY"], [179, 190, "GGP"], [170, 179, "ENTITY"], [0, 6, "ENTITY"], [10, 19, "ENTITY"], [24, 35, "ENTITY"], [167, 170, "CHEBI"], [24, 35, "CELL"], [24, 35, "ENTITY"], [40, 51, "ENTITY"], [179, 190, "PROTEIN"], [149, 162, "ORGANISM"], [35, 40, "ENTITY"], [149, 170, "PROTEIN"], [179, 190, "ENTITY"], [24, 35, "TAXON"]]}
{"text": "We previously demonstrated that the influenza virus M2 protein ( a proton-selective ion channel ) , its H37 G mutant ( which has lost its proton selectivity and enables the transport of other cations such as Na + and K + ) , and the EMCV 2B protein ( a Ca 2 + channel ) stimulates NLRP3 inflammasome-mediated IL-1\u03b2 secretion ( Ichinohe et al. , 2010 ; Ito et al. , 2012 ) .", "labels": [[241, 260, "PROTEIN"], [200, 208, "SIMPLE_CHEMICAL"], [46, 52, "TAXON"], [233, 241, "CHEBI"], [67, 88, "ENTITY"], [55, 63, "CHEBI"], [88, 98, "ENTITY"], [200, 208, "ENTITY"], [100, 110, "ENTITY"], [104, 110, "SO"], [225, 241, "ENTITY"], [36, 63, "PROTEIN"], [225, 233, "ORGANISM"], [67, 88, "PROTEIN"], [100, 110, "PROTEIN"], [200, 213, "PROTEIN"], [55, 63, "CHEMICAL"], [270, 287, "ENTITY"], [225, 241, "PROTEIN"], [200, 208, "CHEBI"], [36, 63, "ENTITY"], [287, 315, "ENTITY"], [241, 260, "ENTITY"], [134, 145, "ENTITY"]]}
{"text": "This data suggests that the deletion of the 226 RGV 228 in the A4 mutant may disrupt a domain of nsp 2 required for proper replication complex interaction , though the formation of the replication complexes is apparently not hindered , as evidenced by the localization of nsps 1 and 8 .", "labels": [[269, 277, "ENTITY"], [28, 37, "ENTITY"], [5, 10, "ENTITY"], [123, 143, "ENTITY"], [63, 73, "PROTEIN"], [66, 73, "SO"], [97, 103, "GENE_OR_GENE_PRODUCT"], [97, 103, "PROTEIN"], [123, 135, "ENTITY"], [63, 73, "ENTITY"], [87, 94, "SO"], [97, 103, "ENTITY"], [87, 94, "ENTITY"], [269, 277, "GENE_OR_GENE_PRODUCT"], [28, 37, "SO"], [48, 52, "ENTITY"], [143, 155, "ENTITY"], [269, 283, "PROTEIN"], [123, 135, "PROTEIN"]]}
{"text": "However , the Y414 virus was virulent in mice , whereas the Y414H mutant was completely attenuated , even in the absence of the mutation in the 2a protein ( Sperry et al. , 2005 ) .", "labels": [[77, 88, "ENTITY"], [144, 147, "CHEBI"], [140, 147, "PROTEIN"], [140, 147, "ENTITY"], [14, 19, "ENTITY"], [60, 66, "SO"], [56, 66, "PROTEIN"], [56, 66, "ENTITY"]]}
{"text": "The FI values for proteins S1 , S2 , S3 , S4 , S5 , 3a , N and 9b to sera from SARS patients were statistically significantly more than those from healthy people ( P < 0.01 , using SPSS 10.0 software ) ( Fig. 2 ) , but the FI values for proteins E , M , 3b , 6 and 7a to sera from SARS patients had no significant difference with those from healthy people ( P > 0.05 ) .", "labels": [[69, 74, "ENTITY"], [265, 271, "ENTITY"], [69, 74, "ORGANISM"], [79, 84, "ORGANISM"], [173, 191, "ENTITY"], [18, 27, "CHEBI"], [7, 14, "ENTITY"], [63, 66, "ENTITY"], [7, 14, "ENTITY"], [325, 341, "ENTITY"], [136, 147, "ORGANISM"], [147, 155, "ORGANISM"], [42, 45, "ENTITY"], [63, 66, "ORGANISM_SUBSTANCE"], [79, 84, "ENTITY"], [4, 7, "ENTITY"], [281, 299, "ENTITY"], [7, 14, "CHEBI"], [265, 271, "DISEASE"], [93, 112, "ENTITY"], [142, 155, "ENTITY"], [18, 30, "ENTITY"]]}
{"text": "Our study highlighted interactions between SARS-CoV-2 proteins and human proteins with a range of functions including DNA replication ( Nsp1 ) , epigenetic and gene expression regulators ( Nsp5 , Nsp8 , Nsp13 , E ) , vesicle trafficking ( Nsp6 , Nsp7 , Nsp10 , Nsp13 , Nsp15 , Orf3a , E , M , Orf8 ) , lipid modification ( Spike ) , RNA processing and regulation ( Nsp8 , N ) , ubiquitin ligases ( Orf10 ) , signaling ( Nsp8 , Nsp13 , N , Orf9b ) , nuclear transport machinery ( Nsp8, Orf9c), and extracellular matrix , Nsp15 , Orf6 ) , cytoskeleton ( Nsp1 , Nsp13 ) , mitochondria ( Nsp4 , Nsp8 , Orf9c ) , and extracellular matrix ( Nsp8, Orf9c), and extracellular matrix ) ( Fig. 3 ) .", "labels": [[457, 467, "ENTITY"], [67, 82, "TAXON"], [43, 54, "CHEMICAL"], [209, 225, "ENTITY"], [4, 10, "ENTITY"], [-1, 8, "ENTITY"], [408, 439, "ENTITY"], [246, 253, "ENTITY"], [370, 376, "ENTITY"], [302, 308, "ENTITY"], [439, 447, "GGP"], [449, 457, "PROTEIN"], [203, 209, "GENE_OR_GENE_PRODUCT"], [239, 253, "CHEMICAL"], [189, 196, "GGP"], [67, 82, "ENTITY"], [398, 408, "CHEMICAL"], [43, 54, "GENE_OR_GENE_PRODUCT"], [196, 203, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [189, 196, "ENTITY"], [370, 376, "CHEMICAL"], [246, 253, "GGP"], [225, 239, "ENTITY"], [457, 467, "GO"], [196, 203, "GGP"], [253, 267, "CHEMICAL"], [98, 108, "ENTITY"], [176, 189, "ENTITY"], [-1, 8, "GENE_OR_GENE_PRODUCT"], [176, 189, "GENE_OR_GENE_PRODUCT"], [408, 420, "CELLULAR_COMPONENT"], [378, 388, "ENTITY"], [209, 215, "CELLULAR_COMPONENT"], [209, 215, "GO"], [203, 209, "ENTITY"], [370, 376, "GGP"], [449, 457, "GGP"], [370, 376, "SIMPLE_CHEMICAL"], [-1, 5, "ENTITY"], [494, 503, "CELLULAR_COMPONENT"], [239, 246, "ENTITY"], [239, 246, "GGP"], [225, 239, "CHEMICAL"], [494, 503, "GO"], [43, 63, "PROTEIN"], [308, 323, "ENTITY"], [352, 365, "ENTITY"], [-1, 5, "CHEMICAL"], [-1, 8, "GGP"], [118, 122, "SO"], [203, 209, "GGP"], [118, 122, "CELLULAR_COMPONENT"], [176, 189, "GGP"], [352, 365, "PROTEIN"], [246, 253, "GENE_OR_GENE_PRODUCT"], [494, 503, "ENTITY"], [54, 63, "CHEBI"], [-1, 11, "CELLULAR_COMPONENT"], [283, 300, "CHEBI"], [439, 447, "GENE_OR_GENE_PRODUCT"], [225, 239, "GENE_OR_GENE_PRODUCT"], [329, 337, "ENTITY"], [457, 477, "PROTEIN"], [449, 457, "ENTITY"], [398, 404, "ENTITY"], [370, 376, "PROTEIN"], [457, 467, "CELLULAR_COMPONENT"], [156, 176, "ENTITY"], [-1, 5, "GGP"], [-1, 11, "GO"], [176, 189, "PROTEIN"], [225, 239, "GGP"], [-1, 5, "GENE_OR_GENE_PRODUCT"], [118, 134, "ENTITY"], [408, 420, "GO"], [253, 261, "ENTITY"], [253, 261, "GGP"], [22, 35, "ENTITY"], [196, 203, "GENE_OR_GENE_PRODUCT"], [-1, 11, "ENTITY"], [203, 209, "DNA"], [449, 457, "GENE_OR_GENE_PRODUCT"], [439, 447, "PROTEIN"], [189, 196, "GENE_OR_GENE_PRODUCT"], [43, 63, "ENTITY"], [439, 447, "ENTITY"], [-1, 8, "PROTEIN"], [283, 300, "ENTITY"], [239, 246, "GENE_OR_GENE_PRODUCT"], [67, 73, "ORGANISM"], [196, 203, "CHEMICAL"], [-1, 8, "CHEMICAL"], [209, 213, "SIMPLE_CHEMICAL"], [253, 261, "DNA"], [67, 82, "PROTEIN"]]}
{"text": "Strikingly , LY6E significantly inhibited VSVpp entry mediated by S proteins from HCoV-229E ( Fig. 2a ) , MERS-CoV ( Fig. 2b ) , SARS-CoV ( Fig. 2c ) , and SARS-CoV-2 ( 2c), and SARS-CoV-2 ) .", "labels": [[0, 11, "ENTITY"], [145, 156, "CHEMICAL"], [122, 129, "GGP"], [122, 129, "PROTEIN"], [122, 129, "ORGANISM"], [122, 129, "ENTITY"], [145, 156, "ENTITY"], [145, 156, "GENE_OR_GENE_PRODUCT"]]}
{"text": "LY6E potently inhibited CoV S protein-mediated syncytia formation ( Fig. 2e-f ) .", "labels": [[30, 56, "ENTITY"], [0, 5, "ENTITY"], [5, 14, "ENTITY"], [24, 30, "ENTITY"], [14, 24, "ENTITY"], [68, 73, "SIMPLE_CHEMICAL"], [0, 5, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [24, 56, "ORGANISM"], [24, 30, "PROTEIN"]]}
{"text": "For instance , a variety of human proteases , such as trypsin , tryptase Clara , human airway trypsin-like protease ( HAT ) and transmembrane protease serine 2 ( TMPRSS2 ) , are known to cleave and activate the S protein of SARS-CoV ( Bosch et al. 2008 ; Bertram et al. 2011 ) .", "labels": [[198, 211, "PROTEIN"], [213, 224, "GGP"], [34, 43, "ENTITY"], [34, 43, "ORGANISM"], [213, 224, "ENTITY"], [151, 162, "GENE_OR_GENE_PRODUCT"], [73, 81, "TAXON"], [122, 151, "GGP"], [73, 107, "ORGANISM"], [34, 43, "DISEASE"], [187, 198, "ENTITY"], [62, 73, "ENTITY"], [62, 73, "PROTEIN"], [198, 211, "CHEBI"], [213, 224, "ORGANISM"], [122, 151, "PROTEIN"], [122, 151, "GENE_OR_GENE_PRODUCT"], [151, 162, "GGP"], [34, 43, "PROTEIN"], [151, 162, "PROTEIN"], [122, 151, "ENTITY"], [62, 73, "GENE_OR_GENE_PRODUCT"], [198, 211, "ENTITY"], [28, 34, "PROTEIN"], [73, 107, "PROTEIN"], [151, 162, "ENTITY"], [73, 81, "ENTITY"]]}
{"text": "In addition , the SARS-CoV 3a protein contains a cysteine-rich domain ( amino acid residues 127\u2013133 ) that is involved in the formation of a homodimer to generate the ion channel ( Lu et al. , 2006 ; Chan et al. , 2009 ) . Thus , mutation of the cysteine-rich domain blocks the ion conductivity by the 3a protein ( Chan et al. , 2009 ) .", "labels": [[230, 260, "ENTITY"], [221, 228, "SO"], [163, 171, "ENTITY"], [18, 27, "ORGANISM"], [70, 92, "PROTEIN"], [70, 83, "CHEBI"], [49, 63, "ENTITY"], [49, 63, "PROTEIN"], [70, 92, "AMINO_ACID"], [282, 302, "PROTEIN"], [295, 302, "CHEBI"], [282, 302, "ENTITY"], [230, 246, "PROTEIN"], [267, 282, "ENTITY"], [221, 228, "ENTITY"], [18, 30, "GGP"], [18, 30, "ENTITY"], [70, 83, "ENTITY"], [70, 78, "CHEMICAL"], [18, 30, "PROTEIN"]]}
{"text": "In addition , a U274 mutant ( U274mut2 ) that lacks sorting signals in the cytoplasmic domain ( see Table \u200bTable11 and Discussion ) was also not transported to the cell surface , suggesting that this domain is essential for the transportation of U274 to the cell surface .", "labels": [[100, 106, "ENTITY"], [16, 21, "ENTITY"], [157, 169, "ENTITY"], [71, 87, "GO"], [160, 169, "CELLULAR_COMPONENT"], [160, 169, "GO"], [71, 87, "ENTITY"], [228, 243, "PROTEIN"], [16, 21, "PROTEIN"], [46, 60, "ENTITY"], [71, 87, "PROTEIN"], [100, 106, "GENE_OR_GENE_PRODUCT"], [220, 228, "ENTITY"], [160, 169, "ENTITY"], [157, 169, "CELLULAR_COMPONENT"], [228, 243, "ENTITY"]]}
{"text": "In addition , the SARS-CoV 3a protein contains a cysteine-rich domain ( amino acid residues 127\u2013133 ) that is involved in the formation of a homodimer to generate the ion channel ( Lu et al. , 2006 ; Chan et al. , 2009 ) . Thus , mutation of the cysteine-rich domain blocks the ion conductivity by the 3a protein ( Chan et al. , 2009 ) .", "labels": [[230, 260, "ENTITY"], [221, 228, "SO"], [163, 171, "ENTITY"], [18, 27, "ORGANISM"], [70, 92, "PROTEIN"], [70, 83, "CHEBI"], [49, 63, "ENTITY"], [49, 63, "PROTEIN"], [70, 92, "AMINO_ACID"], [282, 302, "PROTEIN"], [295, 302, "CHEBI"], [282, 302, "ENTITY"], [230, 246, "PROTEIN"], [267, 282, "ENTITY"], [221, 228, "ENTITY"], [18, 30, "GGP"], [18, 30, "ENTITY"], [70, 83, "ENTITY"], [70, 78, "CHEMICAL"], [18, 30, "PROTEIN"]]}
{"text": "When compared with 3a-WT , we observed a\u223c5-fold reduction of the number of condensed nuclei in cell population expressing the 3a-CS-YA-DE triple mutant protein ( Fig. 2B ) .", "labels": [[72, 85, "ENTITY"], [39, 48, "ENTITY"], [75, 85, "GO"], [138, 152, "SO"], [92, 100, "ENTITY"], [5, 14, "ENTITY"], [72, 85, "CELLULAR_COMPONENT"], [100, 111, "ENTITY"], [122, 152, "ENTITY"], [122, 152, "PROTEIN"]]}
{"text": "Similarly , the plasma membrane localization of 3a-YA ( Fig. 1D and F ) and 3a-DE ( Fig. 1E and F ) mutants was partially reduced with a concomitant increase in cytoplasmic signals .", "labels": [[149, 173, "ENTITY"], [112, 122, "ENTITY"], [68, 72, "SO"], [16, 23, "GO"], [16, 23, "CELLULAR_COMPONENT"], [149, 161, "ORGANISM_SUBSTANCE"], [149, 161, "GO"], [68, 72, "ENTITY"], [130, 137, "ENTITY"], [137, 149, "ENTITY"]]}
{"text": "Unlike 3a-CS-YA-DE triple mutant , cells expressing single mutant proteins ( 3a-CS , 3a-DE and 3a-YA ) displayed more prominent nuclear condensation ( Fig. 2C ) .", "labels": [[26, 33, "SO"], [7, 33, "CELL_LINE"], [118, 128, "GO"], [7, 33, "ENTITY"], [26, 33, "PROTEIN"], [52, 66, "ENTITY"], [118, 136, "ENTITY"], [26, 33, "SO"], [118, 128, "CELLULAR_COMPONENT"]]}
{"text": "Consistent with the caspase inhibition results , we further showed that the activities of caspase-8 and -9 were significantly reduced in all 3a mutant expressing cells ( Fig. 2E and F ) .", "labels": [[28, 39, "ENTITY"], [0, 16, "ENTITY"], [141, 144, "SO"], [151, 162, "ENTITY"], [87, 104, "PROTEIN"], [141, 144, "ENTITY"], [151, 162, "CL"], [20, 28, "PROTEIN"], [20, 28, "GENE_OR_GENE_PRODUCT"], [168, 175, "CELL"], [39, 47, "ENTITY"], [151, 162, "CELL"], [20, 28, "ENTITY"]]}
{"text": "Consistent with the caspase inhibition results , we further showed that the activities of caspase-8 and -9 were significantly reduced in all 3a mutant expressing cells ( Fig. 2E and F ) .", "labels": [[28, 39, "ENTITY"], [0, 16, "ENTITY"], [141, 144, "SO"], [151, 162, "ENTITY"], [87, 104, "PROTEIN"], [141, 144, "ENTITY"], [151, 162, "CL"], [20, 28, "PROTEIN"], [20, 28, "GENE_OR_GENE_PRODUCT"], [168, 175, "CELL"], [39, 47, "ENTITY"], [151, 162, "CELL"], [20, 28, "ENTITY"]]}
{"text": "Nevertheless , we found that both 3a-WT ( Fig. 4 G ) and 3a mutants ( Fig. 4H \u2013 J ) caused disruption of external eye morphology by scanning electron microscopy .", "labels": [[34, 37, "SO"], [84, 91, "ENTITY"], [118, 150, "ENTITY"], [53, 60, "ENTITY"], [132, 141, "CHEBI"], [91, 105, "ENTITY"], [105, 118, "ENTITY"], [60, 75, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In contrast to 3a-WT , relatively few number of AO-positive cells were detected in 3a-CS , 3a-YA and 3a-DE mutant animals ( Fig. 5C \u2013 E ) .", "labels": [[122, 129, "CELL"], [107, 114, "ENTITY"], [48, 60, "CELL_TYPE"], [101, 114, "SO"], [101, 107, "ENTITY"], [48, 60, "ENTITY"]]}
{"text": "We also detected channel activities in 3a-YA-EGFP and 3a-DE-EGFP- expressing cells ( Fig. 6C and D ) , however , the activities were found to be different from that observed in 3a- WT-EGFP-expressing cells .", "labels": [[177, 200, "ENTITY"], [39, 50, "ENTITY"], [181, 200, "CL"], [77, 83, "CELL"], [17, 36, "ENTITY"], [174, 200, "CELL"], [8, 17, "ENTITY"], [85, 90, "GENE_OR_GENE_PRODUCT"], [54, 83, "ENTITY"], [174, 200, "CELL_LINE"], [77, 83, "CL"]]}
{"text": "We further found that addition of ion channel blocker barium chloride ( Ba ) altered the cell membrane current mediated by 3a-WT-EGFP , 3a-YA-EGFP and 3a-DE-EGFP proteins ( Fig. 6B \u2013 D ) .", "labels": [[54, 70, "CHEMICAL"], [147, 162, "ENTITY"], [85, 94, "GO"], [61, 70, "CHEBI"], [134, 162, "PROTEIN"], [34, 54, "CHEBI"], [85, 94, "CELLULAR_COMPONENT"], [34, 70, "ENTITY"], [151, 162, "CHEBI"], [85, 94, "ENTITY"]]}
{"text": "In contrast to 3a-WT , the 3a-CS mutant protein lost the plasma membrane localization and became more concentrated in the cytoplasm and the perinuclear region ( Fig. 1C and F ) .", "labels": [[57, 64, "ENTITY"], [33, 40, "SO"], [140, 152, "ENTITY"], [140, 152, "GO"], [33, 40, "ENTITY"], [57, 64, "GO"], [57, 64, "CELLULAR_COMPONENT"]]}
{"text": "In contrast to 3a-WT , the 3a-CS mutant protein lost the plasma membrane localization and became more concentrated in the cytoplasm and the perinuclear region ( Fig. 1C and F ) .", "labels": [[57, 64, "ENTITY"], [33, 40, "SO"], [140, 152, "ENTITY"], [33, 40, "ENTITY"], [57, 64, "GO"], [140, 152, "GO"], [57, 64, "CELLULAR_COMPONENT"]]}
{"text": "Unlike 3a-CS-YA-DE triple mutant , cells expressing single mutant proteins ( 3a-CS , 3a-DE and 3a-YA ) displayed more prominent nuclear condensation ( Fig. 2C ) .", "labels": [[26, 33, "SO"], [7, 33, "CELL_LINE"], [118, 128, "GO"], [7, 33, "ENTITY"], [26, 33, "PROTEIN"], [52, 66, "ENTITY"], [118, 136, "ENTITY"], [26, 33, "SO"], [118, 128, "CELLULAR_COMPONENT"]]}
{"text": "Consistent with the caspase inhibition results , we further showed that the activities of caspase-8 and -9 were significantly reduced in all 3a mutant expressing cells ( Fig. 2E and F ) .", "labels": [[28, 39, "ENTITY"], [0, 16, "ENTITY"], [141, 144, "SO"], [151, 162, "ENTITY"], [87, 104, "PROTEIN"], [141, 144, "ENTITY"], [151, 162, "CL"], [20, 28, "PROTEIN"], [20, 28, "GENE_OR_GENE_PRODUCT"], [168, 175, "CELL"], [39, 47, "ENTITY"], [151, 162, "CELL"], [20, 28, "ENTITY"]]}
{"text": "Consistent with the caspase inhibition results , we further showed that the activities of caspase-8 and -9 were significantly reduced in all 3a mutant expressing cells ( Fig. 2E and F ) .", "labels": [[28, 39, "ENTITY"], [0, 16, "ENTITY"], [141, 144, "SO"], [151, 162, "ENTITY"], [87, 104, "PROTEIN"], [141, 144, "ENTITY"], [151, 162, "CL"], [20, 28, "PROTEIN"], [20, 28, "GENE_OR_GENE_PRODUCT"], [168, 175, "CELL"], [39, 47, "ENTITY"], [151, 162, "CELL"], [20, 28, "ENTITY"]]}
{"text": "Nevertheless , we found that both 3a-WT ( Fig. 4 G ) and 3a mutants ( Fig. 4H \u2013 J ) caused disruption of external eye morphology by scanning electron microscopy .", "labels": [[34, 37, "SO"], [84, 91, "ENTITY"], [118, 150, "ENTITY"], [53, 60, "ENTITY"], [132, 141, "CHEBI"], [91, 105, "ENTITY"], [105, 118, "ENTITY"], [60, 75, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In contrast to 3a-WT , relatively few number of AO-positive cells were detected in 3a-CS , 3a-YA and 3a-DE mutant animals ( Fig. 5C \u2013 E ) .", "labels": [[122, 129, "CELL"], [107, 114, "ENTITY"], [48, 60, "CELL_TYPE"], [101, 114, "SO"], [101, 107, "ENTITY"], [48, 60, "ENTITY"]]}
{"text": "Notably , 3a-CS-EGFP-expressing cells displayed whole cell currents that were similar to that of mock transfected cells ( Fig. 6E ) , indicating the 3a-CS mutant protein lacks ion channel activity .", "labels": [[149, 162, "SO"], [97, 114, "CELL_LINE"], [170, 176, "CHEBI"], [149, 162, "ENTITY"], [32, 37, "ENTITY"], [10, 32, "CELL_LINE"], [97, 114, "ENTITY"], [120, 127, "CELL"]]}
{"text": "To this end , we substituted amino acids Cys-127 , Cys-130 , and Cys-133 within the cysteine-rich domain of the SARS-CoV 3a protein with serine to generate a lentivirus expressing the ion channel activity-loss mutant , 3a-CS ( Chan et al. , 2009 ; Figure 2A ) .", "labels": [[180, 188, "CHEBI"], [158, 169, "ENTITY"], [108, 124, "ENTITY"], [188, 196, "CHEMICAL"], [80, 98, "ENTITY"], [108, 124, "GGP"], [80, 98, "PROTEIN"], [108, 121, "ORGANISM"], [210, 219, "PROTEIN"], [29, 65, "PROTEIN"], [219, 227, "GENE_OR_GENE_PRODUCT"], [29, 41, "ENTITY"], [196, 210, "SO"], [29, 41, "CHEMICAL"], [84, 98, "SO"], [29, 35, "CHEBI"], [108, 124, "PROTEIN"], [180, 210, "PROTEIN"], [180, 210, "ENTITY"]]}
{"text": "Notably , the 3a-CS mutant completely abrogated IL-1\u03b2 secretion ( Figure 2B ) , suggesting that the ion channel activity of the 3a protein is required for SARS-CoV 3a-induced IL-1\u03b2 secretion .", "labels": [[14, 20, "ENTITY"], [48, 54, "ENTITY"], [64, 73, "ENTITY"], [14, 20, "SO"], [164, 175, "GGP"], [48, 54, "ENTITY"], [38, 48, "PROTEIN"], [10, 17, "CHEBI"], [10, 17, "PROTEIN"], [38, 48, "GGP"], [164, 175, "PROTEIN"], [151, 175, "ORGANISM"], [38, 48, "ENTITY"], [96, 104, "ENTITY"], [164, 175, "ENTITY"], [27, 38, "ENTITY"], [38, 48, "GENE_OR_GENE_PRODUCT"], [10, 17, "ENTITY"]]}
{"text": "Notably , 3a-CS-EGFP-expressing cells displayed whole cell currents that were similar to that of mock transfected cells ( Fig. 6E ) , indicating the 3a-CS mutant protein lacks ion channel activity .", "labels": [[149, 162, "SO"], [97, 114, "CELL_LINE"], [170, 176, "CHEBI"], [149, 162, "ENTITY"], [32, 37, "ENTITY"], [10, 32, "CELL_LINE"], [97, 114, "ENTITY"], [120, 127, "CELL"]]}
{"text": "Although cells expressing the ion channel activity-loss mutants 3a-CS or V25F uniformly expressed NLRP3 throughout the cytoplasm , it was redistributed to the perinuclear region in SARS-CoV 3a- or E-expressing cells ( Figure 4 ) .", "labels": [[119, 129, "ORGANISM_SUBSTANCE"], [181, 190, "PROTEIN"], [181, 190, "ENTITY"], [98, 104, "ENTITY"], [30, 56, "ENTITY"], [119, 129, "GO"], [159, 171, "GO"], [9, 15, "CELL"], [98, 104, "CHEMICAL"], [9, 15, "ENTITY"], [73, 78, "ENTITY"], [88, 98, "ENTITY"], [119, 129, "ENTITY"], [181, 190, "ORGANISM"], [98, 104, "GGP"], [197, 210, "CELL_LINE"], [98, 104, "PROTEIN"], [15, 26, "ENTITY"], [216, 225, "ENTITY"], [30, 64, "PROTEIN"], [159, 171, "ENTITY"], [98, 104, "GENE_OR_GENE_PRODUCT"], [30, 42, "CHEBI"], [197, 210, "ENTITY"], [9, 15, "CL"], [56, 64, "SO"], [42, 56, "CHEMICAL"]]}
{"text": "However , mutation M6 on cysteine 133 led to near abrogation of both dimers and tetramers of the protein , suggesting that this cysteine is involved in 3a protein polymerization .", "labels": [[152, 155, "CHEBI"], [149, 163, "ENTITY"], [25, 34, "ENTITY"]]}
{"text": "The 3a protein expression for both wild-type and M6 mutant was revealed on the oocyte cell membranes by anti-LH21 Ab and confocal microscopy ( Fig. 4 B and C ) .", "labels": [[104, 117, "ENTITY"], [52, 59, "SO"], [79, 101, "CL"], [121, 141, "ENTITY"], [86, 101, "ENTITY"], [79, 101, "CELL"], [79, 86, "ENTITY"], [104, 117, "PROTEIN"], [114, 117, "TAXON"], [15, 26, "ENTITY"], [7, 15, "CHEBI"], [35, 45, "ENTITY"], [52, 59, "ENTITY"], [4, 15, "ENTITY"]]}
{"text": "Expression of M6 mutant 3a protein , in contrast to expression of the native 3a protein , did not result in an increase of membrane current when extracellular potassium concentration was kept at 100 mM ; the current was similar to that of noninjected oocytes ( Fig. 4E ) .", "labels": [[70, 80, "SO"], [17, 24, "SO"], [159, 169, "ENTITY"], [14, 27, "GENE_OR_GENE_PRODUCT"], [251, 261, "CELL"], [145, 159, "ENTITY"], [14, 35, "ENTITY"], [0, 11, "ENTITY"], [239, 251, "CL"], [70, 80, "PROTEIN"], [236, 251, "CELL_TYPE"], [140, 159, "CELLULAR_COMPONENT"], [14, 35, "PROTEIN"], [239, 251, "ENTITY"], [145, 159, "CHEMICAL"], [70, 80, "ENTITY"], [239, 251, "TISSUE"], [27, 35, "CHEBI"], [140, 159, "GO"]]}
{"text": "It has previously been shown that the C133S point mutation ( Lu et al. , 2006 ) compromised 3a \u2019s ion channel activity .", "labels": [[44, 59, "SO"], [80, 102, "ENTITY"], [38, 59, "ENTITY"]]}
{"text": "Similarly , the plasma membrane localization of 3a-YA ( Fig. 1D and F ) and 3a-DE ( Fig. 1E and F ) mutants was partially reduced with a concomitant increase in cytoplasmic signals .", "labels": [[149, 173, "ENTITY"], [112, 122, "ENTITY"], [68, 72, "SO"], [16, 23, "GO"], [16, 23, "CELLULAR_COMPONENT"], [149, 161, "ORGANISM_SUBSTANCE"], [149, 161, "GO"], [68, 72, "ENTITY"], [130, 137, "ENTITY"], [137, 149, "ENTITY"]]}
{"text": "Unlike 3a-CS-YA-DE triple mutant , cells expressing single mutant proteins ( 3a-CS , 3a-DE and 3a-YA ) displayed more prominent nuclear condensation ( Fig. 2C ) .", "labels": [[26, 33, "SO"], [7, 33, "CELL_LINE"], [118, 128, "GO"], [7, 33, "ENTITY"], [26, 33, "PROTEIN"], [52, 66, "ENTITY"], [118, 136, "ENTITY"], [26, 33, "SO"], [118, 128, "CELLULAR_COMPONENT"]]}
{"text": "Consistent with the caspase inhibition results , we further showed that the activities of caspase-8 and -9 were significantly reduced in all 3a mutant expressing cells ( Fig. 2E and F ) .", "labels": [[28, 39, "ENTITY"], [0, 16, "ENTITY"], [141, 144, "SO"], [151, 162, "ENTITY"], [87, 104, "PROTEIN"], [141, 144, "ENTITY"], [151, 162, "CL"], [20, 28, "PROTEIN"], [20, 28, "GENE_OR_GENE_PRODUCT"], [168, 175, "CELL"], [39, 47, "ENTITY"], [151, 162, "CELL"], [20, 28, "ENTITY"]]}
{"text": "Consistent with the caspase inhibition results , we further showed that the activities of caspase-8 and -9 were significantly reduced in all 3a mutant expressing cells ( Fig. 2E and F ) .", "labels": [[28, 39, "ENTITY"], [0, 16, "ENTITY"], [141, 144, "SO"], [151, 162, "ENTITY"], [87, 104, "PROTEIN"], [141, 144, "ENTITY"], [151, 162, "CL"], [20, 28, "PROTEIN"], [20, 28, "GENE_OR_GENE_PRODUCT"], [168, 175, "CELL"], [39, 47, "ENTITY"], [151, 162, "CELL"], [20, 28, "ENTITY"]]}
{"text": "Nevertheless , we found that both 3a-WT ( Fig. 4 G ) and 3a mutants ( Fig. 4H \u2013 J ) caused disruption of external eye morphology by scanning electron microscopy .", "labels": [[34, 37, "SO"], [84, 91, "ENTITY"], [118, 150, "ENTITY"], [53, 60, "ENTITY"], [132, 141, "CHEBI"], [91, 105, "ENTITY"], [105, 118, "ENTITY"], [60, 75, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In contrast to 3a-WT , relatively few number of AO-positive cells were detected in 3a-CS , 3a-YA and 3a-DE mutant animals ( Fig. 5C \u2013 E ) .", "labels": [[122, 129, "CELL"], [107, 114, "ENTITY"], [48, 60, "CELL_TYPE"], [101, 114, "SO"], [101, 107, "ENTITY"], [48, 60, "ENTITY"]]}
{"text": "We also detected channel activities in 3a-YA-EGFP and 3a-DE-EGFP- expressing cells ( Fig. 6C and D ) , however , the activities were found to be different from that observed in 3a- WT-EGFP-expressing cells .", "labels": [[177, 200, "ENTITY"], [39, 50, "ENTITY"], [181, 200, "CL"], [77, 83, "CELL"], [17, 36, "ENTITY"], [174, 200, "CELL"], [8, 17, "ENTITY"], [85, 90, "GENE_OR_GENE_PRODUCT"], [54, 83, "ENTITY"], [174, 200, "CELL_LINE"], [77, 83, "CL"]]}
{"text": "We further found that addition of ion channel blocker barium chloride ( Ba ) altered the cell membrane current mediated by 3a-WT-EGFP , 3a-YA-EGFP and 3a-DE-EGFP proteins ( Fig. 6B \u2013 D ) .", "labels": [[54, 70, "CHEMICAL"], [147, 162, "ENTITY"], [85, 94, "GO"], [61, 70, "CHEBI"], [134, 162, "PROTEIN"], [34, 54, "CHEBI"], [85, 94, "CELLULAR_COMPONENT"], [34, 70, "ENTITY"], [151, 162, "CHEBI"], [85, 94, "ENTITY"]]}
{"text": "Previous studies demonstrated that the N-terminal 40 amino acids of the SARS-CoV E protein are important for ion channel formation , and that mutations N15A and V25F [ located in the transmembrane domain ( from amino acid residues 7\u201338 ) ] prevent ion conductivity ( Wilson et al. , 2004 ; Torres et al. , 2007 ; Verdia-Baguena et al. , 2012 ) .", "labels": [[206, 222, "ENTITY"], [109, 121, "CHEBI"], [206, 217, "CHEMICAL"], [252, 267, "DISEASE"], [109, 121, "ENTITY"], [72, 91, "GGP"], [206, 231, "AMINO_ACID"], [206, 222, "CHEBI"], [72, 91, "PROTEIN"], [240, 252, "ENTITY"], [179, 197, "PROTEIN"], [72, 91, "ENTITY"], [39, 65, "ENTITY"], [39, 65, "CHEMICAL"], [152, 157, "GENE_OR_GENE_PRODUCT"], [121, 131, "ENTITY"], [179, 197, "ENTITY"], [9, 17, "ENTITY"], [39, 65, "PROTEIN"], [179, 197, "GO"], [72, 83, "ORGANISM"], [53, 65, "CHEBI"]]}
{"text": "Previous studies demonstrated that the N-terminal 40 amino acids of the SARS-CoV E protein are important for ion channel formation , and that mutations N15A and V25F [ located in the transmembrane domain ( from amino acid residues 7\u201338 ) ] prevent ion conductivity ( Wilson et al. , 2004 ; Torres et al. , 2007 ; Verdia-Baguena et al. , 2012 ) .", "labels": [[206, 222, "ENTITY"], [109, 121, "CHEBI"], [206, 217, "CHEMICAL"], [252, 267, "DISEASE"], [109, 121, "ENTITY"], [72, 91, "GGP"], [206, 231, "AMINO_ACID"], [206, 222, "CHEBI"], [72, 91, "PROTEIN"], [240, 252, "ENTITY"], [179, 197, "PROTEIN"], [72, 91, "ENTITY"], [39, 65, "ENTITY"], [39, 65, "CHEMICAL"], [152, 157, "GENE_OR_GENE_PRODUCT"], [121, 131, "ENTITY"], [179, 197, "ENTITY"], [9, 17, "ENTITY"], [39, 65, "PROTEIN"], [179, 197, "GO"], [72, 83, "ORGANISM"], [53, 65, "CHEBI"]]}
{"text": "Previous studies demonstrated that the N-terminal 40 amino acids of the SARS-CoV E protein are important for ion channel formation , and that mutations N15A and V25F [ located in the transmembrane domain ( from amino acid residues 7\u201338 ) ] prevent ion conductivity ( Wilson et al. , 2004 ; Torres et al. , 2007 ; Verdia-Baguena et al. , 2012 ) .", "labels": [[206, 222, "ENTITY"], [109, 121, "CHEBI"], [206, 217, "CHEMICAL"], [252, 267, "DISEASE"], [109, 121, "ENTITY"], [72, 91, "GGP"], [206, 231, "AMINO_ACID"], [206, 222, "CHEBI"], [72, 91, "PROTEIN"], [240, 252, "ENTITY"], [179, 197, "PROTEIN"], [72, 91, "ENTITY"], [39, 65, "ENTITY"], [39, 65, "CHEMICAL"], [152, 157, "GENE_OR_GENE_PRODUCT"], [121, 131, "ENTITY"], [179, 197, "ENTITY"], [9, 17, "ENTITY"], [39, 65, "PROTEIN"], [179, 197, "GO"], [72, 83, "ORGANISM"], [53, 65, "CHEBI"]]}
{"text": "Although cells expressing the ion channel activity-loss mutants 3a-CS or V25F uniformly expressed NLRP3 throughout the cytoplasm , it was redistributed to the perinuclear region in SARS-CoV 3a- or E-expressing cells ( Figure 4 ) .", "labels": [[119, 129, "ORGANISM_SUBSTANCE"], [181, 190, "PROTEIN"], [181, 190, "ENTITY"], [98, 104, "ENTITY"], [30, 56, "ENTITY"], [119, 129, "GO"], [159, 171, "GO"], [9, 15, "CELL"], [98, 104, "CHEMICAL"], [9, 15, "ENTITY"], [73, 78, "ENTITY"], [88, 98, "ENTITY"], [119, 129, "ENTITY"], [181, 190, "ORGANISM"], [98, 104, "GGP"], [197, 210, "CELL_LINE"], [98, 104, "PROTEIN"], [15, 26, "ENTITY"], [216, 225, "ENTITY"], [30, 64, "PROTEIN"], [159, 171, "ENTITY"], [98, 104, "GENE_OR_GENE_PRODUCT"], [30, 42, "CHEBI"], [197, 210, "ENTITY"], [9, 15, "CL"], [56, 64, "SO"], [42, 56, "CHEMICAL"]]}
{"text": "Accessory proteins 8b and 8ab of SARS-CoV can suppress the INF-\u03b2 signaling pathway ( and thus interferon production ) by their participation in the ubiquitin-mediated rapid degradation of INF regulatory factor 3 ( IRF3 ) ( Wong et al. , 2018 ) .", "labels": [[59, 65, "ENTITY"], [33, 42, "ORGANISM"], [59, 65, "PROTEIN"], [26, 30, "GENE_OR_GENE_PRODUCT"], [26, 30, "PROTEIN"], [188, 210, "ENTITY"], [46, 55, "ENTITY"], [167, 173, "ENTITY"], [26, 30, "ENTITY"], [185, 210, "PROTEIN"], [33, 42, "PROTEIN"], [65, 83, "ENTITY"], [0, 22, "PROTEIN"], [33, 42, "ENTITY"], [185, 210, "GENE_OR_GENE_PRODUCT"], [94, 105, "ENTITY"], [10, 19, "CHEBI"], [59, 65, "GENE_OR_GENE_PRODUCT"], [0, 22, "GENE_OR_GENE_PRODUCT"], [33, 42, "GGP"], [185, 210, "GGP"], [0, 22, "ENTITY"]]}
{"text": "Accessory proteins 8b and 8ab of SARS-CoV can suppress the INF-\u03b2 signaling pathway ( and thus interferon production ) by their participation in the ubiquitin-mediated rapid degradation of INF regulatory factor 3 ( IRF3 ) ( Wong et al. , 2018 ) .", "labels": [[33, 42, "GGP"], [59, 65, "ENTITY"], [33, 42, "ORGANISM"], [59, 65, "PROTEIN"], [26, 30, "GENE_OR_GENE_PRODUCT"], [26, 30, "PROTEIN"], [188, 210, "ENTITY"], [46, 55, "ENTITY"], [167, 173, "ENTITY"], [26, 30, "ENTITY"], [185, 210, "PROTEIN"], [33, 42, "ENTITY"], [0, 22, "PROTEIN"], [65, 83, "ENTITY"], [33, 42, "PROTEIN"], [185, 210, "GENE_OR_GENE_PRODUCT"], [94, 105, "ENTITY"], [10, 19, "CHEBI"], [59, 65, "GENE_OR_GENE_PRODUCT"], [0, 22, "GENE_OR_GENE_PRODUCT"], [185, 210, "GGP"], [0, 22, "ENTITY"]]}
{"text": "Several studies revealed that CoV implements some strategies to evade the immune response by antagonizing the arms of IFN signaling pathway (32).In this regard , Frieman et al. indicated that SARS-CoV ORF6 protein blocks the expression of STAT1-activated genes and finally acts as an IFN antagonist ( 33 ) .", "labels": [[118, 122, "ENTITY"], [118, 122, "GGP"], [192, 206, "PROTEIN"], [8, 16, "ENTITY"], [118, 122, "GENE_OR_GENE_PRODUCT"], [239, 255, "SO"], [30, 34, "PROTEIN"], [192, 214, "ENTITY"], [239, 255, "DNA"], [74, 90, "ENTITY"], [192, 206, "GGP"], [192, 201, "ORGANISM"], [118, 122, "GGP"], [118, 122, "PROTEIN"], [140, 148, "GENE_OR_GENE_PRODUCT"], [118, 140, "ENTITY"], [239, 255, "ENTITY"], [30, 34, "ENTITY"]]}
{"text": "As mentioned above , SARS-CoV ORF6 protein antagonizes the function of STAT1 .", "labels": [[21, 30, "ORGANISM"], [21, 35, "GGP"], [21, 35, "ENTITY"], [21, 35, "PROTEIN"]]}
{"text": "Several studies revealed that CoV implements some strategies to evade the immune response by antagonizing the arms of IFN signaling pathway (32).In this regard , Frieman et al. indicated that SARS-CoV ORF6 protein blocks the expression of STAT1-activated genes and finally acts as an IFN antagonist ( 33 ) .", "labels": [[118, 122, "ENTITY"], [239, 255, "SO"], [118, 122, "GGP"], [192, 206, "PROTEIN"], [118, 140, "ENTITY"], [8, 16, "ENTITY"], [118, 122, "GENE_OR_GENE_PRODUCT"], [239, 255, "ENTITY"], [192, 214, "ENTITY"], [30, 34, "PROTEIN"], [239, 255, "DNA"], [74, 90, "ENTITY"], [192, 201, "ORGANISM"], [118, 122, "GGP"], [118, 122, "PROTEIN"], [140, 148, "GENE_OR_GENE_PRODUCT"], [192, 206, "GGP"], [30, 34, "ENTITY"]]}
{"text": "We previously demonstrated that the influenza virus M2 protein ( a proton-selective ion channel ) , its H37 G mutant ( which has lost its proton selectivity and enables the transport of other cations such as Na + and K + ) , and the EMCV 2B protein ( a Ca 2 + channel ) stimulates NLRP3 inflammasome-mediated IL-1\u03b2 secretion ( Ichinohe et al. , 2010 ; Ito et al. , 2012 ) .", "labels": [[241, 260, "PROTEIN"], [200, 208, "SIMPLE_CHEMICAL"], [46, 52, "TAXON"], [233, 241, "CHEBI"], [67, 88, "ENTITY"], [55, 63, "CHEBI"], [88, 98, "ENTITY"], [200, 208, "ENTITY"], [100, 110, "ENTITY"], [104, 110, "SO"], [225, 241, "ENTITY"], [36, 63, "PROTEIN"], [225, 233, "ORGANISM"], [67, 88, "PROTEIN"], [100, 110, "PROTEIN"], [200, 213, "PROTEIN"], [55, 63, "CHEMICAL"], [270, 287, "ENTITY"], [225, 241, "PROTEIN"], [200, 208, "CHEBI"], [36, 63, "ENTITY"], [287, 315, "ENTITY"], [241, 260, "ENTITY"], [134, 145, "ENTITY"]]}
{"text": "We previously demonstrated that the influenza virus M2 protein ( a proton-selective ion channel ) , its H37 G mutant ( which has lost its proton selectivity and enables the transport of other cations such as Na + and K + ) , and the EMCV 2B protein ( a Ca 2 + channel ) stimulates NLRP3 inflammasome-mediated IL-1\u03b2 secretion ( Ichinohe et al. , 2010 ; Ito et al. , 2012 ) .", "labels": [[241, 260, "PROTEIN"], [200, 208, "SIMPLE_CHEMICAL"], [233, 241, "CHEBI"], [67, 88, "ENTITY"], [55, 63, "CHEBI"], [88, 98, "ENTITY"], [200, 208, "ENTITY"], [100, 110, "ENTITY"], [104, 110, "SO"], [225, 241, "ENTITY"], [36, 63, "PROTEIN"], [225, 233, "ORGANISM"], [67, 88, "PROTEIN"], [100, 110, "PROTEIN"], [46, 52, "TAXON"], [200, 213, "PROTEIN"], [55, 63, "CHEMICAL"], [270, 287, "ENTITY"], [225, 241, "PROTEIN"], [200, 208, "CHEBI"], [36, 63, "ENTITY"], [287, 315, "ENTITY"], [241, 260, "ENTITY"], [134, 145, "ENTITY"]]}
{"text": "IL-1\u03b2 was released from LPS-primed BMMs transduced with the M2- and 2B-expressing lentivirus ( Figure 1D ) . Similarly , the lentiviruses expressing the SARS-CoV E or 3a proteins stimulated IL-1\u03b2 release from LPS-primed BMMs ( Figure 1D ) .", "labels": [[125, 138, "ENTITY"], [82, 93, "TAXON"], [24, 40, "CELL_LINE"], [82, 93, "ENTITY"], [19, 35, "CELL_LINE"], [82, 93, "ORGANISM"], [35, 40, "CELL"], [164, 170, "ENTITY"], [0, 6, "GENE_OR_GENE_PRODUCT"], [95, 102, "ENTITY"], [0, 6, "CHEMICAL"], [0, 6, "PROTEIN"], [0, 6, "ENTITY"], [179, 190, "GENE_OR_GENE_PRODUCT"], [0, 6, "GGP"], [220, 227, "ENTITY"], [60, 64, "CHEMICAL"], [179, 190, "GGP"], [60, 64, "GENE_OR_GENE_PRODUCT"], [170, 179, "ENTITY"], [0, 6, "ENTITY"], [10, 19, "ENTITY"], [60, 64, "ENTITY"], [24, 35, "ENTITY"], [167, 170, "CHEBI"], [24, 35, "CELL"], [24, 35, "ENTITY"], [40, 51, "ENTITY"], [179, 190, "PROTEIN"], [149, 162, "ORGANISM"], [35, 40, "ENTITY"], [149, 170, "PROTEIN"], [179, 190, "ENTITY"], [24, 35, "TAXON"]]}
{"text": "Accessory proteins 8b and 8ab of SARS-CoV can suppress the INF-\u03b2 signaling pathway ( and thus interferon production ) by their participation in the ubiquitin-mediated rapid degradation of INF regulatory factor 3 ( IRF3 ) ( Wong et al. , 2018 ) .", "labels": [[59, 65, "ENTITY"], [33, 42, "ORGANISM"], [59, 65, "PROTEIN"], [26, 30, "GENE_OR_GENE_PRODUCT"], [26, 30, "PROTEIN"], [188, 210, "ENTITY"], [46, 55, "ENTITY"], [167, 173, "ENTITY"], [26, 30, "ENTITY"], [185, 210, "PROTEIN"], [33, 42, "PROTEIN"], [65, 83, "ENTITY"], [0, 22, "PROTEIN"], [33, 42, "ENTITY"], [185, 210, "GENE_OR_GENE_PRODUCT"], [94, 105, "ENTITY"], [10, 19, "CHEBI"], [59, 65, "GENE_OR_GENE_PRODUCT"], [0, 22, "GENE_OR_GENE_PRODUCT"], [33, 42, "GGP"], [185, 210, "GGP"], [0, 22, "ENTITY"]]}
{"text": "Particularly , ORF3 and ORF8 in SARS-CoV-2 are highly divergent from ORF3a and ORF8b in SARS-CoV that are known to induce NLRP3 inflammasome activation .", "labels": []}
{"text": "Accessory proteins 8b and 8ab of SARS-CoV can suppress the INF-\u03b2 signaling pathway ( and thus interferon production ) by their participation in the ubiquitin-mediated rapid degradation of INF regulatory factor 3 ( IRF3 ) ( Wong et al. , 2018 ) .", "labels": [[33, 42, "GGP"], [59, 65, "ENTITY"], [33, 42, "ORGANISM"], [59, 65, "PROTEIN"], [26, 30, "GENE_OR_GENE_PRODUCT"], [26, 30, "PROTEIN"], [188, 210, "ENTITY"], [46, 55, "ENTITY"], [167, 173, "ENTITY"], [26, 30, "ENTITY"], [185, 210, "PROTEIN"], [33, 42, "ENTITY"], [0, 22, "PROTEIN"], [65, 83, "ENTITY"], [33, 42, "PROTEIN"], [185, 210, "GENE_OR_GENE_PRODUCT"], [94, 105, "ENTITY"], [10, 19, "CHEBI"], [59, 65, "GENE_OR_GENE_PRODUCT"], [0, 22, "GENE_OR_GENE_PRODUCT"], [185, 210, "GGP"], [0, 22, "ENTITY"]]}
{"text": "A study involving MERS-CoV described that ORF 8b strongly antagonizes the INF-beta ( \u03b2 ) promoter and ORF4b and 8b significantly suppress IFN induction ( Lee et al. , 2019b ) .", "labels": [[129, 138, "ENTITY"], [74, 83, "ENTITY"], [74, 83, "GENE_OR_GENE_PRODUCT"], [74, 89, "DNA"], [129, 138, "GENE_OR_GENE_PRODUCT"], [18, 27, "GGP"], [58, 70, "ENTITY"], [18, 27, "PROTEIN"], [42, 49, "ENTITY"], [2, 8, "ENTITY"], [42, 49, "PROTEIN"], [115, 129, "ENTITY"], [129, 138, "CHEMICAL"], [42, 46, "SO"], [138, 142, "ENTITY"], [129, 138, "PROTEIN"], [18, 27, "ENTITY"], [129, 138, "GGP"]]}
{"text": "A study involving MERS-CoV described that ORF 8b strongly antagonizes the INF-beta ( \u03b2 ) promoter and ORF4b and 8b significantly suppress IFN induction ( Lee et al. , 2019b ) .", "labels": [[138, 142, "ENTITY"], [74, 83, "ENTITY"], [74, 83, "GENE_OR_GENE_PRODUCT"], [74, 89, "DNA"], [18, 27, "GGP"], [129, 138, "GENE_OR_GENE_PRODUCT"], [18, 27, "PROTEIN"], [58, 70, "ENTITY"], [42, 49, "ENTITY"], [2, 8, "ENTITY"], [42, 49, "PROTEIN"], [115, 129, "ENTITY"], [18, 27, "ENTITY"], [42, 46, "SO"], [129, 138, "CHEMICAL"], [129, 138, "PROTEIN"], [129, 138, "ENTITY"], [129, 138, "GGP"]]}
{"text": "In contrast , when we focused on MERS-CoV from bats and camels , ORF 8b antagonized melanoma differentiation-associated protein 5-mediated nuclear factor kappa B ( NF-\u03baB ) activation .", "labels": [[84, 160, "ENTITY"], [69, 72, "ENTITY"], [72, 84, "ENTITY"], [128, 139, "GO"], [72, 84, "CANCER"], [72, 160, "PROTEIN"], [63, 69, "PROTEIN"], [72, 84, "DISEASE"], [164, 172, "ENTITY"], [93, 120, "CHEBI"], [63, 69, "ENTITY"]]}
{"text": "ORF 8b strongly inhibited TANK-binding kinase 1-mediated induction of NF-\u03baB signaling , but not I\u03baB kinase epsilon and IRF3-mediated activations ( Lee et al. , 2019a ) .", "labels": [[70, 86, "ENTITY"], [0, 4, "SO"], [26, 46, "PROTEIN"], [96, 107, "PROTEIN"], [26, 57, "ENTITY"], [70, 76, "GENE_OR_GENE_PRODUCT"], [70, 76, "CHEMICAL"], [26, 57, "GGP"], [70, 76, "DNA"], [57, 67, "ENTITY"], [0, 7, "PROTEIN"], [0, 7, "ENTITY"], [16, 26, "ENTITY"], [96, 107, "ENTITY"], [26, 57, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Similarly , the existence of 29 nucleotide deletions in ORF 8b has been described in SARS-CoV ( Oostra et al. , 2007 ) .", "labels": [[32, 43, "ENTITY"], [32, 43, "SO"], [29, 43, "DNA"], [56, 60, "ENTITY"], [56, 60, "DNA"]]}
{"text": "Strikingly , LY6E significantly inhibited VSVpp entry mediated by S proteins from HCoV-229E ( Fig. 2a ) , MERS-CoV ( Fig. 2b ) , SARS-CoV ( Fig. 2c ) , and SARS-CoV-2 ( 2c), and SARS-CoV-2 ) .", "labels": [[0, 11, "ENTITY"], [145, 156, "CHEMICAL"], [122, 129, "GGP"], [122, 129, "PROTEIN"], [122, 129, "ORGANISM"], [122, 129, "ENTITY"], [145, 156, "ENTITY"], [145, 156, "GENE_OR_GENE_PRODUCT"]]}
{"text": "LY6E potently inhibited CoV S protein-mediated syncytia formation ( Fig. 2e-f ) .", "labels": [[30, 56, "ENTITY"], [0, 5, "ENTITY"], [5, 14, "ENTITY"], [24, 30, "ENTITY"], [14, 24, "ENTITY"], [68, 73, "SIMPLE_CHEMICAL"], [0, 5, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [24, 56, "ORGANISM"], [24, 30, "PROTEIN"]]}
{"text": "Moreover , the frequencies of regulatory T cells ( the frequencies of regulatory T cells ) ( CD4+CD25+CD127low+ ) and CD45RA+the frequencies of regulatory T cells were reduced ( below LLN ) in nearly all the severe and moderate cases , with CD45RA+the frequencies of regulatory T cells proportion was markedly lower in severe cases ( 0.5 % ) than in moderate cases ( 1.1 % ) .", "labels": [[30, 43, "CL"], [15, 30, "PROTEIN"], [43, 49, "ENTITY"], [-1, 10, "ENTITY"], [15, 30, "GENE_OR_GENE_PRODUCT"], [30, 43, "ENTITY"], [114, 129, "ENTITY"], [30, 43, "ENTITY"], [-1, 5, "CELL"], [-1, 11, "ENTITY"], [155, 164, "ENTITY"], [-1, 11, "PROTEIN"], [15, 30, "ENTITY"], [15, 30, "ENTITY"], [104, 114, "ENTITY"], [-1, 5, "ENTITY"], [30, 43, "CELL_TYPE"], [-1, 11, "GENE_OR_GENE_PRODUCT"], [104, 114, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The FI values for proteins S1 , S2 , S3 , S4 , S5 , 3a , N and 9b to sera from SARS patients were statistically significantly more than those from healthy people ( P < 0.01 , using SPSS 10.0 software ) ( Fig. 2 ) , but the FI values for proteins E , M , 3b , 6 and 7a to sera from SARS patients had no significant difference with those from healthy people ( P > 0.05 ) .", "labels": [[69, 74, "ENTITY"], [265, 271, "ENTITY"], [69, 74, "ORGANISM"], [79, 84, "ORGANISM"], [173, 191, "ENTITY"], [18, 27, "CHEBI"], [7, 14, "ENTITY"], [63, 66, "ENTITY"], [7, 14, "ENTITY"], [325, 341, "ENTITY"], [136, 147, "ORGANISM"], [147, 155, "ORGANISM"], [42, 45, "ENTITY"], [63, 66, "ORGANISM_SUBSTANCE"], [79, 84, "ENTITY"], [4, 7, "ENTITY"], [281, 299, "ENTITY"], [7, 14, "CHEBI"], [265, 271, "DISEASE"], [93, 112, "ENTITY"], [142, 155, "ENTITY"], [18, 30, "ENTITY"]]}
{"text": "Both anti-N and anti-S3 anti-bodies were positive in all the serum samples , whereas anti-3a and anti-9b antibodies were only positive in part of these samples .", "labels": [[16, 36, "PROTEIN"], [5, 12, "ENTITY"], [61, 75, "ENTITY"], [41, 50, "ENTITY"], [16, 36, "ENTITY"], [97, 105, "PROTEIN"], [5, 12, "GENE_OR_GENE_PRODUCT"], [61, 75, "ORGANISM_SUBSTANCE"], [97, 105, "GENE_OR_GENE_PRODUCT"], [16, 24, "GENE_OR_GENE_PRODUCT"]]}
{"text": "As Fig. 4 shows , anti-N and anti-S3 antibodies persisted until week 30 ; their levels rapidly increased from weeks 2 to 4 , and decreased from weeks 20 to 30 .", "labels": [[3, 10, "SIMPLE_CHEMICAL"], [87, 95, "ENTITY"], [29, 37, "GENE_OR_GENE_PRODUCT"], [29, 37, "PROTEIN"], [29, 37, "ENTITY"]]}
{"text": "As Fig. 4 shows , anti-N and anti-S3 antibodies persisted until week 30 ; their levels rapidly increased from weeks 2 to 4 , and decreased from weeks 20 to 30 .", "labels": [[3, 10, "SIMPLE_CHEMICAL"], [87, 95, "ENTITY"], [29, 37, "GENE_OR_GENE_PRODUCT"], [29, 37, "PROTEIN"], [29, 37, "ENTITY"]]}
{"text": "Anti-S3 serum showed significant neutralizing activity to the SARS-CoV infection , with a neutralizing antibody titer of 708 , whereas the other antisera and control serum from non-immunized rabbit lacked neutralizing antibodies ( Table 2 ) .", "labels": [[62, 81, "DISEASE"], [0, 14, "GENE_OR_GENE_PRODUCT"], [62, 71, "ORGANISM"], [154, 166, "ENTITY"], [33, 55, "ENTITY"], [177, 191, "ORGANISM"], [172, 191, "ENTITY"], [0, 14, "ENTITY"], [62, 81, "ENTITY"], [177, 191, "TAXON"], [158, 166, "ORGANISM_SUBSTANCE"], [33, 46, "ENTITY"], [198, 218, "ENTITY"], [33, 46, "GO"]]}
{"text": "All 6 infants had antibodies detected in their serum .", "labels": [[18, 29, "PROTEIN"], [47, 53, "ENTITY"], [6, 14, "ORGANISM"], [18, 29, "ENTITY"], [47, 53, "ORGANISM_SUBSTANCE"], [29, 38, "ENTITY"], [18, 29, "GO"], [6, 14, "ENTITY"]]}
{"text": "For the longitudinal tracking of the characteristics each monkey , the specific antibody against SARS-CoV-2 of M2 , M3 and M4 monkey was significantly elevated at 14 dpi or 21 dpi and 28 dpi compared to that at 3 dpi and 7dpi ( * P<0.05 , * * P<0.01 , Figure 2 g ) .", "labels": [[230, 243, "PROTEIN"], [243, 252, "ENTITY"], [243, 252, "GENE_OR_GENE_PRODUCT"], [37, 53, "ENTITY"], [119, 126, "ENTITY"], [97, 111, "ENTITY"], [8, 30, "ENTITY"], [58, 65, "TAXON"], [111, 116, "GENE_OR_GENE_PRODUCT"], [58, 65, "ENTITY"], [137, 151, "ENTITY"]]}
{"text": "Increased antibody-secreting cells (ASCs),follicular helper T cells ( TFH cells ) , activated CD4 + T cells and CD8 + T cells and immunoglobulin M ( IgM ) and IgG antibodies that bound the COVID-19- causing coronavirus SARS-CoV-2 were detected in blood before symptomatic recovery .", "labels": [[84, 102, "GGP"], [235, 244, "ENTITY"], [70, 74, "ENTITY"], [0, 10, "ENTITY"], [53, 68, "CELL_TYPE"], [153, 163, "PROTEIN"], [70, 74, "CELL"], [53, 68, "ENTITY"], [84, 102, "ENTITY"], [60, 68, "CL"], [29, 35, "CL"], [70, 74, "CELL_TYPE"], [207, 219, "CHEMICAL"], [199, 219, "ENTITY"], [235, 244, "ORGANISM_SUBSTANCE"], [219, 235, "ENTITY"], [10, 35, "ENTITY"], [153, 163, "ENTITY"], [179, 189, "PROTEIN"], [108, 120, "CELL_TYPE"], [10, 35, "CELL"], [179, 189, "ENTITY"], [199, 219, "ORGANISM"], [163, 174, "ENTITY"], [155, 163, "GO"], [260, 272, "ENTITY"], [84, 94, "GENE_OR_GENE_PRODUCT"], [179, 189, "GENE_OR_GENE_PRODUCT"], [130, 147, "ENTITY"], [10, 35, "CELL_TYPE"], [130, 147, "PROTEIN"], [153, 163, "GENE_OR_GENE_PRODUCT"], [108, 120, "ENTITY"], [108, 120, "GGP"], [82, 102, "CELL_TYPE"], [130, 147, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Global proteomic and microarray analyses have shown that the expression of several genes related to the ER stress , such as glucose-regulated protein 94 ( GRP94 ) and glucose-regulated protein 78(GRP78 , also known as immunoglobulin heavy chain-binding protein , or BiP ) , is up-regulated in cells infected with SARS-CoV or in cells overexpressing the SARS-CoV S2 subunit ( Jiang et al. , 2005;Yeung et al. , 2008 ) . Using a luciferase reporter system , Chan et al. ( 2006 ) found that both GRP94 and GRP78 were induced in SARS-CoV-infected FRhK4 cells .", "labels": [[415, 438, "ENTITY"], [83, 89, "ENTITY"], [124, 150, "GENE_OR_GENE_PRODUCT"], [509, 525, "ENTITY"], [61, 72, "ENTITY"], [509, 525, "CELL_LINE"], [334, 365, "ORGANISM"], [334, 365, "ENTITY"], [104, 107, "PROTEIN"], [415, 425, "GENE_OR_GENE_PRODUCT"], [21, 41, "ENTITY"], [415, 427, "DNA"], [124, 142, "GGP"], [477, 483, "GGP"], [215, 253, "GGP"], [163, 185, "ENTITY"], [163, 185, "GGP"], [215, 253, "PROTEIN"], [438, 447, "GENE_OR_GENE_PRODUCT"], [215, 253, "ENTITY"], [277, 290, "CL"], [334, 365, "PROTEIN"], [277, 290, "CELL"], [299, 313, "GGP"], [334, 365, "GGP"], [299, 313, "ENTITY"], [270, 277, "ENTITY"], [104, 107, "GENE_OR_GENE_PRODUCT"], [477, 483, "GENE_OR_GENE_PRODUCT"], [163, 193, "PROTEIN"], [124, 150, "PROTEIN"], [293, 299, "ENTITY"], [293, 299, "ENTITY"], [104, 114, "ENTITY"], [477, 483, "PROTEIN"], [124, 150, "ENTITY"], [277, 290, "ENTITY"], [477, 483, "ENTITY"], [299, 313, "PROTEIN"], [7, 17, "ENTITY"], [215, 239, "GENE_OR_GENE_PRODUCT"], [0, 7, "ENTITY"], [83, 89, "SO"], [299, 313, "ORGANISM"]]}
{"text": "Global proteomic and microarray analyses have shown that the expression of several genes related to the ER stress , such as glucose-regulated protein 94 ( GRP94 ) and glucose-regulated protein 78(GRP78 , also known as immunoglobulin heavy chain-binding protein , or BiP ) , is up-regulated in cells infected with SARS-CoV or in cells overexpressing the SARS-CoV S2 subunit ( Jiang et al. , 2005;Yeung et al. , 2008 ) . Using a luciferase reporter system , Chan et al. ( 2006 ) found that both GRP94 and GRP78 were induced in SARS-CoV-infected FRhK4 cells .", "labels": [[415, 438, "ENTITY"], [83, 89, "ENTITY"], [124, 150, "GENE_OR_GENE_PRODUCT"], [509, 525, "ENTITY"], [61, 72, "ENTITY"], [509, 525, "CELL_LINE"], [104, 114, "ENTITY"], [334, 365, "ORGANISM"], [334, 365, "ENTITY"], [104, 107, "PROTEIN"], [415, 425, "GENE_OR_GENE_PRODUCT"], [21, 41, "ENTITY"], [415, 427, "DNA"], [124, 142, "GGP"], [477, 483, "GGP"], [215, 253, "GGP"], [163, 185, "ENTITY"], [163, 185, "GGP"], [215, 253, "PROTEIN"], [438, 447, "GENE_OR_GENE_PRODUCT"], [215, 253, "ENTITY"], [277, 290, "CL"], [334, 365, "PROTEIN"], [277, 290, "CELL"], [299, 313, "GGP"], [334, 365, "GGP"], [299, 313, "ENTITY"], [270, 277, "ENTITY"], [104, 107, "GENE_OR_GENE_PRODUCT"], [477, 483, "GENE_OR_GENE_PRODUCT"], [163, 193, "PROTEIN"], [124, 150, "PROTEIN"], [293, 299, "ENTITY"], [293, 299, "ENTITY"], [477, 483, "PROTEIN"], [124, 150, "ENTITY"], [277, 290, "ENTITY"], [477, 483, "ENTITY"], [299, 313, "PROTEIN"], [7, 17, "ENTITY"], [215, 239, "GENE_OR_GENE_PRODUCT"], [0, 7, "ENTITY"], [83, 89, "SO"], [299, 313, "ORGANISM"]]}
{"text": "Global proteomic and microarray analyses have shown that the expression of several genes related to the ER stress , such as glucose-regulated protein 94 ( GRP94 ) and glucose-regulated protein 78(GRP78 , also known as immunoglobulin heavy chain-binding protein , or BiP ) , is up-regulated in cells infected with SARS-CoV or in cells overexpressing the SARS-CoV S2 subunit ( Jiang et al. , 2005;Yeung et al. , 2008 ) . Using a luciferase reporter system , Chan et al. ( 2006 ) found that both GRP94 and GRP78 were induced in SARS-CoV-infected FRhK4 cells .", "labels": [[415, 438, "ENTITY"], [83, 89, "ENTITY"], [124, 150, "GENE_OR_GENE_PRODUCT"], [509, 525, "ENTITY"], [61, 72, "ENTITY"], [509, 525, "CELL_LINE"], [104, 114, "ENTITY"], [334, 365, "ORGANISM"], [334, 365, "ENTITY"], [104, 107, "PROTEIN"], [415, 425, "GENE_OR_GENE_PRODUCT"], [21, 41, "ENTITY"], [415, 427, "DNA"], [124, 142, "GGP"], [477, 483, "GGP"], [215, 253, "GGP"], [163, 185, "ENTITY"], [163, 185, "GGP"], [215, 253, "PROTEIN"], [438, 447, "GENE_OR_GENE_PRODUCT"], [215, 253, "ENTITY"], [277, 290, "CL"], [334, 365, "PROTEIN"], [277, 290, "CELL"], [299, 313, "GGP"], [334, 365, "GGP"], [299, 313, "ENTITY"], [270, 277, "ENTITY"], [104, 107, "GENE_OR_GENE_PRODUCT"], [477, 483, "GENE_OR_GENE_PRODUCT"], [163, 193, "PROTEIN"], [124, 150, "PROTEIN"], [293, 299, "ENTITY"], [293, 299, "ENTITY"], [477, 483, "PROTEIN"], [124, 150, "ENTITY"], [277, 290, "ENTITY"], [477, 483, "ENTITY"], [299, 313, "PROTEIN"], [7, 17, "ENTITY"], [215, 239, "GENE_OR_GENE_PRODUCT"], [0, 7, "ENTITY"], [83, 89, "SO"], [299, 313, "ORGANISM"]]}
{"text": "Consistently , the mRNA level of homocysteine-inducible , ER stress-inducible , ubiquitin-like domain member 1 ( HERPUD1 ) , an ER stress marker , was up-regulated in L cells infected with mouse hepatitis virus ( MHV ) or SARS-CoV ( Versteeg et al. , 2007 ) .", "labels": [[0, 13, "ENTITY"], [175, 195, "ORGANISM"], [151, 167, "CL"], [213, 219, "ORGANISM"], [151, 167, "CELL"], [175, 184, "TAXON"], [167, 175, "ENTITY"], [175, 195, "ENTITY"], [58, 61, "ENTITY"], [213, 219, "GGP"], [61, 102, "ENTITY"], [184, 195, "DISEASE"], [151, 167, "CELL_TYPE"], [121, 138, "PROTEIN"], [213, 219, "PROTEIN"], [61, 102, "PROTEIN"], [213, 219, "ENTITY"], [121, 138, "ENTITY"], [138, 151, "ENTITY"], [151, 167, "ENTITY"], [80, 95, "SO"]]}
{"text": "Also , co-localization has been observed between SARS-CoV non-structural proteins and protein disulfide isomerase ( PDI ) , an ER marker ( Snijder et al. , 2006 ) .", "labels": [[58, 73, "ENTITY"], [86, 104, "GENE_OR_GENE_PRODUCT"], [49, 58, "ORGANISM"], [124, 130, "PROTEIN"], [86, 104, "ENTITY"], [124, 130, "ENTITY"], [86, 104, "GGP"], [49, 73, "PROTEIN"], [86, 104, "PROTEIN"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[50, 56, "ENTITY"], [257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [50, 56, "DISEASE"], [76, 89, "DISEASE"], [257, 271, "ENTITY"], [28, 37, "ENTITY"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "Fever was present in 43.8 % of the patients on admission but developed in 88.7 % during hospitalization .", "labels": [[0, 6, "DISEASE"], [0, 6, "ENTITY"]]}
{"text": "The most common symptoms on admission were fever and cough , followed by sputum production and fatigue ( table 1 ) .", "labels": [[28, 38, "ENTITY"], [43, 49, "DISEASE"], [53, 59, "ENTITY"], [43, 49, "ENTITY"], [73, 80, "ENTITY"], [53, 59, "DISEASE"], [16, 25, "ENTITY"]]}
{"text": "The clinical features include fever , dry cough , shortness of breath , normal or low levels of peripheral white blood cells , and inflammatory changes on chest X-ray .", "labels": [[48, 63, "ENTITY"], [38, 42, "ENTITY"], [107, 119, "CELL"], [4, 22, "ENTITY"], [107, 119, "CL"], [82, 86, "ENTITY"], [127, 144, "ENTITY"], [30, 36, "ENTITY"], [38, 42, "DISEASE"], [48, 63, "DISEASE"], [152, 161, "ENTITY"], [93, 119, "ENTITY"], [93, 119, "CELL_TYPE"], [30, 36, "DISEASE"]]}
{"text": "Most patients presented cough and fever ( mainly low fever , temperature ranges from 37.3 to 38.0 ) ( Table 1 ) . Four patients had the symptom of productive cough ( white phlegm ) and sore throat . Three patients reported headache and nausea . One patient only existed chest congestion ( patient 7 ) .", "labels": [[214, 223, "ENTITY"], [172, 185, "ENTITY"], [24, 30, "ENTITY"], [236, 245, "ENTITY"], [5, 14, "ENTITY"], [128, 136, "ENTITY"], [61, 73, "ENTITY"], [136, 158, "ENTITY"], [276, 287, "ORGANISM"], [197, 205, "ENTITY"], [223, 232, "DISEASE"], [147, 158, "DISEASE"], [158, 172, "ENTITY"], [172, 185, "DISEASE"], [223, 232, "ENTITY"], [158, 172, "DISEASE"], [49, 53, "ENTITY"], [34, 40, "ENTITY"], [24, 30, "DISEASE"], [5, 14, "ORGANISM"], [34, 40, "DISEASE"], [257, 276, "ENTITY"], [214, 223, "DISEASE"], [197, 205, "ORGANISM"], [236, 245, "ORGANISM"], [257, 276, "DISEASE"]]}
{"text": "Most COVID-19 patients initially suffered from fever , cough , fatigue , and shortness of breath , while other symptoms included muscle pain , headache , chest pain , and diarrhea , similar to the symptoms observed after chemotherapy , targeted and immune therapy1", "labels": [[73, 90, "ENTITY"], [47, 53, "ENTITY"], [143, 154, "DISEASE"], [120, 136, "DISEASE"], [120, 136, "ENTITY"], [206, 221, "ENTITY"], [14, 23, "ENTITY"], [47, 53, "DISEASE"], [5, 14, "ENTITY"], [5, 23, "ORGANISM"], [236, 256, "CELL"], [5, 14, "DISEASE"], [73, 90, "DISEASE"], [143, 154, "ORGAN"], [221, 236, "ENTITY"], [236, 256, "ENTITY"], [71, 77, "ENTITY"], [190, 197, "ENTITY"], [111, 120, "ENTITY"], [136, 143, "ENTITY"], [136, 143, "DISEASE"], [120, 129, "ORGAN"], [143, 154, "ENTITY"], [71, 77, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [219, 230, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "A 69-year old woman had persistent fever ( > 38 \u2103 ) accompanied by a dry cough , headache , sore throat , myalgia and fatigue for three days .", "labels": [[67, 73, "ENTITY"], [97, 106, "DISEASE"], [67, 73, "DISEASE"], [24, 35, "ENTITY"], [14, 20, "ORGANISM"], [14, 20, "ENTITY"], [81, 97, "ENTITY"], [35, 41, "DISEASE"], [97, 106, "ENTITY"], [35, 41, "ENTITY"], [81, 97, "DISEASE"]]}
{"text": "The viral infection incubation period varies from 2 to 14 days and typical clinical symptoms are fever , dry cough , dyspnea , headache , and pneumonia . Disease onset may result in progressive respiratory failure due to alveolar damage and even death ( Chan et al. 2020 ; Chen et al. 2020 ; Huang et al. 2020 ) .", "labels": [[172, 182, "ENTITY"], [97, 103, "DISEASE"], [182, 206, "DISEASE"], [75, 93, "ENTITY"], [31, 38, "ENTITY"], [97, 103, "ENTITY"], [105, 109, "DISEASE"], [214, 230, "DISEASE"], [214, 221, "TISSUE"], [4, 20, "ENTITY"], [4, 20, "DISEASE"], [105, 109, "ENTITY"], [182, 206, "ENTITY"], [4, 10, "TAXON"], [142, 162, "ENTITY"], [214, 230, "ENTITY"], [58, 63, "ENTITY"], [20, 31, "ENTITY"]]}
{"text": "Fever , cough and sputum production were the most common symptoms . Of the aforementioned symptoms , 29 ( 39.19 % ) , 23 ( 31.08 % ) , 8 ( 10.81 % ) and 16 ( 21.62 % ) patients with COVID-19 with GI symptoms had > 38.5 \u00b0 C fever , fatigue , shortness of breath and headache , respectively , substantially higher than their respective counterparts without GI symptoms .", "labels": [[241, 251, "ENTITY"], [276, 287, "ENTITY"], [208, 214, "ENTITY"], [276, 287, "ORGAN"], [241, 251, "DISEASE"], [177, 191, "ENTITY"], [0, 6, "DISEASE"], [57, 66, "DISEASE"], [57, 66, "ENTITY"], [208, 214, "DISEASE"], [219, 239, "DISEASE"], [0, 6, "ENTITY"], [149, 158, "ENTITY"], [149, 158, "ORGANISM"], [75, 90, "ENTITY"], [219, 239, "ENTITY"], [18, 25, "ENTITY"]]}
{"text": "Patient 1 , a 52-year-old woman with a history of hypothyroidism , was admitted on 21 January 2020 , complaining of fever of 5 days duration with 38.6\u0005C as the highest body temperature .", "labels": [[160, 168, "ORGANISM_SUBDIVISION"], [127, 132, "ENTITY"], [0, 10, "ENTITY"], [160, 173, "ENTITY"], [0, 10, "ORGANISM"]]}
{"text": "The most common symptom was fever on or after hospitalisation ( 88.0 % ) , followed by dry cough ( 70.2 % ) . Fatigue ( 42.8 % ) and productive cough ( 36.0 % ) were less common .", "labels": [[28, 34, "DISEASE"], [84, 91, "DISEASE"], [120, 133, "ENTITY"], [84, 91, "ENTITY"], [28, 34, "ENTITY"], [46, 62, "ENTITY"], [16, 24, "ENTITY"]]}
{"text": "the most common clinical manifestations at onset of illness include fever , cough , fatigue and myalgia", "labels": [[52, 60, "ENTITY"], [68, 74, "DISEASE"], [43, 52, "ENTITY"], [68, 74, "ENTITY"], [16, 40, "ENTITY"]]}
{"text": "The common clinical manifestations of fever and cough in conjunction with laboratory results of progressively increasing neutrophil counts and leukocytopenia in serum samples taken from COVID-19 patients at various stages of the illness indicates uncontrolled neutrophil extravasation and activation 11,12 .", "labels": [[121, 132, "CL"], [195, 204, "ENTITY"], [229, 237, "ENTITY"], [121, 132, "ENTITY"], [186, 195, "ENTITY"], [57, 69, "ENTITY"], [132, 139, "ENTITY"], [143, 158, "ENTITY"], [260, 285, "ENTITY"], [121, 132, "CELL"], [121, 132, "CELL"], [11, 35, "ENTITY"], [186, 204, "ORGANISM"], [247, 260, "ENTITY"], [74, 93, "ENTITY"], [121, 132, "CL"], [48, 54, "ENTITY"], [110, 121, "ENTITY"], [121, 132, "CELL_TYPE"], [161, 175, "ORGANISM_SUBSTANCE"], [289, 300, "ENTITY"], [121, 132, "CELL_TYPE"], [38, 44, "DISEASE"], [161, 175, "ENTITY"], [38, 44, "ENTITY"], [215, 222, "ENTITY"], [143, 158, "DISEASE"], [48, 54, "DISEASE"]]}
{"text": "Through a literature review , we identified a list of important symptoms and mechanisms linked to SARS-CoV-2 , including fever , fatigue , cough 17 , breathing difficulty , septic shock , viral proliferation , immunodeficiency and pulmonary fibrosis 18 ( Figure 4 ) .", "labels": [[145, 160, "ENTITY"], [180, 194, "ENTITY"], [180, 186, "TAXON"], [160, 180, "ENTITY"], [129, 139, "DISEASE"], [231, 241, "DISEASE"], [194, 210, "ORGANISM"], [210, 241, "ENTITY"], [194, 210, "ENTITY"], [241, 255, "ENTITY"], [210, 231, "ORGAN"], [160, 180, "DISEASE"], [129, 139, "ENTITY"], [111, 121, "DISEASE"], [111, 121, "ENTITY"], [10, 28, "ENTITY"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [76, 89, "DISEASE"], [257, 271, "ENTITY"], [50, 56, "ENTITY"], [28, 37, "ENTITY"], [50, 56, "DISEASE"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "The second most common symptom was cough ( 67.8 % ) ; nausea or vomiting ( 5.0 % ) and diarrhea ( 3.8 % ) were uncommon .", "labels": [[23, 31, "ENTITY"], [35, 41, "ENTITY"], [35, 41, "DISEASE"], [81, 87, "ENTITY"], [81, 87, "DISEASE"]]}
{"text": "The most common symptoms on admission were fever and cough , followed by sputum production and fatigue ( table 1 ) .", "labels": [[28, 38, "ENTITY"], [43, 49, "ENTITY"], [53, 59, "DISEASE"], [43, 49, "DISEASE"], [53, 59, "ENTITY"], [73, 80, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "The clinical features include fever , dry cough , shortness of breath , normal or low levels of peripheral white blood cells , and inflammatory changes on chest X-ray .", "labels": [[48, 63, "ENTITY"], [38, 42, "ENTITY"], [107, 119, "CELL"], [4, 22, "ENTITY"], [107, 119, "CL"], [82, 86, "ENTITY"], [127, 144, "ENTITY"], [30, 36, "ENTITY"], [38, 42, "DISEASE"], [48, 63, "DISEASE"], [152, 161, "ENTITY"], [93, 119, "ENTITY"], [93, 119, "CELL_TYPE"], [30, 36, "DISEASE"]]}
{"text": "Most patients presented cough and fever ( mainly low fever , temperature ranges from 37.3 to 38.0 ) ( Table 1 ) . Four patients had the symptom of productive cough ( white phlegm ) and sore throat . Three patients reported headache and nausea . One patient only existed chest congestion ( patient 7 ) .", "labels": [[214, 223, "ENTITY"], [172, 185, "ENTITY"], [236, 245, "ENTITY"], [5, 14, "ENTITY"], [128, 136, "ENTITY"], [61, 73, "ENTITY"], [136, 158, "ENTITY"], [24, 30, "ENTITY"], [197, 205, "ENTITY"], [223, 232, "DISEASE"], [276, 287, "ORGANISM"], [34, 40, "ENTITY"], [147, 158, "DISEASE"], [158, 172, "ENTITY"], [172, 185, "DISEASE"], [223, 232, "ENTITY"], [49, 53, "ENTITY"], [5, 14, "ORGANISM"], [158, 172, "DISEASE"], [34, 40, "DISEASE"], [24, 30, "DISEASE"], [257, 276, "ENTITY"], [214, 223, "DISEASE"], [197, 205, "ORGANISM"], [236, 245, "ORGANISM"], [257, 276, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [219, 230, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "A 69-year old woman had persistent fever ( > 38 \u2103 ) accompanied by a dry cough , headache , sore throat , myalgia and fatigue for three days .", "labels": [[35, 41, "ENTITY"], [67, 73, "ENTITY"], [97, 106, "DISEASE"], [67, 73, "DISEASE"], [24, 35, "ENTITY"], [14, 20, "ORGANISM"], [14, 20, "ENTITY"], [35, 41, "DISEASE"], [81, 97, "ENTITY"], [97, 106, "ENTITY"], [81, 97, "DISEASE"]]}
{"text": "The viral infection incubation period varies from 2 to 14 days and typical clinical symptoms are fever , dry cough , dyspnea , headache , and pneumonia . Disease onset may result in progressive respiratory failure due to alveolar damage and even death ( Chan et al. 2020 ; Chen et al. 2020 ; Huang et al. 2020 ) .", "labels": [[172, 182, "ENTITY"], [182, 206, "DISEASE"], [75, 93, "ENTITY"], [31, 38, "ENTITY"], [97, 103, "DISEASE"], [105, 109, "DISEASE"], [214, 230, "DISEASE"], [214, 221, "TISSUE"], [4, 20, "ENTITY"], [4, 20, "DISEASE"], [105, 109, "ENTITY"], [182, 206, "ENTITY"], [97, 103, "ENTITY"], [142, 162, "ENTITY"], [4, 10, "TAXON"], [214, 230, "ENTITY"], [58, 63, "ENTITY"], [20, 31, "ENTITY"]]}
{"text": "On presentation , the most common symptom was fever in 22 patients ( 96 % ) , followed by cough in five ( 22 % ) , chills in four ( 17 % ) , and dyspnoea in four ( 17 % ; table ) .", "labels": [[78, 90, "DISEASE"], [3, 16, "ENTITY"], [78, 90, "ENTITY"]]}
{"text": "Fever , cough and sputum production were the most common symptoms . Of the aforementioned symptoms , 29 ( 39.19 % ) , 23 ( 31.08 % ) , 8 ( 10.81 % ) and 16 ( 21.62 % ) patients with COVID-19 with GI symptoms had > 38.5 \u00b0 C fever , fatigue , shortness of breath and headache , respectively , substantially higher than their respective counterparts without GI symptoms .", "labels": [[241, 251, "ENTITY"], [276, 287, "ENTITY"], [208, 214, "ENTITY"], [276, 287, "ORGAN"], [241, 251, "DISEASE"], [177, 191, "ENTITY"], [57, 66, "DISEASE"], [57, 66, "ENTITY"], [208, 214, "DISEASE"], [219, 239, "ENTITY"], [149, 158, "ORGANISM"], [149, 158, "ENTITY"], [0, 6, "DISEASE"], [75, 90, "ENTITY"], [0, 6, "ENTITY"], [219, 239, "DISEASE"], [18, 25, "ENTITY"]]}
{"text": "The most common symptom was fever on or after hospitalisation ( 88.0 % ) , followed by dry cough ( 70.2 % ) . Fatigue ( 42.8 % ) and productive cough ( 36.0 % ) were less common .", "labels": [[84, 91, "DISEASE"], [28, 34, "DISEASE"], [28, 34, "ENTITY"], [120, 133, "ENTITY"], [84, 91, "ENTITY"], [46, 62, "ENTITY"], [16, 24, "ENTITY"]]}
{"text": "the most common clinical manifestations at onset of illness include fever , cough , fatigue and myalgia", "labels": [[52, 60, "ENTITY"], [43, 52, "ENTITY"], [68, 74, "ENTITY"], [68, 74, "DISEASE"], [16, 40, "ENTITY"]]}
{"text": "The common clinical manifestations of fever and cough in conjunction with laboratory results of progressively increasing neutrophil counts and leukocytopenia in serum samples taken from COVID-19 patients at various stages of the illness indicates uncontrolled neutrophil extravasation and activation 11,12 .", "labels": [[121, 132, "CL"], [195, 204, "ENTITY"], [229, 237, "ENTITY"], [121, 132, "ENTITY"], [186, 195, "ENTITY"], [57, 69, "ENTITY"], [132, 139, "ENTITY"], [38, 44, "ENTITY"], [143, 158, "ENTITY"], [48, 54, "DISEASE"], [260, 285, "ENTITY"], [48, 54, "ENTITY"], [121, 132, "CELL"], [121, 132, "CELL"], [11, 35, "ENTITY"], [186, 204, "ORGANISM"], [247, 260, "ENTITY"], [74, 93, "ENTITY"], [121, 132, "CL"], [121, 132, "CELL_TYPE"], [110, 121, "ENTITY"], [38, 44, "DISEASE"], [161, 175, "ORGANISM_SUBSTANCE"], [289, 300, "ENTITY"], [121, 132, "CELL_TYPE"], [161, 175, "ENTITY"], [215, 222, "ENTITY"], [143, 158, "DISEASE"]]}
{"text": "Through a literature review , we identified a list of important symptoms and mechanisms linked to SARS-CoV-2 , including fever , fatigue , cough 17 , breathing difficulty , septic shock , viral proliferation , immunodeficiency and pulmonary fibrosis 18 ( Figure 4 ) .", "labels": [[145, 160, "ENTITY"], [180, 194, "ENTITY"], [180, 186, "TAXON"], [160, 180, "ENTITY"], [129, 139, "DISEASE"], [231, 241, "DISEASE"], [194, 210, "ORGANISM"], [210, 241, "ENTITY"], [194, 210, "ENTITY"], [241, 255, "ENTITY"], [210, 231, "ORGAN"], [160, 180, "DISEASE"], [129, 139, "ENTITY"], [111, 121, "DISEASE"], [111, 121, "ENTITY"], [10, 28, "ENTITY"]]}
{"text": "Fever was the most common symptom ( 92.8 % ; n = 258 ) , followed by cough ( 69.8 % ; n = 194 ) , dyspnoea ( 34.5 % ; n = 96 ) , myalgia ( 27.7 % ; n = 77 ) , headache ( 7.2 % ; n = 20 ) and diarrhoea ( 6.1 % ; n = 17 ) .", "labels": [[57, 69, "DISEASE"], [26, 34, "ENTITY"], [41, 49, "DISEASE"], [0, 6, "DISEASE"], [0, 6, "ENTITY"], [57, 69, "ENTITY"], [41, 49, "ENTITY"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [76, 89, "DISEASE"], [257, 271, "ENTITY"], [50, 56, "ENTITY"], [28, 37, "ENTITY"], [50, 56, "DISEASE"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "The second most common symptom was cough ( 67.8 % ) ; nausea or vomiting ( 5.0 % ) and diarrhea ( 3.8 % ) were uncommon .", "labels": [[23, 31, "ENTITY"], [35, 41, "ENTITY"], [81, 87, "ENTITY"], [81, 87, "DISEASE"], [35, 41, "DISEASE"]]}
{"text": "Most patients presented cough and fever ( mainly low fever , temperature ranges from 37.3 to 38.0 ) ( Table 1 ) . Four patients had the symptom of productive cough ( white phlegm ) and sore throat . Three patients reported headache and nausea . One patient only existed chest congestion ( patient 7 ) .", "labels": [[214, 223, "ENTITY"], [172, 185, "ENTITY"], [24, 30, "ENTITY"], [5, 14, "ENTITY"], [128, 136, "ENTITY"], [61, 73, "ENTITY"], [136, 158, "ENTITY"], [276, 287, "ORGANISM"], [197, 205, "ENTITY"], [223, 232, "DISEASE"], [34, 40, "ENTITY"], [147, 158, "DISEASE"], [158, 172, "ENTITY"], [172, 185, "DISEASE"], [223, 232, "ENTITY"], [158, 172, "DISEASE"], [49, 53, "ENTITY"], [24, 30, "DISEASE"], [5, 14, "ORGANISM"], [34, 40, "DISEASE"], [236, 245, "ENTITY"], [257, 276, "ENTITY"], [214, 223, "DISEASE"], [236, 245, "ORGANISM"], [197, 205, "ORGANISM"], [257, 276, "DISEASE"]]}
{"text": "She developed chest tightness , shortness of breath , loss of appetite , 62 nausea , and diarrhea", "labels": [[52, 62, "ENTITY"], [52, 62, "DISEASE"], [4, 14, "ENTITY"], [14, 30, "ENTITY"], [32, 45, "ENTITY"], [14, 30, "DISEASE"], [32, 45, "DISEASE"]]}
{"text": "In detail , of 74 patients with COVID-19 with GI symptoms , 53 patients had only the symptom of diarrhoea , 11 patients had only the symptom of vomiting and 10 patients had only the symptom of nausea .", "labels": [[46, 49, "DISEASE"], [46, 49, "ENTITY"]]}
{"text": "ACE2 in the gastrointestinal tract may underly early gastrointestinal symptoms such as nausea , vomiting , and diarrhea , and ACE2 in the heart may be related to cardiac damage and fulminant myocarditis that have been reported in COVID-19 [ 14,15 ] .", "labels": [[227, 241, "GENE_OR_GENE_PRODUCT"], [12, 35, "ORGAN"], [12, 29, "ORGAN"], [0, 5, "GGP"], [0, 5, "ENTITY"], [177, 191, "ENTITY"], [12, 35, "DISEASE"], [159, 170, "ENTITY"], [12, 35, "ENTITY"], [159, 170, "DISEASE"], [177, 191, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"], [87, 94, "ENTITY"], [87, 94, "DISEASE"], [53, 79, "ENTITY"], [0, 5, "PROTEIN"], [53, 79, "DISEASE"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [76, 89, "DISEASE"], [257, 271, "ENTITY"], [50, 56, "ENTITY"], [28, 37, "ENTITY"], [50, 56, "DISEASE"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "Most COVID-19 patients initially suffered from fever , cough , fatigue , and shortness of breath , while other symptoms included muscle pain , headache , chest pain , and diarrhea , similar to the symptoms observed after chemotherapy , targeted and immune therapy1", "labels": [[73, 90, "ENTITY"], [143, 154, "DISEASE"], [120, 136, "DISEASE"], [120, 136, "ENTITY"], [47, 53, "ENTITY"], [206, 221, "ENTITY"], [14, 23, "ENTITY"], [5, 14, "ENTITY"], [5, 23, "ORGANISM"], [236, 256, "CELL"], [5, 14, "DISEASE"], [73, 90, "DISEASE"], [143, 154, "ORGAN"], [221, 236, "ENTITY"], [236, 256, "ENTITY"], [71, 77, "ENTITY"], [190, 197, "ENTITY"], [111, 120, "ENTITY"], [136, 143, "ENTITY"], [136, 143, "DISEASE"], [120, 129, "ORGAN"], [47, 53, "DISEASE"], [143, 154, "ENTITY"], [71, 77, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [219, 230, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "A 69-year old woman had persistent fever ( > 38 \u2103 ) accompanied by a dry cough , headache , sore throat , myalgia and fatigue for three days .", "labels": [[35, 41, "ENTITY"], [67, 73, "ENTITY"], [97, 106, "DISEASE"], [67, 73, "DISEASE"], [24, 35, "ENTITY"], [14, 20, "ORGANISM"], [14, 20, "ENTITY"], [35, 41, "DISEASE"], [81, 97, "ENTITY"], [97, 106, "ENTITY"], [81, 97, "DISEASE"]]}
{"text": "the most common clinical manifestations at onset of illness include fever , cough , fatigue and myalgia", "labels": [[52, 60, "ENTITY"], [43, 52, "ENTITY"], [68, 74, "ENTITY"], [68, 74, "DISEASE"], [16, 40, "ENTITY"]]}
{"text": "Fever was the most common symptom ( 92.8 % ; n = 258 ) , followed by cough ( 69.8 % ; n = 194 ) , dyspnoea ( 34.5 % ; n = 96 ) , myalgia ( 27.7 % ; n = 77 ) , headache ( 7.2 % ; n = 20 ) and diarrhoea ( 6.1 % ; n = 17 ) .", "labels": [[57, 69, "DISEASE"], [26, 34, "ENTITY"], [41, 49, "DISEASE"], [0, 6, "DISEASE"], [0, 6, "ENTITY"], [57, 69, "ENTITY"], [41, 49, "ENTITY"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [76, 89, "DISEASE"], [257, 271, "ENTITY"], [50, 56, "ENTITY"], [28, 37, "ENTITY"], [50, 56, "DISEASE"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "Other prevalent symptoms at onset of illness in deceased patients included fatigue , dyspnoea , chest tightness , and sputum production ; less common symptoms included anorexia , diarrhoea , and myalgia .", "labels": [[112, 118, "DISEASE"], [143, 150, "ENTITY"], [168, 179, "DISEASE"], [66, 75, "ENTITY"], [112, 118, "ENTITY"], [16, 25, "ENTITY"], [168, 179, "ENTITY"], [48, 57, "ENTITY"], [28, 37, "ENTITY"], [94, 102, "DISEASE"], [114, 125, "ENTITY"], [66, 75, "CANCER"], [75, 83, "DISEASE"], [94, 102, "ENTITY"], [75, 83, "ENTITY"], [57, 66, "ORGANISM"], [66, 75, "DISEASE"], [37, 45, "ENTITY"], [6, 16, "ENTITY"], [57, 66, "ENTITY"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [76, 89, "DISEASE"], [257, 271, "ENTITY"], [50, 56, "ENTITY"], [28, 37, "ENTITY"], [50, 56, "DISEASE"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "Most patients presented cough and fever ( mainly low fever , temperature ranges from 37.3 to 38.0 ) ( Table 1 ) . Four patients had the symptom of productive cough ( white phlegm ) and sore throat . Three patients reported headache and nausea . One patient only existed chest congestion ( patient 7 ) .", "labels": [[214, 223, "ENTITY"], [172, 185, "ENTITY"], [24, 30, "ENTITY"], [236, 245, "ENTITY"], [5, 14, "ENTITY"], [223, 232, "ENTITY"], [128, 136, "ENTITY"], [61, 73, "ENTITY"], [136, 158, "ENTITY"], [276, 287, "ORGANISM"], [197, 205, "ENTITY"], [34, 40, "ENTITY"], [147, 158, "DISEASE"], [158, 172, "ENTITY"], [172, 185, "DISEASE"], [158, 172, "DISEASE"], [49, 53, "ENTITY"], [24, 30, "DISEASE"], [5, 14, "ORGANISM"], [34, 40, "DISEASE"], [257, 276, "ENTITY"], [214, 223, "DISEASE"], [197, 205, "ORGANISM"], [236, 245, "ORGANISM"], [257, 276, "DISEASE"], [223, 232, "DISEASE"]]}
{"text": "Most COVID-19 patients initially suffered from fever , cough , fatigue , and shortness of breath , while other symptoms included muscle pain , headache , chest pain , and diarrhea , similar to the symptoms observed after chemotherapy , targeted and immune therapy1", "labels": [[73, 90, "ENTITY"], [143, 154, "DISEASE"], [120, 136, "DISEASE"], [120, 136, "ENTITY"], [47, 53, "ENTITY"], [206, 221, "ENTITY"], [14, 23, "ENTITY"], [5, 14, "ENTITY"], [5, 23, "ORGANISM"], [236, 256, "CELL"], [5, 14, "DISEASE"], [73, 90, "DISEASE"], [221, 236, "ENTITY"], [236, 256, "ENTITY"], [143, 154, "ORGAN"], [71, 77, "ENTITY"], [190, 197, "ENTITY"], [111, 120, "ENTITY"], [136, 143, "DISEASE"], [143, 154, "ENTITY"], [120, 129, "ORGAN"], [47, 53, "DISEASE"], [136, 143, "ENTITY"], [71, 77, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [219, 230, "ENTITY"], [24, 33, "ORGANISM"], [219, 230, "DISEASE"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "A 69-year old woman had persistent fever ( > 38 \u2103 ) accompanied by a dry cough , headache , sore throat , myalgia and fatigue for three days .", "labels": [[35, 41, "ENTITY"], [67, 73, "ENTITY"], [97, 106, "DISEASE"], [67, 73, "DISEASE"], [24, 35, "ENTITY"], [14, 20, "ORGANISM"], [81, 97, "ENTITY"], [14, 20, "ENTITY"], [35, 41, "DISEASE"], [97, 106, "ENTITY"], [81, 97, "DISEASE"]]}
{"text": "The viral infection incubation period varies from 2 to 14 days and typical clinical symptoms are fever , dry cough , dyspnea , headache , and pneumonia . Disease onset may result in progressive respiratory failure due to alveolar damage and even death ( Chan et al. 2020 ; Chen et al. 2020 ; Huang et al. 2020 ) .", "labels": [[172, 182, "ENTITY"], [182, 206, "DISEASE"], [75, 93, "ENTITY"], [31, 38, "ENTITY"], [97, 103, "DISEASE"], [105, 109, "DISEASE"], [214, 230, "DISEASE"], [214, 221, "TISSUE"], [4, 20, "ENTITY"], [4, 20, "DISEASE"], [105, 109, "ENTITY"], [182, 206, "ENTITY"], [97, 103, "ENTITY"], [142, 162, "ENTITY"], [4, 10, "TAXON"], [214, 230, "ENTITY"], [58, 63, "ENTITY"], [20, 31, "ENTITY"]]}
{"text": "Fever , cough and sputum production were the most common symptoms . Of the aforementioned symptoms , 29 ( 39.19 % ) , 23 ( 31.08 % ) , 8 ( 10.81 % ) and 16 ( 21.62 % ) patients with COVID-19 with GI symptoms had > 38.5 \u00b0 C fever , fatigue , shortness of breath and headache , respectively , substantially higher than their respective counterparts without GI symptoms .", "labels": [[241, 251, "ENTITY"], [276, 287, "ENTITY"], [208, 214, "ENTITY"], [276, 287, "ORGAN"], [241, 251, "DISEASE"], [177, 191, "ENTITY"], [57, 66, "DISEASE"], [57, 66, "ENTITY"], [208, 214, "DISEASE"], [219, 239, "ENTITY"], [149, 158, "ORGANISM"], [149, 158, "ENTITY"], [0, 6, "DISEASE"], [75, 90, "ENTITY"], [0, 6, "ENTITY"], [219, 239, "DISEASE"], [18, 25, "ENTITY"]]}
{"text": "Fever was the most common symptom ( 92.8 % ; n = 258 ) , followed by cough ( 69.8 % ; n = 194 ) , dyspnoea ( 34.5 % ; n = 96 ) , myalgia ( 27.7 % ; n = 77 ) , headache ( 7.2 % ; n = 20 ) and diarrhoea ( 6.1 % ; n = 17 ) .", "labels": [[57, 69, "DISEASE"], [26, 34, "ENTITY"], [41, 49, "DISEASE"], [0, 6, "DISEASE"], [0, 6, "ENTITY"], [57, 69, "ENTITY"], [41, 49, "ENTITY"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [76, 89, "DISEASE"], [257, 271, "ENTITY"], [50, 56, "ENTITY"], [28, 37, "ENTITY"], [50, 56, "DISEASE"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "Fever was the most common symptom ( 92.8 % ; n = 258 ) , followed by cough ( 69.8 % ; n = 194 ) , dyspnoea ( 34.5 % ; n = 96 ) , myalgia ( 27.7 % ; n = 77 ) , headache ( 7.2 % ; n = 20 ) and diarrhoea ( 6.1 % ; n = 17 ) .", "labels": [[57, 69, "DISEASE"], [26, 34, "ENTITY"], [41, 49, "DISEASE"], [0, 6, "DISEASE"], [0, 6, "ENTITY"], [57, 69, "ENTITY"], [41, 49, "ENTITY"]]}
{"text": "The second most common symptom was cough ( 67.8 % ) ; nausea or vomiting ( 5.0 % ) and diarrhea ( 3.8 % ) were uncommon .", "labels": [[23, 31, "ENTITY"], [35, 41, "ENTITY"], [81, 87, "ENTITY"], [81, 87, "DISEASE"], [35, 41, "DISEASE"]]}
{"text": "Most COVID-19 patients initially suffered from fever , cough , fatigue , and shortness of breath , while other symptoms included muscle pain , headache , chest pain , and diarrhea , similar to the symptoms observed after chemotherapy , targeted and immune therapy1", "labels": [[73, 90, "ENTITY"], [143, 154, "DISEASE"], [120, 136, "DISEASE"], [120, 136, "ENTITY"], [47, 53, "ENTITY"], [206, 221, "ENTITY"], [14, 23, "ENTITY"], [5, 14, "ENTITY"], [5, 23, "ORGANISM"], [236, 256, "CELL"], [5, 14, "DISEASE"], [73, 90, "DISEASE"], [143, 154, "ORGAN"], [221, 236, "ENTITY"], [236, 256, "ENTITY"], [71, 77, "ENTITY"], [190, 197, "ENTITY"], [111, 120, "ENTITY"], [136, 143, "ENTITY"], [136, 143, "DISEASE"], [120, 129, "ORGAN"], [47, 53, "DISEASE"], [143, 154, "ENTITY"], [71, 77, "DISEASE"]]}
{"text": "Finally , the presentation of diarrhea in two young adults from the same family also suggests the possibility for gastrointestinal involvement in SARS-CoV-2 infection and fecal \u2013 oral transmission .", "labels": [[46, 52, "ENTITY"], [146, 157, "DISEASE"], [177, 184, "ENTITY"], [146, 157, "ENTITY"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [219, 230, "DISEASE"], [176, 191, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"]]}
{"text": "She developed chest tightness , shortness of breath , loss of appetite , 62 nausea , and diarrhea", "labels": [[52, 62, "ENTITY"], [52, 62, "DISEASE"], [4, 14, "ENTITY"], [14, 30, "ENTITY"], [32, 45, "ENTITY"], [14, 30, "DISEASE"], [32, 45, "DISEASE"]]}
{"text": "ACE2 in the gastrointestinal tract may underly early gastrointestinal symptoms such as nausea , vomiting , and diarrhea , and ACE2 in the heart may be related to cardiac damage and fulminant myocarditis that have been reported in COVID-19 [ 14,15 ] .", "labels": [[227, 241, "GENE_OR_GENE_PRODUCT"], [12, 35, "ORGAN"], [87, 94, "DISEASE"], [12, 29, "ORGAN"], [87, 94, "ENTITY"], [0, 5, "GGP"], [0, 5, "ENTITY"], [177, 191, "ENTITY"], [12, 35, "DISEASE"], [159, 170, "ENTITY"], [12, 35, "ENTITY"], [159, 170, "DISEASE"], [177, 191, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"], [53, 79, "ENTITY"], [0, 5, "PROTEIN"], [53, 79, "DISEASE"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [257, 271, "ENTITY"], [76, 89, "DISEASE"], [50, 56, "ENTITY"], [28, 37, "ENTITY"], [50, 56, "DISEASE"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "The most common symptoms at onset of COVID-19 illness are fever , cough , and fatigue , while other symptoms include sputum production , headache , haemoptysis , diarrhoea , dyspnoea , and lymphopenia [ 5,6,8,13 ] .", "labels": [[109, 117, "TISSUE"], [148, 162, "DISEASE"], [174, 189, "DISEASE"], [124, 137, "DISEASE"], [37, 54, "DISEASE"], [137, 148, "DISEASE"], [109, 124, "ENTITY"], [37, 54, "ENTITY"], [148, 162, "ENTITY"], [124, 137, "ENTITY"], [137, 148, "ENTITY"], [58, 64, "DISEASE"], [37, 46, "GENE_OR_GENE_PRODUCT"], [162, 174, "ENTITY"], [58, 64, "ENTITY"], [174, 189, "ENTITY"], [162, 174, "DISEASE"], [16, 25, "ENTITY"]]}
{"text": "The blood counts of patients on admission showed leucopenia ( white blood cell count less than 4 \u00d7 10\u2079/L;ten [ 25 % ] of 40 patients ) and lymphopenia ( lymphocyte count < 1\u00b70 \u00d7 10\u2079/L ; 26 [ 63 % ] patients ; table 2 ) .", "labels": [[4, 10, "CL"], [32, 42, "ENTITY"], [20, 29, "ORGANISM"], [4, 10, "ORGANISM_SUBSTANCE"], [49, 60, "DISEASE"], [4, 17, "ENTITY"], [62, 74, "ENTITY"], [139, 164, "ENTITY"], [4, 10, "CELL"], [20, 29, "ENTITY"], [139, 153, "CELL"], [139, 153, "CL"], [49, 60, "ENTITY"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer . Patients with severe disease had more prominent laboratory abnormalities ( including lymphocytopenia and leukopenia ) than those with nonsevere disease .", "labels": [[12, 21, "ENTITY"], [264, 274, "ENTITY"], [101, 109, "PROTEIN"], [44, 63, "PROTEIN"], [155, 166, "PROTEIN"], [274, 294, "DISEASE"], [274, 294, "ENTITY"], [198, 210, "ENTITY"], [264, 274, "DISEASE"], [101, 109, "ENTITY"], [126, 138, "PROTEIN"], [126, 138, "GENE_OR_GENE_PRODUCT"], [25, 34, "ENTITY"], [44, 63, "GGP"], [179, 189, "ORGANISM"], [101, 109, "GGP"], [179, 189, "ENTITY"], [44, 55, "GENE_OR_GENE_PRODUCT"], [34, 41, "ENTITY"], [227, 248, "ENTITY"], [312, 333, "ENTITY"], [12, 21, "ORGANISM"], [126, 138, "CHEBI"], [126, 138, "ENTITY"], [44, 63, "ENTITY"], [155, 166, "ENTITY"], [227, 248, "DISEASE"], [101, 109, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Most laboratory tests were within normal ranges , except for mild leukopenia [ 3.37 \u00d7 109 /L , reference range : ( 3.5~9.5 ) \u00d7109 /L ] and neutropenia [ 1.47 \u00d7 109 /L , reference range : ( 1.8~6.3 ) \u00d7109 /L ] .", "labels": [[105, 113, "GENE_OR_GENE_PRODUCT"], [130, 139, "DISEASE"], [61, 66, "ENTITY"], [153, 169, "ENTITY"], [105, 113, "PROTEIN"], [130, 139, "ENTITY"], [34, 48, "ENTITY"], [5, 22, "ENTITY"], [90, 105, "ENTITY"]]}
{"text": "On admission , lymphocytopenia was present in 83.2 % of the patients , thrombocytopenia in 36.2 % , and leukopenia in 33.7 %", "labels": [[3, 13, "ENTITY"]]}
{"text": "The blood counts of patients on admission showed leucopenia ( white blood cell count less than 4 \u00d7 10\u2079/L;ten [ 25 % ] of 40 patients ) and lymphopenia ( lymphocyte count < 1\u00b70 \u00d7 10\u2079/L ; 26 [ 63 % ] patients ; table 2 ) .", "labels": [[4, 10, "CL"], [32, 42, "ENTITY"], [20, 29, "ORGANISM"], [4, 10, "ORGANISM_SUBSTANCE"], [4, 17, "ENTITY"], [62, 74, "ENTITY"], [49, 60, "ENTITY"], [139, 164, "ENTITY"], [4, 10, "CELL"], [20, 29, "ENTITY"], [49, 60, "DISEASE"], [139, 153, "CELL"], [139, 153, "CL"]]}
{"text": "The most common symptoms at onset of COVID-19 illness are fever , cough , and fatigue , while other symptoms include sputum production , headache , haemoptysis , diarrhoea , dyspnoea , and lymphopenia [ 5,6,8,13 ] .", "labels": [[148, 162, "ENTITY"], [174, 189, "DISEASE"], [109, 117, "TISSUE"], [124, 137, "DISEASE"], [37, 54, "DISEASE"], [137, 148, "DISEASE"], [109, 124, "ENTITY"], [37, 54, "ENTITY"], [124, 137, "ENTITY"], [137, 148, "ENTITY"], [58, 64, "DISEASE"], [37, 46, "GENE_OR_GENE_PRODUCT"], [148, 162, "DISEASE"], [162, 174, "ENTITY"], [58, 64, "ENTITY"], [174, 189, "ENTITY"], [162, 174, "DISEASE"], [16, 25, "ENTITY"]]}
{"text": "Lymphocytopenia occurred in 77 ( 40 % ) patients . 181 ( 95 % ) patients received antibiotics and 41 ( 21 % ) received antivirals ( lopinavir/ritonavir ; table 2 ) .", "labels": [[73, 82, "CHEBI"], [119, 132, "SIMPLE_CHEMICAL"], [119, 132, "ENTITY"], [0, 16, "CHEMICAL"], [73, 82, "ENTITY"], [73, 82, "ENTITY"], [73, 82, "GO"], [119, 132, "CHEMICAL"], [0, 16, "ENTITY"]]}
{"text": "The clinical features include fever , dry cough , shortness of breath , normal or low levels of peripheral white blood cells , and inflammatory changes on chest X-ray .", "labels": [[48, 63, "ENTITY"], [38, 42, "ENTITY"], [107, 119, "CELL"], [4, 22, "ENTITY"], [107, 119, "CL"], [82, 86, "ENTITY"], [127, 144, "ENTITY"], [30, 36, "ENTITY"], [38, 42, "DISEASE"], [48, 63, "DISEASE"], [152, 161, "ENTITY"], [93, 119, "ENTITY"], [93, 119, "CELL_TYPE"], [30, 36, "DISEASE"]]}
{"text": "Recent studies have shown that in addition to dyspnea , hypoxemia , and acute respiratory distress , lymphopenia , and cytokine release syndrome are also important clinical features in patients with severe SARS- CoV-2 infection.3", "labels": [[212, 218, "ENTITY"], [199, 212, "ENTITY"], [46, 54, "DISEASE"], [115, 128, "ENTITY"], [154, 173, "ENTITY"], [68, 90, "ENTITY"], [199, 218, "PROTEIN"], [68, 90, "DISEASE"], [46, 54, "ENTITY"], [128, 136, "ENTITY"], [7, 15, "ENTITY"], [199, 212, "ORGANISM"]]}
{"text": "Lymphopenia and neutrophilia were present in a higher proportion of patients with severe disease than in those with mild disease , but the differences were not significant ( p=0\u00b7090 and p=0\u00b7068 , respectively ) .", "labels": [[0, 12, "DISEASE"], [54, 65, "ENTITY"], [116, 129, "ENTITY"], [68, 77, "ENTITY"], [0, 12, "ENTITY"], [82, 97, "ENTITY"], [16, 29, "ENTITY"], [68, 77, "ORGANISM"], [16, 29, "DISEASE"]]}
{"text": "Deceased patients had persistent and more severe lymphopenia than recovered patients ; 44 ( 39 % ) deceased patients and eight ( 5 % ) recovered patients had lymphocyte counts below 0.5 \u00d7 109/L.", "labels": [[99, 108, "ORGANISM"], [66, 76, "ENTITY"], [9, 22, "ENTITY"], [176, 186, "GENE_OR_GENE_PRODUCT"], [9, 18, "ENTITY"], [176, 186, "PROTEIN"], [0, 9, "ENTITY"], [9, 22, "CL"], [9, 18, "ENTITY"], [66, 76, "ENTITY"], [9, 18, "ORGANISM"], [9, 18, "ORGANISM"], [66, 76, "ORGANISM"], [42, 49, "ENTITY"], [49, 61, "ENTITY"], [99, 108, "ENTITY"], [49, 61, "DISEASE"], [22, 33, "ENTITY"], [9, 22, "CELL"]]}
{"text": "Levels of aspartate aminotransferase were increased in 15 ( 37 % ) of 41 patients , including eight ( 62 % ) of 13 ICU patients and seven ( 25 % ) of 28 non-ICU patients .", "labels": [[42, 52, "ENTITY"], [10, 37, "PROTEIN"], [0, 7, "ENTITY"], [63, 70, "ENTITY"], [10, 37, "GENE_OR_GENE_PRODUCT"], [10, 37, "CHEBI"], [10, 37, "ENTITY"], [10, 20, "CHEMICAL"], [112, 119, "ENTITY"], [112, 119, "ORGANISM"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer . Patients with severe disease had more prominent laboratory abnormalities ( including lymphocytopenia and leukopenia ) than those with nonsevere disease .", "labels": [[12, 21, "ENTITY"], [264, 274, "ENTITY"], [101, 109, "PROTEIN"], [44, 63, "PROTEIN"], [155, 166, "PROTEIN"], [274, 294, "DISEASE"], [274, 294, "ENTITY"], [198, 210, "ENTITY"], [264, 274, "DISEASE"], [101, 109, "ENTITY"], [126, 138, "PROTEIN"], [126, 138, "GENE_OR_GENE_PRODUCT"], [25, 34, "ENTITY"], [44, 63, "GGP"], [179, 189, "ORGANISM"], [101, 109, "GGP"], [179, 189, "ENTITY"], [44, 55, "GENE_OR_GENE_PRODUCT"], [34, 41, "ENTITY"], [227, 248, "ENTITY"], [312, 333, "ENTITY"], [12, 21, "ORGANISM"], [126, 138, "CHEBI"], [126, 138, "ENTITY"], [44, 63, "ENTITY"], [155, 166, "ENTITY"], [227, 248, "DISEASE"], [101, 109, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Some patients demonstrated liver injury with elevated aspartate aminotransferase(AST;59 of 198[29.8%])and alanine aminotransferase(ALT ; 43of198[21.7 % ] )", "labels": [[27, 33, "ORGAN"], [45, 54, "ENTITY"], [54, 88, "GENE_OR_GENE_PRODUCT"], [54, 64, "CHEBI"], [106, 114, "CHEBI"], [54, 64, "CHEMICAL"], [106, 114, "CHEMICAL"], [5, 14, "ENTITY"], [106, 114, "ENTITY"], [5, 14, "ORGANISM"], [27, 40, "ENTITY"], [54, 88, "ENTITY"], [27, 40, "DISEASE"], [106, 114, "AMINO_ACID"]]}
{"text": "Concentrations of alanine aminotransferase , aspartate aminotransferase , total bilirubin , alkaline phosphatase , and \u03b3-glutamyl transpeptidase were markedly higher in deceased patients than in recovered patients", "labels": [[115, 130, "PROTEIN"], [45, 55, "CHEBI"], [90, 101, "PROTEIN"], [18, 43, "PROTEIN"], [195, 205, "ENTITY"], [18, 43, "ENTITY"], [0, 15, "ENTITY"], [115, 130, "ENTITY"], [18, 43, "GENE_OR_GENE_PRODUCT"], [115, 130, "GENE_OR_GENE_PRODUCT"], [74, 80, "CHEMICAL"], [74, 80, "PROTEIN"], [18, 26, "CHEBI"], [45, 55, "GENE_OR_GENE_PRODUCT"], [169, 178, "ORGANISM"], [90, 101, "SIMPLE_CHEMICAL"], [74, 80, "GGP"], [195, 205, "ORGANISM"], [74, 80, "SIMPLE_CHEMICAL"], [72, 80, "ENTITY"], [169, 178, "ENTITY"], [45, 55, "PROTEIN"], [18, 26, "CHEMICAL"], [90, 101, "ENTITY"], [45, 55, "ENTITY"]]}
{"text": "Alanine aminotransferase ( ALT ) and aspartate aminotransferase ( AST ) levels were significantly higher in severe cases than moderate cases .", "labels": [[108, 115, "ENTITY"], [66, 72, "ENTITY"], [33, 47, "ENTITY"], [0, 25, "ENTITY"], [126, 135, "ENTITY"], [33, 47, "PROTEIN"], [33, 47, "GENE_OR_GENE_PRODUCT"], [33, 47, "GGP"], [0, 25, "GGP"], [0, 25, "GENE_OR_GENE_PRODUCT"], [0, 8, "CHEMICAL"], [0, 25, "PROTEIN"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer .", "labels": [[126, 138, "PROTEIN"], [34, 41, "ENTITY"], [126, 138, "GENE_OR_GENE_PRODUCT"], [12, 21, "ENTITY"], [101, 109, "PROTEIN"], [155, 166, "ENTITY"], [44, 63, "PROTEIN"], [25, 34, "ENTITY"], [155, 166, "PROTEIN"], [44, 63, "GGP"], [12, 21, "ORGANISM"], [101, 109, "GENE_OR_GENE_PRODUCT"], [126, 138, "ENTITY"], [101, 109, "GGP"], [44, 55, "GENE_OR_GENE_PRODUCT"], [126, 138, "CHEBI"], [101, 109, "ENTITY"], [44, 63, "ENTITY"]]}
{"text": "Hypersensitive troponin I ( hs-cTnI ) was increased substantially in five patients , in whom the diagnosis of virus-related cardiac injury was made .", "labels": [[15, 26, "GENE_OR_GENE_PRODUCT"], [107, 132, "DISEASE"], [110, 124, "ORGAN"], [107, 132, "ENTITY"], [15, 26, "GGP"], [0, 26, "ENTITY"]]}
{"text": "Concentrations of hypersensitive cardiac troponin I and N-terminal pro-brain natriuretic peptide were markedly higher in deceased patients ( 40.8 pg/mL and 800.0 pg/mL ) than in recovered patients ( 3.3 pg/mL and 72.0 pg/mL ) , with eight deceased patients having cardiac troponin I above 1000 pg/mL and two above 10 000 pg/mL.", "labels": [[67, 97, "GGP"], [33, 41, "PROTEIN"], [41, 52, "GGP"], [67, 97, "GENE_OR_GENE_PRODUCT"], [121, 130, "ENTITY"], [33, 41, "GGP"], [18, 52, "PROTEIN"], [0, 15, "ENTITY"], [178, 188, "ORGANISM"], [121, 130, "ENTITY"], [18, 52, "ENTITY"], [121, 130, "ORGANISM"], [257, 272, "ENTITY"], [56, 97, "ENTITY"], [130, 139, "ENTITY"], [33, 52, "GENE_OR_GENE_PRODUCT"], [178, 188, "ENTITY"], [257, 272, "GENE_OR_GENE_PRODUCT"], [130, 139, "ORGANISM"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [96, 103, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [89, 96, "PROTEIN"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [15, 20, "ENTITY"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [82, 89, "GGP"], [8, 20, "PROTEIN"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [82, 89, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [48, 55, "PROTEIN"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [67, 72, "ENTITY"], [119, 126, "PROTEIN"], [119, 126, "GENE_OR_GENE_PRODUCT"], [82, 89, "ENTITY"], [89, 96, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [89, 96, "GGP"], [8, 15, "ENTITY"], [8, 20, "ORGANISM_SUBSTANCE"], [0, 8, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [121, 127, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [121, 127, "GENE_OR_GENE_PRODUCT"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "The levels of inflammatory cytokines ( IL-1 , TNF ) are high in the lungs of COVID-19 patients and these cytokines are strong inducers of HA-synthase-2 ( HAS2 ) in CD31 + endothelium , EpCAM + lung alveolar epithelial cells , and fibroblasts [ 13 ] .", "labels": [[77, 86, "ENTITY"], [14, 37, "ENTITY"], [164, 171, "ENTITY"], [14, 37, "PROTEIN"], [74, 86, "ORGANISM"], [159, 164, "PROTEIN"], [224, 230, "CL"], [224, 230, "ENTITY"], [171, 218, "CELL_TYPE"], [4, 11, "ENTITY"], [224, 230, "CELL_TYPE"], [159, 164, "GGP"], [159, 164, "GENE_OR_GENE_PRODUCT"], [185, 218, "CELL"], [171, 185, "ENTITY"], [171, 185, "GGP"], [185, 218, "ENTITY"], [138, 154, "GGP"], [138, 154, "PROTEIN"], [119, 126, "ENTITY"], [198, 218, "CL"], [159, 164, "ENTITY"], [171, 185, "GENE_OR_GENE_PRODUCT"], [224, 230, "CELL"], [138, 154, "GENE_OR_GENE_PRODUCT"], [138, 154, "ENTITY"]]}
{"text": "In particular , in a recent study by Qin C , et al.in which among 452 patients with COVID-19 , most of them had increase of several inflammatory cytokines such as tumor necrosis factor (TNF)-\u03b1 , interleukin (IL)-1and IL-6 [ 3 ] .", "labels": [[207, 217, "PROTEIN"], [132, 145, "ENTITY"], [160, 185, "GGP"], [207, 217, "GENE_OR_GENE_PRODUCT"], [160, 185, "GENE_OR_GENE_PRODUCT"], [207, 217, "GGP"], [124, 145, "PROTEIN"], [160, 185, "PROTEIN"], [207, 217, "ENTITY"], [185, 195, "ENTITY"], [185, 195, "PROTEIN"], [185, 195, "GGP"], [185, 195, "GENE_OR_GENE_PRODUCT"], [37, 41, "ENTITY"], [160, 185, "ENTITY"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [141, 160, "PROTEIN"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [111, 120, "GENE_OR_GENE_PRODUCT"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [103, 111, "GGP"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [141, 160, "GGP"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [528, 540, "ENTITY"], [127, 132, "GGP"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [141, 160, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "PROTEIN"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [103, 111, "ENTITY"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [103, 111, "CHEMICAL"], [141, 160, "ENTITY"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [528, 540, "GGP"], [167, 176, "ENTITY"], [103, 111, "PROTEIN"], [354, 400, "PROTEIN"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [96, 103, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [89, 96, "PROTEIN"], [8, 20, "ORGANISM_SUBSTANCE"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [48, 55, "PROTEIN"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [82, 89, "GGP"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [82, 89, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [67, 72, "ENTITY"], [8, 20, "PROTEIN"], [119, 126, "PROTEIN"], [82, 89, "ENTITY"], [119, 126, "GENE_OR_GENE_PRODUCT"], [89, 96, "ENTITY"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [89, 96, "GGP"], [8, 15, "ENTITY"], [0, 8, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [111, 120, "PROTEIN"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [111, 120, "GENE_OR_GENE_PRODUCT"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [96, 103, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [89, 96, "PROTEIN"], [8, 20, "ORGANISM_SUBSTANCE"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [48, 55, "PROTEIN"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [82, 89, "GGP"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [82, 89, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [67, 72, "ENTITY"], [8, 20, "PROTEIN"], [119, 126, "PROTEIN"], [82, 89, "ENTITY"], [119, 126, "GENE_OR_GENE_PRODUCT"], [89, 96, "ENTITY"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [89, 96, "GGP"], [8, 15, "ENTITY"], [0, 8, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [137, 141, "GENE_OR_GENE_PRODUCT"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [137, 141, "GGP"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [137, 141, "ENTITY"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "PROTEIN"], [149, 155, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [137, 141, "GENE_OR_GENE_PRODUCT"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [137, 141, "GGP"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [137, 141, "ENTITY"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "PROTEIN"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [120, 125, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [120, 125, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [120, 125, "ENTITY"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [96, 103, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [89, 96, "PROTEIN"], [8, 20, "ORGANISM_SUBSTANCE"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [48, 55, "PROTEIN"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [82, 89, "GGP"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [82, 89, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [67, 72, "ENTITY"], [8, 20, "PROTEIN"], [119, 126, "PROTEIN"], [82, 89, "ENTITY"], [119, 126, "GENE_OR_GENE_PRODUCT"], [89, 96, "ENTITY"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [89, 96, "GGP"], [8, 15, "ENTITY"], [0, 8, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Of patients with available data , concentrations of interleukin 2 receptor , interleukin 6 , interleukin 8 , interleukin 10 , and tumour necrosis factor \u03b1 were significantly higher in deceased patients than in recovered patients .", "labels": [[126, 146, "PROTEIN"], [75, 89, "GENE_OR_GENE_PRODUCT"], [3, 12, "ENTITY"], [52, 66, "PROTEIN"], [75, 89, "PROTEIN"], [184, 193, "ORGANISM"], [75, 89, "ENTITY"], [27, 32, "ENTITY"], [52, 66, "GGP"], [52, 66, "GENE_OR_GENE_PRODUCT"], [75, 89, "GGP"], [202, 210, "ENTITY"], [52, 66, "ENTITY"], [126, 146, "ENTITY"], [184, 193, "ENTITY"], [126, 146, "GENE_OR_GENE_PRODUCT"], [210, 220, "ENTITY"], [210, 220, "ORGANISM"], [174, 184, "ENTITY"], [126, 146, "GGP"], [126, 137, "DISEASE"], [3, 12, "ORGANISM"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "GENE_OR_GENE_PRODUCT"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [127, 132, "CHEMICAL"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "GGP"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [127, 132, "PROTEIN"], [120, 125, "ENTITY"], [127, 132, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "The expression of IL-6 , IL-8 and IL-10 in the serum of patients with COVID-19 increased significantly compared with the control group ( P<0.05 ) .", "labels": [[18, 23, "GGP"], [4, 15, "ENTITY"], [121, 129, "ENTITY"], [18, 23, "GENE_OR_GENE_PRODUCT"], [18, 23, "PROTEIN"], [18, 23, "ENTITY"]]}
{"text": "Chemical signals such as Interleukin-8 ( IL-8 ) and IL-6 stimulate neutrophil chemotaxis and recruitment to the site of infection where they congregate and cause the release of more proinflammatory mediators that in turn activate additional inflammatory signals , leading to cytokine storms that may progress to vital organ failure 13 .", "labels": [[57, 78, "ENTITY"], [25, 39, "ENTITY"], [57, 67, "CELL"], [177, 198, "ENTITY"], [312, 318, "ORGAN"], [25, 39, "GENE_OR_GENE_PRODUCT"], [230, 254, "ENTITY"], [216, 221, "ENTITY"], [0, 9, "CHEBI"], [0, 17, "ENTITY"], [312, 324, "ENTITY"], [57, 67, "CL"], [312, 324, "DISEASE"], [272, 284, "ENTITY"], [25, 39, "PROTEIN"], [177, 198, "PROTEIN"], [57, 67, "CELL_TYPE"]]}
{"text": "The elevation of IL-8 and IL-6 but not IL-17 in PMBCs collected from COVID-19 patients indicates possible roles for IL-8/IL-6 in the severe inflammatory response induced by SARS-CoV-2 ( Fig.3d-e and Extended Data Fig.5e ) .", "labels": [[162, 170, "ENTITY"], [26, 31, "GENE_OR_GENE_PRODUCT"], [17, 22, "GGP"], [39, 45, "GENE_OR_GENE_PRODUCT"], [17, 22, "PROTEIN"], [133, 140, "ENTITY"], [116, 126, "ENTITY"], [173, 184, "GGP"], [39, 45, "ENTITY"], [116, 126, "GENE_OR_GENE_PRODUCT"], [26, 31, "ENTITY"], [26, 31, "PROTEIN"], [116, 126, "GGP"], [116, 126, "PROTEIN"], [26, 31, "GGP"], [4, 14, "ENTITY"], [48, 54, "CELL"], [69, 78, "ENTITY"], [39, 45, "PROTEIN"], [173, 184, "ENTITY"], [140, 162, "ENTITY"], [69, 87, "ORGANISM"], [78, 87, "ENTITY"], [48, 54, "CELL_TYPE"], [48, 54, "ENTITY"], [17, 22, "GENE_OR_GENE_PRODUCT"], [17, 22, "ENTITY"], [173, 184, "CHEMICAL"], [199, 213, "ENTITY"], [39, 45, "GGP"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [96, 103, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [89, 96, "PROTEIN"], [8, 20, "ORGANISM_SUBSTANCE"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [48, 55, "PROTEIN"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [103, 109, "GGP"], [82, 89, "GGP"], [42, 48, "GENE_OR_GENE_PRODUCT"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [82, 89, "GENE_OR_GENE_PRODUCT"], [42, 48, "PROTEIN"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [119, 126, "PROTEIN"], [67, 72, "ENTITY"], [8, 20, "PROTEIN"], [119, 126, "GENE_OR_GENE_PRODUCT"], [82, 89, "ENTITY"], [89, 96, "ENTITY"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [89, 96, "GGP"], [8, 15, "ENTITY"], [0, 8, "ENTITY"], [42, 48, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [149, 155, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [190, 197, "GENE_OR_GENE_PRODUCT"], [149, 155, "ENTITY"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [149, 155, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [134, 139, "PROTEIN"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [134, 139, "ENTITY"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [134, 139, "GENE_OR_GENE_PRODUCT"], [134, 139, "GGP"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [303, 354, "CL"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [89, 96, "CHEMICAL"], [96, 103, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [89, 96, "GENE_OR_GENE_PRODUCT"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [8, 20, "PROTEIN"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [82, 89, "GGP"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "PROTEIN"], [103, 109, "GENE_OR_GENE_PRODUCT"], [89, 96, "GGP"], [82, 89, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [48, 55, "PROTEIN"], [67, 72, "PROTEIN"], [42, 48, "ENTITY"], [67, 72, "ENTITY"], [119, 126, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [82, 89, "ENTITY"], [119, 126, "GENE_OR_GENE_PRODUCT"], [61, 65, "GGP"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [8, 15, "ENTITY"], [8, 20, "ORGANISM_SUBSTANCE"], [89, 96, "ENTITY"], [0, 8, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [197, 204, "GENE_OR_GENE_PRODUCT"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [197, 204, "ENTITY"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [197, 204, "PROTEIN"], [446, 462, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [197, 204, "DISEASE"], [197, 204, "ENTITY"], [74, 83, "ORGANISM"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [227, 235, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [155, 162, "PROTEIN"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [197, 204, "CHEMICAL"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [197, 204, "GGP"], [197, 204, "PROTEIN"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [197, 204, "GENE_OR_GENE_PRODUCT"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [197, 204, "ENTITY"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [197, 204, "PROTEIN"], [446, 462, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [197, 204, "DISEASE"], [197, 204, "ENTITY"], [74, 83, "ORGANISM"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [227, 235, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [155, 162, "PROTEIN"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [197, 204, "CHEMICAL"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [197, 204, "GGP"], [197, 204, "PROTEIN"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [59, 82, "PROTEIN"], [36, 50, "PROTEIN"], [227, 249, "GGP"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [59, 73, "DISEASE"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [36, 50, "ENTITY"], [292, 317, "GENE_OR_GENE_PRODUCT"], [227, 249, "ENTITY"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [132, 142, "ENTITY"], [205, 212, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [59, 82, "ENTITY"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [227, 249, "PROTEIN"], [227, 249, "GENE_OR_GENE_PRODUCT"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "TBNK lymphocyte subset analysis revealed decreased percentage of CD16 + CD56 + lymphocytes ( 4/8 ) and Th/Ts ( 1/8 ) , and increased percentage of CD3 + ( 2/8 ) , CD4 + ( 4/8 ) and CD8 + ( 1/8 ) lymphocytes . Cytokine detection assays showed increased levels of IL-6 ( 2/8 ) , IL-10 ( 5/8 ) and IFN-\u03b3 ( 2/8 ) .", "labels": [[-1, 25, "ENTITY"], [281, 287, "GENE_OR_GENE_PRODUCT"], [199, 222, "ENTITY"], [127, 137, "ENTITY"], [127, 137, "GENE_OR_GENE_PRODUCT"], [41, 51, "ENTITY"], [5, 16, "CELL"], [266, 271, "ENTITY"], [127, 137, "ENTITY"], [5, 16, "ENTITY"], [0, 5, "ENTITY"], [159, 199, "CELL_TYPE"], [239, 246, "ENTITY"], [281, 293, "PROTEIN"], [175, 199, "ENTITY"], [127, 137, "PROTEIN"], [51, 65, "GGP"], [65, 70, "GENE_OR_GENE_PRODUCT"], [281, 287, "CHEMICAL"], [232, 239, "ENTITY"], [127, 137, "GGP"], [5, 16, "CL"], [51, 62, "GENE_OR_GENE_PRODUCT"], [137, 157, "ENTITY"], [-1, 25, "CELL_LINE"], [137, 157, "CELL_TYPE"], [266, 271, "PROTEIN"], [281, 287, "ENTITY"], [185, 199, "CL"], [266, 271, "GGP"], [0, 23, "CELL_LINE"], [266, 271, "GENE_OR_GENE_PRODUCT"], [51, 62, "ENTITY"], [83, 95, "CL"]]}
{"text": "Of patients with available data , concentrations of interleukin 2 receptor , interleukin 6 , interleukin 8 , interleukin 10 , and tumour necrosis factor \u03b1 were significantly higher in deceased patients than in recovered patients .", "labels": [[126, 146, "PROTEIN"], [75, 89, "GENE_OR_GENE_PRODUCT"], [3, 12, "ENTITY"], [52, 66, "PROTEIN"], [75, 89, "PROTEIN"], [184, 193, "ORGANISM"], [75, 89, "ENTITY"], [27, 32, "ENTITY"], [52, 66, "GGP"], [52, 66, "GENE_OR_GENE_PRODUCT"], [75, 89, "GGP"], [202, 210, "ENTITY"], [52, 66, "ENTITY"], [126, 146, "ENTITY"], [184, 193, "ENTITY"], [126, 146, "GENE_OR_GENE_PRODUCT"], [210, 220, "ENTITY"], [210, 220, "ORGANISM"], [174, 184, "ENTITY"], [126, 146, "GGP"], [126, 137, "DISEASE"], [3, 12, "ORGANISM"]]}
{"text": "Evaluation of serum cytokines on admission revealed that levels of interleukin (IL)- 2R , IL-6 , IL-10 , and tumor necrosis factor-\u03b1 ( TNF-\u03b1 ) were markedly higher in severe cases than in moderate cases ( Figure 2 , Supplementary Table 1 ) .", "labels": [[205, 230, "GENE_OR_GENE_PRODUCT"], [105, 115, "DISEASE"], [157, 167, "ENTITY"], [33, 43, "ENTITY"], [124, 135, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [0, 11, "ENTITY"], [14, 20, "ENTITY"], [105, 124, "PROTEIN"], [14, 20, "ORGANISM_SUBSTANCE"], [124, 135, "PROTEIN"], [105, 124, "ENTITY"], [105, 124, "GENE_OR_GENE_PRODUCT"], [67, 88, "ENTITY"], [197, 205, "ENTITY"], [180, 188, "ENTITY"], [67, 88, "GGP"], [124, 135, "ENTITY"], [20, 30, "ENTITY"], [205, 230, "ENTITY"], [57, 64, "ENTITY"], [67, 88, "GENE_OR_GENE_PRODUCT"], [188, 197, "ENTITY"], [67, 88, "PROTEIN"], [14, 30, "PROTEIN"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[134, 139, "ENTITY"], [141, 160, "GGP"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [103, 111, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [111, 120, "GENE_OR_GENE_PRODUCT"], [519, 528, "ENTITY"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [528, 540, "ENTITY"], [127, 132, "GGP"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [303, 354, "CL"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [103, 111, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [303, 354, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [111, 120, "ENTITY"], [141, 160, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [111, 120, "PROTEIN"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [303, 354, "ENTITY"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [103, 111, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [303, 354, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [528, 540, "GGP"], [103, 111, "CHEMICAL"], [167, 176, "ENTITY"], [103, 111, "PROTEIN"], [354, 400, "PROTEIN"]]}
{"text": "We only found the levels of TNF-\u03b1 , IL-6 and IL-10 were significantly increased in infected patients , and statistical analysis illustrated that their levels in ICU patients are significantly higher than in Non-ICU patients ( Figure 2A ) .", "labels": [[161, 165, "ENTITY"], [28, 34, "CHEMICAL"], [207, 215, "ORGANISM"], [207, 215, "ENTITY"], [28, 34, "PROTEIN"], [103, 119, "ENTITY"], [224, 233, "ENTITY"], [28, 34, "ENTITY"], [28, 34, "GENE_OR_GENE_PRODUCT"], [161, 165, "ORGANISM"], [18, 25, "ENTITY"]]}
{"text": "Interestingly , serum levels of IFN-\u03b3 , IL-10 , IL-6 and TNF-\u03b1 were significantly decreased in these patients in the decline period as compared with illness period , while counts of total T cells , CD4 + , and CD8 + T cell subsets recovered during the decline period ( Figure 2C ) .", "labels": [[117, 125, "ENTITY"], [182, 190, "CL"], [68, 82, "ENTITY"], [182, 190, "CELL"], [16, 22, "ENTITY"], [260, 269, "ENTITY"], [206, 218, "GGP"], [149, 157, "ENTITY"], [206, 223, "ENTITY"], [117, 125, "ENTITY"], [190, 198, "ENTITY"], [179, 190, "CELL_TYPE"], [179, 190, "ENTITY"], [190, 223, "CELL_TYPE"], [190, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expression of IL-6 , IL-8 and IL-10 in the serum of patients with COVID-19 increased significantly compared with the control group ( P<0.05 ) .", "labels": [[18, 23, "GGP"], [4, 15, "ENTITY"], [121, 129, "ENTITY"], [18, 23, "GENE_OR_GENE_PRODUCT"], [18, 23, "PROTEIN"], [18, 23, "ENTITY"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "ENTITY"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [196, 208, "GGP"], [208, 227, "CHEMICAL"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [40, 59, "ENTITY"], [26, 38, "SIMPLE_CHEMICAL"], [170, 179, "ENTITY"], [179, 194, "GGP"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "ENTITY"], [144, 154, "GGP"], [253, 271, "ENTITY"], [26, 40, "CHEBI"], [170, 179, "GGP"], [26, 38, "CHEMICAL"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [144, 154, "GENE_OR_GENE_PRODUCT"], [196, 208, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [179, 194, "GENE_OR_GENE_PRODUCT"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [26, 38, "ENTITY"], [196, 208, "CHEMICAL"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [196, 208, "PROTEIN"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [96, 103, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [89, 96, "PROTEIN"], [8, 20, "ORGANISM_SUBSTANCE"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [48, 55, "PROTEIN"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [82, 89, "GGP"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [82, 89, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [67, 72, "ENTITY"], [8, 20, "PROTEIN"], [119, 126, "PROTEIN"], [82, 89, "ENTITY"], [119, 126, "GENE_OR_GENE_PRODUCT"], [89, 96, "ENTITY"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [89, 96, "GGP"], [8, 15, "ENTITY"], [0, 8, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 176, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [167, 174, "ENTITY"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 174, "GGP"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [167, 174, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [167, 176, "GENE_OR_GENE_PRODUCT"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [167, 176, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [167, 176, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "PROTEIN"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [354, 400, "PROTEIN"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [67, 72, "CHEMICAL"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [96, 103, "GENE_OR_GENE_PRODUCT"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [89, 96, "PROTEIN"], [8, 20, "ORGANISM_SUBSTANCE"], [181, 194, "ENTITY"], [48, 55, "PROTEIN"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [82, 89, "GGP"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [82, 89, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [103, 109, "PROTEIN"], [42, 48, "ENTITY"], [119, 126, "PROTEIN"], [8, 20, "PROTEIN"], [119, 126, "GENE_OR_GENE_PRODUCT"], [82, 89, "ENTITY"], [67, 72, "ENTITY"], [89, 96, "ENTITY"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [89, 96, "GGP"], [8, 15, "ENTITY"], [0, 8, "ENTITY"], [67, 72, "GGP"], [61, 65, "ENTITY"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [175, 180, "GENE_OR_GENE_PRODUCT"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "GGP"], [211, 219, "GGP"], [384, 388, "GENE_OR_GENE_PRODUCT"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [175, 180, "CHEMICAL"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [254, 262, "ENTITY"], [143, 149, "ENTITY"], [175, 180, "ENTITY"], [155, 162, "PROTEIN"], [143, 149, "GENE_OR_GENE_PRODUCT"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [175, 180, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [175, 180, "GENE_OR_GENE_PRODUCT"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "GGP"], [211, 219, "GGP"], [384, 388, "GENE_OR_GENE_PRODUCT"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [175, 180, "CHEMICAL"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [254, 262, "ENTITY"], [143, 149, "ENTITY"], [175, 180, "ENTITY"], [155, 162, "PROTEIN"], [143, 149, "GENE_OR_GENE_PRODUCT"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [175, 180, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [277, 292, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [292, 317, "GGP"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [235, 272, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [235, 253, "CHEMICAL"], [167, 176, "ENTITY"], [284, 303, "GENE_OR_GENE_PRODUCT"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [235, 272, "GGP"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "PROTEIN"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [284, 303, "ENTITY"], [235, 272, "GENE_OR_GENE_PRODUCT"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [96, 103, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [89, 96, "PROTEIN"], [8, 20, "ORGANISM_SUBSTANCE"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [48, 55, "PROTEIN"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [82, 89, "GGP"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [82, 89, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [67, 72, "ENTITY"], [8, 20, "PROTEIN"], [119, 126, "PROTEIN"], [82, 89, "ENTITY"], [119, 126, "GENE_OR_GENE_PRODUCT"], [89, 96, "ENTITY"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [89, 96, "GGP"], [8, 15, "ENTITY"], [0, 8, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [284, 303, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [284, 303, "PROTEIN"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [235, 272, "ENTITY"], [141, 160, "PROTEIN"], [235, 272, "GENE_OR_GENE_PRODUCT"], [214, 226, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [235, 253, "CHEMICAL"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [235, 272, "GGP"], [284, 303, "GENE_OR_GENE_PRODUCT"], [167, 174, "GENE_OR_GENE_PRODUCT"], [235, 272, "PROTEIN"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [96, 103, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [82, 89, "GGP"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [89, 96, "PROTEIN"], [8, 20, "ORGANISM_SUBSTANCE"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [48, 55, "PROTEIN"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [67, 72, "ENTITY"], [8, 20, "PROTEIN"], [119, 126, "PROTEIN"], [119, 126, "GENE_OR_GENE_PRODUCT"], [89, 96, "ENTITY"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [82, 89, "GENE_OR_GENE_PRODUCT"], [89, 96, "GGP"], [82, 89, "ENTITY"], [82, 89, "PROTEIN"], [8, 15, "ENTITY"], [0, 8, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Baricitinib , fedratinib , and ruxolitinib are potent and selective JAK inhibitors approved for indications such as rheumatoid arthritis and myelofibrosis . All three are powerful antiinflammatories that , as JAK \u2013 STAT signalling inhibitors , are likely to be effective against the consequences of the elevated levels of cytokines ( including interferon-\u03b3 ) typically observed in people with COVID-19\u00b72", "labels": [[58, 72, "GGP"], [68, 72, "ENTITY"], [248, 261, "ENTITY"], [296, 303, "ENTITY"], [113, 127, "ENTITY"], [271, 283, "ENTITY"], [312, 322, "ENTITY"], [220, 231, "CHEBI"], [204, 213, "GENE_OR_GENE_PRODUCT"], [113, 127, "DISEASE"], [0, 12, "ENTITY"], [334, 344, "PROTEIN"], [58, 68, "GENE_OR_GENE_PRODUCT"], [369, 378, "ENTITY"], [334, 344, "ENTITY"], [381, 393, "ENTITY"], [68, 72, "PROTEIN"], [381, 393, "PROTEIN"], [0, 12, "CHEMICAL"], [68, 72, "GGP"], [0, 12, "GENE_OR_GENE_PRODUCT"], [369, 378, "ORGANISM"], [381, 393, "CHEMICAL"], [171, 180, "ENTITY"], [312, 322, "PROTEIN"], [58, 72, "ENTITY"], [334, 344, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [190, 197, "PROTEIN"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "GGP"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [190, 197, "ENTITY"], [168, 173, "ENTITY"], [190, 197, "GENE_OR_GENE_PRODUCT"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "TBNK lymphocyte subset analysis revealed decreased percentage of CD16 + CD56 + lymphocytes ( 4/8 ) and Th/Ts ( 1/8 ) , and increased percentage of CD3 + ( 2/8 ) , CD4 + ( 4/8 ) and CD8 + ( 1/8 ) lymphocytes . Cytokine detection assays showed increased levels of IL-6 ( 2/8 ) , IL-10 ( 5/8 ) and IFN-\u03b3 ( 2/8 ) .", "labels": [[-1, 25, "ENTITY"], [281, 287, "GENE_OR_GENE_PRODUCT"], [199, 222, "ENTITY"], [127, 137, "ENTITY"], [127, 137, "GENE_OR_GENE_PRODUCT"], [41, 51, "ENTITY"], [5, 16, "CELL"], [266, 271, "ENTITY"], [281, 293, "PROTEIN"], [127, 137, "ENTITY"], [5, 16, "ENTITY"], [0, 5, "ENTITY"], [281, 287, "ENTITY"], [159, 199, "CELL_TYPE"], [239, 246, "ENTITY"], [175, 199, "ENTITY"], [127, 137, "PROTEIN"], [51, 65, "GGP"], [65, 70, "GENE_OR_GENE_PRODUCT"], [232, 239, "ENTITY"], [281, 287, "CHEMICAL"], [127, 137, "GGP"], [5, 16, "CL"], [51, 62, "GENE_OR_GENE_PRODUCT"], [137, 157, "ENTITY"], [-1, 25, "CELL_LINE"], [137, 157, "CELL_TYPE"], [266, 271, "PROTEIN"], [185, 199, "CL"], [266, 271, "GGP"], [0, 23, "CELL_LINE"], [266, 271, "GENE_OR_GENE_PRODUCT"], [51, 62, "ENTITY"], [83, 95, "CL"]]}
{"text": "Among the differentially expressed functional molecules , the levels of interferon-\u03b3 ( IFN-\u03b3 ) and TNF-\u03b1 in CD4 + T cells were lower in the severe group than in the mild group , whereas the levels of granzyme B and perforin in CD8 + T cells were higher in the severe group than in the mild group .", "labels": [[140, 147, "ENTITY"], [62, 72, "ENTITY"], [35, 56, "ENTITY"], [62, 72, "GENE_OR_GENE_PRODUCT"], [133, 140, "ENTITY"], [105, 116, "ENTITY"], [140, 147, "ENTITY"], [215, 235, "ENTITY"], [25, 35, "ENTITY"], [62, 72, "PROTEIN"], [158, 170, "ENTITY"], [46, 56, "CHEBI"], [105, 116, "CELL_TYPE"], [161, 170, "ENTITY"], [215, 235, "CELL_TYPE"], [215, 224, "GENE_OR_GENE_PRODUCT"], [10, 25, "ENTITY"], [62, 72, "GGP"], [215, 235, "GGP"], [105, 116, "GGP"]]}
{"text": "Compared with the healthy control and mild group , the frequency of multi-functional CD4 + T cells ( positive for at least two cytokines ) decreased significantly in the severe group , whereas the proportion of non-functional ( IFN-\u03b3 \u2212TNF-\u03b1\u2212IL-2\u2212 ) subsets increased significantly .", "labels": [[211, 228, "ENTITY"], [127, 139, "ENTITY"], [38, 49, "ENTITY"], [170, 177, "ENTITY"], [234, 249, "ENTITY"], [68, 93, "CELL_TYPE"], [18, 34, "ENTITY"], [197, 211, "ENTITY"], [89, 93, "CL"], [0, 9, "ENTITY"], [249, 257, "ENTITY"], [211, 228, "GENE_OR_GENE_PRODUCT"], [85, 93, "ENTITY"]]}
{"text": "The reduced expressions of interferon-\u03b3 ( IFN-\u03b3 ) by CD4+T , CD8+T and NK cells below LLN were observed in some patients with severe ( 50 % , 16.7 % and 16.7 % ) or moderate COVID-19 ( 14.3 % , 0 % and 14.3 % ) .", "labels": [[27, 40, "ENTITY"], [165, 174, "ENTITY"], [27, 40, "GENE_OR_GENE_PRODUCT"], [4, 12, "ENTITY"], [27, 40, "PROTEIN"], [165, 174, "GENE_OR_GENE_PRODUCT"], [67, 74, "ENTITY"], [67, 74, "CELL"], [12, 24, "ENTITY"], [67, 74, "CL"], [153, 165, "ENTITY"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[214, 226, "PROTEIN"], [303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [235, 253, "CHEMICAL"], [127, 132, "CHEMICAL"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [235, 272, "GENE_OR_GENE_PRODUCT"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [214, 226, "GGP"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [235, 272, "GGP"], [235, 272, "PROTEIN"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [214, 226, "ENTITY"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [214, 226, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [235, 272, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Interestingly , serum levels of IFN-\u03b3 , IL-10 , IL-6 and TNF-\u03b1 were significantly decreased in these patients in the decline period as compared with illness period , while counts of total T cells , CD4 + , and CD8 + T cell subsets recovered during the decline period ( Figure 2C ) .", "labels": [[117, 125, "ENTITY"], [182, 190, "CL"], [68, 82, "ENTITY"], [182, 190, "CELL"], [16, 22, "ENTITY"], [260, 269, "ENTITY"], [206, 218, "GGP"], [149, 157, "ENTITY"], [206, 223, "ENTITY"], [117, 125, "ENTITY"], [190, 198, "ENTITY"], [179, 190, "CELL_TYPE"], [179, 190, "ENTITY"], [190, 223, "CELL_TYPE"], [190, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [144, 154, "GGP"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [208, 227, "GENE_OR_GENE_PRODUCT"], [40, 59, "ENTITY"], [26, 38, "SIMPLE_CHEMICAL"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GENE_OR_GENE_PRODUCT"], [253, 271, "ENTITY"], [26, 40, "CHEBI"], [170, 179, "GGP"], [26, 38, "CHEMICAL"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [144, 154, "PROTEIN"], [40, 59, "SIMPLE_CHEMICAL"], [144, 154, "ENTITY"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [26, 38, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [96, 103, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [89, 96, "PROTEIN"], [8, 20, "ORGANISM_SUBSTANCE"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [48, 55, "PROTEIN"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [82, 89, "GGP"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [82, 89, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [67, 72, "ENTITY"], [8, 20, "PROTEIN"], [119, 126, "PROTEIN"], [82, 89, "ENTITY"], [119, 126, "GENE_OR_GENE_PRODUCT"], [89, 96, "ENTITY"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [89, 96, "GGP"], [8, 15, "ENTITY"], [0, 8, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [96, 103, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [89, 96, "PROTEIN"], [8, 20, "ORGANISM_SUBSTANCE"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [48, 55, "PROTEIN"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [82, 89, "GGP"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [82, 89, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [67, 72, "ENTITY"], [8, 20, "PROTEIN"], [119, 126, "PROTEIN"], [82, 89, "ENTITY"], [119, 126, "GENE_OR_GENE_PRODUCT"], [89, 96, "ENTITY"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [89, 96, "GGP"], [8, 15, "ENTITY"], [0, 8, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "We found low levels of the chemokine MCP-1 ( CCL2 ) in the patient \u2019s plasma ( Extended Data Fig. 2a ) , although this was comparable to results obtained for healthy donors ( 22.15 \u00b1 13.81 ; n = 5 ) , patients infected with influenza A virus or influenza B , assessed at days 7\u20139 ( 33.85 \u00b1 30.12 ; n = 5 ) , and a patient infected with the human coronavirus HCoV-229e ( 40.56 ) .", "labels": [[191, 199, "ORGANISM"], [236, 245, "ENTITY"], [37, 43, "GENE_OR_GENE_PRODUCT"], [308, 314, "ENTITY"], [37, 43, "ENTITY"], [331, 358, "CHEMICAL"], [13, 20, "ENTITY"], [145, 158, "ENTITY"], [70, 88, "ENTITY"], [191, 199, "ENTITY"], [210, 219, "TAXON"], [55, 70, "ORGANISM"], [27, 43, "PROTEIN"], [67, 70, "ENTITY"], [346, 358, "GENE_OR_GENE_PRODUCT"], [9, 13, "ENTITY"], [322, 346, "ORGANISM"], [259, 268, "GENE_OR_GENE_PRODUCT"], [123, 137, "ENTITY"], [158, 166, "ENTITY"], [158, 166, "ORGANISM"], [210, 224, "ORGANISM"], [55, 67, "ENTITY"], [210, 245, "DISEASE"], [245, 257, "ENTITY"], [210, 224, "ENTITY"], [27, 37, "ENTITY"], [210, 219, "ENTITY"], [37, 43, "GGP"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [96, 103, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [89, 96, "PROTEIN"], [8, 20, "ORGANISM_SUBSTANCE"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [48, 55, "PROTEIN"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [82, 89, "GGP"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [82, 89, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [67, 72, "ENTITY"], [8, 20, "PROTEIN"], [119, 126, "PROTEIN"], [82, 89, "ENTITY"], [119, 126, "GENE_OR_GENE_PRODUCT"], [89, 96, "ENTITY"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [89, 96, "GGP"], [8, 15, "ENTITY"], [0, 8, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [96, 103, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [89, 96, "PROTEIN"], [8, 20, "ORGANISM_SUBSTANCE"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [48, 55, "PROTEIN"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [82, 89, "GGP"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [82, 89, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [67, 72, "ENTITY"], [8, 20, "PROTEIN"], [119, 126, "PROTEIN"], [82, 89, "ENTITY"], [119, 126, "GENE_OR_GENE_PRODUCT"], [89, 96, "ENTITY"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [89, 96, "GGP"], [8, 15, "ENTITY"], [0, 8, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [126, 137, "ENTITY"], [96, 103, "GENE_OR_GENE_PRODUCT"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [89, 96, "PROTEIN"], [8, 20, "ORGANISM_SUBSTANCE"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [48, 55, "PROTEIN"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [82, 89, "GGP"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [82, 89, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [67, 72, "ENTITY"], [8, 20, "PROTEIN"], [119, 126, "PROTEIN"], [82, 89, "ENTITY"], [119, 126, "GENE_OR_GENE_PRODUCT"], [89, 96, "ENTITY"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [89, 96, "GGP"], [8, 15, "ENTITY"], [0, 8, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "Among the differentially expressed functional molecules , the levels of interferon-\u03b3 ( IFN-\u03b3 ) and TNF-\u03b1 in CD4 + T cells were lower in the severe group than in the mild group , whereas the levels of granzyme B and perforin in CD8 + T cells were higher in the severe group than in the mild group .", "labels": [[140, 147, "ENTITY"], [62, 72, "ENTITY"], [35, 56, "ENTITY"], [62, 72, "GENE_OR_GENE_PRODUCT"], [133, 140, "ENTITY"], [105, 116, "ENTITY"], [140, 147, "ENTITY"], [215, 235, "ENTITY"], [25, 35, "ENTITY"], [62, 72, "PROTEIN"], [158, 170, "ENTITY"], [46, 56, "CHEBI"], [105, 116, "CELL_TYPE"], [161, 170, "ENTITY"], [215, 235, "CELL_TYPE"], [215, 224, "GENE_OR_GENE_PRODUCT"], [10, 25, "ENTITY"], [62, 72, "GGP"], [215, 235, "GGP"], [105, 116, "GGP"]]}
{"text": "Compared with the healthy control and mild group , the frequency of multi-functional CD4 + T cells ( positive for at least two cytokines ) decreased significantly in the severe group , whereas the proportion of non-functional ( IFN-\u03b3 \u2212TNF-\u03b1\u2212IL-2\u2212 ) subsets increased significantly .", "labels": [[234, 249, "ENTITY"], [211, 228, "ENTITY"], [127, 139, "ENTITY"], [38, 49, "ENTITY"], [170, 177, "ENTITY"], [68, 93, "CELL_TYPE"], [18, 34, "ENTITY"], [197, 211, "ENTITY"], [89, 93, "CL"], [0, 9, "ENTITY"], [249, 257, "ENTITY"], [211, 228, "GENE_OR_GENE_PRODUCT"], [85, 93, "ENTITY"]]}
{"text": "In any case , blocking IL-6 may be effective . Blocking IL-1 and TNF may also benefit patients .", "labels": [[47, 56, "PROTEIN"], [47, 56, "GENE_OR_GENE_PRODUCT"], [78, 86, "ORGANISM"], [78, 86, "ENTITY"], [7, 12, "ENTITY"], [47, 56, "ENTITY"], [47, 56, "GGP"]]}
{"text": "The levels of inflammatory cytokines ( IL-1 , TNF ) are high in the lungs of COVID-19 patients and these cytokines are strong inducers of HA-synthase-2 ( HAS2 ) in CD31 + endothelium , EpCAM + lung alveolar epithelial cells , and fibroblasts [ 13 ] .", "labels": [[77, 86, "ENTITY"], [14, 37, "ENTITY"], [164, 171, "ENTITY"], [14, 37, "PROTEIN"], [74, 86, "ORGANISM"], [159, 164, "PROTEIN"], [224, 230, "CL"], [224, 230, "ENTITY"], [171, 218, "CELL_TYPE"], [4, 11, "ENTITY"], [224, 230, "CELL_TYPE"], [159, 164, "GGP"], [159, 164, "GENE_OR_GENE_PRODUCT"], [185, 218, "CELL"], [171, 185, "ENTITY"], [171, 185, "GGP"], [185, 218, "ENTITY"], [138, 154, "GGP"], [138, 154, "PROTEIN"], [119, 126, "ENTITY"], [198, 218, "CL"], [159, 164, "ENTITY"], [171, 185, "GENE_OR_GENE_PRODUCT"], [224, 230, "CELL"], [138, 154, "GENE_OR_GENE_PRODUCT"], [138, 154, "ENTITY"]]}
{"text": "Of patients with available data , concentrations of interleukin 2 receptor , interleukin 6 , interleukin 8 , interleukin 10 , and tumour necrosis factor \u03b1 were significantly higher in deceased patients than in recovered patients .", "labels": [[126, 146, "PROTEIN"], [75, 89, "GENE_OR_GENE_PRODUCT"], [3, 12, "ENTITY"], [52, 66, "PROTEIN"], [75, 89, "PROTEIN"], [184, 193, "ORGANISM"], [75, 89, "ENTITY"], [27, 32, "ENTITY"], [52, 66, "GGP"], [52, 66, "GENE_OR_GENE_PRODUCT"], [75, 89, "GGP"], [202, 210, "ENTITY"], [52, 66, "ENTITY"], [126, 146, "ENTITY"], [184, 193, "ENTITY"], [126, 146, "GENE_OR_GENE_PRODUCT"], [210, 220, "ENTITY"], [210, 220, "ORGANISM"], [174, 184, "ENTITY"], [126, 146, "GGP"], [126, 137, "DISEASE"], [3, 12, "ORGANISM"]]}
{"text": "Evaluation of serum cytokines on admission revealed that levels of interleukin (IL)- 2R , IL-6 , IL-10 , and tumor necrosis factor-\u03b1 ( TNF-\u03b1 ) were markedly higher in severe cases than in moderate cases ( Figure 2 , Supplementary Table 1 ) .", "labels": [[205, 230, "GENE_OR_GENE_PRODUCT"], [105, 115, "DISEASE"], [157, 167, "ENTITY"], [33, 43, "ENTITY"], [124, 135, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [0, 11, "ENTITY"], [14, 20, "ENTITY"], [105, 124, "PROTEIN"], [14, 20, "ORGANISM_SUBSTANCE"], [124, 135, "PROTEIN"], [105, 124, "ENTITY"], [105, 124, "GENE_OR_GENE_PRODUCT"], [67, 88, "ENTITY"], [197, 205, "ENTITY"], [180, 188, "ENTITY"], [67, 88, "GGP"], [124, 135, "ENTITY"], [20, 30, "ENTITY"], [205, 230, "ENTITY"], [57, 64, "ENTITY"], [67, 88, "GENE_OR_GENE_PRODUCT"], [188, 197, "ENTITY"], [67, 88, "PROTEIN"], [14, 30, "PROTEIN"]]}
{"text": "In particular , in a recent study by Qin C , et al.in which among 452 patients with COVID-19 , most of them had increase of several inflammatory cytokines such as tumor necrosis factor (TNF)-\u03b1 , interleukin (IL)-1and IL-6 [ 3 ] .", "labels": [[207, 217, "PROTEIN"], [132, 145, "ENTITY"], [160, 185, "GGP"], [185, 195, "GENE_OR_GENE_PRODUCT"], [160, 185, "GENE_OR_GENE_PRODUCT"], [207, 217, "GGP"], [124, 145, "PROTEIN"], [160, 185, "PROTEIN"], [207, 217, "ENTITY"], [207, 217, "GENE_OR_GENE_PRODUCT"], [185, 195, "PROTEIN"], [185, 195, "GGP"], [37, 41, "ENTITY"], [185, 195, "ENTITY"], [160, 185, "ENTITY"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "We only found the levels of TNF-\u03b1 , IL-6 and IL-10 were significantly increased in infected patients , and statistical analysis illustrated that their levels in ICU patients are significantly higher than in Non-ICU patients ( Figure 2A ) .", "labels": [[161, 165, "ENTITY"], [207, 215, "ORGANISM"], [207, 215, "ENTITY"], [28, 34, "ENTITY"], [103, 119, "ENTITY"], [224, 233, "ENTITY"], [28, 34, "CHEMICAL"], [28, 34, "GENE_OR_GENE_PRODUCT"], [28, 34, "PROTEIN"], [161, 165, "ORGANISM"], [18, 25, "ENTITY"]]}
{"text": "Interestingly , serum levels of IFN-\u03b3 , IL-10 , IL-6 and TNF-\u03b1 were significantly decreased in these patients in the decline period as compared with illness period , while counts of total T cells , CD4 + , and CD8 + T cell subsets recovered during the decline period ( Figure 2C ) .", "labels": [[117, 125, "ENTITY"], [182, 190, "CL"], [68, 82, "ENTITY"], [182, 190, "CELL"], [16, 22, "ENTITY"], [260, 269, "ENTITY"], [206, 218, "GGP"], [149, 157, "ENTITY"], [206, 223, "ENTITY"], [117, 125, "ENTITY"], [190, 198, "ENTITY"], [179, 190, "CELL_TYPE"], [179, 190, "ENTITY"], [190, 223, "CELL_TYPE"], [190, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Another biomarker of uncontrolled pro-inflammatory cytokine response , TNF-\u03b1 , was up-regulated 40-fold during virus infection ( Figure 7D ) . Only the combination of ATV/RTV could significantly prevent the induction of TNF-\u03b1 release ( Figure 7D ) .", "labels": [[207, 220, "CHEMICAL"], [152, 167, "PROTEIN"], [34, 51, "ENTITY"], [207, 220, "GENE_OR_GENE_PRODUCT"], [152, 167, "ENTITY"], [8, 18, "ENTITY"], [71, 77, "ENTITY"], [207, 220, "PROTEIN"], [226, 236, "ENTITY"], [104, 117, "ENTITY"], [34, 60, "PROTEIN"], [152, 167, "CHEMICAL"], [104, 117, "DISEASE"], [152, 167, "GENE_OR_GENE_PRODUCT"], [207, 220, "ENTITY"], [127, 136, "ENTITY"], [21, 34, "ENTITY"]]}
{"text": "Initial plasma IL1B , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1A , MIP1B , PDGF , TNF\u03b1 , and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults ( appendix pp 6\u20137 ) .", "labels": [[162, 172, "ORGANISM"], [96, 103, "GENE_OR_GENE_PRODUCT"], [126, 137, "ENTITY"], [42, 48, "PROTEIN"], [36, 42, "GENE_OR_GENE_PRODUCT"], [119, 126, "ENTITY"], [36, 42, "ENTITY"], [162, 172, "ENTITY"], [219, 227, "ENTITY"], [119, 126, "GGP"], [82, 89, "PROTEIN"], [89, 96, "PROTEIN"], [8, 20, "ORGANISM_SUBSTANCE"], [181, 194, "ENTITY"], [67, 72, "CHEMICAL"], [48, 55, "PROTEIN"], [89, 96, "GENE_OR_GENE_PRODUCT"], [61, 65, "GENE_OR_GENE_PRODUCT"], [202, 216, "ENTITY"], [42, 48, "GENE_OR_GENE_PRODUCT"], [103, 109, "GGP"], [82, 89, "GGP"], [61, 65, "PROTEIN"], [61, 65, "CHEMICAL"], [96, 103, "ENTITY"], [96, 103, "GGP"], [89, 96, "CHEMICAL"], [103, 109, "GENE_OR_GENE_PRODUCT"], [82, 89, "GENE_OR_GENE_PRODUCT"], [36, 42, "DNA"], [96, 103, "CHEMICAL"], [181, 194, "ORGANISM"], [96, 103, "PROTEIN"], [177, 181, "ENTITY"], [67, 72, "GGP"], [103, 109, "PROTEIN"], [67, 72, "PROTEIN"], [67, 72, "GENE_OR_GENE_PRODUCT"], [42, 48, "ENTITY"], [67, 72, "ENTITY"], [8, 20, "PROTEIN"], [119, 126, "PROTEIN"], [82, 89, "ENTITY"], [119, 126, "GENE_OR_GENE_PRODUCT"], [89, 96, "ENTITY"], [15, 20, "ENTITY"], [103, 109, "ENTITY"], [61, 65, "GGP"], [89, 96, "GGP"], [8, 15, "ENTITY"], [0, 8, "ENTITY"], [61, 65, "ENTITY"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [246, 254, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [450, 483, "CL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [450, 483, "ENTITY"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "All patients had pneumonia . Common complications included ARDS ( 12 [ 29 % ] of 41 patients ) , followed by RNAaemia ( six [ 15 % ] patients ) , acute cardiac injury ( five [ 12 % ] patients ) , and secondary infection ( four [ 10 % ] patients ; table 3 ) .", "labels": [[210, 222, "ORGANISM"], [97, 109, "ENTITY"], [97, 109, "PROTEIN"], [78, 84, "ORGANISM"], [97, 109, "GENE_OR_GENE_PRODUCT"], [120, 131, "ENTITY"], [78, 84, "ENTITY"], [17, 27, "ENTITY"], [181, 200, "ENTITY"], [120, 131, "ORGANISM"], [167, 174, "ENTITY"], [4, 13, "ENTITY"], [84, 97, "ORGAN"], [133, 152, "DISEASE"], [167, 174, "ORGANISM"], [181, 200, "DISEASE"], [133, 152, "ENTITY"], [210, 222, "ENTITY"], [17, 27, "DISEASE"], [4, 13, "ORGANISM"]]}
{"text": "Patients with severe disease had a higher incidence of physician-diagnosed pneumonia than those with nonsevere disease ( 99.4 % vs. 89.5 % ) .", "labels": [[55, 85, "DISEASE"], [42, 52, "ENTITY"], [101, 119, "ENTITY"], [55, 85, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "ORGANISM"], [14, 29, "ENTITY"]]}
{"text": "A recent hypothesis suggested that angiotensin receptor 1 ( AT1R ) inhibitors might be beneficial for patients infected by COVID-19 who experience pneumonia ( Sun , Yang , Sun , & Su , 2020 ) .", "labels": [[35, 58, "ENTITY"], [35, 58, "GENE_OR_GENE_PRODUCT"], [35, 47, "CHEMICAL"], [35, 58, "PROTEIN"], [9, 20, "ENTITY"], [102, 111, "ENTITY"], [136, 147, "ENTITY"], [35, 58, "GGP"], [136, 147, "DISEASE"]]}
{"text": "If bacterial infection is suspected according to the patient \u2019s clinical and imaging findings , patients of mild type can take oral antibiotics for community-acquired pneumonia , such as second- generation cephalosporins or fluoroquinolones .", "labels": [[127, 132, "CHEBI"], [26, 36, "ENTITY"], [53, 61, "ENTITY"], [105, 113, "ENTITY"], [144, 167, "ENTITY"], [3, 23, "DISEASE"], [195, 206, "CHEBI"], [144, 167, "DISEASE"], [195, 206, "CHEMICAL"], [3, 23, "ENTITY"], [53, 61, "ORGANISM"], [3, 13, "TAXON"], [187, 206, "ENTITY"]]}
{"text": "The clinical manifestations of COVID-19 are protean , which include asymptomatic carrier , ARD , and pneumonia of varying degrees of severity . First , asymptomatic cases were diagnosed based on positive viral nucleic acid test results , but without any COVID-19 symptoms , such as fever , gastrointestinal , or respiratory symptoms , and no significant abnormalities on chest radiograph [ 7,8 ] .", "labels": [[186, 195, "ENTITY"], [290, 324, "ENTITY"], [68, 81, "ENTITY"], [223, 228, "ENTITY"], [31, 40, "ENTITY"], [31, 40, "ENTITY"], [144, 152, "ENTITY"], [114, 122, "ENTITY"], [242, 254, "ENTITY"], [204, 218, "CHEMICAL"], [354, 377, "ENTITY"], [342, 354, "ENTITY"], [282, 290, "ENTITY"], [195, 218, "TAXON"], [242, 254, "GENE_OR_GENE_PRODUCT"], [282, 290, "ORGAN"], [44, 52, "ENTITY"], [195, 223, "ENTITY"], [4, 28, "ENTITY"], [31, 40, "DISEASE"], [31, 40, "GENE_OR_GENE_PRODUCT"], [324, 342, "ENTITY"]]}
{"text": "Six patients had bilateral pneumonia and two unilateral pneumonia .", "labels": [[27, 37, "DISEASE"], [45, 56, "ENTITY"], [27, 37, "DISEASE"], [17, 37, "ENTITY"], [27, 37, "ENTITY"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "The bedside chest X-ray showed progression of the pneumonia , since the bilateral diffuse opacities , so-called \u201c white lungs \u201d , with air bronchogram occurred on February 15 ( Figure 3C , 3D and 3E ) .", "labels": [[50, 60, "DISEASE"], [177, 184, "ENTITY"], [50, 60, "ENTITY"], [135, 139, "DISEASE"], [31, 43, "ENTITY"], [4, 24, "ENTITY"], [130, 139, "ENTITY"], [72, 90, "ENTITY"], [135, 139, "ORGAN"], [114, 120, "MULTI-TISSUE_STRUCTURE"], [112, 120, "ENTITY"], [189, 192, "PROTEIN"], [189, 192, "ENTITY"]]}
{"text": "The viral infection incubation period varies from 2 to 14 days and typical clinical symptoms are fever , dry cough , dyspnea , headache , and pneumonia . Disease onset may result in progressive respiratory failure due to alveolar damage and even death ( Chan et al. 2020 ; Chen et al. 2020 ; Huang et al. 2020 ) .", "labels": [[172, 182, "ENTITY"], [182, 206, "DISEASE"], [75, 93, "ENTITY"], [31, 38, "ENTITY"], [97, 103, "DISEASE"], [105, 109, "DISEASE"], [214, 230, "DISEASE"], [214, 221, "TISSUE"], [4, 20, "ENTITY"], [4, 20, "DISEASE"], [105, 109, "ENTITY"], [142, 162, "ENTITY"], [182, 206, "ENTITY"], [97, 103, "ENTITY"], [4, 10, "TAXON"], [214, 230, "ENTITY"], [58, 63, "ENTITY"], [20, 31, "ENTITY"]]}
{"text": "Finally , although most radiographic presentations were similar between patients with COVID-19 with and without GI symptoms , the rate of unilateral pneumonia was 12.16 % in patients with GI symptoms , much lower than 23.22 % in those without GI symptoms ( p=0.030 ) .", "labels": [[183, 191, "ENTITY"], [138, 149, "ENTITY"], [112, 115, "ENTITY"], [104, 115, "ENTITY"], [138, 149, "DISEASE"]]}
{"text": "A chest radiographic image showed pneumonia , but other laboratory tests ( except procalcitonin ) were normal", "labels": [[2, 8, "ENTITY"], [34, 44, "DISEASE"], [56, 67, "ENTITY"], [34, 44, "ENTITY"]]}
{"text": "A chest radiographic image showed pneumonia .", "labels": [[2, 27, "ENTITY"], [34, 44, "DISEASE"], [34, 44, "ENTITY"]]}
{"text": "Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation , caffeine , and antibiotics .", "labels": [[137, 147, "ENTITY"], [152, 176, "ENTITY"], [66, 72, "MULTI-TISSUE_STRUCTURE"], [66, 91, "ENTITY"], [9, 39, "DISEASE"], [9, 39, "ENTITY"], [126, 131, "ENTITY"], [43, 53, "ENTITY"], [0, 9, "ENTITY"], [43, 53, "DISEASE"], [116, 120, "ENTITY"], [94, 104, "ENTITY"]]}
{"text": "During hospital admission , most of the patients received a diagnosis of pneumonia from a physician ( 91.1 % ) , followed by ARDS ( 3.4 % ) and shock ( 1.1 % ) .", "labels": [[113, 125, "ENTITY"], [7, 26, "ENTITY"], [113, 125, "DISEASE"]]}
{"text": "Chest CT scan revealed bilateral pneumonia in all patients", "labels": [[23, 43, "ENTITY"], [6, 9, "PROTEIN"], [33, 43, "DISEASE"], [0, 14, "ENTITY"]]}
{"text": "All patients had pneumonia . Common complications included ARDS ( 12 [ 29 % ] of 41 patients ) , followed by RNAaemia ( six [ 15 % ] patients ) , acute cardiac injury ( five [ 12 % ] patients ) , and secondary infection ( four [ 10 % ] patients ; table 3 ) .", "labels": [[210, 222, "ORGANISM"], [97, 109, "ENTITY"], [17, 27, "DISEASE"], [97, 109, "PROTEIN"], [78, 84, "ORGANISM"], [97, 109, "GENE_OR_GENE_PRODUCT"], [120, 131, "ENTITY"], [17, 27, "ENTITY"], [78, 84, "ENTITY"], [181, 200, "ENTITY"], [120, 131, "ORGANISM"], [167, 174, "ENTITY"], [4, 13, "ENTITY"], [84, 97, "ORGAN"], [133, 152, "DISEASE"], [167, 174, "ORGANISM"], [181, 200, "DISEASE"], [133, 152, "ENTITY"], [210, 222, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "All patients had pneumonia . Common complications included ARDS ( 12 [ 29 % ] of 41 patients ) , followed by RNAaemia ( six [ 15 % ] patients ) , acute cardiac injury ( five [ 12 % ] patients ) , and secondary infection ( four [ 10 % ] patients ; table 3 ) .", "labels": [[210, 222, "ORGANISM"], [97, 109, "ENTITY"], [17, 27, "DISEASE"], [97, 109, "PROTEIN"], [78, 84, "ORGANISM"], [97, 109, "GENE_OR_GENE_PRODUCT"], [120, 131, "ENTITY"], [17, 27, "ENTITY"], [78, 84, "ENTITY"], [181, 200, "ENTITY"], [120, 131, "ORGANISM"], [167, 174, "ENTITY"], [4, 13, "ENTITY"], [84, 97, "ORGAN"], [133, 152, "DISEASE"], [167, 174, "ORGANISM"], [181, 200, "DISEASE"], [133, 152, "ENTITY"], [210, 222, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "ACE2 in the gastrointestinal tract may underly early gastrointestinal symptoms such as nausea , vomiting , and diarrhea , and ACE2 in the heart may be related to cardiac damage and fulminant myocarditis that have been reported in COVID-19 [ 14,15 ] .", "labels": [[227, 241, "GENE_OR_GENE_PRODUCT"], [12, 35, "ORGAN"], [87, 94, "DISEASE"], [12, 29, "ORGAN"], [87, 94, "ENTITY"], [0, 5, "GGP"], [0, 5, "ENTITY"], [177, 191, "ENTITY"], [12, 35, "DISEASE"], [159, 170, "ENTITY"], [12, 35, "ENTITY"], [159, 170, "DISEASE"], [177, 191, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"], [53, 79, "ENTITY"], [0, 5, "PROTEIN"], [53, 79, "DISEASE"]]}
{"text": "Consistent with clinical observations , the lungs are the most injured organs , followed by moderate injury in the heart , liver , kidney , and brain .", "labels": [[16, 38, "ENTITY"], [0, 16, "ENTITY"], [123, 131, "ENTITY"], [92, 101, "ENTITY"], [123, 131, "ORGAN"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "All patients had pneumonia . Common complications included ARDS ( 12 [ 29 % ] of 41 patients ) , followed by RNAaemia ( six [ 15 % ] patients ) , acute cardiac injury ( five [ 12 % ] patients ) , and secondary infection ( four [ 10 % ] patients ; table 3 ) .", "labels": [[97, 109, "ENTITY"], [17, 27, "DISEASE"], [97, 109, "PROTEIN"], [78, 84, "ORGANISM"], [97, 109, "GENE_OR_GENE_PRODUCT"], [120, 131, "ENTITY"], [210, 222, "ENTITY"], [17, 27, "ENTITY"], [78, 84, "ENTITY"], [181, 200, "ENTITY"], [120, 131, "ORGANISM"], [167, 174, "ENTITY"], [4, 13, "ENTITY"], [84, 97, "ORGAN"], [133, 152, "DISEASE"], [167, 174, "ORGANISM"], [181, 200, "DISEASE"], [133, 152, "ENTITY"], [210, 222, "ORGANISM"], [4, 13, "ORGANISM"]]}
{"text": "All patients were administered with empirical antibiotic treatment , and 38 ( 93 % ) patients received antiviral therapy ( oseltamivir ) .", "labels": [[46, 57, "CHEBI"], [36, 46, "ENTITY"], [18, 31, "ENTITY"], [94, 113, "ENTITY"], [113, 123, "CHEMICAL"], [46, 67, "ENTITY"], [113, 123, "ENTITY"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "SARS-CoV-2 was found to be a positive-sense , single-stranded RNA virus belonging to the genus Betacoronavirus [ 22\u201324 ] .", "labels": [[95, 113, "CHEMICAL"], [62, 66, "SO"], [0, 11, "SIMPLE_CHEMICAL"], [29, 44, "ENTITY"], [0, 11, "ENTITY"], [0, 11, "CHEMICAL"], [46, 66, "ENTITY"]]}
{"text": "Until today , six different strains of Human coronaviruses ( HCoVs ) have been reported , in addition to the newly emerged COVID-19 [ 2,12 ] . 229E and NL63 strains of HCoVs belong to Alphacoronaviruses while OC43 , HKU1 , SARS , MERS , and COVID-19 HCoVs belong to Betacoronaviruses [ 2,11 ] .", "labels": [[28, 36, "ORGANISM"], [39, 45, "ORGANISM"], [39, 45, "ENTITY"], [39, 45, "PROTEIN"], [28, 36, "PROTEIN"], [174, 184, "GENE_OR_GENE_PRODUCT"], [230, 241, "ENTITY"], [230, 241, "GENE_OR_GENE_PRODUCT"], [143, 157, "ORGANISM"], [115, 123, "ENTITY"], [174, 184, "ORGANISM"], [28, 36, "ENTITY"], [174, 184, "ENTITY"], [143, 157, "ENTITY"], [28, 36, "DISEASE"], [230, 241, "PROTEIN"], [174, 184, "ENTITY"], [115, 134, "GENE_OR_GENE_PRODUCT"], [203, 214, "PROTEIN"]]}
{"text": "Among adult patients , cardiovascular disease and hypertension were the most common underlying diseases , followed by diabetes mellitus .", "labels": [[12, 21, "ORGANISM"], [115, 127, "DISEASE"], [23, 38, "ENTITY"], [115, 127, "ENTITY"], [12, 21, "ENTITY"], [23, 38, "DISEASE"], [6, 12, "ENTITY"]]}
{"text": "Among adult patients , cardiovascular disease and hypertension were the most common underlying diseases , followed by diabetes mellitus .", "labels": [[12, 21, "ORGANISM"], [115, 127, "DISEASE"], [23, 38, "ENTITY"], [115, 127, "ENTITY"], [23, 38, "DISEASE"], [12, 21, "ENTITY"], [6, 12, "ENTITY"]]}
{"text": "Among the overall population , 23.7 % had at least one coexisting illness ( e.g. , hypertension and chronic obstructive pulmonary disease ) .", "labels": [[108, 120, "ORGAN"], [10, 29, "ENTITY"], [96, 130, "DISEASE"], [96, 130, "ENTITY"], [76, 83, "ENTITY"], [76, 83, "DISEASE"], [55, 66, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [50, 60, "ENTITY"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [136, 146, "ORGAN"], [136, 158, "ENTITY"], [144, 166, "ENTITY"], [254, 285, "ENTITY"]]}
{"text": "Comorbidities were present in nearly half of patients , with hypertension being the most common comorbidity , followed by diabetes and coronary heart disease ( table 1 ) .", "labels": [[0, 14, "ENTITY"], [131, 150, "ENTITY"], [131, 150, "DISEASE"], [131, 144, "CANCER"], [45, 54, "ENTITY"], [45, 54, "ORGANISM"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "In this study , Guan et al reported more severe disease outcomes in patients with hypertension , coronary artery disease , diabetes , and chronic renal disease ( Table 1 ) . 6", "labels": [[8, 14, "ENTITY"], [134, 152, "DISEASE"], [134, 152, "ENTITY"], [95, 113, "DISEASE"], [95, 113, "ENTITY"], [138, 146, "ORGAN"], [95, 106, "MULTI-TISSUE_STRUCTURE"], [48, 56, "ENTITY"]]}
{"text": "In an analysis of 45,000 confirmed cases in China , the crude case fatality rate was 0.9 % for patients without any documented comorbidities , whereas the case fatality rate was much higher for patients with CVD ( 10.5 % ) , diabetes ( 7.3 % ) , or hypertension ( 6.3 % )", "labels": [[151, 160, "ENTITY"], [116, 127, "ENTITY"], [56, 67, "ENTITY"], [44, 50, "ENTITY"], [6, 15, "ENTITY"], [236, 249, "ENTITY"], [35, 41, "ENTITY"], [236, 249, "DISEASE"]]}
{"text": "In comparison with patients with mild COVID-19 ( such as those who did not require ICU stays , did not develop ARDS or pneumonia , and who survived ) , patients with severe COVID-19 have higher comorbidities , including 56 % for hypertension , 21 % for heart diseases , 18 % for diabetes , 12 % for cerebrovascular diseases , and 7 % for cancer ( Table 1 ) ( 79 , 97 ) .", "labels": [[103, 111, "DISEASE"], [129, 135, "CANCER"], [223, 229, "DISEASE"], [38, 47, "DISEASE"], [19, 28, "ORGANISM"], [279, 299, "ENTITY"], [244, 259, "ENTITY"], [129, 135, "ENTITY"], [244, 259, "DISEASE"], [33, 47, "ENTITY"], [129, 135, "DISEASE"], [279, 299, "DISEASE"], [223, 229, "ENTITY"], [3, 14, "ENTITY"], [103, 111, "ENTITY"], [38, 47, "GENE_OR_GENE_PRODUCT"], [166, 173, "DISEASE"], [187, 194, "ENTITY"], [166, 173, "ENTITY"], [166, 173, "GENE_OR_GENE_PRODUCT"], [19, 28, "ENTITY"]]}
{"text": "Hypertension , cardiovascular disease , and cerebrovascular disease were much more frequent among deceased patients ( 54 ( 48 % ) , 16 ( 14 % ) , and 4 ( 4 % ) ) than among recovered patients ( 39 ( 24 % ) , 7 ( 4 % ) , and 0 ( 0 % ) ) .", "labels": [[15, 30, "ENTITY"], [40, 60, "ENTITY"], [0, 13, "ENTITY"], [98, 107, "ENTITY"], [15, 30, "DISEASE"], [158, 167, "ENTITY"], [40, 60, "DISEASE"], [98, 107, "ORGANISM"], [0, 13, "DISEASE"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [259, 269, "ORGAN"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Among adult patients , cardiovascular disease and hypertension were the most common underlying diseases , followed by diabetes mellitus .", "labels": [[12, 21, "ORGANISM"], [115, 127, "DISEASE"], [23, 38, "ENTITY"], [23, 38, "DISEASE"], [12, 21, "ENTITY"], [115, 127, "ENTITY"], [6, 12, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [50, 60, "ENTITY"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [136, 146, "ORGAN"], [136, 158, "ENTITY"], [144, 166, "ENTITY"], [254, 285, "ENTITY"]]}
{"text": "Comorbidities were present in nearly half of patients , with hypertension being the most common comorbidity , followed by diabetes and coronary heart disease ( table 1 ) .", "labels": [[0, 14, "ENTITY"], [131, 150, "ENTITY"], [131, 150, "DISEASE"], [131, 144, "CANCER"], [45, 54, "ENTITY"], [45, 54, "ORGANISM"]]}
{"text": "In this study , Guan et al reported more severe disease outcomes in patients with hypertension , coronary artery disease , diabetes , and chronic renal disease ( Table 1 ) . 6", "labels": [[8, 14, "ENTITY"], [134, 152, "DISEASE"], [134, 152, "ENTITY"], [95, 113, "DISEASE"], [95, 113, "ENTITY"], [138, 146, "ORGAN"], [95, 106, "MULTI-TISSUE_STRUCTURE"], [48, 56, "ENTITY"]]}
{"text": "In an analysis of 45,000 confirmed cases in China , the crude case fatality rate was 0.9 % for patients without any documented comorbidities , whereas the case fatality rate was much higher for patients with CVD ( 10.5 % ) , diabetes ( 7.3 % ) , or hypertension ( 6.3 % )", "labels": [[151, 160, "ENTITY"], [116, 127, "ENTITY"], [56, 67, "ENTITY"], [44, 50, "ENTITY"], [6, 15, "ENTITY"], [236, 249, "ENTITY"], [35, 41, "ENTITY"], [236, 249, "DISEASE"]]}
{"text": "In comparison with patients with mild COVID-19 ( such as those who did not require ICU stays , did not develop ARDS or pneumonia , and who survived ) , patients with severe COVID-19 have higher comorbidities , including 56 % for hypertension , 21 % for heart diseases , 18 % for diabetes , 12 % for cerebrovascular diseases , and 7 % for cancer ( Table 1 ) ( 79 , 97 ) .", "labels": [[103, 111, "DISEASE"], [129, 135, "CANCER"], [223, 229, "DISEASE"], [38, 47, "DISEASE"], [19, 28, "ORGANISM"], [279, 299, "ENTITY"], [244, 259, "ENTITY"], [129, 135, "ENTITY"], [244, 259, "DISEASE"], [33, 47, "ENTITY"], [129, 135, "DISEASE"], [279, 299, "DISEASE"], [223, 229, "ENTITY"], [3, 14, "ENTITY"], [103, 111, "ENTITY"], [38, 47, "GENE_OR_GENE_PRODUCT"], [166, 173, "DISEASE"], [187, 194, "ENTITY"], [166, 173, "ENTITY"], [166, 173, "GENE_OR_GENE_PRODUCT"], [19, 28, "ENTITY"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [259, 269, "ORGAN"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Comorbidities , including diabetes mellitus , cardiovascular and cerebrovascular diseases , were found in 4 and 5 of the patients from the DIP and control group , respectively .", "labels": [[44, 81, "DISEASE"], [0, 14, "ENTITY"], [26, 35, "DISEASE"], [143, 155, "ENTITY"], [61, 81, "ENTITY"], [26, 35, "ENTITY"]]}
{"text": "Fever was the most common symptom ( 92.8 % ; n = 258 ) , followed by cough ( 69.8 % ; n = 194 ) , dyspnoea ( 34.5 % ; n = 96 ) , myalgia ( 27.7 % ; n = 77 ) , headache ( 7.2 % ; n = 20 ) and diarrhoea ( 6.1 % ; n = 17 ) .", "labels": [[57, 69, "DISEASE"], [26, 34, "ENTITY"], [41, 49, "DISEASE"], [0, 6, "DISEASE"], [0, 6, "ENTITY"], [57, 69, "ENTITY"], [41, 49, "ENTITY"]]}
{"text": "The clinical features include fever , dry cough , shortness of breath , normal or low levels of peripheral white blood cells , and inflammatory changes on chest X-ray .", "labels": [[48, 63, "ENTITY"], [38, 42, "ENTITY"], [107, 119, "CELL"], [4, 22, "ENTITY"], [107, 119, "CL"], [82, 86, "ENTITY"], [127, 144, "ENTITY"], [30, 36, "ENTITY"], [38, 42, "DISEASE"], [48, 63, "DISEASE"], [152, 161, "ENTITY"], [93, 119, "ENTITY"], [93, 119, "CELL_TYPE"], [30, 36, "DISEASE"]]}
{"text": "She developed chest tightness , shortness of breath , loss of appetite , 62 nausea , and diarrhea", "labels": [[52, 62, "ENTITY"], [52, 62, "DISEASE"], [4, 14, "ENTITY"], [14, 30, "ENTITY"], [32, 45, "ENTITY"], [14, 30, "DISEASE"], [32, 45, "DISEASE"]]}
{"text": "The viral infection incubation period varies from 2 to 14 days and typical clinical symptoms are fever , dry cough , dyspnea , headache , and pneumonia . Disease onset may result in progressive respiratory failure due to alveolar damage and even death ( Chan et al. 2020 ; Chen et al. 2020 ; Huang et al. 2020 ) .", "labels": [[172, 182, "ENTITY"], [182, 206, "DISEASE"], [75, 93, "ENTITY"], [31, 38, "ENTITY"], [97, 103, "DISEASE"], [105, 109, "DISEASE"], [214, 230, "DISEASE"], [214, 221, "TISSUE"], [4, 20, "ENTITY"], [4, 20, "DISEASE"], [105, 109, "ENTITY"], [182, 206, "ENTITY"], [97, 103, "ENTITY"], [142, 162, "ENTITY"], [4, 10, "TAXON"], [214, 230, "ENTITY"], [58, 63, "ENTITY"], [20, 31, "ENTITY"]]}
{"text": "Recent studies have shown that in addition to dyspnea , hypoxemia , and acute respiratory distress , lymphopenia , and cytokine release syndrome are also important clinical features in patients with severe SARS- CoV-2 infection.3", "labels": [[46, 54, "ENTITY"], [212, 218, "ENTITY"], [46, 54, "DISEASE"], [199, 212, "ENTITY"], [115, 128, "ENTITY"], [154, 173, "ENTITY"], [68, 90, "ENTITY"], [199, 218, "PROTEIN"], [68, 90, "DISEASE"], [128, 136, "ENTITY"], [7, 15, "ENTITY"], [199, 212, "ORGANISM"]]}
{"text": "On presentation , the most common symptom was fever in 22 patients ( 96 % ) , followed by cough in five ( 22 % ) , chills in four ( 17 % ) , and dyspnoea in four ( 17 % ; table ) .", "labels": [[78, 90, "DISEASE"], [3, 16, "ENTITY"], [78, 90, "ENTITY"]]}
{"text": "Dyspnoea was significantly more frequent among the ten patients with severe disease than among those with mild disease ( four [ 40 % ] of ten vs none [ 0 % ] of 13 ; p=0\u00b7024 ) .", "labels": [[0, 9, "DISEASE"], [55, 64, "ORGANISM"], [55, 64, "ENTITY"], [69, 84, "ENTITY"], [32, 41, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [0, 9, "ENTITY"], [106, 119, "ENTITY"]]}
{"text": "Fever , cough and sputum production were the most common symptoms . Of the aforementioned symptoms , 29 ( 39.19 % ) , 23 ( 31.08 % ) , 8 ( 10.81 % ) and 16 ( 21.62 % ) patients with COVID-19 with GI symptoms had > 38.5 \u00b0 C fever , fatigue , shortness of breath and headache , respectively , substantially higher than their respective counterparts without GI symptoms .", "labels": [[241, 251, "ENTITY"], [276, 287, "ENTITY"], [208, 214, "ENTITY"], [276, 287, "ORGAN"], [241, 251, "DISEASE"], [177, 191, "ENTITY"], [57, 66, "DISEASE"], [57, 66, "ENTITY"], [208, 214, "DISEASE"], [219, 239, "ENTITY"], [149, 158, "ORGANISM"], [149, 158, "ENTITY"], [0, 6, "DISEASE"], [75, 90, "ENTITY"], [0, 6, "ENTITY"], [219, 239, "DISEASE"], [18, 25, "ENTITY"]]}
{"text": "Compared to moderate cases , chest tightness tended to be more common in severe cases . In addition , tachypnea and dyspnea were only developed in severe cases .", "labels": [[29, 35, "DISEASE"], [21, 27, "ENTITY"], [73, 80, "ENTITY"], [0, 9, "ENTITY"], [12, 21, "ENTITY"], [29, 35, "ENTITY"]]}
{"text": "Through a literature review , we identified a list of important symptoms and mechanisms linked to SARS-CoV-2 , including fever , fatigue , cough 17 , breathing difficulty , septic shock , viral proliferation , immunodeficiency and pulmonary fibrosis 18 ( Figure 4 ) .", "labels": [[145, 160, "ENTITY"], [180, 194, "ENTITY"], [180, 186, "TAXON"], [160, 180, "ENTITY"], [129, 139, "DISEASE"], [231, 241, "DISEASE"], [194, 210, "ORGANISM"], [210, 241, "ENTITY"], [194, 210, "ENTITY"], [241, 255, "ENTITY"], [210, 231, "ORGAN"], [160, 180, "DISEASE"], [129, 139, "ENTITY"], [111, 121, "DISEASE"], [111, 121, "ENTITY"], [10, 28, "ENTITY"]]}
{"text": "Imaging examination revealed that most patients with fever , dry cough , and dyspnoea showed bilateral ground-glass opacities on chest CT scans 14 .", "labels": [[86, 116, "ENTITY"], [39, 48, "ENTITY"], [61, 65, "ENTITY"], [39, 48, "ORGANISM"], [61, 65, "DISEASE"], [0, 20, "ENTITY"], [126, 138, "ENTITY"], [53, 59, "DISEASE"], [53, 59, "ENTITY"]]}
{"text": "The majority ( n = 154 [ 76.6 % ] ) of patients had fever with cough ; 74 ( 36.8 % ) had feverwith dyspnea ; 66 ( 32.8 % ) had feverwith fatigue , myalgia , or headache ; and only 13 ( 6.5 % ) presentedwith fever alone ( eTable 1 in the Supplement ) .", "labels": [[34, 39, "ENTITY"], [81, 89, "ENTITY"], [213, 228, "ENTITY"], [89, 99, "ENTITY"], [81, 89, "DISEASE"], [34, 39, "ORGANISM"], [114, 127, "ENTITY"], [89, 99, "DISEASE"]]}
{"text": "On day 2 of life , the infant experienced lethargy and fever , with unremarkable physical examination results , and was moved to the neonatal intensive care unit .", "labels": [[133, 157, "ENTITY"], [3, 7, "ENTITY"], [90, 102, "ENTITY"], [129, 157, "DNA"], [12, 17, "ENTITY"], [68, 90, "ENTITY"]]}
{"text": "He presented with lethargy , vomiting , and fever .", "labels": [[18, 27, "DISEASE"], [18, 27, "ENTITY"]]}
{"text": "Fever and cough were the most prevalent symptoms at disease onset in both deceased patients ( 104 ( 92 % ) and 79 ( 70 % ) ) and recovered patients ( 145 ( 90 % ) and 106 ( 66 % ) ) , and the proportions of patients reporting these symptoms in the two groups were comparable .", "labels": [[121, 129, "ENTITY"], [129, 139, "ENTITY"], [40, 49, "ENTITY"], [83, 92, "ENTITY"], [74, 83, "ENTITY"], [52, 66, "ENTITY"], [0, 6, "DISEASE"], [129, 139, "ORGANISM"], [83, 92, "ORGANISM"], [0, 6, "ENTITY"], [30, 40, "ENTITY"], [10, 16, "ENTITY"], [40, 49, "ENTITY"], [10, 16, "DISEASE"]]}
{"text": "Persons infected with SARS-CoV-2 present with a wide range of symptoms similar to other respiratory infections ( e.g. , fever , cough , and shortness of breath ) or may be silent carriers .", "labels": [[88, 111, "DISEASE"], [88, 111, "ENTITY"], [62, 71, "ENTITY"], [136, 153, "ENTITY"], [165, 172, "ENTITY"], [172, 179, "ENTITY"], [136, 153, "DISEASE"], [0, 8, "ENTITY"], [22, 33, "SIMPLE_CHEMICAL"], [22, 33, "ENTITY"], [8, 17, "ENTITY"], [22, 33, "CHEMICAL"]]}
{"text": "Imaging examination revealed that most patients with fever , dry cough , and dyspnoea showed bilateral ground-glass opacities on chest CT scans 14 .", "labels": [[86, 116, "ENTITY"], [39, 48, "ENTITY"], [61, 65, "ENTITY"], [39, 48, "ORGANISM"], [61, 65, "DISEASE"], [53, 59, "ENTITY"], [53, 59, "DISEASE"], [0, 20, "ENTITY"], [126, 138, "ENTITY"]]}
{"text": "The majority ( n = 154 [ 76.6 % ] ) of patients had fever with cough ; 74 ( 36.8 % ) had feverwith dyspnea ; 66 ( 32.8 % ) had feverwith fatigue , myalgia , or headache ; and only 13 ( 6.5 % ) presentedwith fever alone ( eTable 1 in the Supplement ) .", "labels": [[34, 39, "ENTITY"], [89, 99, "DISEASE"], [81, 89, "ENTITY"], [213, 228, "ENTITY"], [89, 99, "ENTITY"], [81, 89, "DISEASE"], [34, 39, "ORGANISM"], [114, 127, "ENTITY"]]}
{"text": "Fever and cough were the most prevalent symptoms at disease onset in both deceased patients ( 104 ( 92 % ) and 79 ( 70 % ) ) and recovered patients ( 145 ( 90 % ) and 106 ( 66 % ) ) , and the proportions of patients reporting these symptoms in the two groups were comparable .", "labels": [[121, 129, "ENTITY"], [129, 139, "ENTITY"], [40, 49, "ENTITY"], [83, 92, "ENTITY"], [74, 83, "ENTITY"], [52, 66, "ENTITY"], [129, 139, "ORGANISM"], [10, 16, "ENTITY"], [83, 92, "ORGANISM"], [10, 16, "DISEASE"], [0, 6, "DISEASE"], [0, 6, "ENTITY"], [30, 40, "ENTITY"], [40, 49, "ENTITY"]]}
{"text": "Persons infected with SARS-CoV-2 present with a wide range of symptoms similar to other respiratory infections ( e.g. , fever , cough , and shortness of breath ) or may be silent carriers .", "labels": [[88, 111, "DISEASE"], [88, 111, "ENTITY"], [62, 71, "ENTITY"], [136, 153, "ENTITY"], [165, 172, "ENTITY"], [172, 179, "ENTITY"], [136, 153, "DISEASE"], [0, 8, "ENTITY"], [22, 33, "SIMPLE_CHEMICAL"], [22, 33, "ENTITY"], [8, 17, "ENTITY"], [22, 33, "CHEMICAL"]]}
{"text": "All patients manifested cough and most of them felt shortness of breath , and 60.0 % patients had nausea and vomiting", "labels": [[52, 65, "ENTITY"], [52, 72, "DISEASE"], [65, 72, "ENTITY"], [24, 30, "DISEASE"], [24, 30, "ENTITY"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Imaging examination revealed that most patients with fever , dry cough , and dyspnoea showed bilateral ground-glass opacities on chest CT scans 14 .", "labels": [[86, 116, "ENTITY"], [39, 48, "ENTITY"], [61, 65, "ENTITY"], [39, 48, "ORGANISM"], [61, 65, "DISEASE"], [53, 59, "ENTITY"], [53, 59, "DISEASE"], [0, 20, "ENTITY"], [126, 138, "ENTITY"]]}
{"text": "The majority ( n = 154 [ 76.6 % ] ) of patients had fever with cough ; 74 ( 36.8 % ) had feverwith dyspnea ; 66 ( 32.8 % ) had feverwith fatigue , myalgia , or headache ; and only 13 ( 6.5 % ) presentedwith fever alone ( eTable 1 in the Supplement ) .", "labels": [[34, 39, "ENTITY"], [89, 99, "DISEASE"], [81, 89, "ENTITY"], [213, 228, "ENTITY"], [89, 99, "ENTITY"], [81, 89, "DISEASE"], [34, 39, "ORGANISM"], [114, 127, "ENTITY"]]}
{"text": "The most common symptom was shortness of breath ( 4 of 33 neonates )", "labels": [[28, 48, "DISEASE"], [16, 24, "ENTITY"], [28, 48, "ENTITY"]]}
{"text": "Persons infected with SARS-CoV-2 present with a wide range of symptoms similar to other respiratory infections ( e.g. , fever , cough , and shortness of breath ) or may be silent carriers .", "labels": [[88, 111, "DISEASE"], [88, 111, "ENTITY"], [62, 71, "ENTITY"], [136, 153, "ENTITY"], [165, 172, "ENTITY"], [172, 179, "ENTITY"], [136, 153, "DISEASE"], [0, 8, "ENTITY"], [22, 33, "SIMPLE_CHEMICAL"], [22, 33, "ENTITY"], [8, 17, "ENTITY"], [22, 33, "CHEMICAL"]]}
{"text": "All patients manifested cough and most of them felt shortness of breath , and 60.0 % patients had nausea and vomiting", "labels": [[52, 65, "ENTITY"], [24, 30, "ENTITY"], [24, 30, "DISEASE"], [65, 72, "ENTITY"], [52, 72, "DISEASE"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "However , the most characteristic symptom of patients is respiratory distress ( ~55 % ) .", "labels": [[57, 69, "ENTITY"], [57, 69, "DISEASE"]]}
{"text": "Other prevalent symptoms at onset of illness in deceased patients included fatigue , dyspnoea , chest tightness , and sputum production ; less common symptoms included anorexia , diarrhoea , and myalgia .", "labels": [[112, 118, "DISEASE"], [143, 150, "ENTITY"], [168, 179, "DISEASE"], [66, 75, "ENTITY"], [112, 118, "ENTITY"], [114, 125, "ENTITY"], [16, 25, "ENTITY"], [168, 179, "ENTITY"], [48, 57, "ENTITY"], [28, 37, "ENTITY"], [94, 102, "DISEASE"], [66, 75, "CANCER"], [75, 83, "DISEASE"], [94, 102, "ENTITY"], [75, 83, "ENTITY"], [57, 66, "ORGANISM"], [66, 75, "DISEASE"], [37, 45, "ENTITY"], [6, 16, "ENTITY"], [57, 66, "ENTITY"]]}
{"text": "The second most common symptom was cough ( 67.8 % ) ; nausea or vomiting ( 5.0 % ) and diarrhea ( 3.8 % ) were uncommon .", "labels": [[23, 31, "ENTITY"], [35, 41, "ENTITY"], [81, 87, "ENTITY"], [81, 87, "DISEASE"], [35, 41, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[219, 230, "DISEASE"], [7, 14, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "DISEASE"], [150, 168, "DISEASE"], [126, 150, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "In detail , of 74 patients with COVID-19 with GI symptoms , 53 patients had only the symptom of diarrhoea , 11 patients had only the symptom of vomiting and 10 patients had only the symptom of nausea .", "labels": [[46, 49, "DISEASE"], [46, 49, "ENTITY"]]}
{"text": "ACE2 in the gastrointestinal tract may underly early gastrointestinal symptoms such as nausea , vomiting , and diarrhea , and ACE2 in the heart may be related to cardiac damage and fulminant myocarditis that have been reported in COVID-19 [ 14,15 ] .", "labels": [[227, 241, "GENE_OR_GENE_PRODUCT"], [12, 35, "ORGAN"], [87, 94, "DISEASE"], [12, 29, "ORGAN"], [87, 94, "ENTITY"], [0, 5, "GGP"], [0, 5, "ENTITY"], [177, 191, "ENTITY"], [12, 35, "DISEASE"], [159, 170, "ENTITY"], [12, 35, "ENTITY"], [159, 170, "DISEASE"], [177, 191, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"], [53, 79, "ENTITY"], [0, 5, "PROTEIN"], [53, 79, "DISEASE"]]}
{"text": "Patients with at least one comorbidity were older ( mean : 60.8 versus 44.8 years ) , were more likely to have shortness of breath ( 41.4 % versus 17.8 % ) , nausea or vomiting ( 10.4 % versus 4.3 % ) , and tended to have abnormal chest X-ray manifestations ( 29.2 % versus 15.1 % ) ( table 1 ) .", "labels": [[27, 39, "ENTITY"], [219, 245, "ENTITY"], [160, 170, "DISEASE"], [44, 50, "ENTITY"], [209, 219, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "ORGANISM"], [27, 39, "DISEASE"], [108, 126, "DISEASE"], [209, 245, "DISEASE"], [108, 126, "ENTITY"], [160, 170, "ENTITY"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "Among the overall population , 23.7 % had at least one coexisting illness ( e.g. , hypertension and chronic obstructive pulmonary disease ) .", "labels": [[96, 130, "DISEASE"], [10, 29, "ENTITY"], [96, 130, "ENTITY"], [108, 120, "ORGAN"], [76, 83, "ENTITY"], [76, 83, "DISEASE"], [55, 66, "ENTITY"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "DISEASE"], [292, 299, "DISEASE"], [249, 278, "ENTITY"], [214, 237, "DISEASE"], [259, 269, "ORGAN"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer . Patients with severe disease had more prominent laboratory abnormalities ( including lymphocytopenia and leukopenia ) than those with nonsevere disease .", "labels": [[12, 21, "ENTITY"], [264, 274, "ENTITY"], [101, 109, "PROTEIN"], [155, 166, "PROTEIN"], [274, 294, "DISEASE"], [274, 294, "ENTITY"], [198, 210, "ENTITY"], [264, 274, "DISEASE"], [101, 109, "ENTITY"], [126, 138, "PROTEIN"], [44, 63, "GGP"], [126, 138, "GENE_OR_GENE_PRODUCT"], [25, 34, "ENTITY"], [179, 189, "ORGANISM"], [101, 109, "GGP"], [179, 189, "ENTITY"], [44, 55, "GENE_OR_GENE_PRODUCT"], [34, 41, "ENTITY"], [44, 63, "ENTITY"], [227, 248, "ENTITY"], [312, 333, "ENTITY"], [12, 21, "ORGANISM"], [126, 138, "CHEBI"], [126, 138, "ENTITY"], [44, 63, "PROTEIN"], [155, 166, "ENTITY"], [227, 248, "DISEASE"], [101, 109, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Of 194 patients,166(85.6%)demonstrated increased high sensitivity C- reactive protein .", "labels": [[7, 39, "DISEASE"], [66, 86, "ENTITY"], [49, 66, "ENTITY"], [39, 49, "ENTITY"], [78, 86, "CHEBI"], [7, 39, "ENTITY"]]}
{"text": "Most values of C-reactive protein ( CRP , normal range : 0\u201310 mg/L ) were above the upper bound of normal range , and over half of the fibrinogen levels ( FIB , normal range : 1.8\u20133.5 g/L ) were high during the observed period ( Figure 3 ) .", "labels": [[155, 161, "ENTITY"], [200, 211, "ENTITY"], [15, 34, "PROTEIN"], [146, 153, "ENTITY"], [15, 34, "GGP"], [220, 227, "ENTITY"], [146, 153, "SIMPLE_CHEMICAL"], [40, 49, "ENTITY"], [5, 12, "ENTITY"], [96, 106, "ENTITY"], [15, 34, "ENTITY"], [131, 146, "ENTITY"], [146, 153, "DNA"]]}
{"text": "In terms of inflammation indicators , patients on admission showed increase in lactate dehydrogenase ( 25 [ 41 % ] of 61 patients ) , c reactive protein ( 42 [ 67 % ] of 63 patients ) , and erythrocyte sedimentation rate ( 30 [ 52 % ] of 58 patients ) , but not procalcitonin .", "labels": [[132, 147, "ENTITY"], [81, 103, "GGP"], [81, 89, "CHEMICAL"], [243, 260, "GENE_OR_GENE_PRODUCT"], [25, 36, "ENTITY"], [12, 25, "DISEASE"], [81, 103, "PROTEIN"], [81, 103, "ENTITY"], [123, 147, "PROTEIN"], [12, 25, "ENTITY"], [243, 260, "ENTITY"], [123, 147, "GENE_OR_GENE_PRODUCT"], [175, 192, "CL"], [69, 78, "ENTITY"], [113, 120, "ORGANISM"], [175, 204, "ENTITY"], [52, 62, "ENTITY"], [113, 120, "ENTITY"], [138, 147, "CHEBI"], [243, 260, "PROTEIN"], [175, 192, "CELL"], [81, 103, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Increased C-reactive protein , procalcitonin and lactate dehydrogenase were found in five patients ( 5/8 ) , and increased alanine aminotransferase ( ALT ) in four ( 4/8 ) .", "labels": [[113, 123, "CHEBI"], [49, 57, "GENE_OR_GENE_PRODUCT"], [49, 57, "PROTEIN"], [49, 57, "GGP"], [10, 21, "GENE_OR_GENE_PRODUCT"], [10, 29, "PROTEIN"], [49, 57, "ENTITY"], [10, 29, "ENTITY"], [0, 10, "ENTITY"], [113, 123, "CHEMICAL"], [113, 131, "GENE_OR_GENE_PRODUCT"], [131, 148, "ENTITY"], [113, 131, "ENTITY"], [131, 148, "PROTEIN"], [131, 148, "GENE_OR_GENE_PRODUCT"], [10, 29, "GGP"], [113, 131, "PROTEIN"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [236, 242, "ENTITY"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [300, 315, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "Concentrations of procalcitonin , high sensitivity C-reactive protein , and ferritin , as well as erythrocyte sedimentation rate , were significantly higher in deceased patients than in recovered patients .", "labels": [[186, 196, "ENTITY"], [51, 62, "PROTEIN"], [160, 169, "ENTITY"], [18, 32, "ENTITY"], [0, 15, "ENTITY"], [186, 196, "ORGANISM"], [18, 32, "PROTEIN"], [18, 32, "GGP"], [18, 32, "GENE_OR_GENE_PRODUCT"], [160, 169, "ORGANISM"], [51, 62, "ENTITY"], [51, 62, "GGP"], [34, 39, "ENTITY"]]}
{"text": "Levels of lactate dehydrogenase ( LDH ) , concentrations of serum high-sensitivity C-reactive protein ( hsCRP ) , ferritin and D-dimer levels were markedly higher in severe cases than moderate cases .", "labels": [[10, 18, "CHEMICAL"], [129, 137, "ENTITY"], [59, 96, "PROTEIN"], [149, 158, "ENTITY"], [0, 7, "ENTITY"], [10, 32, "GGP"], [10, 32, "PROTEIN"], [158, 168, "ENTITY"], [62, 96, "ENTITY"], [10, 32, "ENTITY"], [68, 96, "GGP"], [168, 175, "ENTITY"], [10, 32, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"]]}
{"text": "Consistent with others , most of severe COVID-19 patients in our ICU ward had persistent very high level of erythematosus sedimentation rate ( ESR ) , CRP , and high level of IL-6,TNFa , IL-1B , IL-8 , IL2R , etc , and were associated with ARDS , hypercoagulation and disseminated intravascular coagulation ( DIC ) , manifested as thrombosis , thrombocytopenia , gangrene of extremities .", "labels": [[0, 16, "ENTITY"], [175, 187, "GENE_OR_GENE_PRODUCT"], [328, 344, "ENTITY"], [175, 187, "ENTITY"], [175, 187, "DNA"], [328, 344, "DISEASE"], [99, 108, "GGP"], [65, 69, "ENTITY"], [235, 247, "DISEASE"], [108, 136, "ENTITY"], [344, 363, "ENTITY"], [235, 247, "ENTITY"], [187, 193, "ENTITY"], [99, 108, "DNA"], [187, 193, "GENE_OR_GENE_PRODUCT"], [268, 281, "IMMATERIAL_ANATOMICAL_ENTITY"], [268, 295, "DISEASE"], [99, 108, "ENTITY"], [344, 363, "ORGAN"], [175, 187, "GGP"], [317, 328, "DISEASE"], [94, 99, "ENTITY"], [187, 193, "PROTEIN"], [247, 295, "ENTITY"], [40, 49, "GENE_OR_GENE_PRODUCT"], [215, 224, "ENTITY"], [187, 193, "GGP"], [99, 108, "GENE_OR_GENE_PRODUCT"], [317, 328, "ENTITY"]]}
{"text": "Analysis of the global proteomic changes reveal significant upregulation of CXCR2 , PRG3 , LBP , MMP25 , CRP , NLRP1 in the COVID-19-MS PBMC cohort ( Fig.3c ) .", "labels": [[76, 82, "GENE_OR_GENE_PRODUCT"], [23, 33, "ENTITY"], [97, 105, "GENE_OR_GENE_PRODUCT"], [105, 111, "GENE_OR_GENE_PRODUCT"], [105, 111, "GGP"], [76, 82, "PROTEIN"], [105, 111, "ENTITY"], [141, 150, "SIMPLE_CHEMICAL"], [124, 136, "ENTITY"], [16, 23, "ENTITY"], [97, 105, "PROTEIN"], [89, 97, "GENE_OR_GENE_PRODUCT"], [97, 105, "GGP"], [60, 73, "ENTITY"], [76, 82, "GGP"], [105, 111, "PROTEIN"], [97, 105, "ENTITY"], [136, 141, "ENTITY"], [76, 82, "ENTITY"], [0, 9, "ENTITY"], [120, 136, "CELL"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [40, 59, "ENTITY"], [26, 38, "SIMPLE_CHEMICAL"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GGP"], [253, 271, "ENTITY"], [26, 40, "CHEBI"], [170, 179, "GGP"], [26, 38, "CHEMICAL"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [144, 154, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [26, 38, "ENTITY"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "Blood C-reactive protein was elevated at 83.2 , with normal counts of lymphocytes ( 4.3 \u00d7 109 cells per liter ( range , 4.0 \u00d7 109 to 12.0 \u00d7 109 cells per liter ) ) and neutrophils ( 6.3 \u00d7 109 cells per liter ( range , 2.0 \u00d7 109 to 8.0 \u00d7 109 \u00d7 109 cells per liter ) ) .", "labels": [[6, 25, "GGP"], [162, 168, "CL"], [29, 38, "ENTITY"], [162, 168, "ENTITY"], [162, 168, "CELL"], [53, 60, "ENTITY"], [0, 25, "ENTITY"], [0, 25, "PROTEIN"], [0, 17, "ORGANISM_SUBSTANCE"], [162, 168, "CELL_TYPE"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer . Patients with severe disease had more prominent laboratory abnormalities ( including lymphocytopenia and leukopenia ) than those with nonsevere disease .", "labels": [[12, 21, "ENTITY"], [264, 274, "ENTITY"], [101, 109, "PROTEIN"], [44, 63, "PROTEIN"], [155, 166, "PROTEIN"], [274, 294, "DISEASE"], [274, 294, "ENTITY"], [198, 210, "ENTITY"], [264, 274, "DISEASE"], [101, 109, "ENTITY"], [126, 138, "PROTEIN"], [126, 138, "GENE_OR_GENE_PRODUCT"], [25, 34, "ENTITY"], [44, 63, "GGP"], [179, 189, "ORGANISM"], [101, 109, "GGP"], [179, 189, "ENTITY"], [44, 55, "GENE_OR_GENE_PRODUCT"], [34, 41, "ENTITY"], [227, 248, "ENTITY"], [312, 333, "ENTITY"], [12, 21, "ORGANISM"], [126, 138, "CHEBI"], [126, 138, "ENTITY"], [44, 63, "ENTITY"], [155, 166, "ENTITY"], [227, 248, "DISEASE"], [101, 109, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Some patients demonstrated liver injury with elevated aspartate aminotransferase(AST;59 of 198[29.8%])and alanine aminotransferase(ALT ; 43of198[21.7 % ] )", "labels": [[27, 33, "ORGAN"], [45, 54, "ENTITY"], [54, 88, "GENE_OR_GENE_PRODUCT"], [54, 64, "CHEBI"], [106, 114, "CHEBI"], [54, 64, "CHEMICAL"], [106, 114, "CHEMICAL"], [5, 14, "ENTITY"], [106, 114, "ENTITY"], [5, 14, "ORGANISM"], [27, 40, "ENTITY"], [54, 88, "ENTITY"], [27, 40, "DISEASE"], [106, 114, "AMINO_ACID"]]}
{"text": "Increased C-reactive protein , procalcitonin and lactate dehydrogenase were found in five patients ( 5/8 ) , and increased alanine aminotransferase ( ALT ) in four ( 4/8 ) .", "labels": [[113, 123, "CHEBI"], [49, 57, "GENE_OR_GENE_PRODUCT"], [10, 29, "ENTITY"], [49, 57, "PROTEIN"], [49, 57, "GGP"], [10, 21, "GENE_OR_GENE_PRODUCT"], [10, 29, "GGP"], [49, 57, "ENTITY"], [113, 123, "CHEMICAL"], [0, 10, "ENTITY"], [113, 131, "GENE_OR_GENE_PRODUCT"], [131, 148, "ENTITY"], [10, 29, "PROTEIN"], [113, 131, "ENTITY"], [131, 148, "PROTEIN"], [131, 148, "GENE_OR_GENE_PRODUCT"], [113, 131, "PROTEIN"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [236, 242, "ENTITY"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [300, 315, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "Concentrations of alanine aminotransferase , aspartate aminotransferase , total bilirubin , alkaline phosphatase , and \u03b3-glutamyl transpeptidase were markedly higher in deceased patients than in recovered patients", "labels": [[115, 130, "PROTEIN"], [45, 55, "CHEBI"], [90, 101, "PROTEIN"], [18, 43, "PROTEIN"], [195, 205, "ENTITY"], [0, 15, "ENTITY"], [115, 130, "ENTITY"], [115, 130, "GENE_OR_GENE_PRODUCT"], [74, 80, "CHEMICAL"], [74, 80, "PROTEIN"], [18, 26, "CHEBI"], [45, 55, "GENE_OR_GENE_PRODUCT"], [169, 178, "ORGANISM"], [90, 101, "SIMPLE_CHEMICAL"], [74, 80, "GGP"], [18, 43, "GENE_OR_GENE_PRODUCT"], [195, 205, "ORGANISM"], [74, 80, "SIMPLE_CHEMICAL"], [72, 80, "ENTITY"], [18, 43, "ENTITY"], [169, 178, "ENTITY"], [45, 55, "PROTEIN"], [18, 26, "CHEMICAL"], [90, 101, "ENTITY"], [45, 55, "ENTITY"]]}
{"text": "Alanine aminotransferase ( ALT ) and aspartate aminotransferase ( AST ) levels were significantly higher in severe cases than moderate cases .", "labels": [[0, 25, "GGP"], [108, 115, "ENTITY"], [0, 25, "PROTEIN"], [66, 72, "ENTITY"], [33, 47, "ENTITY"], [0, 25, "GENE_OR_GENE_PRODUCT"], [126, 135, "ENTITY"], [33, 47, "PROTEIN"], [33, 47, "GENE_OR_GENE_PRODUCT"], [0, 25, "ENTITY"], [33, 47, "GGP"], [0, 8, "CHEMICAL"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer .", "labels": [[126, 138, "PROTEIN"], [34, 41, "ENTITY"], [126, 138, "GENE_OR_GENE_PRODUCT"], [12, 21, "ENTITY"], [101, 109, "PROTEIN"], [155, 166, "ENTITY"], [44, 63, "PROTEIN"], [25, 34, "ENTITY"], [155, 166, "PROTEIN"], [44, 63, "GGP"], [12, 21, "ORGANISM"], [101, 109, "GENE_OR_GENE_PRODUCT"], [126, 138, "ENTITY"], [101, 109, "GGP"], [44, 55, "GENE_OR_GENE_PRODUCT"], [126, 138, "CHEBI"], [101, 109, "ENTITY"], [44, 63, "ENTITY"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer . Patients with severe disease had more prominent laboratory abnormalities ( including lymphocytopenia and leukopenia ) than those with nonsevere disease .", "labels": [[12, 21, "ENTITY"], [264, 274, "ENTITY"], [101, 109, "PROTEIN"], [44, 63, "PROTEIN"], [155, 166, "PROTEIN"], [274, 294, "DISEASE"], [274, 294, "ENTITY"], [198, 210, "ENTITY"], [264, 274, "DISEASE"], [101, 109, "ENTITY"], [126, 138, "PROTEIN"], [126, 138, "GENE_OR_GENE_PRODUCT"], [25, 34, "ENTITY"], [44, 63, "GGP"], [179, 189, "ORGANISM"], [101, 109, "GGP"], [179, 189, "ENTITY"], [44, 55, "GENE_OR_GENE_PRODUCT"], [34, 41, "ENTITY"], [227, 248, "ENTITY"], [312, 333, "ENTITY"], [12, 21, "ORGANISM"], [126, 138, "CHEBI"], [126, 138, "ENTITY"], [44, 63, "ENTITY"], [155, 166, "ENTITY"], [227, 248, "DISEASE"], [101, 109, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Most patients presented with an elevated myocardial indices : 194 of 198 ( 98.0 % ) had elevated lactate dehydrogenase (LDH),and 9 of 198 ( 4.5 % ) had an elevated creatinekinase muscle-brain isoform .", "labels": [[41, 52, "MULTI-TISSUE_STRUCTURE"], [88, 105, "PROTEIN"], [155, 192, "PROTEIN"], [41, 60, "ENTITY"], [155, 179, "GENE_OR_GENE_PRODUCT"], [5, 14, "ENTITY"], [179, 192, "SO"], [5, 14, "ORGANISM"], [88, 105, "GENE_OR_GENE_PRODUCT"], [148, 155, "ENTITY"], [88, 105, "GGP"], [32, 41, "CHEMICAL"], [179, 192, "ENTITY"], [88, 105, "ENTITY"], [32, 41, "ENTITY"]]}
{"text": "Laboratory tests showed leukocytosis , lymphocytopenia , and an elevated creatine kinase \u2013 MB fraction .", "labels": [[0, 17, "ENTITY"], [91, 94, "ENTITY"], [24, 37, "ENTITY"], [24, 37, "DISEASE"], [64, 89, "GENE_OR_GENE_PRODUCT"], [64, 73, "CHEBI"], [82, 89, "ENTITY"], [64, 73, "CHEMICAL"], [64, 82, "ENTITY"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "This may explain the clinical manifestation of CK elevation among 13 % of COVID-19 patients . 2", "labels": [[47, 50, "ENTITY"], [47, 50, "GENE_OR_GENE_PRODUCT"], [21, 44, "ENTITY"], [50, 60, "ENTITY"], [74, 83, "GENE_OR_GENE_PRODUCT"], [47, 50, "PROTEIN"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer .", "labels": [[126, 138, "PROTEIN"], [34, 41, "ENTITY"], [126, 138, "GENE_OR_GENE_PRODUCT"], [12, 21, "ENTITY"], [101, 109, "PROTEIN"], [155, 166, "ENTITY"], [44, 63, "PROTEIN"], [25, 34, "ENTITY"], [155, 166, "PROTEIN"], [44, 63, "GGP"], [12, 21, "ORGANISM"], [101, 109, "GENE_OR_GENE_PRODUCT"], [126, 138, "ENTITY"], [101, 109, "GGP"], [44, 55, "GENE_OR_GENE_PRODUCT"], [126, 138, "CHEBI"], [101, 109, "ENTITY"], [44, 63, "ENTITY"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer . Patients with severe disease had more prominent laboratory abnormalities ( including lymphocytopenia and leukopenia ) than those with nonsevere disease .", "labels": [[12, 21, "ENTITY"], [264, 274, "ENTITY"], [101, 109, "PROTEIN"], [44, 63, "PROTEIN"], [155, 166, "PROTEIN"], [274, 294, "DISEASE"], [274, 294, "ENTITY"], [198, 210, "ENTITY"], [264, 274, "DISEASE"], [101, 109, "ENTITY"], [126, 138, "PROTEIN"], [126, 138, "GENE_OR_GENE_PRODUCT"], [25, 34, "ENTITY"], [44, 63, "GGP"], [179, 189, "ORGANISM"], [101, 109, "GGP"], [179, 189, "ENTITY"], [44, 55, "GENE_OR_GENE_PRODUCT"], [34, 41, "ENTITY"], [227, 248, "ENTITY"], [312, 333, "ENTITY"], [12, 21, "ORGANISM"], [126, 138, "CHEBI"], [126, 138, "ENTITY"], [44, 63, "ENTITY"], [155, 166, "ENTITY"], [227, 248, "DISEASE"], [101, 109, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Most patients presented with an elevated myocardial indices : 194 of 198 ( 98.0 % ) had elevated lactate dehydrogenase (LDH),and 9 of 198 ( 4.5 % ) had an elevated creatinekinase muscle-brain isoform .", "labels": [[41, 52, "MULTI-TISSUE_STRUCTURE"], [88, 105, "PROTEIN"], [155, 192, "PROTEIN"], [41, 60, "ENTITY"], [155, 179, "GENE_OR_GENE_PRODUCT"], [5, 14, "ENTITY"], [179, 192, "SO"], [5, 14, "ORGANISM"], [88, 105, "GENE_OR_GENE_PRODUCT"], [148, 155, "ENTITY"], [88, 105, "GGP"], [32, 41, "CHEMICAL"], [179, 192, "ENTITY"], [88, 105, "ENTITY"], [32, 41, "ENTITY"]]}
{"text": "Laboratory tests showed leukocytosis , lymphocytopenia , and an elevated creatine kinase \u2013 MB fraction .", "labels": [[0, 17, "ENTITY"], [91, 94, "ENTITY"], [24, 37, "ENTITY"], [24, 37, "DISEASE"], [64, 89, "GENE_OR_GENE_PRODUCT"], [64, 73, "CHEBI"], [82, 89, "ENTITY"], [64, 73, "CHEMICAL"], [64, 82, "ENTITY"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer . Patients with severe disease had more prominent laboratory abnormalities ( including lymphocytopenia and leukopenia ) than those with nonsevere disease .", "labels": [[12, 21, "ENTITY"], [264, 274, "ENTITY"], [101, 109, "PROTEIN"], [44, 63, "PROTEIN"], [155, 166, "PROTEIN"], [274, 294, "DISEASE"], [198, 210, "ENTITY"], [264, 274, "DISEASE"], [101, 109, "ENTITY"], [126, 138, "PROTEIN"], [126, 138, "GENE_OR_GENE_PRODUCT"], [25, 34, "ENTITY"], [44, 63, "GGP"], [179, 189, "ORGANISM"], [101, 109, "GGP"], [179, 189, "ENTITY"], [44, 55, "GENE_OR_GENE_PRODUCT"], [34, 41, "ENTITY"], [227, 248, "ENTITY"], [312, 333, "ENTITY"], [12, 21, "ORGANISM"], [126, 138, "CHEBI"], [126, 138, "ENTITY"], [44, 63, "ENTITY"], [274, 294, "ENTITY"], [155, 166, "ENTITY"], [227, 248, "DISEASE"], [101, 109, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Since lymphocytopenia is often seen in severe COVID-19 patients , the CRS caused by SARS-CoV-2 virus has to be mediated by leukocytes other than T cells , as in patients receiving CAR-T therapy ; a high WBC-count is common , suggesting it , in association with lymphocytopenia , as a differential diagnostic criterion for COVID-19 .", "labels": [[46, 55, "DISEASE"], [55, 64, "ENTITY"], [239, 244, "ENTITY"], [46, 64, "SIMPLE_CHEMICAL"], [170, 180, "CHEMICAL"], [84, 95, "GENE_OR_GENE_PRODUCT"], [198, 203, "ENTITY"], [6, 22, "ENTITY"], [308, 322, "PROTEIN"], [84, 95, "ENTITY"], [39, 46, "ENTITY"], [308, 322, "GENE_OR_GENE_PRODUCT"], [284, 308, "ENTITY"], [6, 22, "DISEASE"], [170, 186, "ENTITY"], [170, 180, "CELL_TYPE"], [170, 180, "CELL"], [198, 203, "GENE_OR_GENE_PRODUCT"], [308, 322, "ENTITY"], [46, 55, "ENTITY"]]}
{"text": "On admission , lymphocytopenia was present in 83.2 % of the patients , thrombocytopenia in 36.2 % , and leukopenia in 33.7 %", "labels": [[3, 13, "ENTITY"]]}
{"text": "Systemic glucocorticoids were given to 204 patients ( 18.6 % ) , with a higher percentage among those with severe disease than nonsevere disease ( 44.5 % vs. 13.7 % ) .", "labels": [[43, 52, "ENTITY"], [0, 9, "ENTITY"], [72, 79, "ENTITY"], [122, 137, "ENTITY"], [9, 25, "SIMPLE_CHEMICAL"], [9, 25, "ENTITY"], [9, 25, "CHEBI"], [9, 25, "CHEMICAL"], [43, 52, "ORGANISM"]]}
{"text": "Extracorporeal membrane oxygenation was performed in 5 patients ( 0.5 % ) with severe disease .", "labels": [[0, 36, "ENTITY"], [15, 24, "GO"], [55, 64, "ORGANISM"], [74, 86, "ENTITY"], [55, 64, "ENTITY"]]}
{"text": "Both coronavirus disease 2019 ( COVID-19 ) and severe acute respiratory syndrome ( SARS ) are characterised by an overexuberant inflammatory response and , for SARS , viral load is not correlated with the worsening of symptoms.1,2", "labels": [[5, 30, "DISEASE"], [114, 141, "ENTITY"], [160, 167, "ENTITY"], [196, 205, "ENTITY"], [5, 30, "ORGANISM"], [47, 72, "DISEASE"], [205, 218, "GGP"], [178, 185, "ENTITY"], [5, 30, "ENTITY"], [160, 167, "TAXON"], [205, 218, "ENTITY"], [5, 17, "TAXON"], [47, 72, "ENTITY"]]}
{"text": "These results suggest an increased level of systemic inflammation in severe cases .", "labels": [[6, 14, "ENTITY"], [35, 41, "ENTITY"], [76, 82, "ENTITY"], [25, 35, "ENTITY"], [53, 66, "DISEASE"], [44, 66, "ENTITY"], [69, 76, "ENTITY"]]}
{"text": "Patients infected with COVID-19 showed higher leukocyte numbers , abnormal respiratory findings , and increased levels of plasma pro-inflammatory cytokines .", "labels": [[23, 32, "GENE_OR_GENE_PRODUCT"], [46, 56, "CELL"], [39, 46, "ENTITY"], [102, 112, "ENTITY"], [46, 56, "CL"], [119, 146, "PROTEIN"], [129, 146, "ENTITY"], [122, 129, "ENTITY"], [23, 32, "PROTEIN"], [23, 32, "DISEASE"], [46, 56, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "ORGANISM"], [75, 87, "ENTITY"], [23, 32, "ENTITY"], [9, 18, "ENTITY"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [197, 204, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [168, 173, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [168, 173, "ENTITY"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "CHEMICAL"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [168, 173, "GENE_OR_GENE_PRODUCT"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[384, 388, "GGP"], [246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [211, 219, "GGP"], [227, 235, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [227, 235, "PROTEIN"], [384, 388, "PROTEIN"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [384, 388, "CHEMICAL"], [384, 388, "ENTITY"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Significantly high blood levels of cytokines and chemokines were noted in patients with COVID-19 infection that included IL1-\u03b2 , IL1RA , IL7 , IL8 , IL9 , IL10 , basic FGF2 , GCSF , GMCSF , IFN\u03b3 , IP10 , MCP1 , MIP1\u03b1 , MIP1\u03b2 , PDGFB , TNF\u03b1 , and VEGFA . Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2 , IL7 , IL10 , GCSF , IP10 , MCP1 , MIP1\u03b1 , and TNF\u03b1 that are reasoned to promote disease severity [ 6 ] .", "labels": [[246, 254, "ENTITY"], [175, 180, "GENE_OR_GENE_PRODUCT"], [168, 173, "GGP"], [197, 204, "PROTEIN"], [168, 173, "PROTEIN"], [211, 219, "PROTEIN"], [384, 388, "ENTITY"], [219, 225, "DISEASE"], [121, 127, "GENE_OR_GENE_PRODUCT"], [175, 180, "CHEMICAL"], [168, 173, "CHEMICAL"], [168, 173, "GENE_OR_GENE_PRODUCT"], [74, 83, "ENTITY"], [190, 197, "PROTEIN"], [384, 388, "GENE_OR_GENE_PRODUCT"], [227, 235, "PROTEIN"], [204, 211, "PROTEIN"], [88, 97, "SIMPLE_CHEMICAL"], [35, 45, "PROTEIN"], [325, 347, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [384, 388, "PROTEIN"], [325, 347, "PROTEIN"], [19, 25, "ORGANISM_SUBSTANCE"], [35, 45, "GENE_OR_GENE_PRODUCT"], [197, 204, "CHEMICAL"], [384, 388, "CHEMICAL"], [190, 197, "GGP"], [175, 180, "PROTEIN"], [211, 219, "GGP"], [204, 211, "CHEMICAL"], [197, 204, "GGP"], [219, 225, "GENE_OR_GENE_PRODUCT"], [143, 149, "DNA"], [384, 388, "GGP"], [137, 141, "PROTEIN"], [149, 155, "ENTITY"], [446, 462, "ENTITY"], [204, 211, "GENE_OR_GENE_PRODUCT"], [211, 219, "ENTITY"], [74, 83, "ORGANISM"], [197, 204, "DISEASE"], [14, 32, "ENTITY"], [149, 155, "GENE_OR_GENE_PRODUCT"], [190, 197, "GENE_OR_GENE_PRODUCT"], [273, 279, "ENTITY"], [197, 204, "GENE_OR_GENE_PRODUCT"], [197, 204, "ENTITY"], [227, 235, "ENTITY"], [197, 204, "PROTEIN"], [197, 204, "ENTITY"], [88, 107, "DISEASE"], [204, 211, "GGP"], [121, 127, "ENTITY"], [35, 45, "ENTITY"], [168, 173, "ENTITY"], [289, 305, "ENTITY"], [227, 235, "GENE_OR_GENE_PRODUCT"], [204, 211, "ENTITY"], [49, 60, "ENTITY"], [49, 60, "PROTEIN"], [211, 219, "GENE_OR_GENE_PRODUCT"], [88, 107, "ENTITY"], [175, 180, "ENTITY"], [254, 262, "ENTITY"], [175, 180, "GGP"], [143, 149, "ENTITY"], [143, 149, "GENE_OR_GENE_PRODUCT"], [155, 162, "PROTEIN"], [137, 141, "GGP"], [35, 45, "PROTEIN"], [35, 45, "ENTITY"], [219, 225, "PROTEIN"], [190, 197, "ENTITY"], [219, 225, "ENTITY"], [227, 235, "GGP"], [137, 141, "GENE_OR_GENE_PRODUCT"], [137, 141, "ENTITY"], [149, 155, "PROTEIN"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "Compared with the healthy control and mild group , the frequency of multi-functional CD4 + T cells ( positive for at least two cytokines ) decreased significantly in the severe group , whereas the proportion of non-functional ( IFN-\u03b3 \u2212TNF-\u03b1\u2212IL-2\u2212 ) subsets increased significantly .", "labels": [[211, 228, "ENTITY"], [127, 139, "ENTITY"], [38, 49, "ENTITY"], [170, 177, "ENTITY"], [234, 249, "ENTITY"], [68, 93, "CELL_TYPE"], [18, 34, "ENTITY"], [197, 211, "ENTITY"], [89, 93, "CL"], [0, 9, "ENTITY"], [249, 257, "ENTITY"], [211, 228, "GENE_OR_GENE_PRODUCT"], [85, 93, "ENTITY"]]}
{"text": "Evaluation of serum cytokines on admission revealed that levels of interleukin (IL)- 2R , IL-6 , IL-10 , and tumor necrosis factor-\u03b1 ( TNF-\u03b1 ) were markedly higher in severe cases than in moderate cases ( Figure 2 , Supplementary Table 1 ) .", "labels": [[205, 230, "GENE_OR_GENE_PRODUCT"], [105, 115, "DISEASE"], [157, 167, "ENTITY"], [33, 43, "ENTITY"], [124, 135, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [0, 11, "ENTITY"], [14, 20, "ENTITY"], [105, 124, "PROTEIN"], [14, 20, "ORGANISM_SUBSTANCE"], [124, 135, "PROTEIN"], [105, 124, "ENTITY"], [105, 124, "GENE_OR_GENE_PRODUCT"], [67, 88, "ENTITY"], [197, 205, "ENTITY"], [180, 188, "ENTITY"], [67, 88, "GGP"], [124, 135, "ENTITY"], [20, 30, "ENTITY"], [205, 230, "ENTITY"], [57, 64, "ENTITY"], [67, 88, "GENE_OR_GENE_PRODUCT"], [188, 197, "ENTITY"], [67, 88, "PROTEIN"], [14, 30, "PROTEIN"]]}
{"text": "A tentative suggestion based on existing therapeutics , which would likely be resistant to new coronavirus mutations , is to use available angiotensin receptor 1 ( AT1R ) blockers , such as losartan , as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections .", "labels": [[95, 107, "ENTITY"], [182, 190, "ENTITY"], [129, 160, "GENE_OR_GENE_PRODUCT"], [95, 107, "DISEASE"], [182, 190, "SIMPLE_CHEMICAL"], [221, 234, "DISEASE"], [234, 253, "ENTITY"], [221, 234, "ENTITY"], [263, 285, "ENTITY"], [268, 279, "TAXON"], [263, 279, "ORGANISM"], [199, 204, "ENTITY"], [129, 160, "GGP"], [204, 221, "ENTITY"], [129, 171, "PROTEIN"], [41, 54, "ENTITY"], [12, 23, "ENTITY"], [129, 160, "ENTITY"], [182, 190, "CHEMICAL"]]}
{"text": "This may be accounted for by two complementary mechanisms : blocking the excessive angiotensin-mediated AT1R activation caused by the viral infection , as well as upregulating ACE2 , thereby reducing angiotensin production by ACE and increasing the production of the vasodilator angiotensin 1\u20137 .", "labels": [[134, 140, "ENTITY"], [191, 200, "GGP"], [163, 176, "GGP"], [163, 176, "GENE_OR_GENE_PRODUCT"], [83, 95, "ENTITY"], [47, 58, "ENTITY"], [263, 291, "ENTITY"], [163, 176, "PROTEIN"], [191, 200, "ENTITY"], [163, 176, "ENTITY"], [267, 291, "CHEMICAL"], [134, 140, "DISEASE"], [191, 200, "CHEMICAL"], [263, 291, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In a small study , patients with Covid-19 appeared to have elevated levels of plasma angiotensin II , which were in turn correlated with total viral load and degree of lung injury.44", "labels": [[165, 173, "DISEASE"], [78, 97, "ENTITY"], [116, 121, "ENTITY"], [78, 97, "GENE_OR_GENE_PRODUCT"], [137, 149, "ENTITY"], [137, 143, "TAXON"], [85, 97, "CHEMICAL"], [5, 17, "ENTITY"], [78, 97, "GGP"], [78, 97, "PROTEIN"]]}
{"text": "If the latter percentage would be found to be significantly smaller , this would support the notion that AT1R antagonists confer protection from severe symptoms among SARS-CoV-2 infected individuals .", "labels": [[105, 110, "ENTITY"], [14, 25, "ENTITY"]]}
{"text": "This virus , named \u201c Severe Acute Respiratory Syndrome-related Coronavirus 2 \u201d ( Severe Acute Respiratory Syndrome-related Coronavirus 2\u201d ) , can cause a severe and even fatal respiratory disease , called Coronavirus disease-19 ( COVID-19 ) , and lead to acute respiratory distress syndrome ( ARDS ) .", "labels": [[106, 124, "PROTEIN"], [46, 75, "ORGANISM"], [106, 115, "TAXON"], [-1, 10, "CHEMICAL"], [-1, 18, "ENTITY"], [106, 124, "ENTITY"], [-1, 18, "DISEASE"], [184, 195, "DISEASE"], [21, 34, "ENTITY"], [5, 11, "TAXON"], [159, 184, "DISEASE"], [46, 63, "ENTITY"], [34, 46, "ENTITY"], [34, 75, "CHEMICAL"], [5, 11, "ENTITY"], [152, 184, "ENTITY"], [106, 124, "DISEASE"], [106, 124, "ORGANISM"], [184, 195, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"]]}
{"text": "More patients with ARDS presented with initial symptoms of dyspnea compared with those without ARDS ( difference , 33.9%;95%CI , 19.7%-48.1%;P < .001 )", "labels": [[19, 24, "DISEASE"], [59, 67, "DISEASE"], [5, 14, "ENTITY"], [59, 67, "ENTITY"], [19, 24, "DISEASE"], [5, 14, "ORGANISM"], [19, 24, "ENTITY"], [19, 24, "ENTITY"], [47, 56, "ENTITY"]]}
{"text": "For those patients with most severe ARDS , extracorporeal membrane oxygenation or prone position is recommended .", "labels": [[82, 88, "ENTITY"], [29, 36, "ENTITY"], [10, 19, "ENTITY"], [36, 41, "ENTITY"], [43, 67, "ENTITY"], [10, 19, "ORGANISM"], [36, 41, "DISEASE"]]}
{"text": "The clinical manifestations of COVID-19 are protean , which include asymptomatic carrier , ARD , and pneumonia of varying degrees of severity . First , asymptomatic cases were diagnosed based on positive viral nucleic acid test results , but without any COVID-19 symptoms , such as fever , gastrointestinal , or respiratory symptoms , and no significant abnormalities on chest radiograph [ 7,8 ] .", "labels": [[186, 195, "ENTITY"], [290, 324, "ENTITY"], [68, 81, "ENTITY"], [223, 228, "ENTITY"], [31, 40, "ENTITY"], [31, 40, "ENTITY"], [144, 152, "ENTITY"], [114, 122, "ENTITY"], [242, 254, "ENTITY"], [204, 218, "CHEMICAL"], [354, 377, "ENTITY"], [342, 354, "ENTITY"], [282, 290, "ENTITY"], [195, 218, "TAXON"], [242, 254, "GENE_OR_GENE_PRODUCT"], [282, 290, "ORGAN"], [44, 52, "ENTITY"], [195, 223, "ENTITY"], [4, 28, "ENTITY"], [31, 40, "DISEASE"], [31, 40, "GENE_OR_GENE_PRODUCT"], [324, 342, "ENTITY"]]}
{"text": "Recent studies have shown that in addition to dyspnea , hypoxemia , and acute respiratory distress , lymphopenia , and cytokine release syndrome are also important clinical features in patients with severe SARS- CoV-2 infection.3", "labels": [[212, 218, "ENTITY"], [199, 212, "ENTITY"], [46, 54, "DISEASE"], [115, 128, "ENTITY"], [154, 173, "ENTITY"], [199, 218, "PROTEIN"], [46, 54, "ENTITY"], [68, 90, "DISEASE"], [128, 136, "ENTITY"], [68, 90, "ENTITY"], [7, 15, "ENTITY"], [199, 212, "ORGANISM"]]}
{"text": "As shown in table 3 , 5 ( 6.76 % ) , 13 ( 17.57 % ) and 1 ( 1.35 % ) patient with COVID-19 with GI symptoms had complications of ARDS , liver injury and shock , respectively , where the former two were significantly higher than their counterparts of 2.08 % and 8.84 % in patients with COVID-19 without GI symptoms , respectively ( p=0.034 ; p=0.035 ) .", "labels": [[69, 77, "GENE_OR_GENE_PRODUCT"], [82, 96, "ENTITY"], [99, 112, "ENTITY"], [69, 77, "ENTITY"], [112, 136, "ENTITY"], [82, 91, "ENTITY"], [82, 96, "DISEASE"], [112, 136, "DISEASE"], [112, 129, "ORGAN"], [255, 261, "ORGANISM"], [255, 261, "ENTITY"]]}
{"text": "Because most patients who die from COVID-19 appear to develop ARDS as they decompensate , the definition of severe disease should include death , need for intensive care and organ support such as mechanical ventilation , or acute respiratory distress syndrome .", "labels": [[221, 251, "ENTITY"], [224, 251, "DISEASE"], [26, 30, "ENTITY"], [13, 22, "ENTITY"], [193, 207, "ENTITY"], [13, 22, "ORGANISM"], [151, 165, "ENTITY"], [35, 44, "PROTEIN"], [62, 67, "ENTITY"], [62, 67, "DISEASE"], [75, 88, "ENTITY"], [35, 44, "SIMPLE_CHEMICAL"], [75, 88, "DISEASE"], [35, 44, "ENTITY"], [108, 115, "ENTITY"]]}
{"text": "Moreover , all the deceased patients and 14 ( 44 % ) recovered patients had an arterial partial pressure of oxygen to fraction of inspired oxygen ratio of 300 , indicating that these patients had developed acute respiratory distress syndrome , whereas severe acute respiratory distress syndrome ( \u2264100 ) developed only in deceased patients ( 16 ; 46 % ) .", "labels": [[196, 233, "DISEASE"], [19, 28, "ORGANISM"], [196, 233, "ENTITY"], [76, 96, "ENTITY"], [127, 146, "ENTITY"], [19, 28, "ENTITY"], [130, 139, "CHEMICAL"], [314, 322, "ENTITY"], [53, 63, "ENTITY"], [53, 63, "ORGANISM"], [130, 139, "CHEBI"], [252, 286, "ENTITY"], [206, 233, "DISEASE"], [130, 139, "SIMPLE_CHEMICAL"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [114, 133, "DISEASE"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [60, 96, "ENTITY"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [133, 141, "ENTITY"], [66, 96, "DISEASE"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"]]}
{"text": "COVID-19 ARDS patients and SARS patients have typical ARDS pathology in the lung.17", "labels": [[9, 14, "ENTITY"], [27, 32, "DISEASE"], [9, 14, "ENTITY"], [14, 23, "ENTITY"], [27, 32, "ENTITY"], [9, 14, "DISEASE"], [0, 9, "GENE_OR_GENE_PRODUCT"], [14, 23, "ORGANISM"], [14, 23, "ENTITY"], [27, 41, "ORGANISM"], [59, 69, "ENTITY"], [0, 9, "ENTITY"], [9, 14, "DISEASE"]]}
{"text": "Consistent with others , most of severe COVID-19 patients in our ICU ward had persistent very high level of erythematosus sedimentation rate ( ESR ) , CRP , and high level of IL-6,TNFa , IL-1B , IL-8 , IL2R , etc , and were associated with ARDS , hypercoagulation and disseminated intravascular coagulation ( DIC ) , manifested as thrombosis , thrombocytopenia , gangrene of extremities .", "labels": [[0, 16, "ENTITY"], [175, 187, "GENE_OR_GENE_PRODUCT"], [328, 344, "ENTITY"], [175, 187, "ENTITY"], [175, 187, "DNA"], [328, 344, "DISEASE"], [99, 108, "GGP"], [65, 69, "ENTITY"], [235, 247, "DISEASE"], [108, 136, "ENTITY"], [344, 363, "ENTITY"], [235, 247, "ENTITY"], [187, 193, "ENTITY"], [99, 108, "DNA"], [187, 193, "GENE_OR_GENE_PRODUCT"], [268, 281, "IMMATERIAL_ANATOMICAL_ENTITY"], [268, 295, "DISEASE"], [99, 108, "ENTITY"], [344, 363, "ORGAN"], [175, 187, "GGP"], [317, 328, "DISEASE"], [94, 99, "ENTITY"], [187, 193, "PROTEIN"], [247, 295, "ENTITY"], [40, 49, "GENE_OR_GENE_PRODUCT"], [215, 224, "ENTITY"], [187, 193, "GGP"], [99, 108, "GENE_OR_GENE_PRODUCT"], [317, 328, "ENTITY"]]}
{"text": "Infection with these highly pathogenic coronaviruses can result in Acute Respiratory Distress Syndrome ( ARDS ) , which may lead to long-term reduction in lung function , arrhythmia , and death .", "labels": [[152, 160, "ENTITY"], [73, 103, "DISEASE"], [39, 53, "ORGANISM"], [28, 39, "ENTITY"], [132, 142, "ENTITY"], [0, 10, "DISEASE"], [160, 171, "DISEASE"], [39, 53, "ENTITY"], [160, 171, "ENTITY"], [0, 10, "ENTITY"], [67, 103, "ENTITY"], [67, 105, "ORGANISM"]]}
{"text": "Infiltrate of occasional lymphocytes was observed in esophageal squamous epithelium .", "labels": [[53, 84, "CANCER"], [25, 37, "CL"], [53, 84, "ENTITY"], [14, 25, "ENTITY"], [0, 11, "ENTITY"], [25, 37, "ENTITY"], [25, 37, "CELL"], [14, 37, "CELL_TYPE"]]}
{"text": "In lamina propria of the stomach , duodenum , and rectum , numerous infiltrating plasma cells and lymphocytes with interstitial edema were seen .", "labels": [[110, 128, "TISSUE"], [59, 68, "ENTITY"], [68, 88, "ENTITY"], [3, 18, "TISSUE"], [110, 128, "ENTITY"], [68, 88, "CELL"], [10, 18, "ENTITY"], [81, 88, "CL"], [25, 33, "ORGAN"], [59, 88, "CELL_TYPE"], [3, 10, "ENTITY"], [110, 128, "DISEASE"], [25, 33, "ENTITY"]]}
{"text": "The blood counts of patients on admission showed decrease in neutrophils ( 26 [ 39 % ] of 67 patients ) , lymphocytes ( 28 [ 42 % ] of 67 patients ) , and eosinophils ( 48 [ 72 % ] of 67 patients ) , among which , the number of eosinophils in 31 patients was zero .", "labels": [[179, 191, "CELL_TYPE"], [-1, 11, "ENTITY"], [130, 147, "ENTITY"], [264, 270, "ENTITY"], [117, 128, "ENTITY"], [-1, 18, "ENTITY"], [14, 21, "ENTITY"], [264, 270, "ORGANISM"], [-1, 18, "CELL"], [130, 147, "CL"], [-1, 18, "CL"], [179, 191, "CELL"], [242, 252, "ENTITY"], [242, 252, "CELL"], [-1, 18, "CELL_TYPE"], [242, 252, "CELL_TYPE"], [130, 147, "CELL_TYPE"], [179, 191, "ENTITY"], [-1, 11, "ORGANISM"], [6, 12, "ORGANISM_SUBSTANCE"], [117, 128, "ORGANISM"], [130, 147, "CELL"]]}
{"text": "From our data of more than 600 NCP patients in Jiangsu Province , age , lymphocyte count , oxygen supplementation and aggressive pulmonary radiographic infiltrations are independent risk factors for NCP progressing to a critical condition .", "labels": [[218, 229, "ENTITY"], [31, 35, "CHEMICAL"], [70, 83, "ENTITY"], [89, 98, "ENTITY"], [35, 44, "ENTITY"], [114, 152, "DISEASE"], [9, 14, "ENTITY"], [170, 187, "ENTITY"], [118, 152, "ENTITY"], [47, 64, "ENTITY"], [31, 35, "ENTITY"], [118, 129, "ORGAN"], [47, 64, "ORGANISM"]]}
{"text": "The lymphocyte count was lower among patients with severe disease than among those with mild disease ( 0\u00b765 \u00d7 10\u2079 cells per L [ range 0\u00b730\u20131\u00b790 ] vs 1\u00b703 [ 0\u00b757\u20132\u00b725 ] ) , but this difference was not significant ( p=0\u00b7088 ) .", "labels": [[4, 15, "CL"], [51, 66, "ENTITY"], [4, 15, "ENTITY"], [37, 46, "ENTITY"], [4, 15, "CELL"], [88, 101, "ENTITY"], [200, 214, "PROTEIN"], [37, 46, "ORGANISM"]]}
{"text": "The lymphocyte numbers of the patients were estimated from the routine blood test data at the time of admission or initial diagnosis . Spearman \u2019s correlation statistical analysis was performed on lymphocyte numbers and CT staging with results of p<0.05 and r\u00bc\u00010.780 , suggesting a moderate negative correlation between the two .", "labels": [[123, 133, "ENTITY"], [4, 15, "ENTITY"], [115, 123, "ENTITY"], [71, 82, "ENTITY"], [291, 300, "ENTITY"], [135, 171, "ENTITY"], [63, 71, "ENTITY"], [30, 39, "ENTITY"], [94, 102, "ENTITY"], [102, 112, "ENTITY"], [30, 39, "ORGANISM"], [82, 87, "ENTITY"], [282, 291, "ENTITY"], [135, 144, "GENE_OR_GENE_PRODUCT"], [4, 15, "ENTITY"], [4, 15, "CL"], [216, 223, "ENTITY"], [4, 15, "CELL"], [71, 77, "ORGANISM_SUBSTANCE"], [15, 23, "ENTITY"]]}
{"text": "Laboratory findings of the 3 patients ( Supplementary Table 3 ) indicated cell count reduction of various types of immune cells including lymphocytes in patients \u2019 blood .", "labels": [[29, 38, "ORGANISM"], [153, 164, "ENTITY"], [128, 138, "CELL"], [0, 11, "ENTITY"], [64, 79, "ENTITY"], [112, 122, "CELL_TYPE"], [112, 122, "CELL"], [79, 85, "ENTITY"], [40, 60, "ENTITY"], [112, 122, "ENTITY"], [128, 138, "ENTITY"], [128, 138, "CELL_TYPE"], [128, 138, "CL"], [112, 122, "CL"], [29, 38, "ENTITY"], [11, 20, "ENTITY"]]}
{"text": "In lamina propria of the stomach , duodenum , and rectum , numerous infiltrating plasma cells and lymphocytes with interstitial edema were seen .", "labels": [[110, 128, "TISSUE"], [59, 68, "ENTITY"], [68, 88, "ENTITY"], [3, 18, "TISSUE"], [110, 128, "ENTITY"], [68, 88, "CELL"], [10, 18, "ENTITY"], [81, 88, "CL"], [25, 33, "ORGAN"], [59, 88, "CELL_TYPE"], [3, 10, "ENTITY"], [110, 128, "DISEASE"], [25, 33, "ENTITY"]]}
{"text": "In lamina propria of the stomach , duodenum , and rectum , numerous infiltrating plasma cells and lymphocytes with interstitial edema were seen .", "labels": [[110, 128, "TISSUE"], [59, 68, "ENTITY"], [68, 88, "ENTITY"], [3, 18, "TISSUE"], [110, 128, "ENTITY"], [68, 88, "CELL"], [10, 18, "ENTITY"], [81, 88, "CL"], [25, 33, "ORGAN"], [59, 88, "CELL_TYPE"], [3, 10, "ENTITY"], [110, 128, "DISEASE"], [25, 33, "ENTITY"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [406, 420, "CHEMICAL"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [406, 420, "ENTITY"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [451, 464, "CHEMICAL"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [706, 717, "ENTITY"], [480, 493, "CHEMICAL"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [480, 493, "SIMPLE_CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [480, 493, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [495, 511, "ENTITY"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [451, 464, "SIMPLE_CHEMICAL"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [590, 602, "CHEBI"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [451, 464, "ENTITY"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [590, 602, "CHEMICAL"], [530, 543, "CHEMICAL"], [545, 556, "ENTITY"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [590, 602, "ENTITY"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [451, 464, "CHEMICAL"], [12, 21, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [602, 616, "ENTITY"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [573, 588, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [616, 630, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [616, 630, "SIMPLE_CHEMICAL"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [665, 676, "GENE_OR_GENE_PRODUCT"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [678, 691, "SIMPLE_CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [678, 691, "CHEMICAL"], [451, 464, "ENTITY"], [436, 449, "SIMPLE_CHEMICAL"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [678, 691, "ENTITY"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [706, 717, "CHEMICAL"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "SIMPLE_CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [706, 717, "ENTITY"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [939, 948, "ORGANISM"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University performed drug screening in silicon and an enzyme activity test , and they reported 30 agents with potential antiviral activity against SARS-CoV-2 on January 25 , 2020 ( 19 ) . These agents are indinavir , saquinavir , lopinavir , carfilzomib , ritonavir , remdesivir , atazanavir , darunavir , tipranavir , fosamprenavir , enzaplatovir , presatovir , abacavir , bortezomib , elvitegravir , maribavir , raltegravir , montelukast , deoxyrhapontin , polydatin , chalcone , disulfiram , carmofur , shikonin , ebselen , tideglusib , PX-12 , TDZD-8 , cyclosporin A , and cinanserin . The same study also found that Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis may contain active ingredients against SARS-COV-2 ( 19 ) .", "labels": [[480, 493, "ENTITY"], [678, 691, "ENTITY"], [756, 763, "CHEMICAL"], [834, 840, "GENE_OR_GENE_PRODUCT"], [530, 543, "SIMPLE_CHEMICAL"], [950, 962, "GENE_OR_GENE_PRODUCT"], [590, 602, "CHEMICAL"], [651, 661, "SIMPLE_CHEMICAL"], [731, 744, "SIMPLE_CHEMICAL"], [406, 420, "ENTITY"], [422, 434, "SIMPLE_CHEMICAL"], [590, 602, "SIMPLE_CHEMICAL"], [495, 511, "SIMPLE_CHEMICAL"], [756, 763, "ENTITY"], [-1, 30, "ENTITY"], [-1, 21, "ENTITY"], [530, 543, "ENTITY"], [756, 763, "SIMPLE_CHEMICAL"], [731, 744, "ENTITY"], [480, 493, "SIMPLE_CHEMICAL"], [632, 647, "ENTITY"], [632, 647, "SIMPLE_CHEMICAL"], [573, 588, "SIMPLE_CHEMICAL"], [436, 449, "ENTITY"], [632, 647, "CHEMICAL"], [989, 1001, "ENTITY"], [651, 661, "GGP"], [678, 691, "SIMPLE_CHEMICAL"], [188, 193, "SO"], [665, 676, "GENE_OR_GENE_PRODUCT"], [392, 404, "CHEMICAL"], [545, 556, "ENTITY"], [406, 420, "SIMPLE_CHEMICAL"], [480, 493, "CHEMICAL"], [706, 717, "ENTITY"], [616, 630, "ENTITY"], [513, 526, "ENTITY"], [651, 661, "CHEMICAL"], [939, 948, "ORGANISM"], [530, 543, "CHEMICAL"], [756, 763, "CHEBI"], [436, 449, "SIMPLE_CHEMICAL"], [451, 464, "ENTITY"], [590, 602, "CHEBI"], [-1, 9, "ENTITY"], [422, 434, "ENTITY"], [495, 511, "ENTITY"], [392, 404, "SIMPLE_CHEMICAL"], [731, 744, "CHEBI"], [451, 464, "SIMPLE_CHEMICAL"], [451, 464, "CHEMICAL"], [495, 511, "CHEMICAL"], [616, 630, "SIMPLE_CHEMICAL"], [602, 616, "CHEMICAL"], [602, 616, "ENTITY"], [834, 840, "ENTITY"], [706, 717, "CHEMICAL"], [177, 186, "ENTITY"], [406, 420, "CHEMICAL"], [12, 21, "ENTITY"], [590, 602, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [436, 449, "CHEBI"], [513, 526, "SIMPLE_CHEMICAL"], [706, 717, "SIMPLE_CHEMICAL"], [4, 10, "MULTI-TISSUE_STRUCTURE"], [989, 1001, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"], [693, 704, "CHEBI"], [130, 140, "ENTITY"], [731, 744, "CHEMICAL"], [678, 691, "CHEMICAL"], [392, 404, "ENTITY"], [513, 526, "CHEMICAL"], [651, 661, "ENTITY"], [573, 588, "CHEMICAL"], [-1, 10, "CHEMICAL"]]}
{"text": "The majority ( n = 154 [ 76.6 % ] ) of patients had fever with cough ; 74 ( 36.8 % ) had feverwith dyspnea ; 66 ( 32.8 % ) had feverwith fatigue , myalgia , or headache ; and only 13 ( 6.5 % ) presentedwith fever alone ( eTable 1 in the Supplement ) .", "labels": [[34, 39, "ENTITY"], [89, 99, "DISEASE"], [81, 89, "ENTITY"], [213, 228, "ENTITY"], [89, 99, "ENTITY"], [81, 89, "DISEASE"], [34, 39, "ORGANISM"], [114, 127, "ENTITY"]]}
{"text": "Other prevalent symptoms at onset of illness in deceased patients included fatigue , dyspnoea , chest tightness , and sputum production ; less common symptoms included anorexia , diarrhoea , and myalgia .", "labels": [[75, 83, "ENTITY"], [112, 118, "DISEASE"], [143, 150, "ENTITY"], [75, 83, "DISEASE"], [168, 179, "DISEASE"], [66, 75, "ENTITY"], [112, 118, "ENTITY"], [114, 125, "ENTITY"], [16, 25, "ENTITY"], [168, 179, "ENTITY"], [48, 57, "ENTITY"], [28, 37, "ENTITY"], [94, 102, "DISEASE"], [66, 75, "CANCER"], [94, 102, "ENTITY"], [57, 66, "ORGANISM"], [66, 75, "DISEASE"], [37, 45, "ENTITY"], [6, 16, "ENTITY"], [57, 66, "ENTITY"]]}
{"text": "The majority ( n = 154 [ 76.6 % ] ) of patients had fever with cough ; 74 ( 36.8 % ) had feverwith dyspnea ; 66 ( 32.8 % ) had feverwith fatigue , myalgia , or headache ; and only 13 ( 6.5 % ) presentedwith fever alone ( eTable 1 in the Supplement ) .", "labels": [[34, 39, "ENTITY"], [89, 99, "DISEASE"], [81, 89, "ENTITY"], [213, 228, "ENTITY"], [89, 99, "ENTITY"], [81, 89, "DISEASE"], [34, 39, "ORGANISM"], [114, 127, "ENTITY"]]}
{"text": "The majority ( n = 154 [ 76.6 % ] ) of patients had fever with cough ; 74 ( 36.8 % ) had feverwith dyspnea ; 66 ( 32.8 % ) had feverwith fatigue , myalgia , or headache ; and only 13 ( 6.5 % ) presentedwith fever alone ( eTable 1 in the Supplement ) .", "labels": [[34, 39, "ENTITY"], [89, 99, "DISEASE"], [81, 89, "ENTITY"], [213, 228, "ENTITY"], [89, 99, "ENTITY"], [81, 89, "DISEASE"], [34, 39, "ORGANISM"], [114, 127, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [50, 60, "ENTITY"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [254, 285, "ENTITY"], [136, 146, "ORGAN"], [136, 158, "ENTITY"], [144, 166, "ENTITY"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "Intriguingly , the rate of chronic liver disease was 10.81 % in patients with COVID-19 with GI symptoms , which was significantly higher than that of 2.95 % in those without GI symptoms ( p=0.004 ) .", "labels": [[35, 41, "DISEASE"], [87, 95, "ENTITY"], [92, 95, "ENTITY"], [27, 41, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [50, 60, "ENTITY"], [136, 146, "ORGAN"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [136, 158, "ENTITY"], [144, 166, "ENTITY"], [254, 285, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [50, 60, "ENTITY"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [136, 146, "ORGAN"], [136, 158, "ENTITY"], [144, 166, "ENTITY"], [254, 285, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [136, 146, "ORGAN"], [50, 60, "ENTITY"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [136, 158, "ENTITY"], [144, 166, "ENTITY"], [254, 285, "ENTITY"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "In this study , Guan et al reported more severe disease outcomes in patients with hypertension , coronary artery disease , diabetes , and chronic renal disease ( Table 1 ) . 6", "labels": [[8, 14, "ENTITY"], [134, 152, "DISEASE"], [134, 152, "ENTITY"], [95, 113, "DISEASE"], [95, 113, "ENTITY"], [138, 146, "ORGAN"], [95, 106, "MULTI-TISSUE_STRUCTURE"], [48, 56, "ENTITY"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [259, 269, "ORGAN"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [136, 146, "ORGAN"], [50, 60, "ENTITY"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [136, 158, "ENTITY"], [144, 166, "ENTITY"], [254, 285, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [50, 60, "ENTITY"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [136, 146, "ORGAN"], [136, 158, "ENTITY"], [144, 166, "ENTITY"], [254, 285, "ENTITY"]]}
{"text": "More than half ( 126of197[64.0 % ] ) of this cohort had lymphocytopenia .", "labels": [[10, 15, "ENTITY"]]}
{"text": "Laboratory tests showed leukocytosis , lymphocytopenia , and an elevated creatine kinase \u2013 MB fraction .", "labels": [[0, 17, "ENTITY"], [91, 94, "ENTITY"], [24, 37, "ENTITY"], [24, 37, "DISEASE"], [64, 89, "GENE_OR_GENE_PRODUCT"], [64, 73, "CHEBI"], [82, 89, "ENTITY"], [64, 73, "CHEMICAL"], [64, 82, "ENTITY"]]}
{"text": "One study analyzed the lymphocyte subsets and cytokines in 123 patients , all patients had lymphcytopenia", "labels": [[10, 19, "ENTITY"], [23, 34, "CELL"], [23, 34, "CL"], [63, 72, "ORGANISM"], [46, 56, "ENTITY"], [63, 72, "ENTITY"], [46, 56, "PROTEIN"], [23, 34, "ENTITY"], [4, 10, "ENTITY"], [23, 42, "CELL_TYPE"]]}
{"text": "Spleen atrophy was observed in all reported cases with decreased numbers of lymphocyte , and significant cell degeneration , focal hemorrhagic necrosis , macrophage proliferation and macrophage phagocytosis were found in spleen .", "labels": [[76, 87, "CELL"], [65, 73, "ENTITY"], [123, 143, "ENTITY"], [0, 15, "DISEASE"], [0, 7, "ORGAN"], [55, 65, "ENTITY"], [76, 87, "CELL_TYPE"], [0, 15, "ENTITY"], [105, 110, "ENTITY"], [154, 165, "ENTITY"], [76, 87, "CL"], [105, 110, "DISEASE"], [123, 143, "DISEASE"], [44, 50, "ENTITY"], [152, 165, "ENTITY"], [76, 87, "ENTITY"]]}
{"text": "About one-third ( 68of 197[34.5 % ] ) of patients had neutrophilia .", "labels": [[6, 16, "ENTITY"]]}
{"text": "Lymphopenia and neutrophilia were present in a higher proportion of patients with severe disease than in those with mild disease , but the differences were not significant ( p=0\u00b7090 and p=0\u00b7068 , respectively ) .", "labels": [[0, 12, "DISEASE"], [68, 77, "ORGANISM"], [54, 65, "ENTITY"], [116, 129, "ENTITY"], [68, 77, "ENTITY"], [16, 29, "DISEASE"], [82, 97, "ENTITY"], [16, 29, "ENTITY"], [0, 12, "ENTITY"]]}
{"text": "Approximately one-quarter ( 46 of 197 [ 23.4 % ] ) of patients had leukocytosis .", "labels": [[49, 54, "ENTITY"], [49, 54, "ORGANISM"]]}
{"text": "Laboratory tests showed leukocytosis , lymphocytopenia , and an elevated creatine kinase \u2013 MB fraction .", "labels": [[0, 17, "ENTITY"], [91, 94, "ENTITY"], [64, 89, "GENE_OR_GENE_PRODUCT"], [24, 37, "DISEASE"], [64, 73, "CHEBI"], [82, 89, "ENTITY"], [24, 37, "ENTITY"], [64, 73, "CHEMICAL"], [64, 82, "ENTITY"]]}
{"text": "Fifty six ( 50 % ) deceased patients and only six ( 4 % ) who recovered developed leukocytosis ( white blood cell count \u226510 \u00d7 109/L ) .", "labels": [[72, 82, "DISEASE"], [82, 109, "ENTITY"], [97, 103, "CELL"], [97, 103, "CL"], [56, 62, "ENTITY"], [72, 82, "ENTITY"], [19, 28, "ENTITY"], [19, 28, "ORGANISM"]]}
{"text": "Some patients demonstrated liver injury with elevated aspartate aminotransferase(AST;59 of 198[29.8%])and alanine aminotransferase(ALT ; 43of198[21.7 % ] )", "labels": [[27, 33, "ORGAN"], [45, 54, "ENTITY"], [54, 88, "GENE_OR_GENE_PRODUCT"], [54, 64, "CHEBI"], [106, 114, "CHEBI"], [54, 64, "CHEMICAL"], [106, 114, "CHEMICAL"], [5, 14, "ENTITY"], [106, 114, "ENTITY"], [5, 14, "ORGANISM"], [27, 40, "ENTITY"], [54, 88, "ENTITY"], [27, 40, "DISEASE"], [106, 114, "AMINO_ACID"]]}
{"text": "Concentrations of alanine aminotransferase , aspartate aminotransferase , total bilirubin , alkaline phosphatase , and \u03b3-glutamyl transpeptidase were markedly higher in deceased patients than in recovered patients", "labels": [[115, 130, "PROTEIN"], [45, 55, "CHEBI"], [90, 101, "PROTEIN"], [18, 43, "PROTEIN"], [195, 205, "ENTITY"], [18, 43, "ENTITY"], [0, 15, "ENTITY"], [115, 130, "ENTITY"], [18, 43, "GENE_OR_GENE_PRODUCT"], [115, 130, "GENE_OR_GENE_PRODUCT"], [74, 80, "CHEMICAL"], [74, 80, "PROTEIN"], [18, 26, "CHEBI"], [45, 55, "GENE_OR_GENE_PRODUCT"], [169, 178, "ORGANISM"], [90, 101, "SIMPLE_CHEMICAL"], [74, 80, "GGP"], [195, 205, "ORGANISM"], [74, 80, "SIMPLE_CHEMICAL"], [72, 80, "ENTITY"], [169, 178, "ENTITY"], [45, 55, "PROTEIN"], [18, 26, "CHEMICAL"], [90, 101, "ENTITY"], [45, 55, "ENTITY"]]}
{"text": "Alanine aminotransferase ( ALT ) and aspartate aminotransferase ( AST ) levels were significantly higher in severe cases than moderate cases .", "labels": [[108, 115, "ENTITY"], [66, 72, "ENTITY"], [33, 47, "ENTITY"], [0, 25, "ENTITY"], [126, 135, "ENTITY"], [33, 47, "PROTEIN"], [33, 47, "GENE_OR_GENE_PRODUCT"], [33, 47, "GGP"], [0, 25, "GGP"], [0, 25, "GENE_OR_GENE_PRODUCT"], [0, 8, "CHEMICAL"], [0, 25, "PROTEIN"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer .", "labels": [[126, 138, "PROTEIN"], [34, 41, "ENTITY"], [126, 138, "GENE_OR_GENE_PRODUCT"], [12, 21, "ENTITY"], [101, 109, "PROTEIN"], [155, 166, "ENTITY"], [44, 63, "PROTEIN"], [25, 34, "ENTITY"], [155, 166, "PROTEIN"], [44, 63, "GGP"], [12, 21, "ORGANISM"], [101, 109, "GENE_OR_GENE_PRODUCT"], [126, 138, "ENTITY"], [101, 109, "GGP"], [44, 55, "GENE_OR_GENE_PRODUCT"], [126, 138, "CHEBI"], [101, 109, "ENTITY"], [44, 63, "ENTITY"]]}
{"text": "Most patients presented with an elevated myocardial indices : 194 of 198 ( 98.0 % ) had elevated lactate dehydrogenase (LDH),and 9 of 198 ( 4.5 % ) had an elevated creatinekinase muscle-brain isoform .", "labels": [[41, 52, "MULTI-TISSUE_STRUCTURE"], [88, 105, "PROTEIN"], [155, 192, "PROTEIN"], [41, 60, "ENTITY"], [155, 179, "GENE_OR_GENE_PRODUCT"], [5, 14, "ENTITY"], [179, 192, "SO"], [5, 14, "ORGANISM"], [88, 105, "GENE_OR_GENE_PRODUCT"], [148, 155, "ENTITY"], [88, 105, "GGP"], [32, 41, "CHEMICAL"], [179, 192, "ENTITY"], [88, 105, "ENTITY"], [32, 41, "ENTITY"]]}
{"text": "Increased C-reactive protein , procalcitonin and lactate dehydrogenase were found in five patients ( 5/8 ) , and increased alanine aminotransferase ( ALT ) in four ( 4/8 ) .", "labels": [[113, 123, "CHEBI"], [49, 57, "GENE_OR_GENE_PRODUCT"], [10, 29, "ENTITY"], [49, 57, "PROTEIN"], [49, 57, "GGP"], [10, 21, "GENE_OR_GENE_PRODUCT"], [10, 29, "GGP"], [49, 57, "ENTITY"], [113, 123, "CHEMICAL"], [0, 10, "ENTITY"], [113, 131, "GENE_OR_GENE_PRODUCT"], [131, 148, "ENTITY"], [10, 29, "PROTEIN"], [113, 131, "ENTITY"], [131, 148, "PROTEIN"], [131, 148, "GENE_OR_GENE_PRODUCT"], [113, 131, "PROTEIN"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [236, 242, "ENTITY"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [300, 315, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Levels of lactate dehydrogenase ( LDH ) , concentrations of serum high-sensitivity C-reactive protein ( hsCRP ) , ferritin and D-dimer levels were markedly higher in severe cases than moderate cases .", "labels": [[10, 18, "CHEMICAL"], [129, 137, "ENTITY"], [59, 96, "PROTEIN"], [149, 158, "ENTITY"], [0, 7, "ENTITY"], [10, 32, "GGP"], [10, 32, "PROTEIN"], [158, 168, "ENTITY"], [62, 96, "ENTITY"], [10, 32, "ENTITY"], [68, 96, "GGP"], [168, 175, "ENTITY"], [10, 32, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"]]}
{"text": "Most patients presented with an elevated myocardial indices : 194 of 198 ( 98.0 % ) had elevated lactate dehydrogenase (LDH),and 9 of 198 ( 4.5 % ) had an elevated creatinekinase muscle-brain isoform .", "labels": [[41, 52, "MULTI-TISSUE_STRUCTURE"], [88, 105, "PROTEIN"], [155, 192, "PROTEIN"], [41, 60, "ENTITY"], [155, 179, "GENE_OR_GENE_PRODUCT"], [5, 14, "ENTITY"], [179, 192, "SO"], [5, 14, "ORGANISM"], [88, 105, "GENE_OR_GENE_PRODUCT"], [148, 155, "ENTITY"], [88, 105, "GGP"], [32, 41, "CHEMICAL"], [179, 192, "ENTITY"], [88, 105, "ENTITY"], [32, 41, "ENTITY"]]}
{"text": "Increased C-reactive protein , procalcitonin and lactate dehydrogenase were found in five patients ( 5/8 ) , and increased alanine aminotransferase ( ALT ) in four ( 4/8 ) .", "labels": [[113, 123, "CHEBI"], [49, 57, "GENE_OR_GENE_PRODUCT"], [10, 29, "ENTITY"], [49, 57, "PROTEIN"], [49, 57, "GGP"], [10, 21, "GENE_OR_GENE_PRODUCT"], [10, 29, "GGP"], [49, 57, "ENTITY"], [113, 123, "CHEMICAL"], [0, 10, "ENTITY"], [113, 131, "GENE_OR_GENE_PRODUCT"], [131, 148, "ENTITY"], [10, 29, "PROTEIN"], [113, 131, "ENTITY"], [131, 148, "PROTEIN"], [131, 148, "GENE_OR_GENE_PRODUCT"], [113, 131, "PROTEIN"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Levels of lactate dehydrogenase ( LDH ) , concentrations of serum high-sensitivity C-reactive protein ( hsCRP ) , ferritin and D-dimer levels were markedly higher in severe cases than moderate cases .", "labels": [[10, 18, "CHEMICAL"], [129, 137, "ENTITY"], [59, 96, "PROTEIN"], [149, 158, "ENTITY"], [0, 7, "ENTITY"], [10, 32, "GGP"], [10, 32, "PROTEIN"], [158, 168, "ENTITY"], [62, 96, "ENTITY"], [10, 32, "ENTITY"], [68, 96, "GGP"], [168, 175, "ENTITY"], [10, 32, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"]]}
{"text": "Most patients presented with an elevated myocardial indices : 194 of 198 ( 98.0 % ) had elevated lactate dehydrogenase (LDH),and 9 of 198 ( 4.5 % ) had an elevated creatinekinase muscle-brain isoform .", "labels": [[41, 52, "MULTI-TISSUE_STRUCTURE"], [88, 105, "PROTEIN"], [155, 192, "PROTEIN"], [41, 60, "ENTITY"], [155, 179, "GENE_OR_GENE_PRODUCT"], [5, 14, "ENTITY"], [179, 192, "SO"], [5, 14, "ORGANISM"], [88, 105, "GENE_OR_GENE_PRODUCT"], [148, 155, "ENTITY"], [88, 105, "GGP"], [32, 41, "CHEMICAL"], [179, 192, "ENTITY"], [88, 105, "ENTITY"], [32, 41, "ENTITY"]]}
{"text": "Increased C-reactive protein , procalcitonin and lactate dehydrogenase were found in five patients ( 5/8 ) , and increased alanine aminotransferase ( ALT ) in four ( 4/8 ) .", "labels": [[113, 123, "CHEBI"], [49, 57, "GENE_OR_GENE_PRODUCT"], [10, 29, "ENTITY"], [49, 57, "PROTEIN"], [49, 57, "GGP"], [10, 21, "GENE_OR_GENE_PRODUCT"], [10, 29, "GGP"], [49, 57, "ENTITY"], [113, 123, "CHEMICAL"], [0, 10, "ENTITY"], [113, 131, "GENE_OR_GENE_PRODUCT"], [131, 148, "ENTITY"], [10, 29, "PROTEIN"], [113, 131, "ENTITY"], [131, 148, "PROTEIN"], [131, 148, "GENE_OR_GENE_PRODUCT"], [113, 131, "PROTEIN"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Levels of lactate dehydrogenase ( LDH ) , concentrations of serum high-sensitivity C-reactive protein ( hsCRP ) , ferritin and D-dimer levels were markedly higher in severe cases than moderate cases .", "labels": [[10, 18, "CHEMICAL"], [129, 137, "ENTITY"], [59, 96, "PROTEIN"], [149, 158, "ENTITY"], [0, 7, "ENTITY"], [10, 32, "GGP"], [10, 32, "PROTEIN"], [158, 168, "ENTITY"], [62, 96, "ENTITY"], [10, 32, "ENTITY"], [68, 96, "GGP"], [168, 175, "ENTITY"], [10, 32, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"]]}
{"text": "Most patients presented with an elevated myocardial indices : 194 of 198 ( 98.0 % ) had elevated lactate dehydrogenase (LDH),and 9 of 198 ( 4.5 % ) had an elevated creatinekinase muscle-brain isoform .", "labels": [[41, 52, "MULTI-TISSUE_STRUCTURE"], [88, 105, "PROTEIN"], [155, 192, "PROTEIN"], [41, 60, "ENTITY"], [155, 179, "GENE_OR_GENE_PRODUCT"], [5, 14, "ENTITY"], [179, 192, "SO"], [5, 14, "ORGANISM"], [88, 105, "GENE_OR_GENE_PRODUCT"], [148, 155, "ENTITY"], [88, 105, "GGP"], [32, 41, "CHEMICAL"], [179, 192, "ENTITY"], [88, 105, "ENTITY"], [32, 41, "ENTITY"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Few patients had kidney injury indicated by elevated plasma urea ( 9 of 198 [ 4.5 % ] ) and serum creatinine ( 9 of 198 [ 4.5 % ] ) .", "labels": [[44, 53, "ENTITY"], [60, 65, "CHEBI"], [17, 31, "ENTITY"], [92, 98, "CHEBI"], [88, 98, "ENTITY"], [92, 98, "CHEMICAL"], [53, 65, "ENTITY"], [17, 24, "ORGAN"], [60, 65, "CHEMICAL"], [53, 65, "ORGANISM_SUBSTANCE"], [88, 98, "ORGANISM_SUBSTANCE"], [17, 31, "DISEASE"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "But in the severe patients , the neutrophil count , D-dimer , blood urea , and creatinine levels were higher significantly , and the lymphocyte counts continued to decrease .", "labels": [[11, 18, "ENTITY"], [79, 90, "ENTITY"], [60, 68, "GGP"], [33, 44, "ENTITY"], [60, 68, "DISEASE"], [18, 27, "ENTITY"], [60, 68, "ENTITY"], [18, 27, "ORGANISM"], [60, 68, "ORGANISM_SUBSTANCE"], [151, 164, "ENTITY"], [133, 144, "ENTITY"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 90, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [65, 90, "PROTEIN"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Few patients had kidney injury indicated by elevated plasma urea ( 9 of 198 [ 4.5 % ] ) and serum creatinine ( 9 of 198 [ 4.5 % ] ) .", "labels": [[44, 53, "ENTITY"], [60, 65, "CHEBI"], [17, 31, "ENTITY"], [92, 98, "CHEBI"], [88, 98, "ENTITY"], [92, 98, "CHEMICAL"], [53, 65, "ENTITY"], [17, 24, "ORGAN"], [60, 65, "CHEMICAL"], [53, 65, "ORGANISM_SUBSTANCE"], [88, 98, "ORGANISM_SUBSTANCE"], [17, 31, "DISEASE"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [154, 163, "ORGANISM"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [154, 163, "ENTITY"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [24, 38, "CHEBI"], [18, 29, "ORGANISM_SUBSTANCE"], [144, 154, "ENTITY"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Of 195 patients , 4 ( 2.1 % ) presented with prolonged prothrombin times ( PTs ) .", "labels": [[7, 16, "ENTITY"], [67, 73, "ENTITY"], [7, 16, "ORGANISM"], [45, 55, "PROTEIN"], [67, 73, "CANCER"], [45, 67, "ENTITY"], [45, 55, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Median prothrombin time was significantly longer in deceased patients than in recovered patients , whereas activated partial thromboplastin time was comparable between the two groups .", "labels": [[0, 7, "ENTITY"], [61, 70, "ENTITY"], [52, 61, "ENTITY"], [61, 70, "ORGANISM"], [61, 70, "ENTITY"], [61, 70, "ORGANISM"], [7, 24, "ENTITY"], [7, 19, "PROTEIN"], [7, 19, "GENE_OR_GENE_PRODUCT"], [78, 88, "ENTITY"]]}
{"text": "Decreased platelet counts were observed in 25 ( 20.2 % ) patients , prolonged prothrombin time ( PT ) was observed in 77 ( 62.1 % ) patients , fibrinogen ( FIB ) levels were increased in 27 ( 21.8 % ) patients , and D-dimer levels were increased in 26 ( 21.0 % ) patients .", "labels": [[216, 224, "ENTITY"], [57, 68, "ENTITY"], [10, 19, "CL"], [57, 68, "ENTITY"], [10, 26, "ENTITY"], [68, 78, "GENE_OR_GENE_PRODUCT"], [236, 252, "ORGANISM"], [162, 169, "ENTITY"], [68, 90, "ENTITY"], [143, 156, "ENTITY"], [57, 68, "PROTEIN"], [90, 95, "ENTITY"], [10, 19, "CELL"], [236, 252, "ENTITY"], [57, 68, "GENE_OR_GENE_PRODUCT"], [57, 68, "ENTITY"], [0, 10, "ENTITY"], [68, 78, "PROTEIN"]]}
{"text": "But in the severe patients , the neutrophil count , D-dimer , blood urea , and creatinine levels were higher significantly , and the lymphocyte counts continued to decrease .", "labels": [[11, 18, "ENTITY"], [60, 68, "GGP"], [60, 68, "DISEASE"], [33, 44, "ENTITY"], [18, 27, "ENTITY"], [60, 68, "ENTITY"], [18, 27, "ORGANISM"], [79, 90, "ENTITY"], [60, 68, "ORGANISM_SUBSTANCE"], [151, 164, "ENTITY"], [133, 144, "ENTITY"]]}
{"text": "The blood counts of patients on admission showed decrease in neutrophils ( 26 [ 39 % ] of 67 patients ) , lymphocytes ( 28 [ 42 % ] of 67 patients ) , and eosinophils ( 48 [ 72 % ] of 67 patients ) , among which , the number of eosinophils in 31 patients was zero .", "labels": [[179, 191, "CELL_TYPE"], [-1, 18, "CELL_TYPE"], [-1, 11, "ENTITY"], [130, 147, "CELL_TYPE"], [264, 270, "ENTITY"], [117, 128, "ENTITY"], [-1, 18, "ENTITY"], [130, 147, "CL"], [-1, 18, "CL"], [14, 21, "ENTITY"], [264, 270, "ORGANISM"], [130, 147, "CELL"], [179, 191, "CELL"], [130, 147, "ENTITY"], [242, 252, "ENTITY"], [242, 252, "CELL"], [242, 252, "CELL_TYPE"], [179, 191, "ENTITY"], [-1, 11, "ORGANISM"], [6, 12, "ORGANISM_SUBSTANCE"], [117, 128, "ORGANISM"], [-1, 18, "CELL"]]}
{"text": "On admission , physical examinations and pulmonary auscultation were normal ; laboratory tests indicated a reduction in leukocytes ( 1.92 \u00d7 109/L ) , neutrophils ( 1.20 \u00d7 109/L ) , lymphocytes ( 0.47 \u00d7 109/L ) , and eosinophils ( 0 \u00d7 109 /L ) counts , normal CRP and PCT concentrations , and slightly increased concentration of serum amyloid A [ SAA , 36.84 mg/L , reference range : ( 0~10 ) mg/L ]", "labels": [[301, 311, "ENTITY"], [138, 150, "ENTITY"], [271, 285, "PROTEIN"], [143, 146, "ENTITY"], [15, 24, "ENTITY"], [301, 311, "ORGANISM_SUBSTANCE"], [140, 150, "ENTITY"], [250, 263, "ENTITY"], [140, 150, "CELL"], [143, 146, "GGP"], [301, 311, "GGP"], [271, 285, "GENE_OR_GENE_PRODUCT"], [138, 150, "CL"], [334, 352, "ENTITY"], [3, 13, "ENTITY"], [301, 311, "PROTEIN"], [143, 146, "GENE_OR_GENE_PRODUCT"], [41, 51, "ENTITY"], [150, 162, "GENE_OR_GENE_PRODUCT"], [271, 285, "ENTITY"], [76, 89, "ENTITY"], [140, 150, "CELL_TYPE"], [271, 288, "ENTITY"], [143, 146, "PROTEIN"], [138, 150, "CELL_TYPE"], [138, 150, "CELL"], [216, 228, "ENTITY"], [140, 150, "CL"], [288, 301, "ENTITY"], [138, 148, "CELL"], [138, 148, "CELL_TYPE"], [138, 148, "ENTITY"]]}
{"text": "Remarkable abnormalities in the CBC were detected on January 29 , including increased neutrophils ( 10.67 \u00d7 109/L ) , leukocytes ( 11.73 \u00d7 109/L ) , and decreased lymphocytes ( 0.51 \u00d7 109 /L ) , and on February 4 decreased erythrocytes ( 2.40 \u00d7 1012/L ) and platelets ( 73 \u00d7 109 /L ) .", "labels": [[195, 202, "ENTITY"], [202, 213, "CL"], [202, 213, "CELL"], [41, 50, "ENTITY"], [153, 163, "CELL_TYPE"], [108, 118, "ENTITY"], [108, 118, "CELL"], [153, 163, "CL"], [108, 118, "CELL_TYPE"], [153, 163, "ENTITY"], [202, 213, "ENTITY"], [32, 36, "CELL_TYPE"], [108, 118, "ENTITY"], [32, 36, "ENTITY"], [153, 163, "CELL"], [11, 25, "ENTITY"], [108, 118, "CL"], [32, 36, "GENE_OR_GENE_PRODUCT"], [202, 213, "CELL_TYPE"]]}
{"text": "Laboratory tests showed a slight decrease of leukocytes ( 3.19 \u00d7 109/L ) and neutrophils ( 1.57 \u00d7 109/L ) and a mildly elevated CRP concentration ( 29.2 mg/L ) , with all other tested parameters within normal ranges .", "labels": [[119, 132, "ENTITY"], [0, 17, "ENTITY"], [45, 56, "CELL_TYPE"], [33, 42, "ENTITY"], [112, 119, "ENTITY"], [184, 202, "ENTITY"], [45, 56, "CL"], [45, 56, "CELL"], [45, 56, "ENTITY"], [171, 184, "ENTITY"]]}
{"text": "A CBC showed slightly increased neutrophils ( 7.53 \u00d7 109/L ) and markedly decreased lymphocytes ( 0.27 \u00d7 109/L ) .", "labels": [[74, 84, "ENTITY"], [65, 74, "ENTITY"], [32, 44, "CELL"], [22, 32, "ENTITY"], [32, 44, "ENTITY"], [32, 44, "CL"], [74, 84, "CELL"], [32, 44, "CELL_TYPE"], [74, 84, "CL"], [2, 6, "ENTITY"], [2, 6, "CELL_TYPE"], [74, 84, "CELL_TYPE"]]}
{"text": "Both WBC and neutrophil counts were significantly higher in severe cases than moderate cases . Whereas lymphocyte counts were significantly lower in severe cases ( 0.7 \u00d7 109/L ) than moderate cases ( 1.1 \u00d7 109/L ) .", "labels": [[62, 69, "ENTITY"], [105, 116, "CL"], [5, 9, "PROTEIN"], [5, 9, "GO"], [80, 89, "ENTITY"], [26, 33, "ENTITY"], [15, 26, "ENTITY"], [105, 116, "CELL"], [62, 69, "ENTITY"], [105, 116, "ENTITY"], [69, 75, "ENTITY"], [69, 75, "ENTITY"], [26, 33, "ENTITY"], [15, 26, "CL"], [5, 9, "ENTITY"], [80, 89, "ENTITY"], [5, 9, "SIMPLE_CHEMICAL"], [15, 26, "CELL_TYPE"], [69, 75, "ENTITY"], [15, 26, "CELL"]]}
{"text": "The common clinical manifestations of fever and cough in conjunction with laboratory results of progressively increasing neutrophil counts and leukocytopenia in serum samples taken from COVID-19 patients at various stages of the illness indicates uncontrolled neutrophil extravasation and activation 11,12 .", "labels": [[121, 132, "CL"], [195, 204, "ENTITY"], [229, 237, "ENTITY"], [121, 132, "ENTITY"], [186, 195, "ENTITY"], [57, 69, "ENTITY"], [132, 139, "ENTITY"], [38, 44, "ENTITY"], [143, 158, "ENTITY"], [260, 285, "ENTITY"], [121, 132, "CELL"], [121, 132, "CELL"], [11, 35, "ENTITY"], [186, 204, "ORGANISM"], [247, 260, "ENTITY"], [74, 93, "ENTITY"], [121, 132, "CL"], [48, 54, "ENTITY"], [110, 121, "ENTITY"], [121, 132, "CELL_TYPE"], [38, 44, "DISEASE"], [161, 175, "ORGANISM_SUBSTANCE"], [289, 300, "ENTITY"], [121, 132, "CELL_TYPE"], [161, 175, "ENTITY"], [215, 222, "ENTITY"], [143, 158, "DISEASE"], [48, 54, "DISEASE"]]}
{"text": "But in the severe patients , the neutrophil count , D-dimer , blood urea , and creatinine levels were higher significantly , and the lymphocyte counts continued to decrease .", "labels": [[11, 18, "ENTITY"], [33, 44, "ENTITY"], [60, 68, "ENTITY"], [18, 27, "ENTITY"], [60, 68, "GGP"], [18, 27, "ORGANISM"], [79, 90, "ENTITY"], [151, 164, "ENTITY"], [60, 68, "ORGANISM_SUBSTANCE"], [60, 68, "DISEASE"], [133, 144, "ENTITY"]]}
{"text": "But in the severe patients , the neutrophil count , D-dimer , blood urea , and creatinine levels were higher significantly , and the lymphocyte counts continued to decrease .", "labels": [[11, 18, "ENTITY"], [60, 68, "GGP"], [60, 68, "DISEASE"], [33, 44, "ENTITY"], [18, 27, "ENTITY"], [60, 68, "ENTITY"], [18, 27, "ORGANISM"], [79, 90, "ENTITY"], [60, 68, "ORGANISM_SUBSTANCE"], [151, 164, "ENTITY"], [133, 144, "ENTITY"]]}
{"text": "lymphocyte count slightly decreased [ 0.81 \u00d7 109/L , reference range : ( 1.1~3.2 ) \u00d7109/L ] , and the concentration of serum high-sensitivity C-reactive protein ( hsCRP ) increased [ 49.9 mg/L , reference range : ( 0~3 ) mg/L ] , with leukocyte count and procalcitonin ( PCT ) concentration within normal ranges .", "labels": [[26, 36, "ENTITY"], [215, 226, "CELL"], [125, 142, "GGP"], [215, 226, "CL"], [255, 271, "ENTITY"], [102, 142, "ENTITY"], [0, 11, "CELL"], [215, 230, "ENTITY"], [161, 169, "ENTITY"], [235, 255, "GENE_OR_GENE_PRODUCT"], [183, 195, "ENTITY"], [45, 63, "ENTITY"], [102, 142, "PROTEIN"], [0, 11, "CL"], [94, 102, "ENTITY"], [102, 116, "ENTITY"], [235, 251, "PROTEIN"], [235, 251, "ENTITY"], [0, 11, "ENTITY"], [102, 116, "ORGANISM_SUBSTANCE"]]}
{"text": "Remarkable abnormalities in the CBC were detected on January 29 , including increased neutrophils ( 10.67 \u00d7 109/L ) , leukocytes ( 11.73 \u00d7 109/L ) , and decreased lymphocytes ( 0.51 \u00d7 109 /L ) , and on February 4 decreased erythrocytes ( 2.40 \u00d7 1012/L ) and platelets ( 73 \u00d7 109 /L ) .", "labels": [[195, 202, "ENTITY"], [202, 213, "CL"], [202, 213, "CELL"], [41, 50, "ENTITY"], [153, 163, "CELL_TYPE"], [108, 118, "ENTITY"], [108, 118, "CELL"], [153, 163, "CL"], [108, 118, "CELL_TYPE"], [153, 163, "ENTITY"], [202, 213, "ENTITY"], [32, 36, "CELL_TYPE"], [108, 118, "ENTITY"], [32, 36, "ENTITY"], [153, 163, "CELL"], [11, 25, "ENTITY"], [108, 118, "CL"], [32, 36, "GENE_OR_GENE_PRODUCT"], [202, 213, "CELL_TYPE"]]}
{"text": "A CBC showed slightly increased neutrophils ( 7.53 \u00d7 109/L ) and markedly decreased lymphocytes ( 0.27 \u00d7 109/L ) .", "labels": [[74, 84, "ENTITY"], [65, 74, "ENTITY"], [22, 32, "ENTITY"], [74, 84, "CELL_TYPE"], [32, 44, "ENTITY"], [32, 44, "CELL"], [74, 84, "CELL"], [32, 44, "CL"], [74, 84, "CL"], [2, 6, "ENTITY"], [2, 6, "CELL_TYPE"], [32, 44, "CELL_TYPE"]]}
{"text": "Both WBC and neutrophil counts were significantly higher in severe cases than moderate cases . Whereas lymphocyte counts were significantly lower in severe cases ( 0.7 \u00d7 109/L ) than moderate cases ( 1.1 \u00d7 109/L ) .", "labels": [[62, 69, "ENTITY"], [105, 116, "CL"], [5, 9, "PROTEIN"], [5, 9, "GO"], [26, 33, "ENTITY"], [80, 89, "ENTITY"], [15, 26, "ENTITY"], [105, 116, "CELL"], [62, 69, "ENTITY"], [105, 116, "ENTITY"], [69, 75, "ENTITY"], [69, 75, "ENTITY"], [15, 26, "CL"], [5, 9, "ENTITY"], [80, 89, "ENTITY"], [26, 33, "ENTITY"], [5, 9, "SIMPLE_CHEMICAL"], [15, 26, "CELL_TYPE"], [69, 75, "ENTITY"], [15, 26, "CELL"]]}
{"text": "Additionally , inflammatory factors ( interleukin (IL)-6 , IL-10 , tumor necrosis factor-\u03b1(TNF-\u03b1 ) increase , indicating the immune status of patients . The data showed that ICU patients had higher plasma levels of IL-2 , IL-7 , IL-10 , granulocyte colony-stimulating factor ( GCSF ) , 10 kD interferon-gamma-induced protein ( IP-10 ) , monocyte chemo-attractant protein-1 ( MCP-1 ) , macrophage inflammatory protein 1-\u03b1(MIP-1\u03b1 ) , and TNF-\u03b1[48 ] .", "labels": [[191, 198, "ENTITY"], [36, 50, "PROTEIN"], [191, 198, "ORGANISM_SUBSTANCE"], [371, 417, "GENE_OR_GENE_PRODUCT"], [205, 212, "ENTITY"], [249, 268, "ENTITY"], [249, 268, "GENE_OR_GENE_PRODUCT"], [371, 417, "ENTITY"], [198, 205, "ENTITY"], [178, 191, "ENTITY"], [292, 317, "PROTEIN"], [15, 28, "PROTEIN"], [-1, 20, "ENTITY"], [169, 178, "ENTITY"], [59, 82, "ENTITY"], [36, 50, "ENTITY"], [227, 249, "GGP"], [59, 82, "PROTEIN"], [292, 317, "GENE_OR_GENE_PRODUCT"], [292, 317, "ENTITY"], [15, 28, "ENTITY"], [59, 73, "DISEASE"], [-1, 20, "GENE_OR_GENE_PRODUCT"], [371, 417, "PROTEIN"], [425, 436, "PROTEIN"], [249, 268, "CHEMICAL"], [371, 404, "GGP"], [205, 212, "PROTEIN"], [227, 249, "PROTEIN"], [132, 142, "ENTITY"], [59, 82, "GENE_OR_GENE_PRODUCT"], [205, 212, "GENE_OR_GENE_PRODUCT"], [227, 249, "GENE_OR_GENE_PRODUCT"], [132, 142, "ORGANISM"], [329, 337, "CL"], [82, 99, "ENTITY"], [162, 169, "ENTITY"], [249, 268, "GGP"], [169, 178, "ORGANISM"], [249, 268, "PROTEIN"], [110, 132, "ENTITY"], [227, 249, "ENTITY"], [277, 292, "ENTITY"], [292, 317, "GGP"]]}
{"text": "TBNK lymphocyte subset analysis revealed decreased percentage of CD16 + CD56 + lymphocytes ( 4/8 ) and Th/Ts ( 1/8 ) , and increased percentage of CD3 + ( 2/8 ) , CD4 + ( 4/8 ) and CD8 + ( 1/8 ) lymphocytes . Cytokine detection assays showed increased levels of IL-6 ( 2/8 ) , IL-10 ( 5/8 ) and IFN-\u03b3 ( 2/8 ) .", "labels": [[-1, 25, "ENTITY"], [281, 287, "GENE_OR_GENE_PRODUCT"], [199, 222, "ENTITY"], [127, 137, "ENTITY"], [266, 271, "PROTEIN"], [41, 51, "ENTITY"], [127, 137, "GENE_OR_GENE_PRODUCT"], [5, 16, "CELL"], [266, 271, "ENTITY"], [281, 293, "PROTEIN"], [127, 137, "ENTITY"], [5, 16, "ENTITY"], [266, 271, "GGP"], [0, 5, "ENTITY"], [266, 271, "GENE_OR_GENE_PRODUCT"], [281, 287, "ENTITY"], [159, 199, "CELL_TYPE"], [239, 246, "ENTITY"], [175, 199, "ENTITY"], [127, 137, "PROTEIN"], [51, 65, "GGP"], [65, 70, "GENE_OR_GENE_PRODUCT"], [232, 239, "ENTITY"], [281, 287, "CHEMICAL"], [127, 137, "GGP"], [5, 16, "CL"], [51, 62, "GENE_OR_GENE_PRODUCT"], [137, 157, "ENTITY"], [-1, 25, "CELL_LINE"], [137, 157, "CELL_TYPE"], [185, 199, "CL"], [0, 23, "CELL_LINE"], [51, 62, "ENTITY"], [83, 95, "CL"]]}
{"text": "In any case , blocking IL-6 may be effective . Blocking IL-1 and TNF may also benefit patients .", "labels": [[47, 56, "PROTEIN"], [47, 56, "GENE_OR_GENE_PRODUCT"], [78, 86, "ORGANISM"], [78, 86, "ENTITY"], [7, 12, "ENTITY"], [47, 56, "ENTITY"], [47, 56, "GGP"]]}
{"text": "Inflammatory cytokine IL-6 was significantly increased in all infants .", "labels": [[22, 27, "GGP"], [45, 55, "ENTITY"], [62, 70, "ORGANISM"], [0, 22, "ENTITY"], [0, 27, "PROTEIN"], [22, 27, "GENE_OR_GENE_PRODUCT"], [62, 70, "ENTITY"], [22, 27, "ENTITY"]]}
{"text": "Of patients with available data , concentrations of interleukin 2 receptor , interleukin 6 , interleukin 8 , interleukin 10 , and tumour necrosis factor \u03b1 were significantly higher in deceased patients than in recovered patients .", "labels": [[126, 146, "PROTEIN"], [75, 89, "GENE_OR_GENE_PRODUCT"], [3, 12, "ENTITY"], [52, 66, "PROTEIN"], [75, 89, "PROTEIN"], [184, 193, "ORGANISM"], [75, 89, "ENTITY"], [27, 32, "ENTITY"], [52, 66, "GGP"], [52, 66, "GENE_OR_GENE_PRODUCT"], [75, 89, "GGP"], [202, 210, "ENTITY"], [52, 66, "ENTITY"], [126, 146, "ENTITY"], [184, 193, "ENTITY"], [126, 146, "GENE_OR_GENE_PRODUCT"], [210, 220, "ENTITY"], [210, 220, "ORGANISM"], [174, 184, "ENTITY"], [126, 146, "GGP"], [126, 137, "DISEASE"], [3, 12, "ORGANISM"]]}
{"text": "Evaluation of serum cytokines on admission revealed that levels of interleukin (IL)- 2R , IL-6 , IL-10 , and tumor necrosis factor-\u03b1 ( TNF-\u03b1 ) were markedly higher in severe cases than in moderate cases ( Figure 2 , Supplementary Table 1 ) .", "labels": [[205, 230, "GENE_OR_GENE_PRODUCT"], [105, 115, "DISEASE"], [157, 167, "ENTITY"], [33, 43, "ENTITY"], [124, 135, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [0, 11, "ENTITY"], [14, 20, "ENTITY"], [105, 124, "PROTEIN"], [14, 20, "ORGANISM_SUBSTANCE"], [124, 135, "PROTEIN"], [105, 124, "ENTITY"], [105, 124, "GENE_OR_GENE_PRODUCT"], [67, 88, "ENTITY"], [197, 205, "ENTITY"], [180, 188, "ENTITY"], [67, 88, "GGP"], [124, 135, "ENTITY"], [20, 30, "ENTITY"], [205, 230, "ENTITY"], [57, 64, "ENTITY"], [67, 88, "GENE_OR_GENE_PRODUCT"], [188, 197, "ENTITY"], [67, 88, "PROTEIN"], [14, 30, "PROTEIN"]]}
{"text": "Of note , IL-6 levels were increased in both moderate and severe cases .", "labels": []}
{"text": "In particular , in a recent study by Qin C , et al.in which among 452 patients with COVID-19 , most of them had increase of several inflammatory cytokines such as tumor necrosis factor (TNF)-\u03b1 , interleukin (IL)-1and IL-6 [ 3 ] .", "labels": [[207, 217, "PROTEIN"], [132, 145, "ENTITY"], [160, 185, "GGP"], [207, 217, "GENE_OR_GENE_PRODUCT"], [160, 185, "GENE_OR_GENE_PRODUCT"], [207, 217, "GGP"], [124, 145, "PROTEIN"], [160, 185, "PROTEIN"], [207, 217, "ENTITY"], [185, 195, "ENTITY"], [185, 195, "PROTEIN"], [185, 195, "GGP"], [185, 195, "GENE_OR_GENE_PRODUCT"], [37, 41, "ENTITY"], [160, 185, "ENTITY"]]}
{"text": "Consistent with others , most of severe COVID-19 patients in our ICU ward had persistent very high level of erythematosus sedimentation rate ( ESR ) , CRP , and high level of IL-6,TNFa , IL-1B , IL-8 , IL2R , etc , and were associated with ARDS , hypercoagulation and disseminated intravascular coagulation ( DIC ) , manifested as thrombosis , thrombocytopenia , gangrene of extremities .", "labels": [[0, 16, "ENTITY"], [175, 187, "GENE_OR_GENE_PRODUCT"], [328, 344, "ENTITY"], [175, 187, "ENTITY"], [175, 187, "DNA"], [328, 344, "DISEASE"], [99, 108, "GGP"], [65, 69, "ENTITY"], [235, 247, "DISEASE"], [108, 136, "ENTITY"], [344, 363, "ENTITY"], [235, 247, "ENTITY"], [187, 193, "ENTITY"], [99, 108, "DNA"], [187, 193, "GENE_OR_GENE_PRODUCT"], [268, 281, "IMMATERIAL_ANATOMICAL_ENTITY"], [268, 295, "DISEASE"], [99, 108, "ENTITY"], [344, 363, "ORGAN"], [175, 187, "GGP"], [317, 328, "DISEASE"], [94, 99, "ENTITY"], [187, 193, "PROTEIN"], [247, 295, "ENTITY"], [40, 49, "GENE_OR_GENE_PRODUCT"], [215, 224, "ENTITY"], [187, 193, "GGP"], [99, 108, "GENE_OR_GENE_PRODUCT"], [317, 328, "ENTITY"]]}
{"text": "Studies have shown that IL-6 levels significantly correlated with the severity of COVID-19 , C-reactive protein ( CRP ) , lactate dehydrogenase ( LDH ) , and D-dimer levels and T cell counts , and it has been suggested that Tocilizumab , with its inhibitory effect on IL-6 , may be effective in treatment of COVID-19 ( 10 , 11 ) .", "labels": [[152, 158, "GGP"], [295, 305, "GENE_OR_GENE_PRODUCT"], [82, 91, "GENE_OR_GENE_PRODUCT"], [82, 91, "PROTEIN"], [238, 247, "ENTITY"], [24, 29, "GGP"], [152, 166, "ENTITY"], [118, 130, "GGP"], [70, 79, "ENTITY"], [152, 158, "PROTEIN"], [93, 104, "GGP"], [118, 130, "PROTEIN"], [166, 177, "ENTITY"], [130, 144, "GENE_OR_GENE_PRODUCT"], [50, 61, "ENTITY"], [24, 29, "GENE_OR_GENE_PRODUCT"], [82, 91, "ENTITY"], [282, 295, "ENTITY"], [130, 144, "PROTEIN"], [24, 29, "ENTITY"], [295, 305, "ENTITY"], [177, 184, "ENTITY"], [152, 158, "GENE_OR_GENE_PRODUCT"], [0, 8, "ENTITY"], [130, 144, "ENTITY"], [118, 130, "ENTITY"], [118, 130, "GENE_OR_GENE_PRODUCT"], [166, 177, "CL"], [24, 29, "PROTEIN"], [166, 177, "CELL"], [273, 282, "ENTITY"], [93, 104, "ENTITY"], [209, 224, "ENTITY"], [209, 224, "SIMPLE_CHEMICAL"], [93, 104, "PROTEIN"], [29, 36, "ENTITY"]]}
{"text": "We only found the levels of TNF-\u03b1 , IL-6 and IL-10 were significantly increased in infected patients , and statistical analysis illustrated that their levels in ICU patients are significantly higher than in Non-ICU patients ( Figure 2A ) .", "labels": [[161, 165, "ENTITY"], [28, 34, "CHEMICAL"], [207, 215, "ORGANISM"], [207, 215, "ENTITY"], [28, 34, "PROTEIN"], [103, 119, "ENTITY"], [224, 233, "ENTITY"], [28, 34, "ENTITY"], [28, 34, "GENE_OR_GENE_PRODUCT"], [161, 165, "ORGANISM"], [18, 25, "ENTITY"]]}
{"text": "Interestingly , serum levels of IFN-\u03b3 , IL-10 , IL-6 and TNF-\u03b1 were significantly decreased in these patients in the decline period as compared with illness period , while counts of total T cells , CD4 + , and CD8 + T cell subsets recovered during the decline period ( Figure 2C ) .", "labels": [[117, 125, "ENTITY"], [182, 190, "CL"], [68, 82, "ENTITY"], [182, 190, "CELL"], [16, 22, "ENTITY"], [260, 269, "ENTITY"], [206, 218, "GGP"], [149, 157, "ENTITY"], [206, 223, "ENTITY"], [117, 125, "ENTITY"], [190, 198, "ENTITY"], [179, 190, "CELL_TYPE"], [179, 190, "ENTITY"], [190, 223, "CELL_TYPE"], [190, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expression of IL-6 , IL-8 and IL-10 in the serum of patients with COVID-19 increased significantly compared with the control group ( P<0.05 ) .", "labels": [[4, 15, "ENTITY"], [121, 129, "ENTITY"], [18, 23, "GENE_OR_GENE_PRODUCT"], [18, 23, "PROTEIN"], [18, 23, "ENTITY"], [18, 23, "GGP"]]}
{"text": "Chemical signals such as Interleukin-8 ( IL-8 ) and IL-6 stimulate neutrophil chemotaxis and recruitment to the site of infection where they congregate and cause the release of more proinflammatory mediators that in turn activate additional inflammatory signals , leading to cytokine storms that may progress to vital organ failure 13 .", "labels": [[25, 39, "ENTITY"], [57, 78, "ENTITY"], [57, 67, "CELL"], [177, 198, "ENTITY"], [312, 318, "ORGAN"], [230, 254, "ENTITY"], [216, 221, "ENTITY"], [0, 9, "CHEBI"], [0, 17, "ENTITY"], [312, 324, "ENTITY"], [57, 67, "CL"], [312, 324, "DISEASE"], [177, 198, "PROTEIN"], [25, 39, "GENE_OR_GENE_PRODUCT"], [272, 284, "ENTITY"], [25, 39, "PROTEIN"], [57, 67, "CELL_TYPE"]]}
{"text": "The elevation of IL-8 and IL-6 but not IL-17 in PMBCs collected from COVID-19 patients indicates possible roles for IL-8/IL-6 in the severe inflammatory response induced by SARS-CoV-2 ( Fig.3d-e and Extended Data Fig.5e ) .", "labels": [[162, 170, "ENTITY"], [26, 31, "ENTITY"], [17, 22, "ENTITY"], [17, 22, "GENE_OR_GENE_PRODUCT"], [39, 45, "GENE_OR_GENE_PRODUCT"], [133, 140, "ENTITY"], [116, 126, "ENTITY"], [26, 31, "GGP"], [173, 184, "GGP"], [39, 45, "ENTITY"], [26, 31, "GENE_OR_GENE_PRODUCT"], [116, 126, "GENE_OR_GENE_PRODUCT"], [17, 22, "GGP"], [116, 126, "GGP"], [116, 126, "PROTEIN"], [4, 14, "ENTITY"], [48, 54, "CELL"], [69, 78, "ENTITY"], [39, 45, "PROTEIN"], [173, 184, "ENTITY"], [140, 162, "ENTITY"], [26, 31, "PROTEIN"], [78, 87, "ENTITY"], [69, 87, "ORGANISM"], [48, 54, "CELL_TYPE"], [48, 54, "ENTITY"], [173, 184, "CHEMICAL"], [39, 45, "GGP"], [199, 213, "ENTITY"], [17, 22, "PROTEIN"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [40, 59, "ENTITY"], [26, 38, "SIMPLE_CHEMICAL"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GGP"], [253, 271, "ENTITY"], [26, 40, "CHEBI"], [170, 179, "GGP"], [26, 38, "CHEMICAL"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [144, 154, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [26, 38, "ENTITY"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "Moreover , we observed that infections by SARS-CoV-2 triggered the expected increase in the IL-6 levels in the culture supernatant , which ranged from 20- to 60-fold depending on the cell donor ( Figure 7C , open circles in nil-treated cells ) . The virus-induced enhancement of IL-6 levels were significantly prevented by treatment with ATV at 10 \u00b5M , ATV/RTV at both 1 and 10 \u00b5M and CQ at 10 \u00b5M ( Figure 7C ) .", "labels": [[244, 264, "ENTITY"], [179, 188, "ENTITY"], [203, 213, "ENTITY"], [348, 351, "ENTITY"], [224, 236, "CL"], [194, 203, "ENTITY"], [348, 351, "SIMPLE_CHEMICAL"], [345, 353, "CHEMICAL"], [264, 276, "PROTEIN"], [348, 351, "CHEMICAL"], [310, 323, "ENTITY"], [221, 236, "CELL_LINE"], [224, 236, "CELL"], [264, 276, "GENE_OR_GENE_PRODUCT"], [264, 276, "GGP"], [221, 236, "ENTITY"], [345, 353, "ENTITY"], [111, 119, "ENTITY"], [92, 97, "ENTITY"], [264, 276, "ENTITY"], [345, 353, "SIMPLE_CHEMICAL"], [391, 399, "ENTITY"], [345, 353, "PROTEIN"]]}
{"text": "Comorbidities were present in nearly half of patients , with hypertension being the most common comorbidity , followed by diabetes and coronary heart disease ( table 1 ) .", "labels": [[0, 14, "ENTITY"], [131, 150, "ENTITY"], [131, 150, "DISEASE"], [131, 144, "CANCER"], [45, 54, "ENTITY"], [45, 54, "ORGANISM"]]}
{"text": "In this study , Guan et al reported more severe disease outcomes in patients with hypertension , coronary artery disease , diabetes , and chronic renal disease ( Table 1 ) . 6", "labels": [[8, 14, "ENTITY"], [134, 152, "DISEASE"], [134, 152, "ENTITY"], [95, 113, "DISEASE"], [95, 106, "MULTI-TISSUE_STRUCTURE"], [138, 146, "ORGAN"], [48, 56, "ENTITY"], [95, 113, "ENTITY"]]}
{"text": "The most common symptoms on admission were fever and cough , followed by sputum production and fatigue ( table 1 ) .", "labels": [[28, 38, "ENTITY"], [53, 59, "ENTITY"], [43, 49, "ENTITY"], [43, 49, "DISEASE"], [73, 80, "ENTITY"], [53, 59, "DISEASE"], [16, 25, "ENTITY"]]}
{"text": "Most COVID-19 patients initially suffered from fever , cough , fatigue , and shortness of breath , while other symptoms included muscle pain , headache , chest pain , and diarrhea , similar to the symptoms observed after chemotherapy , targeted and immune therapy1", "labels": [[73, 90, "ENTITY"], [143, 154, "DISEASE"], [120, 136, "DISEASE"], [120, 136, "ENTITY"], [47, 53, "ENTITY"], [206, 221, "ENTITY"], [14, 23, "ENTITY"], [5, 14, "ENTITY"], [5, 23, "ORGANISM"], [236, 256, "CELL"], [5, 14, "DISEASE"], [73, 90, "DISEASE"], [143, 154, "ORGAN"], [221, 236, "ENTITY"], [236, 256, "ENTITY"], [71, 77, "ENTITY"], [190, 197, "ENTITY"], [111, 120, "ENTITY"], [136, 143, "ENTITY"], [136, 143, "DISEASE"], [120, 129, "ORGAN"], [47, 53, "DISEASE"], [143, 154, "ENTITY"], [71, 77, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [219, 230, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "She experienced only mild symptoms such as a sore throat and fatigue , without any signs of pneumonia such as cough and chest tightness .", "labels": [[45, 57, "DISEASE"], [61, 69, "ENTITY"], [45, 57, "ENTITY"], [61, 69, "DISEASE"], [120, 126, "ENTITY"], [21, 35, "ENTITY"], [120, 126, "DISEASE"], [4, 16, "ENTITY"]]}
{"text": "A 69-year old woman had persistent fever ( > 38 \u2103 ) accompanied by a dry cough , headache , sore throat , myalgia and fatigue for three days .", "labels": [[35, 41, "ENTITY"], [67, 73, "ENTITY"], [97, 106, "DISEASE"], [67, 73, "DISEASE"], [24, 35, "ENTITY"], [14, 20, "ORGANISM"], [14, 20, "ENTITY"], [35, 41, "DISEASE"], [81, 97, "ENTITY"], [97, 106, "ENTITY"], [81, 97, "DISEASE"]]}
{"text": "Fever , cough and sputum production were the most common symptoms . Of the aforementioned symptoms , 29 ( 39.19 % ) , 23 ( 31.08 % ) , 8 ( 10.81 % ) and 16 ( 21.62 % ) patients with COVID-19 with GI symptoms had > 38.5 \u00b0 C fever , fatigue , shortness of breath and headache , respectively , substantially higher than their respective counterparts without GI symptoms .", "labels": [[241, 251, "ENTITY"], [276, 287, "ENTITY"], [208, 214, "ENTITY"], [276, 287, "ORGAN"], [241, 251, "DISEASE"], [177, 191, "ENTITY"], [57, 66, "DISEASE"], [57, 66, "ENTITY"], [208, 214, "DISEASE"], [149, 158, "ORGANISM"], [149, 158, "ENTITY"], [0, 6, "DISEASE"], [75, 90, "ENTITY"], [0, 6, "ENTITY"], [219, 239, "DISEASE"], [18, 25, "ENTITY"], [219, 239, "ENTITY"]]}
{"text": "The most common symptom was fever on or after hospitalisation ( 88.0 % ) , followed by dry cough ( 70.2 % ) . Fatigue ( 42.8 % ) and productive cough ( 36.0 % ) were less common .", "labels": [[84, 91, "DISEASE"], [28, 34, "DISEASE"], [28, 34, "ENTITY"], [120, 133, "ENTITY"], [84, 91, "ENTITY"], [46, 62, "ENTITY"], [16, 24, "ENTITY"]]}
{"text": "the most common clinical manifestations at onset of illness include fever , cough , fatigue and myalgia", "labels": [[52, 60, "ENTITY"], [43, 52, "ENTITY"], [68, 74, "ENTITY"], [68, 74, "DISEASE"], [16, 40, "ENTITY"]]}
{"text": "Sepsis was the most frequently observed complication , followed by respiratory failure , ARDS , heart failure , and septic shock ( table 2 ) .", "labels": [[31, 40, "ENTITY"], [0, 7, "ENTITY"], [67, 79, "ENTITY"], [94, 102, "DISEASE"], [40, 53, "ENTITY"], [112, 123, "ENTITY"], [0, 7, "DISEASE"], [112, 123, "DISEASE"], [67, 79, "DISEASE"], [94, 102, "ENTITY"]]}
{"text": "The clinical features include fever , dry cough , shortness of breath , normal or low levels of peripheral white blood cells , and inflammatory changes on chest X-ray .", "labels": [[48, 63, "ENTITY"], [38, 42, "ENTITY"], [107, 119, "CELL"], [4, 22, "ENTITY"], [107, 119, "CL"], [82, 86, "ENTITY"], [127, 144, "ENTITY"], [30, 36, "ENTITY"], [38, 42, "DISEASE"], [48, 63, "DISEASE"], [152, 161, "ENTITY"], [93, 119, "ENTITY"], [93, 119, "CELL_TYPE"], [30, 36, "DISEASE"]]}
{"text": "Mehta and colleagues postulate that hyperinflammation in coronavirus disease 2019 ( COVID-19 ) could be a driver of severity that is amenable to therapeutic targeting since retro spective data have shown that systemic inflammation is associated with adverse outcome", "labels": [[57, 82, "ORGANISM"], [57, 82, "ENTITY"], [204, 218, "ENTITY"], [57, 82, "DISEASE"], [245, 258, "ENTITY"], [231, 245, "ENTITY"], [209, 218, "DISEASE"], [36, 54, "ENTITY"], [179, 188, "ENTITY"], [145, 157, "ENTITY"], [0, 6, "ENTITY"], [10, 21, "ENTITY"]]}
{"text": "Functional analysis by DAVID and Cluster Profiler revealed that these genes were enriched in specific cellular biological processes , including positive regulation of neutrophil chemotaxis , neutrophil activation , type I interferon signaling pathway , inflammatory response , and antigen processing and presentation ( Fig.3b and Extended Data Fig.5c-d ) , suggesting an active innate immune response against SARS-CoV-2 infection .", "labels": [[102, 132, "ENTITY"], [277, 289, "ENTITY"], [304, 319, "GENE_OR_GENE_PRODUCT"], [102, 111, "CL"], [23, 29, "CHEMICAL"], [401, 420, "DISEASE"], [70, 76, "SO"], [0, 20, "ENTITY"], [357, 368, "ENTITY"], [304, 319, "ENTITY"], [339, 344, "SIMPLE_CHEMICAL"], [102, 111, "CELL"], [213, 222, "GGP"], [243, 266, "ENTITY"], [70, 76, "ENTITY"], [213, 222, "GENE_OR_GENE_PRODUCT"], [319, 344, "ENTITY"], [213, 222, "PROTEIN"], [23, 29, "ENTITY"], [213, 243, "ENTITY"], [339, 344, "CHEMICAL"], [33, 50, "ENTITY"], [189, 202, "ENTITY"], [371, 392, "ENTITY"], [167, 178, "ENTITY"], [401, 420, "ENTITY"]]}
{"text": "Chest radiology at early stage is characteristic of multiple small patchy shadows and interstitial changes , more prominent in the extrapulmonary bands . Multiple ground-glass opacities and infiltrations may develop bilaterally with disease progression , with possible consolidation in severe cases .", "labels": [[0, 16, "ENTITY"], [74, 82, "ENTITY"], [286, 293, "ENTITY"], [228, 241, "ENTITY"], [208, 228, "ENTITY"], [61, 74, "ENTITY"], [131, 146, "ENTITY"], [152, 176, "ENTITY"], [19, 31, "ENTITY"], [86, 99, "ENTITY"]]}
{"text": "The main abnormalities in chest CT images were air-space shadowing : patchy ground-glass opacities ( in patients 2 , 3 , 6 and 9 ) ( Figure 2A ) or patchy hyperdense areas ( patients 1 , 4 , 5 , 8 and 10 ) ( Figure 2B ) on the initial chest radiograph . The radiographic opacities were mostly in the lower lung zones ( patients 1 , 2 , 3 , 4 , 5 , 6 , 8 and 9 ) .", "labels": [[47, 67, "ENTITY"], [286, 300, "MULTI-TISSUE_STRUCTURE"], [26, 35, "TISSUE"], [69, 76, "ENTITY"], [195, 204, "ENTITY"], [300, 311, "ENTITY"], [166, 174, "ORGANISM"], [220, 235, "ENTITY"], [26, 35, "ENTITY"], [35, 42, "ENTITY"], [166, 174, "ENTITY"], [76, 89, "ENTITY"], [286, 300, "ENTITY"], [32, 35, "PROTEIN"], [300, 311, "ORGANISM"], [47, 57, "MULTI-TISSUE_STRUCTURE"], [9, 23, "ENTITY"], [241, 258, "ENTITY"]]}
{"text": "Third , an asymptomatic child was found to have ground-glass opacities in his lung and SARS-CoV-2 RNA in his sputum sample", "labels": [[109, 116, "ENTITY"], [87, 98, "ENTITY"], [48, 61, "ENTITY"]]}
{"text": "On February 6 , the third chest CT scan showed bilateral multiple ground-glass opacities indicating viral pneumonia ( Figure 1B ) and she was admitted to the designated hospital immediately .", "labels": [[47, 79, "ENTITY"], [116, 125, "ENTITY"], [100, 106, "ENTITY"], [158, 169, "ENTITY"], [20, 35, "ENTITY"], [3, 12, "ENTITY"], [100, 106, "DISEASE"]]}
{"text": "On January 23 , the second chest CT scan revealed bilateral extended ground\u2010glass opacities with scattered consolidation , indicating rapid progression of the disease ( Figure 3B ) .", "labels": [[20, 36, "ENTITY"], [3, 11, "ENTITY"], [69, 82, "ENTITY"], [123, 134, "ENTITY"], [134, 140, "ENTITY"], [167, 176, "ENTITY"]]}
{"text": "Multifocal ground-glass lung opacities were seen in 17 ( 74 % ) patients on CT .", "labels": [[0, 39, "ENTITY"]]}
{"text": "SARS-CoV-2 nucleic acid positive in samples of sputum , pharynx swabs , and secretions of lower respiratory tract tested by real-time reverse- transcriptase \u2013 polymerase-chain reaction ( reverse- transcriptase\u2013polymerase-chain reaction ) assay .", "labels": [[47, 54, "ENTITY"], [47, 54, "TISSUE"], [90, 108, "ENTITY"], [24, 33, "ENTITY"], [108, 114, "ENTITY"], [36, 44, "CANCER"], [11, 24, "CHEBI"], [56, 64, "CANCER"], [0, 24, "GENE_OR_GENE_PRODUCT"], [134, 159, "GENE_OR_GENE_PRODUCT"], [0, 24, "ENTITY"], [56, 64, "ENTITY"], [36, 44, "ENTITY"], [121, 176, "ENTITY"], [0, 24, "CHEMICAL"]]}
{"text": "Patients with hypoxemia should be given oxygen therapy immediately and maintain a blood oxygen saturation level to no less than 90 % in man and non-pregnant women , and between 92 % and 95 % in pregnant women .", "labels": [[40, 47, "CHEMICAL"], [40, 47, "CHEBI"], [14, 24, "DISEASE"], [148, 157, "ORGANISM"], [40, 47, "SIMPLE_CHEMICAL"], [144, 157, "ORGANISM"], [191, 203, "ENTITY"], [40, 55, "ENTITY"], [40, 47, "CHEMICAL"], [0, 9, "ENTITY"], [0, 9, "ORGANISM"], [40, 47, "CHEBI"], [82, 95, "ORGANISM_SUBSTANCE"], [106, 112, "ENTITY"], [82, 106, "ENTITY"], [14, 24, "ENTITY"]]}
{"text": "COVID-19 was defined as the respiratory disease caused by SARS-CoV-2 that emerged in China in 2019 ( https://www.who.int/westernpacific/emergencies/covid-19 ) .", "labels": [[58, 69, "ENTITY"], [28, 48, "DISEASE"], [58, 69, "CHEMICAL"], [0, 9, "SIMPLE_CHEMICAL"], [85, 91, "ENTITY"], [58, 69, "SIMPLE_CHEMICAL"], [0, 9, "PROTEIN"], [28, 48, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "DISEASE"]]}
{"text": "The clinical manifestations of COVID-19 are protean , which include asymptomatic carrier , ARD , and pneumonia of varying degrees of severity . First , asymptomatic cases were diagnosed based on positive viral nucleic acid test results , but without any COVID-19 symptoms , such as fever , gastrointestinal , or respiratory symptoms , and no significant abnormalities on chest radiograph [ 7,8 ] .", "labels": [[186, 195, "ENTITY"], [290, 324, "ENTITY"], [223, 228, "ENTITY"], [68, 81, "ENTITY"], [31, 40, "ENTITY"], [31, 40, "ENTITY"], [144, 152, "ENTITY"], [114, 122, "ENTITY"], [242, 254, "ENTITY"], [204, 218, "CHEMICAL"], [354, 377, "ENTITY"], [342, 354, "ENTITY"], [282, 290, "ENTITY"], [195, 218, "TAXON"], [242, 254, "GENE_OR_GENE_PRODUCT"], [282, 290, "ORGAN"], [44, 52, "ENTITY"], [195, 223, "ENTITY"], [4, 28, "ENTITY"], [31, 40, "DISEASE"], [31, 40, "GENE_OR_GENE_PRODUCT"], [324, 342, "ENTITY"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "Fever , cough and sputum production were the most common symptoms . Of the aforementioned symptoms , 29 ( 39.19 % ) , 23 ( 31.08 % ) , 8 ( 10.81 % ) and 16 ( 21.62 % ) patients with COVID-19 with GI symptoms had > 38.5 \u00b0 C fever , fatigue , shortness of breath and headache , respectively , substantially higher than their respective counterparts without GI symptoms .", "labels": [[241, 251, "ENTITY"], [276, 287, "ENTITY"], [18, 25, "ENTITY"], [208, 214, "ENTITY"], [276, 287, "ORGAN"], [241, 251, "DISEASE"], [177, 191, "ENTITY"], [57, 66, "DISEASE"], [57, 66, "ENTITY"], [208, 214, "DISEASE"], [219, 239, "ENTITY"], [149, 158, "ORGANISM"], [149, 158, "ENTITY"], [0, 6, "DISEASE"], [75, 90, "ENTITY"], [0, 6, "ENTITY"], [219, 239, "DISEASE"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [236, 242, "ENTITY"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [300, 315, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "Leukopenia ( less than 3.5 \u00d7 10 9 leucocytes per liter ) and lymphopenia ( less than 1.1 \u00d7 10 9 lymphocytes per liter ) were observed in two patients , respectively .", "labels": [[134, 141, "ENTITY"], [0, 11, "ENTITY"], [134, 141, "ORGANISM"], [0, 11, "DISEASE"], [80, 89, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Leukopenia ( less than 3.5 \u00d7 10 9 leucocytes per liter ) and lymphopenia ( less than 1.1 \u00d7 10 9 lymphocytes per liter ) were observed in two patients , respectively .", "labels": [[134, 141, "ENTITY"], [0, 11, "DISEASE"], [134, 141, "ORGANISM"], [80, 89, "GENE_OR_GENE_PRODUCT"], [0, 11, "ENTITY"]]}
{"text": "Patient 6 presented with pleural effusions .", "labels": [[25, 43, "DISEASE"], [25, 43, "CANCER"], [25, 43, "ENTITY"], [0, 8, "ORGANISM"], [0, 8, "ENTITY"]]}
{"text": "The eosinophil values of patients 1 , 2 and 3 were all less than the lower bound of normal range before they were transferred to the First Affiliated Hospital of Zhejiang University ( Figure 4 ) .", "labels": [[15, 22, "ENTITY"], [4, 15, "CL"], [25, 34, "ORGANISM"], [4, 15, "ENTITY"], [84, 91, "ENTITY"], [4, 15, "CELL_TYPE"], [4, 15, "CELL"], [25, 36, "ENTITY"], [182, 191, "ENTITY"]]}
{"text": "The blood counts of patients on admission showed decrease in neutrophils ( 26 [ 39 % ] of 67 patients ) , lymphocytes ( 28 [ 42 % ] of 67 patients ) , and eosinophils ( 48 [ 72 % ] of 67 patients ) , among which , the number of eosinophils in 31 patients was zero .", "labels": [[179, 191, "CELL"], [-1, 11, "ENTITY"], [130, 147, "CELL_TYPE"], [264, 270, "ENTITY"], [117, 128, "ENTITY"], [-1, 18, "ENTITY"], [130, 147, "CL"], [14, 21, "ENTITY"], [264, 270, "ORGANISM"], [-1, 18, "CELL"], [179, 191, "CELL_TYPE"], [130, 147, "CELL"], [179, 191, "ENTITY"], [-1, 18, "CL"], [130, 147, "ENTITY"], [242, 252, "ENTITY"], [242, 252, "CELL"], [-1, 18, "CELL_TYPE"], [242, 252, "CELL_TYPE"], [-1, 11, "ORGANISM"], [6, 12, "ORGANISM_SUBSTANCE"], [117, 128, "ORGANISM"]]}
{"text": "The enrolled patients showed increase in alanine aminotransferase ( 23 [ 33 % ] of 69 patients ) and aspartate aminotransferase ( 19 [ 28 % ] of 69 patients ) , most of which count less than 100 U/L.", "labels": [[13, 22, "ENTITY"], [78, 86, "ENTITY"], [29, 38, "ENTITY"], [161, 169, "ENTITY"], [41, 49, "CHEMICAL"], [97, 111, "GGP"], [13, 22, "ORGANISM"], [41, 66, "ENTITY"], [78, 86, "ORGANISM"], [97, 111, "ENTITY"], [41, 66, "GENE_OR_GENE_PRODUCT"], [41, 71, "PROTEIN"], [97, 128, "PROTEIN"], [97, 111, "GENE_OR_GENE_PRODUCT"], [41, 49, "CHEBI"]]}
{"text": "The enrolled patients showed increase in alanine aminotransferase ( 23 [ 33 % ] of 69 patients ) and aspartate aminotransferase ( 19 [ 28 % ] of 69 patients ) , most of which count less than 100 U/L.", "labels": [[13, 22, "ENTITY"], [78, 86, "ENTITY"], [29, 38, "ENTITY"], [161, 169, "ENTITY"], [41, 49, "CHEMICAL"], [97, 111, "GGP"], [13, 22, "ORGANISM"], [41, 66, "ENTITY"], [78, 86, "ORGANISM"], [97, 111, "ENTITY"], [41, 66, "GENE_OR_GENE_PRODUCT"], [97, 128, "PROTEIN"], [41, 71, "PROTEIN"], [97, 111, "GENE_OR_GENE_PRODUCT"], [41, 49, "CHEBI"]]}
{"text": "In terms of inflammation indicators , patients on admission showed increase in lactate dehydrogenase ( 25 [ 41 % ] of 61 patients ) , c reactive protein ( 42 [ 67 % ] of 63 patients ) , and erythrocyte sedimentation rate ( 30 [ 52 % ] of 58 patients ) , but not procalcitonin .", "labels": [[132, 147, "ENTITY"], [81, 89, "CHEMICAL"], [81, 103, "GENE_OR_GENE_PRODUCT"], [243, 260, "GENE_OR_GENE_PRODUCT"], [25, 36, "ENTITY"], [12, 25, "DISEASE"], [123, 147, "PROTEIN"], [81, 103, "ENTITY"], [81, 103, "PROTEIN"], [12, 25, "ENTITY"], [243, 260, "ENTITY"], [123, 147, "GENE_OR_GENE_PRODUCT"], [69, 78, "ENTITY"], [113, 120, "ORGANISM"], [175, 204, "ENTITY"], [52, 62, "ENTITY"], [81, 103, "GGP"], [113, 120, "ENTITY"], [138, 147, "CHEBI"], [243, 260, "PROTEIN"], [175, 192, "CELL"], [175, 192, "CL"]]}
{"text": "In terms of inflammation indicators , patients on admission showed increase in lactate dehydrogenase ( 25 [ 41 % ] of 61 patients ) , c reactive protein ( 42 [ 67 % ] of 63 patients ) , and erythrocyte sedimentation rate ( 30 [ 52 % ] of 58 patients ) , but not procalcitonin .", "labels": [[132, 147, "ENTITY"], [81, 103, "GGP"], [81, 89, "CHEMICAL"], [243, 260, "GENE_OR_GENE_PRODUCT"], [25, 36, "ENTITY"], [12, 25, "DISEASE"], [81, 103, "PROTEIN"], [81, 103, "ENTITY"], [123, 147, "PROTEIN"], [12, 25, "ENTITY"], [243, 260, "ENTITY"], [123, 147, "GENE_OR_GENE_PRODUCT"], [175, 192, "CL"], [69, 78, "ENTITY"], [113, 120, "ORGANISM"], [175, 204, "ENTITY"], [52, 62, "ENTITY"], [113, 120, "ENTITY"], [138, 147, "CHEBI"], [243, 260, "PROTEIN"], [175, 192, "CELL"], [81, 103, "GENE_OR_GENE_PRODUCT"]]}
{"text": "It appears that Arbidol treatment could improve the discharging rate and decrease the mortality rate ( Table 5).The efficiency of antifungal agent and corticosteroids were also analyzed in Supplementary Table 1 and Table 2 . Antifungal agent did not show influence on the outcome of COVID-19 patients . And use of corticosteroids were associated with a higher risk of death .", "labels": [[16, 24, "CHEMICAL"], [203, 229, "CELL"], [239, 260, "ENTITY"], [349, 367, "ENTITY"], [203, 229, "ENTITY"], [-1, 20, "ENTITY"], [159, 175, "CHEMICAL"], [-1, 11, "ENTITY"], [118, 129, "ENTITY"], [73, 82, "ENTITY"], [159, 175, "CHEBI"], [159, 175, "SIMPLE_CHEMICAL"], [306, 317, "ENTITY"], [159, 175, "CHEBI"], [159, 175, "ENTITY"], [40, 48, "ENTITY"], [297, 306, "ENTITY"], [297, 306, "DISEASE"], [286, 297, "ENTITY"], [-1, 20, "SIMPLE_CHEMICAL"], [16, 34, "ENTITY"], [159, 175, "ENTITY"], [86, 101, "ENTITY"], [52, 69, "ENTITY"], [297, 317, "ORGANISM"], [269, 282, "ENTITY"], [159, 175, "SIMPLE_CHEMICAL"]]}
{"text": "Most COVID-19 patients initially suffered from fever , cough , fatigue , and shortness of breath , while other symptoms included muscle pain , headache , chest pain , and diarrhea , similar to the symptoms observed after chemotherapy , targeted and immune therapy1", "labels": [[73, 90, "ENTITY"], [143, 154, "DISEASE"], [120, 136, "DISEASE"], [120, 136, "ENTITY"], [47, 53, "ENTITY"], [206, 221, "ENTITY"], [14, 23, "ENTITY"], [5, 14, "ENTITY"], [5, 23, "ORGANISM"], [236, 256, "CELL"], [5, 14, "DISEASE"], [73, 90, "DISEASE"], [143, 154, "ORGAN"], [221, 236, "ENTITY"], [236, 256, "ENTITY"], [71, 77, "ENTITY"], [190, 197, "ENTITY"], [111, 120, "ENTITY"], [136, 143, "ENTITY"], [136, 143, "DISEASE"], [120, 129, "ORGAN"], [47, 53, "DISEASE"], [143, 154, "ENTITY"], [71, 77, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [219, 230, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "Patients with at least one comorbidity were older ( mean : 60.8 versus 44.8 years ) , were more likely to have shortness of breath ( 41.4 % versus 17.8 % ) , nausea or vomiting ( 10.4 % versus 4.3 % ) , and tended to have abnormal chest X-ray manifestations ( 29.2 % versus 15.1 % ) ( table 1 ) .", "labels": [[27, 39, "ENTITY"], [219, 245, "ENTITY"], [160, 170, "DISEASE"], [44, 50, "ENTITY"], [209, 219, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "ORGANISM"], [27, 39, "DISEASE"], [108, 126, "DISEASE"], [209, 245, "DISEASE"], [108, 126, "ENTITY"], [160, 170, "ENTITY"]]}
{"text": "Most COVID-19 patients initially suffered from fever , cough , fatigue , and shortness of breath , while other symptoms included muscle pain , headache , chest pain , and diarrhea , similar to the symptoms observed after chemotherapy , targeted and immune therapy1", "labels": [[73, 90, "ENTITY"], [136, 143, "DISEASE"], [143, 154, "DISEASE"], [120, 136, "DISEASE"], [120, 136, "ENTITY"], [47, 53, "ENTITY"], [206, 221, "ENTITY"], [14, 23, "ENTITY"], [5, 14, "ENTITY"], [5, 23, "ORGANISM"], [71, 77, "DISEASE"], [236, 256, "CELL"], [5, 14, "DISEASE"], [73, 90, "DISEASE"], [143, 154, "ORGAN"], [221, 236, "ENTITY"], [236, 256, "ENTITY"], [71, 77, "ENTITY"], [190, 197, "ENTITY"], [111, 120, "ENTITY"], [120, 129, "ORGAN"], [47, 53, "DISEASE"], [143, 154, "ENTITY"], [136, 143, "ENTITY"]]}
{"text": "According to the latest study revealing the correlation between COVID-19 and cancer , 18 ( 1 % ) of 1590 COVID-19 cases had a history of cancer , which was higher than the incidence of cancer ( 0.29 % ) in the overall Chinese population ; meanwhile , cancer patients were found to have a higher risk of severe events than patients without cancer.2", "labels": [[64, 73, "ENTITY"], [210, 226, "ENTITY"], [77, 84, "CANCER"], [172, 185, "DISEASE"], [288, 300, "ENTITY"], [258, 267, "SIMPLE_CHEMICAL"], [120, 126, "ENTITY"], [64, 73, "GENE_OR_GENE_PRODUCT"], [310, 317, "ENTITY"], [77, 84, "ENTITY"], [258, 267, "PROTEIN"], [310, 317, "ORGANISM"], [239, 251, "CANCER"], [258, 267, "ENTITY"], [77, 84, "DISEASE"], [172, 185, "ENTITY"], [172, 185, "CANCER"], [24, 30, "ENTITY"], [44, 56, "ENTITY"], [64, 73, "ENTITY"]]}
{"text": "In comparison with patients with mild COVID-19 ( such as those who did not require ICU stays , did not develop ARDS or pneumonia , and who survived ) , patients with severe COVID-19 have higher comorbidities , including 56 % for hypertension , 21 % for heart diseases , 18 % for diabetes , 12 % for cerebrovascular diseases , and 7 % for cancer ( Table 1 ) ( 79 , 97 ) .", "labels": [[103, 111, "DISEASE"], [129, 135, "CANCER"], [223, 229, "DISEASE"], [38, 47, "DISEASE"], [19, 28, "ORGANISM"], [279, 299, "ENTITY"], [244, 259, "ENTITY"], [129, 135, "ENTITY"], [244, 259, "DISEASE"], [33, 47, "ENTITY"], [129, 135, "DISEASE"], [279, 299, "DISEASE"], [223, 229, "ENTITY"], [3, 14, "ENTITY"], [103, 111, "ENTITY"], [38, 47, "GENE_OR_GENE_PRODUCT"], [166, 173, "DISEASE"], [187, 194, "ENTITY"], [166, 173, "ENTITY"], [166, 173, "GENE_OR_GENE_PRODUCT"], [19, 28, "ENTITY"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [259, 269, "ORGAN"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "The mortality appears to be around 2 % ; early published data indicate 25.9 % with SARS-CoV-2 pneumonia required ICU admission and 20.1 % developed acute respiratory distress syndrome", "labels": [[104, 117, "ENTITY"], [78, 94, "ENTITY"], [138, 175, "ENTITY"], [78, 94, "CHEMICAL"], [148, 175, "DISEASE"], [41, 57, "ENTITY"], [4, 14, "ENTITY"]]}
{"text": "For patients with ARDS or pulmonary extensive effusion in CT scan , high-flow nasal cannula oxygen therapy ( high-flow nasal cannula oxygen therapy ) or non-invasive mechanical ventilation ( NIV ) was used to maintain positive end expiratory pressure ( PEEP ) to prevent alveolar collapse even if some of these patients did not have refractory hypoxemia .", "labels": [[268, 277, "ENTITY"], [18, 23, "ENTITY"], [268, 277, "DISEASE"], [58, 61, "PROTEIN"], [184, 193, "ENTITY"], [26, 55, "ENTITY"], [4, 13, "ENTITY"], [197, 208, "ENTITY"], [26, 36, "ORGAN"], [68, 84, "ENTITY"], [68, 99, "ENTITY"], [18, 23, "DISEASE"], [255, 268, "ENTITY"], [4, 13, "ORGANISM"], [58, 66, "ENTITY"], [175, 184, "ENTITY"]]}
{"text": "During hospital admission , most of the patients received a diagnosis of pneumonia from a physician ( 91.1 % ) , followed by ARDS ( 3.4 % ) and shock ( 1.1 % ) .", "labels": [[113, 125, "ENTITY"], [7, 26, "ENTITY"], [113, 125, "DISEASE"]]}
{"text": "This coronavirus , named SARS-CoV-2 ( formerly 2019-nCoV ) , is responsible for respiratory infections including pneumonia with a mortality rate estimated about 2%-2.5 % , increasing with age and the existence of underlying diseases", "labels": [[5, 17, "ENTITY"], [213, 224, "ENTITY"], [76, 92, "DISEASE"], [25, 47, "GENE_OR_GENE_PRODUCT"], [5, 17, "DISEASE"], [103, 113, "DISEASE"], [123, 140, "ENTITY"], [76, 92, "ENTITY"], [5, 17, "TAXON"], [103, 113, "ENTITY"], [5, 17, "ORGANISM"]]}
{"text": "Viral pneumonia and potentially fatal respiratory failure may result in susceptible persons after 10 - 14 days . 5", "labels": [[84, 92, "ORGANISM"], [32, 38, "ENTITY"], [0, 16, "DISEASE"], [72, 84, "ENTITY"], [38, 58, "DISEASE"], [0, 16, "ENTITY"], [0, 6, "TAXON"], [84, 92, "ENTITY"], [38, 58, "ENTITY"]]}
{"text": "CT showed multiple scattered GGO shadows in the periphery zone of both lungs with a typical Rosa roxburghii sign , suggesting a high possibility of viral pneumonia in both lungs .", "labels": [[48, 63, "ENTITY"], [29, 41, "ENTITY"], [0, 3, "PROTEIN"], [10, 19, "ENTITY"], [92, 108, "TISSUE"], [71, 77, "ORGAN"], [92, 108, "ENTITY"], [0, 3, "ENTITY"], [71, 77, "ENTITY"], [148, 154, "DISEASE"], [148, 154, "ENTITY"]]}
{"text": "Furthermore , the lesions occurred mainly in the lung confirmed by the HE staining and anti-spike protein of SARS-CoV-2 staining , with mild to moderate interstitial pneumonia characterized by thickened alveolar septa , accumulation of alveolar macrophages in the alveoli , degeneration of the alveolar epithelia , and infiltration of inflammatory cells ( Figure 3a ) .", "labels": [[319, 348, "ENTITY"], [264, 274, "ENTITY"], [233, 245, "CELL"], [290, 303, "TISSUE"], [348, 356, "ENTITY"], [233, 245, "ENTITY"], [109, 120, "ENTITY"], [144, 166, "DISEASE"], [87, 98, "ENTITY"], [335, 348, "CELL"], [144, 166, "ENTITY"], [290, 303, "ENTITY"], [319, 348, "CELL_TYPE"], [193, 212, "MULTI-TISSUE_STRUCTURE"], [348, 356, "GENE_OR_GENE_PRODUCT"], [233, 245, "CL"], [166, 176, "ENTITY"], [233, 245, "CELL_TYPE"], [190, 212, "ENTITY"], [335, 348, "CL"], [87, 98, "PROTEIN"]]}
{"text": "Viral pneumonia and potentially fatal respiratory failure may result in susceptible persons after 10 - 14 days . 5", "labels": [[84, 92, "ORGANISM"], [32, 38, "ENTITY"], [0, 6, "TAXON"], [72, 84, "ENTITY"], [38, 58, "ENTITY"], [38, 58, "DISEASE"], [0, 16, "DISEASE"], [0, 16, "ENTITY"], [84, 92, "ENTITY"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [66, 96, "DISEASE"], [0, 7, "ENTITY"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [133, 141, "DISEASE"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "According to WHO guidelines , infected patients will receive supportive care including oxygen therapy , fluid therapy , and antibiotics for treating secondary bacterial infections .", "labels": [[17, 28, "ENTITY"], [102, 110, "ENTITY"], [149, 159, "TAXON"], [61, 72, "ENTITY"], [149, 169, "DISEASE"], [140, 149, "ENTITY"], [149, 169, "ENTITY"], [87, 94, "ENTITY"]]}
{"text": "Furthermore , RNA synthesis inhibitors ( like 3TC , TDF ) , remdesivir , neuraminidase inhibitors , peptide ( EK1 ) , anti-inflammatory drugs , abidol , Chinese traditional medicine , such as Lianhuaqingwen and ShuFengJieDu Capsules , could be the promising COVID-19 treatments.2", "labels": [[14, 18, "ENTITY"], [87, 100, "ENTITY"], [108, 118, "ENTITY"], [60, 87, "CHEBI"], [118, 136, "ENTITY"], [173, 192, "ENTITY"], [87, 100, "SO"], [244, 258, "PROTEIN"], [248, 258, "CHEMICAL"], [192, 211, "ORGANISM"], [60, 87, "ENTITY"], [60, 100, "SIMPLE_CHEMICAL"], [192, 211, "ENTITY"]]}
{"text": "Once SpO2 < 93 % , RR > 30/min , HR > 120/min or any signs of organ failure were observed , patients would be transferred to intensive care unit ( ICU ) and ICU physicians and nurses would take over their treatment .", "labels": [[5, 10, "ENTITY"], [134, 152, "ENTITY"], [152, 157, "ENTITY"], [71, 80, "ENTITY"], [71, 80, "DISEASE"], [93, 104, "ORGANISM"], [163, 173, "ENTITY"], [39, 44, "ENTITY"], [173, 188, "ENTITY"], [93, 104, "ENTITY"]]}
{"text": "The range of SPO2 under the natural breathing conditions of the patients in this study was 70e99 % . Spearman \u2019s correlation statistical analysis was performed on SPO2 and CT staging with results of p<0.05 and r\u00bce0.446 , suggesting a weak negative correlation between the two .", "labels": [[64, 73, "ENTITY"], [234, 239, "ENTITY"], [13, 18, "ENTITY"], [64, 73, "ORGANISM"], [239, 248, "ENTITY"], [81, 87, "ENTITY"], [99, 137, "ENTITY"], [168, 175, "ENTITY"], [101, 110, "GENE_OR_GENE_PRODUCT"], [28, 46, "ENTITY"], [4, 10, "ENTITY"], [221, 234, "ENTITY"]]}
{"text": "Once SpO2 < 93 % , RR > 30/min , HR > 120/min or any signs of organ failure were observed , patients would be transferred to intensive care unit ( ICU ) and ICU physicians and nurses would take over their treatment .", "labels": [[5, 10, "ENTITY"], [134, 152, "ENTITY"], [152, 157, "ENTITY"], [71, 80, "ENTITY"], [71, 80, "DISEASE"], [93, 104, "ORGANISM"], [163, 173, "ENTITY"], [39, 44, "ENTITY"], [173, 188, "ENTITY"], [93, 104, "ENTITY"]]}
{"text": "Respiratory rates were significantly higher in deceased patients ( 24.0 breaths per minute ) than in recovered patients ( 20.0 breaths per minute ) .", "labels": [[0, 18, "ENTITY"], [101, 111, "ENTITY"], [101, 111, "ORGANISM"], [23, 44, "ENTITY"], [56, 65, "ORGANISM"], [56, 65, "ENTITY"], [47, 56, "ENTITY"]]}
{"text": "Once SpO2 < 93 % , RR > 30/min , HR > 120/min or any signs of organ failure were observed , patients would be transferred to intensive care unit ( ICU ) and ICU physicians and nurses would take over their treatment .", "labels": [[5, 10, "ENTITY"], [134, 152, "ENTITY"], [152, 157, "ENTITY"], [71, 80, "ENTITY"], [71, 80, "DISEASE"], [93, 104, "ORGANISM"], [163, 173, "ENTITY"], [39, 44, "ENTITY"], [173, 188, "ENTITY"], [93, 104, "ENTITY"]]}
{"text": "Heart rates were much higher in deceased patients ( 101.0 beats per minute ) than in recovered patients ( 91.0 beats per minute ) .", "labels": [[32, 41, "ENTITY"], [85, 95, "ENTITY"], [0, 12, "ENTITY"], [85, 95, "ORGANISM"], [0, 6, "ORGAN"], [22, 29, "ENTITY"], [41, 50, "ENTITY"], [41, 50, "ORGANISM"]]}
{"text": "Once SpO2 < 93 % , RR > 30/min , HR > 120/min or any signs of organ failure were observed , patients would be transferred to intensive care unit ( ICU ) and ICU physicians and nurses would take over their treatment .", "labels": [[5, 10, "ENTITY"], [134, 152, "ENTITY"], [71, 80, "DISEASE"], [152, 157, "ENTITY"], [93, 104, "ORGANISM"], [163, 173, "ENTITY"], [39, 44, "ENTITY"], [173, 188, "ENTITY"], [71, 80, "ENTITY"], [93, 104, "ENTITY"]]}
{"text": "From our data of more than 600 NCP patients in Jiangsu Province , age , lymphocyte count , oxygen supplementation and aggressive pulmonary radiographic infiltrations are independent risk factors for NCP progressing to a critical condition .", "labels": [[218, 229, "ENTITY"], [31, 35, "CHEMICAL"], [89, 98, "ENTITY"], [35, 44, "ENTITY"], [114, 152, "DISEASE"], [9, 14, "ENTITY"], [70, 83, "ENTITY"], [118, 152, "ENTITY"], [170, 187, "ENTITY"], [47, 64, "ENTITY"], [31, 35, "ENTITY"], [118, 129, "ORGAN"], [47, 64, "ORGANISM"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [300, 315, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [236, 242, "ENTITY"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "From our data of more than 600 NCP patients in Jiangsu Province , age , lymphocyte count , oxygen supplementation and aggressive pulmonary radiographic infiltrations are independent risk factors for NCP progressing to a critical condition .", "labels": [[89, 98, "ENTITY"], [218, 229, "ENTITY"], [31, 35, "CHEMICAL"], [35, 44, "ENTITY"], [114, 152, "DISEASE"], [9, 14, "ENTITY"], [70, 83, "ENTITY"], [118, 152, "ENTITY"], [170, 187, "ENTITY"], [47, 64, "ENTITY"], [31, 35, "ENTITY"], [118, 129, "ORGAN"], [47, 64, "ORGANISM"]]}
{"text": "( 2 ) Restrictive fluid resuscitation under the premise of adequate tissue perfusion is performed to relieve pulmonary edema .", "labels": [[101, 119, "ENTITY"], [6, 24, "ENTITY"], [59, 75, "ENTITY"], [101, 119, "CANCER"], [101, 119, "DISEASE"], [59, 68, "TISSUE"]]}
{"text": "Therapeutic options include steroids , intravenous immunoglobulin , selective cytokine blockade ( eg , anakinra or tocilizumab ) and JAK inhibition .", "labels": [[68, 78, "PROTEIN"], [28, 37, "CHEMICAL"], [39, 51, "ENTITY"], [68, 78, "ENTITY"], [39, 51, "PROTEIN"], [98, 103, "CHEMICAL"], [12, 20, "ENTITY"], [28, 37, "ENTITY"], [28, 37, "CHEBI"], [0, 12, "ENTITY"], [78, 87, "ENTITY"], [98, 103, "SIMPLE_CHEMICAL"], [28, 37, "SIMPLE_CHEMICAL"], [39, 51, "ORGANISM_SUBSTANCE"], [133, 137, "ENTITY"], [98, 103, "ENTITY"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [219, 230, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [126, 150, "DISEASE"], [219, 230, "DISEASE"], [126, 150, "ENTITY"], [7, 14, "ENTITY"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "Increased C-reactive protein , procalcitonin and lactate dehydrogenase were found in five patients ( 5/8 ) , and increased alanine aminotransferase ( ALT ) in four ( 4/8 ) .", "labels": [[113, 123, "CHEBI"], [49, 57, "GENE_OR_GENE_PRODUCT"], [10, 29, "ENTITY"], [49, 57, "PROTEIN"], [49, 57, "GGP"], [10, 21, "GENE_OR_GENE_PRODUCT"], [10, 29, "GGP"], [49, 57, "ENTITY"], [113, 123, "CHEMICAL"], [0, 10, "ENTITY"], [113, 131, "GENE_OR_GENE_PRODUCT"], [131, 148, "ENTITY"], [10, 29, "PROTEIN"], [113, 131, "ENTITY"], [131, 148, "PROTEIN"], [131, 148, "GENE_OR_GENE_PRODUCT"], [113, 131, "PROTEIN"]]}
{"text": "Besides , serum levels of procalcitonin tended to be higher in severe cases than in moderate cases .", "labels": []}
{"text": "Two patients ( 2/5 ) had high D-dimer level .", "labels": [[30, 38, "ENTITY"], [25, 30, "PROTEIN"], [25, 30, "GGP"], [25, 30, "ENTITY"], [25, 30, "GENE_OR_GENE_PRODUCT"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Levels of lactate dehydrogenase ( LDH ) , concentrations of serum high-sensitivity C-reactive protein ( hsCRP ) , ferritin and D-dimer levels were markedly higher in severe cases than moderate cases .", "labels": [[10, 18, "CHEMICAL"], [129, 137, "ENTITY"], [59, 96, "PROTEIN"], [149, 158, "ENTITY"], [0, 7, "ENTITY"], [10, 32, "GGP"], [10, 32, "PROTEIN"], [158, 168, "ENTITY"], [62, 96, "ENTITY"], [10, 32, "ENTITY"], [68, 96, "GGP"], [168, 175, "ENTITY"], [10, 32, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer .", "labels": [[126, 138, "PROTEIN"], [34, 41, "ENTITY"], [126, 138, "GENE_OR_GENE_PRODUCT"], [12, 21, "ENTITY"], [101, 109, "PROTEIN"], [155, 166, "ENTITY"], [44, 63, "PROTEIN"], [25, 34, "ENTITY"], [155, 166, "PROTEIN"], [44, 63, "GGP"], [12, 21, "ORGANISM"], [101, 109, "GENE_OR_GENE_PRODUCT"], [126, 138, "ENTITY"], [101, 109, "GGP"], [44, 55, "GENE_OR_GENE_PRODUCT"], [126, 138, "CHEBI"], [101, 109, "ENTITY"], [44, 63, "ENTITY"]]}
{"text": "TBNK lymphocyte subset analysis revealed decreased percentage of CD16 + CD56 + lymphocytes ( 4/8 ) and Th/Ts ( 1/8 ) , and increased percentage of CD3 + ( 2/8 ) , CD4 + ( 4/8 ) and CD8 + ( 1/8 ) lymphocytes . Cytokine detection assays showed increased levels of IL-6 ( 2/8 ) , IL-10 ( 5/8 ) and IFN-\u03b3 ( 2/8 ) .", "labels": [[-1, 25, "ENTITY"], [281, 287, "GENE_OR_GENE_PRODUCT"], [199, 222, "ENTITY"], [127, 137, "ENTITY"], [127, 137, "GENE_OR_GENE_PRODUCT"], [41, 51, "ENTITY"], [5, 16, "CELL"], [266, 271, "ENTITY"], [281, 293, "PROTEIN"], [127, 137, "ENTITY"], [5, 16, "ENTITY"], [0, 5, "ENTITY"], [281, 287, "ENTITY"], [159, 199, "CELL_TYPE"], [239, 246, "ENTITY"], [175, 199, "ENTITY"], [127, 137, "PROTEIN"], [51, 65, "GGP"], [65, 70, "GENE_OR_GENE_PRODUCT"], [232, 239, "ENTITY"], [281, 287, "CHEMICAL"], [127, 137, "GGP"], [5, 16, "CL"], [51, 62, "GENE_OR_GENE_PRODUCT"], [137, 157, "ENTITY"], [-1, 25, "CELL_LINE"], [137, 157, "CELL_TYPE"], [266, 271, "PROTEIN"], [185, 199, "CL"], [266, 271, "GGP"], [0, 23, "CELL_LINE"], [266, 271, "GENE_OR_GENE_PRODUCT"], [51, 62, "ENTITY"], [83, 95, "CL"]]}
{"text": "Preliminary analysis of circulating immune cells subsets as shown in Table 3 demonstrated that absolute numbers of total T lymphocytes , CD4+T cells and CD8+T cells were reduced below the lower limit of normal ( LLN ) in the vast majority of patients with either severe or moderate COVID-19 , and they were reduced more profoundly in severe cases ( 294.0 , 177.5 and 89.0 \u00d7 106/L ) than in moderate cases ( 640.5 , 381.5 and 254.0 \u00d7 106/L ) ( Figure 3A , 161 3B ) .", "labels": [[343, 349, "PROTEIN"], [36, 49, "CELL"], [24, 57, "CELL_TYPE"], [121, 135, "CELL"], [137, 143, "ENTITY"], [265, 272, "ENTITY"], [49, 57, "ENTITY"], [384, 392, "ENTITY"], [137, 143, "CELL"], [153, 159, "ENTITY"], [137, 143, "CELL_TYPE"], [275, 284, "GENE_OR_GENE_PRODUCT"], [121, 135, "CL"], [137, 143, "CL"], [104, 112, "ENTITY"], [115, 135, "CELL_TYPE"], [153, 159, "CELL"], [24, 36, "ENTITY"], [153, 159, "CELL_TYPE"], [435, 445, "ENTITY"], [115, 135, "ENTITY"], [275, 284, "ENTITY"], [0, 21, "ENTITY"], [153, 159, "CL"], [36, 49, "ENTITY"], [95, 104, "ENTITY"], [275, 284, "ENTITY"], [36, 49, "CL"]]}
{"text": "The reduced expressions of interferon-\u03b3 ( IFN-\u03b3 ) by CD4+T , CD8+T and NK cells below LLN were observed in some patients with severe ( 50 % , 16.7 % and 16.7 % ) or moderate COVID-19 ( 14.3 % , 0 % and 14.3 % ) .", "labels": [[27, 40, "ENTITY"], [165, 174, "ENTITY"], [27, 40, "GENE_OR_GENE_PRODUCT"], [4, 12, "ENTITY"], [27, 40, "PROTEIN"], [165, 174, "GENE_OR_GENE_PRODUCT"], [67, 74, "ENTITY"], [67, 74, "CELL"], [12, 24, "ENTITY"], [67, 74, "CL"], [153, 165, "ENTITY"]]}
{"text": "We identified several hub proteins including JUN , XPO1 , NPM1 , and HNRNPA1 , with the highest number of connections within the 119 proteins .", "labels": [[24, 37, "ENTITY"], [127, 135, "PROTEIN"], [53, 58, "GENE_OR_GENE_PRODUCT"], [47, 51, "ENTITY"], [53, 58, "ENTITY"], [5, 16, "ENTITY"], [53, 58, "PROTEIN"], [47, 51, "PROTEIN"], [47, 51, "GENE_OR_GENE_PRODUCT"], [24, 37, "PROTEIN"], [53, 58, "GGP"], [28, 37, "CHEBI"]]}
{"text": "We identified several hub proteins including JUN , XPO1 , NPM1 , and HNRNPA1 , with the highest number of connections within the 119 proteins .", "labels": [[24, 37, "ENTITY"], [53, 58, "GGP"], [53, 58, "GENE_OR_GENE_PRODUCT"], [53, 58, "PROTEIN"], [5, 16, "ENTITY"], [53, 58, "ENTITY"], [47, 51, "GENE_OR_GENE_PRODUCT"], [127, 135, "PROTEIN"], [47, 51, "PROTEIN"], [24, 37, "PROTEIN"], [47, 51, "ENTITY"], [28, 37, "CHEBI"]]}
{"text": "We identified several hub proteins including JUN , XPO1 , NPM1 , and HNRNPA1 , with the highest number of connections within the 119 proteins .", "labels": [[24, 37, "ENTITY"], [127, 135, "PROTEIN"], [53, 58, "GENE_OR_GENE_PRODUCT"], [5, 16, "ENTITY"], [53, 58, "ENTITY"], [53, 58, "PROTEIN"], [47, 51, "GENE_OR_GENE_PRODUCT"], [24, 37, "PROTEIN"], [47, 51, "PROTEIN"], [53, 58, "GGP"], [47, 51, "ENTITY"], [28, 37, "CHEBI"]]}
{"text": "We identified several hub proteins including JUN , XPO1 , NPM1 , and HNRNPA1 , with the highest number of connections within the 119 proteins .", "labels": [[24, 37, "ENTITY"], [127, 135, "PROTEIN"], [53, 58, "GENE_OR_GENE_PRODUCT"], [5, 16, "ENTITY"], [53, 58, "ENTITY"], [53, 58, "PROTEIN"], [47, 51, "GENE_OR_GENE_PRODUCT"], [24, 37, "PROTEIN"], [47, 51, "PROTEIN"], [53, 58, "GGP"], [47, 51, "ENTITY"], [28, 37, "CHEBI"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[542, 550, "ENTITY"], [416, 427, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [301, 311, "TAXON"], [139, 151, "PROTEIN"], [439, 444, "ENTITY"], [162, 193, "ENTITY"], [408, 416, "ENTITY"], [477, 487, "ENTITY"], [320, 326, "ENTITY"], [115, 125, "DISEASE"], [221, 233, "ENTITY"], [162, 187, "ORGANISM"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [125, 139, "ENTITY"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [487, 507, "ENTITY"], [125, 135, "SO"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[542, 550, "ENTITY"], [416, 427, "ENTITY"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [301, 311, "TAXON"], [439, 444, "ENTITY"], [125, 135, "SO"], [162, 193, "ENTITY"], [408, 416, "ENTITY"], [477, 487, "ENTITY"], [320, 326, "ENTITY"], [115, 125, "DISEASE"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [162, 187, "ORGANISM"], [139, 151, "PROTEIN"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [487, 507, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[542, 550, "ENTITY"], [416, 427, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [301, 311, "TAXON"], [139, 151, "PROTEIN"], [439, 444, "ENTITY"], [125, 135, "SO"], [162, 193, "ENTITY"], [408, 416, "ENTITY"], [477, 487, "ENTITY"], [320, 326, "ENTITY"], [115, 125, "DISEASE"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [162, 187, "ORGANISM"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [487, 507, "ENTITY"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[416, 427, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [162, 193, "DISEASE"], [301, 311, "TAXON"], [139, 151, "PROTEIN"], [162, 193, "ENTITY"], [174, 187, "TAXON"], [439, 444, "ENTITY"], [125, 135, "SO"], [408, 416, "ENTITY"], [477, 487, "ENTITY"], [320, 326, "ENTITY"], [427, 439, "ENTITY"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [115, 125, "DISEASE"], [162, 187, "ORGANISM"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [487, 507, "ENTITY"], [542, 550, "ENTITY"], [487, 496, "TAXON"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[542, 550, "ENTITY"], [416, 427, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [301, 311, "TAXON"], [139, 151, "PROTEIN"], [439, 444, "ENTITY"], [125, 135, "SO"], [162, 193, "ENTITY"], [408, 416, "ENTITY"], [477, 487, "ENTITY"], [320, 326, "ENTITY"], [115, 125, "DISEASE"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [162, 187, "ORGANISM"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [487, 507, "ENTITY"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[542, 550, "ENTITY"], [416, 427, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [301, 311, "TAXON"], [139, 151, "PROTEIN"], [469, 477, "ENTITY"], [439, 444, "ENTITY"], [125, 135, "SO"], [162, 193, "ENTITY"], [477, 487, "ENTITY"], [115, 125, "DISEASE"], [162, 187, "ORGANISM"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [408, 416, "ENTITY"], [554, 561, "CL"], [408, 416, "TAXON"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [320, 326, "ENTITY"], [397, 408, "ENTITY"], [554, 561, "CELL"], [487, 507, "ENTITY"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[416, 427, "ENTITY"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [301, 311, "TAXON"], [439, 444, "ENTITY"], [125, 135, "SO"], [162, 193, "ENTITY"], [408, 416, "ENTITY"], [477, 487, "ENTITY"], [320, 326, "ENTITY"], [115, 125, "DISEASE"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [162, 187, "ORGANISM"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [139, 151, "PROTEIN"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [542, 550, "ENTITY"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [487, 507, "ENTITY"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[542, 550, "ENTITY"], [416, 427, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [301, 311, "TAXON"], [139, 151, "PROTEIN"], [439, 444, "ENTITY"], [125, 135, "SO"], [162, 193, "ENTITY"], [408, 416, "ENTITY"], [115, 125, "DISEASE"], [162, 187, "ORGANISM"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [477, 487, "ENTITY"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [320, 326, "ENTITY"], [487, 507, "ENTITY"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[542, 550, "ENTITY"], [416, 427, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [301, 311, "TAXON"], [139, 151, "PROTEIN"], [439, 444, "ENTITY"], [125, 135, "SO"], [162, 193, "ENTITY"], [408, 416, "ENTITY"], [477, 487, "ENTITY"], [320, 326, "ENTITY"], [115, 125, "DISEASE"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [162, 187, "ORGANISM"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [487, 507, "ENTITY"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "She experienced only mild symptoms such as a sore throat and fatigue , without any signs of pneumonia such as cough and chest tightness .", "labels": [[45, 57, "DISEASE"], [45, 57, "ENTITY"], [120, 126, "ENTITY"], [61, 69, "DISEASE"], [21, 35, "ENTITY"], [120, 126, "DISEASE"], [4, 16, "ENTITY"], [61, 69, "ENTITY"]]}
{"text": "A 69-year old woman had persistent fever ( > 38 \u2103 ) accompanied by a dry cough , headache , sore throat , myalgia and fatigue for three days .", "labels": [[35, 41, "ENTITY"], [67, 73, "ENTITY"], [97, 106, "DISEASE"], [67, 73, "DISEASE"], [24, 35, "ENTITY"], [14, 20, "ORGANISM"], [14, 20, "ENTITY"], [35, 41, "DISEASE"], [81, 97, "ENTITY"], [97, 106, "ENTITY"], [81, 97, "DISEASE"]]}
{"text": "She developed chest tightness , shortness of breath , loss of appetite , 62 nausea , and diarrhea", "labels": [[14, 30, "ENTITY"], [52, 62, "ENTITY"], [52, 62, "DISEASE"], [4, 14, "ENTITY"], [32, 45, "ENTITY"], [14, 30, "DISEASE"], [32, 45, "DISEASE"]]}
{"text": "Other prevalent symptoms at onset of illness in deceased patients included fatigue , dyspnoea , chest tightness , and sputum production ; less common symptoms included anorexia , diarrhoea , and myalgia .", "labels": [[112, 118, "DISEASE"], [143, 150, "ENTITY"], [168, 179, "DISEASE"], [66, 75, "ENTITY"], [112, 118, "ENTITY"], [114, 125, "ENTITY"], [16, 25, "ENTITY"], [168, 179, "ENTITY"], [48, 57, "ENTITY"], [28, 37, "ENTITY"], [94, 102, "DISEASE"], [66, 75, "CANCER"], [75, 83, "DISEASE"], [94, 102, "ENTITY"], [75, 83, "ENTITY"], [57, 66, "ORGANISM"], [66, 75, "DISEASE"], [37, 45, "ENTITY"], [6, 16, "ENTITY"], [57, 66, "ENTITY"]]}
{"text": "Compared to moderate cases , chest tightness tended to be more common in severe cases . In addition , tachypnea and dyspnea were only developed in severe cases .", "labels": [[29, 35, "DISEASE"], [21, 27, "ENTITY"], [73, 80, "ENTITY"], [0, 9, "ENTITY"], [12, 21, "ENTITY"], [29, 35, "ENTITY"]]}
{"text": "She developed chest tightness , shortness of breath , loss of appetite , 62 nausea , and diarrhea", "labels": [[52, 62, "ENTITY"], [52, 62, "DISEASE"], [4, 14, "ENTITY"], [14, 30, "ENTITY"], [32, 45, "ENTITY"], [14, 30, "DISEASE"], [32, 45, "DISEASE"]]}
{"text": "Other clinical signs such as reduced appetite , increased respiration rate and hunched posture were transient after the initial challenge .", "labels": [[79, 87, "ENTITY"], [6, 21, "ENTITY"], [37, 46, "CHEMICAL"], [37, 46, "ENTITY"], [29, 37, "ENTITY"]]}
{"text": "lymphocyte count slightly decreased [ 0.81 \u00d7 109/L , reference range : ( 1.1~3.2 ) \u00d7109/L ] , and the concentration of serum high-sensitivity C-reactive protein ( hsCRP ) increased [ 49.9 mg/L , reference range : ( 0~3 ) mg/L ] , with leukocyte count and procalcitonin ( PCT ) concentration within normal ranges .", "labels": [[26, 36, "ENTITY"], [235, 255, "GENE_OR_GENE_PRODUCT"], [215, 226, "CELL"], [125, 142, "GGP"], [215, 226, "CL"], [255, 271, "ENTITY"], [102, 142, "ENTITY"], [0, 11, "CELL"], [215, 230, "ENTITY"], [161, 169, "ENTITY"], [183, 195, "ENTITY"], [45, 63, "ENTITY"], [102, 142, "PROTEIN"], [0, 11, "CL"], [94, 102, "ENTITY"], [102, 116, "ENTITY"], [235, 251, "PROTEIN"], [235, 251, "ENTITY"], [0, 11, "ENTITY"], [102, 116, "ORGANISM_SUBSTANCE"]]}
{"text": "The CBC was normal except for the development of eosinopenia ( 0 \u00d7 109 /L ) and an elevated erythrocyte sedimentation rate ( ESR ) and CRP concentration ( 39 mm/h and 60.41 mg/L , respectively ) .", "labels": [[158, 163, "GENE_OR_GENE_PRODUCT"], [4, 8, "ENTITY"], [131, 139, "ENTITY"], [83, 92, "CL"], [49, 61, "DISEASE"], [4, 8, "CELL_TYPE"], [83, 92, "CELL"], [49, 61, "ENTITY"], [34, 46, "ENTITY"], [4, 8, "GENE_OR_GENE_PRODUCT"], [83, 118, "ENTITY"], [118, 123, "ENTITY"]]}
{"text": "Unfortunately , during the operation of ECMO she suffered a sudden cardiac arrest and survived by rescue of cardiopulmonary resuscitation ( CPR ) .", "labels": [[67, 75, "DISEASE"], [60, 75, "ENTITY"], [108, 124, "ENTITY"]]}
{"text": "Laboratory tests showed a slight decrease of leukocytes ( 3.19 \u00d7 109/L ) and neutrophils ( 1.57 \u00d7 109/L ) and a mildly elevated CRP concentration ( 29.2 mg/L ) , with all other tested parameters within normal ranges .", "labels": [[0, 17, "ENTITY"], [45, 56, "CELL_TYPE"], [33, 42, "ENTITY"], [112, 119, "ENTITY"], [184, 202, "ENTITY"], [45, 56, "CL"], [45, 56, "CELL"], [45, 56, "ENTITY"], [171, 184, "ENTITY"], [119, 132, "ENTITY"]]}
{"text": "Other abnormal results of laboratory parameters included significantly increased CRP 186 concentration ( > 160 mg/L ) and slightly increased PCT concentration ( 0.39 ng/ml ) .", "labels": [[141, 145, "ENTITY"], [81, 89, "GENE_OR_GENE_PRODUCT"], [15, 23, "ENTITY"], [71, 81, "GENE_OR_GENE_PRODUCT"], [71, 81, "PROTEIN"], [81, 85, "ENTITY"], [122, 131, "ENTITY"], [89, 103, "ENTITY"], [71, 81, "ENTITY"], [26, 37, "ENTITY"], [37, 48, "ENTITY"], [81, 89, "PROTEIN"], [71, 81, "ENTITY"], [6, 15, "ENTITY"]]}
{"text": "Most laboratory tests were within normal ranges , except for mild leukopenia [ 3.37 \u00d7 109 /L , reference range : ( 3.5~9.5 ) \u00d7109 /L ] and neutropenia [ 1.47 \u00d7 109 /L , reference range : ( 1.8~6.3 ) \u00d7109 /L ] .", "labels": [[105, 113, "GENE_OR_GENE_PRODUCT"], [130, 139, "DISEASE"], [61, 66, "ENTITY"], [153, 169, "ENTITY"], [105, 113, "PROTEIN"], [130, 139, "ENTITY"], [34, 48, "ENTITY"], [5, 22, "ENTITY"], [90, 105, "ENTITY"]]}
{"text": "On admission , physical examinations and pulmonary auscultation were normal ; laboratory tests indicated a reduction in leukocytes ( 1.92 \u00d7 109/L ) , neutrophils ( 1.20 \u00d7 109/L ) , lymphocytes ( 0.47 \u00d7 109/L ) , and eosinophils ( 0 \u00d7 109 /L ) counts , normal CRP and PCT concentrations , and slightly increased concentration of serum amyloid A [ SAA , 36.84 mg/L , reference range : ( 0~10 ) mg/L ]", "labels": [[138, 150, "ENTITY"], [301, 311, "GGP"], [271, 285, "PROTEIN"], [143, 146, "ENTITY"], [15, 24, "ENTITY"], [140, 150, "ENTITY"], [250, 263, "ENTITY"], [140, 150, "CELL"], [143, 146, "GGP"], [150, 162, "GENE_OR_GENE_PRODUCT"], [271, 285, "GENE_OR_GENE_PRODUCT"], [138, 150, "CL"], [301, 311, "PROTEIN"], [334, 352, "ENTITY"], [3, 13, "ENTITY"], [301, 311, "ENTITY"], [143, 146, "GENE_OR_GENE_PRODUCT"], [41, 51, "ENTITY"], [271, 285, "ENTITY"], [76, 89, "ENTITY"], [140, 150, "CELL_TYPE"], [271, 288, "ENTITY"], [143, 146, "PROTEIN"], [138, 150, "CELL_TYPE"], [138, 150, "CELL"], [216, 228, "ENTITY"], [140, 150, "CL"], [288, 301, "ENTITY"], [138, 148, "CELL"], [138, 148, "CELL_TYPE"], [301, 311, "ORGANISM_SUBSTANCE"], [138, 148, "ENTITY"]]}
{"text": "The CBC was normal except for the development of eosinopenia ( 0 \u00d7 109 /L ) and an elevated erythrocyte sedimentation rate ( ESR ) and CRP concentration ( 39 mm/h and 60.41 mg/L , respectively ) .", "labels": [[158, 163, "GENE_OR_GENE_PRODUCT"], [49, 61, "DISEASE"], [83, 92, "CELL"], [4, 8, "ENTITY"], [131, 139, "ENTITY"], [83, 92, "CL"], [4, 8, "CELL_TYPE"], [4, 8, "GENE_OR_GENE_PRODUCT"], [34, 46, "ENTITY"], [83, 118, "ENTITY"], [49, 61, "ENTITY"], [118, 123, "ENTITY"]]}
{"text": "On admission , physical examinations and pulmonary auscultation were normal ; laboratory tests indicated a reduction in leukocytes ( 1.92 \u00d7 109/L ) , neutrophils ( 1.20 \u00d7 109/L ) , lymphocytes ( 0.47 \u00d7 109/L ) , and eosinophils ( 0 \u00d7 109 /L ) counts , normal CRP and PCT concentrations , and slightly increased concentration of serum amyloid A [ SAA , 36.84 mg/L , reference range : ( 0~10 ) mg/L ]", "labels": [[301, 311, "ENTITY"], [138, 150, "ENTITY"], [271, 285, "PROTEIN"], [143, 146, "ENTITY"], [15, 24, "ENTITY"], [301, 311, "ORGANISM_SUBSTANCE"], [140, 150, "ENTITY"], [250, 263, "ENTITY"], [140, 150, "CELL"], [143, 146, "GGP"], [150, 162, "GENE_OR_GENE_PRODUCT"], [301, 311, "GGP"], [271, 285, "GENE_OR_GENE_PRODUCT"], [138, 150, "CL"], [334, 352, "ENTITY"], [3, 13, "ENTITY"], [301, 311, "PROTEIN"], [143, 146, "GENE_OR_GENE_PRODUCT"], [41, 51, "ENTITY"], [271, 285, "ENTITY"], [76, 89, "ENTITY"], [140, 150, "CELL_TYPE"], [271, 288, "ENTITY"], [143, 146, "PROTEIN"], [138, 150, "CELL_TYPE"], [138, 150, "CELL"], [216, 228, "ENTITY"], [140, 150, "CL"], [288, 301, "ENTITY"], [138, 148, "CELL"], [138, 148, "CELL_TYPE"], [138, 148, "ENTITY"]]}
{"text": "The CBC was normal except for the development of eosinopenia ( 0 \u00d7 109 /L ) and an elevated erythrocyte sedimentation rate ( ESR ) and CRP concentration ( 39 mm/h and 60.41 mg/L , respectively ) .", "labels": [[158, 163, "GENE_OR_GENE_PRODUCT"], [83, 92, "CL"], [118, 123, "ENTITY"], [4, 8, "ENTITY"], [83, 118, "ENTITY"], [49, 61, "DISEASE"], [4, 8, "CELL_TYPE"], [83, 92, "CELL"], [49, 61, "ENTITY"], [34, 46, "ENTITY"], [4, 8, "GENE_OR_GENE_PRODUCT"], [131, 139, "ENTITY"]]}
{"text": "Concentrations of procalcitonin , high sensitivity C-reactive protein , and ferritin , as well as erythrocyte sedimentation rate , were significantly higher in deceased patients than in recovered patients .", "labels": [[186, 196, "ENTITY"], [51, 62, "PROTEIN"], [160, 169, "ENTITY"], [18, 32, "ENTITY"], [0, 15, "ENTITY"], [186, 196, "ORGANISM"], [18, 32, "PROTEIN"], [18, 32, "GGP"], [18, 32, "GENE_OR_GENE_PRODUCT"], [160, 169, "ORGANISM"], [51, 62, "ENTITY"], [51, 62, "GGP"], [34, 39, "ENTITY"]]}
{"text": "Consistent with others , most of severe COVID-19 patients in our ICU ward had persistent very high level of erythematosus sedimentation rate ( ESR ) , CRP , and high level of IL-6,TNFa , IL-1B , IL-8 , IL2R , etc , and were associated with ARDS , hypercoagulation and disseminated intravascular coagulation ( DIC ) , manifested as thrombosis , thrombocytopenia , gangrene of extremities .", "labels": [[0, 16, "ENTITY"], [175, 187, "GENE_OR_GENE_PRODUCT"], [108, 136, "ENTITY"], [328, 344, "ENTITY"], [175, 187, "ENTITY"], [175, 187, "DNA"], [328, 344, "DISEASE"], [99, 108, "GGP"], [65, 69, "ENTITY"], [235, 247, "DISEASE"], [344, 363, "ENTITY"], [235, 247, "ENTITY"], [187, 193, "ENTITY"], [99, 108, "DNA"], [187, 193, "GENE_OR_GENE_PRODUCT"], [268, 281, "IMMATERIAL_ANATOMICAL_ENTITY"], [268, 295, "DISEASE"], [99, 108, "ENTITY"], [344, 363, "ORGAN"], [175, 187, "GGP"], [317, 328, "DISEASE"], [94, 99, "ENTITY"], [187, 193, "PROTEIN"], [247, 295, "ENTITY"], [40, 49, "GENE_OR_GENE_PRODUCT"], [215, 224, "ENTITY"], [187, 193, "GGP"], [99, 108, "GENE_OR_GENE_PRODUCT"], [317, 328, "ENTITY"]]}
{"text": "Remarkable abnormalities in the CBC were detected on January 29 , including increased neutrophils ( 10.67 \u00d7 109/L ) , leukocytes ( 11.73 \u00d7 109/L ) , and decreased lymphocytes ( 0.51 \u00d7 109 /L ) , and on February 4 decreased erythrocytes ( 2.40 \u00d7 1012/L ) and platelets ( 73 \u00d7 109 /L ) .", "labels": [[195, 202, "ENTITY"], [202, 213, "CL"], [202, 213, "CELL"], [41, 50, "ENTITY"], [153, 163, "CELL_TYPE"], [108, 118, "ENTITY"], [108, 118, "CELL"], [153, 163, "CL"], [108, 118, "CELL_TYPE"], [153, 163, "ENTITY"], [202, 213, "ENTITY"], [32, 36, "CELL_TYPE"], [108, 118, "ENTITY"], [32, 36, "ENTITY"], [153, 163, "CELL"], [11, 25, "ENTITY"], [108, 118, "CL"], [32, 36, "GENE_OR_GENE_PRODUCT"], [202, 213, "CELL_TYPE"]]}
{"text": "Laboratory tests showed a slight decrease of leukocytes ( 3.19 \u00d7 109/L ) and neutrophils ( 1.57 \u00d7 109/L ) and a mildly elevated CRP concentration ( 29.2 mg/L ) , with all other tested parameters within normal ranges .", "labels": [[119, 132, "ENTITY"], [0, 17, "ENTITY"], [45, 56, "CELL_TYPE"], [33, 42, "ENTITY"], [112, 119, "ENTITY"], [184, 202, "ENTITY"], [45, 56, "CL"], [45, 56, "CELL"], [45, 56, "ENTITY"], [171, 184, "ENTITY"]]}
{"text": "Remarkable abnormalities in the CBC were detected on January 29 , including increased neutrophils ( 10.67 \u00d7 109/L ) , leukocytes ( 11.73 \u00d7 109/L ) , and decreased lymphocytes ( 0.51 \u00d7 109 /L ) , and on February 4 decreased erythrocytes ( 2.40 \u00d7 1012/L ) and platelets ( 73 \u00d7 109 /L ) .", "labels": [[195, 202, "ENTITY"], [202, 213, "CL"], [202, 213, "CELL"], [41, 50, "ENTITY"], [153, 163, "CELL_TYPE"], [108, 118, "ENTITY"], [108, 118, "CELL"], [153, 163, "CL"], [108, 118, "CELL_TYPE"], [153, 163, "ENTITY"], [202, 213, "ENTITY"], [32, 36, "CELL_TYPE"], [108, 118, "ENTITY"], [32, 36, "ENTITY"], [153, 163, "CELL"], [11, 25, "ENTITY"], [108, 118, "CL"], [32, 36, "GENE_OR_GENE_PRODUCT"], [202, 213, "CELL_TYPE"]]}
{"text": "Remarkable abnormalities in the CBC were detected on January 29 , including increased neutrophils ( 10.67 \u00d7 109/L ) , leukocytes ( 11.73 \u00d7 109/L ) , and decreased lymphocytes ( 0.51 \u00d7 109 /L ) , and on February 4 decreased erythrocytes ( 2.40 \u00d7 1012/L ) and platelets ( 73 \u00d7 109 /L ) .", "labels": [[195, 202, "ENTITY"], [202, 213, "CL"], [202, 213, "CELL"], [41, 50, "ENTITY"], [153, 163, "CELL_TYPE"], [108, 118, "ENTITY"], [108, 118, "CELL"], [153, 163, "CL"], [108, 118, "CELL_TYPE"], [153, 163, "ENTITY"], [202, 213, "ENTITY"], [32, 36, "CELL_TYPE"], [108, 118, "ENTITY"], [32, 36, "ENTITY"], [153, 163, "CELL"], [11, 25, "ENTITY"], [108, 118, "CL"], [32, 36, "GENE_OR_GENE_PRODUCT"], [202, 213, "CELL_TYPE"]]}
{"text": "Unfortunately , during the operation of ECMO she suffered a sudden cardiac arrest and survived by rescue of cardiopulmonary resuscitation ( CPR ) .", "labels": [[67, 75, "DISEASE"], [60, 75, "ENTITY"], [108, 124, "ENTITY"]]}
{"text": "On February 10 , bedside bronchoscopy and bronchial lavage were performed , revealing hyperemia in mucous membranes of the trachea and bronchi with bleeding tendency and a large amount of yellow sticky sputum obstructing the entrance of the bilateral main bronchi and some bronchial lumens , which were aspirated completely .", "labels": [[96, 106, "TISSUE"], [96, 106, "ENTITY"], [76, 86, "ENTITY"], [172, 178, "ENTITY"], [17, 25, "ENTITY"], [185, 202, "ENTITY"], [42, 52, "ENTITY"], [76, 86, "DISEASE"], [42, 52, "TISSUE"], [148, 157, "ENTITY"], [268, 283, "ENTITY"], [251, 256, "ENTITY"], [3, 12, "ENTITY"], [251, 256, "TISSUE"], [268, 283, "TISSUE"]]}
{"text": "All the laboratory results were within normal ranges , including CBC and biochemical parameters , except for elevated levels of serum IgE ( 173 IU/mL ) .", "labels": [[125, 134, "ENTITY"], [128, 134, "CHEMICAL"], [125, 134, "ORGANISM_SUBSTANCE"], [8, 19, "ENTITY"], [39, 53, "ENTITY"], [125, 134, "PROTEIN"], [109, 118, "ENTITY"]]}
{"text": "Recent studies have shown that in addition to dyspnea , hypoxemia , and acute respiratory distress , lymphopenia , and cytokine release syndrome are also important clinical features in patients with severe SARS- CoV-2 infection.3", "labels": [[212, 218, "ENTITY"], [199, 212, "ENTITY"], [46, 54, "DISEASE"], [115, 128, "ENTITY"], [154, 173, "ENTITY"], [68, 90, "ENTITY"], [199, 218, "PROTEIN"], [68, 90, "DISEASE"], [46, 54, "ENTITY"], [128, 136, "ENTITY"], [7, 15, "ENTITY"], [199, 212, "ORGANISM"]]}
{"text": "Instead , we found that the severe group had a significant reduction in granulocytes compared to the mild group ( Fig. 1a )", "labels": [[101, 106, "ENTITY"]]}
{"text": "Although patients had higher sCD14 levels than healthy people , there were no significant differences between the severe and mild groups ( Fig. 1b ) .", "labels": [[35, 42, "ENTITY"], [55, 62, "ORGANISM"], [9, 18, "ORGANISM"], [29, 35, "GENE_OR_GENE_PRODUCT"], [29, 35, "PROTEIN"], [125, 130, "ENTITY"], [29, 35, "ENTITY"], [22, 29, "ENTITY"], [47, 62, "ENTITY"], [29, 35, "GGP"], [9, 18, "ENTITY"]]}
{"text": "Among the differentially expressed functional molecules , the levels of interferon-\u03b3 ( IFN-\u03b3 ) and TNF-\u03b1 in CD4 + T cells were lower in the severe group than in the mild group , whereas the levels of granzyme B and perforin in CD8 + T cells were higher in the severe group than in the mild group .", "labels": [[140, 147, "ENTITY"], [62, 72, "ENTITY"], [35, 56, "ENTITY"], [62, 72, "GENE_OR_GENE_PRODUCT"], [133, 140, "ENTITY"], [105, 116, "ENTITY"], [140, 147, "ENTITY"], [215, 235, "ENTITY"], [25, 35, "ENTITY"], [62, 72, "PROTEIN"], [158, 170, "ENTITY"], [46, 56, "CHEBI"], [105, 116, "CELL_TYPE"], [161, 170, "ENTITY"], [215, 235, "CELL_TYPE"], [215, 224, "GENE_OR_GENE_PRODUCT"], [10, 25, "ENTITY"], [62, 72, "GGP"], [215, 235, "GGP"], [105, 116, "GGP"]]}
{"text": "Among the differentially expressed functional molecules , the levels of interferon-\u03b3 ( IFN-\u03b3 ) and TNF-\u03b1 in CD4 + T cells were lower in the severe group than in the mild group , whereas the levels of granzyme B and perforin in CD8 + T cells were higher in the severe group than in the mild group .", "labels": [[140, 147, "ENTITY"], [62, 72, "ENTITY"], [35, 56, "ENTITY"], [62, 72, "GENE_OR_GENE_PRODUCT"], [133, 140, "ENTITY"], [215, 224, "GENE_OR_GENE_PRODUCT"], [105, 116, "ENTITY"], [140, 147, "ENTITY"], [215, 235, "CELL_TYPE"], [25, 35, "ENTITY"], [62, 72, "PROTEIN"], [158, 170, "ENTITY"], [46, 56, "CHEBI"], [105, 116, "CELL_TYPE"], [215, 235, "ENTITY"], [215, 235, "GGP"], [161, 170, "ENTITY"], [10, 25, "ENTITY"], [62, 72, "GGP"], [105, 116, "GGP"]]}
{"text": "The activation molecules showed no differences in CD4 + T cells , whereas the levels of HLA-DR and TIGIT in CD8 + T cells were higher in the severe group than in the mild group ( Fig. 1c ) .", "labels": [[50, 58, "CELL_TYPE"], [50, 54, "GENE_OR_GENE_PRODUCT"], [141, 148, "ENTITY"], [105, 116, "CELL_TYPE"], [105, 116, "ENTITY"], [4, 25, "PROTEIN"], [15, 25, "CHEBI"], [105, 116, "GGP"], [4, 25, "ENTITY"], [162, 171, "ENTITY"], [50, 58, "GGP"], [50, 58, "ENTITY"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [192, 203, "ENTITY"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [271, 279, "PROTEIN"], [182, 192, "ENTITY"], [88, 113, "ENTITY"], [203, 214, "CL"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "DNA"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [382, 411, "DISEASE"], [271, 279, "GGP"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "DNA"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [203, 238, "ENTITY"], [192, 203, "CHEMICAL"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [203, 214, "CELL"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [77, 84, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The activation molecules showed no differences in CD4 + T cells , whereas the levels of HLA-DR and TIGIT in CD8 + T cells were higher in the severe group than in the mild group ( Fig. 1c ) .", "labels": [[50, 58, "CELL_TYPE"], [50, 54, "GENE_OR_GENE_PRODUCT"], [141, 148, "ENTITY"], [105, 116, "CELL_TYPE"], [105, 116, "ENTITY"], [4, 25, "PROTEIN"], [15, 25, "CHEBI"], [105, 116, "GGP"], [4, 25, "ENTITY"], [162, 171, "ENTITY"], [50, 58, "GGP"], [50, 58, "ENTITY"]]}
{"text": "In CD8 + T cells , the frequency of the nonexhausted ( PD-1\u2212CTLA-4\u2212TIGIT\u2212 ) subset in the severe group was significantly lower than that in the other two groups ( Fig. 1d ) .", "labels": [[3, 11, "CELL_TYPE"], [90, 97, "ENTITY"], [3, 11, "GGP"], [3, 7, "GENE_OR_GENE_PRODUCT"], [3, 11, "ENTITY"]]}
{"text": "These data indicate that COVID-19 , similar to some chronic infections , damages the function of CD4 + T cells and promotes excessive activation and possibly subsequent exhaustion of CD8 + T cells .", "labels": [[94, 105, "GGP"], [115, 124, "ENTITY"], [94, 105, "ENTITY"], [25, 34, "PROTEIN"], [94, 105, "CELL_TYPE"], [180, 191, "GGP"], [25, 34, "ENTITY"], [52, 60, "ENTITY"], [25, 34, "GENE_OR_GENE_PRODUCT"], [52, 60, "DISEASE"], [158, 169, "ENTITY"], [124, 134, "ENTITY"], [180, 191, "CELL_TYPE"], [180, 191, "ENTITY"], [6, 11, "ENTITY"]]}
{"text": "Studies have shown that multi-functional T cells can better control human immunodeficiency virus in natural infection and are correlated with better outcomes during vaccination ; thus , the functional damage of CD4 + T cells may have predisposed COVID-19 patients to severe disease.8", "labels": [[68, 74, "ENTITY"], [41, 49, "CELL"], [41, 49, "CL"], [234, 255, "ORGANISM"], [149, 158, "ENTITY"], [208, 219, "CELL_TYPE"], [68, 97, "ORGANISM"], [208, 219, "GENE_OR_GENE_PRODUCT"], [165, 177, "ENTITY"], [24, 49, "ENTITY"], [246, 255, "ENTITY"], [68, 97, "DISEASE"], [267, 274, "CHEMICAL"], [100, 118, "ENTITY"], [126, 137, "ENTITY"], [208, 219, "GGP"], [234, 246, "ENTITY"], [0, 8, "ENTITY"], [91, 97, "TAXON"], [30, 41, "ENTITY"], [208, 219, "ENTITY"], [100, 118, "DISEASE"], [234, 246, "DISEASE"], [24, 49, "CELL_TYPE"], [74, 97, "ENTITY"], [68, 74, "TAXON"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "These data indicate that COVID-19 , similar to some chronic infections , damages the function of CD4 + T cells and promotes excessive activation and possibly subsequent exhaustion of CD8 + T cells .", "labels": [[94, 105, "GGP"], [115, 124, "ENTITY"], [94, 105, "ENTITY"], [25, 34, "PROTEIN"], [94, 105, "CELL_TYPE"], [180, 191, "GGP"], [25, 34, "ENTITY"], [52, 60, "ENTITY"], [25, 34, "GENE_OR_GENE_PRODUCT"], [52, 60, "DISEASE"], [158, 169, "ENTITY"], [124, 134, "ENTITY"], [180, 191, "CELL_TYPE"], [180, 191, "ENTITY"], [6, 11, "ENTITY"]]}
{"text": "Compared with the healthy control and mild group , the frequency of multi-functional CD4 + T cells ( positive for at least two cytokines ) decreased significantly in the severe group , whereas the proportion of non-functional ( IFN-\u03b3 \u2212TNF-\u03b1\u2212IL-2\u2212 ) subsets increased significantly .", "labels": [[211, 228, "ENTITY"], [127, 139, "ENTITY"], [38, 49, "ENTITY"], [170, 177, "ENTITY"], [234, 249, "ENTITY"], [68, 93, "CELL_TYPE"], [18, 34, "ENTITY"], [197, 211, "ENTITY"], [89, 93, "CL"], [0, 9, "ENTITY"], [249, 257, "ENTITY"], [211, 228, "GENE_OR_GENE_PRODUCT"], [85, 93, "ENTITY"]]}
{"text": "Because functional blockade of PD-1 , CTLA-4 , and TIGIT is beneficial for CD8 + T cells to maintain lasting antigen-specific immunity and antiviral effects,10,11 the excessive exhaustion of CD8 + T cells in severe patients may reduce their cellular immune response to SARS- CoV-2 .", "labels": [[188, 199, "GGP"], [208, 215, "ORGANISM"], [266, 275, "PROTEIN"], [71, 83, "CELL_TYPE"], [266, 275, "ENTITY"], [31, 36, "ENTITY"], [135, 149, "ENTITY"], [235, 257, "ENTITY"], [71, 83, "ENTITY"], [31, 36, "GENE_OR_GENE_PRODUCT"], [101, 126, "ENTITY"], [19, 28, "ENTITY"], [188, 199, "ENTITY"], [188, 199, "CELL_TYPE"], [266, 275, "ORGANISM"], [71, 83, "GGP"], [8, 19, "ENTITY"], [208, 215, "ENTITY"], [31, 36, "PROTEIN"], [167, 177, "ENTITY"]]}
{"text": "5.75 % ( 359/499 ) , 75.95 % ( 379/499 ) and 71.54 % ( 359/499), 75.95% (379/499) and 71.54% ) patients had remarkably low total T cell counts , CD4 + and CD8 + T cell counts , respectively .", "labels": [[93, 101, "ENTITY"], [74, 93, "CELL_TYPE"], [78, 93, "ENTITY"], [78, 93, "GGP"]]}
{"text": "The counts of total T cells , CD4 + and CD8 + T cells were significantly lower in ICU patients than Non-ICU cases ( Figure 1B ) .", "labels": [[114, 123, "ENTITY"], [14, 28, "ENTITY"], [4, 11, "ENTITY"], [30, 48, "CELL_TYPE"], [40, 48, "ENTITY"], [20, 28, "CELL"], [20, 28, "CL"], [40, 48, "GGP"], [30, 34, "GGP"], [14, 28, "CELL_TYPE"], [30, 34, "ENTITY"]]}
{"text": "Interestingly , serum levels of IFN-\u03b3 , IL-10 , IL-6 and TNF-\u03b1 were significantly decreased in these patients in the decline period as compared with illness period , while counts of total T cells , CD4 + , and CD8 + T cell subsets recovered during the decline period ( Figure 2C ) .", "labels": [[117, 125, "ENTITY"], [182, 190, "CL"], [68, 82, "ENTITY"], [182, 190, "CELL"], [16, 22, "ENTITY"], [260, 269, "ENTITY"], [206, 218, "GGP"], [149, 157, "ENTITY"], [206, 223, "ENTITY"], [117, 125, "ENTITY"], [190, 198, "ENTITY"], [179, 190, "CELL_TYPE"], [179, 190, "ENTITY"], [190, 223, "CELL_TYPE"], [190, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Furthermore , statistical analysis showed that the percentage of PD-1 + CD8 + T cells from ICU patients was significantly higher than from both Non-ICU cases and healthy controls ( Figure 3B ) , indicating that SARS-CoV-2 viruses induce T cell exhaustion in COVID-19 patients , particularly in those requiring ICU care .", "labels": [[230, 239, "CELL"], [65, 80, "CELL_LINE"], [72, 80, "ENTITY"], [206, 222, "ENTITY"], [162, 170, "ENTITY"], [144, 152, "ENTITY"], [179, 188, "ENTITY"], [222, 230, "ENTITY"], [230, 239, "ENTITY"], [258, 267, "ENTITY"], [300, 314, "ENTITY"], [14, 26, "ENTITY"], [211, 222, "TAXON"], [230, 239, "CL"], [255, 267, "ORGANISM"], [80, 85, "ENTITY"], [65, 80, "GGP"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [40, 59, "ENTITY"], [26, 38, "SIMPLE_CHEMICAL"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GGP"], [253, 271, "ENTITY"], [26, 40, "CHEBI"], [170, 179, "GGP"], [26, 38, "CHEMICAL"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [144, 154, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [26, 38, "ENTITY"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "Increased antibody-secreting cells (ASCs),follicular helper T cells ( TFH cells ) , activated CD4 + T cells and CD8 + T cells and immunoglobulin M ( IgM ) and IgG antibodies that bound the COVID-19- causing coronavirus SARS-CoV-2 were detected in blood before symptomatic recovery .", "labels": [[84, 102, "GGP"], [235, 244, "ENTITY"], [70, 74, "ENTITY"], [0, 10, "ENTITY"], [53, 68, "CELL_TYPE"], [153, 163, "PROTEIN"], [70, 74, "CELL"], [53, 68, "ENTITY"], [84, 102, "ENTITY"], [60, 68, "CL"], [29, 35, "CL"], [70, 74, "CELL_TYPE"], [207, 219, "CHEMICAL"], [199, 219, "ENTITY"], [235, 244, "ORGANISM_SUBSTANCE"], [219, 235, "ENTITY"], [10, 35, "ENTITY"], [153, 163, "ENTITY"], [179, 189, "PROTEIN"], [108, 120, "CELL_TYPE"], [10, 35, "CELL"], [179, 189, "ENTITY"], [199, 219, "ORGANISM"], [163, 174, "ENTITY"], [155, 163, "GO"], [260, 272, "ENTITY"], [84, 94, "GENE_OR_GENE_PRODUCT"], [179, 189, "GENE_OR_GENE_PRODUCT"], [130, 147, "ENTITY"], [10, 35, "CELL_TYPE"], [130, 147, "PROTEIN"], [153, 163, "GENE_OR_GENE_PRODUCT"], [108, 120, "ENTITY"], [108, 120, "GGP"], [82, 102, "CELL_TYPE"], [130, 147, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In CD8 + T cells , the frequency of the nonexhausted ( PD-1\u2212CTLA-4\u2212TIGIT\u2212 ) subset in the severe group was significantly lower than that in the other two groups ( Fig. 1d ) .", "labels": [[3, 11, "CELL_TYPE"], [90, 97, "ENTITY"], [3, 11, "GGP"], [3, 7, "GENE_OR_GENE_PRODUCT"], [3, 11, "ENTITY"]]}
{"text": "FACs analysis illustrated that , T cells from COVID-19 patients have markedly higher levels of PD-1 compared to healthy controls ( Figure 3A ) .", "labels": [[46, 55, "ORGANISM"], [0, 5, "CELL"], [129, 138, "ENTITY"], [0, 5, "ENTITY"], [5, 14, "ENTITY"], [112, 120, "ENTITY"]]}
{"text": "Furthermore , statistical analysis showed that the percentage of PD-1 + CD8 + T cells from ICU patients was significantly higher than from both Non-ICU cases and healthy controls ( Figure 3B ) , indicating that SARS-CoV-2 viruses induce T cell exhaustion in COVID-19 patients , particularly in those requiring ICU care .", "labels": [[230, 239, "CELL"], [65, 80, "CELL_LINE"], [72, 80, "ENTITY"], [206, 222, "ENTITY"], [162, 170, "ENTITY"], [144, 152, "ENTITY"], [179, 188, "ENTITY"], [222, 230, "ENTITY"], [230, 239, "ENTITY"], [258, 267, "ENTITY"], [300, 314, "ENTITY"], [14, 26, "ENTITY"], [211, 222, "TAXON"], [230, 239, "CL"], [255, 267, "ORGANISM"], [80, 85, "ENTITY"], [65, 80, "GGP"]]}
{"text": "FACs showed that these patients have very low level of PD-1 and Tim-3 on CD8 + and CD4 + T cells in the prodromal stage , however , their levels on CD8 + T cells was increased in overtly symptomatic stages , and highest levels were seen in ICU period ( Figure 3C , D ) .", "labels": [[23, 32, "ORGANISM"], [83, 97, "GGP"], [73, 79, "GGP"], [73, 97, "CELL_TYPE"], [104, 120, "ENTITY"], [179, 187, "ENTITY"], [187, 199, "ENTITY"], [55, 60, "ENTITY"], [83, 97, "ENTITY"], [0, 5, "ENTITY"], [83, 87, "GENE_OR_GENE_PRODUCT"], [55, 60, "PROTEIN"], [64, 70, "GENE_OR_GENE_PRODUCT"], [240, 244, "ENTITY"], [64, 70, "ENTITY"], [0, 5, "CELL"], [244, 253, "ENTITY"], [23, 32, "ENTITY"], [145, 156, "GGP"], [55, 60, "GENE_OR_GENE_PRODUCT"], [73, 77, "GENE_OR_GENE_PRODUCT"], [46, 52, "ENTITY"], [145, 156, "ENTITY"], [145, 156, "CELL_TYPE"], [73, 79, "ENTITY"], [212, 220, "ENTITY"], [64, 70, "PROTEIN"], [64, 70, "GGP"]]}
{"text": "FACs showed that these patients have very low level of PD-1 and Tim-3 on CD8 + and CD4 + T cells in the prodromal stage , however , their levels on CD8 + T cells was increased in overtly symptomatic stages , and highest levels were seen in ICU period ( Figure 3C , D ) .", "labels": [[23, 32, "ORGANISM"], [83, 97, "GGP"], [73, 79, "GGP"], [73, 97, "CELL_TYPE"], [104, 120, "ENTITY"], [179, 187, "ENTITY"], [187, 199, "ENTITY"], [55, 60, "ENTITY"], [83, 97, "ENTITY"], [0, 5, "ENTITY"], [83, 87, "GENE_OR_GENE_PRODUCT"], [55, 60, "PROTEIN"], [64, 70, "GENE_OR_GENE_PRODUCT"], [240, 244, "ENTITY"], [64, 70, "ENTITY"], [0, 5, "CELL"], [244, 253, "ENTITY"], [23, 32, "ENTITY"], [145, 156, "GGP"], [55, 60, "GENE_OR_GENE_PRODUCT"], [73, 77, "GENE_OR_GENE_PRODUCT"], [46, 52, "ENTITY"], [145, 156, "ENTITY"], [145, 156, "CELL_TYPE"], [73, 79, "ENTITY"], [212, 220, "ENTITY"], [64, 70, "PROTEIN"], [64, 70, "GGP"]]}
{"text": "In CD8 + T cells , the frequency of the nonexhausted ( PD-1\u2212CTLA-4\u2212TIGIT\u2212 ) subset in the severe group was significantly lower than that in the other two groups ( Fig. 1d ) .", "labels": [[3, 11, "CELL_TYPE"], [90, 97, "ENTITY"], [3, 11, "GGP"], [3, 7, "GENE_OR_GENE_PRODUCT"], [3, 11, "ENTITY"]]}
{"text": "Although the nature of the clear jelly has yet to be determined , hyaluronan ( HA ) is associated with ARDS [ 12 ] ; moreover , during SARS infection , the production and regulation of hyaluronan is defective .", "labels": [[128, 140, "ENTITY"], [128, 140, "DISEASE"], [84, 98, "ENTITY"], [171, 185, "ENTITY"], [171, 185, "GENE_OR_GENE_PRODUCT"], [33, 39, "ENTITY"], [156, 171, "ENTITY"], [171, 185, "CHEMICAL"], [171, 185, "GGP"], [171, 185, "PROTEIN"], [185, 199, "ENTITY"], [140, 156, "ENTITY"]]}
{"text": "On presentation , the most common symptom was fever in 22 patients ( 96 % ) , followed by cough in five ( 22 % ) , chills in four ( 17 % ) , and dyspnoea in four ( 17 % ; table ) .", "labels": [[78, 90, "DISEASE"], [3, 16, "ENTITY"], [78, 90, "ENTITY"]]}
{"text": "Serum alkaline phosphatase was significantly higher among patients with severe disease than among those with mild disease ( 74 U/L [ range 56\u2013149 ] vs 60 U/L [ 38\u2013118 ] ; p=0\u00b7026 ) .", "labels": [[0, 27, "ORGANISM_SUBSTANCE"], [58, 67, "ORGANISM"], [58, 67, "ENTITY"], [31, 52, "ENTITY"], [109, 122, "ENTITY"], [72, 87, "ENTITY"], [0, 27, "PROTEIN"], [6, 15, "CHEBI"], [0, 27, "ENTITY"]]}
{"text": "In detail , of 74 patients with COVID-19 with GI symptoms , 53 patients had only the symptom of diarrhoea , 11 patients had only the symptom of vomiting and 10 patients had only the symptom of nausea .", "labels": [[46, 49, "DISEASE"], [46, 49, "ENTITY"]]}
{"text": "As shown in table 3 , 5 ( 6.76 % ) , 13 ( 17.57 % ) and 1 ( 1.35 % ) patient with COVID-19 with GI symptoms had complications of ARDS , liver injury and shock , respectively , where the former two were significantly higher than their counterparts of 2.08 % and 8.84 % in patients with COVID-19 without GI symptoms , respectively ( p=0.034 ; p=0.035 ) .", "labels": [[69, 77, "GENE_OR_GENE_PRODUCT"], [255, 261, "ENTITY"], [82, 96, "ENTITY"], [99, 112, "ENTITY"], [69, 77, "ENTITY"], [112, 136, "ENTITY"], [82, 91, "ENTITY"], [82, 96, "DISEASE"], [112, 136, "DISEASE"], [112, 129, "ORGAN"], [255, 261, "ORGANISM"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [236, 242, "ENTITY"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [300, 315, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [236, 242, "ENTITY"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [300, 315, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [236, 242, "ENTITY"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [300, 315, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "All 6 infants had antibodies detected in their serum .", "labels": [[18, 29, "PROTEIN"], [47, 53, "ENTITY"], [6, 14, "ORGANISM"], [18, 29, "ENTITY"], [47, 53, "ORGANISM_SUBSTANCE"], [29, 38, "ENTITY"], [18, 29, "GO"], [6, 14, "ENTITY"]]}
{"text": "Increased antibody-secreting cells (ASCs),follicular helper T cells ( TFH cells ) , activated CD4 + T cells and CD8 + T cells and immunoglobulin M ( IgM ) and IgG antibodies that bound the COVID-19- causing coronavirus SARS-CoV-2 were detected in blood before symptomatic recovery .", "labels": [[84, 102, "GGP"], [235, 244, "ENTITY"], [70, 74, "ENTITY"], [0, 10, "ENTITY"], [53, 68, "CELL_TYPE"], [153, 163, "PROTEIN"], [130, 147, "PROTEIN"], [53, 68, "ENTITY"], [70, 74, "CELL"], [84, 102, "ENTITY"], [60, 68, "CL"], [29, 35, "CL"], [70, 74, "CELL_TYPE"], [207, 219, "CHEMICAL"], [199, 219, "ENTITY"], [235, 244, "ORGANISM_SUBSTANCE"], [219, 235, "ENTITY"], [10, 35, "ENTITY"], [153, 163, "ENTITY"], [179, 189, "PROTEIN"], [108, 120, "CELL_TYPE"], [10, 35, "CELL"], [179, 189, "ENTITY"], [199, 219, "ORGANISM"], [163, 174, "ENTITY"], [155, 163, "GO"], [260, 272, "ENTITY"], [84, 94, "GENE_OR_GENE_PRODUCT"], [153, 163, "GENE_OR_GENE_PRODUCT"], [10, 35, "CELL_TYPE"], [108, 120, "ENTITY"], [108, 120, "GGP"], [130, 147, "GENE_OR_GENE_PRODUCT"], [130, 147, "ENTITY"], [82, 102, "CELL_TYPE"], [179, 189, "GENE_OR_GENE_PRODUCT"]]}
{"text": "On day 2 of life , the infant experienced lethargy and fever , with unremarkable physical examination results , and was moved to the neonatal intensive care unit .", "labels": [[133, 157, "ENTITY"], [3, 7, "ENTITY"], [90, 102, "ENTITY"], [129, 157, "DNA"], [12, 17, "ENTITY"], [68, 90, "ENTITY"]]}
{"text": "He presented with lethargy , vomiting , and fever .", "labels": [[18, 27, "ENTITY"], [18, 27, "DISEASE"]]}
{"text": "A chest radiographic image showed pneumonia , but other laboratory tests ( except procalcitonin ) were normal", "labels": [[2, 8, "ENTITY"], [34, 44, "ENTITY"], [56, 67, "ENTITY"], [34, 44, "DISEASE"]]}
{"text": "Concentrations of procalcitonin , high sensitivity C-reactive protein , and ferritin , as well as erythrocyte sedimentation rate , were significantly higher in deceased patients than in recovered patients .", "labels": [[186, 196, "ENTITY"], [51, 62, "PROTEIN"], [160, 169, "ENTITY"], [18, 32, "ENTITY"], [0, 15, "ENTITY"], [186, 196, "ORGANISM"], [18, 32, "PROTEIN"], [18, 32, "GGP"], [18, 32, "GENE_OR_GENE_PRODUCT"], [160, 169, "ORGANISM"], [51, 62, "ENTITY"], [51, 62, "GGP"], [34, 39, "ENTITY"]]}
{"text": "He presented with lethargy , vomiting , and fever .", "labels": [[18, 27, "DISEASE"], [18, 27, "ENTITY"]]}
{"text": "Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation , caffeine , and antibiotics .", "labels": [[137, 147, "ENTITY"], [152, 176, "ENTITY"], [66, 72, "MULTI-TISSUE_STRUCTURE"], [66, 91, "ENTITY"], [9, 39, "DISEASE"], [43, 53, "DISEASE"], [126, 131, "ENTITY"], [0, 9, "ENTITY"], [116, 120, "ENTITY"], [9, 39, "ENTITY"], [43, 53, "ENTITY"], [94, 104, "ENTITY"]]}
{"text": "He also had suspected sepsis , with an Enterobacter agglomerates\u2013 positive blood culture , leukocytosis , thrombocytopenia ( 11 cells \u00d7 103/\u03bcL ; to convert to cells \u00d7 109/L , multiply by 1.0 ) , and coagulopathy ( prothrombin time , 21 seconds ; activated partial thromboplastin time , 81.9 seconds ) , which improved with antibiotic treatment .", "labels": [[246, 264, "PROTEIN"], [191, 199, "ENTITY"], [148, 159, "CELL"], [148, 159, "CL"], [246, 264, "GENE_OR_GENE_PRODUCT"], [309, 323, "ENTITY"], [22, 29, "ENTITY"], [148, 159, "ENTITY"], [309, 318, "CHEBI"], [39, 52, "ENTITY"], [22, 29, "DISEASE"], [199, 214, "ENTITY"], [199, 214, "GENE_OR_GENE_PRODUCT"], [12, 22, "ENTITY"], [236, 264, "ENTITY"], [191, 199, "DISEASE"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "He also had suspected sepsis , with an Enterobacter agglomerates\u2013 positive blood culture , leukocytosis , thrombocytopenia ( 11 cells \u00d7 103/\u03bcL ; to convert to cells \u00d7 109/L , multiply by 1.0 ) , and coagulopathy ( prothrombin time , 21 seconds ; activated partial thromboplastin time , 81.9 seconds ) , which improved with antibiotic treatment .", "labels": [[246, 264, "PROTEIN"], [191, 199, "ENTITY"], [148, 159, "CELL"], [148, 159, "CL"], [246, 264, "GENE_OR_GENE_PRODUCT"], [309, 323, "ENTITY"], [22, 29, "ENTITY"], [148, 159, "ENTITY"], [309, 318, "CHEBI"], [39, 52, "ENTITY"], [22, 29, "DISEASE"], [199, 214, "ENTITY"], [199, 214, "GENE_OR_GENE_PRODUCT"], [12, 22, "ENTITY"], [236, 264, "ENTITY"], [191, 199, "DISEASE"]]}
{"text": "On admission , lymphocytopenia was present in 83.2 % of the patients , thrombocytopenia in 36.2 % , and leukopenia in 33.7 %", "labels": [[3, 13, "ENTITY"]]}
{"text": "He also had suspected sepsis , with an Enterobacter agglomerates\u2013 positive blood culture , leukocytosis , thrombocytopenia ( 11 cells \u00d7 103/\u03bcL ; to convert to cells \u00d7 109/L , multiply by 1.0 ) , and coagulopathy ( prothrombin time , 21 seconds ; activated partial thromboplastin time , 81.9 seconds ) , which improved with antibiotic treatment .", "labels": [[246, 264, "PROTEIN"], [191, 199, "ENTITY"], [148, 159, "CELL"], [148, 159, "CL"], [246, 264, "GENE_OR_GENE_PRODUCT"], [309, 323, "ENTITY"], [22, 29, "ENTITY"], [148, 159, "ENTITY"], [309, 318, "CHEBI"], [39, 52, "ENTITY"], [22, 29, "DISEASE"], [199, 214, "ENTITY"], [199, 214, "GENE_OR_GENE_PRODUCT"], [12, 22, "ENTITY"], [236, 264, "ENTITY"], [191, 199, "DISEASE"]]}
{"text": "In an analysis of 45,000 confirmed cases in China , the crude case fatality rate was 0.9 % for patients without any documented comorbidities , whereas the case fatality rate was much higher for patients with CVD ( 10.5 % ) , diabetes ( 7.3 % ) , or hypertension ( 6.3 % )", "labels": [[151, 160, "ENTITY"], [116, 127, "ENTITY"], [56, 67, "ENTITY"], [44, 50, "ENTITY"], [6, 15, "ENTITY"], [236, 249, "ENTITY"], [35, 41, "ENTITY"], [236, 249, "DISEASE"]]}
{"text": "In comparison with patients with mild COVID-19 ( such as those who did not require ICU stays , did not develop ARDS or pneumonia , and who survived ) , patients with severe COVID-19 have higher comorbidities , including 56 % for hypertension , 21 % for heart diseases , 18 % for diabetes , 12 % for cerebrovascular diseases , and 7 % for cancer ( Table 1 ) ( 79 , 97 ) .", "labels": [[103, 111, "DISEASE"], [129, 135, "CANCER"], [223, 229, "DISEASE"], [38, 47, "DISEASE"], [19, 28, "ORGANISM"], [279, 299, "ENTITY"], [244, 259, "ENTITY"], [129, 135, "ENTITY"], [244, 259, "DISEASE"], [33, 47, "ENTITY"], [129, 135, "DISEASE"], [279, 299, "DISEASE"], [223, 229, "ENTITY"], [3, 14, "ENTITY"], [103, 111, "ENTITY"], [38, 47, "GENE_OR_GENE_PRODUCT"], [166, 173, "DISEASE"], [187, 194, "ENTITY"], [166, 173, "ENTITY"], [166, 173, "GENE_OR_GENE_PRODUCT"], [19, 28, "ENTITY"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [259, 269, "ORGAN"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Lastly , SARS-CoV-2 infection may downregulate ACE2 function , possibly to a greater extent in patients with pre-existing CVD .", "labels": [[9, 20, "ENTITY"], [109, 122, "ENTITY"], [9, 20, "DISEASE"]]}
{"text": "Some centers are anecdotally reporting de novo cardiomyopathy ; if this is true , this too should be considered in the definition of severe disease , although the mechanism could differ , and it is unclear if cardiomyopathy associated with COVID-19 occurs in the absence of ARDS .", "labels": [[209, 235, "ENTITY"], [5, 13, "ENTITY"], [47, 62, "DISEASE"], [39, 62, "ENTITY"], [130, 140, "ENTITY"]]}
{"text": "Consistent with clinical observations , the lungs are the most injured organs , followed by moderate injury in the heart , liver , kidney , and brain .", "labels": [[16, 38, "ENTITY"], [0, 16, "ENTITY"], [123, 131, "ENTITY"], [92, 101, "ENTITY"], [123, 131, "ORGAN"]]}
{"text": "Consistent with clinical observations , the lungs are the most injured organs , followed by moderate injury in the heart , liver , kidney , and brain .", "labels": [[16, 38, "ENTITY"], [0, 16, "ENTITY"], [123, 131, "ENTITY"], [92, 101, "ENTITY"], [123, 131, "ORGAN"]]}
{"text": "Consistent with clinical observations , the lungs are the most injured organs , followed by moderate injury in the heart , liver , kidney , and brain .", "labels": [[16, 38, "ENTITY"], [0, 16, "ENTITY"], [123, 131, "ENTITY"], [92, 101, "ENTITY"], [123, 131, "ORGAN"]]}
{"text": "Consistent with clinical observations , the lungs are the most injured organs , followed by moderate injury in the heart , liver , kidney , and brain .", "labels": [[16, 38, "ENTITY"], [0, 16, "ENTITY"], [123, 131, "ENTITY"], [92, 101, "ENTITY"], [123, 131, "ORGAN"]]}
{"text": "In comparison with patients with mild COVID-19 ( such as those who did not require ICU stays , did not develop ARDS or pneumonia , and who survived ) , patients with severe COVID-19 have higher comorbidities , including 56 % for hypertension , 21 % for heart diseases , 18 % for diabetes , 12 % for cerebrovascular diseases , and 7 % for cancer ( Table 1 ) ( 79 , 97 ) .", "labels": [[103, 111, "DISEASE"], [129, 135, "CANCER"], [223, 229, "DISEASE"], [38, 47, "DISEASE"], [19, 28, "ORGANISM"], [279, 299, "ENTITY"], [244, 259, "ENTITY"], [129, 135, "ENTITY"], [244, 259, "DISEASE"], [33, 47, "ENTITY"], [129, 135, "DISEASE"], [279, 299, "DISEASE"], [223, 229, "ENTITY"], [3, 14, "ENTITY"], [103, 111, "ENTITY"], [38, 47, "GENE_OR_GENE_PRODUCT"], [166, 173, "DISEASE"], [187, 194, "ENTITY"], [166, 173, "ENTITY"], [166, 173, "GENE_OR_GENE_PRODUCT"], [19, 28, "ENTITY"]]}
{"text": "In the present study , the lung lesions of 48 cases ( 43.6 % ) were located in the peripheral zone and lesions of 62 cases ( 56.4 % ) involved both the peripheral and the central zones ( Fig 1 ) .", "labels": [[163, 171, "ENTITY"], [79, 94, "TISSUE"], [163, 171, "ANATOMICAL_SYSTEM"], [143, 152, "ENTITY"], [79, 94, "ENTITY"], [179, 185, "GENE_OR_GENE_PRODUCT"], [143, 152, "TISSUE"], [27, 32, "CANCER"], [27, 32, "ENTITY"], [15, 21, "ENTITY"]]}
{"text": "Hypertension , cardiovascular disease , and cerebrovascular disease were much more frequent among deceased patients ( 54 ( 48 % ) , 16 ( 14 % ) , and 4 ( 4 % ) ) than among recovered patients ( 39 ( 24 % ) , 7 ( 4 % ) , and 0 ( 0 % ) ) .", "labels": [[40, 60, "ENTITY"], [98, 107, "ENTITY"], [15, 30, "DISEASE"], [158, 167, "ENTITY"], [0, 13, "DISEASE"], [0, 13, "ENTITY"], [40, 60, "DISEASE"], [15, 30, "ENTITY"], [98, 107, "ORGANISM"]]}
{"text": "Comorbidities , including diabetes mellitus , cardiovascular and cerebrovascular diseases , were found in 4 and 5 of the patients from the DIP and control group , respectively .", "labels": [[26, 35, "DISEASE"], [0, 14, "ENTITY"], [143, 155, "ENTITY"], [26, 35, "ENTITY"], [61, 81, "ENTITY"], [44, 81, "DISEASE"]]}
{"text": "Hypertension , cardiovascular disease , and cerebrovascular disease were much more frequent among deceased patients ( 54 ( 48 % ) , 16 ( 14 % ) , and 4 ( 4 % ) ) than among recovered patients ( 39 ( 24 % ) , 7 ( 4 % ) , and 0 ( 0 % ) ) .", "labels": [[15, 30, "DISEASE"], [98, 107, "ENTITY"], [158, 167, "ENTITY"], [15, 30, "ENTITY"], [0, 13, "DISEASE"], [0, 13, "ENTITY"], [40, 60, "DISEASE"], [98, 107, "ORGANISM"], [40, 60, "ENTITY"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [111, 136, "ENTITY"], [79, 100, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [111, 136, "DISEASE"], [259, 269, "ORGAN"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Comorbidities , including diabetes mellitus , cardiovascular and cerebrovascular diseases , were found in 4 and 5 of the patients from the DIP and control group , respectively .", "labels": [[26, 35, "DISEASE"], [44, 81, "DISEASE"], [0, 14, "ENTITY"], [143, 155, "ENTITY"], [26, 35, "ENTITY"], [61, 81, "ENTITY"]]}
{"text": "Median systolic blood pressure was significantly higher in deceased patients ( 137.0 mm Hg ) than recovered patients ( 125.0 mm Hg ) .", "labels": [[68, 77, "ENTITY"], [7, 31, "ENTITY"], [0, 7, "ENTITY"], [59, 68, "ENTITY"], [98, 108, "ENTITY"], [98, 108, "ORGANISM"], [85, 88, "CHEBI"], [68, 77, "ORGANISM"], [16, 22, "ORGANISM_SUBSTANCE"]]}
{"text": "More patients who died than who recovered had arterial pressure of 140 mm Hg or higher ( 50 ( 44 % ) v 33 ( 20 % ) )", "labels": [[80, 87, "ENTITY"], [46, 55, "MULTI-TISSUE_STRUCTURE"], [5, 14, "ENTITY"], [46, 64, "ENTITY"], [5, 14, "ORGANISM"], [18, 23, "ENTITY"], [32, 42, "ENTITY"], [74, 77, "CHEBI"]]}
{"text": "Deceased patients more often developed tachycardia and tachypnoea ( respiratory rate \u226524 breaths per minute ) ( 56 ( 50 % ) and 66 ( 58 % ) ) than did recovered patients ( 48 ( 30 % ) and 22 ( 14 % ) ) .", "labels": [[142, 151, "ENTITY"], [9, 18, "ORGANISM"], [39, 51, "ENTITY"], [68, 80, "ENTITY"], [0, 9, "ENTITY"], [55, 66, "DISEASE"], [39, 51, "DISEASE"], [9, 18, "ENTITY"], [55, 66, "ENTITY"]]}
{"text": "Deceased patients more often developed tachycardia and tachypnoea ( respiratory rate \u226524 breaths per minute ) ( 56 ( 50 % ) and 66 ( 58 % ) ) than did recovered patients ( 48 ( 30 % ) and 22 ( 14 % ) ) .", "labels": [[142, 151, "ENTITY"], [9, 18, "ORGANISM"], [39, 51, "DISEASE"], [55, 66, "DISEASE"], [68, 80, "ENTITY"], [0, 9, "ENTITY"], [55, 66, "ENTITY"], [39, 51, "ENTITY"], [9, 18, "ENTITY"]]}
{"text": "Other clinical signs such as reduced appetite , increased respiration rate and hunched posture were transient after the initial challenge .", "labels": [[79, 87, "ENTITY"], [6, 21, "ENTITY"], [37, 46, "CHEMICAL"], [37, 46, "ENTITY"], [29, 37, "ENTITY"]]}
{"text": "Median platelet counts were significantly lower in deceased patients", "labels": [[7, 16, "CL"], [0, 7, "ENTITY"], [51, 60, "ENTITY"], [7, 16, "CELL"], [7, 23, "ENTITY"]]}
{"text": "Decreased platelet counts were observed in 25 ( 20.2 % ) patients , prolonged prothrombin time ( PT ) was observed in 77 ( 62.1 % ) patients , fibrinogen ( FIB ) levels were increased in 27 ( 21.8 % ) patients , and D-dimer levels were increased in 26 ( 21.0 % ) patients .", "labels": [[216, 224, "ENTITY"], [57, 68, "ENTITY"], [10, 19, "CL"], [57, 68, "ENTITY"], [68, 78, "GENE_OR_GENE_PRODUCT"], [236, 252, "ORGANISM"], [162, 169, "ENTITY"], [68, 90, "ENTITY"], [10, 26, "ENTITY"], [143, 156, "ENTITY"], [90, 95, "ENTITY"], [57, 68, "PROTEIN"], [236, 252, "ENTITY"], [10, 19, "CELL"], [57, 68, "GENE_OR_GENE_PRODUCT"], [57, 68, "ENTITY"], [0, 10, "ENTITY"], [68, 78, "PROTEIN"]]}
{"text": "Concentrations of alanine aminotransferase , aspartate aminotransferase , total bilirubin , alkaline phosphatase , and \u03b3-glutamyl transpeptidase were markedly higher in deceased patients than in recovered patients", "labels": [[115, 130, "PROTEIN"], [45, 55, "CHEBI"], [90, 101, "PROTEIN"], [18, 43, "PROTEIN"], [195, 205, "ENTITY"], [18, 43, "ENTITY"], [0, 15, "ENTITY"], [115, 130, "ENTITY"], [18, 43, "GENE_OR_GENE_PRODUCT"], [115, 130, "GENE_OR_GENE_PRODUCT"], [74, 80, "CHEMICAL"], [74, 80, "PROTEIN"], [18, 26, "CHEBI"], [45, 55, "GENE_OR_GENE_PRODUCT"], [169, 178, "ORGANISM"], [90, 101, "SIMPLE_CHEMICAL"], [74, 80, "GGP"], [195, 205, "ORGANISM"], [74, 80, "SIMPLE_CHEMICAL"], [72, 80, "ENTITY"], [169, 178, "ENTITY"], [45, 55, "PROTEIN"], [18, 26, "CHEMICAL"], [90, 101, "ENTITY"], [45, 55, "ENTITY"]]}
{"text": "Concentrations of alanine aminotransferase , aspartate aminotransferase , total bilirubin , alkaline phosphatase , and \u03b3-glutamyl transpeptidase were markedly higher in deceased patients than in recovered patients", "labels": [[115, 130, "PROTEIN"], [45, 55, "CHEBI"], [90, 101, "PROTEIN"], [18, 43, "PROTEIN"], [195, 205, "ENTITY"], [18, 43, "ENTITY"], [0, 15, "ENTITY"], [115, 130, "ENTITY"], [18, 43, "GENE_OR_GENE_PRODUCT"], [115, 130, "GENE_OR_GENE_PRODUCT"], [74, 80, "CHEMICAL"], [74, 80, "PROTEIN"], [18, 26, "CHEBI"], [45, 55, "GENE_OR_GENE_PRODUCT"], [169, 178, "ORGANISM"], [90, 101, "SIMPLE_CHEMICAL"], [74, 80, "GGP"], [195, 205, "ORGANISM"], [74, 80, "SIMPLE_CHEMICAL"], [72, 80, "ENTITY"], [169, 178, "ENTITY"], [45, 55, "PROTEIN"], [18, 26, "CHEMICAL"], [90, 101, "ENTITY"], [45, 55, "ENTITY"]]}
{"text": "Concentrations of alanine aminotransferase , aspartate aminotransferase , total bilirubin , alkaline phosphatase , and \u03b3-glutamyl transpeptidase were markedly higher in deceased patients than in recovered patients", "labels": [[115, 130, "ENTITY"], [45, 55, "CHEBI"], [115, 130, "GENE_OR_GENE_PRODUCT"], [90, 101, "PROTEIN"], [18, 43, "PROTEIN"], [115, 130, "PROTEIN"], [195, 205, "ENTITY"], [18, 43, "ENTITY"], [0, 15, "ENTITY"], [18, 43, "GENE_OR_GENE_PRODUCT"], [74, 80, "CHEMICAL"], [74, 80, "PROTEIN"], [18, 26, "CHEBI"], [45, 55, "GENE_OR_GENE_PRODUCT"], [169, 178, "ORGANISM"], [90, 101, "SIMPLE_CHEMICAL"], [74, 80, "GGP"], [195, 205, "ORGANISM"], [74, 80, "SIMPLE_CHEMICAL"], [72, 80, "ENTITY"], [169, 178, "ENTITY"], [45, 55, "PROTEIN"], [18, 26, "CHEMICAL"], [90, 101, "ENTITY"], [45, 55, "ENTITY"]]}
{"text": "Albumin concentrations were significantly lower in deceased patients than in recovered patients .", "labels": [[0, 8, "ENTITY"], [60, 69, "ORGANISM"], [0, 8, "SIMPLE_CHEMICAL"], [8, 23, "ENTITY"], [60, 69, "ENTITY"], [0, 8, "GGP"], [60, 69, "ENTITY"], [77, 87, "ENTITY"], [51, 60, "ENTITY"], [60, 69, "ORGANISM"]]}
{"text": "Albumin concentrations were significantly lower in severe cases than moderate cases , and hypoalbuminemia ( albumin<32g/L ) was more frequent in severe cases ( Table 2 ) .", "labels": [[0, 8, "ENTITY"], [0, 8, "SIMPLE_CHEMICAL"], [8, 23, "ENTITY"], [58, 64, "ENTITY"], [58, 64, "ENTITY"], [69, 78, "ENTITY"], [0, 8, "GGP"], [51, 58, "ENTITY"], [51, 58, "ENTITY"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [24, 38, "CHEBI"], [65, 90, "PROTEIN"], [154, 163, "ORGANISM"], [99, 111, "PROTEIN"], [65, 81, "CHEBI"], [65, 81, "CHEMICAL"], [65, 81, "SIMPLE_CHEMICAL"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [154, 163, "ENTITY"], [144, 154, "ENTITY"], [65, 90, "ENTITY"], [18, 29, "ORGANISM_SUBSTANCE"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Concentrations of hypersensitive cardiac troponin I and N-terminal pro-brain natriuretic peptide were markedly higher in deceased patients ( 40.8 pg/mL and 800.0 pg/mL ) than in recovered patients ( 3.3 pg/mL and 72.0 pg/mL ) , with eight deceased patients having cardiac troponin I above 1000 pg/mL and two above 10 000 pg/mL.", "labels": [[67, 97, "GGP"], [33, 41, "PROTEIN"], [41, 52, "GGP"], [67, 97, "GENE_OR_GENE_PRODUCT"], [121, 130, "ENTITY"], [33, 41, "GGP"], [18, 52, "PROTEIN"], [0, 15, "ENTITY"], [33, 52, "GENE_OR_GENE_PRODUCT"], [178, 188, "ORGANISM"], [121, 130, "ENTITY"], [18, 52, "ENTITY"], [121, 130, "ORGANISM"], [257, 272, "ENTITY"], [56, 97, "ENTITY"], [130, 139, "ENTITY"], [178, 188, "ENTITY"], [257, 272, "GENE_OR_GENE_PRODUCT"], [130, 139, "ORGANISM"]]}
{"text": "Median prothrombin time was significantly longer in deceased patients than in recovered patients , whereas activated partial thromboplastin time was comparable between the two groups .", "labels": [[0, 7, "ENTITY"], [61, 70, "ENTITY"], [52, 61, "ENTITY"], [61, 70, "ORGANISM"], [61, 70, "ENTITY"], [61, 70, "ORGANISM"], [7, 24, "ENTITY"], [7, 19, "PROTEIN"], [7, 19, "GENE_OR_GENE_PRODUCT"], [78, 88, "ENTITY"]]}
{"text": "D-dimer concentrations were markedly greater in deceased patients ( 4.6 \u03bcg/mL ) than in recovered patients ( 0.6 \u03bcg/mL ) .", "labels": [[0, 8, "GGP"], [88, 98, "ENTITY"], [0, 8, "GENE_OR_GENE_PRODUCT"], [48, 57, "ENTITY"], [8, 23, "ENTITY"], [0, 8, "PROTEIN"], [57, 66, "ORGANISM"], [57, 66, "ENTITY"], [88, 98, "ORGANISM"], [0, 8, "ENTITY"]]}
{"text": "Decreased platelet counts were observed in 25 ( 20.2 % ) patients , prolonged prothrombin time ( PT ) was observed in 77 ( 62.1 % ) patients , fibrinogen ( FIB ) levels were increased in 27 ( 21.8 % ) patients , and D-dimer levels were increased in 26 ( 21.0 % ) patients .", "labels": [[57, 68, "ENTITY"], [10, 19, "CL"], [57, 68, "ENTITY"], [10, 26, "ENTITY"], [216, 224, "ENTITY"], [68, 78, "GENE_OR_GENE_PRODUCT"], [236, 252, "ORGANISM"], [162, 169, "ENTITY"], [68, 90, "ENTITY"], [143, 156, "ENTITY"], [57, 68, "PROTEIN"], [90, 95, "ENTITY"], [10, 19, "CELL"], [236, 252, "ENTITY"], [57, 68, "GENE_OR_GENE_PRODUCT"], [57, 68, "ENTITY"], [0, 10, "ENTITY"], [68, 78, "PROTEIN"]]}
{"text": "Concentrations of procalcitonin , high sensitivity C-reactive protein , and ferritin , as well as erythrocyte sedimentation rate , were significantly higher in deceased patients than in recovered patients .", "labels": [[186, 196, "ENTITY"], [51, 62, "PROTEIN"], [160, 169, "ENTITY"], [18, 32, "ENTITY"], [0, 15, "ENTITY"], [186, 196, "ORGANISM"], [18, 32, "PROTEIN"], [18, 32, "GGP"], [18, 32, "GENE_OR_GENE_PRODUCT"], [160, 169, "ORGANISM"], [51, 62, "ENTITY"], [51, 62, "GGP"], [34, 39, "ENTITY"]]}
{"text": "Thyroid stimulating hormone and free triiodothyronine concentrations were significantly lower in deceased patients ( 0.7 mIU/mL and 2.8 pmol/L ) than in recovered patients ( 1.4 mIU/mL and 4.3 pmol/L ) .", "labels": [[37, 54, "ENTITY"], [20, 28, "ENTITY"], [106, 115, "ORGANISM"], [0, 28, "GENE_OR_GENE_PRODUCT"], [153, 163, "ORGANISM"], [37, 54, "SIMPLE_CHEMICAL"], [54, 69, "ENTITY"], [153, 163, "ENTITY"], [97, 106, "ENTITY"], [37, 54, "CHEBI"], [37, 54, "CHEMICAL"], [0, 20, "ENTITY"], [106, 115, "ENTITY"], [20, 28, "CHEBI"], [32, 37, "ENTITY"]]}
{"text": "Thyroid stimulating hormone and free triiodothyronine concentrations were significantly lower in deceased patients ( 0.7 mIU/mL and 2.8 pmol/L ) than in recovered patients ( 1.4 mIU/mL and 4.3 pmol/L ) .", "labels": [[37, 54, "ENTITY"], [20, 28, "ENTITY"], [106, 115, "ORGANISM"], [153, 163, "ORGANISM"], [37, 54, "SIMPLE_CHEMICAL"], [54, 69, "ENTITY"], [153, 163, "ENTITY"], [97, 106, "ENTITY"], [37, 54, "CHEBI"], [37, 54, "CHEMICAL"], [0, 20, "ENTITY"], [0, 28, "GENE_OR_GENE_PRODUCT"], [106, 115, "ENTITY"], [20, 28, "CHEBI"], [32, 37, "ENTITY"]]}
{"text": "Serum circulating immunoglobulin A , immunoglobulin G , and immunoglobulin M did not differ significantly between the two groups , whereas complement 3 and complement 4 concentrations were markedly lower in deceased patients than in recovered patients", "labels": [[0, 35, "PROTEIN"], [189, 198, "ENTITY"], [18, 33, "GENE_OR_GENE_PRODUCT"], [0, 6, "ORGANISM_SUBSTANCE"], [18, 35, "ENTITY"], [207, 216, "ENTITY"], [207, 216, "ORGANISM"], [233, 243, "ENTITY"], [18, 33, "PROTEIN"], [18, 33, "ENTITY"], [6, 18, "ENTITY"], [18, 35, "GENE_OR_GENE_PRODUCT"], [0, 6, "ENTITY"], [233, 243, "ORGANISM"], [56, 75, "GENE_OR_GENE_PRODUCT"], [56, 75, "ENTITY"], [56, 75, "PROTEIN"], [18, 35, "GGP"]]}
{"text": "Serum circulating immunoglobulin A , immunoglobulin G , and immunoglobulin M did not differ significantly between the two groups , whereas complement 3 and complement 4 concentrations were markedly lower in deceased patients than in recovered patients", "labels": [[0, 35, "PROTEIN"], [189, 198, "ENTITY"], [18, 33, "GENE_OR_GENE_PRODUCT"], [0, 6, "ORGANISM_SUBSTANCE"], [18, 35, "ENTITY"], [207, 216, "ENTITY"], [207, 216, "ORGANISM"], [233, 243, "ENTITY"], [18, 33, "PROTEIN"], [18, 33, "ENTITY"], [6, 18, "ENTITY"], [18, 35, "GENE_OR_GENE_PRODUCT"], [0, 6, "ENTITY"], [233, 243, "ORGANISM"], [56, 75, "GENE_OR_GENE_PRODUCT"], [56, 75, "ENTITY"], [56, 75, "PROTEIN"], [18, 35, "GGP"]]}
{"text": "Of patients with available data , concentrations of interleukin 2 receptor , interleukin 6 , interleukin 8 , interleukin 10 , and tumour necrosis factor \u03b1 were significantly higher in deceased patients than in recovered patients .", "labels": [[126, 146, "PROTEIN"], [75, 89, "GENE_OR_GENE_PRODUCT"], [3, 12, "ENTITY"], [52, 66, "PROTEIN"], [75, 89, "PROTEIN"], [184, 193, "ORGANISM"], [75, 89, "ENTITY"], [27, 32, "ENTITY"], [52, 66, "GGP"], [52, 66, "GENE_OR_GENE_PRODUCT"], [75, 89, "GGP"], [202, 210, "ENTITY"], [52, 66, "ENTITY"], [126, 146, "ENTITY"], [184, 193, "ENTITY"], [126, 146, "GENE_OR_GENE_PRODUCT"], [210, 220, "ENTITY"], [210, 220, "ORGANISM"], [174, 184, "ENTITY"], [126, 146, "GGP"], [126, 137, "DISEASE"], [3, 12, "ORGANISM"]]}
{"text": "Consistent with others , most of severe COVID-19 patients in our ICU ward had persistent very high level of erythematosus sedimentation rate ( ESR ) , CRP , and high level of IL-6,TNFa , IL-1B , IL-8 , IL2R , etc , and were associated with ARDS , hypercoagulation and disseminated intravascular coagulation ( DIC ) , manifested as thrombosis , thrombocytopenia , gangrene of extremities .", "labels": [[0, 16, "ENTITY"], [175, 187, "GENE_OR_GENE_PRODUCT"], [328, 344, "ENTITY"], [175, 187, "ENTITY"], [175, 187, "DNA"], [328, 344, "DISEASE"], [99, 108, "GGP"], [65, 69, "ENTITY"], [235, 247, "DISEASE"], [108, 136, "ENTITY"], [344, 363, "ENTITY"], [235, 247, "ENTITY"], [187, 193, "ENTITY"], [99, 108, "DNA"], [187, 193, "GENE_OR_GENE_PRODUCT"], [268, 281, "IMMATERIAL_ANATOMICAL_ENTITY"], [268, 295, "DISEASE"], [99, 108, "ENTITY"], [344, 363, "ORGAN"], [175, 187, "GGP"], [317, 328, "DISEASE"], [94, 99, "ENTITY"], [187, 193, "PROTEIN"], [247, 295, "ENTITY"], [40, 49, "GENE_OR_GENE_PRODUCT"], [215, 224, "ENTITY"], [187, 193, "GGP"], [99, 108, "GENE_OR_GENE_PRODUCT"], [317, 328, "ENTITY"]]}
{"text": "Of patients with available data , concentrations of interleukin 2 receptor , interleukin 6 , interleukin 8 , interleukin 10 , and tumour necrosis factor \u03b1 were significantly higher in deceased patients than in recovered patients .", "labels": [[126, 146, "PROTEIN"], [75, 89, "GENE_OR_GENE_PRODUCT"], [3, 12, "ENTITY"], [52, 66, "PROTEIN"], [75, 89, "PROTEIN"], [184, 193, "ORGANISM"], [75, 89, "ENTITY"], [27, 32, "ENTITY"], [52, 66, "GGP"], [52, 66, "GENE_OR_GENE_PRODUCT"], [75, 89, "GGP"], [202, 210, "ENTITY"], [52, 66, "ENTITY"], [126, 146, "ENTITY"], [184, 193, "ENTITY"], [126, 146, "GENE_OR_GENE_PRODUCT"], [210, 220, "ENTITY"], [210, 220, "ORGANISM"], [174, 184, "ENTITY"], [126, 146, "GGP"], [126, 137, "DISEASE"], [3, 12, "ORGANISM"]]}
{"text": "Forty two ( 86 % ) of 49 deceased patients and 58 ( 50 % ) of 117 recovered patients had proteinuria , and 40 ( 82 % ) of 49 deceased patients and 44 ( 38 % ) of 117 recovered patients showed microscopic haematuria .", "labels": [[15, 22, "ENTITY"], [176, 192, "ENTITY"], [76, 89, "ENTITY"], [76, 89, "DISEASE"], [66, 76, "ENTITY"], [59, 66, "ENTITY"], [66, 76, "ORGANISM"], [25, 34, "ENTITY"], [25, 34, "ORGANISM"], [152, 162, "ENTITY"]]}
{"text": "Forty two ( 86 % ) of 49 deceased patients and 58 ( 50 % ) of 117 recovered patients had proteinuria , and 40 ( 82 % ) of 49 deceased patients and 44 ( 38 % ) of 117 recovered patients showed microscopic haematuria .", "labels": [[15, 22, "ENTITY"], [176, 192, "ENTITY"], [76, 89, "ENTITY"], [76, 89, "DISEASE"], [66, 76, "ENTITY"], [59, 66, "ENTITY"], [66, 76, "ORGANISM"], [25, 34, "ENTITY"], [25, 34, "ORGANISM"], [152, 162, "ENTITY"]]}
{"text": "Moreover , all the deceased patients and 14 ( 44 % ) recovered patients had an arterial partial pressure of oxygen to fraction of inspired oxygen ratio of 300 , indicating that these patients had developed acute respiratory distress syndrome , whereas severe acute respiratory distress syndrome ( \u2264100 ) developed only in deceased patients ( 16 ; 46 % ) .", "labels": [[252, 286, "ENTITY"], [19, 28, "ORGANISM"], [196, 233, "DISEASE"], [76, 96, "ENTITY"], [127, 146, "ENTITY"], [19, 28, "ENTITY"], [130, 139, "CHEMICAL"], [196, 233, "ENTITY"], [53, 63, "ENTITY"], [314, 322, "ENTITY"], [130, 139, "CHEBI"], [53, 63, "ORGANISM"], [130, 139, "SIMPLE_CHEMICAL"], [206, 233, "DISEASE"]]}
{"text": "Actual bicarbonate and total carbon dioxide concentration were markedly lower in deceased patients than in recovered patients .", "labels": [[29, 44, "CHEMICAL"], [81, 90, "ENTITY"], [44, 58, "ENTITY"], [0, 7, "ENTITY"], [107, 117, "ENTITY"], [7, 19, "CHEBI"], [90, 99, "ORGANISM"], [29, 44, "CHEBI"], [90, 99, "ORGANISM"], [90, 99, "ENTITY"], [72, 78, "ENTITY"], [9, 16, "ENTITY"], [7, 19, "CHEMICAL"], [7, 19, "ENTITY"], [7, 19, "SIMPLE_CHEMICAL"], [90, 99, "ENTITY"]]}
{"text": "Actual bicarbonate and total carbon dioxide concentration were markedly lower in deceased patients than in recovered patients .", "labels": [[81, 90, "ENTITY"], [44, 58, "ENTITY"], [0, 7, "ENTITY"], [107, 117, "ENTITY"], [7, 19, "CHEBI"], [90, 99, "ORGANISM"], [90, 99, "ORGANISM"], [90, 99, "ENTITY"], [72, 78, "ENTITY"], [29, 44, "CHEBI"], [9, 16, "ENTITY"], [7, 19, "CHEMICAL"], [7, 19, "ENTITY"], [29, 44, "CHEMICAL"], [7, 19, "SIMPLE_CHEMICAL"], [90, 99, "ENTITY"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ENTITY"], [133, 141, "DISEASE"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [335, 352, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "One patient who died developed gastrointestinal bleeding .", "labels": [[31, 48, "ORGAN"], [4, 12, "ENTITY"], [31, 57, "ENTITY"], [4, 12, "ORGANISM"], [16, 21, "ENTITY"], [31, 57, "DISEASE"]]}
{"text": "Fewer deceased patients ( 25 ; 22 % ) than recovered patients ( 64 ; 40 % ) received interferon \u03b1 inhalation treatment .", "labels": [[76, 85, "ENTITY"], [6, 15, "ENTITY"], [76, 85, "PROTEIN"], [43, 53, "ENTITY"], [15, 24, "ORGANISM"], [85, 98, "ENTITY"], [15, 24, "ENTITY"], [43, 53, "ORGANISM"], [98, 109, "ENTITY"]]}
{"text": "At least one abnormal chest CT manifestation ( including ground-glass opacities , pulmonary infiltrates and interstitial disorders ) was identified in more than 70 % of patients .", "labels": [[57, 70, "ENTITY"], [104, 121, "DISEASE"], [80, 92, "MULTI-TISSUE_STRUCTURE"], [28, 31, "PROTEIN"], [13, 22, "ENTITY"], [22, 31, "ENTITY"], [80, 92, "ENTITY"], [31, 45, "ENTITY"], [104, 121, "ENTITY"]]}
{"text": "Interstitial lung abnormalities were observed in chest computed tomography ( CT ) scans of all patients on admission", "labels": [[0, 32, "ENTITY"], [0, 32, "DISEASE"], [0, 18, "TISSUE"], [49, 75, "ENTITY"], [49, 55, "TISSUE"]]}
{"text": "At least one abnormal chest CT manifestation ( including ground-glass opacities , pulmonary infiltrates and interstitial disorders ) was identified in more than 70 % of patients .", "labels": [[80, 92, "MULTI-TISSUE_STRUCTURE"], [57, 70, "ENTITY"], [28, 31, "PROTEIN"], [80, 92, "ENTITY"], [13, 22, "ENTITY"], [22, 31, "ENTITY"], [104, 121, "DISEASE"], [104, 121, "ENTITY"], [31, 45, "ENTITY"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [259, 269, "ORGAN"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [259, 269, "ORGAN"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Compared to moderate cases , chest tightness tended to be more common in severe cases . In addition , tachypnea and dyspnea were only developed in severe cases .", "labels": [[29, 35, "DISEASE"], [21, 27, "ENTITY"], [73, 80, "ENTITY"], [0, 9, "ENTITY"], [12, 21, "ENTITY"], [29, 35, "ENTITY"]]}
{"text": "Compared with normal range , the whole blood count on admission of three ( 30 % ) moderatevcases showed mild leucopenia , while white blood cell ( WBC ) counts were normal or slightly increased above the upper limit of normal ( ULN ) in all the severe cases ( Table 2 ) .", "labels": [[140, 145, "ENTITY"], [14, 27, "ENTITY"], [128, 140, "CELL"], [140, 145, "PROTEIN"], [97, 109, "ENTITY"], [122, 140, "ENTITY"], [104, 109, "DISEASE"], [140, 145, "SIMPLE_CHEMICAL"], [33, 45, "ENTITY"], [175, 184, "ENTITY"], [0, 9, "ENTITY"], [122, 140, "CELL_TYPE"], [128, 140, "CL"], [147, 153, "ENTITY"]]}
{"text": "Compared with normal range , the whole blood count on admission of three ( 30 % ) moderatevcases showed mild leucopenia , while white blood cell ( WBC ) counts were normal or slightly increased above the upper limit of normal ( ULN ) in all the severe cases ( Table 2 ) .", "labels": [[140, 145, "ENTITY"], [14, 27, "ENTITY"], [128, 140, "CELL"], [140, 145, "PROTEIN"], [97, 109, "ENTITY"], [122, 140, "ENTITY"], [104, 109, "DISEASE"], [140, 145, "SIMPLE_CHEMICAL"], [33, 45, "ENTITY"], [175, 184, "ENTITY"], [0, 9, "ENTITY"], [122, 140, "CELL_TYPE"], [128, 140, "CL"], [147, 153, "ENTITY"]]}
{"text": "The common clinical manifestations of fever and cough in conjunction with laboratory results of progressively increasing neutrophil counts and leukocytopenia in serum samples taken from COVID-19 patients at various stages of the illness indicates uncontrolled neutrophil extravasation and activation 11,12 .", "labels": [[121, 132, "CL"], [195, 204, "ENTITY"], [229, 237, "ENTITY"], [121, 132, "ENTITY"], [186, 195, "ENTITY"], [57, 69, "ENTITY"], [132, 139, "ENTITY"], [38, 44, "ENTITY"], [143, 158, "ENTITY"], [260, 285, "ENTITY"], [121, 132, "CELL"], [121, 132, "CELL"], [11, 35, "ENTITY"], [186, 204, "ORGANISM"], [247, 260, "ENTITY"], [74, 93, "ENTITY"], [121, 132, "CL"], [48, 54, "ENTITY"], [110, 121, "ENTITY"], [121, 132, "CELL_TYPE"], [38, 44, "DISEASE"], [161, 175, "ORGANISM_SUBSTANCE"], [289, 300, "ENTITY"], [121, 132, "CELL_TYPE"], [161, 175, "ENTITY"], [215, 222, "ENTITY"], [143, 158, "DISEASE"], [48, 54, "DISEASE"]]}
{"text": "Albumin concentrations were significantly lower in severe cases than moderate cases , and hypoalbuminemia ( albumin<32g/L ) was more frequent in severe cases ( Table 2 ) .", "labels": [[0, 8, "SIMPLE_CHEMICAL"], [0, 8, "ENTITY"], [8, 23, "ENTITY"], [58, 64, "ENTITY"], [58, 64, "ENTITY"], [69, 78, "ENTITY"], [51, 58, "ENTITY"], [0, 8, "GGP"], [51, 58, "ENTITY"]]}
{"text": "Levels of lactate dehydrogenase ( LDH ) , concentrations of serum high-sensitivity C-reactive protein ( hsCRP ) , ferritin and D-dimer levels were markedly higher in severe cases than moderate cases .", "labels": [[10, 18, "CHEMICAL"], [129, 137, "ENTITY"], [59, 96, "PROTEIN"], [149, 158, "ENTITY"], [0, 7, "ENTITY"], [10, 32, "GGP"], [10, 32, "PROTEIN"], [158, 168, "ENTITY"], [62, 96, "ENTITY"], [10, 32, "ENTITY"], [68, 96, "GGP"], [168, 175, "ENTITY"], [10, 32, "GENE_OR_GENE_PRODUCT"], [186, 195, "ENTITY"]]}
{"text": "Moreover , the frequencies of regulatory T cells ( the frequencies of regulatory T cells ) ( CD4+CD25+CD127low+ ) and CD45RA+the frequencies of regulatory T cells were reduced ( below LLN ) in nearly all the severe and moderate cases , with CD45RA+the frequencies of regulatory T cells proportion was markedly lower in severe cases ( 0.5 % ) than in moderate cases ( 1.1 % ) .", "labels": [[30, 43, "CL"], [15, 30, "PROTEIN"], [43, 49, "ENTITY"], [-1, 10, "ENTITY"], [15, 30, "GENE_OR_GENE_PRODUCT"], [30, 43, "ENTITY"], [114, 129, "ENTITY"], [30, 43, "ENTITY"], [-1, 5, "CELL"], [-1, 11, "ENTITY"], [155, 164, "ENTITY"], [-1, 11, "PROTEIN"], [15, 30, "ENTITY"], [15, 30, "ENTITY"], [104, 114, "ENTITY"], [-1, 5, "ENTITY"], [30, 43, "CELL_TYPE"], [-1, 11, "GENE_OR_GENE_PRODUCT"], [104, 114, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The reduced expressions of interferon-\u03b3 ( IFN-\u03b3 ) by CD4+T , CD8+T and NK cells below LLN were observed in some patients with severe ( 50 % , 16.7 % and 16.7 % ) or moderate COVID-19 ( 14.3 % , 0 % and 14.3 % ) .", "labels": [[27, 40, "ENTITY"], [165, 174, "ENTITY"], [27, 40, "GENE_OR_GENE_PRODUCT"], [4, 12, "ENTITY"], [27, 40, "PROTEIN"], [165, 174, "GENE_OR_GENE_PRODUCT"], [67, 74, "ENTITY"], [67, 74, "CELL"], [12, 24, "ENTITY"], [67, 74, "CL"], [153, 165, "ENTITY"]]}
{"text": "We know that angiotensin converting enzyme is involved in corona virus infection . Pathogenic coronaviruses ( severe acute respiratory syndrome coronavirus [ SARS-CoV ] and SARS-CoV-2 ) bind to their target cells through angiotensin-converting enzyme 2 ( ACE2 ) , [ 3,4 ] .", "labels": [[221, 244, "SO"], [244, 253, "GENE_OR_GENE_PRODUCT"], [36, 43, "ENTITY"], [200, 207, "CELL"], [244, 253, "PROTEIN"], [58, 71, "SIMPLE_CHEMICAL"], [200, 207, "ENTITY"], [213, 244, "ENTITY"], [13, 43, "PROTEIN"], [13, 25, "CHEMICAL"], [65, 81, "DISEASE"], [213, 244, "GENE_OR_GENE_PRODUCT"], [65, 71, "TAXON"], [200, 207, "CL"], [244, 253, "ENTITY"], [244, 253, "GGP"], [13, 43, "GGP"], [194, 207, "CELL_TYPE"], [117, 135, "DISEASE"], [135, 144, "ORGANISM"], [13, 25, "ENTITY"], [58, 81, "ENTITY"], [213, 244, "PROTEIN"], [173, 186, "ENTITY"], [83, 94, "ENTITY"], [25, 36, "ENTITY"], [110, 144, "ENTITY"]]}
{"text": "It should also be noted that the two Asian countries which were initially severely hit by the virus , China and Korea , are also characterized by low D allele frequencies .", "labels": [[143, 159, "ENTITY"], [94, 100, "TAXON"], [74, 83, "ENTITY"], [37, 43, "ENTITY"], [43, 53, "ENTITY"], [94, 100, "ENTITY"]]}
{"text": "These data suggest that ACE1 D/I polymorphism may be regarded as a confounder in the spread of COVID-19 and the outcome of the infection in various European populations . These findings are in agreement with the role of ACE in pulmonary infections caused by coronaviruses [ 4 ] .", "labels": [[24, 33, "ENTITY"], [29, 33, "CHEMICAL"], [67, 78, "ENTITY"], [148, 169, "ENTITY"], [6, 11, "ENTITY"], [112, 120, "ENTITY"], [127, 137, "ENTITY"], [85, 92, "ENTITY"], [95, 104, "PROTEIN"], [95, 104, "ENTITY"], [148, 169, "CELL_LINE"], [95, 104, "DISEASE"], [33, 46, "ENTITY"], [227, 237, "ENTITY"], [227, 237, "DISEASE"], [95, 104, "GENE_OR_GENE_PRODUCT"], [258, 274, "ORGANISM"], [24, 29, "GENE_OR_GENE_PRODUCT"], [127, 137, "DISEASE"]]}
{"text": "These data suggest that ACE1 D/I polymorphism may be regarded as a confounder in the spread of COVID-19 and the outcome of the infection in various European populations . These findings are in agreement with the role of ACE in pulmonary infections caused by coronaviruses [ 4 ] .", "labels": [[29, 33, "CHEMICAL"], [67, 78, "ENTITY"], [148, 169, "ENTITY"], [6, 11, "ENTITY"], [112, 120, "ENTITY"], [127, 137, "ENTITY"], [85, 92, "ENTITY"], [95, 104, "PROTEIN"], [24, 29, "GENE_OR_GENE_PRODUCT"], [95, 104, "ENTITY"], [148, 169, "CELL_LINE"], [95, 104, "DISEASE"], [33, 46, "ENTITY"], [227, 237, "ENTITY"], [227, 237, "DISEASE"], [95, 104, "GENE_OR_GENE_PRODUCT"], [258, 274, "ORGANISM"], [24, 33, "ENTITY"], [127, 137, "DISEASE"]]}
{"text": "In our opinion , during the COVID-19 pandemic , it would be more prudent to replace these drugs , when possible , with calcium channel blockers , adrenergic receptor blockers , diuretics or vasodilators .", "labels": [[114, 135, "ENTITY"], [135, 166, "ENTITY"], [135, 146, "SIMPLE_CHEMICAL"], [135, 146, "ENTITY"], [7, 15, "ENTITY"], [177, 190, "CHEBI"], [114, 127, "CHEBI"], [28, 37, "ENTITY"], [177, 190, "ENTITY"], [135, 166, "GENE_OR_GENE_PRODUCT"], [135, 157, "CHEBI"], [135, 146, "CHEBI"], [114, 135, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In our opinion , during the COVID-19 pandemic , it would be more prudent to replace these drugs , when possible , with calcium channel blockers , adrenergic receptor blockers , diuretics or vasodilators .", "labels": [[135, 166, "ENTITY"], [7, 15, "ENTITY"], [177, 190, "CHEBI"], [114, 135, "ENTITY"], [114, 127, "CHEBI"], [28, 37, "ENTITY"], [177, 190, "ENTITY"], [135, 146, "ENTITY"], [135, 166, "GENE_OR_GENE_PRODUCT"], [114, 135, "GENE_OR_GENE_PRODUCT"], [135, 157, "CHEBI"], [135, 146, "SIMPLE_CHEMICAL"], [135, 146, "CHEBI"]]}
{"text": "In our opinion , during the COVID-19 pandemic , it would be more prudent to replace these drugs , when possible , with calcium channel blockers , adrenergic receptor blockers , diuretics or vasodilators .", "labels": [[135, 166, "ENTITY"], [7, 15, "ENTITY"], [114, 135, "ENTITY"], [114, 127, "CHEBI"], [28, 37, "ENTITY"], [135, 166, "GENE_OR_GENE_PRODUCT"], [135, 146, "ENTITY"], [135, 146, "SIMPLE_CHEMICAL"], [114, 135, "GENE_OR_GENE_PRODUCT"], [135, 157, "CHEBI"], [177, 190, "ENTITY"], [135, 146, "CHEBI"], [177, 190, "CHEBI"]]}
{"text": "In our opinion , during the COVID-19 pandemic , it would be more prudent to replace these drugs , when possible , with calcium channel blockers , adrenergic receptor blockers , diuretics or vasodilators .", "labels": [[135, 166, "ENTITY"], [7, 15, "ENTITY"], [177, 190, "CHEBI"], [114, 135, "ENTITY"], [114, 127, "CHEBI"], [28, 37, "ENTITY"], [177, 190, "ENTITY"], [135, 146, "ENTITY"], [135, 166, "GENE_OR_GENE_PRODUCT"], [114, 135, "GENE_OR_GENE_PRODUCT"], [135, 157, "CHEBI"], [135, 146, "SIMPLE_CHEMICAL"], [135, 146, "CHEBI"]]}
{"text": "Accumulating evidence revealed that a part of severe COVID-19 patients have a elevated cytokine profile resembling CS in SARS and MERS .", "labels": [[13, 22, "ENTITY"], [87, 96, "PROTEIN"], [53, 62, "ENTITY"], [53, 71, "ORGANISM"], [87, 104, "ENTITY"], [0, 13, "ENTITY"], [53, 62, "DISEASE"], [46, 53, "ENTITY"], [115, 118, "ENTITY"], [121, 126, "DISEASE"], [121, 126, "ENTITY"], [62, 71, "ENTITY"], [78, 87, "ENTITY"], [130, 135, "DISEASE"], [130, 135, "ENTITY"]]}
{"text": "They measured cytokine levels in 41 inpatients ( including 13 ICU patients and 28 non ICU patients ) , IL-1B , IL-1RA , IL-7 , IL-8 , IL-9 , IL-10 , fibroblast growth factor ( FGF ) , granulocyte-macrophage colony stimulating factor ( GM-CSF ) , IFN\u03b3 , granulocyte-colony stimulating factor ( G-CSF ) , interferon-\u03b3-inducible protein ( IP10 ) , monocyte chemoattractant protein ( MCP1 ) , macrophage inflammatory protein 1 alpha ( macrophage inflammatory protein 1 alpha ) , platelet derived growth factor ( PDGF ) , tumor necrosis factor ( TNF\u03b1 ) , vascular endothelial growth factor ( VEGF ) were increased , among which IL-2 , IL-7 , IL-10 , G-CSF , IP10 , MCP1 , macrophage inflammatory protein 1 alpha , TNF\u03b1 were h igher in severe patients[3 , 4 ] .", "labels": [[303, 354, "GENE_OR_GENE_PRODUCT"], [134, 139, "ENTITY"], [214, 226, "ENTITY"], [167, 184, "CL"], [14, 30, "ENTITY"], [303, 354, "ENTITY"], [36, 47, "ENTITY"], [134, 139, "PROTEIN"], [354, 400, "ENTITY"], [127, 132, "CHEMICAL"], [214, 226, "PROTEIN"], [413, 423, "CL"], [167, 214, "GENE_OR_GENE_PRODUCT"], [235, 253, "CHEMICAL"], [134, 139, "GGP"], [167, 176, "GENE_OR_GENE_PRODUCT"], [14, 23, "PROTEIN"], [160, 167, "CHEMICAL"], [167, 214, "ENTITY"], [160, 167, "ENTITY"], [167, 176, "ENTITY"], [118, 127, "ENTITY"], [214, 226, "CHEMICAL"], [103, 111, "CHEMICAL"], [413, 431, "PROTEIN"], [284, 303, "ENTITY"], [120, 125, "GENE_OR_GENE_PRODUCT"], [103, 111, "GGP"], [141, 160, "GENE_OR_GENE_PRODUCT"], [483, 489, "ENTITY"], [127, 132, "ENTITY"], [519, 528, "ENTITY"], [141, 160, "GGP"], [483, 489, "GENE_OR_GENE_PRODUCT"], [160, 167, "GGP"], [111, 120, "GENE_OR_GENE_PRODUCT"], [528, 540, "ENTITY"], [127, 132, "GGP"], [141, 160, "PROTEIN"], [214, 226, "GENE_OR_GENE_PRODUCT"], [284, 303, "GENE_OR_GENE_PRODUCT"], [196, 207, "ENTITY"], [519, 528, "GENE_OR_GENE_PRODUCT"], [354, 400, "GGP"], [556, 561, "GGP"], [528, 540, "GENE_OR_GENE_PRODUCT"], [354, 400, "GENE_OR_GENE_PRODUCT"], [127, 132, "GENE_OR_GENE_PRODUCT"], [556, 561, "GENE_OR_GENE_PRODUCT"], [111, 120, "ENTITY"], [167, 214, "PROTEIN"], [-1, 32, "PROTEIN"], [5, 14, "ENTITY"], [120, 125, "GGP"], [-1, 32, "ENTITY"], [586, 597, "ENTITY"], [303, 354, "PROTEIN"], [214, 226, "GGP"], [235, 272, "PROTEIN"], [103, 111, "ENTITY"], [400, 423, "DISEASE"], [120, 125, "PROTEIN"], [483, 489, "GGP"], [235, 272, "ENTITY"], [111, 120, "PROTEIN"], [450, 483, "ENTITY"], [303, 354, "CL"], [134, 139, "GENE_OR_GENE_PRODUCT"], [36, 47, "ORGANISM"], [-1, 32, "GGP"], [167, 174, "PROTEIN"], [167, 174, "GENE_OR_GENE_PRODUCT"], [284, 303, "PROTEIN"], [235, 272, "GGP"], [235, 272, "GENE_OR_GENE_PRODUCT"], [160, 167, "GENE_OR_GENE_PRODUCT"], [167, 174, "ENTITY"], [167, 176, "PROTEIN"], [450, 483, "CL"], [127, 132, "PROTEIN"], [483, 489, "PROTEIN"], [519, 528, "PROTEIN"], [160, 167, "PROTEIN"], [141, 160, "ENTITY"], [-1, 32, "GENE_OR_GENE_PRODUCT"], [103, 111, "PROTEIN"], [-1, 28, "GENE_OR_GENE_PRODUCT"], [413, 423, "ENTITY"], [528, 540, "PROTEIN"], [120, 125, "ENTITY"], [556, 561, "ENTITY"], [167, 174, "GGP"], [556, 561, "PROTEIN"], [103, 111, "GENE_OR_GENE_PRODUCT"], [528, 540, "GGP"], [167, 176, "ENTITY"], [354, 400, "PROTEIN"]]}
{"text": "Consistent with others , most of severe COVID-19 patients in our ICU ward had persistent very high level of erythematosus sedimentation rate ( ESR ) , CRP , and high level of IL-6,TNFa , IL-1B , IL-8 , IL2R , etc , and were associated with ARDS , hypercoagulation and disseminated intravascular coagulation ( DIC ) , manifested as thrombosis , thrombocytopenia , gangrene of extremities .", "labels": [[0, 16, "ENTITY"], [175, 187, "GENE_OR_GENE_PRODUCT"], [328, 344, "ENTITY"], [175, 187, "ENTITY"], [175, 187, "DNA"], [328, 344, "DISEASE"], [99, 108, "GGP"], [65, 69, "ENTITY"], [235, 247, "DISEASE"], [108, 136, "ENTITY"], [344, 363, "ENTITY"], [235, 247, "ENTITY"], [187, 193, "ENTITY"], [99, 108, "DNA"], [187, 193, "GENE_OR_GENE_PRODUCT"], [268, 281, "IMMATERIAL_ANATOMICAL_ENTITY"], [268, 295, "DISEASE"], [99, 108, "ENTITY"], [344, 363, "ORGAN"], [175, 187, "GGP"], [317, 328, "DISEASE"], [94, 99, "ENTITY"], [187, 193, "PROTEIN"], [247, 295, "ENTITY"], [40, 49, "GENE_OR_GENE_PRODUCT"], [215, 224, "ENTITY"], [187, 193, "GGP"], [99, 108, "GENE_OR_GENE_PRODUCT"], [317, 328, "ENTITY"]]}
{"text": "Consistent with others , most of severe COVID-19 patients in our ICU ward had persistent very high level of erythematosus sedimentation rate ( ESR ) , CRP , and high level of IL-6,TNFa , IL-1B , IL-8 , IL2R , etc , and were associated with ARDS , hypercoagulation and disseminated intravascular coagulation ( DIC ) , manifested as thrombosis , thrombocytopenia , gangrene of extremities .", "labels": [[0, 16, "ENTITY"], [268, 295, "DISEASE"], [175, 187, "GENE_OR_GENE_PRODUCT"], [328, 344, "ENTITY"], [175, 187, "ENTITY"], [175, 187, "DNA"], [328, 344, "DISEASE"], [99, 108, "GGP"], [65, 69, "ENTITY"], [235, 247, "DISEASE"], [108, 136, "ENTITY"], [344, 363, "ENTITY"], [235, 247, "ENTITY"], [187, 193, "ENTITY"], [99, 108, "DNA"], [187, 193, "GENE_OR_GENE_PRODUCT"], [268, 281, "IMMATERIAL_ANATOMICAL_ENTITY"], [99, 108, "ENTITY"], [344, 363, "ORGAN"], [175, 187, "GGP"], [317, 328, "DISEASE"], [94, 99, "ENTITY"], [187, 193, "PROTEIN"], [40, 49, "GENE_OR_GENE_PRODUCT"], [215, 224, "ENTITY"], [187, 193, "GGP"], [99, 108, "GENE_OR_GENE_PRODUCT"], [317, 328, "ENTITY"], [247, 295, "ENTITY"]]}
{"text": "Both T cells and NK cells in patients with COVID-19 were reduced .", "labels": [[17, 26, "CL"], [5, 13, "CL"], [17, 26, "CELL_TYPE"], [57, 65, "ENTITY"], [43, 52, "ENTITY"], [29, 38, "ORGANISM"], [17, 26, "CELL"], [5, 13, "CELL"], [17, 26, "ENTITY"], [5, 13, "CELL_TYPE"], [5, 13, "ENTITY"], [43, 52, "SIMPLE_CHEMICAL"], [29, 38, "ENTITY"]]}
{"text": "Both T cells and NK cells in patients with COVID-19 were reduced .", "labels": [[17, 26, "CL"], [5, 13, "CL"], [17, 26, "CELL_TYPE"], [43, 52, "ENTITY"], [57, 65, "ENTITY"], [17, 26, "CELL"], [29, 38, "ORGANISM"], [5, 13, "CELL"], [17, 26, "ENTITY"], [5, 13, "CELL_TYPE"], [5, 13, "ENTITY"], [43, 52, "SIMPLE_CHEMICAL"], [29, 38, "ENTITY"]]}
{"text": "Spleen atrophy was observed in all reported cases with decreased numbers of lymphocyte , and significant cell degeneration , focal hemorrhagic necrosis , macrophage proliferation and macrophage phagocytosis were found in spleen .", "labels": [[76, 87, "CELL"], [65, 73, "ENTITY"], [123, 143, "ENTITY"], [0, 15, "DISEASE"], [0, 7, "ORGAN"], [55, 65, "ENTITY"], [76, 87, "CELL_TYPE"], [0, 15, "ENTITY"], [105, 110, "ENTITY"], [154, 165, "ENTITY"], [76, 87, "CL"], [105, 110, "DISEASE"], [123, 143, "DISEASE"], [44, 50, "ENTITY"], [152, 165, "ENTITY"], [76, 87, "ENTITY"]]}
{"text": "Spleen atrophy was observed in all reported cases with decreased numbers of lymphocyte , and significant cell degeneration , focal hemorrhagic necrosis , macrophage proliferation and macrophage phagocytosis were found in spleen .", "labels": [[76, 87, "CELL"], [65, 73, "ENTITY"], [123, 143, "ENTITY"], [0, 15, "DISEASE"], [0, 7, "ORGAN"], [55, 65, "ENTITY"], [76, 87, "CELL_TYPE"], [0, 15, "ENTITY"], [123, 143, "DISEASE"], [105, 110, "ENTITY"], [154, 165, "ENTITY"], [76, 87, "CL"], [105, 110, "DISEASE"], [152, 165, "ENTITY"], [44, 50, "ENTITY"], [76, 87, "ENTITY"]]}
{"text": "Spleen atrophy was observed in all reported cases with decreased numbers of lymphocyte , and significant cell degeneration , focal hemorrhagic necrosis , macrophage proliferation and macrophage phagocytosis were found in spleen .", "labels": [[76, 87, "CELL"], [65, 73, "ENTITY"], [123, 143, "ENTITY"], [0, 15, "DISEASE"], [0, 7, "ORGAN"], [55, 65, "ENTITY"], [76, 87, "CELL_TYPE"], [0, 15, "ENTITY"], [105, 110, "ENTITY"], [154, 165, "ENTITY"], [76, 87, "CL"], [105, 110, "DISEASE"], [123, 143, "DISEASE"], [44, 50, "ENTITY"], [152, 165, "ENTITY"], [76, 87, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Similarly , lymph node atrophy and the number of lymph nodes decreased , accompanied by necrosis .", "labels": [[12, 23, "DISEASE"], [12, 18, "MULTI-TISSUE_STRUCTURE"], [12, 23, "ENTITY"], [12, 18, "MULTI-TISSUE_STRUCTURE"], [12, 18, "ENTITY"]]}
{"text": "Immunohistochemical staining showed that CD4+T cells and CD8+T cells were decreased in spleen and lymph nodes [ 13 ] .", "labels": [[98, 110, "ENTITY"], [74, 84, "ENTITY"], [87, 94, "ORGAN"], [41, 53, "ENTITY"], [57, 69, "CELL"], [98, 110, "MULTI-TISSUE_STRUCTURE"], [57, 69, "CELL_TYPE"], [41, 53, "CELL"], [0, 29, "ENTITY"], [87, 94, "ENTITY"], [41, 53, "CL"], [57, 69, "CL"], [57, 69, "ENTITY"], [41, 53, "CELL_TYPE"]]}
{"text": "Immunohistochemical staining showed that CD4+T cells and CD8+T cells were decreased in spleen and lymph nodes [ 13 ] .", "labels": [[98, 110, "ENTITY"], [87, 94, "ORGAN"], [41, 53, "ENTITY"], [57, 69, "CELL"], [98, 110, "MULTI-TISSUE_STRUCTURE"], [57, 69, "CELL_TYPE"], [41, 53, "CELL"], [0, 29, "ENTITY"], [74, 84, "ENTITY"], [87, 94, "ENTITY"], [41, 53, "CL"], [57, 69, "CL"], [57, 69, "ENTITY"], [41, 53, "CELL_TYPE"]]}
{"text": "In addition , in the lung with characteristic diffused alveolar damage ( DAD ) , the major infiltrated cells were monocytes and macrophages , moderate multinucleated giant cells , but very few lymphocytes .", "labels": [[128, 142, "ENTITY"], [184, 193, "CELL_TYPE"], [55, 64, "ENTITY"], [91, 103, "CELL"], [142, 172, "CELL"], [184, 193, "CELL"], [184, 193, "ENTITY"], [184, 193, "CL"], [81, 103, "CELL_TYPE"], [85, 91, "ENTITY"], [166, 172, "CL"], [91, 103, "CL"], [142, 172, "ENTITY"], [91, 103, "ENTITY"]]}
{"text": "Importantly , virus inclusion bodies can still be detected in type II alveolar epithelia and macrophages , despite that the PCR test was negative in blood or throat swabs [ 10 , 12 , 14 ] .", "labels": [[14, 30, "TAXON"], [62, 79, "ENTITY"], [62, 79, "CANCER"], [155, 165, "ENTITY"], [120, 128, "ENTITY"], [155, 165, "CANCER"]]}
{"text": "Clinically , many critical ill patients have vasculitis-like manifestations , or even gangrene at their extremities ; Pathology examination revealed the blood vessels of alveolar septum were congested and edematous , with modest infiltration of monocytes and lymphocytes within and around blood vessels .", "labels": [[282, 295, "MULTI-TISSUE_STRUCTURE"], [149, 159, "MULTI-TISSUE_STRUCTURE"], [0, 11, "ENTITY"], [282, 295, "ENTITY"], [18, 27, "ENTITY"], [167, 179, "TISSUE"], [116, 128, "ENTITY"], [149, 159, "ENTITY"], [222, 229, "ENTITY"], [167, 179, "ENTITY"], [45, 61, "ENTITY"]]}
{"text": "Clinically , many critical ill patients have vasculitis-like manifestations , or even gangrene at their extremities ; Pathology examination revealed the blood vessels of alveolar septum were congested and edematous , with modest infiltration of monocytes and lymphocytes within and around blood vessels .", "labels": [[282, 295, "MULTI-TISSUE_STRUCTURE"], [149, 159, "MULTI-TISSUE_STRUCTURE"], [0, 11, "ENTITY"], [282, 295, "ENTITY"], [18, 27, "ENTITY"], [167, 179, "TISSUE"], [116, 128, "ENTITY"], [222, 229, "ENTITY"], [167, 179, "ENTITY"], [45, 61, "ENTITY"], [149, 159, "ENTITY"]]}
{"text": "Small vessels showed hyperplasia , vessel wall thickening , lumen stenosis , occlusion and focal hemorrhage .", "labels": [[0, 14, "MULTI-TISSUE_STRUCTURE"], [0, 14, "ENTITY"], [35, 47, "ENTITY"], [6, 13, "MULTI-TISSUE_STRUCTURE"], [87, 97, "ENTITY"], [21, 33, "DISEASE"], [21, 33, "ENTITY"], [58, 66, "ENTITY"], [21, 33, "CANCER"], [75, 97, "DISEASE"], [58, 66, "DISEASE"]]}
{"text": "Small vessels showed hyperplasia , vessel wall thickening , lumen stenosis , occlusion and focal hemorrhage .", "labels": [[0, 14, "MULTI-TISSUE_STRUCTURE"], [21, 33, "DISEASE"], [0, 14, "ENTITY"], [35, 47, "ENTITY"], [6, 13, "MULTI-TISSUE_STRUCTURE"], [87, 97, "ENTITY"], [58, 66, "ENTITY"], [75, 97, "DISEASE"], [21, 33, "ENTITY"], [58, 66, "DISEASE"], [21, 33, "CANCER"]]}
{"text": "Small vessels showed hyperplasia , vessel wall thickening , lumen stenosis , occlusion and focal hemorrhage .", "labels": [[0, 14, "MULTI-TISSUE_STRUCTURE"], [21, 33, "DISEASE"], [0, 14, "ENTITY"], [35, 47, "ENTITY"], [6, 13, "MULTI-TISSUE_STRUCTURE"], [87, 97, "ENTITY"], [58, 66, "ENTITY"], [75, 97, "DISEASE"], [21, 33, "ENTITY"], [58, 66, "DISEASE"], [21, 33, "CANCER"]]}
{"text": "Small vessels showed hyperplasia , vessel wall thickening , lumen stenosis , occlusion and focal hemorrhage .", "labels": [[0, 14, "MULTI-TISSUE_STRUCTURE"], [21, 33, "DISEASE"], [0, 14, "ENTITY"], [35, 47, "ENTITY"], [6, 13, "MULTI-TISSUE_STRUCTURE"], [87, 97, "ENTITY"], [58, 66, "ENTITY"], [75, 97, "DISEASE"], [21, 33, "ENTITY"], [58, 66, "DISEASE"], [21, 33, "CANCER"]]}
{"text": "In this phase , use of corticosteroids may be justified in concert with the use of cytokine inhibitors such as tocilizumab ( IL-6 inhibitor ) or anakinra ( IL-1 receptor antagonist ) .", "labels": [[83, 92, "CHEBI"], [145, 170, "ENTITY"], [8, 14, "ENTITY"], [125, 130, "ENTITY"], [123, 130, "GGP"], [145, 170, "GGP"], [145, 170, "PROTEIN"], [145, 170, "GENE_OR_GENE_PRODUCT"], [83, 92, "ENTITY"]]}
{"text": "The recent data from the coronavirus disease 2019 ( COVID-19 ) caused by the 2019 novel coronavirus ( 2019-nCoV ) , confirm that diabetes , along with advanced age , is a major risk factor for an adverse outcome .", "labels": [[82, 102, "DISEASE"], [11, 16, "ENTITY"], [4, 11, "ENTITY"], [189, 204, "ENTITY"], [25, 50, "ORGANISM"], [171, 182, "ENTITY"], [25, 50, "ENTITY"], [25, 50, "DISEASE"]]}
{"text": "Taken together , these results suggested that SARS-CoV-2 infection in the human heart might attack pericytes , and cause capillary ECs dysfunction , thus inducing micro-circulation disorder .", "labels": [[115, 135, "DISEASE"], [154, 181, "DISEASE"], [46, 57, "ENTITY"], [154, 181, "ENTITY"], [121, 131, "CL"], [115, 131, "CELL"], [74, 80, "ORGANISM"], [46, 57, "DISEASE"], [115, 135, "ENTITY"], [121, 131, "CELL_TYPE"]]}
{"text": "Among patients with unstable clinical status , myocardial injury associated with Covid-19 may pose even higher early risks after withdrawal of RAAS inhibitors .", "labels": [[47, 58, "DISEASE"], [6, 15, "ENTITY"], [6, 15, "ORGANISM"], [47, 58, "ENTITY"], [143, 148, "GGP"], [29, 45, "ENTITY"], [143, 148, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [99, 108, "ORGANISM"], [63, 73, "DNA"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "The common clinical manifestations of fever and cough in conjunction with laboratory results of progressively increasing neutrophil counts and leukocytopenia in serum samples taken from COVID-19 patients at various stages of the illness indicates uncontrolled neutrophil extravasation and activation 11,12 .", "labels": [[121, 132, "CL"], [195, 204, "ENTITY"], [229, 237, "ENTITY"], [121, 132, "ENTITY"], [186, 195, "ENTITY"], [57, 69, "ENTITY"], [132, 139, "ENTITY"], [38, 44, "ENTITY"], [143, 158, "ENTITY"], [260, 285, "ENTITY"], [121, 132, "CELL"], [121, 132, "CELL"], [11, 35, "ENTITY"], [186, 204, "ORGANISM"], [247, 260, "ENTITY"], [74, 93, "ENTITY"], [121, 132, "CL"], [48, 54, "ENTITY"], [110, 121, "ENTITY"], [121, 132, "CELL_TYPE"], [38, 44, "DISEASE"], [289, 300, "ENTITY"], [161, 175, "ORGANISM_SUBSTANCE"], [121, 132, "CELL_TYPE"], [161, 175, "ENTITY"], [215, 222, "ENTITY"], [143, 158, "DISEASE"], [48, 54, "DISEASE"]]}
{"text": "Functional analysis by DAVID and Cluster Profiler revealed that these genes were enriched in specific cellular biological processes , including positive regulation of neutrophil chemotaxis , neutrophil activation , type I interferon signaling pathway , inflammatory response , and antigen processing and presentation ( Fig.3b and Extended Data Fig.5c-d ) , suggesting an active innate immune response against SARS-CoV-2 infection .", "labels": [[102, 132, "ENTITY"], [277, 289, "ENTITY"], [304, 319, "GENE_OR_GENE_PRODUCT"], [102, 111, "CL"], [23, 29, "CHEMICAL"], [401, 420, "DISEASE"], [70, 76, "SO"], [0, 20, "ENTITY"], [357, 368, "ENTITY"], [304, 319, "ENTITY"], [339, 344, "SIMPLE_CHEMICAL"], [102, 111, "CELL"], [213, 222, "GGP"], [70, 76, "ENTITY"], [213, 222, "GENE_OR_GENE_PRODUCT"], [243, 266, "ENTITY"], [319, 344, "ENTITY"], [213, 222, "PROTEIN"], [23, 29, "ENTITY"], [213, 243, "ENTITY"], [339, 344, "CHEMICAL"], [33, 50, "ENTITY"], [189, 202, "ENTITY"], [371, 392, "ENTITY"], [167, 178, "ENTITY"], [401, 420, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "The number of MPs in patients with COVID-19 was significantly higher than that in the control group ( P<0.05 ) .", "labels": [[35, 44, "ENTITY"], [21, 30, "ENTITY"], [86, 100, "ENTITY"], [21, 30, "ORGANISM"], [14, 18, "CELL_TYPE"], [14, 18, "GGP"], [35, 44, "DISEASE"], [14, 18, "GENE_OR_GENE_PRODUCT"], [35, 44, "SIMPLE_CHEMICAL"], [14, 18, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 2 . GO-term and KEGG pathway enrichment of up-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[0, 9, "ENTITY"], [63, 73, "DNA"], [99, 108, "ORGANISM"], [0, 9, "GENE_OR_GENE_PRODUCT"], [23, 28, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [19, 26, "CL"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 3 . GO-term and KEGG pathway enrichment of down-regulated expressed genes in BALF and PBMC of COVID-19 patients .", "labels": [[101, 110, "ORGANISM"], [23, 28, "ENTITY"], [0, 9, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [91, 127, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [114, 127, "ENTITY"], [261, 273, "PROTEIN"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [223, 230, "ENTITY"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [261, 273, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [261, 273, "GGP"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [193, 201, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [176, 186, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [176, 186, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [176, 186, "GGP"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [176, 186, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [261, 273, "ENTITY"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [223, 230, "ENTITY"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "GGP"], [134, 140, "GGP"], [407, 421, "ENTITY"], [261, 273, "GENE_OR_GENE_PRODUCT"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Moreover , the relative expression of a subset of genes associated with the NF-kB and TNF\u03b1 pathways ( e.g. IL18 , IL18R1 , NFKB2 , NFKBIA , TNFA , and TNFAIP3 ) is mostly unchanged all throughout the infection in bronchial HAE but it is highly upregulated in nasal HAE at 48 hpi and onwards ( Fig. 3C and Data S1 ) .", "labels": [[114, 123, "GENE_OR_GENE_PRODUCT"], [244, 256, "ENTITY"], [102, 107, "PROTEIN"], [293, 301, "ENTITY"], [145, 151, "GGP"], [185, 200, "DISEASE"], [123, 131, "GGP"], [131, 138, "ENTITY"], [102, 107, "GENE_OR_GENE_PRODUCT"], [123, 131, "GENE_OR_GENE_PRODUCT"], [185, 200, "ENTITY"], [102, 107, "ENTITY"], [114, 123, "ENTITY"], [283, 291, "ENTITY"], [114, 123, "PROTEIN"], [145, 151, "ENTITY"], [145, 151, "GENE_OR_GENE_PRODUCT"], [131, 138, "DNA"], [200, 213, "ENTITY"], [237, 244, "ENTITY"], [200, 213, "DISEASE"], [123, 131, "DNA"], [223, 227, "ENTITY"], [114, 123, "GGP"], [145, 151, "PROTEIN"], [200, 213, "CANCER"], [244, 259, "CANCER"], [123, 131, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [26, 36, "ENTITY"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [266, 279, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[186, 193, "GGP"], [168, 174, "GENE_OR_GENE_PRODUCT"], [186, 193, "PROTEIN"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [132, 139, "GENE_OR_GENE_PRODUCT"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [146, 152, "CHEMICAL"], [176, 186, "ENTITY"], [139, 146, "GGP"], [176, 186, "GGP"], [193, 201, "GGP"], [36, 44, "ENTITY"], [84, 88, "PROTEIN"], [84, 107, "ENTITY"], [168, 174, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [70, 80, "ENTITY"], [132, 139, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [186, 193, "GENE_OR_GENE_PRODUCT"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [132, 139, "GGP"], [132, 139, "PROTEIN"], [139, 146, "PROTEIN"], [176, 186, "GENE_OR_GENE_PRODUCT"], [186, 193, "ENTITY"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [139, 146, "ENTITY"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[168, 174, "GENE_OR_GENE_PRODUCT"], [132, 139, "GGP"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [146, 152, "CHEMICAL"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [132, 139, "PROTEIN"], [36, 44, "ENTITY"], [84, 88, "PROTEIN"], [186, 193, "PROTEIN"], [84, 107, "ENTITY"], [168, 174, "PROTEIN"], [186, 193, "GENE_OR_GENE_PRODUCT"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [139, 146, "ENTITY"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [139, 146, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [210, 216, "ENTITY"], [132, 139, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [186, 193, "ENTITY"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [186, 193, "GGP"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [132, 139, "GENE_OR_GENE_PRODUCT"], [161, 166, "GGP"], [139, 146, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [146, 152, "ENTITY"], [146, 152, "GGP"], [201, 208, "PROTEIN"], [218, 223, "PROTEIN"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "PROTEIN"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [146, 152, "GENE_OR_GENE_PRODUCT"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"], [146, 152, "CHEMICAL"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [241, 248, "SIMPLE_CHEMICAL"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [154, 159, "GGP"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [154, 159, "PROTEIN"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[186, 193, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [132, 139, "ENTITY"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [132, 139, "GENE_OR_GENE_PRODUCT"], [84, 88, "GGP"], [146, 152, "CHEMICAL"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [161, 166, "GGP"], [36, 44, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [84, 88, "PROTEIN"], [139, 146, "PROTEIN"], [186, 193, "ENTITY"], [84, 107, "ENTITY"], [161, 166, "PROTEIN"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [132, 139, "PROTEIN"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GGP"], [146, 152, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [139, 146, "GENE_OR_GENE_PRODUCT"], [176, 186, "GENE_OR_GENE_PRODUCT"], [132, 139, "GGP"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [161, 166, "ENTITY"], [139, 146, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [139, 146, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [168, 174, "PROTEIN"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [168, 174, "GGP"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [186, 193, "ENTITY"], [84, 88, "GGP"], [146, 152, "CHEMICAL"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [36, 44, "ENTITY"], [186, 193, "GGP"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [84, 107, "ENTITY"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [186, 193, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [132, 139, "ENTITY"], [176, 186, "GENE_OR_GENE_PRODUCT"], [139, 146, "ENTITY"], [132, 139, "GGP"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [139, 146, "PROTEIN"], [132, 139, "GENE_OR_GENE_PRODUCT"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [139, 146, "GENE_OR_GENE_PRODUCT"], [161, 166, "GGP"], [139, 146, "GGP"], [186, 193, "PROTEIN"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [193, 201, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [146, 152, "CHEMICAL"], [176, 186, "GGP"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [241, 248, "SIMPLE_CHEMICAL"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [193, 201, "ENTITY"], [132, 139, "GENE_OR_GENE_PRODUCT"], [201, 208, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [193, 201, "GGP"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"], [193, 201, "PROTEIN"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [201, 208, "GENE_OR_GENE_PRODUCT"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [201, 208, "GGP"], [70, 80, "ENTITY"], [201, 208, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [210, 216, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [201, 208, "PROTEIN"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [146, 152, "GGP"], [132, 139, "ENTITY"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [210, 216, "GGP"], [168, 174, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [210, 216, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [210, 216, "PROTEIN"], [109, 116, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [201, 208, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [201, 208, "PROTEIN"], [218, 223, "PROTEIN"], [146, 152, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [218, 223, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [218, 223, "GGP"], [146, 152, "PROTEIN"], [154, 159, "GENE_OR_GENE_PRODUCT"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [168, 174, "ENTITY"], [210, 216, "GGP"], [218, 223, "GENE_OR_GENE_PRODUCT"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [70, 80, "ENTITY"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "Following the initial infection , three of the four monkeys showed the weight loss ranging from 200 g to 400 g ( Figure 2a ) , but the changes of rectal temperature in all the animals were not observed ( Figure 2b ) .", "labels": [[193, 204, "ENTITY"], [22, 32, "ENTITY"], [14, 22, "ENTITY"], [22, 32, "DISEASE"], [71, 78, "ENTITY"], [71, 78, "DISEASE"], [111, 120, "ENTITY"], [143, 153, "ENTITY"]]}
{"text": "Other clinical signs such as reduced appetite , increased respiration rate and hunched posture were transient after the initial challenge .", "labels": [[79, 87, "ENTITY"], [6, 21, "ENTITY"], [37, 46, "CHEMICAL"], [37, 46, "ENTITY"], [29, 37, "ENTITY"]]}
{"text": "As shown in Figure 2c and 2d , the viral loads in nasal swabs and pharyngeal swabs reached the highest levels ( average , approximately 6.5 log10 RNA copies/mL ) at 3 days post-infection ( dpi ) and then declined naturally .", "labels": [[12, 22, "GENE_OR_GENE_PRODUCT"], [50, 56, "CANCER"], [162, 167, "ENTITY"], [26, 29, "GENE_OR_GENE_PRODUCT"], [50, 56, "ENTITY"], [66, 77, "ENTITY"], [26, 29, "ENTITY"], [12, 22, "ENTITY"], [172, 187, "ENTITY"], [66, 77, "CANCER"], [140, 146, "SO"], [167, 172, "ENTITY"], [35, 41, "ENTITY"]]}
{"text": "Similarly , viral loads from anal swabs reached the peak about 4.5 log10 RNA copies/mL at 3 dpi and then declined to undetectable level at 14 dpi ( Figure 2e ) .", "labels": [[29, 34, "ENTITY"], [29, 34, "CANCER"], [146, 155, "ENTITY"], [12, 18, "ENTITY"]]}
{"text": "As shown in Figure 2f ( left panel ) , viral replication was found in nose ( 107 to 108 copies/mL ) , pharynx ( 105 to 106 copies/mL ) , lung ( 104 to 107 copies/mL ) , gut ( 104 to 106 copies/mL ) , spinal cord ( approximately 104 copies/mL ) , heart ( approximately 104 copies/mL ) , skeletal muscle ( approximately 104 copies/mL ) and bladder ( approximately 104 copies/mL ) .", "labels": [[214, 232, "ENTITY"], [24, 29, "ENTITY"], [214, 232, "TISSUE"], [88, 98, "ENTITY"], [214, 232, "ORGAN"], [88, 98, "ENTITY"], [88, 102, "ENTITY"], [12, 22, "ENTITY"], [88, 102, "ORGAN"], [88, 98, "MULTI-TISSUE_STRUCTURE"], [37, 45, "ENTITY"], [214, 232, "ENTITY"], [12, 22, "SIMPLE_CHEMICAL"], [88, 98, "ORGAN"]]}
{"text": "5.75 % ( 359/499 ) , 75.95 % ( 379/499 ) and 71.54 % ( 359/499), 75.95% (379/499) and 71.54% ) patients had remarkably low total T cell counts , CD4 + and CD8 + T cell counts , respectively .", "labels": [[93, 101, "ENTITY"], [74, 93, "CELL_TYPE"], [78, 93, "ENTITY"], [78, 93, "GGP"]]}
{"text": "The counts of total T cells , CD4 + and CD8 + T cells were significantly lower in ICU patients than Non-ICU cases ( Figure 1B ) .", "labels": [[114, 123, "ENTITY"], [14, 28, "ENTITY"], [4, 11, "ENTITY"], [30, 48, "CELL_TYPE"], [40, 48, "ENTITY"], [20, 28, "CL"], [40, 48, "GGP"], [30, 34, "GGP"], [20, 28, "CELL"], [14, 28, "CELL_TYPE"], [30, 34, "ENTITY"]]}
{"text": "Interestingly , serum levels of IFN-\u03b3 , IL-10 , IL-6 and TNF-\u03b1 were significantly decreased in these patients in the decline period as compared with illness period , while counts of total T cells , CD4 + , and CD8 + T cell subsets recovered during the decline period ( Figure 2C ) .", "labels": [[117, 125, "ENTITY"], [182, 190, "CL"], [68, 82, "ENTITY"], [182, 190, "CELL"], [16, 22, "ENTITY"], [260, 269, "ENTITY"], [206, 218, "GGP"], [149, 157, "ENTITY"], [206, 223, "ENTITY"], [117, 125, "ENTITY"], [190, 198, "ENTITY"], [179, 190, "CELL_TYPE"], [179, 190, "ENTITY"], [190, 223, "CELL_TYPE"], [190, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "This result is consistent with the recent study , which represented that the number of T cells in patients with COVID-19 were reduced and functionally exhausted , especially among elderly patients ( \u226560 ) and in patients requiring Intensive Care Unit ( ICU ) ( 47 ) .", "labels": [[15, 31, "ENTITY"], [246, 251, "ENTITY"], [5, 12, "ENTITY"], [221, 246, "ENTITY"], [180, 188, "ORGANISM"], [180, 188, "ENTITY"], [42, 48, "ENTITY"]]}
{"text": "5.75 % ( 359/499 ) , 75.95 % ( 379/499 ) and 71.54 % ( 359/499), 75.95% (379/499) and 71.54% ) patients had remarkably low total T cell counts , CD4 + and CD8 + T cell counts , respectively .", "labels": [[93, 101, "ENTITY"], [74, 93, "CELL_TYPE"], [78, 93, "ENTITY"], [78, 93, "GGP"]]}
{"text": "The counts of total T cells , CD4 + and CD8 + T cells were significantly lower in ICU patients than Non-ICU cases ( Figure 1B ) .", "labels": [[114, 123, "ENTITY"], [14, 28, "ENTITY"], [4, 11, "ENTITY"], [30, 48, "CELL_TYPE"], [40, 48, "ENTITY"], [20, 28, "CELL"], [20, 28, "CL"], [40, 48, "GGP"], [30, 34, "GGP"], [14, 28, "CELL_TYPE"], [30, 34, "ENTITY"]]}
{"text": "Interestingly , serum levels of IFN-\u03b3 , IL-10 , IL-6 and TNF-\u03b1 were significantly decreased in these patients in the decline period as compared with illness period , while counts of total T cells , CD4 + , and CD8 + T cell subsets recovered during the decline period ( Figure 2C ) .", "labels": [[117, 125, "ENTITY"], [182, 190, "CL"], [68, 82, "ENTITY"], [182, 190, "CELL"], [16, 22, "ENTITY"], [260, 269, "ENTITY"], [206, 218, "GGP"], [149, 157, "ENTITY"], [206, 223, "ENTITY"], [117, 125, "ENTITY"], [190, 198, "ENTITY"], [179, 190, "CELL_TYPE"], [179, 190, "ENTITY"], [190, 223, "CELL_TYPE"], [190, 196, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Before being treated with thalidomide + methylprednisolone , the patient showed an increase in C-reactive protein ( CRP ) and cytokine levels , including interleukin 6 ( IL-6 ) , interleukin 10 ( IL-10 ) and interferon gamma ( IFN-gamma ) together with reduced CD4 + and CD8 + T cells counts .", "labels": [[179, 194, "GGP"], [170, 179, "GENE_OR_GENE_PRODUCT"], [253, 271, "GGP"], [208, 227, "PROTEIN"], [208, 227, "CHEMICAL"], [196, 208, "GGP"], [144, 154, "PROTEIN"], [208, 227, "GENE_OR_GENE_PRODUCT"], [40, 59, "ENTITY"], [26, 38, "SIMPLE_CHEMICAL"], [179, 194, "GENE_OR_GENE_PRODUCT"], [196, 208, "PROTEIN"], [170, 179, "ENTITY"], [196, 208, "ENTITY"], [271, 279, "ENTITY"], [248, 271, "CELL_TYPE"], [196, 208, "CHEMICAL"], [144, 154, "GGP"], [253, 271, "ENTITY"], [26, 40, "CHEBI"], [170, 179, "GGP"], [26, 38, "CHEMICAL"], [196, 208, "GENE_OR_GENE_PRODUCT"], [122, 135, "ENTITY"], [95, 106, "PROTEIN"], [179, 194, "ENTITY"], [144, 154, "GENE_OR_GENE_PRODUCT"], [208, 227, "ENTITY"], [95, 106, "GGP"], [170, 179, "PROTEIN"], [95, 106, "ENTITY"], [40, 59, "SIMPLE_CHEMICAL"], [26, 38, "ENTITY"], [179, 194, "PROTEIN"], [13, 26, "ENTITY"], [253, 261, "GENE_OR_GENE_PRODUCT"], [144, 154, "ENTITY"], [40, 59, "CHEMICAL"]]}
{"text": "FACs showed that these patients have very low level of PD-1 and Tim-3 on CD8 + and CD4 + T cells in the prodromal stage , however , their levels on CD8 + T cells was increased in overtly symptomatic stages , and highest levels were seen in ICU period ( Figure 3C , D ) .", "labels": [[23, 32, "ORGANISM"], [83, 97, "GGP"], [73, 79, "GGP"], [73, 97, "CELL_TYPE"], [55, 60, "ENTITY"], [64, 70, "ENTITY"], [104, 120, "ENTITY"], [179, 187, "ENTITY"], [64, 70, "GGP"], [187, 199, "ENTITY"], [55, 60, "PROTEIN"], [64, 70, "GENE_OR_GENE_PRODUCT"], [83, 97, "ENTITY"], [0, 5, "ENTITY"], [83, 87, "GENE_OR_GENE_PRODUCT"], [55, 60, "GENE_OR_GENE_PRODUCT"], [240, 244, "ENTITY"], [0, 5, "CELL"], [244, 253, "ENTITY"], [23, 32, "ENTITY"], [145, 156, "GGP"], [73, 77, "GENE_OR_GENE_PRODUCT"], [46, 52, "ENTITY"], [145, 156, "ENTITY"], [145, 156, "CELL_TYPE"], [73, 79, "ENTITY"], [212, 220, "ENTITY"], [64, 70, "PROTEIN"]]}
{"text": "Similarly , higher levels of Tim-3 was observed on CD4 + T cells from patients who are in ICU stage , although enhancing the expression of PD-1 on CD4 + T cells was not obviously during disease progress ( Figure 3C , D ) .", "labels": [[90, 94, "ENTITY"], [203, 212, "ENTITY"], [51, 59, "CELL_TYPE"], [48, 59, "GGP"], [51, 59, "GGP"], [212, 215, "ENTITY"], [51, 59, "ENTITY"], [179, 194, "ENTITY"], [48, 59, "ENTITY"], [48, 59, "CELL_TYPE"]]}
{"text": "SGs are induced by protein kinase R (PKR)-mediated phosphorylation of eIF2\u03b1 upon viral dsRNA recognition [ 57 ] . Promoting G3BP aggregation via the eIF4A inhibitor Zotatafin [ 58,59 ] or reducing SG disassembly by Silmitasertib inhibition of CK2 [ 60 ] warrant investigation for treatment of SARS-CoV-2 . The mTOR inhibitor rapamycin disrupts the binding of LARP1 to mTORC1 [ 61 ] and has been shown to reduce MERS infection by \u223c60 % in vitro [ 62 ] , another drug that could be tested for repurposing .", "labels": [[51, 67, "ENTITY"], [19, 36, "GENE_OR_GENE_PRODUCT"], [254, 262, "ENTITY"], [70, 76, "PROTEIN"], [293, 306, "ENTITY"], [293, 325, "GGP"], [114, 124, "PROTEIN"], [155, 165, "SIMPLE_CHEMICAL"], [70, 76, "ENTITY"], [19, 36, "PROTEIN"], [229, 240, "ENTITY"], [280, 293, "CHEMICAL"], [0, 4, "ENTITY"], [200, 215, "CHEMICAL"], [401, 416, "DISEASE"], [335, 348, "ENTITY"], [114, 124, "ENTITY"], [306, 315, "ENTITY"], [395, 401, "ENTITY"], [81, 93, "TAXON"], [124, 129, "ENTITY"], [145, 155, "CHEBI"], [19, 36, "ENTITY"], [200, 215, "ORGANISM"], [293, 306, "GENE_OR_GENE_PRODUCT"], [0, 4, "GO"], [262, 280, "ENTITY"], [8, 16, "ENTITY"], [229, 243, "GENE_OR_GENE_PRODUCT"], [348, 356, "GENE_OR_GENE_PRODUCT"], [348, 356, "PROTEIN"], [145, 155, "ENTITY"], [0, 4, "GENE_OR_GENE_PRODUCT"], [145, 165, "PROTEIN"], [416, 433, "ENTITY"], [188, 200, "ENTITY"], [348, 356, "ENTITY"], [19, 27, "CHEBI"], [477, 487, "ENTITY"], [155, 165, "CHEMICAL"], [280, 293, "ENTITY"], [280, 293, "SIMPLE_CHEMICAL"], [359, 368, "GENE_OR_GENE_PRODUCT"], [70, 76, "GENE_OR_GENE_PRODUCT"], [200, 229, "ENTITY"], [155, 165, "ENTITY"], [404, 416, "ENTITY"], [114, 124, "GENE_OR_GENE_PRODUCT"], [229, 240, "PROTEIN"], [359, 365, "PROTEIN"], [81, 105, "ENTITY"], [114, 124, "GGP"], [325, 335, "ENTITY"], [348, 356, "GGP"], [359, 365, "ENTITY"], [0, 4, "PROTEIN"]]}
{"text": "Most of the patients had elevated levels of C-reactive protein ; less common were elevated levels of alanine aminotransferase , aspartate aminotransferase , creatine kinase , and d-dimer .", "labels": [[126, 138, "PROTEIN"], [34, 41, "ENTITY"], [44, 63, "GGP"], [44, 63, "ENTITY"], [12, 21, "ENTITY"], [44, 63, "PROTEIN"], [155, 166, "ENTITY"], [101, 109, "PROTEIN"], [25, 34, "ENTITY"], [155, 166, "PROTEIN"], [12, 21, "ORGANISM"], [44, 55, "GENE_OR_GENE_PRODUCT"], [126, 138, "GENE_OR_GENE_PRODUCT"], [101, 109, "GGP"], [101, 109, "GENE_OR_GENE_PRODUCT"], [126, 138, "CHEBI"], [101, 109, "ENTITY"], [126, 138, "ENTITY"]]}
{"text": "During hospital admission , most of the patients received a diagnosis of pneumonia from a physician ( 91.1 % ) , followed by ARDS ( 3.4 % ) and shock ( 1.1 % ) .", "labels": [[113, 125, "ENTITY"], [7, 26, "ENTITY"], [113, 125, "DISEASE"]]}
{"text": "The common clinical manifestations of fever and cough in conjunction with laboratory results of progressively increasing neutrophil counts and leukocytopenia in serum samples taken from COVID-19 patients at various stages of the illness indicates uncontrolled neutrophil extravasation and activation 11,12 .", "labels": [[121, 132, "CL"], [195, 204, "ENTITY"], [229, 237, "ENTITY"], [121, 132, "ENTITY"], [186, 195, "ENTITY"], [57, 69, "ENTITY"], [132, 139, "ENTITY"], [38, 44, "ENTITY"], [143, 158, "ENTITY"], [121, 132, "CELL"], [121, 132, "CELL"], [11, 35, "ENTITY"], [186, 204, "ORGANISM"], [247, 260, "ENTITY"], [74, 93, "ENTITY"], [121, 132, "CL"], [48, 54, "ENTITY"], [110, 121, "ENTITY"], [121, 132, "CELL_TYPE"], [260, 285, "ENTITY"], [38, 44, "DISEASE"], [161, 175, "ORGANISM_SUBSTANCE"], [289, 300, "ENTITY"], [121, 132, "CELL_TYPE"], [161, 175, "ENTITY"], [215, 222, "ENTITY"], [143, 158, "DISEASE"], [48, 54, "DISEASE"]]}
{"text": "Functional analysis by DAVID and Cluster Profiler revealed that these genes were enriched in specific cellular biological processes , including positive regulation of neutrophil chemotaxis , neutrophil activation , type I interferon signaling pathway , inflammatory response , and antigen processing and presentation ( Fig.3b and Extended Data Fig.5c-d ) , suggesting an active innate immune response against SARS-CoV-2 infection .", "labels": [[102, 132, "ENTITY"], [277, 289, "ENTITY"], [304, 319, "GENE_OR_GENE_PRODUCT"], [102, 111, "CL"], [23, 29, "CHEMICAL"], [401, 420, "DISEASE"], [70, 76, "SO"], [0, 20, "ENTITY"], [357, 368, "ENTITY"], [304, 319, "ENTITY"], [339, 344, "SIMPLE_CHEMICAL"], [189, 202, "ENTITY"], [102, 111, "CELL"], [213, 222, "GGP"], [70, 76, "ENTITY"], [213, 222, "GENE_OR_GENE_PRODUCT"], [243, 266, "ENTITY"], [319, 344, "ENTITY"], [213, 222, "PROTEIN"], [23, 29, "ENTITY"], [213, 243, "ENTITY"], [339, 344, "CHEMICAL"], [33, 50, "ENTITY"], [371, 392, "ENTITY"], [167, 178, "ENTITY"], [401, 420, "ENTITY"]]}
{"text": "Functional analysis by DAVID and Cluster Profiler revealed that these genes were enriched in specific cellular biological processes , including positive regulation of neutrophil chemotaxis , neutrophil activation , type I interferon signaling pathway , inflammatory response , and antigen processing and presentation ( Fig.3b and Extended Data Fig.5c-d ) , suggesting an active innate immune response against SARS-CoV-2 infection .", "labels": [[102, 132, "ENTITY"], [277, 289, "ENTITY"], [213, 243, "ENTITY"], [304, 319, "GENE_OR_GENE_PRODUCT"], [102, 111, "CL"], [23, 29, "CHEMICAL"], [401, 420, "DISEASE"], [70, 76, "SO"], [0, 20, "ENTITY"], [357, 368, "ENTITY"], [304, 319, "ENTITY"], [339, 344, "SIMPLE_CHEMICAL"], [102, 111, "CELL"], [213, 222, "GGP"], [70, 76, "ENTITY"], [213, 222, "GENE_OR_GENE_PRODUCT"], [243, 266, "ENTITY"], [319, 344, "ENTITY"], [213, 222, "PROTEIN"], [23, 29, "ENTITY"], [339, 344, "CHEMICAL"], [33, 50, "ENTITY"], [189, 202, "ENTITY"], [371, 392, "ENTITY"], [167, 178, "ENTITY"], [401, 420, "ENTITY"]]}
{"text": "Functional analysis by DAVID and Cluster Profiler revealed that these genes were enriched in specific cellular biological processes , including positive regulation of neutrophil chemotaxis , neutrophil activation , type I interferon signaling pathway , inflammatory response , and antigen processing and presentation ( Fig.3b and Extended Data Fig.5c-d ) , suggesting an active innate immune response against SARS-CoV-2 infection .", "labels": [[102, 132, "ENTITY"], [304, 319, "GENE_OR_GENE_PRODUCT"], [277, 289, "ENTITY"], [102, 111, "CL"], [23, 29, "CHEMICAL"], [401, 420, "DISEASE"], [70, 76, "SO"], [0, 20, "ENTITY"], [357, 368, "ENTITY"], [339, 344, "SIMPLE_CHEMICAL"], [304, 319, "ENTITY"], [102, 111, "CELL"], [213, 222, "GGP"], [70, 76, "ENTITY"], [213, 222, "GENE_OR_GENE_PRODUCT"], [243, 266, "ENTITY"], [319, 344, "ENTITY"], [213, 222, "PROTEIN"], [23, 29, "ENTITY"], [213, 243, "ENTITY"], [339, 344, "CHEMICAL"], [33, 50, "ENTITY"], [189, 202, "ENTITY"], [371, 392, "ENTITY"], [167, 178, "ENTITY"], [401, 420, "ENTITY"]]}
{"text": "Analysis of the global proteomic changes reveal significant upregulation of CXCR2 , PRG3 , LBP , MMP25 , CRP , NLRP1 in the COVID-19-MS PBMC cohort ( Fig.3c ) .", "labels": [[23, 33, "ENTITY"], [97, 105, "GENE_OR_GENE_PRODUCT"], [105, 111, "GENE_OR_GENE_PRODUCT"], [76, 82, "PROTEIN"], [105, 111, "ENTITY"], [76, 82, "ENTITY"], [141, 150, "SIMPLE_CHEMICAL"], [76, 82, "GGP"], [124, 136, "ENTITY"], [16, 23, "ENTITY"], [97, 105, "PROTEIN"], [89, 97, "GENE_OR_GENE_PRODUCT"], [97, 105, "GGP"], [105, 111, "GGP"], [105, 111, "PROTEIN"], [60, 73, "ENTITY"], [76, 82, "GENE_OR_GENE_PRODUCT"], [97, 105, "ENTITY"], [136, 141, "ENTITY"], [0, 9, "ENTITY"], [120, 136, "CELL"]]}
{"text": "Analysis of the global proteomic changes reveal significant upregulation of CXCR2 , PRG3 , LBP , MMP25 , CRP , NLRP1 in the COVID-19-MS PBMC cohort ( Fig.3c ) .", "labels": [[76, 82, "GENE_OR_GENE_PRODUCT"], [23, 33, "ENTITY"], [97, 105, "GENE_OR_GENE_PRODUCT"], [105, 111, "GENE_OR_GENE_PRODUCT"], [105, 111, "ENTITY"], [76, 82, "PROTEIN"], [141, 150, "SIMPLE_CHEMICAL"], [124, 136, "ENTITY"], [16, 23, "ENTITY"], [97, 105, "PROTEIN"], [89, 97, "GENE_OR_GENE_PRODUCT"], [97, 105, "GGP"], [105, 111, "GGP"], [105, 111, "PROTEIN"], [60, 73, "ENTITY"], [76, 82, "GGP"], [97, 105, "ENTITY"], [136, 141, "ENTITY"], [76, 82, "ENTITY"], [0, 9, "ENTITY"], [120, 136, "CELL"]]}
{"text": "Analysis of the global proteomic changes reveal significant upregulation of CXCR2 , PRG3 , LBP , MMP25 , CRP , NLRP1 in the COVID-19-MS PBMC cohort ( Fig.3c ) .", "labels": [[76, 82, "GENE_OR_GENE_PRODUCT"], [89, 97, "GENE_OR_GENE_PRODUCT"], [23, 33, "ENTITY"], [97, 105, "GENE_OR_GENE_PRODUCT"], [105, 111, "GENE_OR_GENE_PRODUCT"], [105, 111, "ENTITY"], [76, 82, "PROTEIN"], [141, 150, "SIMPLE_CHEMICAL"], [124, 136, "ENTITY"], [16, 23, "ENTITY"], [97, 105, "PROTEIN"], [97, 105, "GGP"], [105, 111, "GGP"], [105, 111, "PROTEIN"], [60, 73, "ENTITY"], [76, 82, "GGP"], [97, 105, "ENTITY"], [136, 141, "ENTITY"], [76, 82, "ENTITY"], [0, 9, "ENTITY"], [120, 136, "CELL"]]}
{"text": "Analysis of the global proteomic changes reveal significant upregulation of CXCR2 , PRG3 , LBP , MMP25 , CRP , NLRP1 in the COVID-19-MS PBMC cohort ( Fig.3c ) .", "labels": [[76, 82, "GENE_OR_GENE_PRODUCT"], [23, 33, "ENTITY"], [97, 105, "PROTEIN"], [105, 111, "GENE_OR_GENE_PRODUCT"], [97, 105, "GENE_OR_GENE_PRODUCT"], [105, 111, "ENTITY"], [76, 82, "PROTEIN"], [141, 150, "SIMPLE_CHEMICAL"], [124, 136, "ENTITY"], [16, 23, "ENTITY"], [97, 105, "GGP"], [89, 97, "GENE_OR_GENE_PRODUCT"], [97, 105, "ENTITY"], [105, 111, "GGP"], [105, 111, "PROTEIN"], [60, 73, "ENTITY"], [76, 82, "GGP"], [136, 141, "ENTITY"], [76, 82, "ENTITY"], [0, 9, "ENTITY"], [120, 136, "CELL"]]}
{"text": "Analysis of the global proteomic changes reveal significant upregulation of CXCR2 , PRG3 , LBP , MMP25 , CRP , NLRP1 in the COVID-19-MS PBMC cohort ( Fig.3c ) .", "labels": [[76, 82, "GENE_OR_GENE_PRODUCT"], [23, 33, "ENTITY"], [97, 105, "GENE_OR_GENE_PRODUCT"], [105, 111, "GENE_OR_GENE_PRODUCT"], [105, 111, "ENTITY"], [76, 82, "PROTEIN"], [141, 150, "SIMPLE_CHEMICAL"], [124, 136, "ENTITY"], [16, 23, "ENTITY"], [97, 105, "PROTEIN"], [89, 97, "GENE_OR_GENE_PRODUCT"], [97, 105, "GGP"], [105, 111, "GGP"], [105, 111, "PROTEIN"], [60, 73, "ENTITY"], [76, 82, "GGP"], [97, 105, "ENTITY"], [136, 141, "ENTITY"], [76, 82, "ENTITY"], [0, 9, "ENTITY"], [120, 136, "CELL"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [61, 69, "GGP"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [54, 61, "PROTEIN"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [54, 61, "ENTITY"], [248, 271, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [61, 69, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [54, 61, "PROTEIN"], [113, 125, "DNA"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [61, 69, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [61, 69, "GENE_OR_GENE_PRODUCT"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [248, 271, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [54, 61, "ENTITY"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [61, 69, "GGP"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"], [54, 61, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [69, 75, "ENTITY"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [271, 279, "PROTEIN"], [77, 84, "GGP"], [113, 125, "DNA"], [88, 113, "CELL"], [54, 61, "PROTEIN"], [77, 84, "GENE_OR_GENE_PRODUCT"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [77, 84, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [77, 84, "PROTEIN"], [54, 61, "ENTITY"], [161, 170, "PROTEIN"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [88, 113, "ENTITY"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [396, 409, "CELL_TYPE"], [88, 113, "PROTEIN"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [88, 94, "CL"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [88, 113, "ENTITY"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [88, 113, "CELL"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "ENTITY"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [125, 129, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [192, 203, "GENE_OR_GENE_PRODUCT"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [125, 129, "PROTEIN"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [138, 161, "GENE_OR_GENE_PRODUCT"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [138, 161, "PROTEIN"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [138, 161, "ENTITY"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [138, 161, "GENE_OR_GENE_PRODUCT"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "PROTEIN"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"], [138, 161, "ENTITY"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [138, 161, "ENTITY"], [138, 161, "PROTEIN"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "GENE_OR_GENE_PRODUCT"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [182, 192, "ENTITY"], [113, 123, "PROTEIN"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [182, 192, "DNA"], [54, 61, "PROTEIN"], [203, 238, "ENTITY"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [192, 203, "DNA"], [382, 411, "DISEASE"], [271, 279, "GGP"], [192, 203, "GENE_OR_GENE_PRODUCT"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [192, 203, "ENTITY"], [125, 129, "PROTEIN"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [192, 203, "CHEMICAL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [182, 192, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [77, 84, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"], [203, 214, "CL"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [203, 238, "ENTITY"], [396, 409, "ENTITY"], [88, 113, "PROTEIN"], [113, 123, "ENTITY"], [271, 279, "ENTITY"], [203, 214, "CL"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [192, 203, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [192, 203, "DNA"], [125, 129, "ENTITY"], [77, 84, "GENE_OR_GENE_PRODUCT"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [248, 271, "ENTITY"], [182, 192, "DNA"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [77, 84, "ENTITY"], [203, 214, "CELL"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [203, 214, "CL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [113, 123, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [182, 192, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "CELL"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [203, 214, "CELL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [192, 203, "DNA"], [125, 129, "ENTITY"], [77, 84, "GENE_OR_GENE_PRODUCT"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [182, 192, "DNA"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [203, 238, "ENTITY"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [248, 271, "ENTITY"], [192, 203, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [182, 192, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [192, 203, "CHEMICAL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [77, 84, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of T cell receptor ( TCR ) subunits ( CD3e , CD3 g , CD247 , TRAC , and TRBC1 ) , T cell surface molecules ( CD4 , CD8a , CD8b , and CD2 ) , MHC class II molecules ( HLA-DRA , HLA-DRB1 , HLA-DRB4 , and HLA-DRB5 ) , T cell migration stimulators ( DDP4 ) , and TCR signaling kinases ( ZAP70 , LCK , and FYN ) were dramatically diminished in COVID-19-SS as compared to COVID-19-MS ( Fig.3a , h ) , suggesting a failure of T cells activation and function .", "labels": [[88, 94, "CL"], [113, 123, "PROTEIN"], [182, 192, "DNA"], [248, 271, "PROTEIN"], [396, 409, "CELL"], [88, 113, "PROTEIN"], [396, 409, "ENTITY"], [113, 123, "ENTITY"], [203, 238, "ENTITY"], [271, 279, "ENTITY"], [19, 43, "PROTEIN"], [396, 409, "CL"], [88, 113, "CELL"], [77, 84, "ENTITY"], [271, 279, "PROTEIN"], [88, 113, "ENTITY"], [113, 125, "DNA"], [54, 61, "PROTEIN"], [192, 203, "CHEMICAL"], [161, 170, "ENTITY"], [424, 432, "ENTITY"], [77, 84, "GGP"], [77, 84, "GENE_OR_GENE_PRODUCT"], [125, 129, "ENTITY"], [271, 279, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [382, 396, "ENTITY"], [382, 411, "DISEASE"], [271, 279, "GGP"], [203, 214, "CL"], [125, 129, "GENE_OR_GENE_PRODUCT"], [54, 61, "GENE_OR_GENE_PRODUCT"], [19, 35, "ENTITY"], [182, 192, "GENE_OR_GENE_PRODUCT"], [192, 203, "ENTITY"], [19, 26, "CL"], [155, 161, "CHEBI"], [161, 170, "PROTEIN"], [54, 61, "ENTITY"], [138, 161, "PROTEIN"], [125, 129, "PROTEIN"], [192, 203, "DNA"], [4, 16, "ENTITY"], [69, 75, "ENTITY"], [138, 161, "ENTITY"], [192, 203, "GENE_OR_GENE_PRODUCT"], [248, 271, "ENTITY"], [19, 35, "CELL"], [113, 123, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [248, 271, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [161, 170, "GENE_OR_GENE_PRODUCT"], [203, 214, "CELL"], [113, 125, "ENTITY"], [113, 125, "GENE_OR_GENE_PRODUCT"], [138, 161, "GENE_OR_GENE_PRODUCT"], [182, 192, "ENTITY"], [161, 170, "GGP"], [77, 84, "PROTEIN"], [396, 409, "CELL_TYPE"]]}
{"text": "The expressions of immunoglobulin subunits ( IGHG1 , IGHG2 , IGHG4 , IGLC2 , IGLL1 , and IGHE ) were also significant lower in COVID-19-SS ( Fig.3a , h ) , indicating reduced antibody secretion by B cells .", "labels": [[19, 43, "PROTEIN"], [167, 175, "ENTITY"], [61, 69, "GENE_OR_GENE_PRODUCT"], [19, 43, "GGP"], [127, 139, "GENE_OR_GENE_PRODUCT"], [69, 77, "DNA"], [19, 43, "ENTITY"], [69, 77, "ENTITY"], [61, 69, "ENTITY"], [118, 127, "ENTITY"], [61, 69, "GGP"], [127, 139, "ENTITY"], [69, 77, "GGP"], [156, 167, "ENTITY"], [4, 16, "ENTITY"], [69, 77, "GENE_OR_GENE_PRODUCT"], [156, 167, "GO"], [61, 69, "DNA"], [19, 34, "GENE_OR_GENE_PRODUCT"], [118, 127, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expressions of immunoglobulin subunits ( IGHG1 , IGHG2 , IGHG4 , IGLC2 , IGLL1 , and IGHE ) were also significant lower in COVID-19-SS ( Fig.3a , h ) , indicating reduced antibody secretion by B cells .", "labels": [[19, 43, "PROTEIN"], [167, 175, "ENTITY"], [61, 69, "DNA"], [61, 69, "GGP"], [19, 43, "GGP"], [127, 139, "GENE_OR_GENE_PRODUCT"], [69, 77, "DNA"], [19, 43, "ENTITY"], [69, 77, "ENTITY"], [61, 69, "GENE_OR_GENE_PRODUCT"], [118, 127, "ENTITY"], [127, 139, "ENTITY"], [69, 77, "GGP"], [156, 167, "ENTITY"], [4, 16, "ENTITY"], [61, 69, "ENTITY"], [69, 77, "GENE_OR_GENE_PRODUCT"], [156, 167, "GO"], [19, 34, "GENE_OR_GENE_PRODUCT"], [118, 127, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expressions of immunoglobulin subunits ( IGHG1 , IGHG2 , IGHG4 , IGLC2 , IGLL1 , and IGHE ) were also significant lower in COVID-19-SS ( Fig.3a , h ) , indicating reduced antibody secretion by B cells .", "labels": [[61, 69, "ENTITY"], [19, 43, "PROTEIN"], [167, 175, "ENTITY"], [19, 43, "GGP"], [127, 139, "GENE_OR_GENE_PRODUCT"], [69, 77, "DNA"], [19, 43, "ENTITY"], [69, 77, "ENTITY"], [118, 127, "ENTITY"], [127, 139, "ENTITY"], [69, 77, "GGP"], [61, 69, "DNA"], [156, 167, "ENTITY"], [61, 69, "GGP"], [4, 16, "ENTITY"], [69, 77, "GENE_OR_GENE_PRODUCT"], [61, 69, "GENE_OR_GENE_PRODUCT"], [156, 167, "GO"], [19, 34, "GENE_OR_GENE_PRODUCT"], [118, 127, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expressions of immunoglobulin subunits ( IGHG1 , IGHG2 , IGHG4 , IGLC2 , IGLL1 , and IGHE ) were also significant lower in COVID-19-SS ( Fig.3a , h ) , indicating reduced antibody secretion by B cells .", "labels": [[19, 43, "PROTEIN"], [167, 175, "ENTITY"], [61, 69, "DNA"], [69, 77, "DNA"], [19, 43, "GGP"], [127, 139, "GENE_OR_GENE_PRODUCT"], [69, 77, "ENTITY"], [19, 43, "ENTITY"], [61, 69, "GENE_OR_GENE_PRODUCT"], [118, 127, "ENTITY"], [127, 139, "ENTITY"], [61, 69, "GGP"], [156, 167, "ENTITY"], [4, 16, "ENTITY"], [69, 77, "GGP"], [156, 167, "GO"], [69, 77, "GENE_OR_GENE_PRODUCT"], [61, 69, "ENTITY"], [19, 34, "GENE_OR_GENE_PRODUCT"], [118, 127, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expressions of immunoglobulin subunits ( IGHG1 , IGHG2 , IGHG4 , IGLC2 , IGLL1 , and IGHE ) were also significant lower in COVID-19-SS ( Fig.3a , h ) , indicating reduced antibody secretion by B cells .", "labels": [[19, 43, "PROTEIN"], [167, 175, "ENTITY"], [61, 69, "DNA"], [19, 43, "GGP"], [127, 139, "GENE_OR_GENE_PRODUCT"], [69, 77, "DNA"], [19, 43, "ENTITY"], [69, 77, "ENTITY"], [61, 69, "GENE_OR_GENE_PRODUCT"], [118, 127, "ENTITY"], [127, 139, "ENTITY"], [61, 69, "GGP"], [69, 77, "GGP"], [156, 167, "ENTITY"], [4, 16, "ENTITY"], [69, 77, "GENE_OR_GENE_PRODUCT"], [156, 167, "GO"], [61, 69, "ENTITY"], [19, 34, "GENE_OR_GENE_PRODUCT"], [118, 127, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The expressions of immunoglobulin subunits ( IGHG1 , IGHG2 , IGHG4 , IGLC2 , IGLL1 , and IGHE ) were also significant lower in COVID-19-SS ( Fig.3a , h ) , indicating reduced antibody secretion by B cells .", "labels": [[19, 43, "PROTEIN"], [61, 69, "ENTITY"], [167, 175, "ENTITY"], [19, 43, "GGP"], [127, 139, "GENE_OR_GENE_PRODUCT"], [69, 77, "DNA"], [19, 43, "ENTITY"], [69, 77, "ENTITY"], [118, 127, "ENTITY"], [127, 139, "ENTITY"], [69, 77, "GGP"], [61, 69, "DNA"], [61, 69, "GENE_OR_GENE_PRODUCT"], [156, 167, "ENTITY"], [4, 16, "ENTITY"], [69, 77, "GENE_OR_GENE_PRODUCT"], [61, 69, "GGP"], [156, 167, "GO"], [19, 34, "GENE_OR_GENE_PRODUCT"], [118, 127, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Through a literature review , we identified a list of important symptoms and mechanisms linked to SARS-CoV-2 , including fever , fatigue , cough 17 , breathing difficulty , septic shock , viral proliferation , immunodeficiency and pulmonary fibrosis 18 ( Figure 4 ) .", "labels": [[145, 160, "ENTITY"], [180, 194, "ENTITY"], [180, 186, "TAXON"], [160, 180, "ENTITY"], [129, 139, "DISEASE"], [231, 241, "DISEASE"], [194, 210, "ORGANISM"], [210, 241, "ENTITY"], [194, 210, "ENTITY"], [241, 255, "ENTITY"], [210, 231, "ORGAN"], [160, 180, "DISEASE"], [129, 139, "ENTITY"], [111, 121, "DISEASE"], [111, 121, "ENTITY"], [10, 28, "ENTITY"]]}
{"text": "Through a literature review , we identified a list of important symptoms and mechanisms linked to SARS-CoV-2 , including fever , fatigue , cough 17 , breathing difficulty , septic shock , viral proliferation , immunodeficiency and pulmonary fibrosis 18 ( Figure 4 ) .", "labels": [[145, 160, "ENTITY"], [180, 194, "ENTITY"], [180, 186, "TAXON"], [160, 180, "ENTITY"], [129, 139, "DISEASE"], [231, 241, "DISEASE"], [194, 210, "ORGANISM"], [210, 241, "ENTITY"], [194, 210, "ENTITY"], [241, 255, "ENTITY"], [210, 231, "ORGAN"], [160, 180, "DISEASE"], [129, 139, "ENTITY"], [111, 121, "DISEASE"], [111, 121, "ENTITY"], [10, 28, "ENTITY"]]}
{"text": "At 48 hpi , both HAE exhibited a well-established infection , with ciliated , goblet and to a lesser extent basal cells showing active production of viral progeny .", "labels": [[101, 114, "CELL"], [101, 114, "CL"], [101, 114, "ENTITY"], [120, 135, "ENTITY"], [146, 155, "ENTITY"], [6, 10, "ENTITY"], [146, 155, "CELL_TYPE"], [101, 114, "CELL_TYPE"]]}
{"text": "Large electron-dense structures corresponding to the accumulation of viral material in active virus replication zones as well as typical double-membrane spherules containing pieces of membranes interspaced among virions being formed were also observed at 48 hpi ( Fig. 2B , D ) .", "labels": [[258, 262, "ENTITY"], [69, 75, "TAXON"], [137, 153, "GO"], [6, 32, "ENTITY"], [184, 194, "ENTITY"], [184, 194, "CELLULAR_COMPONENT"], [137, 163, "ENTITY"], [69, 84, "ENTITY"], [212, 220, "ENTITY"], [53, 66, "ENTITY"], [94, 100, "TAXON"], [137, 163, "CELLULAR_COMPONENT"], [87, 100, "ENTITY"], [112, 118, "ENTITY"]]}
{"text": "Through a literature review , we identified a list of important symptoms and mechanisms linked to SARS-CoV-2 , including fever , fatigue , cough 17 , breathing difficulty , septic shock , viral proliferation , immunodeficiency and pulmonary fibrosis 18 ( Figure 4 ) .", "labels": [[145, 160, "ENTITY"], [180, 194, "ENTITY"], [180, 186, "TAXON"], [160, 180, "ENTITY"], [129, 139, "DISEASE"], [231, 241, "DISEASE"], [210, 241, "ENTITY"], [194, 210, "ORGANISM"], [194, 210, "ENTITY"], [241, 255, "ENTITY"], [160, 180, "DISEASE"], [129, 139, "ENTITY"], [111, 121, "DISEASE"], [210, 231, "ORGAN"], [111, 121, "ENTITY"], [10, 28, "ENTITY"]]}
{"text": "Through a literature review , we identified a list of important symptoms and mechanisms linked to SARS-CoV-2 , including fever , fatigue , cough 17 , breathing difficulty , septic shock , viral proliferation , immunodeficiency and pulmonary fibrosis 18 ( Figure 4 ) .", "labels": [[145, 160, "ENTITY"], [180, 194, "ENTITY"], [180, 186, "TAXON"], [160, 180, "ENTITY"], [129, 139, "DISEASE"], [194, 210, "ORGANISM"], [210, 241, "ENTITY"], [194, 210, "ENTITY"], [231, 241, "DISEASE"], [241, 255, "ENTITY"], [210, 231, "ORGAN"], [160, 180, "DISEASE"], [129, 139, "ENTITY"], [111, 121, "DISEASE"], [111, 121, "ENTITY"], [10, 28, "ENTITY"]]}
{"text": "Two weeks after initiation of DIP treatment , 3 of the 6 severe cases ( 50 % ) and all 4 of the mild cases ( 100 % ) were discharged from the hospital", "labels": [[115, 122, "ENTITY"], [16, 27, "ENTITY"], [4, 10, "ENTITY"], [30, 34, "ENTITY"], [30, 34, "SIMPLE_CHEMICAL"], [34, 44, "ENTITY"], [92, 101, "ENTITY"], [133, 142, "ENTITY"], [30, 34, "CHEMICAL"]]}
{"text": "Moreover , the phosphorylation of STAT1 and STAT5 was increased in the activated na\u00efve CD4 + T cells taken from young adults in order to lower their response threshold to type I IFN stimulation", "labels": [[81, 95, "ENTITY"], [168, 178, "GENE_OR_GENE_PRODUCT"], [107, 118, "ENTITY"], [168, 178, "ENTITY"], [149, 158, "ENTITY"], [168, 178, "GGP"], [178, 182, "ENTITY"], [91, 95, "CL"]]}
{"text": "Moreover , the phosphorylation of STAT1 and STAT5 was increased in the activated na\u00efve CD4 + T cells taken from young adults in order to lower their response threshold to type I IFN stimulation", "labels": [[81, 95, "ENTITY"], [168, 178, "GENE_OR_GENE_PRODUCT"], [107, 118, "ENTITY"], [168, 178, "ENTITY"], [149, 158, "ENTITY"], [168, 178, "GGP"], [178, 182, "ENTITY"], [91, 95, "CL"]]}
{"text": "High viral replication correlated with a reduction in epithelium integrity at 48 hpi , reflected by more than 2.8- and 4-fold decreases in bronchial and nasal HAE TEER values , respectively , followed by a partial recovery in the case of bronchial HAE ( Fig. 1E ) .", "labels": [[235, 248, "ENTITY"], [81, 85, "ENTITY"], [153, 163, "CELL"], [126, 159, "DISEASE"], [23, 34, "ENTITY"], [206, 214, "ENTITY"], [235, 254, "CELL"], [5, 11, "TAXON"], [41, 51, "ENTITY"], [65, 75, "ENTITY"], [235, 248, "DISEASE"], [5, 23, "ENTITY"], [54, 65, "ENTITY"], [0, 5, "ENTITY"], [54, 65, "TISSUE"]]}
{"text": "Large electron-dense structures corresponding to the accumulation of viral material in active virus replication zones as well as typical double-membrane spherules containing pieces of membranes interspaced among virions being formed were also observed at 48 hpi ( Fig. 2B , D ) .", "labels": [[258, 262, "ENTITY"], [69, 75, "TAXON"], [137, 153, "GO"], [6, 32, "ENTITY"], [137, 163, "ENTITY"], [184, 194, "ENTITY"], [184, 194, "CELLULAR_COMPONENT"], [69, 84, "ENTITY"], [212, 220, "ENTITY"], [53, 66, "ENTITY"], [94, 100, "TAXON"], [87, 100, "ENTITY"], [137, 163, "CELLULAR_COMPONENT"], [112, 118, "ENTITY"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [142, 150, "GENE_OR_GENE_PRODUCT"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "GGP"], [315, 328, "DISEASE"], [142, 148, "GGP"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [134, 140, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [407, 421, "ENTITY"], [134, 140, "DNA"], [407, 421, "GGP"], [7, 17, "ENTITY"], [275, 282, "GENE_OR_GENE_PRODUCT"], [134, 140, "ENTITY"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [142, 150, "GENE_OR_GENE_PRODUCT"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "GGP"], [315, 328, "DISEASE"], [142, 148, "GGP"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [134, 140, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [407, 421, "ENTITY"], [134, 140, "DNA"], [407, 421, "GGP"], [7, 17, "ENTITY"], [275, 282, "GENE_OR_GENE_PRODUCT"], [134, 140, "ENTITY"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [134, 140, "DNA"], [142, 150, "GENE_OR_GENE_PRODUCT"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [223, 230, "ENTITY"], [142, 148, "GGP"], [142, 148, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [134, 140, "DNA"], [142, 150, "GENE_OR_GENE_PRODUCT"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [223, 230, "ENTITY"], [142, 148, "GGP"], [142, 148, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 150, "GENE_OR_GENE_PRODUCT"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [142, 150, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [142, 150, "GENE_OR_GENE_PRODUCT"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [275, 282, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [275, 282, "GGP"], [315, 328, "DISEASE"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [275, 282, "PROTEIN"], [407, 421, "SIMPLE_CHEMICAL"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [275, 282, "GGP"], [127, 134, "PROTEIN"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [275, 282, "ENTITY"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "GENE_OR_GENE_PRODUCT"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [297, 304, "ENTITY"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Moreover , the relative expression of a subset of genes associated with the NF-kB and TNF\u03b1 pathways ( e.g. IL18 , IL18R1 , NFKB2 , NFKBIA , TNFA , and TNFAIP3 ) is mostly unchanged all throughout the infection in bronchial HAE but it is highly upregulated in nasal HAE at 48 hpi and onwards ( Fig. 3C and Data S1 ) .", "labels": [[114, 123, "GENE_OR_GENE_PRODUCT"], [114, 123, "ENTITY"], [244, 256, "ENTITY"], [102, 107, "PROTEIN"], [293, 301, "ENTITY"], [145, 151, "GGP"], [185, 200, "DISEASE"], [123, 131, "GGP"], [131, 138, "ENTITY"], [102, 107, "GENE_OR_GENE_PRODUCT"], [123, 131, "GENE_OR_GENE_PRODUCT"], [185, 200, "ENTITY"], [102, 107, "ENTITY"], [283, 291, "ENTITY"], [145, 151, "ENTITY"], [145, 151, "GENE_OR_GENE_PRODUCT"], [131, 138, "DNA"], [114, 123, "PROTEIN"], [200, 213, "ENTITY"], [237, 244, "ENTITY"], [200, 213, "DISEASE"], [123, 131, "DNA"], [223, 227, "ENTITY"], [114, 123, "GGP"], [145, 151, "PROTEIN"], [200, 213, "CANCER"], [244, 259, "CANCER"], [123, 131, "ENTITY"]]}
{"text": "Moreover , the relative expression of a subset of genes associated with the NF-kB and TNF\u03b1 pathways ( e.g. IL18 , IL18R1 , NFKB2 , NFKBIA , TNFA , and TNFAIP3 ) is mostly unchanged all throughout the infection in bronchial HAE but it is highly upregulated in nasal HAE at 48 hpi and onwards ( Fig. 3C and Data S1 ) .", "labels": [[114, 123, "GENE_OR_GENE_PRODUCT"], [244, 256, "ENTITY"], [114, 123, "ENTITY"], [114, 123, "GGP"], [102, 107, "PROTEIN"], [293, 301, "ENTITY"], [145, 151, "GGP"], [123, 131, "GENE_OR_GENE_PRODUCT"], [114, 123, "PROTEIN"], [123, 131, "ENTITY"], [185, 200, "DISEASE"], [131, 138, "ENTITY"], [102, 107, "GENE_OR_GENE_PRODUCT"], [185, 200, "ENTITY"], [102, 107, "ENTITY"], [283, 291, "ENTITY"], [145, 151, "ENTITY"], [145, 151, "GENE_OR_GENE_PRODUCT"], [131, 138, "DNA"], [123, 131, "DNA"], [200, 213, "ENTITY"], [237, 244, "ENTITY"], [123, 131, "GGP"], [200, 213, "DISEASE"], [223, 227, "ENTITY"], [145, 151, "PROTEIN"], [200, 213, "CANCER"], [244, 259, "CANCER"]]}
{"text": "Moreover , the relative expression of a subset of genes associated with the NF-kB and TNF\u03b1 pathways ( e.g. IL18 , IL18R1 , NFKB2 , NFKBIA , TNFA , and TNFAIP3 ) is mostly unchanged all throughout the infection in bronchial HAE but it is highly upregulated in nasal HAE at 48 hpi and onwards ( Fig. 3C and Data S1 ) .", "labels": [[114, 123, "GENE_OR_GENE_PRODUCT"], [244, 256, "ENTITY"], [114, 123, "ENTITY"], [114, 123, "GGP"], [102, 107, "PROTEIN"], [293, 301, "ENTITY"], [145, 151, "GGP"], [114, 123, "PROTEIN"], [185, 200, "DISEASE"], [123, 131, "GGP"], [131, 138, "ENTITY"], [102, 107, "GENE_OR_GENE_PRODUCT"], [123, 131, "GENE_OR_GENE_PRODUCT"], [185, 200, "ENTITY"], [102, 107, "ENTITY"], [283, 291, "ENTITY"], [145, 151, "ENTITY"], [145, 151, "GENE_OR_GENE_PRODUCT"], [131, 138, "DNA"], [200, 213, "ENTITY"], [237, 244, "ENTITY"], [200, 213, "DISEASE"], [123, 131, "DNA"], [223, 227, "ENTITY"], [145, 151, "PROTEIN"], [200, 213, "CANCER"], [244, 259, "CANCER"], [123, 131, "ENTITY"]]}
{"text": "Moreover , the relative expression of a subset of genes associated with the NF-kB and TNF\u03b1 pathways ( e.g. IL18 , IL18R1 , NFKB2 , NFKBIA , TNFA , and TNFAIP3 ) is mostly unchanged all throughout the infection in bronchial HAE but it is highly upregulated in nasal HAE at 48 hpi and onwards ( Fig. 3C and Data S1 ) .", "labels": [[114, 123, "GENE_OR_GENE_PRODUCT"], [244, 256, "ENTITY"], [114, 123, "ENTITY"], [114, 123, "GGP"], [102, 107, "PROTEIN"], [293, 301, "ENTITY"], [145, 151, "GGP"], [114, 123, "PROTEIN"], [185, 200, "DISEASE"], [123, 131, "GGP"], [131, 138, "ENTITY"], [102, 107, "GENE_OR_GENE_PRODUCT"], [123, 131, "GENE_OR_GENE_PRODUCT"], [185, 200, "ENTITY"], [102, 107, "ENTITY"], [283, 291, "ENTITY"], [145, 151, "ENTITY"], [145, 151, "GENE_OR_GENE_PRODUCT"], [131, 138, "DNA"], [200, 213, "ENTITY"], [237, 244, "ENTITY"], [200, 213, "DISEASE"], [123, 131, "DNA"], [223, 227, "ENTITY"], [145, 151, "PROTEIN"], [200, 213, "CANCER"], [244, 259, "CANCER"], [123, 131, "ENTITY"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [0, 10, "CHEMICAL"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [0, 10, "ENTITY"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [198, 232, "ENTITY"], [0, 10, "SIMPLE_CHEMICAL"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [0, 10, "CHEMICAL"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [0, 10, "ENTITY"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [198, 232, "ENTITY"], [0, 10, "SIMPLE_CHEMICAL"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [0, 10, "CHEMICAL"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [0, 10, "ENTITY"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [198, 232, "ENTITY"], [0, 10, "SIMPLE_CHEMICAL"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [0, 10, "CHEMICAL"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [0, 10, "ENTITY"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [198, 232, "ENTITY"], [0, 10, "SIMPLE_CHEMICAL"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Diltiazem is a voltage gated Ca 2 + channel antagonist currently used as anti-hypertensive for the control of angina pectoris and cardiac arrhythmia ( 26 ) , which we have recently repurposed as an effective host-directed influenza inhibitor due to its so far undescribed capacity of inducing the interferon ( IFN ) antiviral response , particularly type III IFNs ( Fig. S2 ) ( 8) .", "labels": [[15, 29, "ENTITY"], [29, 44, "SIMPLE_CHEMICAL"], [130, 138, "ENTITY"], [297, 308, "ENTITY"], [337, 355, "ENTITY"], [29, 36, "ENTITY"], [0, 10, "CHEMICAL"], [293, 316, "PROTEIN"], [260, 272, "ENTITY"], [130, 138, "DISEASE"], [110, 117, "DISEASE"], [337, 355, "GGP"], [110, 117, "ENTITY"], [222, 232, "CHEBI"], [337, 355, "GENE_OR_GENE_PRODUCT"], [0, 10, "ENTITY"], [310, 326, "ENTITY"], [293, 308, "GGP"], [337, 355, "PROTEIN"], [198, 232, "ENTITY"], [0, 10, "SIMPLE_CHEMICAL"], [359, 366, "GENE_OR_GENE_PRODUCT"], [29, 32, "CHEMICAL"]]}
{"text": "Increased antibody-secreting cells (ASCs),follicular helper T cells ( TFH cells ) , activated CD4 + T cells and CD8 + T cells and immunoglobulin M ( IgM ) and IgG antibodies that bound the COVID-19- causing coronavirus SARS-CoV-2 were detected in blood before symptomatic recovery .", "labels": [[84, 102, "GGP"], [10, 35, "CELL_TYPE"], [235, 244, "ENTITY"], [70, 74, "ENTITY"], [0, 10, "ENTITY"], [53, 68, "CELL_TYPE"], [153, 163, "PROTEIN"], [70, 74, "CELL"], [53, 68, "ENTITY"], [84, 102, "ENTITY"], [60, 68, "CL"], [29, 35, "CL"], [70, 74, "CELL_TYPE"], [207, 219, "CHEMICAL"], [199, 219, "ENTITY"], [235, 244, "ORGANISM_SUBSTANCE"], [219, 235, "ENTITY"], [153, 163, "ENTITY"], [179, 189, "PROTEIN"], [108, 120, "CELL_TYPE"], [179, 189, "ENTITY"], [199, 219, "ORGANISM"], [163, 174, "ENTITY"], [155, 163, "GO"], [260, 272, "ENTITY"], [84, 94, "GENE_OR_GENE_PRODUCT"], [179, 189, "GENE_OR_GENE_PRODUCT"], [130, 147, "ENTITY"], [130, 147, "PROTEIN"], [153, 163, "GENE_OR_GENE_PRODUCT"], [108, 120, "ENTITY"], [108, 120, "GGP"], [10, 35, "CELL"], [82, 102, "CELL_TYPE"], [130, 147, "GENE_OR_GENE_PRODUCT"], [10, 35, "ENTITY"]]}
{"text": "Increased antibody-secreting cells (ASCs),follicular helper T cells ( TFH cells ) , activated CD4 + T cells and CD8 + T cells and immunoglobulin M ( IgM ) and IgG antibodies that bound the COVID-19- causing coronavirus SARS-CoV-2 were detected in blood before symptomatic recovery .", "labels": [[84, 102, "GGP"], [235, 244, "ENTITY"], [70, 74, "ENTITY"], [0, 10, "ENTITY"], [153, 163, "PROTEIN"], [53, 68, "CELL_TYPE"], [70, 74, "CELL"], [84, 102, "ENTITY"], [60, 68, "CL"], [29, 35, "CL"], [70, 74, "CELL_TYPE"], [207, 219, "CHEMICAL"], [199, 219, "ENTITY"], [235, 244, "ORGANISM_SUBSTANCE"], [219, 235, "ENTITY"], [10, 35, "ENTITY"], [153, 163, "ENTITY"], [179, 189, "PROTEIN"], [108, 120, "CELL_TYPE"], [10, 35, "CELL"], [179, 189, "ENTITY"], [199, 219, "ORGANISM"], [163, 174, "ENTITY"], [155, 163, "GO"], [260, 272, "ENTITY"], [84, 94, "GENE_OR_GENE_PRODUCT"], [179, 189, "GENE_OR_GENE_PRODUCT"], [130, 147, "ENTITY"], [10, 35, "CELL_TYPE"], [130, 147, "PROTEIN"], [153, 163, "GENE_OR_GENE_PRODUCT"], [108, 120, "ENTITY"], [108, 120, "GGP"], [82, 102, "CELL_TYPE"], [53, 68, "ENTITY"], [130, 147, "GENE_OR_GENE_PRODUCT"]]}
{"text": "As the single-nucleotide polymorphism rs12252-C/C in the gene IFITM3 ( which encodes interferon-induced transmembrane protein 3 ) is linked to severe influenza6,7 , we analyzed IFITM3-rs12252 in the patient with COVID-19 and found the \u2018 risk \u2019 IFITM3-rs12252-C/C variant ( Extended Data Fig. 2b ) .", "labels": [[7, 38, "SO"], [7, 38, "ENTITY"], [57, 69, "ENTITY"], [143, 150, "ENTITY"], [244, 263, "SO"], [168, 177, "DISEASE"], [143, 150, "PROTEIN"], [85, 126, "GENE_OR_GENE_PRODUCT"], [7, 50, "DNA"], [62, 69, "GENE_OR_GENE_PRODUCT"], [168, 177, "PROTEIN"], [38, 50, "GENE_OR_GENE_PRODUCT"], [237, 263, "PROTEIN"], [85, 126, "ENTITY"], [57, 69, "SO"], [237, 244, "CHEMICAL"], [237, 263, "ENTITY"], [263, 273, "ENTITY"], [85, 126, "PROTEIN"], [231, 237, "ENTITY"], [62, 69, "PROTEIN"]]}
{"text": "These results show that blocking CD147 on the host cells has an inhibitory effect on SARS-CoV-2 , suggesting an essential role of CD147 in facilitating SARS-CoV-2 invasion for host cells .", "labels": [[85, 96, "ENTITY"], [85, 96, "ENTITY"], [46, 51, "CL"], [64, 75, "ENTITY"], [46, 57, "CELL_TYPE"], [6, 14, "ENTITY"], [33, 39, "GGP"], [33, 39, "GENE_OR_GENE_PRODUCT"], [46, 51, "CELL_TYPE"], [46, 51, "CELL"], [46, 57, "CL"], [46, 57, "CELL"], [33, 39, "ENTITY"], [24, 33, "ENTITY"], [85, 96, "CHEMICAL"], [46, 57, "ENTITY"], [46, 51, "ENTITY"], [85, 96, "SIMPLE_CHEMICAL"], [33, 39, "PROTEIN"]]}
{"text": "The infection of SARS virus is initiated by the attachment of S protein to the receptor ACE2 [ 19 ] , followed by cleavage with host cell protease TMPRSS2 [ 20 - 22 ] . The viruses are then transported through the early and late endosomes , subsequently endo/lysosomes , during which host protein extracellular proteases including cathepsin L mediates the further cleavage of S protein in endocytic vesicles [ 23 - 26 ] . The activated S protein will then activate the fusion between viral and cell membranes and release the genome of SARS-CoV into cytoplasm .", "labels": [[88, 95, "GENE_OR_GENE_PRODUCT"], [181, 190, "ENTITY"], [64, 72, "ENTITY"], [4, 14, "DISEASE"], [271, 297, "TAXON"], [321, 331, "ENTITY"], [535, 544, "ENTITY"], [48, 59, "ENTITY"], [214, 229, "ENTITY"], [62, 72, "ENTITY"], [364, 376, "CHEBI"], [64, 72, "CHEBI"], [476, 494, "CELLULAR_COMPONENT"], [138, 147, "GGP"], [123, 147, "CELL"], [364, 376, "ENTITY"], [535, 544, "ORGANISM_SUBSTANCE"], [271, 311, "PROTEIN"], [17, 28, "ORGANISM"], [364, 376, "PROTEIN"], [321, 331, "GGP"], [4, 14, "ENTITY"], [88, 93, "GGP"], [17, 28, "ENTITY"], [284, 311, "CELLULAR_COMPONENT"], [535, 544, "GO"], [476, 494, "GO"], [476, 494, "ENTITY"], [378, 389, "GO"], [62, 72, "PROTEIN"], [278, 311, "ENTITY"], [321, 331, "PROTEIN"], [123, 147, "ENTITY"], [123, 133, "CL"], [321, 331, "GENE_OR_GENE_PRODUCT"], [378, 389, "CELLULAR_COMPONENT"], [214, 229, "CELLULAR_COMPONENT"], [123, 157, "PROTEIN"], [22, 28, "TAXON"], [165, 173, "ENTITY"], [79, 93, "ENTITY"], [241, 254, "ENTITY"], [378, 389, "ENTITY"], [17, 22, "DISEASE"], [165, 173, "TAXON"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "This virus , named \u201c Severe Acute Respiratory Syndrome-related Coronavirus 2 \u201d ( Severe Acute Respiratory Syndrome-related Coronavirus 2\u201d ) , can cause a severe and even fatal respiratory disease , called Coronavirus disease-19 ( COVID-19 ) , and lead to acute respiratory distress syndrome ( ARDS ) .", "labels": [[106, 124, "PROTEIN"], [46, 75, "ORGANISM"], [106, 115, "TAXON"], [-1, 10, "CHEMICAL"], [-1, 18, "ENTITY"], [106, 124, "ENTITY"], [-1, 18, "DISEASE"], [184, 195, "DISEASE"], [21, 34, "ENTITY"], [5, 11, "TAXON"], [159, 184, "DISEASE"], [46, 63, "ENTITY"], [34, 46, "ENTITY"], [34, 75, "CHEMICAL"], [5, 11, "ENTITY"], [152, 184, "ENTITY"], [106, 124, "DISEASE"], [106, 124, "ORGANISM"], [184, 195, "ENTITY"], [-1, 10, "SIMPLE_CHEMICAL"], [-1, 10, "ENTITY"]]}
{"text": "More patients with ARDS presented with initial symptoms of dyspnea compared with those without ARDS ( difference , 33.9%;95%CI , 19.7%-48.1%;P < .001 )", "labels": [[19, 24, "DISEASE"], [59, 67, "DISEASE"], [5, 14, "ENTITY"], [59, 67, "ENTITY"], [19, 24, "DISEASE"], [5, 14, "ORGANISM"], [19, 24, "ENTITY"], [19, 24, "ENTITY"], [47, 56, "ENTITY"]]}
{"text": "For those patients with most severe ARDS , extracorporeal membrane oxygenation or prone position is recommended .", "labels": [[82, 88, "ENTITY"], [29, 36, "ENTITY"], [10, 19, "ENTITY"], [36, 41, "ENTITY"], [43, 67, "ENTITY"], [10, 19, "ORGANISM"], [36, 41, "DISEASE"]]}
{"text": "The clinical manifestations of COVID-19 are protean , which include asymptomatic carrier , ARD , and pneumonia of varying degrees of severity . First , asymptomatic cases were diagnosed based on positive viral nucleic acid test results , but without any COVID-19 symptoms , such as fever , gastrointestinal , or respiratory symptoms , and no significant abnormalities on chest radiograph [ 7,8 ] .", "labels": [[186, 195, "ENTITY"], [290, 324, "ENTITY"], [68, 81, "ENTITY"], [223, 228, "ENTITY"], [31, 40, "ENTITY"], [31, 40, "ENTITY"], [144, 152, "ENTITY"], [114, 122, "ENTITY"], [242, 254, "ENTITY"], [204, 218, "CHEMICAL"], [354, 377, "ENTITY"], [342, 354, "ENTITY"], [282, 290, "ENTITY"], [195, 218, "TAXON"], [242, 254, "GENE_OR_GENE_PRODUCT"], [282, 290, "ORGAN"], [44, 52, "ENTITY"], [195, 223, "ENTITY"], [4, 28, "ENTITY"], [31, 40, "DISEASE"], [31, 40, "GENE_OR_GENE_PRODUCT"], [324, 342, "ENTITY"]]}
{"text": "Moreover , all the deceased patients and 14 ( 44 % ) recovered patients had an arterial partial pressure of oxygen to fraction of inspired oxygen ratio of 300 , indicating that these patients had developed acute respiratory distress syndrome , whereas severe acute respiratory distress syndrome ( \u2264100 ) developed only in deceased patients ( 16 ; 46 % ) .", "labels": [[196, 233, "DISEASE"], [19, 28, "ORGANISM"], [196, 233, "ENTITY"], [76, 96, "ENTITY"], [127, 146, "ENTITY"], [19, 28, "ENTITY"], [130, 139, "CHEMICAL"], [314, 322, "ENTITY"], [53, 63, "ENTITY"], [53, 63, "ORGANISM"], [130, 139, "CHEBI"], [252, 286, "ENTITY"], [206, 233, "DISEASE"], [130, 139, "SIMPLE_CHEMICAL"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [114, 133, "DISEASE"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [60, 96, "ENTITY"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [133, 141, "ENTITY"], [66, 96, "DISEASE"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"]]}
{"text": "Consistent with others , most of severe COVID-19 patients in our ICU ward had persistent very high level of erythematosus sedimentation rate ( ESR ) , CRP , and high level of IL-6,TNFa , IL-1B , IL-8 , IL2R , etc , and were associated with ARDS , hypercoagulation and disseminated intravascular coagulation ( DIC ) , manifested as thrombosis , thrombocytopenia , gangrene of extremities .", "labels": [[0, 16, "ENTITY"], [175, 187, "GENE_OR_GENE_PRODUCT"], [328, 344, "ENTITY"], [175, 187, "ENTITY"], [175, 187, "DNA"], [328, 344, "DISEASE"], [99, 108, "GGP"], [65, 69, "ENTITY"], [235, 247, "DISEASE"], [108, 136, "ENTITY"], [344, 363, "ENTITY"], [235, 247, "ENTITY"], [187, 193, "ENTITY"], [99, 108, "DNA"], [187, 193, "GENE_OR_GENE_PRODUCT"], [268, 281, "IMMATERIAL_ANATOMICAL_ENTITY"], [268, 295, "DISEASE"], [99, 108, "ENTITY"], [344, 363, "ORGAN"], [175, 187, "GGP"], [317, 328, "DISEASE"], [94, 99, "ENTITY"], [187, 193, "PROTEIN"], [247, 295, "ENTITY"], [40, 49, "GENE_OR_GENE_PRODUCT"], [215, 224, "ENTITY"], [187, 193, "GGP"], [99, 108, "GENE_OR_GENE_PRODUCT"], [317, 328, "ENTITY"]]}
{"text": "Infection with these highly pathogenic coronaviruses can result in Acute Respiratory Distress Syndrome ( ARDS ) , which may lead to long-term reduction in lung function , arrhythmia , and death .", "labels": [[152, 160, "ENTITY"], [73, 103, "DISEASE"], [39, 53, "ORGANISM"], [28, 39, "ENTITY"], [132, 142, "ENTITY"], [0, 10, "DISEASE"], [160, 171, "DISEASE"], [39, 53, "ENTITY"], [160, 171, "ENTITY"], [0, 10, "ENTITY"], [67, 103, "ENTITY"], [67, 105, "ORGANISM"]]}
{"text": "More patients with ARDS presented with initial symptoms of dyspnea compared with those without ARDS ( difference , 33.9%;95%CI , 19.7%-48.1%;P < .001 )", "labels": [[19, 24, "ENTITY"], [19, 24, "DISEASE"], [59, 67, "ENTITY"], [5, 14, "ENTITY"], [19, 24, "DISEASE"], [5, 14, "ORGANISM"], [59, 67, "DISEASE"], [19, 24, "ENTITY"], [47, 56, "ENTITY"]]}
{"text": "Compared with patients without ARDS , patients with ARDS had a higher proportion of comorbidities , including hypertension ( difference , 13.7 % ; 95%CI , 1.3%-26.1 % ; P = .02 ) and diabetes ( difference , 13.9 % ; 95 % CI , 3.6%-24.2 % ; P = .002 ) .", "labels": [[100, 110, "ENTITY"], [31, 36, "ENTITY"], [14, 23, "ORGANISM"], [14, 23, "ENTITY"], [31, 36, "DISEASE"], [100, 110, "DISEASE"], [0, 9, "ENTITY"], [183, 194, "ENTITY"]]}
{"text": "Compared with patients without ARDS , patients with ARDS had a higher proportion of comorbidities , including hypertension ( difference , 13.7 % ; 95%CI , 1.3%-26.1 % ; P = .02 ) and diabetes ( difference , 13.9 % ; 95 % CI , 3.6%-24.2 % ; P = .002 ) .", "labels": [[100, 110, "ENTITY"], [31, 36, "ENTITY"], [14, 23, "ORGANISM"], [14, 23, "ENTITY"], [31, 36, "DISEASE"], [100, 110, "DISEASE"], [0, 9, "ENTITY"], [183, 194, "ENTITY"]]}
{"text": "Compared with patients without ARDS , for patients with ARDS , the value of liver damage indices ( total bilirubin [ difference , 1.90mg/dL ; 95%CI , 0.60 - 3.30 mg/dL ; P = .004 ] ) , renal dysfunction indices ( urea [ difference , 1.69 mM ; 95 % CI , 1.10 - 2.29mM;P < .001 ] ) , inflammation-related indices ( interleukin- 6 [ IL-6 ] [ difference , 0.93 pg/L ; 95%CI , 0.07 - 1.98 pg/L ; P = .03 ] ) , and coagulation function indices ( D-dimer [ difference , 0.52 \u03bcg/mL ; 95 % CI , 0.21 - 0.94 \u03bcg/mL ; P < .001 ] ) were significantly elevated .", "labels": [[99, 105, "GGP"], [403, 409, "ENTITY"], [258, 282, "ENTITY"], [31, 36, "ENTITY"], [194, 203, "CHEMICAL"], [14, 23, "ENTITY"], [403, 409, "PROTEIN"], [0, 9, "ENTITY"], [73, 89, "ENTITY"], [409, 421, "ENTITY"], [73, 82, "DISEASE"], [191, 203, "CHEMICAL"], [99, 105, "SIMPLE_CHEMICAL"], [172, 191, "ENTITY"], [191, 203, "CHEBI"], [31, 36, "DISEASE"], [89, 99, "ENTITY"], [130, 142, "CHEMICAL"], [191, 203, "ENTITY"], [105, 117, "ENTITY"], [14, 23, "ORGANISM"], [372, 401, "ENTITY"], [99, 105, "CHEMICAL"], [97, 105, "ENTITY"], [403, 409, "GGP"]]}
{"text": "For patients with ARDS who died , the value of liver damage indices ( total bilirubin [ difference , 2.60 mg/dL ; 95 % CI , 0.30 - 5.20mg/dL;P = .03 ] ) , renal dysfunction indices ( urea [ difference , 1.50 mM ; 95%CI , 0.50 - 2.70 mM ; P = .004 ] ) , inflammation- related indices ( IL-6 [ difference , 3.88 pg/L ; 95 % CI , 2.20 - 6.13pg/L;P < .001 ] ) , and coagulation function indices ( Ddimer [ difference , 2.10 \u03bcg/mL ; 95 % CI , 0.89 - 5.27 \u03bcg/mL ; P = .001 ] ) were significantly elevated compared with patients with ARDS who survived .", "labels": [[60, 70, "ENTITY"], [47, 60, "ENTITY"], [161, 173, "ENTITY"], [292, 310, "SIMPLE_CHEMICAL"], [469, 476, "ENTITY"], [68, 76, "ENTITY"], [327, 356, "ENTITY"], [70, 76, "CHEMICAL"], [161, 173, "CHEBI"], [469, 476, "ORGANISM"], [70, 76, "SIMPLE_CHEMICAL"], [4, 13, "ENTITY"], [267, 275, "ENTITY"], [88, 99, "CHEMICAL"], [18, 23, "ENTITY"], [47, 53, "DISEASE"], [88, 101, "CHEMICAL"], [143, 161, "ENTITY"], [18, 23, "DISEASE"], [143, 161, "DISEASE"], [70, 76, "GGP"], [161, 173, "CHEMICAL"], [27, 32, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Compared with patients without ARDS , for patients with ARDS , the value of liver damage indices ( total bilirubin [ difference , 1.90mg/dL ; 95%CI , 0.60 - 3.30 mg/dL ; P = .004 ] ) , renal dysfunction indices ( urea [ difference , 1.69 mM ; 95 % CI , 1.10 - 2.29mM;P < .001 ] ) , inflammation-related indices ( interleukin- 6 [ IL-6 ] [ difference , 0.93 pg/L ; 95%CI , 0.07 - 1.98 pg/L ; P = .03 ] ) , and coagulation function indices ( D-dimer [ difference , 0.52 \u03bcg/mL ; 95 % CI , 0.21 - 0.94 \u03bcg/mL ; P < .001 ] ) were significantly elevated .", "labels": [[99, 105, "GGP"], [403, 409, "ENTITY"], [258, 282, "ENTITY"], [31, 36, "ENTITY"], [194, 203, "CHEMICAL"], [14, 23, "ENTITY"], [403, 409, "PROTEIN"], [0, 9, "ENTITY"], [73, 89, "ENTITY"], [409, 421, "ENTITY"], [73, 82, "DISEASE"], [191, 203, "CHEMICAL"], [99, 105, "SIMPLE_CHEMICAL"], [172, 191, "ENTITY"], [191, 203, "CHEBI"], [31, 36, "DISEASE"], [89, 99, "ENTITY"], [130, 142, "CHEMICAL"], [191, 203, "ENTITY"], [105, 117, "ENTITY"], [14, 23, "ORGANISM"], [372, 401, "ENTITY"], [99, 105, "CHEMICAL"], [97, 105, "ENTITY"], [403, 409, "GGP"]]}
{"text": "For patients with ARDS who died , the value of liver damage indices ( total bilirubin [ difference , 2.60 mg/dL ; 95 % CI , 0.30 - 5.20mg/dL;P = .03 ] ) , renal dysfunction indices ( urea [ difference , 1.50 mM ; 95%CI , 0.50 - 2.70 mM ; P = .004 ] ) , inflammation- related indices ( IL-6 [ difference , 3.88 pg/L ; 95 % CI , 2.20 - 6.13pg/L;P < .001 ] ) , and coagulation function indices ( Ddimer [ difference , 2.10 \u03bcg/mL ; 95 % CI , 0.89 - 5.27 \u03bcg/mL ; P = .001 ] ) were significantly elevated compared with patients with ARDS who survived .", "labels": [[60, 70, "ENTITY"], [47, 60, "ENTITY"], [161, 173, "ENTITY"], [292, 310, "SIMPLE_CHEMICAL"], [469, 476, "ENTITY"], [68, 76, "ENTITY"], [327, 356, "ENTITY"], [70, 76, "CHEMICAL"], [161, 173, "CHEBI"], [469, 476, "ORGANISM"], [70, 76, "SIMPLE_CHEMICAL"], [267, 275, "ENTITY"], [4, 13, "ENTITY"], [88, 99, "CHEMICAL"], [18, 23, "ENTITY"], [47, 53, "DISEASE"], [88, 101, "CHEMICAL"], [143, 161, "ENTITY"], [18, 23, "DISEASE"], [143, 161, "DISEASE"], [70, 76, "GGP"], [161, 173, "CHEMICAL"], [27, 32, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Compared with patients without ARDS , for patients with ARDS , the value of liver damage indices ( total bilirubin [ difference , 1.90mg/dL ; 95%CI , 0.60 - 3.30 mg/dL ; P = .004 ] ) , renal dysfunction indices ( urea [ difference , 1.69 mM ; 95 % CI , 1.10 - 2.29mM;P < .001 ] ) , inflammation-related indices ( interleukin- 6 [ IL-6 ] [ difference , 0.93 pg/L ; 95%CI , 0.07 - 1.98 pg/L ; P = .03 ] ) , and coagulation function indices ( D-dimer [ difference , 0.52 \u03bcg/mL ; 95 % CI , 0.21 - 0.94 \u03bcg/mL ; P < .001 ] ) were significantly elevated .", "labels": [[99, 105, "GGP"], [403, 409, "ENTITY"], [258, 282, "ENTITY"], [31, 36, "ENTITY"], [194, 203, "CHEMICAL"], [14, 23, "ENTITY"], [403, 409, "PROTEIN"], [0, 9, "ENTITY"], [73, 89, "ENTITY"], [409, 421, "ENTITY"], [73, 82, "DISEASE"], [191, 203, "CHEMICAL"], [99, 105, "SIMPLE_CHEMICAL"], [172, 191, "ENTITY"], [191, 203, "CHEBI"], [31, 36, "DISEASE"], [89, 99, "ENTITY"], [130, 142, "CHEMICAL"], [191, 203, "ENTITY"], [105, 117, "ENTITY"], [14, 23, "ORGANISM"], [372, 401, "ENTITY"], [99, 105, "CHEMICAL"], [97, 105, "ENTITY"], [403, 409, "GGP"]]}
{"text": "For patients with ARDS who died , the value of liver damage indices ( total bilirubin [ difference , 2.60 mg/dL ; 95 % CI , 0.30 - 5.20mg/dL;P = .03 ] ) , renal dysfunction indices ( urea [ difference , 1.50 mM ; 95%CI , 0.50 - 2.70 mM ; P = .004 ] ) , inflammation- related indices ( IL-6 [ difference , 3.88 pg/L ; 95 % CI , 2.20 - 6.13pg/L;P < .001 ] ) , and coagulation function indices ( Ddimer [ difference , 2.10 \u03bcg/mL ; 95 % CI , 0.89 - 5.27 \u03bcg/mL ; P = .001 ] ) were significantly elevated compared with patients with ARDS who survived .", "labels": [[60, 70, "ENTITY"], [47, 60, "ENTITY"], [161, 173, "ENTITY"], [292, 310, "SIMPLE_CHEMICAL"], [469, 476, "ENTITY"], [68, 76, "ENTITY"], [327, 356, "ENTITY"], [70, 76, "CHEMICAL"], [161, 173, "CHEBI"], [469, 476, "ORGANISM"], [70, 76, "SIMPLE_CHEMICAL"], [4, 13, "ENTITY"], [267, 275, "ENTITY"], [88, 99, "CHEMICAL"], [18, 23, "ENTITY"], [47, 53, "DISEASE"], [88, 101, "CHEMICAL"], [143, 161, "ENTITY"], [18, 23, "DISEASE"], [143, 161, "DISEASE"], [70, 76, "GGP"], [161, 173, "CHEMICAL"], [27, 32, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Compared with patients without ARDS , for patients with ARDS , the value of liver damage indices ( total bilirubin [ difference , 1.90mg/dL ; 95%CI , 0.60 - 3.30 mg/dL ; P = .004 ] ) , renal dysfunction indices ( urea [ difference , 1.69 mM ; 95 % CI , 1.10 - 2.29mM;P < .001 ] ) , inflammation-related indices ( interleukin- 6 [ IL-6 ] [ difference , 0.93 pg/L ; 95%CI , 0.07 - 1.98 pg/L ; P = .03 ] ) , and coagulation function indices ( D-dimer [ difference , 0.52 \u03bcg/mL ; 95 % CI , 0.21 - 0.94 \u03bcg/mL ; P < .001 ] ) were significantly elevated .", "labels": [[99, 105, "GGP"], [403, 409, "ENTITY"], [258, 282, "ENTITY"], [31, 36, "ENTITY"], [194, 203, "CHEMICAL"], [14, 23, "ENTITY"], [403, 409, "PROTEIN"], [0, 9, "ENTITY"], [73, 89, "ENTITY"], [409, 421, "ENTITY"], [73, 82, "DISEASE"], [191, 203, "CHEMICAL"], [99, 105, "SIMPLE_CHEMICAL"], [172, 191, "ENTITY"], [191, 203, "CHEBI"], [31, 36, "DISEASE"], [89, 99, "ENTITY"], [130, 142, "CHEMICAL"], [191, 203, "ENTITY"], [105, 117, "ENTITY"], [14, 23, "ORGANISM"], [372, 401, "ENTITY"], [99, 105, "CHEMICAL"], [97, 105, "ENTITY"], [403, 409, "GGP"]]}
{"text": "For patients with ARDS who died , the value of liver damage indices ( total bilirubin [ difference , 2.60 mg/dL ; 95 % CI , 0.30 - 5.20mg/dL;P = .03 ] ) , renal dysfunction indices ( urea [ difference , 1.50 mM ; 95%CI , 0.50 - 2.70 mM ; P = .004 ] ) , inflammation- related indices ( IL-6 [ difference , 3.88 pg/L ; 95 % CI , 2.20 - 6.13pg/L;P < .001 ] ) , and coagulation function indices ( Ddimer [ difference , 2.10 \u03bcg/mL ; 95 % CI , 0.89 - 5.27 \u03bcg/mL ; P = .001 ] ) were significantly elevated compared with patients with ARDS who survived .", "labels": [[60, 70, "ENTITY"], [47, 60, "ENTITY"], [161, 173, "ENTITY"], [292, 310, "SIMPLE_CHEMICAL"], [469, 476, "ENTITY"], [68, 76, "ENTITY"], [327, 356, "ENTITY"], [70, 76, "CHEMICAL"], [161, 173, "CHEBI"], [469, 476, "ORGANISM"], [70, 76, "SIMPLE_CHEMICAL"], [4, 13, "ENTITY"], [267, 275, "ENTITY"], [88, 99, "CHEMICAL"], [18, 23, "ENTITY"], [47, 53, "DISEASE"], [88, 101, "CHEMICAL"], [143, 161, "ENTITY"], [18, 23, "DISEASE"], [143, 161, "DISEASE"], [70, 76, "GGP"], [161, 173, "CHEMICAL"], [27, 32, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "However , lymphocyte counts ( difference,\u2212 0.34 \u00d7 109/mL;95%CI,\u22120.47 to\u22120.22 \u00d7 109/mL;P < .001 ) and CD8 T cells ( difference , \u221266.00 cells/\u03bcL ; 95%CI , \u2212129.00 to \u22127.00 cells/\u03bcL ; P = .03 ) were significantly decreased .", "labels": [[95, 105, "CELL_TYPE"], [115, 135, "CHEMICAL"], [144, 154, "ENTITY"], [107, 115, "ENTITY"], [95, 105, "GGP"], [95, 105, "GENE_OR_GENE_PRODUCT"], [154, 165, "DNA"], [154, 165, "GENE_OR_GENE_PRODUCT"], [154, 165, "CHEMICAL"], [95, 105, "ENTITY"], [115, 135, "GENE_OR_GENE_PRODUCT"], [30, 41, "ENTITY"]]}
{"text": "However , lymphocyte counts ( difference,\u2212 0.34 \u00d7 109/mL;95%CI,\u22120.47 to\u22120.22 \u00d7 109/mL;P < .001 ) and CD8 T cells ( difference , \u221266.00 cells/\u03bcL ; 95%CI , \u2212129.00 to \u22127.00 cells/\u03bcL ; P = .03 ) were significantly decreased .", "labels": [[95, 105, "CELL_TYPE"], [115, 135, "CHEMICAL"], [144, 154, "ENTITY"], [107, 115, "ENTITY"], [95, 105, "GGP"], [95, 105, "GENE_OR_GENE_PRODUCT"], [154, 165, "DNA"], [154, 165, "GENE_OR_GENE_PRODUCT"], [154, 165, "CHEMICAL"], [95, 105, "ENTITY"], [115, 135, "GENE_OR_GENE_PRODUCT"], [30, 41, "ENTITY"]]}
{"text": "The innate immune response to tissue damage caused by the virus could lead to acute respiratory distress syndrome ( ARDS ) , in which respiratory failure is characterized by the rapid onset of widespread inflammation in the lungs and subsequent fatality [ 4 ] .", "labels": [[234, 245, "ENTITY"], [58, 64, "TAXON"], [128, 146, "ENTITY"], [78, 114, "ENTITY"], [30, 44, "DISEASE"], [84, 114, "DISEASE"], [30, 44, "ENTITY"], [30, 37, "TISSUE"], [128, 146, "DISEASE"], [193, 204, "DISEASE"], [193, 204, "ENTITY"], [58, 64, "ENTITY"], [4, 27, "ENTITY"]]}
{"text": "Infection with these highly pathogenic coronaviruses can result in Acute Respiratory Distress Syndrome ( ARDS ) , which may lead to long-term reduction in lung function , arrhythmia , and death .", "labels": [[152, 160, "ENTITY"], [73, 103, "DISEASE"], [39, 53, "ORGANISM"], [28, 39, "ENTITY"], [132, 142, "ENTITY"], [0, 10, "DISEASE"], [160, 171, "DISEASE"], [39, 53, "ENTITY"], [160, 171, "ENTITY"], [0, 10, "ENTITY"], [67, 103, "ENTITY"], [67, 105, "ORGANISM"]]}
{"text": "The symptoms of ARDS patients include short/rapid breathing , and cyanosis .", "labels": [[16, 21, "DISEASE"], [4, 13, "ENTITY"], [21, 30, "ORGANISM"], [16, 21, "ENTITY"], [21, 30, "ENTITY"], [38, 60, "ENTITY"]]}
{"text": "The symptoms of ARDS patients include short/rapid breathing , and cyanosis .", "labels": [[16, 21, "DISEASE"], [4, 13, "ENTITY"], [21, 30, "ORGANISM"], [16, 21, "ENTITY"], [21, 30, "ENTITY"], [38, 60, "ENTITY"]]}
{"text": "CT images revealed that there are characteristic white patches called \u201c ground glass \u201d , containing fluid in the lungs [ 2 ] .", "labels": [[70, 85, "CELL_LINE"], [3, 10, "ENTITY"], [0, 3, "PROTEIN"], [49, 63, "ENTITY"], [72, 79, "ENTITY"], [79, 85, "GENE_OR_GENE_PRODUCT"], [0, 3, "ENTITY"], [34, 49, "ENTITY"]]}
{"text": "Although the nature of the clear jelly has yet to be determined , hyaluronan ( HA ) is associated with ARDS [ 12 ] ; moreover , during SARS infection , the production and regulation of hyaluronan is defective .", "labels": [[128, 140, "ENTITY"], [128, 140, "DISEASE"], [84, 98, "ENTITY"], [171, 185, "ENTITY"], [171, 185, "GENE_OR_GENE_PRODUCT"], [33, 39, "ENTITY"], [156, 171, "ENTITY"], [171, 185, "CHEMICAL"], [171, 185, "GGP"], [171, 185, "PROTEIN"], [185, 199, "ENTITY"], [140, 156, "ENTITY"]]}
{"text": "Mechanistic evidence suggests two competing hypotheses : 1 ) RAS blockade decreases proinflammatory activity of Ang II , decreasing the risk of ARDS , myocarditis , or mortality in COVID-19 , or 2 ) RAS blockade increases ACE2 expression , promoting SARS-CoV-2 virulence in the lungs and heart that leads to ARDS , myocarditis , and death .", "labels": [[144, 151, "ENTITY"], [144, 151, "DISEASE"], [0, 12, "ENTITY"], [240, 261, "ENTITY"], [305, 315, "DISEASE"], [109, 116, "ENTITY"], [168, 181, "ENTITY"], [59, 65, "ENTITY"], [65, 74, "ENTITY"], [109, 116, "PROTEIN"], [151, 165, "ENTITY"], [305, 315, "ENTITY"], [109, 116, "GENE_OR_GENE_PRODUCT"], [74, 100, "ENTITY"], [278, 284, "ORGAN"], [44, 55, "ENTITY"], [240, 250, "SIMPLE_CHEMICAL"], [65, 74, "ENTITY"], [61, 65, "ENTITY"], [212, 227, "ENTITY"], [163, 168, "ENTITY"], [168, 181, "GENE_OR_GENE_PRODUCT"], [299, 305, "ENTITY"], [109, 116, "CHEMICAL"], [240, 250, "CHEMICAL"], [299, 305, "DISEASE"], [168, 195, "CELL_LINE"], [278, 284, "ENTITY"], [109, 116, "GGP"], [12, 21, "ENTITY"], [151, 165, "DISEASE"]]}
{"text": "ARDS is a clinical high-mortality disease , and ACE2 has a protective effect on this type of acute lung injury .", "labels": [[93, 104, "DISEASE"], [10, 42, "ENTITY"], [0, 5, "DISEASE"], [93, 104, "ENTITY"], [0, 5, "ENTITY"], [59, 70, "ENTITY"]]}
{"text": "ARDS(acute respiratory distress syndrome)is the most severe form of acute lung injury .", "labels": [[0, 32, "ENTITY"], [74, 79, "ORGAN"], [32, 44, "GENE_OR_GENE_PRODUCT"], [68, 86, "ENTITY"], [53, 60, "ENTITY"], [68, 86, "DISEASE"]]}
{"text": "It is characterized mainly by increased pulmonary vascular permeability and pulmonary edema .", "labels": [[76, 92, "DISEASE"], [6, 20, "ENTITY"], [76, 92, "ENTITY"], [40, 72, "ENTITY"], [30, 40, "ENTITY"], [40, 59, "MULTI-TISSUE_STRUCTURE"], [76, 92, "CANCER"]]}
{"text": "It is characterized mainly by increased pulmonary vascular permeability and pulmonary edema .", "labels": [[40, 72, "ENTITY"], [6, 20, "ENTITY"], [76, 92, "DISEASE"], [40, 59, "MULTI-TISSUE_STRUCTURE"], [76, 92, "CANCER"], [76, 92, "ENTITY"], [30, 40, "ENTITY"]]}
{"text": "Infection with these highly pathogenic coronaviruses can result in Acute Respiratory Distress Syndrome ( ARDS ) , which may lead to long-term reduction in lung function , arrhythmia , and death .", "labels": [[152, 160, "ENTITY"], [73, 103, "DISEASE"], [39, 53, "ORGANISM"], [28, 39, "ENTITY"], [132, 142, "ENTITY"], [0, 10, "DISEASE"], [160, 171, "DISEASE"], [39, 53, "ENTITY"], [160, 171, "ENTITY"], [0, 10, "ENTITY"], [67, 103, "ENTITY"], [67, 105, "ORGANISM"]]}
{"text": "Infection with these highly pathogenic coronaviruses can result in Acute Respiratory Distress Syndrome ( ARDS ) , which may lead to long-term reduction in lung function , arrhythmia , and death .", "labels": [[152, 160, "ENTITY"], [73, 103, "DISEASE"], [39, 53, "ORGANISM"], [28, 39, "ENTITY"], [132, 142, "ENTITY"], [0, 10, "DISEASE"], [160, 171, "DISEASE"], [39, 53, "ENTITY"], [160, 171, "ENTITY"], [0, 10, "ENTITY"], [67, 103, "ENTITY"], [67, 105, "ORGANISM"]]}
{"text": "He also had suspected sepsis , with an Enterobacter agglomerates\u2013 positive blood culture , leukocytosis , thrombocytopenia ( 11 cells \u00d7 103/\u03bcL ; to convert to cells \u00d7 109/L , multiply by 1.0 ) , and coagulopathy ( prothrombin time , 21 seconds ; activated partial thromboplastin time , 81.9 seconds ) , which improved with antibiotic treatment .", "labels": [[246, 264, "PROTEIN"], [191, 199, "ENTITY"], [148, 159, "CELL"], [148, 159, "CL"], [246, 264, "GENE_OR_GENE_PRODUCT"], [309, 323, "ENTITY"], [22, 29, "ENTITY"], [148, 159, "ENTITY"], [309, 318, "CHEBI"], [39, 52, "ENTITY"], [22, 29, "DISEASE"], [199, 214, "ENTITY"], [199, 214, "GENE_OR_GENE_PRODUCT"], [12, 22, "ENTITY"], [236, 264, "ENTITY"], [191, 199, "DISEASE"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "He also had suspected sepsis , with an Enterobacter agglomerates\u2013 positive blood culture , leukocytosis , thrombocytopenia ( 11 cells \u00d7 103/\u03bcL ; to convert to cells \u00d7 109/L , multiply by 1.0 ) , and coagulopathy ( prothrombin time , 21 seconds ; activated partial thromboplastin time , 81.9 seconds ) , which improved with antibiotic treatment .", "labels": [[246, 264, "PROTEIN"], [191, 199, "ENTITY"], [148, 159, "CELL"], [148, 159, "CL"], [246, 264, "GENE_OR_GENE_PRODUCT"], [309, 323, "ENTITY"], [22, 29, "ENTITY"], [148, 159, "ENTITY"], [309, 318, "CHEBI"], [39, 52, "ENTITY"], [22, 29, "DISEASE"], [199, 214, "ENTITY"], [199, 214, "GENE_OR_GENE_PRODUCT"], [12, 22, "ENTITY"], [236, 264, "ENTITY"], [191, 199, "DISEASE"]]}
{"text": "Several neoplasms , such as breast and lung cancer , may be associated with increased ACE2 expression .", "labels": [[76, 86, "GENE_OR_GENE_PRODUCT"], [39, 44, "ENTITY"], [8, 18, "ENTITY"], [76, 86, "ENTITY"], [86, 91, "ENTITY"], [8, 18, "CANCER"], [76, 86, "GGP"], [39, 44, "CANCER"], [8, 18, "DISEASE"], [28, 44, "DISEASE"], [57, 71, "ENTITY"], [76, 86, "PROTEIN"]]}
{"text": "In an analysis of 45,000 confirmed cases in China , the crude case fatality rate was 0.9 % for patients without any documented comorbidities , whereas the case fatality rate was much higher for patients with CVD ( 10.5 % ) , diabetes ( 7.3 % ) , or hypertension ( 6.3 % )", "labels": [[151, 160, "ENTITY"], [116, 127, "ENTITY"], [56, 67, "ENTITY"], [44, 50, "ENTITY"], [6, 15, "ENTITY"], [236, 249, "ENTITY"], [35, 41, "ENTITY"], [236, 249, "DISEASE"]]}
{"text": "In an analysis of 45,000 confirmed cases in China , the crude case fatality rate was 0.9 % for patients without any documented comorbidities , whereas the case fatality rate was much higher for patients with CVD ( 10.5 % ) , diabetes ( 7.3 % ) , or hypertension ( 6.3 % )", "labels": [[151, 160, "ENTITY"], [116, 127, "ENTITY"], [56, 67, "ENTITY"], [44, 50, "ENTITY"], [6, 15, "ENTITY"], [236, 249, "ENTITY"], [35, 41, "ENTITY"], [236, 249, "DISEASE"]]}
{"text": "In an analysis of 45,000 confirmed cases in China , the crude case fatality rate was 0.9 % for patients without any documented comorbidities , whereas the case fatality rate was much higher for patients with CVD ( 10.5 % ) , diabetes ( 7.3 % ) , or hypertension ( 6.3 % )", "labels": [[151, 160, "ENTITY"], [116, 127, "ENTITY"], [56, 67, "ENTITY"], [44, 50, "ENTITY"], [6, 15, "ENTITY"], [236, 249, "ENTITY"], [35, 41, "ENTITY"], [236, 249, "DISEASE"]]}
{"text": "In comparison with patients with mild COVID-19 ( such as those who did not require ICU stays , did not develop ARDS or pneumonia , and who survived ) , patients with severe COVID-19 have higher comorbidities , including 56 % for hypertension , 21 % for heart diseases , 18 % for diabetes , 12 % for cerebrovascular diseases , and 7 % for cancer ( Table 1 ) ( 79 , 97 ) .", "labels": [[103, 111, "DISEASE"], [129, 135, "CANCER"], [223, 229, "DISEASE"], [38, 47, "DISEASE"], [19, 28, "ORGANISM"], [279, 299, "ENTITY"], [244, 259, "ENTITY"], [129, 135, "ENTITY"], [244, 259, "DISEASE"], [33, 47, "ENTITY"], [129, 135, "DISEASE"], [279, 299, "DISEASE"], [223, 229, "ENTITY"], [3, 14, "ENTITY"], [103, 111, "ENTITY"], [38, 47, "GENE_OR_GENE_PRODUCT"], [166, 173, "DISEASE"], [187, 194, "ENTITY"], [166, 173, "ENTITY"], [166, 173, "GENE_OR_GENE_PRODUCT"], [19, 28, "ENTITY"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [259, 269, "ORGAN"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Indeed , increased ACE2 levels are seen in multiple cardiovascular conditions and related comorbidities such as diabetes and hypertension [ 8,18,25 ] .", "labels": []}
{"text": "RAS activity in patients with CVD or cardiovascular comorbidities could increase the likelihood and severity of SARS-CoV-2 infection in the lung or heart and may explain heterogeneity in the clinical course of COVID-19 , but in what direction ? ?", "labels": [[112, 133, "DISEASE"], [37, 52, "ORGANISM_SUBDIVISION"], [16, 25, "ORGANISM"], [4, 13, "ENTITY"], [85, 96, "ENTITY"], [100, 109, "ENTITY"], [30, 66, "DISEASE"], [148, 154, "ENTITY"], [210, 219, "GENE_OR_GENE_PRODUCT"], [140, 145, "ENTITY"], [30, 34, "ENTITY"], [16, 25, "ENTITY"], [191, 207, "ENTITY"], [0, 4, "ENTITY"], [72, 81, "ENTITY"], [140, 145, "ORGAN"], [112, 123, "SIMPLE_CHEMICAL"], [210, 219, "ENTITY"], [112, 133, "ENTITY"], [148, 154, "ORGAN"], [210, 219, "PROTEIN"], [170, 184, "ENTITY"], [37, 66, "ENTITY"], [0, 4, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Hypertension , cardiovascular disease , and cerebrovascular disease were much more frequent among deceased patients ( 54 ( 48 % ) , 16 ( 14 % ) , and 4 ( 4 % ) ) than among recovered patients ( 39 ( 24 % ) , 7 ( 4 % ) , and 0 ( 0 % ) ) .", "labels": [[15, 30, "DISEASE"], [98, 107, "ENTITY"], [158, 167, "ENTITY"], [15, 30, "ENTITY"], [0, 13, "DISEASE"], [0, 13, "ENTITY"], [40, 60, "DISEASE"], [98, 107, "ORGANISM"], [40, 60, "ENTITY"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [111, 136, "ENTITY"], [79, 100, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [111, 136, "DISEASE"], [259, 269, "ORGAN"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Comorbidities , including diabetes mellitus , cardiovascular and cerebrovascular diseases , were found in 4 and 5 of the patients from the DIP and control group , respectively .", "labels": [[26, 35, "DISEASE"], [44, 81, "DISEASE"], [0, 14, "ENTITY"], [143, 155, "ENTITY"], [26, 35, "ENTITY"], [61, 81, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [136, 146, "ORGAN"], [50, 60, "ENTITY"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [136, 158, "ENTITY"], [144, 166, "ENTITY"], [254, 285, "ENTITY"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "In this study , Guan et al reported more severe disease outcomes in patients with hypertension , coronary artery disease , diabetes , and chronic renal disease ( Table 1 ) . 6", "labels": [[8, 14, "ENTITY"], [134, 152, "DISEASE"], [134, 152, "ENTITY"], [95, 113, "DISEASE"], [95, 113, "ENTITY"], [138, 146, "ORGAN"], [95, 106, "MULTI-TISSUE_STRUCTURE"], [48, 56, "ENTITY"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [259, 269, "ORGAN"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Patients with elevated TnT levels had significantly higher rates of comorbidities including hypertension ( 33 [ 63.5 % ] vs 28 [ 20.7 % ] ) , coronary heart disease ( 17 [ 32.7 % ] vs4[3.0 % ] ) , cardiomyopathy ( 8[15.4%]vs0 ) , diabetes ( 16 [ 30.8 % ] vs 12 [ 8.9 % ] ) , chronic obstructive pulmonary disease ( 4 [ 7.7 % ] vs 0 ) , and chronic kidney disease ( 1 [ 0.7 % ] vs 5 [ 9.6 % ] ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [246, 283, "ENTITY"], [181, 195, "ENTITY"], [27, 34, "ENTITY"], [134, 151, "DISEASE"], [92, 105, "ENTITY"], [197, 214, "ENTITY"], [68, 82, "ENTITY"], [23, 27, "PROTEIN"], [246, 283, "DISEASE"], [0, 9, "ORGANISM"], [134, 151, "ENTITY"], [305, 327, "ENTITY"], [197, 214, "DISEASE"], [59, 65, "ENTITY"], [0, 9, "ENTITY"], [92, 105, "DISEASE"], [23, 27, "GENE_OR_GENE_PRODUCT"], [181, 195, "DISEASE"], [305, 327, "DISEASE"]]}
{"text": "Among the overall population , 23.7 % had at least one coexisting illness ( e.g. , hypertension and chronic obstructive pulmonary disease ) .", "labels": [[96, 130, "DISEASE"], [10, 29, "ENTITY"], [96, 130, "ENTITY"], [108, 120, "ORGAN"], [76, 83, "ENTITY"], [76, 83, "DISEASE"], [55, 66, "ENTITY"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "DISEASE"], [292, 299, "DISEASE"], [249, 278, "ENTITY"], [214, 237, "DISEASE"], [259, 269, "ORGAN"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Patients with elevated TnT levels had significantly higher rates of comorbidities including hypertension ( 33 [ 63.5 % ] vs 28 [ 20.7 % ] ) , coronary heart disease ( 17 [ 32.7 % ] vs4[3.0 % ] ) , cardiomyopathy ( 8[15.4%]vs0 ) , diabetes ( 16 [ 30.8 % ] vs 12 [ 8.9 % ] ) , chronic obstructive pulmonary disease ( 4 [ 7.7 % ] vs 0 ) , and chronic kidney disease ( 1 [ 0.7 % ] vs 5 [ 9.6 % ] ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [246, 283, "ENTITY"], [181, 195, "ENTITY"], [27, 34, "ENTITY"], [134, 151, "DISEASE"], [92, 105, "ENTITY"], [197, 214, "ENTITY"], [68, 82, "ENTITY"], [23, 27, "PROTEIN"], [246, 283, "DISEASE"], [0, 9, "ORGANISM"], [134, 151, "ENTITY"], [305, 327, "ENTITY"], [197, 214, "DISEASE"], [59, 65, "ENTITY"], [0, 9, "ENTITY"], [92, 105, "DISEASE"], [23, 27, "GENE_OR_GENE_PRODUCT"], [181, 195, "DISEASE"], [305, 327, "DISEASE"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [259, 269, "ORGAN"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "RNA sequencing revealed that myocardial ACE2 expression was significantly increased in patients with heart failure ( Figure 1J , fold change = 3.00 , P<0.0001 ) , which was further validated at the protein level by proteomics profiling ( Figure 1 K , fold change=1.82 , P<0.0001 ) .", "labels": [[194, 206, "ENTITY"], [29, 45, "MULTI-TISSUE_STRUCTURE"], [101, 115, "ENTITY"], [101, 115, "DISEASE"], [249, 270, "CHEMICAL"], [127, 134, "GENE_OR_GENE_PRODUCT"], [40, 45, "ENTITY"], [40, 45, "PROTEIN"], [45, 56, "ENTITY"], [117, 124, "ENTITY"], [87, 96, "ORGANISM"], [101, 107, "ORGAN"], [29, 40, "ENTITY"], [0, 4, "SO"], [74, 84, "ENTITY"], [87, 96, "ENTITY"], [206, 226, "ENTITY"], [0, 15, "ENTITY"], [226, 238, "ENTITY"], [40, 45, "GGP"]]}
{"text": "RNA sequencing revealed that myocardial ACE2 expression was significantly increased in patients with heart failure ( Figure 1J , fold change = 3.00 , P<0.0001 ) , which was further validated at the protein level by proteomics profiling ( Figure 1 K , fold change=1.82 , P<0.0001 ) .", "labels": [[194, 206, "ENTITY"], [29, 45, "MULTI-TISSUE_STRUCTURE"], [101, 115, "ENTITY"], [101, 115, "DISEASE"], [249, 270, "CHEMICAL"], [127, 134, "GENE_OR_GENE_PRODUCT"], [40, 45, "ENTITY"], [40, 45, "PROTEIN"], [45, 56, "ENTITY"], [117, 124, "ENTITY"], [87, 96, "ORGANISM"], [101, 107, "ORGAN"], [29, 40, "ENTITY"], [0, 4, "SO"], [74, 84, "ENTITY"], [87, 96, "ENTITY"], [206, 226, "ENTITY"], [0, 15, "ENTITY"], [226, 238, "ENTITY"], [40, 45, "GGP"]]}
{"text": "Comorbidities were present in nearly half of patients , with hypertension being the most common comorbidity , followed by diabetes and coronary heart disease ( table 1 ) .", "labels": [[0, 14, "ENTITY"], [131, 150, "ENTITY"], [131, 150, "DISEASE"], [131, 144, "CANCER"], [45, 54, "ENTITY"], [45, 54, "ORGANISM"]]}
{"text": "In this study , Guan et al reported more severe disease outcomes in patients with hypertension , coronary artery disease , diabetes , and chronic renal disease ( Table 1 ) . 6", "labels": [[8, 14, "ENTITY"], [134, 152, "DISEASE"], [134, 152, "ENTITY"], [95, 113, "DISEASE"], [95, 106, "MULTI-TISSUE_STRUCTURE"], [138, 146, "ORGAN"], [48, 56, "ENTITY"], [95, 113, "ENTITY"]]}
{"text": "In univariable analysis , odds of in-hospital death was higher in patients with diabetes or coronary heart disease ( table 3 ) .", "labels": [[3, 24, "ENTITY"], [92, 107, "DISEASE"], [92, 101, "CANCER"], [92, 107, "ENTITY"], [34, 46, "ENTITY"]]}
{"text": "Among adult patients , cardiovascular disease and hypertension were the most common underlying diseases , followed by diabetes mellitus .", "labels": [[12, 21, "ORGANISM"], [115, 127, "DISEASE"], [23, 38, "ENTITY"], [23, 38, "DISEASE"], [12, 21, "ENTITY"], [115, 127, "ENTITY"], [6, 12, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [50, 60, "ENTITY"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [136, 146, "ORGAN"], [136, 158, "ENTITY"], [144, 166, "ENTITY"], [254, 285, "ENTITY"]]}
{"text": "Comorbidities were present in nearly half of patients , with hypertension being the most common comorbidity , followed by diabetes and coronary heart disease ( table 1 ) .", "labels": [[0, 14, "ENTITY"], [131, 150, "ENTITY"], [131, 150, "DISEASE"], [131, 144, "CANCER"], [45, 54, "ENTITY"], [45, 54, "ORGANISM"]]}
{"text": "In this study , Guan et al reported more severe disease outcomes in patients with hypertension , coronary artery disease , diabetes , and chronic renal disease ( Table 1 ) . 6", "labels": [[8, 14, "ENTITY"], [134, 152, "DISEASE"], [134, 152, "ENTITY"], [95, 113, "DISEASE"], [95, 113, "ENTITY"], [138, 146, "ORGAN"], [95, 106, "MULTI-TISSUE_STRUCTURE"], [48, 56, "ENTITY"]]}
{"text": "In an analysis of 45,000 confirmed cases in China , the crude case fatality rate was 0.9 % for patients without any documented comorbidities , whereas the case fatality rate was much higher for patients with CVD ( 10.5 % ) , diabetes ( 7.3 % ) , or hypertension ( 6.3 % )", "labels": [[151, 160, "ENTITY"], [116, 127, "ENTITY"], [56, 67, "ENTITY"], [44, 50, "ENTITY"], [6, 15, "ENTITY"], [236, 249, "ENTITY"], [35, 41, "ENTITY"], [236, 249, "DISEASE"]]}
{"text": "In comparison with patients with mild COVID-19 ( such as those who did not require ICU stays , did not develop ARDS or pneumonia , and who survived ) , patients with severe COVID-19 have higher comorbidities , including 56 % for hypertension , 21 % for heart diseases , 18 % for diabetes , 12 % for cerebrovascular diseases , and 7 % for cancer ( Table 1 ) ( 79 , 97 ) .", "labels": [[103, 111, "DISEASE"], [129, 135, "CANCER"], [223, 229, "DISEASE"], [38, 47, "DISEASE"], [19, 28, "ORGANISM"], [279, 299, "ENTITY"], [244, 259, "ENTITY"], [129, 135, "ENTITY"], [244, 259, "DISEASE"], [33, 47, "ENTITY"], [129, 135, "DISEASE"], [279, 299, "DISEASE"], [223, 229, "ENTITY"], [3, 14, "ENTITY"], [103, 111, "ENTITY"], [38, 47, "GENE_OR_GENE_PRODUCT"], [166, 173, "DISEASE"], [187, 194, "ENTITY"], [166, 173, "ENTITY"], [166, 173, "GENE_OR_GENE_PRODUCT"], [19, 28, "ENTITY"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [259, 269, "ORGAN"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Comorbidities , including diabetes mellitus , cardiovascular and cerebrovascular diseases , were found in 4 and 5 of the patients from the DIP and control group , respectively .", "labels": [[44, 81, "DISEASE"], [0, 14, "ENTITY"], [26, 35, "DISEASE"], [143, 155, "ENTITY"], [61, 81, "ENTITY"], [26, 35, "ENTITY"]]}
{"text": "Compared with patients without ARDS , patients with ARDS had a higher proportion of comorbidities , including hypertension ( difference , 13.7 % ; 95%CI , 1.3%-26.1 % ; P = .02 ) and diabetes ( difference , 13.9 % ; 95 % CI , 3.6%-24.2 % ; P = .002 ) .", "labels": [[100, 110, "ENTITY"], [31, 36, "ENTITY"], [14, 23, "ORGANISM"], [14, 23, "ENTITY"], [31, 36, "DISEASE"], [100, 110, "DISEASE"], [0, 9, "ENTITY"], [183, 194, "ENTITY"]]}
{"text": "In univariable analysis , odds of in-hospital death was higher in patients with diabetes or coronary heart disease ( table 3 ) .", "labels": [[3, 24, "ENTITY"], [92, 107, "ENTITY"], [92, 107, "DISEASE"], [34, 46, "ENTITY"], [92, 101, "CANCER"]]}
{"text": "In an analysis of 45,000 confirmed cases in China , the crude case fatality rate was 0.9 % for patients without any documented comorbidities , whereas the case fatality rate was much higher for patients with CVD ( 10.5 % ) , diabetes ( 7.3 % ) , or hypertension ( 6.3 % )", "labels": [[151, 160, "ENTITY"], [116, 127, "ENTITY"], [56, 67, "ENTITY"], [44, 50, "ENTITY"], [6, 15, "ENTITY"], [236, 249, "ENTITY"], [35, 41, "ENTITY"], [236, 249, "DISEASE"]]}
{"text": "In an analysis of 45,000 confirmed cases in China , the crude case fatality rate was 0.9 % for patients without any documented comorbidities , whereas the case fatality rate was much higher for patients with CVD ( 10.5 % ) , diabetes ( 7.3 % ) , or hypertension ( 6.3 % )", "labels": [[151, 160, "ENTITY"], [116, 127, "ENTITY"], [56, 67, "ENTITY"], [44, 50, "ENTITY"], [6, 15, "ENTITY"], [236, 249, "ENTITY"], [35, 41, "ENTITY"], [236, 249, "DISEASE"]]}
{"text": "Indeed , increased ACE2 levels are seen in multiple cardiovascular conditions and related comorbidities such as diabetes and hypertension [ 8,18,25 ] .", "labels": []}
{"text": "Patients with elevated TnT levels had significantly higher rates of comorbidities including hypertension ( 33 [ 63.5 % ] vs 28 [ 20.7 % ] ) , coronary heart disease ( 17 [ 32.7 % ] vs4[3.0 % ] ) , cardiomyopathy ( 8[15.4%]vs0 ) , diabetes ( 16 [ 30.8 % ] vs 12 [ 8.9 % ] ) , chronic obstructive pulmonary disease ( 4 [ 7.7 % ] vs 0 ) , and chronic kidney disease ( 1 [ 0.7 % ] vs 5 [ 9.6 % ] ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [246, 283, "ENTITY"], [181, 195, "ENTITY"], [27, 34, "ENTITY"], [134, 151, "DISEASE"], [92, 105, "ENTITY"], [197, 214, "ENTITY"], [68, 82, "ENTITY"], [23, 27, "PROTEIN"], [246, 283, "DISEASE"], [0, 9, "ORGANISM"], [134, 151, "ENTITY"], [305, 327, "ENTITY"], [197, 214, "DISEASE"], [59, 65, "ENTITY"], [0, 9, "ENTITY"], [92, 105, "DISEASE"], [23, 27, "GENE_OR_GENE_PRODUCT"], [181, 195, "DISEASE"], [305, 327, "DISEASE"]]}
{"text": "71.4 % of non-survivors meet the criteria of the International Society on Thrombosis and Haemostasis ( International Society on Thrombosis and Haemostasis ) for disseminated intravascular coagulation ( DIC ) , suggesting the coexistence of coagulation activation and hyper-fibrinolysis in patients with severe COVID-19 infection ( 78 , 85 ) .", "labels": [[114, 127, "ENTITY"], [89, 101, "DISEASE"], [49, 89, "ENTITY"], [163, 178, "ENTITY"], [205, 220, "ENTITY"], [141, 153, "ENTITY"], [71, 89, "DISEASE"], [141, 163, "ENTITY"], [205, 216, "SIMPLE_CHEMICAL"], [89, 101, "ENTITY"], [205, 220, "DISEASE"], [49, 71, "ENTITY"]]}
{"text": "Consistent with others , most of severe COVID-19 patients in our ICU ward had persistent very high level of erythematosus sedimentation rate ( ESR ) , CRP , and high level of IL-6,TNFa , IL-1B , IL-8 , IL2R , etc , and were associated with ARDS , hypercoagulation and disseminated intravascular coagulation ( DIC ) , manifested as thrombosis , thrombocytopenia , gangrene of extremities .", "labels": [[0, 16, "ENTITY"], [268, 295, "DISEASE"], [175, 187, "GENE_OR_GENE_PRODUCT"], [328, 344, "ENTITY"], [175, 187, "ENTITY"], [175, 187, "DNA"], [328, 344, "DISEASE"], [99, 108, "GGP"], [65, 69, "ENTITY"], [235, 247, "DISEASE"], [108, 136, "ENTITY"], [344, 363, "ENTITY"], [235, 247, "ENTITY"], [187, 193, "ENTITY"], [99, 108, "DNA"], [187, 193, "GENE_OR_GENE_PRODUCT"], [268, 281, "IMMATERIAL_ANATOMICAL_ENTITY"], [99, 108, "ENTITY"], [344, 363, "ORGAN"], [175, 187, "GGP"], [317, 328, "DISEASE"], [94, 99, "ENTITY"], [187, 193, "PROTEIN"], [40, 49, "GENE_OR_GENE_PRODUCT"], [215, 224, "ENTITY"], [187, 193, "GGP"], [99, 108, "GENE_OR_GENE_PRODUCT"], [317, 328, "ENTITY"], [247, 295, "ENTITY"]]}
{"text": "However , corticosteroid therapy could be associated with delayed MERS-CoV RNA clearance ( adjusted hazard ratio , 0.35 ; 95 % CI , 0.17\u20130.72 ; p = 0.005 ) for critically ill patients with MERS,[40 ] and early corticosteroid treatment could be associated with higher subsequent plasma RNA load of SARS-CoV for adults with SARS.[41 ] Moreover , corticosteroid-associated psychosis and diabetes were observed in the treatment of SARS.[42,43 ] .", "labels": [[148, 160, "ENTITY"], [297, 306, "ENTITY"], [148, 160, "DISEASE"], [10, 25, "ENTITY"], [200, 210, "SIMPLE_CHEMICAL"], [370, 380, "ENTITY"], [310, 322, "PROTEIN"], [66, 75, "ENTITY"], [267, 278, "ENTITY"], [370, 380, "DISEASE"], [398, 410, "ENTITY"], [160, 175, "ORGANISM"], [414, 427, "GENE_OR_GENE_PRODUCT"], [333, 344, "ENTITY"], [200, 210, "ENTITY"], [310, 322, "ENTITY"], [414, 427, "ENTITY"], [175, 189, "GENE_OR_GENE_PRODUCT"], [160, 175, "ENTITY"], [333, 344, "DISEASE"], [267, 278, "SO"], [289, 297, "ORGANISM"], [33, 42, "ENTITY"], [10, 25, "ENTITY"], [414, 427, "PROTEIN"], [66, 75, "RNA"], [267, 278, "RNA"], [278, 285, "ENTITY"], [175, 189, "CHEMICAL"], [91, 107, "ENTITY"], [289, 297, "GGP"], [289, 297, "PROTEIN"], [289, 297, "ENTITY"], [175, 189, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [136, 146, "ORGAN"], [50, 60, "ENTITY"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [136, 158, "ENTITY"], [144, 166, "ENTITY"], [254, 285, "ENTITY"]]}
{"text": "The clinical manifestations of COVID-19 are protean , which include asymptomatic carrier , ARD , and pneumonia of varying degrees of severity . First , asymptomatic cases were diagnosed based on positive viral nucleic acid test results , but without any COVID-19 symptoms , such as fever , gastrointestinal , or respiratory symptoms , and no significant abnormalities on chest radiograph [ 7,8 ] .", "labels": [[186, 195, "ENTITY"], [290, 324, "ENTITY"], [223, 228, "ENTITY"], [68, 81, "ENTITY"], [31, 40, "ENTITY"], [31, 40, "ENTITY"], [144, 152, "ENTITY"], [114, 122, "ENTITY"], [242, 254, "ENTITY"], [204, 218, "CHEMICAL"], [354, 377, "ENTITY"], [342, 354, "ENTITY"], [282, 290, "ENTITY"], [195, 218, "TAXON"], [242, 254, "GENE_OR_GENE_PRODUCT"], [282, 290, "ORGAN"], [44, 52, "ENTITY"], [195, 223, "ENTITY"], [4, 28, "ENTITY"], [31, 40, "DISEASE"], [31, 40, "GENE_OR_GENE_PRODUCT"], [324, 342, "ENTITY"]]}
{"text": "In comparison with patients with mild COVID-19 ( such as those who did not require ICU stays , did not develop ARDS or pneumonia , and who survived ) , patients with severe COVID-19 have higher comorbidities , including 56 % for hypertension , 21 % for heart diseases , 18 % for diabetes , 12 % for cerebrovascular diseases , and 7 % for cancer ( Table 1 ) ( 79 , 97 ) .", "labels": [[103, 111, "DISEASE"], [129, 135, "CANCER"], [223, 229, "DISEASE"], [38, 47, "DISEASE"], [19, 28, "ORGANISM"], [279, 299, "ENTITY"], [244, 259, "ENTITY"], [129, 135, "ENTITY"], [244, 259, "DISEASE"], [33, 47, "ENTITY"], [129, 135, "DISEASE"], [279, 299, "DISEASE"], [223, 229, "ENTITY"], [3, 14, "ENTITY"], [103, 111, "ENTITY"], [38, 47, "GENE_OR_GENE_PRODUCT"], [166, 173, "DISEASE"], [187, 194, "ENTITY"], [166, 173, "ENTITY"], [166, 173, "GENE_OR_GENE_PRODUCT"], [19, 28, "ENTITY"]]}
{"text": "Remarkably , in SJIA patients , the pulmonary involvement triggers a hyper-inflammatory reaction and occurrence of secondary haemophagocytic lymphohistiocytosis ( sHLH ) , since the up-regulation of IFN-signature , IL-1\u03b2 and IL-6 may be observed [ 5,8 ] .", "labels": [[141, 163, "ENTITY"], [115, 141, "DISEASE"], [172, 182, "ENTITY"], [141, 163, "GENE_OR_GENE_PRODUCT"], [67, 88, "ENTITY"], [112, 141, "ENTITY"], [199, 213, "CHEMICAL"], [115, 125, "CHEBI"], [182, 199, "PROTEIN"], [215, 221, "GGP"], [36, 46, "ENTITY"], [215, 221, "PROTEIN"], [199, 213, "PROTEIN"], [215, 221, "ENTITY"], [199, 213, "ENTITY"], [215, 221, "GENE_OR_GENE_PRODUCT"], [199, 213, "GENE_OR_GENE_PRODUCT"], [182, 199, "ENTITY"], [182, 199, "GENE_OR_GENE_PRODUCT"], [199, 213, "GGP"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [259, 269, "ORGAN"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Lopinavir/ritonavir is a medication for the human immunodeficiency virus ( human immunodeficiency virus ) used in combination with other medications to treat adults and children over 14 days of age who are infected with human immunodeficiency virus -1 ( 5 ) . Chu et al. found that lopinavir/ritonavir has anti-SARS-CoV activity in vitro and in clinical studies ( 6 ) .", "labels": [[257, 274, "ENTITY"], [235, 244, "ENTITY"], [257, 274, "SIMPLE_CHEMICAL"], [54, 60, "ENTITY"], [-1, 7, "ENTITY"], [280, 305, "ENTITY"], [-1, 16, "ENTITY"], [-1, 7, "ENTITY"], [-1, 24, "ORGANISM"], [-1, 10, "ORGANISM"], [29, 40, "ENTITY"], [54, 60, "ORGANISM"], [-1, 21, "ENTITY"], [-1, 16, "SO"], [-1, 10, "ENTITY"], [0, 20, "ENTITY"], [257, 274, "CHEMICAL"]]}
{"text": "We also observed that several autoimmune disorders , especially inflammatory bowel diseases may be casually associated with ACE2 expression .", "labels": [[8, 17, "ENTITY"], [64, 83, "ENTITY"], [30, 51, "DISEASE"], [30, 51, "ENTITY"], [64, 83, "DISEASE"]]}
{"text": "At least one abnormal chest CT manifestation ( including ground-glass opacities , pulmonary infiltrates and interstitial disorders ) was identified in more than 70 % of patients .", "labels": [[57, 70, "ENTITY"], [104, 121, "DISEASE"], [80, 92, "MULTI-TISSUE_STRUCTURE"], [28, 31, "PROTEIN"], [13, 22, "ENTITY"], [22, 31, "ENTITY"], [80, 92, "ENTITY"], [31, 45, "ENTITY"], [104, 121, "ENTITY"]]}
{"text": "Interstitial lung abnormalities were observed in chest computed tomography ( CT ) scans of all patients on admission", "labels": [[0, 32, "ENTITY"], [0, 32, "DISEASE"], [0, 18, "TISSUE"], [49, 75, "ENTITY"], [49, 55, "TISSUE"]]}
{"text": "RhACE2 can reduce blood pressure while reducing renal damage34", "labels": [[0, 7, "GENE_OR_GENE_PRODUCT"], [0, 7, "ENTITY"], [18, 24, "ORGANISM_SUBSTANCE"], [0, 7, "DNA"], [39, 48, "ENTITY"], [18, 33, "ENTITY"], [11, 18, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [50, 60, "ENTITY"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [254, 285, "ENTITY"], [136, 146, "ORGAN"], [136, 158, "ENTITY"], [144, 166, "ENTITY"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "As for other traits , high alanine aminotransferase ( ALT ) , commonly associated with liver diseases , may be related to elevated ACE2 expression .", "labels": [[13, 20, "ENTITY"], [62, 82, "ENTITY"], [82, 93, "ENTITY"], [122, 131, "ENTITY"], [22, 35, "ENTITY"], [27, 35, "GENE_OR_GENE_PRODUCT"], [122, 131, "GENE_OR_GENE_PRODUCT"], [122, 131, "GGP"], [82, 93, "DISEASE"], [122, 131, "PROTEIN"], [27, 35, "PROTEIN"], [111, 122, "ENTITY"], [131, 136, "ENTITY"]]}
{"text": "Several neoplasms , such as breast and lung cancer , may be associated with increased ACE2 expression .", "labels": [[76, 86, "GENE_OR_GENE_PRODUCT"], [39, 44, "ENTITY"], [8, 18, "ENTITY"], [76, 86, "ENTITY"], [86, 91, "ENTITY"], [8, 18, "CANCER"], [76, 86, "GGP"], [39, 44, "CANCER"], [8, 18, "DISEASE"], [28, 44, "DISEASE"], [57, 71, "ENTITY"], [76, 86, "PROTEIN"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [236, 242, "ENTITY"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [300, 315, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "Not only has ACE2 facilitated the invasion of SARS virus for rapid replication , but also ACE2 is depleted from the cell membrane and therefore the damaging effects of Ang II are enhanced , resulting in acute deterioration of lung tissues [ 5 ] .", "labels": [[51, 57, "TAXON"], [223, 231, "TISSUE"], [223, 231, "ENTITY"], [148, 157, "ENTITY"], [168, 172, "GGP"], [116, 121, "CL"], [46, 51, "DISEASE"], [13, 18, "GENE_OR_GENE_PRODUCT"], [46, 57, "ORGANISM"], [61, 67, "ENTITY"], [168, 172, "PROTEIN"], [168, 172, "CHEMICAL"], [34, 43, "ENTITY"], [46, 57, "ENTITY"], [67, 79, "ENTITY"], [13, 18, "GGP"], [168, 172, "GENE_OR_GENE_PRODUCT"], [116, 121, "CELLULAR_COMPONENT"], [13, 18, "PROTEIN"], [13, 18, "ENTITY"], [116, 121, "ENTITY"], [200, 209, "ENTITY"], [168, 172, "ENTITY"]]}
{"text": "Infection with these highly pathogenic coronaviruses can result in Acute Respiratory Distress Syndrome ( ARDS ) , which may lead to long-term reduction in lung function , arrhythmia , and death .", "labels": [[152, 160, "ENTITY"], [73, 103, "DISEASE"], [39, 53, "ORGANISM"], [28, 39, "ENTITY"], [132, 142, "ENTITY"], [0, 10, "DISEASE"], [160, 171, "DISEASE"], [39, 53, "ENTITY"], [160, 171, "ENTITY"], [0, 10, "ENTITY"], [67, 103, "ENTITY"], [67, 105, "ORGANISM"]]}
{"text": "Among patients with unstable clinical status , myocardial injury associated with Covid-19 may pose even higher early risks after withdrawal of RAAS inhibitors .", "labels": [[47, 58, "DISEASE"], [6, 15, "ENTITY"], [6, 15, "ORGANISM"], [47, 58, "ENTITY"], [143, 148, "GGP"], [29, 45, "ENTITY"], [143, 148, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [50, 60, "ENTITY"], [136, 146, "ORGAN"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [136, 158, "ENTITY"], [144, 166, "ENTITY"], [254, 285, "ENTITY"]]}
{"text": "In the present study , the lung lesions of 48 cases ( 43.6 % ) were located in the peripheral zone and lesions of 62 cases ( 56.4 % ) involved both the peripheral and the central zones ( Fig 1 ) .", "labels": [[163, 171, "ENTITY"], [79, 94, "TISSUE"], [163, 171, "ANATOMICAL_SYSTEM"], [143, 152, "ENTITY"], [79, 94, "ENTITY"], [179, 185, "GENE_OR_GENE_PRODUCT"], [143, 152, "TISSUE"], [27, 32, "CANCER"], [27, 32, "ENTITY"], [15, 21, "ENTITY"]]}
{"text": "( 2 ) Restrictive fluid resuscitation under the premise of adequate tissue perfusion is performed to relieve pulmonary edema .", "labels": [[101, 119, "ENTITY"], [6, 24, "ENTITY"], [59, 75, "ENTITY"], [101, 119, "CANCER"], [101, 119, "DISEASE"], [59, 68, "TISSUE"]]}
{"text": "Through a literature review , we identified a list of important symptoms and mechanisms linked to SARS-CoV-2 , including fever , fatigue , cough 17 , breathing difficulty , septic shock , viral proliferation , immunodeficiency and pulmonary fibrosis 18 ( Figure 4 ) .", "labels": [[145, 160, "ENTITY"], [180, 194, "ENTITY"], [180, 186, "TAXON"], [160, 180, "ENTITY"], [129, 139, "DISEASE"], [194, 210, "ORGANISM"], [210, 241, "ENTITY"], [194, 210, "ENTITY"], [231, 241, "DISEASE"], [241, 255, "ENTITY"], [210, 231, "ORGAN"], [160, 180, "DISEASE"], [129, 139, "ENTITY"], [111, 121, "DISEASE"], [111, 121, "ENTITY"], [10, 28, "ENTITY"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [66, 96, "DISEASE"], [0, 7, "ENTITY"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [133, 141, "DISEASE"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "Patients with elevated TnT levels had evidence of more severe respiratory dysfunction , with lower partial pressure of oxygen ( PaO2 ) ( median [ IQR ] , 64.0[51.0 - 93.0 ] vs 91.0[75.0 - 121.0]mmHg),HCO3 ( median [ IQR ] , 23.3 [ 20.0 - 27.1 ] vs 25.7 [ 23.8 - 27.9 ] mEq/L [ to convert to to millimoles per liter , multiply by 1 ] ) , and PaO2/ fraction of inspired oxygen ( FiO2 ) ( median [ IQR ] , 153.3 [ 103.3- 323.8 ] vs 390.5 [285.7 - 461.9]mmHg ) , and higher levels of lactic acid ( median [ IQR ] , 2.10 [ 1.40 - 3.10 ] vs 1.80 [1.30 - 2.10]mm Hg ) ( P < .001,P < .001,P = .004,P = .001 , respectively ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [309, 317, "GENE_OR_GENE_PRODUCT"], [62, 86, "DISEASE"], [331, 341, "ENTITY"], [27, 34, "ENTITY"], [309, 317, "ENTITY"], [444, 459, "ENTITY"], [146, 150, "CHEBI"], [23, 27, "PROTEIN"], [0, 9, "ORGANISM"], [135, 152, "ENTITY"], [55, 62, "ENTITY"], [137, 144, "ENTITY"], [146, 154, "SIMPLE_CHEMICAL"], [269, 280, "ENTITY"], [38, 47, "ENTITY"], [188, 205, "ENTITY"], [0, 9, "ENTITY"], [93, 119, "ENTITY"], [62, 86, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"], [135, 146, "SIMPLE_CHEMICAL"], [317, 326, "ENTITY"], [347, 359, "ENTITY"], [166, 188, "SIMPLE_CHEMICAL"], [135, 150, "CHEMICAL"]]}
{"text": "Large doses of ribavirin could cause decreased hemoglobin and serious heart damage .", "labels": [[47, 58, "CHEBI"], [37, 47, "ENTITY"], [0, 6, "ENTITY"], [6, 12, "ENTITY"], [70, 76, "ORGAN"], [15, 25, "ENTITY"], [47, 58, "GENE_OR_GENE_PRODUCT"], [47, 58, "PROTEIN"], [15, 25, "SIMPLE_CHEMICAL"], [70, 83, "ENTITY"], [15, 25, "CHEMICAL"], [47, 58, "ENTITY"], [70, 83, "DISEASE"]]}
{"text": "Conventional light microscopy ( LM ) demonstrated widespread damage of the lung parenchyma , with extensive fibrin exudate , edema , interstitial thickening , and extensive hyaline membrane formation ( Fig. 1B ) .", "labels": [[0, 30, "ENTITY"], [163, 190, "ENTITY"], [163, 181, "MULTI-TISSUE_STRUCTURE"], [125, 146, "ENTITY"], [98, 115, "ENTITY"], [157, 163, "ENTITY"], [115, 125, "PATHOLOGICAL_FORMATION"], [71, 80, "MULTI-TISSUE_STRUCTURE"], [71, 80, "ENTITY"], [115, 125, "DISEASE"], [98, 108, "GENE_OR_GENE_PRODUCT"], [50, 61, "ENTITY"], [115, 125, "ENTITY"]]}
{"text": "Conventional light microscopy ( LM ) demonstrated widespread damage of the lung parenchyma , with extensive fibrin exudate , edema , interstitial thickening , and extensive hyaline membrane formation ( Fig. 1B ) .", "labels": [[0, 30, "ENTITY"], [163, 190, "ENTITY"], [163, 181, "MULTI-TISSUE_STRUCTURE"], [125, 146, "ENTITY"], [98, 115, "ENTITY"], [157, 163, "ENTITY"], [115, 125, "PATHOLOGICAL_FORMATION"], [71, 80, "MULTI-TISSUE_STRUCTURE"], [71, 80, "ENTITY"], [115, 125, "DISEASE"], [98, 108, "GENE_OR_GENE_PRODUCT"], [50, 61, "ENTITY"], [115, 125, "ENTITY"]]}
{"text": "There was extensive alveolar collapse , and the remaining alveoli were filled with fluid and desquamated alveolar and bronchial epithelial cells . Alveolar epithelial hyperplasia was evident .", "labels": [[105, 139, "CELL_TYPE"], [20, 29, "TISSUE"], [128, 139, "CL"], [20, 38, "ENTITY"], [93, 105, "ENTITY"], [118, 139, "CELL"], [145, 167, "TISSUE"], [118, 139, "ENTITY"], [145, 167, "ENTITY"], [10, 20, "ENTITY"]]}
{"text": "Conventional light microscopy ( LM ) demonstrated widespread damage of the lung parenchyma , with extensive fibrin exudate , edema , interstitial thickening , and extensive hyaline membrane formation ( Fig. 1B ) .", "labels": [[0, 30, "ENTITY"], [163, 190, "ENTITY"], [163, 181, "MULTI-TISSUE_STRUCTURE"], [125, 146, "ENTITY"], [98, 115, "ENTITY"], [157, 163, "ENTITY"], [115, 125, "PATHOLOGICAL_FORMATION"], [71, 80, "MULTI-TISSUE_STRUCTURE"], [71, 80, "ENTITY"], [115, 125, "DISEASE"], [98, 108, "GENE_OR_GENE_PRODUCT"], [50, 61, "ENTITY"], [115, 125, "ENTITY"]]}
{"text": "Conventional light microscopy ( LM ) demonstrated widespread damage of the lung parenchyma , with extensive fibrin exudate , edema , interstitial thickening , and extensive hyaline membrane formation ( Fig. 1B ) .", "labels": [[0, 30, "ENTITY"], [163, 181, "MULTI-TISSUE_STRUCTURE"], [125, 146, "ENTITY"], [98, 115, "ENTITY"], [157, 163, "ENTITY"], [115, 125, "PATHOLOGICAL_FORMATION"], [71, 80, "MULTI-TISSUE_STRUCTURE"], [71, 80, "ENTITY"], [115, 125, "DISEASE"], [163, 190, "ENTITY"], [98, 108, "GENE_OR_GENE_PRODUCT"], [50, 61, "ENTITY"], [115, 125, "ENTITY"]]}
{"text": "There was extensive alveolar collapse , and the remaining alveoli were filled with fluid and desquamated alveolar and bronchial epithelial cells . Alveolar epithelial hyperplasia was evident .", "labels": [[105, 139, "CELL_TYPE"], [128, 139, "CL"], [20, 38, "ENTITY"], [20, 29, "TISSUE"], [93, 105, "ENTITY"], [118, 139, "CELL"], [145, 167, "TISSUE"], [118, 139, "ENTITY"], [145, 167, "ENTITY"], [10, 20, "ENTITY"]]}
{"text": "There was extensive alveolar collapse , and the remaining alveoli were filled with fluid and desquamated alveolar and bronchial epithelial cells . Alveolar epithelial hyperplasia was evident .", "labels": [[105, 139, "CELL_TYPE"], [20, 29, "TISSUE"], [128, 139, "CL"], [20, 38, "ENTITY"], [93, 105, "ENTITY"], [118, 139, "CELL"], [145, 167, "TISSUE"], [118, 139, "ENTITY"], [145, 167, "ENTITY"], [10, 20, "ENTITY"]]}
{"text": "There was extensive alveolar collapse , and the remaining alveoli were filled with fluid and desquamated alveolar and bronchial epithelial cells . Alveolar epithelial hyperplasia was evident .", "labels": [[105, 139, "CELL_TYPE"], [20, 29, "TISSUE"], [128, 139, "CL"], [20, 38, "ENTITY"], [93, 105, "ENTITY"], [118, 139, "CELL"], [145, 167, "TISSUE"], [118, 139, "ENTITY"], [145, 167, "ENTITY"], [10, 20, "ENTITY"]]}
{"text": "Large syncytial cells with multiple nuclei were present . Small vessel vasculitis was seen .", "labels": [[58, 71, "ENTITY"], [27, 43, "ENTITY"], [58, 71, "DISEASE"], [6, 22, "CELL_TYPE"], [0, 22, "CELL"], [0, 6, "ENTITY"], [36, 43, "TISSUE"], [36, 43, "GO"], [6, 22, "CL"], [6, 22, "ENTITY"]]}
{"text": "Large syncytial cells with multiple nuclei were present . Small vessel vasculitis was seen .", "labels": [[6, 22, "CL"], [6, 22, "ENTITY"], [27, 43, "ENTITY"], [0, 22, "CELL"], [0, 6, "ENTITY"], [58, 71, "DISEASE"], [58, 71, "ENTITY"], [36, 43, "TISSUE"], [36, 43, "GO"], [6, 22, "CELL_TYPE"]]}
{"text": "Among the 22 SARS blood samples that were obtained from the early stages of the disease , EM detected SARS-like viral particles in monocytes and lymphocytes of six patients . These round viral particles , with diameters of 80\u2013120 nm , were located in the cytoplasm .", "labels": [[102, 118, "ENTITY"], [13, 18, "DISEASE"], [60, 73, "ENTITY"], [13, 18, "ENTITY"], [18, 32, "ENTITY"], [181, 193, "ENTITY"], [80, 88, "ENTITY"], [181, 187, "TAXON"]]}
{"text": "Most of the infected cells were T cells . Some B cells and NK cells also were infected by the virus . By EM , the viral particles tended to form clusters and were located within or near the endoplasmic reticulum .", "labels": [[32, 40, "CELL_TYPE"], [110, 120, "ENTITY"], [59, 62, "CL"], [12, 27, "CELL_TYPE"], [21, 27, "ENTITY"], [140, 145, "ENTITY"], [186, 202, "ENTITY"], [32, 40, "CELL"], [32, 40, "CL"], [32, 40, "ENTITY"], [59, 62, "CELL_TYPE"], [21, 27, "CELL"], [59, 62, "CELL"], [186, 202, "CELLULAR_COMPONENT"], [21, 27, "CL"], [186, 202, "GO"], [12, 21, "ENTITY"], [59, 62, "ENTITY"]]}
{"text": "A large proportion of lymphocytes in the circulation and lymphoid organs contained the virus ( Fig. 2 , A and B ) .", "labels": [[87, 93, "ENTITY"], [22, 34, "CL"], [57, 73, "ENTITY"], [22, 34, "CELL_TYPE"], [8, 19, "ENTITY"], [57, 73, "TISSUE"], [22, 34, "ENTITY"], [87, 93, "TAXON"], [22, 34, "CELL"], [41, 53, "ENTITY"]]}
{"text": "In addition , the epithelial cells of mucosa of the small and large intestines were found to be infected by the virus by in situ hybridization and EM ( Fig. 3 G ) .", "labels": [[18, 29, "CELL_TYPE"], [18, 29, "CELL"], [121, 129, "ENTITY"], [18, 29, "CL"], [18, 29, "ENTITY"]]}
{"text": "Clusters of SARS viral particles also were detected in the cytoplasm of the distal tubular epithelium by EM ( Fig. 3 , M and N ) .", "labels": [[17, 33, "ENTITY"], [83, 102, "ENTITY"], [105, 108, "ENTITY"], [83, 102, "TISSUE"], [43, 52, "ENTITY"], [59, 69, "GO"], [0, 9, "ENTITY"], [105, 108, "PROTEIN"], [12, 17, "ENTITY"], [17, 23, "TAXON"], [59, 69, "ENTITY"], [76, 83, "ENTITY"], [12, 17, "DISEASE"], [59, 69, "ORGANISM_SUBSTANCE"]]}
{"text": "The spleen and lymph nodes were atrophic ( Fig. 2 L ) .", "labels": [[32, 41, "ENTITY"], [4, 11, "ENTITY"], [4, 11, "ORGAN"], [15, 27, "ENTITY"], [15, 27, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "In five out of the eight confirmed cases , hepatocytes in the centrilobular zone showed apparent degenerative changes . The testes of the seven male patients displayed focal atrophy .", "labels": [[35, 41, "ENTITY"], [158, 174, "ENTITY"], [144, 149, "ENTITY"], [62, 76, "ENTITY"], [158, 174, "DISEASE"], [144, 149, "ORGANISM"], [62, 76, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "LM with hematoxylin and eosin staining revealed a notable decrease of lymphocytes in these organs ( Fig. 2 C ) .", "labels": [[70, 82, "ENTITY"], [0, 3, "CELL"], [58, 67, "ENTITY"], [70, 82, "CELL_TYPE"], [91, 98, "ORGAN"], [0, 3, "ENTITY"], [8, 20, "ENTITY"], [24, 39, "ENTITY"], [70, 82, "CELL"], [91, 98, "ENTITY"], [70, 82, "CL"]]}
{"text": "All immune cell types , including dendritic cells , were decreased significantly ( P < 0.01 ) , and CD68 positive macrophages , which were decreased in number , were noticeably ( P < 0.01 ) increased in size and gave the impression of macrophage activation ( Fig. 2 , D and E ) .", "labels": [[4, 22, "ENTITY"], [34, 44, "CELL_TYPE"], [34, 44, "ENTITY"], [221, 235, "CELL"], [221, 246, "ENTITY"], [11, 16, "CL"], [212, 221, "ENTITY"], [259, 264, "ENTITY"], [105, 114, "CELL"], [94, 114, "CELL_TYPE"], [34, 44, "CL"], [100, 105, "ENTITY"], [34, 44, "CELL"], [105, 114, "CL"], [128, 139, "ENTITY"], [4, 16, "CELL"], [221, 235, "GGP"]]}
{"text": "All immune cell types , including dendritic cells , were decreased significantly ( P < 0.01 ) , and CD68 positive macrophages , which were decreased in number , were noticeably ( P < 0.01 ) increased in size and gave the impression of macrophage activation ( Fig. 2 , D and E ) .", "labels": [[4, 22, "ENTITY"], [34, 44, "CL"], [221, 235, "CELL"], [105, 114, "CL"], [221, 246, "ENTITY"], [11, 16, "CL"], [94, 114, "CELL_TYPE"], [212, 221, "ENTITY"], [259, 264, "ENTITY"], [105, 114, "CELL"], [4, 16, "CELL"], [34, 44, "CELL"], [100, 105, "ENTITY"], [34, 44, "CELL_TYPE"], [128, 139, "ENTITY"], [221, 235, "GGP"], [34, 44, "ENTITY"]]}
{"text": "All immune cell types , including dendritic cells , were decreased significantly ( P < 0.01 ) , and CD68 positive macrophages , which were decreased in number , were noticeably ( P < 0.01 ) increased in size and gave the impression of macrophage activation ( Fig. 2 , D and E ) .", "labels": [[4, 22, "ENTITY"], [34, 44, "CL"], [221, 235, "CELL"], [221, 246, "ENTITY"], [11, 16, "CL"], [212, 221, "ENTITY"], [259, 264, "ENTITY"], [105, 114, "CELL"], [94, 114, "CELL_TYPE"], [4, 16, "CELL"], [100, 105, "ENTITY"], [34, 44, "CELL"], [105, 114, "CL"], [34, 44, "CELL_TYPE"], [128, 139, "ENTITY"], [221, 235, "GGP"], [34, 44, "ENTITY"]]}
{"text": "The lymphoid follicles ( Peyer \u2019s patches ) showed markedly decreased lymphocytes ( Fig. 3 A ) , and in severe cases only the depleted stromal framework of the structure remained . EM detected viral particles in the submucosa of the gut ( Fig. 3 , B and C ) and within the residual lymphocytes .", "labels": [[273, 282, "CL"], [273, 282, "ENTITY"], [84, 91, "GENE_OR_GENE_PRODUCT"], [4, 23, "ENTITY"], [60, 70, "CL"], [25, 31, "CELL"], [70, 89, "CELL"], [126, 135, "ENTITY"], [153, 160, "ENTITY"], [135, 143, "ENTITY"], [209, 216, "ENTITY"], [104, 111, "ENTITY"], [273, 282, "CELL_TYPE"], [60, 70, "ENTITY"], [60, 70, "CELL_TYPE"], [60, 70, "CELL"], [4, 23, "CELL_TYPE"], [51, 60, "ENTITY"], [117, 126, "ENTITY"], [4, 23, "MULTI-TISSUE_STRUCTURE"], [184, 199, "ENTITY"], [170, 184, "ENTITY"], [126, 135, "CELL"], [97, 104, "ENTITY"], [209, 216, "MULTI-TISSUE_STRUCTURE"], [273, 282, "CELL"], [25, 34, "ENTITY"]]}
{"text": "T lymphocytes ( CD3 + , CD4 + , and CD8 + cells ) were decreased at the onset of symptoms ; this decrease persisted until the recovery phase .", "labels": [[0, 14, "CL"], [16, 20, "ENTITY"], [32, 42, "ENTITY"], [65, 72, "ENTITY"], [90, 97, "ENTITY"], [16, 24, "CELL_TYPE"], [32, 42, "CELL_TYPE"], [116, 126, "ENTITY"], [32, 42, "GGP"], [0, 14, "CELL"], [32, 42, "GENE_OR_GENE_PRODUCT"], [0, 14, "ENTITY"], [72, 81, "ENTITY"], [0, 14, "CELL_TYPE"], [48, 55, "ENTITY"]]}
{"text": "T lymphocytes ( CD3 + , CD4 + , and CD8 + cells ) were decreased at the onset of symptoms ; this decrease persisted until the recovery phase .", "labels": [[0, 14, "CL"], [16, 20, "ENTITY"], [32, 42, "ENTITY"], [65, 72, "ENTITY"], [90, 97, "ENTITY"], [16, 24, "CELL_TYPE"], [32, 42, "CELL_TYPE"], [116, 126, "ENTITY"], [32, 42, "GGP"], [0, 14, "CELL"], [32, 42, "GENE_OR_GENE_PRODUCT"], [0, 14, "ENTITY"], [72, 81, "ENTITY"], [0, 14, "CELL_TYPE"], [48, 55, "ENTITY"]]}
{"text": "Results show that SARS patients \u2019 sera contain high levels of IgG recognizing 3a protein ( Fig. 1A ) .", "labels": [[0, 8, "ENTITY"], [23, 32, "ORGANISM"], [23, 32, "ENTITY"], [78, 81, "ENTITY"], [18, 23, "ENTITY"], [18, 23, "DISEASE"]]}
{"text": "As shown in Fig. 5A , prophylactic administration at 50 mg/kg QD or 25 mg/kg BID ameliorated SARS-CoV \u2013 induced weight loss seen with vehicle treatment .", "labels": [[104, 119, "DISEASE"], [93, 102, "DISEASE"], [12, 20, "CANCER"], [104, 119, "ENTITY"], [129, 142, "ENTITY"], [22, 35, "ENTITY"], [17, 20, "ENTITY"], [93, 102, "ORGANISM"]]}
{"text": "Both coronavirus disease 2019 ( COVID-19 ) and severe acute respiratory syndrome ( SARS ) are characterised by an overexuberant inflammatory response and , for SARS , viral load is not correlated with the worsening of symptoms.1,2", "labels": [[5, 30, "DISEASE"], [114, 141, "ENTITY"], [47, 72, "DISEASE"], [160, 167, "ENTITY"], [196, 205, "ENTITY"], [5, 30, "ENTITY"], [5, 30, "ORGANISM"], [205, 218, "GGP"], [178, 185, "ENTITY"], [47, 72, "ENTITY"], [160, 167, "TAXON"], [205, 218, "ENTITY"], [5, 17, "TAXON"]]}
{"text": "Moreover , all the deceased patients and 14 ( 44 % ) recovered patients had an arterial partial pressure of oxygen to fraction of inspired oxygen ratio of 300 , indicating that these patients had developed acute respiratory distress syndrome , whereas severe acute respiratory distress syndrome ( \u2264100 ) developed only in deceased patients ( 16 ; 46 % ) .", "labels": [[252, 286, "ENTITY"], [19, 28, "ORGANISM"], [196, 233, "DISEASE"], [76, 96, "ENTITY"], [127, 146, "ENTITY"], [19, 28, "ENTITY"], [130, 139, "CHEMICAL"], [196, 233, "ENTITY"], [53, 63, "ENTITY"], [314, 322, "ENTITY"], [130, 139, "CHEBI"], [53, 63, "ORGANISM"], [130, 139, "SIMPLE_CHEMICAL"], [206, 233, "DISEASE"]]}
{"text": "During hospitalization , patients with elevated TnT levels developed more frequent complications ( Table 1 ) , including acute respiratory distress syndrome ( 30 [ 57.7 % ] vs 16 [ 11.9 % ] ) , malignant arrhythmias ( 6 [ 11.5 % ] vs 7 [ 5.2 % ] ) including ventricular tachycardia/ ventricular fibrillation , acute coagulopathy ( 25 [ 65.8 % ] vs 17 [ 20.0 % ] ) , and acute kidney injury ( 14 [ 36.8 % ] vs 4 [ 4.7 % ] ) , compared with those with normal TnT levels .", "labels": [[336, 358, "DISEASE"], [336, 358, "ENTITY"], [345, 351, "ORGAN"], [238, 283, "ENTITY"], [121, 148, "DISEASE"], [7, 23, "ENTITY"], [258, 270, "DISEASE"], [258, 270, "ENTITY"], [238, 283, "DISEASE"], [111, 148, "ENTITY"], [238, 270, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "Therefore , the downregulation of ACE2 expression in SARS-CoV infection may play a causal role in the pathogenesis of SARS , which provides a reasonable explanation for the progression of SARS patients into ARDS .", "labels": [[53, 62, "DISEASE"], [53, 58, "ENTITY"], [115, 123, "ORGANISM"], [53, 62, "ENTITY"]]}
{"text": "Experimental affinity measurements ( e.g. surface plasmon resonance , SPR ) confirm the high affinity of SARS-2002 RBD \u2014 ACE2 binding , with an equilibrium dissociation constant ( K D ) of ~15 mM ( 18 - 21 ) , similar to the binding affinity of ACE2 and the COVID-19 RBD ( 22 , 23 ) .", "labels": [[115, 121, "GENE_OR_GENE_PRODUCT"], [0, 22, "ENTITY"], [22, 35, "ENTITY"], [102, 115, "PROTEIN"], [245, 254, "GENE_OR_GENE_PRODUCT"], [115, 121, "GGP"], [245, 258, "ENTITY"], [210, 221, "ENTITY"], [245, 267, "PROTEIN"], [115, 121, "ENTITY"], [121, 126, "ENTITY"], [115, 121, "PROTEIN"], [105, 115, "ENTITY"], [136, 169, "ENTITY"], [88, 93, "ENTITY"], [42, 58, "ENTITY"]]}
{"text": "We observed totally five diabetes-related traits that showed nominally significant MR results , and they were all positively associated with ACE2 expression .", "labels": [[83, 86, "PROTEIN"], [25, 42, "ENTITY"], [61, 83, "ENTITY"], [3, 12, "ENTITY"], [86, 94, "ENTITY"], [42, 49, "ENTITY"], [83, 86, "ENTITY"]]}
{"text": "The recent data from the coronavirus disease 2019 ( COVID-19 ) caused by the 2019 novel coronavirus ( 2019-nCoV ) , confirm that diabetes , along with advanced age , is a major risk factor for an adverse outcome .", "labels": [[82, 102, "DISEASE"], [11, 16, "ENTITY"], [4, 11, "ENTITY"], [189, 204, "ENTITY"], [25, 50, "ORGANISM"], [171, 182, "ENTITY"], [25, 50, "ENTITY"], [25, 50, "DISEASE"]]}
{"text": "Individuals with type 2 diabetes and obesity are commonly prescribed with DPP-4 inhibitors and/or GLP-1 receptor analogs .", "labels": [[37, 45, "DISEASE"], [98, 104, "SIMPLE_CHEMICAL"], [80, 91, "CHEBI"], [98, 113, "GGP"], [17, 33, "DISEASE"], [58, 69, "ENTITY"], [113, 121, "ENTITY"], [0, 12, "ENTITY"], [98, 113, "PROTEIN"], [74, 91, "ENTITY"], [98, 113, "ENTITY"], [17, 33, "ENTITY"], [37, 45, "ENTITY"], [0, 12, "TAXON"], [74, 80, "GENE_OR_GENE_PRODUCT"]]}
{"text": "We observed totally five diabetes-related traits that showed nominally significant MR results , and they were all positively associated with ACE2 expression .", "labels": [[83, 86, "PROTEIN"], [25, 42, "ENTITY"], [61, 83, "ENTITY"], [3, 12, "ENTITY"], [86, 94, "ENTITY"], [42, 49, "ENTITY"], [83, 86, "ENTITY"]]}
{"text": "Two mechanisms may protect children from COVID-19 infections : ( 1 ) cross-protective antibodies from multiple upper respiratory tract infections caused by the common cold-causing alpha coronaviruses , and ( 2 ) fewer ACE2 receptors in their lower respiratory tracts to attract the binding S proteins of the beta coronaviruses .", "labels": [[212, 223, "ENTITY"], [102, 117, "PATHOLOGICAL_FORMATION"], [212, 223, "PROTEIN"], [27, 36, "ENTITY"], [27, 36, "ORGANISM"], [242, 260, "ENTITY"], [301, 313, "GENE_OR_GENE_PRODUCT"], [160, 186, "PROTEIN"], [97, 135, "ENTITY"], [301, 313, "ENTITY"], [282, 292, "CHEBI"], [41, 50, "SIMPLE_CHEMICAL"], [270, 292, "PROTEIN"], [69, 86, "GO"], [301, 313, "PROTEIN"], [67, 86, "ENTITY"], [41, 61, "DISEASE"], [41, 61, "ENTITY"], [4, 15, "ENTITY"], [160, 186, "ENTITY"], [67, 86, "PROTEIN"], [270, 292, "ENTITY"]]}
{"text": "This coronavirus , named SARS-CoV-2 ( formerly 2019-nCoV ) , is responsible for respiratory infections including pneumonia with a mortality rate estimated about 2%-2.5 % , increasing with age and the existence of underlying diseases", "labels": [[5, 17, "ENTITY"], [213, 224, "ENTITY"], [76, 92, "DISEASE"], [25, 47, "GENE_OR_GENE_PRODUCT"], [5, 17, "DISEASE"], [103, 113, "DISEASE"], [123, 140, "ENTITY"], [76, 92, "ENTITY"], [5, 17, "TAXON"], [103, 113, "ENTITY"], [5, 17, "ORGANISM"]]}
{"text": "CT showed multiple scattered GGO shadows in the periphery zone of both lungs with a typical Rosa roxburghii sign , suggesting a high possibility of viral pneumonia in both lungs .", "labels": [[48, 63, "ENTITY"], [29, 41, "ENTITY"], [0, 3, "PROTEIN"], [10, 19, "ENTITY"], [92, 108, "TISSUE"], [71, 77, "ORGAN"], [92, 108, "ENTITY"], [0, 3, "ENTITY"], [71, 77, "ENTITY"], [148, 154, "DISEASE"], [148, 154, "ENTITY"]]}
{"text": "Furthermore , the lesions occurred mainly in the lung confirmed by the HE staining and anti-spike protein of SARS-CoV-2 staining , with mild to moderate interstitial pneumonia characterized by thickened alveolar septa , accumulation of alveolar macrophages in the alveoli , degeneration of the alveolar epithelia , and infiltration of inflammatory cells ( Figure 3a ) .", "labels": [[319, 348, "ENTITY"], [264, 274, "ENTITY"], [233, 245, "CELL"], [290, 303, "TISSUE"], [348, 356, "ENTITY"], [233, 245, "ENTITY"], [109, 120, "ENTITY"], [144, 166, "DISEASE"], [87, 98, "ENTITY"], [335, 348, "CELL"], [144, 166, "ENTITY"], [290, 303, "ENTITY"], [319, 348, "CELL_TYPE"], [193, 212, "MULTI-TISSUE_STRUCTURE"], [348, 356, "GENE_OR_GENE_PRODUCT"], [233, 245, "CL"], [166, 176, "ENTITY"], [233, 245, "CELL_TYPE"], [190, 212, "ENTITY"], [335, 348, "CL"], [87, 98, "PROTEIN"]]}
{"text": "A multicentre , randomised controlled trial of tocilizumab ( IL-6 receptor blockade , licensed for cytokine release syndrome ) , has been approved in patients with COVID-19 pneumonia and elevated IL-6 in China ( ChiCTR2000029765 ) [ 9 ] . Janus kinase ( JAK ) inhibition could affect both inflammation and cellular viral entry in COVID-19 [ 10 ] .", "labels": [[66, 75, "ENTITY"], [187, 196, "GENE_OR_GENE_PRODUCT"], [245, 258, "ENTITY"], [59, 66, "ENTITY"], [277, 289, "DISEASE"], [187, 196, "PROTEIN"], [164, 173, "DISEASE"], [239, 245, "GGP"], [289, 306, "CL"], [138, 150, "ORGANISM"], [315, 330, "GENE_OR_GENE_PRODUCT"], [289, 315, "ENTITY"], [239, 245, "GENE_OR_GENE_PRODUCT"], [315, 327, "ENTITY"], [2, 14, "ENTITY"], [59, 66, "GENE_OR_GENE_PRODUCT"], [204, 212, "PROTEIN"], [159, 173, "ENTITY"], [277, 289, "ENTITY"], [16, 38, "ENTITY"], [289, 302, "CELL"], [187, 196, "ENTITY"], [138, 150, "ENTITY"], [196, 204, "ENTITY"], [59, 66, "GGP"], [239, 245, "PROTEIN"], [187, 196, "GGP"], [95, 116, "ENTITY"]]}
{"text": "On February 6 , the third chest CT scan showed bilateral multiple ground-glass opacities indicating viral pneumonia ( Figure 1B ) and she was admitted to the designated hospital immediately .", "labels": [[47, 79, "ENTITY"], [100, 106, "DISEASE"], [116, 125, "ENTITY"], [100, 106, "ENTITY"], [158, 169, "ENTITY"], [20, 35, "ENTITY"], [3, 12, "ENTITY"]]}
{"text": "Furthermore , the lesions occurred mainly in the lung confirmed by the HE staining and anti-spike protein of SARS-CoV-2 staining , with mild to moderate interstitial pneumonia characterized by thickened alveolar septa , accumulation of alveolar macrophages in the alveoli , degeneration of the alveolar epithelia , and infiltration of inflammatory cells ( Figure 3a ) .", "labels": [[233, 245, "CL"], [319, 348, "ENTITY"], [233, 245, "CELL_TYPE"], [348, 356, "ENTITY"], [290, 303, "TISSUE"], [109, 120, "ENTITY"], [144, 166, "DISEASE"], [87, 98, "ENTITY"], [335, 348, "CELL"], [233, 245, "ENTITY"], [264, 274, "ENTITY"], [144, 166, "ENTITY"], [319, 348, "CELL_TYPE"], [193, 212, "MULTI-TISSUE_STRUCTURE"], [290, 303, "ENTITY"], [348, 356, "GENE_OR_GENE_PRODUCT"], [166, 176, "ENTITY"], [190, 212, "ENTITY"], [233, 245, "CELL"], [335, 348, "CL"], [87, 98, "PROTEIN"]]}
{"text": "Furthermore , the lesions occurred mainly in the lung confirmed by the HE staining and anti-spike protein of SARS-CoV-2 staining , with mild to moderate interstitial pneumonia characterized by thickened alveolar septa , accumulation of alveolar macrophages in the alveoli , degeneration of the alveolar epithelia , and infiltration of inflammatory cells ( Figure 3a ) .", "labels": [[319, 348, "ENTITY"], [233, 245, "CELL"], [290, 303, "TISSUE"], [233, 245, "ENTITY"], [264, 274, "ENTITY"], [109, 120, "ENTITY"], [144, 166, "DISEASE"], [87, 98, "ENTITY"], [335, 348, "CELL"], [144, 166, "ENTITY"], [290, 303, "ENTITY"], [319, 348, "CELL_TYPE"], [193, 212, "MULTI-TISSUE_STRUCTURE"], [233, 245, "CL"], [348, 356, "ENTITY"], [166, 176, "ENTITY"], [233, 245, "CELL_TYPE"], [190, 212, "ENTITY"], [335, 348, "CL"], [87, 98, "PROTEIN"], [348, 356, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Interestingly , asthma and tobacco use also showed nominal significant associations with higher ACE2 expression .", "labels": []}
{"text": "Ang II promotes atherosclerosis in the cardiovascular system and promotes inflammation , oxidative stress , and migration of endothelial cells and vascular smooth muscle cells.24", "labels": [[143, 163, "ENTITY"], [122, 137, "CL"], [16, 32, "DISEASE"], [122, 137, "CELL"], [39, 61, "ENTITY"], [74, 87, "DISEASE"], [0, 7, "GENE_OR_GENE_PRODUCT"], [122, 137, "ENTITY"], [7, 16, "ENTITY"], [74, 87, "ENTITY"], [122, 137, "CELL_TYPE"], [0, 7, "ENTITY"], [143, 170, "CELL_TYPE"], [89, 99, "ENTITY"], [7, 16, "ENTITY"], [143, 170, "GENE_OR_GENE_PRODUCT"], [0, 7, "PROTEIN"], [16, 32, "ENTITY"]]}
{"text": "Ang II promotes atherosclerosis in the cardiovascular system and promotes inflammation , oxidative stress , and migration of endothelial cells and vascular smooth muscle cells.24", "labels": [[143, 163, "ENTITY"], [74, 87, "ENTITY"], [122, 137, "CL"], [16, 32, "DISEASE"], [39, 61, "ENTITY"], [0, 7, "GENE_OR_GENE_PRODUCT"], [74, 87, "DISEASE"], [122, 137, "CELL"], [89, 99, "ENTITY"], [122, 137, "ENTITY"], [7, 16, "ENTITY"], [122, 137, "CELL_TYPE"], [143, 170, "CELL_TYPE"], [0, 7, "ENTITY"], [7, 16, "ENTITY"], [143, 170, "GENE_OR_GENE_PRODUCT"], [0, 7, "PROTEIN"], [16, 32, "ENTITY"]]}
{"text": "Ang II promotes atherosclerosis in the cardiovascular system and promotes inflammation , oxidative stress , and migration of endothelial cells and vascular smooth muscle cells.24", "labels": [[143, 163, "ENTITY"], [74, 87, "ENTITY"], [122, 137, "CELL_TYPE"], [16, 32, "DISEASE"], [39, 61, "ENTITY"], [0, 7, "GENE_OR_GENE_PRODUCT"], [74, 87, "DISEASE"], [122, 137, "CELL"], [7, 16, "ENTITY"], [143, 170, "CELL_TYPE"], [0, 7, "ENTITY"], [89, 99, "ENTITY"], [7, 16, "ENTITY"], [143, 170, "GENE_OR_GENE_PRODUCT"], [0, 7, "PROTEIN"], [16, 32, "ENTITY"], [122, 137, "CL"], [122, 137, "ENTITY"]]}
{"text": "Ang II promotes atherosclerosis in the cardiovascular system and promotes inflammation , oxidative stress , and migration of endothelial cells and vascular smooth muscle cells.24", "labels": [[143, 163, "ENTITY"], [74, 87, "ENTITY"], [122, 137, "CL"], [16, 32, "DISEASE"], [39, 61, "ENTITY"], [0, 7, "GENE_OR_GENE_PRODUCT"], [74, 87, "DISEASE"], [122, 137, "CELL"], [143, 170, "GENE_OR_GENE_PRODUCT"], [122, 137, "ENTITY"], [7, 16, "ENTITY"], [122, 137, "CELL_TYPE"], [0, 7, "ENTITY"], [89, 99, "ENTITY"], [7, 16, "ENTITY"], [0, 7, "PROTEIN"], [16, 32, "ENTITY"], [143, 170, "CELL_TYPE"]]}
{"text": "It was also found that RAS blockade could prevent atherosclerosis in ApoE/ACE2 double knockout mice .", "labels": [[69, 79, "GENE_OR_GENE_PRODUCT"], [23, 27, "ENTITY"], [27, 36, "ENTITY"], [50, 66, "ENTITY"], [95, 100, "TAXON"], [42, 50, "ENTITY"], [50, 66, "DISEASE"], [95, 100, "ORGANISM"], [69, 79, "CHEMICAL"], [69, 100, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Fig 6 . In contrast , mice deficient in either CCR1 , CCR2 , or CCR5 exhibited more prominent airway epithelial cell apoptosis , a severe denuding bronchiolitis with an accumulation of cohesive apoptotic debris within the airway ( empty arrowhead ) , and perivenular/periarterial cuffing ( filled arrowhead ) but there was a distinct lack of cuffing around the affected airways .", "labels": [[325, 339, "ENTITY"], [247, 255, "CHEMICAL"], [84, 112, "CELL"], [84, 94, "ENTITY"], [138, 147, "DISEASE"], [94, 112, "CL"], [112, 117, "ENTITY"], [94, 112, "ENTITY"], [161, 169, "ENTITY"], [325, 339, "CELLULAR_COMPONENT"], [247, 280, "TISSUE"], [131, 138, "ENTITY"], [185, 194, "ENTITY"], [222, 237, "ENTITY"], [247, 280, "ENTITY"], [22, 27, "ENTITY"], [280, 297, "ENTITY"], [138, 147, "ENTITY"], [127, 131, "ENTITY"]]}
{"text": "According to the latest study revealing the correlation between COVID-19 and cancer , 18 ( 1 % ) of 1590 COVID-19 cases had a history of cancer , which was higher than the incidence of cancer ( 0.29 % ) in the overall Chinese population ; meanwhile , cancer patients were found to have a higher risk of severe events than patients without cancer.2", "labels": [[64, 73, "ENTITY"], [210, 226, "ENTITY"], [77, 84, "CANCER"], [172, 185, "DISEASE"], [288, 300, "ENTITY"], [258, 267, "SIMPLE_CHEMICAL"], [120, 126, "ENTITY"], [64, 73, "GENE_OR_GENE_PRODUCT"], [310, 317, "ENTITY"], [77, 84, "ENTITY"], [258, 267, "PROTEIN"], [310, 317, "ORGANISM"], [239, 251, "CANCER"], [258, 267, "ENTITY"], [77, 84, "DISEASE"], [172, 185, "ENTITY"], [172, 185, "CANCER"], [24, 30, "ENTITY"], [44, 56, "ENTITY"], [64, 73, "ENTITY"]]}
{"text": "In comparison with patients with mild COVID-19 ( such as those who did not require ICU stays , did not develop ARDS or pneumonia , and who survived ) , patients with severe COVID-19 have higher comorbidities , including 56 % for hypertension , 21 % for heart diseases , 18 % for diabetes , 12 % for cerebrovascular diseases , and 7 % for cancer ( Table 1 ) ( 79 , 97 ) .", "labels": [[103, 111, "DISEASE"], [129, 135, "CANCER"], [223, 229, "DISEASE"], [38, 47, "DISEASE"], [19, 28, "ORGANISM"], [279, 299, "ENTITY"], [244, 259, "ENTITY"], [129, 135, "ENTITY"], [244, 259, "DISEASE"], [33, 47, "ENTITY"], [129, 135, "DISEASE"], [279, 299, "DISEASE"], [223, 229, "ENTITY"], [3, 14, "ENTITY"], [103, 111, "ENTITY"], [38, 47, "GENE_OR_GENE_PRODUCT"], [166, 173, "DISEASE"], [187, 194, "ENTITY"], [166, 173, "ENTITY"], [166, 173, "GENE_OR_GENE_PRODUCT"], [19, 28, "ENTITY"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [259, 269, "ORGAN"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Patients with elevated TnT levels had significantly higher rates of comorbidities including hypertension ( 33 [ 63.5 % ] vs 28 [ 20.7 % ] ) , coronary heart disease ( 17 [ 32.7 % ] vs4[3.0 % ] ) , cardiomyopathy ( 8[15.4%]vs0 ) , diabetes ( 16 [ 30.8 % ] vs 12 [ 8.9 % ] ) , chronic obstructive pulmonary disease ( 4 [ 7.7 % ] vs 0 ) , and chronic kidney disease ( 1 [ 0.7 % ] vs 5 [ 9.6 % ] ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [246, 283, "ENTITY"], [181, 195, "ENTITY"], [27, 34, "ENTITY"], [134, 151, "DISEASE"], [197, 214, "ENTITY"], [92, 105, "ENTITY"], [68, 82, "ENTITY"], [23, 27, "PROTEIN"], [246, 283, "DISEASE"], [0, 9, "ORGANISM"], [134, 151, "ENTITY"], [305, 327, "ENTITY"], [59, 65, "ENTITY"], [0, 9, "ENTITY"], [92, 105, "DISEASE"], [197, 214, "DISEASE"], [23, 27, "GENE_OR_GENE_PRODUCT"], [181, 195, "DISEASE"], [305, 327, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [219, 230, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [76, 89, "DISEASE"], [257, 271, "ENTITY"], [50, 56, "ENTITY"], [28, 37, "ENTITY"], [50, 56, "DISEASE"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "Fever was the most common symptom ( 92.8 % ; n = 258 ) , followed by cough ( 69.8 % ; n = 194 ) , dyspnoea ( 34.5 % ; n = 96 ) , myalgia ( 27.7 % ; n = 77 ) , headache ( 7.2 % ; n = 20 ) and diarrhoea ( 6.1 % ; n = 17 ) .", "labels": [[57, 69, "DISEASE"], [26, 34, "ENTITY"], [41, 49, "DISEASE"], [0, 6, "DISEASE"], [0, 6, "ENTITY"], [57, 69, "ENTITY"], [41, 49, "ENTITY"]]}
{"text": "The second most common symptom was cough ( 67.8 % ) ; nausea or vomiting ( 5.0 % ) and diarrhea ( 3.8 % ) were uncommon .", "labels": [[23, 31, "ENTITY"], [35, 41, "ENTITY"], [81, 87, "ENTITY"], [81, 87, "DISEASE"], [35, 41, "DISEASE"]]}
{"text": "Most COVID-19 patients initially suffered from fever , cough , fatigue , and shortness of breath , while other symptoms included muscle pain , headache , chest pain , and diarrhea , similar to the symptoms observed after chemotherapy , targeted and immune therapy1", "labels": [[73, 90, "ENTITY"], [143, 154, "DISEASE"], [120, 136, "DISEASE"], [120, 136, "ENTITY"], [47, 53, "ENTITY"], [206, 221, "ENTITY"], [14, 23, "ENTITY"], [5, 14, "ENTITY"], [5, 23, "ORGANISM"], [236, 256, "CELL"], [5, 14, "DISEASE"], [73, 90, "DISEASE"], [143, 154, "ORGAN"], [221, 236, "ENTITY"], [236, 256, "ENTITY"], [71, 77, "ENTITY"], [190, 197, "ENTITY"], [111, 120, "ENTITY"], [136, 143, "ENTITY"], [136, 143, "DISEASE"], [120, 129, "ORGAN"], [47, 53, "DISEASE"], [143, 154, "ENTITY"], [71, 77, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [219, 230, "DISEASE"], [176, 191, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"]]}
{"text": "She developed chest tightness , shortness of breath , loss of appetite , 62 nausea , and diarrhea", "labels": [[52, 62, "ENTITY"], [52, 62, "DISEASE"], [4, 14, "ENTITY"], [14, 30, "ENTITY"], [32, 45, "ENTITY"], [14, 30, "DISEASE"], [32, 45, "DISEASE"]]}
{"text": "Adverse reactions include nausea , diarrhea , dizziness , elevated serum aminotransferase , etc .", "labels": [[26, 33, "DISEASE"], [58, 73, "PROTEIN"], [26, 33, "ENTITY"], [58, 73, "ENTITY"], [58, 73, "ORGANISM_SUBSTANCE"], [0, 18, "ENTITY"]]}
{"text": "ACE2 in the gastrointestinal tract may underly early gastrointestinal symptoms such as nausea , vomiting , and diarrhea , and ACE2 in the heart may be related to cardiac damage and fulminant myocarditis that have been reported in COVID-19 [ 14,15 ] .", "labels": [[12, 35, "ORGAN"], [87, 94, "DISEASE"], [12, 29, "ORGAN"], [87, 94, "ENTITY"], [0, 5, "PROTEIN"], [177, 191, "ENTITY"], [12, 35, "DISEASE"], [159, 170, "ENTITY"], [12, 35, "ENTITY"], [0, 5, "ENTITY"], [159, 170, "DISEASE"], [177, 191, "DISEASE"], [227, 241, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [53, 79, "ENTITY"], [53, 79, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Among adult patients , cardiovascular disease and hypertension were the most common underlying diseases , followed by diabetes mellitus .", "labels": [[12, 21, "ORGANISM"], [115, 127, "DISEASE"], [23, 38, "ENTITY"], [115, 127, "ENTITY"], [23, 38, "DISEASE"], [12, 21, "ENTITY"], [6, 12, "ENTITY"]]}
{"text": "Among the overall population , 23.7 % had at least one coexisting illness ( e.g. , hypertension and chronic obstructive pulmonary disease ) .", "labels": [[108, 120, "ORGAN"], [10, 29, "ENTITY"], [96, 130, "DISEASE"], [96, 130, "ENTITY"], [76, 83, "ENTITY"], [76, 83, "DISEASE"], [55, 66, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [50, 60, "ENTITY"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [136, 146, "ORGAN"], [136, 158, "ENTITY"], [144, 166, "ENTITY"], [254, 285, "ENTITY"]]}
{"text": "Comorbidities were present in nearly half of patients , with hypertension being the most common comorbidity , followed by diabetes and coronary heart disease ( table 1 ) .", "labels": [[0, 14, "ENTITY"], [131, 150, "ENTITY"], [131, 150, "DISEASE"], [131, 144, "CANCER"], [45, 54, "ENTITY"], [45, 54, "ORGANISM"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "In this study , Guan et al reported more severe disease outcomes in patients with hypertension , coronary artery disease , diabetes , and chronic renal disease ( Table 1 ) . 6", "labels": [[8, 14, "ENTITY"], [134, 152, "DISEASE"], [134, 152, "ENTITY"], [95, 113, "DISEASE"], [95, 113, "ENTITY"], [138, 146, "ORGAN"], [95, 106, "MULTI-TISSUE_STRUCTURE"], [48, 56, "ENTITY"]]}
{"text": "In an analysis of 45,000 confirmed cases in China , the crude case fatality rate was 0.9 % for patients without any documented comorbidities , whereas the case fatality rate was much higher for patients with CVD ( 10.5 % ) , diabetes ( 7.3 % ) , or hypertension ( 6.3 % )", "labels": [[151, 160, "ENTITY"], [116, 127, "ENTITY"], [56, 67, "ENTITY"], [44, 50, "ENTITY"], [6, 15, "ENTITY"], [236, 249, "ENTITY"], [35, 41, "ENTITY"], [236, 249, "DISEASE"]]}
{"text": "In comparison with patients with mild COVID-19 ( such as those who did not require ICU stays , did not develop ARDS or pneumonia , and who survived ) , patients with severe COVID-19 have higher comorbidities , including 56 % for hypertension , 21 % for heart diseases , 18 % for diabetes , 12 % for cerebrovascular diseases , and 7 % for cancer ( Table 1 ) ( 79 , 97 ) .", "labels": [[103, 111, "DISEASE"], [129, 135, "CANCER"], [223, 229, "DISEASE"], [38, 47, "DISEASE"], [19, 28, "ORGANISM"], [279, 299, "ENTITY"], [244, 259, "ENTITY"], [129, 135, "ENTITY"], [244, 259, "DISEASE"], [33, 47, "ENTITY"], [129, 135, "DISEASE"], [279, 299, "DISEASE"], [223, 229, "ENTITY"], [3, 14, "ENTITY"], [103, 111, "ENTITY"], [38, 47, "GENE_OR_GENE_PRODUCT"], [166, 173, "DISEASE"], [187, 194, "ENTITY"], [166, 173, "ENTITY"], [166, 173, "GENE_OR_GENE_PRODUCT"], [19, 28, "ENTITY"]]}
{"text": "Hypertension , cardiovascular disease , and cerebrovascular disease were much more frequent among deceased patients ( 54 ( 48 % ) , 16 ( 14 % ) , and 4 ( 4 % ) ) than among recovered patients ( 39 ( 24 % ) , 7 ( 4 % ) , and 0 ( 0 % ) ) .", "labels": [[15, 30, "ENTITY"], [40, 60, "ENTITY"], [0, 13, "ENTITY"], [98, 107, "ENTITY"], [15, 30, "DISEASE"], [158, 167, "ENTITY"], [40, 60, "DISEASE"], [98, 107, "ORGANISM"], [0, 13, "DISEASE"]]}
{"text": "The prevalence of specific comorbidities was : hypertension ( 269 ; 16.9 % ) , other cardiovascular diseases ( 53.7 % ) cerebrovascular diseases ( 30 ; 1.9 % ) , diabetes ( 130 ; 8.2 % ) , hepatitis B infections ( 28 ; 1.8 % ) , chronic obstructive pulmonary disease ( 24 ; 1.5 % ) , chronic kidney diseases ( 21 ; 1.3 % ) , malignancy ( 18 ; 1.1 % ) and immunodeficiency ( 3 ; 0.2 % ) .", "labels": [[4, 15, "ENTITY"], [292, 299, "ENTITY"], [27, 41, "ENTITY"], [18, 27, "ENTITY"], [79, 100, "DISEASE"], [79, 100, "ENTITY"], [111, 136, "ENTITY"], [249, 278, "ENTITY"], [292, 299, "DISEASE"], [259, 269, "ORGAN"], [214, 237, "DISEASE"], [249, 278, "DISEASE"], [111, 136, "DISEASE"], [201, 237, "ENTITY"]]}
{"text": "Compared with patients without ARDS , patients with ARDS had a higher proportion of comorbidities , including hypertension ( difference , 13.7 % ; 95%CI , 1.3%-26.1 % ; P = .02 ) and diabetes ( difference , 13.9 % ; 95 % CI , 3.6%-24.2 % ; P = .002 ) .", "labels": [[100, 110, "ENTITY"], [31, 36, "ENTITY"], [14, 23, "ORGANISM"], [14, 23, "ENTITY"], [31, 36, "DISEASE"], [100, 110, "DISEASE"], [0, 9, "ENTITY"], [183, 194, "ENTITY"]]}
{"text": "In an analysis of 45,000 confirmed cases in China , the crude case fatality rate was 0.9 % for patients without any documented comorbidities , whereas the case fatality rate was much higher for patients with CVD ( 10.5 % ) , diabetes ( 7.3 % ) , or hypertension ( 6.3 % )", "labels": [[151, 160, "ENTITY"], [116, 127, "ENTITY"], [56, 67, "ENTITY"], [44, 50, "ENTITY"], [6, 15, "ENTITY"], [236, 249, "ENTITY"], [35, 41, "ENTITY"], [236, 249, "DISEASE"]]}
{"text": "In an analysis of 45,000 confirmed cases in China , the crude case fatality rate was 0.9 % for patients without any documented comorbidities , whereas the case fatality rate was much higher for patients with CVD ( 10.5 % ) , diabetes ( 7.3 % ) , or hypertension ( 6.3 % )", "labels": [[151, 160, "ENTITY"], [116, 127, "ENTITY"], [56, 67, "ENTITY"], [44, 50, "ENTITY"], [6, 15, "ENTITY"], [236, 249, "ENTITY"], [35, 41, "ENTITY"], [236, 249, "DISEASE"]]}
{"text": "Indeed , increased ACE2 levels are seen in multiple cardiovascular conditions and related comorbidities such as diabetes and hypertension [ 8,18,25 ] .", "labels": []}
{"text": "For this , both ACE and AII have been widely exploited as pharmacological targets in the treatment of hypertension , heart failure or diabetic nephropathy by means of ACE inhibitors and AII receptor antagonists , respectively [ 1 ] .", "labels": [[182, 199, "GENE_OR_GENE_PRODUCT"], [16, 20, "CHEBI"], [115, 123, "DISEASE"], [164, 171, "ENTITY"], [131, 143, "DISEASE"], [131, 143, "ENTITY"], [115, 123, "ENTITY"], [20, 28, "GGP"], [182, 199, "ENTITY"]]}
{"text": "Multivariate regression further links hypertension with increased incidence and fatality ( 85 , 89 , 101 ) .", "labels": [[38, 51, "DISEASE"], [56, 66, "ENTITY"], [66, 76, "ENTITY"], [0, 24, "ENTITY"], [80, 89, "DISEASE"], [38, 51, "ENTITY"], [80, 89, "ENTITY"]]}
{"text": "Patients with elevated TnT levels had significantly higher rates of comorbidities including hypertension ( 33 [ 63.5 % ] vs 28 [ 20.7 % ] ) , coronary heart disease ( 17 [ 32.7 % ] vs4[3.0 % ] ) , cardiomyopathy ( 8[15.4%]vs0 ) , diabetes ( 16 [ 30.8 % ] vs 12 [ 8.9 % ] ) , chronic obstructive pulmonary disease ( 4 [ 7.7 % ] vs 0 ) , and chronic kidney disease ( 1 [ 0.7 % ] vs 5 [ 9.6 % ] ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [246, 283, "ENTITY"], [181, 195, "ENTITY"], [27, 34, "ENTITY"], [134, 151, "DISEASE"], [197, 214, "ENTITY"], [68, 82, "ENTITY"], [23, 27, "PROTEIN"], [246, 283, "DISEASE"], [59, 65, "ENTITY"], [0, 9, "ORGANISM"], [134, 151, "ENTITY"], [305, 327, "ENTITY"], [197, 214, "DISEASE"], [0, 9, "ENTITY"], [92, 105, "DISEASE"], [23, 27, "GENE_OR_GENE_PRODUCT"], [92, 105, "ENTITY"], [181, 195, "DISEASE"], [305, 327, "DISEASE"]]}
{"text": "RAS activation is an important pathophysiological mechanism of hypertension , and RAS blockers are widely used .", "labels": [[0, 4, "ENTITY"], [4, 15, "ENTITY"], [50, 60, "ENTITY"], [0, 4, "ENTITY"], [63, 76, "DISEASE"], [0, 4, "GENE_OR_GENE_PRODUCT"], [0, 4, "GENE_OR_GENE_PRODUCT"], [31, 50, "ENTITY"], [0, 4, "PROTEIN"], [63, 76, "ENTITY"], [0, 4, "PROTEIN"]]}
{"text": "Studies by Ferrario27 and others showed that ACE2 levels increased by 4.7 and 2.8 times when blood pressure decreased after applying ACEIs ( lisinopril ) and ARBs ( losartan ) to rats .", "labels": [[11, 22, "SIMPLE_CHEMICAL"], [133, 139, "CHEMICAL"], [45, 50, "ENTITY"], [50, 57, "ENTITY"], [11, 22, "ENTITY"], [45, 50, "GGP"], [0, 8, "ENTITY"], [45, 50, "GENE_OR_GENE_PRODUCT"], [133, 139, "SIMPLE_CHEMICAL"], [108, 118, "ENTITY"], [133, 139, "ENTITY"], [93, 99, "ORGANISM_SUBSTANCE"], [11, 22, "CHEMICAL"], [57, 67, "ENTITY"], [93, 108, "ENTITY"], [45, 50, "PROTEIN"]]}
{"text": "RhACE2 can reduce blood pressure while reducing renal damage34", "labels": [[0, 7, "GENE_OR_GENE_PRODUCT"], [0, 7, "ENTITY"], [18, 24, "ORGANISM_SUBSTANCE"], [0, 7, "DNA"], [39, 48, "ENTITY"], [18, 33, "ENTITY"], [11, 18, "ENTITY"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Adverse reactions of IFN-\u03b1 mainly include low-grade fever and flu-like symptoms ( both in children with intramuscularly injection ) [ 11 ] .", "labels": [[52, 58, "ENTITY"], [21, 27, "PROTEIN"], [62, 71, "ORGAN"], [104, 120, "ENTITY"], [21, 27, "ENTITY"], [62, 80, "ENTITY"], [42, 52, "ENTITY"], [52, 58, "DISEASE"], [21, 27, "GENE_OR_GENE_PRODUCT"], [42, 52, "CANCER"], [0, 18, "ENTITY"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[542, 550, "ENTITY"], [416, 427, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [301, 311, "TAXON"], [139, 151, "PROTEIN"], [439, 444, "ENTITY"], [125, 135, "SO"], [162, 193, "ENTITY"], [408, 416, "ENTITY"], [477, 487, "ENTITY"], [320, 326, "ENTITY"], [115, 125, "DISEASE"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [162, 187, "ORGANISM"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [487, 507, "ENTITY"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "As the single-nucleotide polymorphism rs12252-C/C in the gene IFITM3 ( which encodes interferon-induced transmembrane protein 3 ) is linked to severe influenza6,7 , we analyzed IFITM3-rs12252 in the patient with COVID-19 and found the \u2018 risk \u2019 IFITM3-rs12252-C/C variant ( Extended Data Fig. 2b ) .", "labels": [[7, 38, "SO"], [7, 38, "ENTITY"], [143, 150, "ENTITY"], [168, 177, "DISEASE"], [62, 69, "GENE_OR_GENE_PRODUCT"], [143, 150, "PROTEIN"], [85, 126, "GENE_OR_GENE_PRODUCT"], [7, 50, "DNA"], [168, 177, "PROTEIN"], [85, 126, "ENTITY"], [237, 244, "CHEMICAL"], [57, 69, "ENTITY"], [244, 263, "SO"], [237, 263, "PROTEIN"], [38, 50, "GENE_OR_GENE_PRODUCT"], [57, 69, "SO"], [237, 263, "ENTITY"], [263, 273, "ENTITY"], [62, 69, "PROTEIN"], [231, 237, "ENTITY"], [85, 126, "PROTEIN"]]}
{"text": "The blood counts of patients on admission showed leucopenia ( white blood cell count less than 4 \u00d7 10\u2079/L;ten [ 25 % ] of 40 patients ) and lymphopenia ( lymphocyte count < 1\u00b70 \u00d7 10\u2079/L ; 26 [ 63 % ] patients ; table 2 ) .", "labels": [[4, 10, "CL"], [32, 42, "ENTITY"], [20, 29, "ORGANISM"], [4, 10, "ORGANISM_SUBSTANCE"], [49, 60, "DISEASE"], [4, 17, "ENTITY"], [62, 74, "ENTITY"], [139, 164, "ENTITY"], [4, 10, "CELL"], [20, 29, "ENTITY"], [139, 153, "CELL"], [139, 153, "CL"], [49, 60, "ENTITY"]]}
{"text": "On admission , lymphocytopenia was present in 83.2 % of the patients , thrombocytopenia in 36.2 % , and leukopenia in 33.7 %", "labels": [[3, 13, "ENTITY"]]}
{"text": "The blood counts of patients on admission showed leucopenia ( white blood cell count less than 4 \u00d7 10\u2079/L;ten [ 25 % ] of 40 patients ) and lymphopenia ( lymphocyte count < 1\u00b70 \u00d7 10\u2079/L ; 26 [ 63 % ] patients ; table 2 ) .", "labels": [[4, 10, "CL"], [32, 42, "ENTITY"], [20, 29, "ORGANISM"], [4, 10, "ORGANISM_SUBSTANCE"], [4, 17, "ENTITY"], [62, 74, "ENTITY"], [49, 60, "ENTITY"], [139, 164, "ENTITY"], [4, 10, "CELL"], [20, 29, "ENTITY"], [49, 60, "DISEASE"], [139, 153, "CELL"], [139, 153, "CL"]]}
{"text": "The most common symptoms at onset of COVID-19 illness are fever , cough , and fatigue , while other symptoms include sputum production , headache , haemoptysis , diarrhoea , dyspnoea , and lymphopenia [ 5,6,8,13 ] .", "labels": [[148, 162, "ENTITY"], [174, 189, "DISEASE"], [109, 117, "TISSUE"], [124, 137, "DISEASE"], [37, 54, "DISEASE"], [137, 148, "DISEASE"], [109, 124, "ENTITY"], [37, 54, "ENTITY"], [124, 137, "ENTITY"], [137, 148, "ENTITY"], [58, 64, "DISEASE"], [37, 46, "GENE_OR_GENE_PRODUCT"], [148, 162, "DISEASE"], [162, 174, "ENTITY"], [58, 64, "ENTITY"], [174, 189, "ENTITY"], [162, 174, "DISEASE"], [16, 25, "ENTITY"]]}
{"text": "The clinical features include fever , dry cough , shortness of breath , normal or low levels of peripheral white blood cells , and inflammatory changes on chest X-ray .", "labels": [[48, 63, "ENTITY"], [38, 42, "ENTITY"], [107, 119, "CELL"], [4, 22, "ENTITY"], [107, 119, "CL"], [82, 86, "ENTITY"], [127, 144, "ENTITY"], [30, 36, "ENTITY"], [38, 42, "DISEASE"], [48, 63, "DISEASE"], [152, 161, "ENTITY"], [93, 119, "ENTITY"], [93, 119, "CELL_TYPE"], [30, 36, "DISEASE"]]}
{"text": "Deceased patients had persistent and more severe lymphopenia than recovered patients ; 44 ( 39 % ) deceased patients and eight ( 5 % ) recovered patients had lymphocyte counts below 0.5 \u00d7 109/L.", "labels": [[99, 108, "ORGANISM"], [66, 76, "ENTITY"], [9, 22, "ENTITY"], [176, 186, "GENE_OR_GENE_PRODUCT"], [9, 18, "ENTITY"], [176, 186, "PROTEIN"], [0, 9, "ENTITY"], [9, 22, "CL"], [9, 18, "ENTITY"], [66, 76, "ENTITY"], [9, 18, "ORGANISM"], [9, 18, "ORGANISM"], [66, 76, "ORGANISM"], [42, 49, "ENTITY"], [49, 61, "ENTITY"], [99, 108, "ENTITY"], [49, 61, "DISEASE"], [22, 33, "ENTITY"], [9, 22, "CELL"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses [ 3 ] .", "labels": [[113, 124, "CANCER"], [0, 31, "ENTITY"], [0, 31, "CHEMICAL"], [193, 197, "SO"], [35, 46, "ENTITY"], [222, 231, "ENTITY"], [222, 245, "ORGANISM"], [113, 124, "ENTITY"], [0, 31, "SIMPLE_CHEMICAL"], [193, 197, "ENTITY"], [113, 124, "DISEASE"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses [ 3 ] .", "labels": [[113, 124, "CANCER"], [0, 31, "CHEMICAL"], [193, 197, "SO"], [35, 46, "ENTITY"], [0, 31, "ENTITY"], [222, 231, "ENTITY"], [222, 245, "ORGANISM"], [0, 31, "SIMPLE_CHEMICAL"], [113, 124, "ENTITY"], [193, 197, "ENTITY"], [113, 124, "DISEASE"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[542, 550, "ENTITY"], [416, 427, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [301, 311, "TAXON"], [139, 151, "PROTEIN"], [439, 444, "ENTITY"], [162, 193, "ENTITY"], [408, 416, "ENTITY"], [477, 487, "ENTITY"], [320, 326, "ENTITY"], [115, 125, "DISEASE"], [221, 233, "ENTITY"], [162, 187, "ORGANISM"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [174, 187, "TAXON"], [125, 139, "ENTITY"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [427, 439, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [487, 507, "ENTITY"], [125, 135, "SO"], [487, 496, "TAXON"], [162, 193, "DISEASE"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Mechanistic evidence suggests two competing hypotheses : 1 ) RAS blockade decreases proinflammatory activity of Ang II , decreasing the risk of ARDS , myocarditis , or mortality in COVID-19 , or 2 ) RAS blockade increases ACE2 expression , promoting SARS-CoV-2 virulence in the lungs and heart that leads to ARDS , myocarditis , and death .", "labels": [[151, 165, "ENTITY"], [144, 151, "ENTITY"], [144, 151, "DISEASE"], [0, 12, "ENTITY"], [240, 261, "ENTITY"], [305, 315, "DISEASE"], [109, 116, "ENTITY"], [168, 181, "ENTITY"], [59, 65, "ENTITY"], [65, 74, "ENTITY"], [109, 116, "PROTEIN"], [305, 315, "ENTITY"], [109, 116, "GENE_OR_GENE_PRODUCT"], [74, 100, "ENTITY"], [278, 284, "ORGAN"], [44, 55, "ENTITY"], [240, 250, "SIMPLE_CHEMICAL"], [65, 74, "ENTITY"], [61, 65, "ENTITY"], [212, 227, "ENTITY"], [163, 168, "ENTITY"], [168, 181, "GENE_OR_GENE_PRODUCT"], [299, 305, "ENTITY"], [109, 116, "CHEMICAL"], [240, 250, "CHEMICAL"], [299, 305, "DISEASE"], [151, 165, "DISEASE"], [168, 195, "CELL_LINE"], [278, 284, "ENTITY"], [109, 116, "GGP"], [12, 21, "ENTITY"]]}
{"text": "Individuals with type 2 diabetes and obesity are commonly prescribed with DPP-4 inhibitors and/or GLP-1 receptor analogs .", "labels": [[98, 104, "SIMPLE_CHEMICAL"], [80, 91, "CHEBI"], [98, 113, "GGP"], [58, 69, "ENTITY"], [17, 33, "DISEASE"], [37, 45, "ENTITY"], [113, 121, "ENTITY"], [0, 12, "ENTITY"], [98, 113, "PROTEIN"], [74, 91, "ENTITY"], [37, 45, "DISEASE"], [98, 113, "ENTITY"], [17, 33, "ENTITY"], [0, 12, "TAXON"], [74, 80, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "Interestingly , by 6 dpi , the severity of PBV edema and denuding bronchiolitis in MyD88-/- mice had waned , and signs of lung inflammation were evident , with marked PBV infiltrates and perivascular cuffing even more severe than that seen in WT mice at similar times post infection .", "labels": [[57, 66, "DISEASE"], [83, 92, "ORGANISM"], [240, 246, "SO"], [43, 47, "ENTITY"], [268, 273, "ENTITY"], [160, 167, "ENTITY"], [183, 200, "ENTITY"], [119, 127, "DISEASE"], [43, 47, "PATHOLOGICAL_FORMATION"], [80, 92, "ENTITY"], [240, 246, "ENTITY"], [268, 273, "DISEASE"], [83, 92, "TAXON"], [119, 127, "ENTITY"], [40, 47, "ENTITY"], [57, 66, "ENTITY"], [43, 47, "DISEASE"], [183, 200, "TISSUE"], [160, 171, "CELL_TYPE"], [43, 47, "TISSUE"], [240, 246, "ORGANISM"], [262, 268, "ENTITY"]]}
{"text": "Interestingly , by 6 dpi , the severity of PBV edema and denuding bronchiolitis in MyD88-/- mice had waned , and signs of lung inflammation were evident , with marked PBV infiltrates and perivascular cuffing even more severe than that seen in WT mice at similar times post infection .", "labels": [[57, 66, "DISEASE"], [83, 92, "ORGANISM"], [240, 246, "SO"], [43, 47, "ENTITY"], [268, 273, "ENTITY"], [160, 167, "ENTITY"], [183, 200, "ENTITY"], [119, 127, "DISEASE"], [43, 47, "PATHOLOGICAL_FORMATION"], [80, 92, "ENTITY"], [240, 246, "ENTITY"], [268, 273, "DISEASE"], [83, 92, "TAXON"], [119, 127, "ENTITY"], [40, 47, "ENTITY"], [57, 66, "ENTITY"], [43, 47, "DISEASE"], [183, 200, "TISSUE"], [160, 171, "CELL_TYPE"], [43, 47, "TISSUE"], [240, 246, "ORGANISM"], [262, 268, "ENTITY"]]}
{"text": "All patients had pneumonia . Common complications included ARDS ( 12 [ 29 % ] of 41 patients ) , followed by RNAaemia ( six [ 15 % ] patients ) , acute cardiac injury ( five [ 12 % ] patients ) , and secondary infection ( four [ 10 % ] patients ; table 3 ) .", "labels": [[210, 222, "ORGANISM"], [97, 109, "ENTITY"], [97, 109, "PROTEIN"], [78, 84, "ORGANISM"], [97, 109, "GENE_OR_GENE_PRODUCT"], [120, 131, "ENTITY"], [78, 84, "ENTITY"], [17, 27, "ENTITY"], [181, 200, "ENTITY"], [120, 131, "ORGANISM"], [167, 174, "ENTITY"], [4, 13, "ENTITY"], [84, 97, "ORGAN"], [133, 152, "DISEASE"], [167, 174, "ORGANISM"], [181, 200, "DISEASE"], [133, 152, "ENTITY"], [210, 222, "ENTITY"], [17, 27, "DISEASE"], [4, 13, "ORGANISM"]]}
{"text": "A recent hypothesis suggested that angiotensin receptor 1 ( AT1R ) inhibitors might be beneficial for patients infected by COVID-19 who experience pneumonia ( Sun , Yang , Sun , & Su , 2020 ) .", "labels": [[35, 58, "ENTITY"], [35, 58, "GENE_OR_GENE_PRODUCT"], [35, 47, "CHEMICAL"], [35, 58, "PROTEIN"], [9, 20, "ENTITY"], [102, 111, "ENTITY"], [136, 147, "ENTITY"], [35, 58, "GGP"], [136, 147, "DISEASE"]]}
{"text": "If bacterial infection is suspected according to the patient \u2019s clinical and imaging findings , patients of mild type can take oral antibiotics for community-acquired pneumonia , such as second- generation cephalosporins or fluoroquinolones .", "labels": [[127, 132, "CHEBI"], [26, 36, "ENTITY"], [53, 61, "ENTITY"], [105, 113, "ENTITY"], [144, 167, "ENTITY"], [3, 23, "DISEASE"], [195, 206, "CHEBI"], [144, 167, "DISEASE"], [195, 206, "CHEMICAL"], [3, 23, "ENTITY"], [53, 61, "ORGANISM"], [3, 13, "TAXON"], [187, 206, "ENTITY"]]}
{"text": "The clinical manifestations of COVID-19 are protean , which include asymptomatic carrier , ARD , and pneumonia of varying degrees of severity . First , asymptomatic cases were diagnosed based on positive viral nucleic acid test results , but without any COVID-19 symptoms , such as fever , gastrointestinal , or respiratory symptoms , and no significant abnormalities on chest radiograph [ 7,8 ] .", "labels": [[186, 195, "ENTITY"], [290, 324, "ENTITY"], [68, 81, "ENTITY"], [223, 228, "ENTITY"], [31, 40, "ENTITY"], [31, 40, "ENTITY"], [144, 152, "ENTITY"], [114, 122, "ENTITY"], [242, 254, "ENTITY"], [204, 218, "CHEMICAL"], [354, 377, "ENTITY"], [342, 354, "ENTITY"], [282, 290, "ENTITY"], [195, 218, "TAXON"], [242, 254, "GENE_OR_GENE_PRODUCT"], [282, 290, "ORGAN"], [44, 52, "ENTITY"], [195, 223, "ENTITY"], [4, 28, "ENTITY"], [31, 40, "DISEASE"], [31, 40, "GENE_OR_GENE_PRODUCT"], [324, 342, "ENTITY"]]}
{"text": "Six patients had bilateral pneumonia and two unilateral pneumonia .", "labels": [[27, 37, "DISEASE"], [45, 56, "ENTITY"], [27, 37, "DISEASE"], [17, 37, "ENTITY"], [27, 37, "ENTITY"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "The bedside chest X-ray showed progression of the pneumonia , since the bilateral diffuse opacities , so-called \u201c white lungs \u201d , with air bronchogram occurred on February 15 ( Figure 3C , 3D and 3E ) .", "labels": [[50, 60, "DISEASE"], [177, 184, "ENTITY"], [50, 60, "ENTITY"], [135, 139, "DISEASE"], [31, 43, "ENTITY"], [4, 24, "ENTITY"], [130, 139, "ENTITY"], [72, 90, "ENTITY"], [135, 139, "ORGAN"], [114, 120, "MULTI-TISSUE_STRUCTURE"], [112, 120, "ENTITY"], [189, 192, "PROTEIN"], [189, 192, "ENTITY"]]}
{"text": "A chest radiographic image showed pneumonia , but other laboratory tests ( except procalcitonin ) were normal", "labels": [[2, 8, "ENTITY"], [34, 44, "DISEASE"], [56, 67, "ENTITY"], [34, 44, "ENTITY"]]}
{"text": "A chest radiographic image showed pneumonia .", "labels": [[2, 27, "ENTITY"], [34, 44, "DISEASE"], [34, 44, "ENTITY"]]}
{"text": "Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation , caffeine , and antibiotics .", "labels": [[137, 147, "ENTITY"], [152, 176, "ENTITY"], [66, 72, "MULTI-TISSUE_STRUCTURE"], [66, 91, "ENTITY"], [9, 39, "DISEASE"], [9, 39, "ENTITY"], [126, 131, "ENTITY"], [43, 53, "ENTITY"], [0, 9, "ENTITY"], [43, 53, "DISEASE"], [116, 120, "ENTITY"], [94, 104, "ENTITY"]]}
{"text": "During hospital admission , most of the patients received a diagnosis of pneumonia from a physician ( 91.1 % ) , followed by ARDS ( 3.4 % ) and shock ( 1.1 % ) .", "labels": [[113, 125, "ENTITY"], [7, 26, "ENTITY"], [113, 125, "DISEASE"]]}
{"text": "Chest CT scan revealed bilateral pneumonia in all patients", "labels": [[23, 43, "ENTITY"], [6, 9, "PROTEIN"], [33, 43, "DISEASE"], [0, 14, "ENTITY"]]}
{"text": "Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation , caffeine , and antibiotics .", "labels": [[137, 147, "ENTITY"], [152, 176, "ENTITY"], [66, 72, "MULTI-TISSUE_STRUCTURE"], [66, 91, "ENTITY"], [9, 39, "DISEASE"], [9, 39, "ENTITY"], [126, 131, "ENTITY"], [43, 53, "ENTITY"], [0, 9, "ENTITY"], [43, 53, "DISEASE"], [116, 120, "ENTITY"], [94, 104, "ENTITY"]]}
{"text": "Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation , caffeine , and antibiotics .", "labels": [[137, 147, "ENTITY"], [152, 176, "ENTITY"], [66, 72, "MULTI-TISSUE_STRUCTURE"], [66, 91, "ENTITY"], [9, 39, "DISEASE"], [9, 39, "ENTITY"], [126, 131, "ENTITY"], [43, 53, "ENTITY"], [0, 9, "ENTITY"], [43, 53, "DISEASE"], [116, 120, "ENTITY"], [94, 104, "ENTITY"]]}
{"text": "It is often induced by sepsis , aspiration , and pneumonia ( including that caused by SARS coronavirus , bird flu , and human influenza viruses ) .", "labels": [[116, 136, "ORGANISM"], [12, 20, "ENTITY"], [23, 30, "DISEASE"], [23, 30, "ENTITY"], [126, 136, "TAXON"], [86, 91, "ORGANISM"], [120, 136, "ENTITY"], [83, 91, "DISEASE"], [91, 110, "ENTITY"], [83, 91, "ENTITY"]]}
{"text": "A retrospective study of 8866 cases22 showed that these factors , such as being male , being over 60 years of age , and having pneumonia at diagnosis , were significantly positively correlated with the increase in mortality .", "labels": [[2, 22, "ENTITY"], [56, 64, "ENTITY"], [171, 182, "ENTITY"], [25, 38, "CHEMICAL"], [30, 38, "ENTITY"]]}
{"text": "Forty two ( 86 % ) of 49 deceased patients and 58 ( 50 % ) of 117 recovered patients had proteinuria , and 40 ( 82 % ) of 49 deceased patients and 44 ( 38 % ) of 117 recovered patients showed microscopic haematuria .", "labels": [[15, 22, "ENTITY"], [176, 192, "ENTITY"], [76, 89, "ENTITY"], [76, 89, "DISEASE"], [66, 76, "ENTITY"], [59, 66, "ENTITY"], [66, 76, "ORGANISM"], [25, 34, "ENTITY"], [25, 34, "ORGANISM"], [152, 162, "ENTITY"]]}
{"text": "He also had suspected sepsis , with an Enterobacter agglomerates\u2013 positive blood culture , leukocytosis , thrombocytopenia ( 11 cells \u00d7 103/\u03bcL ; to convert to cells \u00d7 109/L , multiply by 1.0 ) , and coagulopathy ( prothrombin time , 21 seconds ; activated partial thromboplastin time , 81.9 seconds ) , which improved with antibiotic treatment .", "labels": [[246, 264, "PROTEIN"], [191, 199, "ENTITY"], [148, 159, "CELL"], [148, 159, "CL"], [246, 264, "GENE_OR_GENE_PRODUCT"], [309, 323, "ENTITY"], [22, 29, "ENTITY"], [148, 159, "ENTITY"], [309, 318, "CHEBI"], [39, 52, "ENTITY"], [22, 29, "DISEASE"], [199, 214, "ENTITY"], [199, 214, "GENE_OR_GENE_PRODUCT"], [12, 22, "ENTITY"], [236, 264, "ENTITY"], [191, 199, "DISEASE"]]}
{"text": "On admission , lymphocytopenia was present in 83.2 % of the patients , thrombocytopenia in 36.2 % , and leukopenia in 33.7 %", "labels": [[3, 13, "ENTITY"]]}
{"text": "He also had suspected sepsis , with an Enterobacter agglomerates\u2013 positive blood culture , leukocytosis , thrombocytopenia ( 11 cells \u00d7 103/\u03bcL ; to convert to cells \u00d7 109/L , multiply by 1.0 ) , and coagulopathy ( prothrombin time , 21 seconds ; activated partial thromboplastin time , 81.9 seconds ) , which improved with antibiotic treatment .", "labels": [[246, 264, "PROTEIN"], [191, 199, "ENTITY"], [148, 159, "CELL"], [148, 159, "CL"], [246, 264, "GENE_OR_GENE_PRODUCT"], [309, 323, "ENTITY"], [22, 29, "ENTITY"], [148, 159, "ENTITY"], [309, 318, "CHEBI"], [39, 52, "ENTITY"], [22, 29, "DISEASE"], [199, 214, "ENTITY"], [199, 214, "GENE_OR_GENE_PRODUCT"], [12, 22, "ENTITY"], [236, 264, "ENTITY"], [191, 199, "DISEASE"]]}
{"text": "Consistent with others , most of severe COVID-19 patients in our ICU ward had persistent very high level of erythematosus sedimentation rate ( ESR ) , CRP , and high level of IL-6,TNFa , IL-1B , IL-8 , IL2R , etc , and were associated with ARDS , hypercoagulation and disseminated intravascular coagulation ( DIC ) , manifested as thrombosis , thrombocytopenia , gangrene of extremities .", "labels": [[0, 16, "ENTITY"], [175, 187, "GENE_OR_GENE_PRODUCT"], [328, 344, "ENTITY"], [175, 187, "ENTITY"], [175, 187, "DNA"], [328, 344, "DISEASE"], [99, 108, "GGP"], [65, 69, "ENTITY"], [235, 247, "DISEASE"], [108, 136, "ENTITY"], [344, 363, "ENTITY"], [235, 247, "ENTITY"], [187, 193, "ENTITY"], [99, 108, "DNA"], [187, 193, "GENE_OR_GENE_PRODUCT"], [268, 281, "IMMATERIAL_ANATOMICAL_ENTITY"], [268, 295, "DISEASE"], [99, 108, "ENTITY"], [344, 363, "ORGAN"], [175, 187, "GGP"], [317, 328, "DISEASE"], [94, 99, "ENTITY"], [187, 193, "PROTEIN"], [247, 295, "ENTITY"], [40, 49, "GENE_OR_GENE_PRODUCT"], [215, 224, "ENTITY"], [187, 193, "GGP"], [99, 108, "GENE_OR_GENE_PRODUCT"], [317, 328, "ENTITY"]]}
{"text": "Clinically , many critical ill patients have vasculitis-like manifestations , or even gangrene at their extremities ; Pathology examination revealed the blood vessels of alveolar septum were congested and edematous , with modest infiltration of monocytes and lymphocytes within and around blood vessels .", "labels": [[282, 295, "MULTI-TISSUE_STRUCTURE"], [149, 159, "MULTI-TISSUE_STRUCTURE"], [0, 11, "ENTITY"], [282, 295, "ENTITY"], [18, 27, "ENTITY"], [167, 179, "TISSUE"], [116, 128, "ENTITY"], [149, 159, "ENTITY"], [222, 229, "ENTITY"], [167, 179, "ENTITY"], [45, 61, "ENTITY"]]}
{"text": "Global proteomic and microarray analyses have shown that the expression of several genes related to the ER stress , such as glucose-regulated protein 94 ( GRP94 ) and glucose-regulated protein 78(GRP78 , also known as immunoglobulin heavy chain-binding protein , or BiP ) , is up-regulated in cells infected with SARS-CoV or in cells overexpressing the SARS-CoV S2 subunit ( Jiang et al. , 2005;Yeung et al. , 2008 ) . Using a luciferase reporter system , Chan et al. ( 2006 ) found that both GRP94 and GRP78 were induced in SARS-CoV-infected FRhK4 cells .", "labels": [[415, 438, "ENTITY"], [83, 89, "ENTITY"], [124, 150, "GENE_OR_GENE_PRODUCT"], [509, 525, "ENTITY"], [61, 72, "ENTITY"], [509, 525, "CELL_LINE"], [334, 365, "ORGANISM"], [334, 365, "ENTITY"], [104, 107, "PROTEIN"], [415, 425, "GENE_OR_GENE_PRODUCT"], [21, 41, "ENTITY"], [415, 427, "DNA"], [124, 142, "GGP"], [477, 483, "GGP"], [215, 253, "GGP"], [163, 185, "ENTITY"], [163, 185, "GGP"], [215, 253, "PROTEIN"], [438, 447, "GENE_OR_GENE_PRODUCT"], [215, 253, "ENTITY"], [277, 290, "CL"], [334, 365, "PROTEIN"], [277, 290, "CELL"], [299, 313, "GGP"], [334, 365, "GGP"], [299, 313, "ENTITY"], [270, 277, "ENTITY"], [104, 107, "GENE_OR_GENE_PRODUCT"], [477, 483, "GENE_OR_GENE_PRODUCT"], [163, 193, "PROTEIN"], [124, 150, "PROTEIN"], [293, 299, "ENTITY"], [293, 299, "ENTITY"], [104, 114, "ENTITY"], [477, 483, "PROTEIN"], [124, 150, "ENTITY"], [277, 290, "ENTITY"], [477, 483, "ENTITY"], [299, 313, "PROTEIN"], [7, 17, "ENTITY"], [215, 239, "GENE_OR_GENE_PRODUCT"], [0, 7, "ENTITY"], [83, 89, "SO"], [299, 313, "ORGANISM"]]}
{"text": "Global proteomic and microarray analyses have shown that the expression of several genes related to the ER stress , such as glucose-regulated protein 94 ( GRP94 ) and glucose-regulated protein 78(GRP78 , also known as immunoglobulin heavy chain-binding protein , or BiP ) , is up-regulated in cells infected with SARS-CoV or in cells overexpressing the SARS-CoV S2 subunit ( Jiang et al. , 2005;Yeung et al. , 2008 ) . Using a luciferase reporter system , Chan et al. ( 2006 ) found that both GRP94 and GRP78 were induced in SARS-CoV-infected FRhK4 cells .", "labels": [[415, 438, "ENTITY"], [83, 89, "ENTITY"], [124, 150, "GENE_OR_GENE_PRODUCT"], [509, 525, "ENTITY"], [61, 72, "ENTITY"], [509, 525, "CELL_LINE"], [334, 365, "ORGANISM"], [334, 365, "ENTITY"], [104, 107, "PROTEIN"], [415, 425, "GENE_OR_GENE_PRODUCT"], [21, 41, "ENTITY"], [415, 427, "DNA"], [124, 142, "GGP"], [477, 483, "GGP"], [215, 253, "GGP"], [163, 185, "ENTITY"], [163, 185, "GGP"], [215, 253, "PROTEIN"], [438, 447, "GENE_OR_GENE_PRODUCT"], [215, 253, "ENTITY"], [277, 290, "CL"], [334, 365, "PROTEIN"], [277, 290, "CELL"], [299, 313, "GGP"], [334, 365, "GGP"], [299, 313, "ENTITY"], [270, 277, "ENTITY"], [104, 107, "GENE_OR_GENE_PRODUCT"], [477, 483, "GENE_OR_GENE_PRODUCT"], [163, 193, "PROTEIN"], [124, 150, "PROTEIN"], [293, 299, "ENTITY"], [293, 299, "ENTITY"], [104, 114, "ENTITY"], [477, 483, "PROTEIN"], [124, 150, "ENTITY"], [277, 290, "ENTITY"], [477, 483, "ENTITY"], [299, 313, "PROTEIN"], [7, 17, "ENTITY"], [215, 239, "GENE_OR_GENE_PRODUCT"], [0, 7, "ENTITY"], [83, 89, "SO"], [299, 313, "ORGANISM"]]}
{"text": "Global proteomic and microarray analyses have shown that the expression of several genes related to the ER stress , such as glucose-regulated protein 94 ( GRP94 ) and glucose-regulated protein 78(GRP78 , also known as immunoglobulin heavy chain-binding protein , or BiP ) , is up-regulated in cells infected with SARS-CoV or in cells overexpressing the SARS-CoV S2 subunit ( Jiang et al. , 2005;Yeung et al. , 2008 ) . Using a luciferase reporter system , Chan et al. ( 2006 ) found that both GRP94 and GRP78 were induced in SARS-CoV-infected FRhK4 cells .", "labels": [[415, 438, "ENTITY"], [83, 89, "ENTITY"], [124, 150, "GENE_OR_GENE_PRODUCT"], [509, 525, "ENTITY"], [61, 72, "ENTITY"], [509, 525, "CELL_LINE"], [334, 365, "ORGANISM"], [334, 365, "ENTITY"], [104, 107, "PROTEIN"], [415, 425, "GENE_OR_GENE_PRODUCT"], [21, 41, "ENTITY"], [415, 427, "DNA"], [124, 142, "GGP"], [477, 483, "GGP"], [215, 253, "GGP"], [163, 185, "ENTITY"], [163, 185, "GGP"], [215, 253, "PROTEIN"], [438, 447, "GENE_OR_GENE_PRODUCT"], [215, 253, "ENTITY"], [277, 290, "CL"], [334, 365, "PROTEIN"], [277, 290, "CELL"], [299, 313, "GGP"], [334, 365, "GGP"], [299, 313, "ENTITY"], [270, 277, "ENTITY"], [104, 107, "GENE_OR_GENE_PRODUCT"], [477, 483, "GENE_OR_GENE_PRODUCT"], [163, 193, "PROTEIN"], [124, 150, "PROTEIN"], [293, 299, "ENTITY"], [293, 299, "ENTITY"], [104, 114, "ENTITY"], [477, 483, "PROTEIN"], [124, 150, "ENTITY"], [277, 290, "ENTITY"], [477, 483, "ENTITY"], [299, 313, "PROTEIN"], [7, 17, "ENTITY"], [215, 239, "GENE_OR_GENE_PRODUCT"], [0, 7, "ENTITY"], [83, 89, "SO"], [299, 313, "ORGANISM"]]}
{"text": "Consistently , the mRNA level of homocysteine-inducible , ER stress-inducible , ubiquitin-like domain member 1 ( HERPUD1 ) , an ER stress marker , was up-regulated in L cells infected with mouse hepatitis virus ( MHV ) or SARS-CoV ( Versteeg et al. , 2007 ) .", "labels": [[0, 13, "ENTITY"], [175, 195, "ORGANISM"], [151, 167, "CL"], [213, 219, "ORGANISM"], [151, 167, "CELL"], [175, 184, "TAXON"], [167, 175, "ENTITY"], [175, 195, "ENTITY"], [58, 61, "ENTITY"], [213, 219, "GGP"], [61, 102, "ENTITY"], [184, 195, "DISEASE"], [151, 167, "CELL_TYPE"], [121, 138, "PROTEIN"], [213, 219, "PROTEIN"], [61, 102, "PROTEIN"], [213, 219, "ENTITY"], [121, 138, "ENTITY"], [138, 151, "ENTITY"], [151, 167, "ENTITY"], [80, 95, "SO"]]}
{"text": "Previous studies have shown that the mRNA and protein levels of DUSP1 are modulated by ER stress ( Boutros et al. , 2008;Li et al. , 2011 ) . ER stress-induced DUSP1 up-regulation is likely to be mediated by ATF3 in the PERK pathway , since knock-down of ATF3 significantly reduced DUSP1 induction in cells under ER stress ( Gora et al. , 2010 ) .", "labels": [[145, 160, "ENTITY"], [64, 70, "ENTITY"], [288, 301, "ENTITY"], [288, 301, "CELL"], [145, 160, "PROTEIN"], [241, 252, "PROTEIN"], [64, 70, "GGP"], [274, 282, "PROTEIN"], [196, 208, "GGP"], [37, 42, "CHEBI"], [196, 208, "GENE_OR_GENE_PRODUCT"], [274, 282, "GENE_OR_GENE_PRODUCT"], [87, 90, "GENE_OR_GENE_PRODUCT"], [87, 90, "PROTEIN"], [274, 282, "GGP"], [241, 252, "ENTITY"], [37, 42, "RNA"], [145, 160, "GENE_OR_GENE_PRODUCT"], [64, 70, "ENTITY"], [274, 282, "ENTITY"], [288, 301, "CL"], [216, 225, "ENTITY"], [87, 97, "ENTITY"], [46, 61, "ENTITY"], [241, 252, "GENE_OR_GENE_PRODUCT"], [307, 316, "ENTITY"], [64, 70, "GENE_OR_GENE_PRODUCT"], [37, 42, "ENTITY"], [196, 208, "ENTITY"], [64, 70, "ENTITY"], [196, 208, "PROTEIN"], [64, 70, "PROTEIN"], [260, 274, "ENTITY"], [145, 160, "GGP"], [9, 17, "ENTITY"], [46, 54, "CHEBI"], [241, 252, "GGP"]]}
{"text": "Previous studies have shown that the mRNA and protein levels of DUSP1 are modulated by ER stress ( Boutros et al. , 2008;Li et al. , 2011 ) . ER stress-induced DUSP1 up-regulation is likely to be mediated by ATF3 in the PERK pathway , since knock-down of ATF3 significantly reduced DUSP1 induction in cells under ER stress ( Gora et al. , 2010 ) .", "labels": [[145, 160, "ENTITY"], [64, 70, "ENTITY"], [288, 301, "ENTITY"], [288, 301, "CELL"], [145, 160, "PROTEIN"], [241, 252, "PROTEIN"], [64, 70, "GGP"], [274, 282, "PROTEIN"], [196, 208, "GGP"], [37, 42, "CHEBI"], [196, 208, "GENE_OR_GENE_PRODUCT"], [274, 282, "GENE_OR_GENE_PRODUCT"], [87, 90, "GENE_OR_GENE_PRODUCT"], [87, 90, "PROTEIN"], [274, 282, "GGP"], [241, 252, "ENTITY"], [37, 42, "RNA"], [145, 160, "GENE_OR_GENE_PRODUCT"], [64, 70, "ENTITY"], [274, 282, "ENTITY"], [288, 301, "CL"], [216, 225, "ENTITY"], [87, 97, "ENTITY"], [46, 61, "ENTITY"], [241, 252, "GENE_OR_GENE_PRODUCT"], [307, 316, "ENTITY"], [64, 70, "GENE_OR_GENE_PRODUCT"], [37, 42, "ENTITY"], [196, 208, "ENTITY"], [64, 70, "ENTITY"], [196, 208, "PROTEIN"], [64, 70, "PROTEIN"], [260, 274, "ENTITY"], [145, 160, "GGP"], [9, 17, "ENTITY"], [46, 54, "CHEBI"], [241, 252, "GGP"]]}
{"text": "Previous studies have shown that the mRNA and protein levels of DUSP1 are modulated by ER stress ( Boutros et al. , 2008;Li et al. , 2011 ) . ER stress-induced DUSP1 up-regulation is likely to be mediated by ATF3 in the PERK pathway , since knock-down of ATF3 significantly reduced DUSP1 induction in cells under ER stress ( Gora et al. , 2010 ) .", "labels": [[145, 160, "ENTITY"], [288, 301, "ENTITY"], [64, 70, "ENTITY"], [288, 301, "CELL"], [145, 160, "PROTEIN"], [241, 252, "PROTEIN"], [274, 282, "PROTEIN"], [196, 208, "GGP"], [37, 42, "CHEBI"], [196, 208, "GENE_OR_GENE_PRODUCT"], [64, 70, "GGP"], [274, 282, "GENE_OR_GENE_PRODUCT"], [87, 90, "GENE_OR_GENE_PRODUCT"], [87, 90, "PROTEIN"], [274, 282, "GGP"], [241, 252, "ENTITY"], [37, 42, "RNA"], [145, 160, "GENE_OR_GENE_PRODUCT"], [64, 70, "ENTITY"], [274, 282, "ENTITY"], [288, 301, "CL"], [216, 225, "ENTITY"], [87, 97, "ENTITY"], [46, 61, "ENTITY"], [241, 252, "GENE_OR_GENE_PRODUCT"], [307, 316, "ENTITY"], [37, 42, "ENTITY"], [64, 70, "PROTEIN"], [196, 208, "ENTITY"], [64, 70, "ENTITY"], [196, 208, "PROTEIN"], [260, 274, "ENTITY"], [145, 160, "GGP"], [9, 17, "ENTITY"], [46, 54, "CHEBI"], [241, 252, "GGP"], [64, 70, "GENE_OR_GENE_PRODUCT"]]}
{"text": "It was found that the kinase domain but not the RNase activity of IRE1 was required , and treatment of a JNK inhibitor ( SP600125 ) abolished autophagosome formation after ER stress ( Ogata et al.,2006 ) .", "labels": [[132, 142, "CELLULAR_COMPONENT"], [66, 71, "ENTITY"], [132, 142, "ENTITY"], [48, 54, "GENE_OR_GENE_PRODUCT"], [66, 71, "GGP"], [22, 36, "ENTITY"], [66, 71, "PROTEIN"], [132, 142, "GO"], [142, 156, "ENTITY"], [105, 109, "ENTITY"], [48, 63, "ENTITY"], [22, 36, "PROTEIN"], [166, 175, "ENTITY"], [66, 71, "GENE_OR_GENE_PRODUCT"], [29, 36, "SO"], [48, 54, "PROTEIN"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Clinical features revealed by a chest CT scan presented as pneumonia , however , there were abnormal features such as RNAaemia , acute respiratory distress syndrome , acute cardiac injury , and incidence of grand-glass opacities that led to death [ 6 ] .", "labels": [[194, 219, "ENTITY"], [0, 18, "ENTITY"], [129, 135, "ORGAN"], [234, 241, "ENTITY"], [32, 46, "ENTITY"], [156, 181, "ENTITY"], [38, 41, "PROTEIN"], [167, 181, "DISEASE"], [59, 69, "ENTITY"], [234, 241, "DISEASE"], [59, 69, "DISEASE"], [92, 101, "ENTITY"], [129, 156, "DISEASE"], [127, 156, "ENTITY"]]}
{"text": "The mortality appears to be around 2 % ; early published data indicate 25.9 % with SARS-CoV-2 pneumonia required ICU admission and 20.1 % developed acute respiratory distress syndrome", "labels": [[104, 117, "ENTITY"], [78, 94, "ENTITY"], [138, 175, "ENTITY"], [78, 94, "CHEMICAL"], [148, 175, "DISEASE"], [41, 57, "ENTITY"], [4, 14, "ENTITY"]]}
{"text": "For patients with ARDS or pulmonary extensive effusion in CT scan , high-flow nasal cannula oxygen therapy ( high-flow nasal cannula oxygen therapy ) or non-invasive mechanical ventilation ( NIV ) was used to maintain positive end expiratory pressure ( PEEP ) to prevent alveolar collapse even if some of these patients did not have refractory hypoxemia .", "labels": [[268, 277, "ENTITY"], [18, 23, "ENTITY"], [268, 277, "DISEASE"], [58, 61, "PROTEIN"], [184, 193, "ENTITY"], [26, 55, "ENTITY"], [4, 13, "ENTITY"], [197, 208, "ENTITY"], [26, 36, "ORGAN"], [68, 84, "ENTITY"], [68, 99, "ENTITY"], [18, 23, "DISEASE"], [255, 268, "ENTITY"], [4, 13, "ORGANISM"], [58, 66, "ENTITY"], [175, 184, "ENTITY"]]}
{"text": "During hospital admission , most of the patients received a diagnosis of pneumonia from a physician ( 91.1 % ) , followed by ARDS ( 3.4 % ) and shock ( 1.1 % ) .", "labels": [[113, 125, "ENTITY"], [7, 26, "ENTITY"], [113, 125, "DISEASE"]]}
{"text": "For patients with ARDS or pulmonary extensive effusion in CT scan , high-flow nasal cannula oxygen therapy ( high-flow nasal cannula oxygen therapy ) or non-invasive mechanical ventilation ( NIV ) was used to maintain positive end expiratory pressure ( PEEP ) to prevent alveolar collapse even if some of these patients did not have refractory hypoxemia .", "labels": [[268, 277, "ENTITY"], [18, 23, "ENTITY"], [268, 277, "DISEASE"], [58, 61, "PROTEIN"], [184, 193, "ENTITY"], [26, 55, "ENTITY"], [4, 13, "ENTITY"], [197, 208, "ENTITY"], [26, 36, "ORGAN"], [68, 84, "ENTITY"], [68, 99, "ENTITY"], [18, 23, "DISEASE"], [255, 268, "ENTITY"], [4, 13, "ORGANISM"], [58, 66, "ENTITY"], [175, 184, "ENTITY"]]}
{"text": "For patients with ARDS or pulmonary extensive effusion in CT scan , high-flow nasal cannula oxygen therapy ( high-flow nasal cannula oxygen therapy ) or non-invasive mechanical ventilation ( NIV ) was used to maintain positive end expiratory pressure ( PEEP ) to prevent alveolar collapse even if some of these patients did not have refractory hypoxemia .", "labels": [[268, 277, "ENTITY"], [18, 23, "ENTITY"], [268, 277, "DISEASE"], [58, 61, "PROTEIN"], [184, 193, "ENTITY"], [26, 55, "ENTITY"], [4, 13, "ENTITY"], [197, 208, "ENTITY"], [26, 36, "ORGAN"], [68, 84, "ENTITY"], [68, 99, "ENTITY"], [18, 23, "DISEASE"], [255, 268, "ENTITY"], [4, 13, "ORGANISM"], [58, 66, "ENTITY"], [175, 184, "ENTITY"]]}
{"text": "The leading causes of deaths are ARDS , septic shock with MOF , hemorrhage/coagulopathy ( disseminated intravascular coagulopathy , DIC ) , acute heart/liver/kidney injury , and secondary bacterial infections ( 97 , 101 )", "labels": [[178, 188, "TAXON"], [40, 47, "DISEASE"], [132, 165, "ENTITY"], [117, 132, "ENTITY"], [90, 103, "IMMATERIAL_ANATOMICAL_ENTITY"], [178, 198, "DISEASE"], [40, 47, "ENTITY"], [22, 29, "ENTITY"], [33, 38, "ENTITY"], [90, 117, "DISEASE"], [22, 29, "DISEASE"], [117, 132, "DISEASE"], [88, 117, "ENTITY"], [33, 38, "DISEASE"], [140, 146, "PATHOLOGICAL_FORMATION"], [172, 198, "ENTITY"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses [ 3 ] .", "labels": [[0, 31, "ENTITY"], [0, 31, "CHEMICAL"], [113, 124, "ENTITY"], [113, 124, "CANCER"], [193, 197, "SO"], [35, 46, "ENTITY"], [222, 231, "ENTITY"], [222, 245, "ORGANISM"], [0, 31, "SIMPLE_CHEMICAL"], [193, 197, "ENTITY"], [113, 124, "DISEASE"]]}
{"text": "Chloroquine/hydroxychloroquine , a front-line drug used in the treatment and prophylaxis of malaria also used in autoimmune disease had been shown to inhibit the replication of several DNA and RNA viruses , including most of human coronaviruses [ 3 ] .", "labels": [[113, 124, "ENTITY"], [113, 124, "CANCER"], [0, 31, "CHEMICAL"], [193, 197, "SO"], [35, 46, "ENTITY"], [0, 31, "ENTITY"], [222, 231, "ENTITY"], [222, 245, "ORGANISM"], [0, 31, "SIMPLE_CHEMICAL"], [193, 197, "ENTITY"], [113, 124, "DISEASE"]]}
{"text": "Among adult patients , cardiovascular disease and hypertension were the most common underlying diseases , followed by diabetes mellitus .", "labels": [[12, 21, "ORGANISM"], [115, 127, "DISEASE"], [23, 38, "ENTITY"], [115, 127, "ENTITY"], [12, 21, "ENTITY"], [23, 38, "DISEASE"], [6, 12, "ENTITY"]]}
{"text": "Remarkably , in SJIA patients , the pulmonary involvement triggers a hyper-inflammatory reaction and occurrence of secondary haemophagocytic lymphohistiocytosis ( sHLH ) , since the up-regulation of IFN-signature , IL-1\u03b2 and IL-6 may be observed [ 5,8 ] .", "labels": [[141, 163, "ENTITY"], [115, 141, "DISEASE"], [172, 182, "ENTITY"], [67, 88, "ENTITY"], [112, 141, "ENTITY"], [199, 213, "CHEMICAL"], [115, 125, "CHEBI"], [182, 199, "PROTEIN"], [215, 221, "GGP"], [36, 46, "ENTITY"], [215, 221, "PROTEIN"], [199, 213, "PROTEIN"], [141, 163, "GENE_OR_GENE_PRODUCT"], [215, 221, "ENTITY"], [199, 213, "ENTITY"], [215, 221, "GENE_OR_GENE_PRODUCT"], [199, 213, "GENE_OR_GENE_PRODUCT"], [182, 199, "ENTITY"], [182, 199, "GENE_OR_GENE_PRODUCT"], [199, 213, "GGP"]]}
{"text": "Remarkably , in SJIA patients , the pulmonary involvement triggers a hyper-inflammatory reaction and occurrence of secondary haemophagocytic lymphohistiocytosis ( sHLH ) , since the up-regulation of IFN-signature , IL-1\u03b2 and IL-6 may be observed [ 5,8 ] .", "labels": [[141, 163, "ENTITY"], [115, 141, "DISEASE"], [172, 182, "ENTITY"], [67, 88, "ENTITY"], [112, 141, "ENTITY"], [199, 213, "GENE_OR_GENE_PRODUCT"], [115, 125, "CHEBI"], [182, 199, "PROTEIN"], [215, 221, "GGP"], [36, 46, "ENTITY"], [199, 213, "ENTITY"], [215, 221, "PROTEIN"], [141, 163, "GENE_OR_GENE_PRODUCT"], [199, 213, "CHEMICAL"], [215, 221, "ENTITY"], [215, 221, "GENE_OR_GENE_PRODUCT"], [182, 199, "ENTITY"], [182, 199, "GENE_OR_GENE_PRODUCT"], [199, 213, "GGP"], [199, 213, "PROTEIN"]]}
{"text": "Remarkably , in SJIA patients , the pulmonary involvement triggers a hyper-inflammatory reaction and occurrence of secondary haemophagocytic lymphohistiocytosis ( sHLH ) , since the up-regulation of IFN-signature , IL-1\u03b2 and IL-6 may be observed [ 5,8 ] .", "labels": [[215, 221, "GGP"], [141, 163, "ENTITY"], [115, 141, "DISEASE"], [172, 182, "ENTITY"], [67, 88, "ENTITY"], [112, 141, "ENTITY"], [199, 213, "CHEMICAL"], [115, 125, "CHEBI"], [215, 221, "ENTITY"], [182, 199, "PROTEIN"], [36, 46, "ENTITY"], [215, 221, "PROTEIN"], [199, 213, "PROTEIN"], [141, 163, "GENE_OR_GENE_PRODUCT"], [199, 213, "ENTITY"], [199, 213, "GENE_OR_GENE_PRODUCT"], [182, 199, "ENTITY"], [182, 199, "GENE_OR_GENE_PRODUCT"], [215, 221, "GENE_OR_GENE_PRODUCT"], [199, 213, "GGP"]]}
{"text": "Remarkably , in SJIA patients , the pulmonary involvement triggers a hyper-inflammatory reaction and occurrence of secondary haemophagocytic lymphohistiocytosis ( sHLH ) , since the up-regulation of IFN-signature , IL-1\u03b2 and IL-6 may be observed [ 5,8 ] .", "labels": [[141, 163, "ENTITY"], [115, 141, "DISEASE"], [172, 182, "ENTITY"], [67, 88, "ENTITY"], [112, 141, "ENTITY"], [199, 213, "CHEMICAL"], [115, 125, "CHEBI"], [182, 199, "PROTEIN"], [215, 221, "GGP"], [36, 46, "ENTITY"], [215, 221, "PROTEIN"], [199, 213, "PROTEIN"], [141, 163, "GENE_OR_GENE_PRODUCT"], [215, 221, "ENTITY"], [199, 213, "ENTITY"], [215, 221, "GENE_OR_GENE_PRODUCT"], [199, 213, "GENE_OR_GENE_PRODUCT"], [182, 199, "ENTITY"], [182, 199, "GENE_OR_GENE_PRODUCT"], [199, 213, "GGP"]]}
{"text": "Remarkably , human dipeptidyl peptidase 4 ( DPP4 was identified as a functional receptor for the spike protein of the MERS-Co-V [ 4 ] . MERS-CoV binds to the receptor-binding domain and interacts with T cells and nuclear factors , such as NF-\u03baB , highly involved in the pathogenesis of inflammatory disorders .", "labels": [[93, 103, "ENTITY"], [154, 175, "ENTITY"], [67, 80, "ENTITY"], [136, 145, "ENTITY"], [154, 175, "PROTEIN"], [270, 299, "ENTITY"], [97, 103, "CHEBI"], [93, 103, "PROTEIN"], [263, 270, "ENTITY"], [196, 203, "ENTITY"], [209, 221, "PROTEIN"], [231, 239, "DNA"], [19, 40, "ENTITY"], [196, 203, "CL"], [13, 40, "GENE_OR_GENE_PRODUCT"], [231, 239, "CHEMICAL"], [196, 203, "CELL_TYPE"], [270, 299, "DISEASE"], [209, 221, "ENTITY"], [231, 239, "ENTITY"], [158, 175, "SO"], [13, 40, "GGP"], [13, 40, "PROTEIN"], [231, 239, "SIMPLE_CHEMICAL"], [196, 203, "CELL"]]}
{"text": "Other commonly measured blood measures that may lead to altered ACE2 expression also included red cell distribution width ( often associated with iron-deficiency , folate or B12 deficiency anemia ) , basophil percentage ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) , calcium level , urate level , HDL-cholesterol and LDL cholesterol ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) .", "labels": [[-1, 14, "ENTITY"], [277, 293, "CHEMICAL"], [94, 103, "CL"], [64, 69, "GGP"], [247, 255, "CHEBI"], [-1, 13, "CHEMICAL"], [247, 255, "SIMPLE_CHEMICAL"], [15, 24, "ENTITY"], [247, 255, "ENTITY"], [263, 269, "CHEBI"], [247, 255, "CHEMICAL"], [209, 222, "ENTITY"], [64, 69, "PROTEIN"], [-1, 13, "SIMPLE_CHEMICAL"], [171, 189, "ENTITY"], [263, 269, "CHEMICAL"], [-1, 13, "ENTITY"], [24, 30, "ORGANISM_SUBSTANCE"], [200, 209, "ENTITY"], [277, 293, "SIMPLE_CHEMICAL"], [94, 122, "ENTITY"], [-1, 14, "ENTITY"], [24, 39, "ENTITY"], [64, 69, "GENE_OR_GENE_PRODUCT"], [277, 293, "ENTITY"], [171, 189, "CHEMICAL"], [-1, 13, "CHEBI"], [263, 269, "SIMPLE_CHEMICAL"], [-1, 12, "ENTITY"], [64, 69, "ENTITY"], [69, 80, "ENTITY"], [255, 263, "ENTITY"], [94, 103, "CELL"]]}
{"text": "Similarly , lymph node atrophy and the number of lymph nodes decreased , accompanied by necrosis .", "labels": [[12, 23, "DISEASE"], [12, 18, "MULTI-TISSUE_STRUCTURE"], [12, 23, "ENTITY"], [12, 18, "MULTI-TISSUE_STRUCTURE"], [12, 18, "ENTITY"]]}
{"text": "The leading causes of deaths are ARDS , septic shock with MOF , hemorrhage/coagulopathy ( disseminated intravascular coagulopathy , DIC ) , acute heart/liver/kidney injury , and secondary bacterial infections ( 97 , 101 )", "labels": [[178, 188, "TAXON"], [40, 47, "DISEASE"], [117, 132, "ENTITY"], [90, 103, "IMMATERIAL_ANATOMICAL_ENTITY"], [33, 38, "DISEASE"], [178, 198, "DISEASE"], [40, 47, "ENTITY"], [22, 29, "ENTITY"], [90, 117, "DISEASE"], [22, 29, "DISEASE"], [88, 117, "ENTITY"], [132, 165, "ENTITY"], [117, 132, "DISEASE"], [140, 146, "PATHOLOGICAL_FORMATION"], [33, 38, "ENTITY"], [172, 198, "ENTITY"]]}
{"text": "Consistent with clinical observations , the lungs are the most injured organs , followed by moderate injury in the heart , liver , kidney , and brain .", "labels": [[16, 38, "ENTITY"], [0, 16, "ENTITY"], [123, 131, "ENTITY"], [92, 101, "ENTITY"], [123, 131, "ORGAN"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [335, 352, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "During hospitalization , patients with elevated TnT levels developed more frequent complications ( Table 1 ) , including acute respiratory distress syndrome ( 30 [ 57.7 % ] vs 16 [ 11.9 % ] ) , malignant arrhythmias ( 6 [ 11.5 % ] vs 7 [ 5.2 % ] ) including ventricular tachycardia/ ventricular fibrillation , acute coagulopathy ( 25 [ 65.8 % ] vs 17 [ 20.0 % ] ) , and acute kidney injury ( 14 [ 36.8 % ] vs 4 [ 4.7 % ] ) , compared with those with normal TnT levels .", "labels": [[336, 358, "DISEASE"], [336, 358, "ENTITY"], [345, 351, "ORGAN"], [238, 283, "ENTITY"], [7, 23, "ENTITY"], [258, 270, "DISEASE"], [258, 270, "ENTITY"], [121, 148, "DISEASE"], [238, 283, "DISEASE"], [111, 148, "ENTITY"], [238, 270, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "Most COVID-19 patients initially suffered from fever , cough , fatigue , and shortness of breath , while other symptoms included muscle pain , headache , chest pain , and diarrhea , similar to the symptoms observed after chemotherapy , targeted and immune therapy1", "labels": [[73, 90, "ENTITY"], [143, 154, "DISEASE"], [120, 136, "DISEASE"], [120, 136, "ENTITY"], [47, 53, "ENTITY"], [206, 221, "ENTITY"], [14, 23, "ENTITY"], [5, 14, "ENTITY"], [5, 23, "ORGANISM"], [236, 256, "CELL"], [5, 14, "DISEASE"], [73, 90, "DISEASE"], [143, 154, "ORGAN"], [221, 236, "ENTITY"], [236, 256, "ENTITY"], [71, 77, "ENTITY"], [190, 197, "ENTITY"], [111, 120, "ENTITY"], [136, 143, "ENTITY"], [136, 143, "DISEASE"], [120, 129, "ORGAN"], [47, 53, "DISEASE"], [143, 154, "ENTITY"], [71, 77, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [219, 230, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "Patients with at least one comorbidity were older ( mean : 60.8 versus 44.8 years ) , were more likely to have shortness of breath ( 41.4 % versus 17.8 % ) , nausea or vomiting ( 10.4 % versus 4.3 % ) , and tended to have abnormal chest X-ray manifestations ( 29.2 % versus 15.1 % ) ( table 1 ) .", "labels": [[27, 39, "ENTITY"], [219, 245, "ENTITY"], [160, 170, "DISEASE"], [44, 50, "ENTITY"], [209, 219, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "ORGANISM"], [27, 39, "DISEASE"], [108, 126, "DISEASE"], [209, 245, "DISEASE"], [108, 126, "ENTITY"], [160, 170, "ENTITY"]]}
{"text": "She developed chest tightness , shortness of breath , loss of appetite , 62 nausea , and diarrhea", "labels": [[14, 30, "ENTITY"], [52, 62, "ENTITY"], [52, 62, "DISEASE"], [4, 14, "ENTITY"], [32, 45, "ENTITY"], [14, 30, "DISEASE"], [32, 45, "DISEASE"]]}
{"text": "Other prevalent symptoms at onset of illness in deceased patients included fatigue , dyspnoea , chest tightness , and sputum production ; less common symptoms included anorexia , diarrhoea , and myalgia .", "labels": [[112, 118, "DISEASE"], [143, 150, "ENTITY"], [168, 179, "DISEASE"], [66, 75, "ENTITY"], [112, 118, "ENTITY"], [114, 125, "ENTITY"], [16, 25, "ENTITY"], [168, 179, "ENTITY"], [48, 57, "ENTITY"], [28, 37, "ENTITY"], [94, 102, "DISEASE"], [66, 75, "CANCER"], [75, 83, "DISEASE"], [94, 102, "ENTITY"], [75, 83, "ENTITY"], [57, 66, "ORGANISM"], [66, 75, "DISEASE"], [37, 45, "ENTITY"], [6, 16, "ENTITY"], [57, 66, "ENTITY"]]}
{"text": "Compared to moderate cases , chest tightness tended to be more common in severe cases . In addition , tachypnea and dyspnea were only developed in severe cases .", "labels": [[29, 35, "DISEASE"], [21, 27, "ENTITY"], [73, 80, "ENTITY"], [0, 9, "ENTITY"], [12, 21, "ENTITY"], [29, 35, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [50, 60, "ENTITY"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [136, 146, "ORGAN"], [136, 158, "ENTITY"], [144, 166, "ENTITY"], [254, 285, "ENTITY"]]}
{"text": "Both T cells and NK cells in patients with COVID-19 were reduced .", "labels": [[17, 26, "CL"], [5, 13, "CL"], [17, 26, "CELL_TYPE"], [57, 65, "ENTITY"], [43, 52, "ENTITY"], [29, 38, "ORGANISM"], [17, 26, "CELL"], [5, 13, "CELL"], [17, 26, "ENTITY"], [5, 13, "CELL_TYPE"], [5, 13, "ENTITY"], [43, 52, "SIMPLE_CHEMICAL"], [29, 38, "ENTITY"]]}
{"text": "Other commonly measured blood measures that may lead to altered ACE2 expression also included red cell distribution width ( often associated with iron-deficiency , folate or B12 deficiency anemia ) , basophil percentage ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) , calcium level , urate level , HDL-cholesterol and LDL cholesterol ( relationship), calcium level, urate level, HDL-cholesterol and LDL cholesterol ) .", "labels": [[-1, 14, "ENTITY"], [277, 293, "CHEMICAL"], [64, 69, "GGP"], [247, 255, "CHEBI"], [-1, 13, "CHEMICAL"], [247, 255, "SIMPLE_CHEMICAL"], [15, 24, "ENTITY"], [247, 255, "ENTITY"], [263, 269, "CHEBI"], [247, 255, "CHEMICAL"], [94, 103, "CELL"], [209, 222, "ENTITY"], [64, 69, "PROTEIN"], [-1, 13, "SIMPLE_CHEMICAL"], [171, 189, "ENTITY"], [263, 269, "CHEMICAL"], [-1, 13, "ENTITY"], [24, 30, "ORGANISM_SUBSTANCE"], [200, 209, "ENTITY"], [277, 293, "SIMPLE_CHEMICAL"], [94, 122, "ENTITY"], [-1, 14, "ENTITY"], [24, 39, "ENTITY"], [64, 69, "GENE_OR_GENE_PRODUCT"], [94, 103, "CL"], [277, 293, "ENTITY"], [171, 189, "CHEMICAL"], [-1, 13, "CHEBI"], [263, 269, "SIMPLE_CHEMICAL"], [-1, 12, "ENTITY"], [64, 69, "ENTITY"], [69, 80, "ENTITY"], [255, 263, "ENTITY"]]}
{"text": "On admission , physical examinations and pulmonary auscultation were normal ; laboratory tests indicated a reduction in leukocytes ( 1.92 \u00d7 109/L ) , neutrophils ( 1.20 \u00d7 109/L ) , lymphocytes ( 0.47 \u00d7 109/L ) , and eosinophils ( 0 \u00d7 109 /L ) counts , normal CRP and PCT concentrations , and slightly increased concentration of serum amyloid A [ SAA , 36.84 mg/L , reference range : ( 0~10 ) mg/L ]", "labels": [[138, 150, "ENTITY"], [301, 311, "GGP"], [271, 285, "PROTEIN"], [143, 146, "ENTITY"], [15, 24, "ENTITY"], [140, 150, "ENTITY"], [250, 263, "ENTITY"], [140, 150, "CELL"], [143, 146, "GGP"], [150, 162, "GENE_OR_GENE_PRODUCT"], [271, 285, "GENE_OR_GENE_PRODUCT"], [138, 150, "CL"], [301, 311, "PROTEIN"], [334, 352, "ENTITY"], [3, 13, "ENTITY"], [301, 311, "ENTITY"], [143, 146, "GENE_OR_GENE_PRODUCT"], [41, 51, "ENTITY"], [271, 285, "ENTITY"], [76, 89, "ENTITY"], [140, 150, "CELL_TYPE"], [271, 288, "ENTITY"], [143, 146, "PROTEIN"], [138, 150, "CELL_TYPE"], [138, 150, "CELL"], [216, 228, "ENTITY"], [140, 150, "CL"], [288, 301, "ENTITY"], [138, 148, "CELL"], [138, 148, "CELL_TYPE"], [301, 311, "ORGANISM_SUBSTANCE"], [138, 148, "ENTITY"]]}
{"text": "The CBC was normal except for the development of eosinopenia ( 0 \u00d7 109 /L ) and an elevated erythrocyte sedimentation rate ( ESR ) and CRP concentration ( 39 mm/h and 60.41 mg/L , respectively ) .", "labels": [[158, 163, "GENE_OR_GENE_PRODUCT"], [49, 61, "DISEASE"], [83, 92, "CELL"], [4, 8, "ENTITY"], [131, 139, "ENTITY"], [83, 92, "CL"], [4, 8, "CELL_TYPE"], [4, 8, "GENE_OR_GENE_PRODUCT"], [34, 46, "ENTITY"], [83, 118, "ENTITY"], [49, 61, "ENTITY"], [118, 123, "ENTITY"]]}
{"text": "Large doses of ribavirin could cause decreased hemoglobin and serious heart damage .", "labels": [[47, 58, "CHEBI"], [37, 47, "ENTITY"], [0, 6, "ENTITY"], [6, 12, "ENTITY"], [70, 76, "ORGAN"], [15, 25, "ENTITY"], [47, 58, "GENE_OR_GENE_PRODUCT"], [47, 58, "PROTEIN"], [15, 25, "SIMPLE_CHEMICAL"], [70, 83, "ENTITY"], [15, 25, "CHEMICAL"], [47, 58, "ENTITY"], [70, 83, "DISEASE"]]}
{"text": "Immunohistochemical staining showed that CD4+T cells and CD8+T cells were decreased in spleen and lymph nodes [ 13 ] .", "labels": [[98, 110, "ENTITY"], [74, 84, "ENTITY"], [87, 94, "ORGAN"], [41, 53, "ENTITY"], [57, 69, "CELL"], [98, 110, "MULTI-TISSUE_STRUCTURE"], [57, 69, "CELL_TYPE"], [41, 53, "CELL"], [0, 29, "ENTITY"], [87, 94, "ENTITY"], [41, 53, "CL"], [57, 69, "CL"], [57, 69, "ENTITY"], [41, 53, "CELL_TYPE"]]}
{"text": "Immunohistochemical staining showed that CD4+T cells and CD8+T cells were decreased in spleen and lymph nodes [ 13 ] .", "labels": [[98, 110, "ENTITY"], [87, 94, "ORGAN"], [41, 53, "ENTITY"], [57, 69, "CELL"], [98, 110, "MULTI-TISSUE_STRUCTURE"], [57, 69, "CELL_TYPE"], [41, 53, "CELL"], [0, 29, "ENTITY"], [74, 84, "ENTITY"], [87, 94, "ENTITY"], [41, 53, "CL"], [57, 69, "CL"], [57, 69, "ENTITY"], [41, 53, "CELL_TYPE"]]}
{"text": "However , Ang II can also promote the occurrence of pulmonary edema and impair lung function.14", "labels": [[10, 14, "GGP"], [10, 14, "GENE_OR_GENE_PRODUCT"], [52, 62, "ENTITY"], [10, 14, "PROTEIN"], [52, 62, "CANCER"], [10, 14, "ENTITY"], [52, 62, "DISEASE"], [79, 84, "ENTITY"], [79, 84, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "In addition , in the lung with characteristic diffused alveolar damage ( DAD ) , the major infiltrated cells were monocytes and macrophages , moderate multinucleated giant cells , but very few lymphocytes .", "labels": [[128, 142, "ENTITY"], [184, 193, "CELL_TYPE"], [55, 64, "ENTITY"], [91, 103, "CELL"], [142, 172, "CELL"], [184, 193, "CELL"], [184, 193, "ENTITY"], [184, 193, "CL"], [81, 103, "CELL_TYPE"], [85, 91, "ENTITY"], [166, 172, "CL"], [91, 103, "CL"], [142, 172, "ENTITY"], [91, 103, "ENTITY"]]}
{"text": "lymphocyte count slightly decreased [ 0.81 \u00d7 109/L , reference range : ( 1.1~3.2 ) \u00d7109/L ] , and the concentration of serum high-sensitivity C-reactive protein ( hsCRP ) increased [ 49.9 mg/L , reference range : ( 0~3 ) mg/L ] , with leukocyte count and procalcitonin ( PCT ) concentration within normal ranges .", "labels": [[26, 36, "ENTITY"], [235, 255, "GENE_OR_GENE_PRODUCT"], [215, 226, "CELL"], [125, 142, "GGP"], [215, 226, "CL"], [255, 271, "ENTITY"], [102, 142, "ENTITY"], [0, 11, "CELL"], [215, 230, "ENTITY"], [161, 169, "ENTITY"], [183, 195, "ENTITY"], [45, 63, "ENTITY"], [102, 142, "PROTEIN"], [0, 11, "CL"], [94, 102, "ENTITY"], [102, 116, "ENTITY"], [235, 251, "PROTEIN"], [235, 251, "ENTITY"], [0, 11, "ENTITY"], [102, 116, "ORGANISM_SUBSTANCE"]]}
{"text": "The CBC was normal except for the development of eosinopenia ( 0 \u00d7 109 /L ) and an elevated erythrocyte sedimentation rate ( ESR ) and CRP concentration ( 39 mm/h and 60.41 mg/L , respectively ) .", "labels": [[158, 163, "GENE_OR_GENE_PRODUCT"], [4, 8, "ENTITY"], [131, 139, "ENTITY"], [83, 92, "CL"], [49, 61, "DISEASE"], [4, 8, "CELL_TYPE"], [83, 92, "CELL"], [49, 61, "ENTITY"], [34, 46, "ENTITY"], [4, 8, "GENE_OR_GENE_PRODUCT"], [83, 118, "ENTITY"], [118, 123, "ENTITY"]]}
{"text": "Unfortunately , during the operation of ECMO she suffered a sudden cardiac arrest and survived by rescue of cardiopulmonary resuscitation ( CPR ) .", "labels": [[67, 75, "DISEASE"], [60, 75, "ENTITY"], [108, 124, "ENTITY"]]}
{"text": "Laboratory tests showed a slight decrease of leukocytes ( 3.19 \u00d7 109/L ) and neutrophils ( 1.57 \u00d7 109/L ) and a mildly elevated CRP concentration ( 29.2 mg/L ) , with all other tested parameters within normal ranges .", "labels": [[0, 17, "ENTITY"], [45, 56, "CELL_TYPE"], [33, 42, "ENTITY"], [112, 119, "ENTITY"], [184, 202, "ENTITY"], [45, 56, "CL"], [45, 56, "CELL"], [45, 56, "ENTITY"], [171, 184, "ENTITY"], [119, 132, "ENTITY"]]}
{"text": "Other abnormal results of laboratory parameters included significantly increased CRP 186 concentration ( > 160 mg/L ) and slightly increased PCT concentration ( 0.39 ng/ml ) .", "labels": [[141, 145, "ENTITY"], [81, 89, "GENE_OR_GENE_PRODUCT"], [15, 23, "ENTITY"], [71, 81, "GENE_OR_GENE_PRODUCT"], [71, 81, "PROTEIN"], [81, 85, "ENTITY"], [122, 131, "ENTITY"], [89, 103, "ENTITY"], [71, 81, "ENTITY"], [26, 37, "ENTITY"], [37, 48, "ENTITY"], [81, 89, "PROTEIN"], [71, 81, "ENTITY"], [6, 15, "ENTITY"]]}
{"text": "The CBC was normal except for the development of eosinopenia ( 0 \u00d7 109 /L ) and an elevated erythrocyte sedimentation rate ( ESR ) and CRP concentration ( 39 mm/h and 60.41 mg/L , respectively ) .", "labels": [[158, 163, "GENE_OR_GENE_PRODUCT"], [83, 92, "CL"], [118, 123, "ENTITY"], [4, 8, "ENTITY"], [83, 118, "ENTITY"], [49, 61, "DISEASE"], [4, 8, "CELL_TYPE"], [83, 92, "CELL"], [49, 61, "ENTITY"], [34, 46, "ENTITY"], [4, 8, "GENE_OR_GENE_PRODUCT"], [131, 139, "ENTITY"]]}
{"text": "Concentrations of procalcitonin , high sensitivity C-reactive protein , and ferritin , as well as erythrocyte sedimentation rate , were significantly higher in deceased patients than in recovered patients .", "labels": [[186, 196, "ENTITY"], [51, 62, "PROTEIN"], [160, 169, "ENTITY"], [18, 32, "ENTITY"], [0, 15, "ENTITY"], [186, 196, "ORGANISM"], [18, 32, "PROTEIN"], [18, 32, "GGP"], [18, 32, "GENE_OR_GENE_PRODUCT"], [160, 169, "ORGANISM"], [51, 62, "ENTITY"], [51, 62, "GGP"], [34, 39, "ENTITY"]]}
{"text": "Consistent with others , most of severe COVID-19 patients in our ICU ward had persistent very high level of erythematosus sedimentation rate ( ESR ) , CRP , and high level of IL-6,TNFa , IL-1B , IL-8 , IL2R , etc , and were associated with ARDS , hypercoagulation and disseminated intravascular coagulation ( DIC ) , manifested as thrombosis , thrombocytopenia , gangrene of extremities .", "labels": [[0, 16, "ENTITY"], [175, 187, "GENE_OR_GENE_PRODUCT"], [108, 136, "ENTITY"], [328, 344, "ENTITY"], [175, 187, "ENTITY"], [175, 187, "DNA"], [328, 344, "DISEASE"], [99, 108, "GGP"], [65, 69, "ENTITY"], [235, 247, "DISEASE"], [344, 363, "ENTITY"], [235, 247, "ENTITY"], [187, 193, "ENTITY"], [99, 108, "DNA"], [187, 193, "GENE_OR_GENE_PRODUCT"], [268, 281, "IMMATERIAL_ANATOMICAL_ENTITY"], [268, 295, "DISEASE"], [99, 108, "ENTITY"], [344, 363, "ORGAN"], [175, 187, "GGP"], [317, 328, "DISEASE"], [94, 99, "ENTITY"], [187, 193, "PROTEIN"], [247, 295, "ENTITY"], [40, 49, "GENE_OR_GENE_PRODUCT"], [215, 224, "ENTITY"], [187, 193, "GGP"], [99, 108, "GENE_OR_GENE_PRODUCT"], [317, 328, "ENTITY"]]}
{"text": "Median systolic blood pressure was significantly higher in deceased patients ( 137.0 mm Hg ) than recovered patients ( 125.0 mm Hg ) .", "labels": [[68, 77, "ENTITY"], [7, 31, "ENTITY"], [0, 7, "ENTITY"], [59, 68, "ENTITY"], [98, 108, "ENTITY"], [98, 108, "ORGANISM"], [85, 88, "CHEBI"], [68, 77, "ORGANISM"], [16, 22, "ORGANISM_SUBSTANCE"]]}
{"text": "One patient who died developed gastrointestinal bleeding .", "labels": [[31, 48, "ORGAN"], [4, 12, "ENTITY"], [31, 57, "ENTITY"], [4, 12, "ORGANISM"], [16, 21, "ENTITY"], [31, 57, "DISEASE"]]}
{"text": "Chest radiology at early stage is characteristic of multiple small patchy shadows and interstitial changes , more prominent in the extrapulmonary bands . Multiple ground-glass opacities and infiltrations may develop bilaterally with disease progression , with possible consolidation in severe cases .", "labels": [[0, 16, "ENTITY"], [74, 82, "ENTITY"], [286, 293, "ENTITY"], [228, 241, "ENTITY"], [208, 228, "ENTITY"], [61, 74, "ENTITY"], [131, 146, "ENTITY"], [152, 176, "ENTITY"], [19, 31, "ENTITY"], [86, 99, "ENTITY"]]}
{"text": "The main abnormalities in chest CT images were air-space shadowing : patchy ground-glass opacities ( in patients 2 , 3 , 6 and 9 ) ( Figure 2A ) or patchy hyperdense areas ( patients 1 , 4 , 5 , 8 and 10 ) ( Figure 2B ) on the initial chest radiograph . The radiographic opacities were mostly in the lower lung zones ( patients 1 , 2 , 3 , 4 , 5 , 6 , 8 and 9 ) .", "labels": [[47, 67, "ENTITY"], [286, 300, "MULTI-TISSUE_STRUCTURE"], [26, 35, "TISSUE"], [69, 76, "ENTITY"], [195, 204, "ENTITY"], [300, 311, "ENTITY"], [166, 174, "ORGANISM"], [220, 235, "ENTITY"], [26, 35, "ENTITY"], [35, 42, "ENTITY"], [166, 174, "ENTITY"], [76, 89, "ENTITY"], [286, 300, "ENTITY"], [32, 35, "PROTEIN"], [300, 311, "ORGANISM"], [47, 57, "MULTI-TISSUE_STRUCTURE"], [9, 23, "ENTITY"], [241, 258, "ENTITY"]]}
{"text": "On February 6 , the third chest CT scan showed bilateral multiple ground-glass opacities indicating viral pneumonia ( Figure 1B ) and she was admitted to the designated hospital immediately .", "labels": [[47, 79, "ENTITY"], [116, 125, "ENTITY"], [100, 106, "ENTITY"], [158, 169, "ENTITY"], [20, 35, "ENTITY"], [3, 12, "ENTITY"], [100, 106, "DISEASE"]]}
{"text": "On January 23 , the second chest CT scan revealed bilateral extended ground\u2010glass opacities with scattered consolidation , indicating rapid progression of the disease ( Figure 3B ) .", "labels": [[20, 36, "ENTITY"], [3, 11, "ENTITY"], [69, 82, "ENTITY"], [123, 134, "ENTITY"], [134, 140, "ENTITY"], [167, 176, "ENTITY"]]}
{"text": "On February 6 , the third chest CT scan showed bilateral multiple ground-glass opacities indicating viral pneumonia ( Figure 1B ) and she was admitted to the designated hospital immediately .", "labels": [[47, 79, "ENTITY"], [100, 106, "DISEASE"], [116, 125, "ENTITY"], [100, 106, "ENTITY"], [158, 169, "ENTITY"], [20, 35, "ENTITY"], [3, 12, "ENTITY"]]}
{"text": "ACE2 antagonizes the activation of the classical RAS system and protects against organ damage , protecting against hypertension , diabetes , and cardiovascular disease .", "labels": [[21, 32, "ENTITY"], [39, 60, "ENTITY"], [81, 94, "ENTITY"], [0, 5, "GGP"], [0, 5, "ENTITY"], [5, 17, "ENTITY"], [64, 73, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [49, 53, "GENE_OR_GENE_PRODUCT"], [81, 94, "DISEASE"], [81, 87, "ORGAN"], [141, 160, "ENTITY"], [0, 5, "PROTEIN"], [141, 160, "DISEASE"]]}
{"text": "RAS activation is an important pathophysiological mechanism of hypertension , and RAS blockers are widely used .", "labels": [[0, 4, "ENTITY"], [4, 15, "ENTITY"], [50, 60, "ENTITY"], [0, 4, "ENTITY"], [63, 76, "DISEASE"], [0, 4, "GENE_OR_GENE_PRODUCT"], [0, 4, "GENE_OR_GENE_PRODUCT"], [31, 50, "ENTITY"], [0, 4, "PROTEIN"], [63, 76, "ENTITY"], [0, 4, "PROTEIN"]]}
{"text": "ACE2 antagonizes the activation of the classical RAS system and protects against organ damage , protecting against hypertension , diabetes , and cardiovascular disease .", "labels": [[21, 32, "ENTITY"], [39, 60, "ENTITY"], [81, 94, "ENTITY"], [0, 5, "GGP"], [0, 5, "ENTITY"], [5, 17, "ENTITY"], [64, 73, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [49, 53, "GENE_OR_GENE_PRODUCT"], [81, 94, "DISEASE"], [81, 87, "ORGAN"], [141, 160, "ENTITY"], [0, 5, "PROTEIN"], [141, 160, "DISEASE"]]}
{"text": "ACE2 antagonizes the activation of the classical RAS system and protects against organ damage , protecting against hypertension , diabetes , and cardiovascular disease .", "labels": [[21, 32, "ENTITY"], [39, 60, "ENTITY"], [81, 94, "ENTITY"], [0, 5, "GGP"], [0, 5, "ENTITY"], [5, 17, "ENTITY"], [64, 73, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [49, 53, "GENE_OR_GENE_PRODUCT"], [81, 94, "DISEASE"], [81, 87, "ORGAN"], [0, 5, "PROTEIN"], [141, 160, "ENTITY"], [141, 160, "DISEASE"]]}
{"text": "The renin-angiotensin system ( RAS ) is a critical homeostasis regulation of the human body ( showed in Fig.1.).1", "labels": [[42, 51, "ENTITY"], [51, 63, "ENTITY"], [77, 87, "TAXON"], [4, 29, "GENE_OR_GENE_PRODUCT"], [81, 87, "ENTITY"], [77, 87, "ORGANISM"], [4, 29, "ENTITY"]]}
{"text": "It was also found that RAS blockade could prevent atherosclerosis in ApoE/ACE2 double knockout mice .", "labels": [[69, 79, "GENE_OR_GENE_PRODUCT"], [23, 27, "ENTITY"], [27, 36, "ENTITY"], [50, 66, "ENTITY"], [95, 100, "TAXON"], [42, 50, "ENTITY"], [50, 66, "DISEASE"], [95, 100, "ORGANISM"], [69, 79, "CHEMICAL"], [69, 100, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Indeed , in experimental mouse models , exposure to SARS-CoV-1 spike protein induced acute lung injury , which is limited by RAAS blockade.45", "labels": [[63, 69, "CHEBI"], [49, 69, "ENTITY"], [38, 49, "ENTITY"], [77, 96, "ENTITY"], [77, 96, "DISEASE"], [122, 130, "PROTEIN"], [12, 31, "ENTITY"], [85, 91, "ORGAN"], [49, 69, "PROTEIN"]]}
{"text": "With SARS-CoV , animal models showed that infection with the virus downregulated ACE2 expression , generating an inflammatory response correlated with acute lung injury and impaired cardiac contractility [ 26\u201328 ] .", "labels": [[16, 23, "ENTITY"], [126, 135, "ENTITY"], [146, 162, "DISEASE"], [110, 126, "ENTITY"], [5, 14, "ORGANISM"], [5, 14, "ENTITY"], [151, 157, "ORGAN"], [173, 190, "ENTITY"], [146, 162, "ENTITY"], [173, 182, "ORGAN"]]}
{"text": "Few patients had kidney injury indicated by elevated plasma urea ( 9 of 198 [ 4.5 % ] ) and serum creatinine ( 9 of 198 [ 4.5 % ] ) .", "labels": [[44, 53, "ENTITY"], [60, 65, "CHEBI"], [17, 31, "ENTITY"], [92, 98, "CHEBI"], [88, 98, "ENTITY"], [92, 98, "CHEMICAL"], [53, 65, "ENTITY"], [17, 24, "ORGAN"], [60, 65, "CHEMICAL"], [53, 65, "ORGANISM_SUBSTANCE"], [88, 98, "ORGANISM_SUBSTANCE"], [17, 31, "DISEASE"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Concentrations of blood urea nitrogen , creatinine , potassium , triglycerides , creatine kinase , and lactate dehydrogenase were significantly higher in deceased patients than in recovered patients .", "labels": [[99, 111, "ENTITY"], [154, 163, "ORGANISM"], [65, 81, "SIMPLE_CHEMICAL"], [65, 90, "ENTITY"], [65, 81, "CHEMICAL"], [0, 15, "ENTITY"], [99, 111, "GENE_OR_GENE_PRODUCT"], [180, 190, "ORGANISM"], [154, 163, "ENTITY"], [99, 111, "PROTEIN"], [65, 90, "PROTEIN"], [65, 81, "CHEBI"], [18, 38, "ENTITY"], [172, 180, "ENTITY"], [24, 38, "CHEBI"], [18, 29, "ORGANISM_SUBSTANCE"], [144, 154, "ENTITY"], [180, 190, "ENTITY"], [99, 111, "GGP"], [18, 38, "CHEMICAL"]]}
{"text": "Compared with patients without ARDS , for patients with ARDS , the value of liver damage indices ( total bilirubin [ difference , 1.90mg/dL ; 95%CI , 0.60 - 3.30 mg/dL ; P = .004 ] ) , renal dysfunction indices ( urea [ difference , 1.69 mM ; 95 % CI , 1.10 - 2.29mM;P < .001 ] ) , inflammation-related indices ( interleukin- 6 [ IL-6 ] [ difference , 0.93 pg/L ; 95%CI , 0.07 - 1.98 pg/L ; P = .03 ] ) , and coagulation function indices ( D-dimer [ difference , 0.52 \u03bcg/mL ; 95 % CI , 0.21 - 0.94 \u03bcg/mL ; P < .001 ] ) were significantly elevated .", "labels": [[99, 105, "GGP"], [403, 409, "ENTITY"], [258, 282, "ENTITY"], [31, 36, "ENTITY"], [194, 203, "CHEMICAL"], [14, 23, "ENTITY"], [403, 409, "PROTEIN"], [0, 9, "ENTITY"], [73, 89, "ENTITY"], [409, 421, "ENTITY"], [73, 82, "DISEASE"], [191, 203, "CHEMICAL"], [99, 105, "SIMPLE_CHEMICAL"], [172, 191, "ENTITY"], [191, 203, "CHEBI"], [31, 36, "DISEASE"], [89, 99, "ENTITY"], [130, 142, "CHEMICAL"], [191, 203, "ENTITY"], [105, 117, "ENTITY"], [14, 23, "ORGANISM"], [372, 401, "ENTITY"], [99, 105, "CHEMICAL"], [97, 105, "ENTITY"], [403, 409, "GGP"]]}
{"text": "For patients with ARDS who died , the value of liver damage indices ( total bilirubin [ difference , 2.60 mg/dL ; 95 % CI , 0.30 - 5.20mg/dL;P = .03 ] ) , renal dysfunction indices ( urea [ difference , 1.50 mM ; 95%CI , 0.50 - 2.70 mM ; P = .004 ] ) , inflammation- related indices ( IL-6 [ difference , 3.88 pg/L ; 95 % CI , 2.20 - 6.13pg/L;P < .001 ] ) , and coagulation function indices ( Ddimer [ difference , 2.10 \u03bcg/mL ; 95 % CI , 0.89 - 5.27 \u03bcg/mL ; P = .001 ] ) were significantly elevated compared with patients with ARDS who survived .", "labels": [[60, 70, "ENTITY"], [47, 60, "ENTITY"], [161, 173, "ENTITY"], [292, 310, "SIMPLE_CHEMICAL"], [469, 476, "ENTITY"], [68, 76, "ENTITY"], [327, 356, "ENTITY"], [70, 76, "CHEMICAL"], [161, 173, "CHEBI"], [469, 476, "ORGANISM"], [70, 76, "SIMPLE_CHEMICAL"], [267, 275, "ENTITY"], [4, 13, "ENTITY"], [88, 99, "CHEMICAL"], [18, 23, "ENTITY"], [47, 53, "DISEASE"], [88, 101, "CHEMICAL"], [143, 161, "ENTITY"], [18, 23, "DISEASE"], [143, 161, "DISEASE"], [70, 76, "GGP"], [161, 173, "CHEMICAL"], [27, 32, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Adverse reactions of IFN-\u03b1 mainly include low-grade fever and flu-like symptoms ( both in children with intramuscularly injection ) [ 11 ] .", "labels": [[52, 58, "ENTITY"], [21, 27, "PROTEIN"], [62, 71, "ORGAN"], [42, 52, "ENTITY"], [104, 120, "ENTITY"], [21, 27, "ENTITY"], [62, 80, "ENTITY"], [52, 58, "DISEASE"], [21, 27, "GENE_OR_GENE_PRODUCT"], [0, 18, "ENTITY"], [42, 52, "CANCER"]]}
{"text": "ACE2 can also antagonize cardiac fibrosis and ventricular remodeling caused by the long-term effects of Ang II .", "labels": [[33, 42, "DISEASE"], [46, 69, "ENTITY"], [25, 42, "ENTITY"], [46, 58, "MULTI-TISSUE_STRUCTURE"], [0, 5, "GGP"], [104, 111, "GGP"], [0, 5, "ENTITY"], [104, 111, "GENE_OR_GENE_PRODUCT"], [104, 111, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [83, 93, "ENTITY"], [93, 101, "ENTITY"], [25, 33, "ORGAN"], [14, 25, "ENTITY"], [0, 5, "PROTEIN"], [104, 111, "ENTITY"]]}
{"text": "Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation , caffeine , and antibiotics .", "labels": [[137, 147, "ENTITY"], [152, 176, "ENTITY"], [66, 72, "MULTI-TISSUE_STRUCTURE"], [66, 91, "ENTITY"], [9, 39, "DISEASE"], [43, 53, "DISEASE"], [126, 131, "ENTITY"], [0, 9, "ENTITY"], [116, 120, "ENTITY"], [9, 39, "ENTITY"], [43, 53, "ENTITY"], [94, 104, "ENTITY"]]}
{"text": "Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation , caffeine , and antibiotics .", "labels": [[137, 147, "ENTITY"], [152, 176, "ENTITY"], [66, 72, "MULTI-TISSUE_STRUCTURE"], [66, 91, "ENTITY"], [9, 39, "DISEASE"], [43, 53, "DISEASE"], [126, 131, "ENTITY"], [0, 9, "ENTITY"], [116, 120, "ENTITY"], [9, 39, "ENTITY"], [43, 53, "ENTITY"], [94, 104, "ENTITY"]]}
{"text": "Neonatal respiratory distress syndrome and pneumonia confirmed by chest radiographic image on admission resolved on day 14 of life after treatment with noninvasive ventilation , caffeine , and antibiotics .", "labels": [[137, 147, "ENTITY"], [152, 176, "ENTITY"], [66, 72, "MULTI-TISSUE_STRUCTURE"], [66, 91, "ENTITY"], [9, 39, "DISEASE"], [43, 53, "DISEASE"], [126, 131, "ENTITY"], [0, 9, "ENTITY"], [116, 120, "ENTITY"], [9, 39, "ENTITY"], [43, 53, "ENTITY"], [94, 104, "ENTITY"]]}
{"text": "She developed chest tightness , shortness of breath , loss of appetite , 62 nausea , and diarrhea", "labels": [[52, 62, "ENTITY"], [52, 62, "DISEASE"], [4, 14, "ENTITY"], [14, 30, "ENTITY"], [32, 45, "ENTITY"], [14, 30, "DISEASE"], [32, 45, "DISEASE"]]}
{"text": "Other clinical signs such as reduced appetite , increased respiration rate and hunched posture were transient after the initial challenge .", "labels": [[79, 87, "ENTITY"], [6, 21, "ENTITY"], [37, 46, "CHEMICAL"], [37, 46, "ENTITY"], [29, 37, "ENTITY"]]}
{"text": "Of 195 patients , 4 ( 2.1 % ) presented with prolonged prothrombin times ( PTs ) .", "labels": [[7, 16, "ENTITY"], [67, 73, "ENTITY"], [7, 16, "ORGANISM"], [45, 55, "PROTEIN"], [67, 73, "CANCER"], [45, 67, "ENTITY"], [45, 55, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Median prothrombin time was significantly longer in deceased patients than in recovered patients , whereas activated partial thromboplastin time was comparable between the two groups .", "labels": [[0, 7, "ENTITY"], [61, 70, "ENTITY"], [52, 61, "ENTITY"], [61, 70, "ORGANISM"], [61, 70, "ENTITY"], [61, 70, "ORGANISM"], [7, 24, "ENTITY"], [7, 19, "PROTEIN"], [7, 19, "GENE_OR_GENE_PRODUCT"], [78, 88, "ENTITY"]]}
{"text": "Decreased platelet counts were observed in 25 ( 20.2 % ) patients , prolonged prothrombin time ( PT ) was observed in 77 ( 62.1 % ) patients , fibrinogen ( FIB ) levels were increased in 27 ( 21.8 % ) patients , and D-dimer levels were increased in 26 ( 21.0 % ) patients .", "labels": [[216, 224, "ENTITY"], [57, 68, "ENTITY"], [10, 19, "CL"], [57, 68, "ENTITY"], [10, 26, "ENTITY"], [68, 78, "GENE_OR_GENE_PRODUCT"], [236, 252, "ORGANISM"], [162, 169, "ENTITY"], [68, 90, "ENTITY"], [143, 156, "ENTITY"], [57, 68, "PROTEIN"], [90, 95, "ENTITY"], [10, 19, "CELL"], [236, 252, "ENTITY"], [57, 68, "GENE_OR_GENE_PRODUCT"], [57, 68, "ENTITY"], [0, 10, "ENTITY"], [68, 78, "PROTEIN"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [168, 187, "ENTITY"], [168, 187, "CHEBI"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [168, 187, "SIMPLE_CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [168, 187, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [62, 103, "GENE_OR_GENE_PRODUCT"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Patients with elevated TnT levels also had significantly longer prothrombin time ( median [ IQR ] , 12.4 [ 12.0 - 13.0 ] vs 13.3 [ 12.2 - 15.3 ] seconds ; P = .005 ) , shorter activated partial thromboplastin time ( median [ IQR ] , 31.2 [ 27.5 - 33.2 ] vs 32.7 [ 31.0 - 35.8 ] seconds ; P = .003 ) , and a significant higher level of D-dimer ( median [ IQR ] , 0.29 [ 0.17 - 0.60 ] vs 3.85 [ 0.51 - 25.58 ] \u03bcg/mL[to convert to nanomoles per liter , multiply by 5.476 ] ; P < .001 ) .", "labels": [[176, 194, "GENE_OR_GENE_PRODUCT"], [23, 27, "ENTITY"], [14, 23, "ENTITY"], [145, 155, "ENTITY"], [23, 27, "PROTEIN"], [319, 326, "ENTITY"], [23, 27, "GENE_OR_GENE_PRODUCT"], [27, 34, "ENTITY"], [0, 9, "ENTITY"], [64, 76, "PROTEIN"], [0, 9, "ORGANISM"], [64, 76, "GENE_OR_GENE_PRODUCT"], [176, 194, "PROTEIN"], [417, 425, "GENE_OR_GENE_PRODUCT"], [64, 81, "ENTITY"], [43, 55, "ENTITY"]]}
{"text": "From our data of more than 600 NCP patients in Jiangsu Province , age , lymphocyte count , oxygen supplementation and aggressive pulmonary radiographic infiltrations are independent risk factors for NCP progressing to a critical condition .", "labels": [[218, 229, "ENTITY"], [31, 35, "CHEMICAL"], [89, 98, "ENTITY"], [35, 44, "ENTITY"], [114, 152, "DISEASE"], [9, 14, "ENTITY"], [70, 83, "ENTITY"], [118, 152, "ENTITY"], [170, 187, "ENTITY"], [47, 64, "ENTITY"], [31, 35, "ENTITY"], [118, 129, "ORGAN"], [47, 64, "ORGANISM"]]}
{"text": "At least one abnormal chest CT manifestation ( including ground-glass opacities , pulmonary infiltrates and interstitial disorders ) was identified in more than 70 % of patients .", "labels": [[80, 92, "MULTI-TISSUE_STRUCTURE"], [57, 70, "ENTITY"], [28, 31, "PROTEIN"], [80, 92, "ENTITY"], [13, 22, "ENTITY"], [22, 31, "ENTITY"], [104, 121, "DISEASE"], [104, 121, "ENTITY"], [31, 45, "ENTITY"]]}
{"text": "These data suggest that ACE1 D/I polymorphism may be regarded as a confounder in the spread of COVID-19 and the outcome of the infection in various European populations . These findings are in agreement with the role of ACE in pulmonary infections caused by coronaviruses [ 4 ] .", "labels": [[29, 33, "CHEMICAL"], [67, 78, "ENTITY"], [148, 169, "ENTITY"], [6, 11, "ENTITY"], [112, 120, "ENTITY"], [127, 137, "ENTITY"], [85, 92, "ENTITY"], [95, 104, "PROTEIN"], [24, 29, "GENE_OR_GENE_PRODUCT"], [95, 104, "ENTITY"], [148, 169, "CELL_LINE"], [95, 104, "DISEASE"], [33, 46, "ENTITY"], [227, 237, "ENTITY"], [227, 237, "DISEASE"], [95, 104, "GENE_OR_GENE_PRODUCT"], [258, 274, "ORGANISM"], [24, 33, "ENTITY"], [127, 137, "DISEASE"]]}
{"text": "Both T cells and NK cells in patients with COVID-19 were reduced .", "labels": [[17, 26, "CL"], [5, 13, "CL"], [17, 26, "CELL_TYPE"], [43, 52, "ENTITY"], [57, 65, "ENTITY"], [17, 26, "CELL"], [29, 38, "ORGANISM"], [5, 13, "CELL"], [17, 26, "ENTITY"], [5, 13, "CELL_TYPE"], [5, 13, "ENTITY"], [43, 52, "SIMPLE_CHEMICAL"], [29, 38, "ENTITY"]]}
{"text": "However , the most characteristic symptom of patients is respiratory distress ( ~55 % ) .", "labels": [[57, 69, "ENTITY"], [57, 69, "DISEASE"]]}
{"text": "Other prevalent symptoms at onset of illness in deceased patients included fatigue , dyspnoea , chest tightness , and sputum production ; less common symptoms included anorexia , diarrhoea , and myalgia .", "labels": [[112, 118, "DISEASE"], [143, 150, "ENTITY"], [168, 179, "DISEASE"], [66, 75, "ENTITY"], [112, 118, "ENTITY"], [114, 125, "ENTITY"], [16, 25, "ENTITY"], [168, 179, "ENTITY"], [48, 57, "ENTITY"], [28, 37, "ENTITY"], [94, 102, "DISEASE"], [66, 75, "CANCER"], [75, 83, "DISEASE"], [94, 102, "ENTITY"], [75, 83, "ENTITY"], [57, 66, "ORGANISM"], [66, 75, "DISEASE"], [37, 45, "ENTITY"], [6, 16, "ENTITY"], [57, 66, "ENTITY"]]}
{"text": "These results indicated that the persistently infected Vero E6 cells produce infectious viruses .", "labels": [[6, 14, "ENTITY"], [63, 69, "CL"], [55, 60, "ENTITY"], [46, 55, "ENTITY"], [55, 69, "CELL_LINE"], [55, 69, "CELL"], [60, 69, "ENTITY"], [88, 96, "TAXON"], [77, 96, "ENTITY"]]}
{"text": "The amount of mRNA8 and 9 of the persistent cells are 81.4 % of the acute infected cells .", "labels": [[44, 50, "CELL"], [33, 50, "ENTITY"], [14, 20, "ENTITY"], [44, 50, "CL"], [33, 50, "CELL_TYPE"], [68, 83, "ENTITY"], [14, 26, "PROTEIN"], [4, 11, "ENTITY"], [68, 83, "CELL_TYPE"], [14, 20, "GGP"]]}
{"text": "During hospitalization , patients with elevated TnT levels developed more frequent complications ( Table 1 ) , including acute respiratory distress syndrome ( 30 [ 57.7 % ] vs 16 [ 11.9 % ] ) , malignant arrhythmias ( 6 [ 11.5 % ] vs 7 [ 5.2 % ] ) including ventricular tachycardia/ ventricular fibrillation , acute coagulopathy ( 25 [ 65.8 % ] vs 17 [ 20.0 % ] ) , and acute kidney injury ( 14 [ 36.8 % ] vs 4 [ 4.7 % ] ) , compared with those with normal TnT levels .", "labels": [[336, 358, "DISEASE"], [336, 358, "ENTITY"], [258, 270, "DISEASE"], [238, 283, "ENTITY"], [345, 351, "ORGAN"], [7, 23, "ENTITY"], [258, 270, "ENTITY"], [121, 148, "DISEASE"], [238, 283, "DISEASE"], [111, 148, "ENTITY"], [238, 270, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "During hospitalization , patients with elevated TnT levels developed more frequent complications ( Table 1 ) , including acute respiratory distress syndrome ( 30 [ 57.7 % ] vs 16 [ 11.9 % ] ) , malignant arrhythmias ( 6 [ 11.5 % ] vs 7 [ 5.2 % ] ) including ventricular tachycardia/ ventricular fibrillation , acute coagulopathy ( 25 [ 65.8 % ] vs 17 [ 20.0 % ] ) , and acute kidney injury ( 14 [ 36.8 % ] vs 4 [ 4.7 % ] ) , compared with those with normal TnT levels .", "labels": [[336, 358, "DISEASE"], [336, 358, "ENTITY"], [345, 351, "ORGAN"], [238, 283, "ENTITY"], [7, 23, "ENTITY"], [258, 270, "DISEASE"], [238, 283, "DISEASE"], [258, 270, "ENTITY"], [121, 148, "DISEASE"], [111, 148, "ENTITY"], [238, 270, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "Following the initial infection , three of the four monkeys showed the weight loss ranging from 200 g to 400 g ( Figure 2a ) , but the changes of rectal temperature in all the animals were not observed ( Figure 2b ) .", "labels": [[193, 204, "ENTITY"], [22, 32, "ENTITY"], [14, 22, "ENTITY"], [22, 32, "DISEASE"], [71, 78, "ENTITY"], [71, 78, "DISEASE"], [111, 120, "ENTITY"], [143, 153, "ENTITY"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "It is often induced by sepsis , aspiration , and pneumonia ( including that caused by SARS coronavirus , bird flu , and human influenza viruses ) .", "labels": [[116, 136, "ORGANISM"], [12, 20, "ENTITY"], [23, 30, "DISEASE"], [23, 30, "ENTITY"], [126, 136, "TAXON"], [86, 91, "ORGANISM"], [120, 136, "ENTITY"], [83, 91, "DISEASE"], [91, 110, "ENTITY"], [83, 91, "ENTITY"]]}
{"text": "Imaging examination revealed that most patients with fever , dry cough , and dyspnoea showed bilateral ground-glass opacities on chest CT scans 14 .", "labels": [[86, 116, "ENTITY"], [39, 48, "ENTITY"], [61, 65, "ENTITY"], [39, 48, "ORGANISM"], [61, 65, "DISEASE"], [53, 59, "ENTITY"], [53, 59, "DISEASE"], [0, 20, "ENTITY"], [126, 138, "ENTITY"]]}
{"text": "The majority ( n = 154 [ 76.6 % ] ) of patients had fever with cough ; 74 ( 36.8 % ) had feverwith dyspnea ; 66 ( 32.8 % ) had feverwith fatigue , myalgia , or headache ; and only 13 ( 6.5 % ) presentedwith fever alone ( eTable 1 in the Supplement ) .", "labels": [[34, 39, "ENTITY"], [89, 99, "DISEASE"], [81, 89, "ENTITY"], [213, 228, "ENTITY"], [89, 99, "ENTITY"], [81, 89, "DISEASE"], [34, 39, "ORGANISM"], [114, 127, "ENTITY"]]}
{"text": "Fever and cough were the most prevalent symptoms at disease onset in both deceased patients ( 104 ( 92 % ) and 79 ( 70 % ) ) and recovered patients ( 145 ( 90 % ) and 106 ( 66 % ) ) , and the proportions of patients reporting these symptoms in the two groups were comparable .", "labels": [[121, 129, "ENTITY"], [129, 139, "ENTITY"], [40, 49, "ENTITY"], [83, 92, "ENTITY"], [74, 83, "ENTITY"], [52, 66, "ENTITY"], [129, 139, "ORGANISM"], [10, 16, "ENTITY"], [83, 92, "ORGANISM"], [10, 16, "DISEASE"], [0, 6, "DISEASE"], [0, 6, "ENTITY"], [30, 40, "ENTITY"], [40, 49, "ENTITY"]]}
{"text": "Persons infected with SARS-CoV-2 present with a wide range of symptoms similar to other respiratory infections ( e.g. , fever , cough , and shortness of breath ) or may be silent carriers .", "labels": [[88, 111, "DISEASE"], [88, 111, "ENTITY"], [62, 71, "ENTITY"], [136, 153, "ENTITY"], [165, 172, "ENTITY"], [172, 179, "ENTITY"], [136, 153, "DISEASE"], [0, 8, "ENTITY"], [22, 33, "SIMPLE_CHEMICAL"], [22, 33, "ENTITY"], [8, 17, "ENTITY"], [22, 33, "CHEMICAL"]]}
{"text": "All patients manifested cough and most of them felt shortness of breath , and 60.0 % patients had nausea and vomiting", "labels": [[52, 65, "ENTITY"], [52, 72, "DISEASE"], [65, 72, "ENTITY"], [24, 30, "DISEASE"], [24, 30, "ENTITY"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Imaging examination revealed that most patients with fever , dry cough , and dyspnoea showed bilateral ground-glass opacities on chest CT scans 14 .", "labels": [[86, 116, "ENTITY"], [39, 48, "ENTITY"], [61, 65, "ENTITY"], [39, 48, "ORGANISM"], [61, 65, "DISEASE"], [53, 59, "ENTITY"], [53, 59, "DISEASE"], [0, 20, "ENTITY"], [126, 138, "ENTITY"]]}
{"text": "The majority ( n = 154 [ 76.6 % ] ) of patients had fever with cough ; 74 ( 36.8 % ) had feverwith dyspnea ; 66 ( 32.8 % ) had feverwith fatigue , myalgia , or headache ; and only 13 ( 6.5 % ) presentedwith fever alone ( eTable 1 in the Supplement ) .", "labels": [[34, 39, "ENTITY"], [89, 99, "DISEASE"], [81, 89, "ENTITY"], [213, 228, "ENTITY"], [89, 99, "ENTITY"], [81, 89, "DISEASE"], [34, 39, "ORGANISM"], [114, 127, "ENTITY"]]}
{"text": "The most common symptom was shortness of breath ( 4 of 33 neonates )", "labels": [[28, 48, "DISEASE"], [16, 24, "ENTITY"], [28, 48, "ENTITY"]]}
{"text": "Persons infected with SARS-CoV-2 present with a wide range of symptoms similar to other respiratory infections ( e.g. , fever , cough , and shortness of breath ) or may be silent carriers .", "labels": [[88, 111, "DISEASE"], [88, 111, "ENTITY"], [62, 71, "ENTITY"], [136, 153, "ENTITY"], [165, 172, "ENTITY"], [172, 179, "ENTITY"], [136, 153, "DISEASE"], [0, 8, "ENTITY"], [22, 33, "SIMPLE_CHEMICAL"], [22, 33, "ENTITY"], [8, 17, "ENTITY"], [22, 33, "CHEMICAL"]]}
{"text": "All patients manifested cough and most of them felt shortness of breath , and 60.0 % patients had nausea and vomiting", "labels": [[52, 65, "ENTITY"], [24, 30, "ENTITY"], [24, 30, "DISEASE"], [65, 72, "ENTITY"], [52, 72, "DISEASE"], [4, 13, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "More patients with ARDS presented with initial symptoms of dyspnea compared with those without ARDS ( difference , 33.9%;95%CI , 19.7%-48.1%;P < .001 )", "labels": [[19, 24, "ENTITY"], [19, 24, "DISEASE"], [59, 67, "ENTITY"], [5, 14, "ENTITY"], [19, 24, "DISEASE"], [5, 14, "ORGANISM"], [59, 67, "DISEASE"], [19, 24, "ENTITY"], [47, 56, "ENTITY"]]}
{"text": "Clinically , many critical ill patients have vasculitis-like manifestations , or even gangrene at their extremities ; Pathology examination revealed the blood vessels of alveolar septum were congested and edematous , with modest infiltration of monocytes and lymphocytes within and around blood vessels .", "labels": [[282, 295, "MULTI-TISSUE_STRUCTURE"], [149, 159, "MULTI-TISSUE_STRUCTURE"], [0, 11, "ENTITY"], [282, 295, "ENTITY"], [18, 27, "ENTITY"], [167, 179, "TISSUE"], [116, 128, "ENTITY"], [222, 229, "ENTITY"], [167, 179, "ENTITY"], [45, 61, "ENTITY"], [149, 159, "ENTITY"]]}
{"text": "The majority ( n = 154 [ 76.6 % ] ) of patients had fever with cough ; 74 ( 36.8 % ) had feverwith dyspnea ; 66 ( 32.8 % ) had feverwith fatigue , myalgia , or headache ; and only 13 ( 6.5 % ) presentedwith fever alone ( eTable 1 in the Supplement ) .", "labels": [[34, 39, "ENTITY"], [89, 99, "DISEASE"], [81, 89, "ENTITY"], [213, 228, "ENTITY"], [89, 99, "ENTITY"], [81, 89, "DISEASE"], [34, 39, "ORGANISM"], [114, 127, "ENTITY"]]}
{"text": "Other prevalent symptoms at onset of illness in deceased patients included fatigue , dyspnoea , chest tightness , and sputum production ; less common symptoms included anorexia , diarrhoea , and myalgia .", "labels": [[75, 83, "ENTITY"], [112, 118, "DISEASE"], [143, 150, "ENTITY"], [75, 83, "DISEASE"], [168, 179, "DISEASE"], [66, 75, "ENTITY"], [112, 118, "ENTITY"], [114, 125, "ENTITY"], [16, 25, "ENTITY"], [168, 179, "ENTITY"], [48, 57, "ENTITY"], [28, 37, "ENTITY"], [94, 102, "DISEASE"], [66, 75, "CANCER"], [94, 102, "ENTITY"], [57, 66, "ORGANISM"], [66, 75, "DISEASE"], [37, 45, "ENTITY"], [6, 16, "ENTITY"], [57, 66, "ENTITY"]]}
{"text": "Imaging examination revealed that most patients with fever , dry cough , and dyspnoea showed bilateral ground-glass opacities on chest CT scans 14 .", "labels": [[86, 116, "ENTITY"], [39, 48, "ENTITY"], [61, 65, "ENTITY"], [39, 48, "ORGANISM"], [61, 65, "DISEASE"], [0, 20, "ENTITY"], [126, 138, "ENTITY"], [53, 59, "DISEASE"], [53, 59, "ENTITY"]]}
{"text": "The majority ( n = 154 [ 76.6 % ] ) of patients had fever with cough ; 74 ( 36.8 % ) had feverwith dyspnea ; 66 ( 32.8 % ) had feverwith fatigue , myalgia , or headache ; and only 13 ( 6.5 % ) presentedwith fever alone ( eTable 1 in the Supplement ) .", "labels": [[34, 39, "ENTITY"], [81, 89, "ENTITY"], [213, 228, "ENTITY"], [89, 99, "ENTITY"], [81, 89, "DISEASE"], [34, 39, "ORGANISM"], [114, 127, "ENTITY"], [89, 99, "DISEASE"]]}
{"text": "On day 2 of life , the infant experienced lethargy and fever , with unremarkable physical examination results , and was moved to the neonatal intensive care unit .", "labels": [[133, 157, "ENTITY"], [3, 7, "ENTITY"], [90, 102, "ENTITY"], [129, 157, "DNA"], [12, 17, "ENTITY"], [68, 90, "ENTITY"]]}
{"text": "He presented with lethargy , vomiting , and fever .", "labels": [[18, 27, "DISEASE"], [18, 27, "ENTITY"]]}
{"text": "Fever and cough were the most prevalent symptoms at disease onset in both deceased patients ( 104 ( 92 % ) and 79 ( 70 % ) ) and recovered patients ( 145 ( 90 % ) and 106 ( 66 % ) ) , and the proportions of patients reporting these symptoms in the two groups were comparable .", "labels": [[121, 129, "ENTITY"], [129, 139, "ENTITY"], [40, 49, "ENTITY"], [83, 92, "ENTITY"], [74, 83, "ENTITY"], [52, 66, "ENTITY"], [0, 6, "DISEASE"], [129, 139, "ORGANISM"], [83, 92, "ORGANISM"], [0, 6, "ENTITY"], [30, 40, "ENTITY"], [10, 16, "ENTITY"], [40, 49, "ENTITY"], [10, 16, "DISEASE"]]}
{"text": "Persons infected with SARS-CoV-2 present with a wide range of symptoms similar to other respiratory infections ( e.g. , fever , cough , and shortness of breath ) or may be silent carriers .", "labels": [[88, 111, "DISEASE"], [88, 111, "ENTITY"], [62, 71, "ENTITY"], [136, 153, "ENTITY"], [165, 172, "ENTITY"], [172, 179, "ENTITY"], [136, 153, "DISEASE"], [0, 8, "ENTITY"], [22, 33, "SIMPLE_CHEMICAL"], [22, 33, "ENTITY"], [8, 17, "ENTITY"], [22, 33, "CHEMICAL"]]}
{"text": "The majority ( n = 154 [ 76.6 % ] ) of patients had fever with cough ; 74 ( 36.8 % ) had feverwith dyspnea ; 66 ( 32.8 % ) had feverwith fatigue , myalgia , or headache ; and only 13 ( 6.5 % ) presentedwith fever alone ( eTable 1 in the Supplement ) .", "labels": [[34, 39, "ENTITY"], [89, 99, "DISEASE"], [81, 89, "ENTITY"], [213, 228, "ENTITY"], [89, 99, "ENTITY"], [81, 89, "DISEASE"], [34, 39, "ORGANISM"], [114, 127, "ENTITY"]]}
{"text": "Forty two ( 86 % ) of 49 deceased patients and 58 ( 50 % ) of 117 recovered patients had proteinuria , and 40 ( 82 % ) of 49 deceased patients and 44 ( 38 % ) of 117 recovered patients showed microscopic haematuria .", "labels": [[15, 22, "ENTITY"], [176, 192, "ENTITY"], [76, 89, "ENTITY"], [76, 89, "DISEASE"], [66, 76, "ENTITY"], [59, 66, "ENTITY"], [66, 76, "ORGANISM"], [25, 34, "ENTITY"], [25, 34, "ORGANISM"], [152, 162, "ENTITY"]]}
{"text": "The existence of significantly increased fibrin-degraded products and reduced platelets in severe COVID-19 patients is consistent with the presence of hyper-fibrinolysis .", "labels": [[41, 57, "CHEMICAL"], [139, 148, "ENTITY"], [31, 41, "ENTITY"], [78, 88, "CELL_TYPE"], [91, 98, "ENTITY"], [98, 107, "ENTITY"], [151, 170, "CHEMICAL"], [57, 66, "SO"], [70, 78, "ENTITY"], [4, 14, "ENTITY"], [98, 107, "DISEASE"], [107, 116, "ENTITY"], [41, 66, "ENTITY"], [78, 88, "CELL"], [78, 88, "CL"], [41, 66, "PROTEIN"], [98, 116, "ORGANISM"], [151, 170, "ENTITY"], [78, 88, "ENTITY"], [119, 135, "ENTITY"]]}
{"text": "The existence of significantly increased fibrin-degraded products and reduced platelets in severe COVID-19 patients is consistent with the presence of hyper-fibrinolysis .", "labels": [[139, 148, "ENTITY"], [31, 41, "ENTITY"], [41, 57, "CHEMICAL"], [78, 88, "CELL_TYPE"], [91, 98, "ENTITY"], [98, 107, "ENTITY"], [41, 66, "ENTITY"], [151, 170, "CHEMICAL"], [57, 66, "SO"], [70, 78, "ENTITY"], [4, 14, "ENTITY"], [98, 107, "DISEASE"], [107, 116, "ENTITY"], [78, 88, "CELL"], [78, 88, "CL"], [98, 116, "ORGANISM"], [151, 170, "ENTITY"], [78, 88, "ENTITY"], [41, 66, "PROTEIN"], [119, 135, "ENTITY"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "Patients with hypoxemia should be given oxygen therapy immediately and maintain a blood oxygen saturation level to no less than 90 % in man and non-pregnant women , and between 92 % and 95 % in pregnant women .", "labels": [[40, 47, "CHEMICAL"], [40, 47, "CHEBI"], [14, 24, "DISEASE"], [148, 157, "ORGANISM"], [40, 47, "SIMPLE_CHEMICAL"], [144, 157, "ORGANISM"], [191, 203, "ENTITY"], [40, 55, "ENTITY"], [40, 47, "CHEMICAL"], [0, 9, "ENTITY"], [0, 9, "ORGANISM"], [40, 47, "CHEBI"], [82, 95, "ORGANISM_SUBSTANCE"], [106, 112, "ENTITY"], [82, 106, "ENTITY"], [14, 24, "ENTITY"]]}
{"text": "Through a literature review , we identified a list of important symptoms and mechanisms linked to SARS-CoV-2 , including fever , fatigue , cough 17 , breathing difficulty , septic shock , viral proliferation , immunodeficiency and pulmonary fibrosis 18 ( Figure 4 ) .", "labels": [[145, 160, "ENTITY"], [180, 194, "ENTITY"], [180, 186, "TAXON"], [160, 180, "ENTITY"], [129, 139, "DISEASE"], [231, 241, "DISEASE"], [210, 241, "ENTITY"], [194, 210, "ORGANISM"], [194, 210, "ENTITY"], [241, 255, "ENTITY"], [160, 180, "DISEASE"], [129, 139, "ENTITY"], [111, 121, "DISEASE"], [210, 231, "ORGAN"], [111, 121, "ENTITY"], [10, 28, "ENTITY"]]}
{"text": "On day 2 of life , the infant experienced lethargy and fever , with unremarkable physical examination results , and was moved to the neonatal intensive care unit .", "labels": [[133, 157, "ENTITY"], [3, 7, "ENTITY"], [90, 102, "ENTITY"], [129, 157, "DNA"], [12, 17, "ENTITY"], [68, 90, "ENTITY"]]}
{"text": "He presented with lethargy , vomiting , and fever .", "labels": [[18, 27, "ENTITY"], [18, 27, "DISEASE"]]}
{"text": "Approximately one-quarter ( 46 of 197 [ 23.4 % ] ) of patients had leukocytosis .", "labels": [[49, 54, "ENTITY"], [49, 54, "ORGANISM"]]}
{"text": "Laboratory tests showed leukocytosis , lymphocytopenia , and an elevated creatine kinase \u2013 MB fraction .", "labels": [[0, 17, "ENTITY"], [91, 94, "ENTITY"], [64, 89, "GENE_OR_GENE_PRODUCT"], [24, 37, "DISEASE"], [64, 73, "CHEBI"], [82, 89, "ENTITY"], [24, 37, "ENTITY"], [64, 73, "CHEMICAL"], [64, 82, "ENTITY"]]}
{"text": "Fifty six ( 50 % ) deceased patients and only six ( 4 % ) who recovered developed leukocytosis ( white blood cell count \u226510 \u00d7 109/L ) .", "labels": [[72, 82, "DISEASE"], [82, 109, "ENTITY"], [97, 103, "CELL"], [97, 103, "CL"], [56, 62, "ENTITY"], [72, 82, "ENTITY"], [19, 28, "ENTITY"], [19, 28, "ORGANISM"]]}
{"text": "The majority ( n = 154 [ 76.6 % ] ) of patients had fever with cough ; 74 ( 36.8 % ) had feverwith dyspnea ; 66 ( 32.8 % ) had feverwith fatigue , myalgia , or headache ; and only 13 ( 6.5 % ) presentedwith fever alone ( eTable 1 in the Supplement ) .", "labels": [[34, 39, "ENTITY"], [89, 99, "DISEASE"], [81, 89, "ENTITY"], [213, 228, "ENTITY"], [89, 99, "ENTITY"], [81, 89, "DISEASE"], [34, 39, "ORGANISM"], [114, 127, "ENTITY"]]}
{"text": "Sixty-six ( 32.8 % ) patients had comorbidities , including hypertension ( n = 39 [ 19.4 % ] ) , diabetes ( n = 22 [ 10.9 % ] ) , liver disease ( n = 7 [ 3.5 % ] ) , nervous system disease ( n = 7 [ 3.5 % ] ) , chronic lung disease ( n = 5 [ 2.5 % ] ) , chronic kidney disease ( n = 2 [ 1.0 % ] ) , endocrine system diseases not including diabetes ( n = 2 [ 1.0 % ] ) , and tumors ( n = 1 [ 0.5 % ] ) .", "labels": [[144, 166, "DISEASE"], [75, 79, "ORGAN"], [219, 242, "DISEASE"], [50, 60, "ENTITY"], [136, 158, "DISEASE"], [50, 60, "DISEASE"], [219, 242, "ENTITY"], [136, 146, "ORGAN"], [136, 158, "ENTITY"], [144, 166, "ENTITY"], [254, 285, "ENTITY"]]}
{"text": "About one-third ( 68of 197[34.5 % ] ) of patients had neutrophilia .", "labels": [[6, 16, "ENTITY"]]}
{"text": "Pearson correlation analysis results showed a remarkably positive correlation of MP production and the expression of IL-6 , IL-8 and IL-10 with the severity of COVID-19 ( Table 4 ) .", "labels": [[81, 84, "ENTITY"], [81, 84, "GENE_OR_GENE_PRODUCT"], [0, 29, "ENTITY"], [57, 66, "ENTITY"], [117, 122, "PROTEIN"], [117, 122, "GGP"], [8, 20, "ENTITY"], [117, 122, "ENTITY"], [29, 37, "ENTITY"], [117, 122, "GENE_OR_GENE_PRODUCT"], [103, 114, "ENTITY"], [84, 95, "ENTITY"], [81, 84, "DISEASE"]]}
{"text": "Pearson correlation analysis results showed a remarkably positive correlation of MP production and the expression of IL-6 , IL-8 and IL-10 with the severity of COVID-19 ( Table 4 ) .", "labels": [[117, 122, "GGP"], [81, 84, "ENTITY"], [81, 84, "GENE_OR_GENE_PRODUCT"], [0, 29, "ENTITY"], [117, 122, "PROTEIN"], [57, 66, "ENTITY"], [117, 122, "ENTITY"], [117, 122, "GENE_OR_GENE_PRODUCT"], [8, 20, "ENTITY"], [29, 37, "ENTITY"], [103, 114, "ENTITY"], [84, 95, "ENTITY"], [81, 84, "DISEASE"]]}
{"text": "Pearson correlation analysis results showed a remarkably positive correlation of MP production and the expression of IL-6 , IL-8 and IL-10 with the severity of COVID-19 ( Table 4 ) .", "labels": [[81, 84, "ENTITY"], [81, 84, "GENE_OR_GENE_PRODUCT"], [0, 29, "ENTITY"], [57, 66, "ENTITY"], [117, 122, "PROTEIN"], [117, 122, "GGP"], [8, 20, "ENTITY"], [117, 122, "ENTITY"], [29, 37, "ENTITY"], [117, 122, "GENE_OR_GENE_PRODUCT"], [103, 114, "ENTITY"], [84, 95, "ENTITY"], [81, 84, "DISEASE"]]}
{"text": "Pearson correlation analysis results showed a remarkably positive correlation of MP production and the expression of IL-6 , IL-8 and IL-10 with the severity of COVID-19 ( Table 4 ) .", "labels": [[81, 84, "ENTITY"], [81, 84, "GENE_OR_GENE_PRODUCT"], [0, 29, "ENTITY"], [57, 66, "ENTITY"], [117, 122, "PROTEIN"], [117, 122, "GGP"], [8, 20, "ENTITY"], [117, 122, "ENTITY"], [29, 37, "ENTITY"], [117, 122, "GENE_OR_GENE_PRODUCT"], [103, 114, "ENTITY"], [84, 95, "ENTITY"], [81, 84, "DISEASE"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "Deceased patients more often developed tachycardia and tachypnoea ( respiratory rate \u226524 breaths per minute ) ( 56 ( 50 % ) and 66 ( 58 % ) ) than did recovered patients ( 48 ( 30 % ) and 22 ( 14 % ) ) .", "labels": [[142, 151, "ENTITY"], [9, 18, "ORGANISM"], [39, 51, "ENTITY"], [68, 80, "ENTITY"], [0, 9, "ENTITY"], [55, 66, "DISEASE"], [39, 51, "DISEASE"], [9, 18, "ENTITY"], [55, 66, "ENTITY"]]}
{"text": "Deceased patients more often developed tachycardia and tachypnoea ( respiratory rate \u226524 breaths per minute ) ( 56 ( 50 % ) and 66 ( 58 % ) ) than did recovered patients ( 48 ( 30 % ) and 22 ( 14 % ) ) .", "labels": [[142, 151, "ENTITY"], [9, 18, "ORGANISM"], [39, 51, "DISEASE"], [55, 66, "DISEASE"], [68, 80, "ENTITY"], [0, 9, "ENTITY"], [55, 66, "ENTITY"], [39, 51, "ENTITY"], [9, 18, "ENTITY"]]}
{"text": "Other clinical signs such as reduced appetite , increased respiration rate and hunched posture were transient after the initial challenge .", "labels": [[79, 87, "ENTITY"], [6, 21, "ENTITY"], [37, 46, "CHEMICAL"], [37, 46, "ENTITY"], [29, 37, "ENTITY"]]}
{"text": "He presented with lethargy , vomiting , and fever .", "labels": [[18, 27, "DISEASE"], [18, 27, "ENTITY"]]}
{"text": "With SARS-CoV , animal models showed that infection with the virus downregulated ACE2 expression , generating an inflammatory response correlated with acute lung injury and impaired cardiac contractility [ 26\u201328 ] .", "labels": [[16, 23, "ENTITY"], [126, 135, "ENTITY"], [173, 190, "ENTITY"], [146, 162, "DISEASE"], [110, 126, "ENTITY"], [5, 14, "ORGANISM"], [173, 182, "ORGAN"], [5, 14, "ENTITY"], [151, 157, "ORGAN"], [146, 162, "ENTITY"]]}
{"text": "The leading causes of deaths are ARDS , septic shock with MOF , hemorrhage/coagulopathy ( disseminated intravascular coagulopathy , DIC ) , acute heart/liver/kidney injury , and secondary bacterial infections ( 97 , 101 )", "labels": [[178, 188, "TAXON"], [40, 47, "DISEASE"], [132, 165, "ENTITY"], [117, 132, "ENTITY"], [90, 103, "IMMATERIAL_ANATOMICAL_ENTITY"], [33, 38, "DISEASE"], [178, 198, "DISEASE"], [40, 47, "ENTITY"], [22, 29, "ENTITY"], [90, 117, "DISEASE"], [22, 29, "DISEASE"], [88, 117, "ENTITY"], [117, 132, "DISEASE"], [140, 146, "PATHOLOGICAL_FORMATION"], [33, 38, "ENTITY"], [172, 198, "ENTITY"]]}
{"text": "Consistent with clinical observations , the lungs are the most injured organs , followed by moderate injury in the heart , liver , kidney , and brain .", "labels": [[16, 38, "ENTITY"], [0, 16, "ENTITY"], [123, 131, "ENTITY"], [92, 101, "ENTITY"], [123, 131, "ORGAN"]]}
{"text": "ACE2 is highly expressed in the lung , and Imai14 et al. confirmed the protective effect of ACE2 in acute lung injury .", "labels": [[0, 5, "PROTEIN"], [15, 25, "ENTITY"], [71, 82, "ENTITY"], [100, 111, "ENTITY"], [100, 111, "DISEASE"], [0, 5, "ENTITY"], [32, 37, "ENTITY"], [0, 5, "GGP"], [32, 37, "ORGAN"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "These mice showed increased severity of pathological conditions in acute lung injury .", "labels": [[28, 37, "ENTITY"], [67, 85, "DISEASE"], [18, 28, "ENTITY"], [67, 85, "ENTITY"], [6, 11, "ORGANISM"], [6, 11, "TAXON"], [73, 78, "ORGAN"], [40, 53, "ENTITY"], [6, 11, "ENTITY"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [29, 58, "PROTEIN"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [29, 58, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [29, 58, "PROTEIN"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [29, 58, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"]]}
{"text": "During hospitalization , patients with elevated TnT levels developed more frequent complications ( Table 1 ) , including acute respiratory distress syndrome ( 30 [ 57.7 % ] vs 16 [ 11.9 % ] ) , malignant arrhythmias ( 6 [ 11.5 % ] vs 7 [ 5.2 % ] ) including ventricular tachycardia/ ventricular fibrillation , acute coagulopathy ( 25 [ 65.8 % ] vs 17 [ 20.0 % ] ) , and acute kidney injury ( 14 [ 36.8 % ] vs 4 [ 4.7 % ] ) , compared with those with normal TnT levels .", "labels": [[336, 358, "DISEASE"], [336, 358, "ENTITY"], [345, 351, "ORGAN"], [238, 283, "ENTITY"], [7, 23, "ENTITY"], [258, 270, "DISEASE"], [258, 270, "ENTITY"], [121, 148, "DISEASE"], [238, 283, "DISEASE"], [111, 148, "ENTITY"], [238, 270, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "Infection with these highly pathogenic coronaviruses can result in Acute Respiratory Distress Syndrome ( ARDS ) , which may lead to long-term reduction in lung function , arrhythmia , and death .", "labels": [[152, 160, "ENTITY"], [73, 103, "DISEASE"], [39, 53, "ORGANISM"], [28, 39, "ENTITY"], [132, 142, "ENTITY"], [0, 10, "DISEASE"], [160, 171, "DISEASE"], [39, 53, "ENTITY"], [160, 171, "ENTITY"], [0, 10, "ENTITY"], [67, 103, "ENTITY"], [67, 105, "ORGANISM"]]}
{"text": "According to WHO guidelines , infected patients will receive supportive care including oxygen therapy , fluid therapy , and antibiotics for treating secondary bacterial infections .", "labels": [[17, 28, "ENTITY"], [102, 110, "ENTITY"], [149, 159, "TAXON"], [61, 72, "ENTITY"], [149, 169, "DISEASE"], [140, 149, "ENTITY"], [149, 169, "ENTITY"], [87, 94, "ENTITY"]]}
{"text": "The leading causes of deaths are ARDS , septic shock with MOF , hemorrhage/coagulopathy ( disseminated intravascular coagulopathy , DIC ) , acute heart/liver/kidney injury , and secondary bacterial infections ( 97 , 101 )", "labels": [[178, 188, "TAXON"], [40, 47, "DISEASE"], [132, 165, "ENTITY"], [117, 132, "ENTITY"], [90, 103, "IMMATERIAL_ANATOMICAL_ENTITY"], [33, 38, "DISEASE"], [178, 198, "DISEASE"], [40, 47, "ENTITY"], [22, 29, "ENTITY"], [90, 117, "DISEASE"], [22, 29, "DISEASE"], [88, 117, "ENTITY"], [117, 132, "DISEASE"], [140, 146, "PATHOLOGICAL_FORMATION"], [33, 38, "ENTITY"], [172, 198, "ENTITY"]]}
{"text": "He also had suspected sepsis , with an Enterobacter agglomerates\u2013 positive blood culture , leukocytosis , thrombocytopenia ( 11 cells \u00d7 103/\u03bcL ; to convert to cells \u00d7 109/L , multiply by 1.0 ) , and coagulopathy ( prothrombin time , 21 seconds ; activated partial thromboplastin time , 81.9 seconds ) , which improved with antibiotic treatment .", "labels": [[246, 264, "PROTEIN"], [191, 199, "ENTITY"], [148, 159, "CELL"], [148, 159, "CL"], [246, 264, "GENE_OR_GENE_PRODUCT"], [309, 323, "ENTITY"], [22, 29, "ENTITY"], [148, 159, "ENTITY"], [309, 318, "CHEBI"], [39, 52, "ENTITY"], [22, 29, "DISEASE"], [199, 214, "ENTITY"], [199, 214, "GENE_OR_GENE_PRODUCT"], [12, 22, "ENTITY"], [236, 264, "ENTITY"], [191, 199, "DISEASE"]]}
{"text": "He also had suspected sepsis , with an Enterobacter agglomerates\u2013 positive blood culture , leukocytosis , thrombocytopenia ( 11 cells \u00d7 103/\u03bcL ; to convert to cells \u00d7 109/L , multiply by 1.0 ) , and coagulopathy ( prothrombin time , 21 seconds ; activated partial thromboplastin time , 81.9 seconds ) , which improved with antibiotic treatment .", "labels": [[246, 264, "PROTEIN"], [191, 199, "ENTITY"], [148, 159, "CELL"], [148, 159, "CL"], [246, 264, "GENE_OR_GENE_PRODUCT"], [309, 323, "ENTITY"], [22, 29, "ENTITY"], [148, 159, "ENTITY"], [309, 318, "CHEBI"], [39, 52, "ENTITY"], [22, 29, "DISEASE"], [199, 214, "ENTITY"], [199, 214, "GENE_OR_GENE_PRODUCT"], [12, 22, "ENTITY"], [236, 264, "ENTITY"], [191, 199, "DISEASE"]]}
{"text": "During hospitalization , patients with elevated TnT levels developed more frequent complications ( Table 1 ) , including acute respiratory distress syndrome ( 30 [ 57.7 % ] vs 16 [ 11.9 % ] ) , malignant arrhythmias ( 6 [ 11.5 % ] vs 7 [ 5.2 % ] ) including ventricular tachycardia/ ventricular fibrillation , acute coagulopathy ( 25 [ 65.8 % ] vs 17 [ 20.0 % ] ) , and acute kidney injury ( 14 [ 36.8 % ] vs 4 [ 4.7 % ] ) , compared with those with normal TnT levels .", "labels": [[336, 358, "DISEASE"], [336, 358, "ENTITY"], [345, 351, "ORGAN"], [238, 283, "ENTITY"], [7, 23, "ENTITY"], [258, 270, "DISEASE"], [258, 270, "ENTITY"], [121, 148, "DISEASE"], [238, 283, "DISEASE"], [111, 148, "ENTITY"], [238, 270, "MULTI-TISSUE_STRUCTURE"]]}
{"text": "All patients with severe COVID-19 should be screened for hyperinflammation using laboratory trends ( eg , increasing ferritin , decreasing platelet counts , or erythrocyte sedimentation rate ) and the HScore [ 11 ] ( table ) to identify the subgroup of patients for whom immunosuppression could improve mortality .", "labels": [[25, 34, "GENE_OR_GENE_PRODUCT"], [18, 25, "ENTITY"], [106, 117, "CHEBI"], [25, 34, "DISEASE"], [81, 99, "ENTITY"], [57, 75, "DISEASE"], [262, 271, "ENTITY"], [128, 139, "CELL"], [241, 253, "ORGANISM"], [271, 289, "ENTITY"], [4, 13, "ENTITY"], [106, 117, "ENTITY"], [128, 148, "ENTITY"], [128, 139, "CL"], [106, 117, "PROTEIN"], [106, 117, "GENE_OR_GENE_PRODUCT"], [25, 34, "ENTITY"], [228, 241, "ENTITY"], [157, 186, "ENTITY"], [295, 303, "ENTITY"], [57, 75, "ENTITY"], [241, 253, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "The leading causes of deaths are ARDS , septic shock with MOF , hemorrhage/coagulopathy ( disseminated intravascular coagulopathy , DIC ) , acute heart/liver/kidney injury , and secondary bacterial infections ( 97 , 101 )", "labels": [[178, 188, "TAXON"], [40, 47, "DISEASE"], [132, 165, "ENTITY"], [117, 132, "ENTITY"], [90, 103, "IMMATERIAL_ANATOMICAL_ENTITY"], [33, 38, "DISEASE"], [178, 198, "DISEASE"], [40, 47, "ENTITY"], [22, 29, "ENTITY"], [90, 117, "DISEASE"], [22, 29, "DISEASE"], [88, 117, "ENTITY"], [117, 132, "DISEASE"], [140, 146, "PATHOLOGICAL_FORMATION"], [33, 38, "ENTITY"], [172, 198, "ENTITY"]]}
{"text": "Consistent with clinical observations , the lungs are the most injured organs , followed by moderate injury in the heart , liver , kidney , and brain .", "labels": [[16, 38, "ENTITY"], [0, 16, "ENTITY"], [123, 131, "ENTITY"], [92, 101, "ENTITY"], [123, 131, "ORGAN"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [29, 58, "PROTEIN"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [29, 58, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [29, 58, "PROTEIN"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [29, 58, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"]]}
{"text": "Hypertension , cardiovascular disease , and cerebrovascular disease were much more frequent among deceased patients ( 54 ( 48 % ) , 16 ( 14 % ) , and 4 ( 4 % ) ) than among recovered patients ( 39 ( 24 % ) , 7 ( 4 % ) , and 0 ( 0 % ) ) .", "labels": [[40, 60, "ENTITY"], [98, 107, "ENTITY"], [15, 30, "DISEASE"], [158, 167, "ENTITY"], [0, 13, "DISEASE"], [0, 13, "ENTITY"], [40, 60, "DISEASE"], [15, 30, "ENTITY"], [98, 107, "ORGANISM"]]}
{"text": "Comorbidities , including diabetes mellitus , cardiovascular and cerebrovascular diseases , were found in 4 and 5 of the patients from the DIP and control group , respectively .", "labels": [[26, 35, "DISEASE"], [0, 14, "ENTITY"], [143, 155, "ENTITY"], [26, 35, "ENTITY"], [61, 81, "ENTITY"], [44, 81, "DISEASE"]]}
{"text": "Patients with underlying CVD were more likely to exhibit elevation of TnT levels ( 36 [ 54.5 % ] ) compared with patients without CVD ( 16 [ 13.2 % ] ) .", "labels": [[57, 67, "ENTITY"], [25, 29, "ENTITY"], [74, 81, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "ORGANISM"], [70, 74, "GENE_OR_GENE_PRODUCT"], [70, 74, "ENTITY"], [70, 74, "PROTEIN"]]}
{"text": "Most COVID-19 patients initially suffered from fever , cough , fatigue , and shortness of breath , while other symptoms included muscle pain , headache , chest pain , and diarrhea , similar to the symptoms observed after chemotherapy , targeted and immune therapy1", "labels": [[73, 90, "ENTITY"], [136, 143, "DISEASE"], [143, 154, "DISEASE"], [120, 136, "DISEASE"], [120, 136, "ENTITY"], [47, 53, "ENTITY"], [206, 221, "ENTITY"], [14, 23, "ENTITY"], [5, 14, "ENTITY"], [5, 23, "ORGANISM"], [71, 77, "DISEASE"], [236, 256, "CELL"], [5, 14, "DISEASE"], [73, 90, "DISEASE"], [143, 154, "ORGAN"], [221, 236, "ENTITY"], [236, 256, "ENTITY"], [71, 77, "ENTITY"], [190, 197, "ENTITY"], [111, 120, "ENTITY"], [120, 129, "ORGAN"], [47, 53, "DISEASE"], [143, 154, "ENTITY"], [136, 143, "ENTITY"]]}
{"text": "Small vessels showed hyperplasia , vessel wall thickening , lumen stenosis , occlusion and focal hemorrhage .", "labels": [[0, 14, "MULTI-TISSUE_STRUCTURE"], [21, 33, "DISEASE"], [0, 14, "ENTITY"], [35, 47, "ENTITY"], [6, 13, "MULTI-TISSUE_STRUCTURE"], [87, 97, "ENTITY"], [58, 66, "ENTITY"], [75, 97, "DISEASE"], [21, 33, "ENTITY"], [58, 66, "DISEASE"], [21, 33, "CANCER"]]}
{"text": "Patients with elevated TnT levels had significantly higher rates of comorbidities including hypertension ( 33 [ 63.5 % ] vs 28 [ 20.7 % ] ) , coronary heart disease ( 17 [ 32.7 % ] vs4[3.0 % ] ) , cardiomyopathy ( 8[15.4%]vs0 ) , diabetes ( 16 [ 30.8 % ] vs 12 [ 8.9 % ] ) , chronic obstructive pulmonary disease ( 4 [ 7.7 % ] vs 0 ) , and chronic kidney disease ( 1 [ 0.7 % ] vs 5 [ 9.6 % ] ) .", "labels": [[23, 27, "ENTITY"], [14, 23, "ENTITY"], [246, 283, "ENTITY"], [181, 195, "ENTITY"], [27, 34, "ENTITY"], [134, 151, "DISEASE"], [92, 105, "ENTITY"], [197, 214, "ENTITY"], [68, 82, "ENTITY"], [23, 27, "PROTEIN"], [246, 283, "DISEASE"], [0, 9, "ORGANISM"], [134, 151, "ENTITY"], [305, 327, "ENTITY"], [197, 214, "DISEASE"], [59, 65, "ENTITY"], [0, 9, "ENTITY"], [92, 105, "DISEASE"], [23, 27, "GENE_OR_GENE_PRODUCT"], [181, 195, "DISEASE"], [305, 327, "DISEASE"]]}
{"text": "Small vessels showed hyperplasia , vessel wall thickening , lumen stenosis , occlusion and focal hemorrhage .", "labels": [[0, 14, "MULTI-TISSUE_STRUCTURE"], [21, 33, "DISEASE"], [0, 14, "ENTITY"], [35, 47, "ENTITY"], [6, 13, "MULTI-TISSUE_STRUCTURE"], [87, 97, "ENTITY"], [58, 66, "ENTITY"], [75, 97, "DISEASE"], [21, 33, "ENTITY"], [58, 66, "DISEASE"], [21, 33, "CANCER"]]}
{"text": "Taken together , coronavirus infection results in : ( 1 ) massive morphological rearrangement of the ER ; ( 2 ) significant increase ER burden for protein synthesis , folding and modification ; and ( 3 ) extensive depletion of ER lipid component . These factors together may contribute to the coronavirus-induced ER stress .", "labels": [[124, 136, "ENTITY"], [136, 155, "ENTITY"], [17, 29, "ENTITY"], [112, 124, "ENTITY"], [236, 248, "ENTITY"], [275, 293, "ENTITY"], [17, 29, "DISEASE"], [194, 202, "ENTITY"], [214, 224, "GENE_OR_GENE_PRODUCT"], [155, 167, "ENTITY"], [58, 66, "ENTITY"], [167, 179, "ENTITY"], [214, 230, "PROTEIN"], [136, 147, "CHEBI"], [167, 179, "SO"]]}
{"text": "Taken together , coronavirus infection results in : ( 1 ) massive morphological rearrangement of the ER ; ( 2 ) significant increase ER burden for protein synthesis , folding and modification ; and ( 3 ) extensive depletion of ER lipid component . These factors together may contribute to the coronavirus-induced ER stress .", "labels": [[124, 136, "ENTITY"], [136, 155, "ENTITY"], [17, 29, "ENTITY"], [112, 124, "ENTITY"], [236, 248, "ENTITY"], [275, 293, "ENTITY"], [17, 29, "DISEASE"], [194, 202, "ENTITY"], [214, 224, "GENE_OR_GENE_PRODUCT"], [155, 167, "ENTITY"], [58, 66, "ENTITY"], [167, 179, "ENTITY"], [214, 230, "PROTEIN"], [136, 147, "CHEBI"], [167, 179, "SO"]]}
{"text": "Taken together , coronavirus infection results in : ( 1 ) massive morphological rearrangement of the ER ; ( 2 ) significant increase ER burden for protein synthesis , folding and modification ; and ( 3 ) extensive depletion of ER lipid component . These factors together may contribute to the coronavirus-induced ER stress .", "labels": [[124, 136, "ENTITY"], [136, 155, "ENTITY"], [17, 29, "ENTITY"], [112, 124, "ENTITY"], [236, 248, "ENTITY"], [275, 293, "ENTITY"], [17, 29, "DISEASE"], [194, 202, "ENTITY"], [214, 224, "GENE_OR_GENE_PRODUCT"], [155, 167, "ENTITY"], [58, 66, "ENTITY"], [167, 179, "ENTITY"], [214, 230, "PROTEIN"], [136, 147, "CHEBI"], [167, 179, "SO"]]}
{"text": "Taken together , coronavirus infection results in : ( 1 ) massive morphological rearrangement of the ER ; ( 2 ) significant increase ER burden for protein synthesis , folding and modification ; and ( 3 ) extensive depletion of ER lipid component . These factors together may contribute to the coronavirus-induced ER stress .", "labels": [[124, 136, "ENTITY"], [136, 155, "ENTITY"], [17, 29, "ENTITY"], [112, 124, "ENTITY"], [236, 248, "ENTITY"], [275, 293, "ENTITY"], [17, 29, "DISEASE"], [194, 202, "ENTITY"], [214, 224, "GENE_OR_GENE_PRODUCT"], [155, 167, "ENTITY"], [58, 66, "ENTITY"], [167, 179, "ENTITY"], [214, 230, "PROTEIN"], [136, 147, "CHEBI"], [167, 179, "SO"]]}
{"text": "Taken together , IRE1 may modulate IBV-induced apoptosis and serve as a survival factor during coronavirus infection .", "labels": [[88, 107, "ENTITY"], [70, 81, "ENTITY"], [88, 107, "DISEASE"], [26, 47, "ENTITY"], [26, 35, "GENE_OR_GENE_PRODUCT"]]}
{"text": "For this , both ACE and AII have been widely exploited as pharmacological targets in the treatment of hypertension , heart failure or diabetic nephropathy by means of ACE inhibitors and AII receptor antagonists , respectively [ 1 ] .", "labels": [[182, 199, "GENE_OR_GENE_PRODUCT"], [16, 20, "CHEBI"], [115, 123, "DISEASE"], [164, 171, "ENTITY"], [131, 143, "DISEASE"], [20, 28, "GGP"], [115, 123, "ENTITY"], [131, 143, "ENTITY"], [182, 199, "ENTITY"]]}
{"text": "The leading causes of deaths are ARDS , septic shock with MOF , hemorrhage/coagulopathy ( disseminated intravascular coagulopathy , DIC ) , acute heart/liver/kidney injury , and secondary bacterial infections ( 97 , 101 )", "labels": [[178, 188, "TAXON"], [40, 47, "DISEASE"], [132, 165, "ENTITY"], [117, 132, "ENTITY"], [88, 117, "ENTITY"], [33, 38, "DISEASE"], [178, 198, "DISEASE"], [40, 47, "ENTITY"], [22, 29, "ENTITY"], [22, 29, "DISEASE"], [90, 117, "DISEASE"], [90, 103, "IMMATERIAL_ANATOMICAL_ENTITY"], [117, 132, "DISEASE"], [140, 146, "PATHOLOGICAL_FORMATION"], [33, 38, "ENTITY"], [172, 198, "ENTITY"]]}
{"text": "KEGG pathway enrichment analysis revealed multiple significant biological pathways ( adjusted P value < 0.05 ) , including measles , RNA transport , NF-kappa B signaling , Epstein-Barr virus infection , and influenza ( Fig. 3b ) . Gene ontology ( GO ) biological process enrichment analysis further confirmed multiple viral infection-related processes ( adjusted P value < 0.001 ) , including viral life cycle , modulation by virus of host morphology or physiology , viral process , positive regulation of viral life cycle , transport of virus , and virion attachment to host cell ( Fig. 3c ) .", "labels": [[416, 427, "ENTITY"], [139, 151, "GENE_OR_GENE_PRODUCT"], [238, 254, "ENTITY"], [221, 226, "SO"], [139, 149, "ENTITY"], [162, 193, "DISEASE"], [301, 311, "TAXON"], [139, 151, "PROTEIN"], [162, 193, "ENTITY"], [174, 187, "TAXON"], [439, 444, "ENTITY"], [125, 135, "SO"], [408, 416, "ENTITY"], [477, 487, "ENTITY"], [320, 326, "ENTITY"], [427, 439, "ENTITY"], [221, 233, "ENTITY"], [125, 139, "ENTITY"], [115, 125, "DISEASE"], [162, 187, "ORGANISM"], [111, 125, "ENTITY"], [0, 13, "ENTITY"], [63, 83, "ENTITY"], [554, 561, "CL"], [416, 427, "TAXON"], [203, 209, "ENTITY"], [115, 125, "ENTITY"], [408, 416, "TAXON"], [24, 33, "ENTITY"], [115, 125, "ORGANISM"], [301, 326, "ENTITY"], [554, 561, "ENTITY"], [139, 162, "ENTITY"], [469, 477, "ENTITY"], [554, 561, "CELL"], [397, 408, "ENTITY"], [487, 507, "ENTITY"], [542, 550, "ENTITY"], [487, 496, "TAXON"]]}
{"text": "Extracorporeal membrane oxygenation was performed in 5 patients ( 0.5 % ) with severe disease .", "labels": [[0, 36, "ENTITY"], [15, 24, "GO"], [55, 64, "ORGANISM"], [74, 86, "ENTITY"], [55, 64, "ENTITY"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [29, 58, "PROTEIN"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [29, 58, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [29, 58, "PROTEIN"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [29, 58, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"]]}
{"text": "After uncoating , the genomic RNA first acts as an mRNA for translation of the replicase polyprotein .", "labels": [[79, 89, "PROTEIN"], [22, 30, "SO"], [79, 89, "ENTITY"], [6, 16, "ENTITY"], [22, 30, "RNA"], [22, 30, "ENTITY"]]}
{"text": "The N proteins are translated in the cytoplasm and encapsidate the nascent progeny genomic RNA to form the nucleocapsids .", "labels": [[75, 83, "ENTITY"], [83, 95, "ENTITY"], [37, 47, "GO"], [67, 75, "ENTITY"], [37, 47, "ORGANISM_SUBSTANCE"], [107, 121, "ENTITY"], [4, 15, "PROTEIN"], [37, 47, "ENTITY"], [51, 63, "ENTITY"], [83, 95, "SO"], [4, 15, "ENTITY"], [107, 121, "TISSUE"], [6, 15, "CHEBI"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ENTITY"], [133, 141, "DISEASE"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "For this , both ACE and AII have been widely exploited as pharmacological targets in the treatment of hypertension , heart failure or diabetic nephropathy by means of ACE inhibitors and AII receptor antagonists , respectively [ 1 ] .", "labels": [[182, 199, "GENE_OR_GENE_PRODUCT"], [16, 20, "CHEBI"], [164, 171, "ENTITY"], [115, 123, "DISEASE"], [131, 143, "ENTITY"], [20, 28, "GGP"], [131, 143, "DISEASE"], [115, 123, "ENTITY"], [182, 199, "ENTITY"]]}
{"text": "All patients had pneumonia . Common complications included ARDS ( 12 [ 29 % ] of 41 patients ) , followed by RNAaemia ( six [ 15 % ] patients ) , acute cardiac injury ( five [ 12 % ] patients ) , and secondary infection ( four [ 10 % ] patients ; table 3 ) .", "labels": [[210, 222, "ORGANISM"], [97, 109, "ENTITY"], [17, 27, "DISEASE"], [97, 109, "PROTEIN"], [78, 84, "ORGANISM"], [97, 109, "GENE_OR_GENE_PRODUCT"], [120, 131, "ENTITY"], [17, 27, "ENTITY"], [78, 84, "ENTITY"], [181, 200, "ENTITY"], [120, 131, "ORGANISM"], [167, 174, "ENTITY"], [4, 13, "ENTITY"], [84, 97, "ORGAN"], [133, 152, "DISEASE"], [167, 174, "ORGANISM"], [181, 200, "DISEASE"], [133, 152, "ENTITY"], [210, 222, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Consistent with clinical observations , the lungs are the most injured organs , followed by moderate injury in the heart , liver , kidney , and brain .", "labels": [[16, 38, "ENTITY"], [0, 16, "ENTITY"], [123, 131, "ENTITY"], [92, 101, "ENTITY"], [123, 131, "ORGAN"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "ACE2 in the gastrointestinal tract may underly early gastrointestinal symptoms such as nausea , vomiting , and diarrhea , and ACE2 in the heart may be related to cardiac damage and fulminant myocarditis that have been reported in COVID-19 [ 14,15 ] .", "labels": [[12, 35, "ORGAN"], [87, 94, "DISEASE"], [12, 29, "ORGAN"], [87, 94, "ENTITY"], [0, 5, "PROTEIN"], [177, 191, "ENTITY"], [12, 35, "DISEASE"], [159, 170, "ENTITY"], [12, 35, "ENTITY"], [0, 5, "ENTITY"], [159, 170, "DISEASE"], [177, 191, "DISEASE"], [227, 241, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [53, 79, "ENTITY"], [53, 79, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "ACE2 has a well-recognized role in myocardial recovery and injury response ; in one study , ACE2 knockout in animal models contributed to adverse left ventricular remodeling in response to acute injury driven by angiotensin II.55", "labels": [[35, 46, "ENTITY"], [106, 116, "ENTITY"], [0, 5, "ENTITY"], [0, 5, "GGP"], [0, 5, "ENTITY"], [59, 66, "ENTITY"], [186, 195, "DISEASE"], [135, 163, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [138, 151, "MULTI-TISSUE_STRUCTURE"], [35, 46, "MULTI-TISSUE_STRUCTURE"], [46, 55, "ENTITY"], [209, 224, "TISSUE"], [0, 5, "PROTEIN"], [66, 75, "ENTITY"], [186, 195, "ENTITY"]]}
{"text": "Common complications observed in deceased patients included acute respiratory distress syndrome ( 113 ; 100 % ) , type I respiratory failure ( 18/35 ; 51 % ) , sepsis ( 113 ; 100 % ) , acute cardiac injury ( 72/94 ; 77 % ) , heart failure ( 41/83 ; 49 % ) , shock ( 46 ; 41 % ) , alkalosis ( 14/35 ; 40 % ) , hyperkalaemia ( 42 ; 37 % ) , acute kidney injury ( 28 ; 25 % ) , and hypoxic encephalopathy ( 23 ; 20 % ) .", "labels": [[110, 133, "ENTITY"], [169, 191, "ENTITY"], [335, 352, "ENTITY"], [0, 7, "ENTITY"], [133, 141, "DISEASE"], [42, 51, "ENTITY"], [175, 191, "DISEASE"], [7, 21, "ENTITY"], [66, 96, "DISEASE"], [60, 96, "ENTITY"], [133, 141, "ENTITY"], [42, 51, "ORGANISM"], [335, 352, "DISEASE"], [33, 42, "ENTITY"], [114, 133, "DISEASE"]]}
{"text": "When compared with mild and common COVID-19 , initial univariate analysis of epidemiological , clinical and laboratory variables identified 11 significantly changed risk factors for severe/critical COVID-19 , including increased ORs of age , age \u226550 years , period between illness onset and hospital visit , sputum production , any existing medical condition , multiple lung infection , ALT , lactate dehydrogenase ( LDH ) , glucose and CRP , as well as decreased OR of the infected area ( online supplementary table 1 ) .", "labels": [[375, 401, "ENTITY"], [375, 401, "PROTEIN"], [236, 242, "ENTITY"], [441, 446, "ENTITY"], [401, 417, "CHEBI"], [273, 281, "ENTITY"], [5, 14, "ENTITY"], [54, 65, "ENTITY"], [209, 219, "ENTITY"], [401, 417, "SIMPLE_CHEMICAL"], [19, 24, "ENTITY"], [349, 375, "ENTITY"], [236, 240, "GENE_OR_GENE_PRODUCT"], [401, 417, "ENTITY"], [300, 315, "ENTITY"], [250, 258, "ENTITY"], [35, 44, "ENTITY"], [375, 401, "GENE_OR_GENE_PRODUCT"], [332, 349, "ENTITY"], [474, 497, "ENTITY"], [375, 401, "GGP"], [454, 467, "ENTITY"], [236, 240, "CHEMICAL"], [219, 229, "PROTEIN"], [349, 375, "DISEASE"], [104, 119, "ENTITY"], [300, 308, "TISSUE"], [157, 170, "ENTITY"], [287, 300, "ENTITY"], [35, 44, "GENE_OR_GENE_PRODUCT"], [375, 391, "CHEMICAL"], [178, 198, "ENTITY"], [401, 417, "CHEMICAL"], [219, 229, "ENTITY"]]}
{"text": "At the later stages , diffuse alveolar damage ( DAD ) is observed in addition to hemorrhage and some areas of interstitial fibrosis ( 48 ) .", "labels": [[30, 39, "DISEASE"], [22, 39, "ENTITY"], [107, 123, "ENTITY"], [13, 20, "ENTITY"], [107, 123, "DISEASE"]]}
{"text": "Critically , this injury was attenuated by blocking the renin- angiotensin pathway and depended on ACE2 expression [ 12 ] .", "labels": [[0, 11, "ENTITY"], [56, 75, "ENTITY"], [56, 63, "GENE_OR_GENE_PRODUCT"]]}
{"text": "This suggests that excessive ACE2 may competitively bind with SARS- CoV-2 not only to neutralize the virus but also rescue cellular ACE2 activity which negatively regulates the renin-angiotensin system ( RAS ) to protect the lung from injury [ 12 , 30 ] .", "labels": [[62, 74, "ENTITY"], [123, 137, "CELL"], [116, 123, "ENTITY"], [29, 34, "ENTITY"], [86, 97, "ENTITY"], [101, 107, "TAXON"], [177, 202, "GENE_OR_GENE_PRODUCT"], [177, 202, "ENTITY"], [137, 146, "ENTITY"], [123, 132, "ENTITY"], [29, 34, "PROTEIN"], [38, 52, "ENTITY"], [101, 107, "ENTITY"], [62, 74, "PROTEIN"], [163, 173, "ENTITY"], [62, 74, "ORGANISM"], [19, 29, "ENTITY"], [29, 34, "GENE_OR_GENE_PRODUCT"], [52, 57, "ENTITY"], [29, 34, "PROTEIN"], [29, 34, "ENTITY"], [29, 34, "GGP"], [123, 137, "CL"]]}
{"text": "Critically , this injury was attenuated by blocking the renin- angiotensin pathway and depended on ACE2 expression [ 12 ] .", "labels": [[0, 11, "ENTITY"], [56, 63, "GENE_OR_GENE_PRODUCT"], [56, 75, "ENTITY"]]}
{"text": "Kuba et al. [ 10 ] demonstrated in mice that SARS-CoV downregulates ACE2 protein ( but not ACE ) by binding its spike protein , contributing to severe lung injury .", "labels": [[54, 73, "PROTEIN"], [108, 118, "PROTEIN"], [144, 156, "ENTITY"], [54, 73, "GGP"], [45, 54, "ENTITY"], [112, 118, "CHEBI"], [144, 156, "DISEASE"], [54, 73, "ENTITY"], [128, 144, "ENTITY"], [144, 151, "ORGAN"], [54, 68, "GENE_OR_GENE_PRODUCT"], [108, 118, "ENTITY"]]}
{"text": "Thus , for SARS-CoV pathogenesis , ACE2 is not only the entry receptor of the virus but also protects from lung injury .", "labels": [[52, 62, "ENTITY"], [102, 112, "ENTITY"], [102, 112, "DISEASE"]]}
{"text": "Indeed , enhanced ACE activity and decreased ACE2 availability contribute to lung injury during acid- and ventilator-induced lung injury [ 12 , 31 , 32 ] .", "labels": [[106, 130, "ENTITY"], [96, 102, "ENTITY"], [77, 82, "DISEASE"], [77, 82, "ENTITY"], [106, 130, "DISEASE"]]}
{"text": "Thus , treatment with a soluble form of ACE2 itself may exert dual functions : ( 1 ) slow viral entry into cells and hence viral spread [ 7 , 9 ] and ( 2 ) protect the lung from injury [ 10 , 12 , 31 , 32 ]", "labels": [[85, 90, "TAXON"], [168, 173, "ENTITY"], [117, 129, "ENTITY"], [156, 164, "ENTITY"], [156, 164, "ORGAN"], [62, 67, "ENTITY"], [85, 96, "ENTITY"]]}
{"text": "Therefore , higher ACE2 expression following chronically medicating SARS-CoV-2 infected patients with AT1R blockers , while seemingly paradoxical , may protect them against acute lung injury rather than putting them at higher risk to develop SARS .", "labels": [[234, 242, "ENTITY"], [234, 242, "DISEASE"], [124, 134, "ENTITY"], [102, 107, "GGP"], [165, 184, "DISEASE"], [102, 107, "ENTITY"], [12, 19, "ENTITY"], [45, 57, "ENTITY"], [173, 179, "ORGAN"], [102, 107, "GENE_OR_GENE_PRODUCT"], [165, 184, "ENTITY"]]}
{"text": "We therefore previously suggested that in contrast to most other coronaviruses , SARS-CoV became highly lethal because the virus deregulates a lung protective pathway [ 10 , 12 ] .", "labels": [[65, 79, "ENTITY"], [143, 159, "ENTITY"], [65, 79, "PROTEIN"], [65, 79, "ORGANISM"]]}
{"text": "Indeed , enhanced ACE activity and decreased ACE2 availability contribute to lung injury during acid- and ventilator-induced lung injury [ 12 , 31 , 32 ] .", "labels": [[106, 130, "ENTITY"], [96, 102, "ENTITY"], [77, 82, "DISEASE"], [77, 82, "ENTITY"], [106, 130, "DISEASE"]]}
{"text": "This in turn contributes to lung injury , as angiotensin-stimulated AT1R results in increased pulmonary vascular permeability , thereby mediating increased lung pathology ( Imai et al. , 2005 ; Kuba et al. , 2005 ) .", "labels": [[136, 146, "ENTITY"], [28, 40, "ENTITY"], [94, 113, "ENTITY"], [28, 40, "DISEASE"], [28, 33, "ORGAN"], [94, 104, "MULTI-TISSUE_STRUCTURE"], [146, 161, "ENTITY"], [84, 94, "ORGAN"]]}
{"text": "The damaged cells induce innate inflammation in the lungs that is largely mediated by pro-inflammatory macrophages and granulocytes . Lung inflammation is the main cause of life-threatening respiratory disorders at the severe stage [ 4 ] .", "labels": [[86, 115, "ENTITY"], [4, 18, "CELL_TYPE"], [103, 115, "CELL"], [119, 132, "ENTITY"], [134, 139, "ENTITY"], [190, 202, "DISEASE"], [219, 226, "ENTITY"], [4, 18, "ENTITY"], [12, 18, "CELL"], [119, 132, "CELL"], [18, 25, "ENTITY"], [52, 58, "ENTITY"], [52, 58, "ORGAN"], [190, 202, "ENTITY"], [119, 132, "CELL_TYPE"], [25, 45, "ENTITY"], [12, 18, "CL"], [32, 45, "DISEASE"], [86, 115, "CL"], [119, 132, "CL"], [86, 115, "CELL_TYPE"]]}
{"text": "The damaged cells induce innate inflammation in the lungs that is largely mediated by pro-inflammatory macrophages and granulocytes . Lung inflammation is the main cause of life-threatening respiratory disorders at the severe stage [ 4 ] .", "labels": [[4, 18, "CELL_TYPE"], [103, 115, "CELL"], [86, 115, "CELL_TYPE"], [119, 132, "CELL_TYPE"], [134, 139, "ENTITY"], [190, 202, "DISEASE"], [219, 226, "ENTITY"], [4, 18, "ENTITY"], [119, 132, "CELL"], [12, 18, "CELL"], [18, 25, "ENTITY"], [52, 58, "ENTITY"], [52, 58, "ORGAN"], [86, 115, "ENTITY"], [190, 202, "ENTITY"], [119, 132, "CL"], [119, 132, "ENTITY"], [25, 45, "ENTITY"], [12, 18, "CL"], [32, 45, "DISEASE"], [86, 115, "CL"]]}
{"text": "The innate immune response to tissue damage caused by the virus could lead to acute respiratory distress syndrome ( ARDS ) , in which respiratory failure is characterized by the rapid onset of widespread inflammation in the lungs and subsequent fatality [ 4 ] .", "labels": [[78, 114, "ENTITY"], [234, 245, "ENTITY"], [58, 64, "TAXON"], [84, 114, "DISEASE"], [30, 44, "DISEASE"], [30, 37, "TISSUE"], [128, 146, "ENTITY"], [30, 44, "ENTITY"], [128, 146, "DISEASE"], [193, 204, "DISEASE"], [193, 204, "ENTITY"], [58, 64, "ENTITY"], [4, 27, "ENTITY"]]}
{"text": "Consistent with clinical observations , the lungs are the most injured organs , followed by moderate injury in the heart , liver , kidney , and brain .", "labels": [[16, 38, "ENTITY"], [0, 16, "ENTITY"], [123, 131, "ENTITY"], [92, 101, "ENTITY"], [123, 131, "ORGAN"]]}
{"text": "ARDS(acute respiratory distress syndrome)is the most severe form of acute lung injury .", "labels": [[0, 32, "ENTITY"], [74, 79, "ORGAN"], [32, 44, "GENE_OR_GENE_PRODUCT"], [68, 86, "ENTITY"], [53, 60, "ENTITY"], [68, 86, "DISEASE"]]}
{"text": "But in the severe patients , the neutrophil count , D-dimer , blood urea , and creatinine levels were higher significantly , and the lymphocyte counts continued to decrease .", "labels": [[11, 18, "ENTITY"], [60, 68, "GGP"], [60, 68, "DISEASE"], [33, 44, "ENTITY"], [18, 27, "ENTITY"], [60, 68, "ENTITY"], [18, 27, "ORGANISM"], [79, 90, "ENTITY"], [60, 68, "ORGANISM_SUBSTANCE"], [151, 164, "ENTITY"], [133, 144, "ENTITY"]]}
{"text": "Both WBC and neutrophil counts were significantly higher in severe cases than moderate cases . Whereas lymphocyte counts were significantly lower in severe cases ( 0.7 \u00d7 109/L ) than moderate cases ( 1.1 \u00d7 109/L ) .", "labels": [[62, 69, "ENTITY"], [105, 116, "CL"], [5, 9, "PROTEIN"], [5, 9, "GO"], [26, 33, "ENTITY"], [80, 89, "ENTITY"], [15, 26, "ENTITY"], [105, 116, "CELL"], [62, 69, "ENTITY"], [105, 116, "ENTITY"], [69, 75, "ENTITY"], [69, 75, "ENTITY"], [15, 26, "CL"], [5, 9, "ENTITY"], [80, 89, "ENTITY"], [26, 33, "ENTITY"], [5, 9, "SIMPLE_CHEMICAL"], [15, 26, "CELL_TYPE"], [69, 75, "ENTITY"], [15, 26, "CELL"]]}
{"text": "Once SpO2 < 93 % , RR > 30/min , HR > 120/min or any signs of organ failure were observed , patients would be transferred to intensive care unit ( ICU ) and ICU physicians and nurses would take over their treatment .", "labels": [[5, 10, "ENTITY"], [134, 152, "ENTITY"], [71, 80, "DISEASE"], [152, 157, "ENTITY"], [93, 104, "ORGANISM"], [163, 173, "ENTITY"], [39, 44, "ENTITY"], [173, 188, "ENTITY"], [71, 80, "ENTITY"], [93, 104, "ENTITY"]]}
{"text": "Patient 6 presented with pleural effusions .", "labels": [[25, 43, "DISEASE"], [25, 43, "CANCER"], [25, 43, "ENTITY"], [0, 8, "ORGANISM"], [0, 8, "ENTITY"]]}
{"text": "Half of non-survivors experienced a secondary infection , and ventilator-associated pneumonia occurred in ten ( 31 % ) of 32 patients requiring invasive mechanical ventilation .", "labels": [[144, 164, "ENTITY"], [36, 56, "ENTITY"], [62, 84, "ENTITY"], [134, 144, "ENTITY"], [36, 56, "DISEASE"], [8, 22, "ENTITY"], [62, 84, "DISEASE"]]}
{"text": "Favipiravir is a new type of RNA-dependent RNA polymerase ( RdRp ) inhibitor . In addition to its anti-influenza virus activity , favipiravir is capable of blocking the replication of flavi- , alpha- , filo- , bunya- , arena- , noro- , and other RNA viruses ( 10 ) .", "labels": [[264, 270, "CELLULAR_COMPONENT"], [29, 58, "PROTEIN"], [-1, 24, "ENTITY"], [280, 293, "SO"], [0, 12, "ENTITY"], [98, 113, "TAXON"], [280, 293, "ENTITY"], [29, 58, "ENTITY"], [0, 12, "DISEASE"], [170, 179, "ENTITY"], [256, 270, "CHEMICAL"], [0, 12, "SIMPLE_CHEMICAL"], [29, 33, "SO"]]}
{"text": "All patients had pneumonia . Common complications included ARDS ( 12 [ 29 % ] of 41 patients ) , followed by RNAaemia ( six [ 15 % ] patients ) , acute cardiac injury ( five [ 12 % ] patients ) , and secondary infection ( four [ 10 % ] patients ; table 3 ) .", "labels": [[210, 222, "ORGANISM"], [97, 109, "ENTITY"], [17, 27, "DISEASE"], [97, 109, "PROTEIN"], [78, 84, "ORGANISM"], [97, 109, "GENE_OR_GENE_PRODUCT"], [120, 131, "ENTITY"], [17, 27, "ENTITY"], [78, 84, "ENTITY"], [181, 200, "ENTITY"], [120, 131, "ORGANISM"], [167, 174, "ENTITY"], [4, 13, "ENTITY"], [84, 97, "ORGAN"], [133, 152, "DISEASE"], [167, 174, "ORGANISM"], [181, 200, "DISEASE"], [133, 152, "ENTITY"], [210, 222, "ENTITY"], [4, 13, "ORGANISM"]]}
{"text": "Through a literature review , we identified a list of important symptoms and mechanisms linked to SARS-CoV-2 , including fever , fatigue , cough 17 , breathing difficulty , septic shock , viral proliferation , immunodeficiency and pulmonary fibrosis 18 ( Figure 4 ) .", "labels": [[145, 160, "ENTITY"], [180, 194, "ENTITY"], [180, 186, "TAXON"], [160, 180, "ENTITY"], [129, 139, "DISEASE"], [231, 241, "DISEASE"], [194, 210, "ORGANISM"], [210, 241, "ENTITY"], [194, 210, "ENTITY"], [241, 255, "ENTITY"], [210, 231, "ORGAN"], [160, 180, "DISEASE"], [129, 139, "ENTITY"], [111, 121, "DISEASE"], [111, 121, "ENTITY"], [10, 28, "ENTITY"]]}
{"text": "In high epidemic areas , members of the public are encouraged to reduce going out ; thus , Tai Chi and Qi Gong , as integrative therapies , might be very suitable indoor exercises to strengthen the constitution .", "labels": [[154, 170, "ENTITY"], [8, 17, "ENTITY"], [113, 128, "ENTITY"], [89, 95, "ENTITY"]]}
{"text": "The WHO also recommends the isolation of patients suspected or confirmed for COVID-19.16", "labels": [[41, 50, "ORGANISM"], [28, 38, "ENTITY"], [50, 60, "ENTITY"], [41, 50, "ENTITY"]]}
{"text": "Growth and development inhibition is more common when combining IFN-\u03b1 with ribavirin . Suicidal ideation is more common in children ( mainly adolescents ) compared with adults ( 2.4%vs . 1 % ) [ 12 ] .", "labels": [[64, 70, "GENE_OR_GENE_PRODUCT"], [64, 70, "ENTITY"], [64, 70, "PROTEIN"], [75, 85, "SIMPLE_CHEMICAL"], [87, 96, "DISEASE"], [11, 23, "ENTITY"], [0, 7, "ENTITY"], [87, 96, "ENTITY"], [75, 85, "CHEMICAL"], [23, 34, "ENTITY"], [75, 85, "ENTITY"]]}
{"text": "Since lymphocytopenia is often seen in severe COVID-19 patients , the CRS caused by SARS-CoV-2 virus has to be mediated by leukocytes other than T cells , as in patients receiving CAR-T therapy ; a high WBC-count is common , suggesting it , in association with lymphocytopenia , as a differential diagnostic criterion for COVID-19 .", "labels": [[55, 64, "ENTITY"], [239, 244, "ENTITY"], [170, 180, "CHEMICAL"], [84, 95, "GENE_OR_GENE_PRODUCT"], [198, 203, "ENTITY"], [46, 64, "SIMPLE_CHEMICAL"], [6, 22, "ENTITY"], [308, 322, "PROTEIN"], [84, 95, "ENTITY"], [39, 46, "ENTITY"], [46, 55, "ENTITY"], [308, 322, "GENE_OR_GENE_PRODUCT"], [284, 308, "ENTITY"], [6, 22, "DISEASE"], [170, 186, "ENTITY"], [170, 180, "CELL_TYPE"], [170, 180, "CELL"], [198, 203, "GENE_OR_GENE_PRODUCT"], [46, 55, "DISEASE"], [308, 322, "ENTITY"]]}
{"text": "Since lymphocytopenia is often seen in severe COVID-19 patients , the CRS caused by SARS-CoV-2 virus has to be mediated by leukocytes other than T cells , as in patients receiving CAR-T therapy ; a high WBC-count is common , suggesting it , in association with lymphocytopenia , as a differential diagnostic criterion for COVID-19 .", "labels": [[46, 55, "DISEASE"], [55, 64, "ENTITY"], [239, 244, "ENTITY"], [46, 64, "SIMPLE_CHEMICAL"], [170, 180, "CHEMICAL"], [84, 95, "GENE_OR_GENE_PRODUCT"], [198, 203, "ENTITY"], [6, 22, "ENTITY"], [308, 322, "PROTEIN"], [84, 95, "ENTITY"], [39, 46, "ENTITY"], [308, 322, "GENE_OR_GENE_PRODUCT"], [284, 308, "ENTITY"], [6, 22, "DISEASE"], [170, 186, "ENTITY"], [170, 180, "CELL_TYPE"], [170, 180, "CELL"], [198, 203, "GENE_OR_GENE_PRODUCT"], [308, 322, "ENTITY"], [46, 55, "ENTITY"]]}
{"text": "On admission , lymphocytopenia was present in 83.2 % of the patients , thrombocytopenia in 36.2 % , and leukopenia in 33.7 %", "labels": [[3, 13, "ENTITY"]]}
{"text": "Interestingly , asthma and tobacco use also showed nominal significant associations with higher ACE2 expression .", "labels": []}
{"text": "ACE2 can also antagonize cardiac fibrosis and ventricular remodeling caused by the long-term effects of Ang II .", "labels": [[33, 42, "DISEASE"], [25, 33, "ORGAN"], [46, 58, "MULTI-TISSUE_STRUCTURE"], [0, 5, "GGP"], [104, 111, "GGP"], [0, 5, "ENTITY"], [104, 111, "GENE_OR_GENE_PRODUCT"], [104, 111, "PROTEIN"], [0, 5, "GENE_OR_GENE_PRODUCT"], [46, 69, "ENTITY"], [83, 93, "ENTITY"], [93, 101, "ENTITY"], [0, 5, "PROTEIN"], [14, 25, "ENTITY"], [25, 42, "ENTITY"], [104, 111, "ENTITY"]]}
{"text": "ACE2 has a well-recognized role in myocardial recovery and injury response ; in one study , ACE2 knockout in animal models contributed to adverse left ventricular remodeling in response to acute injury driven by angiotensin II.55", "labels": [[35, 46, "ENTITY"], [106, 116, "ENTITY"], [0, 5, "ENTITY"], [0, 5, "GGP"], [0, 5, "ENTITY"], [59, 66, "ENTITY"], [186, 195, "DISEASE"], [135, 163, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"], [138, 151, "MULTI-TISSUE_STRUCTURE"], [35, 46, "MULTI-TISSUE_STRUCTURE"], [46, 55, "ENTITY"], [209, 224, "TISSUE"], [0, 5, "PROTEIN"], [66, 75, "ENTITY"], [186, 195, "ENTITY"]]}
{"text": "ACE2 has a well-recognized role in myocardial recovery and injury response ; in one study , ACE2 knockout in animal models contributed to adverse left ventricular remodeling in response to acute injury driven by angiotensin II.55", "labels": [[35, 46, "ENTITY"], [106, 116, "ENTITY"], [0, 5, "PROTEIN"], [59, 66, "ENTITY"], [186, 195, "DISEASE"], [135, 163, "ENTITY"], [0, 5, "ENTITY"], [138, 151, "MULTI-TISSUE_STRUCTURE"], [35, 46, "MULTI-TISSUE_STRUCTURE"], [46, 55, "ENTITY"], [0, 5, "ENTITY"], [0, 5, "GGP"], [209, 224, "TISSUE"], [66, 75, "ENTITY"], [186, 195, "ENTITY"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Other clinical signs such as reduced appetite , increased respiration rate and hunched posture were transient after the initial challenge .", "labels": [[79, 87, "ENTITY"], [6, 21, "ENTITY"], [37, 46, "CHEMICAL"], [37, 46, "ENTITY"], [29, 37, "ENTITY"]]}
{"text": "Moreover , chloroquine has immunomodulatory effects , suppressing the production/release of TNF-\u03b1 and IL-6 . It also works as a novel class of autophagy inhibitor [ 81 ] , which may interfere with viral infection and replication .", "labels": [[143, 153, "ENTITY"], [203, 217, "ENTITY"], [192, 203, "DISEASE"], [27, 44, "ENTITY"], [140, 153, "CHEBI"], [192, 203, "ENTITY"]]}
{"text": "During prolonged ER stress induced by infection , non-specific RNase activity of IRE1 may decay the membrane associated viral mRNA .", "labels": [[17, 20, "GENE_OR_GENE_PRODUCT"], [63, 69, "ENTITY"], [27, 35, "ENTITY"], [17, 27, "ENTITY"], [7, 17, "ENTITY"], [17, 20, "PROTEIN"], [38, 48, "DISEASE"], [38, 48, "ENTITY"], [120, 126, "TAXON"], [100, 126, "RNA"]]}
{"text": "Moreover , chloroquine has immunomodulatory effects , suppressing the production/release of TNF-\u03b1 and IL-6 . It also works as a novel class of autophagy inhibitor [ 81 ] , which may interfere with viral infection and replication .", "labels": [[143, 153, "ENTITY"], [203, 217, "ENTITY"], [192, 203, "DISEASE"], [27, 44, "ENTITY"], [140, 153, "CHEBI"], [192, 203, "ENTITY"]]}
{"text": "As RHO GTPases have been implicated in membrane remodeling and the viral replication cycle , especially entry , replication , and spread [ Van den Broeke et al. ( 2014 ) ] , transient secretory cells may be more permissive to SARS-CoV-2 infection adding to a potential vulnerability caused by considerably high co-expression levels of ACE2 and TMPRSS2 .", "labels": [[212, 226, "IMMATERIAL_ANATOMICAL_ENTITY"], [212, 237, "DISEASE"], [130, 147, "SIMPLE_CHEMICAL"], [39, 48, "CELLULAR_COMPONENT"], [174, 184, "CL"], [335, 344, "GENE_OR_GENE_PRODUCT"], [335, 344, "PROTEIN"], [174, 184, "CELL_TYPE"], [174, 184, "CELL"], [7, 15, "ENTITY"], [247, 259, "ENTITY"], [3, 7, "GENE_OR_GENE_PRODUCT"], [293, 311, "ENTITY"], [325, 332, "ENTITY"], [212, 237, "ENTITY"], [3, 15, "GGP"], [3, 7, "DISEASE"], [39, 48, "GO"], [335, 344, "GGP"], [325, 332, "GGP"], [39, 59, "ENTITY"], [325, 332, "PROTEIN"], [174, 184, "ENTITY"], [335, 344, "ENTITY"], [67, 73, "TAXON"], [325, 332, "GENE_OR_GENE_PRODUCT"], [3, 15, "PROTEIN"], [67, 91, "ENTITY"], [259, 269, "ENTITY"], [3, 7, "ENTITY"]]}
{"text": "As shown in Figure 2c and 2d , the viral loads in nasal swabs and pharyngeal swabs reached the highest levels ( average , approximately 6.5 log10 RNA copies/mL ) at 3 days post-infection ( dpi ) and then declined naturally .", "labels": [[12, 22, "GENE_OR_GENE_PRODUCT"], [50, 56, "CANCER"], [162, 167, "ENTITY"], [26, 29, "GENE_OR_GENE_PRODUCT"], [50, 56, "ENTITY"], [66, 77, "ENTITY"], [26, 29, "ENTITY"], [12, 22, "ENTITY"], [172, 187, "ENTITY"], [66, 77, "CANCER"], [140, 146, "SO"], [167, 172, "ENTITY"], [35, 41, "ENTITY"]]}
{"text": "Similarly , viral loads from anal swabs reached the peak about 4.5 log10 RNA copies/mL at 3 dpi and then declined to undetectable level at 14 dpi ( Figure 2e ) .", "labels": [[29, 34, "ENTITY"], [29, 34, "CANCER"], [146, 155, "ENTITY"], [12, 18, "ENTITY"]]}
{"text": "As shown in Figure 2f ( left panel ) , viral replication was found in nose ( 107 to 108 copies/mL ) , pharynx ( 105 to 106 copies/mL ) , lung ( 104 to 107 copies/mL ) , gut ( 104 to 106 copies/mL ) , spinal cord ( approximately 104 copies/mL ) , heart ( approximately 104 copies/mL ) , skeletal muscle ( approximately 104 copies/mL ) and bladder ( approximately 104 copies/mL ) .", "labels": [[214, 232, "ENTITY"], [24, 29, "ENTITY"], [214, 232, "TISSUE"], [88, 98, "ENTITY"], [214, 232, "ORGAN"], [88, 98, "ENTITY"], [88, 102, "ENTITY"], [12, 22, "ENTITY"], [88, 102, "ORGAN"], [88, 98, "MULTI-TISSUE_STRUCTURE"], [37, 45, "ENTITY"], [214, 232, "ENTITY"], [12, 22, "SIMPLE_CHEMICAL"], [88, 98, "ORGAN"]]}
{"text": "All patients had pneumonia . Common complications included ARDS ( 12 [ 29 % ] of 41 patients ) , followed by RNAaemia ( six [ 15 % ] patients ) , acute cardiac injury ( five [ 12 % ] patients ) , and secondary infection ( four [ 10 % ] patients ; table 3 ) .", "labels": [[97, 109, "ENTITY"], [17, 27, "DISEASE"], [97, 109, "PROTEIN"], [78, 84, "ORGANISM"], [97, 109, "GENE_OR_GENE_PRODUCT"], [120, 131, "ENTITY"], [210, 222, "ENTITY"], [17, 27, "ENTITY"], [78, 84, "ENTITY"], [181, 200, "ENTITY"], [120, 131, "ORGANISM"], [167, 174, "ENTITY"], [4, 13, "ENTITY"], [84, 97, "ORGAN"], [133, 152, "DISEASE"], [167, 174, "ORGANISM"], [181, 200, "DISEASE"], [133, 152, "ENTITY"], [210, 222, "ORGANISM"], [4, 13, "ORGANISM"]]}
{"text": "Half of non-survivors experienced a secondary infection , and ventilator-associated pneumonia occurred in ten ( 31 % ) of 32 patients requiring invasive mechanical ventilation .", "labels": [[144, 164, "ENTITY"], [36, 56, "DISEASE"], [36, 56, "ENTITY"], [62, 84, "DISEASE"], [62, 84, "ENTITY"], [134, 144, "ENTITY"], [8, 22, "ENTITY"]]}
{"text": "China National Biotec Group Co has claimed that 10 seriously ill patients receiving this immunoglobulin therapy demonstrated improved oxygenation and reduced inflammation and viral load [ 7 ] .", "labels": [[6, 28, "ENTITY"], [61, 65, "ENTITY"], [65, 74, "ORGANISM"], [175, 181, "TAXON"], [65, 74, "ENTITY"], [175, 186, "ENTITY"], [134, 146, "ENTITY"], [150, 158, "ENTITY"], [89, 104, "GENE_OR_GENE_PRODUCT"], [0, 6, "ENTITY"], [89, 112, "ENTITY"], [158, 171, "ENTITY"], [89, 104, "PROTEIN"], [158, 171, "DISEASE"]]}
{"text": "China National Biotec Group Co has claimed that 10 seriously ill patients receiving this immunoglobulin therapy demonstrated improved oxygenation and reduced inflammation and viral load [ 7 ] .", "labels": [[134, 146, "ENTITY"], [6, 28, "ENTITY"], [61, 65, "ENTITY"], [65, 74, "ORGANISM"], [175, 181, "TAXON"], [65, 74, "ENTITY"], [175, 186, "ENTITY"], [150, 158, "ENTITY"], [89, 104, "GENE_OR_GENE_PRODUCT"], [0, 6, "ENTITY"], [89, 112, "ENTITY"], [158, 171, "ENTITY"], [89, 104, "PROTEIN"], [158, 171, "DISEASE"]]}
{"text": "China National Biotec Group Co has claimed that 10 seriously ill patients receiving this immunoglobulin therapy demonstrated improved oxygenation and reduced inflammation and viral load [ 7 ] .", "labels": [[6, 28, "ENTITY"], [61, 65, "ENTITY"], [65, 74, "ORGANISM"], [158, 171, "ENTITY"], [175, 181, "TAXON"], [65, 74, "ENTITY"], [175, 186, "ENTITY"], [134, 146, "ENTITY"], [150, 158, "ENTITY"], [0, 6, "ENTITY"], [89, 112, "ENTITY"], [158, 171, "DISEASE"], [89, 104, "PROTEIN"], [89, 104, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [76, 89, "DISEASE"], [257, 271, "ENTITY"], [50, 56, "ENTITY"], [28, 37, "ENTITY"], [50, 56, "DISEASE"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "The second most common symptom was cough ( 67.8 % ) ; nausea or vomiting ( 5.0 % ) and diarrhea ( 3.8 % ) were uncommon .", "labels": [[23, 31, "ENTITY"], [35, 41, "ENTITY"], [35, 41, "DISEASE"], [81, 87, "ENTITY"], [81, 87, "DISEASE"]]}
{"text": "The clinical features include fever , dry cough , shortness of breath , normal or low levels of peripheral white blood cells , and inflammatory changes on chest X-ray .", "labels": [[48, 63, "ENTITY"], [38, 42, "ENTITY"], [107, 119, "CELL"], [4, 22, "ENTITY"], [107, 119, "CL"], [82, 86, "ENTITY"], [127, 144, "ENTITY"], [30, 36, "ENTITY"], [38, 42, "DISEASE"], [48, 63, "DISEASE"], [152, 161, "ENTITY"], [93, 119, "ENTITY"], [93, 119, "CELL_TYPE"], [30, 36, "DISEASE"]]}
{"text": "Most patients presented cough and fever ( mainly low fever , temperature ranges from 37.3 to 38.0 ) ( Table 1 ) . Four patients had the symptom of productive cough ( white phlegm ) and sore throat . Three patients reported headache and nausea . One patient only existed chest congestion ( patient 7 ) .", "labels": [[214, 223, "ENTITY"], [172, 185, "ENTITY"], [236, 245, "ENTITY"], [5, 14, "ENTITY"], [128, 136, "ENTITY"], [61, 73, "ENTITY"], [136, 158, "ENTITY"], [24, 30, "ENTITY"], [197, 205, "ENTITY"], [223, 232, "DISEASE"], [276, 287, "ORGANISM"], [34, 40, "ENTITY"], [147, 158, "DISEASE"], [158, 172, "ENTITY"], [172, 185, "DISEASE"], [223, 232, "ENTITY"], [49, 53, "ENTITY"], [5, 14, "ORGANISM"], [158, 172, "DISEASE"], [34, 40, "DISEASE"], [24, 30, "DISEASE"], [257, 276, "ENTITY"], [214, 223, "DISEASE"], [197, 205, "ORGANISM"], [236, 245, "ORGANISM"], [257, 276, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [219, 230, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "A 69-year old woman had persistent fever ( > 38 \u2103 ) accompanied by a dry cough , headache , sore throat , myalgia and fatigue for three days .", "labels": [[35, 41, "ENTITY"], [67, 73, "ENTITY"], [97, 106, "DISEASE"], [67, 73, "DISEASE"], [24, 35, "ENTITY"], [14, 20, "ORGANISM"], [14, 20, "ENTITY"], [35, 41, "DISEASE"], [81, 97, "ENTITY"], [97, 106, "ENTITY"], [81, 97, "DISEASE"]]}
{"text": "The most common symptom was fever on or after hospitalisation ( 88.0 % ) , followed by dry cough ( 70.2 % ) . Fatigue ( 42.8 % ) and productive cough ( 36.0 % ) were less common .", "labels": [[84, 91, "DISEASE"], [28, 34, "DISEASE"], [28, 34, "ENTITY"], [120, 133, "ENTITY"], [84, 91, "ENTITY"], [46, 62, "ENTITY"], [16, 24, "ENTITY"]]}
{"text": "the most common clinical manifestations at onset of illness include fever , cough , fatigue and myalgia", "labels": [[52, 60, "ENTITY"], [43, 52, "ENTITY"], [68, 74, "ENTITY"], [68, 74, "DISEASE"], [16, 40, "ENTITY"]]}
{"text": "The common clinical manifestations of fever and cough in conjunction with laboratory results of progressively increasing neutrophil counts and leukocytopenia in serum samples taken from COVID-19 patients at various stages of the illness indicates uncontrolled neutrophil extravasation and activation 11,12 .", "labels": [[121, 132, "CL"], [195, 204, "ENTITY"], [229, 237, "ENTITY"], [121, 132, "ENTITY"], [186, 195, "ENTITY"], [57, 69, "ENTITY"], [132, 139, "ENTITY"], [38, 44, "ENTITY"], [143, 158, "ENTITY"], [48, 54, "DISEASE"], [260, 285, "ENTITY"], [48, 54, "ENTITY"], [121, 132, "CELL"], [121, 132, "CELL"], [11, 35, "ENTITY"], [186, 204, "ORGANISM"], [247, 260, "ENTITY"], [74, 93, "ENTITY"], [121, 132, "CL"], [121, 132, "CELL_TYPE"], [110, 121, "ENTITY"], [38, 44, "DISEASE"], [161, 175, "ORGANISM_SUBSTANCE"], [289, 300, "ENTITY"], [121, 132, "CELL_TYPE"], [161, 175, "ENTITY"], [215, 222, "ENTITY"], [143, 158, "DISEASE"]]}
{"text": "Through a literature review , we identified a list of important symptoms and mechanisms linked to SARS-CoV-2 , including fever , fatigue , cough 17 , breathing difficulty , septic shock , viral proliferation , immunodeficiency and pulmonary fibrosis 18 ( Figure 4 ) .", "labels": [[145, 160, "ENTITY"], [180, 194, "ENTITY"], [180, 186, "TAXON"], [160, 180, "ENTITY"], [129, 139, "DISEASE"], [231, 241, "DISEASE"], [194, 210, "ORGANISM"], [210, 241, "ENTITY"], [194, 210, "ENTITY"], [241, 255, "ENTITY"], [210, 231, "ORGAN"], [160, 180, "DISEASE"], [129, 139, "ENTITY"], [111, 121, "DISEASE"], [111, 121, "ENTITY"], [10, 28, "ENTITY"]]}
{"text": "Fever was the most common symptom ( 92.8 % ; n = 258 ) , followed by cough ( 69.8 % ; n = 194 ) , dyspnoea ( 34.5 % ; n = 96 ) , myalgia ( 27.7 % ; n = 77 ) , headache ( 7.2 % ; n = 20 ) and diarrhoea ( 6.1 % ; n = 17 ) .", "labels": [[57, 69, "DISEASE"], [26, 34, "ENTITY"], [41, 49, "DISEASE"], [0, 6, "DISEASE"], [0, 6, "ENTITY"], [57, 69, "ENTITY"], [41, 49, "ENTITY"]]}
{"text": "The symptoms of ARDS patients include short/rapid breathing , and cyanosis .", "labels": [[16, 21, "DISEASE"], [4, 13, "ENTITY"], [21, 30, "ORGANISM"], [16, 21, "ENTITY"], [21, 30, "ENTITY"], [38, 60, "ENTITY"]]}
{"text": "Clinical features revealed by a chest CT scan presented as pneumonia , however , there were abnormal features such as RNAaemia , acute respiratory distress syndrome , acute cardiac injury , and incidence of grand-glass opacities that led to death [ 6 ] .", "labels": [[194, 219, "ENTITY"], [0, 18, "ENTITY"], [129, 135, "ORGAN"], [234, 241, "ENTITY"], [32, 46, "ENTITY"], [156, 181, "ENTITY"], [38, 41, "PROTEIN"], [167, 181, "DISEASE"], [59, 69, "ENTITY"], [234, 241, "DISEASE"], [59, 69, "DISEASE"], [92, 101, "ENTITY"], [129, 156, "DISEASE"], [127, 156, "ENTITY"]]}
{"text": "However , IL-6 was statistically significantly associated with death ( Table 4 ) .", "labels": [[19, 33, "ENTITY"]]}
{"text": "However , in another retrospective , multicentre cohort study , the same study group reported a significantly elevation of IL-6 level in non-survival group of patients with COVID-19 , as compared with that of the survivals [ 5 ] .", "labels": [[123, 128, "ENTITY"], [35, 56, "ENTITY"], [137, 150, "ENTITY"], [96, 110, "ENTITY"], [56, 62, "ENTITY"]]}
{"text": "The administration of methylprednisolone appears to have reduced the risk of death in patients with ARDS ( HR , 0.38 ; 95 % CI , 0.20 - 0.72 ; P = .003 ) ( Figure ) .", "labels": [[100, 105, "DISEASE"], [22, 41, "SIMPLE_CHEMICAL"], [86, 95, "ORGANISM"], [69, 83, "ENTITY"], [22, 41, "CHEMICAL"], [57, 65, "ENTITY"], [22, 41, "ENTITY"], [4, 19, "ENTITY"], [100, 105, "ENTITY"], [77, 83, "DISEASE"], [22, 41, "CHEBI"], [86, 95, "ENTITY"]]}
{"text": "It appears that Arbidol treatment could improve the discharging rate and decrease the mortality rate ( Table 5).The efficiency of antifungal agent and corticosteroids were also analyzed in Supplementary Table 1 and Table 2 . Antifungal agent did not show influence on the outcome of COVID-19 patients . And use of corticosteroids were associated with a higher risk of death .", "labels": [[297, 306, "ENTITY"], [16, 24, "CHEMICAL"], [203, 229, "CELL"], [239, 260, "ENTITY"], [159, 175, "SIMPLE_CHEMICAL"], [297, 317, "ORGANISM"], [349, 367, "ENTITY"], [203, 229, "ENTITY"], [-1, 20, "ENTITY"], [159, 175, "ENTITY"], [159, 175, "CHEBI"], [159, 175, "ENTITY"], [-1, 11, "ENTITY"], [159, 175, "CHEBI"], [118, 129, "ENTITY"], [73, 82, "ENTITY"], [306, 317, "ENTITY"], [159, 175, "SIMPLE_CHEMICAL"], [40, 48, "ENTITY"], [159, 175, "CHEMICAL"], [286, 297, "ENTITY"], [-1, 20, "SIMPLE_CHEMICAL"], [16, 34, "ENTITY"], [86, 101, "ENTITY"], [52, 69, "ENTITY"], [297, 306, "DISEASE"], [269, 282, "ENTITY"]]}
{"text": "Infection with these highly pathogenic coronaviruses can result in Acute Respiratory Distress Syndrome ( ARDS ) , which may lead to long-term reduction in lung function , arrhythmia , and death .", "labels": [[152, 160, "ENTITY"], [73, 103, "DISEASE"], [39, 53, "ORGANISM"], [28, 39, "ENTITY"], [132, 142, "ENTITY"], [0, 10, "DISEASE"], [160, 171, "DISEASE"], [39, 53, "ENTITY"], [160, 171, "ENTITY"], [0, 10, "ENTITY"], [67, 103, "ENTITY"], [67, 105, "ORGANISM"]]}
{"text": "Gastrointestinal adverse events including nausea , vomiting , and diarrhea were more common in lopinavir \u2013 ritonavir group than in the standard-care group ( Table 4 ) .", "labels": [[107, 117, "ENTITY"], [42, 49, "DISEASE"], [131, 149, "ENTITY"], [42, 49, "ENTITY"], [92, 107, "CHEMICAL"], [95, 107, "ENTITY"], [0, 32, "ENTITY"], [95, 107, "SIMPLE_CHEMICAL"]]}
{"text": "Adverse reactions include nausea , diarrhea , dizziness , elevated serum aminotransferase , etc .", "labels": [[26, 33, "DISEASE"], [58, 73, "PROTEIN"], [26, 33, "ENTITY"], [58, 73, "ENTITY"], [58, 73, "ORGANISM_SUBSTANCE"], [0, 18, "ENTITY"]]}
{"text": "The clinical features include fever , dry cough , shortness of breath , normal or low levels of peripheral white blood cells , and inflammatory changes on chest X-ray .", "labels": [[48, 63, "ENTITY"], [38, 42, "ENTITY"], [107, 119, "CELL"], [4, 22, "ENTITY"], [107, 119, "CL"], [82, 86, "ENTITY"], [127, 144, "ENTITY"], [30, 36, "ENTITY"], [38, 42, "DISEASE"], [48, 63, "DISEASE"], [152, 161, "ENTITY"], [93, 119, "ENTITY"], [93, 119, "CELL_TYPE"], [30, 36, "DISEASE"]]}
{"text": "She developed chest tightness , shortness of breath , loss of appetite , 62 nausea , and diarrhea", "labels": [[52, 62, "ENTITY"], [52, 62, "DISEASE"], [4, 14, "ENTITY"], [14, 30, "ENTITY"], [32, 45, "ENTITY"], [14, 30, "DISEASE"], [32, 45, "DISEASE"]]}
{"text": "Compared to moderate cases , chest tightness tended to be more common in severe cases . In addition , tachypnea and dyspnea were only developed in severe cases .", "labels": [[29, 35, "DISEASE"], [21, 27, "ENTITY"], [73, 80, "ENTITY"], [0, 9, "ENTITY"], [12, 21, "ENTITY"], [29, 35, "ENTITY"]]}
{"text": "Through a literature review , we identified a list of important symptoms and mechanisms linked to SARS-CoV-2 , including fever , fatigue , cough 17 , breathing difficulty , septic shock , viral proliferation , immunodeficiency and pulmonary fibrosis 18 ( Figure 4 ) .", "labels": [[145, 160, "ENTITY"], [180, 194, "ENTITY"], [180, 186, "TAXON"], [160, 180, "ENTITY"], [129, 139, "DISEASE"], [231, 241, "DISEASE"], [194, 210, "ORGANISM"], [210, 241, "ENTITY"], [194, 210, "ENTITY"], [241, 255, "ENTITY"], [210, 231, "ORGAN"], [160, 180, "DISEASE"], [129, 139, "ENTITY"], [111, 121, "DISEASE"], [111, 121, "ENTITY"], [10, 28, "ENTITY"]]}
{"text": "Fever was the most common symptom ( 92.8 % ; n = 258 ) , followed by cough ( 69.8 % ; n = 194 ) , dyspnoea ( 34.5 % ; n = 96 ) , myalgia ( 27.7 % ; n = 77 ) , headache ( 7.2 % ; n = 20 ) and diarrhoea ( 6.1 % ; n = 17 ) .", "labels": [[57, 69, "DISEASE"], [26, 34, "ENTITY"], [41, 49, "DISEASE"], [0, 6, "DISEASE"], [0, 6, "ENTITY"], [57, 69, "ENTITY"], [41, 49, "ENTITY"]]}
{"text": "The symptoms of ARDS patients include short/rapid breathing , and cyanosis .", "labels": [[16, 21, "DISEASE"], [4, 13, "ENTITY"], [21, 30, "ORGANISM"], [16, 21, "ENTITY"], [21, 30, "ENTITY"], [38, 60, "ENTITY"]]}
{"text": "The most common adverse reactions of ribavirin in children include fever ( 80 % ) , headache ( 62 % ) , neutropenia ( 33 % ) , fatigue ( 30 % ) , etc . [ 20 ] .", "labels": [[16, 34, "ENTITY"], [67, 73, "ENTITY"], [67, 73, "DISEASE"], [37, 47, "SIMPLE_CHEMICAL"], [50, 59, "ENTITY"], [37, 47, "ENTITY"], [37, 47, "CHEMICAL"], [50, 59, "ORGANISM"]]}
{"text": "Most COVID-19 patients initially suffered from fever , cough , fatigue , and shortness of breath , while other symptoms included muscle pain , headache , chest pain , and diarrhea , similar to the symptoms observed after chemotherapy , targeted and immune therapy1", "labels": [[73, 90, "ENTITY"], [143, 154, "DISEASE"], [120, 136, "DISEASE"], [120, 136, "ENTITY"], [47, 53, "ENTITY"], [206, 221, "ENTITY"], [14, 23, "ENTITY"], [5, 14, "ENTITY"], [5, 23, "ORGANISM"], [236, 256, "CELL"], [5, 14, "DISEASE"], [73, 90, "DISEASE"], [143, 154, "ORGAN"], [221, 236, "ENTITY"], [236, 256, "ENTITY"], [71, 77, "ENTITY"], [190, 197, "ENTITY"], [111, 120, "ENTITY"], [136, 143, "ENTITY"], [136, 143, "DISEASE"], [120, 129, "ORGAN"], [47, 53, "DISEASE"], [143, 154, "ENTITY"], [71, 77, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [219, 230, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "She experienced only mild symptoms such as a sore throat and fatigue , without any signs of pneumonia such as cough and chest tightness .", "labels": [[45, 57, "DISEASE"], [61, 69, "ENTITY"], [45, 57, "ENTITY"], [61, 69, "DISEASE"], [120, 126, "ENTITY"], [21, 35, "ENTITY"], [120, 126, "DISEASE"], [4, 16, "ENTITY"]]}
{"text": "A 69-year old woman had persistent fever ( > 38 \u2103 ) accompanied by a dry cough , headache , sore throat , myalgia and fatigue for three days .", "labels": [[35, 41, "ENTITY"], [67, 73, "ENTITY"], [97, 106, "DISEASE"], [67, 73, "DISEASE"], [24, 35, "ENTITY"], [14, 20, "ORGANISM"], [14, 20, "ENTITY"], [35, 41, "DISEASE"], [81, 97, "ENTITY"], [97, 106, "ENTITY"], [81, 97, "DISEASE"]]}
{"text": "The most common symptom was fever on or after hospitalisation ( 88.0 % ) , followed by dry cough ( 70.2 % ) . Fatigue ( 42.8 % ) and productive cough ( 36.0 % ) were less common .", "labels": [[84, 91, "DISEASE"], [28, 34, "DISEASE"], [28, 34, "ENTITY"], [120, 133, "ENTITY"], [84, 91, "ENTITY"], [46, 62, "ENTITY"], [16, 24, "ENTITY"]]}
{"text": "the most common clinical manifestations at onset of illness include fever , cough , fatigue and myalgia", "labels": [[52, 60, "ENTITY"], [43, 52, "ENTITY"], [68, 74, "ENTITY"], [68, 74, "DISEASE"], [16, 40, "ENTITY"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[50, 56, "ENTITY"], [257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [50, 56, "DISEASE"], [76, 89, "DISEASE"], [257, 271, "ENTITY"], [28, 37, "ENTITY"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "Fever was present in 43.8 % of the patients on admission but developed in 88.7 % during hospitalization .", "labels": [[0, 6, "DISEASE"], [0, 6, "ENTITY"]]}
{"text": "The clinical features include fever , dry cough , shortness of breath , normal or low levels of peripheral white blood cells , and inflammatory changes on chest X-ray .", "labels": [[48, 63, "ENTITY"], [38, 42, "ENTITY"], [107, 119, "CELL"], [4, 22, "ENTITY"], [107, 119, "CL"], [82, 86, "ENTITY"], [127, 144, "ENTITY"], [30, 36, "ENTITY"], [38, 42, "DISEASE"], [48, 63, "DISEASE"], [152, 161, "ENTITY"], [93, 119, "ENTITY"], [93, 119, "CELL_TYPE"], [30, 36, "DISEASE"]]}
{"text": "Most patients presented cough and fever ( mainly low fever , temperature ranges from 37.3 to 38.0 ) ( Table 1 ) . Four patients had the symptom of productive cough ( white phlegm ) and sore throat . Three patients reported headache and nausea . One patient only existed chest congestion ( patient 7 ) .", "labels": [[214, 223, "ENTITY"], [172, 185, "ENTITY"], [24, 30, "ENTITY"], [236, 245, "ENTITY"], [5, 14, "ENTITY"], [128, 136, "ENTITY"], [61, 73, "ENTITY"], [136, 158, "ENTITY"], [276, 287, "ORGANISM"], [197, 205, "ENTITY"], [223, 232, "DISEASE"], [147, 158, "DISEASE"], [158, 172, "ENTITY"], [172, 185, "DISEASE"], [223, 232, "ENTITY"], [158, 172, "DISEASE"], [49, 53, "ENTITY"], [34, 40, "ENTITY"], [24, 30, "DISEASE"], [5, 14, "ORGANISM"], [34, 40, "DISEASE"], [257, 276, "ENTITY"], [214, 223, "DISEASE"], [197, 205, "ORGANISM"], [236, 245, "ORGANISM"], [257, 276, "DISEASE"]]}
{"text": "Most COVID-19 patients initially suffered from fever , cough , fatigue , and shortness of breath , while other symptoms included muscle pain , headache , chest pain , and diarrhea , similar to the symptoms observed after chemotherapy , targeted and immune therapy1", "labels": [[73, 90, "ENTITY"], [47, 53, "ENTITY"], [143, 154, "DISEASE"], [120, 136, "DISEASE"], [120, 136, "ENTITY"], [206, 221, "ENTITY"], [14, 23, "ENTITY"], [47, 53, "DISEASE"], [5, 14, "ENTITY"], [5, 23, "ORGANISM"], [236, 256, "CELL"], [5, 14, "DISEASE"], [73, 90, "DISEASE"], [143, 154, "ORGAN"], [221, 236, "ENTITY"], [236, 256, "ENTITY"], [71, 77, "ENTITY"], [190, 197, "ENTITY"], [111, 120, "ENTITY"], [136, 143, "ENTITY"], [136, 143, "DISEASE"], [120, 129, "ORGAN"], [143, 154, "ENTITY"], [71, 77, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [219, 230, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "A 69-year old woman had persistent fever ( > 38 \u2103 ) accompanied by a dry cough , headache , sore throat , myalgia and fatigue for three days .", "labels": [[67, 73, "ENTITY"], [97, 106, "DISEASE"], [67, 73, "DISEASE"], [24, 35, "ENTITY"], [14, 20, "ORGANISM"], [14, 20, "ENTITY"], [81, 97, "ENTITY"], [35, 41, "DISEASE"], [97, 106, "ENTITY"], [35, 41, "ENTITY"], [81, 97, "DISEASE"]]}
{"text": "Patient 1 , a 52-year-old woman with a history of hypothyroidism , was admitted on 21 January 2020 , complaining of fever of 5 days duration with 38.6\u0005C as the highest body temperature .", "labels": [[160, 168, "ORGANISM_SUBDIVISION"], [127, 132, "ENTITY"], [0, 10, "ENTITY"], [160, 173, "ENTITY"], [0, 10, "ORGANISM"]]}
{"text": "The most common symptom was fever on or after hospitalisation ( 88.0 % ) , followed by dry cough ( 70.2 % ) . Fatigue ( 42.8 % ) and productive cough ( 36.0 % ) were less common .", "labels": [[28, 34, "DISEASE"], [84, 91, "DISEASE"], [120, 133, "ENTITY"], [84, 91, "ENTITY"], [28, 34, "ENTITY"], [46, 62, "ENTITY"], [16, 24, "ENTITY"]]}
{"text": "the most common clinical manifestations at onset of illness include fever , cough , fatigue and myalgia", "labels": [[52, 60, "ENTITY"], [68, 74, "DISEASE"], [43, 52, "ENTITY"], [68, 74, "ENTITY"], [16, 40, "ENTITY"]]}
{"text": "The common clinical manifestations of fever and cough in conjunction with laboratory results of progressively increasing neutrophil counts and leukocytopenia in serum samples taken from COVID-19 patients at various stages of the illness indicates uncontrolled neutrophil extravasation and activation 11,12 .", "labels": [[121, 132, "CL"], [195, 204, "ENTITY"], [229, 237, "ENTITY"], [121, 132, "ENTITY"], [186, 195, "ENTITY"], [57, 69, "ENTITY"], [132, 139, "ENTITY"], [143, 158, "ENTITY"], [260, 285, "ENTITY"], [121, 132, "CELL"], [121, 132, "CELL"], [11, 35, "ENTITY"], [186, 204, "ORGANISM"], [247, 260, "ENTITY"], [74, 93, "ENTITY"], [121, 132, "CL"], [48, 54, "ENTITY"], [110, 121, "ENTITY"], [121, 132, "CELL_TYPE"], [161, 175, "ORGANISM_SUBSTANCE"], [289, 300, "ENTITY"], [121, 132, "CELL_TYPE"], [38, 44, "DISEASE"], [161, 175, "ENTITY"], [38, 44, "ENTITY"], [215, 222, "ENTITY"], [143, 158, "DISEASE"], [48, 54, "DISEASE"]]}
{"text": "Through a literature review , we identified a list of important symptoms and mechanisms linked to SARS-CoV-2 , including fever , fatigue , cough 17 , breathing difficulty , septic shock , viral proliferation , immunodeficiency and pulmonary fibrosis 18 ( Figure 4 ) .", "labels": [[145, 160, "ENTITY"], [180, 194, "ENTITY"], [180, 186, "TAXON"], [160, 180, "ENTITY"], [129, 139, "DISEASE"], [231, 241, "DISEASE"], [194, 210, "ORGANISM"], [210, 241, "ENTITY"], [194, 210, "ENTITY"], [241, 255, "ENTITY"], [210, 231, "ORGAN"], [160, 180, "DISEASE"], [129, 139, "ENTITY"], [111, 121, "DISEASE"], [111, 121, "ENTITY"], [10, 28, "ENTITY"]]}
{"text": "The most common adverse reactions of ribavirin in children include fever ( 80 % ) , headache ( 62 % ) , neutropenia ( 33 % ) , fatigue ( 30 % ) , etc . [ 20 ] .", "labels": [[16, 34, "ENTITY"], [67, 73, "ENTITY"], [37, 47, "SIMPLE_CHEMICAL"], [50, 59, "ENTITY"], [67, 73, "DISEASE"], [37, 47, "ENTITY"], [37, 47, "CHEMICAL"], [50, 59, "ORGANISM"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [76, 89, "DISEASE"], [257, 271, "ENTITY"], [50, 56, "ENTITY"], [28, 37, "ENTITY"], [50, 56, "DISEASE"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "Most patients presented cough and fever ( mainly low fever , temperature ranges from 37.3 to 38.0 ) ( Table 1 ) . Four patients had the symptom of productive cough ( white phlegm ) and sore throat . Three patients reported headache and nausea . One patient only existed chest congestion ( patient 7 ) .", "labels": [[214, 223, "ENTITY"], [172, 185, "ENTITY"], [24, 30, "ENTITY"], [236, 245, "ENTITY"], [5, 14, "ENTITY"], [223, 232, "ENTITY"], [128, 136, "ENTITY"], [61, 73, "ENTITY"], [136, 158, "ENTITY"], [276, 287, "ORGANISM"], [197, 205, "ENTITY"], [34, 40, "ENTITY"], [147, 158, "DISEASE"], [158, 172, "ENTITY"], [172, 185, "DISEASE"], [158, 172, "DISEASE"], [49, 53, "ENTITY"], [24, 30, "DISEASE"], [5, 14, "ORGANISM"], [34, 40, "DISEASE"], [257, 276, "ENTITY"], [214, 223, "DISEASE"], [197, 205, "ORGANISM"], [236, 245, "ORGANISM"], [257, 276, "DISEASE"], [223, 232, "DISEASE"]]}
{"text": "Most COVID-19 patients initially suffered from fever , cough , fatigue , and shortness of breath , while other symptoms included muscle pain , headache , chest pain , and diarrhea , similar to the symptoms observed after chemotherapy , targeted and immune therapy1", "labels": [[73, 90, "ENTITY"], [143, 154, "DISEASE"], [120, 136, "DISEASE"], [120, 136, "ENTITY"], [47, 53, "ENTITY"], [206, 221, "ENTITY"], [14, 23, "ENTITY"], [5, 14, "ENTITY"], [5, 23, "ORGANISM"], [236, 256, "CELL"], [5, 14, "DISEASE"], [73, 90, "DISEASE"], [221, 236, "ENTITY"], [236, 256, "ENTITY"], [143, 154, "ORGAN"], [71, 77, "ENTITY"], [190, 197, "ENTITY"], [111, 120, "ENTITY"], [136, 143, "DISEASE"], [143, 154, "ENTITY"], [120, 129, "ORGAN"], [47, 53, "DISEASE"], [136, 143, "ENTITY"], [71, 77, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [219, 230, "ENTITY"], [24, 33, "ORGANISM"], [219, 230, "DISEASE"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "A 69-year old woman had persistent fever ( > 38 \u2103 ) accompanied by a dry cough , headache , sore throat , myalgia and fatigue for three days .", "labels": [[35, 41, "ENTITY"], [67, 73, "ENTITY"], [97, 106, "DISEASE"], [67, 73, "DISEASE"], [24, 35, "ENTITY"], [14, 20, "ORGANISM"], [81, 97, "ENTITY"], [14, 20, "ENTITY"], [35, 41, "DISEASE"], [97, 106, "ENTITY"], [81, 97, "DISEASE"]]}
{"text": "Fever was the most common symptom ( 92.8 % ; n = 258 ) , followed by cough ( 69.8 % ; n = 194 ) , dyspnoea ( 34.5 % ; n = 96 ) , myalgia ( 27.7 % ; n = 77 ) , headache ( 7.2 % ; n = 20 ) and diarrhoea ( 6.1 % ; n = 17 ) .", "labels": [[57, 69, "DISEASE"], [26, 34, "ENTITY"], [41, 49, "DISEASE"], [0, 6, "DISEASE"], [0, 6, "ENTITY"], [57, 69, "ENTITY"], [41, 49, "ENTITY"]]}
{"text": "The most common adverse reactions of ribavirin in children include fever ( 80 % ) , headache ( 62 % ) , neutropenia ( 33 % ) , fatigue ( 30 % ) , etc . [ 20 ] .", "labels": [[16, 34, "ENTITY"], [67, 73, "ENTITY"], [67, 73, "DISEASE"], [37, 47, "SIMPLE_CHEMICAL"], [50, 59, "ENTITY"], [37, 47, "ENTITY"], [37, 47, "CHEMICAL"], [50, 59, "ORGANISM"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [257, 271, "ENTITY"], [76, 89, "DISEASE"], [50, 56, "ENTITY"], [28, 37, "ENTITY"], [50, 56, "DISEASE"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "The most common symptoms at onset of COVID-19 illness are fever , cough , and fatigue , while other symptoms include sputum production , headache , haemoptysis , diarrhoea , dyspnoea , and lymphopenia [ 5,6,8,13 ] .", "labels": [[109, 117, "TISSUE"], [148, 162, "DISEASE"], [174, 189, "DISEASE"], [124, 137, "DISEASE"], [37, 54, "DISEASE"], [137, 148, "DISEASE"], [109, 124, "ENTITY"], [37, 54, "ENTITY"], [148, 162, "ENTITY"], [124, 137, "ENTITY"], [137, 148, "ENTITY"], [58, 64, "DISEASE"], [37, 46, "GENE_OR_GENE_PRODUCT"], [162, 174, "ENTITY"], [58, 64, "ENTITY"], [174, 189, "ENTITY"], [162, 174, "DISEASE"], [16, 25, "ENTITY"]]}
{"text": "This opinion is supported by the presence of hemorrhage in multiple organs and a positive correlation between fibrinolysis and mortality .", "labels": [[90, 102, "ENTITY"], [127, 137, "ENTITY"], [45, 56, "DISEASE"], [110, 123, "ENTITY"], [68, 75, "ORGAN"], [5, 13, "ENTITY"], [45, 56, "ENTITY"], [81, 90, "ENTITY"], [59, 75, "ENTITY"], [33, 42, "ENTITY"]]}
{"text": "This opinion is supported by the presence of hemorrhage in multiple organs and a positive correlation between fibrinolysis and mortality .", "labels": [[90, 102, "ENTITY"], [45, 56, "DISEASE"], [110, 123, "ENTITY"], [127, 137, "ENTITY"], [68, 75, "ORGAN"], [5, 13, "ENTITY"], [45, 56, "ENTITY"], [81, 90, "ENTITY"], [59, 75, "ENTITY"], [33, 42, "ENTITY"]]}
{"text": "At the later stages , diffuse alveolar damage ( DAD ) is observed in addition to hemorrhage and some areas of interstitial fibrosis ( 48 ) .", "labels": [[30, 39, "DISEASE"], [22, 39, "ENTITY"], [107, 123, "ENTITY"], [13, 20, "ENTITY"], [107, 123, "DISEASE"]]}
{"text": "Small vessels showed hyperplasia , vessel wall thickening , lumen stenosis , occlusion and focal hemorrhage .", "labels": [[0, 14, "MULTI-TISSUE_STRUCTURE"], [21, 33, "DISEASE"], [0, 14, "ENTITY"], [35, 47, "ENTITY"], [6, 13, "MULTI-TISSUE_STRUCTURE"], [87, 97, "ENTITY"], [58, 66, "ENTITY"], [75, 97, "DISEASE"], [21, 33, "ENTITY"], [58, 66, "DISEASE"], [21, 33, "CANCER"]]}
{"text": "Small vessels showed hyperplasia , vessel wall thickening , lumen stenosis , occlusion and focal hemorrhage .", "labels": [[0, 14, "MULTI-TISSUE_STRUCTURE"], [0, 14, "ENTITY"], [35, 47, "ENTITY"], [6, 13, "MULTI-TISSUE_STRUCTURE"], [87, 97, "ENTITY"], [21, 33, "DISEASE"], [21, 33, "ENTITY"], [58, 66, "ENTITY"], [21, 33, "CANCER"], [75, 97, "DISEASE"], [58, 66, "DISEASE"]]}
{"text": "Albumin concentrations were significantly lower in severe cases than moderate cases , and hypoalbuminemia ( albumin<32g/L ) was more frequent in severe cases ( Table 2 ) .", "labels": [[0, 8, "SIMPLE_CHEMICAL"], [0, 8, "ENTITY"], [8, 23, "ENTITY"], [58, 64, "ENTITY"], [58, 64, "ENTITY"], [69, 78, "ENTITY"], [51, 58, "ENTITY"], [0, 8, "GGP"], [51, 58, "ENTITY"]]}
{"text": "RAS is activated during hypoxia", "labels": [[0, 4, "ENTITY"], [0, 4, "GENE_OR_GENE_PRODUCT"], [7, 17, "ENTITY"], [0, 4, "PROTEIN"]]}
{"text": "However , in hyperinflammation , immunosuppression is likely to be beneficial . Re-analysis of data from a phase 3 randomised controlled trial of IL-1 blockade ( anakinra ) in sepsis , showed significant survival benefit in patients with hyperinflammation , without increased adverse events.[8 ]", "labels": [[213, 224, "ENTITY"], [266, 284, "ENTITY"], [151, 162, "ENTITY"], [204, 213, "ENTITY"], [171, 176, "DISEASE"], [192, 204, "ENTITY"], [171, 176, "ENTITY"], [143, 151, "ENTITY"], [151, 162, "CHEMICAL"], [143, 151, "GGP"], [213, 224, "ORGANISM"], [151, 162, "SIMPLE_CHEMICAL"], [105, 137, "ENTITY"], [185, 192, "ENTITY"]]}
{"text": "Both coronavirus disease 2019 ( COVID-19 ) and severe acute respiratory syndrome ( SARS ) are characterised by an overexuberant inflammatory response and , for SARS , viral load is not correlated with the worsening of symptoms.1,2", "labels": [[5, 30, "DISEASE"], [114, 141, "ENTITY"], [160, 167, "ENTITY"], [196, 205, "ENTITY"], [5, 30, "ORGANISM"], [47, 72, "DISEASE"], [205, 218, "GGP"], [178, 185, "ENTITY"], [5, 30, "ENTITY"], [160, 167, "TAXON"], [205, 218, "ENTITY"], [5, 17, "TAXON"], [47, 72, "ENTITY"]]}
{"text": "These results suggest an increased level of systemic inflammation in severe cases .", "labels": [[6, 14, "ENTITY"], [35, 41, "ENTITY"], [76, 82, "ENTITY"], [25, 35, "ENTITY"], [53, 66, "DISEASE"], [44, 66, "ENTITY"], [69, 76, "ENTITY"]]}
{"text": "Both coronavirus disease 2019 ( COVID-19 ) and severe acute respiratory syndrome ( SARS ) are characterised by an overexuberant inflammatory response and , for SARS , viral load is not correlated with the worsening of symptoms.1,2", "labels": [[5, 30, "DISEASE"], [114, 141, "ENTITY"], [47, 72, "DISEASE"], [160, 167, "ENTITY"], [196, 205, "ENTITY"], [5, 30, "ENTITY"], [5, 30, "ORGANISM"], [205, 218, "GGP"], [178, 185, "ENTITY"], [47, 72, "ENTITY"], [160, 167, "TAXON"], [205, 218, "ENTITY"], [5, 17, "TAXON"]]}
{"text": "DPP4 plays also an important role in immune regulation by activating T cells and upregulating CD86 expression and NF-\u03baB pathway .", "labels": [[94, 99, "GENE_OR_GENE_PRODUCT"], [69, 77, "CL"], [94, 99, "ENTITY"], [99, 110, "ENTITY"], [37, 55, "ENTITY"], [58, 77, "ENTITY"], [0, 5, "GGP"], [0, 5, "GENE_OR_GENE_PRODUCT"], [69, 77, "CELL_TYPE"], [69, 77, "CELL"], [0, 5, "PROTEIN"], [81, 94, "ENTITY"], [0, 5, "ENTITY"], [94, 99, "PROTEIN"], [114, 120, "DNA"], [114, 120, "CHEMICAL"], [114, 120, "GENE_OR_GENE_PRODUCT"], [114, 128, "ENTITY"]]}
{"text": "Age , lymphopenia , leucocytosis , and elevated ALT , lactate dehydrogenase , high-sensitivity cardiac troponin I , creatine kinase , d-dimer , serum ferritin , IL-6 , prothrombin time , creatinine , and procalcitonin were also associated with death ( table 3 ) .", "labels": [[187, 204, "GGP"], [134, 150, "GGP"], [125, 134, "ENTITY"], [134, 150, "ORGANISM_SUBSTANCE"], [159, 168, "GENE_OR_GENE_PRODUCT"], [159, 168, "PROTEIN"], [168, 187, "ENTITY"], [39, 48, "ENTITY"], [159, 168, "ENTITY"], [48, 62, "GENE_OR_GENE_PRODUCT"], [134, 150, "ENTITY"], [187, 204, "ENTITY"], [187, 204, "GENE_OR_GENE_PRODUCT"], [48, 62, "PROTEIN"], [204, 228, "ENTITY"], [103, 125, "PROTEIN"], [103, 116, "CHEMICAL"], [187, 204, "PROTEIN"], [48, 62, "GGP"], [159, 168, "GGP"], [95, 103, "GGP"], [103, 125, "GENE_OR_GENE_PRODUCT"], [62, 103, "ENTITY"], [125, 134, "PROTEIN"], [125, 134, "GGP"], [103, 125, "ENTITY"], [48, 54, "CHEMICAL"], [39, 48, "GENE_OR_GENE_PRODUCT"], [168, 187, "SIMPLE_CHEMICAL"], [62, 103, "GENE_OR_GENE_PRODUCT"], [168, 187, "CHEBI"], [48, 62, "ENTITY"], [0, 4, "ENTITY"], [168, 187, "CHEMICAL"], [134, 150, "PROTEIN"], [62, 103, "PROTEIN"], [125, 134, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Leukopenia ( less than 3.5 \u00d7 10 9 leucocytes per liter ) and lymphopenia ( less than 1.1 \u00d7 10 9 lymphocytes per liter ) were observed in two patients , respectively .", "labels": [[134, 141, "ENTITY"], [0, 11, "ENTITY"], [134, 141, "ORGANISM"], [0, 11, "DISEASE"], [80, 89, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Leukopenia ( less than 3.5 \u00d7 10 9 leucocytes per liter ) and lymphopenia ( less than 1.1 \u00d7 10 9 lymphocytes per liter ) were observed in two patients , respectively .", "labels": [[134, 141, "ENTITY"], [0, 11, "DISEASE"], [134, 141, "ORGANISM"], [80, 89, "GENE_OR_GENE_PRODUCT"], [0, 11, "ENTITY"]]}
{"text": "This opinion is supported by the presence of hemorrhage in multiple organs and a positive correlation between fibrinolysis and mortality .", "labels": [[90, 102, "ENTITY"], [45, 56, "DISEASE"], [110, 123, "ENTITY"], [127, 137, "ENTITY"], [68, 75, "ORGAN"], [5, 13, "ENTITY"], [45, 56, "ENTITY"], [81, 90, "ENTITY"], [59, 75, "ENTITY"], [33, 42, "ENTITY"]]}
{"text": "The leading causes of deaths are ARDS , septic shock with MOF , hemorrhage/coagulopathy ( disseminated intravascular coagulopathy , DIC ) , acute heart/liver/kidney injury , and secondary bacterial infections ( 97 , 101 )", "labels": [[178, 188, "TAXON"], [40, 47, "DISEASE"], [132, 165, "ENTITY"], [117, 132, "ENTITY"], [90, 103, "IMMATERIAL_ANATOMICAL_ENTITY"], [178, 198, "DISEASE"], [40, 47, "ENTITY"], [22, 29, "ENTITY"], [33, 38, "ENTITY"], [90, 117, "DISEASE"], [22, 29, "DISEASE"], [117, 132, "DISEASE"], [88, 117, "ENTITY"], [33, 38, "DISEASE"], [140, 146, "PATHOLOGICAL_FORMATION"], [172, 198, "ENTITY"]]}
{"text": "The leading causes of deaths are ARDS , septic shock with MOF , hemorrhage/coagulopathy ( disseminated intravascular coagulopathy , DIC ) , acute heart/liver/kidney injury , and secondary bacterial infections ( 97 , 101 )", "labels": [[178, 188, "TAXON"], [40, 47, "DISEASE"], [132, 165, "ENTITY"], [117, 132, "ENTITY"], [88, 117, "ENTITY"], [33, 38, "DISEASE"], [178, 198, "DISEASE"], [40, 47, "ENTITY"], [22, 29, "ENTITY"], [22, 29, "DISEASE"], [90, 117, "DISEASE"], [90, 103, "IMMATERIAL_ANATOMICAL_ENTITY"], [117, 132, "DISEASE"], [140, 146, "PATHOLOGICAL_FORMATION"], [33, 38, "ENTITY"], [172, 198, "ENTITY"]]}
{"text": "The leading causes of deaths are ARDS , septic shock with MOF , hemorrhage/coagulopathy ( disseminated intravascular coagulopathy , DIC ) , acute heart/liver/kidney injury , and secondary bacterial infections ( 97 , 101 )", "labels": [[178, 188, "TAXON"], [40, 47, "DISEASE"], [132, 165, "ENTITY"], [117, 132, "ENTITY"], [90, 103, "IMMATERIAL_ANATOMICAL_ENTITY"], [33, 38, "DISEASE"], [178, 198, "DISEASE"], [40, 47, "ENTITY"], [22, 29, "ENTITY"], [90, 117, "DISEASE"], [22, 29, "DISEASE"], [88, 117, "ENTITY"], [117, 132, "DISEASE"], [140, 146, "PATHOLOGICAL_FORMATION"], [33, 38, "ENTITY"], [172, 198, "ENTITY"]]}
{"text": "The leading causes of deaths are ARDS , septic shock with MOF , hemorrhage/coagulopathy ( disseminated intravascular coagulopathy , DIC ) , acute heart/liver/kidney injury , and secondary bacterial infections ( 97 , 101 )", "labels": [[178, 188, "TAXON"], [40, 47, "DISEASE"], [132, 165, "ENTITY"], [117, 132, "ENTITY"], [90, 103, "IMMATERIAL_ANATOMICAL_ENTITY"], [33, 38, "DISEASE"], [178, 198, "DISEASE"], [40, 47, "ENTITY"], [22, 29, "ENTITY"], [90, 117, "DISEASE"], [22, 29, "DISEASE"], [88, 117, "ENTITY"], [117, 132, "DISEASE"], [140, 146, "PATHOLOGICAL_FORMATION"], [33, 38, "ENTITY"], [172, 198, "ENTITY"]]}
{"text": "The leading causes of deaths are ARDS , septic shock with MOF , hemorrhage/coagulopathy ( disseminated intravascular coagulopathy , DIC ) , acute heart/liver/kidney injury , and secondary bacterial infections ( 97 , 101 )", "labels": [[178, 188, "TAXON"], [40, 47, "DISEASE"], [132, 165, "ENTITY"], [117, 132, "ENTITY"], [90, 103, "IMMATERIAL_ANATOMICAL_ENTITY"], [33, 38, "DISEASE"], [178, 198, "DISEASE"], [40, 47, "ENTITY"], [22, 29, "ENTITY"], [90, 117, "DISEASE"], [22, 29, "DISEASE"], [88, 117, "ENTITY"], [117, 132, "DISEASE"], [140, 146, "PATHOLOGICAL_FORMATION"], [33, 38, "ENTITY"], [172, 198, "ENTITY"]]}
{"text": "The leading causes of deaths are ARDS , septic shock with MOF , hemorrhage/coagulopathy ( disseminated intravascular coagulopathy , DIC ) , acute heart/liver/kidney injury , and secondary bacterial infections ( 97 , 101 )", "labels": [[178, 188, "TAXON"], [40, 47, "DISEASE"], [117, 132, "ENTITY"], [90, 103, "IMMATERIAL_ANATOMICAL_ENTITY"], [33, 38, "DISEASE"], [178, 198, "DISEASE"], [40, 47, "ENTITY"], [22, 29, "ENTITY"], [90, 117, "DISEASE"], [22, 29, "DISEASE"], [88, 117, "ENTITY"], [132, 165, "ENTITY"], [117, 132, "DISEASE"], [140, 146, "PATHOLOGICAL_FORMATION"], [33, 38, "ENTITY"], [172, 198, "ENTITY"]]}
{"text": "Multivariate regression further suggests that age and D-dimer levels ( > 1 mg/L ) are two 92 independent risk factors for mortality ( 89 , 101 ) .", "labels": [[0, 24, "ENTITY"], [93, 110, "ENTITY"], [54, 62, "PROTEIN"], [54, 62, "GENE_OR_GENE_PRODUCT"], [54, 62, "GGP"], [46, 50, "ENTITY"], [54, 69, "ENTITY"]]}
{"text": "Higher D-dimer level was strongly related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.717 , P3<0.001,R2 = 0.737,P4<0.001 ) .", "labels": [[7, 15, "ENTITY"], [0, 7, "ENTITY"], [63, 75, "ORGANISM"], [45, 52, "ENTITY"], [63, 85, "DISEASE"], [7, 15, "PROTEIN"], [89, 108, "ENTITY"], [63, 85, "ENTITY"], [7, 15, "GENE_OR_GENE_PRODUCT"], [7, 15, "GGP"], [15, 21, "ENTITY"]]}
{"text": "Multivariate regression further suggests that age and D-dimer levels ( > 1 mg/L ) are two 92 independent risk factors for mortality ( 89 , 101 ) .", "labels": [[0, 24, "ENTITY"], [93, 110, "ENTITY"], [54, 62, "PROTEIN"], [54, 62, "GENE_OR_GENE_PRODUCT"], [54, 62, "GGP"], [46, 50, "ENTITY"], [54, 69, "ENTITY"]]}
{"text": "As shown by Table 1 , < 40 years or > 60 years group was related to higher risk of reaching the composite endpoint ( R2 = 0.203 , P4 = 0.049 ) .", "labels": [[72, 79, "ENTITY"], [100, 110, "ENTITY"], [-1, 8, "ENTITY"]]}
{"text": "As shown by Table 1 , < 40 years or > 60 years group was related to higher risk of reaching the composite endpoint ( R2 = 0.203 , P4 = 0.049 ) .", "labels": [[72, 79, "ENTITY"], [100, 110, "ENTITY"], [-1, 8, "ENTITY"]]}
{"text": "Multivariate regression further links hypertension with increased incidence and fatality ( 85 , 89 , 101 ) .", "labels": [[38, 51, "DISEASE"], [56, 66, "ENTITY"], [66, 76, "ENTITY"], [0, 24, "ENTITY"], [80, 89, "DISEASE"], [38, 51, "ENTITY"], [80, 89, "ENTITY"]]}
{"text": "This is accompanied by a prolonged prothrombin time particularly in non-- survivors ( 31 , 79 , 97 , 101 ) .", "labels": [[35, 52, "ENTITY"], [35, 47, "PROTEIN"], [68, 74, "ENTITY"], [35, 47, "GENE_OR_GENE_PRODUCT"], [74, 84, "ENTITY"], [25, 35, "ENTITY"]]}
{"text": "Platelet counts were decreased significantly in severe and dead patients ( 79 , 97 , 101 )", "labels": [[64, 73, "ORGANISM"], [0, 16, "ENTITY"], [59, 64, "ENTITY"], [0, 9, "CL"], [64, 73, "ENTITY"], [21, 31, "ENTITY"], [48, 55, "ENTITY"], [0, 9, "CELL"]]}
{"text": "71.4 % of non-survivors meet the criteria of the International Society on Thrombosis and Haemostasis ( International Society on Thrombosis and Haemostasis ) for disseminated intravascular coagulation ( DIC ) , suggesting the coexistence of coagulation activation and hyper-fibrinolysis in patients with severe COVID-19 infection ( 78 , 85 ) .", "labels": [[114, 127, "ENTITY"], [89, 101, "DISEASE"], [49, 89, "ENTITY"], [163, 178, "ENTITY"], [205, 220, "ENTITY"], [141, 153, "ENTITY"], [71, 89, "DISEASE"], [141, 163, "ENTITY"], [205, 216, "SIMPLE_CHEMICAL"], [89, 101, "ENTITY"], [205, 220, "DISEASE"], [49, 71, "ENTITY"]]}
{"text": "71.4 % of non-survivors meet the criteria of the International Society on Thrombosis and Haemostasis ( International Society on Thrombosis and Haemostasis ) for disseminated intravascular coagulation ( DIC ) , suggesting the coexistence of coagulation activation and hyper-fibrinolysis in patients with severe COVID-19 infection ( 78 , 85 ) .", "labels": [[114, 127, "ENTITY"], [89, 101, "DISEASE"], [49, 89, "ENTITY"], [163, 178, "ENTITY"], [205, 220, "ENTITY"], [141, 153, "ENTITY"], [71, 89, "DISEASE"], [141, 163, "ENTITY"], [205, 216, "SIMPLE_CHEMICAL"], [89, 101, "ENTITY"], [205, 220, "DISEASE"], [49, 71, "ENTITY"]]}
{"text": "Higher temperature was related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.362 , R2 = 0.383 , P3<0.001 , P4<0.001 ) .", "labels": [[34, 41, "ENTITY"], [52, 74, "DISEASE"], [52, 64, "ORGANISM"], [7, 19, "ENTITY"], [78, 97, "ENTITY"], [52, 74, "ENTITY"], [0, 7, "ENTITY"]]}
{"text": "> 10 * 10 ^ 9/L group were strongly related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.604 , P3<0.001 , R2 = 0.543 , P4<0.001 ) .", "labels": [[61, 79, "DISEASE"], [14, 18, "ENTITY"], [61, 79, "ENTITY"], [89, 103, "ENTITY"]]}
{"text": "Higher neutrophil percentage was strongly related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.641 , P3<0.001 , R2 = 0.492 , P4<0.001 ) .", "labels": [[97, 116, "ENTITY"], [0, 7, "ENTITY"], [7, 18, "CELL"], [18, 29, "ENTITY"], [71, 83, "ORGANISM"], [71, 93, "DISEASE"], [53, 60, "ENTITY"], [7, 18, "CL"], [71, 93, "ENTITY"], [7, 18, "ENTITY"], [7, 18, "CELL_TYPE"]]}
{"text": "Lower lymphocyte count was strongly related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = -0.451 , P3<0.001 , R2 = -0.415 , P4<0.001 ) .", "labels": [[65, 87, "DISEASE"], [0, 17, "CELL"], [47, 54, "ENTITY"], [6, 17, "CL"], [6, 17, "ENTITY"], [65, 77, "ORGANISM"], [91, 110, "ENTITY"], [65, 87, "ENTITY"], [0, 6, "ENTITY"], [17, 23, "ENTITY"]]}
{"text": "Higher C-reactive protein level was strongly related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.572 , P3<0.001 , R2 = 0.503 , P4<0.001 ) .", "labels": [[74, 96, "DISEASE"], [26, 32, "ENTITY"], [7, 26, "ENTITY"], [7, 18, "GENE_OR_GENE_PRODUCT"], [74, 96, "ENTITY"], [7, 26, "PROTEIN"], [74, 86, "ORGANISM"], [56, 63, "ENTITY"], [100, 119, "ENTITY"], [0, 7, "ENTITY"], [7, 26, "GGP"]]}
{"text": "Higher alanine aminotransferase activity was related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.243 , P3 = 0.013 , R2 = 0.306 , P4 = 0.002 ) .", "labels": [[7, 15, "CHEBI"], [74, 86, "ORGANISM"], [32, 41, "ENTITY"], [56, 63, "ENTITY"], [100, 119, "ENTITY"], [7, 32, "PROTEIN"], [7, 15, "CHEMICAL"], [7, 32, "ENTITY"], [74, 96, "ENTITY"], [0, 7, "ENTITY"], [74, 96, "DISEASE"], [7, 32, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Higher aspartate aminotransferase activity was related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.202 , P3 = 0.042 , R2 = 0.325 , P4 = 0.001 ) .", "labels": [[58, 65, "ENTITY"], [7, 34, "ENTITY"], [34, 43, "ENTITY"], [76, 98, "ENTITY"], [7, 17, "CHEMICAL"], [7, 34, "PROTEIN"], [76, 98, "DISEASE"], [76, 88, "ORGANISM"], [7, 34, "GENE_OR_GENE_PRODUCT"], [7, 34, "GGP"], [0, 7, "ENTITY"], [102, 121, "ENTITY"]]}
{"text": "Higher aspartate aminotransferase activity was related to severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.202 , P3 = 0.042 , R2 = 0.325 , P4 = 0.001 ) .", "labels": [[58, 65, "ENTITY"], [7, 34, "ENTITY"], [34, 43, "ENTITY"], [76, 98, "ENTITY"], [7, 17, "CHEMICAL"], [7, 34, "PROTEIN"], [76, 98, "DISEASE"], [76, 88, "ORGANISM"], [7, 34, "GENE_OR_GENE_PRODUCT"], [7, 34, "GGP"], [0, 7, "ENTITY"], [102, 121, "ENTITY"]]}
{"text": "Higher \u03b1 - hydroxybutyrate dehydrogenase activity correlated strongly with severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.449 , P3<0.001 , R2 = 0.439 , P4<0.001 ) .", "labels": [[7, 27, "CHEMICAL"], [93, 115, "ENTITY"], [119, 138, "ENTITY"], [75, 82, "ENTITY"], [11, 41, "GGP"], [7, 41, "ENTITY"], [50, 61, "ENTITY"], [93, 115, "DISEASE"], [7, 41, "GENE_OR_GENE_PRODUCT"], [41, 50, "ENTITY"], [0, 7, "ENTITY"], [93, 105, "ORGANISM"]]}
{"text": "Higher lactate dehydrogenase activity correlated strongly with severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.454 , P3<0.001 , R2 = 0.453 , P4<0.001 ) .", "labels": [[7, 29, "GGP"], [107, 126, "ENTITY"], [38, 49, "ENTITY"], [7, 15, "CHEMICAL"], [7, 29, "PROTEIN"], [63, 70, "ENTITY"], [7, 29, "GENE_OR_GENE_PRODUCT"], [81, 103, "ENTITY"], [81, 93, "ORGANISM"], [7, 29, "ENTITY"], [0, 7, "ENTITY"], [81, 103, "DISEASE"]]}
{"text": "Higher lactate dehydrogenase activity correlated strongly with severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.454 , P3<0.001 , R2 = 0.453 , P4<0.001 ) .", "labels": [[7, 29, "GGP"], [107, 126, "ENTITY"], [38, 49, "ENTITY"], [7, 15, "CHEMICAL"], [7, 29, "PROTEIN"], [63, 70, "ENTITY"], [7, 29, "GENE_OR_GENE_PRODUCT"], [81, 103, "ENTITY"], [81, 93, "ORGANISM"], [7, 29, "ENTITY"], [0, 7, "ENTITY"], [81, 103, "DISEASE"]]}
{"text": "Higher creatine kinase activity correlated strongly with severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = 0.231 , P3 = 0.019 , R2 = 0.289 , P4 = 0.003 ) .", "labels": [[7, 16, "CHEBI"], [7, 23, "PROTEIN"], [32, 43, "ENTITY"], [75, 97, "DISEASE"], [7, 32, "ENTITY"], [101, 120, "ENTITY"], [7, 16, "CHEMICAL"], [7, 16, "SIMPLE_CHEMICAL"], [75, 87, "ORGANISM"], [0, 7, "ENTITY"], [75, 97, "ENTITY"], [57, 64, "ENTITY"]]}
{"text": "Lower total protein level correlated with severe 2019 novel coronavirus pneumonia and composite endpoint . ( R1 = \u2212 0.340 , P3 = 0.001 , R2 = \u2212 0.252 , P4 = 0.015 ) .", "labels": [[0, 20, "ENTITY"], [60, 72, "ORGANISM"], [60, 82, "DISEASE"], [26, 37, "ENTITY"], [42, 49, "ENTITY"], [12, 20, "CHEBI"], [86, 105, "ENTITY"], [60, 82, "ENTITY"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [76, 89, "DISEASE"], [257, 271, "ENTITY"], [50, 56, "ENTITY"], [28, 37, "ENTITY"], [50, 56, "DISEASE"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "Most COVID-19 patients initially suffered from fever , cough , fatigue , and shortness of breath , while other symptoms included muscle pain , headache , chest pain , and diarrhea , similar to the symptoms observed after chemotherapy , targeted and immune therapy1", "labels": [[73, 90, "ENTITY"], [143, 154, "DISEASE"], [120, 136, "DISEASE"], [120, 136, "ENTITY"], [47, 53, "ENTITY"], [206, 221, "ENTITY"], [14, 23, "ENTITY"], [5, 14, "ENTITY"], [5, 23, "ORGANISM"], [236, 256, "CELL"], [5, 14, "DISEASE"], [73, 90, "DISEASE"], [143, 154, "ORGAN"], [221, 236, "ENTITY"], [236, 256, "ENTITY"], [71, 77, "ENTITY"], [190, 197, "ENTITY"], [111, 120, "ENTITY"], [136, 143, "ENTITY"], [136, 143, "DISEASE"], [120, 129, "ORGAN"], [47, 53, "DISEASE"], [143, 154, "ENTITY"], [71, 77, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[150, 168, "DISEASE"], [219, 230, "DISEASE"], [7, 14, "ENTITY"], [126, 150, "DISEASE"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "A 69-year old woman had persistent fever ( > 38 \u2103 ) accompanied by a dry cough , headache , sore throat , myalgia and fatigue for three days .", "labels": [[35, 41, "ENTITY"], [67, 73, "ENTITY"], [97, 106, "DISEASE"], [67, 73, "DISEASE"], [24, 35, "ENTITY"], [14, 20, "ORGANISM"], [14, 20, "ENTITY"], [35, 41, "DISEASE"], [81, 97, "ENTITY"], [97, 106, "ENTITY"], [81, 97, "DISEASE"]]}
{"text": "the most common clinical manifestations at onset of illness include fever , cough , fatigue and myalgia", "labels": [[52, 60, "ENTITY"], [43, 52, "ENTITY"], [68, 74, "ENTITY"], [68, 74, "DISEASE"], [16, 40, "ENTITY"]]}
{"text": "Fever was the most common symptom ( 92.8 % ; n = 258 ) , followed by cough ( 69.8 % ; n = 194 ) , dyspnoea ( 34.5 % ; n = 96 ) , myalgia ( 27.7 % ; n = 77 ) , headache ( 7.2 % ; n = 20 ) and diarrhoea ( 6.1 % ; n = 17 ) .", "labels": [[57, 69, "DISEASE"], [26, 34, "ENTITY"], [41, 49, "DISEASE"], [0, 6, "DISEASE"], [0, 6, "ENTITY"], [57, 69, "ENTITY"], [41, 49, "ENTITY"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [76, 89, "DISEASE"], [257, 271, "ENTITY"], [50, 56, "ENTITY"], [28, 37, "ENTITY"], [50, 56, "DISEASE"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "The second most common symptom was cough ( 67.8 % ) ; nausea or vomiting ( 5.0 % ) and diarrhea ( 3.8 % ) were uncommon .", "labels": [[23, 31, "ENTITY"], [35, 41, "ENTITY"], [81, 87, "ENTITY"], [81, 87, "DISEASE"], [35, 41, "DISEASE"]]}
{"text": "Most patients presented cough and fever ( mainly low fever , temperature ranges from 37.3 to 38.0 ) ( Table 1 ) . Four patients had the symptom of productive cough ( white phlegm ) and sore throat . Three patients reported headache and nausea . One patient only existed chest congestion ( patient 7 ) .", "labels": [[214, 223, "ENTITY"], [172, 185, "ENTITY"], [24, 30, "ENTITY"], [5, 14, "ENTITY"], [128, 136, "ENTITY"], [61, 73, "ENTITY"], [136, 158, "ENTITY"], [276, 287, "ORGANISM"], [197, 205, "ENTITY"], [223, 232, "DISEASE"], [34, 40, "ENTITY"], [147, 158, "DISEASE"], [158, 172, "ENTITY"], [172, 185, "DISEASE"], [223, 232, "ENTITY"], [158, 172, "DISEASE"], [49, 53, "ENTITY"], [24, 30, "DISEASE"], [5, 14, "ORGANISM"], [34, 40, "DISEASE"], [236, 245, "ENTITY"], [257, 276, "ENTITY"], [214, 223, "DISEASE"], [236, 245, "ORGANISM"], [197, 205, "ORGANISM"], [257, 276, "DISEASE"]]}
{"text": "She developed chest tightness , shortness of breath , loss of appetite , 62 nausea , and diarrhea", "labels": [[52, 62, "ENTITY"], [52, 62, "DISEASE"], [4, 14, "ENTITY"], [14, 30, "ENTITY"], [32, 45, "ENTITY"], [14, 30, "DISEASE"], [32, 45, "DISEASE"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "Adverse reactions include nausea , diarrhea , dizziness , elevated serum aminotransferase , etc .", "labels": [[58, 73, "PROTEIN"], [58, 73, "ENTITY"], [26, 33, "DISEASE"], [58, 73, "ORGANISM_SUBSTANCE"], [0, 18, "ENTITY"], [26, 33, "ENTITY"]]}
{"text": "Gastrointestinal adverse events including nausea , vomiting , and diarrhea were more common in lopinavir \u2013 ritonavir group than in the standard-care group ( Table 4 ) .", "labels": [[107, 117, "ENTITY"], [42, 49, "DISEASE"], [131, 149, "ENTITY"], [42, 49, "ENTITY"], [92, 107, "CHEMICAL"], [95, 107, "ENTITY"], [0, 32, "ENTITY"], [95, 107, "SIMPLE_CHEMICAL"]]}
{"text": "ACE2 in the gastrointestinal tract may underly early gastrointestinal symptoms such as nausea , vomiting , and diarrhea , and ACE2 in the heart may be related to cardiac damage and fulminant myocarditis that have been reported in COVID-19 [ 14,15 ] .", "labels": [[12, 35, "ORGAN"], [12, 29, "ORGAN"], [0, 5, "PROTEIN"], [177, 191, "ENTITY"], [12, 35, "DISEASE"], [159, 170, "ENTITY"], [12, 35, "ENTITY"], [0, 5, "ENTITY"], [159, 170, "DISEASE"], [177, 191, "DISEASE"], [227, 241, "GENE_OR_GENE_PRODUCT"], [87, 94, "ENTITY"], [0, 5, "GGP"], [87, 94, "DISEASE"], [53, 79, "ENTITY"], [53, 79, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The most common adverse reactions of ribavirin in children include fever ( 80 % ) , headache ( 62 % ) , neutropenia ( 33 % ) , fatigue ( 30 % ) , etc . [ 20 ] .", "labels": [[16, 34, "ENTITY"], [67, 73, "ENTITY"], [67, 73, "DISEASE"], [37, 47, "SIMPLE_CHEMICAL"], [50, 59, "ENTITY"], [37, 47, "ENTITY"], [37, 47, "CHEMICAL"], [50, 59, "ORGANISM"]]}
{"text": "Chemoinformatics searches yielded 15 approved drugs , four investigational new drugs ( clinical ) , and 18 pre-clinical candidates ( Table 1a ) , while specialist knowledge revealed 12 approved drugs , 10 investigational new drugs ( clinical ) , and 10 preclinical candidates ( Table 1b ) .", "labels": [[146, 163, "ENTITY"], [194, 205, "ENTITY"], [59, 75, "ENTITY"], [37, 46, "ENTITY"], [173, 185, "ENTITY"], [46, 52, "ENTITY"], [0, 26, "ENTITY"], [242, 265, "ENTITY"], [79, 87, "ENTITY"]]}
{"text": "She experienced only mild symptoms such as a sore throat and fatigue , without any signs of pneumonia such as cough and chest tightness .", "labels": [[45, 57, "DISEASE"], [45, 57, "ENTITY"], [120, 126, "ENTITY"], [61, 69, "DISEASE"], [21, 35, "ENTITY"], [120, 126, "DISEASE"], [4, 16, "ENTITY"], [61, 69, "ENTITY"]]}
{"text": "A 69-year old woman had persistent fever ( > 38 \u2103 ) accompanied by a dry cough , headache , sore throat , myalgia and fatigue for three days .", "labels": [[35, 41, "ENTITY"], [67, 73, "ENTITY"], [97, 106, "DISEASE"], [67, 73, "DISEASE"], [24, 35, "ENTITY"], [14, 20, "ORGANISM"], [14, 20, "ENTITY"], [35, 41, "DISEASE"], [81, 97, "ENTITY"], [97, 106, "ENTITY"], [81, 97, "DISEASE"]]}
{"text": "Sepsis was the most frequently observed complication , followed by respiratory failure , ARDS , heart failure , and septic shock ( table 2 ) .", "labels": [[31, 40, "ENTITY"], [0, 7, "ENTITY"], [67, 79, "DISEASE"], [94, 102, "DISEASE"], [67, 79, "ENTITY"], [40, 53, "ENTITY"], [112, 123, "ENTITY"], [0, 7, "DISEASE"], [112, 123, "DISEASE"], [94, 102, "ENTITY"]]}
{"text": "It is often induced by sepsis , aspiration , and pneumonia ( including that caused by SARS coronavirus , bird flu , and human influenza viruses ) .", "labels": [[116, 136, "ORGANISM"], [12, 20, "ENTITY"], [23, 30, "ENTITY"], [126, 136, "TAXON"], [86, 91, "ORGANISM"], [120, 136, "ENTITY"], [83, 91, "DISEASE"], [91, 110, "ENTITY"], [23, 30, "DISEASE"], [83, 91, "ENTITY"]]}
{"text": "Sepsis was the most frequently observed complication , followed by respiratory failure , ARDS , heart failure , and septic shock ( table 2 ) .", "labels": [[31, 40, "ENTITY"], [0, 7, "ENTITY"], [67, 79, "ENTITY"], [0, 7, "DISEASE"], [40, 53, "ENTITY"], [94, 102, "DISEASE"], [112, 123, "ENTITY"], [94, 102, "ENTITY"], [112, 123, "DISEASE"], [67, 79, "DISEASE"]]}
{"text": "Sepsis was the most frequently observed complication , followed by respiratory failure , ARDS , heart failure , and septic shock ( table 2 ) .", "labels": [[31, 40, "ENTITY"], [0, 7, "ENTITY"], [67, 79, "ENTITY"], [94, 102, "DISEASE"], [40, 53, "ENTITY"], [112, 123, "ENTITY"], [0, 7, "DISEASE"], [112, 123, "DISEASE"], [67, 79, "DISEASE"], [94, 102, "ENTITY"]]}
{"text": "Sepsis developed at a median of 9\u00b70 days ( 7\u00b70\u201313\u00b70 ) after illness onset among all patients , followed by ARDS ( 12\u00b70 days [ 8\u00b70\u201315\u00b70 ] ) , acute cardiac injury ( 15\u00b70 days [ 10\u00b70\u201317\u00b70 ] ) , acute kidney injury ( 15\u00b70 days [ 13\u00b70\u201319\u00b75 ] ) , and secondary infection ( 17\u00b70 days [ 13\u00b70\u201319\u00b70 ] ) .", "labels": [[139, 147, "ORGAN"], [0, 7, "ENTITY"], [22, 29, "ENTITY"], [246, 256, "ENTITY"], [176, 198, "DISEASE"], [36, 41, "ENTITY"], [226, 246, "DISEASE"], [176, 198, "ENTITY"], [60, 68, "ENTITY"], [126, 147, "ENTITY"], [0, 7, "DISEASE"], [139, 147, "DISEASE"], [226, 246, "ENTITY"]]}
{"text": "Sepsis developed at a median of 9\u00b70 days ( 7\u00b70\u201313\u00b70 ) after illness onset among all patients , followed by ARDS ( 12\u00b70 days [ 8\u00b70\u201315\u00b70 ] ) , acute cardiac injury ( 15\u00b70 days [ 10\u00b70\u201317\u00b70 ] ) , acute kidney injury ( 15\u00b70 days [ 13\u00b70\u201319\u00b75 ] ) , and secondary infection ( 17\u00b70 days [ 13\u00b70\u201319\u00b70 ] ) .", "labels": [[139, 147, "DISEASE"], [0, 7, "ENTITY"], [22, 29, "ENTITY"], [246, 256, "ENTITY"], [176, 198, "DISEASE"], [36, 41, "ENTITY"], [226, 246, "DISEASE"], [176, 198, "ENTITY"], [60, 68, "ENTITY"], [126, 147, "ENTITY"], [0, 7, "DISEASE"], [226, 246, "ENTITY"], [139, 147, "ORGAN"]]}
{"text": "Sepsis developed at a median of 9\u00b70 days ( 7\u00b70\u201313\u00b70 ) after illness onset among all patients , followed by ARDS ( 12\u00b70 days [ 8\u00b70\u201315\u00b70 ] ) , acute cardiac injury ( 15\u00b70 days [ 10\u00b70\u201317\u00b70 ] ) , acute kidney injury ( 15\u00b70 days [ 13\u00b70\u201319\u00b75 ] ) , and secondary infection ( 17\u00b70 days [ 13\u00b70\u201319\u00b70 ] ) .", "labels": [[139, 147, "DISEASE"], [0, 7, "ENTITY"], [22, 29, "ENTITY"], [246, 256, "ENTITY"], [176, 198, "DISEASE"], [36, 41, "ENTITY"], [226, 246, "DISEASE"], [176, 198, "ENTITY"], [60, 68, "ENTITY"], [126, 147, "ENTITY"], [0, 7, "DISEASE"], [226, 246, "ENTITY"], [139, 147, "ORGAN"]]}
{"text": "During hospital admission , most of the patients received a diagnosis of pneumonia from a physician ( 91.1 % ) , followed by ARDS ( 3.4 % ) and shock ( 1.1 % ) .", "labels": [[113, 125, "ENTITY"], [7, 26, "ENTITY"], [113, 125, "DISEASE"]]}
{"text": "The most common symptoms at onset of illness were fever ( 40 [ 98 % ] of 41 patients ) , cough ( 31 [ 76 % ] ) , and myalgia or fatigue ( 18 [ 44 % ] ) ; less common symptoms were sputum production ( 11 [ 28 % ] of 39 ) , headache ( three [ 8 % ] of 38 ) , haemoptysis ( two [ 5 % ] of 39 ) , and diarrhoea ( one [ 3 % ] of 38 ; table 1 ) .", "labels": [[257, 271, "DISEASE"], [9, 16, "ORGAN"], [159, 180, "ENTITY"], [222, 239, "DISEASE"], [76, 89, "DISEASE"], [257, 271, "ENTITY"], [50, 56, "ENTITY"], [28, 37, "ENTITY"], [50, 56, "DISEASE"], [37, 45, "ENTITY"], [222, 239, "ENTITY"], [76, 89, "ENTITY"], [16, 25, "ENTITY"]]}
{"text": "Other prevalent symptoms at onset of illness in deceased patients included fatigue , dyspnoea , chest tightness , and sputum production ; less common symptoms included anorexia , diarrhoea , and myalgia .", "labels": [[112, 118, "DISEASE"], [143, 150, "ENTITY"], [168, 179, "DISEASE"], [66, 75, "ENTITY"], [112, 118, "ENTITY"], [16, 25, "ENTITY"], [168, 179, "ENTITY"], [48, 57, "ENTITY"], [28, 37, "ENTITY"], [94, 102, "DISEASE"], [114, 125, "ENTITY"], [66, 75, "CANCER"], [75, 83, "DISEASE"], [94, 102, "ENTITY"], [75, 83, "ENTITY"], [57, 66, "ORGANISM"], [66, 75, "DISEASE"], [37, 45, "ENTITY"], [6, 16, "ENTITY"], [57, 66, "ENTITY"]]}
{"text": "Compared to moderate cases , chest tightness tended to be more common in severe cases . In addition , tachypnea and dyspnea were only developed in severe cases .", "labels": [[29, 35, "DISEASE"], [21, 27, "ENTITY"], [73, 80, "ENTITY"], [0, 9, "ENTITY"], [12, 21, "ENTITY"], [29, 35, "ENTITY"]]}
{"text": "The second most common symptom was cough ( 67.8 % ) ; nausea or vomiting ( 5.0 % ) and diarrhea ( 3.8 % ) were uncommon .", "labels": [[23, 31, "ENTITY"], [35, 41, "ENTITY"], [81, 87, "ENTITY"], [81, 87, "DISEASE"], [35, 41, "DISEASE"]]}
{"text": "In the severe pediatric patients , the most common symptom was polypnea ( 8/8 ) , followed by fever ( 6/8 ) , cough ( 6/8 ) , expectoration ( 4/8 ) , nausea/vomiting ( 4/8 ) , diarrhea ( 3/8 ) , fatigue/myalgia ( 1/8 ) , headache ( 1/8 ) and constipation ( 1/8 ) ( Table 1 ) .", "labels": [[219, 230, "DISEASE"], [7, 14, "ENTITY"], [150, 168, "ENTITY"], [24, 33, "ENTITY"], [219, 230, "ENTITY"], [126, 150, "DISEASE"], [150, 168, "DISEASE"], [126, 150, "ENTITY"], [24, 33, "ORGANISM"], [14, 24, "ENTITY"], [176, 191, "DISEASE"]]}
{"text": "Patients with at least one comorbidity were older ( mean : 60.8 versus 44.8 years ) , were more likely to have shortness of breath ( 41.4 % versus 17.8 % ) , nausea or vomiting ( 10.4 % versus 4.3 % ) , and tended to have abnormal chest X-ray manifestations ( 29.2 % versus 15.1 % ) ( table 1 ) .", "labels": [[27, 39, "ENTITY"], [219, 245, "ENTITY"], [160, 170, "DISEASE"], [44, 50, "ENTITY"], [209, 219, "ENTITY"], [0, 9, "ENTITY"], [0, 9, "ORGANISM"], [27, 39, "DISEASE"], [108, 126, "DISEASE"], [209, 245, "DISEASE"], [108, 126, "ENTITY"], [160, 170, "ENTITY"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "Gastrointestinal adverse events including nausea , vomiting , and diarrhea were more common in lopinavir \u2013 ritonavir group than in the standard-care group ( Table 4 ) .", "labels": [[107, 117, "ENTITY"], [42, 49, "DISEASE"], [131, 149, "ENTITY"], [42, 49, "ENTITY"], [92, 107, "CHEMICAL"], [95, 107, "ENTITY"], [0, 32, "ENTITY"], [95, 107, "SIMPLE_CHEMICAL"]]}
{"text": "ACE2 in the gastrointestinal tract may underly early gastrointestinal symptoms such as nausea , vomiting , and diarrhea , and ACE2 in the heart may be related to cardiac damage and fulminant myocarditis that have been reported in COVID-19 [ 14,15 ] .", "labels": [[12, 35, "ORGAN"], [87, 94, "DISEASE"], [12, 29, "ORGAN"], [87, 94, "ENTITY"], [0, 5, "PROTEIN"], [177, 191, "ENTITY"], [12, 35, "DISEASE"], [159, 170, "ENTITY"], [12, 35, "ENTITY"], [0, 5, "ENTITY"], [159, 170, "DISEASE"], [177, 191, "DISEASE"], [227, 241, "GENE_OR_GENE_PRODUCT"], [0, 5, "GGP"], [53, 79, "ENTITY"], [53, 79, "DISEASE"], [0, 5, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Among a pooled analysis of 468 patients with pneumonia ( Table 2 ) based on five studies with detailed description of clinical features of the disease , [ 11 , 12 , 13 , 14,23 ] male sex comprised 60.3 % of patients and the mean age was 53 years .", "labels": [[197, 207, "ORGANISM"], [216, 224, "ENTITY"], [45, 55, "DISEASE"], [45, 55, "ENTITY"], [31, 40, "ORGANISM"], [15, 24, "ENTITY"], [229, 237, "ENTITY"], [197, 207, "ENTITY"], [8, 15, "ENTITY"], [31, 40, "ENTITY"], [115, 127, "ENTITY"]]}
{"text": "Moreover , E protein also suppresses ER stress induced by RSV and drugs ( thapsigargin and tunicamycin ; DeDiego et al.,2011 ) .", "labels": [[37, 40, "ENTITY"]]}
{"text": "RNA sequencing revealed that myocardial ACE2 expression was significantly increased in patients with heart failure ( Figure 1J , fold change = 3.00 , P<0.0001 ) , which was further validated at the protein level by proteomics profiling ( Figure 1 K , fold change=1.82 , P<0.0001 ) .", "labels": [[194, 206, "ENTITY"], [29, 45, "MULTI-TISSUE_STRUCTURE"], [101, 115, "ENTITY"], [101, 115, "DISEASE"], [249, 270, "CHEMICAL"], [127, 134, "GENE_OR_GENE_PRODUCT"], [40, 45, "ENTITY"], [40, 45, "PROTEIN"], [45, 56, "ENTITY"], [117, 124, "ENTITY"], [87, 96, "ORGANISM"], [101, 107, "ORGAN"], [29, 40, "ENTITY"], [0, 4, "SO"], [74, 84, "ENTITY"], [87, 96, "ENTITY"], [206, 226, "ENTITY"], [0, 15, "ENTITY"], [226, 238, "ENTITY"], [40, 45, "GGP"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [26, 36, "ENTITY"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [266, 279, "ENTITY"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [168, 174, "PROTEIN"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [168, 174, "GGP"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [261, 273, "ENTITY"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [223, 230, "ENTITY"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "GGP"], [134, 140, "GGP"], [407, 421, "ENTITY"], [261, 273, "GENE_OR_GENE_PRODUCT"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [210, 216, "GGP"], [168, 174, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [210, 216, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [210, 216, "PROTEIN"], [109, 116, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [201, 208, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[168, 174, "GENE_OR_GENE_PRODUCT"], [132, 139, "GGP"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [146, 152, "CHEMICAL"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [132, 139, "PROTEIN"], [36, 44, "ENTITY"], [84, 88, "PROTEIN"], [186, 193, "PROTEIN"], [84, 107, "ENTITY"], [168, 174, "PROTEIN"], [186, 193, "GENE_OR_GENE_PRODUCT"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [139, 146, "ENTITY"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [139, 146, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [210, 216, "ENTITY"], [132, 139, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [186, 193, "ENTITY"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [186, 193, "GGP"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [132, 139, "GENE_OR_GENE_PRODUCT"], [161, 166, "GGP"], [139, 146, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[186, 193, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [132, 139, "ENTITY"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [132, 139, "GENE_OR_GENE_PRODUCT"], [84, 88, "GGP"], [146, 152, "CHEMICAL"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [161, 166, "GGP"], [36, 44, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [84, 88, "PROTEIN"], [139, 146, "PROTEIN"], [186, 193, "ENTITY"], [84, 107, "ENTITY"], [161, 166, "PROTEIN"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [132, 139, "PROTEIN"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GGP"], [146, 152, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [139, 146, "GENE_OR_GENE_PRODUCT"], [176, 186, "GENE_OR_GENE_PRODUCT"], [132, 139, "GGP"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [161, 166, "ENTITY"], [139, 146, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [139, 146, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[186, 193, "GGP"], [168, 174, "GENE_OR_GENE_PRODUCT"], [186, 193, "PROTEIN"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [132, 139, "GENE_OR_GENE_PRODUCT"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [146, 152, "CHEMICAL"], [176, 186, "ENTITY"], [139, 146, "GGP"], [176, 186, "GGP"], [193, 201, "GGP"], [36, 44, "ENTITY"], [84, 88, "PROTEIN"], [84, 107, "ENTITY"], [168, 174, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [70, 80, "ENTITY"], [132, 139, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [186, 193, "GENE_OR_GENE_PRODUCT"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [132, 139, "GGP"], [132, 139, "PROTEIN"], [139, 146, "PROTEIN"], [176, 186, "GENE_OR_GENE_PRODUCT"], [186, 193, "ENTITY"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [139, 146, "ENTITY"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [186, 193, "ENTITY"], [84, 88, "GGP"], [146, 152, "CHEMICAL"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [36, 44, "ENTITY"], [186, 193, "GGP"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [84, 107, "ENTITY"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [186, 193, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [132, 139, "ENTITY"], [176, 186, "GENE_OR_GENE_PRODUCT"], [139, 146, "ENTITY"], [132, 139, "GGP"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [139, 146, "PROTEIN"], [132, 139, "GENE_OR_GENE_PRODUCT"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [139, 146, "GENE_OR_GENE_PRODUCT"], [161, 166, "GGP"], [139, 146, "GGP"], [186, 193, "PROTEIN"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [91, 127, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [114, 127, "ENTITY"], [261, 273, "PROTEIN"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [223, 230, "ENTITY"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [261, 273, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [261, 273, "GGP"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [146, 152, "ENTITY"], [146, 152, "GGP"], [201, 208, "PROTEIN"], [218, 223, "PROTEIN"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "PROTEIN"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [146, 152, "GENE_OR_GENE_PRODUCT"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"], [146, 152, "CHEMICAL"]]}
{"text": "The DRP1 shRNA appropriately decreased DRP1 expression , but did not impact endogenous MAVS expression ( Fig. 3J ) . This indicates that the ORF-9b mediated reduction in DRP1 may contributes to the decrease in type I interferon signaling , however other mechanisms must be operant .", "labels": [[265, 273, "ENTITY"], [4, 9, "ENTITY"], [207, 217, "GGP"], [44, 55, "ENTITY"], [4, 9, "PROTEIN"], [4, 9, "GENE_OR_GENE_PRODUCT"], [207, 217, "PROTEIN"], [207, 228, "ENTITY"], [9, 15, "ENTITY"], [4, 9, "GENE_OR_GENE_PRODUCT"], [148, 157, "ENTITY"], [4, 9, "GGP"], [29, 39, "ENTITY"], [207, 217, "GENE_OR_GENE_PRODUCT"], [4, 9, "GGP"], [4, 9, "ENTITY"], [4, 15, "RNA"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [142, 150, "GENE_OR_GENE_PRODUCT"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "GGP"], [315, 328, "DISEASE"], [142, 148, "GGP"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [134, 140, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [407, 421, "ENTITY"], [134, 140, "DNA"], [407, 421, "GGP"], [7, 17, "ENTITY"], [275, 282, "GENE_OR_GENE_PRODUCT"], [134, 140, "ENTITY"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [142, 150, "GENE_OR_GENE_PRODUCT"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "GGP"], [315, 328, "DISEASE"], [142, 148, "GGP"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [134, 140, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [407, 421, "ENTITY"], [134, 140, "DNA"], [407, 421, "GGP"], [7, 17, "ENTITY"], [275, 282, "GENE_OR_GENE_PRODUCT"], [134, 140, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [134, 140, "DNA"], [142, 150, "GENE_OR_GENE_PRODUCT"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [223, 230, "ENTITY"], [142, 148, "GGP"], [142, 148, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [134, 140, "DNA"], [142, 150, "GENE_OR_GENE_PRODUCT"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [223, 230, "ENTITY"], [142, 148, "GGP"], [142, 148, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 150, "GENE_OR_GENE_PRODUCT"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [142, 150, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [142, 150, "GENE_OR_GENE_PRODUCT"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [201, 208, "GENE_OR_GENE_PRODUCT"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [201, 208, "GGP"], [70, 80, "ENTITY"], [201, 208, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [210, 216, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [201, 208, "PROTEIN"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [146, 152, "GGP"], [132, 139, "ENTITY"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Moreover , the relative expression of a subset of genes associated with the NF-kB and TNF\u03b1 pathways ( e.g. IL18 , IL18R1 , NFKB2 , NFKBIA , TNFA , and TNFAIP3 ) is mostly unchanged all throughout the infection in bronchial HAE but it is highly upregulated in nasal HAE at 48 hpi and onwards ( Fig. 3C and Data S1 ) .", "labels": [[114, 123, "GENE_OR_GENE_PRODUCT"], [244, 256, "ENTITY"], [102, 107, "PROTEIN"], [293, 301, "ENTITY"], [145, 151, "GGP"], [185, 200, "DISEASE"], [123, 131, "GGP"], [131, 138, "ENTITY"], [102, 107, "GENE_OR_GENE_PRODUCT"], [123, 131, "GENE_OR_GENE_PRODUCT"], [185, 200, "ENTITY"], [102, 107, "ENTITY"], [114, 123, "ENTITY"], [283, 291, "ENTITY"], [114, 123, "PROTEIN"], [145, 151, "ENTITY"], [145, 151, "GENE_OR_GENE_PRODUCT"], [131, 138, "DNA"], [200, 213, "ENTITY"], [237, 244, "ENTITY"], [200, 213, "DISEASE"], [123, 131, "DNA"], [223, 227, "ENTITY"], [114, 123, "GGP"], [145, 151, "PROTEIN"], [200, 213, "CANCER"], [244, 259, "CANCER"], [123, 131, "ENTITY"]]}
{"text": "Moreover , the relative expression of a subset of genes associated with the NF-kB and TNF\u03b1 pathways ( e.g. IL18 , IL18R1 , NFKB2 , NFKBIA , TNFA , and TNFAIP3 ) is mostly unchanged all throughout the infection in bronchial HAE but it is highly upregulated in nasal HAE at 48 hpi and onwards ( Fig. 3C and Data S1 ) .", "labels": [[114, 123, "GENE_OR_GENE_PRODUCT"], [114, 123, "ENTITY"], [244, 256, "ENTITY"], [102, 107, "PROTEIN"], [293, 301, "ENTITY"], [145, 151, "GGP"], [185, 200, "DISEASE"], [123, 131, "GGP"], [131, 138, "ENTITY"], [102, 107, "GENE_OR_GENE_PRODUCT"], [123, 131, "GENE_OR_GENE_PRODUCT"], [185, 200, "ENTITY"], [102, 107, "ENTITY"], [283, 291, "ENTITY"], [145, 151, "ENTITY"], [145, 151, "GENE_OR_GENE_PRODUCT"], [131, 138, "DNA"], [114, 123, "PROTEIN"], [200, 213, "ENTITY"], [237, 244, "ENTITY"], [200, 213, "DISEASE"], [123, 131, "DNA"], [223, 227, "ENTITY"], [114, 123, "GGP"], [145, 151, "PROTEIN"], [200, 213, "CANCER"], [244, 259, "CANCER"], [123, 131, "ENTITY"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [275, 282, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [275, 282, "GGP"], [315, 328, "DISEASE"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [275, 282, "PROTEIN"], [407, 421, "SIMPLE_CHEMICAL"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [275, 282, "GGP"], [127, 134, "PROTEIN"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [275, 282, "ENTITY"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "GENE_OR_GENE_PRODUCT"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [297, 304, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "Moreover , the relative expression of a subset of genes associated with the NF-kB and TNF\u03b1 pathways ( e.g. IL18 , IL18R1 , NFKB2 , NFKBIA , TNFA , and TNFAIP3 ) is mostly unchanged all throughout the infection in bronchial HAE but it is highly upregulated in nasal HAE at 48 hpi and onwards ( Fig. 3C and Data S1 ) .", "labels": [[114, 123, "GENE_OR_GENE_PRODUCT"], [244, 256, "ENTITY"], [114, 123, "ENTITY"], [114, 123, "GGP"], [102, 107, "PROTEIN"], [293, 301, "ENTITY"], [145, 151, "GGP"], [123, 131, "GENE_OR_GENE_PRODUCT"], [114, 123, "PROTEIN"], [123, 131, "ENTITY"], [185, 200, "DISEASE"], [131, 138, "ENTITY"], [102, 107, "GENE_OR_GENE_PRODUCT"], [185, 200, "ENTITY"], [102, 107, "ENTITY"], [283, 291, "ENTITY"], [145, 151, "ENTITY"], [145, 151, "GENE_OR_GENE_PRODUCT"], [131, 138, "DNA"], [123, 131, "DNA"], [200, 213, "ENTITY"], [237, 244, "ENTITY"], [123, 131, "GGP"], [200, 213, "DISEASE"], [223, 227, "ENTITY"], [145, 151, "PROTEIN"], [200, 213, "CANCER"], [244, 259, "CANCER"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [193, 201, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [146, 152, "CHEMICAL"], [176, 186, "GGP"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [241, 248, "SIMPLE_CHEMICAL"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [193, 201, "ENTITY"], [132, 139, "GENE_OR_GENE_PRODUCT"], [201, 208, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [193, 201, "GGP"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"], [193, 201, "PROTEIN"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [241, 248, "SIMPLE_CHEMICAL"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [154, 159, "GGP"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [154, 159, "PROTEIN"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [201, 208, "PROTEIN"], [218, 223, "PROTEIN"], [146, 152, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [218, 223, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [218, 223, "GGP"], [146, 152, "PROTEIN"], [154, 159, "GENE_OR_GENE_PRODUCT"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [168, 174, "ENTITY"], [210, 216, "GGP"], [218, 223, "GENE_OR_GENE_PRODUCT"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "Moreover , the relative expression of a subset of genes associated with the NF-kB and TNF\u03b1 pathways ( e.g. IL18 , IL18R1 , NFKB2 , NFKBIA , TNFA , and TNFAIP3 ) is mostly unchanged all throughout the infection in bronchial HAE but it is highly upregulated in nasal HAE at 48 hpi and onwards ( Fig. 3C and Data S1 ) .", "labels": [[114, 123, "GENE_OR_GENE_PRODUCT"], [244, 256, "ENTITY"], [114, 123, "ENTITY"], [114, 123, "GGP"], [102, 107, "PROTEIN"], [293, 301, "ENTITY"], [145, 151, "GGP"], [114, 123, "PROTEIN"], [185, 200, "DISEASE"], [123, 131, "GGP"], [131, 138, "ENTITY"], [102, 107, "GENE_OR_GENE_PRODUCT"], [123, 131, "GENE_OR_GENE_PRODUCT"], [185, 200, "ENTITY"], [102, 107, "ENTITY"], [283, 291, "ENTITY"], [145, 151, "ENTITY"], [145, 151, "GENE_OR_GENE_PRODUCT"], [131, 138, "DNA"], [200, 213, "ENTITY"], [237, 244, "ENTITY"], [200, 213, "DISEASE"], [123, 131, "DNA"], [223, 227, "ENTITY"], [145, 151, "PROTEIN"], [200, 213, "CANCER"], [244, 259, "CANCER"], [123, 131, "ENTITY"]]}
{"text": "Moreover , the relative expression of a subset of genes associated with the NF-kB and TNF\u03b1 pathways ( e.g. IL18 , IL18R1 , NFKB2 , NFKBIA , TNFA , and TNFAIP3 ) is mostly unchanged all throughout the infection in bronchial HAE but it is highly upregulated in nasal HAE at 48 hpi and onwards ( Fig. 3C and Data S1 ) .", "labels": [[114, 123, "GENE_OR_GENE_PRODUCT"], [244, 256, "ENTITY"], [114, 123, "ENTITY"], [114, 123, "GGP"], [102, 107, "PROTEIN"], [293, 301, "ENTITY"], [145, 151, "GGP"], [114, 123, "PROTEIN"], [185, 200, "DISEASE"], [123, 131, "GGP"], [131, 138, "ENTITY"], [102, 107, "GENE_OR_GENE_PRODUCT"], [123, 131, "GENE_OR_GENE_PRODUCT"], [185, 200, "ENTITY"], [102, 107, "ENTITY"], [283, 291, "ENTITY"], [145, 151, "ENTITY"], [145, 151, "GENE_OR_GENE_PRODUCT"], [131, 138, "DNA"], [200, 213, "ENTITY"], [237, 244, "ENTITY"], [200, 213, "DISEASE"], [123, 131, "DNA"], [223, 227, "ENTITY"], [145, 151, "PROTEIN"], [200, 213, "CANCER"], [244, 259, "CANCER"], [123, 131, "ENTITY"]]}
{"text": "Figure 4 . Inflammatory cytokines expression in COVID-19 patients . Heat map depicting inflammatory cytokine genes expression in COVID-19 patients BALF ( A , WHU01 - 02 vs. Ctrl1 - 3 ) and PBMC ( B , P1 - 3 vs. N1 - 3 ) compared with control . Genes significantly up-regulated and down-regulated are labelled with asterisks .", "labels": [[26, 35, "ENTITY"], [246, 252, "ENTITY"], [171, 175, "CHEMICAL"], [26, 36, "PROTEIN"], [191, 196, "ENTITY"], [171, 175, "GENE_OR_GENE_PRODUCT"], [50, 59, "ENTITY"], [158, 166, "GENE_OR_GENE_PRODUCT"], [207, 216, "ENTITY"], [36, 47, "ENTITY"], [59, 68, "ENTITY"], [171, 175, "GGP"], [89, 111, "DNA"], [266, 279, "ENTITY"], [171, 175, "ENTITY"], [50, 59, "DISEASE"], [70, 75, "ENTITY"], [50, 68, "ORGANISM"], [13, 26, "ENTITY"], [202, 205, "ENTITY"], [202, 205, "GENE_OR_GENE_PRODUCT"], [50, 68, "ORGANISM"], [50, 68, "CELL_TYPE"], [26, 36, "ENTITY"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [193, 201, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [176, 186, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [176, 186, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [176, 186, "GGP"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [176, 186, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "We found that several significantly altered genes are enriched to the apoptosis and P53 signaling pathways ( Figure 5 ) , including CTSL , CTSB , DDIT4 , RRAS , CTSD , BIRC5 , TNFSF10 , CTSZ , NTRK1 , IGFBP3 , CCNB1 , RRM2 , CCNB2 , GTSE1 , CDK1 , STEAP3 , and TP53I3 .", "labels": [[139, 146, "PROTEIN"], [168, 174, "GENE_OR_GENE_PRODUCT"], [218, 223, "PROTEIN"], [201, 208, "PROTEIN"], [146, 152, "ENTITY"], [218, 223, "ENTITY"], [84, 88, "GGP"], [139, 146, "GGP"], [176, 186, "ENTITY"], [193, 201, "GGP"], [176, 186, "GGP"], [146, 152, "CHEMICAL"], [36, 44, "ENTITY"], [132, 139, "PROTEIN"], [84, 88, "PROTEIN"], [186, 193, "ENTITY"], [186, 193, "PROTEIN"], [139, 146, "GENE_OR_GENE_PRODUCT"], [84, 107, "ENTITY"], [139, 146, "ENTITY"], [132, 139, "GGP"], [168, 174, "PROTEIN"], [193, 201, "PROTEIN"], [44, 50, "SO"], [122, 132, "PROTEIN"], [161, 166, "ENTITY"], [146, 152, "GENE_OR_GENE_PRODUCT"], [84, 88, "GENE_OR_GENE_PRODUCT"], [154, 159, "ENTITY"], [186, 193, "GENE_OR_GENE_PRODUCT"], [70, 80, "ENTITY"], [193, 201, "GENE_OR_GENE_PRODUCT"], [241, 248, "CHEMICAL"], [122, 132, "ENTITY"], [193, 201, "ENTITY"], [241, 248, "ENTITY"], [161, 166, "GENE_OR_GENE_PRODUCT"], [109, 116, "ENTITY"], [201, 208, "GENE_OR_GENE_PRODUCT"], [132, 139, "GENE_OR_GENE_PRODUCT"], [210, 216, "GENE_OR_GENE_PRODUCT"], [241, 248, "SIMPLE_CHEMICAL"], [218, 223, "GGP"], [168, 174, "GGP"], [201, 208, "GGP"], [176, 186, "GENE_OR_GENE_PRODUCT"], [154, 159, "GENE_OR_GENE_PRODUCT"], [146, 152, "PROTEIN"], [176, 186, "PROTEIN"], [161, 166, "PROTEIN"], [44, 50, "ENTITY"], [210, 216, "ENTITY"], [154, 159, "PROTEIN"], [154, 159, "GGP"], [122, 132, "GENE_OR_GENE_PRODUCT"], [201, 208, "ENTITY"], [132, 139, "ENTITY"], [146, 152, "GGP"], [210, 216, "PROTEIN"], [218, 223, "GENE_OR_GENE_PRODUCT"], [168, 174, "ENTITY"], [210, 216, "GGP"], [161, 166, "GGP"], [186, 193, "GGP"]]}
{"text": "Whereas the unspliced XBP1 mRNA ( XBP1u ) encodes an inhibitor of the UPR , XBP1s encode a potent transcriptional activator , which translocates to the nucleus and enhances the expression of many UPR genes , including those encoding molecular chaperones and proteins contributing to ER-associated degradation ( Ng et al. , 2000;Lee et al. , 2003;Figure 4 ) .", "labels": [[91, 114, "ENTITY"], [70, 74, "ENTITY"], [283, 297, "ENTITY"], [267, 283, "ENTITY"], [91, 114, "PROTEIN"], [22, 27, "GENE_OR_GENE_PRODUCT"], [70, 74, "SO"], [22, 32, "GGP"], [12, 22, "ENTITY"], [27, 32, "ENTITY"], [224, 243, "ENTITY"], [224, 233, "CHEBI"], [267, 283, "GENE_OR_GENE_PRODUCT"], [12, 32, "RNA"], [224, 243, "PROTEIN"], [22, 27, "ENTITY"], [191, 200, "DNA"], [267, 283, "GO"]]}
{"text": "In the nasal HAE , the response after 24 hpi ( peak at 72 - 96 hpi ) is driven by a strong upregulation of type I and type III IFNs ( IFNB1 , IFNL1 , IFNL2 - 3 - 4 ) as well as other immunity-related genes . Whereas only a subset of these genes ( CXCL10/IP10 , CXCL2/MIP2A , IL1A , IL1B , Mx1 and ZBP1 ) follow the same pattern in the bronchial HAE , though at overall lower expression levels , the initial modulation of IFNB1 , IFNL1 , CCL2/MCP1 and IL6 in this tissue seems to fade at 96 hpi .", "labels": [[223, 230, "SO"], [91, 107, "GENE_OR_GENE_PRODUCT"], [84, 91, "ENTITY"], [351, 361, "ENTITY"], [169, 183, "ENTITY"], [407, 421, "PROTEIN"], [261, 273, "GENE_OR_GENE_PRODUCT"], [297, 304, "ENTITY"], [91, 127, "PROTEIN"], [114, 127, "ENTITY"], [407, 421, "SIMPLE_CHEMICAL"], [275, 282, "PROTEIN"], [463, 470, "ENTITY"], [142, 148, "ENTITY"], [134, 140, "DNA"], [127, 134, "ENTITY"], [127, 134, "PROTEIN"], [275, 282, "GGP"], [169, 183, "DNA"], [127, 134, "GENE_OR_GENE_PRODUCT"], [386, 395, "ENTITY"], [134, 140, "ENTITY"], [315, 328, "DISEASE"], [142, 148, "GGP"], [142, 150, "GENE_OR_GENE_PRODUCT"], [223, 230, "ENTITY"], [261, 273, "GGP"], [127, 134, "GGP"], [320, 328, "ENTITY"], [114, 127, "GENE_OR_GENE_PRODUCT"], [91, 107, "ENTITY"], [275, 282, "ENTITY"], [261, 273, "PROTEIN"], [261, 273, "ENTITY"], [134, 140, "GGP"], [407, 421, "ENTITY"], [407, 421, "GGP"], [7, 17, "ENTITY"], [134, 140, "GENE_OR_GENE_PRODUCT"], [275, 282, "GENE_OR_GENE_PRODUCT"]]}
{"text": "The N proteins are translated in the cytoplasm and encapsidate the nascent progeny genomic RNA to form the nucleocapsids .", "labels": [[75, 83, "ENTITY"], [83, 95, "ENTITY"], [37, 47, "GO"], [67, 75, "ENTITY"], [37, 47, "ORGANISM_SUBSTANCE"], [107, 121, "ENTITY"], [4, 15, "PROTEIN"], [37, 47, "ENTITY"], [51, 63, "ENTITY"], [83, 95, "SO"], [4, 15, "ENTITY"], [107, 121, "TISSUE"], [6, 15, "CHEBI"]]}
{"text": "Based on our analyses of differential gene expression , we report significant transcriptional upregulation of multiple genes associated with activation of ER sensors IRE1 , ATF6 , and PERK , such as Edem1 , Hspa5 ( encoding BiP protein ) , and Ddit3 ( encoding CHOP ) , in response to virus replication , with the most robust response detected in cells infected with the wild-type or DUBmut virus infection ( Fig. 5B , C , and D ) .", "labels": [[319, 326, "ENTITY"], [155, 158, "ENTITY"], [244, 252, "ENTITY"], [215, 228, "PROTEIN"], [273, 291, "ENTITY"], [371, 391, "DISEASE"], [38, 54, "ENTITY"], [397, 407, "GENE_OR_GENE_PRODUCT"], [199, 207, "ENTITY"], [199, 207, "GENE_OR_GENE_PRODUCT"], [335, 347, "ENTITY"], [199, 207, "PROTEIN"], [371, 391, "ENTITY"], [38, 43, "SO"], [305, 314, "ENTITY"], [215, 228, "ENTITY"], [110, 119, "ENTITY"], [397, 407, "ENTITY"], [371, 384, "TAXON"], [409, 414, "ENTITY"], [261, 270, "ENTITY"], [199, 207, "GGP"], [215, 228, "GGP"], [25, 38, "ENTITY"], [207, 215, "ENTITY"], [353, 367, "ENTITY"], [13, 22, "ENTITY"]]}
{"text": "Based on our analyses of differential gene expression , we report significant transcriptional upregulation of multiple genes associated with activation of ER sensors IRE1 , ATF6 , and PERK , such as Edem1 , Hspa5 ( encoding BiP protein ) , and Ddit3 ( encoding CHOP ) , in response to virus replication , with the most robust response detected in cells infected with the wild-type or DUBmut virus infection ( Fig. 5B , C , and D ) .", "labels": [[199, 207, "PROTEIN"], [244, 252, "ENTITY"], [319, 326, "ENTITY"], [155, 158, "ENTITY"], [215, 228, "PROTEIN"], [273, 291, "ENTITY"], [371, 391, "DISEASE"], [38, 54, "ENTITY"], [397, 407, "GENE_OR_GENE_PRODUCT"], [199, 207, "GENE_OR_GENE_PRODUCT"], [335, 347, "ENTITY"], [371, 391, "ENTITY"], [38, 43, "SO"], [305, 314, "ENTITY"], [215, 228, "ENTITY"], [110, 119, "ENTITY"], [397, 407, "ENTITY"], [199, 207, "ENTITY"], [199, 207, "GGP"], [371, 384, "TAXON"], [409, 414, "ENTITY"], [261, 270, "ENTITY"], [215, 228, "GGP"], [25, 38, "ENTITY"], [207, 215, "ENTITY"], [353, 367, "ENTITY"], [13, 22, "ENTITY"]]}
{"text": "Based on our analyses of differential gene expression , we report significant transcriptional upregulation of multiple genes associated with activation of ER sensors IRE1 , ATF6 , and PERK , such as Edem1 , Hspa5 ( encoding BiP protein ) , and Ddit3 ( encoding CHOP ) , in response to virus replication , with the most robust response detected in cells infected with the wild-type or DUBmut virus infection ( Fig. 5B , C , and D ) .", "labels": [[244, 252, "ENTITY"], [319, 326, "ENTITY"], [155, 158, "ENTITY"], [215, 228, "PROTEIN"], [273, 291, "ENTITY"], [371, 391, "DISEASE"], [38, 54, "ENTITY"], [397, 407, "GENE_OR_GENE_PRODUCT"], [199, 207, "ENTITY"], [199, 207, "GENE_OR_GENE_PRODUCT"], [335, 347, "ENTITY"], [199, 207, "PROTEIN"], [207, 215, "ENTITY"], [371, 391, "ENTITY"], [38, 43, "SO"], [305, 314, "ENTITY"], [215, 228, "ENTITY"], [110, 119, "ENTITY"], [397, 407, "ENTITY"], [371, 384, "TAXON"], [409, 414, "ENTITY"], [261, 270, "ENTITY"], [199, 207, "GGP"], [215, 228, "GGP"], [25, 38, "ENTITY"], [353, 367, "ENTITY"], [13, 22, "ENTITY"]]}
{"text": "We found that the WT- and DUBmut-viruses exhibit higher proportions of spliced XBP-1 mRNA at 9 hpi and 12 hpi compared to EndoUmut infected cells ( Fig. 5E ) , consistent with activation of the IRE-1 arm of the unfolded protein response .", "labels": [[26, 41, "ENTITY"], [71, 79, "ENTITY"], [79, 85, "ENTITY"], [95, 99, "ENTITY"], [148, 153, "GENE_OR_GENE_PRODUCT"], [190, 200, "ENTITY"], [18, 22, "ENTITY"], [85, 90, "ENTITY"], [190, 200, "PROTEIN"], [140, 146, "CL"], [207, 220, "PROTEIN"], [79, 90, "RNA"], [56, 68, "ENTITY"], [122, 146, "ENTITY"], [79, 85, "GENE_OR_GENE_PRODUCT"], [26, 41, "GENE_OR_GENE_PRODUCT"], [140, 146, "CELL"], [158, 171, "ENTITY"], [122, 146, "CELL_LINE"], [207, 228, "ENTITY"], [85, 90, "CHEBI"], [95, 99, "ENTITY"], [211, 220, "CHEBI"], [18, 41, "PROTEIN"]]}
